$RDFILE 1
$DATM 08/24/2025 11:36:00
$RFMT $RIREG SCHEME1 STEP1
$RXN



  2  1
$MOL
Benzoic acid
C7H6O2
65-85-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-2-Propyn-1-ylbenzamide
C10H9NO
1464-98-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 N 5.3348 2.3100 0.0 0
M  V30 3 O 4.0011 0.0000 0.0 0
M  V30 4 C 6.6684 1.5400 0.0 0
M  V30 5 C 8.0022 2.3100 0.0 0
M  V30 6 C 9.3359 3.0800 0.0 0
M  V30 7 C 2.6675 2.3100 0.0 0
M  V30 8 C 1.3337 1.5400 0.0 0
M  V30 9 C 2.6675 3.8500 0.0 0
M  V30 10 C 0.0000 2.3100 0.0 0
M  V30 11 C 1.3337 4.6201 0.0 0
M  V30 12 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 3 5 6
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 65-85-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1464-98-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22706649
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM The bioisosteric modification of pyrazinamide derivatives led to potent
antitubercular agents: Synthesis via click approach and molecular docking
of pyrazine-1,2,3-triazoles
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Reddyrajula, Rajkumar; Dalimba, Udayakumar
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(2), 126846

$RFMT $RIREG SCHEME2 STEP1
$RXN



  2  1
$MOL
Anthranilic acid
C7H7NO2
118-92-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 3.0801 4.0010 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-methylbenzamide
C8H10N2O
4141-08-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 N 5.3901 4.0010 0.0 0
M  V30 3 O 5.3901 1.3337 0.0 0
M  V30 4 C 6.9302 4.0010 0.0 0
M  V30 5 N 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 2.3101 1.3337 0.0 0
M  V30 8 C 2.3101 4.0010 0.0 0
M  V30 9 C 0.7700 1.3337 0.0 0
M  V30 10 C 0.7700 4.0010 0.0 0
M  V30 11 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 4
M  V30 5 1 5 7
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 118-92-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 4141-08-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40087715
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 12125-02-9
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for
Platelet Degranulation Modulation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bayrak, Alp; Mohr, Florian; Kolb, Kyra; Szpakowska, Martyna; Shevchenko,
Ekaterina; Dicenta, Valerie; Rohlfing, Anne-Katrin; Kudolo, Mark;
Pantsar, Tatu; Guenther, Marcel; Kaczor, Agnieszka A.; Poso, Antti;
Chevigne, Andy; Pillaiyar, Thanigaimalai; Gawaz, Meinrad; Laufer, Stefan
A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(19), 13365-13384

$RFMT $RIREG SCHEME3 STEP1
$RXN



  2  1
$MOL
3-Bromobenzoic acid
C7H5BrO2
585-76-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 Br 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Bromo-N-methylbenzamide
C8H8BrNO
49834-22-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 1.5400 0.0 0
M  V30 2 N 6.6685 2.3100 0.0 0
M  V30 3 O 5.3347 0.0000 0.0 0
M  V30 4 C 8.0021 1.5400 0.0 0
M  V30 5 Br 0.0000 1.5400 0.0 0
M  V30 6 C 4.0011 2.3100 0.0 0
M  V30 7 C 2.6674 1.5400 0.0 0
M  V30 8 C 4.0011 3.8500 0.0 0
M  V30 9 C 1.3336 2.3100 0.0 0
M  V30 10 C 2.6674 4.6200 0.0 0
M  V30 11 C 1.3336 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 4
M  V30 5 1 5 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 585-76-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 49834-22-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35037410
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat
Conjugates
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ota, Yosuke; Itoh, Yukihiro; Kurohara, Takashi; Singh, Ritesh; Elboray,
Elghareeb E.; Hu, Chenliang; Zamani, Farzad; Mukherjee, Anirban; Takada,
Yuri; Yamashita, Yasunobu; Morita, Mie; Horinaka, Mano; Sowa, Yoshihiro;
Masuda, Mitsuharu; Sakai, Toshiyuki; Suzuki, Takayoshi
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(10), 1568-1573

$RFMT $RIREG SCHEME4 STEP1
$RXN



  2  1
$MOL
4-(Bromomethyl)benzoic acid
C8H7BrO2
6232-88-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6687 4.6201 0.0 0
M  V30 5 Br 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethylamine
C2H7N
75-04-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 C 0.0000 0.7700 0.0 0
M  V30 3 N 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Bromomethyl)-N-ethylbenzamide
C10H12BrNO
566885-71-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 N 8.0023 2.3101 0.0 0
M  V30 3 O 6.6685 0.0000 0.0 0
M  V30 4 C 9.3360 1.5400 0.0 0
M  V30 5 C 10.6697 2.3101 0.0 0
M  V30 6 C 1.3337 4.6201 0.0 0
M  V30 7 Br 0.0000 3.8501 0.0 0
M  V30 8 C 5.3348 2.3101 0.0 0
M  V30 9 C 4.0012 1.5400 0.0 0
M  V30 10 C 5.3348 3.8501 0.0 0
M  V30 11 C 2.6673 2.3101 0.0 0
M  V30 12 C 4.0012 4.6201 0.0 0
M  V30 13 C 2.6673 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 6 7
M  V30 7 1 6 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6232-88-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 75-04-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 566885-71-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44298742
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to
Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Bing-yan; Li, Pei; Wei, Lin-yin; Zou, Jia; Wang, Yu-hang; You,
Qi-dong; Jiang, Cheng; Di, Bin; Xu, Li-li
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(12), 9869-9895

$RFMT $RIREG SCHEME5 STEP1
$RXN



  2  1
$MOL
Nicotinic acid
C6H5NO2
59-67-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 N 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-2-Propyn-1-yl-3-pyridinecarboxamide
C9H8N2O
18327-30-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 N 5.3348 2.3100 0.0 0
M  V30 3 O 4.0011 0.0000 0.0 0
M  V30 4 C 6.6684 1.5400 0.0 0
M  V30 5 C 8.0022 2.3100 0.0 0
M  V30 6 C 9.3359 3.0800 0.0 0
M  V30 7 C 2.6675 2.3100 0.0 0
M  V30 8 C 1.3337 1.5400 0.0 0
M  V30 9 C 2.6675 3.8500 0.0 0
M  V30 10 C 0.0000 2.3100 0.0 0
M  V30 11 N 1.3337 4.6201 0.0 0
M  V30 12 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 3 5 6
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 59-67-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 18327-30-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22706648
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM The bioisosteric modification of pyrazinamide derivatives led to potent
antitubercular agents: Synthesis via click approach and molecular docking
of pyrazine-1,2,3-triazoles
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Reddyrajula, Rajkumar; Dalimba, Udayakumar
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(2), 126846

$RFMT $RIREG SCHEME6 STEP1
$RXN



  2  1
$MOL
2-Pyrazinecarboxylic acid
C5H4N2O2
98-97-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 N 3.0801 2.6673 0.0 0
M  V30 7 N 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-2-Propyn-1-yl-2-pyrazinecarboxamide
C8H7N3O
1090998-64-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 N 5.3348 2.3100 0.0 0
M  V30 3 O 4.0011 0.0000 0.0 0
M  V30 4 C 6.6684 1.5400 0.0 0
M  V30 5 C 8.0022 2.3100 0.0 0
M  V30 6 C 9.3359 3.0800 0.0 0
M  V30 7 C 2.6675 2.3100 0.0 0
M  V30 8 C 1.3337 1.5400 0.0 0
M  V30 9 N 2.6675 3.8500 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 1.3337 4.6201 0.0 0
M  V30 12 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 3 5 6
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 98-97-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1090998-64-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22706647
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM The bioisosteric modification of pyrazinamide derivatives led to potent
antitubercular agents: Synthesis via click approach and molecular docking
of pyrazine-1,2,3-triazoles
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Reddyrajula, Rajkumar; Dalimba, Udayakumar
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(2), 126846

$RFMT $RIREG SCHEME7 STEP1
$RXN



  2  1
$MOL
4-(Bromomethyl)benzoic acid
C8H7BrO2
6232-88-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6687 4.6201 0.0 0
M  V30 5 Br 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propylamine
C3H9N
107-10-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 C 2.6673 0.7700 0.0 0
M  V30 3 C 0.0000 0.7700 0.0 0
M  V30 4 N 4.0010 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Bromomethyl)-N-propylbenzamide
C11H14BrNO
1225777-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 N 8.0022 2.3101 0.0 0
M  V30 3 O 6.6685 0.0000 0.0 0
M  V30 4 C 9.3360 1.5400 0.0 0
M  V30 5 C 10.6697 2.3101 0.0 0
M  V30 6 C 12.0033 1.5400 0.0 0
M  V30 7 C 1.3337 4.6201 0.0 0
M  V30 8 Br 0.0000 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 5.3348 3.8501 0.0 0
M  V30 11 C 4.0012 1.5400 0.0 0
M  V30 12 C 4.0012 4.6201 0.0 0
M  V30 13 C 2.6673 2.3101 0.0 0
M  V30 14 C 2.6673 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 7 8
M  V30 8 1 7 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6232-88-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 107-10-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1225777-88-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44298741
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to
Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Bing-yan; Li, Pei; Wei, Lin-yin; Zou, Jia; Wang, Yu-hang; You,
Qi-dong; Jiang, Cheng; Di, Bin; Xu, Li-li
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(12), 9869-9895

$RFMT $RIREG SCHEME8 STEP1
$RXN



  2  1
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phenylpropiolic acid
C9H6O2
637-44-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 6.1601 1.3337 0.0 0
M  V30 3 C 7.7002 1.3337 0.0 0
M  V30 4 O 8.4702 2.6673 0.0 0
M  V30 5 O 8.4702 0.0000 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 2.3101 2.6673 0.0 0
M  V30 8 C 2.3101 0.0000 0.0 0
M  V30 9 C 0.7700 2.6673 0.0 0
M  V30 10 C 0.7700 0.0000 0.0 0
M  V30 11 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 3 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N,3-Diphenyl-2-propynamide
C15H11NO
7342-02-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 5.3901 2.6673 0.0 0
M  V30 3 C 6.9302 2.6673 0.0 0
M  V30 4 O 4.6201 4.0010 0.0 0
M  V30 5 C 8.4702 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 2.3101 2.6673 0.0 0
M  V30 8 C 2.3101 0.0000 0.0 0
M  V30 9 C 0.7700 2.6673 0.0 0
M  V30 10 C 0.7700 0.0000 0.0 0
M  V30 11 C 0.0000 1.3337 0.0 0
M  V30 12 C 10.0102 2.6673 0.0 0
M  V30 13 C 10.7802 4.0010 0.0 0
M  V30 14 C 10.7802 1.3337 0.0 0
M  V30 15 C 12.3203 4.0010 0.0 0
M  V30 16 C 12.3203 1.3337 0.0 0
M  V30 17 C 13.0903 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 3 3 5
M  V30 6 1 5 12
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 8 10
M  V30 11 2 9 11
M  V30 12 1 10 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 637-44-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 7342-02-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41322613
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 4
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 67-56-1
$DTYPE RXN:VAR(1):NOTES
$DATUM alternate reaction conditions gave lower yield,alternative preparation
shown
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization and Development of a Scalable Palladium-Catalyzed C-H
Activation Process for the Geometry-Selective Preparation of Kilograms of
YLF466D, a Potent AMP-Activated Protein Kinase Activator
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yin, Jianpeng; Zhan, Desheng; Ma, Hui; Liu, Huanan; Yu, Lifang; Zhang,
Yangming; Nan, Fajun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(10), 2260-2269

$RFMT $RIREG SCHEME9 STEP1
$RXN



  2  1
$MOL
2-Nitrobenzoic acid
C7H5NO4
552-16-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 4.0011 0.0 0
M  V30 2 O 0.0000 4.0011 0.0 0
M  V30 3 O 2.3100 5.3349 0.0 0
M  V30 4 N 4.6200 4.0011 0.0 0 VAL=5
M  V30 5 O 3.8500 5.3349 0.0 0
M  V30 6 O 6.1600 4.0011 0.0 0
M  V30 7 C 2.3100 2.6674 0.0 0
M  V30 8 C 3.8500 2.6674 0.0 0
M  V30 9 C 1.5400 1.3338 0.0 0
M  V30 10 C 4.6200 1.3338 0.0 0
M  V30 11 C 2.3100 0.0000 0.0 0
M  V30 12 C 3.8500 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 8
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-Methyl-2-nitrobenzamide
C8H8N2O3
3400-29-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0011 0.0 0
M  V30 2 N 6.1600 4.0011 0.0 0
M  V30 3 O 3.8500 5.3349 0.0 0
M  V30 4 C 6.9300 5.3349 0.0 0
M  V30 5 N 1.5400 4.0011 0.0 0 VAL=5
M  V30 6 O 0.0000 4.0011 0.0 0
M  V30 7 O 2.3100 5.3349 0.0 0
M  V30 8 C 3.8500 2.6674 0.0 0
M  V30 9 C 2.3100 2.6674 0.0 0
M  V30 10 C 4.6200 1.3338 0.0 0
M  V30 11 C 1.5400 1.3338 0.0 0
M  V30 12 C 3.8500 0.0000 0.0 0
M  V30 13 C 2.3100 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 9
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 552-16-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3400-29-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36735488
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-05-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and evaluation of sulfonamide derivatives targeting
EGFR790M/L858R mutations and ALK rearrangement as anticancer agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Cao, Longcai; Yao, Han; Yu, Linlin; Ren, Yuanyuan; Liu, Jiadai; Li,
Xingshu; Jia, Xian
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2023), 85117241

$RFMT $RIREG SCHEME10 STEP1
$RXN



  2  1
$MOL
Isobutylamine
C4H11N
78-81-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 2.6673 2.3101 0.0 0
M  V30 3 C 1.3337 0.0000 0.0 0
M  V30 4 C 0.0000 2.3101 0.0 0
M  V30 5 N 4.0010 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Iodophenylacetic acid
C8H7IO2
1798-06-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6673 0.0 0
M  V30 2 C 6.9302 1.3337 0.0 0
M  V30 3 O 6.1601 0.0000 0.0 0
M  V30 4 O 8.4702 1.3337 0.0 0
M  V30 5 I 0.0000 2.6673 0.0 0
M  V30 6 C 4.6201 2.6673 0.0 0
M  V30 7 C 3.8501 4.0010 0.0 0
M  V30 8 C 3.8501 1.3337 0.0 0
M  V30 9 C 2.3101 4.0010 0.0 0
M  V30 10 C 2.3101 1.3337 0.0 0
M  V30 11 C 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, 4-iodo-N-(2-methylpropyl)-
C12H16INO
3054131-08-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 N 8.0022 1.5400 0.0 0
M  V30 4 O 6.6685 3.8501 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 C 10.6697 0.0000 0.0 0
M  V30 8 C 12.0033 2.3101 0.0 0
M  V30 9 I 0.0000 4.6201 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 1.5400 0.0 0
M  V30 12 C 4.0012 3.8501 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 9 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 78-81-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1798-06-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3054131-08-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39248679
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a novel lead characterized by a stilbene-extended scaffold
against sepsis as soluble epoxide hydrolase inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Feng, Zi-Qiang; Ding, Jing; Zhu, Min-Zhen; Xie, Wei-Song; Liu, Rui-Chen;
Liu, Si-Si; Liu, Si-Meng; Yu, Ming-Jia; Zhu, Xin-Hong; Liang, Jian-Hua
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 266116113

$RFMT $RIREG SCHEME11 STEP1
$RXN



  2  1
$MOL
4-Pyridinecarboxylic acid
C6H5NO2
55-22-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 N 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Isonicotinanilide
C12H10N2O
3034-31-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6673 0.0 0
M  V30 2 N 4.6201 1.3337 0.0 0
M  V30 3 O 4.6201 4.0010 0.0 0
M  V30 4 C 6.9302 2.6673 0.0 0
M  V30 5 C 7.7002 4.0010 0.0 0
M  V30 6 C 7.7002 1.3337 0.0 0
M  V30 7 C 9.2402 4.0010 0.0 0
M  V30 8 C 9.2402 1.3337 0.0 0
M  V30 9 N 10.0102 2.6673 0.0 0
M  V30 10 C 3.0801 1.3337 0.0 0
M  V30 11 C 2.3101 0.0000 0.0 0
M  V30 12 C 2.3101 2.6673 0.0 0
M  V30 13 C 0.7700 0.0000 0.0 0
M  V30 14 C 0.7700 2.6673 0.0 0
M  V30 15 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 2 10
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 8 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 55-22-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3034-31-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31442449
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 96-47-9
$DTYPE RXN:VAR(1):NOTES
$DATUM reaction conducted in the presence of air
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit
of the Polycomb Repressive Complex 2 Methyltransferase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bagal, Sharan K.; Gregson, Clare; O Donovan, Daniel H.; Pike, Kurt G.;
Bloecher, Andrew; Barton, Peter; Borodovsky, Alexandra; Code, Erin;
Fillery, Shaun M.; Hsu, Jessie Hao-Ru; Kawatkar, Sameer P.; Li, Chengzhi;
Longmire, David; Nai, Youfeng; Nash, Samuel C.; Pike, Andrew; Robinson,
James; Read, Jon A.; Rawlins, Phillip B.; Shen, Minhui; Tang, Jia; Wang,
Peng; Woods, Haley; Williamson, Beth
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(23), 17146-17183

$RFMT $RIREG SCHEME12 STEP1
$RXN



  2  1
$MOL
4-(Bromomethyl)benzoic acid
C8H7BrO2
6232-88-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6687 4.6201 0.0 0
M  V30 5 Br 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Butylamine
C4H11N
109-73-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0.7700 0.0 0
M  V30 2 C 1.3338 0.0000 0.0 0
M  V30 3 C 4.0010 0.0000 0.0 0
M  V30 4 C 0.0000 0.7700 0.0 0
M  V30 5 N 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Bromomethyl)-N-butylbenzamide
C12H16BrNO
118507-19-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 N 8.0022 2.3101 0.0 0
M  V30 3 O 6.6685 0.0000 0.0 0
M  V30 4 C 9.3360 1.5400 0.0 0
M  V30 5 C 10.6697 2.3101 0.0 0
M  V30 6 C 12.0033 1.5400 0.0 0
M  V30 7 C 13.3370 2.3101 0.0 0
M  V30 8 C 1.3337 4.6201 0.0 0
M  V30 9 Br 0.0000 3.8501 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 12 C 4.0010 1.5400 0.0 0
M  V30 13 C 4.0010 4.6201 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 2.6673 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 8 9
M  V30 9 1 8 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6232-88-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 109-73-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 118507-19-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44298740
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to
Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Bing-yan; Li, Pei; Wei, Lin-yin; Zou, Jia; Wang, Yu-hang; You,
Qi-dong; Jiang, Cheng; Di, Bin; Xu, Li-li
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(12), 9869-9895

$RFMT $RIREG SCHEME13 STEP1
$RXN



  2  1
$MOL
4-(Bromomethyl)benzoic acid
C8H7BrO2
6232-88-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6687 4.6201 0.0 0
M  V30 5 Br 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Pentylamine
C5H13N
110-58-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 0.7700 0.0 0
M  V30 2 C 4.0012 0.0000 0.0 0
M  V30 3 C 1.3338 0.0000 0.0 0
M  V30 4 C 5.3348 0.7700 0.0 0
M  V30 5 C 0.0000 0.7700 0.0 0
M  V30 6 N 6.6687 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Bromomethyl)-N-pentylbenzamide
C13H18BrNO
1225982-52-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 N 8.0022 2.3101 0.0 0
M  V30 3 O 6.6685 0.0000 0.0 0
M  V30 4 C 9.3358 1.5400 0.0 0
M  V30 5 C 10.6697 2.3101 0.0 0
M  V30 6 C 12.0033 1.5400 0.0 0
M  V30 7 C 13.3370 2.3101 0.0 0
M  V30 8 C 14.6707 1.5400 0.0 0
M  V30 9 C 1.3337 4.6201 0.0 0
M  V30 10 Br 0.0000 3.8501 0.0 0
M  V30 11 C 5.3348 2.3101 0.0 0
M  V30 12 C 4.0010 1.5400 0.0 0
M  V30 13 C 5.3348 3.8501 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 4.0010 4.6201 0.0 0
M  V30 16 C 2.6673 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 9 10
M  V30 10 1 9 16
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6232-88-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 110-58-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1225982-52-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44298735
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to
Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Bing-yan; Li, Pei; Wei, Lin-yin; Zou, Jia; Wang, Yu-hang; You,
Qi-dong; Jiang, Cheng; Di, Bin; Xu, Li-li
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(12), 9869-9895

$RFMT $RIREG SCHEME14 STEP1
$RXN



  2  1
$MOL
2-Amino-4-bromobenzoic acid
C7H6BrNO2
20776-50-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 Br 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-bromo-N-methylbenzamide
C8H9BrN2O
864866-77-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 2.6673 0.0 0
M  V30 2 N 1.5400 4.0010 0.0 0
M  V30 3 O 1.5400 1.3337 0.0 0
M  V30 4 C 0.0000 4.0010 0.0 0
M  V30 5 N 3.8501 0.0000 0.0 0
M  V30 6 Br 8.4702 2.6673 0.0 0
M  V30 7 C 3.8501 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 6.1601 1.3337 0.0 0
M  V30 11 C 6.1601 4.0010 0.0 0
M  V30 12 C 6.9302 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 8
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 20776-50-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 864866-77-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35966979
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 64-17-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials
Targeting PfATP4
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ashton, Trent D.; Dans, Madeline G.; Favuzza, Paola; Ngo, Anna; Lehane,
Adele M.; Zhang, Xinxin; Qiu, Deyun; Chandra Maity, Bikash; De, Nirupam;
Schindler, Kyra A.; Yeo, Tomas; Park, Heekuk; Uhlemann, Anne-Catrin;
Churchyard, Alisje; Baum, Jake; Fidock, David A.; Jarman, Kate E.; Lowes,
Kym N.; Baud, Delphine; Brand, Stephen; Jackson, Paul F.; Cowman, Alan
F.; Sleebs, Brad E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3540-3565

$RFMT $RIREG SCHEME15 STEP1
$RXN



  2  1
$MOL
2-Amino-4-chlorobenzoic acid
C7H6ClNO2
89-77-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 Cl 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-chloro-N-methylbenzamide
C8H9ClN2O
104775-66-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 2.6673 0.0 0
M  V30 2 N 1.5400 4.0010 0.0 0
M  V30 3 O 1.5400 1.3337 0.0 0
M  V30 4 C 0.0000 4.0010 0.0 0
M  V30 5 N 3.8501 0.0000 0.0 0
M  V30 6 Cl 8.4702 2.6673 0.0 0
M  V30 7 C 3.8501 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 6.1601 1.3337 0.0 0
M  V30 11 C 6.1601 4.0010 0.0 0
M  V30 12 C 6.9302 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 8
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 89-77-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 104775-66-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35966982
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 64-17-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials
Targeting PfATP4
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ashton, Trent D.; Dans, Madeline G.; Favuzza, Paola; Ngo, Anna; Lehane,
Adele M.; Zhang, Xinxin; Qiu, Deyun; Chandra Maity, Bikash; De, Nirupam;
Schindler, Kyra A.; Yeo, Tomas; Park, Heekuk; Uhlemann, Anne-Catrin;
Churchyard, Alisje; Baum, Jake; Fidock, David A.; Jarman, Kate E.; Lowes,
Kym N.; Baud, Delphine; Brand, Stephen; Jackson, Paul F.; Cowman, Alan
F.; Sleebs, Brad E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3540-3565

$RFMT $RIREG SCHEME16 STEP1
$RXN



  2  1
$MOL
2-Amino-4-fluorobenzoic acid
C7H6FNO2
446-32-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 F 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-fluoro-N-methylbenzamide
C8H9FN2O
917343-25-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 2.6673 0.0 0
M  V30 2 N 1.5400 4.0010 0.0 0
M  V30 3 O 1.5400 1.3337 0.0 0
M  V30 4 C 0.0000 4.0010 0.0 0
M  V30 5 N 3.8501 0.0000 0.0 0
M  V30 6 F 8.4702 2.6673 0.0 0
M  V30 7 C 3.8501 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 6.1601 1.3337 0.0 0
M  V30 11 C 6.1601 4.0010 0.0 0
M  V30 12 C 6.9302 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 8
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 446-32-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 917343-25-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35966986
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 64-17-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials
Targeting PfATP4
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ashton, Trent D.; Dans, Madeline G.; Favuzza, Paola; Ngo, Anna; Lehane,
Adele M.; Zhang, Xinxin; Qiu, Deyun; Chandra Maity, Bikash; De, Nirupam;
Schindler, Kyra A.; Yeo, Tomas; Park, Heekuk; Uhlemann, Anne-Catrin;
Churchyard, Alisje; Baum, Jake; Fidock, David A.; Jarman, Kate E.; Lowes,
Kym N.; Baud, Delphine; Brand, Stephen; Jackson, Paul F.; Cowman, Alan
F.; Sleebs, Brad E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3540-3565

$RFMT $RIREG SCHEME17 STEP1
$RXN



  2  1
$MOL
1-Naphthaleneacetic acid
C12H10O2
86-87-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 2.3100 0.0 0
M  V30 2 C 6.6685 3.0800 0.0 0
M  V30 3 O 6.6685 4.6200 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 C 2.6674 2.3100 0.0 0
M  V30 6 C 1.3336 3.0800 0.0 0
M  V30 7 C 4.0011 3.0800 0.0 0
M  V30 8 C 2.6674 0.7700 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 C 0.0000 2.3100 0.0 0
M  V30 11 C 4.0011 4.6200 0.0 0
M  V30 12 C 1.3336 0.0000 0.0 0
M  V30 13 C 2.6674 5.3900 0.0 0
M  V30 14 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 2 9 13
M  V30 13 2 10 14
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-2-Propyn-1-yl-1-naphthaleneacetamide
C15H13NO
19762-30-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 2.3101 0.0 0
M  V30 2 C 6.6685 3.0801 0.0 0
M  V30 3 N 8.0022 2.3101 0.0 0
M  V30 4 O 6.6685 4.6201 0.0 0
M  V30 5 C 9.3360 3.0801 0.0 0
M  V30 6 C 10.6697 2.3101 0.0 0
M  V30 7 C 12.0033 1.5400 0.0 0
M  V30 8 C 2.6673 2.3101 0.0 0
M  V30 9 C 4.0012 3.0801 0.0 0
M  V30 10 C 1.3337 3.0801 0.0 0
M  V30 11 C 2.6673 0.7700 0.0 0
M  V30 12 C 4.0012 4.6201 0.0 0
M  V30 13 C 1.3337 4.6201 0.0 0
M  V30 14 C 0.0000 2.3101 0.0 0
M  V30 15 C 1.3337 0.0000 0.0 0
M  V30 16 C 2.6673 5.3901 0.0 0
M  V30 17 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 3 6 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 11
M  V30 11 2 9 12
M  V30 12 1 10 13
M  V30 13 1 10 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 2 13 16
M  V30 17 2 14 17
M  V30 18 1 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 86-87-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 19762-30-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37043008
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM NSAID-Au(I) Complexes Induce ROS-Driven DAMPs and Interpose Inflammation
to Stimulate the Immune Response against Ovarian Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Xu, Zhongren; Lu, Qiuyue; Shan, Min; Jiang, Guizhi; Liu, Yuanhao; Yang,
Zhibin; Lu, Yunlong; Liu, Wukun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(12), 7813-7833

$RFMT $RIREG SCHEME18 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-3-fluorobenzoic acid
C7H6FNO2
825-22-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 3.0800 0.0 0
M  V30 2 O 6.6685 2.3100 0.0 0
M  V30 3 O 5.3347 4.6200 0.0 0
M  V30 4 N 2.6674 4.6200 0.0 0
M  V30 5 F 0.0000 3.0800 0.0 0
M  V30 6 C 4.0011 2.3100 0.0 0
M  V30 7 C 2.6674 3.0800 0.0 0
M  V30 8 C 4.0011 0.7700 0.0 0
M  V30 9 C 1.3338 2.3100 0.0 0
M  V30 10 C 2.6674 0.0000 0.0 0
M  V30 11 C 1.3338 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-3-fluoro-N-methylbenzamide
C8H9FN2O
1017789-26-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 3.0800 0.0 0
M  V30 2 N 6.6685 2.3100 0.0 0
M  V30 3 O 5.3347 4.6200 0.0 0
M  V30 4 C 8.0021 3.0800 0.0 0
M  V30 5 N 2.6674 4.6200 0.0 0
M  V30 6 F 0.0000 3.0800 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 2.6674 3.0800 0.0 0
M  V30 9 C 4.0011 0.7700 0.0 0
M  V30 10 C 1.3336 2.3100 0.0 0
M  V30 11 C 2.6674 0.0000 0.0 0
M  V30 12 C 1.3336 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 8
M  V30 6 1 6 10
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 825-22-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1017789-26-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35966994
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials
Targeting PfATP4
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ashton, Trent D.; Dans, Madeline G.; Favuzza, Paola; Ngo, Anna; Lehane,
Adele M.; Zhang, Xinxin; Qiu, Deyun; Chandra Maity, Bikash; De, Nirupam;
Schindler, Kyra A.; Yeo, Tomas; Park, Heekuk; Uhlemann, Anne-Catrin;
Churchyard, Alisje; Baum, Jake; Fidock, David A.; Jarman, Kate E.; Lowes,
Kym N.; Baud, Delphine; Brand, Stephen; Jackson, Paul F.; Cowman, Alan
F.; Sleebs, Brad E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3540-3565

$RFMT $RIREG SCHEME19 STEP1
$RXN



  2  1
$MOL
4-(Bromomethyl)benzoic acid
C8H7BrO2
6232-88-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6687 4.6201 0.0 0
M  V30 5 Br 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Methoxyethylamine
C3H9NO
109-85-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0.7700 0.0 0
M  V30 2 C 1.3338 0.0000 0.0 0
M  V30 3 O 4.0010 0.0000 0.0 0
M  V30 4 N 0.0000 0.7700 0.0 0
M  V30 5 C 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Bromomethyl)-N-(2-methoxyethyl)benzamide
C11H14BrNO2
1225949-34-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 N 8.0022 2.3101 0.0 0
M  V30 3 O 6.6685 0.0000 0.0 0
M  V30 4 C 9.3360 1.5400 0.0 0
M  V30 5 C 10.6697 2.3101 0.0 0
M  V30 6 O 12.0033 1.5400 0.0 0
M  V30 7 C 13.3370 2.3101 0.0 0
M  V30 8 C 1.3337 4.6201 0.0 0
M  V30 9 Br 0.0000 3.8501 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 12 C 4.0010 1.5400 0.0 0
M  V30 13 C 4.0010 4.6201 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 2.6673 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 8 9
M  V30 9 1 8 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6232-88-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 109-85-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1225949-34-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44298736
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to
Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Bing-yan; Li, Pei; Wei, Lin-yin; Zou, Jia; Wang, Yu-hang; You,
Qi-dong; Jiang, Cheng; Di, Bin; Xu, Li-li
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(12), 9869-9895

$RFMT $RIREG SCHEME20 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-chlorobenzoic acid
C7H6ClNO2
635-21-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 Cl 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-chloro-N-methylbenzamide
C8H9ClN2O
19178-37-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6675 0.0 0
M  V30 2 N 5.3901 4.0011 0.0 0
M  V30 3 O 5.3901 1.3338 0.0 0
M  V30 4 C 6.9301 4.0011 0.0 0
M  V30 5 N 3.0800 0.0000 0.0 0
M  V30 6 Cl 0.0000 5.3349 0.0 0
M  V30 7 C 3.0800 2.6675 0.0 0
M  V30 8 C 2.3100 1.3338 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 0.7700 1.3338 0.0 0
M  V30 11 C 0.7700 4.0011 0.0 0
M  V30 12 C 0.0000 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 8
M  V30 6 1 6 11
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 635-21-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 19178-37-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35967000
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials
Targeting PfATP4
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ashton, Trent D.; Dans, Madeline G.; Favuzza, Paola; Ngo, Anna; Lehane,
Adele M.; Zhang, Xinxin; Qiu, Deyun; Chandra Maity, Bikash; De, Nirupam;
Schindler, Kyra A.; Yeo, Tomas; Park, Heekuk; Uhlemann, Anne-Catrin;
Churchyard, Alisje; Baum, Jake; Fidock, David A.; Jarman, Kate E.; Lowes,
Kym N.; Baud, Delphine; Brand, Stephen; Jackson, Paul F.; Cowman, Alan
F.; Sleebs, Brad E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3540-3565

$RFMT $RIREG SCHEME21 STEP1
$RXN



  2  1
$MOL
2-Amino-6-fluorobenzoic acid
C7H6FNO2
434-76-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 1.3338 0.0 0
M  V30 3 O 0.0000 4.0012 0.0 0
M  V30 4 F 2.3101 5.3350 0.0 0
M  V30 5 N 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6675 0.0 0
M  V30 7 C 3.0801 4.0012 0.0 0
M  V30 8 C 3.0801 1.3338 0.0 0
M  V30 9 C 4.6201 4.0012 0.0 0
M  V30 10 C 4.6201 1.3338 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 8
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-6-fluoro-N-methylbenzamide
C8H9FN2O
869936-86-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6675 0.0 0
M  V30 2 N 5.3901 4.0011 0.0 0
M  V30 3 O 5.3901 1.3338 0.0 0
M  V30 4 C 6.9301 4.0011 0.0 0
M  V30 5 F 3.0800 0.0000 0.0 0
M  V30 6 N 3.0800 5.3349 0.0 0
M  V30 7 C 3.0800 2.6675 0.0 0
M  V30 8 C 2.3100 1.3338 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 0.7700 1.3338 0.0 0
M  V30 11 C 0.7700 4.0011 0.0 0
M  V30 12 C 0.0000 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 8
M  V30 6 1 6 9
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 434-76-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 869936-86-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35966990
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials
Targeting PfATP4
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ashton, Trent D.; Dans, Madeline G.; Favuzza, Paola; Ngo, Anna; Lehane,
Adele M.; Zhang, Xinxin; Qiu, Deyun; Chandra Maity, Bikash; De, Nirupam;
Schindler, Kyra A.; Yeo, Tomas; Park, Heekuk; Uhlemann, Anne-Catrin;
Churchyard, Alisje; Baum, Jake; Fidock, David A.; Jarman, Kate E.; Lowes,
Kym N.; Baud, Delphine; Brand, Stephen; Jackson, Paul F.; Cowman, Alan
F.; Sleebs, Brad E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3540-3565

$RFMT $RIREG SCHEME22 STEP1
$RXN



  2  1
$MOL
2-Amino-5-fluorobenzoic acid
C7H6FNO2
446-08-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 F 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-fluoro-N-methylbenzamide
C8H9FN2O
773846-62-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6675 0.0 0
M  V30 2 N 5.3901 4.0011 0.0 0
M  V30 3 O 5.3901 1.3338 0.0 0
M  V30 4 C 6.9301 4.0011 0.0 0
M  V30 5 N 3.0800 0.0000 0.0 0
M  V30 6 F 0.0000 5.3349 0.0 0
M  V30 7 C 3.0800 2.6675 0.0 0
M  V30 8 C 2.3100 1.3338 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 0.7700 1.3338 0.0 0
M  V30 11 C 0.7700 4.0011 0.0 0
M  V30 12 C 0.0000 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 8
M  V30 6 1 6 11
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 446-08-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 773846-62-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35966995
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials
Targeting PfATP4
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ashton, Trent D.; Dans, Madeline G.; Favuzza, Paola; Ngo, Anna; Lehane,
Adele M.; Zhang, Xinxin; Qiu, Deyun; Chandra Maity, Bikash; De, Nirupam;
Schindler, Kyra A.; Yeo, Tomas; Park, Heekuk; Uhlemann, Anne-Catrin;
Churchyard, Alisje; Baum, Jake; Fidock, David A.; Jarman, Kate E.; Lowes,
Kym N.; Baud, Delphine; Brand, Stephen; Jackson, Paul F.; Cowman, Alan
F.; Sleebs, Brad E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3540-3565

$RFMT $RIREG SCHEME23 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Bromo-5-methoxybenzoic acid
C8H7BrO3
157893-14-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 4.6201 0.0 0
M  V30 2 O 1.3337 6.1601 0.0 0
M  V30 3 O 0.0000 3.8500 0.0 0
M  V30 4 O 6.6686 4.6201 0.0 0
M  V30 5 C 8.0022 3.8500 0.0 0
M  V30 6 Br 4.0011 0.0000 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 4.0011 4.6201 0.0 0
M  V30 9 C 2.6675 2.3100 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 11 C 4.0011 1.5400 0.0 0
M  V30 12 C 5.3348 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 5
M  V30 5 1 4 10
M  V30 6 1 6 11
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Bromo-5-methoxy-N-methylbenzamide
C9H10BrNO2
2211082-88-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 8.0023 3.8501 0.0 0
M  V30 3 O 6.6685 6.1601 0.0 0
M  V30 4 C 9.3360 4.6201 0.0 0
M  V30 5 O 1.3337 4.6201 0.0 0
M  V30 6 C 0.0000 3.8501 0.0 0
M  V30 7 Br 4.0012 0.0000 0.0 0
M  V30 8 C 5.3348 3.8501 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 2.6675 3.8501 0.0 0
M  V30 12 C 4.0012 1.5400 0.0 0
M  V30 13 C 2.6675 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 11
M  V30 7 1 7 12
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 157893-14-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2211082-88-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-43930961
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM combinatorial
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Integrating a phenotypic screening with a structural simplification
strategy to identify 4-phenoxy-quinoline derivatives to potently disrupt
the mitotic localization of Aurora kinase B
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Lv, Gang; Shi, Qiong; Zhang, Ting; Li, Jinhua; Long, Yan; Zhang, Wenhui;
Choudhry, Namrta; Yang, Kevin; Li, Hongmei; Kalashova, Julia; Yang,
Chenglu; Zhou, Xiaohu; Reddy, Mallu Chenna; Anantoju, Kishore Kumar;
Zhang, Shenqiu; Zhang, Jing; Allen, Thaddeus D.; Liu, Hong; Nimishetti,
Naganna; Yang, Dun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2023), 80117173

$RFMT $RIREG SCHEME24 STEP1
$RXN



  2  1
$MOL
()-1-Amino-2-propanol
C3H9NO
78-96-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 2.6673 2.3101 0.0 0
M  V30 3 C 1.3337 0.0000 0.0 0
M  V30 4 O 0.0000 2.3101 0.0 0
M  V30 5 N 4.0010 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Phenylsulfonyl)butanoic acid
C10H12O4S
6178-52-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 4.6200 4.0009 0.0 0 VAL=6
M  V30 2 C 6.1600 4.0009 0.0 0
M  V30 3 O 4.6200 2.4609 0.0 0
M  V30 4 O 4.6200 5.5409 0.0 0
M  V30 5 C 6.9300 2.6673 0.0 0
M  V30 6 C 8.4700 2.6673 0.0 0
M  V30 7 C 9.2400 1.3336 0.0 0
M  V30 8 O 10.7800 1.3336 0.0 0
M  V30 9 O 8.4700 0.0000 0.0 0
M  V30 10 C 3.0800 4.0009 0.0 0
M  V30 11 C 2.3100 2.6673 0.0 0
M  V30 12 C 2.3100 5.3347 0.0 0
M  V30 13 C 0.7700 2.6673 0.0 0
M  V30 14 C 0.7700 5.3347 0.0 0
M  V30 15 C 0.0000 4.0009 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(2-Hydroxypropyl)-4-(phenylsulfonyl)butanamide
C13H19NO4S
2334110-56-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 4.0010 3.0801 0.0 0 VAL=6
M  V30 2 C 5.3348 3.8501 0.0 0
M  V30 3 O 4.7710 1.7464 0.0 0
M  V30 4 O 3.2310 4.4137 0.0 0
M  V30 5 C 6.6685 3.0801 0.0 0
M  V30 6 C 8.0022 3.8501 0.0 0
M  V30 7 C 9.3358 3.0801 0.0 0
M  V30 8 N 10.6697 3.8501 0.0 0
M  V30 9 O 9.3358 1.5400 0.0 0
M  V30 10 C 12.0033 3.0801 0.0 0
M  V30 11 C 13.3370 3.8501 0.0 0
M  V30 12 C 13.3370 5.3901 0.0 0
M  V30 13 O 14.6707 3.0801 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 2.6673 0.7700 0.0 0
M  V30 16 C 1.3337 3.0801 0.0 0
M  V30 17 C 1.3337 0.0000 0.0 0
M  V30 18 C 0.0000 2.3101 0.0 0
M  V30 19 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 14
M  V30 5 1 2 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 78-96-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6178-52-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2334110-56-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41763296
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Efficient Total Synthesis of Bilirubin IX from Butyrolactone
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chen, Fapu; Chen, Yage; Luo, Zhanglong; Pan, Feng; Zhao, Xiliang; Zhou,
Jun; Chen, Rui; Eisen, Moris S.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2024), 28(7), 2777-2788

$RFMT $RIREG SCHEME25 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Pyridazinecarboxylic acid, 4,6-dichloro-, lithium salt (1:1)
C5H2Cl2N2O2.Li
2245238-80-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 4.2073 0.0 0
M  V30 2 O 0.0000 5.5410 0.0 0
M  V30 3 O 0.0000 2.8737 0.0 0
M  V30 4 Cl 2.3101 1.5400 0.0 0
M  V30 5 Cl 6.9302 4.2073 0.0 0
M  V30 6 C 2.3101 4.2073 0.0 0
M  V30 7 C 3.0801 2.8737 0.0 0
M  V30 8 N 3.0801 5.5410 0.0 0
M  V30 9 C 4.6201 2.8737 0.0 0
M  V30 10 N 4.6201 5.5410 0.0 0
M  V30 11 C 5.3901 4.2073 0.0 0
M  V30 12 Li 3.4651 0.0000 0.0 0 VAL=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4,6-Dichloro-N-(methyl-d3)-3-pyridazinecarboxamide
C6H2Cl2D3N3O
1609393-89-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.6674 0.0 0
M  V30 2 N 3.0800 4.0011 0.0 0
M  V30 3 O 3.0800 1.3338 0.0 0
M  V30 4 C 1.5400 4.0011 0.0 0
M  V30 5 Cl 5.3900 0.0000 0.0 0
M  V30 6 Cl 10.0100 2.6674 0.0 0
M  V30 7 C 5.3900 2.6674 0.0 0
M  V30 8 C 6.1600 1.3338 0.0 0
M  V30 9 N 6.1600 4.0011 0.0 0
M  V30 10 C 7.7000 1.3338 0.0 0
M  V30 11 N 7.7000 4.0011 0.0 0
M  V30 12 C 8.4700 2.6674 0.0 0
M  V30 13 H 0.7700 2.6674 0.0 0 MASS=2
M  V30 14 H 0.0000 4.0011 0.0 0 MASS=2
M  V30 15 H 0.7700 5.3349 0.0 0 MASS=2
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 4 13
M  V30 6 1 4 14
M  V30 7 1 4 15
M  V30 8 1 5 8
M  V30 9 1 6 12
M  V30 10 2 7 8
M  V30 11 1 7 9
M  V30 12 1 8 10
M  V30 13 2 9 11
M  V30 14 2 10 12
M  V30 15 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2245238-80-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1609393-89-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34405403
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide
Skeleton for the Treatment of Autoimmune Diseases
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liu, Fei; Wang, Bin; Liu, Yanlong; Shi, Wei; Tang, Xujing; Wang, Xiaojin;
Hu, Zhongyuan; Zhang, Ying; Guo, Yahui; Chang, Xiayun; He, Xiangyi; Xu,
Hongjiang; He, Ying
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(11), 1730-1738

$RFMT $RIREG SCHEME26 STEP1
$RXN



  2  1
$MOL
2,2,2-Trifluoroethylamine
C2H4F3N
753-90-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.3337 0.0 0
M  V30 2 C 2.6673 2.1037 0.0 0
M  V30 3 F 2.1037 0.0000 0.0 0
M  V30 4 F 0.0000 0.5637 0.0 0
M  V30 5 F 0.5637 2.6673 0.0 0
M  V30 6 N 4.0010 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-2-thiophenecarboxylic acid
C5H3BrO2S
7311-63-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 Br 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 S 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 C 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N-(2,2,2-trifluoroethyl)-2-thiophenecarboxamide
C7H5BrF3NOS
1247648-41-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 2.6675 1.5400 0.0 0
M  V30 5 C 1.3338 2.3101 0.0 0
M  V30 6 F 0.0000 3.0801 0.0 0
M  V30 7 F 0.5638 0.9764 0.0 0
M  V30 8 F 2.1038 3.6437 0.0 0
M  V30 9 Br 10.6376 2.6672 0.0 0
M  V30 10 C 6.6687 2.3101 0.0 0
M  V30 11 S 8.0755 1.6836 0.0 0
M  V30 12 C 6.8296 3.8416 0.0 0
M  V30 13 C 9.1059 2.8281 0.0 0
M  V30 14 C 8.3359 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 13
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 753-90-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7311-63-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1247648-41-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39327164
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of potent and selective ULK1/2 inhibitors based on
7-azaindole scaffold with favorable in vivo properties
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Morozova, Alisa; Chan, Sean Chin; Bayle, Simon; Sun, Luxin; Grassie,
Dylan; Iermolaieva, Anna; Kalaga, Mahalakshmi N.; Frydman, Sylvia;
Sansil, Samer; Schonbrunn, Ernst; Duckett, Derek; Monastyrskyi, Andrii
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 266116101

$RFMT $RIREG SCHEME27 STEP1
$RXN



  2  1
$MOL
4-(Bromomethyl)benzoic acid
C8H7BrO2
6232-88-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6687 4.6201 0.0 0
M  V30 5 Br 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Methoxypropylamine
C4H11NO
5332-73-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 0.7700 0.0 0
M  V30 2 C 4.0012 0.0000 0.0 0
M  V30 3 C 1.3338 0.0000 0.0 0
M  V30 4 O 5.3348 0.7700 0.0 0
M  V30 5 N 0.0000 0.7700 0.0 0
M  V30 6 C 6.6687 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Bromomethyl)-N-(3-methoxypropyl)benzamide
C12H16BrNO2
1108194-39-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 N 8.0022 2.3101 0.0 0
M  V30 3 O 6.6685 0.0000 0.0 0
M  V30 4 C 9.3358 1.5400 0.0 0
M  V30 5 C 10.6697 2.3101 0.0 0
M  V30 6 C 12.0033 1.5400 0.0 0
M  V30 7 O 13.3370 2.3101 0.0 0
M  V30 8 C 14.6707 1.5400 0.0 0
M  V30 9 C 1.3337 4.6201 0.0 0
M  V30 10 Br 0.0000 3.8501 0.0 0
M  V30 11 C 5.3348 2.3101 0.0 0
M  V30 12 C 4.0010 1.5400 0.0 0
M  V30 13 C 5.3348 3.8501 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 4.0010 4.6201 0.0 0
M  V30 16 C 2.6673 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 9 10
M  V30 10 1 9 16
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6232-88-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5332-73-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1108194-39-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44298691
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to
Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Bing-yan; Li, Pei; Wei, Lin-yin; Zou, Jia; Wang, Yu-hang; You,
Qi-dong; Jiang, Cheng; Di, Bin; Xu, Li-li
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(12), 9869-9895

$RFMT $RIREG SCHEME28 STEP1
$RXN



  2  1
$MOL
2,2,2-Trifluoroethylamine
C2H4F3N
753-90-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.3337 0.0 0
M  V30 2 C 2.6673 2.1037 0.0 0
M  V30 3 F 2.1037 0.0000 0.0 0
M  V30 4 F 0.0000 0.5637 0.0 0
M  V30 5 F 0.5637 2.6673 0.0 0
M  V30 6 N 4.0010 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Bromo-5-thiazolecarboxylic acid
C4H2BrNO2S
54045-76-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 Br 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 S 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 N 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Thiazolecarboxamide, 2-bromo-N-(2,2,2-trifluoroethyl)-
C6H4BrF3N2OS
2922532-52-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 2.6675 1.5400 0.0 0
M  V30 5 C 1.3338 2.3101 0.0 0
M  V30 6 F 0.0000 3.0801 0.0 0
M  V30 7 F 0.5638 0.9764 0.0 0
M  V30 8 F 2.1038 3.6437 0.0 0
M  V30 9 Br 10.6376 2.6672 0.0 0
M  V30 10 C 6.6687 2.3101 0.0 0
M  V30 11 S 8.0755 1.6836 0.0 0
M  V30 12 C 6.8296 3.8416 0.0 0
M  V30 13 C 9.1059 2.8281 0.0 0
M  V30 14 N 8.3359 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 13
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 753-90-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 54045-76-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2922532-52-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39327168
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of potent and selective ULK1/2 inhibitors based on
7-azaindole scaffold with favorable in vivo properties
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Morozova, Alisa; Chan, Sean Chin; Bayle, Simon; Sun, Luxin; Grassie,
Dylan; Iermolaieva, Anna; Kalaga, Mahalakshmi N.; Frydman, Sylvia;
Sansil, Samer; Schonbrunn, Ernst; Duckett, Derek; Monastyrskyi, Andrii
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 266116101

$RFMT $RIREG SCHEME29 STEP1
$RXN



  2  1
$MOL
3-Formylbenzoic acid
C8H6O3
619-21-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 1.3337 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 C 6.6687 1.5400 0.0 0
M  V30 5 O 8.0023 2.3101 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 2 4 5
M  V30 5 1 4 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(S)-1-Phenylethylamine
C8H11N
2627-86-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0 CFG=1
M  V30 2 C 0.0000 2.6673 0.0 0
M  V30 3 N 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
3-Formyl-N-[(1S)-1-phenylethyl]benzamide
C16H15NO2
2852783-67-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 O 6.6685 0.0000 0.0 0
M  V30 4 C 4.0010 1.5400 0.0 0 CFG=2
M  V30 5 C 4.0010 0.0000 0.0 0
M  V30 6 C 12.0033 1.5400 0.0 0
M  V30 7 O 13.3370 2.3101 0.0 0
M  V30 8 C 8.0022 2.3101 0.0 0
M  V30 9 C 9.3360 1.5400 0.0 0
M  V30 10 C 8.0022 3.8501 0.0 0
M  V30 11 C 10.6697 2.3101 0.0 0
M  V30 12 C 9.3360 4.6201 0.0 0
M  V30 13 C 10.6697 3.8501 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 1.3337 1.5400 0.0 0
M  V30 16 C 2.6673 3.8501 0.0 0
M  V30 17 C 0.0000 2.3101 0.0 0
M  V30 18 C 1.3337 4.6201 0.0 0
M  V30 19 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=1
M  V30 6 1 4 14
M  V30 7 2 6 7
M  V30 8 1 6 11
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 619-21-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2627-86-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2852783-67-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34588037
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 5
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the
Treatment of Malaria
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM de Lera Ruiz, Manuel; Favuzza, Paola; Guo, Zhuyan; Zhao, Lianyun; Hu,
Bin; Lei, Zhiyu; Zhan, Dongmei; Murgolo, Nicholas; Boyce, Christopher W.;
Vavrek, Marissa; Thompson, Jennifer; Ngo, Anna; Jarman, Kate E.; Robbins,
Johnathan; Boddey, Justin; Sleebs, Brad E.; Lowes, Kym N.; Cowman, Alan
F.; Olsen, David B.; McCauley, John A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(11), 1745-1754

$RFMT $RIREG SCHEME30 STEP1
$RXN



  2  1
$MOL
2-Chloroethylamine hydrochloride
C2H6ClN.ClH
870-24-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 2.6673 2.3100 0.0 0
M  V30 3 Cl 0.0000 2.3100 0.0 0
M  V30 4 N 4.0010 1.5400 0.0 0
M  V30 5 Cl 2.0005 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Methyl-1H-pyrrole-2-carboxylic acid
C6H7NO2
90724-57-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 1.5400 0.0 0
M  V30 2 O 5.1049 2.3100 0.0 0
M  V30 3 O 3.7711 0.0000 0.0 0
M  V30 4 C 0.7104 0.1773 0.0 0
M  V30 5 C 2.4374 2.3100 0.0 0
M  V30 6 C 1.0306 1.6836 0.0 0
M  V30 7 N 2.2765 3.8416 0.0 0
M  V30 8 C 0.0000 2.8281 0.0 0
M  V30 9 C 0.7700 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(2-Chloroethyl)-3-methyl-1H-pyrrole-2-carboxamide
C8H11ClN2O
2411226-25-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 2.6218 0.0 0
M  V30 2 N 5.1048 1.8517 0.0 0
M  V30 3 O 3.7711 4.1618 0.0 0
M  V30 4 C 6.4386 2.6218 0.0 0
M  V30 5 C 7.7722 1.8517 0.0 0
M  V30 6 Cl 9.1059 2.6218 0.0 0
M  V30 7 C 0.7103 3.9845 0.0 0
M  V30 8 C 2.4374 1.8517 0.0 0
M  V30 9 C 1.0304 2.4782 0.0 0
M  V30 10 N 2.2763 0.3202 0.0 0
M  V30 11 C 0.0000 1.3337 0.0 0
M  V30 12 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 7 9
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 870-24-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 90724-57-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2411226-25-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24357848
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as
Highly Potent and Selective Bromodomain and Extra-Terminal (BET)
Bromodomain Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Zizhou; Xiao, Senhao; Yang, Yaxi; Chen, Chao; Lu, Tian; Chen,
Zhifeng; Jiang, Hualiang; Chen, Shijie; Luo, Cheng; Zhou, Bing
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(8), 3956-3975

$RFMT $RIREG SCHEME31 STEP1
$RXN



  2  1
$MOL
3,5-Dimethylaniline
C8H11N
108-69-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 4.6200 0.0 0
M  V30 2 C 5.3349 4.6200 0.0 0
M  V30 3 N 2.6674 0.0000 0.0 0
M  V30 4 C 2.6674 4.6200 0.0 0
M  V30 5 C 1.3338 3.8500 0.0 0
M  V30 6 C 4.0011 3.8500 0.0 0
M  V30 7 C 1.3338 2.3100 0.0 0
M  V30 8 C 4.0011 2.3100 0.0 0
M  V30 9 C 2.6674 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 5
M  V30 2 1 2 6
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Hydroxyphenylacetic acid
C8H8O3
156-38-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6673 0.0 0
M  V30 2 C 6.9302 1.3337 0.0 0
M  V30 3 O 6.1601 0.0000 0.0 0
M  V30 4 O 8.4702 1.3337 0.0 0
M  V30 5 O 0.0000 2.6673 0.0 0
M  V30 6 C 4.6201 2.6673 0.0 0
M  V30 7 C 3.8501 4.0010 0.0 0
M  V30 8 C 3.8501 1.3337 0.0 0
M  V30 9 C 2.3101 4.0010 0.0 0
M  V30 10 C 2.3101 1.3337 0.0 0
M  V30 11 C 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3,5-Dimethylphenyl)-4-hydroxybenzeneacetamide
C16H17NO2
131179-77-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 4.6201 0.0 0
M  V30 2 C 6.6685 3.8501 0.0 0
M  V30 3 C 8.0022 4.6201 0.0 0
M  V30 4 O 6.6685 2.3101 0.0 0
M  V30 5 C 0.0000 4.6201 0.0 0
M  V30 6 C 2.6673 0.0000 0.0 0
M  V30 7 O 13.3370 1.5400 0.0 0
M  V30 8 C 4.0010 3.8501 0.0 0
M  V30 9 C 2.6673 4.6201 0.0 0
M  V30 10 C 4.0010 2.3101 0.0 0
M  V30 11 C 1.3337 3.8501 0.0 0
M  V30 12 C 2.6673 1.5400 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 9.3360 3.8501 0.0 0
M  V30 15 C 9.3360 2.3101 0.0 0
M  V30 16 C 10.6697 4.6201 0.0 0
M  V30 17 C 10.6697 1.5400 0.0 0
M  V30 18 C 12.0033 3.8501 0.0 0
M  V30 19 C 12.0033 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 14
M  V30 6 1 5 11
M  V30 7 1 6 12
M  V30 8 1 7 19
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 108-69-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 156-38-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 131179-77-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24900179
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 2135447-74-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM Multi-gram scale, sealed flask used
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Insights into Fast Amide Couplings in Aqueous Nanomicelles
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sharma, Sudripet; Kaur, Gaganpreet; Handa, Sachin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(8), 1960-1965

$RFMT $RIREG SCHEME32 STEP1
$RXN



  2  1
$MOL
BOC-L-leucine
C11H21NO4
13139-15-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8501 0.0 0 CFG=2
M  V30 2 N 4.0012 4.6201 0.0 0
M  V30 3 C 2.6675 2.3101 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8501 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 O 0.0000 3.8501 0.0 0
M  V30 8 O 1.3337 6.1601 0.0 0
M  V30 9 O 6.6685 4.6201 0.0 0
M  V30 10 O 5.3348 2.3101 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 2.3101 0.0 0
M  V30 13 C 8.0023 3.8501 0.0 0
M  V30 14 C 7.2323 2.5164 0.0 0
M  V30 15 C 9.3360 3.0801 0.0 0
M  V30 16 C 8.7723 5.1838 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 6 12
M  V30 12 1 9 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[(1S)-3-methyl-1-[(2-propyn-1-ylamino)carbonyl]butyl]carb...
C14H24N2O3
1268671-03-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 4.0011 0.0 0 CFG=1
M  V30 2 N 5.3900 5.3347 0.0 0
M  V30 3 C 7.7000 4.0011 0.0 0
M  V30 4 C 5.3900 2.6674 0.0 0
M  V30 5 C 3.8500 5.3347 0.0 0
M  V30 6 N 8.4700 5.3347 0.0 0
M  V30 7 O 8.4700 2.6674 0.0 0
M  V30 8 C 6.1600 1.3338 0.0 0
M  V30 9 O 3.0800 6.6685 0.0 0
M  V30 10 O 3.0800 4.0011 0.0 0
M  V30 11 C 10.0100 5.3347 0.0 0
M  V30 12 C 7.7000 1.3338 0.0 0
M  V30 13 C 5.3900 0.0000 0.0 0
M  V30 14 C 1.5400 6.6685 0.0 0
M  V30 15 C 10.7800 6.6685 0.0 0
M  V30 16 C 1.5400 8.2085 0.0 0
M  V30 17 C 0.0000 6.6685 0.0 0
M  V30 18 C 1.5400 5.1285 0.0 0
M  V30 19 C 11.5500 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 13 1 9 14
M  V30 14 1 11 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 14 18
M  V30 18 3 15 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 13139-15-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1268671-03-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40676337
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 543-27-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dipeptide-derived alkynes as potent and selective irreversible inhibitors
of cysteine cathepsins
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Behring, Lydia; Ruiz-Gomez, Gloria; Trapp, Christian; Morales, Maryann;
Wodtke, Robert; Koeckerling, Martin; Kopka, Klaus; Pisabarro, M. Teresa;
Pietzsch, Jens; Loeser, Reik
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(6), 3818-3851

$RFMT $RIREG SCHEME33 STEP1
$RXN



  2  1
$MOL
2,2,2-Trifluoroethylamine
C2H4F3N
753-90-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.3337 0.0 0
M  V30 2 C 2.6673 2.1037 0.0 0
M  V30 3 F 2.1037 0.0000 0.0 0
M  V30 4 F 0.0000 0.5637 0.0 0
M  V30 5 F 0.5637 2.6673 0.0 0
M  V30 6 N 4.0010 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Bromoisonicotinic acid
C6H4BrNO2
66572-56-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 Br 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 N 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Bromo-N-(2,2,2-trifluoroethyl)-4-pyridinecarboxamide
C8H6BrF3N2O
1691123-87-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 2.6673 1.5400 0.0 0
M  V30 5 C 1.3337 2.3101 0.0 0
M  V30 6 F 0.0000 3.0801 0.0 0
M  V30 7 F 0.5637 0.9764 0.0 0
M  V30 8 F 2.1037 3.6437 0.0 0
M  V30 9 Br 10.6697 1.5400 0.0 0
M  V30 10 C 6.6685 2.3101 0.0 0
M  V30 11 C 8.0023 1.5400 0.0 0
M  V30 12 C 6.6685 3.8501 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 14 C 8.0023 4.6201 0.0 0
M  V30 15 N 9.3360 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 13
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 753-90-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 66572-56-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1691123-87-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39327165
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of potent and selective ULK1/2 inhibitors based on
7-azaindole scaffold with favorable in vivo properties
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Morozova, Alisa; Chan, Sean Chin; Bayle, Simon; Sun, Luxin; Grassie,
Dylan; Iermolaieva, Anna; Kalaga, Mahalakshmi N.; Frydman, Sylvia;
Sansil, Samer; Schonbrunn, Ernst; Duckett, Derek; Monastyrskyi, Andrii
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 266116101

$RFMT $RIREG SCHEME34 STEP1
$RXN



  2  1
$MOL
3-(3-Bromophenyl)propionic acid
C9H9BrO2
42287-90-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 C 6.6684 2.3100 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 9.3359 2.3100 0.0 0
M  V30 5 O 8.0022 0.0000 0.0 0
M  V30 6 Br 0.0000 1.5400 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 2.6675 1.5400 0.0 0
M  V30 9 C 4.0011 3.8500 0.0 0
M  V30 10 C 1.3337 2.3100 0.0 0
M  V30 11 C 2.6675 4.6201 0.0 0
M  V30 12 C 1.3337 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 10
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Bromo-N-phenylbenzenepropanamide
C15H14BrNO
1459714-80-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0022 3.0801 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 5.3348 3.0801 0.0 0
M  V30 4 N 4.0010 2.3101 0.0 0
M  V30 5 O 5.3348 4.6201 0.0 0
M  V30 6 Br 13.3370 3.0801 0.0 0
M  V30 7 C 9.3360 2.3101 0.0 0
M  V30 8 C 10.6697 3.0801 0.0 0
M  V30 9 C 9.3360 0.7700 0.0 0
M  V30 10 C 12.0033 2.3101 0.0 0
M  V30 11 C 10.6697 0.0000 0.0 0
M  V30 12 C 12.0033 0.7700 0.0 0
M  V30 13 C 2.6673 3.0801 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 2.3101 0.0 0
M  V30 16 C 1.3337 5.3901 0.0 0
M  V30 17 C 0.0000 3.0801 0.0 0
M  V30 18 C 0.0000 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 13
M  V30 7 1 6 10
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 42287-90-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1459714-80-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40064533
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the Novel 1H-Pyrrolo[2,3-b]pyridine Derivative as a Potent
Type II CDK8 Inhibitor against Colorectal Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Xing Xing; Xiao, Yun; Yan, Yao Yao; Wang, Yu Meng; Jiang, Han; Wu,
Lei; Shi, Jing-bo; Liu, Xin Hua
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(18), 12095-12123

$RFMT $RIREG SCHEME35 STEP1
$RXN



  2  1
$MOL
3-Chloro-4-methylbenzoic acid
C8H7ClO2
5162-82-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 Cl 5.3901 0.0000 0.0 0
M  V30 5 C 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethanolamine
C2H7NO
141-43-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 C 2.6673 0.7700 0.0 0
M  V30 3 N 0.0000 0.7700 0.0 0
M  V30 4 O 4.0010 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Chloro-N-(2-hydroxyethyl)-4-methylbenzamide
C10H12ClNO2
431925-37-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 C 9.2400 5.3349 0.0 0
M  V30 6 O 10.7800 5.3349 0.0 0
M  V30 7 Cl 1.5400 0.0000 0.0 0
M  V30 8 C 0.0000 2.6674 0.0 0
M  V30 9 C 4.6200 2.6674 0.0 0
M  V30 10 C 3.8500 1.3338 0.0 0
M  V30 11 C 3.8500 4.0011 0.0 0
M  V30 12 C 2.3100 1.3338 0.0 0
M  V30 13 C 2.3100 4.0011 0.0 0
M  V30 14 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 7 12
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5162-82-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 141-43-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 431925-37-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34952962
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Orally Bioavailable N-Benzylpiperidinol Derivatives as
Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity
Activity against Colon Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Xing; Yang, Shanlin; Zhang, Honghan; Liu, Xipeng; Gao, Yuchen; Chen,
Yuqi; Liu, Liu; Wang, Dalin; Liang, Zijiang; Liu, Shengjie; Dai, Liang;
Xu, Qinglong; Yuan, Haoliang; Chen, Caiping; Sun, Hongbin; Wen, Xiaoan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(24), 16622-16639

$RFMT $RIREG SCHEME36 STEP1
$RXN



  2  1
$MOL
2-Amino-5-bromobenzoic acid
C7H6BrNO2
5794-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 Br 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethylamine
C2H7N
75-04-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 C 0.0000 0.7700 0.0 0
M  V30 3 N 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-bromo-N-ethylbenzamide
C9H11BrN2O
1263377-68-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 4.6200 0.0 0
M  V30 2 N 5.3347 3.8500 0.0 0
M  V30 3 O 4.0011 6.1600 0.0 0
M  V30 4 C 6.6685 4.6200 0.0 0
M  V30 5 C 8.0021 3.8500 0.0 0
M  V30 6 N 1.3336 6.1600 0.0 0
M  V30 7 Br 1.3336 0.0000 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 C 2.6674 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 1.5400 0.0 0
M  V30 13 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 6 9
M  V30 7 1 7 12
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5794-88-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 75-04-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1263377-68-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24398148
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Piperazinyl Bicyclic Derivatives as Selective Ligands of the 2-1
Subunit of Voltage-Gated Calcium Channels
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fernandez, Ariadna; Diaz, Jose Luis; Garcia, Monica; Rodriguez-Escrich,
Sergi; Lorente, Adriana; Enrech, Raquel; Dordal, Albert; Portillo-Salido,
Enrique; Porras, Monica; Fernandez, Begona; Reinoso, Raquel F.; Vela,
Jose Miguel; Almansa, Carmen
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2021), 12(11), 1802-1809

$RFMT $RIREG SCHEME37 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[2-oxo-2-(phenylamino)ethyl]carbamate
C13H18N2O3
27904-92-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0010 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 O 5.3348 0.7700 0.0 0
M  V30 5 N 8.0022 2.3101 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 O 10.6697 2.3101 0.0 0
M  V30 8 O 9.3360 4.6201 0.0 0
M  V30 9 C 12.0033 3.0801 0.0 0
M  V30 10 C 11.2333 4.4137 0.0 0
M  V30 11 C 13.3370 3.8501 0.0 0
M  V30 12 C 12.7733 1.7464 0.0 0
M  V30 13 C 2.6673 2.3101 0.0 0
M  V30 14 C 2.6673 0.7700 0.0 0
M  V30 15 C 1.3337 3.0801 0.0 0
M  V30 16 C 1.3337 0.0000 0.0 0
M  V30 17 C 0.0000 2.3101 0.0 0
M  V30 18 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 27904-92-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-42074935
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 37868-93-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of aromatic 2-(3-(methylcarbamoyl) guanidino)-N-aylacetamides
as highly potent chitinase inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhao, Zhixiang; Li, Fang; Chen, Wei; Yang, Qing; Lu, Huizhe; Zhang,
Jianjun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2023), 80117172

$RFMT $RIREG SCHEME38 STEP1
$RXN



  2  1
$MOL
2,2,2-Trifluoroethylamine
C2H4F3N
753-90-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.3337 0.0 0
M  V30 2 C 2.6673 2.1037 0.0 0
M  V30 3 F 2.1037 0.0000 0.0 0
M  V30 4 F 0.0000 0.5637 0.0 0
M  V30 5 F 0.5637 2.6673 0.0 0
M  V30 6 N 4.0010 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromo-2-thiophenecarboxylic acid
C5H3BrO2S
16694-18-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 Br 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 S 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 C 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromo-N-(2,2,2-trifluoroethyl)-2-thiophenecarboxamide
C7H5BrF3NOS
2327050-90-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 2.6675 1.5400 0.0 0
M  V30 5 C 1.3338 2.3101 0.0 0
M  V30 6 F 0.0000 3.0801 0.0 0
M  V30 7 F 0.5638 0.9764 0.0 0
M  V30 8 F 2.1038 3.6437 0.0 0
M  V30 9 Br 10.6376 2.6672 0.0 0
M  V30 10 C 6.6687 2.3101 0.0 0
M  V30 11 C 8.0755 1.6836 0.0 0
M  V30 12 S 6.8296 3.8416 0.0 0
M  V30 13 C 9.1059 2.8281 0.0 0
M  V30 14 C 8.3359 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 13
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 753-90-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 16694-18-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2327050-90-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39327166
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of potent and selective ULK1/2 inhibitors based on
7-azaindole scaffold with favorable in vivo properties
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Morozova, Alisa; Chan, Sean Chin; Bayle, Simon; Sun, Luxin; Grassie,
Dylan; Iermolaieva, Anna; Kalaga, Mahalakshmi N.; Frydman, Sylvia;
Sansil, Samer; Schonbrunn, Ernst; Duckett, Derek; Monastyrskyi, Andrii
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 266116101

$RFMT $RIREG SCHEME39 STEP1
$RXN



  2  1
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4,5-Dibromo-2-thiophenecarboxylic acid
C5H2Br2O2S
6324-10-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3026 4.0287 0.0 0
M  V30 2 O 6.6363 3.2587 0.0 0
M  V30 3 O 5.3026 5.5688 0.0 0
M  V30 4 Br 0.0000 2.9016 0.0 0
M  V30 5 Br 1.6752 0.0000 0.0 0
M  V30 6 C 3.9690 3.2587 0.0 0
M  V30 7 C 2.5620 3.8850 0.0 0
M  V30 8 S 3.8079 1.7271 0.0 0
M  V30 9 C 1.5316 2.7406 0.0 0
M  V30 10 C 2.3016 1.4070 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4,5-Dibromo-N-2-propyn-1-yl-2-thiophenecarboxamide
C8H5Br2NOS
1097429-88-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3028 4.0287 0.0 0
M  V30 2 N 6.6365 3.2587 0.0 0
M  V30 3 O 5.3028 5.5688 0.0 0
M  V30 4 C 7.9701 4.0287 0.0 0
M  V30 5 C 9.3038 3.2587 0.0 0
M  V30 6 C 10.6376 2.4887 0.0 0
M  V30 7 Br 0.0000 2.9016 0.0 0
M  V30 8 Br 1.6752 0.0000 0.0 0
M  V30 9 C 3.9690 3.2587 0.0 0
M  V30 10 C 2.5622 3.8850 0.0 0
M  V30 11 S 3.8080 1.7271 0.0 0
M  V30 12 C 1.5317 2.7406 0.0 0
M  V30 13 C 2.3017 1.4070 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 3 5 6
M  V30 7 1 7 12
M  V30 8 1 8 13
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6324-10-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1097429-88-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24359775
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM From Synthetic Simplified Marine Metabolite Analogues to New Selective
Allosteric Inhibitor of Aurora B Kinase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Juillet, Charlotte; Ermolenko, Ludmila; Boyarskaya, Dina; Baratte,
Blandine; Josselin, Beatrice; Nedev, Hristo; Bach, Stephane; Iorga,
Bogdan I.; Bignon, Jerome; Ruchaud, Sandrine; Al-Mourabit, Ali
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(2), 1197-1219

$RFMT $RIREG SCHEME40 STEP1
$RXN



  2  1
$MOL
Isopropylamine
C3H9N
75-31-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 0.0000 2.3101 0.0 0
M  V30 3 C 2.6673 2.3101 0.0 0
M  V30 4 N 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-6-fluorobenzoic acid
C7H6FNO2
434-76-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 1.3338 0.0 0
M  V30 3 O 0.0000 4.0012 0.0 0
M  V30 4 F 2.3101 5.3350 0.0 0
M  V30 5 N 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6675 0.0 0
M  V30 7 C 3.0801 4.0012 0.0 0
M  V30 8 C 3.0801 1.3338 0.0 0
M  V30 9 C 4.6201 4.0012 0.0 0
M  V30 10 C 4.6201 1.3338 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 8
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-6-fluoro-N-(1-methylethyl)benzamide
C10H13FN2O
1042434-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 N 5.3347 2.3100 0.0 0
M  V30 3 O 4.0011 4.6200 0.0 0
M  V30 4 C 6.6685 3.0800 0.0 0
M  V30 5 C 6.6685 4.6200 0.0 0
M  V30 6 C 8.0021 2.3100 0.0 0
M  V30 7 F 4.0011 0.0000 0.0 0
M  V30 8 N 1.3336 4.6200 0.0 0
M  V30 9 C 2.6674 2.3100 0.0 0
M  V30 10 C 2.6674 0.7700 0.0 0
M  V30 11 C 1.3336 3.0800 0.0 0
M  V30 12 C 1.3336 0.0000 0.0 0
M  V30 13 C 0.0000 2.3100 0.0 0
M  V30 14 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 7 10
M  V30 8 1 8 11
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-31-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 434-76-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1042434-88-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32020159
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of
(S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one
(IHMT-PI3K-372) as a Potent and Selective PI3K Inhibitor for the
Treatment of Chronic Obstructive Pulmonary Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Feng; Liang, Xiaofei; Jiang, Zongru; Wang, Aoli; Wang, Junjie; Chen,
Cheng; Wang, Wenliang; Zou, Fengming; Qi, Ziping; Liu, Qingwang; Hu,
Zhenquan; Cao, Jiangyan; Wu, Hong; Wang, Beilei; Wang, Li; Liu, Jing;
Liu, Qingsong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(22), 13973-13993

$RFMT $RIREG SCHEME41 STEP1
$RXN



  2  1
$MOL
1-Adamantaneacetic acid
C12H18O2
4942-47-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5315 3.0177 0.0 0
M  V30 2 C 6.8679 2.2462 0.0 0
M  V30 3 O 6.8679 0.7033 0.0 0
M  V30 4 O 8.2040 3.0177 0.0 0
M  V30 5 C 4.1954 2.2462 0.0 0
M  V30 6 C 2.9049 3.0865 0.0 0
M  V30 7 C 4.2778 0.7085 0.0 0
M  V30 8 C 2.4985 2.2354 0.0 0
M  V30 9 C 1.6968 2.3889 0.0 0
M  V30 10 C 3.0696 0.0111 0.0 0
M  V30 11 C 1.2903 1.5378 0.0 0
M  V30 12 C 0.0000 2.3778 0.0 0
M  V30 13 C 1.7793 0.8512 0.0 0
M  V30 14 C 1.3729 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 9 13
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 1 11 12
M  V30 16 1 11 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-1-butanol
C4H11NO
13325-10-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 0.7700 0.0 0
M  V30 2 C 4.0012 0.0000 0.0 0
M  V30 3 C 1.3338 0.0000 0.0 0
M  V30 4 C 5.3348 0.7700 0.0 0
M  V30 5 N 0.0000 0.7700 0.0 0
M  V30 6 O 6.6687 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(4-Hydroxybutyl)tricyclo[3.3.1.13,7]decane-1-acetamide
C16H27NO2
1972135-11-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5213 3.0120 0.0 0
M  V30 2 C 6.8550 2.2420 0.0 0
M  V30 3 N 8.1887 3.0120 0.0 0
M  V30 4 O 6.8550 0.7019 0.0 0
M  V30 5 C 9.5225 2.2420 0.0 0
M  V30 6 C 10.8562 3.0120 0.0 0
M  V30 7 C 12.1898 2.2420 0.0 0
M  V30 8 C 13.5235 3.0120 0.0 0
M  V30 9 O 14.8573 2.2420 0.0 0
M  V30 10 C 4.1877 2.2420 0.0 0
M  V30 11 C 2.8994 3.0807 0.0 0
M  V30 12 C 4.2697 0.7072 0.0 0
M  V30 13 C 2.4938 2.2312 0.0 0
M  V30 14 C 1.6937 2.3844 0.0 0
M  V30 15 C 3.0641 0.0111 0.0 0
M  V30 16 C 1.2881 1.5350 0.0 0
M  V30 17 C 0.0000 2.3733 0.0 0
M  V30 18 C 1.7760 0.8496 0.0 0
M  V30 19 C 1.3703 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 13 1 11 14
M  V30 14 1 12 15
M  V30 15 1 13 16
M  V30 16 1 14 17
M  V30 17 1 14 18
M  V30 18 1 15 18
M  V30 19 1 15 19
M  V30 20 1 16 17
M  V30 21 1 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4942-47-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13325-10-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1972135-11-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31556145
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors
activating the ER stress pathway
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rastelli, Ettore J.; Sannino, Sara; Hart, Duncan J.; Sharlow, Elizabeth
R.; Lazo, John S.; Brodsky, Jeffrey L.; Wipf, Peter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2021), 46128167

$RFMT $RIREG SCHEME42 STEP1
$RXN



  2  1
$MOL
N2-[(1,1-Dimethylethoxy)carbonyl]lysine
C11H22N2O4
186706-75-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.9537 2.6675 0.0 0
M  V30 2 N 4.4137 2.6675 0.0 0
M  V30 3 C 6.7237 4.0011 0.0 0
M  V30 4 C 6.7237 1.3338 0.0 0
M  V30 5 C 3.6437 4.0011 0.0 0
M  V30 6 C 8.2637 4.0011 0.0 0
M  V30 7 O 5.9537 0.0000 0.0 0
M  V30 8 O 8.2637 1.3338 0.0 0
M  V30 9 O 2.1037 4.0011 0.0 0
M  V30 10 O 4.4137 5.3348 0.0 0
M  V30 11 C 9.0337 5.3348 0.0 0
M  V30 12 C 1.3337 5.3348 0.0 0
M  V30 13 C 10.5738 5.3348 0.0 0
M  V30 14 C 0.0000 4.5648 0.0 0
M  V30 15 C 0.5636 6.6686 0.0 0
M  V30 16 C 2.6673 6.1048 0.0 0
M  V30 17 N 11.3438 6.6686 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 9 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 15 1 12 16
M  V30 16 1 13 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Azidoaniline
C6H6N4
14860-64-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 3.0800 0.0 0
M  V30 2 N 6.6686 2.3100 0.0 0 CHG=1 VAL=4
M  V30 3 N 8.0022 1.5400 0.0 0 CHG=-1
M  V30 4 N 0.0000 0.0000 0.0 0
M  V30 5 C 4.0011 2.3100 0.0 0
M  V30 6 C 2.6675 3.0800 0.0 0
M  V30 7 C 4.0011 0.7700 0.0 0
M  V30 8 C 1.3337 2.3100 0.0 0
M  V30 9 C 2.6675 0.0000 0.0 0
M  V30 10 C 1.3337 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 5
M  V30 3 2 2 3
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Hexanamide, 2,6-diamino-N-(4-azidophenyl)-, (2S)-
C12H18N6O
3074623-69-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 8.0023 1.5400 0.0 0
M  V30 2 C 9.3360 2.3101 0.0 0
M  V30 3 C 10.6697 1.5400 0.0 0 CFG=1
M  V30 4 O 9.3360 3.8501 0.0 0
M  V30 5 C 12.0035 2.3101 0.0 0
M  V30 6 N 10.6697 0.0000 0.0 0
M  V30 7 C 13.3372 1.5400 0.0 0
M  V30 8 C 14.6708 2.3101 0.0 0
M  V30 9 C 16.0045 1.5400 0.0 0
M  V30 10 N 17.3383 2.3101 0.0 0
M  V30 11 N 2.6675 4.6201 0.0 0
M  V30 12 N 1.3338 3.8501 0.0 0 CHG=1 VAL=4
M  V30 13 N 0.0000 3.0801 0.0 0 CHG=-1
M  V30 14 C 6.6687 2.3101 0.0 0
M  V30 15 C 5.3348 1.5400 0.0 0
M  V30 16 C 6.6687 3.8501 0.0 0
M  V30 17 C 4.0012 2.3101 0.0 0
M  V30 18 C 5.3348 4.6201 0.0 0
M  V30 19 C 4.0012 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 3 6 CFG=3
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 11 12
M  V30 12 1 11 19
M  V30 13 2 12 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 186706-75-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 14860-64-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3074623-69-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39561294
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Selective Recognition of c-KIT 1 G-Quadruplex by Structural Tuning of
Heteroaromatic Scaffolds and Side Chains
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fatma, Khushnood; Thumpati, Prasanth; Panda, Deepanjan; Velayutham,
Ravichandiran; Dash, Jyotirmayee
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2024), 15(3), 388-395

$RFMT $RIREG SCHEME43 STEP1
$RXN



  2  1
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Chloro-4-[(1-methylethyl)amino]-3-pyridinecarboxylic acid
C9H11ClN2O2
1447226-47-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 5.3348 0.0 0
M  V30 2 O 6.9301 5.3348 0.0 0
M  V30 3 O 4.6201 6.6686 0.0 0
M  V30 4 N 2.3100 5.3348 0.0 0
M  V30 5 C 0.7700 5.3348 0.0 0
M  V30 6 C 0.0000 6.6686 0.0 0
M  V30 7 C 0.0000 4.0011 0.0 0
M  V30 8 Cl 2.3100 0.0000 0.0 0
M  V30 9 C 4.6201 4.0011 0.0 0
M  V30 10 C 3.0800 4.0011 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 12 C 2.3100 2.6675 0.0 0
M  V30 13 N 4.6201 1.3338 0.0 0
M  V30 14 C 3.0800 1.3338 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 4 5
M  V30 5 1 4 10
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 8 14
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Chloro-N-methyl-4-[(1-methylethyl)amino]-3-pyridinecarboxamide
C10H14ClN3O
2808391-84-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 2.6674 0.0 0
M  V30 2 C 3.8500 1.3338 0.0 0
M  V30 3 C 4.6200 0.0000 0.0 0
M  V30 4 C 2.3100 1.3338 0.0 0
M  V30 5 C 6.1600 5.3347 0.0 0
M  V30 6 N 6.9300 6.6685 0.0 0
M  V30 7 O 6.9300 4.0011 0.0 0
M  V30 8 C 8.4700 6.6685 0.0 0
M  V30 9 Cl 0.0000 5.3347 0.0 0
M  V30 10 C 3.8500 4.0011 0.0 0
M  V30 11 C 4.6200 5.3347 0.0 0
M  V30 12 C 2.3100 4.0011 0.0 0
M  V30 13 C 3.8500 6.6685 0.0 0
M  V30 14 C 1.5400 5.3347 0.0 0
M  V30 15 N 2.3100 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 1 6 8
M  V30 9 1 9 14
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1447226-47-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2808391-84-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33447248
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing
Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant
Non-Small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Eno, Meredith S.; Brubaker, Jason D.; Campbell, John E.; De Savi, Chris;
Guzi, Timothy J.; Williams, Brett D.; Wilson, Douglas; Wilson, Kevin;
Brooijmans, Natasja; Kim, Joseph; Ozen, Aysegul; Perola, Emanuele; Hsieh,
John; Brown, Victoria; Fetalvero, Kristina; Garner, Andrew; Zhang, Zhuo;
Stevison, Faith; Woessner, Rich; Singh, Jatinder; Timsit, Yoav; Kinkema,
Caitlin; Medendorp, Clare; Lee, Christopher; Albayya, Faris; Zalutskaya,
Alena; Schalm, Stefanie; Dineen, Thomas A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(14), 9662-9677

$RFMT $RIREG SCHEME44 STEP1
$RXN



  2  1
$MOL
2,2,2-Trifluoroethylamine
C2H4F3N
753-90-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.3337 0.0 0
M  V30 2 C 2.6673 2.1037 0.0 0
M  V30 3 F 2.1037 0.0000 0.0 0
M  V30 4 F 0.0000 0.5637 0.0 0
M  V30 5 F 0.5637 2.6673 0.0 0
M  V30 6 N 4.0010 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromopicolinic acid
C6H4BrNO2
30766-03-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 Br 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 N 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Pyridinecarboxamide, 4-bromo-N-(2,2,2-trifluoroethyl)-
C8H6BrF3N2O
2922532-53-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 2.6673 1.5400 0.0 0
M  V30 5 C 1.3337 2.3101 0.0 0
M  V30 6 F 0.0000 3.0801 0.0 0
M  V30 7 F 2.1037 3.6437 0.0 0
M  V30 8 F 0.5637 0.9764 0.0 0
M  V30 9 Br 10.6697 1.5400 0.0 0
M  V30 10 C 6.6685 2.3101 0.0 0
M  V30 11 C 8.0023 1.5400 0.0 0
M  V30 12 N 6.6685 3.8501 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 14 C 8.0023 4.6201 0.0 0
M  V30 15 C 9.3360 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 13
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 753-90-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 30766-03-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2922532-53-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39327172
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of potent and selective ULK1/2 inhibitors based on
7-azaindole scaffold with favorable in vivo properties
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Morozova, Alisa; Chan, Sean Chin; Bayle, Simon; Sun, Luxin; Grassie,
Dylan; Iermolaieva, Anna; Kalaga, Mahalakshmi N.; Frydman, Sylvia;
Sansil, Samer; Schonbrunn, Ernst; Duckett, Derek; Monastyrskyi, Andrii
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 266116101

$RFMT $RIREG SCHEME45 STEP1
$RXN



  2  1
$MOL
5-Bromo-2-furancarboxylic acid
C5H3BrO3
585-70-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 Br 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 O 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 C 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2,2,2-Trifluoroethylamine
C2H4F3N
753-90-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.3337 0.0 0
M  V30 2 C 2.6673 2.1037 0.0 0
M  V30 3 F 2.1037 0.0000 0.0 0
M  V30 4 F 0.0000 0.5637 0.0 0
M  V30 5 F 0.5637 2.6673 0.0 0
M  V30 6 N 4.0010 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N-(2,2,2-trifluoroethyl)-2-furancarboxamide
C7H5BrF3NO2
1250040-96-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 2.6675 1.5400 0.0 0
M  V30 5 C 1.3338 2.3101 0.0 0
M  V30 6 F 0.0000 3.0801 0.0 0
M  V30 7 F 0.5638 0.9764 0.0 0
M  V30 8 F 2.1038 3.6437 0.0 0
M  V30 9 Br 10.6376 2.6672 0.0 0
M  V30 10 C 6.6687 2.3101 0.0 0
M  V30 11 O 8.0755 1.6836 0.0 0
M  V30 12 C 6.8296 3.8416 0.0 0
M  V30 13 C 9.1059 2.8281 0.0 0
M  V30 14 C 8.3359 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 13
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 585-70-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 753-90-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1250040-96-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39327163
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of potent and selective ULK1/2 inhibitors based on
7-azaindole scaffold with favorable in vivo properties
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Morozova, Alisa; Chan, Sean Chin; Bayle, Simon; Sun, Luxin; Grassie,
Dylan; Iermolaieva, Anna; Kalaga, Mahalakshmi N.; Frydman, Sylvia;
Sansil, Samer; Schonbrunn, Ernst; Duckett, Derek; Monastyrskyi, Andrii
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 266116101

$RFMT $RIREG SCHEME46 STEP1
$RXN



  2  1
$MOL
Isobutylamine
C4H11N
78-81-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 2.6673 2.3101 0.0 0
M  V30 3 C 1.3337 0.0000 0.0 0
M  V30 4 C 0.0000 2.3101 0.0 0
M  V30 5 N 4.0010 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-6-fluorobenzoic acid
C7H6FNO2
434-76-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 1.3338 0.0 0
M  V30 3 O 0.0000 4.0012 0.0 0
M  V30 4 F 2.3101 5.3350 0.0 0
M  V30 5 N 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6675 0.0 0
M  V30 7 C 3.0801 4.0012 0.0 0
M  V30 8 C 3.0801 1.3338 0.0 0
M  V30 9 C 4.6201 4.0012 0.0 0
M  V30 10 C 4.6201 1.3338 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 8
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-6-fluoro-N-(2-methylpropyl)benzamide
C11H15FN2O
1880139-21-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 N 5.3347 2.3100 0.0 0
M  V30 3 O 4.0011 0.0000 0.0 0
M  V30 4 C 6.6684 1.5400 0.0 0
M  V30 5 C 8.0021 2.3100 0.0 0
M  V30 6 C 9.3358 1.5400 0.0 0
M  V30 7 C 8.0021 3.8500 0.0 0
M  V30 8 F 1.3336 0.0000 0.0 0
M  V30 9 N 4.0011 4.6200 0.0 0
M  V30 10 C 2.6674 2.3100 0.0 0
M  V30 11 C 1.3336 1.5400 0.0 0
M  V30 12 C 2.6674 3.8500 0.0 0
M  V30 13 C 0.0000 2.3100 0.0 0
M  V30 14 C 1.3336 4.6200 0.0 0
M  V30 15 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 8 11
M  V30 9 1 9 12
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 78-81-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 434-76-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1880139-21-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32020154
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of
(S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one
(IHMT-PI3K-372) as a Potent and Selective PI3K Inhibitor for the
Treatment of Chronic Obstructive Pulmonary Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Feng; Liang, Xiaofei; Jiang, Zongru; Wang, Aoli; Wang, Junjie; Chen,
Cheng; Wang, Wenliang; Zou, Fengming; Qi, Ziping; Liu, Qingwang; Hu,
Zhenquan; Cao, Jiangyan; Wu, Hong; Wang, Beilei; Wang, Li; Liu, Jing;
Liu, Qingsong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(22), 13973-13993

$RFMT $RIREG SCHEME47 STEP1
$RXN



  2  1
$MOL
4-Acetylbenzoic acid
C9H8O3
586-89-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6686 1.5400 0.0 0
M  V30 2 C 8.0022 2.3100 0.0 0
M  V30 3 O 6.6686 0.0000 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 O 0.0000 3.8500 0.0 0
M  V30 6 O 1.3337 6.1601 0.0 0
M  V30 7 C 5.3348 2.3100 0.0 0
M  V30 8 C 4.0011 1.5400 0.0 0
M  V30 9 C 5.3348 3.8500 0.0 0
M  V30 10 C 2.6675 2.3100 0.0 0
M  V30 11 C 4.0011 4.6201 0.0 0
M  V30 12 C 2.6675 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-(aminomethyl)-, methyl ester, hydrochloride (1:1)
C9H11NO2.ClH
6232-11-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0800 0.0 0
M  V30 2 O 1.3337 3.8501 0.0 0
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 C 0.0000 3.0800 0.0 0
M  V30 5 C 8.0023 6.1601 0.0 0
M  V30 6 N 9.3360 5.3901 0.0 0
M  V30 7 C 4.0012 3.8501 0.0 0
M  V30 8 C 4.0012 5.3901 0.0 0
M  V30 9 C 5.3348 3.0800 0.0 0
M  V30 10 C 5.3348 6.1601 0.0 0
M  V30 11 C 6.6685 3.8501 0.0 0
M  V30 12 C 6.6685 5.3901 0.0 0
M  V30 13 Cl 4.6680 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[[(4-acetylbenzoyl)amino]methyl]benzoate
C18H17NO4
2718890-12-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6686 1.5400 0.0 0
M  V30 2 N 8.0022 2.3100 0.0 0
M  V30 3 O 6.6686 0.0000 0.0 0
M  V30 4 C 9.3359 1.5400 0.0 0
M  V30 5 C 1.3338 4.6201 0.0 0
M  V30 6 C 1.3338 6.1601 0.0 0
M  V30 7 O 0.0000 3.8500 0.0 0
M  V30 8 C 14.6707 4.6201 0.0 0
M  V30 9 O 16.0043 3.8500 0.0 0
M  V30 10 O 14.6707 6.1601 0.0 0
M  V30 11 C 17.3381 4.6201 0.0 0
M  V30 12 C 5.3348 2.3100 0.0 0
M  V30 13 C 5.3348 3.8500 0.0 0
M  V30 14 C 4.0011 1.5400 0.0 0
M  V30 15 C 4.0011 4.6201 0.0 0
M  V30 16 C 2.6675 2.3100 0.0 0
M  V30 17 C 2.6675 3.8500 0.0 0
M  V30 18 C 10.6695 2.3100 0.0 0
M  V30 19 C 12.0034 1.5400 0.0 0
M  V30 20 C 10.6695 3.8500 0.0 0
M  V30 21 C 13.3370 2.3100 0.0 0
M  V30 22 C 12.0034 4.6201 0.0 0
M  V30 23 C 13.3370 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 4
M  V30 5 1 4 18
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 17
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 8 23
M  V30 12 1 9 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 586-89-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6232-11-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2718890-12-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24558300
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liang, Tao; Zhou, Yi; Elhassan, Reham M.; Hou, Xuben; Yang, Xinying;
Fang, Hao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 12083-12099

$RFMT $RIREG SCHEME48 STEP1
$RXN



  2  1
$MOL
Allylamine
C3H7N
107-11-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 C 2.6673 0.7700 0.0 0
M  V30 3 C 0.0000 0.7700 0.0 0
M  V30 4 N 4.0010 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Benzyloxycarbonylamino)butyric acid
C12H15NO4
5105-78-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 3.0801 0.0 0
M  V30 2 O 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 N 8.0022 2.3101 0.0 0
M  V30 5 O 6.6685 4.6201 0.0 0
M  V30 6 C 9.3358 3.0801 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 C 12.0033 3.0801 0.0 0
M  V30 9 C 13.3370 2.3101 0.0 0
M  V30 10 O 14.6707 3.0801 0.0 0
M  V30 11 O 13.3370 0.7700 0.0 0
M  V30 12 C 2.6673 2.3101 0.0 0
M  V30 13 C 2.6673 0.7700 0.0 0
M  V30 14 C 1.3337 3.0801 0.0 0
M  V30 15 C 1.3337 0.0000 0.0 0
M  V30 16 C 0.0000 2.3101 0.0 0
M  V30 17 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C15H20N2O3
2676166-04-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0801 0.0 0
M  V30 2 O 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 N 8.0023 2.3101 0.0 0
M  V30 5 O 6.6685 4.6201 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 C 12.0035 3.0801 0.0 0
M  V30 9 C 13.3372 2.3101 0.0 0
M  V30 10 N 14.6708 3.0801 0.0 0
M  V30 11 O 13.3372 0.7700 0.0 0
M  V30 12 C 16.0045 2.3101 0.0 0
M  V30 13 C 17.3383 3.0801 0.0 0
M  V30 14 C 18.6720 2.3101 0.0 0
M  V30 15 C 2.6675 2.3101 0.0 0
M  V30 16 C 2.6675 0.7700 0.0 0
M  V30 17 C 1.3337 3.0801 0.0 0
M  V30 18 C 1.3337 0.0000 0.0 0
M  V30 19 C 0.0000 2.3101 0.0 0
M  V30 20 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 107-11-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5105-78-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2676166-04-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36226435
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM literature preparation
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Optimization of a Novel Macrocyclic Amidinourea Series
Active as Acidic Mammalian Chitinase Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Balestri, Lorenzo Jacopo Ilic; Trivisani, Claudia Immacolata; Orofino,
Francesco; Fiorucci, Diego; Truglio, Giuseppina Ivana; D'Agostino,
Ilaria; Poggialini, Federica; Botta, Lorenzo; Docquier, Jean-Denis;
Dreassi, Elena
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2023), 14(4), 417-424

$RFMT $RIREG SCHEME49 STEP1
$RXN



  2  1
$MOL
4-Acetylbenzoic acid
C9H8O3
586-89-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6686 1.5400 0.0 0
M  V30 2 C 8.0022 2.3100 0.0 0
M  V30 3 O 6.6686 0.0000 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 O 0.0000 3.8500 0.0 0
M  V30 6 O 1.3337 6.1601 0.0 0
M  V30 7 C 5.3348 2.3100 0.0 0
M  V30 8 C 4.0011 1.5400 0.0 0
M  V30 9 C 5.3348 3.8500 0.0 0
M  V30 10 C 2.6675 2.3100 0.0 0
M  V30 11 C 4.0011 4.6201 0.0 0
M  V30 12 C 2.6675 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Pentanoic acid, 5-amino-, methyl ester, hydrochloride (1:1)
C6H13NO2.ClH
29840-56-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0800 0.0 0
M  V30 2 C 4.0012 3.8501 0.0 0
M  V30 3 O 1.3337 3.8501 0.0 0
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 C 5.3348 3.0800 0.0 0
M  V30 6 C 0.0000 3.0800 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 8.0023 3.0800 0.0 0
M  V30 9 N 9.3360 3.8501 0.0 0
M  V30 10 Cl 4.6680 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 5-[(4-acetylbenzoyl)amino]pentanoate
C15H19NO4
1385785-74-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6687 4.6201 0.0 0
M  V30 2 N 8.0023 3.8501 0.0 0
M  V30 3 O 6.6687 6.1601 0.0 0
M  V30 4 C 9.3360 4.6201 0.0 0
M  V30 5 C 10.6697 3.8501 0.0 0
M  V30 6 C 12.0035 4.6201 0.0 0
M  V30 7 C 13.3372 3.8501 0.0 0
M  V30 8 C 14.6708 4.6201 0.0 0
M  V30 9 O 16.0045 3.8501 0.0 0
M  V30 10 O 14.6708 6.1601 0.0 0
M  V30 11 C 17.3383 4.6201 0.0 0
M  V30 12 C 1.3338 1.5400 0.0 0
M  V30 13 C 1.3338 0.0000 0.0 0
M  V30 14 O 0.0000 2.3101 0.0 0
M  V30 15 C 5.3348 3.8501 0.0 0
M  V30 16 C 5.3348 2.3101 0.0 0
M  V30 17 C 4.0012 4.6201 0.0 0
M  V30 18 C 4.0012 1.5400 0.0 0
M  V30 19 C 2.6675 3.8501 0.0 0
M  V30 20 C 2.6675 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 12 20
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 586-89-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 29840-56-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1385785-74-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24558277
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liang, Tao; Zhou, Yi; Elhassan, Reham M.; Hou, Xuben; Yang, Xinying;
Fang, Hao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 12083-12099

$RFMT $RIREG SCHEME50 STEP1
$RXN



  2  1
$MOL
3,3-Dimethylbutanoic acid
C6H12O2
1070-83-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 1.5400 0.0 0
M  V30 2 C 1.5400 1.5400 0.0 0
M  V30 3 C 3.8500 2.8736 0.0 0
M  V30 4 C 1.5400 0.0000 0.0 0
M  V30 5 C 0.0000 1.5400 0.0 0
M  V30 6 C 1.5400 3.0800 0.0 0
M  V30 7 O 3.0800 4.2073 0.0 0
M  V30 8 O 5.3900 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 2 3 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Phenylalanine, methyl ester, hydrochloride
C10H13NO2.ClH
7524-50-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0 CFG=2
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 N 5.3347 5.3900 0.0 0
M  V30 5 O 8.0021 3.8500 0.0 0
M  V30 6 O 6.6684 1.5400 0.0 0
M  V30 7 C 9.3358 3.0800 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 3.0800 0.0 0
M  V30 10 C 2.6674 5.3900 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 6.1600 0.0 0
M  V30 13 C 0.0000 5.3900 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(3,3-Dimethyl-1-oxobutyl)-L-phenylalanine methyl ester
C16H23NO3
1887235-21-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 4.0011 0.0 0 CFG=1
M  V30 2 C 4.6200 5.3347 0.0 0
M  V30 3 N 6.9300 4.0011 0.0 0
M  V30 4 C 4.6200 2.6674 0.0 0
M  V30 5 C 7.7000 5.3347 0.0 0
M  V30 6 O 5.3900 1.3336 0.0 0
M  V30 7 O 3.0800 2.6674 0.0 0
M  V30 8 C 9.2400 5.3347 0.0 0
M  V30 9 O 6.9300 6.6685 0.0 0
M  V30 10 C 4.6200 0.0000 0.0 0
M  V30 11 C 10.0100 6.6685 0.0 0
M  V30 12 C 8.6764 7.4385 0.0 0
M  V30 13 C 10.7800 8.0021 0.0 0
M  V30 14 C 11.3436 5.8985 0.0 0
M  V30 15 C 3.0800 5.3347 0.0 0
M  V30 16 C 2.3100 6.6685 0.0 0
M  V30 17 C 2.3100 4.0011 0.0 0
M  V30 18 C 0.7700 6.6685 0.0 0
M  V30 19 C 0.7700 4.0011 0.0 0
M  V30 20 C 0.0000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 15
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1070-83-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7524-50-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1887235-21-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37263132
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 497-19-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Serendipitous Discovery of Leucine and Methionine Depletion Agents during
the Search for Polyamine Transport Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Massaro, Chelsea; Thomas, Jenna; Ikhlef, Houssine; Dinara, Sharifa;
Cronk, Sara; Moots, Holly; Phanstiel, Otto
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(6), 2814-2832

$RFMT $RIREG SCHEME51 STEP1
$RXN



  2  1
$MOL
3-(1-Methylethyl)-4-nitro-1H-pyrazole-5-carboxylic acid
C7H9N3O4
1365354-76-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.8549 0.7700 0.0 0 VAL=5
M  V30 2 O 5.1886 0.0000 0.0 0
M  V30 3 O 2.5213 0.0000 0.0 0
M  V30 4 C 6.5655 2.7392 0.0 0
M  V30 5 C 7.7099 3.7698 0.0 0
M  V30 6 C 6.8857 1.2329 0.0 0
M  V30 7 C 1.1444 2.7392 0.0 0
M  V30 8 O 0.8242 1.2329 0.0 0
M  V30 9 O 0.0000 3.7698 0.0 0
M  V30 10 C 3.8549 2.3100 0.0 0
M  V30 11 C 5.1008 3.2152 0.0 0
M  V30 12 C 2.6091 3.2152 0.0 0
M  V30 13 N 4.6250 4.6798 0.0 0
M  V30 14 N 3.0849 4.6798 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 4 11
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 7 12
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Pyrazole-5-carboxamide, N-methyl-3-(1-methylethyl)-4-nitro-
C8H12N4O3
3032452-60-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.1471 1.0304 0.0 0 VAL=5
M  V30 2 O 4.2915 0.0000 0.0 0
M  V30 3 O 1.6823 0.5546 0.0 0
M  V30 4 C 6.2079 2.3932 0.0 0
M  V30 5 N 7.5415 3.1632 0.0 0
M  V30 6 O 6.2079 0.8532 0.0 0
M  V30 7 C 8.8752 2.3932 0.0 0
M  V30 8 C 0.9052 3.5204 0.0 0
M  V30 9 C 0.0000 4.7663 0.0 0
M  V30 10 C 0.2787 2.1134 0.0 0
M  V30 11 C 3.4672 2.5369 0.0 0
M  V30 12 C 4.8742 3.1632 0.0 0
M  V30 13 C 2.4368 3.6813 0.0 0
M  V30 14 N 4.7131 4.6948 0.0 0
M  V30 15 N 3.2068 5.0150 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 12
M  V30 7 1 5 7
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 8 13
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1365354-76-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3032452-60-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39410607
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 64-17-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Lead Optimization of the 5-Phenylpyrazolopyrimidinone NPD-2975 toward
Compounds with Improved Antitrypanosomal Efficacy
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zheng, Yang; van den Kerkhof, Magali; Ibrahim, Mohamed; De Esch, Iwan J.
P.; Maes, Louis; Sterk, Geert Jan; Caljon, Guy; Leurs, Rob
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(4), 2849-2863

$RFMT $RIREG SCHEME52 STEP1
$RXN



  2  1
$MOL
4-Acetylbenzoic acid
C9H8O3
586-89-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6686 1.5400 0.0 0
M  V30 2 C 8.0022 2.3100 0.0 0
M  V30 3 O 6.6686 0.0000 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 O 0.0000 3.8500 0.0 0
M  V30 6 O 1.3337 6.1601 0.0 0
M  V30 7 C 5.3348 2.3100 0.0 0
M  V30 8 C 4.0011 1.5400 0.0 0
M  V30 9 C 5.3348 3.8500 0.0 0
M  V30 10 C 2.6675 2.3100 0.0 0
M  V30 11 C 4.0011 4.6201 0.0 0
M  V30 12 C 2.6675 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Heptanoic acid, 7-amino-, methyl ester, hydrochloride (1:1)
C8H17NO2.ClH
17994-94-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.0800 0.0 0
M  V30 2 C 4.0012 3.8501 0.0 0
M  V30 3 C 6.6685 3.8501 0.0 0
M  V30 4 C 2.6673 3.0800 0.0 0
M  V30 5 C 8.0022 3.0800 0.0 0
M  V30 6 O 1.3337 3.8501 0.0 0
M  V30 7 O 2.6673 1.5400 0.0 0
M  V30 8 C 9.3360 3.8501 0.0 0
M  V30 9 C 0.0000 3.0800 0.0 0
M  V30 10 C 10.6697 3.0800 0.0 0
M  V30 11 N 12.0033 3.8501 0.0 0
M  V30 12 Cl 6.0017 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 7-[(4-acetylbenzoyl)amino]heptanoate
C17H23NO4
2718890-11-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 8.0023 3.8501 0.0 0
M  V30 3 O 6.6685 6.1601 0.0 0
M  V30 4 C 9.3360 4.6201 0.0 0
M  V30 5 C 10.6697 3.8501 0.0 0
M  V30 6 C 12.0033 4.6201 0.0 0
M  V30 7 C 13.3372 3.8501 0.0 0
M  V30 8 C 14.6708 4.6201 0.0 0
M  V30 9 C 16.0045 3.8501 0.0 0
M  V30 10 C 17.3382 4.6201 0.0 0
M  V30 11 O 18.6720 3.8501 0.0 0
M  V30 12 O 17.3382 6.1601 0.0 0
M  V30 13 C 20.0057 4.6201 0.0 0
M  V30 14 C 1.3337 1.5400 0.0 0
M  V30 15 C 1.3337 0.0000 0.0 0
M  V30 16 O 0.0000 2.3101 0.0 0
M  V30 17 C 5.3348 3.8501 0.0 0
M  V30 18 C 5.3348 2.3101 0.0 0
M  V30 19 C 4.0012 4.6201 0.0 0
M  V30 20 C 4.0012 1.5400 0.0 0
M  V30 21 C 2.6675 3.8501 0.0 0
M  V30 22 C 2.6675 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 11 13
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 14 22
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 586-89-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 17994-94-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2718890-11-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24558288
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liang, Tao; Zhou, Yi; Elhassan, Reham M.; Hou, Xuben; Yang, Xinying;
Fang, Hao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 12083-12099

$RFMT $RIREG SCHEME53 STEP1
$RXN



  3  3
$MOL
L-Serine, methyl ester, hydrochloride (1:1)
C4H9NO3.ClH
5680-80-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.8500 0.0 0 CFG=1
M  V30 2 C 4.0011 3.0800 0.0 0
M  V30 3 C 1.3338 3.0800 0.0 0
M  V30 4 N 2.6674 5.3900 0.0 0
M  V30 5 O 5.3347 3.8500 0.0 0
M  V30 6 O 4.0011 1.5400 0.0 0
M  V30 7 O 0.0000 3.8500 0.0 0
M  V30 8 C 6.6685 3.0800 0.0 0
M  V30 9 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Dicyclohexylcarbodiimide
C13H22N2
538-75-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 4.0011 0.0 0
M  V30 2 C 5.3900 2.6674 0.0 0
M  V30 3 N 6.1600 1.3338 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 2.3100 2.6674 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 C 0.7700 2.6674 0.0 0
M  V30 8 C 0.7700 5.3349 0.0 0
M  V30 9 C 0.0000 4.0011 0.0 0
M  V30 10 C 7.7000 1.3338 0.0 0
M  V30 11 C 8.4700 0.0000 0.0 0
M  V30 12 C 8.4700 2.6674 0.0 0
M  V30 13 C 10.0100 0.0000 0.0 0
M  V30 14 C 10.0100 2.6674 0.0 0
M  V30 15 C 10.7800 1.3338 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2 CFG=2
M  V30 2 1 1 4
M  V30 3 2 2 3 CFG=2
M  V30 4 1 3 10
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 9
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(2E)-3-(4-Methylphenyl)-2-propenoic acid
C10H10O2
940-61-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 C 6.6684 2.3100 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 9.3359 2.3100 0.0 0
M  V30 5 O 8.0022 0.0000 0.0 0
M  V30 6 C 0.0000 4.6201 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 2.6675 1.5400 0.0 0
M  V30 9 C 4.0011 3.8500 0.0 0
M  V30 10 C 1.3337 2.3100 0.0 0
M  V30 11 C 2.6675 4.6201 0.0 0
M  V30 12 C 1.3337 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(Cyclohexylamino)(cyclohexylimino)methyl (2E)-3-(4-methylphenyl)-2-propenoate
C23H32N2O2
1240512-89-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0
M  V30 2 N 4.6200 6.6684 0.0 0
M  V30 3 N 4.6200 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 7.7000 6.6684 0.0 0
M  V30 6 C 9.2400 6.6684 0.0 0
M  V30 7 O 6.9300 8.0021 0.0 0
M  V30 8 C 10.0100 8.0021 0.0 0
M  V30 9 C 16.1700 8.0021 0.0 0
M  V30 10 C 3.0800 6.6684 0.0 0
M  V30 11 C 2.3100 5.3347 0.0 0
M  V30 12 C 2.3100 8.0021 0.0 0
M  V30 13 C 0.7700 5.3347 0.0 0
M  V30 14 C 0.7700 8.0021 0.0 0
M  V30 15 C 0.0000 6.6684 0.0 0
M  V30 16 C 5.3900 2.6674 0.0 0
M  V30 17 C 4.6200 1.3336 0.0 0
M  V30 18 C 6.9300 2.6674 0.0 0
M  V30 19 C 5.3900 0.0000 0.0 0
M  V30 20 C 7.7000 1.3336 0.0 0
M  V30 21 C 6.9300 0.0000 0.0 0
M  V30 22 C 11.5500 8.0021 0.0 0
M  V30 23 C 12.3200 6.6684 0.0 0
M  V30 24 C 12.3200 9.3358 0.0 0
M  V30 25 C 13.8600 6.6684 0.0 0
M  V30 26 C 13.8600 9.3358 0.0 0
M  V30 27 C 14.6300 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2 CFG=2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 10
M  V30 5 1 3 16
M  V30 6 1 4 5
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 2 6 8
M  V30 10 1 8 22
M  V30 11 1 9 27
M  V30 12 1 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 1 13 15
M  V30 17 1 14 15
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(2E)-3-(4-Methylphenyl)-1-oxo-2-propen-1-yl]-L-serine methyl ester
C14H17NO4
2414059-79-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.0022 2.3101 0.0 0
M  V30 2 C 6.6685 3.0801 0.0 0
M  V30 3 C 5.3348 2.3101 0.0 0
M  V30 4 N 4.0010 3.0801 0.0 0
M  V30 5 O 5.3348 0.7700 0.0 0
M  V30 6 C 2.6673 2.3101 0.0 0 CFG=1
M  V30 7 C 1.3337 3.0801 0.0 0
M  V30 8 C 2.6673 0.7700 0.0 0
M  V30 9 O 1.3337 4.6201 0.0 0
M  V30 10 O 0.0000 2.3101 0.0 0
M  V30 11 O 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 5.3901 0.0 0
M  V30 13 C 13.3370 5.3901 0.0 0
M  V30 14 C 9.3360 3.0801 0.0 0
M  V30 15 C 9.3360 4.6201 0.0 0
M  V30 16 C 10.6697 2.3101 0.0 0
M  V30 17 C 10.6697 5.3901 0.0 0
M  V30 18 C 12.0033 3.0801 0.0 0
M  V30 19 C 12.0033 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8 CFG=1
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 13 19
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(2S)-3-Methoxy-2-[[(2E)-3-(4-methylphenyl)-1-oxo-2-propen-1-yl]amino]-3-oxopr...
C24H25NO5
2414059-88-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 16.1700 6.6684 0.0 0
M  V30 2 C 15.4000 5.3347 0.0 0
M  V30 3 C 13.8600 5.3347 0.0 0
M  V30 4 N 13.0900 4.0011 0.0 0
M  V30 5 O 13.0900 6.6684 0.0 0
M  V30 6 C 11.5500 4.0011 0.0 0 CFG=2
M  V30 7 C 10.7800 5.3347 0.0 0
M  V30 8 C 10.7800 2.6674 0.0 0
M  V30 9 O 9.2400 5.3347 0.0 0
M  V30 10 O 11.5500 1.3336 0.0 0
M  V30 11 O 9.2400 2.6674 0.0 0
M  V30 12 C 8.4700 6.6684 0.0 0
M  V30 13 C 10.7800 0.0000 0.0 0
M  V30 14 C 6.9300 6.6684 0.0 0
M  V30 15 O 9.2400 8.0021 0.0 0
M  V30 16 C 6.1600 8.0021 0.0 0
M  V30 17 C 22.3300 6.6684 0.0 0
M  V30 18 C 0.0000 8.0021 0.0 0
M  V30 19 C 17.7100 6.6684 0.0 0
M  V30 20 C 18.4800 8.0021 0.0 0
M  V30 21 C 18.4800 5.3347 0.0 0
M  V30 22 C 20.0200 8.0021 0.0 0
M  V30 23 C 20.0200 5.3347 0.0 0
M  V30 24 C 20.7900 6.6684 0.0 0
M  V30 25 C 4.6200 8.0021 0.0 0
M  V30 26 C 3.8500 9.3358 0.0 0
M  V30 27 C 3.8500 6.6684 0.0 0
M  V30 28 C 2.3100 9.3358 0.0 0
M  V30 29 C 2.3100 6.6684 0.0 0
M  V30 30 C 1.5400 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 4 CFG=3
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 2 14 16
M  V30 17 1 16 25
M  V30 18 1 17 24
M  V30 19 1 18 30
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5680-80-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:RCT(3):CAS_RN
$DATUM 940-61-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1240512-89-3
$DTYPE RXN:PRO(2):CAS_RN
$DATUM 2414059-79-1
$DTYPE RXN:PRO(3):CAS_RN
$DATUM 2414059-88-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-356-CAS-22071802
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(2):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):PRO(3):YIELD
$DATUM 7
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and in vitro evaluation of antimycobacterial and cytotoxic
activity of new ,-unsaturated amide, oxazoline and oxazole derivatives
from L-serine
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Aguirre-Renteria, Saul A.; Carrizales-Castillo, Juan J. J.; Camacho
Corona, Maria del Rayo; Hernandez-Fernandez, Eugenio; Garza-Gonzalez,
Elvira; Rivas-Galindo, Veronica M.; Arredondo-Espinoza, Eder;
Avalos-Alanis, Francisco G.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(9), 127074

$RFMT $RIREG SCHEME54 STEP1
$RXN



  2  1
$MOL
(S)--[[(1,1-Dimethylethoxy)carbonyl]amino]benzenepropanoic acid
C14H19NO4
103365-47-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0011 0.0 0 CFG=2
M  V30 2 N 5.3900 5.3347 0.0 0
M  V30 3 C 5.3900 2.6674 0.0 0
M  V30 4 C 6.9300 5.3347 0.0 0
M  V30 5 C 4.6200 1.3338 0.0 0
M  V30 6 O 7.7000 6.6685 0.0 0
M  V30 7 O 7.7000 4.0011 0.0 0
M  V30 8 O 5.3900 0.0000 0.0 0
M  V30 9 O 3.0800 1.3338 0.0 0
M  V30 10 C 9.2400 6.6685 0.0 0
M  V30 11 C 9.2400 5.1285 0.0 0
M  V30 12 C 10.7800 6.6685 0.0 0
M  V30 13 C 9.2400 8.2085 0.0 0
M  V30 14 C 3.0800 4.0011 0.0 0
M  V30 15 C 2.3100 2.6674 0.0 0
M  V30 16 C 2.3100 5.3347 0.0 0
M  V30 17 C 0.7700 2.6674 0.0 0
M  V30 18 C 0.7700 5.3347 0.0 0
M  V30 19 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C15H22N2O3
2734274-03-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 5.3347 0.0 0 CFG=2
M  V30 2 N 5.3900 6.6685 0.0 0
M  V30 3 C 5.3900 4.0011 0.0 0
M  V30 4 C 6.9300 6.6685 0.0 0
M  V30 5 C 4.6200 2.6674 0.0 0
M  V30 6 O 7.7000 8.0021 0.0 0
M  V30 7 O 7.7000 5.3347 0.0 0
M  V30 8 N 5.3900 1.3336 0.0 0
M  V30 9 O 3.0800 2.6674 0.0 0
M  V30 10 C 9.2400 8.0021 0.0 0
M  V30 11 C 4.6200 0.0000 0.0 0
M  V30 12 C 9.2400 6.4621 0.0 0
M  V30 13 C 10.7800 8.0021 0.0 0
M  V30 14 C 9.2400 9.5421 0.0 0
M  V30 15 C 3.0800 5.3347 0.0 0
M  V30 16 C 2.3100 4.0011 0.0 0
M  V30 17 C 2.3100 6.6685 0.0 0
M  V30 18 C 0.7700 4.0011 0.0 0
M  V30 19 C 0.7700 6.6685 0.0 0
M  V30 20 C 0.0000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 15
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 103365-47-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2734274-03-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38476171
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Nanomolar DCAF1 Small Molecule Ligands
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Alice Shi Ming; Kimani, Serah; Wilson, Brian; Noureldin, Mahmoud;
Gonzalez-Alvarez, Hector; Mamai, Ahmed; Hoffer, Laurent; Guilinger, John
P.; Zhang, Ying; von Rechenberg, Moritz; Disch, Jeremy S.; Mulhern,
Christopher J.; Slakman, Belinda L.; Cuozzo, John W.; Dong, Aiping; Poda,
Gennady; Mohammed, Mohammed; Saraon, Punit; Mittal, Manish; Modh, Pratik;
Rathod, Vaibhavi; Patel, Bhashant; Ackloo, Suzanne; Santhakumar,
Vijayaratnam; Szewczyk, Magdalena M.; Barsyte-Lovejoy, Dalia; Arrowsmith,
Cheryl H.; Marcellus, Richard; Guie, Marie-Aude; Keefe, Anthony D.;
Brown, Peter J.; Halabelian, Levon; Al-awar, Rima; Vedadi, Masoud
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(7), 5041-5060

$RFMT $RIREG SCHEME55 STEP1
$RXN



  2  1
$MOL
2-Butenoic acid, 3-(4-methoxyphenyl)-4-phenyl-
C17H16O3
1562348-91-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 4.0011 0.0 0
M  V30 2 C 4.6200 5.3347 0.0 0
M  V30 3 C 4.6200 2.6674 0.0 0
M  V30 4 C 5.3900 1.3338 0.0 0
M  V30 5 O 4.6200 0.0000 0.0 0
M  V30 6 O 6.9300 1.3338 0.0 0
M  V30 7 O 11.5500 4.0011 0.0 0
M  V30 8 C 12.3200 5.3347 0.0 0
M  V30 9 C 6.9300 4.0011 0.0 0
M  V30 10 C 7.7000 5.3347 0.0 0
M  V30 11 C 7.7000 2.6674 0.0 0
M  V30 12 C 9.2400 5.3347 0.0 0
M  V30 13 C 9.2400 2.6674 0.0 0
M  V30 14 C 10.0100 4.0011 0.0 0
M  V30 15 C 3.0800 5.3347 0.0 0
M  V30 16 C 2.3100 6.6685 0.0 0
M  V30 17 C 2.3100 4.0011 0.0 0
M  V30 18 C 0.7700 6.6685 0.0 0
M  V30 19 C 0.7700 4.0011 0.0 0
M  V30 20 C 0.0000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3 CFG=2
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 3 4
M  V30 6 1 4 5
M  V30 7 2 4 6
M  V30 8 1 7 8
M  V30 9 1 7 14
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propylamine
C3H9N
107-10-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 C 2.6673 0.7700 0.0 0
M  V30 3 C 0.0000 0.7700 0.0 0
M  V30 4 N 4.0010 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Methoxy--(phenylmethylene)-N-propylbenzenepropanamide
C20H23NO2
2415251-33-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9301 5.3348 0.0 0
M  V30 2 C 7.7001 4.0011 0.0 0
M  V30 3 C 7.7001 6.6684 0.0 0
M  V30 4 C 9.2401 6.6684 0.0 0
M  V30 5 N 10.0101 8.0022 0.0 0
M  V30 6 O 10.0101 5.3348 0.0 0
M  V30 7 C 11.5501 8.0022 0.0 0
M  V30 8 C 12.3201 9.3359 0.0 0
M  V30 9 C 13.8602 9.3359 0.0 0
M  V30 10 O 0.7700 5.3348 0.0 0
M  V30 11 C 0.0000 6.6684 0.0 0
M  V30 12 C 5.3901 5.3348 0.0 0
M  V30 13 C 4.6201 4.0011 0.0 0
M  V30 14 C 4.6201 6.6684 0.0 0
M  V30 15 C 3.0800 4.0011 0.0 0
M  V30 16 C 3.0800 6.6684 0.0 0
M  V30 17 C 2.3100 5.3348 0.0 0
M  V30 18 C 6.9301 2.6675 0.0 0
M  V30 19 C 7.7001 1.3337 0.0 0
M  V30 20 C 5.3901 2.6675 0.0 0
M  V30 21 C 6.9301 0.0000 0.0 0
M  V30 22 C 4.6201 1.3337 0.0 0
M  V30 23 C 5.3901 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2 CFG=2
M  V30 2 1 1 3
M  V30 3 1 1 12
M  V30 4 1 2 18
M  V30 5 1 3 4
M  V30 6 1 4 5
M  V30 7 2 4 6
M  V30 8 1 5 7
M  V30 9 1 7 8
M  V30 10 1 8 9
M  V30 11 1 10 11
M  V30 12 1 10 17
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1562348-91-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 107-10-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2415251-33-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-117-CAS-22288687
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Induced osteoblast differentiation by amide derivatives of stilbene: The
possible osteogenic agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Imran Ahamad, Mohd.; Prakash, Ravi; John, Aijaz A.; Wani, Zahoor; Yadav,
Deepika; Bawankule, Dnyaneshwar U.; Luqman, Suaib; Khan, Feroz; Singh,
Divya; Gupta, Atul
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(11), 127138

$RFMT $RIREG SCHEME56 STEP1
$RXN



  2  1
$MOL
tert-Butylamine
C4H11N
75-64-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 1.5400 0.0 0
M  V30 2 C 0.0000 1.5400 0.0 0
M  V30 3 C 1.5400 3.0800 0.0 0
M  V30 4 C 3.0800 1.5400 0.0 0
M  V30 5 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-(trifluoromethyl)benzoic acid
C8H6F3NO2
402-13-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 2.6673 0.0 0
M  V30 2 F 6.9300 4.2073 0.0 0
M  V30 3 F 8.4700 2.6673 0.0 0
M  V30 4 F 6.9300 1.1273 0.0 0
M  V30 5 N 2.3100 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 O 0.0000 4.0011 0.0 0
M  V30 8 O 0.0000 1.3336 0.0 0
M  V30 9 C 5.3900 2.6673 0.0 0
M  V30 10 C 4.6200 1.3336 0.0 0
M  V30 11 C 4.6200 4.0011 0.0 0
M  V30 12 C 3.0800 1.3336 0.0 0
M  V30 13 C 3.0800 4.0011 0.0 0
M  V30 14 C 2.3100 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 9
M  V30 5 1 5 12
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 6 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-(1,1-dimethylethyl)-4-(trifluoromethyl)benzamide
C12H15F3N2O
142641-24-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.6673 0.0 0
M  V30 2 N 3.0800 4.0009 0.0 0
M  V30 3 O 3.0800 1.3336 0.0 0
M  V30 4 C 1.5400 4.0009 0.0 0
M  V30 5 C 1.5400 5.5409 0.0 0
M  V30 6 C 0.0000 4.0009 0.0 0
M  V30 7 C 1.5400 2.4609 0.0 0
M  V30 8 N 5.3900 0.0000 0.0 0
M  V30 9 C 10.0100 2.6673 0.0 0
M  V30 10 F 10.0100 1.1273 0.0 0
M  V30 11 F 11.5500 2.6673 0.0 0
M  V30 12 F 10.0100 4.2073 0.0 0
M  V30 13 C 5.3900 2.6673 0.0 0
M  V30 14 C 6.1600 1.3336 0.0 0
M  V30 15 C 6.1600 4.0009 0.0 0
M  V30 16 C 7.7000 1.3336 0.0 0
M  V30 17 C 7.7000 4.0009 0.0 0
M  V30 18 C 8.4700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 14
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 9 12
M  V30 12 1 9 18
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-64-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 402-13-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 142641-24-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40329134
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of HDAC6, HDAC8, and 6/8 Inhibitors and Development of
Cell-Based Drug Screening Models for the Treatment of TGF--Induced
Idiopathic Pulmonary Fibrosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yu, Wei-Chieh; Yeh, Tsung-Yu; Ye, Chih-Hung; Chong, Patrick Chun Theng;
Ho, Yi-Hsun; So, Dorothy Kazuno; Yap, Kah Yi; Peng, Guan-Ru; Shao,
Chi-Hsuan; Jagtap, Ajit Dhananjay; Chern, Ji-Wang; Lin, Chen-Si; Lin,
Shau-Ping; Lin, Shuei-Liong; Yu, Shu-Han; Yu, Chao-Wu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(15), 10528-10557

$RFMT $RIREG SCHEME57 STEP1
$RXN



  2  1
$MOL
BOC-D-alanine
C8H15NO4
7764-95-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0 CFG=2
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 8.0023 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 1.3337 2.3101 0.0 0
M  V30 9 O 8.0023 0.0000 0.0 0
M  V30 10 O 9.3360 2.3101 0.0 0
M  V30 11 C 0.5637 0.9764 0.0 0
M  V30 12 C 0.0000 3.0801 0.0 0
M  V30 13 C 2.1037 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7 CFG=3
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzylamine
C7H9N
100-46-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 N 5.3901 2.6673 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 2.3101 2.6673 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, [(1R)-1-methyl-2-oxo-2-[(phenylmethyl)amino]ethyl]-, 1,1-dimet...
C15H22N2O3
140866-04-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 C 8.0022 2.3101 0.0 0 CFG=1
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 N 9.3358 1.5400 0.0 0
M  V30 7 C 8.0022 3.8501 0.0 0
M  V30 8 C 10.6697 2.3101 0.0 0
M  V30 9 O 12.0033 1.5400 0.0 0
M  V30 10 O 10.6697 3.8501 0.0 0
M  V30 11 C 13.3370 2.3101 0.0 0
M  V30 12 C 14.1070 0.9764 0.0 0
M  V30 13 C 14.6707 3.0801 0.0 0
M  V30 14 C 12.5670 3.6437 0.0 0
M  V30 15 C 2.6673 2.3101 0.0 0
M  V30 16 C 1.3337 1.5400 0.0 0
M  V30 17 C 2.6673 3.8501 0.0 0
M  V30 18 C 0.0000 2.3101 0.0 0
M  V30 19 C 1.3337 4.6201 0.0 0
M  V30 20 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 4 7 CFG=1
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7764-95-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 100-46-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 140866-04-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33804705
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide
[(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like
Properties and Potent Antiseizure Activity In Vivo
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Abram, Michal; Jakubiec, Marcin; Reeb, Katelyn; Cheng, Mary Hongying;
Gedschold, Robin; Rapacz, Anna; Mogilski, Szczepan; Socala, Katarzyna;
Nieoczym, Dorota; Szafarz, Malgorzata; Latacz, Gniewomir; Szulczyk,
Bartlomiej; Kalinowska-Tluscik, Justyna; Gawel, Kinga; Esguerra, Camila
V.; Wyska, Elzbieta; Muller, Christa E.; Bahar, Ivet; Fontana, Andreia C.
K.; Wlaz, Piotr; Kaminski, Rafal M.; Kaminski, Krzysztof
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(17), 11703-11725

$RFMT $RIREG SCHEME58 STEP1
$RXN



  2  1
$MOL
Boc-L-alanine
C8H15NO4
15761-38-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0 CFG=1
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 8.0023 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 1.3337 2.3101 0.0 0
M  V30 9 O 8.0023 0.0000 0.0 0
M  V30 10 O 9.3360 2.3101 0.0 0
M  V30 11 C 0.5637 0.9764 0.0 0
M  V30 12 C 0.0000 3.0801 0.0 0
M  V30 13 C 2.1037 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7 CFG=1
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzylamine
C7H9N
100-46-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 N 5.3901 2.6673 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 2.3101 2.6673 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[(1S)-1-methyl-2-oxo-2-[(phenylmethyl)amino]ethyl]carbamate
C15H22N2O3
51814-55-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 C 8.0022 2.3101 0.0 0 CFG=2
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 N 9.3358 1.5400 0.0 0
M  V30 7 C 8.0022 3.8501 0.0 0
M  V30 8 C 10.6697 2.3101 0.0 0
M  V30 9 O 12.0033 1.5400 0.0 0
M  V30 10 O 10.6697 3.8501 0.0 0
M  V30 11 C 13.3370 2.3101 0.0 0
M  V30 12 C 14.1070 0.9764 0.0 0
M  V30 13 C 14.6707 3.0801 0.0 0
M  V30 14 C 12.5670 3.6437 0.0 0
M  V30 15 C 2.6673 2.3101 0.0 0
M  V30 16 C 1.3337 1.5400 0.0 0
M  V30 17 C 2.6673 3.8501 0.0 0
M  V30 18 C 0.0000 2.3101 0.0 0
M  V30 19 C 1.3337 4.6201 0.0 0
M  V30 20 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 4 7 CFG=3
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 15761-38-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 100-46-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 51814-55-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34105356
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide
[(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like
Properties and Potent Antiseizure Activity In Vivo
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Abram, Michal; Jakubiec, Marcin; Reeb, Katelyn; Cheng, Mary Hongying;
Gedschold, Robin; Rapacz, Anna; Mogilski, Szczepan; Socala, Katarzyna;
Nieoczym, Dorota; Szafarz, Malgorzata; Latacz, Gniewomir; Szulczyk,
Bartlomiej; Kalinowska-Tluscik, Justyna; Gawel, Kinga; Esguerra, Camila
V.; Wyska, Elzbieta; Muller, Christa E.; Bahar, Ivet; Fontana, Andreia C.
K.; Wlaz, Piotr; Kaminski, Rafal M.; Kaminski, Krzysztof
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(17), 11703-11725

$RFMT $RIREG SCHEME59 STEP1
$RXN



  2  1
$MOL
Benzyloxycarbonylglycine
C10H11NO4
1138-80-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 O 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 N 8.0022 2.3101 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 9.3360 1.5400 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 O 12.0033 1.5400 0.0 0
M  V30 9 O 10.6697 3.8501 0.0 0
M  V30 10 C 2.6673 2.3101 0.0 0
M  V30 11 C 2.6673 3.8501 0.0 0
M  V30 12 C 1.3337 1.5400 0.0 0
M  V30 13 C 1.3337 4.6201 0.0 0
M  V30 14 C 0.0000 2.3101 0.0 0
M  V30 15 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Glycine methyl ester hydrochloride
C3H7NO2.ClH
5680-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.0800 0.0 0
M  V30 2 C 1.3338 3.8500 0.0 0
M  V30 3 O 4.0011 3.8500 0.0 0
M  V30 4 O 2.6674 1.5400 0.0 0
M  V30 5 N 0.0000 3.0800 0.0 0
M  V30 6 C 5.3349 3.0800 0.0 0
M  V30 7 Cl 2.6674 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(Phenylmethoxy)carbonyl]glycylglycine methyl ester
C13H16N2O5
13437-63-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 O 5.3348 2.3100 0.0 0
M  V30 3 C 6.6686 3.0800 0.0 0
M  V30 4 N 8.0022 2.3100 0.0 0
M  V30 5 O 6.6686 4.6201 0.0 0
M  V30 6 C 9.3359 3.0800 0.0 0
M  V30 7 C 10.6695 2.3100 0.0 0
M  V30 8 N 12.0034 3.0800 0.0 0
M  V30 9 O 10.6695 0.7700 0.0 0
M  V30 10 C 13.3370 2.3100 0.0 0
M  V30 11 C 14.6707 3.0800 0.0 0
M  V30 12 O 16.0043 2.3100 0.0 0
M  V30 13 O 14.6707 4.6201 0.0 0
M  V30 14 C 17.3381 3.0800 0.0 0
M  V30 15 C 2.6675 2.3100 0.0 0
M  V30 16 C 1.3338 3.0800 0.0 0
M  V30 17 C 2.6675 0.7700 0.0 0
M  V30 18 C 0.0000 2.3100 0.0 0
M  V30 19 C 1.3338 0.0000 0.0 0
M  V30 20 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 12 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1138-80-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5680-79-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 13437-63-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23860462
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Exploring Structural Determinants of Inhibitor Affinity and Selectivity
in Complexes with Histone Deacetylase 6
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Osko, Jeremy D.; Porter, Nicholas J.; Narayana Reddy, Poli Adi; Xiao,
You-Cai; Rokka, Johanna; Jung, Manfred; Hooker, Jacob M.; Salvino, Joseph
M.; Christianson, David W.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(1), 295-308

$RFMT $RIREG SCHEME60 STEP1
$RXN



  2  1
$MOL
3-Cyano-5-fluorobenzoic acid
C8H4FNO2
327056-74-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 4.6201 0.0 0
M  V30 2 O 0.0000 3.8500 0.0 0
M  V30 3 O 1.3337 6.1601 0.0 0
M  V30 4 C 6.6686 4.6201 0.0 0
M  V30 5 N 8.0022 5.3901 0.0 0
M  V30 6 F 4.0011 0.0000 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 4.0011 4.6201 0.0 0
M  V30 9 C 2.6675 2.3100 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 11 C 4.0011 1.5400 0.0 0
M  V30 12 C 5.3348 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 3 4 5
M  V30 5 1 4 10
M  V30 6 1 6 11
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(S)-1-Phenylethylamine
C8H11N
2627-86-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0 CFG=1
M  V30 2 C 0.0000 2.6673 0.0 0
M  V30 3 N 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
3-Cyano-5-fluoro-N-[(1S)-1-phenylethyl]benzamide
C16H13FN2O
2852783-58-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 5.3348 3.8501 0.0 0
M  V30 3 O 6.6685 6.1601 0.0 0
M  V30 4 C 4.0010 4.6201 0.0 0 CFG=2
M  V30 5 C 4.0010 6.1601 0.0 0
M  V30 6 C 12.0033 4.6201 0.0 0
M  V30 7 N 13.3370 5.3901 0.0 0
M  V30 8 F 9.3360 0.0000 0.0 0
M  V30 9 C 8.0022 3.8501 0.0 0
M  V30 10 C 9.3360 4.6201 0.0 0
M  V30 11 C 8.0022 2.3101 0.0 0
M  V30 12 C 10.6697 3.8501 0.0 0
M  V30 13 C 9.3360 1.5400 0.0 0
M  V30 14 C 10.6697 2.3101 0.0 0
M  V30 15 C 2.6673 3.8501 0.0 0
M  V30 16 C 1.3337 4.6201 0.0 0
M  V30 17 C 2.6673 2.3101 0.0 0
M  V30 18 C 0.0000 3.8501 0.0 0
M  V30 19 C 1.3337 1.5400 0.0 0
M  V30 20 C 0.0000 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=3
M  V30 6 1 4 15
M  V30 7 3 6 7
M  V30 8 1 6 12
M  V30 9 1 8 13
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 327056-74-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2627-86-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2852783-58-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34588001
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the
Treatment of Malaria
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM de Lera Ruiz, Manuel; Favuzza, Paola; Guo, Zhuyan; Zhao, Lianyun; Hu,
Bin; Lei, Zhiyu; Zhan, Dongmei; Murgolo, Nicholas; Boyce, Christopher W.;
Vavrek, Marissa; Thompson, Jennifer; Ngo, Anna; Jarman, Kate E.; Robbins,
Johnathan; Boddey, Justin; Sleebs, Brad E.; Lowes, Kym N.; Cowman, Alan
F.; Olsen, David B.; McCauley, John A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(11), 1745-1754

$RFMT $RIREG SCHEME61 STEP1
$RXN



  2  1
$MOL
3-Furancarboxylic acid
C5H4O3
488-93-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7710 1.5400 0.0 0
M  V30 2 O 5.1048 2.3100 0.0 0
M  V30 3 O 3.7710 0.0000 0.0 0
M  V30 4 C 2.4374 2.3100 0.0 0
M  V30 5 C 1.0306 1.6835 0.0 0
M  V30 6 C 2.2764 3.8416 0.0 0
M  V30 7 C 0.0000 2.8281 0.0 0
M  V30 8 O 0.7700 4.1617 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Valine, methyl ester, hydrochloride (1:1)
C6H13NO2.ClH
6306-52-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.0800 0.0 0 CFG=1
M  V30 2 C 4.0011 3.8500 0.0 0
M  V30 3 C 1.3338 3.8500 0.0 0
M  V30 4 N 2.6674 1.5400 0.0 0
M  V30 5 O 5.3347 3.0800 0.0 0
M  V30 6 O 4.0011 5.3900 0.0 0
M  V30 7 C 0.0000 3.0800 0.0 0
M  V30 8 C 1.3338 5.3900 0.0 0
M  V30 9 C 6.6685 3.8500 0.0 0
M  V30 10 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 5 9
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(3-Furanylcarbonyl)-L-valine methyl ester
C11H15NO4
1189054-05-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 2.3101 0.0 0 CFG=1
M  V30 2 N 4.0012 3.0801 0.0 0
M  V30 3 C 1.3337 3.0801 0.0 0
M  V30 4 C 2.6673 0.7700 0.0 0
M  V30 5 C 5.3348 2.3101 0.0 0
M  V30 6 O 1.3337 4.6201 0.0 0
M  V30 7 O 0.0000 2.3101 0.0 0
M  V30 8 C 4.0012 0.0000 0.0 0
M  V30 9 C 1.3337 0.0000 0.0 0
M  V30 10 O 5.3348 0.7700 0.0 0
M  V30 11 C 0.0000 5.3901 0.0 0
M  V30 12 C 6.6685 3.0801 0.0 0
M  V30 13 C 6.8296 4.6116 0.0 0
M  V30 14 C 8.0755 2.4537 0.0 0
M  V30 15 C 8.3359 4.9318 0.0 0
M  V30 16 O 9.1059 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 4 9
M  V30 9 2 5 10
M  V30 10 1 5 12
M  V30 11 1 6 11
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 488-93-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6306-52-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1189054-05-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24775907
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of New Potent Positive Allosteric Modulators of Dopamine D2
Receptors: Insights into the Bioisosteric Replacement of Proline to
3-Furoic Acid in the Melanostatin Neuropeptide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sampaio-Dias, Ivo E.; Reis-Mendes, Ana; Costa, Vera Marisa; Garcia-Mera,
Xerardo; Brea, Jose; Loza, Maria Isabel; Pires-Lima, Beatriz L.;
Alcoholado, Cristina; Algarra, Manuel; Rodriguez-Borges, Jose E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(9), 6209-6220

$RFMT $RIREG SCHEME62 STEP1
$RXN



  2  1
$MOL
Naproxen
C14H14O3
22204-53-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 1.5400 0.0 0 CFG=2
M  V30 2 C 1.3337 2.3101 0.0 0
M  V30 3 C 2.6673 0.0000 0.0 0
M  V30 4 O 1.3337 3.8501 0.0 0
M  V30 5 O 0.0000 1.5400 0.0 0
M  V30 6 O 10.6697 4.6201 0.0 0
M  V30 7 C 12.0033 3.8501 0.0 0
M  V30 8 C 6.6685 2.3101 0.0 0
M  V30 9 C 6.6685 3.8501 0.0 0
M  V30 10 C 5.3348 1.5400 0.0 0
M  V30 11 C 8.0022 1.5400 0.0 0
M  V30 12 C 8.0022 4.6201 0.0 0
M  V30 13 C 5.3348 4.6201 0.0 0
M  V30 14 C 4.0012 2.3101 0.0 0
M  V30 15 C 9.3360 2.3101 0.0 0
M  V30 16 C 9.3360 3.8501 0.0 0
M  V30 17 C 4.0012 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 6 7
M  V30 7 1 6 16
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 9 13
M  V30 13 2 10 14
M  V30 14 2 11 15
M  V30 15 2 12 16
M  V30 16 2 13 17
M  V30 17 1 14 17
M  V30 18 1 15 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(S)-6-Methoxy--methyl-N-2-propyn-1-yl-2-naphthaleneacetamide
C17H17NO2
1060964-03-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 1.5400 0.0 0 CFG=2
M  V30 2 C 10.6698 2.3101 0.0 0
M  V30 3 C 9.3360 0.0000 0.0 0
M  V30 4 N 12.0035 1.5400 0.0 0
M  V30 5 O 10.6698 3.8501 0.0 0
M  V30 6 C 13.3372 2.3101 0.0 0
M  V30 7 C 14.6708 1.5400 0.0 0
M  V30 8 C 16.0046 0.7700 0.0 0
M  V30 9 O 1.3338 4.6201 0.0 0
M  V30 10 C 0.0000 3.8501 0.0 0
M  V30 11 C 5.3348 2.3101 0.0 0
M  V30 12 C 5.3348 3.8501 0.0 0
M  V30 13 C 6.6687 1.5400 0.0 0
M  V30 14 C 4.0012 1.5400 0.0 0
M  V30 15 C 4.0012 4.6201 0.0 0
M  V30 16 C 6.6687 4.6201 0.0 0
M  V30 17 C 8.0023 2.3101 0.0 0
M  V30 18 C 2.6675 2.3101 0.0 0
M  V30 19 C 2.6675 3.8501 0.0 0
M  V30 20 C 8.0023 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 3 7 8
M  V30 9 1 9 10
M  V30 10 1 9 19
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 11 14
M  V30 14 1 12 15
M  V30 15 1 12 16
M  V30 16 2 13 17
M  V30 17 2 14 18
M  V30 18 2 15 19
M  V30 19 2 16 20
M  V30 20 1 17 20
M  V30 21 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 22204-53-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1060964-03-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37043002
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM NSAID-Au(I) Complexes Induce ROS-Driven DAMPs and Interpose Inflammation
to Stimulate the Immune Response against Ovarian Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Xu, Zhongren; Lu, Qiuyue; Shan, Min; Jiang, Guizhi; Liu, Yuanhao; Yang,
Zhibin; Lu, Yunlong; Liu, Wukun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(12), 7813-7833

$RFMT $RIREG SCHEME63 STEP1
$RXN



  2  1
$MOL
4-(Trifluoromethyl)benzoic acid
C8H5F3O2
455-24-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 1.5400 0.0 0
M  V30 2 F 6.9300 3.0800 0.0 0
M  V30 3 F 8.4700 1.5400 0.0 0
M  V30 4 F 6.9300 0.0000 0.0 0
M  V30 5 C 0.7700 1.5400 0.0 0
M  V30 6 O 0.0000 0.2064 0.0 0
M  V30 7 O 0.0000 2.8736 0.0 0
M  V30 8 C 5.3900 1.5400 0.0 0
M  V30 9 C 4.6200 0.2064 0.0 0
M  V30 10 C 4.6200 2.8736 0.0 0
M  V30 11 C 3.0800 0.2064 0.0 0
M  V30 12 C 3.0800 2.8736 0.0 0
M  V30 13 C 2.3100 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Bromoaniline
C6H6BrN
591-19-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0.0000 3.0800 0.0 0
M  V30 2 N 5.3349 3.0800 0.0 0
M  V30 3 C 2.6675 3.0800 0.0 0
M  V30 4 C 1.3338 2.3100 0.0 0
M  V30 5 C 4.0011 2.3100 0.0 0
M  V30 6 C 1.3338 0.7700 0.0 0
M  V30 7 C 4.0011 0.7700 0.0 0
M  V30 8 C 2.6675 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3-Bromophenyl)-4-(trifluoromethyl)benzamide
C14H9BrF3NO
447431-41-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.4137 0.0 0
M  V30 2 N 8.0022 3.6437 0.0 0
M  V30 3 O 6.6685 5.9538 0.0 0
M  V30 4 C 1.3337 1.3337 0.0 0
M  V30 5 F 0.5637 2.6673 0.0 0
M  V30 6 F 0.0000 0.5637 0.0 0
M  V30 7 F 2.1037 0.0000 0.0 0
M  V30 8 Br 13.3370 3.6437 0.0 0
M  V30 9 C 5.3348 3.6437 0.0 0
M  V30 10 C 4.0010 4.4137 0.0 0
M  V30 11 C 5.3348 2.1037 0.0 0
M  V30 12 C 2.6673 3.6437 0.0 0
M  V30 13 C 4.0010 1.3337 0.0 0
M  V30 14 C 2.6673 2.1037 0.0 0
M  V30 15 C 9.3360 4.4137 0.0 0
M  V30 16 C 10.6697 3.6437 0.0 0
M  V30 17 C 9.3358 5.9538 0.0 0
M  V30 18 C 12.0033 4.4137 0.0 0
M  V30 19 C 10.6697 6.7238 0.0 0
M  V30 20 C 12.0033 5.9538 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 4 14
M  V30 9 1 8 18
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 455-24-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 591-19-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 447431-41-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23643185
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of 1H-indazole derivatives as
novel ASK1 inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hou, Shaohua; Yang, Xiping; Yang, Yuejing; Tong, Yu; Chen, Quanwei; Wan,
Boheng; Wei, Ran; Lu, Tao; Chen, Yadong; Hu, Qinghua
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 220113482

$RFMT $RIREG SCHEME64 STEP1
$RXN



  2  1
$MOL
4-Pyridinecarboxylic acid
C6H5NO2
55-22-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 N 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Leucine, ethyl ester, hydrochloride (1:1)
C8H17NO2.ClH
2743-40-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.8500 0.0 0 CFG=1
M  V30 2 C 5.3348 3.0800 0.0 0
M  V30 3 C 2.6675 3.0800 0.0 0
M  V30 4 N 4.0011 5.3900 0.0 0
M  V30 5 O 6.6684 3.8500 0.0 0
M  V30 6 O 5.3348 1.5400 0.0 0
M  V30 7 C 1.3337 3.8500 0.0 0
M  V30 8 C 8.0022 3.0800 0.0 0
M  V30 9 C 0.0000 3.0800 0.0 0
M  V30 10 C 1.3337 5.3900 0.0 0
M  V30 11 C 9.3359 3.8500 0.0 0
M  V30 12 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H20N2O3
3054992-10-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 5.3347 0.0 0 CFG=1
M  V30 2 N 4.6200 5.3347 0.0 0
M  V30 3 C 2.3100 4.0011 0.0 0
M  V30 4 C 2.3100 6.6685 0.0 0
M  V30 5 C 5.3900 6.6685 0.0 0
M  V30 6 O 3.0800 2.6674 0.0 0
M  V30 7 O 0.7700 4.0011 0.0 0
M  V30 8 C 0.7700 6.6685 0.0 0
M  V30 9 O 4.6200 8.0021 0.0 0
M  V30 10 C 2.3100 1.3336 0.0 0
M  V30 11 C 0.0000 8.0021 0.0 0
M  V30 12 C 0.0000 5.3347 0.0 0
M  V30 13 C 3.0800 0.0000 0.0 0
M  V30 14 C 6.9300 6.6685 0.0 0
M  V30 15 C 7.7000 5.3347 0.0 0
M  V30 16 C 7.7000 8.0021 0.0 0
M  V30 17 C 9.2400 5.3347 0.0 0
M  V30 18 C 9.2400 8.0021 0.0 0
M  V30 19 N 10.0100 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 2 5 9
M  V30 9 1 5 14
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 1 10 13
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 55-22-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2743-40-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3054992-10-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36966237
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing
Covalent Reversible -Fluorovinylsulfones and -Sulfonates as Potential
Immunomodulators in Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fuchs, Natalie; Meta, Mergim; Lantzberg, Bellinda; Bros, Matthias; Ling
Kuan, Seah; Weil, Tanja; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(15), e202300160

$RFMT $RIREG SCHEME65 STEP1
$RXN



  2  1
$MOL
trans-Cinnamic acid
C9H8O2
140-10-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 C 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-(aminomethyl)-, methyl ester, hydrochloride (1:1)
C9H11NO2.ClH
6232-11-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0800 0.0 0
M  V30 2 O 1.3337 3.8501 0.0 0
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 C 0.0000 3.0800 0.0 0
M  V30 5 C 8.0023 6.1601 0.0 0
M  V30 6 N 9.3360 5.3901 0.0 0
M  V30 7 C 4.0012 3.8501 0.0 0
M  V30 8 C 4.0012 5.3901 0.0 0
M  V30 9 C 5.3348 3.0800 0.0 0
M  V30 10 C 5.3348 6.1601 0.0 0
M  V30 11 C 6.6685 3.8501 0.0 0
M  V30 12 C 6.6685 5.3901 0.0 0
M  V30 13 Cl 4.6680 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[[[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]methyl]benzoate
C18H17NO3
2222630-45-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 14.6705 1.5400 0.0 0
M  V30 2 O 16.0041 2.3100 0.0 0
M  V30 3 O 14.6705 0.0000 0.0 0
M  V30 4 C 17.3379 1.5400 0.0 0
M  V30 5 C 9.3358 4.6200 0.0 0
M  V30 6 N 8.0021 3.8500 0.0 0
M  V30 7 C 6.6685 4.6200 0.0 0
M  V30 8 C 5.3347 3.8500 0.0 0
M  V30 9 O 6.6685 6.1600 0.0 0
M  V30 10 C 4.0011 4.6200 0.0 0
M  V30 11 C 13.3369 2.3100 0.0 0
M  V30 12 C 13.3369 3.8500 0.0 0
M  V30 13 C 12.0032 1.5400 0.0 0
M  V30 14 C 12.0032 4.6200 0.0 0
M  V30 15 C 10.6694 2.3100 0.0 0
M  V30 16 C 10.6694 3.8500 0.0 0
M  V30 17 C 2.6674 3.8500 0.0 0
M  V30 18 C 1.3338 4.6200 0.0 0
M  V30 19 C 2.6674 2.3100 0.0 0
M  V30 20 C 0.0000 3.8500 0.0 0
M  V30 21 C 1.3338 1.5400 0.0 0
M  V30 22 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 16
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 10 17
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 140-10-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6232-11-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2222630-45-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39787033
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 584-08-7
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Determination of Slow-Binding HDAC Inhibitor Potency and Subclass
Selectivity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Moreno-Yruela, Carlos; Olsen, Christian A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(5), 779-785

$RFMT $RIREG SCHEME66 STEP1
$RXN



  2  1
$MOL
4-Fluorobenzoic acid
C7H5FO2
456-22-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 0.0000 0.0 0
M  V30 3 O 0.0000 2.6673 0.0 0
M  V30 4 F 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-(Trifluoromethyl)aniline
C7H6F3N
98-16-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 3.0801 0.0 0
M  V30 2 F 2.1038 4.4137 0.0 0
M  V30 3 F 0.0000 3.8501 0.0 0
M  V30 4 F 0.5638 1.7464 0.0 0
M  V30 5 N 6.6687 3.0801 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 3.0801 0.0 0
M  V30 8 C 2.6675 0.7700 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 0.0000 0.0 0
M  V30 11 C 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 6
M  V30 5 1 5 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluoro-N-[3-(trifluoromethyl)phenyl]benzamide
C14H9F4NO
2054-00-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0022 2.3101 0.0 0
M  V30 2 N 6.6685 3.0801 0.0 0
M  V30 3 O 8.0022 0.7700 0.0 0
M  V30 4 F 13.3370 5.3901 0.0 0
M  V30 5 C 1.3337 3.0801 0.0 0
M  V30 6 F 2.1037 4.4137 0.0 0
M  V30 7 F 0.0000 3.8501 0.0 0
M  V30 8 F 0.5637 1.7464 0.0 0
M  V30 9 C 9.3360 3.0801 0.0 0
M  V30 10 C 10.6697 2.3101 0.0 0
M  V30 11 C 9.3360 4.6201 0.0 0
M  V30 12 C 12.0033 3.0801 0.0 0
M  V30 13 C 10.6697 5.3901 0.0 0
M  V30 14 C 12.0033 4.6201 0.0 0
M  V30 15 C 5.3348 2.3101 0.0 0
M  V30 16 C 4.0010 3.0801 0.0 0
M  V30 17 C 5.3348 0.7700 0.0 0
M  V30 18 C 2.6673 2.3101 0.0 0
M  V30 19 C 4.0010 0.0000 0.0 0
M  V30 20 C 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 4 14
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 5 18
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 456-22-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 98-16-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2054-00-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36209034
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Activity of N-phenylbenzamide analogs against the neglected disease
pathogen, Schistosoma mansoni
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kanyanta, Masebe; Lengwe, Chilufya; Mambwe, Dickson; Francisco, Karol R.;
Liu, Lawrence J.; Uli Sun, Yujie; Amarasinghe, Dilini K.; Caffrey, Conor
R.; Mubanga Cheuka, Peter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2023), 82129164

$RFMT $RIREG SCHEME67 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Ethynylaniline
C8H7N
54060-30-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.0801 0.0 0
M  V30 2 C 6.6687 3.8501 0.0 0
M  V30 3 N 0.0000 3.0801 0.0 0
M  V30 4 C 4.0012 2.3101 0.0 0
M  V30 5 C 2.6675 3.0801 0.0 0
M  V30 6 C 4.0012 0.7700 0.0 0
M  V30 7 C 1.3338 2.3101 0.0 0
M  V30 8 C 2.6675 0.0000 0.0 0
M  V30 9 C 1.3338 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 3 1 2
M  V30 2 1 1 4
M  V30 3 1 3 7
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[2-[(3-ethynylphenyl)amino]-2-oxoethyl]carbamate
C15H18N2O3
913845-55-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 9.3360 3.0801 0.0 0
M  V30 2 C 8.0023 2.3101 0.0 0
M  V30 3 C 6.6687 3.0801 0.0 0
M  V30 4 O 8.0023 0.7700 0.0 0
M  V30 5 N 5.3348 2.3101 0.0 0
M  V30 6 C 4.0012 3.0801 0.0 0
M  V30 7 O 2.6675 2.3101 0.0 0
M  V30 8 O 4.0012 4.6201 0.0 0
M  V30 9 C 1.3338 3.0801 0.0 0
M  V30 10 C 0.5638 1.7464 0.0 0
M  V30 11 C 0.0000 3.8501 0.0 0
M  V30 12 C 2.1038 4.4137 0.0 0
M  V30 13 C 14.6708 3.0801 0.0 0
M  V30 14 C 16.0046 3.8501 0.0 0
M  V30 15 C 10.6698 2.3101 0.0 0
M  V30 16 C 12.0035 3.0801 0.0 0
M  V30 17 C 10.6698 0.7700 0.0 0
M  V30 18 C 13.3372 2.3101 0.0 0
M  V30 19 C 12.0035 0.0000 0.0 0
M  V30 20 C 13.3372 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 3 13 14
M  V30 14 1 13 18
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 54060-30-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 913845-55-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37259405
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Metal binding pharmacophore click-derived discovery of new broad-spectrum
metallo--lactamase inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yan, Yu-Hang; Ding, Hao-Sheng; Zhu, Kai-Rong; Mu, Bin-Song; Zheng, Yang;
Huang, Meng-Yi; Zhou, Cong; Li, Wen-Fang; Wang, Zhenling; Wu, Yong; Li,
Guo-Bo
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 257115473

$RFMT $RIREG SCHEME68 STEP1
$RXN



  2  1
$MOL
tert-Butylamine
C4H11N
75-64-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 1.5400 0.0 0
M  V30 2 C 0.0000 1.5400 0.0 0
M  V30 3 C 1.5400 3.0800 0.0 0
M  V30 4 C 3.0800 1.5400 0.0 0
M  V30 5 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Piperidine-1,4-dicarboxylic acid mono-tert-butyl ester
C11H19NO4
84358-13-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9301 2.8737 0.0 0
M  V30 2 O 7.7001 1.5400 0.0 0
M  V30 3 O 7.7001 4.2073 0.0 0
M  V30 4 C 9.2401 1.5400 0.0 0
M  V30 5 C 9.2401 3.0800 0.0 0
M  V30 6 C 10.7801 1.5400 0.0 0
M  V30 7 C 9.2401 0.0000 0.0 0
M  V30 8 C 0.7700 2.8737 0.0 0
M  V30 9 O 0.0000 4.2073 0.0 0
M  V30 10 O 0.0000 1.5400 0.0 0
M  V30 11 N 5.3901 2.8737 0.0 0
M  V30 12 C 4.6201 4.2073 0.0 0
M  V30 13 C 4.6201 1.5400 0.0 0
M  V30 14 C 3.0800 4.2073 0.0 0
M  V30 15 C 3.0800 1.5400 0.0 0
M  V30 16 C 2.3100 2.8737 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 16
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinecarboxylate
C15H28N2O3
1050585-74-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8736 0.0 0
M  V30 2 N 3.0800 4.2073 0.0 0
M  V30 3 O 3.0800 1.5400 0.0 0
M  V30 4 C 1.5400 4.2073 0.0 0
M  V30 5 C 1.5400 5.7473 0.0 0
M  V30 6 C 0.0000 4.2073 0.0 0
M  V30 7 C 1.5400 2.6673 0.0 0
M  V30 8 C 10.0100 2.8736 0.0 0
M  V30 9 O 10.7800 1.5400 0.0 0
M  V30 10 O 10.7800 4.2073 0.0 0
M  V30 11 C 12.3200 1.5400 0.0 0
M  V30 12 C 12.3200 0.0000 0.0 0
M  V30 13 C 13.8600 1.5400 0.0 0
M  V30 14 C 12.3200 3.0800 0.0 0
M  V30 15 C 5.3900 2.8736 0.0 0
M  V30 16 C 6.1600 1.5400 0.0 0
M  V30 17 C 6.1600 4.2073 0.0 0
M  V30 18 C 7.7000 1.5400 0.0 0
M  V30 19 C 7.7000 4.2073 0.0 0
M  V30 20 N 8.4700 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 20
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-64-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 84358-13-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1050585-74-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40640896
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for
Platelet Degranulation Modulation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bayrak, Alp; Mohr, Florian; Kolb, Kyra; Szpakowska, Martyna; Shevchenko,
Ekaterina; Dicenta, Valerie; Rohlfing, Anne-Katrin; Kudolo, Mark;
Pantsar, Tatu; Guenther, Marcel; Kaczor, Agnieszka A.; Poso, Antti;
Chevigne, Andy; Pillaiyar, Thanigaimalai; Gawaz, Meinrad; Laufer, Stefan
A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(19), 13365-13384

$RFMT $RIREG SCHEME69 STEP1
$RXN



  2  1
$MOL
2,4-Dichloronicotinic acid
C6H3Cl2NO2
262423-77-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 1.3338 0.0 0
M  V30 3 O 0.0000 4.0012 0.0 0
M  V30 4 Cl 2.3101 5.3350 0.0 0
M  V30 5 Cl 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6675 0.0 0
M  V30 7 C 3.0801 4.0012 0.0 0
M  V30 8 C 3.0801 1.3338 0.0 0
M  V30 9 C 4.6201 4.0012 0.0 0
M  V30 10 N 4.6201 1.3338 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 8
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
D-Alaninol
C3H9NO
35320-23-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0 CFG=2
M  V30 2 C 2.6673 2.3101 0.0 0
M  V30 3 C 1.3337 0.0000 0.0 0
M  V30 4 N 0.0000 2.3101 0.0 0
M  V30 5 O 4.0010 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
3-Pyridinecarboxamide, 2,4-dichloro-N-[(1R)-2-chloro-1-methylethyl]-
C9H9Cl3N2O
3034305-31-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 N 5.3347 2.3100 0.0 0
M  V30 3 O 4.0011 4.6200 0.0 0
M  V30 4 C 6.6684 3.0800 0.0 0 CFG=2
M  V30 5 C 8.0021 2.3100 0.0 0
M  V30 6 C 6.6684 4.6200 0.0 0
M  V30 7 Cl 9.3358 3.0800 0.0 0
M  V30 8 Cl 4.0011 0.0000 0.0 0
M  V30 9 Cl 1.3336 4.6200 0.0 0
M  V30 10 C 2.6674 2.3100 0.0 0
M  V30 11 C 2.6674 0.7700 0.0 0
M  V30 12 C 1.3336 3.0800 0.0 0
M  V30 13 C 1.3336 0.0000 0.0 0
M  V30 14 N 0.0000 2.3100 0.0 0
M  V30 15 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 1 8 11
M  V30 9 1 9 12
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 262423-77-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 35320-23-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3034305-31-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39945512
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 4
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 108-88-3
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Commercial Route Development Toward PF-07265807, an AXL-MER Inhibitor
Oncology Candidate
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Critcher, Douglas J.; Ashcroft, Christopher Paul; Pettman, Alan J.;
Badland, Matthew; Szpera, Robert; Waddington, William
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2024), 28(7), 2646-2658

$RFMT $RIREG SCHEME70 STEP1
$RXN



  2  1
$MOL
3-Bromo-5-iodobenzoic acid
C7H4BrIO2
188815-32-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 4.6200 0.0 0
M  V30 2 O 6.6685 3.8500 0.0 0
M  V30 3 O 5.3347 6.1600 0.0 0
M  V30 4 Br 0.0000 4.6200 0.0 0
M  V30 5 I 2.6674 0.0000 0.0 0
M  V30 6 C 4.0011 3.8500 0.0 0
M  V30 7 C 2.6674 4.6200 0.0 0
M  V30 8 C 4.0011 2.3100 0.0 0
M  V30 9 C 1.3338 3.8500 0.0 0
M  V30 10 C 2.6674 1.5400 0.0 0
M  V30 11 C 1.3338 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(+)-1-Phenylpropylamine
C9H13N
3082-64-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0 CFG=2
M  V30 2 C 5.3901 2.6673 0.0 0
M  V30 3 N 5.3901 0.0000 0.0 0
M  V30 4 C 6.9302 2.6673 0.0 0
M  V30 5 C 3.0801 1.3337 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 2.3101 0.0000 0.0 0
M  V30 8 C 0.7700 2.6673 0.0 0
M  V30 9 C 0.7700 0.0000 0.0 0
M  V30 10 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 5
M  V30 4 1 2 4
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzamide, 3-bromo-5-iodo-N-[(1R)-1-phenylpropyl]-
C16H15BrINO
3028287-93-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 4.6200 0.0 0
M  V30 2 N 5.3347 3.8500 0.0 0
M  V30 3 O 6.6684 6.1600 0.0 0
M  V30 4 C 4.0011 4.6200 0.0 0 CFG=1
M  V30 5 C 4.0011 6.1600 0.0 0
M  V30 6 C 2.6673 6.9300 0.0 0
M  V30 7 Br 9.3358 0.0000 0.0 0
M  V30 8 I 12.0031 4.6200 0.0 0
M  V30 9 C 8.0020 3.8500 0.0 0
M  V30 10 C 8.0020 2.3100 0.0 0
M  V30 11 C 9.3358 4.6200 0.0 0
M  V30 12 C 9.3358 1.5400 0.0 0
M  V30 13 C 10.6694 3.8500 0.0 0
M  V30 14 C 10.6694 2.3100 0.0 0
M  V30 15 C 2.6673 3.8500 0.0 0
M  V30 16 C 1.3336 4.6200 0.0 0
M  V30 17 C 2.6673 2.3100 0.0 0
M  V30 18 C 0.0000 3.8500 0.0 0
M  V30 19 C 1.3336 1.5400 0.0 0
M  V30 20 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=1
M  V30 6 1 4 15
M  V30 7 1 5 6
M  V30 8 1 7 12
M  V30 9 1 8 13
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 188815-32-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3082-64-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3028287-93-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37155046
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic
Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft
Model
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Maddeboina, Krishnaiah; Jonnalagadda, Sravan K.; Morsy, Ahmed; Duan,
Ling; Chhonker, Yashpal S.; Murry, Daryl J.; Penning, Trevor M.;
Trippier, Paul C.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(14), 9894-9915

$RFMT $RIREG SCHEME71 STEP1
$RXN



  2  1
$MOL
2-Fluoro-2-propenoic acid
C3H3FO2
430-99-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 1.5400 0.0 0
M  V30 2 C 1.3337 2.3101 0.0 0
M  V30 3 C 4.0010 2.3101 0.0 0
M  V30 4 F 2.6673 0.0000 0.0 0
M  V30 5 O 1.3337 3.8501 0.0 0
M  V30 6 O 0.0000 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
C12H18BNO2
214360-73-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.2114 4.5526 0.0 0
M  V30 2 C 0.0000 2.8854 0.0 0
M  V30 3 C 0.0000 1.6672 0.0 0
M  V30 4 C 1.2114 0.0000 0.0 0
M  V30 5 N 10.0615 2.2763 0.0 0
M  V30 6 B 3.9015 2.2763 0.0 0
M  V30 7 O 2.9962 3.5222 0.0 0
M  V30 8 O 2.9962 1.0304 0.0 0
M  V30 9 C 1.5315 3.0463 0.0 0
M  V30 10 C 1.5315 1.5063 0.0 0
M  V30 11 C 5.4415 2.2763 0.0 0
M  V30 12 C 6.2115 3.6099 0.0 0
M  V30 13 C 6.2115 0.9426 0.0 0
M  V30 14 C 7.7515 3.6099 0.0 0
M  V30 15 C 7.7515 0.9426 0.0 0
M  V30 16 C 8.5215 2.2763 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 1 2 9
M  V30 3 1 3 10
M  V30 4 1 4 10
M  V30 5 1 5 16
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 11
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, 2-fluoro-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe...
C15H19BFNO3
2901130-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.2114 4.5527 0.0 0
M  V30 2 C 0.0000 2.8853 0.0 0
M  V30 3 C 0.0000 1.6674 0.0 0
M  V30 4 C 1.2114 0.0000 0.0 0
M  V30 5 N 10.0614 2.2763 0.0 0
M  V30 6 C 10.8314 3.6101 0.0 0
M  V30 7 C 12.3714 3.6101 0.0 0
M  V30 8 O 10.0614 4.9437 0.0 0
M  V30 9 C 13.1414 4.9437 0.0 0
M  V30 10 F 13.1414 2.2764 0.0 0
M  V30 11 B 3.9014 2.2763 0.0 0
M  V30 12 O 2.9962 3.5223 0.0 0
M  V30 13 O 2.9962 1.0304 0.0 0
M  V30 14 C 1.5315 3.0463 0.0 0
M  V30 15 C 1.5315 1.5063 0.0 0
M  V30 16 C 5.4414 2.2763 0.0 0
M  V30 17 C 6.2114 0.9426 0.0 0
M  V30 18 C 6.2114 3.6101 0.0 0
M  V30 19 C 7.7514 0.9426 0.0 0
M  V30 20 C 7.7514 3.6101 0.0 0
M  V30 21 C 8.5214 2.2763 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 14
M  V30 2 1 2 14
M  V30 3 1 3 15
M  V30 4 1 4 15
M  V30 5 1 5 6
M  V30 6 1 5 21
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 7 10
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 11 16
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 430-99-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 214360-73-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2901130-88-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40816897
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of LHQ490 as a highly selective fibroblast growth factor
receptor 2 (FGFR2) inhibitor
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Huiqiong; Ke, Ran; Zhou, Yang; Chang, Shaohua; Wang, Jie; Su, Chen;
Wu, Pinglian; Yang, Bowen; Wang, Zhen; Ding, Ke; Ma, Dawei
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 272116473

$RFMT $RIREG SCHEME72 STEP1
$RXN



  2  1
$MOL
4,5-Dibromo-2-furancarboxylic acid
C5H2Br2O3
2434-03-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3026 4.0287 0.0 0
M  V30 2 O 6.6363 3.2587 0.0 0
M  V30 3 O 5.3026 5.5688 0.0 0
M  V30 4 Br 1.6752 0.0000 0.0 0
M  V30 5 Br 0.0000 2.9016 0.0 0
M  V30 6 C 3.9690 3.2587 0.0 0
M  V30 7 C 3.8079 1.7271 0.0 0
M  V30 8 O 2.5620 3.8850 0.0 0
M  V30 9 C 2.3016 1.4070 0.0 0
M  V30 10 C 1.5316 2.7406 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4,5-Dibromo-N-2-propyn-1-yl-2-furancarboxamide
C8H5Br2NO2
2698371-56-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3028 4.0287 0.0 0
M  V30 2 N 6.6365 3.2587 0.0 0
M  V30 3 O 5.3028 5.5688 0.0 0
M  V30 4 C 7.9701 4.0287 0.0 0
M  V30 5 C 9.3038 3.2587 0.0 0
M  V30 6 C 10.6376 2.4887 0.0 0
M  V30 7 Br 0.0000 2.9016 0.0 0
M  V30 8 Br 1.6752 0.0000 0.0 0
M  V30 9 C 3.9690 3.2587 0.0 0
M  V30 10 C 2.5622 3.8850 0.0 0
M  V30 11 O 3.8080 1.7271 0.0 0
M  V30 12 C 1.5317 2.7406 0.0 0
M  V30 13 C 2.3017 1.4070 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 3 5 6
M  V30 7 1 7 12
M  V30 8 1 8 13
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2434-03-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2698371-56-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24359763
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM From Synthetic Simplified Marine Metabolite Analogues to New Selective
Allosteric Inhibitor of Aurora B Kinase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Juillet, Charlotte; Ermolenko, Ludmila; Boyarskaya, Dina; Baratte,
Blandine; Josselin, Beatrice; Nedev, Hristo; Bach, Stephane; Iorga,
Bogdan I.; Bignon, Jerome; Ruchaud, Sandrine; Al-Mourabit, Ali
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(2), 1197-1219

$RFMT $RIREG SCHEME73 STEP1
$RXN



  2  1
$MOL
Benzoic acid
C7H6O2
65-85-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
C12H18BNO2
214360-73-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.2114 4.5526 0.0 0
M  V30 2 C 0.0000 2.8854 0.0 0
M  V30 3 C 0.0000 1.6672 0.0 0
M  V30 4 C 1.2114 0.0000 0.0 0
M  V30 5 N 10.0615 2.2763 0.0 0
M  V30 6 B 3.9015 2.2763 0.0 0
M  V30 7 O 2.9962 3.5222 0.0 0
M  V30 8 O 2.9962 1.0304 0.0 0
M  V30 9 C 1.5315 3.0463 0.0 0
M  V30 10 C 1.5315 1.5063 0.0 0
M  V30 11 C 5.4415 2.2763 0.0 0
M  V30 12 C 6.2115 3.6099 0.0 0
M  V30 13 C 6.2115 0.9426 0.0 0
M  V30 14 C 7.7515 3.6099 0.0 0
M  V30 15 C 7.7515 0.9426 0.0 0
M  V30 16 C 8.5215 2.2763 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 1 2 9
M  V30 3 1 3 10
M  V30 4 1 4 10
M  V30 5 1 5 16
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 11
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzamide
C19H22BNO3
935660-75-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.2114 0.0000 0.0 0
M  V30 2 C 0.0000 1.6674 0.0 0
M  V30 3 C 0.0000 2.8853 0.0 0
M  V30 4 C 1.2114 4.5527 0.0 0
M  V30 5 N 10.0614 2.2763 0.0 0
M  V30 6 C 10.8314 3.6101 0.0 0
M  V30 7 O 10.0614 4.9437 0.0 0
M  V30 8 B 3.9014 2.2763 0.0 0
M  V30 9 O 2.9962 1.0304 0.0 0
M  V30 10 O 2.9962 3.5223 0.0 0
M  V30 11 C 1.5315 1.5063 0.0 0
M  V30 12 C 1.5315 3.0463 0.0 0
M  V30 13 C 5.4414 2.2763 0.0 0
M  V30 14 C 6.2114 0.9426 0.0 0
M  V30 15 C 6.2114 3.6101 0.0 0
M  V30 16 C 7.7514 0.9426 0.0 0
M  V30 17 C 7.7514 3.6101 0.0 0
M  V30 18 C 8.5214 2.2763 0.0 0
M  V30 19 C 12.3714 3.6101 0.0 0
M  V30 20 C 13.1414 2.2764 0.0 0
M  V30 21 C 13.1414 4.9437 0.0 0
M  V30 22 C 14.6814 2.2764 0.0 0
M  V30 23 C 14.6814 4.9437 0.0 0
M  V30 24 C 15.4514 3.6101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 1 2 11
M  V30 3 1 3 12
M  V30 4 1 4 12
M  V30 5 1 5 6
M  V30 6 1 5 18
M  V30 7 2 6 7
M  V30 8 1 6 19
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 8 13
M  V30 12 1 9 11
M  V30 13 1 10 12
M  V30 14 1 11 12
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 65-85-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 214360-73-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 935660-75-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34637960
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain
of STAT3
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Deng, Lin; Mo, Jianshan; Zhang, Yi; Peng, Keren; Li, Huaxuan; Ouyang,
Shumin; Feng, Zongbo; Fang, Wei; Wei, Jianwei; Rong, Deqin; Zhang,
Xiaolei; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(19), 13094-13111

$RFMT $RIREG SCHEME74 STEP1
$RXN



  2  1
$MOL
3-Furancarboxylic acid
C5H4O3
488-93-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7710 1.5400 0.0 0
M  V30 2 O 5.1048 2.3100 0.0 0
M  V30 3 O 3.7710 0.0000 0.0 0
M  V30 4 C 2.4374 2.3100 0.0 0
M  V30 5 C 1.0306 1.6835 0.0 0
M  V30 6 C 2.2764 3.8416 0.0 0
M  V30 7 C 0.0000 2.8281 0.0 0
M  V30 8 O 0.7700 4.1617 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Leucine methyl ester hydrochloride
C7H15NO2.ClH
7517-19-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.8500 0.0 0 CFG=1
M  V30 2 C 5.3347 3.0800 0.0 0
M  V30 3 C 2.6674 3.0800 0.0 0
M  V30 4 N 4.0011 5.3900 0.0 0
M  V30 5 O 6.6685 3.8500 0.0 0
M  V30 6 O 5.3347 1.5400 0.0 0
M  V30 7 C 1.3336 3.8500 0.0 0
M  V30 8 C 8.0021 3.0800 0.0 0
M  V30 9 C 1.3336 5.3900 0.0 0
M  V30 10 C 0.0000 3.0800 0.0 0
M  V30 11 Cl 4.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(3-Furanylcarbonyl)-L-leucine methyl ester
C12H17NO4
2732919-57-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 4.0011 0.0 0 CFG=1
M  V30 2 N 4.6200 4.0011 0.0 0
M  V30 3 C 2.3100 2.6674 0.0 0
M  V30 4 C 2.3100 5.3347 0.0 0
M  V30 5 C 5.3900 5.3347 0.0 0
M  V30 6 O 3.0800 1.3338 0.0 0
M  V30 7 O 0.7700 2.6674 0.0 0
M  V30 8 C 0.7700 5.3347 0.0 0
M  V30 9 O 4.6200 6.6685 0.0 0
M  V30 10 C 2.3100 0.0000 0.0 0
M  V30 11 C 0.0000 4.0011 0.0 0
M  V30 12 C 0.0000 6.6685 0.0 0
M  V30 13 C 6.9300 5.3347 0.0 0
M  V30 14 C 7.8352 6.5807 0.0 0
M  V30 15 C 7.8352 4.0889 0.0 0
M  V30 16 C 9.2998 6.1047 0.0 0
M  V30 17 O 9.2998 4.5647 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 2 5 9
M  V30 9 1 5 13
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 488-93-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7517-19-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2732919-57-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24533574
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of New Potent Positive Allosteric Modulators of Dopamine D2
Receptors: Insights into the Bioisosteric Replacement of Proline to
3-Furoic Acid in the Melanostatin Neuropeptide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sampaio-Dias, Ivo E.; Reis-Mendes, Ana; Costa, Vera Marisa; Garcia-Mera,
Xerardo; Brea, Jose; Loza, Maria Isabel; Pires-Lima, Beatriz L.;
Alcoholado, Cristina; Algarra, Manuel; Rodriguez-Borges, Jose E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(9), 6209-6220

$RFMT $RIREG SCHEME75 STEP1
$RXN



  2  1
$MOL
Benzoic acid
C7H6O2
65-85-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Phenylalanine, methyl ester, hydrochloride
C10H13NO2.ClH
7524-50-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0 CFG=2
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 N 5.3347 5.3900 0.0 0
M  V30 5 O 8.0021 3.8500 0.0 0
M  V30 6 O 6.6684 1.5400 0.0 0
M  V30 7 C 9.3358 3.0800 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 3.0800 0.0 0
M  V30 10 C 2.6674 5.3900 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 6.1600 0.0 0
M  V30 13 C 0.0000 5.3900 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-Benzoylphenylalanine methyl ester
C17H17NO3
3005-61-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 5.3347 0.0 0 CFG=1
M  V30 2 C 2.3100 4.0011 0.0 0
M  V30 3 N 4.6200 5.3347 0.0 0
M  V30 4 C 2.3100 6.6685 0.0 0
M  V30 5 C 5.3900 6.6685 0.0 0
M  V30 6 O 0.7700 6.6685 0.0 0
M  V30 7 O 3.0800 8.0021 0.0 0
M  V30 8 O 4.6200 8.0021 0.0 0
M  V30 9 C 0.0000 8.0021 0.0 0
M  V30 10 C 3.0800 2.6674 0.0 0
M  V30 11 C 2.3100 1.3336 0.0 0
M  V30 12 C 4.6200 2.6674 0.0 0
M  V30 13 C 3.0800 0.0000 0.0 0
M  V30 14 C 5.3900 1.3336 0.0 0
M  V30 15 C 4.6200 0.0000 0.0 0
M  V30 16 C 6.9300 6.6685 0.0 0
M  V30 17 C 7.7000 5.3347 0.0 0
M  V30 18 C 7.7000 8.0021 0.0 0
M  V30 19 C 9.2400 5.3347 0.0 0
M  V30 20 C 9.2400 8.0021 0.0 0
M  V30 21 C 10.0100 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 10
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 5 16
M  V30 10 1 6 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 65-85-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7524-50-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3005-61-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-29435452
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 2135447-74-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM sealed flask used, Multi-gram scale, optimization study, optimized on
reagent and catalyst
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Insights into Fast Amide Couplings in Aqueous Nanomicelles
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sharma, Sudripet; Kaur, Gaganpreet; Handa, Sachin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(8), 1960-1965

$RFMT $RIREG SCHEME76 STEP1
$RXN



  2  1
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Butylamine
C4H11N
109-73-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0.7700 0.0 0
M  V30 2 C 1.3338 0.0000 0.0 0
M  V30 3 C 4.0010 0.0000 0.0 0
M  V30 4 C 0.0000 0.7700 0.0 0
M  V30 5 N 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-butyl-5-nitrobenzamide
C11H15N3O3
502144-21-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 C 9.2400 5.3347 0.0 0
M  V30 6 C 10.7800 5.3347 0.0 0
M  V30 7 C 11.5500 6.6685 0.0 0
M  V30 8 N 4.6200 0.0000 0.0 0
M  V30 9 N 1.5400 5.3347 0.0 0 VAL=5
M  V30 10 O 2.3100 6.6685 0.0 0
M  V30 11 O 0.0000 5.3347 0.0 0
M  V30 12 C 4.6200 2.6674 0.0 0
M  V30 13 C 3.8500 4.0011 0.0 0
M  V30 14 C 3.8500 1.3338 0.0 0
M  V30 15 C 2.3100 4.0011 0.0 0
M  V30 16 C 2.3100 1.3338 0.0 0
M  V30 17 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 2 9 11
M  V30 11 1 9 15
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 109-73-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 502144-21-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38624463
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of Quinazolinones and Quinazolinediones for
Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating
COP1-ATGL Axis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sarkar, Dipayan; Chowdhury, Saheli; Goon, Sunny; Sen, Abhishek; Dastidar,
Uddipta Ghosh; Mondal, Mohabul Alam; Chakrabarti, Partha; Talukdar,
Arindam
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(24), 16728-16761

$RFMT $RIREG SCHEME77 STEP1
$RXN



  2  1
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-nitrobenzoic acid
C7H6N2O4
619-17-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 4.6200 0.0 0 VAL=5
M  V30 2 O 8.0021 3.8500 0.0 0
M  V30 3 O 6.6685 6.1600 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 C 1.3336 1.5400 0.0 0
M  V30 6 O 0.0000 2.3100 0.0 0
M  V30 7 O 1.3336 0.0000 0.0 0
M  V30 8 C 5.3347 3.8500 0.0 0
M  V30 9 C 4.0011 4.6200 0.0 0
M  V30 10 C 5.3347 2.3100 0.0 0
M  V30 11 C 2.6674 3.8500 0.0 0
M  V30 12 C 4.0011 1.5400 0.0 0
M  V30 13 C 2.6674 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 11
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-nitro-N-phenylbenzamide
C13H11N3O3
2284567-70-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9301 2.6675 0.0 0
M  V30 2 N 7.7001 4.0011 0.0 0
M  V30 3 O 7.7001 1.3338 0.0 0
M  V30 4 N 5.3901 0.0000 0.0 0
M  V30 5 N 0.7700 2.6675 0.0 0 VAL=5
M  V30 6 O 0.0000 1.3338 0.0 0
M  V30 7 O 0.0000 4.0011 0.0 0
M  V30 8 C 5.3901 2.6675 0.0 0
M  V30 9 C 4.6201 1.3338 0.0 0
M  V30 10 C 4.6201 4.0011 0.0 0
M  V30 11 C 3.0800 1.3338 0.0 0
M  V30 12 C 3.0800 4.0011 0.0 0
M  V30 13 C 2.3100 2.6675 0.0 0
M  V30 14 C 9.2401 4.0011 0.0 0
M  V30 15 C 10.0101 5.3349 0.0 0
M  V30 16 C 10.0101 2.6675 0.0 0
M  V30 17 C 11.5501 5.3349 0.0 0
M  V30 18 C 11.5501 2.6675 0.0 0
M  V30 19 C 12.3201 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 14
M  V30 5 1 4 9
M  V30 6 2 5 6
M  V30 7 2 5 7
M  V30 8 1 5 13
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 619-17-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2284567-70-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31626803
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Piperazinobenzodiazepinones: New Encephalitic Alphavirus Inhibitors via
Ring Expansion of 2-Dichloromethylquinazolinones
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ryan, Michael C.; Kim, Eunjung; Cao, Xufeng; Reichard, Walter; Ogorek,
Tyler J.; Das, Pronay; Jonsson, Colleen B.; Baudry, Jerome; Chung,
Donghoon; Golden, Jennifer E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(4), 546-553

$RFMT $RIREG SCHEME78 STEP1
$RXN



  2  1
$MOL
2-Furanmethanamine
C5H7NO
617-89-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 2.6217 0.0 0
M  V30 2 N 5.1049 1.8517 0.0 0
M  V30 3 C 2.4374 1.8517 0.0 0
M  V30 4 C 2.2765 0.3202 0.0 0
M  V30 5 O 1.0306 2.4782 0.0 0
M  V30 6 C 0.7700 0.0000 0.0 0
M  V30 7 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
8-Azidooctanoic acid
C8H15N3O2
217180-76-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 C 8.0022 2.3101 0.0 0
M  V30 3 C 5.3348 2.3101 0.0 0
M  V30 4 C 9.3358 1.5400 0.0 0
M  V30 5 C 4.0010 1.5400 0.0 0
M  V30 6 C 10.6697 2.3101 0.0 0
M  V30 7 C 2.6673 2.3101 0.0 0
M  V30 8 N 12.0033 1.5400 0.0 0
M  V30 9 C 1.3337 1.5400 0.0 0
M  V30 10 N 13.3370 2.3101 0.0 0 CHG=1 VAL=4
M  V30 11 O 0.0000 2.3101 0.0 0
M  V30 12 O 1.3337 0.0000 0.0 0
M  V30 13 N 14.6707 3.0801 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 1 9 11
M  V30 11 2 9 12
M  V30 12 2 10 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Octanamide, 8-azido-N-(2-furanylmethyl)-
C13H20N4O2
2920115-45-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 1.5400 0.0 0
M  V30 2 N 5.1047 2.3101 0.0 0
M  V30 3 C 6.4386 1.5400 0.0 0
M  V30 4 C 7.7722 2.3101 0.0 0
M  V30 5 O 6.4386 0.0000 0.0 0
M  V30 6 C 9.1059 1.5400 0.0 0
M  V30 7 C 10.4396 2.3101 0.0 0
M  V30 8 C 11.7734 1.5400 0.0 0
M  V30 9 C 13.1071 2.3101 0.0 0
M  V30 10 C 14.4407 1.5400 0.0 0
M  V30 11 C 15.7744 2.3101 0.0 0
M  V30 12 N 17.1082 1.5400 0.0 0
M  V30 13 N 18.4419 2.3101 0.0 0 CHG=1 VAL=4
M  V30 14 N 19.7756 3.0801 0.0 0 CHG=-1
M  V30 15 C 2.4374 2.3101 0.0 0
M  V30 16 C 2.2763 3.8416 0.0 0
M  V30 17 O 1.0304 1.6836 0.0 0
M  V30 18 C 0.7700 4.1618 0.0 0
M  V30 19 C 0.0000 2.8281 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 2 13 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 617-89-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 217180-76-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2920115-45-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36300086
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and structure-activity relationship of new nicotinamide
phosphoribosyltransferase inhibitors with antitumor activity on solid and
haematological cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fratta, Simone; Biniecka, Paulina; Moreno-Vargas, Antonio J.; Carmona,
Ana T.; Nahimana, Aimable; Duchosal, Michel A.; Piacente, Francesco;
Bruzzone, Santina; Caffa, Irene; Nencioni, Alessio; Robina, Inmaculada
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 250115170

$RFMT $RIREG SCHEME79 STEP1
$RXN



  2  1
$MOL
4-Carboxyphenylboronic acid
C7H7BO4
14047-29-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 B 6.6686 1.5400 0.0 0
M  V30 2 O 8.0022 2.3100 0.0 0
M  V30 3 O 6.6686 0.0000 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 O 0.0000 3.8500 0.0 0
M  V30 6 O 1.3337 6.1601 0.0 0
M  V30 7 C 5.3348 2.3100 0.0 0
M  V30 8 C 4.0011 1.5400 0.0 0
M  V30 9 C 5.3348 3.8500 0.0 0
M  V30 10 C 2.6675 2.3100 0.0 0
M  V30 11 C 4.0011 4.6201 0.0 0
M  V30 12 C 2.6675 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 7
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Aminopyridine
C5H6N2
504-29-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 N 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
B-[4-[(2-Pyridinylamino)carbonyl]phenyl]boronic acid
C12H11BN2O3
850568-25-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6673 0.0 0
M  V30 2 N 4.6201 1.3337 0.0 0
M  V30 3 O 4.6201 4.0010 0.0 0
M  V30 4 B 11.5503 2.6673 0.0 0
M  V30 5 O 12.3203 1.3337 0.0 0
M  V30 6 O 12.3203 4.0010 0.0 0
M  V30 7 C 6.9302 2.6673 0.0 0
M  V30 8 C 7.7002 4.0010 0.0 0
M  V30 9 C 7.7002 1.3337 0.0 0
M  V30 10 C 9.2402 4.0010 0.0 0
M  V30 11 C 9.2402 1.3337 0.0 0
M  V30 12 C 10.0102 2.6673 0.0 0
M  V30 13 C 3.0801 1.3337 0.0 0
M  V30 14 C 2.3101 2.6673 0.0 0
M  V30 15 N 2.3101 0.0000 0.0 0
M  V30 16 C 0.7700 2.6673 0.0 0
M  V30 17 C 0.7700 0.0000 0.0 0
M  V30 18 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 13
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 12
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 14047-29-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 504-29-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 850568-25-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34952224
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1112-67-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 108-88-3
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of Commercial Manufacturing Processes for Acalabrutinib
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bethel, Paul A.; Chan, Lai Chun; Cooper, Katie; Ensor, Gareth J.; Evarts,
Jerry; Garrey, Rustam; Ford, J. Gair; Harding, Daniel; Hughes, Shaun;
Jackson, Lucy; Golden, Michael; Millard, Kirsty; Phillips, Andrew;
Robbins, Andrew; Short, David; Telford, Alex; Whittaker, David T. E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2022), 26(12), 3303-3311

$RFMT $RIREG SCHEME80 STEP1
$RXN



  2  1
$MOL
3-Bromobenzoic acid
C7H5BrO2
585-76-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 Br 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Furanamine, tetrahydro-, hydrochloride (1:1), (3R)-
C4H9NO.ClH
1072015-52-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.9098 2.7859 0.0 0
M  V30 2 C 2.3698 2.7859 0.0 0 CFG=1
M  V30 3 C 1.4645 4.0317 0.0 0
M  V30 4 C 1.4645 1.5400 0.0 0
M  V30 5 C 0.0000 3.5559 0.0 0
M  V30 6 O 0.0000 2.0159 0.0 0
M  V30 7 Cl 1.9549 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 6
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzamide, 3-bromo-N-[(3R)-tetrahydro-3-furanyl]-
C11H12BrNO2
3058601-45-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.1047 3.0801 0.0 0
M  V30 2 N 3.7711 2.3100 0.0 0
M  V30 3 O 5.1047 4.6201 0.0 0
M  V30 4 Br 10.4395 3.0801 0.0 0
M  V30 5 C 6.4384 2.3100 0.0 0
M  V30 6 C 7.7722 3.0801 0.0 0
M  V30 7 C 6.4384 0.7700 0.0 0
M  V30 8 C 9.1059 2.3100 0.0 0
M  V30 9 C 7.7722 0.0000 0.0 0
M  V30 10 C 9.1059 0.7700 0.0 0
M  V30 11 C 2.4374 3.0801 0.0 0 CFG=1
M  V30 12 C 2.2763 4.6116 0.0 0
M  V30 13 C 1.0304 2.4536 0.0 0
M  V30 14 C 0.7700 4.9318 0.0 0
M  V30 15 O 0.0000 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 11 2 CFG=1
M  V30 5 1 4 8
M  V30 6 2 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 10
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 11)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 585-76-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1072015-52-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3058601-45-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39283196
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-14-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 100-66-3
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM stereoselective
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Metal catalyzed C-N bond forming reaction selection and process
development for the manufacture of AZD7594
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Aydin, Gulsevim; Ball, Matthew; Bishop, Thomas George; Burns, Matthew;
Campbell, Andrew D.; Cox, Robert J.; Dai, Kuangchu; Dave, David; Fisk,
Heidi; Hamilton, Laura; Heffernan, Claire; Henry, Jean-Marc; Holman,
Stephen W.; Jones, Martin F.; Noonan, Gary; Patel, Bharti; Streather,
David; Tomasi, Simone
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2024), 28(2), 559-576

$RFMT $RIREG SCHEME81 STEP1
$RXN



  2  1
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-(4-Fluorobenzoyl)propionic acid
C10H9FO3
366-77-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0011 0.0 0
M  V30 2 C 3.8500 2.6674 0.0 0
M  V30 3 O 3.8500 5.3349 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 1.5400 1.3338 0.0 0
M  V30 6 O 0.0000 1.3338 0.0 0
M  V30 7 O 2.3100 0.0000 0.0 0
M  V30 8 F 10.7800 4.0011 0.0 0
M  V30 9 C 6.1600 4.0011 0.0 0
M  V30 10 C 6.9300 5.3349 0.0 0
M  V30 11 C 6.9300 2.6674 0.0 0
M  V30 12 C 8.4700 5.3349 0.0 0
M  V30 13 C 8.4700 2.6674 0.0 0
M  V30 14 C 9.2400 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluoro--oxo-N-phenylbenzenebutanamide
C16H14FNO2
38752-59-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.3358 1.5400 0.0 0
M  V30 2 C 8.0022 2.3101 0.0 0
M  V30 3 O 9.3358 0.0000 0.0 0
M  V30 4 C 6.6685 1.5400 0.0 0
M  V30 5 C 5.3348 2.3101 0.0 0
M  V30 6 N 4.0010 1.5400 0.0 0
M  V30 7 O 5.3348 3.8501 0.0 0
M  V30 8 F 14.6707 4.6201 0.0 0
M  V30 9 C 10.6697 2.3101 0.0 0
M  V30 10 C 10.6697 3.8501 0.0 0
M  V30 11 C 12.0033 1.5400 0.0 0
M  V30 12 C 12.0033 4.6201 0.0 0
M  V30 13 C 13.3370 2.3101 0.0 0
M  V30 14 C 13.3370 3.8501 0.0 0
M  V30 15 C 2.6673 2.3101 0.0 0
M  V30 16 C 1.3337 1.5400 0.0 0
M  V30 17 C 2.6673 3.8501 0.0 0
M  V30 18 C 0.0000 2.3101 0.0 0
M  V30 19 C 1.3337 4.6201 0.0 0
M  V30 20 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 15
M  V30 9 1 8 14
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 366-77-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 38752-59-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24031232
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Benzenesulfonamide Derivatives as Calcium/Calmodulin-Dependent Protein
Kinase Inhibitors and Antiviral Agents against Dengue and Zika Virus
Infections
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chen, Wei-Chia; Simanjuntak, Yogy; Chu, Li-Wei; Ping, Yueh-Hsin; Lee,
Yi-Ling; Lin, Yi-Ling; Li, Wen-Shan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(3), 1313-1327

$RFMT $RIREG SCHEME82 STEP1
$RXN



  2  1
$MOL
2-Amino-5-methylthiazole
C4H6N2S
7305-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 2.6218 0.0 0
M  V30 2 N 5.3026 1.4946 0.0 0
M  V30 3 S 2.7406 2.4782 0.0 0
M  V30 4 C 1.3337 1.8517 0.0 0
M  V30 5 C 3.7711 1.3337 0.0 0
M  V30 6 C 1.4946 0.3202 0.0 0
M  V30 7 N 3.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Methyl-1,2,3-thiadiazole-5-carboxylic acid
C4H4N2O2S
18212-21-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 1.5400 0.0 0
M  V30 2 O 5.1049 2.3100 0.0 0
M  V30 3 O 3.7711 0.0000 0.0 0
M  V30 4 C 0.7104 0.1773 0.0 0
M  V30 5 C 2.4374 2.3100 0.0 0
M  V30 6 C 1.0306 1.6836 0.0 0
M  V30 7 S 2.2765 3.8416 0.0 0
M  V30 8 N 0.0000 2.8281 0.0 0
M  V30 9 N 0.7700 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Methyl-N-(5-methyl-2-thiazolyl)-1,2,3-thiadiazole-5-carboxamide
C8H8N4OS2
908298-37-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.1049 1.8517 0.0 0
M  V30 2 C 3.7711 2.6218 0.0 0
M  V30 3 O 3.7711 4.1618 0.0 0
M  V30 4 C 10.4075 2.9789 0.0 0
M  V30 5 C 0.7103 3.9845 0.0 0
M  V30 6 C 6.4386 2.6218 0.0 0
M  V30 7 N 6.5995 4.1533 0.0 0
M  V30 8 S 7.8454 1.9954 0.0 0
M  V30 9 C 8.1060 4.4735 0.0 0
M  V30 10 C 8.8760 3.1398 0.0 0
M  V30 11 C 2.4374 1.8517 0.0 0
M  V30 12 C 1.0306 2.4781 0.0 0
M  V30 13 S 2.2765 0.3202 0.0 0
M  V30 14 N 0.0000 1.3337 0.0 0
M  V30 15 N 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 2 2 3
M  V30 4 1 2 11
M  V30 5 1 4 10
M  V30 6 1 5 12
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7305-71-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 18212-21-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 908298-37-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-42622982
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM On-Demand Production of Two Commercial Plant Activators, Tiadinil and
Methiadinil, under an Integrated Continuous Flow System
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Zhengqi; Zhou, Jian; Xing, Dong; He, Haibing; Gao, Shuanhu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2024), 28(8), 3143-3151

$RFMT $RIREG SCHEME83 STEP1
$RXN



  2  1
$MOL
3,5-Difluorobenzoic acid
C7H4F2O2
455-40-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 4.6200 0.0 0
M  V30 2 O 6.6685 3.8500 0.0 0
M  V30 3 O 5.3347 6.1600 0.0 0
M  V30 4 F 0.0000 4.6200 0.0 0
M  V30 5 F 2.6674 0.0000 0.0 0
M  V30 6 C 4.0011 3.8500 0.0 0
M  V30 7 C 2.6674 4.6200 0.0 0
M  V30 8 C 4.0011 2.3100 0.0 0
M  V30 9 C 1.3338 3.8500 0.0 0
M  V30 10 C 2.6674 1.5400 0.0 0
M  V30 11 C 1.3338 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Aminoacetophenone
C8H9NO
99-03-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 C 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 N 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3-Acetylphenyl)-3,5-difluorobenzamide
C15H11F2NO2
923829-43-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 4.6201 0.0 0
M  V30 2 N 6.6685 3.8501 0.0 0
M  V30 3 O 5.3348 6.1601 0.0 0
M  V30 4 F 0.0000 4.6201 0.0 0
M  V30 5 F 2.6673 0.0000 0.0 0
M  V30 6 C 12.0033 3.8501 0.0 0
M  V30 7 C 12.0033 2.3101 0.0 0
M  V30 8 O 13.3370 4.6201 0.0 0
M  V30 9 C 4.0010 3.8501 0.0 0
M  V30 10 C 2.6673 4.6201 0.0 0
M  V30 11 C 4.0010 2.3101 0.0 0
M  V30 12 C 1.3337 3.8501 0.0 0
M  V30 13 C 2.6673 1.5400 0.0 0
M  V30 14 C 1.3337 2.3101 0.0 0
M  V30 15 C 8.0022 4.6201 0.0 0
M  V30 16 C 9.3360 3.8501 0.0 0
M  V30 17 C 8.0022 6.1601 0.0 0
M  V30 18 C 10.6697 4.6201 0.0 0
M  V30 19 C 9.3360 6.9302 0.0 0
M  V30 20 C 10.6697 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 4 12
M  V30 6 1 5 13
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 18
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 455-40-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 99-03-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 923829-43-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34601332
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and anti-tumor efficacy of novel phenyl
thiazole/triazole derivatives as selective TrkA inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Xinyu; Tan, Zehui; Wang, Fuyi; Zhang, Jiahao; Yang, Juanjuan; Liu,
Shuyu; Jiang, Nan; Zhai, Xin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2022), 72116995

$RFMT $RIREG SCHEME84 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-Methyl-1,2-phenylenediamine
C7H10N2
4760-34-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 2.6673 0.0 0
M  V30 2 C 5.3901 4.0010 0.0 0
M  V30 3 N 3.0801 0.0000 0.0 0
M  V30 4 C 3.0801 2.6673 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 2.3101 4.0010 0.0 0
M  V30 7 C 0.7700 1.3337 0.0 0
M  V30 8 C 0.7700 4.0010 0.0 0
M  V30 9 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 5
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C14H21N3O3
2245166-17-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0010 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 O 5.3348 0.7700 0.0 0
M  V30 5 N 8.0022 2.3101 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 O 10.6697 2.3101 0.0 0
M  V30 8 O 9.3360 4.6201 0.0 0
M  V30 9 C 12.0033 3.0801 0.0 0
M  V30 10 C 12.7733 1.7464 0.0 0
M  V30 11 C 13.3370 3.8501 0.0 0
M  V30 12 C 11.2333 4.4137 0.0 0
M  V30 13 N 1.3337 4.6201 0.0 0
M  V30 14 C 0.0000 5.3901 0.0 0
M  V30 15 C 2.6673 2.3101 0.0 0
M  V30 16 C 1.3337 3.0801 0.0 0
M  V30 17 C 2.6673 0.7700 0.0 0
M  V30 18 C 0.0000 2.3101 0.0 0
M  V30 19 C 1.3337 0.0000 0.0 0
M  V30 20 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 1 13 14
M  V30 14 1 13 16
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4760-34-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2245166-17-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24985530
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1075198-30-9
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Virtual Screening Approach to Identifying a Novel and Tractable Series of
Pseudomonas aeruginosa Elastase Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Leiris, Simon; Davies, David T.; Sprynski, Nicolas; Castandet, Jerome;
Beyria, Lilha; Bodnarchuk, Michael S.; Sutton, Jonathan M.; Mullins, Toby
M. G.; Jones, Mark W.; Forrest, Andrew K.; Pallin, T. David; Karunakar,
Paduri; Martha, Sathish Kumar; Parusharamulu, Battu; Ramula, Ramesh;
Kotha, Venkatesh; Pottabathini, Narender; Pothukanuri, Srinivasu;
Lemonnier, Marc; Everett, Martin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2021), 12(2), 217-227

$RFMT $RIREG SCHEME85 STEP1
$RXN



  2  1
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-nitro-N-phenylbenzamide
C13H11N3O3
30481-54-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6675 0.0 0
M  V30 2 N 6.9302 4.0012 0.0 0
M  V30 3 O 6.9302 1.3338 0.0 0
M  V30 4 N 4.6201 0.0000 0.0 0
M  V30 5 N 1.5400 5.3348 0.0 0 VAL=5
M  V30 6 O 0.0000 5.3348 0.0 0
M  V30 7 O 2.3101 6.6687 0.0 0
M  V30 8 C 4.6201 2.6675 0.0 0
M  V30 9 C 3.8501 4.0012 0.0 0
M  V30 10 C 3.8501 1.3338 0.0 0
M  V30 11 C 2.3101 4.0012 0.0 0
M  V30 12 C 2.3101 1.3338 0.0 0
M  V30 13 C 1.5400 2.6675 0.0 0
M  V30 14 C 8.4702 4.0012 0.0 0
M  V30 15 C 9.2402 2.6675 0.0 0
M  V30 16 C 9.2402 5.3348 0.0 0
M  V30 17 C 10.7802 2.6675 0.0 0
M  V30 18 C 10.7802 5.3348 0.0 0
M  V30 19 C 11.5503 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 14
M  V30 5 1 4 10
M  V30 6 2 5 6
M  V30 7 2 5 7
M  V30 8 1 5 11
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 30481-54-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31626798
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Piperazinobenzodiazepinones: New Encephalitic Alphavirus Inhibitors via
Ring Expansion of 2-Dichloromethylquinazolinones
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ryan, Michael C.; Kim, Eunjung; Cao, Xufeng; Reichard, Walter; Ogorek,
Tyler J.; Das, Pronay; Jonsson, Colleen B.; Baudry, Jerome; Chung,
Donghoon; Golden, Jennifer E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(4), 546-553

$RFMT $RIREG SCHEME86 STEP1
$RXN



  2  1
$MOL
2-Thiophenebutanoic acid
C8H10O2S
4653-11-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 2.6218 0.0 0
M  V30 2 C 5.1048 1.8517 0.0 0
M  V30 3 C 6.4386 2.6218 0.0 0
M  V30 4 C 7.7722 1.8517 0.0 0
M  V30 5 O 9.1059 2.6218 0.0 0
M  V30 6 O 7.7722 0.3117 0.0 0
M  V30 7 C 2.4374 1.8517 0.0 0
M  V30 8 C 2.2763 0.3202 0.0 0
M  V30 9 S 1.0304 2.4782 0.0 0
M  V30 10 C 0.7700 0.0000 0.0 0
M  V30 11 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Trifluoromethyl)aniline
C7H6F3N
455-14-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 1.5400 0.0 0
M  V30 2 F 1.5400 3.0800 0.0 0
M  V30 3 F 0.0000 1.5400 0.0 0
M  V30 4 F 1.5400 0.0000 0.0 0
M  V30 5 N 7.7000 1.5400 0.0 0
M  V30 6 C 3.0800 1.5400 0.0 0
M  V30 7 C 3.8500 0.2064 0.0 0
M  V30 8 C 3.8500 2.8736 0.0 0
M  V30 9 C 5.3900 0.2064 0.0 0
M  V30 10 C 5.3900 2.8736 0.0 0
M  V30 11 C 6.1600 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 6
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[4-(Trifluoromethyl)phenyl]-2-thiophenebutanamide
C15H14F3NOS
2326943-98-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.3337 0.0 0
M  V30 2 F 2.1038 0.0000 0.0 0
M  V30 3 F 0.0000 0.5637 0.0 0
M  V30 4 F 0.5638 2.6673 0.0 0
M  V30 5 N 6.6687 4.4137 0.0 0
M  V30 6 C 8.0023 3.6437 0.0 0
M  V30 7 C 9.3360 4.4137 0.0 0
M  V30 8 O 8.0023 2.1037 0.0 0
M  V30 9 C 10.6697 3.6437 0.0 0
M  V30 10 C 12.0035 4.4137 0.0 0
M  V30 11 C 2.6675 2.1037 0.0 0
M  V30 12 C 4.0012 1.3337 0.0 0
M  V30 13 C 2.6675 3.6437 0.0 0
M  V30 14 C 5.3348 2.1037 0.0 0
M  V30 15 C 4.0012 4.4137 0.0 0
M  V30 16 C 5.3348 3.6437 0.0 0
M  V30 17 C 13.3372 3.6437 0.0 0
M  V30 18 C 13.4981 2.1122 0.0 0
M  V30 19 S 14.7440 4.2701 0.0 0
M  V30 20 C 15.0045 1.7920 0.0 0
M  V30 21 C 15.7746 3.1257 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 11
M  V30 5 1 5 6
M  V30 6 1 5 16
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 17
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4653-11-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 455-14-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2326943-98-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22303119
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of aryl piperazines with
potential as antidiabetic agents via the stimulation of glucose uptake
and inhibition of NADH:ubiquinone oxidoreductase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Devine, R.; Kelada, M.; Leonard, S.; Martin, D. S. D.; Walsh, J. M. D.;
Breen, C. J.; Driver, R. B.; Kinsella, G. K.; Findlay, J. B. C.;
Stephens, J. C.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 202112416

$RFMT $RIREG SCHEME87 STEP1
$RXN



  3  3
$MOL
L-Serine, methyl ester, hydrochloride (1:1)
C4H9NO3.ClH
5680-80-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.8500 0.0 0 CFG=1
M  V30 2 C 4.0011 3.0800 0.0 0
M  V30 3 C 1.3338 3.0800 0.0 0
M  V30 4 N 2.6674 5.3900 0.0 0
M  V30 5 O 5.3347 3.8500 0.0 0
M  V30 6 O 4.0011 1.5400 0.0 0
M  V30 7 O 0.0000 3.8500 0.0 0
M  V30 8 C 6.6685 3.0800 0.0 0
M  V30 9 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Dicyclohexylcarbodiimide
C13H22N2
538-75-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 4.0011 0.0 0
M  V30 2 C 5.3900 2.6674 0.0 0
M  V30 3 N 6.1600 1.3338 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 2.3100 2.6674 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 C 0.7700 2.6674 0.0 0
M  V30 8 C 0.7700 5.3349 0.0 0
M  V30 9 C 0.0000 4.0011 0.0 0
M  V30 10 C 7.7000 1.3338 0.0 0
M  V30 11 C 8.4700 0.0000 0.0 0
M  V30 12 C 8.4700 2.6674 0.0 0
M  V30 13 C 10.0100 0.0000 0.0 0
M  V30 14 C 10.0100 2.6674 0.0 0
M  V30 15 C 10.7800 1.3338 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2 CFG=2
M  V30 2 1 1 4
M  V30 3 2 2 3 CFG=2
M  V30 4 1 3 10
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 9
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
trans-4-Fluorocinnamic acid
C9H7FO2
14290-86-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 C 6.6684 2.3100 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 9.3359 2.3100 0.0 0
M  V30 5 O 8.0022 0.0000 0.0 0
M  V30 6 F 0.0000 4.6201 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 2.6675 1.5400 0.0 0
M  V30 9 C 4.0011 3.8500 0.0 0
M  V30 10 C 1.3337 2.3100 0.0 0
M  V30 11 C 2.6675 4.6201 0.0 0
M  V30 12 C 1.3337 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(2E)-3-(4-Fluorophenyl)-1-oxo-2-propen-1-yl]-L-serine methyl ester
C13H14FNO4
2414059-77-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.0022 2.3101 0.0 0
M  V30 2 C 6.6685 3.0801 0.0 0
M  V30 3 C 5.3348 2.3101 0.0 0
M  V30 4 N 4.0010 3.0801 0.0 0
M  V30 5 O 5.3348 0.7700 0.0 0
M  V30 6 C 2.6673 2.3101 0.0 0 CFG=1
M  V30 7 C 1.3337 3.0801 0.0 0
M  V30 8 C 2.6673 0.7700 0.0 0
M  V30 9 O 1.3337 4.6201 0.0 0
M  V30 10 O 0.0000 2.3101 0.0 0
M  V30 11 O 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 5.3901 0.0 0
M  V30 13 F 13.3370 5.3901 0.0 0
M  V30 14 C 9.3360 3.0801 0.0 0
M  V30 15 C 9.3360 4.6201 0.0 0
M  V30 16 C 10.6697 2.3101 0.0 0
M  V30 17 C 10.6697 5.3901 0.0 0
M  V30 18 C 12.0033 3.0801 0.0 0
M  V30 19 C 12.0033 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8 CFG=1
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 13 19
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(2S)-2-[[(2E)-3-(4-Fluorophenyl)-1-oxo-2-propen-1-yl]amino]-3-methoxy-3-oxopr...
C22H19F2NO5
2414059-84-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 16.1700 6.6684 0.0 0
M  V30 2 C 15.4000 5.3347 0.0 0
M  V30 3 C 13.8600 5.3347 0.0 0
M  V30 4 N 13.0900 4.0011 0.0 0
M  V30 5 O 13.0900 6.6684 0.0 0
M  V30 6 C 11.5500 4.0011 0.0 0 CFG=2
M  V30 7 C 10.7800 5.3347 0.0 0
M  V30 8 C 10.7800 2.6674 0.0 0
M  V30 9 O 9.2400 5.3347 0.0 0
M  V30 10 O 11.5500 1.3336 0.0 0
M  V30 11 O 9.2400 2.6674 0.0 0
M  V30 12 C 8.4700 6.6684 0.0 0
M  V30 13 C 10.7800 0.0000 0.0 0
M  V30 14 C 6.9300 6.6684 0.0 0
M  V30 15 O 9.2400 8.0021 0.0 0
M  V30 16 C 6.1600 8.0021 0.0 0
M  V30 17 F 22.3300 6.6684 0.0 0
M  V30 18 F 0.0000 8.0021 0.0 0
M  V30 19 C 17.7100 6.6684 0.0 0
M  V30 20 C 18.4800 8.0021 0.0 0
M  V30 21 C 18.4800 5.3347 0.0 0
M  V30 22 C 20.0200 8.0021 0.0 0
M  V30 23 C 20.0200 5.3347 0.0 0
M  V30 24 C 20.7900 6.6684 0.0 0
M  V30 25 C 4.6200 8.0021 0.0 0
M  V30 26 C 3.8500 9.3358 0.0 0
M  V30 27 C 3.8500 6.6684 0.0 0
M  V30 28 C 2.3100 9.3358 0.0 0
M  V30 29 C 2.3100 6.6684 0.0 0
M  V30 30 C 1.5400 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 4 CFG=3
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 2 14 16
M  V30 17 1 16 25
M  V30 18 1 17 24
M  V30 19 1 18 30
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(Cyclohexylamino)(cyclohexylimino)methyl (2E)-3-(4-fluorophenyl)-2-propenoate
C22H29FN2O2
2414146-71-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0
M  V30 2 N 4.6200 6.6684 0.0 0
M  V30 3 N 4.6200 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 7.7000 6.6684 0.0 0
M  V30 6 C 9.2400 6.6684 0.0 0
M  V30 7 O 6.9300 8.0021 0.0 0
M  V30 8 C 10.0100 8.0021 0.0 0
M  V30 9 F 16.1700 8.0021 0.0 0
M  V30 10 C 3.0800 6.6684 0.0 0
M  V30 11 C 2.3100 5.3347 0.0 0
M  V30 12 C 2.3100 8.0021 0.0 0
M  V30 13 C 0.7700 5.3347 0.0 0
M  V30 14 C 0.7700 8.0021 0.0 0
M  V30 15 C 0.0000 6.6684 0.0 0
M  V30 16 C 5.3900 2.6674 0.0 0
M  V30 17 C 4.6200 1.3336 0.0 0
M  V30 18 C 6.9300 2.6674 0.0 0
M  V30 19 C 5.3900 0.0000 0.0 0
M  V30 20 C 7.7000 1.3336 0.0 0
M  V30 21 C 6.9300 0.0000 0.0 0
M  V30 22 C 11.5500 8.0021 0.0 0
M  V30 23 C 12.3200 6.6684 0.0 0
M  V30 24 C 12.3200 9.3358 0.0 0
M  V30 25 C 13.8600 6.6684 0.0 0
M  V30 26 C 13.8600 9.3358 0.0 0
M  V30 27 C 14.6300 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2 CFG=2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 10
M  V30 5 1 3 16
M  V30 6 1 4 5
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 2 6 8
M  V30 10 1 8 22
M  V30 11 1 9 27
M  V30 12 1 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 1 13 15
M  V30 17 1 14 15
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5680-80-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:RCT(3):CAS_RN
$DATUM 14290-86-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2414059-77-9
$DTYPE RXN:PRO(2):CAS_RN
$DATUM 2414059-84-8
$DTYPE RXN:PRO(3):CAS_RN
$DATUM 2414146-71-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-356-CAS-22071800
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):PRO(2):YIELD
$DATUM 8
$DTYPE RXN:VAR(1):PRO(3):YIELD
$DATUM 13
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and in vitro evaluation of antimycobacterial and cytotoxic
activity of new ,-unsaturated amide, oxazoline and oxazole derivatives
from L-serine
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Aguirre-Renteria, Saul A.; Carrizales-Castillo, Juan J. J.; Camacho
Corona, Maria del Rayo; Hernandez-Fernandez, Eugenio; Garza-Gonzalez,
Elvira; Rivas-Galindo, Veronica M.; Arredondo-Espinoza, Eder;
Avalos-Alanis, Francisco G.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(9), 127074

$RFMT $RIREG SCHEME88 STEP1
$RXN



  2  1
$MOL
Hexahydro--oxo-1H-azepine-1-butanoic acid
C10H17NO3
154740-93-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6403 1.5400 0.0 0
M  V30 2 C 5.9741 2.3100 0.0 0
M  V30 3 O 4.6403 0.0000 0.0 0
M  V30 4 C 7.3078 1.5400 0.0 0
M  V30 5 C 8.6414 2.3100 0.0 0
M  V30 6 O 9.9751 1.5400 0.0 0
M  V30 7 O 8.6414 3.8501 0.0 0
M  V30 8 N 3.3066 2.3100 0.0 0
M  V30 9 C 2.0342 1.4425 0.0 0
M  V30 10 C 3.4216 3.8458 0.0 0
M  V30 11 C 0.5626 1.8964 0.0 0
M  V30 12 C 2.2928 4.8933 0.0 0
M  V30 13 C 0.0000 3.3300 0.0 0
M  V30 14 C 0.7700 4.6637 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Alanine, methyl ester, hydrochloride (1:1)
C4H9NO2.ClH
13515-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.8500 0.0 0
M  V30 2 C 1.3338 3.0800 0.0 0
M  V30 3 O 4.0011 3.0800 0.0 0
M  V30 4 O 2.6674 5.3900 0.0 0
M  V30 5 C 0.0000 3.8500 0.0 0
M  V30 6 N 1.3338 1.5400 0.0 0
M  V30 7 C 5.3349 3.8500 0.0 0
M  V30 8 Cl 2.6674 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Alanine, N-[4-(hexahydro-1H-azepin-1-yl)-1,4-dioxobutyl]-, methyl ester
C14H24N2O4
3007690-41-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6404 3.3532 0.0 0
M  V30 2 C 5.9741 2.5832 0.0 0
M  V30 3 O 4.6404 4.8933 0.0 0
M  V30 4 C 7.3077 3.3532 0.0 0
M  V30 5 C 8.6415 2.5832 0.0 0
M  V30 6 N 9.9752 3.3532 0.0 0
M  V30 7 O 8.6415 1.0432 0.0 0
M  V30 8 C 11.3088 2.5832 0.0 0
M  V30 9 C 12.6425 3.3532 0.0 0
M  V30 10 C 11.3088 1.0432 0.0 0
M  V30 11 O 13.9763 2.5832 0.0 0
M  V30 12 O 12.6425 4.8933 0.0 0
M  V30 13 C 15.3100 3.3532 0.0 0
M  V30 14 N 3.3067 2.5832 0.0 0
M  V30 15 C 2.0342 3.4507 0.0 0
M  V30 16 C 3.4218 1.0475 0.0 0
M  V30 17 C 0.5627 2.9969 0.0 0
M  V30 18 C 2.2928 0.0000 0.0 0
M  V30 19 C 0.0000 1.5633 0.0 0
M  V30 20 C 0.7700 0.2296 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 11 13
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 154740-93-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13515-97-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3007690-41-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37335627
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 3282-30-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Nonpeptidic Oxazole Based Prolyl Oligopeptidase Ligands with Disease
Modifying Effects on alpha Synuclein Mouse Models of Parkinson Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kilpelainen, Tommi P.; Patsi, Henri T.; Svarcbahs, Reinis; Julku, Ulrika
H.; Etelainen, Tony S.; Cui, Hengjing; Auno, Samuli; Sipari, Nina;
Norrbacka, Susanna; Leino, Teppo O.; Jantti, Maria; Myohanen, Timo T.;
Wallen, Erik A. A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(11), 7475-7496

$RFMT $RIREG SCHEME89 STEP1
$RXN



  2  2
$MOL
L-Serine, methyl ester, hydrochloride (1:1)
C4H9NO3.ClH
5680-80-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.8500 0.0 0 CFG=1
M  V30 2 C 4.0011 3.0800 0.0 0
M  V30 3 C 1.3338 3.0800 0.0 0
M  V30 4 N 2.6674 5.3900 0.0 0
M  V30 5 O 5.3347 3.8500 0.0 0
M  V30 6 O 4.0011 1.5400 0.0 0
M  V30 7 O 0.0000 3.8500 0.0 0
M  V30 8 C 6.6685 3.0800 0.0 0
M  V30 9 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
trans-4-Methoxycinnamic acid
C10H10O3
943-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 C 2.6673 2.3101 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 O 0.0000 2.3101 0.0 0
M  V30 5 O 1.3337 0.0000 0.0 0
M  V30 6 O 9.3360 4.6201 0.0 0
M  V30 7 C 10.6697 3.8501 0.0 0
M  V30 8 C 5.3348 2.3101 0.0 0
M  V30 9 C 6.6685 1.5400 0.0 0
M  V30 10 C 5.3348 3.8501 0.0 0
M  V30 11 C 8.0022 2.3101 0.0 0
M  V30 12 C 6.6685 4.6201 0.0 0
M  V30 13 C 8.0022 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(2E)-3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-L-serine methyl ester
C14H17NO5
2414059-78-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.0022 2.3101 0.0 0
M  V30 2 C 6.6685 3.0801 0.0 0
M  V30 3 C 5.3348 2.3101 0.0 0
M  V30 4 N 4.0010 3.0801 0.0 0
M  V30 5 O 5.3348 0.7700 0.0 0
M  V30 6 C 2.6673 2.3101 0.0 0 CFG=1
M  V30 7 C 1.3337 3.0801 0.0 0
M  V30 8 C 2.6673 0.7700 0.0 0
M  V30 9 O 1.3337 4.6201 0.0 0
M  V30 10 O 0.0000 2.3101 0.0 0
M  V30 11 O 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 5.3901 0.0 0
M  V30 13 O 13.3370 5.3901 0.0 0
M  V30 14 C 14.6707 4.6201 0.0 0
M  V30 15 C 9.3358 3.0801 0.0 0
M  V30 16 C 9.3358 4.6201 0.0 0
M  V30 17 C 10.6697 2.3101 0.0 0
M  V30 18 C 10.6697 5.3901 0.0 0
M  V30 19 C 12.0033 3.0801 0.0 0
M  V30 20 C 12.0033 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8 CFG=1
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 13 14
M  V30 14 1 13 20
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(2S)-3-Methoxy-2-[[(2E)-3-(4-methoxyphenyl)-1-oxo-2-propen-1-yl]amino]-3-oxop...
C24H25NO7
2414059-86-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 16.9400 6.6684 0.0 0
M  V30 2 C 16.1700 5.3347 0.0 0
M  V30 3 C 14.6300 5.3347 0.0 0
M  V30 4 N 13.8600 4.0011 0.0 0
M  V30 5 O 13.8600 6.6684 0.0 0
M  V30 6 C 12.3200 4.0011 0.0 0 CFG=2
M  V30 7 C 11.5500 5.3347 0.0 0
M  V30 8 C 11.5500 2.6674 0.0 0
M  V30 9 O 10.0100 5.3347 0.0 0
M  V30 10 O 12.3200 1.3336 0.0 0
M  V30 11 O 10.0100 2.6674 0.0 0
M  V30 12 C 9.2400 6.6684 0.0 0
M  V30 13 C 11.5500 0.0000 0.0 0
M  V30 14 C 7.7000 6.6684 0.0 0
M  V30 15 O 10.0100 8.0021 0.0 0
M  V30 16 C 6.9300 8.0021 0.0 0
M  V30 17 O 23.1000 6.6684 0.0 0
M  V30 18 C 23.8700 8.0021 0.0 0
M  V30 19 O 0.7700 8.0021 0.0 0
M  V30 20 C 0.0000 9.3358 0.0 0
M  V30 21 C 18.4800 6.6684 0.0 0
M  V30 22 C 19.2500 5.3347 0.0 0
M  V30 23 C 19.2500 8.0021 0.0 0
M  V30 24 C 20.7900 5.3347 0.0 0
M  V30 25 C 20.7900 8.0021 0.0 0
M  V30 26 C 21.5600 6.6684 0.0 0
M  V30 27 C 5.3900 8.0021 0.0 0
M  V30 28 C 4.6200 6.6684 0.0 0
M  V30 29 C 4.6200 9.3358 0.0 0
M  V30 30 C 3.0800 6.6684 0.0 0
M  V30 31 C 3.0800 9.3358 0.0 0
M  V30 32 C 2.3100 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 21
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 4 CFG=3
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 2 14 16
M  V30 17 1 16 27
M  V30 18 1 17 18
M  V30 19 1 17 26
M  V30 20 1 19 20
M  V30 21 1 19 32
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 25
M  V30 26 2 24 26
M  V30 27 1 25 26
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 2 29 31
M  V30 32 2 30 32
M  V30 33 1 31 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5680-80-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 943-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2414059-78-0
$DTYPE RXN:PRO(2):CAS_RN
$DATUM 2414059-86-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-356-CAS-22071801
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):PRO(2):YIELD
$DATUM 7
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and in vitro evaluation of antimycobacterial and cytotoxic
activity of new ,-unsaturated amide, oxazoline and oxazole derivatives
from L-serine
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Aguirre-Renteria, Saul A.; Carrizales-Castillo, Juan J. J.; Camacho
Corona, Maria del Rayo; Hernandez-Fernandez, Eugenio; Garza-Gonzalez,
Elvira; Rivas-Galindo, Veronica M.; Arredondo-Espinoza, Eder;
Avalos-Alanis, Francisco G.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(9), 127074

$RFMT $RIREG SCHEME90 STEP1
$RXN



  2  1
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-O-methyl-L-serine
C9H17NO5
51293-47-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8500 0.0 0 CFG=2
M  V30 2 N 4.0011 4.6201 0.0 0
M  V30 3 C 2.6675 2.3100 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8500 0.0 0
M  V30 6 O 1.3337 1.5400 0.0 0
M  V30 7 O 1.3337 6.1601 0.0 0
M  V30 8 O 0.0000 3.8500 0.0 0
M  V30 9 O 6.6684 4.6201 0.0 0
M  V30 10 O 5.3348 2.3100 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 8.0022 3.8500 0.0 0
M  V30 13 C 8.7722 5.1837 0.0 0
M  V30 14 C 9.3359 3.0800 0.0 0
M  V30 15 C 7.2322 2.5164 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Cysteine, S-methyl-, methyl ester, hydrochloride (1:1)
C5H11NO2S.ClH
34017-27-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0 CFG=1
M  V30 2 C 2.6675 3.8500 0.0 0
M  V30 3 C 5.3348 3.8500 0.0 0
M  V30 4 N 4.0011 1.5400 0.0 0
M  V30 5 O 1.3337 3.0800 0.0 0
M  V30 6 O 2.6675 5.3900 0.0 0
M  V30 7 S 6.6686 3.0800 0.0 0
M  V30 8 C 0.0000 3.8500 0.0 0
M  V30 9 C 8.0022 3.8500 0.0 0
M  V30 10 Cl 4.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-O-methyl-L-seryl-S-methyl-L-cysteine methyl ...
C14H26N2O6S
2387522-85-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 6.9302 0.0 0 CFG=2
M  V30 2 C 5.3348 6.1601 0.0 0
M  V30 3 N 8.0022 6.1601 0.0 0
M  V30 4 C 6.6685 8.4702 0.0 0
M  V30 5 N 5.3348 4.6201 0.0 0
M  V30 6 O 4.0010 6.9302 0.0 0
M  V30 7 C 9.3360 6.9302 0.0 0
M  V30 8 O 5.3348 9.2402 0.0 0
M  V30 9 C 4.0012 3.8501 0.0 0 CFG=1
M  V30 10 O 10.6697 6.1601 0.0 0
M  V30 11 O 9.3360 8.4702 0.0 0
M  V30 12 C 5.3348 10.7802 0.0 0
M  V30 13 C 4.0010 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 12.0033 6.9302 0.0 0
M  V30 16 O 2.6673 1.5400 0.0 0
M  V30 17 O 5.3348 1.5400 0.0 0
M  V30 18 S 1.3337 3.8501 0.0 0
M  V30 19 C 11.2333 8.2638 0.0 0
M  V30 20 C 13.3370 7.7002 0.0 0
M  V30 21 C 12.7733 5.5965 0.0 0
M  V30 22 C 2.6673 0.0000 0.0 0
M  V30 23 C 0.0000 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=3
M  V30 14 1 10 15
M  V30 15 1 13 16
M  V30 16 2 13 17
M  V30 17 1 14 18
M  V30 18 1 15 19
M  V30 19 1 15 20
M  V30 20 1 15 21
M  V30 21 1 16 22
M  V30 22 1 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 51293-47-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 34017-27-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2387522-85-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31381010
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME91 STEP1
$RXN



  2  1
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Methoxyethylamine
C3H9NO
109-85-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0.7700 0.0 0
M  V30 2 C 1.3338 0.0000 0.0 0
M  V30 3 O 4.0010 0.0000 0.0 0
M  V30 4 N 0.0000 0.7700 0.0 0
M  V30 5 C 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-(2-methoxyethyl)-5-nitrobenzamide
C10H13N3O4
1275562-02-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 C 9.2400 5.3347 0.0 0
M  V30 6 O 10.7800 5.3347 0.0 0
M  V30 7 C 11.5500 6.6685 0.0 0
M  V30 8 N 4.6200 0.0000 0.0 0
M  V30 9 N 1.5400 5.3347 0.0 0 VAL=5
M  V30 10 O 2.3100 6.6685 0.0 0
M  V30 11 O 0.0000 5.3347 0.0 0
M  V30 12 C 4.6200 2.6674 0.0 0
M  V30 13 C 3.8500 4.0011 0.0 0
M  V30 14 C 3.8500 1.3338 0.0 0
M  V30 15 C 2.3100 4.0011 0.0 0
M  V30 16 C 2.3100 1.3338 0.0 0
M  V30 17 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 2 9 11
M  V30 11 1 9 15
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 109-85-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1275562-02-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38624467
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of Quinazolinones and Quinazolinediones for
Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating
COP1-ATGL Axis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sarkar, Dipayan; Chowdhury, Saheli; Goon, Sunny; Sen, Abhishek; Dastidar,
Uddipta Ghosh; Mondal, Mohabul Alam; Chakrabarti, Partha; Talukdar,
Arindam
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(24), 16728-16761

$RFMT $RIREG SCHEME92 STEP1
$RXN



  2  1
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N,N-Dimethylethylenediamine
C4H12N2
108-00-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 2.3100 0.0 0
M  V30 2 N 1.3338 1.5400 0.0 0
M  V30 3 C 4.0011 1.5400 0.0 0
M  V30 4 C 0.0000 2.3100 0.0 0
M  V30 5 C 1.3338 0.0000 0.0 0
M  V30 6 N 5.3349 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-[2-(dimethylamino)ethyl]-5-nitrobenzamide
C11H16N4O3
1442089-34-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6675 0.0 0
M  V30 2 N 6.9301 4.0011 0.0 0
M  V30 3 O 6.9301 1.3338 0.0 0
M  V30 4 C 8.4701 4.0011 0.0 0
M  V30 5 C 9.2401 5.3348 0.0 0
M  V30 6 N 10.7801 5.3348 0.0 0
M  V30 7 C 11.5501 4.0011 0.0 0
M  V30 8 C 11.5501 6.6686 0.0 0
M  V30 9 N 4.6201 0.0000 0.0 0
M  V30 10 N 1.5400 5.3348 0.0 0 VAL=5
M  V30 11 O 2.3100 6.6686 0.0 0
M  V30 12 O 0.0000 5.3348 0.0 0
M  V30 13 C 4.6201 2.6675 0.0 0
M  V30 14 C 3.8500 4.0011 0.0 0
M  V30 15 C 3.8500 1.3338 0.0 0
M  V30 16 C 2.3100 4.0011 0.0 0
M  V30 17 C 2.3100 1.3338 0.0 0
M  V30 18 C 1.5400 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 9 15
M  V30 10 2 10 11
M  V30 11 2 10 12
M  V30 12 1 10 16
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 108-00-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1442089-34-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38624474
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of Quinazolinones and Quinazolinediones for
Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating
COP1-ATGL Axis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sarkar, Dipayan; Chowdhury, Saheli; Goon, Sunny; Sen, Abhishek; Dastidar,
Uddipta Ghosh; Mondal, Mohabul Alam; Chakrabarti, Partha; Talukdar,
Arindam
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(24), 16728-16761

$RFMT $RIREG SCHEME93 STEP1
$RXN



  2  1
$MOL
3,5-Difluorobenzoic acid
C7H4F2O2
455-40-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 4.6200 0.0 0
M  V30 2 O 6.6685 3.8500 0.0 0
M  V30 3 O 5.3347 6.1600 0.0 0
M  V30 4 F 0.0000 4.6200 0.0 0
M  V30 5 F 2.6674 0.0000 0.0 0
M  V30 6 C 4.0011 3.8500 0.0 0
M  V30 7 C 2.6674 4.6200 0.0 0
M  V30 8 C 4.0011 2.3100 0.0 0
M  V30 9 C 1.3338 3.8500 0.0 0
M  V30 10 C 2.6674 1.5400 0.0 0
M  V30 11 C 1.3338 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Nitroaniline
C6H6N2O2
99-09-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3338 1.5400 0.0 0 VAL=5
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 N 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,5-Difluoro-N-(3-nitrophenyl)benzamide
C13H8F2N2O3
952898-80-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 4.6201 0.0 0
M  V30 2 N 6.6685 3.8501 0.0 0
M  V30 3 O 5.3348 6.1601 0.0 0
M  V30 4 F 0.0000 4.6201 0.0 0
M  V30 5 F 2.6673 0.0000 0.0 0
M  V30 6 N 12.0033 3.8501 0.0 0 VAL=5
M  V30 7 O 12.0033 2.3101 0.0 0
M  V30 8 O 13.3370 4.6201 0.0 0
M  V30 9 C 4.0010 3.8501 0.0 0
M  V30 10 C 2.6673 4.6201 0.0 0
M  V30 11 C 4.0010 2.3101 0.0 0
M  V30 12 C 1.3337 3.8501 0.0 0
M  V30 13 C 2.6673 1.5400 0.0 0
M  V30 14 C 1.3337 2.3101 0.0 0
M  V30 15 C 8.0022 4.6201 0.0 0
M  V30 16 C 9.3360 3.8501 0.0 0
M  V30 17 C 8.0022 6.1601 0.0 0
M  V30 18 C 10.6697 4.6201 0.0 0
M  V30 19 C 9.3360 6.9302 0.0 0
M  V30 20 C 10.6697 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 4 12
M  V30 6 1 5 13
M  V30 7 2 6 7
M  V30 8 2 6 8
M  V30 9 1 6 18
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 455-40-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 99-09-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 952898-80-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34604232
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Fragment-based discovery of novel phenyltriazolyl derivatives as
allosteric type ALK inhibitors with promising antitumor effects
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Cui, Youbao; Tan, Zehui; Liu, Shuyu; Cao, Zhi; Shao, Bin; Guo, Mengrao;
Jiang, Nan; Zhai, Xin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2022), 75128990

$RFMT $RIREG SCHEME93 STEP1
$RXN



  2  1
$MOL
3,5-Difluorobenzoic acid
C7H4F2O2
455-40-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 4.6200 0.0 0
M  V30 2 O 6.6685 3.8500 0.0 0
M  V30 3 O 5.3347 6.1600 0.0 0
M  V30 4 F 0.0000 4.6200 0.0 0
M  V30 5 F 2.6674 0.0000 0.0 0
M  V30 6 C 4.0011 3.8500 0.0 0
M  V30 7 C 2.6674 4.6200 0.0 0
M  V30 8 C 4.0011 2.3100 0.0 0
M  V30 9 C 1.3338 3.8500 0.0 0
M  V30 10 C 2.6674 1.5400 0.0 0
M  V30 11 C 1.3338 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Nitroaniline
C6H6N2O2
99-09-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3338 1.5400 0.0 0 VAL=5
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 N 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,5-Difluoro-N-(3-nitrophenyl)benzamide
C13H8F2N2O3
952898-80-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 4.6201 0.0 0
M  V30 2 N 6.6685 3.8501 0.0 0
M  V30 3 O 5.3348 6.1601 0.0 0
M  V30 4 F 0.0000 4.6201 0.0 0
M  V30 5 F 2.6673 0.0000 0.0 0
M  V30 6 N 12.0033 3.8501 0.0 0 VAL=5
M  V30 7 O 12.0033 2.3101 0.0 0
M  V30 8 O 13.3370 4.6201 0.0 0
M  V30 9 C 4.0010 3.8501 0.0 0
M  V30 10 C 2.6673 4.6201 0.0 0
M  V30 11 C 4.0010 2.3101 0.0 0
M  V30 12 C 1.3337 3.8501 0.0 0
M  V30 13 C 2.6673 1.5400 0.0 0
M  V30 14 C 1.3337 2.3101 0.0 0
M  V30 15 C 8.0022 4.6201 0.0 0
M  V30 16 C 9.3360 3.8501 0.0 0
M  V30 17 C 8.0022 6.1601 0.0 0
M  V30 18 C 10.6697 4.6201 0.0 0
M  V30 19 C 9.3360 6.9302 0.0 0
M  V30 20 C 10.6697 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 4 12
M  V30 6 1 5 13
M  V30 7 2 6 7
M  V30 8 2 6 8
M  V30 9 1 6 18
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 455-40-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 99-09-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 952898-80-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34601305
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and anti-tumor efficacy of novel phenyl
thiazole/triazole derivatives as selective TrkA inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Xinyu; Tan, Zehui; Wang, Fuyi; Zhang, Jiahao; Yang, Juanjuan; Liu,
Shuyu; Jiang, Nan; Zhai, Xin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2022), 72116995

$RFMT $RIREG SCHEME94 STEP1
$RXN



  2  1
$MOL
Leucine methyl ester hydrochloride
C7H15NO2.ClH
7517-19-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.8500 0.0 0 CFG=1
M  V30 2 C 5.3347 3.0800 0.0 0
M  V30 3 C 2.6674 3.0800 0.0 0
M  V30 4 N 4.0011 5.3900 0.0 0
M  V30 5 O 6.6685 3.8500 0.0 0
M  V30 6 O 5.3347 1.5400 0.0 0
M  V30 7 C 1.3336 3.8500 0.0 0
M  V30 8 C 8.0021 3.0800 0.0 0
M  V30 9 C 1.3336 5.3900 0.0 0
M  V30 10 C 0.0000 3.0800 0.0 0
M  V30 11 Cl 4.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
BOC-L-leucine
C11H21NO4
13139-15-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8501 0.0 0 CFG=2
M  V30 2 N 4.0012 4.6201 0.0 0
M  V30 3 C 2.6675 2.3101 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8501 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 O 0.0000 3.8501 0.0 0
M  V30 8 O 1.3337 6.1601 0.0 0
M  V30 9 O 6.6685 4.6201 0.0 0
M  V30 10 O 5.3348 2.3101 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 2.3101 0.0 0
M  V30 13 C 8.0023 3.8501 0.0 0
M  V30 14 C 7.2323 2.5164 0.0 0
M  V30 15 C 9.3360 3.0801 0.0 0
M  V30 16 C 8.7723 5.1838 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 6 12
M  V30 12 1 9 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-leucyl-L-leucine methyl ester
C18H34N2O5
15136-12-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 6.9301 0.0 0 CFG=2
M  V30 2 C 5.3348 6.1601 0.0 0
M  V30 3 N 8.0021 6.1601 0.0 0
M  V30 4 C 6.6684 8.4701 0.0 0
M  V30 5 N 5.3348 4.6201 0.0 0
M  V30 6 O 4.0010 6.9301 0.0 0
M  V30 7 C 9.3359 6.9301 0.0 0
M  V30 8 C 5.3348 9.2401 0.0 0
M  V30 9 C 4.0010 3.8500 0.0 0 CFG=1
M  V30 10 O 10.6695 6.1601 0.0 0
M  V30 11 O 9.3359 8.4701 0.0 0
M  V30 12 C 5.3348 10.7801 0.0 0
M  V30 13 C 4.0010 8.4701 0.0 0
M  V30 14 C 4.0010 2.3100 0.0 0
M  V30 15 C 2.6673 4.6201 0.0 0
M  V30 16 C 12.0032 6.9301 0.0 0
M  V30 17 O 5.3348 1.5400 0.0 0
M  V30 18 O 2.6673 1.5400 0.0 0
M  V30 19 C 1.3337 3.8500 0.0 0
M  V30 20 C 11.2332 8.2637 0.0 0
M  V30 21 C 13.3369 7.7001 0.0 0
M  V30 22 C 12.7732 5.5964 0.0 0
M  V30 23 C 5.3348 0.0000 0.0 0
M  V30 24 C 1.3337 2.3100 0.0 0
M  V30 25 C 0.0000 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 13 1 9 14
M  V30 14 1 9 15 CFG=3
M  V30 15 1 10 16
M  V30 16 1 14 17
M  V30 17 2 14 18
M  V30 18 1 15 19
M  V30 19 1 16 20
M  V30 20 1 16 21
M  V30 21 1 16 22
M  V30 22 1 17 23
M  V30 23 1 19 24
M  V30 24 1 19 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7517-19-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13139-15-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 15136-12-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40776767
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7647-14-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A new class of -ketoamide derivatives with potent anticancer and
anti-SARS-CoV-2 activities
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Juan; Liang, Boqiang; Chen, Yiling; Fuk-Woo Chan, Jasper; Yuan,
Shuofeng; Ye, Hui; Nie, Linlin; Zhou, Jiao; Wu, Yi; Wu, Meixian; Huang,
Lina S.; An, Jing; Warshel, Arieh; Yuen, Kwok-Yung; Ciechanover, Aaron;
Huang, Ziwei; Xu, Yan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 215113267

$RFMT $RIREG SCHEME95 STEP1
$RXN



  2  1
$MOL
4-Fluorobenzoic acid
C7H5FO2
456-22-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 0.0000 0.0 0
M  V30 3 O 0.0000 2.6673 0.0 0
M  V30 4 F 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Acetic acid, 2-[(4-aminophenyl)thio]-, ethyl ester
C10H13NO2S
24477-57-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 9.3360 2.3101 0.0 0
M  V30 5 O 8.0022 0.0000 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 C 12.0033 2.3101 0.0 0
M  V30 8 N 0.0000 4.6201 0.0 0
M  V30 9 C 4.0012 2.3101 0.0 0
M  V30 10 C 2.6673 1.5400 0.0 0
M  V30 11 C 4.0012 3.8501 0.0 0
M  V30 12 C 1.3337 2.3101 0.0 0
M  V30 13 C 2.6673 4.6201 0.0 0
M  V30 14 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethyl 2-[[4-[(4-fluorobenzoyl)amino]phenyl]thio]acetate
C17H16FNO3S
913248-18-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.8501 0.0 0
M  V30 2 N 6.6685 4.6201 0.0 0
M  V30 3 O 5.3348 2.3101 0.0 0
M  V30 4 F 0.0000 6.9302 0.0 0
M  V30 5 S 12.0035 1.5400 0.0 0
M  V30 6 C 13.3372 2.3101 0.0 0
M  V30 7 C 14.6708 1.5400 0.0 0
M  V30 8 O 16.0045 2.3101 0.0 0
M  V30 9 O 14.6708 0.0000 0.0 0
M  V30 10 C 17.3383 1.5400 0.0 0
M  V30 11 C 18.6720 2.3101 0.0 0
M  V30 12 C 4.0012 4.6201 0.0 0
M  V30 13 C 2.6675 3.8501 0.0 0
M  V30 14 C 4.0012 6.1601 0.0 0
M  V30 15 C 1.3337 4.6201 0.0 0
M  V30 16 C 2.6675 6.9302 0.0 0
M  V30 17 C 1.3337 6.1601 0.0 0
M  V30 18 C 8.0023 3.8501 0.0 0
M  V30 19 C 8.0023 2.3101 0.0 0
M  V30 20 C 9.3360 4.6201 0.0 0
M  V30 21 C 9.3360 1.5400 0.0 0
M  V30 22 C 10.6697 3.8501 0.0 0
M  V30 23 C 10.6697 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 18
M  V30 5 1 4 17
M  V30 6 1 5 6
M  V30 7 1 5 23
M  V30 8 1 6 7
M  V30 9 1 7 8
M  V30 10 2 7 9
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 456-22-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 24477-57-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 913248-18-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38045830
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-Based Ligand Discovery Targeting the Transmembrane Domain of
Frizzled Receptor FZD7
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Cuixia; Wu, Yiran; Wang, Wenli; Xu, Lu; Zhou, Yan; Yue, Yang; Wu,
Tingting; Yang, Meifang; Qiu, Yanli; Huang, Minhao; Zhou, Fangfang; Zhou,
Yiqing; Hao, Piliang; Lin, Zhixiong; Wang, Ming-Wei; Zhao, Suwen; Yang,
Dehua; Xu, Fei; Tao, Houchao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(17), 11855-11868

$RFMT $RIREG SCHEME96 STEP1
$RXN



  2  1
$MOL
Ibuprofen
C13H18O2
15687-27-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 2.6674 0.0 0
M  V30 2 C 1.5400 1.3338 0.0 0
M  V30 3 C 1.5400 4.0011 0.0 0
M  V30 4 O 2.3100 0.0000 0.0 0
M  V30 5 O 0.0000 1.3338 0.0 0
M  V30 6 C 8.4700 2.6674 0.0 0
M  V30 7 C 9.2400 4.0011 0.0 0
M  V30 8 C 10.7800 4.0011 0.0 0
M  V30 9 C 8.4700 5.3349 0.0 0
M  V30 10 C 3.8500 2.6674 0.0 0
M  V30 11 C 4.6200 4.0011 0.0 0
M  V30 12 C 4.6200 1.3338 0.0 0
M  V30 13 C 6.1600 4.0011 0.0 0
M  V30 14 C 6.1600 1.3338 0.0 0
M  V30 15 C 6.9300 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 6 7
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1,N1-Didodecyl-N2-methyl-1,2-ethanediamine
C27H59N2.I
2128731-38-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 13.8600 5.3900 0.0 0 CHG=1 VAL=4
M  V30 2 C 12.3200 5.3900 0.0 0
M  V30 3 C 15.4000 5.3900 0.0 0
M  V30 4 C 13.8600 3.8500 0.0 0
M  V30 5 C 13.8600 6.9300 0.0 0
M  V30 6 C 11.5500 6.7236 0.0 0
M  V30 7 C 16.1700 6.7236 0.0 0
M  V30 8 C 12.5264 3.0800 0.0 0
M  V30 9 C 10.0100 6.7236 0.0 0
M  V30 10 C 17.7100 6.7236 0.0 0
M  V30 11 N 12.5264 1.5400 0.0 0
M  V30 12 C 9.2400 8.0574 0.0 0
M  V30 13 C 18.4800 8.0574 0.0 0
M  V30 14 C 7.7000 8.0574 0.0 0
M  V30 15 C 20.0200 8.0574 0.0 0
M  V30 16 C 6.9300 9.3911 0.0 0
M  V30 17 C 20.7900 9.3911 0.0 0
M  V30 18 C 5.3900 9.3911 0.0 0
M  V30 19 C 22.3300 9.3911 0.0 0
M  V30 20 C 4.6200 10.7247 0.0 0
M  V30 21 C 23.1000 10.7247 0.0 0
M  V30 22 C 3.0800 10.7247 0.0 0
M  V30 23 C 24.6400 10.7247 0.0 0
M  V30 24 C 2.3100 12.0585 0.0 0
M  V30 25 C 25.4100 12.0585 0.0 0
M  V30 26 C 0.7700 12.0585 0.0 0
M  V30 27 C 26.9500 12.0585 0.0 0
M  V30 28 C 0.0000 13.3921 0.0 0
M  V30 29 C 27.7200 13.3921 0.0 0
M  V30 30 I 13.8600 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 10 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Dodecanaminium, N-dodecyl-N-methyl-N-[2-[[2-[4-(2-methylpropyl)phenyl]-1-ox...
C40H75N2O.I
3055833-32-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  44 43 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.4702 21.5457 0.0 0
M  V30 2 C 9.2402 20.2118 0.0 0
M  V30 3 C 9.2402 22.8793 0.0 0
M  V30 4 N 10.7802 20.2118 0.0 0
M  V30 5 O 8.4702 18.8782 0.0 0
M  V30 6 C 11.5503 18.8782 0.0 0
M  V30 7 C 13.0903 18.8782 0.0 0
M  V30 8 N 13.8603 17.5445 0.0 0 CHG=1 VAL=4
M  V30 9 C 14.6303 16.2108 0.0 0
M  V30 10 C 15.1941 18.3145 0.0 0
M  V30 11 C 12.5266 16.7745 0.0 0
M  V30 12 C 13.8603 14.8770 0.0 0
M  V30 13 C 16.5278 17.5445 0.0 0
M  V30 14 C 14.6303 13.5433 0.0 0
M  V30 15 C 17.8615 18.3145 0.0 0
M  V30 16 C 13.8603 12.2097 0.0 0
M  V30 17 C 19.1951 17.5445 0.0 0
M  V30 18 C 14.6303 10.8760 0.0 0
M  V30 19 C 20.5290 18.3145 0.0 0
M  V30 20 C 13.8603 9.5422 0.0 0
M  V30 21 C 21.8626 17.5445 0.0 0
M  V30 22 C 14.6303 8.2085 0.0 0
M  V30 23 C 23.1963 18.3145 0.0 0
M  V30 24 C 13.8603 6.8748 0.0 0
M  V30 25 C 24.5300 17.5445 0.0 0
M  V30 26 C 14.6303 5.5412 0.0 0
M  V30 27 C 25.8638 18.3145 0.0 0
M  V30 28 C 13.8603 4.2073 0.0 0
M  V30 29 C 27.1975 17.5445 0.0 0
M  V30 30 C 14.6303 2.8737 0.0 0
M  V30 31 C 28.5311 18.3145 0.0 0
M  V30 32 C 13.8603 1.5400 0.0 0
M  V30 33 C 29.8649 17.5445 0.0 0
M  V30 34 C 2.3101 21.5457 0.0 0
M  V30 35 C 1.5400 22.8793 0.0 0
M  V30 36 C 2.3101 24.2130 0.0 0
M  V30 37 C 0.0000 22.8793 0.0 0
M  V30 38 C 6.9302 21.5457 0.0 0
M  V30 39 C 6.1601 20.2118 0.0 0
M  V30 40 C 6.1601 22.8793 0.0 0
M  V30 41 C 4.6201 20.2118 0.0 0
M  V30 42 C 4.6201 22.8793 0.0 0
M  V30 43 C 3.8501 21.5457 0.0 0
M  V30 44 I 14.9325 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 38
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 1 29 31
M  V30 32 1 30 32
M  V30 33 1 31 33
M  V30 34 1 34 35
M  V30 35 1 34 43
M  V30 36 1 35 36
M  V30 37 1 35 37
M  V30 38 2 38 39
M  V30 39 1 38 40
M  V30 40 1 39 41
M  V30 41 2 40 42
M  V30 42 2 41 43
M  V30 43 1 42 43
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 15687-27-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2128731-38-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3055833-32-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37275694
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM inert in stage 2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and Characterization of a New Cationic Lipid: Efficient siRNA
Delivery and Anticancer Activity of Survivin-siRNA Lipoplexes for the
Treatment of Lung and Breast Cancers
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Vaidya, Sandeep; Mohod, Annie; Eedara, Abhisheik Chowdary; Andugulapati,
Sai Balaji; Pabbaraja, Srihari
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(16), e202300097

$RFMT $RIREG SCHEME97 STEP1
$RXN



  2  1
$MOL
Phenylacetic acid
C8H8O2
103-82-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 C 5.3901 1.3337 0.0 0
M  V30 3 O 4.6201 0.0000 0.0 0
M  V30 4 O 6.9302 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 2.3101 4.0010 0.0 0
M  V30 7 C 2.3101 1.3337 0.0 0
M  V30 8 C 0.7700 4.0010 0.0 0
M  V30 9 C 0.7700 1.3337 0.0 0
M  V30 10 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,4-Dimethoxyphenethylamine
C10H15NO2
120-20-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3349 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3349 0.0 0
M  V30 7 N 9.2400 5.3349 0.0 0
M  V30 8 C 3.0800 2.6674 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.0800 5.3349 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 4.6200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)ethyl]benzeneacetamide
C18H21NO3
4876-02-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 4.6201 0.0 0
M  V30 2 C 0.0000 6.1601 0.0 0
M  V30 3 O 0.0000 1.5400 0.0 0
M  V30 4 C 0.0000 0.0000 0.0 0
M  V30 5 C 5.3348 4.6201 0.0 0
M  V30 6 C 6.6685 3.8501 0.0 0
M  V30 7 N 8.0022 4.6201 0.0 0
M  V30 8 C 9.3358 3.8501 0.0 0
M  V30 9 C 10.6697 4.6201 0.0 0
M  V30 10 O 9.3358 2.3101 0.0 0
M  V30 11 C 1.3337 3.8501 0.0 0
M  V30 12 C 1.3337 2.3101 0.0 0
M  V30 13 C 2.6673 4.6201 0.0 0
M  V30 14 C 2.6673 1.5400 0.0 0
M  V30 15 C 4.0010 3.8501 0.0 0
M  V30 16 C 4.0010 2.3101 0.0 0
M  V30 17 C 12.0033 3.8501 0.0 0
M  V30 18 C 12.0033 2.3101 0.0 0
M  V30 19 C 13.3370 4.6201 0.0 0
M  V30 20 C 13.3370 1.5400 0.0 0
M  V30 21 C 14.6707 3.8501 0.0 0
M  V30 22 C 14.6707 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 3 4
M  V30 4 1 3 12
M  V30 5 1 5 6
M  V30 6 1 5 15
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 17
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 103-82-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 120-20-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 4876-02-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23042059
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME98 STEP1
$RXN



  2  1
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Bromo-2-fluoro-6-methoxybenzeneacetic acid
C9H8BrFO3
1784193-80-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0011 0.0 0
M  V30 2 C 5.3900 5.3347 0.0 0
M  V30 3 O 6.9300 5.3347 0.0 0
M  V30 4 O 4.6200 6.6685 0.0 0
M  V30 5 O 3.0800 1.3338 0.0 0
M  V30 6 C 2.3100 0.0000 0.0 0
M  V30 7 F 3.0800 6.6685 0.0 0
M  V30 8 Br 0.0000 6.6685 0.0 0
M  V30 9 C 3.0800 4.0011 0.0 0
M  V30 10 C 2.3100 2.6674 0.0 0
M  V30 11 C 2.3100 5.3347 0.0 0
M  V30 12 C 0.7700 2.6674 0.0 0
M  V30 13 C 0.7700 5.3347 0.0 0
M  V30 14 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 1 5 10
M  V30 7 1 7 11
M  V30 8 1 8 13
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Bromo-2-fluoro-6-methoxy-N-methylbenzeneacetamide
C10H11BrFNO2
2420449-19-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 5.3347 0.0 0
M  V30 2 C 2.3100 5.3347 0.0 0
M  V30 3 N 1.5400 6.6685 0.0 0
M  V30 4 O 1.5400 4.0011 0.0 0
M  V30 5 C 0.0000 6.6685 0.0 0
M  V30 6 O 6.9300 5.3347 0.0 0
M  V30 7 C 8.4700 5.3347 0.0 0
M  V30 8 F 2.3100 2.6674 0.0 0
M  V30 9 Br 3.8500 0.0000 0.0 0
M  V30 10 C 4.6200 4.0011 0.0 0
M  V30 11 C 6.1600 4.0011 0.0 0
M  V30 12 C 3.8500 2.6674 0.0 0
M  V30 13 C 6.9300 2.6674 0.0 0
M  V30 14 C 4.6200 1.3338 0.0 0
M  V30 15 C 6.1600 1.3338 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 6 7
M  V30 7 1 6 11
M  V30 8 1 8 12
M  V30 9 1 9 14
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1784193-80-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2420449-19-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22513054
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Multigram Synthesis of BMS-929075, an Allosteric, Palm Site Inhibitor of
HCV NS5B Replicase, Involving the Synthesis of a Highly Functionalized
Benzofuran through a Telescoped Process
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Smith, Daniel; Krishnananthan, Subramaniam; Meanwell, Nicholas A.;
Mathur, Arvind; Li, Jianqing
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2020), 24(6), 1157-1163

$RFMT $RIREG SCHEME99 STEP1
$RXN



  2  1
$MOL
3-Amino-4-methylbenzoic acid
C8H9NO2
2458-12-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 5.3901 0.0000 0.0 0
M  V30 5 C 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Pyridinemethanamine
C6H8N2
3731-52-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 N 5.3901 2.6673 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 2.3101 2.6673 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 N 0.7700 0.0000 0.0 0
M  V30 8 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 2 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzamide, 3-amino-4-methyl-N-(3-pyridinylmethyl)-
C14H15N3O
85366-81-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 6.6685 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 8.0022 1.5400 0.0 0
M  V30 5 N 0.0000 1.5400 0.0 0
M  V30 6 C 0.0000 4.6201 0.0 0
M  V30 7 C 4.0012 2.3101 0.0 0
M  V30 8 C 2.6673 1.5400 0.0 0
M  V30 9 C 4.0012 3.8501 0.0 0
M  V30 10 C 1.3337 2.3101 0.0 0
M  V30 11 C 2.6673 4.6201 0.0 0
M  V30 12 C 1.3337 3.8501 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 14 C 10.6697 1.5400 0.0 0
M  V30 15 C 9.3360 3.8501 0.0 0
M  V30 16 C 12.0033 2.3101 0.0 0
M  V30 17 N 10.6697 4.6201 0.0 0
M  V30 18 C 12.0033 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 4 13
M  V30 6 1 5 10
M  V30 7 1 6 12
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2458-12-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3731-52-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 85366-81-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37264191
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin
Inhibitors Targeting the Colchicine Binding Site
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Lin, Songwen; Du, Tingting; Zhang, Jingbo; Wu, Deyu; Tian, Hua; Zhang,
Kehui; Jiang, Lin; Lu, Duo; Sheng, Li; Li, Yan; Ji, Ming; Chen,
Xiaoguang; Xu, Heng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(24), 16372-16391

$RFMT $RIREG SCHEME100 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
tert-Butyl (3-aminopropyl)carbamate
C8H18N2O2
75178-96-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6673 2.3101 0.0 0
M  V30 2 C 4.0012 1.5400 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 N 5.3348 2.3101 0.0 0
M  V30 5 O 4.0012 0.0000 0.0 0
M  V30 6 C 2.1037 0.2064 0.0 0
M  V30 7 C 0.0000 0.7700 0.0 0
M  V30 8 C 0.5637 2.8737 0.0 0
M  V30 9 C 6.6685 1.5400 0.0 0
M  V30 10 C 8.0023 2.3101 0.0 0
M  V30 11 C 9.3360 1.5400 0.0 0
M  V30 12 N 10.6697 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[3-[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]propyl]-...
C16H23N3O3
3031471-24-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 N 8.0023 2.3101 0.0 0
M  V30 5 O 6.6685 4.6201 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 C 12.0035 3.0801 0.0 0
M  V30 9 N 13.3372 2.3101 0.0 0
M  V30 10 C 14.6708 3.0801 0.0 0
M  V30 11 O 16.0045 2.3101 0.0 0
M  V30 12 O 14.6708 4.6201 0.0 0
M  V30 13 C 17.3383 3.0801 0.0 0
M  V30 14 C 16.5683 4.4137 0.0 0
M  V30 15 C 18.6720 3.8501 0.0 0
M  V30 16 C 18.1083 1.7464 0.0 0
M  V30 17 C 2.6675 2.3101 0.0 0
M  V30 18 C 2.6675 0.7700 0.0 0
M  V30 19 C 1.3337 3.0801 0.0 0
M  V30 20 C 1.3337 0.0000 0.0 0
M  V30 21 N 0.0000 2.3101 0.0 0
M  V30 22 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 75178-96-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031471-24-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131881
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME101 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-BOC-ethylenediamine
C7H16N2O2
57260-73-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 2.3101 0.0 0
M  V30 2 C 4.0012 1.5400 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 N 5.3348 2.3101 0.0 0
M  V30 5 O 4.0012 0.0000 0.0 0
M  V30 6 C 2.1037 0.2064 0.0 0
M  V30 7 C 0.0000 0.7700 0.0 0
M  V30 8 C 0.5637 2.8737 0.0 0
M  V30 9 C 6.6685 1.5400 0.0 0
M  V30 10 C 8.0023 2.3101 0.0 0
M  V30 11 N 9.3360 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[2-[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]ethyl]-,...
C15H21N3O3
2521770-65-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6687 1.5400 0.0 0
M  V30 4 N 8.0023 2.3101 0.0 0
M  V30 5 O 6.6687 0.0000 0.0 0
M  V30 6 C 9.3360 1.5400 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 N 12.0035 1.5400 0.0 0
M  V30 9 C 13.3372 2.3101 0.0 0
M  V30 10 O 14.6708 1.5400 0.0 0
M  V30 11 O 13.3372 3.8501 0.0 0
M  V30 12 C 16.0045 2.3101 0.0 0
M  V30 13 C 16.7745 0.9764 0.0 0
M  V30 14 C 17.3383 3.0801 0.0 0
M  V30 15 C 15.2345 3.6437 0.0 0
M  V30 16 C 2.6675 2.3101 0.0 0
M  V30 17 C 1.3338 1.5400 0.0 0
M  V30 18 C 2.6675 3.8501 0.0 0
M  V30 19 C 0.0000 2.3101 0.0 0
M  V30 20 N 1.3338 4.6201 0.0 0
M  V30 21 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 2 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 57260-73-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2521770-65-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131864
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME102 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-3-pyridinamine
C5H5BrN2
13535-01-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0.0000 3.0800 0.0 0
M  V30 2 N 5.3349 3.0800 0.0 0
M  V30 3 C 2.6675 3.0800 0.0 0
M  V30 4 C 1.3338 2.3100 0.0 0
M  V30 5 C 4.0011 2.3100 0.0 0
M  V30 6 C 1.3338 0.7700 0.0 0
M  V30 7 C 4.0011 0.7700 0.0 0
M  V30 8 N 2.6675 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 2 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C12H16BrN3O3
2731006-60-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 9.3358 3.0801 0.0 0
M  V30 2 C 8.0022 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 O 8.0022 0.7700 0.0 0
M  V30 5 N 5.3348 2.3101 0.0 0
M  V30 6 C 4.0010 3.0801 0.0 0
M  V30 7 O 2.6673 2.3101 0.0 0
M  V30 8 O 4.0010 4.6201 0.0 0
M  V30 9 C 1.3337 3.0801 0.0 0
M  V30 10 C 0.5637 1.7464 0.0 0
M  V30 11 C 0.0000 3.8501 0.0 0
M  V30 12 C 2.1037 4.4137 0.0 0
M  V30 13 Br 14.6707 3.0801 0.0 0
M  V30 14 C 10.6697 2.3101 0.0 0
M  V30 15 C 12.0033 3.0801 0.0 0
M  V30 16 C 10.6697 0.7700 0.0 0
M  V30 17 C 13.3370 2.3101 0.0 0
M  V30 18 N 12.0033 0.0000 0.0 0
M  V30 19 C 13.3370 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 1 13 17
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13535-01-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2731006-60-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40478600
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM key intermediate
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide
Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the
Treatment of Autosomal Dominant Polycystic Kidney Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yang, Bowen; Zhang, Haoran; Li, Na; Gao, Lixin; Jiang, Hong; Kan,
Weijuan; Yuan, Haoxing; Li, Jia; Zhao, Dongmei; Xiong, Bing; Zhou, Yubo;
Guo, Dong; Liu, Tongchao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(23), 15770-15788

$RFMT $RIREG SCHEME103 STEP1
$RXN



  2  1
$MOL
Palmitic acid
C16H32O2
57-10-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0023 2.3101 0.0 0
M  V30 2 C 9.3360 1.5400 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 C 10.6697 2.3101 0.0 0
M  V30 5 C 5.3348 2.3101 0.0 0
M  V30 6 C 12.0033 1.5400 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 13.3372 2.3101 0.0 0
M  V30 9 C 2.6673 2.3101 0.0 0
M  V30 10 C 14.6708 1.5400 0.0 0
M  V30 11 C 1.3337 1.5400 0.0 0
M  V30 12 C 16.0045 2.3101 0.0 0
M  V30 13 O 0.0000 2.3101 0.0 0
M  V30 14 O 1.3337 0.0000 0.0 0
M  V30 15 C 17.3382 1.5400 0.0 0
M  V30 16 C 18.6720 2.3101 0.0 0
M  V30 17 C 20.0057 1.5400 0.0 0
M  V30 18 C 21.3393 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 11 14
M  V30 14 1 12 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) hydrogen L-glutamate
C9H17NO4
45120-30-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 2.3101 0.0 0
M  V30 2 C 5.3348 1.5400 0.0 0 CFG=1
M  V30 3 O 2.6673 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 6.6685 2.3101 0.0 0
M  V30 6 N 5.3348 0.0000 0.0 0
M  V30 7 C 1.3337 2.3101 0.0 0
M  V30 8 C 8.0023 1.5400 0.0 0
M  V30 9 C 0.5637 0.9764 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 2.1037 3.6437 0.0 0
M  V30 12 C 9.3360 2.3101 0.0 0
M  V30 13 O 10.6697 1.5400 0.0 0
M  V30 14 O 9.3360 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=3
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) hydrogen N-(1-oxohexadecyl)-L-glutamate
C25H47NO5
536721-25-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 4.6201 0.0 0 CFG=1
M  V30 2 N 5.3348 5.3901 0.0 0
M  V30 3 C 2.6675 5.3901 0.0 0
M  V30 4 C 4.0012 3.0801 0.0 0
M  V30 5 C 6.6687 4.6201 0.0 0
M  V30 6 O 2.6675 6.9302 0.0 0
M  V30 7 O 1.3338 4.6201 0.0 0
M  V30 8 C 2.6675 2.3101 0.0 0
M  V30 9 C 8.0023 5.3901 0.0 0
M  V30 10 O 6.6687 3.0801 0.0 0
M  V30 11 C 1.3338 7.7002 0.0 0
M  V30 12 C 2.6675 0.7700 0.0 0
M  V30 13 C 9.3360 4.6201 0.0 0
M  V30 14 C 0.5638 6.3665 0.0 0
M  V30 15 C 0.0000 8.4702 0.0 0
M  V30 16 C 2.1038 9.0338 0.0 0
M  V30 17 O 1.3338 0.0000 0.0 0
M  V30 18 O 4.0012 0.0000 0.0 0
M  V30 19 C 10.6697 5.3901 0.0 0
M  V30 20 C 12.0035 4.6201 0.0 0
M  V30 21 C 13.3372 5.3901 0.0 0
M  V30 22 C 14.6708 4.6201 0.0 0
M  V30 23 C 16.0045 5.3901 0.0 0
M  V30 24 C 17.3383 4.6201 0.0 0
M  V30 25 C 18.6720 5.3901 0.0 0
M  V30 26 C 20.0057 4.6201 0.0 0
M  V30 27 C 21.3393 5.3901 0.0 0
M  V30 28 C 22.6731 4.6201 0.0 0
M  V30 29 C 24.0068 5.3901 0.0 0
M  V30 30 C 25.3405 4.6201 0.0 0
M  V30 31 C 26.6743 5.3901 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 1 11 15
M  V30 15 1 11 16
M  V30 16 1 12 17
M  V30 17 2 12 18
M  V30 18 1 13 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 57-10-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 45120-30-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 536721-25-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24132347
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 693-13-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 6066-82-6
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-05-8
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Copper(II) lysinate and pseudoproline assistance in the convergent
synthesis of the GLP-1 receptor agonists Liraglutide and Semaglutide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guryanov, Ivan; Orlandin, Andrea; De Paola, Ivan; Viola, Angelo; Biondi,
Barbara; Badocco, Denis; Formaggio, Fernando; Ricci, Antonio; Cabri,
Walter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(7), 1598-1611

$RFMT $RIREG SCHEME104 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)-D-4-chlorophenylalanine
C14H18ClNO4
57292-44-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.7238 4.0012 0.0 0
M  V30 2 C 5.9538 2.6675 0.0 0 CFG=2
M  V30 3 N 4.4137 2.6675 0.0 0
M  V30 4 C 6.7238 1.3338 0.0 0
M  V30 5 C 3.6437 4.0012 0.0 0
M  V30 6 O 8.2638 1.3338 0.0 0
M  V30 7 O 5.9538 0.0000 0.0 0
M  V30 8 O 2.1037 4.0012 0.0 0
M  V30 9 O 4.4137 5.3348 0.0 0
M  V30 10 C 1.3337 5.3348 0.0 0
M  V30 11 C 0.0000 4.5648 0.0 0
M  V30 12 C 0.5637 6.6687 0.0 0
M  V30 13 C 2.6673 6.1048 0.0 0
M  V30 14 Cl 12.8839 4.0012 0.0 0
M  V30 15 C 8.2638 4.0012 0.0 0
M  V30 16 C 9.0338 5.3348 0.0 0
M  V30 17 C 9.0338 2.6675 0.0 0
M  V30 18 C 10.5739 5.3348 0.0 0
M  V30 19 C 10.5739 2.6675 0.0 0
M  V30 20 C 11.3439 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3 CFG=3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 20
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C15H21ClN2O3
3061154-80-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.9536 4.0011 0.0 0 CFG=2
M  V30 2 C 6.7236 5.3347 0.0 0
M  V30 3 N 4.4136 4.0011 0.0 0
M  V30 4 C 6.7236 2.6674 0.0 0
M  V30 5 C 3.6436 5.3347 0.0 0
M  V30 6 N 5.9536 1.3336 0.0 0
M  V30 7 O 8.2636 2.6674 0.0 0
M  V30 8 O 2.1036 5.3347 0.0 0
M  V30 9 O 4.4136 6.6685 0.0 0
M  V30 10 C 6.7236 0.0000 0.0 0
M  V30 11 C 1.3336 6.6685 0.0 0
M  V30 12 C 2.6673 7.4385 0.0 0
M  V30 13 C 0.5636 8.0021 0.0 0
M  V30 14 C 0.0000 5.8985 0.0 0
M  V30 15 Cl 12.8836 5.3347 0.0 0
M  V30 16 C 8.2636 5.3347 0.0 0
M  V30 17 C 9.0336 4.0011 0.0 0
M  V30 18 C 9.0336 6.6685 0.0 0
M  V30 19 C 10.5736 4.0011 0.0 0
M  V30 20 C 10.5736 6.6685 0.0 0
M  V30 21 C 11.3436 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 16
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 15 21
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 57292-44-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3061154-80-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-42895413
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 Mpro
from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent
Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant
Variants
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Xu; Gotchev, Dimitar; Fan, Kristi Yi; Vega, Marvin M.; Mani,
Nagraj; McGovern-Gooch, Kayleigh; Cuconati, Andrea; Tercero, Breanna;
Wang, Xiaohe; Carpino, Philip; Maskos, Klaus; Centrella, Paolo A.;
Schmitt, Andreas; Preuss, Franziska; Prasad, Archna; Chen, Chia-yi;
Clark, Matthew A.; Guilinger, John P.; Johnstone, Shawn; von Konig,
Konstanze; Keefe, Anthony D.; Liu, Jenny; Turcotte, Stephane; Zhang,
Ying; Konz Makino, Debora L.; Lam, Angela M.; Cole, Andrew G.; Sofia,
Michael J.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(21), 19623-19667

$RFMT $RIREG SCHEME105 STEP1
$RXN



  2  1
$MOL
Benzoic acid
C7H6O2
65-85-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,4-Dimethoxyaniline
C8H11NO2
6315-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7700 4.0011 0.0 0
M  V30 2 C 0.0000 5.3349 0.0 0
M  V30 3 O 2.3100 1.3338 0.0 0
M  V30 4 C 3.0800 0.0000 0.0 0
M  V30 5 N 6.9300 4.0011 0.0 0
M  V30 6 C 2.3100 4.0011 0.0 0
M  V30 7 C 3.0800 2.6674 0.0 0
M  V30 8 C 3.0800 5.3349 0.0 0
M  V30 9 C 4.6200 2.6674 0.0 0
M  V30 10 C 4.6200 5.3349 0.0 0
M  V30 11 C 5.3900 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 3 4
M  V30 4 1 3 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3,4-Dimethoxyphenyl)benzamide
C15H15NO3
39078-05-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 4.0011 0.0 0
M  V30 2 C 7.7000 5.3347 0.0 0
M  V30 3 O 6.9300 6.6685 0.0 0
M  V30 4 O 2.3100 1.3338 0.0 0
M  V30 5 C 3.0800 0.0000 0.0 0
M  V30 6 O 0.7700 4.0011 0.0 0
M  V30 7 C 0.0000 5.3347 0.0 0
M  V30 8 C 5.3900 4.0011 0.0 0
M  V30 9 C 4.6200 2.6674 0.0 0
M  V30 10 C 4.6200 5.3347 0.0 0
M  V30 11 C 3.0800 2.6674 0.0 0
M  V30 12 C 3.0800 5.3347 0.0 0
M  V30 13 C 2.3100 4.0011 0.0 0
M  V30 14 C 9.2400 5.3347 0.0 0
M  V30 15 C 10.0100 6.6685 0.0 0
M  V30 16 C 10.0100 4.0011 0.0 0
M  V30 17 C 11.5500 6.6685 0.0 0
M  V30 18 C 11.5500 4.0011 0.0 0
M  V30 19 C 12.3200 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 2 2 3
M  V30 4 1 2 14
M  V30 5 1 4 5
M  V30 6 1 4 11
M  V30 7 1 6 7
M  V30 8 1 6 13
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 65-85-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6315-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 39078-05-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36209050
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Activity of N-phenylbenzamide analogs against the neglected disease
pathogen, Schistosoma mansoni
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kanyanta, Masebe; Lengwe, Chilufya; Mambwe, Dickson; Francisco, Karol R.;
Liu, Lawrence J.; Uli Sun, Yujie; Amarasinghe, Dilini K.; Caffrey, Conor
R.; Mubanga Cheuka, Peter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2023), 82129164

$RFMT $RIREG SCHEME106 STEP1
$RXN



  2  1
$MOL
5-Bromo-2-fluoro-4-methylbenzoic acid
C8H6BrFO2
515135-65-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 4.0011 0.0 0
M  V30 3 O 0.0000 1.3338 0.0 0
M  V30 4 F 2.3100 0.0000 0.0 0
M  V30 5 Br 5.3901 5.3349 0.0 0
M  V30 6 C 6.9301 2.6675 0.0 0
M  V30 7 C 2.3100 2.6675 0.0 0
M  V30 8 C 3.0800 1.3338 0.0 0
M  V30 9 C 3.0800 4.0011 0.0 0
M  V30 10 C 4.6201 1.3338 0.0 0
M  V30 11 C 4.6201 4.0011 0.0 0
M  V30 12 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 8
M  V30 5 1 5 11
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Pentanamine, 4,4-dimethyl-, hydrochloride (1:1)
C7H17N.ClH
1266694-57-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.6437 0.0 0
M  V30 2 C 1.3338 2.8737 0.0 0
M  V30 3 C 4.0012 2.8737 0.0 0
M  V30 4 C 2.1038 1.5400 0.0 0
M  V30 5 C 0.0000 2.1037 0.0 0
M  V30 6 C 0.5638 4.2073 0.0 0
M  V30 7 C 5.3348 3.6437 0.0 0
M  V30 8 N 6.6687 2.8737 0.0 0
M  V30 9 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N-(4,4-dimethylpentyl)-2-fluoro-4-methylbenzamide
C15H21BrFNO
2729996-46-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 4.6201 0.0 0
M  V30 2 N 6.6685 3.8501 0.0 0
M  V30 3 O 5.3348 6.1601 0.0 0
M  V30 4 C 8.0022 4.6201 0.0 0
M  V30 5 C 9.3360 3.8501 0.0 0
M  V30 6 C 10.6697 4.6201 0.0 0
M  V30 7 C 12.0033 3.8501 0.0 0
M  V30 8 C 11.2333 2.5164 0.0 0
M  V30 9 C 13.3370 3.0801 0.0 0
M  V30 10 C 12.7733 5.1838 0.0 0
M  V30 11 F 2.6673 6.1601 0.0 0
M  V30 12 Br 2.6673 0.0000 0.0 0
M  V30 13 C 0.0000 1.5400 0.0 0
M  V30 14 C 4.0010 3.8501 0.0 0
M  V30 15 C 2.6673 4.6201 0.0 0
M  V30 16 C 4.0010 2.3101 0.0 0
M  V30 17 C 1.3337 3.8501 0.0 0
M  V30 18 C 2.6673 1.5400 0.0 0
M  V30 19 C 1.3337 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 1 11 15
M  V30 12 1 12 18
M  V30 13 1 13 19
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 515135-65-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1266694-57-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2729996-46-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24719960
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a
Pyridopyridazinone pan-RAF Kinase Inhibitor
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Huestis, Malcolm P.; Durk, Matthew R.; Eigenbrot, Charles; Gibbons, Paul;
Hunsaker, Thomas L.; La, Hank; Leung, Dennis H.; Liu, Wendy; Malek,
Shiva; Merchant, Mark; Moffat, John G.; Muli, Christine S.; Orr,
Christine J.; Parr, Brendan T.; Shanahan, Frances; Sneeringer,
Christopher J.; Wang, Weiru; Yen, Ivana; Yin, Jianping; Rudolph, Joachim;
Siu, Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2021), 12(5), 791-797

$RFMT $RIREG SCHEME107 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)-1,4-butanediamine
C9H20N2O2
68076-36-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 O 2.6673 2.3101 0.0 0
M  V30 4 O 4.0012 0.0000 0.0 0
M  V30 5 C 6.6685 1.5400 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 C 8.0022 2.3101 0.0 0
M  V30 8 C 2.1037 0.2064 0.0 0
M  V30 9 C 0.0000 0.7700 0.0 0
M  V30 10 C 0.5637 2.8737 0.0 0
M  V30 11 C 9.3360 1.5400 0.0 0
M  V30 12 C 10.6697 2.3101 0.0 0
M  V30 13 N 12.0033 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[4-[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]butyl]-,...
C17H25N3O3
2361527-93-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 N 8.0023 2.3101 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 9.3360 1.5400 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 C 12.0033 1.5400 0.0 0
M  V30 9 C 13.3372 2.3101 0.0 0
M  V30 10 N 14.6708 1.5400 0.0 0
M  V30 11 C 16.0045 2.3101 0.0 0
M  V30 12 O 17.3382 1.5400 0.0 0
M  V30 13 O 16.0045 3.8501 0.0 0
M  V30 14 C 18.6720 2.3101 0.0 0
M  V30 15 C 17.9020 3.6437 0.0 0
M  V30 16 C 20.0057 3.0801 0.0 0
M  V30 17 C 19.4420 0.9764 0.0 0
M  V30 18 C 2.6675 2.3101 0.0 0
M  V30 19 C 2.6675 3.8501 0.0 0
M  V30 20 C 1.3337 1.5400 0.0 0
M  V30 21 C 1.3337 4.6201 0.0 0
M  V30 22 N 0.0000 2.3101 0.0 0
M  V30 23 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 18
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 1 18 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 2 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 68076-36-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2361527-93-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131890
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME108 STEP1
$RXN



  2  1
$MOL
Ethylamine hydrochloride
C2H7N.ClH
557-66-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 0.0000 2.3100 0.0 0
M  V30 3 N 2.6673 2.3100 0.0 0
M  V30 4 Cl 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Methylpyrazolo[1,5-a]pyridine-6-carboxylic acid
C9H8N2O2
1502267-08-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 C 9.2446 3.0800 0.0 0
M  V30 5 N 5.3347 2.3100 0.0 0
M  V30 6 C 5.3347 3.8500 0.0 0
M  V30 7 C 4.0011 1.5400 0.0 0
M  V30 8 N 6.7994 1.8341 0.0 0
M  V30 9 C 4.0011 4.6200 0.0 0
M  V30 10 C 6.7994 4.3259 0.0 0
M  V30 11 C 2.6674 2.3100 0.0 0
M  V30 12 C 7.7046 3.0800 0.0 0
M  V30 13 C 2.6674 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 4 12
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 2 9 13
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Pyrazolo[1,5-a]pyridine-6-carboxamide, N-ethyl-2-methyl-
C11H13N3O
3034366-02-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.9109 1.5400 0.0 0
M  V30 2 N 9.2445 2.3100 0.0 0
M  V30 3 O 7.9109 0.0000 0.0 0
M  V30 4 C 10.5783 1.5400 0.0 0
M  V30 5 C 11.9120 2.3100 0.0 0
M  V30 6 C 0.0000 3.0800 0.0 0
M  V30 7 N 3.9098 2.3100 0.0 0
M  V30 8 C 3.9098 3.8500 0.0 0
M  V30 9 C 5.2436 1.5400 0.0 0
M  V30 10 N 2.4452 1.8341 0.0 0
M  V30 11 C 2.4452 4.3259 0.0 0
M  V30 12 C 5.2436 4.6200 0.0 0
M  V30 13 C 6.5772 2.3100 0.0 0
M  V30 14 C 1.5400 3.0800 0.0 0
M  V30 15 C 6.5772 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 6 14
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 2 8 11
M  V30 11 1 8 12
M  V30 12 2 9 13
M  V30 13 2 10 14
M  V30 14 1 11 14
M  V30 15 2 12 15
M  V30 16 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 557-66-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1502267-08-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3034366-02-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35314257
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of High-Affinity Small-Molecule Binders of the Epigenetic
Reader YEATS4
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Londregan, Allyn T.; Aitmakhanova, Karlygash; Bennett, James; Byrnes,
Laura J.; Canterbury, Daniel P.; Cheng, Xiayun; Christott, Thomas;
Clemens, Jennifer; Coffey, Steven B.; Dias, Joao M.; Dowling, Matthew S.;
Farnie, Gillian; Fedorov, Oleg; Fennell, Kimberly F.; Gamble, Vicki;
Gileadi, Carina; Giroud, Charline; Harris, Michael R.; Hollingshead,
Brett D.; Huber, Kilian; Korczynska, Magdalena; Lapham, Kimberly; Loria,
Paula M.; Narayanan, Arjun; Owen, Dafydd R.; Raux, Brigitt; Sahasrabudhe,
Parag V.; Ruggeri, Roger B.; Saez, Laura Diaz; Stock, Ingrid A.; Thuma,
Benjamin A.; Tsai, Andy; Varghese, Alison E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(1), 460-472

$RFMT $RIREG SCHEME109 STEP1
$RXN



  2  1
$MOL
1,1-Cyclopropanedicarboxylic acid
C5H6O4
598-10-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.8568 0.0 0
M  V30 2 O 1.3337 0.3168 0.0 0
M  V30 3 O 0.0000 2.6268 0.0 0
M  V30 4 C 3.6573 1.4472 0.0 0
M  V30 5 O 5.1739 1.7145 0.0 0
M  V30 6 O 3.1306 0.0000 0.0 0
M  V30 7 C 2.6673 2.6268 0.0 0
M  V30 8 C 2.1406 4.0740 0.0 0
M  V30 9 C 3.6573 3.8066 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-5-methylisoxazole
C4H6N2O
1072-67-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 2.6218 0.0 0
M  V30 2 C 5.3026 1.4946 0.0 0
M  V30 3 C 2.7406 2.4782 0.0 0
M  V30 4 C 1.3337 1.8517 0.0 0
M  V30 5 C 3.7711 1.3337 0.0 0
M  V30 6 N 1.4946 0.3202 0.0 0
M  V30 7 O 3.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 2 4 6
M  V30 6 1 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-[[(5-Methyl-3-isoxazolyl)amino]carbonyl]cyclopropanecarboxylic acid
C9H10N2O4
1250878-70-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8402 2.2172 0.0 0
M  V30 2 N 5.1739 1.4472 0.0 0
M  V30 3 O 3.8402 3.7572 0.0 0
M  V30 4 C 1.5166 2.6268 0.0 0
M  V30 5 O 0.0000 2.3595 0.0 0
M  V30 6 O 2.0433 4.0740 0.0 0
M  V30 7 C 10.4765 2.5743 0.0 0
M  V30 8 C 2.5065 1.4472 0.0 0
M  V30 9 C 3.0332 0.0000 0.0 0
M  V30 10 C 1.5166 0.2673 0.0 0
M  V30 11 C 6.5075 2.2172 0.0 0
M  V30 12 N 6.6686 3.7487 0.0 0
M  V30 13 C 7.9145 1.5907 0.0 0
M  V30 14 O 8.1749 4.0689 0.0 0
M  V30 15 C 8.9449 2.7352 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 11
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 8
M  V30 8 1 7 15
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 598-10-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1072-67-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1250878-70-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40640691
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via
Structure-Based Drug Design Targeting c-Met Kinase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhan, Zhengsheng; Ji, Yinchun; Su, Haixia; Fang, Chen; Peng, Xia; Liu,
Qiufeng; Dai, Yang; Lin, Dongze; Xu, Yechun; Ai, Jing; Duan, Wenhu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(1), 220-234

$RFMT $RIREG SCHEME110 STEP1
$RXN



  2  1
$MOL
4-(1-Naphthalenylamino)-4-oxobutanoic acid
C14H13NO3
37642-93-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 2.3101 0.0 0
M  V30 2 C 6.6685 3.0801 0.0 0
M  V30 3 C 8.0022 2.3101 0.0 0
M  V30 4 O 6.6685 4.6201 0.0 0
M  V30 5 C 9.3360 3.0801 0.0 0
M  V30 6 C 10.6697 2.3101 0.0 0
M  V30 7 O 10.6697 0.7700 0.0 0
M  V30 8 O 12.0033 3.0801 0.0 0
M  V30 9 C 2.6673 2.3101 0.0 0
M  V30 10 C 4.0012 3.0801 0.0 0
M  V30 11 C 1.3337 3.0801 0.0 0
M  V30 12 C 2.6673 0.7700 0.0 0
M  V30 13 C 4.0012 4.6201 0.0 0
M  V30 14 C 1.3337 4.6201 0.0 0
M  V30 15 C 0.0000 2.3101 0.0 0
M  V30 16 C 1.3337 0.0000 0.0 0
M  V30 17 C 2.6673 5.3901 0.0 0
M  V30 18 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 9 12
M  V30 12 2 10 13
M  V30 13 1 11 14
M  V30 14 1 11 15
M  V30 15 2 12 16
M  V30 16 1 13 17
M  V30 17 2 14 17
M  V30 18 2 15 18
M  V30 19 1 16 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethylenediamine
C2H8N2
107-15-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 C 2.6673 0.7700 0.0 0
M  V30 3 N 0.0000 0.7700 0.0 0
M  V30 4 N 4.0010 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(2-Aminoethyl)-N4-1-naphthalenylbutanediamide
C16H19N3O2
1252687-41-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 3.0800 0.0 0
M  V30 2 C 6.6686 2.3100 0.0 0
M  V30 3 C 8.0022 3.0800 0.0 0
M  V30 4 O 6.6686 0.7700 0.0 0
M  V30 5 C 9.3359 2.3100 0.0 0
M  V30 6 C 10.6697 3.0800 0.0 0
M  V30 7 N 12.0034 2.3100 0.0 0
M  V30 8 O 10.6697 4.6201 0.0 0
M  V30 9 C 13.3370 3.0800 0.0 0
M  V30 10 C 14.6707 2.3100 0.0 0
M  V30 11 N 16.0045 3.0800 0.0 0
M  V30 12 C 2.6675 3.0800 0.0 0
M  V30 13 C 4.0011 2.3100 0.0 0
M  V30 14 C 1.3338 2.3100 0.0 0
M  V30 15 C 2.6675 4.6201 0.0 0
M  V30 16 C 4.0011 0.7700 0.0 0
M  V30 17 C 1.3338 0.7700 0.0 0
M  V30 18 C 0.0000 3.0800 0.0 0
M  V30 19 C 1.3338 5.3901 0.0 0
M  V30 20 C 2.6675 0.0000 0.0 0
M  V30 21 C 0.0000 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 12 15
M  V30 15 2 13 16
M  V30 16 1 14 17
M  V30 17 1 14 18
M  V30 18 2 15 19
M  V30 19 1 16 20
M  V30 20 2 17 20
M  V30 21 2 18 21
M  V30 22 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 37642-93-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 107-15-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1252687-41-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38147434
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 6066-82-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 123-91-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A new naphthalene derivative with anti-amyloidogenic activity as
potential therapeutic agent for Alzheimer's disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rivera-Marrero, Suchitil; Bencomo-Martinez, Alberto; Orta Salazar, Erika;
Sablon-Carrazana, Marquiza; Garcia-Pupo, Laura; Zoppolo, Florencia;
Arredondo, Florencia; Dapueto, Rosina; Daniela Santi, Maria; Kreimerman,
Ingrid; Pardo, Tania; Reyes, Laura; Galan, Lidice; Leon-Chaviano, Samila;
Espinosa-Rodriguez, Luis A.; Menendez-Soto del Valle, Roberto; Savio,
Eduardo; Diaz Cintra, Sofia; Rodriguez-Tanty, Chryslaine
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2020), 28(20), 115700

$RFMT $RIREG SCHEME111 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-BOC-1,6-diaminohexane
C11H24N2O2
51857-17-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 O 2.6673 2.3101 0.0 0
M  V30 4 O 4.0010 0.0000 0.0 0
M  V30 5 C 6.6685 1.5400 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 C 8.0022 2.3101 0.0 0
M  V30 8 C 2.1037 0.2064 0.0 0
M  V30 9 C 0.0000 0.7700 0.0 0
M  V30 10 C 0.5637 2.8737 0.0 0
M  V30 11 C 9.3358 1.5400 0.0 0
M  V30 12 C 10.6697 2.3101 0.0 0
M  V30 13 C 12.0033 1.5400 0.0 0
M  V30 14 C 13.3370 2.3101 0.0 0
M  V30 15 N 14.6707 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[6-[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]hexyl]-,...
C19H29N3O3
3031471-26-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 N 8.0022 2.3101 0.0 0
M  V30 5 O 6.6685 4.6201 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 C 12.0033 3.0801 0.0 0
M  V30 9 C 13.3370 2.3101 0.0 0
M  V30 10 C 14.6708 3.0801 0.0 0
M  V30 11 C 16.0045 2.3101 0.0 0
M  V30 12 N 17.3382 3.0801 0.0 0
M  V30 13 C 18.6718 2.3101 0.0 0
M  V30 14 O 20.0057 3.0801 0.0 0
M  V30 15 O 18.6718 0.7700 0.0 0
M  V30 16 C 21.3393 2.3101 0.0 0
M  V30 17 C 20.5693 0.9764 0.0 0
M  V30 18 C 22.6730 1.5400 0.0 0
M  V30 19 C 22.1093 3.6437 0.0 0
M  V30 20 C 2.6673 2.3101 0.0 0
M  V30 21 C 2.6673 0.7700 0.0 0
M  V30 22 C 1.3337 3.0801 0.0 0
M  V30 23 C 1.3337 0.0000 0.0 0
M  V30 24 N 0.0000 2.3101 0.0 0
M  V30 25 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 16 19
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 51857-17-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031471-26-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131901
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME112 STEP1
$RXN



  2  1
$MOL
Benzoic acid
C7H6O2
65-85-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phenylalanine ethyl ester hydrochloride
C11H15NO2.ClH
3182-93-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0800 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0 CFG=2
M  V30 3 C 6.6685 3.0800 0.0 0
M  V30 4 N 5.3348 5.3901 0.0 0
M  V30 5 O 8.0023 3.8501 0.0 0
M  V30 6 O 6.6685 1.5400 0.0 0
M  V30 7 C 9.3360 3.0800 0.0 0
M  V30 8 C 10.6697 3.8501 0.0 0
M  V30 9 C 2.6673 3.8501 0.0 0
M  V30 10 C 1.3337 3.0800 0.0 0
M  V30 11 C 2.6673 5.3901 0.0 0
M  V30 12 C 0.0000 3.8501 0.0 0
M  V30 13 C 1.3337 6.1601 0.0 0
M  V30 14 C 0.0000 5.3901 0.0 0
M  V30 15 Cl 5.3348 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Phenylalanine, N-benzoyl-, ethyl ester
C18H19NO3
7200-18-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0 CFG=1
M  V30 2 C 4.6200 6.6685 0.0 0
M  V30 3 N 6.9300 5.3347 0.0 0
M  V30 4 C 4.6200 4.0011 0.0 0
M  V30 5 C 7.7000 6.6685 0.0 0
M  V30 6 O 5.3900 2.6674 0.0 0
M  V30 7 O 3.0800 4.0011 0.0 0
M  V30 8 O 6.9300 8.0021 0.0 0
M  V30 9 C 4.6200 1.3336 0.0 0
M  V30 10 C 5.3900 0.0000 0.0 0
M  V30 11 C 3.0800 6.6685 0.0 0
M  V30 12 C 2.3100 8.0021 0.0 0
M  V30 13 C 2.3100 5.3347 0.0 0
M  V30 14 C 0.7700 8.0021 0.0 0
M  V30 15 C 0.7700 5.3347 0.0 0
M  V30 16 C 0.0000 6.6685 0.0 0
M  V30 17 C 9.2400 6.6685 0.0 0
M  V30 18 C 10.0100 5.3347 0.0 0
M  V30 19 C 10.0100 8.0021 0.0 0
M  V30 20 C 11.5500 5.3347 0.0 0
M  V30 21 C 11.5500 8.0021 0.0 0
M  V30 22 C 12.3200 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 11
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 5 17
M  V30 10 1 6 9
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 65-85-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3182-93-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 7200-18-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36966240
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing
Covalent Reversible -Fluorovinylsulfones and -Sulfonates as Potential
Immunomodulators in Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fuchs, Natalie; Meta, Mergim; Lantzberg, Bellinda; Bros, Matthias; Ling
Kuan, Seah; Weil, Tanja; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(15), e202300160

$RFMT $RIREG SCHEME113 STEP1
$RXN



  2  1
$MOL
Methyl 4-aminobenzoate
C8H9NO2
619-45-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 1.3337 0.0 0
M  V30 2 O 1.5400 2.6673 0.0 0
M  V30 3 O 1.5400 0.0000 0.0 0
M  V30 4 C 0.0000 2.6673 0.0 0
M  V30 5 N 8.4702 1.3337 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 6.1601 0.0000 0.0 0
M  V30 10 C 6.1601 2.6673 0.0 0
M  V30 11 C 6.9302 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 4
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Benzoylpropionic acid
C10H10O3
2051-95-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 O 4.0011 0.0000 0.0 0
M  V30 4 C 6.6684 1.5400 0.0 0
M  V30 5 C 8.0021 2.3100 0.0 0
M  V30 6 O 9.3358 1.5400 0.0 0
M  V30 7 O 8.0021 3.8500 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 2.6674 3.8500 0.0 0
M  V30 10 C 1.3336 1.5400 0.0 0
M  V30 11 C 1.3336 4.6200 0.0 0
M  V30 12 C 0.0000 2.3100 0.0 0
M  V30 13 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[(1,4-dioxo-4-phenylbutyl)amino]benzoate
C18H17NO4
1097185-95-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 9.3358 4.6200 0.0 0
M  V30 2 C 8.0021 3.8500 0.0 0
M  V30 3 C 6.6685 4.6200 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 C 5.3347 3.8500 0.0 0
M  V30 6 C 4.0011 4.6200 0.0 0
M  V30 7 O 4.0011 6.1600 0.0 0
M  V30 8 C 14.6705 1.5400 0.0 0
M  V30 9 O 16.0041 2.3100 0.0 0
M  V30 10 O 14.6705 0.0000 0.0 0
M  V30 11 C 17.3379 1.5400 0.0 0
M  V30 12 C 10.6694 3.8500 0.0 0
M  V30 13 C 12.0032 4.6200 0.0 0
M  V30 14 C 10.6694 2.3100 0.0 0
M  V30 15 C 13.3369 3.8500 0.0 0
M  V30 16 C 12.0032 1.5400 0.0 0
M  V30 17 C 13.3369 2.3100 0.0 0
M  V30 18 C 2.6674 3.8500 0.0 0
M  V30 19 C 1.3338 4.6200 0.0 0
M  V30 20 C 2.6674 2.3100 0.0 0
M  V30 21 C 0.0000 3.8500 0.0 0
M  V30 22 C 1.3338 1.5400 0.0 0
M  V30 23 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 2 6 7
M  V30 8 1 6 18
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 8 17
M  V30 12 1 9 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 619-45-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2051-95-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1097185-95-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40615614
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small-Molecule Autophagy Inhibitors by Disrupting the
Protein-Protein Interactions Involving Autophagy-Related 5
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Xiang, Honggang; Liu, Ruiqi; Zhang, Xiangying; An, Ran; Zhou, Mi; Tan,
Chang; Li, Qing; Su, Minyi; Guo, Chun; Zhou, Lu; Li, Yingxia; Wang,
Renxiao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(4), 2457-2476

$RFMT $RIREG SCHEME114 STEP1
$RXN



  2  1
$MOL
2-Bromo-4-nitrobenzeneacetic acid
C8H6BrNO4
66949-40-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 4.6201 0.0 0
M  V30 2 C 8.0022 3.8500 0.0 0
M  V30 3 O 8.0022 2.3100 0.0 0
M  V30 4 O 9.3359 4.6201 0.0 0
M  V30 5 Br 4.0011 6.1601 0.0 0
M  V30 6 N 1.3337 1.5400 0.0 0 VAL=5
M  V30 7 O 0.0000 2.3100 0.0 0
M  V30 8 O 1.3337 0.0000 0.0 0
M  V30 9 C 5.3348 3.8500 0.0 0
M  V30 10 C 4.0011 4.6201 0.0 0
M  V30 11 C 5.3348 2.3100 0.0 0
M  V30 12 C 2.6675 3.8500 0.0 0
M  V30 13 C 4.0011 1.5400 0.0 0
M  V30 14 C 2.6675 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 2 6 8
M  V30 8 1 6 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneethanamine
C8H11N
64-04-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 5.3901 2.6673 0.0 0
M  V30 3 N 6.9302 2.6673 0.0 0
M  V30 4 C 3.0801 1.3337 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.7700 2.6673 0.0 0
M  V30 9 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 2 3
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Bromo-4-nitro-N-(2-phenylethyl)benzeneacetamide
C16H15BrN2O3
2412564-61-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6200 0.0 0
M  V30 2 C 8.0021 3.8500 0.0 0
M  V30 3 N 9.3358 4.6200 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 C 10.6696 3.8500 0.0 0
M  V30 6 C 12.0032 4.6200 0.0 0
M  V30 7 Br 4.0011 6.1600 0.0 0
M  V30 8 N 1.3338 1.5400 0.0 0 VAL=5
M  V30 9 O 1.3338 0.0000 0.0 0
M  V30 10 O 0.0000 2.3100 0.0 0
M  V30 11 C 5.3347 3.8500 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 2.3100 0.0 0
M  V30 14 C 2.6674 3.8500 0.0 0
M  V30 15 C 4.0011 1.5400 0.0 0
M  V30 16 C 2.6674 2.3100 0.0 0
M  V30 17 C 13.3369 3.8500 0.0 0
M  V30 18 C 14.6705 4.6200 0.0 0
M  V30 19 C 13.3369 2.3100 0.0 0
M  V30 20 C 16.0043 3.8500 0.0 0
M  V30 21 C 14.6705 1.5400 0.0 0
M  V30 22 C 16.0043 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 17
M  V30 8 1 7 12
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 16
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 66949-40-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 64-04-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2412564-61-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21974278
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Identification of C10 nitrogen-containing aporphines with dopamine D1
versus D5 receptor selectivity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Karki, Anupam; Juarez, Reecan; Namballa, Hari K.; Alberts, Ian; Harding,
Wayne W.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(8), 127053

$RFMT $RIREG SCHEME115 STEP1
$RXN



  2  1
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-L-phenylalanine
C15H21NO4
114873-06-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 4.0012 0.0 0
M  V30 2 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6765 6.1048 0.0 0
M  V30 14 C 0.0000 6.6687 0.0 0
M  V30 15 C 3.0801 4.0012 0.0 0
M  V30 16 C 2.3101 5.3348 0.0 0
M  V30 17 C 2.3101 2.6675 0.0 0
M  V30 18 C 0.7700 5.3348 0.0 0
M  V30 19 C 0.7700 2.6675 0.0 0
M  V30 20 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3 CFG=3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 18
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Acetonitrile, 2-amino-, sulfate (2:1)
C2H4N2.1/2H2O4S
5466-22-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 2.0005 4.6200 0.0 0 VAL=6
M  V30 2 O 0.4605 4.6200 0.0 0
M  V30 3 O 3.5405 4.6200 0.0 0
M  V30 4 O 2.0005 3.0800 0.0 0
M  V30 5 O 2.0005 6.1600 0.0 0
M  V30 6 C 2.6673 0.0000 0.0 0
M  V30 7 C 1.3337 0.7700 0.0 0
M  V30 8 N 4.0010 0.7700 0.0 0
M  V30 9 N 0.0000 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 6 7
M  V30 6 1 6 8
M  V30 7 3 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C17H23N3O3
2380970-89-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 6.6685 0.0 0 CFG=1
M  V30 2 C 4.6201 6.6685 0.0 0
M  V30 3 N 6.9302 5.3348 0.0 0
M  V30 4 C 6.9302 8.0023 0.0 0
M  V30 5 C 6.1601 4.0012 0.0 0
M  V30 6 N 8.4702 8.0023 0.0 0
M  V30 7 O 6.1601 9.3360 0.0 0
M  V30 8 O 6.9302 2.6673 0.0 0
M  V30 9 O 4.6201 4.0012 0.0 0
M  V30 10 C 9.2402 9.3360 0.0 0
M  V30 11 C 6.1601 1.3337 0.0 0
M  V30 12 C 10.7802 9.3360 0.0 0
M  V30 13 C 7.4938 0.5637 0.0 0
M  V30 14 C 5.3901 0.0000 0.0 0
M  V30 15 C 4.8265 2.1037 0.0 0
M  V30 16 N 12.3203 9.3360 0.0 0
M  V30 17 C 0.0000 9.3360 0.0 0
M  V30 18 C 3.8501 8.0023 0.0 0
M  V30 19 C 2.3101 8.0023 0.0 0
M  V30 20 C 4.6201 9.3360 0.0 0
M  V30 21 C 1.5400 9.3360 0.0 0
M  V30 22 C 3.8501 10.6697 0.0 0
M  V30 23 C 2.3101 10.6697 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 18
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 11 15
M  V30 16 3 12 16
M  V30 17 1 17 21
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 114873-06-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5466-22-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2380970-89-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40676332
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 543-27-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 1310-73-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM inverse addition (stage 2)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dipeptide-derived alkynes as potent and selective irreversible inhibitors
of cysteine cathepsins
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Behring, Lydia; Ruiz-Gomez, Gloria; Trapp, Christian; Morales, Maryann;
Wodtke, Robert; Koeckerling, Martin; Kopka, Klaus; Pisabarro, M. Teresa;
Pietzsch, Jens; Loeser, Reik
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(6), 3818-3851

$RFMT $RIREG SCHEME116 STEP1
$RXN



  2  1
$MOL
Benzeneethanamine
C8H11N
64-04-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 5.3901 2.6673 0.0 0
M  V30 3 N 6.9302 2.6673 0.0 0
M  V30 4 C 3.0801 1.3337 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.7700 2.6673 0.0 0
M  V30 9 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 2 3
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
,-Dimethyl-2-nitrobenzeneacetic acid
C10H11NO4
126802-52-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 4.0011 0.0 0
M  V30 2 C 0.7700 4.0011 0.0 0
M  V30 3 C 1.5400 5.3349 0.0 0
M  V30 4 C 3.0800 5.3349 0.0 0
M  V30 5 O 0.0000 2.6674 0.0 0
M  V30 6 O 0.0000 5.3349 0.0 0
M  V30 7 N 5.3900 4.0011 0.0 0 VAL=5
M  V30 8 O 4.6200 5.3349 0.0 0
M  V30 9 O 6.9300 4.0011 0.0 0
M  V30 10 C 3.0800 2.6674 0.0 0
M  V30 11 C 4.6200 2.6674 0.0 0
M  V30 12 C 2.3100 1.3338 0.0 0
M  V30 13 C 5.3900 1.3338 0.0 0
M  V30 14 C 3.0800 0.0000 0.0 0
M  V30 15 C 4.6200 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 2 2 6
M  V30 7 2 7 8
M  V30 8 2 7 9
M  V30 9 1 7 11
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
,-Dimethyl-2-nitro-N-(2-phenylethyl)benzeneacetamide
C18H20N2O3
154078-50-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0011 0.0 0
M  V30 2 C 6.1600 4.0011 0.0 0
M  V30 3 C 5.3900 5.3347 0.0 0
M  V30 4 C 3.8500 5.3347 0.0 0
M  V30 5 N 6.9300 5.3347 0.0 0
M  V30 6 O 6.9300 2.6674 0.0 0
M  V30 7 C 8.4700 5.3347 0.0 0
M  V30 8 C 9.2400 6.6685 0.0 0
M  V30 9 N 1.5400 4.0011 0.0 0 VAL=5
M  V30 10 O 0.0000 4.0011 0.0 0
M  V30 11 O 2.3100 5.3347 0.0 0
M  V30 12 C 3.8500 2.6674 0.0 0
M  V30 13 C 2.3100 2.6674 0.0 0
M  V30 14 C 4.6200 1.3336 0.0 0
M  V30 15 C 1.5400 1.3336 0.0 0
M  V30 16 C 3.8500 0.0000 0.0 0
M  V30 17 C 2.3100 0.0000 0.0 0
M  V30 18 C 10.7800 6.6685 0.0 0
M  V30 19 C 11.5500 5.3347 0.0 0
M  V30 20 C 11.5500 8.0021 0.0 0
M  V30 21 C 13.0900 5.3347 0.0 0
M  V30 22 C 13.0900 8.0021 0.0 0
M  V30 23 C 13.8600 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 12
M  V30 5 1 2 5
M  V30 6 2 2 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 8 18
M  V30 10 2 9 10
M  V30 11 2 9 11
M  V30 12 1 9 13
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 64-04-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 126802-52-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 154078-50-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34871210
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 20734-58-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 39968-33-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-activity relationship study of 4,5-didehydroguadiscine, an
aporphine alkaloid showing potent melanogenesis-inhibitory activity in
B16 melanoma cells
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Takashima, Katsuki; Teramachi, Miyu; Marumoto, Shinsuke; Ishikawa,
Fumihiro; Manse, Yoshiaki; Morikawa, Toshio; Tanabe, Genzoh
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2022), 78129034

$RFMT $RIREG SCHEME117 STEP1
$RXN



  2  1
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-L-phenylalanine
C15H21NO4
114873-06-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 4.0012 0.0 0
M  V30 2 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6765 6.1048 0.0 0
M  V30 14 C 0.0000 6.6687 0.0 0
M  V30 15 C 3.0801 4.0012 0.0 0
M  V30 16 C 2.3101 5.3348 0.0 0
M  V30 17 C 2.3101 2.6675 0.0 0
M  V30 18 C 0.7700 5.3348 0.0 0
M  V30 19 C 0.7700 2.6675 0.0 0
M  V30 20 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3 CFG=3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 18
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C18H24N2O3
3026371-08-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 6.6685 0.0 0 CFG=1
M  V30 2 C 4.6201 6.6685 0.0 0
M  V30 3 N 6.9302 5.3348 0.0 0
M  V30 4 C 6.9302 8.0023 0.0 0
M  V30 5 C 6.1601 4.0012 0.0 0
M  V30 6 N 8.4702 8.0023 0.0 0
M  V30 7 O 6.1601 9.3360 0.0 0
M  V30 8 O 6.9302 2.6673 0.0 0
M  V30 9 O 4.6201 4.0012 0.0 0
M  V30 10 C 9.2402 9.3360 0.0 0
M  V30 11 C 6.1601 1.3337 0.0 0
M  V30 12 C 10.7802 9.3360 0.0 0
M  V30 13 C 7.4938 0.5637 0.0 0
M  V30 14 C 5.3901 0.0000 0.0 0
M  V30 15 C 4.8265 2.1037 0.0 0
M  V30 16 C 12.3203 9.3360 0.0 0
M  V30 17 C 0.0000 9.3360 0.0 0
M  V30 18 C 3.8501 8.0023 0.0 0
M  V30 19 C 2.3101 8.0023 0.0 0
M  V30 20 C 4.6201 9.3360 0.0 0
M  V30 21 C 1.5400 9.3360 0.0 0
M  V30 22 C 3.8501 10.6697 0.0 0
M  V30 23 C 2.3101 10.6697 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 18
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 11 15
M  V30 16 3 12 16
M  V30 17 1 17 21
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 114873-06-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3026371-08-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40676339
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 543-27-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dipeptide-derived alkynes as potent and selective irreversible inhibitors
of cysteine cathepsins
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Behring, Lydia; Ruiz-Gomez, Gloria; Trapp, Christian; Morales, Maryann;
Wodtke, Robert; Koeckerling, Martin; Kopka, Klaus; Pisabarro, M. Teresa;
Pietzsch, Jens; Loeser, Reik
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(6), 3818-3851

$RFMT $RIREG SCHEME118 STEP1
$RXN



  2  1
$MOL
3-Amino-1-propanol
C3H9NO
156-87-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0.7700 0.0 0
M  V30 2 C 1.3338 0.0000 0.0 0
M  V30 3 C 4.0010 0.0000 0.0 0
M  V30 4 N 0.0000 0.7700 0.0 0
M  V30 5 O 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
BOC-L-Phenylalanine
C14H19NO4
13734-34-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 2 C 4.6201 4.0012 0.0 0
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6766 6.1048 0.0 0
M  V30 14 C 3.0801 4.0012 0.0 0
M  V30 15 C 2.3101 5.3348 0.0 0
M  V30 16 C 2.3101 2.6675 0.0 0
M  V30 17 C 0.7700 5.3348 0.0 0
M  V30 18 C 0.7700 2.6675 0.0 0
M  V30 19 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 14
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Carbamic acid, [2-[(3-hydroxypropyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1...
C17H26N2O4
120125-31-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 5.3347 0.0 0 CFG=1
M  V30 2 C 5.3900 4.0011 0.0 0
M  V30 3 N 5.3900 6.6685 0.0 0
M  V30 4 C 7.7000 5.3347 0.0 0
M  V30 5 C 3.8500 6.6685 0.0 0
M  V30 6 N 8.4700 6.6685 0.0 0
M  V30 7 O 8.4700 4.0011 0.0 0
M  V30 8 O 3.0800 8.0021 0.0 0
M  V30 9 O 3.0800 5.3347 0.0 0
M  V30 10 C 10.0100 6.6685 0.0 0
M  V30 11 C 1.5400 8.0021 0.0 0
M  V30 12 C 10.7800 8.0021 0.0 0
M  V30 13 C 1.5400 9.5421 0.0 0
M  V30 14 C 0.0000 8.0021 0.0 0
M  V30 15 C 1.5400 6.4621 0.0 0
M  V30 16 C 12.3200 8.0021 0.0 0
M  V30 17 O 13.0900 9.3358 0.0 0
M  V30 18 C 6.1600 2.6674 0.0 0
M  V30 19 C 5.3900 1.3336 0.0 0
M  V30 20 C 7.7000 2.6674 0.0 0
M  V30 21 C 6.1600 0.0000 0.0 0
M  V30 22 C 8.4700 1.3336 0.0 0
M  V30 23 C 7.7000 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 18
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 16 17
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 156-87-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13734-34-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 120125-31-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33504028
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Process Development and GMP Production of a Conjugate Warhead: Auristatin
F-HPA-Ala/TFA (XMT-1864/TFA)
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Conlon, Patrick R.; Gurijala, Venu Reddy; Kaufman, Michael; Li, Dachang;
Li, Jiuyuan; Li, Yuanyuan; Yin, Mao; Reddy, Bollu Satyanarayan; Wagler,
Thomas; Wang, Zedong; Xu, Zhongmin; Yurkovetskiy, Aleksandr V.; Zhu, Lei
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2022), 26(8), 2124-2137

$RFMT $RIREG SCHEME119 STEP1
$RXN



  2  1
$MOL
3-Iodobenzoic acid
C7H5IO2
618-51-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 I 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluoro--(4-fluorophenyl)benzenepropanamine
C15H15F2N
91472-94-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 3.8500 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 4.0011 1.5400 0.0 0
M  V30 4 N 4.0011 0.0000 0.0 0
M  V30 5 F 0.0000 6.9300 0.0 0
M  V30 6 F 10.6694 6.9300 0.0 0
M  V30 7 C 4.0011 4.6200 0.0 0
M  V30 8 C 2.6673 3.8500 0.0 0
M  V30 9 C 4.0011 6.1600 0.0 0
M  V30 10 C 1.3336 4.6200 0.0 0
M  V30 11 C 2.6673 6.9300 0.0 0
M  V30 12 C 1.3336 6.1600 0.0 0
M  V30 13 C 6.6684 4.6200 0.0 0
M  V30 14 C 8.0021 3.8500 0.0 0
M  V30 15 C 6.6684 6.1600 0.0 0
M  V30 16 C 9.3358 4.6200 0.0 0
M  V30 17 C 8.0021 6.9300 0.0 0
M  V30 18 C 9.3358 6.1600 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 1 13
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 5 12
M  V30 7 1 6 18
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[3,3-Bis(4-fluorophenyl)propyl]-3-iodobenzamide
C22H18F2INO
2709014-32-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 6.1600 0.0 0
M  V30 2 C 6.6685 6.9300 0.0 0
M  V30 3 C 8.0021 6.1600 0.0 0
M  V30 4 N 9.3358 6.9300 0.0 0
M  V30 5 C 10.6696 6.1600 0.0 0
M  V30 6 O 10.6696 4.6200 0.0 0
M  V30 7 F 5.3347 0.0000 0.0 0
M  V30 8 F 0.0000 9.2400 0.0 0
M  V30 9 I 16.0043 6.1600 0.0 0
M  V30 10 C 5.3347 4.6200 0.0 0
M  V30 11 C 6.6685 3.8500 0.0 0
M  V30 12 C 4.0011 3.8500 0.0 0
M  V30 13 C 6.6685 2.3100 0.0 0
M  V30 14 C 4.0011 2.3100 0.0 0
M  V30 15 C 5.3347 1.5400 0.0 0
M  V30 16 C 4.0011 6.9300 0.0 0
M  V30 17 C 2.6674 6.1600 0.0 0
M  V30 18 C 4.0011 8.4700 0.0 0
M  V30 19 C 1.3338 6.9300 0.0 0
M  V30 20 C 2.6674 9.2400 0.0 0
M  V30 21 C 1.3338 8.4700 0.0 0
M  V30 22 C 12.0032 6.9300 0.0 0
M  V30 23 C 13.3369 6.1600 0.0 0
M  V30 24 C 12.0032 8.4700 0.0 0
M  V30 25 C 14.6705 6.9300 0.0 0
M  V30 26 C 13.3369 9.2400 0.0 0
M  V30 27 C 14.6705 8.4700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 1 16
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 4 5
M  V30 7 2 5 6
M  V30 8 1 5 22
M  V30 9 1 7 15
M  V30 10 1 8 21
M  V30 11 1 9 25
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 2 12 14
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 618-51-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 91472-94-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2709014-32-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24414263
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Structure-Activity Relationship Studies of Dual
Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hiesinger, Kerstin; Kramer, Jan S.; Beyer, Sandra; Eckes, Timon; Brunst,
Steffen; Flauaus, Cathrin; Wittmann, Sandra K.; Weizel, Lilia; Kaiser,
Astrid; Kretschmer, Simon B. M.; George, Sven; Angioni, Carlo; Heering,
Jan; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred; Schmidtko, Achim;
Pogoryelov, Denys; Pfeilschifter, Josef; Hofmann, Bettina; Steinhilber,
Dieter; Schwalm, Stephanie; Proschak, Ewgenij
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 11498-11521

$RFMT $RIREG SCHEME120 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(S)-4-Methoxy--methylbenzenemethanamine
C9H13NO
41851-59-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0 CFG=1
M  V30 2 C 0.0000 2.3101 0.0 0
M  V30 3 N 1.3337 0.0000 0.0 0
M  V30 4 O 6.6687 4.6201 0.0 0
M  V30 5 C 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C16H24N2O4
2768892-13-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 1.5400 0.0 0 CFG=2
M  V30 2 N 9.3360 2.3101 0.0 0
M  V30 3 C 10.6697 0.0000 0.0 0
M  V30 4 C 8.0023 1.5400 0.0 0
M  V30 5 C 6.6687 2.3101 0.0 0
M  V30 6 O 8.0023 0.0000 0.0 0
M  V30 7 N 5.3348 1.5400 0.0 0
M  V30 8 C 4.0012 2.3101 0.0 0
M  V30 9 O 2.6675 1.5400 0.0 0
M  V30 10 O 4.0012 3.8501 0.0 0
M  V30 11 C 1.3338 2.3101 0.0 0
M  V30 12 C 2.1038 3.6437 0.0 0
M  V30 13 C 0.0000 3.0801 0.0 0
M  V30 14 C 0.5638 0.9764 0.0 0
M  V30 15 O 16.0045 4.6201 0.0 0
M  V30 16 C 17.3383 3.8501 0.0 0
M  V30 17 C 12.0035 2.3101 0.0 0
M  V30 18 C 13.3372 1.5400 0.0 0
M  V30 19 C 12.0035 3.8501 0.0 0
M  V30 20 C 14.6708 2.3101 0.0 0
M  V30 21 C 13.3372 4.6201 0.0 0
M  V30 22 C 14.6708 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 15 16
M  V30 16 1 15 22
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 22
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 41851-59-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2768892-13-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-25082446
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 39968-33-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Rational drug design of benzothiazole-based derivatives as potent signal
transducer and activator of transcription 3 (STAT3) signaling pathway
inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Gao, Dingding; Jin, Nan; Fu, Yixian; Zhu, Yueyue; Wang, Yujie; Wang,
Ting; Chen, Yuehong; Zhang, Mingming; Xiao, Qiang; Huang, Min; Li,
Yingxia
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 216113333

$RFMT $RIREG SCHEME121 STEP1
$RXN



  2  1
$MOL
Clopyralid
C6H3Cl2NO2
1702-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 Cl 1.3338 4.6201 0.0 0
M  V30 5 Cl 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 N 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,6-Dichloro-N-phenyl-2-pyridinecarboxamide
C12H8Cl2N2O
1021043-37-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 2.6674 0.0 0
M  V30 2 N 5.3900 4.0011 0.0 0
M  V30 3 O 5.3900 1.3338 0.0 0
M  V30 4 Cl 3.0800 0.0000 0.0 0
M  V30 5 Cl 0.0000 5.3349 0.0 0
M  V30 6 C 3.0800 2.6674 0.0 0
M  V30 7 C 2.3100 1.3338 0.0 0
M  V30 8 N 2.3100 4.0011 0.0 0
M  V30 9 C 0.7700 1.3338 0.0 0
M  V30 10 C 0.7700 4.0011 0.0 0
M  V30 11 C 0.0000 2.6674 0.0 0
M  V30 12 C 6.9300 4.0011 0.0 0
M  V30 13 C 7.7000 2.6674 0.0 0
M  V30 14 C 7.7000 5.3349 0.0 0
M  V30 15 C 9.2400 2.6674 0.0 0
M  V30 16 C 9.2400 5.3349 0.0 0
M  V30 17 C 10.0100 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 12
M  V30 5 1 4 7
M  V30 6 1 5 10
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 8 10
M  V30 11 2 9 11
M  V30 12 1 10 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1702-17-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1021043-37-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37213507
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-05-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Rhodium(III)-Picolinamide Complexes Act as Anticancer and Antimetastasis
Agents via Inducing Apoptosis and Autophagy
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Gu, Yun-Qiong; Yang, Kun; Yang, Qi-Yuan; Li, Huan-Qing; Hu, Mei-Qi; Ma,
Meng-Xue; Chen, Nan-Feng; Liu, Yang-Han; Liang, Hong; Chen, Zhen-Feng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(14), 9592-9606

$RFMT $RIREG SCHEME122 STEP1
$RXN



  2  1
$MOL
4-Amino-2-fluorobenzoic acid
C7H6FNO2
446-31-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 F 2.3101 0.0000 0.0 0
M  V30 5 N 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-1-methylpiperidine
C6H14N2
41838-46-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 1.3337 0.0 0
M  V30 2 C 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 N 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-2-fluoro-N-(1-methyl-4-piperidinyl)benzamide
C13H18FN3O
957855-54-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 F 4.6200 0.0000 0.0 0
M  V30 5 N 0.0000 2.6674 0.0 0
M  V30 6 C 13.0900 4.0011 0.0 0
M  V30 7 C 4.6200 2.6674 0.0 0
M  V30 8 C 3.8500 1.3338 0.0 0
M  V30 9 C 3.8500 4.0011 0.0 0
M  V30 10 C 2.3100 1.3338 0.0 0
M  V30 11 C 2.3100 4.0011 0.0 0
M  V30 12 C 1.5400 2.6674 0.0 0
M  V30 13 C 8.4700 4.0011 0.0 0
M  V30 14 C 9.2400 2.6674 0.0 0
M  V30 15 C 9.2400 5.3349 0.0 0
M  V30 16 C 10.7800 2.6674 0.0 0
M  V30 17 C 10.7800 5.3349 0.0 0
M  V30 18 N 11.5500 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 13
M  V30 5 1 4 8
M  V30 6 1 5 12
M  V30 7 1 6 18
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 446-31-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 41838-46-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 957855-54-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31649924
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 1310-73-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Differential BET Bromodomain Inhibition by Dihydropteridinone and
Pyrimidodiazepinone Kinase Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Karim, Rezaul Md; Bikowitz, Melissa J.; Chan, Alice; Zhu, Jin-Yi;
Grassie, Dylan; Becker, Andreas; Berndt, Norbert; Gunawan, Steven;
Lawrence, Nicholas J.; Schonbrunn, Ernst
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(21), 15772-15786

$RFMT $RIREG SCHEME123 STEP1
$RXN



  2  1
$MOL
4-Chloro-2-(trifluoromethyl)benzoic acid
C8H4ClF3O2
142994-09-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 1.3338 0.0 0
M  V30 2 F 3.6437 0.5638 0.0 0
M  V30 3 F 1.5400 0.0000 0.0 0
M  V30 4 F 0.9764 2.1038 0.0 0
M  V30 5 C 0.7700 4.0011 0.0 0
M  V30 6 O 0.0000 2.6675 0.0 0
M  V30 7 O 0.0000 5.3349 0.0 0
M  V30 8 Cl 6.9301 4.0011 0.0 0
M  V30 9 C 3.0800 2.6675 0.0 0
M  V30 10 C 2.3100 4.0011 0.0 0
M  V30 11 C 4.6201 2.6675 0.0 0
M  V30 12 C 3.0800 5.3349 0.0 0
M  V30 13 C 5.3901 4.0011 0.0 0
M  V30 14 C 4.6201 5.3348 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 9
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 10
M  V30 8 1 8 13
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(S)--Methylcyclopropanemethanamine
C5H11N
195604-39-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 6 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.8737 1.5400 0.0 0 CFG=1
M  V30 2 C 4.2074 2.3101 0.0 0
M  V30 3 N 2.8737 0.0000 0.0 0
M  V30 4 C 1.5400 2.3101 0.0 0
M  V30 5 C 0.0000 2.3101 0.0 0
M  V30 6 C 0.7700 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 6
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-Chloro-N-[(1S)-1-cyclopropylethyl]-2-(trifluoromethyl)benzamide
C13H13ClF3NO
2566572-51-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 3.0800 0.0 0
M  V30 2 N 6.6684 3.8500 0.0 0
M  V30 3 O 5.3347 1.5400 0.0 0
M  V30 4 C 8.0021 3.0800 0.0 0 CFG=2
M  V30 5 C 8.0021 1.5400 0.0 0
M  V30 6 C 2.6674 1.5400 0.0 0
M  V30 7 F 4.2074 1.5400 0.0 0
M  V30 8 F 2.6674 0.0000 0.0 0
M  V30 9 F 1.1274 1.5400 0.0 0
M  V30 10 Cl 0.0000 6.1600 0.0 0
M  V30 11 C 4.0011 3.8500 0.0 0
M  V30 12 C 2.6674 3.0800 0.0 0
M  V30 13 C 4.0011 5.3900 0.0 0
M  V30 14 C 1.3336 3.8500 0.0 0
M  V30 15 C 2.6674 6.1600 0.0 0
M  V30 16 C 1.3336 5.3900 0.0 0
M  V30 17 C 9.3358 3.8500 0.0 0
M  V30 18 C 10.1058 5.1836 0.0 0
M  V30 19 C 10.8758 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=3
M  V30 6 1 4 17
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 6 12
M  V30 11 1 10 16
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 142994-09-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 195604-39-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2566572-51-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31542322
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 12125-02-9
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Structure-Activity Relationship Optimization of
Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase 
(PI3K)
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Mata, Guillaume; Miles, Dillon H.; Drew, Samuel L.; Fournier, Jeremy;
Lawson, Kenneth V.; Mailyan, Artur K.; Sharif, Ehesan U.; Yan, Xuelei;
Beatty, Joel W.; Banuelos, Jesus; Chen, Jie; Ginn, Elaine; Chen, Ada;
Gerrick, Kimberline Y.; Pham, Amber T.; Wong, Kent; Soni, Divyank;
Dhanota, Puja; Shaqfeh, Stefan G.; Meleza, Cesar; Narasappa, Nell; Singh,
Hema; Zhao, Xiaoning; Jin, Lixia; Schindler, Ulrike; Walters, Matthew J.;
Young, Stephen W.; Walker, Nigel P.; Leleti, Manmohan Reddy; Powers, Jay
P.; Jeffrey, Jenna L.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(2), 1418-1444

$RFMT $RIREG SCHEME124 STEP1
$RXN



  2  1
$MOL
BOC-D-alanine
C8H15NO4
7764-95-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0 CFG=2
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 8.0023 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 1.3337 2.3101 0.0 0
M  V30 9 O 8.0023 0.0000 0.0 0
M  V30 10 O 9.3360 2.3101 0.0 0
M  V30 11 C 0.5637 0.9764 0.0 0
M  V30 12 C 0.0000 3.0801 0.0 0
M  V30 13 C 2.1037 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7 CFG=3
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
2-Fluorobenzylamine
C7H8FN
89-99-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 N 5.3901 4.0010 0.0 0
M  V30 3 F 3.0801 0.0000 0.0 0
M  V30 4 C 3.0801 2.6673 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 2.3101 4.0010 0.0 0
M  V30 7 C 0.7700 1.3337 0.0 0
M  V30 8 C 0.7700 4.0010 0.0 0
M  V30 9 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 5
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C15H21FN2O3
2506368-03-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 C 8.0022 2.3101 0.0 0 CFG=1
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 N 9.3358 1.5400 0.0 0
M  V30 7 C 8.0022 3.8501 0.0 0
M  V30 8 C 10.6697 2.3101 0.0 0
M  V30 9 O 12.0033 1.5400 0.0 0
M  V30 10 O 10.6697 3.8501 0.0 0
M  V30 11 C 13.3370 2.3101 0.0 0
M  V30 12 C 14.1070 0.9764 0.0 0
M  V30 13 C 14.6707 3.0801 0.0 0
M  V30 14 C 12.5670 3.6437 0.0 0
M  V30 15 F 1.3337 0.0000 0.0 0
M  V30 16 C 2.6673 2.3101 0.0 0
M  V30 17 C 1.3337 1.5400 0.0 0
M  V30 18 C 2.6673 3.8501 0.0 0
M  V30 19 C 0.0000 2.3101 0.0 0
M  V30 20 C 1.3337 4.6201 0.0 0
M  V30 21 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 4 7 CFG=1
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 15 17
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7764-95-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 89-99-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2506368-03-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34105360
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide
[(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like
Properties and Potent Antiseizure Activity In Vivo
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Abram, Michal; Jakubiec, Marcin; Reeb, Katelyn; Cheng, Mary Hongying;
Gedschold, Robin; Rapacz, Anna; Mogilski, Szczepan; Socala, Katarzyna;
Nieoczym, Dorota; Szafarz, Malgorzata; Latacz, Gniewomir; Szulczyk,
Bartlomiej; Kalinowska-Tluscik, Justyna; Gawel, Kinga; Esguerra, Camila
V.; Wyska, Elzbieta; Muller, Christa E.; Bahar, Ivet; Fontana, Andreia C.
K.; Wlaz, Piotr; Kaminski, Rafal M.; Kaminski, Krzysztof
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(17), 11703-11725

$RFMT $RIREG SCHEME125 STEP1
$RXN



  2  1
$MOL
Boc-L-alanine
C8H15NO4
15761-38-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0 CFG=1
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 8.0023 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 1.3337 2.3101 0.0 0
M  V30 9 O 8.0023 0.0000 0.0 0
M  V30 10 O 9.3360 2.3101 0.0 0
M  V30 11 C 0.5637 0.9764 0.0 0
M  V30 12 C 0.0000 3.0801 0.0 0
M  V30 13 C 2.1037 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7 CFG=1
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
2-Fluorobenzylamine
C7H8FN
89-99-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 N 5.3901 4.0010 0.0 0
M  V30 3 F 3.0801 0.0000 0.0 0
M  V30 4 C 3.0801 2.6673 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 2.3101 4.0010 0.0 0
M  V30 7 C 0.7700 1.3337 0.0 0
M  V30 8 C 0.7700 4.0010 0.0 0
M  V30 9 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 5
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C15H21FN2O3
2815216-21-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 C 8.0022 2.3101 0.0 0 CFG=2
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 N 9.3358 1.5400 0.0 0
M  V30 7 C 8.0022 3.8501 0.0 0
M  V30 8 C 10.6697 2.3101 0.0 0
M  V30 9 O 12.0033 1.5400 0.0 0
M  V30 10 O 10.6697 3.8501 0.0 0
M  V30 11 C 13.3370 2.3101 0.0 0
M  V30 12 C 14.1070 0.9764 0.0 0
M  V30 13 C 14.6707 3.0801 0.0 0
M  V30 14 C 12.5670 3.6437 0.0 0
M  V30 15 F 1.3337 0.0000 0.0 0
M  V30 16 C 2.6673 2.3101 0.0 0
M  V30 17 C 1.3337 1.5400 0.0 0
M  V30 18 C 2.6673 3.8501 0.0 0
M  V30 19 C 0.0000 2.3101 0.0 0
M  V30 20 C 1.3337 4.6201 0.0 0
M  V30 21 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 4 7 CFG=3
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 15 17
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 15761-38-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 89-99-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2815216-21-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34105361
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide
[(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like
Properties and Potent Antiseizure Activity In Vivo
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Abram, Michal; Jakubiec, Marcin; Reeb, Katelyn; Cheng, Mary Hongying;
Gedschold, Robin; Rapacz, Anna; Mogilski, Szczepan; Socala, Katarzyna;
Nieoczym, Dorota; Szafarz, Malgorzata; Latacz, Gniewomir; Szulczyk,
Bartlomiej; Kalinowska-Tluscik, Justyna; Gawel, Kinga; Esguerra, Camila
V.; Wyska, Elzbieta; Muller, Christa E.; Bahar, Ivet; Fontana, Andreia C.
K.; Wlaz, Piotr; Kaminski, Rafal M.; Kaminski, Krzysztof
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(17), 11703-11725

$RFMT $RIREG SCHEME126 STEP1
$RXN



  2  1
$MOL
1-Adamantaneacetic acid
C12H18O2
4942-47-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5315 3.0177 0.0 0
M  V30 2 C 6.8679 2.2462 0.0 0
M  V30 3 O 6.8679 0.7033 0.0 0
M  V30 4 O 8.2040 3.0177 0.0 0
M  V30 5 C 4.1954 2.2462 0.0 0
M  V30 6 C 2.9049 3.0865 0.0 0
M  V30 7 C 4.2778 0.7085 0.0 0
M  V30 8 C 2.4985 2.2354 0.0 0
M  V30 9 C 1.6968 2.3889 0.0 0
M  V30 10 C 3.0696 0.0111 0.0 0
M  V30 11 C 1.2903 1.5378 0.0 0
M  V30 12 C 0.0000 2.3778 0.0 0
M  V30 13 C 1.7793 0.8512 0.0 0
M  V30 14 C 1.3729 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 9 13
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 1 11 12
M  V30 16 1 11 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
tert-Butyl (3-aminopropyl)carbamate
C8H18N2O2
75178-96-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6673 2.3101 0.0 0
M  V30 2 C 4.0012 1.5400 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 N 5.3348 2.3101 0.0 0
M  V30 5 O 4.0012 0.0000 0.0 0
M  V30 6 C 2.1037 0.2064 0.0 0
M  V30 7 C 0.0000 0.7700 0.0 0
M  V30 8 C 0.5637 2.8737 0.0 0
M  V30 9 C 6.6685 1.5400 0.0 0
M  V30 10 C 8.0023 2.3101 0.0 0
M  V30 11 C 9.3360 1.5400 0.0 0
M  V30 12 N 10.6697 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C20H34N2O3
2761207-05-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5212 3.0120 0.0 0
M  V30 2 C 6.8550 2.2420 0.0 0
M  V30 3 N 8.1887 3.0120 0.0 0
M  V30 4 O 6.8550 0.7019 0.0 0
M  V30 5 C 9.5223 2.2420 0.0 0
M  V30 6 C 10.8560 3.0120 0.0 0
M  V30 7 C 12.1898 2.2420 0.0 0
M  V30 8 N 13.5235 3.0120 0.0 0
M  V30 9 C 14.8572 2.2420 0.0 0
M  V30 10 O 16.1910 3.0120 0.0 0
M  V30 11 O 14.8572 0.7019 0.0 0
M  V30 12 C 17.5247 2.2420 0.0 0
M  V30 13 C 18.2947 3.5757 0.0 0
M  V30 14 C 18.8583 1.4720 0.0 0
M  V30 15 C 16.7546 0.9083 0.0 0
M  V30 16 C 4.1875 2.2420 0.0 0
M  V30 17 C 2.8994 3.0805 0.0 0
M  V30 18 C 4.2697 0.7072 0.0 0
M  V30 19 C 2.4938 2.2310 0.0 0
M  V30 20 C 1.6936 2.3844 0.0 0
M  V30 21 C 3.0639 0.0109 0.0 0
M  V30 22 C 1.2879 1.5350 0.0 0
M  V30 23 C 0.0000 2.3733 0.0 0
M  V30 24 C 1.7760 0.8496 0.0 0
M  V30 25 C 1.3702 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 16 19
M  V30 19 1 17 20
M  V30 20 1 18 21
M  V30 21 1 19 22
M  V30 22 1 20 23
M  V30 23 1 20 24
M  V30 24 1 21 24
M  V30 25 1 21 25
M  V30 26 1 22 23
M  V30 27 1 22 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4942-47-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 75178-96-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2761207-05-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31556160
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors
activating the ER stress pathway
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rastelli, Ettore J.; Sannino, Sara; Hart, Duncan J.; Sharlow, Elizabeth
R.; Lazo, John S.; Brodsky, Jeffrey L.; Wipf, Peter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2021), 46128167

$RFMT $RIREG SCHEME127 STEP1
$RXN



  2  1
$MOL
3-Chloro-4-methylaniline
C7H8ClN
95-74-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 1.5400 0.0000 0.0 0
M  V30 2 C 0.0000 2.6673 0.0 0
M  V30 3 N 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Methyl-1,2,3-thiadiazole-5-carboxylic acid
C4H4N2O2S
18212-21-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 1.5400 0.0 0
M  V30 2 O 5.1049 2.3100 0.0 0
M  V30 3 O 3.7711 0.0000 0.0 0
M  V30 4 C 0.7104 0.1773 0.0 0
M  V30 5 C 2.4374 2.3100 0.0 0
M  V30 6 C 1.0306 1.6836 0.0 0
M  V30 7 S 2.2765 3.8416 0.0 0
M  V30 8 N 0.0000 2.8281 0.0 0
M  V30 9 N 0.7700 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Tiadinil
C11H10ClN3OS
223580-51-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6798 2.6674 0.0 0
M  V30 2 C 3.9098 4.0011 0.0 0
M  V30 3 O 4.6798 5.3347 0.0 0
M  V30 4 Cl 9.2998 0.0000 0.0 0
M  V30 5 C 10.8398 2.6674 0.0 0
M  V30 6 C 1.9406 6.7117 0.0 0
M  V30 7 C 6.2198 2.6674 0.0 0
M  V30 8 C 6.9898 1.3338 0.0 0
M  V30 9 C 6.9898 4.0011 0.0 0
M  V30 10 C 8.5298 1.3338 0.0 0
M  V30 11 C 8.5298 4.0011 0.0 0
M  V30 12 C 9.2998 2.6674 0.0 0
M  V30 13 C 2.3698 4.0011 0.0 0
M  V30 14 C 1.4645 5.2470 0.0 0
M  V30 15 S 1.4645 2.7552 0.0 0
M  V30 16 N 0.0000 4.7711 0.0 0
M  V30 17 N 0.0000 3.2311 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 2 2 3
M  V30 4 1 2 13
M  V30 5 1 4 10
M  V30 6 1 5 12
M  V30 7 1 6 14
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 95-74-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 18212-21-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 223580-51-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-42622979
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM On-Demand Production of Two Commercial Plant Activators, Tiadinil and
Methiadinil, under an Integrated Continuous Flow System
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Zhengqi; Zhou, Jian; Xing, Dong; He, Haibing; Gao, Shuanhu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2024), 28(8), 3143-3151

$RFMT $RIREG SCHEME128 STEP1
$RXN



  2  1
$MOL
3-Iodobenzoic acid
C7H5IO2
618-51-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 I 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1,N1-Diphenyl-1,2-ethanediamine
C14H16N2
1140-29-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 4.6201 0.0 0
M  V30 2 C 5.3348 5.3901 0.0 0
M  V30 3 C 6.6687 4.6201 0.0 0
M  V30 4 N 8.0023 5.3901 0.0 0
M  V30 5 C 4.0012 3.0801 0.0 0
M  V30 6 C 5.3348 2.3101 0.0 0
M  V30 7 C 2.6675 2.3101 0.0 0
M  V30 8 C 5.3348 0.7700 0.0 0
M  V30 9 C 2.6675 0.7700 0.0 0
M  V30 10 C 4.0012 0.0000 0.0 0
M  V30 11 C 2.6675 5.3901 0.0 0
M  V30 12 C 2.6675 6.9302 0.0 0
M  V30 13 C 1.3337 4.6201 0.0 0
M  V30 14 C 1.3337 7.7002 0.0 0
M  V30 15 C 0.0000 5.3901 0.0 0
M  V30 16 C 0.0000 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 1 11
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 2 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(Diphenylamino)ethyl]-3-iodobenzamide
C21H19IN2O
2709014-34-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0010 4.6201 0.0 0
M  V30 2 C 5.3348 5.3901 0.0 0
M  V30 3 C 6.6685 4.6201 0.0 0
M  V30 4 N 8.0022 5.3901 0.0 0
M  V30 5 C 9.3358 4.6201 0.0 0
M  V30 6 O 9.3358 3.0801 0.0 0
M  V30 7 I 14.6707 4.6201 0.0 0
M  V30 8 C 2.6673 5.3901 0.0 0
M  V30 9 C 1.3337 4.6201 0.0 0
M  V30 10 C 2.6673 6.9302 0.0 0
M  V30 11 C 0.0000 5.3901 0.0 0
M  V30 12 C 1.3337 7.7002 0.0 0
M  V30 13 C 0.0000 6.9302 0.0 0
M  V30 14 C 4.0010 3.0801 0.0 0
M  V30 15 C 2.6673 2.3101 0.0 0
M  V30 16 C 5.3348 2.3101 0.0 0
M  V30 17 C 2.6673 0.7700 0.0 0
M  V30 18 C 5.3348 0.7700 0.0 0
M  V30 19 C 4.0010 0.0000 0.0 0
M  V30 20 C 10.6697 5.3901 0.0 0
M  V30 21 C 12.0033 4.6201 0.0 0
M  V30 22 C 10.6697 6.9302 0.0 0
M  V30 23 C 13.3370 5.3901 0.0 0
M  V30 24 C 12.0033 7.7002 0.0 0
M  V30 25 C 13.3370 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 1 14
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 4 5
M  V30 7 2 5 6
M  V30 8 1 5 20
M  V30 9 1 7 23
M  V30 10 2 8 9
M  V30 11 1 8 10
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 14 2 11 13
M  V30 15 1 12 13
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 618-51-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1140-29-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2709014-34-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24414277
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Structure-Activity Relationship Studies of Dual
Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hiesinger, Kerstin; Kramer, Jan S.; Beyer, Sandra; Eckes, Timon; Brunst,
Steffen; Flauaus, Cathrin; Wittmann, Sandra K.; Weizel, Lilia; Kaiser,
Astrid; Kretschmer, Simon B. M.; George, Sven; Angioni, Carlo; Heering,
Jan; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred; Schmidtko, Achim;
Pogoryelov, Denys; Pfeilschifter, Josef; Hofmann, Bettina; Steinhilber,
Dieter; Schwalm, Stephanie; Proschak, Ewgenij
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 11498-11521

$RFMT $RIREG SCHEME129 STEP1
$RXN



  2  1
$MOL
1-Methyl octanedioate
C9H16O4
3946-32-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 2.3101 0.0 0
M  V30 2 C 9.3360 1.5400 0.0 0
M  V30 3 O 12.0033 1.5400 0.0 0
M  V30 4 O 10.6697 3.8501 0.0 0
M  V30 5 C 8.0022 2.3101 0.0 0
M  V30 6 C 13.3370 2.3101 0.0 0
M  V30 7 C 6.6685 1.5400 0.0 0
M  V30 8 C 5.3348 2.3101 0.0 0
M  V30 9 C 4.0010 1.5400 0.0 0
M  V30 10 C 2.6673 2.3101 0.0 0
M  V30 11 C 1.3337 1.5400 0.0 0
M  V30 12 O 1.3337 0.0000 0.0 0
M  V30 13 O 0.0000 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-4-hydroxybenzaldehyde
C7H7NO2
163036-58-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6673 0.0 0
M  V30 2 O 6.9302 4.0010 0.0 0
M  V30 3 N 1.5400 0.0000 0.0 0
M  V30 4 O 0.0000 2.6673 0.0 0
M  V30 5 C 4.6201 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 3.8501 4.0010 0.0 0
M  V30 8 C 2.3101 1.3337 0.0 0
M  V30 9 C 2.3101 4.0010 0.0 0
M  V30 10 C 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 5
M  V30 3 1 3 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Octanoic acid, 8-[(5-formyl-2-hydroxyphenyl)amino]-8-oxo-, methyl ester
C16H21NO5
3057270-77-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1600 2.6674 0.0 0
M  V30 2 C 6.9300 4.0011 0.0 0
M  V30 3 C 8.4700 4.0011 0.0 0
M  V30 4 O 6.1600 5.3347 0.0 0
M  V30 5 C 9.2400 5.3347 0.0 0
M  V30 6 C 10.7800 5.3347 0.0 0
M  V30 7 C 11.5500 6.6684 0.0 0
M  V30 8 C 13.0900 6.6684 0.0 0
M  V30 9 C 13.8600 8.0021 0.0 0
M  V30 10 C 15.4000 8.0021 0.0 0
M  V30 11 O 16.1700 9.3358 0.0 0
M  V30 12 O 16.1700 6.6684 0.0 0
M  V30 13 C 17.7100 9.3358 0.0 0
M  V30 14 O 4.6200 0.0000 0.0 0
M  V30 15 C 1.5400 5.3347 0.0 0
M  V30 16 O 0.0000 5.3347 0.0 0
M  V30 17 C 4.6200 2.6674 0.0 0
M  V30 18 C 3.8500 4.0011 0.0 0
M  V30 19 C 3.8500 1.3336 0.0 0
M  V30 20 C 2.3100 4.0011 0.0 0
M  V30 21 C 2.3100 1.3336 0.0 0
M  V30 22 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 11 13
M  V30 14 1 14 19
M  V30 15 2 15 16
M  V30 16 1 15 20
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3946-32-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 163036-58-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3057270-77-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39636949
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel estrogen receptor /histone deacetylase dual-targeted near-infrared
fluorescent probes as theranostic agents for imaging and treatment of
prostate cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM He, Pei; Yu, Huiguang; Deng, Xiaofei; Xin, Lilan; Xu, Bin; Zhou,
Hai-Bing; Dong, Chune
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 268116236

$RFMT $RIREG SCHEME130 STEP1
$RXN



  2  1
$MOL
-Oxo-3-pyridinebutanoic acid
C9H9NO3
780750-43-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6684 1.5400 0.0 0
M  V30 4 C 8.0021 2.3100 0.0 0
M  V30 5 O 6.6684 0.0000 0.0 0
M  V30 6 O 9.3358 1.5400 0.0 0
M  V30 7 O 8.0021 3.8500 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 2.6674 3.8500 0.0 0
M  V30 10 C 1.3336 1.5400 0.0 0
M  V30 11 C 1.3336 4.6200 0.0 0
M  V30 12 N 0.0000 2.3100 0.0 0
M  V30 13 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Pyridinemethanamine
C6H8N2
3731-52-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 N 5.3901 2.6673 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 2.3101 2.6673 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 N 0.7700 0.0000 0.0 0
M  V30 8 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 2 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Pyridinebutanamide, -oxo-N-(3-pyridinylmethyl)-
C15H15N3O2
2984600-54-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 2.3101 0.0 0
M  V30 2 C 5.3348 3.0801 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0
M  V30 4 C 8.0022 3.0801 0.0 0
M  V30 5 O 6.6685 0.7700 0.0 0
M  V30 6 N 9.3358 2.3101 0.0 0
M  V30 7 O 8.0022 4.6201 0.0 0
M  V30 8 C 10.6697 3.0801 0.0 0
M  V30 9 C 2.6673 3.0801 0.0 0
M  V30 10 C 2.6673 4.6201 0.0 0
M  V30 11 C 1.3337 2.3101 0.0 0
M  V30 12 C 1.3337 5.3901 0.0 0
M  V30 13 N 0.0000 3.0801 0.0 0
M  V30 14 C 0.0000 4.6201 0.0 0
M  V30 15 C 12.0033 2.3101 0.0 0
M  V30 16 C 13.3370 3.0801 0.0 0
M  V30 17 C 12.0033 0.7700 0.0 0
M  V30 18 C 14.6707 2.3101 0.0 0
M  V30 19 N 13.3370 0.0000 0.0 0
M  V30 20 C 14.6707 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 6 8
M  V30 9 1 8 15
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 14
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 780750-43-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3731-52-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2984600-54-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37713554
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Analysis of Structure-Activity Relationships of Novel Inhibitors of the
Macrophage Infectivity Potentiator (Mip) Proteins of Neisseria
meningitidis, Neisseria gonorrhoeae, and Burkholderia pseudomallei
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Scheuplein, Nicolas J.; Bzdyl, Nicole M.; Lohr, Theresa; Kibble, Emily
A.; Hasenkopf, Anja; Herbst, Carina; Sarkar-Tyson, Mitali; Holzgrabe,
Ulrike
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(13), 8876-8895

$RFMT $RIREG SCHEME131 STEP1
$RXN



  2  1
$MOL
4-Bromo-3-methylaniline
C7H8BrN
6933-10-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 0.0000 0.0 0
M  V30 2 Br 0.0000 2.6673 0.0 0
M  V30 3 N 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Ethylsulfonyl)benzeneacetic acid
C10H12O4S
383135-47-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 2.3100 2.6673 0.0 0 VAL=6
M  V30 2 C 0.7700 2.6673 0.0 0
M  V30 3 O 2.3100 1.1273 0.0 0
M  V30 4 O 2.3100 4.2073 0.0 0
M  V30 5 C 0.0000 4.0011 0.0 0
M  V30 6 C 8.4700 2.6673 0.0 0
M  V30 7 C 9.2400 1.3336 0.0 0
M  V30 8 O 10.7800 1.3336 0.0 0
M  V30 9 O 8.4700 0.0000 0.0 0
M  V30 10 C 3.8500 2.6673 0.0 0
M  V30 11 C 4.6200 1.3336 0.0 0
M  V30 12 C 4.6200 4.0011 0.0 0
M  V30 13 C 6.1600 1.3336 0.0 0
M  V30 14 C 6.1600 4.0011 0.0 0
M  V30 15 C 6.9300 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 6 7
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(4-Bromo-3-methylphenyl)-4-(ethylsulfonyl)benzeneacetamide
C17H18BrNO3S
1426804-76-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0023 4.4137 0.0 0
M  V30 2 C 6.6687 3.6437 0.0 0
M  V30 3 N 5.3348 4.4137 0.0 0
M  V30 4 O 6.6687 2.1037 0.0 0
M  V30 5 S 13.3372 1.3337 0.0 0 VAL=6
M  V30 6 C 14.6708 0.5637 0.0 0
M  V30 7 O 14.1072 2.6673 0.0 0
M  V30 8 O 12.5671 0.0000 0.0 0
M  V30 9 C 16.0046 1.3337 0.0 0
M  V30 10 C 0.0000 4.4137 0.0 0
M  V30 11 Br 0.0000 1.3337 0.0 0
M  V30 12 C 9.3360 3.6437 0.0 0
M  V30 13 C 10.6698 4.4137 0.0 0
M  V30 14 C 9.3360 2.1037 0.0 0
M  V30 15 C 12.0035 3.6437 0.0 0
M  V30 16 C 10.6698 1.3337 0.0 0
M  V30 17 C 12.0035 2.1037 0.0 0
M  V30 18 C 4.0012 3.6437 0.0 0
M  V30 19 C 2.6675 4.4137 0.0 0
M  V30 20 C 4.0012 2.1037 0.0 0
M  V30 21 C 1.3338 3.6437 0.0 0
M  V30 22 C 2.6675 1.3337 0.0 0
M  V30 23 C 1.3338 2.1037 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 18
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 2 5 8
M  V30 9 1 5 17
M  V30 10 1 6 9
M  V30 11 1 10 21
M  V30 12 1 11 23
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6933-10-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 383135-47-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1426804-76-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256028
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME132 STEP1
$RXN



  2  1
$MOL
4-Pyridinecarboxylic acid
C6H5NO2
55-22-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 N 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Cyclohexanepropanoic acid, -amino-, methyl ester, hydrochloride (1:1), (S)-
C10H19NO2.ClH
17193-39-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0 CFG=2
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 N 5.3347 5.3900 0.0 0
M  V30 5 O 8.0021 3.8500 0.0 0
M  V30 6 O 6.6684 1.5400 0.0 0
M  V30 7 C 9.3358 3.0800 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 3.0800 0.0 0
M  V30 10 C 2.6674 5.3900 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 6.1600 0.0 0
M  V30 13 C 0.0000 5.3900 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Cyclohexanepropanoic acid, -[(4-pyridinylcarbonyl)amino]-, methyl ester, (S)-
C16H22N2O3
3085792-09-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 5.3347 0.0 0 CFG=1
M  V30 2 C 2.3100 4.0011 0.0 0
M  V30 3 N 4.6200 5.3347 0.0 0
M  V30 4 C 2.3100 6.6685 0.0 0
M  V30 5 C 5.3900 6.6685 0.0 0
M  V30 6 O 0.7700 6.6685 0.0 0
M  V30 7 O 3.0800 8.0021 0.0 0
M  V30 8 O 4.6200 8.0021 0.0 0
M  V30 9 C 0.0000 8.0021 0.0 0
M  V30 10 C 3.0800 2.6674 0.0 0
M  V30 11 C 2.3100 1.3336 0.0 0
M  V30 12 C 4.6200 2.6674 0.0 0
M  V30 13 C 3.0800 0.0000 0.0 0
M  V30 14 C 5.3900 1.3336 0.0 0
M  V30 15 C 4.6200 0.0000 0.0 0
M  V30 16 C 6.9300 6.6685 0.0 0
M  V30 17 C 7.7000 5.3347 0.0 0
M  V30 18 C 7.7000 8.0021 0.0 0
M  V30 19 C 9.2400 5.3347 0.0 0
M  V30 20 C 9.2400 8.0021 0.0 0
M  V30 21 N 10.0100 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 10
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 5 16
M  V30 10 1 6 9
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 15
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 55-22-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 17193-39-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3085792-09-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41033865
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 108-75-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structural Modifications of Covalent Cathepsin S Inhibitors: Impact on
Affinity, Selectivity, and Permeability
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Meta, Mergim; Zimmer, Collin; Fuchs, Natalie; Zecher, Maximilian
Johannes; Lahu, Albin; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2024), 15(6), 837-844

$RFMT $RIREG SCHEME133 STEP1
$RXN



  2  1
$MOL
3-Amino-6-chloro-2-pyrazinecarboxylic acid
C5H4ClN3O2
2727-13-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 Cl 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 N 4.0012 1.5400 0.0 0
M  V30 9 N 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Glycine ethyl ester hydrochloride
C4H9NO2.ClH
623-33-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0800 0.0 0
M  V30 2 O 4.0011 3.8500 0.0 0
M  V30 3 C 1.3338 3.8500 0.0 0
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 C 5.3348 3.0800 0.0 0
M  V30 6 N 0.0000 3.0800 0.0 0
M  V30 7 C 6.6686 3.8500 0.0 0
M  V30 8 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Glycine, N-[(3-amino-6-chloro-2-pyrazinyl)carbonyl]-, ethyl ester
C9H11ClN4O3
3042822-46-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 4.6201 0.0 0
M  V30 2 N 5.3348 3.8501 0.0 0
M  V30 3 O 4.0012 6.1601 0.0 0
M  V30 4 C 6.6685 4.6201 0.0 0
M  V30 5 C 8.0022 3.8501 0.0 0
M  V30 6 O 9.3360 4.6201 0.0 0
M  V30 7 O 8.0022 2.3101 0.0 0
M  V30 8 C 10.6697 3.8501 0.0 0
M  V30 9 C 12.0033 4.6201 0.0 0
M  V30 10 N 1.3337 6.1601 0.0 0
M  V30 11 Cl 1.3337 0.0000 0.0 0
M  V30 12 C 2.6673 3.8501 0.0 0
M  V30 13 C 1.3337 4.6201 0.0 0
M  V30 14 N 2.6673 2.3101 0.0 0
M  V30 15 N 0.0000 3.8501 0.0 0
M  V30 16 C 1.3337 1.5400 0.0 0
M  V30 17 C 0.0000 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 10 13
M  V30 11 1 11 16
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2727-13-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 623-33-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3042822-46-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39099371
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 1310-73-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-05-8
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 67-56-1
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and development of BI 1265162, an ENaC inhibitor for the
treatment of cystic fibrosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Betzemeier, Bodo; Braun, Clemens; Sieger, Peter; Heckel, Armin; Linz,
Guenter; Linehan, Brian; Veser, Thomas; Wiedenmayer, Dieter; Kley, Joerg
T.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 265116038

$RFMT $RIREG SCHEME134 STEP1
$RXN



  2  1
$MOL
p-Toluic acid
C8H8O2
99-94-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 0.0000 0.0 0
M  V30 3 O 0.0000 2.6673 0.0 0
M  V30 4 C 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 3-amino-5-bromobenzoate
C8H8BrNO2
706791-83-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 4.6200 0.0 0
M  V30 2 O 6.6685 3.8500 0.0 0
M  V30 3 O 5.3347 6.1600 0.0 0
M  V30 4 C 8.0021 4.6200 0.0 0
M  V30 5 Br 0.0000 4.6200 0.0 0
M  V30 6 N 2.6674 0.0000 0.0 0
M  V30 7 C 4.0011 3.8500 0.0 0
M  V30 8 C 2.6674 4.6200 0.0 0
M  V30 9 C 4.0011 2.3100 0.0 0
M  V30 10 C 1.3336 3.8500 0.0 0
M  V30 11 C 2.6674 1.5400 0.0 0
M  V30 12 C 1.3336 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 10
M  V30 6 1 6 11
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 3-bromo-5-[(4-methylbenzoyl)amino]benzoate
C16H14BrNO3
2630379-59-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 4.6201 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0
M  V30 3 O 5.3348 2.3101 0.0 0
M  V30 4 C 12.0033 4.6201 0.0 0
M  V30 5 O 13.3370 3.8501 0.0 0
M  V30 6 O 12.0033 6.1601 0.0 0
M  V30 7 C 14.6707 4.6201 0.0 0
M  V30 8 Br 9.3358 0.0000 0.0 0
M  V30 9 C 0.0000 6.9302 0.0 0
M  V30 10 C 8.0022 3.8501 0.0 0
M  V30 11 C 9.3358 4.6201 0.0 0
M  V30 12 C 8.0022 2.3101 0.0 0
M  V30 13 C 10.6697 3.8501 0.0 0
M  V30 14 C 9.3358 1.5400 0.0 0
M  V30 15 C 10.6697 2.3101 0.0 0
M  V30 16 C 4.0010 4.6201 0.0 0
M  V30 17 C 4.0010 6.1601 0.0 0
M  V30 18 C 2.6673 3.8501 0.0 0
M  V30 19 C 2.6673 6.9302 0.0 0
M  V30 20 C 1.3337 4.6201 0.0 0
M  V30 21 C 1.3337 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 2 2 3
M  V30 4 1 2 16
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 13
M  V30 8 1 5 7
M  V30 9 1 8 14
M  V30 10 1 9 21
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 99-94-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 706791-83-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2630379-59-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23500779
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 595-33-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 56602-33-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and evaluation of 3-amide-5-aryl benzoic acid
derivatives as novel P2Y14R antagonists with potential high efficiency
against acute gouty arthritis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Lu, Ran; Wang, Yilin; Liu, Chunxiao; Zhang, Zhenguo; Li, Baiyang; Meng,
Zibo; Jiang, Cheng; Hu, Qinghua
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 216113313

$RFMT $RIREG SCHEME135 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-(2-aminoethyl)-N-methylcarbamate
C8H18N2O2
121492-06-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 2.3101 0.0 0
M  V30 2 N 5.3348 1.5400 0.0 0
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 6.6685 2.3101 0.0 0
M  V30 6 C 5.3348 0.0000 0.0 0
M  V30 7 C 1.3337 2.3101 0.0 0
M  V30 8 C 8.0023 1.5400 0.0 0
M  V30 9 C 0.5637 0.9764 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 2.1037 3.6437 0.0 0
M  V30 12 N 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-methyl-N-[2-[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino...
C16H23N3O3
3031471-32-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6687 3.0801 0.0 0
M  V30 4 N 8.0023 2.3101 0.0 0
M  V30 5 O 6.6687 4.6201 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 N 12.0035 3.0801 0.0 0
M  V30 9 C 13.3372 2.3101 0.0 0
M  V30 10 C 12.0035 4.6201 0.0 0
M  V30 11 O 14.6708 3.0801 0.0 0
M  V30 12 O 13.3372 0.7700 0.0 0
M  V30 13 C 16.0045 2.3101 0.0 0
M  V30 14 C 15.2345 0.9764 0.0 0
M  V30 15 C 17.3383 1.5400 0.0 0
M  V30 16 C 16.7745 3.6437 0.0 0
M  V30 17 C 2.6675 2.3101 0.0 0
M  V30 18 C 2.6675 0.7700 0.0 0
M  V30 19 C 1.3338 3.0801 0.0 0
M  V30 20 C 1.3338 0.0000 0.0 0
M  V30 21 N 0.0000 2.3101 0.0 0
M  V30 22 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 121492-06-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031471-32-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131929
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME136 STEP1
$RXN



  2  1
$MOL
2-Fluoro-6-nitrobenzoic acid
C7H4FNO4
385-02-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 4.6201 0.0 0
M  V30 2 O 1.3338 5.3901 0.0 0
M  V30 3 O 4.0012 5.3901 0.0 0
M  V30 4 N 5.3348 3.0801 0.0 0 VAL=5
M  V30 5 O 5.3348 4.6201 0.0 0
M  V30 6 O 6.6687 2.3101 0.0 0
M  V30 7 F 0.0000 3.0801 0.0 0
M  V30 8 C 2.6675 3.0801 0.0 0
M  V30 9 C 4.0012 2.3101 0.0 0
M  V30 10 C 1.3338 2.3101 0.0 0
M  V30 11 C 4.0012 0.7700 0.0 0
M  V30 12 C 1.3338 0.7700 0.0 0
M  V30 13 C 2.6675 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 9
M  V30 7 1 7 10
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzylamine
C7H9N
100-46-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 N 5.3901 2.6673 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 2.3101 2.6673 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Fluoro-6-nitro-N-(phenylmethyl)benzamide
C14H11FN2O3
120275-71-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0011 0.0 0
M  V30 2 N 6.1600 4.0011 0.0 0
M  V30 3 O 3.8500 5.3347 0.0 0
M  V30 4 C 6.9300 5.3347 0.0 0
M  V30 5 N 1.5400 4.0011 0.0 0 VAL=5
M  V30 6 O 2.3100 5.3347 0.0 0
M  V30 7 O 0.0000 4.0011 0.0 0
M  V30 8 F 6.1600 1.3338 0.0 0
M  V30 9 C 3.8500 2.6674 0.0 0
M  V30 10 C 2.3100 2.6674 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 1.5400 1.3338 0.0 0
M  V30 13 C 3.8500 0.0000 0.0 0
M  V30 14 C 2.3100 0.0000 0.0 0
M  V30 15 C 8.4700 5.3347 0.0 0
M  V30 16 C 9.2400 6.6685 0.0 0
M  V30 17 C 9.2400 4.0011 0.0 0
M  V30 18 C 10.7800 6.6685 0.0 0
M  V30 19 C 10.7800 4.0011 0.0 0
M  V30 20 C 11.5500 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 15
M  V30 6 2 5 6
M  V30 7 2 5 7
M  V30 8 1 5 10
M  V30 9 1 8 11
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 385-02-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 100-46-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 120275-71-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32020179
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of
(S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one
(IHMT-PI3K-372) as a Potent and Selective PI3K Inhibitor for the
Treatment of Chronic Obstructive Pulmonary Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Feng; Liang, Xiaofei; Jiang, Zongru; Wang, Aoli; Wang, Junjie; Chen,
Cheng; Wang, Wenliang; Zou, Fengming; Qi, Ziping; Liu, Qingwang; Hu,
Zhenquan; Cao, Jiangyan; Wu, Hong; Wang, Beilei; Wang, Li; Liu, Jing;
Liu, Qingsong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(22), 13973-13993

$RFMT $RIREG SCHEME137 STEP1
$RXN



  2  1
$MOL
N-(3-Furanylcarbonyl)-L-valine
C10H13NO4
1103527-41-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 2.3100 0.0 0 CFG=2
M  V30 2 N 4.0011 3.0800 0.0 0
M  V30 3 C 1.3337 3.0800 0.0 0
M  V30 4 C 2.6673 0.7700 0.0 0
M  V30 5 C 5.3348 2.3100 0.0 0
M  V30 6 C 0.0000 2.3100 0.0 0
M  V30 7 C 1.3337 4.6201 0.0 0
M  V30 8 O 4.0011 0.0000 0.0 0
M  V30 9 O 1.3337 0.0000 0.0 0
M  V30 10 O 5.3348 0.7700 0.0 0
M  V30 11 C 6.6684 3.0800 0.0 0
M  V30 12 C 6.8295 4.6116 0.0 0
M  V30 13 C 8.0754 2.4536 0.0 0
M  V30 14 C 8.3358 4.9318 0.0 0
M  V30 15 O 9.1058 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 2 5 10
M  V30 10 1 5 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Glycine methyl ester hydrochloride
C3H7NO2.ClH
5680-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.0800 0.0 0
M  V30 2 C 1.3338 3.8500 0.0 0
M  V30 3 O 4.0011 3.8500 0.0 0
M  V30 4 O 2.6674 1.5400 0.0 0
M  V30 5 N 0.0000 3.0800 0.0 0
M  V30 6 C 5.3349 3.0800 0.0 0
M  V30 7 Cl 2.6674 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C13H18N2O5
2732919-59-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 2.3100 0.0 0
M  V30 2 N 5.1049 3.0801 0.0 0
M  V30 3 O 3.7711 0.7700 0.0 0
M  V30 4 C 6.4386 2.3100 0.0 0 CFG=1
M  V30 5 C 7.7722 3.0801 0.0 0
M  V30 6 C 6.4386 0.7700 0.0 0
M  V30 7 N 9.1060 2.3100 0.0 0
M  V30 8 O 7.7722 4.6201 0.0 0
M  V30 9 C 5.1049 0.0000 0.0 0
M  V30 10 C 7.7722 0.0000 0.0 0
M  V30 11 C 10.4397 3.0801 0.0 0
M  V30 12 C 11.7734 2.3100 0.0 0
M  V30 13 O 13.1070 3.0801 0.0 0
M  V30 14 O 11.7734 0.7700 0.0 0
M  V30 15 C 14.4409 2.3100 0.0 0
M  V30 16 C 2.4374 3.0801 0.0 0
M  V30 17 C 2.2765 4.6116 0.0 0
M  V30 18 C 1.0306 2.4536 0.0 0
M  V30 19 C 0.7700 4.9318 0.0 0
M  V30 20 O 0.0000 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 6 10
M  V30 11 1 7 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1103527-41-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5680-79-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2732919-59-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24775917
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of New Potent Positive Allosteric Modulators of Dopamine D2
Receptors: Insights into the Bioisosteric Replacement of Proline to
3-Furoic Acid in the Melanostatin Neuropeptide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sampaio-Dias, Ivo E.; Reis-Mendes, Ana; Costa, Vera Marisa; Garcia-Mera,
Xerardo; Brea, Jose; Loza, Maria Isabel; Pires-Lima, Beatriz L.;
Alcoholado, Cristina; Algarra, Manuel; Rodriguez-Borges, Jose E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(9), 6209-6220

$RFMT $RIREG SCHEME138 STEP1
$RXN



  2  1
$MOL
Tetrahydro-2H-pyran-4-carboxylic acid
C6H10O3
5337-03-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 O 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Cyclohexanepropanoic acid, -amino-, methyl ester, hydrochloride (1:1), (S)-
C10H19NO2.ClH
17193-39-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0 CFG=2
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 N 5.3347 5.3900 0.0 0
M  V30 5 O 8.0021 3.8500 0.0 0
M  V30 6 O 6.6684 1.5400 0.0 0
M  V30 7 C 9.3358 3.0800 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 3.0800 0.0 0
M  V30 10 C 2.6674 5.3900 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 6.1600 0.0 0
M  V30 13 C 0.0000 5.3900 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Cyclohexanepropanoic acid, -[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-, me...
C16H27NO4
3085792-07-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 5.3347 0.0 0 CFG=1
M  V30 2 C 2.3100 4.0011 0.0 0
M  V30 3 N 4.6200 5.3347 0.0 0
M  V30 4 C 2.3100 6.6685 0.0 0
M  V30 5 C 5.3900 6.6685 0.0 0
M  V30 6 O 0.7700 6.6685 0.0 0
M  V30 7 O 3.0800 8.0021 0.0 0
M  V30 8 O 4.6200 8.0021 0.0 0
M  V30 9 C 0.0000 8.0021 0.0 0
M  V30 10 C 3.0800 2.6674 0.0 0
M  V30 11 C 2.3100 1.3336 0.0 0
M  V30 12 C 4.6200 2.6674 0.0 0
M  V30 13 C 3.0800 0.0000 0.0 0
M  V30 14 C 5.3900 1.3336 0.0 0
M  V30 15 C 4.6200 0.0000 0.0 0
M  V30 16 C 6.9300 6.6685 0.0 0
M  V30 17 C 7.7000 5.3347 0.0 0
M  V30 18 C 7.7000 8.0021 0.0 0
M  V30 19 C 9.2400 5.3347 0.0 0
M  V30 20 C 9.2400 8.0021 0.0 0
M  V30 21 O 10.0100 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 10
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 5 16
M  V30 10 1 6 9
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 15
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5337-03-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 17193-39-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3085792-07-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41033862
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 108-75-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structural Modifications of Covalent Cathepsin S Inhibitors: Impact on
Affinity, Selectivity, and Permeability
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Meta, Mergim; Zimmer, Collin; Fuchs, Natalie; Zecher, Maximilian
Johannes; Lahu, Albin; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2024), 15(6), 837-844

$RFMT $RIREG SCHEME139 STEP1
$RXN



  2  1
$MOL
(Diethoxyphosphinyl)acetic acid
C6H13O5P
3095-95-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 P 3.8500 3.8500 0.0 0 VAL=5
M  V30 2 C 5.3900 3.8500 0.0 0
M  V30 3 O 2.3100 3.8500 0.0 0
M  V30 4 O 3.8500 2.3100 0.0 0
M  V30 5 O 3.8500 5.3900 0.0 0
M  V30 6 C 6.1600 5.1836 0.0 0
M  V30 7 C 1.5400 5.1836 0.0 0
M  V30 8 C 2.5164 1.5400 0.0 0
M  V30 9 O 5.3900 6.5173 0.0 0
M  V30 10 O 7.7000 5.1836 0.0 0
M  V30 11 C 0.0000 5.1836 0.0 0
M  V30 12 C 2.5164 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 2 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(1E)-N-(4-Amino-2-cyanophenyl)-N,N-dimethylmethanimidamide
C10H12N4
2131230-48-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 3.0800 0.0 0
M  V30 2 C 6.6684 3.8500 0.0 0
M  V30 3 N 8.0021 3.0800 0.0 0
M  V30 4 C 9.3358 3.8500 0.0 0
M  V30 5 C 8.0021 1.5400 0.0 0
M  V30 6 C 2.6674 1.5400 0.0 0
M  V30 7 N 2.6674 0.0000 0.0 0
M  V30 8 N 0.0000 6.1600 0.0 0
M  V30 9 C 4.0011 3.8500 0.0 0
M  V30 10 C 2.6674 3.0800 0.0 0
M  V30 11 C 4.0011 5.3900 0.0 0
M  V30 12 C 1.3336 3.8500 0.0 0
M  V30 13 C 2.6674 6.1600 0.0 0
M  V30 14 C 1.3336 5.3900 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 3 5
M  V30 6 3 6 7
M  V30 7 1 6 10
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phosphonic acid, P-[2-[[3-cyano-4-[(E)-[(dimethylamino)methylene]amino]phenyl...
C16H23N4O4P
2364326-50-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 9.2402 6.6685 0.0 0
M  V30 2 C 10.0102 5.3348 0.0 0
M  V30 3 C 11.5503 5.3348 0.0 0
M  V30 4 O 9.2402 4.0012 0.0 0
M  V30 5 P 12.3203 4.0012 0.0 0 VAL=5
M  V30 6 O 13.0903 2.6673 0.0 0
M  V30 7 O 13.6539 4.7712 0.0 0
M  V30 8 O 10.9864 3.2311 0.0 0
M  V30 9 C 12.3203 1.3337 0.0 0
M  V30 10 C 14.9876 4.0012 0.0 0
M  V30 11 C 13.0903 0.0000 0.0 0
M  V30 12 C 16.3213 4.7712 0.0 0
M  V30 13 C 4.6201 9.3360 0.0 0
M  V30 14 N 3.8501 10.6697 0.0 0
M  V30 15 N 3.0801 6.6685 0.0 0
M  V30 16 C 2.3101 5.3348 0.0 0
M  V30 17 N 0.7700 5.3348 0.0 0
M  V30 18 C 0.0000 4.0012 0.0 0
M  V30 19 C 0.0000 6.6685 0.0 0
M  V30 20 C 7.7002 6.6685 0.0 0
M  V30 21 C 6.9302 8.0023 0.0 0
M  V30 22 C 6.9302 5.3348 0.0 0
M  V30 23 C 5.3901 8.0023 0.0 0
M  V30 24 C 5.3901 5.3348 0.0 0
M  V30 25 C 4.6201 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 3 13 14
M  V30 14 1 13 23
M  V30 15 2 15 16
M  V30 16 1 15 25
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 2 22 24
M  V30 24 2 23 25
M  V30 25 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3095-95-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2131230-48-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2364326-50-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40132684
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine
Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Di; Tu, Yuanxiang; Jin, Kaijun; Duan, Lingjun; Hong, Yuan; Xu, Jia;
Chen, Na; Zhang, Zhihui; Zuo, Hongjian; Gong, Wanchun; Zhang, Jing; Wang,
Qian; Qian, Hai; Wang, Xuenan; Ke, Ying; Xia, Guangxin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(7), 5334-5354

$RFMT $RIREG SCHEME140 STEP1
$RXN



  2  1
$MOL
4-Fluoroaniline
C6H6FN
371-40-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 0.0000 1.3337 0.0 0
M  V30 2 N 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-(4-fluorophenyl)-5-nitrobenzamide
C13H10FN3O3
1442088-54-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6675 0.0 0
M  V30 2 N 6.9302 4.0012 0.0 0
M  V30 3 O 6.9302 1.3338 0.0 0
M  V30 4 N 4.6201 0.0000 0.0 0
M  V30 5 N 1.5400 5.3348 0.0 0 VAL=5
M  V30 6 O 0.0000 5.3348 0.0 0
M  V30 7 O 2.3101 6.6687 0.0 0
M  V30 8 F 13.0903 4.0012 0.0 0
M  V30 9 C 4.6201 2.6675 0.0 0
M  V30 10 C 3.8501 4.0012 0.0 0
M  V30 11 C 3.8501 1.3338 0.0 0
M  V30 12 C 2.3101 4.0012 0.0 0
M  V30 13 C 2.3101 1.3338 0.0 0
M  V30 14 C 1.5400 2.6675 0.0 0
M  V30 15 C 8.4702 4.0012 0.0 0
M  V30 16 C 9.2402 2.6675 0.0 0
M  V30 17 C 9.2402 5.3348 0.0 0
M  V30 18 C 10.7802 2.6675 0.0 0
M  V30 19 C 10.7802 5.3348 0.0 0
M  V30 20 C 11.5503 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 4 11
M  V30 6 2 5 6
M  V30 7 2 5 7
M  V30 8 1 5 12
M  V30 9 1 8 20
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 371-40-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1442088-54-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31626791
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Piperazinobenzodiazepinones: New Encephalitic Alphavirus Inhibitors via
Ring Expansion of 2-Dichloromethylquinazolinones
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ryan, Michael C.; Kim, Eunjung; Cao, Xufeng; Reichard, Walter; Ogorek,
Tyler J.; Das, Pronay; Jonsson, Colleen B.; Baudry, Jerome; Chung,
Donghoon; Golden, Jennifer E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(4), 546-553

$RFMT $RIREG SCHEME141 STEP1
$RXN



  2  1
$MOL
2,4-Dichlorobenzoic acid
C7H4Cl2O2
50-84-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 Cl 2.3101 0.0000 0.0 0
M  V30 5 Cl 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-N-phenylbenzamide
C13H12N2O
782-45-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6673 0.0 0
M  V30 2 N 4.6201 1.3337 0.0 0
M  V30 3 O 4.6201 4.0010 0.0 0
M  V30 4 N 11.5503 2.6673 0.0 0
M  V30 5 C 6.9302 2.6673 0.0 0
M  V30 6 C 7.7002 1.3337 0.0 0
M  V30 7 C 7.7002 4.0010 0.0 0
M  V30 8 C 9.2402 1.3337 0.0 0
M  V30 9 C 9.2402 4.0010 0.0 0
M  V30 10 C 10.0102 2.6673 0.0 0
M  V30 11 C 3.0801 1.3337 0.0 0
M  V30 12 C 2.3101 0.0000 0.0 0
M  V30 13 C 2.3101 2.6673 0.0 0
M  V30 14 C 0.7700 0.0000 0.0 0
M  V30 15 C 0.7700 2.6673 0.0 0
M  V30 16 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 2 11
M  V30 5 1 4 10
M  V30 6 2 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2,4-Dichloro-N-[4-[(phenylamino)carbonyl]phenyl]benzamide
C20H14Cl2N2O2
313493-80-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 11.5501 4.0011 0.0 0
M  V30 2 C 12.3201 2.6675 0.0 0
M  V30 3 O 11.5501 1.3338 0.0 0
M  V30 4 C 5.3901 4.0011 0.0 0
M  V30 5 N 4.6201 5.3348 0.0 0
M  V30 6 O 4.6201 2.6675 0.0 0
M  V30 7 Cl 13.8602 0.0000 0.0 0
M  V30 8 Cl 18.4802 2.6675 0.0 0
M  V30 9 C 10.0101 4.0011 0.0 0
M  V30 10 C 9.2401 5.3348 0.0 0
M  V30 11 C 9.2401 2.6675 0.0 0
M  V30 12 C 7.7001 5.3348 0.0 0
M  V30 13 C 7.7001 2.6675 0.0 0
M  V30 14 C 6.9301 4.0011 0.0 0
M  V30 15 C 13.8602 2.6675 0.0 0
M  V30 16 C 14.6302 1.3338 0.0 0
M  V30 17 C 14.6302 4.0011 0.0 0
M  V30 18 C 16.1702 1.3338 0.0 0
M  V30 19 C 16.1702 4.0011 0.0 0
M  V30 20 C 16.9402 2.6675 0.0 0
M  V30 21 C 3.0800 5.3348 0.0 0
M  V30 22 C 2.3100 6.6686 0.0 0
M  V30 23 C 2.3100 4.0011 0.0 0
M  V30 24 C 0.7700 6.6686 0.0 0
M  V30 25 C 0.7700 4.0011 0.0 0
M  V30 26 C 0.0000 5.3348 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 2 2 3
M  V30 4 1 2 15
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 14
M  V30 8 1 5 21
M  V30 9 1 7 16
M  V30 10 1 8 20
M  V30 11 2 9 10
M  V30 12 1 9 11
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 50-84-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 782-45-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 313493-80-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32142514
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-activity relationships of agonists for the orphan G
protein-coupled receptor GPR27
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Pillaiyar, Thanigaimalai; Rosato, Francesca; Wozniak, Monika; Blavier,
Jeremy; Charles, Maelle; Laschet, Celine; Kronenberger, Thales; Mueller,
Christa E.; Hanson, Julien
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 225113777

$RFMT $RIREG SCHEME142 STEP1
$RXN



  2  1
$MOL
Glycine, phenylmethyl ester, hydrochloride (1:1)
C9H11NO2.ClH
2462-31-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 O 5.3348 3.8500 0.0 0
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 C 8.0022 3.8500 0.0 0
M  V30 5 O 6.6684 1.5400 0.0 0
M  V30 6 N 9.3359 3.0800 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 1.3337 3.0800 0.0 0
M  V30 9 C 2.6675 5.3900 0.0 0
M  V30 10 C 0.0000 3.8500 0.0 0
M  V30 11 C 1.3337 6.1601 0.0 0
M  V30 12 C 0.0000 5.3900 0.0 0
M  V30 13 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Boc-L-alanine
C8H15NO4
15761-38-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0 CFG=1
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 8.0023 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 1.3337 2.3101 0.0 0
M  V30 9 O 8.0023 0.0000 0.0 0
M  V30 10 O 9.3360 2.3101 0.0 0
M  V30 11 C 0.5637 0.9764 0.0 0
M  V30 12 C 0.0000 3.0801 0.0 0
M  V30 13 C 2.1037 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7 CFG=1
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-alanylglycine phenylmethyl ester
C17H24N2O5
23632-78-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0801 0.0 0
M  V30 2 O 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 C 8.0023 2.3101 0.0 0
M  V30 5 O 6.6685 4.6201 0.0 0
M  V30 6 N 9.3360 3.0801 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 C 12.0035 3.0801 0.0 0 CFG=2
M  V30 9 O 10.6697 0.7700 0.0 0
M  V30 10 N 13.3372 2.3101 0.0 0
M  V30 11 C 12.0035 4.6201 0.0 0
M  V30 12 C 14.6708 3.0801 0.0 0
M  V30 13 O 16.0045 2.3101 0.0 0
M  V30 14 O 14.6708 4.6201 0.0 0
M  V30 15 C 17.3383 3.0801 0.0 0
M  V30 16 C 16.5683 4.4137 0.0 0
M  V30 17 C 18.6720 3.8501 0.0 0
M  V30 18 C 18.1083 1.7464 0.0 0
M  V30 19 C 2.6675 2.3101 0.0 0
M  V30 20 C 2.6675 0.7700 0.0 0
M  V30 21 C 1.3337 3.0801 0.0 0
M  V30 22 C 1.3337 0.0000 0.0 0
M  V30 23 C 0.0000 2.3101 0.0 0
M  V30 24 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 10
M  V30 11 1 8 11 CFG=3
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 23
M  V30 23 2 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2462-31-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 15761-38-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 23632-78-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35038127
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Lectin-Targeted Prodrugs Activated by Pseudomonas aeruginosa for
Self-Destructive Antibiotic Release
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Meiers, Joscha; Rox, Katharina; Titz, Alexander
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(20), 13988-14014

$RFMT $RIREG SCHEME143 STEP1
$RXN



  2  1
$MOL
Anthranilamide
C7H8N2O
88-68-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 N 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 3.0801 4.0010 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Picolinic acid
C6H5NO2
98-98-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 N 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(Aminocarbonyl)phenyl]-2-pyridinecarboxamide
C13H11N3O2
157979-82-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 4.0011 0.0 0
M  V30 2 C 5.3900 5.3347 0.0 0
M  V30 3 O 4.6200 6.6685 0.0 0
M  V30 4 C 3.0800 1.3338 0.0 0
M  V30 5 N 4.6200 1.3338 0.0 0
M  V30 6 O 2.3100 0.0000 0.0 0
M  V30 7 C 3.0800 4.0011 0.0 0
M  V30 8 C 2.3100 2.6674 0.0 0
M  V30 9 C 2.3100 5.3347 0.0 0
M  V30 10 C 0.7700 2.6674 0.0 0
M  V30 11 C 0.7700 5.3347 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 13 C 6.9300 5.3347 0.0 0
M  V30 14 C 7.7000 6.6685 0.0 0
M  V30 15 N 7.7000 4.0011 0.0 0
M  V30 16 C 9.2400 6.6685 0.0 0
M  V30 17 C 9.2400 4.0011 0.0 0
M  V30 18 C 10.0100 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 2 2 3
M  V30 4 1 2 13
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 8
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 88-68-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 98-98-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 157979-82-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34716368
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline
Series with Efficacy in an In Vivo Model of Trypanosoma cruzi Infection
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tawaraishi, Taisuke; Ochida, Atsuko; Akao, Yuichiro; Itono, Sachiko;
Kamaura, Masahiro; Akther, Thamina; Shimada, Mitsuyuki; Canan, Stacie;
Chowdhury, Sanjoy; Cao, Yafeng; Condroski, Kevin; Engkvist, Ola;
Francisco, Amanda; Ghosh, Sunil; Kaki, Rina; Kelly, John M.; Kimura,
Chiaki; Kogej, Thierry; Nagaoka, Kazuya; Naito, Akira; Pairaudeau, Garry;
Radu, Constantin; Roberts, Ieuan; Shum, David; Watanabe, Nao-aki; Xie,
Huanxu; Yonezawa, Shuji; Yoshida, Osamu; Yoshida, Ryu; Mowbray, Charles;
Perry, Benjamin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(2), 1221-1238

$RFMT $RIREG SCHEME144 STEP1
$RXN



  2  1
$MOL
2-Methyl-5-thiazolecarboxylic acid
C5H5NO2S
40004-69-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 S 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 N 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C7H14N2O3S.C2HF3O2
2760538-81-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 6.7238 0.0 0
M  V30 2 C 8.0022 7.4938 0.0 0 CFG=1
M  V30 3 N 5.3348 7.4938 0.0 0
M  V30 4 O 6.6685 5.1837 0.0 0
M  V30 5 C 9.3360 6.7238 0.0 0
M  V30 6 N 8.0022 9.0338 0.0 0
M  V30 7 C 4.0012 6.7238 0.0 0
M  V30 8 S 10.6697 7.4938 0.0 0
M  V30 9 C 2.6673 7.4938 0.0 0
M  V30 10 C 12.0033 6.7238 0.0 0
M  V30 11 O 1.3337 6.7238 0.0 0
M  V30 12 O 2.6673 9.0338 0.0 0
M  V30 13 C 0.0000 7.4938 0.0 0
M  V30 14 C 5.3348 2.3101 0.0 0
M  V30 15 C 6.6685 1.5400 0.0 0
M  V30 16 F 6.1048 3.6437 0.0 0
M  V30 17 F 4.0012 3.0801 0.0 0
M  V30 18 F 4.5648 0.9764 0.0 0
M  V30 19 O 8.0022 2.3101 0.0 0
M  V30 20 O 6.6685 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=1
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 9 12
M  V30 12 1 11 13
M  V30 13 1 14 15
M  V30 14 1 14 16
M  V30 15 1 14 17
M  V30 16 1 14 18
M  V30 17 1 15 19
M  V30 18 2 15 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C12H17N3O4S2
2760538-94-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0287 5.3348 0.0 0
M  V30 2 N 5.5687 5.3348 0.0 0
M  V30 3 O 3.2587 4.0011 0.0 0
M  V30 4 C 6.3387 4.0011 0.0 0 CFG=1
M  V30 5 C 7.8788 4.0011 0.0 0
M  V30 6 C 5.5687 2.6673 0.0 0
M  V30 7 N 8.6488 5.3348 0.0 0
M  V30 8 O 8.6488 2.6673 0.0 0
M  V30 9 S 6.3387 1.3337 0.0 0
M  V30 10 C 10.1888 5.3348 0.0 0
M  V30 11 C 5.5687 0.0000 0.0 0
M  V30 12 C 10.9588 6.6684 0.0 0
M  V30 13 O 12.4988 6.6684 0.0 0
M  V30 14 O 10.1888 8.0023 0.0 0
M  V30 15 C 13.2688 8.0023 0.0 0
M  V30 16 C 0.0000 8.9622 0.0 0
M  V30 17 C 3.2587 6.6684 0.0 0
M  V30 18 S 1.7271 6.8295 0.0 0
M  V30 19 C 3.8850 8.0754 0.0 0
M  V30 20 C 1.4070 8.3358 0.0 0
M  V30 21 N 2.7406 9.1058 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 16 20
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 2 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 40004-69-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-81-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-94-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545348
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME145 STEP1
$RXN



  2  1
$MOL
4-Iodobenzoic acid
C7H5IO2
619-58-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 0.0000 0.0 0
M  V30 3 O 0.0000 2.6673 0.0 0
M  V30 4 I 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indazol-5-amine
C7H7N3
19335-11-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.3710 3.0800 0.0 0
M  V30 2 C 2.3699 0.7700 0.0 0
M  V30 3 C 2.3699 2.3100 0.0 0
M  V30 4 C 3.7036 0.0000 0.0 0
M  V30 5 N 0.9052 0.2941 0.0 0
M  V30 6 C 3.7036 3.0800 0.0 0
M  V30 7 C 0.9052 2.7859 0.0 0
M  V30 8 C 5.0372 0.7700 0.0 0
M  V30 9 N 0.0000 1.5400 0.0 0
M  V30 10 C 5.0372 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 2 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 2 7 9
M  V30 11 2 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-1H-Indazol-5-yl-4-iodobenzamide
C14H10IN3O
1293169-92-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.2873 2.4782 0.0 0
M  V30 2 C 7.0574 3.8119 0.0 0
M  V30 3 O 6.2873 5.1456 0.0 0
M  V30 4 I 13.2175 3.8119 0.0 0
M  V30 5 C 2.4373 1.1444 0.0 0
M  V30 6 C 1.6672 2.4782 0.0 0
M  V30 7 C 3.9773 1.1444 0.0 0
M  V30 8 C 1.4068 0.0000 0.0 0
M  V30 9 C 2.4373 3.8119 0.0 0
M  V30 10 N 0.1609 2.1579 0.0 0
M  V30 11 C 4.7473 2.4782 0.0 0
M  V30 12 N 0.0000 0.6263 0.0 0
M  V30 13 C 3.9773 3.8119 0.0 0
M  V30 14 C 8.5974 3.8119 0.0 0
M  V30 15 C 9.3674 2.4782 0.0 0
M  V30 16 C 9.3674 5.1456 0.0 0
M  V30 17 C 10.9074 2.4782 0.0 0
M  V30 18 C 10.9074 5.1456 0.0 0
M  V30 19 C 11.6775 3.8119 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 2 2 3
M  V30 4 1 2 14
M  V30 5 1 4 19
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 8
M  V30 9 2 6 9
M  V30 10 1 6 10
M  V30 11 1 7 11
M  V30 12 2 8 12
M  V30 13 1 9 13
M  V30 14 1 10 12
M  V30 15 2 11 13
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 619-58-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 19335-11-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1293169-92-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36827360
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Bioisosteric replacement based on 1,2,4-oxadiazoles in the discovery of
1H-indazole-bearing neuroprotective MAO B inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rullo, Mariagrazia; La Spada, Gabriella; Miniero, Daniela Valeria;
Gottinger, Andrea; Catto, Marco; Delre, Pietro; Mastromarino, Margherita;
Latronico, Tiziana; Marchese, Sara; Mangiatordi, Giuseppe Felice; Binda,
Claudia; Linusson, Anna; Liuzzi, Grazia Maria; Pisani, Leonardo
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 255115352

$RFMT $RIREG SCHEME146 STEP1
$RXN



  2  1
$MOL
3-Bromo-2-methylaniline
C7H8BrN
55289-36-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0.0000 0.0 0
M  V30 2 Br 0.0000 1.5400 0.0 0
M  V30 3 N 5.3349 1.5400 0.0 0
M  V30 4 C 2.6674 1.5400 0.0 0
M  V30 5 C 1.3338 2.3100 0.0 0
M  V30 6 C 4.0011 2.3100 0.0 0
M  V30 7 C 1.3338 3.8500 0.0 0
M  V30 8 C 4.0011 3.8500 0.0 0
M  V30 9 C 2.6674 4.6200 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 6
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Chloro-2-pyridineacetic acid
C7H6ClNO2
1000567-55-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 3.0800 0.0 0
M  V30 2 C 6.6685 2.3100 0.0 0
M  V30 3 O 6.6685 0.7700 0.0 0
M  V30 4 O 8.0021 3.0800 0.0 0
M  V30 5 Cl 0.0000 3.0800 0.0 0
M  V30 6 C 4.0011 2.3100 0.0 0
M  V30 7 C 2.6674 3.0800 0.0 0
M  V30 8 N 4.0011 0.7700 0.0 0
M  V30 9 C 1.3336 2.3100 0.0 0
M  V30 10 C 2.6674 0.0000 0.0 0
M  V30 11 C 1.3336 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3-Bromo-2-methylphenyl)-4-chloro-2-pyridineacetamide
C14H12BrClN2O
2677780-41-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 6.6685 3.8501 0.0 0
M  V30 5 C 2.6673 0.0000 0.0 0
M  V30 6 Br 0.0000 1.5400 0.0 0
M  V30 7 Cl 13.3370 1.5400 0.0 0
M  V30 8 C 4.0010 2.3101 0.0 0
M  V30 9 C 2.6673 1.5400 0.0 0
M  V30 10 C 4.0010 3.8501 0.0 0
M  V30 11 C 1.3337 2.3101 0.0 0
M  V30 12 C 2.6673 4.6201 0.0 0
M  V30 13 C 1.3337 3.8501 0.0 0
M  V30 14 C 9.3360 2.3101 0.0 0
M  V30 15 C 10.6697 1.5400 0.0 0
M  V30 16 N 9.3360 3.8501 0.0 0
M  V30 17 C 12.0033 2.3101 0.0 0
M  V30 18 C 10.6697 4.6201 0.0 0
M  V30 19 C 12.0033 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 14
M  V30 6 1 5 9
M  V30 7 1 6 11
M  V30 8 1 7 17
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 55289-36-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1000567-55-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2677780-41-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-23925515
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Driving Potency with Rotationally Stable Atropisomers: Discovery of
Pyridopyrimidinedione-Carbazole Inhibitors of BTK
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Srivastava, Anurag S.; Ko, Soo; Watterson, Scott H.; Pattoli, Mark A.;
Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney;
Discenza, Lorell N.; D'Arienzo, Celia J.; Gillooly, Kathleen M.; Taylor,
Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Yip, Shiuhang; Li,
Peng; Sun, Dawn; Wu, Dauh-Rurng; Dai, Jun; Wang, Chunlei; Zhang, Yingru;
Wang, Bei; Pawluczyk, Joseph; Kempson, James; Zhao, Rulin; Hou, Xiaoping;
Rampulla, Richard; Mathur, Arvind; Galella, Michael A.; Salter-Cid,
Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.;
Tino, Joseph A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2020), 11(11), 2195-2203

$RFMT $RIREG SCHEME147 STEP1
$RXN



  2  1
$MOL
L-Leucine 1,1-dimethylethyl ester
C10H21NO2
21691-53-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 2.3101 0.0 0
M  V30 2 C 5.3348 1.5400 0.0 0 CFG=1
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 6.6685 2.3101 0.0 0
M  V30 6 N 5.3348 0.0000 0.0 0
M  V30 7 C 1.3337 2.3101 0.0 0
M  V30 8 C 8.0023 1.5400 0.0 0
M  V30 9 C 0.5637 0.9764 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 2.1037 3.6437 0.0 0
M  V30 12 C 8.0023 0.0000 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=3
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-D-valine
C11H21NO4
124655-17-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 2.1037 0.0 0 CFG=1
M  V30 2 N 4.0012 1.3337 0.0 0
M  V30 3 C 1.3337 1.3337 0.0 0
M  V30 4 C 2.6675 3.6437 0.0 0
M  V30 5 C 5.3348 2.1037 0.0 0
M  V30 6 C 2.1037 0.0000 0.0 0
M  V30 7 C 0.0000 0.5637 0.0 0
M  V30 8 C 0.5637 2.6673 0.0 0
M  V30 9 O 1.3337 4.4137 0.0 0
M  V30 10 O 4.0012 4.4137 0.0 0
M  V30 11 O 6.6685 1.3337 0.0 0
M  V30 12 O 5.3348 3.6437 0.0 0
M  V30 13 C 8.0023 2.1037 0.0 0
M  V30 14 C 7.2323 3.4374 0.0 0
M  V30 15 C 9.3360 2.8737 0.0 0
M  V30 16 C 8.7723 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 2 4 10
M  V30 10 1 5 11
M  V30 11 2 5 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C21H40N2O5
3033747-56-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 8.4700 0.0 0 CFG=2
M  V30 2 C 5.3347 7.7000 0.0 0
M  V30 3 N 8.0020 7.7000 0.0 0
M  V30 4 C 6.6684 10.0100 0.0 0
M  V30 5 N 5.3347 6.1600 0.0 0
M  V30 6 O 4.0009 8.4700 0.0 0
M  V30 7 C 9.3358 8.4700 0.0 0
M  V30 8 C 8.2084 10.0100 0.0 0
M  V30 9 C 6.6684 11.5500 0.0 0
M  V30 10 C 5.1284 10.0100 0.0 0
M  V30 11 C 4.0009 5.3900 0.0 0 CFG=1
M  V30 12 O 10.6694 7.7000 0.0 0
M  V30 13 O 9.3358 10.0100 0.0 0
M  V30 14 C 4.0009 3.8500 0.0 0
M  V30 15 C 2.6673 6.1600 0.0 0
M  V30 16 C 12.0031 8.4700 0.0 0
M  V30 17 O 5.3347 3.0800 0.0 0
M  V30 18 O 2.6673 3.0800 0.0 0
M  V30 19 C 1.3336 5.3900 0.0 0
M  V30 20 C 12.7731 7.1364 0.0 0
M  V30 21 C 13.3367 9.2400 0.0 0
M  V30 22 C 11.2331 9.8036 0.0 0
M  V30 23 C 5.3347 1.5400 0.0 0
M  V30 24 C 1.3336 3.8500 0.0 0
M  V30 25 C 0.0000 6.1600 0.0 0
M  V30 26 C 6.8747 1.5400 0.0 0
M  V30 27 C 5.3347 0.0000 0.0 0
M  V30 28 C 3.7947 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 4 9
M  V30 9 1 4 10
M  V30 10 1 5 11
M  V30 11 1 7 12
M  V30 12 2 7 13
M  V30 13 1 11 14
M  V30 14 1 11 15 CFG=3
M  V30 15 1 12 16
M  V30 16 1 14 17
M  V30 17 2 14 18
M  V30 18 1 15 19
M  V30 19 1 16 20
M  V30 20 1 16 21
M  V30 21 1 16 22
M  V30 22 1 17 23
M  V30 23 1 19 24
M  V30 24 1 19 25
M  V30 25 1 23 26
M  V30 26 1 23 27
M  V30 27 1 23 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 11)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 21691-53-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 124655-17-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3033747-56-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37843363
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1075198-30-9
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-Activity Relationship Studies of SARS-CoV-2 Main Protease
Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tsuji, Kohei; Ishii, Takahiro; Kobayakawa, Takuya; Higashi-Kuwata,
Nobuyo; Shinohara, Kouki; Azuma, Chika; Miura, Yutaro; Nakano, Hiroki;
Wada, Naoya; Hattori, Shin-ichiro; Bulut, Haydar; Mitsuya, Hiroaki;
Tamamura, Hirokazu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(19), 13516-13529

$RFMT $RIREG SCHEME148 STEP1
$RXN



  2  1
$MOL
2-Pyrazinecarboxylic acid
C5H4N2O2
98-97-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 N 3.0801 2.6673 0.0 0
M  V30 7 N 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C9H18N2O3S2.C2HF3O2
2760538-76-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 S 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 S 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H20N4O4S2
2760538-86-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 3.8500 0.0 0 CFG=2
M  V30 2 C 5.3348 4.6201 0.0 0
M  V30 3 N 8.0021 4.6201 0.0 0
M  V30 4 C 6.6684 2.3100 0.0 0
M  V30 5 N 5.3348 6.1601 0.0 0
M  V30 6 O 4.0010 3.8500 0.0 0
M  V30 7 C 9.3359 3.8500 0.0 0
M  V30 8 S 5.3348 1.5400 0.0 0
M  V30 9 C 4.0010 6.9301 0.0 0 CFG=1
M  V30 10 O 9.3359 2.3100 0.0 0
M  V30 11 C 5.3348 0.0000 0.0 0
M  V30 12 C 4.0010 8.4701 0.0 0
M  V30 13 C 2.6673 6.1601 0.0 0
M  V30 14 O 2.6673 9.2401 0.0 0
M  V30 15 O 5.3348 9.2401 0.0 0
M  V30 16 S 1.3337 6.9301 0.0 0
M  V30 17 C 2.6673 10.7801 0.0 0
M  V30 18 C 0.0000 6.1601 0.0 0
M  V30 19 C 10.6695 4.6201 0.0 0
M  V30 20 C 10.6695 6.1601 0.0 0
M  V30 21 N 12.0032 3.8500 0.0 0
M  V30 22 N 12.0032 6.9301 0.0 0
M  V30 23 C 13.3369 4.6201 0.0 0
M  V30 24 C 13.3369 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 7 10
M  V30 10 1 7 19
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 9 13 CFG=1
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 98-97-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-76-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-86-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545324
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME149 STEP1
$RXN



  2  1
$MOL
5-Methyl-3-isoxazolecarboxylic acid
C5H5NO3
3405-77-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 N 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 O 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C7H14N2O4.C2HF3O2
2760538-79-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 9.1848 0.0 0 CFG=1
M  V30 2 N 3.8500 10.5185 0.0 0
M  V30 3 C 6.1601 9.1848 0.0 0
M  V30 4 C 3.8500 7.8512 0.0 0
M  V30 5 C 2.3100 10.5185 0.0 0
M  V30 6 O 6.9301 10.5185 0.0 0
M  V30 7 O 6.9301 7.8512 0.0 0
M  V30 8 O 4.6201 6.5175 0.0 0
M  V30 9 C 1.5400 11.8523 0.0 0
M  V30 10 O 1.5400 9.1848 0.0 0
M  V30 11 C 8.4701 10.5185 0.0 0
M  V30 12 C 3.8500 5.1837 0.0 0
M  V30 13 N 0.0000 11.8523 0.0 0
M  V30 14 C 3.5682 2.3101 0.0 0
M  V30 15 C 4.9019 1.5400 0.0 0
M  V30 16 F 4.3382 3.6437 0.0 0
M  V30 17 F 2.2345 3.0801 0.0 0
M  V30 18 F 2.7982 0.9764 0.0 0
M  V30 19 O 6.2356 2.3101 0.0 0
M  V30 20 O 4.9019 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 14 15
M  V30 14 1 14 16
M  V30 15 1 14 17
M  V30 16 1 14 18
M  V30 17 1 15 19
M  V30 18 2 15 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C12H17N3O6
2760538-91-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 4.6201 0.0 0
M  V30 2 N 8.0023 3.8501 0.0 0
M  V30 3 O 9.3360 6.1601 0.0 0
M  V30 4 C 6.6685 4.6201 0.0 0
M  V30 5 C 5.3348 3.8501 0.0 0
M  V30 6 N 4.0012 4.6201 0.0 0
M  V30 7 O 5.3348 2.3101 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0 CFG=1
M  V30 9 C 1.3337 4.6201 0.0 0
M  V30 10 C 2.6675 2.3101 0.0 0
M  V30 11 O 1.3337 6.1601 0.0 0
M  V30 12 O 0.0000 3.8501 0.0 0
M  V30 13 O 1.3337 1.5400 0.0 0
M  V30 14 C 0.0000 6.9302 0.0 0
M  V30 15 C 1.3337 0.0000 0.0 0
M  V30 16 C 14.6386 3.4930 0.0 0
M  V30 17 C 10.6697 3.8501 0.0 0
M  V30 18 N 10.8306 2.3185 0.0 0
M  V30 19 C 12.0765 4.4764 0.0 0
M  V30 20 O 12.3371 1.9983 0.0 0
M  V30 21 C 13.1071 3.3320 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10 CFG=1
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 10 13
M  V30 14 1 11 14
M  V30 15 1 13 15
M  V30 16 1 16 21
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3405-77-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-79-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-91-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545333
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME150 STEP1
$RXN



  2  1
$MOL
2-Pyrazinecarboxylic acid
C5H4N2O2
98-97-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 N 3.0801 2.6673 0.0 0
M  V30 7 N 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C9H18N2O4S.C2HF3O2
2760538-75-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 O 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 S 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H20N4O5S
2760538-85-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 3.8500 0.0 0 CFG=2
M  V30 2 C 5.3348 4.6201 0.0 0
M  V30 3 N 8.0021 4.6201 0.0 0
M  V30 4 C 6.6684 2.3100 0.0 0
M  V30 5 N 5.3348 6.1601 0.0 0
M  V30 6 O 4.0010 3.8500 0.0 0
M  V30 7 C 9.3359 3.8500 0.0 0
M  V30 8 S 5.3348 1.5400 0.0 0
M  V30 9 C 4.0010 6.9301 0.0 0 CFG=1
M  V30 10 O 9.3359 2.3100 0.0 0
M  V30 11 C 5.3348 0.0000 0.0 0
M  V30 12 C 4.0010 8.4701 0.0 0
M  V30 13 C 2.6673 6.1601 0.0 0
M  V30 14 O 2.6673 9.2401 0.0 0
M  V30 15 O 5.3348 9.2401 0.0 0
M  V30 16 O 1.3337 6.9301 0.0 0
M  V30 17 C 2.6673 10.7801 0.0 0
M  V30 18 C 0.0000 6.1601 0.0 0
M  V30 19 C 10.6695 4.6201 0.0 0
M  V30 20 C 10.6695 6.1601 0.0 0
M  V30 21 N 12.0032 3.8500 0.0 0
M  V30 22 N 12.0032 6.9301 0.0 0
M  V30 23 C 13.3369 4.6201 0.0 0
M  V30 24 C 13.3369 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 7 10
M  V30 10 1 7 19
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 9 13 CFG=1
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 98-97-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-75-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-85-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545322
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME151 STEP1
$RXN



  2  1
$MOL
1-(1,1-Dimethylethyl) octadecanedioate
C22H42O4
843666-40-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3338 2.3101 0.0 0
M  V30 4 C 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 2.1038 3.6437 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 0.5638 0.9764 0.0 0
M  V30 9 C 6.6687 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 C 9.3360 2.3101 0.0 0
M  V30 12 C 10.6697 1.5400 0.0 0
M  V30 13 C 12.0035 2.3101 0.0 0
M  V30 14 C 13.3372 1.5400 0.0 0
M  V30 15 C 14.6708 2.3101 0.0 0
M  V30 16 C 16.0045 1.5400 0.0 0
M  V30 17 C 17.3383 2.3101 0.0 0
M  V30 18 C 18.6720 1.5400 0.0 0
M  V30 19 C 20.0057 2.3101 0.0 0
M  V30 20 C 21.3393 1.5400 0.0 0
M  V30 21 C 22.6731 2.3101 0.0 0
M  V30 22 C 24.0068 1.5400 0.0 0
M  V30 23 C 25.3405 2.3101 0.0 0
M  V30 24 C 26.6742 1.5400 0.0 0
M  V30 25 O 26.6742 0.0000 0.0 0
M  V30 26 O 28.0080 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 2 24 26
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) hydrogen L-glutamate
C9H17NO4
45120-30-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 2.3101 0.0 0
M  V30 2 C 5.3348 1.5400 0.0 0 CFG=1
M  V30 3 O 2.6673 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 6.6685 2.3101 0.0 0
M  V30 6 N 5.3348 0.0000 0.0 0
M  V30 7 C 1.3337 2.3101 0.0 0
M  V30 8 C 8.0023 1.5400 0.0 0
M  V30 9 C 0.5637 0.9764 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 2.1037 3.6437 0.0 0
M  V30 12 C 9.3360 2.3101 0.0 0
M  V30 13 O 10.6697 1.5400 0.0 0
M  V30 14 O 9.3360 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=3
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) hydrogen N-[18-(1,1-dimethylethoxy)-1,18-dioxooctadecyl...
C31H57NO7
1188328-39-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  39 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 4.6201 0.0 0 CFG=1
M  V30 2 N 5.3348 5.3901 0.0 0
M  V30 3 C 2.6673 5.3901 0.0 0
M  V30 4 C 4.0012 3.0801 0.0 0
M  V30 5 C 6.6685 4.6201 0.0 0
M  V30 6 O 2.6673 6.9302 0.0 0
M  V30 7 O 1.3337 4.6201 0.0 0
M  V30 8 C 2.6673 2.3101 0.0 0
M  V30 9 C 8.0022 5.3901 0.0 0
M  V30 10 O 6.6685 3.0801 0.0 0
M  V30 11 C 1.3337 7.7002 0.0 0
M  V30 12 C 2.6673 0.7700 0.0 0
M  V30 13 C 9.3360 4.6201 0.0 0
M  V30 14 C 0.5637 6.3665 0.0 0
M  V30 15 C 0.0000 8.4702 0.0 0
M  V30 16 C 2.1037 9.0338 0.0 0
M  V30 17 O 1.3337 0.0000 0.0 0
M  V30 18 O 4.0012 0.0000 0.0 0
M  V30 19 C 10.6697 5.3901 0.0 0
M  V30 20 C 12.0033 4.6201 0.0 0
M  V30 21 C 13.3370 5.3901 0.0 0
M  V30 22 C 14.6708 4.6201 0.0 0
M  V30 23 C 16.0045 5.3901 0.0 0
M  V30 24 C 17.3382 4.6201 0.0 0
M  V30 25 C 18.6718 5.3901 0.0 0
M  V30 26 C 20.0057 4.6201 0.0 0
M  V30 27 C 21.3393 5.3901 0.0 0
M  V30 28 C 22.6730 4.6201 0.0 0
M  V30 29 C 24.0067 5.3901 0.0 0
M  V30 30 C 25.3405 4.6201 0.0 0
M  V30 31 C 26.6742 5.3901 0.0 0
M  V30 32 C 28.0078 4.6201 0.0 0
M  V30 33 C 29.3415 5.3901 0.0 0
M  V30 34 O 30.6753 4.6201 0.0 0
M  V30 35 O 29.3415 6.9302 0.0 0
M  V30 36 C 32.0090 5.3901 0.0 0
M  V30 37 C 32.7790 4.0564 0.0 0
M  V30 38 C 33.3427 6.1601 0.0 0
M  V30 39 C 31.2390 6.7238 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 1 11 15
M  V30 15 1 11 16
M  V30 16 1 12 17
M  V30 17 2 12 18
M  V30 18 1 13 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 2 33 35
M  V30 35 1 34 36
M  V30 36 1 36 37
M  V30 37 1 36 38
M  V30 38 1 36 39
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 843666-40-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 45120-30-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1188328-39-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-24133668
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 693-13-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 6066-82-6
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-05-8
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Copper(II) lysinate and pseudoproline assistance in the convergent
synthesis of the GLP-1 receptor agonists Liraglutide and Semaglutide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guryanov, Ivan; Orlandin, Andrea; De Paola, Ivan; Viola, Angelo; Biondi,
Barbara; Badocco, Denis; Formaggio, Fernando; Ricci, Antonio; Cabri,
Walter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(7), 1598-1611

$RFMT $RIREG SCHEME152 STEP1
$RXN



  2  1
$MOL
BOC--alanine
C8H15NO4
3303-84-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 O 2.6673 2.3101 0.0 0
M  V30 3 N 5.3348 2.3101 0.0 0
M  V30 4 O 4.0012 0.0000 0.0 0
M  V30 5 C 1.3337 1.5400 0.0 0
M  V30 6 C 6.6685 1.5400 0.0 0
M  V30 7 C 2.1037 0.2064 0.0 0
M  V30 8 C 0.0000 0.7700 0.0 0
M  V30 9 C 0.5637 2.8737 0.0 0
M  V30 10 C 8.0023 2.3101 0.0 0
M  V30 11 C 9.3360 1.5400 0.0 0
M  V30 12 O 10.6697 2.3101 0.0 0
M  V30 13 O 9.3360 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,4-Dichloroaniline
C6H5Cl2N
95-76-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 1.5400 0.0000 0.0 0
M  V30 2 Cl 0.0000 2.6673 0.0 0
M  V30 3 N 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[3-[(3,4-dichlorophenyl)amino]-3-oxopropyl]carbamate
C14H18Cl2N2O3
1036620-02-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 3.0801 0.0 0
M  V30 2 C 6.6687 2.3101 0.0 0
M  V30 3 C 8.0023 3.0801 0.0 0
M  V30 4 O 6.6687 0.7700 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 N 10.6698 3.0801 0.0 0
M  V30 7 C 12.0035 2.3101 0.0 0
M  V30 8 O 13.3372 3.0801 0.0 0
M  V30 9 O 12.0035 0.7700 0.0 0
M  V30 10 C 14.6708 2.3101 0.0 0
M  V30 11 C 15.4408 3.6437 0.0 0
M  V30 12 C 16.0046 1.5400 0.0 0
M  V30 13 C 13.9008 0.9764 0.0 0
M  V30 14 Cl 0.0000 3.0801 0.0 0
M  V30 15 Cl 0.0000 0.0000 0.0 0
M  V30 16 C 4.0012 2.3101 0.0 0
M  V30 17 C 2.6675 3.0801 0.0 0
M  V30 18 C 4.0012 0.7700 0.0 0
M  V30 19 C 1.3338 2.3101 0.0 0
M  V30 20 C 2.6675 0.0000 0.0 0
M  V30 21 C 1.3338 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 19
M  V30 15 1 15 21
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3303-84-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 95-76-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1036620-02-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-42806224
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-Activity Relationships and Target Selectivity of
Phenylsulfonylamino-Benzanilide Inhibitors Based on S1647 at the SLC10
Carriers ASBT, NTCP, and SOAT
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wannowius, Marie; Neelen, Christopher; Lotz, Philipp; Daude, Michael;
Neubauer, Anita; Fuehler, Baerbel; Diederich, Wibke E.; Geyer, Joachim
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(21), 19342-19364

$RFMT $RIREG SCHEME153 STEP1
$RXN



  2  1
$MOL
(2S)-2-Bromo-3-(1,1-dimethylethoxy)propanoic acid
C7H13BrO3
191221-33-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 10 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 2.3101 0.0 0
M  V30 2 C 5.3348 1.5400 0.0 0 CFG=2
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 C 6.6687 2.3101 0.0 0
M  V30 5 Br 5.3348 0.0000 0.0 0
M  V30 6 C 1.3337 2.3101 0.0 0
M  V30 7 O 8.0023 1.5400 0.0 0
M  V30 8 O 6.6687 3.8501 0.0 0
M  V30 9 C 2.1037 3.6437 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 0.5637 0.9764 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 2 5 CFG=1
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 1 6 11
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(S)--Amino-4-chlorobenzenepropanol
C9H12ClNO
201864-00-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.0800 0.0 0
M  V30 2 C 6.6684 2.3100 0.0 0 CFG=2
M  V30 3 C 8.0022 3.0800 0.0 0
M  V30 4 N 6.6684 0.7700 0.0 0
M  V30 5 O 9.3359 2.3100 0.0 0
M  V30 6 Cl 0.0000 0.0000 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 2.6675 3.0800 0.0 0
M  V30 9 C 4.0011 0.7700 0.0 0
M  V30 10 C 1.3337 2.3100 0.0 0
M  V30 11 C 2.6675 0.0000 0.0 0
M  V30 12 C 1.3337 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(2R)-2-Bromo-N-[(1S)-2-(4-chlorophenyl)-1-(hydroxymethyl)ethyl]-3-(1,1-dimeth...
C16H23BrClNO3
2088454-18-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.0338 4.0012 0.0 0
M  V30 2 C 8.2638 2.6675 0.0 0 CFG=1
M  V30 3 N 6.7238 2.6675 0.0 0
M  V30 4 C 9.0338 1.3337 0.0 0
M  V30 5 C 5.9538 4.0012 0.0 0
M  V30 6 O 8.2638 0.0000 0.0 0
M  V30 7 C 4.4137 4.0012 0.0 0 CFG=2
M  V30 8 O 6.7238 5.3348 0.0 0
M  V30 9 C 3.6437 5.3348 0.0 0
M  V30 10 Br 3.6437 2.6675 0.0 0
M  V30 11 O 2.1037 5.3348 0.0 0
M  V30 12 C 1.3337 6.6687 0.0 0
M  V30 13 C 0.0000 5.8986 0.0 0
M  V30 14 C 0.5637 8.0023 0.0 0
M  V30 15 C 2.6673 7.4387 0.0 0
M  V30 16 Cl 15.1940 4.0012 0.0 0
M  V30 17 C 10.5739 4.0012 0.0 0
M  V30 18 C 11.3439 5.3348 0.0 0
M  V30 19 C 11.3439 2.6675 0.0 0
M  V30 20 C 12.8839 5.3348 0.0 0
M  V30 21 C 12.8839 2.6675 0.0 0
M  V30 22 C 13.6539 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 7 9
M  V30 10 1 7 10 CFG=3
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 1 16 22
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 22
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 7)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 191221-33-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 201864-00-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2088454-18-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23762561
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential
New Therapeutics for Idiopathic Pulmonary Fibrosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Koralewski, Robert; Dymek, Barbara; Mazur, Marzena; Sklepkiewicz, Piotr;
Olejniczak, Sylwia; Czestkowski, Wojciech; Matyszewski, Krzysztof;
Andryianau, Gleb; Niedziejko, Piotr; Kowalski, Michal; Gruza, Mariusz;
Borek, Bartlomiej; Jedrzejczak, Karol; Bartoszewicz, Agnieszka; Pluta,
Elzbieta; Rymaszewska, Aleksandra; Kania, Magdalena; Rejczak, Tomasz;
Piasecka, Sylwia; Mlacki, Michal; Mazurkiewicz, Marcin; Piotrowicz,
Michal; Salamon, Magdalena; Zagozdzon, Agnieszka; Napiorkowska-Gromadzka,
Agnieszka; Bartlomiejczak, Aneta; Mozga, Witold; Dobrzanski, Pawel;
Dzwonek, Karolina; Golab, Jakub; Nowotny, Marcin; Olczak, Jacek;
Golebiowski, Adam
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(24), 15527-15540

$RFMT $RIREG SCHEME154 STEP1
$RXN



  2  1
$MOL
1-Acetyl-4-piperidinecarboxylic acid
C8H13NO3
25503-90-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6686 1.5400 0.0 0
M  V30 2 O 8.0022 2.3100 0.0 0
M  V30 3 O 6.6686 0.0000 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 0.0000 3.8500 0.0 0
M  V30 6 O 1.3337 6.1601 0.0 0
M  V30 7 C 5.3348 2.3100 0.0 0
M  V30 8 C 4.0011 1.5400 0.0 0
M  V30 9 C 5.3348 3.8500 0.0 0
M  V30 10 C 2.6675 2.3100 0.0 0
M  V30 11 C 4.0011 4.6201 0.0 0
M  V30 12 N 2.6675 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 12
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Chloro-4-methylaniline
C7H8ClN
95-74-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 1.5400 0.0000 0.0 0
M  V30 2 C 0.0000 2.6673 0.0 0
M  V30 3 N 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Acetyl-N-(3-chloro-4-methylphenyl)-4-piperidinecarboxamide
C15H19ClN2O2
898130-92-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 7.7000 2.6674 0.0 0
M  V30 2 C 6.9300 4.0011 0.0 0
M  V30 3 O 7.7000 5.3349 0.0 0
M  V30 4 Cl 12.3200 0.0000 0.0 0
M  V30 5 C 13.8600 2.6674 0.0 0
M  V30 6 C 0.7700 4.0011 0.0 0
M  V30 7 C 0.0000 5.3349 0.0 0
M  V30 8 O 0.0000 2.6674 0.0 0
M  V30 9 C 9.2400 2.6674 0.0 0
M  V30 10 C 10.0100 1.3338 0.0 0
M  V30 11 C 10.0100 4.0011 0.0 0
M  V30 12 C 11.5500 1.3338 0.0 0
M  V30 13 C 11.5500 4.0011 0.0 0
M  V30 14 C 12.3200 2.6674 0.0 0
M  V30 15 C 5.3900 4.0011 0.0 0
M  V30 16 C 4.6200 5.3349 0.0 0
M  V30 17 C 4.6200 2.6674 0.0 0
M  V30 18 C 3.0800 5.3349 0.0 0
M  V30 19 C 3.0800 2.6674 0.0 0
M  V30 20 N 2.3100 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 2 2 3
M  V30 4 1 2 15
M  V30 5 1 4 12
M  V30 6 1 5 14
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 20
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 25503-90-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 95-74-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 898130-92-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36873887
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human
Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5
Coreceptor and gp41 N-Terminal Heptad Repeat Region
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Chao; Wang, Xinling; Wang, Huan; Pu, Jing; Li, Qing; Li, Jiahui;
Liu, Yang; Lu, Lu; Jiang, Shibo
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(15), 11460-11471

$RFMT $RIREG SCHEME155 STEP1
$RXN



  2  1
$MOL
N-(3-Furanylcarbonyl)-L-valine
C10H13NO4
1103527-41-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 2.3100 0.0 0 CFG=2
M  V30 2 N 4.0011 3.0800 0.0 0
M  V30 3 C 1.3337 3.0800 0.0 0
M  V30 4 C 2.6673 0.7700 0.0 0
M  V30 5 C 5.3348 2.3100 0.0 0
M  V30 6 C 0.0000 2.3100 0.0 0
M  V30 7 C 1.3337 4.6201 0.0 0
M  V30 8 O 4.0011 0.0000 0.0 0
M  V30 9 O 1.3337 0.0000 0.0 0
M  V30 10 O 5.3348 0.7700 0.0 0
M  V30 11 C 6.6684 3.0800 0.0 0
M  V30 12 C 6.8295 4.6116 0.0 0
M  V30 13 C 8.0754 2.4536 0.0 0
M  V30 14 C 8.3358 4.9318 0.0 0
M  V30 15 O 9.1058 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 2 5 10
M  V30 10 1 5 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Alanine methyl ester hydrochloride
C4H9NO2.ClH
2491-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.8500 0.0 0
M  V30 2 C 1.3338 3.0800 0.0 0 CFG=1
M  V30 3 O 4.0011 3.0800 0.0 0
M  V30 4 O 2.6674 5.3900 0.0 0
M  V30 5 C 0.0000 3.8500 0.0 0
M  V30 6 N 1.3338 1.5400 0.0 0
M  V30 7 C 5.3349 3.8500 0.0 0
M  V30 8 Cl 2.6674 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=1
M  V30 6 1 3 7
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H20N2O5
2732919-61-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.4385 2.3100 0.0 0 CFG=1
M  V30 2 N 5.1049 3.0800 0.0 0
M  V30 3 C 7.7722 3.0800 0.0 0
M  V30 4 C 6.4385 0.7700 0.0 0
M  V30 5 C 3.7711 2.3100 0.0 0
M  V30 6 N 9.1060 2.3100 0.0 0
M  V30 7 O 7.7722 4.6201 0.0 0
M  V30 8 C 5.1049 0.0000 0.0 0
M  V30 9 C 7.7722 0.0000 0.0 0
M  V30 10 O 3.7711 0.7700 0.0 0
M  V30 11 C 10.4397 3.0800 0.0 0 CFG=1
M  V30 12 C 11.7733 2.3100 0.0 0
M  V30 13 C 10.4397 4.6201 0.0 0
M  V30 14 O 13.1070 3.0800 0.0 0
M  V30 15 O 11.7733 0.7700 0.0 0
M  V30 16 C 14.4408 2.3100 0.0 0
M  V30 17 C 2.4374 3.0800 0.0 0
M  V30 18 C 2.2765 4.6116 0.0 0
M  V30 19 C 1.0306 2.4536 0.0 0
M  V30 20 C 0.7700 4.9318 0.0 0
M  V30 21 O 0.0000 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 4 9
M  V30 9 2 5 10
M  V30 10 1 5 17
M  V30 11 1 6 11
M  V30 12 1 11 12
M  V30 13 1 11 13 CFG=1
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 14 16
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 11)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1103527-41-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2491-20-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2732919-61-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24775908
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of New Potent Positive Allosteric Modulators of Dopamine D2
Receptors: Insights into the Bioisosteric Replacement of Proline to
3-Furoic Acid in the Melanostatin Neuropeptide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sampaio-Dias, Ivo E.; Reis-Mendes, Ana; Costa, Vera Marisa; Garcia-Mera,
Xerardo; Brea, Jose; Loza, Maria Isabel; Pires-Lima, Beatriz L.;
Alcoholado, Cristina; Algarra, Manuel; Rodriguez-Borges, Jose E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(9), 6209-6220

$RFMT $RIREG SCHEME156 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(4-Aminomethylbenzyl)carbamic acid tert-butyl ester
C13H20N2O2
108468-00-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 C 4.0010 1.5400 0.0 0
M  V30 4 O 2.6673 2.3101 0.0 0
M  V30 5 O 4.0010 0.0000 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 C 0.5637 2.8737 0.0 0
M  V30 8 C 0.0000 0.7700 0.0 0
M  V30 9 C 2.1037 0.2064 0.0 0
M  V30 10 C 12.0033 4.6201 0.0 0
M  V30 11 N 13.3370 3.8501 0.0 0
M  V30 12 C 8.0022 2.3101 0.0 0
M  V30 13 C 8.0022 3.8501 0.0 0
M  V30 14 C 9.3360 1.5400 0.0 0
M  V30 15 C 9.3360 4.6201 0.0 0
M  V30 16 C 10.6697 2.3101 0.0 0
M  V30 17 C 10.6697 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 10 11
M  V30 11 1 10 17
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[[4-[[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl...
C21H25N3O3
3031471-27-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 14.6708 4.6201 0.0 0
M  V30 2 N 16.0045 3.8501 0.0 0
M  V30 3 C 17.3382 4.6201 0.0 0
M  V30 4 O 18.6720 3.8501 0.0 0
M  V30 5 O 17.3382 6.1601 0.0 0
M  V30 6 C 20.0057 4.6201 0.0 0
M  V30 7 C 19.2356 5.9538 0.0 0
M  V30 8 C 21.3393 5.3901 0.0 0
M  V30 9 C 20.7757 3.2864 0.0 0
M  V30 10 C 9.3360 1.5400 0.0 0
M  V30 11 N 8.0022 2.3101 0.0 0
M  V30 12 C 6.6685 1.5400 0.0 0
M  V30 13 C 5.3348 2.3101 0.0 0
M  V30 14 O 6.6685 0.0000 0.0 0
M  V30 15 C 4.0012 1.5400 0.0 0
M  V30 16 C 13.3372 3.8501 0.0 0
M  V30 17 C 12.0033 4.6201 0.0 0
M  V30 18 C 13.3372 2.3101 0.0 0
M  V30 19 C 10.6697 3.8501 0.0 0
M  V30 20 C 12.0033 1.5400 0.0 0
M  V30 21 C 10.6697 2.3101 0.0 0
M  V30 22 C 2.6673 2.3101 0.0 0
M  V30 23 C 2.6673 3.8501 0.0 0
M  V30 24 C 1.3337 1.5400 0.0 0
M  V30 25 C 1.3337 4.6201 0.0 0
M  V30 26 N 0.0000 2.3101 0.0 0
M  V30 27 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 10 11
M  V30 11 1 10 21
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 15 22
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 1 22 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 2 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 108468-00-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031471-27-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131889
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME157 STEP1
$RXN



  2  1
$MOL
N-Phenylanthranilic acid
C13H11NO2
91-40-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 4.0011 0.0 0
M  V30 2 C 1.5400 4.0011 0.0 0
M  V30 3 O 2.3100 5.3349 0.0 0
M  V30 4 O 0.0000 4.0011 0.0 0
M  V30 5 C 3.8500 2.6674 0.0 0
M  V30 6 C 2.3100 2.6674 0.0 0
M  V30 7 C 4.6200 1.3338 0.0 0
M  V30 8 C 1.5400 1.3338 0.0 0
M  V30 9 C 3.8500 0.0000 0.0 0
M  V30 10 C 2.3100 0.0000 0.0 0
M  V30 11 C 6.1600 4.0011 0.0 0
M  V30 12 C 6.9300 2.6674 0.0 0
M  V30 13 C 6.9300 5.3349 0.0 0
M  V30 14 C 8.4700 2.6674 0.0 0
M  V30 15 C 8.4700 5.3349 0.0 0
M  V30 16 C 9.2400 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 5
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 6
M  V30 6 2 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Methoxybenzylamine
C8H11NO
2393-23-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.0801 0.0 0
M  V30 2 N 0.0000 2.3101 0.0 0
M  V30 3 O 6.6687 0.0000 0.0 0
M  V30 4 C 8.0023 0.7700 0.0 0
M  V30 5 C 2.6675 2.3101 0.0 0
M  V30 6 C 2.6675 0.7700 0.0 0
M  V30 7 C 4.0012 3.0801 0.0 0
M  V30 8 C 4.0012 0.0000 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 3 4
M  V30 4 1 3 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(4-Methoxyphenyl)methyl]-2-(phenylamino)benzamide
C21H20N2O2
1354149-98-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.7000 4.0011 0.0 0
M  V30 2 N 9.2400 4.0011 0.0 0
M  V30 3 O 6.9300 5.3347 0.0 0
M  V30 4 C 10.0100 5.3347 0.0 0
M  V30 5 N 4.6200 4.0011 0.0 0
M  V30 6 O 16.1700 5.3347 0.0 0
M  V30 7 C 16.9400 6.6685 0.0 0
M  V30 8 C 6.9300 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 7.7000 1.3338 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 6.9300 0.0000 0.0 0
M  V30 13 C 5.3900 0.0000 0.0 0
M  V30 14 C 3.0800 4.0011 0.0 0
M  V30 15 C 2.3100 5.3347 0.0 0
M  V30 16 C 2.3100 2.6674 0.0 0
M  V30 17 C 0.7700 5.3347 0.0 0
M  V30 18 C 0.7700 2.6674 0.0 0
M  V30 19 C 0.0000 4.0011 0.0 0
M  V30 20 C 11.5500 5.3347 0.0 0
M  V30 21 C 12.3200 6.6685 0.0 0
M  V30 22 C 12.3200 4.0011 0.0 0
M  V30 23 C 13.8600 6.6685 0.0 0
M  V30 24 C 13.8600 4.0011 0.0 0
M  V30 25 C 14.6300 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 20
M  V30 6 1 5 9
M  V30 7 1 5 14
M  V30 8 1 6 7
M  V30 9 1 6 25
M  V30 10 2 8 9
M  V30 11 1 8 10
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 14 2 11 13
M  V30 15 1 12 13
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 91-40-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2393-23-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1354149-98-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39627218
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM N-2-(Phenylamino) Benzamide Derivatives as Dual Inhibitors of COX-2 and
Topo I Deter Gastrointestinal Cancers via Targeting Inflammation and
Tumor Progression
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Junfang; Hu, Xiaoling; Zhang, Honghua; Peng, Yan; Li, Shuang; Xiong,
Yongxia; Jiang, Weifan; Wang, Zhen
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(15), 10481-10505

$RFMT $RIREG SCHEME158 STEP1
$RXN



  2  1
$MOL
3-Thiophenecarboxylic acid
C5H4O2S
88-13-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7710 1.5400 0.0 0
M  V30 2 O 5.1048 2.3100 0.0 0
M  V30 3 O 3.7710 0.0000 0.0 0
M  V30 4 C 2.4374 2.3100 0.0 0
M  V30 5 C 1.0306 1.6835 0.0 0
M  V30 6 C 2.2764 3.8416 0.0 0
M  V30 7 C 0.0000 2.8281 0.0 0
M  V30 8 S 0.7700 4.1617 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phenylalanine ethyl ester hydrochloride
C11H15NO2.ClH
3182-93-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0800 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0 CFG=2
M  V30 3 C 6.6685 3.0800 0.0 0
M  V30 4 N 5.3348 5.3901 0.0 0
M  V30 5 O 8.0023 3.8501 0.0 0
M  V30 6 O 6.6685 1.5400 0.0 0
M  V30 7 C 9.3360 3.0800 0.0 0
M  V30 8 C 10.6697 3.8501 0.0 0
M  V30 9 C 2.6673 3.8501 0.0 0
M  V30 10 C 1.3337 3.0800 0.0 0
M  V30 11 C 2.6673 5.3901 0.0 0
M  V30 12 C 0.0000 3.8501 0.0 0
M  V30 13 C 1.3337 6.1601 0.0 0
M  V30 14 C 0.0000 5.3901 0.0 0
M  V30 15 Cl 5.3348 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Phenylalanine, N-(3-thienylcarbonyl)-, ethyl ester
C16H17NO3S
3054992-07-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0 CFG=1
M  V30 2 C 4.6200 6.6685 0.0 0
M  V30 3 N 6.9300 5.3347 0.0 0
M  V30 4 C 4.6200 4.0011 0.0 0
M  V30 5 C 7.7000 6.6685 0.0 0
M  V30 6 O 5.3900 2.6674 0.0 0
M  V30 7 O 3.0800 4.0011 0.0 0
M  V30 8 O 6.9300 8.0021 0.0 0
M  V30 9 C 4.6200 1.3336 0.0 0
M  V30 10 C 5.3900 0.0000 0.0 0
M  V30 11 C 3.0800 6.6685 0.0 0
M  V30 12 C 2.3100 5.3347 0.0 0
M  V30 13 C 2.3100 8.0021 0.0 0
M  V30 14 C 0.7700 5.3347 0.0 0
M  V30 15 C 0.7700 8.0021 0.0 0
M  V30 16 C 0.0000 6.6685 0.0 0
M  V30 17 C 9.2400 6.6685 0.0 0
M  V30 18 C 10.1452 5.4225 0.0 0
M  V30 19 C 10.1452 7.9144 0.0 0
M  V30 20 C 11.6098 5.8985 0.0 0
M  V30 21 S 11.6098 7.4385 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 11
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 5 17
M  V30 10 1 6 9
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 88-13-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3182-93-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3054992-07-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36966242
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing
Covalent Reversible -Fluorovinylsulfones and -Sulfonates as Potential
Immunomodulators in Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fuchs, Natalie; Meta, Mergim; Lantzberg, Bellinda; Bros, Matthias; Ling
Kuan, Seah; Weil, Tanja; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(15), e202300160

$RFMT $RIREG SCHEME159 STEP1
$RXN



  2  1
$MOL
3-Iodobenzoic acid
C7H5IO2
618-51-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 I 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,4-Dichloro--phenylbenzenepropanamine
C15H15Cl2N
114667-11-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 4.6201 0.0 0
M  V30 2 C 6.6685 5.3901 0.0 0
M  V30 3 C 8.0023 4.6201 0.0 0
M  V30 4 N 9.3360 5.3901 0.0 0
M  V30 5 Cl 2.6675 9.2402 0.0 0
M  V30 6 Cl 0.0000 7.7002 0.0 0
M  V30 7 C 4.0012 5.3901 0.0 0
M  V30 8 C 4.0012 6.9302 0.0 0
M  V30 9 C 2.6675 4.6201 0.0 0
M  V30 10 C 2.6675 7.7002 0.0 0
M  V30 11 C 1.3337 5.3901 0.0 0
M  V30 12 C 1.3337 6.9302 0.0 0
M  V30 13 C 5.3348 3.0801 0.0 0
M  V30 14 C 6.6685 2.3101 0.0 0
M  V30 15 C 4.0012 2.3101 0.0 0
M  V30 16 C 6.6685 0.7700 0.0 0
M  V30 17 C 4.0012 0.7700 0.0 0
M  V30 18 C 5.3348 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 1 13
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 5 10
M  V30 7 1 6 12
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[3-(3,4-Dichlorophenyl)-3-phenylpropyl]-3-iodobenzamide
C22H18Cl2INO
2709014-26-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 4.6200 0.0 0
M  V30 2 C 6.6685 5.3900 0.0 0
M  V30 3 C 8.0021 4.6200 0.0 0
M  V30 4 N 9.3358 5.3900 0.0 0
M  V30 5 C 10.6696 4.6200 0.0 0
M  V30 6 O 10.6696 3.0800 0.0 0
M  V30 7 Cl 2.6674 9.2400 0.0 0
M  V30 8 Cl 0.0000 7.7000 0.0 0
M  V30 9 I 16.0043 4.6200 0.0 0
M  V30 10 C 4.0011 5.3900 0.0 0
M  V30 11 C 4.0011 6.9300 0.0 0
M  V30 12 C 2.6674 4.6200 0.0 0
M  V30 13 C 2.6674 7.7000 0.0 0
M  V30 14 C 1.3338 5.3900 0.0 0
M  V30 15 C 1.3338 6.9300 0.0 0
M  V30 16 C 5.3347 3.0800 0.0 0
M  V30 17 C 4.0011 2.3100 0.0 0
M  V30 18 C 6.6685 2.3100 0.0 0
M  V30 19 C 4.0011 0.7700 0.0 0
M  V30 20 C 6.6685 0.7700 0.0 0
M  V30 21 C 5.3347 0.0000 0.0 0
M  V30 22 C 12.0032 5.3900 0.0 0
M  V30 23 C 13.3369 4.6200 0.0 0
M  V30 24 C 12.0032 6.9300 0.0 0
M  V30 25 C 14.6705 5.3900 0.0 0
M  V30 26 C 13.3369 7.7000 0.0 0
M  V30 27 C 14.6705 6.9300 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 1 16
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 4 5
M  V30 7 2 5 6
M  V30 8 1 5 22
M  V30 9 1 7 13
M  V30 10 1 8 15
M  V30 11 1 9 25
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 2 12 14
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 618-51-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 114667-11-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2709014-26-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24414246
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 108-18-9
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):NOTES
$DATUM microwave irradiation
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Structure-Activity Relationship Studies of Dual
Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hiesinger, Kerstin; Kramer, Jan S.; Beyer, Sandra; Eckes, Timon; Brunst,
Steffen; Flauaus, Cathrin; Wittmann, Sandra K.; Weizel, Lilia; Kaiser,
Astrid; Kretschmer, Simon B. M.; George, Sven; Angioni, Carlo; Heering,
Jan; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred; Schmidtko, Achim;
Pogoryelov, Denys; Pfeilschifter, Josef; Hofmann, Bettina; Steinhilber,
Dieter; Schwalm, Stephanie; Proschak, Ewgenij
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 11498-11521

$RFMT $RIREG SCHEME160 STEP1
$RXN



  2  1
$MOL
Boc-L-valine
C10H19NO4
13734-41-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 2.3101 0.0 0 CFG=2
M  V30 2 N 4.0012 1.5400 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 C 2.6675 3.8501 0.0 0
M  V30 5 C 5.3348 2.3101 0.0 0
M  V30 6 C 0.0000 2.3101 0.0 0
M  V30 7 C 1.3337 0.0000 0.0 0
M  V30 8 O 1.3337 4.6201 0.0 0
M  V30 9 O 4.0012 4.6201 0.0 0
M  V30 10 O 6.6685 1.5400 0.0 0
M  V30 11 O 5.3348 3.8501 0.0 0
M  V30 12 C 8.0023 2.3101 0.0 0
M  V30 13 C 8.7723 0.9764 0.0 0
M  V30 14 C 9.3360 3.0801 0.0 0
M  V30 15 C 7.2323 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 1 5 10
M  V30 10 2 5 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Methyl 12-aminododecanoate
C13H27NO2
53005-24-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 2.3101 0.0 0
M  V30 2 C 5.3348 1.5400 0.0 0
M  V30 3 C 8.0023 1.5400 0.0 0
M  V30 4 C 4.0012 2.3101 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 2.6675 1.5400 0.0 0
M  V30 7 C 10.6697 1.5400 0.0 0
M  V30 8 O 1.3337 2.3101 0.0 0
M  V30 9 O 2.6675 0.0000 0.0 0
M  V30 10 C 12.0035 2.3101 0.0 0
M  V30 11 C 0.0000 1.5400 0.0 0
M  V30 12 C 13.3372 1.5400 0.0 0
M  V30 13 C 14.6708 2.3101 0.0 0
M  V30 14 C 16.0045 1.5400 0.0 0
M  V30 15 C 17.3383 2.3101 0.0 0
M  V30 16 N 18.6720 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 12-[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-methyl-1-oxobutyl]...
C23H44N2O5
195147-01-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 5.9538 0.0 0 CFG=1
M  V30 2 N 4.0010 4.4137 0.0 0
M  V30 3 C 5.3348 6.7238 0.0 0
M  V30 4 C 2.6673 6.7238 0.0 0
M  V30 5 C 2.6673 3.6437 0.0 0
M  V30 6 N 6.6685 5.9538 0.0 0
M  V30 7 O 5.3348 8.2638 0.0 0
M  V30 8 C 2.6673 8.2638 0.0 0
M  V30 9 C 1.3337 5.9538 0.0 0
M  V30 10 O 2.6673 2.1037 0.0 0
M  V30 11 O 1.3337 4.4137 0.0 0
M  V30 12 C 8.0022 6.7238 0.0 0
M  V30 13 C 1.3337 1.3337 0.0 0
M  V30 14 C 9.3358 5.9538 0.0 0
M  V30 15 C 2.1037 0.0000 0.0 0
M  V30 16 C 0.0000 0.5637 0.0 0
M  V30 17 C 0.5637 2.6673 0.0 0
M  V30 18 C 10.6697 6.7238 0.0 0
M  V30 19 C 12.0033 5.9538 0.0 0
M  V30 20 C 13.3370 6.7238 0.0 0
M  V30 21 C 14.6707 5.9538 0.0 0
M  V30 22 C 16.0045 6.7238 0.0 0
M  V30 23 C 17.3382 5.9538 0.0 0
M  V30 24 C 18.6718 6.7238 0.0 0
M  V30 25 C 20.0055 5.9538 0.0 0
M  V30 26 C 21.3393 6.7238 0.0 0
M  V30 27 C 22.6730 5.9538 0.0 0
M  V30 28 O 24.0067 6.7238 0.0 0
M  V30 29 O 22.6730 4.4137 0.0 0
M  V30 30 C 25.3403 5.9538 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 4 9
M  V30 9 1 5 10
M  V30 10 2 5 11
M  V30 11 1 6 12
M  V30 12 1 10 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 16 1 13 17
M  V30 17 1 14 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 2 27 29
M  V30 29 1 28 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 13734-41-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 53005-24-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 195147-01-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31901528
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Biomimetic Macrocyclic Inhibitors of Human Cathepsin D:
Structure-Activity Relationship and Binding Mode Analysis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Houstecka, Radka; Hadzima, Martin; Fanfrlik, Jindrich; Brynda, Jiri;
Pallova, Lenka; Hanova, Iva; Mertlikova-Kaiserova, Helena; Lepsik,
Martin; Horn, Martin; Smrcina, Martin; Majer, Pavel; Mares, Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(4), 1576-1596

$RFMT $RIREG SCHEME161 STEP1
$RXN



  2  1
$MOL
4-Aminophenol
C6H7NO
123-30-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 1.3337 0.0 0
M  V30 2 O 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-[[(4-Fluorophenyl)amino]carbonyl]cyclopropanecarboxylic acid
C11H10FNO3
849217-48-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8402 2.2170 0.0 0
M  V30 2 N 5.1740 1.4470 0.0 0
M  V30 3 O 3.8402 3.7570 0.0 0
M  V30 4 C 1.5166 2.6268 0.0 0
M  V30 5 O 0.0000 2.3593 0.0 0
M  V30 6 O 2.0435 4.0740 0.0 0
M  V30 7 F 10.5088 4.5271 0.0 0
M  V30 8 C 2.5065 1.4470 0.0 0
M  V30 9 C 3.0332 0.0000 0.0 0
M  V30 10 C 1.5166 0.2673 0.0 0
M  V30 11 C 6.5077 2.2170 0.0 0
M  V30 12 C 6.5077 3.7570 0.0 0
M  V30 13 C 7.8413 1.4470 0.0 0
M  V30 14 C 7.8413 4.5271 0.0 0
M  V30 15 C 9.1750 2.2170 0.0 0
M  V30 16 C 9.1750 3.7570 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 11
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 8
M  V30 8 1 7 16
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(4-Fluorophenyl)-N-(4-hydroxyphenyl)-1,1-cyclopropanedicarboxamide
C17H15FN2O3
849217-60-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.7998 4.8611 0.0 0
M  V30 2 N 9.1334 5.6311 0.0 0
M  V30 3 O 7.7998 3.3211 0.0 0
M  V30 4 C 5.4762 4.4514 0.0 0
M  V30 5 N 3.9596 4.7188 0.0 0
M  V30 6 O 6.0029 3.0043 0.0 0
M  V30 7 F 14.4682 2.5511 0.0 0
M  V30 8 O 0.0000 0.0000 0.0 0
M  V30 9 C 6.4661 5.6311 0.0 0
M  V30 10 C 6.9928 7.0783 0.0 0
M  V30 11 C 5.4762 6.8109 0.0 0
M  V30 12 C 10.4672 4.8611 0.0 0
M  V30 13 C 10.4672 3.3211 0.0 0
M  V30 14 C 11.8009 5.6311 0.0 0
M  V30 15 C 11.8009 2.5511 0.0 0
M  V30 16 C 13.1346 4.8611 0.0 0
M  V30 17 C 13.1346 3.3211 0.0 0
M  V30 18 C 2.9696 3.5391 0.0 0
M  V30 19 C 3.4963 2.0920 0.0 0
M  V30 20 C 1.4530 3.8065 0.0 0
M  V30 21 C 2.5064 0.9123 0.0 0
M  V30 22 C 0.4631 2.6268 0.0 0
M  V30 23 C 0.9898 1.1797 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 12
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 9
M  V30 8 1 5 18
M  V30 9 1 7 17
M  V30 10 1 8 23
M  V30 11 1 9 10
M  V30 12 1 9 11
M  V30 13 1 10 11
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 1 13 15
M  V30 17 2 14 16
M  V30 18 2 15 17
M  V30 19 1 16 17
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 20 22
M  V30 24 2 21 23
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 123-30-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 849217-48-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 849217-60-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31702986
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-guided design and development of novel
N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Huang, Daowei; Yang, Jixia; Zhang, Qingwei; Wang, Guan; Zhang, Zixue;
Zhang, Yue; Li, Jianqi
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 223113648

$RFMT $RIREG SCHEME162 STEP1
$RXN



  2  1
$MOL
4-(Hexyloxy)benzoic acid
C13H18O3
1142-39-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.6685 4.6201 0.0 0
M  V30 2 C 8.0022 3.8501 0.0 0
M  V30 3 C 9.3358 4.6201 0.0 0
M  V30 4 C 10.6697 3.8501 0.0 0
M  V30 5 C 12.0033 4.6201 0.0 0
M  V30 6 C 13.3370 3.8501 0.0 0
M  V30 7 C 14.6707 4.6201 0.0 0
M  V30 8 C 1.3337 1.5400 0.0 0
M  V30 9 O 1.3337 0.0000 0.0 0
M  V30 10 O 0.0000 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 12 C 5.3348 2.3101 0.0 0
M  V30 13 C 4.0010 4.6201 0.0 0
M  V30 14 C 4.0010 1.5400 0.0 0
M  V30 15 C 2.6673 3.8501 0.0 0
M  V30 16 C 2.6673 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 16
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Valine, methyl ester, hydrochloride (1:1)
C6H13NO2.ClH
6306-52-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.0800 0.0 0 CFG=1
M  V30 2 C 4.0011 3.8500 0.0 0
M  V30 3 C 1.3338 3.8500 0.0 0
M  V30 4 N 2.6674 1.5400 0.0 0
M  V30 5 O 5.3347 3.0800 0.0 0
M  V30 6 O 4.0011 5.3900 0.0 0
M  V30 7 C 0.0000 3.0800 0.0 0
M  V30 8 C 1.3338 5.3900 0.0 0
M  V30 9 C 6.6685 3.8500 0.0 0
M  V30 10 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 5 9
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[4-(Hexyloxy)benzoyl]-L-valine methyl ester
C19H29NO4
2172908-60-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 2.3101 0.0 0
M  V30 2 N 5.3348 3.0801 0.0 0
M  V30 3 O 6.6685 0.7700 0.0 0
M  V30 4 C 4.0012 2.3101 0.0 0 CFG=1
M  V30 5 C 2.6675 3.0801 0.0 0
M  V30 6 C 4.0012 0.7700 0.0 0
M  V30 7 O 1.3337 2.3101 0.0 0
M  V30 8 O 2.6675 4.6201 0.0 0
M  V30 9 C 5.3348 0.0000 0.0 0
M  V30 10 C 2.6675 0.0000 0.0 0
M  V30 11 C 0.0000 3.0801 0.0 0
M  V30 12 O 12.0033 5.3901 0.0 0
M  V30 13 C 13.3372 4.6201 0.0 0
M  V30 14 C 14.6708 5.3901 0.0 0
M  V30 15 C 16.0045 4.6201 0.0 0
M  V30 16 C 17.3382 5.3901 0.0 0
M  V30 17 C 18.6720 4.6201 0.0 0
M  V30 18 C 20.0057 5.3901 0.0 0
M  V30 19 C 8.0023 3.0801 0.0 0
M  V30 20 C 9.3360 2.3101 0.0 0
M  V30 21 C 8.0023 4.6201 0.0 0
M  V30 22 C 10.6697 3.0801 0.0 0
M  V30 23 C 9.3360 5.3901 0.0 0
M  V30 24 C 10.6697 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 19
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=1
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 6 10
M  V30 11 1 7 11
M  V30 12 1 12 13
M  V30 13 1 12 24
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 23
M  V30 23 2 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1142-39-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6306-52-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2172908-60-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-23938870
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 56602-33-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A Novel N-Substituted Valine Derivative with Unique Peroxisome
Proliferator-Activated Receptor  Binding Properties and Biological
Activities
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Peiretti, Franck; Montanari, Roberta; Capelli, Davide; Bonardo,
Bernadette; Colson, Cecilia; Amri, Ez-Zoubir; Grimaldi, Marina; Balaguer,
Patrick; Ito, Keiichi; Roeder, Robert G.; Pochetti, Giorgio; Brunel, Jean
Michel
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(21), 13124-13139

$RFMT $RIREG SCHEME163 STEP1
$RXN



  2  1
$MOL
3-Iodobenzoic acid
C7H5IO2
618-51-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 I 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indazol-5-amine
C7H7N3
19335-11-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.3710 3.0800 0.0 0
M  V30 2 C 2.3699 0.7700 0.0 0
M  V30 3 C 2.3699 2.3100 0.0 0
M  V30 4 C 3.7036 0.0000 0.0 0
M  V30 5 N 0.9052 0.2941 0.0 0
M  V30 6 C 3.7036 3.0800 0.0 0
M  V30 7 C 0.9052 2.7859 0.0 0
M  V30 8 C 5.0372 0.7700 0.0 0
M  V30 9 N 0.0000 1.5400 0.0 0
M  V30 10 C 5.0372 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 2 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 2 7 9
M  V30 11 2 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-1H-Indazol-5-yl-3-iodobenzamide
C14H10IN3O
1303926-40-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.3709 2.3100 0.0 0
M  V30 2 C 7.7045 3.0800 0.0 0
M  V30 3 O 7.7045 4.6200 0.0 0
M  V30 4 I 13.0392 3.0800 0.0 0
M  V30 5 C 2.3698 4.6200 0.0 0
M  V30 6 C 2.3698 3.0800 0.0 0
M  V30 7 C 3.7034 5.3900 0.0 0
M  V30 8 N 0.9052 5.0959 0.0 0
M  V30 9 C 3.7034 2.3100 0.0 0
M  V30 10 C 0.9052 2.6042 0.0 0
M  V30 11 C 5.0372 4.6200 0.0 0
M  V30 12 N 0.0000 3.8500 0.0 0
M  V30 13 C 5.0372 3.0800 0.0 0
M  V30 14 C 9.0382 2.3100 0.0 0
M  V30 15 C 10.3720 3.0800 0.0 0
M  V30 16 C 9.0382 0.7700 0.0 0
M  V30 17 C 11.7056 2.3100 0.0 0
M  V30 18 C 10.3720 0.0000 0.0 0
M  V30 19 C 11.7056 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 2 2 3
M  V30 4 1 2 14
M  V30 5 1 4 17
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 8
M  V30 9 2 6 9
M  V30 10 1 6 10
M  V30 11 1 7 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 2 10 12
M  V30 15 2 11 13
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 618-51-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 19335-11-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1303926-40-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36827354
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Bioisosteric replacement based on 1,2,4-oxadiazoles in the discovery of
1H-indazole-bearing neuroprotective MAO B inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rullo, Mariagrazia; La Spada, Gabriella; Miniero, Daniela Valeria;
Gottinger, Andrea; Catto, Marco; Delre, Pietro; Mastromarino, Margherita;
Latronico, Tiziana; Marchese, Sara; Mangiatordi, Giuseppe Felice; Binda,
Claudia; Linusson, Anna; Liuzzi, Grazia Maria; Pisani, Leonardo
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 255115352

$RFMT $RIREG SCHEME164 STEP1
$RXN



  2  1
$MOL
3,4-Dimethoxyphenethylamine
C10H15NO2
120-20-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3349 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3349 0.0 0
M  V30 7 N 9.2400 5.3349 0.0 0
M  V30 8 C 3.0800 2.6674 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.0800 5.3349 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 4.6200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Thiopheneacetic acid
C6H6O2S
6964-21-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 2.6217 0.0 0
M  V30 2 C 5.1049 1.8517 0.0 0
M  V30 3 O 5.1049 0.3117 0.0 0
M  V30 4 O 6.4385 2.6217 0.0 0
M  V30 5 C 2.4374 1.8517 0.0 0
M  V30 6 C 1.0306 2.4782 0.0 0
M  V30 7 C 2.2765 0.3202 0.0 0
M  V30 8 C 0.0000 1.3337 0.0 0
M  V30 9 S 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)ethyl]-3-thiopheneacetamide
C16H19NO3S
70474-53-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 4.6201 0.0 0
M  V30 2 C 0.0000 6.1601 0.0 0
M  V30 3 O 0.0000 1.5400 0.0 0
M  V30 4 C 0.0000 0.0000 0.0 0
M  V30 5 C 5.3348 4.6201 0.0 0
M  V30 6 C 6.6686 3.8500 0.0 0
M  V30 7 N 8.0022 4.6201 0.0 0
M  V30 8 C 9.3359 3.8500 0.0 0
M  V30 9 C 10.6697 4.6201 0.0 0
M  V30 10 O 9.3359 2.3100 0.0 0
M  V30 11 C 1.3338 3.8500 0.0 0
M  V30 12 C 1.3338 2.3100 0.0 0
M  V30 13 C 2.6675 4.6201 0.0 0
M  V30 14 C 2.6675 1.5400 0.0 0
M  V30 15 C 4.0011 3.8500 0.0 0
M  V30 16 C 4.0011 2.3100 0.0 0
M  V30 17 C 12.0034 3.8500 0.0 0
M  V30 18 C 13.4102 4.4764 0.0 0
M  V30 19 C 12.1643 2.3185 0.0 0
M  V30 20 C 14.4407 3.3320 0.0 0
M  V30 21 S 13.6707 1.9983 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 3 4
M  V30 4 1 3 12
M  V30 5 1 5 6
M  V30 6 1 5 15
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 17
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 120-20-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6964-21-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 70474-53-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23042848
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME165 STEP1
$RXN



  2  1
$MOL
2-Fluorobenzoic acid
C7H5FO2
445-29-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 F 2.3101 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 3.0801 4.0010 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-nitrophenol
C6H6N2O3
121-88-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.7700 2.6673 0.0 0 VAL=5
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 O 5.3901 0.0000 0.0 0
M  V30 5 N 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Fluoro-N-(2-hydroxy-4-nitrophenyl)benzamide
C13H9FN2O4
1007681-02-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6675 0.0 0
M  V30 2 N 5.3901 4.0012 0.0 0
M  V30 3 O 5.3901 1.3338 0.0 0
M  V30 4 F 3.0801 0.0000 0.0 0
M  V30 5 O 6.9302 6.6687 0.0 0
M  V30 6 N 11.5503 4.0012 0.0 0 VAL=5
M  V30 7 O 12.3203 5.3348 0.0 0
M  V30 8 O 12.3203 2.6675 0.0 0
M  V30 9 C 3.0801 2.6675 0.0 0
M  V30 10 C 2.3101 1.3338 0.0 0
M  V30 11 C 2.3101 4.0012 0.0 0
M  V30 12 C 0.7700 1.3338 0.0 0
M  V30 13 C 0.7700 4.0012 0.0 0
M  V30 14 C 0.0000 2.6675 0.0 0
M  V30 15 C 6.9302 4.0012 0.0 0
M  V30 16 C 7.7002 5.3348 0.0 0
M  V30 17 C 7.7002 2.6675 0.0 0
M  V30 18 C 9.2402 5.3348 0.0 0
M  V30 19 C 9.2402 2.6675 0.0 0
M  V30 20 C 10.0102 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 4 10
M  V30 6 1 5 16
M  V30 7 2 6 7
M  V30 8 2 6 8
M  V30 9 1 6 20
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 445-29-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 121-88-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1007681-02-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22370048
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Martinez-Gonzalez, Sonia; Garcia, Ana Belen; Albarran, M. Isabel; Cebria,
Antonio; Amezquita-Alves, Adrian; Garcia-Campos, Francisco Javier;
Martinez-Gago, Jaime; Martinez-Torrecuadrada, Jorge; Munoz, Ines;
Blanco-Aparicio, Carmen; Pastor, Joaquin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 201112443

$RFMT $RIREG SCHEME166 STEP1
$RXN



  2  1
$MOL
3-Iodobenzoic acid
C7H5IO2
618-51-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 I 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(3-Amino-1-phenylpropyl)benzenesulfonamide
C15H18N2O2S
2709014-53-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 4.0011 0.0 0
M  V30 2 C 2.3100 5.3347 0.0 0
M  V30 3 C 0.7700 5.3347 0.0 0
M  V30 4 N 0.0000 6.6685 0.0 0
M  V30 5 S 9.2400 4.0011 0.0 0 VAL=6
M  V30 6 N 10.7800 4.0011 0.0 0
M  V30 7 O 9.2400 5.5411 0.0 0
M  V30 8 O 9.2400 2.4611 0.0 0
M  V30 9 C 4.6200 4.0011 0.0 0
M  V30 10 C 5.3900 5.3347 0.0 0
M  V30 11 C 5.3900 2.6674 0.0 0
M  V30 12 C 6.9300 5.3347 0.0 0
M  V30 13 C 6.9300 2.6674 0.0 0
M  V30 14 C 7.7000 4.0011 0.0 0
M  V30 15 C 2.3100 2.6674 0.0 0
M  V30 16 C 0.7700 2.6674 0.0 0
M  V30 17 C 3.0800 1.3338 0.0 0
M  V30 18 C 0.0000 1.3338 0.0 0
M  V30 19 C 2.3100 0.0000 0.0 0
M  V30 20 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 1 15
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 2 5 8
M  V30 9 1 5 14
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[3-[4-(Aminosulfonyl)phenyl]-3-phenylpropyl]-3-iodobenzamide
C22H21IN2O3S
2709014-29-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6687 4.6201 0.0 0
M  V30 2 C 8.0023 5.3901 0.0 0
M  V30 3 C 9.3360 4.6201 0.0 0
M  V30 4 N 10.6697 5.3901 0.0 0
M  V30 5 C 12.0035 4.6201 0.0 0
M  V30 6 O 12.0035 3.0801 0.0 0
M  V30 7 S 1.3338 7.7002 0.0 0 VAL=6
M  V30 8 N 0.0000 8.4702 0.0 0
M  V30 9 O 0.5638 6.3665 0.0 0
M  V30 10 O 2.1038 9.0338 0.0 0
M  V30 11 I 17.3383 4.6201 0.0 0
M  V30 12 C 5.3348 5.3901 0.0 0
M  V30 13 C 4.0012 4.6201 0.0 0
M  V30 14 C 5.3348 6.9302 0.0 0
M  V30 15 C 2.6675 5.3901 0.0 0
M  V30 16 C 4.0012 7.7002 0.0 0
M  V30 17 C 2.6675 6.9302 0.0 0
M  V30 18 C 6.6687 3.0801 0.0 0
M  V30 19 C 5.3348 2.3101 0.0 0
M  V30 20 C 8.0023 2.3101 0.0 0
M  V30 21 C 5.3348 0.7700 0.0 0
M  V30 22 C 8.0023 0.7700 0.0 0
M  V30 23 C 6.6687 0.0000 0.0 0
M  V30 24 C 13.3372 5.3901 0.0 0
M  V30 25 C 14.6708 4.6201 0.0 0
M  V30 26 C 13.3372 6.9302 0.0 0
M  V30 27 C 16.0045 5.3901 0.0 0
M  V30 28 C 14.6708 7.7002 0.0 0
M  V30 29 C 16.0045 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 1 18
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 4 5
M  V30 7 2 5 6
M  V30 8 1 5 24
M  V30 9 1 7 8
M  V30 10 2 7 9
M  V30 11 2 7 10
M  V30 12 1 7 17
M  V30 13 1 11 27
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 1 13 15
M  V30 17 2 14 16
M  V30 18 2 15 17
M  V30 19 1 16 17
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 20 22
M  V30 24 2 21 23
M  V30 25 1 22 23
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 2 26 28
M  V30 30 2 27 29
M  V30 31 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 618-51-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2709014-53-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2709014-29-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24414253
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):NOTES
$DATUM microwave irradiation
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Structure-Activity Relationship Studies of Dual
Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hiesinger, Kerstin; Kramer, Jan S.; Beyer, Sandra; Eckes, Timon; Brunst,
Steffen; Flauaus, Cathrin; Wittmann, Sandra K.; Weizel, Lilia; Kaiser,
Astrid; Kretschmer, Simon B. M.; George, Sven; Angioni, Carlo; Heering,
Jan; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred; Schmidtko, Achim;
Pogoryelov, Denys; Pfeilschifter, Josef; Hofmann, Bettina; Steinhilber,
Dieter; Schwalm, Stephanie; Proschak, Ewgenij
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 11498-11521

$RFMT $RIREG SCHEME167 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Heptanoic acid, 6,6-difluoro-2-hydroxy-3-[[(1S)-1-phenylethyl](phenylmethyl)a...
C22H27F2NO3
2952552-89-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 4.6201 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0 CFG=2
M  V30 3 C 8.0022 3.8501 0.0 0 CFG=2
M  V30 4 C 6.6685 6.1601 0.0 0
M  V30 5 C 4.0012 4.6201 0.0 0
M  V30 6 C 5.3348 2.3101 0.0 0 CFG=2
M  V30 7 C 8.0022 2.3101 0.0 0
M  V30 8 C 2.6673 3.8501 0.0 0
M  V30 9 C 4.0012 1.5400 0.0 0
M  V30 10 O 6.6685 1.5400 0.0 0
M  V30 11 C 1.3337 4.6201 0.0 0
M  V30 12 O 4.0012 0.0000 0.0 0
M  V30 13 O 2.6673 2.3101 0.0 0
M  V30 14 C 0.0000 5.3901 0.0 0
M  V30 15 F 2.1037 5.9538 0.0 0
M  V30 16 F 0.5637 3.2864 0.0 0
M  V30 17 C 9.3360 4.6201 0.0 0
M  V30 18 C 9.3360 6.1601 0.0 0
M  V30 19 C 10.6697 3.8501 0.0 0
M  V30 20 C 10.6697 6.9302 0.0 0
M  V30 21 C 12.0033 4.6201 0.0 0
M  V30 22 C 12.0033 6.1601 0.0 0
M  V30 23 C 5.3348 6.9302 0.0 0
M  V30 24 C 4.0012 6.1601 0.0 0
M  V30 25 C 5.3348 8.4702 0.0 0
M  V30 26 C 2.6673 6.9302 0.0 0
M  V30 27 C 4.0012 9.2402 0.0 0
M  V30 28 C 2.6673 8.4702 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5 CFG=3
M  V30 5 1 2 6
M  V30 6 1 3 7 CFG=3
M  V30 7 1 3 17
M  V30 8 1 4 23
M  V30 9 1 5 8
M  V30 10 1 6 9
M  V30 11 1 6 10 CFG=3
M  V30 12 1 8 11
M  V30 13 1 9 12
M  V30 14 2 9 13
M  V30 15 1 11 14
M  V30 16 1 11 15
M  V30 17 1 11 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 2 25 27
M  V30 28 2 26 28
M  V30 29 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 2 3 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Heptanamide, 6,6-difluoro-2-hydroxy-N-methyl-3-[[(1S)-1-phenylethyl](phenylme...
C23H30F2N2O2
2952552-91-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 5.3901 0.0 0
M  V30 2 C 5.3348 4.6201 0.0 0 CFG=1
M  V30 3 C 6.6685 6.9302 0.0 0 CFG=2
M  V30 4 C 8.0022 4.6201 0.0 0
M  V30 5 C 5.3348 3.0801 0.0 0 CFG=2
M  V30 6 C 4.0012 5.3901 0.0 0
M  V30 7 C 8.0022 7.7002 0.0 0
M  V30 8 C 6.6685 2.3101 0.0 0
M  V30 9 O 4.0012 2.3101 0.0 0
M  V30 10 C 2.6673 4.6201 0.0 0
M  V30 11 N 6.6685 0.7700 0.0 0
M  V30 12 O 8.0022 3.0801 0.0 0
M  V30 13 C 1.3337 5.3901 0.0 0
M  V30 14 C 8.0022 0.0000 0.0 0
M  V30 15 C 0.0000 6.1601 0.0 0
M  V30 16 F 2.1037 6.7238 0.0 0
M  V30 17 F 0.5637 4.0564 0.0 0
M  V30 18 C 5.3348 7.7002 0.0 0
M  V30 19 C 4.0012 6.9302 0.0 0
M  V30 20 C 5.3348 9.2402 0.0 0
M  V30 21 C 2.6673 7.7002 0.0 0
M  V30 22 C 4.0012 10.0102 0.0 0
M  V30 23 C 2.6673 9.2402 0.0 0
M  V30 24 C 9.3360 5.3901 0.0 0
M  V30 25 C 10.6697 4.6201 0.0 0
M  V30 26 C 9.3360 6.9302 0.0 0
M  V30 27 C 12.0033 5.3901 0.0 0
M  V30 28 C 10.6697 7.7002 0.0 0
M  V30 29 C 12.0033 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=3
M  V30 6 1 3 7 CFG=3
M  V30 7 1 3 18
M  V30 8 1 4 24
M  V30 9 1 5 8
M  V30 10 1 5 9 CFG=1
M  V30 11 1 6 10
M  V30 12 1 8 11
M  V30 13 2 8 12
M  V30 14 1 10 13
M  V30 15 1 11 14
M  V30 16 1 13 15
M  V30 17 1 13 16
M  V30 18 1 13 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 25 2 24 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 2 26 28
M  V30 29 2 27 29
M  V30 30 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 2 3 5)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2952552-89-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2952552-91-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-42085179
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Invention of MK-7845, a SARS-CoV-2 3CL protease inhibitor employing a
novel difluorinated glutamine mimic
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Shurtleff, Valerie W.; Layton, Mark E.; Parish, Craig A.; Perkins, James
J.; Schreier, John D.; Wang, Yunyi; Adam, Gregory C.; Alvarez, Nadine;
Bahmanjah, Soheila; Bahnck-Teets, Carolyn M.; Boyce, Christopher W.;
Burlein, Christine; Cabalu, Tamara D.; Campbell, Brian T.; Carroll,
Steven S.; Chang, Wonsuk; de Lera Ruiz, Manuel; Dolgov, Enriko; Fay, John
F.; Fox, Nicholas G.; Goh, Shih Lin; Hartingh, Timothy J.; Hurzy,
Danielle M.; Kelly, Michael J. III; Klein, Daniel J.; Klingler,
Franca-Maria; Krishnamurthy, Harini; Kudalkar, Shalley; Mayhood, Todd W.;
McKenna, Philip M.; Murray, Edward M.; Nahas, Debbie; Nawrat, Christopher
C.; Park, Steven; Qian, Dongming; Roecker, Anthony J.; Sharma, Vijeta;
Shipe, William D.; Su, Jing; Taggart, Robert V.; Truong, Quang; Wu, Yin;
Zhou, Xiaoyan; Zhuang, Ningning; Perlin, David S.; Olsen, David B.; Howe,
John A.; McCauley, John A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(5), 3935-3958

$RFMT $RIREG SCHEME168 STEP1
$RXN



  2  1
$MOL
4-Pyridinecarboxylic acid
C6H5NO2
55-22-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 N 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phenylalanine ethyl ester hydrochloride
C11H15NO2.ClH
3182-93-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0800 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0 CFG=2
M  V30 3 C 6.6685 3.0800 0.0 0
M  V30 4 N 5.3348 5.3901 0.0 0
M  V30 5 O 8.0023 3.8501 0.0 0
M  V30 6 O 6.6685 1.5400 0.0 0
M  V30 7 C 9.3360 3.0800 0.0 0
M  V30 8 C 10.6697 3.8501 0.0 0
M  V30 9 C 2.6673 3.8501 0.0 0
M  V30 10 C 1.3337 3.0800 0.0 0
M  V30 11 C 2.6673 5.3901 0.0 0
M  V30 12 C 0.0000 3.8501 0.0 0
M  V30 13 C 1.3337 6.1601 0.0 0
M  V30 14 C 0.0000 5.3901 0.0 0
M  V30 15 Cl 5.3348 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(4-Pyridinylcarbonyl)-L-phenylalanine ethyl ester
C17H18N2O3
1957239-71-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0 CFG=1
M  V30 2 C 4.6200 6.6685 0.0 0
M  V30 3 N 6.9300 5.3347 0.0 0
M  V30 4 C 4.6200 4.0011 0.0 0
M  V30 5 C 7.7000 6.6685 0.0 0
M  V30 6 O 5.3900 2.6674 0.0 0
M  V30 7 O 3.0800 4.0011 0.0 0
M  V30 8 O 6.9300 8.0021 0.0 0
M  V30 9 C 4.6200 1.3336 0.0 0
M  V30 10 C 5.3900 0.0000 0.0 0
M  V30 11 C 3.0800 6.6685 0.0 0
M  V30 12 C 2.3100 8.0021 0.0 0
M  V30 13 C 2.3100 5.3347 0.0 0
M  V30 14 C 0.7700 8.0021 0.0 0
M  V30 15 C 0.7700 5.3347 0.0 0
M  V30 16 C 0.0000 6.6685 0.0 0
M  V30 17 C 9.2400 6.6685 0.0 0
M  V30 18 C 10.0100 5.3347 0.0 0
M  V30 19 C 10.0100 8.0021 0.0 0
M  V30 20 C 11.5500 5.3347 0.0 0
M  V30 21 C 11.5500 8.0021 0.0 0
M  V30 22 N 12.3200 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 11
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 5 17
M  V30 10 1 6 9
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 22
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 55-22-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3182-93-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1957239-71-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36966232
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing
Covalent Reversible -Fluorovinylsulfones and -Sulfonates as Potential
Immunomodulators in Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fuchs, Natalie; Meta, Mergim; Lantzberg, Bellinda; Bros, Matthias; Ling
Kuan, Seah; Weil, Tanja; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(15), e202300160

$RFMT $RIREG SCHEME169 STEP1
$RXN



  2  1
$MOL
Diphenylacetic acid
C14H12O2
117-34-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 2.3100 0.0 0
M  V30 2 C 4.0011 0.7700 0.0 0
M  V30 3 O 2.6674 0.0000 0.0 0
M  V30 4 O 5.3347 0.0000 0.0 0
M  V30 5 C 2.6674 3.0800 0.0 0
M  V30 6 C 1.3336 2.3100 0.0 0
M  V30 7 C 2.6674 4.6200 0.0 0
M  V30 8 C 0.0000 3.0800 0.0 0
M  V30 9 C 1.3336 5.3900 0.0 0
M  V30 10 C 0.0000 4.6200 0.0 0
M  V30 11 C 5.3347 3.0800 0.0 0
M  V30 12 C 5.3347 4.6200 0.0 0
M  V30 13 C 6.6685 2.3100 0.0 0
M  V30 14 C 6.6685 5.3900 0.0 0
M  V30 15 C 8.0021 3.0800 0.0 0
M  V30 16 C 8.0021 4.6200 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 1 11
M  V30 4 1 2 3
M  V30 5 2 2 4
M  V30 6 2 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenepropanamide, -amino-3-methyl-N-2-propyn-1-yl-, (S)-, 2,2,2-trifluoro...
C13H16N2O.C2HF3O2
3026372-62-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 6.7238 0.0 0
M  V30 2 C 6.6685 7.4938 0.0 0 CFG=2
M  V30 3 C 8.0022 6.7238 0.0 0
M  V30 4 N 6.6685 9.0338 0.0 0
M  V30 5 N 9.3360 7.4938 0.0 0
M  V30 6 O 8.0022 5.1837 0.0 0
M  V30 7 C 10.6697 6.7238 0.0 0
M  V30 8 C 12.0033 7.4938 0.0 0
M  V30 9 C 13.3370 8.2638 0.0 0
M  V30 10 C 0.0000 6.7238 0.0 0
M  V30 11 C 4.0010 7.4938 0.0 0
M  V30 12 C 2.6673 6.7238 0.0 0
M  V30 13 C 4.0010 9.0338 0.0 0
M  V30 14 C 1.3337 7.4938 0.0 0
M  V30 15 C 2.6673 9.8038 0.0 0
M  V30 16 C 1.3337 9.0338 0.0 0
M  V30 17 C 6.0017 2.3101 0.0 0
M  V30 18 C 7.3353 1.5400 0.0 0
M  V30 19 F 6.7717 3.6437 0.0 0
M  V30 20 F 4.6680 3.0801 0.0 0
M  V30 21 F 5.2316 0.9764 0.0 0
M  V30 22 O 8.6690 2.3101 0.0 0
M  V30 23 O 7.3353 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 3 8 9
M  V30 10 1 10 14
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 17 20
M  V30 20 1 17 21
M  V30 21 1 18 22
M  V30 22 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzenepropanamide, -[(2,2-diphenylacetyl)amino]-3-methyl-N-2-propyn-1-yl-, ...
C27H26N2O2
3026370-13-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 4.6201 0.0 0
M  V30 2 C 5.3348 5.3901 0.0 0
M  V30 3 N 5.3348 6.9302 0.0 0
M  V30 4 O 6.6685 4.6201 0.0 0
M  V30 5 C 6.6685 7.7002 0.0 0 CFG=2
M  V30 6 C 8.0022 6.9302 0.0 0
M  V30 7 C 6.6685 9.2402 0.0 0
M  V30 8 N 5.3348 10.0102 0.0 0
M  V30 9 O 8.0022 10.0102 0.0 0
M  V30 10 C 5.3348 11.5503 0.0 0
M  V30 11 C 4.0010 12.3203 0.0 0
M  V30 12 C 2.6673 13.0903 0.0 0
M  V30 13 C 13.3370 6.9302 0.0 0
M  V30 14 C 4.0010 3.0801 0.0 0
M  V30 15 C 5.3348 2.3101 0.0 0
M  V30 16 C 2.6673 2.3101 0.0 0
M  V30 17 C 5.3348 0.7700 0.0 0
M  V30 18 C 2.6673 0.7700 0.0 0
M  V30 19 C 4.0010 0.0000 0.0 0
M  V30 20 C 2.6673 5.3901 0.0 0
M  V30 21 C 1.3337 4.6201 0.0 0
M  V30 22 C 2.6673 6.9302 0.0 0
M  V30 23 C 0.0000 5.3901 0.0 0
M  V30 24 C 1.3337 7.7002 0.0 0
M  V30 25 C 0.0000 6.9302 0.0 0
M  V30 26 C 9.3360 7.7002 0.0 0
M  V30 27 C 10.6697 6.9302 0.0 0
M  V30 28 C 9.3360 9.2402 0.0 0
M  V30 29 C 12.0033 7.7002 0.0 0
M  V30 30 C 10.6697 10.0102 0.0 0
M  V30 31 C 12.0033 9.2402 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 1 20
M  V30 4 1 2 3
M  V30 5 2 2 4
M  V30 6 1 3 5
M  V30 7 1 5 6 CFG=3
M  V30 8 1 5 7
M  V30 9 1 6 26
M  V30 10 1 7 8
M  V30 11 2 7 9
M  V30 12 1 8 10
M  V30 13 1 10 11
M  V30 14 3 11 12
M  V30 15 1 13 29
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 2 28 30
M  V30 32 2 29 31
M  V30 33 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 5)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 117-34-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3026372-62-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3026370-13-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40676289
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dipeptide-derived alkynes as potent and selective irreversible inhibitors
of cysteine cathepsins
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Behring, Lydia; Ruiz-Gomez, Gloria; Trapp, Christian; Morales, Maryann;
Wodtke, Robert; Koeckerling, Martin; Kopka, Klaus; Pisabarro, M. Teresa;
Pietzsch, Jens; Loeser, Reik
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(6), 3818-3851

$RFMT $RIREG SCHEME170 STEP1
$RXN



  2  1
$MOL
5-Methyl-3-isoxazolecarboxylic acid
C5H5NO3
3405-77-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 N 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 O 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C7H14N2O4.C2HF3O2
2760538-77-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 6.7238 0.0 0
M  V30 2 C 8.0022 7.4938 0.0 0 CFG=1
M  V30 3 N 5.3348 7.4938 0.0 0
M  V30 4 O 6.6685 5.1837 0.0 0
M  V30 5 C 9.3360 6.7238 0.0 0
M  V30 6 N 8.0022 9.0338 0.0 0
M  V30 7 C 4.0012 6.7238 0.0 0
M  V30 8 O 10.6697 7.4938 0.0 0
M  V30 9 C 2.6673 7.4938 0.0 0
M  V30 10 C 12.0033 6.7238 0.0 0
M  V30 11 O 1.3337 6.7238 0.0 0
M  V30 12 O 2.6673 9.0338 0.0 0
M  V30 13 C 0.0000 7.4938 0.0 0
M  V30 14 C 5.3348 2.3101 0.0 0
M  V30 15 C 6.6685 1.5400 0.0 0
M  V30 16 F 6.1048 3.6437 0.0 0
M  V30 17 F 4.0012 3.0801 0.0 0
M  V30 18 F 4.5648 0.9764 0.0 0
M  V30 19 O 8.0022 2.3101 0.0 0
M  V30 20 O 6.6685 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=1
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 9 12
M  V30 12 1 11 13
M  V30 13 1 14 15
M  V30 14 1 14 16
M  V30 15 1 14 17
M  V30 16 1 14 18
M  V30 17 1 15 19
M  V30 18 2 15 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C12H17N3O6
2760538-90-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0287 5.3348 0.0 0
M  V30 2 N 5.5687 5.3348 0.0 0
M  V30 3 O 3.2587 4.0011 0.0 0
M  V30 4 C 6.3387 4.0011 0.0 0 CFG=1
M  V30 5 C 7.8788 4.0011 0.0 0
M  V30 6 C 5.5687 2.6673 0.0 0
M  V30 7 N 8.6488 5.3348 0.0 0
M  V30 8 O 8.6488 2.6673 0.0 0
M  V30 9 O 6.3387 1.3337 0.0 0
M  V30 10 C 10.1888 5.3348 0.0 0
M  V30 11 C 5.5687 0.0000 0.0 0
M  V30 12 C 10.9588 6.6684 0.0 0
M  V30 13 O 12.4988 6.6684 0.0 0
M  V30 14 O 10.1888 8.0023 0.0 0
M  V30 15 C 13.2688 8.0023 0.0 0
M  V30 16 C 0.0000 8.9622 0.0 0
M  V30 17 C 3.2587 6.6684 0.0 0
M  V30 18 C 1.7271 6.8295 0.0 0
M  V30 19 N 3.8850 8.0754 0.0 0
M  V30 20 C 1.4070 8.3358 0.0 0
M  V30 21 O 2.7406 9.1058 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 16 20
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3405-77-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-77-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-90-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545339
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME171 STEP1
$RXN



  2  1
$MOL
4-Methoxybenzoic acid
C8H8O3
100-09-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 O 6.6687 4.6201 0.0 0
M  V30 5 C 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 4.0012 1.5400 0.0 0
M  V30 8 C 2.6675 3.8501 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indazol-5-amine
C7H7N3
19335-11-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.3710 3.0800 0.0 0
M  V30 2 C 2.3699 0.7700 0.0 0
M  V30 3 C 2.3699 2.3100 0.0 0
M  V30 4 C 3.7036 0.0000 0.0 0
M  V30 5 N 0.9052 0.2941 0.0 0
M  V30 6 C 3.7036 3.0800 0.0 0
M  V30 7 C 0.9052 2.7859 0.0 0
M  V30 8 C 5.0372 0.7700 0.0 0
M  V30 9 N 0.0000 1.5400 0.0 0
M  V30 10 C 5.0372 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 2 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 2 7 9
M  V30 11 2 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-1H-Indazol-5-yl-4-methoxybenzamide
C15H13N3O2
710329-45-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.3709 2.3100 0.0 0
M  V30 2 C 7.7046 3.0800 0.0 0
M  V30 3 O 7.7046 4.6201 0.0 0
M  V30 4 O 13.0394 0.0000 0.0 0
M  V30 5 C 14.3730 0.7700 0.0 0
M  V30 6 C 2.3698 3.0800 0.0 0
M  V30 7 C 2.3698 4.6201 0.0 0
M  V30 8 C 3.7034 2.3100 0.0 0
M  V30 9 C 0.9052 2.6042 0.0 0
M  V30 10 C 3.7034 5.3901 0.0 0
M  V30 11 N 0.9052 5.0959 0.0 0
M  V30 12 C 5.0373 3.0800 0.0 0
M  V30 13 N 0.0000 3.8501 0.0 0
M  V30 14 C 5.0373 4.6201 0.0 0
M  V30 15 C 9.0382 2.3100 0.0 0
M  V30 16 C 9.0382 0.7700 0.0 0
M  V30 17 C 10.3720 3.0800 0.0 0
M  V30 18 C 10.3720 0.0000 0.0 0
M  V30 19 C 11.7057 2.3100 0.0 0
M  V30 20 C 11.7057 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 2 2 3
M  V30 4 1 2 15
M  V30 5 1 4 5
M  V30 6 1 4 20
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 9
M  V30 10 2 7 10
M  V30 11 1 7 11
M  V30 12 1 8 12
M  V30 13 2 9 13
M  V30 14 1 10 14
M  V30 15 1 11 13
M  V30 16 2 12 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 100-09-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 19335-11-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 710329-45-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36827364
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Bioisosteric replacement based on 1,2,4-oxadiazoles in the discovery of
1H-indazole-bearing neuroprotective MAO B inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rullo, Mariagrazia; La Spada, Gabriella; Miniero, Daniela Valeria;
Gottinger, Andrea; Catto, Marco; Delre, Pietro; Mastromarino, Margherita;
Latronico, Tiziana; Marchese, Sara; Mangiatordi, Giuseppe Felice; Binda,
Claudia; Linusson, Anna; Liuzzi, Grazia Maria; Pisani, Leonardo
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 255115352

$RFMT $RIREG SCHEME172 STEP1
$RXN



  2  1
$MOL
Di-tert-butoxycarbonyl-L-lysine
C16H30N2O6
2483-46-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.9536 2.6674 0.0 0 CFG=2
M  V30 2 N 4.4136 2.6674 0.0 0
M  V30 3 C 6.7236 4.0011 0.0 0
M  V30 4 C 6.7236 1.3336 0.0 0
M  V30 5 C 3.6436 4.0011 0.0 0
M  V30 6 C 8.2636 4.0011 0.0 0
M  V30 7 O 5.9536 0.0000 0.0 0
M  V30 8 O 8.2636 1.3336 0.0 0
M  V30 9 O 2.1036 4.0011 0.0 0
M  V30 10 O 4.4136 5.3347 0.0 0
M  V30 11 C 9.0336 5.3347 0.0 0
M  V30 12 C 1.3336 5.3347 0.0 0
M  V30 13 C 10.5736 5.3347 0.0 0
M  V30 14 C 2.6673 6.1047 0.0 0
M  V30 15 C 0.5636 6.6684 0.0 0
M  V30 16 C 0.0000 4.5647 0.0 0
M  V30 17 N 11.3436 6.6685 0.0 0
M  V30 18 C 12.8836 6.6685 0.0 0
M  V30 19 O 13.6536 8.0021 0.0 0
M  V30 20 O 13.6536 5.3347 0.0 0
M  V30 21 C 15.1936 8.0021 0.0 0
M  V30 22 C 15.1936 9.5421 0.0 0
M  V30 23 C 16.7336 8.0021 0.0 0
M  V30 24 C 15.1936 6.4621 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 9 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 15 1 12 16
M  V30 16 1 13 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 18 20
M  V30 20 1 19 21
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 21 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Octylamine
C8H19N
111-86-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 0.7700 0.0 0
M  V30 2 C 4.0012 0.0000 0.0 0
M  V30 3 C 6.6685 0.0000 0.0 0
M  V30 4 C 2.6673 0.7700 0.0 0
M  V30 5 C 8.0023 0.7700 0.0 0
M  V30 6 C 1.3337 0.0000 0.0 0
M  V30 7 C 9.3360 0.0000 0.0 0
M  V30 8 C 0.0000 0.7700 0.0 0
M  V30 9 N 10.6697 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
C,C-Bis(1,1-dimethylethyl) N,N-[(1S)-1-[(octylamino)carbonyl]-1,5-pentanedi...
C24H47N3O5
1378989-53-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.7800 6.6684 0.0 0 CFG=1
M  V30 2 N 10.0100 5.3347 0.0 0
M  V30 3 C 12.3200 6.6684 0.0 0
M  V30 4 C 10.0100 8.0020 0.0 0
M  V30 5 C 10.7800 4.0011 0.0 0
M  V30 6 N 13.0900 8.0020 0.0 0
M  V30 7 O 13.0900 5.3347 0.0 0
M  V30 8 C 8.4700 8.0020 0.0 0
M  V30 9 O 10.0100 2.6673 0.0 0
M  V30 10 O 12.3200 4.0011 0.0 0
M  V30 11 C 14.6300 8.0020 0.0 0
M  V30 12 C 7.7000 9.3358 0.0 0
M  V30 13 C 10.7800 1.3336 0.0 0
M  V30 14 C 15.4000 9.3358 0.0 0
M  V30 15 C 6.1600 9.3358 0.0 0
M  V30 16 C 12.1136 2.1036 0.0 0
M  V30 17 C 11.5500 0.0000 0.0 0
M  V30 18 C 9.4464 0.5636 0.0 0
M  V30 19 C 16.9400 9.3358 0.0 0
M  V30 20 N 5.3900 10.6694 0.0 0
M  V30 21 C 17.7100 10.6694 0.0 0
M  V30 22 C 3.8500 10.6694 0.0 0
M  V30 23 C 19.2500 10.6694 0.0 0
M  V30 24 O 3.0800 12.0031 0.0 0
M  V30 25 O 3.0800 9.3358 0.0 0
M  V30 26 C 20.0200 12.0031 0.0 0
M  V30 27 C 1.5400 12.0031 0.0 0
M  V30 28 C 21.5600 12.0031 0.0 0
M  V30 29 C 1.5400 10.4631 0.0 0
M  V30 30 C 0.0000 12.0031 0.0 0
M  V30 31 C 1.5400 13.5431 0.0 0
M  V30 32 C 22.3300 13.3367 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 1 12 15
M  V30 15 1 13 16
M  V30 16 1 13 17
M  V30 17 1 13 18
M  V30 18 1 14 19
M  V30 19 1 15 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 22 25
M  V30 25 1 23 26
M  V30 26 1 24 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 29 1 27 30
M  V30 30 1 27 31
M  V30 31 1 28 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2483-46-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 111-86-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1378989-53-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40947705
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM unspecified reagent used for quenching (stage 2)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent
Anti-Influenza Activity through Two Distinct Endonuclease Polymerase
Acidic-Targeted Degradation Pathways
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ma, Xiaoyu; Wang, Xueyun; Chen, Feifei; Zou, Wenting; Ren, Junrui; Xin,
Lilan; He, Pei; Liang, Jinsen; Xu, Zhichao; Dong, Chune; Lan, Ke; Wu,
Shuwen; Zhou, Hai-Bing
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(11), 8791-8816

$RFMT $RIREG SCHEME173 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[(1E)-2-(4-Aminophenyl)ethenyl]-N,N-dimethylbenzenamine
C16H18N2
161810-34-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9302 2.6673 0.0 0
M  V30 2 C 7.7002 1.3337 0.0 0
M  V30 3 N 0.7700 2.6673 0.0 0
M  V30 4 C 0.0000 4.0010 0.0 0
M  V30 5 C 0.0000 1.3337 0.0 0
M  V30 6 N 13.8603 1.3337 0.0 0
M  V30 7 C 5.3901 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 3.0801 1.3337 0.0 0
M  V30 11 C 3.0801 4.0010 0.0 0
M  V30 12 C 2.3101 2.6673 0.0 0
M  V30 13 C 9.2402 1.3337 0.0 0
M  V30 14 C 10.0102 2.6673 0.0 0
M  V30 15 C 10.0102 0.0000 0.0 0
M  V30 16 C 11.5503 2.6673 0.0 0
M  V30 17 C 11.5503 0.0000 0.0 0
M  V30 18 C 12.3203 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 7
M  V30 3 1 2 13
M  V30 4 1 3 4
M  V30 5 1 3 5
M  V30 6 1 3 12
M  V30 7 1 6 18
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C23H29N3O3
3082557-28-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 C 8.0022 3.8501 0.0 0
M  V30 3 N 1.3337 1.5400 0.0 0
M  V30 4 C 0.0000 2.3101 0.0 0
M  V30 5 C 1.3337 0.0000 0.0 0
M  V30 6 N 13.3370 6.9302 0.0 0
M  V30 7 C 14.6708 6.1601 0.0 0
M  V30 8 C 16.0045 6.9302 0.0 0
M  V30 9 O 14.6708 4.6201 0.0 0
M  V30 10 N 17.3382 6.1601 0.0 0
M  V30 11 C 18.6718 6.9302 0.0 0
M  V30 12 O 20.0057 6.1601 0.0 0
M  V30 13 O 18.6718 8.4702 0.0 0
M  V30 14 C 21.3393 6.9302 0.0 0
M  V30 15 C 20.5693 8.2638 0.0 0
M  V30 16 C 22.6730 7.7002 0.0 0
M  V30 17 C 22.1093 5.5965 0.0 0
M  V30 18 C 5.3348 3.8501 0.0 0
M  V30 19 C 4.0012 4.6201 0.0 0
M  V30 20 C 5.3348 2.3101 0.0 0
M  V30 21 C 2.6673 3.8501 0.0 0
M  V30 22 C 4.0012 1.5400 0.0 0
M  V30 23 C 2.6673 2.3101 0.0 0
M  V30 24 C 9.3360 4.6201 0.0 0
M  V30 25 C 9.3360 6.1601 0.0 0
M  V30 26 C 10.6697 3.8501 0.0 0
M  V30 27 C 10.6697 6.9302 0.0 0
M  V30 28 C 12.0033 4.6201 0.0 0
M  V30 29 C 12.0033 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 18
M  V30 3 1 2 24
M  V30 4 1 3 4
M  V30 5 1 3 5
M  V30 6 1 3 23
M  V30 7 1 6 7
M  V30 8 1 6 29
M  V30 9 1 7 8
M  V30 10 2 7 9
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 2 11 13
M  V30 15 1 12 14
M  V30 16 1 14 15
M  V30 17 1 14 16
M  V30 18 1 14 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 25 2 24 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 2 26 28
M  V30 29 2 27 29
M  V30 30 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 161810-34-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3082557-28-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-45117379
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and bioactivity evaluation of a myelin-specific contrast agent
for magnetic resonance imaging of myelination in central nervous system
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wei, Bin; Weng, Na; Fu, Lei; Li, Yuxuan; Wang, Xu; Yin, Ruijuan; Jiang,
Tao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2023), 84117257

$RFMT $RIREG SCHEME174 STEP1
$RXN



  2  1
$MOL
2-Pyrazinecarboxylic acid
C5H4N2O2
98-97-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 N 3.0801 2.6673 0.0 0
M  V30 7 N 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Cysteine, O-methyl-L-seryl-S-methyl-, methyl ester, 2,2,2-trifluoroacetate ...
C9H18N2O4S.C2HF3O2
2387522-87-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 S 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 O 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H20N4O5S
2760538-84-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 3.8500 0.0 0 CFG=2
M  V30 2 C 5.3348 4.6201 0.0 0
M  V30 3 N 8.0021 4.6201 0.0 0
M  V30 4 C 6.6684 2.3100 0.0 0
M  V30 5 N 5.3348 6.1601 0.0 0
M  V30 6 O 4.0010 3.8500 0.0 0
M  V30 7 C 9.3359 3.8500 0.0 0
M  V30 8 O 5.3348 1.5400 0.0 0
M  V30 9 C 4.0010 6.9301 0.0 0 CFG=1
M  V30 10 O 9.3359 2.3100 0.0 0
M  V30 11 C 5.3348 0.0000 0.0 0
M  V30 12 C 4.0010 8.4701 0.0 0
M  V30 13 C 2.6673 6.1601 0.0 0
M  V30 14 O 2.6673 9.2401 0.0 0
M  V30 15 O 5.3348 9.2401 0.0 0
M  V30 16 S 1.3337 6.9301 0.0 0
M  V30 17 C 2.6673 10.7801 0.0 0
M  V30 18 C 0.0000 6.1601 0.0 0
M  V30 19 C 10.6695 4.6201 0.0 0
M  V30 20 C 10.6695 6.1601 0.0 0
M  V30 21 N 12.0032 3.8500 0.0 0
M  V30 22 N 12.0032 6.9301 0.0 0
M  V30 23 C 13.3369 4.6201 0.0 0
M  V30 24 C 13.3369 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 7 10
M  V30 10 1 7 19
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 9 13 CFG=1
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 98-97-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2387522-87-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-84-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545319
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME175 STEP1
$RXN



  2  1
$MOL
o-Phenylenediamine
C6H8N2
95-54-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 2.6673 0.0 0
M  V30 2 N 3.0801 0.0000 0.0 0
M  V30 3 C 3.0801 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 2.3101 4.0010 0.0 0
M  V30 6 C 0.7700 1.3337 0.0 0
M  V30 7 C 0.7700 4.0010 0.0 0
M  V30 8 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 4
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Glyoxylic acid
C2H2O3
298-12-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 2.6673 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 O 0.0000 2.3101 0.0 0
M  V30 5 O 4.0010 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 2 2 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2(1H)-Quinoxalinone
C8H6N2O
1196-57-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.9302 2.6673 0.0 0
M  V30 2 C 3.0801 1.3337 0.0 0
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 N 4.6201 1.3337 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 N 3.0801 4.0010 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 8 C 5.3901 2.6673 0.0 0
M  V30 9 C 0.7700 0.0000 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 8
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 1 8 10
M  V30 12 2 9 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 95-54-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 298-12-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1196-57-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31857598
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A Computer-Driven Scaffold-Hopping Approach Generating New PTP1B
Inhibitors from the Pyrrolo[1,2-a]quinoxaline Core
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Garcia-Marin, Javier; Griera, Mercedes; Alajarin, Ramon; Rodriguez-Puyol,
Manuel; Rodriguez-Puyol, Diego; Vaquero, Juan J.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2021), 16(18), 2895-2906

$RFMT $RIREG SCHEME176 STEP1
$RXN



  2  1
$MOL
4-Fluoroaniline
C6H6FN
371-40-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 0.0000 1.3337 0.0 0
M  V30 2 N 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-[(4-Hydroxyphenyl)amino]benzoic acid
C13H11NO3
98156-55-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 4.0011 0.0 0
M  V30 2 C 1.5400 4.0011 0.0 0
M  V30 3 O 2.3100 5.3349 0.0 0
M  V30 4 O 0.0000 4.0011 0.0 0
M  V30 5 O 10.7800 4.0011 0.0 0
M  V30 6 C 3.8500 2.6674 0.0 0
M  V30 7 C 2.3100 2.6674 0.0 0
M  V30 8 C 4.6200 1.3338 0.0 0
M  V30 9 C 1.5400 1.3338 0.0 0
M  V30 10 C 3.8500 0.0000 0.0 0
M  V30 11 C 2.3100 0.0000 0.0 0
M  V30 12 C 6.1600 4.0011 0.0 0
M  V30 13 C 6.9300 2.6674 0.0 0
M  V30 14 C 6.9300 5.3349 0.0 0
M  V30 15 C 8.4700 2.6674 0.0 0
M  V30 16 C 8.4700 5.3349 0.0 0
M  V30 17 C 9.2400 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 6
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 7
M  V30 6 1 5 17
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 8 10
M  V30 11 2 9 11
M  V30 12 1 10 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzamide, N-(4-fluorophenyl)-2-[(4-hydroxyphenyl)amino]-
C19H15FN2O2
3037065-19-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 4.6201 0.0 0
M  V30 2 C 8.0022 3.0801 0.0 0
M  V30 3 N 9.3358 2.3101 0.0 0
M  V30 4 O 8.0022 4.6201 0.0 0
M  V30 5 O 0.0000 7.7002 0.0 0
M  V30 6 F 14.6707 5.3901 0.0 0
M  V30 7 C 5.3348 3.0801 0.0 0
M  V30 8 C 6.6685 2.3101 0.0 0
M  V30 9 C 4.0010 2.3101 0.0 0
M  V30 10 C 6.6685 0.7700 0.0 0
M  V30 11 C 4.0010 0.7700 0.0 0
M  V30 12 C 5.3348 0.0000 0.0 0
M  V30 13 C 4.0010 5.3901 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 4.0010 6.9302 0.0 0
M  V30 16 C 1.3337 5.3901 0.0 0
M  V30 17 C 2.6673 7.7002 0.0 0
M  V30 18 C 1.3337 6.9302 0.0 0
M  V30 19 C 10.6697 3.0801 0.0 0
M  V30 20 C 10.6697 4.6201 0.0 0
M  V30 21 C 12.0033 2.3101 0.0 0
M  V30 22 C 12.0033 5.3901 0.0 0
M  V30 23 C 13.3370 3.0801 0.0 0
M  V30 24 C 13.3370 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 7
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 8
M  V30 6 1 3 19
M  V30 7 1 5 18
M  V30 8 1 6 24
M  V30 9 2 7 8
M  V30 10 1 7 9
M  V30 11 1 8 10
M  V30 12 2 9 11
M  V30 13 2 10 12
M  V30 14 1 11 12
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 371-40-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 98156-55-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3037065-19-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31703041
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-guided design and development of novel
N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Huang, Daowei; Yang, Jixia; Zhang, Qingwei; Wang, Guan; Zhang, Zixue;
Zhang, Yue; Li, Jianqi
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 223113648

$RFMT $RIREG SCHEME177 STEP1
$RXN



  2  1
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-Benzyloxycarbonyl-D-valine
C13H17NO4
1685-33-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 3.0801 0.0 0 CFG=1
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 C 2.6673 4.6201 0.0 0
M  V30 5 C 5.3348 3.0801 0.0 0
M  V30 6 C 0.0000 3.0801 0.0 0
M  V30 7 C 1.3337 0.7700 0.0 0
M  V30 8 O 1.3337 5.3901 0.0 0
M  V30 9 O 4.0012 5.3901 0.0 0
M  V30 10 O 6.6685 2.3101 0.0 0
M  V30 11 O 5.3348 4.6201 0.0 0
M  V30 12 C 8.0022 3.0801 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 14 C 9.3360 0.7700 0.0 0
M  V30 15 C 10.6697 3.0801 0.0 0
M  V30 16 C 10.6697 0.0000 0.0 0
M  V30 17 C 12.0033 2.3101 0.0 0
M  V30 18 C 12.0033 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 1 5 10
M  V30 10 2 5 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Carbamic acid, [(1R)-2-methyl-1-[(phenylamino)carbonyl]propyl]-, phenylmethyl...
C19H22N2O3
126727-27-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 5.3901 0.0 0 CFG=1
M  V30 2 C 4.0010 4.6201 0.0 0
M  V30 3 N 6.6685 4.6201 0.0 0
M  V30 4 C 5.3348 6.9302 0.0 0
M  V30 5 N 4.0010 3.0801 0.0 0
M  V30 6 O 2.6673 5.3901 0.0 0
M  V30 7 C 8.0022 5.3901 0.0 0
M  V30 8 C 4.0010 7.7002 0.0 0
M  V30 9 C 6.6685 7.7002 0.0 0
M  V30 10 O 9.3358 4.6201 0.0 0
M  V30 11 O 8.0022 6.9302 0.0 0
M  V30 12 C 10.6697 5.3901 0.0 0
M  V30 13 C 2.6673 2.3101 0.0 0
M  V30 14 C 2.6673 0.7700 0.0 0
M  V30 15 C 1.3337 3.0801 0.0 0
M  V30 16 C 1.3337 0.0000 0.0 0
M  V30 17 C 0.0000 2.3101 0.0 0
M  V30 18 C 0.0000 0.7700 0.0 0
M  V30 19 C 12.0033 4.6201 0.0 0
M  V30 20 C 12.0033 3.0801 0.0 0
M  V30 21 C 13.3370 5.3901 0.0 0
M  V30 22 C 13.3370 2.3101 0.0 0
M  V30 23 C 14.6707 4.6201 0.0 0
M  V30 24 C 14.6707 3.0801 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 4 9
M  V30 9 1 5 13
M  V30 10 1 7 10
M  V30 11 2 7 11
M  V30 12 1 10 12
M  V30 13 1 12 19
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1685-33-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 126727-27-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-29435453
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 2135447-74-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM sealed flask used, Multi-gram scale
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Insights into Fast Amide Couplings in Aqueous Nanomicelles
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sharma, Sudripet; Kaur, Gaganpreet; Handa, Sachin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(8), 1960-1965

$RFMT $RIREG SCHEME178 STEP1
$RXN



  2  1
$MOL
2-[(4-Fluorophenyl)amino]benzoic acid
C13H10FNO2
54-60-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 4.0011 0.0 0
M  V30 2 C 1.5400 4.0011 0.0 0
M  V30 3 O 2.3100 5.3349 0.0 0
M  V30 4 O 0.0000 4.0011 0.0 0
M  V30 5 F 10.7800 4.0011 0.0 0
M  V30 6 C 3.8500 2.6674 0.0 0
M  V30 7 C 2.3100 2.6674 0.0 0
M  V30 8 C 4.6200 1.3338 0.0 0
M  V30 9 C 1.5400 1.3338 0.0 0
M  V30 10 C 3.8500 0.0000 0.0 0
M  V30 11 C 2.3100 0.0000 0.0 0
M  V30 12 C 6.1600 4.0011 0.0 0
M  V30 13 C 6.9300 2.6674 0.0 0
M  V30 14 C 6.9300 5.3349 0.0 0
M  V30 15 C 8.4700 2.6674 0.0 0
M  V30 16 C 8.4700 5.3349 0.0 0
M  V30 17 C 9.2400 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 6
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 7
M  V30 6 1 5 17
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 8 10
M  V30 11 2 9 11
M  V30 12 1 10 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Aminophenol
C6H7NO
123-30-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 1.3337 0.0 0
M  V30 2 O 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-[(4-Fluorophenyl)amino]-N-(4-hydroxyphenyl)benzamide
C19H15FN2O2
1207981-11-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 4.6201 0.0 0
M  V30 2 C 8.0022 3.0801 0.0 0
M  V30 3 N 9.3358 2.3101 0.0 0
M  V30 4 O 8.0022 4.6201 0.0 0
M  V30 5 F 0.0000 7.7002 0.0 0
M  V30 6 O 14.6707 5.3901 0.0 0
M  V30 7 C 5.3348 3.0801 0.0 0
M  V30 8 C 6.6685 2.3101 0.0 0
M  V30 9 C 4.0010 2.3101 0.0 0
M  V30 10 C 6.6685 0.7700 0.0 0
M  V30 11 C 4.0010 0.7700 0.0 0
M  V30 12 C 5.3348 0.0000 0.0 0
M  V30 13 C 4.0010 5.3901 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 4.0010 6.9302 0.0 0
M  V30 16 C 1.3337 5.3901 0.0 0
M  V30 17 C 2.6673 7.7002 0.0 0
M  V30 18 C 1.3337 6.9302 0.0 0
M  V30 19 C 10.6697 3.0801 0.0 0
M  V30 20 C 10.6697 4.6201 0.0 0
M  V30 21 C 12.0033 2.3101 0.0 0
M  V30 22 C 12.0033 5.3901 0.0 0
M  V30 23 C 13.3370 3.0801 0.0 0
M  V30 24 C 13.3370 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 7
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 8
M  V30 6 1 3 19
M  V30 7 1 5 18
M  V30 8 1 6 24
M  V30 9 2 7 8
M  V30 10 1 7 9
M  V30 11 1 8 10
M  V30 12 2 9 11
M  V30 13 2 10 12
M  V30 14 1 11 12
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 54-60-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 123-30-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1207981-11-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31703026
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-guided design and development of novel
N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Huang, Daowei; Yang, Jixia; Zhang, Qingwei; Wang, Guan; Zhang, Zixue;
Zhang, Yue; Li, Jianqi
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 223113648

$RFMT $RIREG SCHEME179 STEP1
$RXN



  2  1
$MOL
Anthranilamide
C7H8N2O
88-68-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 N 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 3.0801 4.0010 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Methylpicolinic acid
C7H7NO2
934-60-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 C 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 N 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(Aminocarbonyl)phenyl]-6-methyl-2-pyridinecarboxamide
C14H13N3O2
733806-23-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 4.0011 0.0 0
M  V30 2 C 6.1600 4.0011 0.0 0
M  V30 3 O 6.9300 2.6674 0.0 0
M  V30 4 C 1.5400 4.0011 0.0 0
M  V30 5 N 2.3100 5.3347 0.0 0
M  V30 6 O 0.0000 4.0011 0.0 0
M  V30 7 C 10.7800 6.6685 0.0 0
M  V30 8 C 3.8500 2.6674 0.0 0
M  V30 9 C 2.3100 2.6674 0.0 0
M  V30 10 C 4.6200 1.3336 0.0 0
M  V30 11 C 1.5400 1.3336 0.0 0
M  V30 12 C 3.8500 0.0000 0.0 0
M  V30 13 C 2.3100 0.0000 0.0 0
M  V30 14 C 6.9300 5.3347 0.0 0
M  V30 15 N 8.4700 5.3347 0.0 0
M  V30 16 C 6.1600 6.6685 0.0 0
M  V30 17 C 9.2400 6.6685 0.0 0
M  V30 18 C 6.9300 8.0021 0.0 0
M  V30 19 C 8.4700 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 2 2 3
M  V30 4 1 2 14
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 9
M  V30 8 1 7 17
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 88-68-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 934-60-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 733806-23-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38047630
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dual inhibition of Mycobacterium tuberculosis and the host TGFBR1 by an
anilinoquinazoline
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Nandakumar, Meganathan; Ollodart, Anja; Fleck, Neil; Kapadia, Nirav R.;
Frando, Andrew; Boradia, Vishant; Smith, Jeffery L.; Chen, Junxi;
Zuercher, William J.; Willson, Timothy M.; Grundner, Christoph
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(21), 14724-14734

$RFMT $RIREG SCHEME180 STEP1
$RXN



  2  1
$MOL
[1,1-Biphenyl]-3-carboxylic acid
C13H10O2
716-76-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0022 3.0800 0.0 0
M  V30 2 O 9.3359 2.3100 0.0 0
M  V30 3 O 8.0022 4.6201 0.0 0
M  V30 4 C 4.0011 2.3100 0.0 0
M  V30 5 C 5.3348 3.0800 0.0 0
M  V30 6 C 4.0011 0.7700 0.0 0
M  V30 7 C 6.6684 2.3100 0.0 0
M  V30 8 C 5.3348 0.0000 0.0 0
M  V30 9 C 6.6684 0.7700 0.0 0
M  V30 10 C 2.6675 3.0800 0.0 0
M  V30 11 C 1.3337 2.3100 0.0 0
M  V30 12 C 2.6675 4.6201 0.0 0
M  V30 13 C 0.0000 3.0800 0.0 0
M  V30 14 C 1.3337 5.3901 0.0 0
M  V30 15 C 0.0000 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 4 10
M  V30 7 1 5 7
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 8 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-5-methylisoxazole
C4H6N2O
1072-67-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 2.6218 0.0 0
M  V30 2 C 5.3026 1.4946 0.0 0
M  V30 3 C 2.7406 2.4782 0.0 0
M  V30 4 C 1.3337 1.8517 0.0 0
M  V30 5 C 3.7711 1.3337 0.0 0
M  V30 6 N 1.4946 0.3202 0.0 0
M  V30 7 O 3.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 2 4 6
M  V30 6 1 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(5-Methyl-3-isoxazolyl)[1,1-biphenyl]-3-carboxamide
C17H14N2O2
2648596-72-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0023 3.0801 0.0 0
M  V30 2 N 9.3360 2.3101 0.0 0
M  V30 3 O 8.0023 4.6201 0.0 0
M  V30 4 C 14.6386 3.4372 0.0 0
M  V30 5 C 4.0012 2.3101 0.0 0
M  V30 6 C 5.3348 3.0801 0.0 0
M  V30 7 C 4.0012 0.7700 0.0 0
M  V30 8 C 6.6685 2.3101 0.0 0
M  V30 9 C 5.3348 0.0000 0.0 0
M  V30 10 C 6.6685 0.7700 0.0 0
M  V30 11 C 2.6673 3.0801 0.0 0
M  V30 12 C 2.6673 4.6201 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 1.3337 5.3901 0.0 0
M  V30 15 C 0.0000 3.0801 0.0 0
M  V30 16 C 0.0000 4.6201 0.0 0
M  V30 17 C 10.6697 3.0801 0.0 0
M  V30 18 N 10.8306 4.6116 0.0 0
M  V30 19 C 12.0765 2.4537 0.0 0
M  V30 20 O 12.3371 4.9318 0.0 0
M  V30 21 C 13.1071 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 17
M  V30 5 1 4 21
M  V30 6 2 5 6
M  V30 7 1 5 7
M  V30 8 1 5 11
M  V30 9 1 6 8
M  V30 10 2 7 9
M  V30 11 2 8 10
M  V30 12 1 9 10
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 716-76-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1072-67-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2648596-72-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35231135
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Identification and Optimization of Novel Small-Molecule Cas9 Inhibitors
by Cell-Based High-Throughput Screening
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Lee, Sang-Woo; Tran, Kim Tai; Vazquez-Uribe, Ruben; Gotfredsen, Charlotte
Held; Clausen, Mads Hartvig; Mendez, Blanca Lopez; Montoya, Guillermo;
Bach, Anders; Sommer, Morten Otto Alexander
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(4), 3266-3305

$RFMT $RIREG SCHEME181 STEP1
$RXN



  2  1
$MOL
6-Bromopicolinic acid
C6H4BrNO2
21190-87-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 Br 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 N 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)-1,4-butanediamine
C9H20N2O2
68076-36-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 O 2.6673 2.3101 0.0 0
M  V30 4 O 4.0012 0.0000 0.0 0
M  V30 5 C 6.6685 1.5400 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 C 8.0022 2.3101 0.0 0
M  V30 8 C 2.1037 0.2064 0.0 0
M  V30 9 C 0.0000 0.7700 0.0 0
M  V30 10 C 0.5637 2.8737 0.0 0
M  V30 11 C 9.3360 1.5400 0.0 0
M  V30 12 C 10.6697 2.3101 0.0 0
M  V30 13 N 12.0033 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C15H22BrN3O3
2967959-89-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 6.6687 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 8.0023 1.5400 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 C 12.0035 2.3101 0.0 0
M  V30 8 N 13.3372 1.5400 0.0 0
M  V30 9 C 14.6708 2.3101 0.0 0
M  V30 10 O 16.0045 1.5400 0.0 0
M  V30 11 O 14.6708 3.8501 0.0 0
M  V30 12 C 17.3383 2.3101 0.0 0
M  V30 13 C 16.5683 3.6437 0.0 0
M  V30 14 C 18.6720 3.0801 0.0 0
M  V30 15 C 18.1083 0.9764 0.0 0
M  V30 16 Br 0.0000 1.5400 0.0 0
M  V30 17 C 4.0012 2.3101 0.0 0
M  V30 18 N 2.6675 1.5400 0.0 0
M  V30 19 C 4.0012 3.8501 0.0 0
M  V30 20 C 1.3337 2.3101 0.0 0
M  V30 21 C 2.6675 4.6201 0.0 0
M  V30 22 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 1 16 20
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 21190-87-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 68076-36-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2967959-89-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40188682
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 4672-38-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of AZD8154, a Dual PI3K Inhibitor for the Treatment of Asthma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Perry, Matthew W. D.; Bjoerhall, Karin; Bold, Peter; Brulls, Mikael;
Boerjesson, Ulf; Carlsson, Johan; Chang, Hui-Fang Amy; Chen, Yunhua;
Eriksson, Anders; Fihn, Britt-Marie; Fransson, Rebecca; Fredlund, Linda;
Ge, Hongbin; Huang, Haijuan; Karabelas, Kostas; Lamm Bergstroem, Eva;
Lever, Sarah; Lindmark, Helena; Mogemark, Mickael; Nikitidis, Antonios;
Palmgren, Anna-Pia; Pemberton, Nils; Petersen, Jens; Rodrigo Blomqvist,
Mio; Smith, Reed W.; Thomas, Matthew J.; Ullah, Victoria; Tyrchan,
Christian; Wennberg, Tiiu; Westin Eriksson, Annika; Yang, Wenzhen; Zhao,
Shuchun; Oester, Linda
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(12), 8053-8075

$RFMT $RIREG SCHEME182 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) 4-(4-carboxyphenyl)-1-piperazinecarboxylate
C16H22N2O4
162046-66-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.5503 2.8737 0.0 0
M  V30 2 O 12.3203 1.5400 0.0 0
M  V30 3 O 12.3203 4.2074 0.0 0
M  V30 4 C 13.8603 1.5400 0.0 0
M  V30 5 C 13.8603 3.0801 0.0 0
M  V30 6 C 15.4003 1.5400 0.0 0
M  V30 7 C 13.8603 0.0000 0.0 0
M  V30 8 C 0.7700 2.8737 0.0 0
M  V30 9 O 0.0000 1.5400 0.0 0
M  V30 10 O 0.0000 4.2074 0.0 0
M  V30 11 N 6.9302 2.8737 0.0 0
M  V30 12 C 7.7002 4.2074 0.0 0
M  V30 13 C 7.7002 1.5400 0.0 0
M  V30 14 C 9.2402 4.2074 0.0 0
M  V30 15 C 9.2402 1.5400 0.0 0
M  V30 16 N 10.0102 2.8737 0.0 0
M  V30 17 C 5.3901 2.8737 0.0 0
M  V30 18 C 4.6201 1.5400 0.0 0
M  V30 19 C 4.6201 4.2074 0.0 0
M  V30 20 C 3.0801 1.5400 0.0 0
M  V30 21 C 3.0801 4.2074 0.0 0
M  V30 22 C 2.3101 2.8737 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 22
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 11 17
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 4-[4-[(methylamino)carbonyl]phenyl]-1-piperazinecarboxylate
C17H25N3O3
1797985-94-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8737 0.0 0
M  V30 2 O 3.0800 1.5400 0.0 0
M  V30 3 O 3.0800 4.2073 0.0 0
M  V30 4 C 1.5400 1.5400 0.0 0
M  V30 5 C 1.5400 3.0800 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 1.5400 0.0000 0.0 0
M  V30 8 C 14.6302 2.8737 0.0 0
M  V30 9 N 15.4002 4.2073 0.0 0
M  V30 10 O 15.4002 1.5400 0.0 0
M  V30 11 C 16.9402 4.2073 0.0 0
M  V30 12 N 8.4701 2.8737 0.0 0
M  V30 13 C 7.7001 4.2073 0.0 0
M  V30 14 C 7.7001 1.5400 0.0 0
M  V30 15 C 6.1601 4.2073 0.0 0
M  V30 16 C 6.1601 1.5400 0.0 0
M  V30 17 N 5.3901 2.8737 0.0 0
M  V30 18 C 10.0101 2.8737 0.0 0
M  V30 19 C 10.7801 4.2073 0.0 0
M  V30 20 C 10.7801 1.5400 0.0 0
M  V30 21 C 12.3201 4.2073 0.0 0
M  V30 22 C 12.3201 1.5400 0.0 0
M  V30 23 C 13.0901 2.8737 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 23
M  V30 11 1 9 11
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 18
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 162046-66-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1797985-94-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38700934
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of
(2S)-N-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide
as a Highly Potent and Selective Topical Androgen Receptor Antagonist for
Androgenetic Alopecia Treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wenqiang; Zhao, Siqi; Luo, Yi; Zhang, Yan; Feng, Yunrui; Tang,
Feng; Zhou, Xiaoyu; Peng, Shaoping; Fan, Yawen; Xie, Shaofei; Li,
Hongmei; Lai, Qianlong; Fu, Lingsheng; Pei, Sheng; Chen, Zhuolin; Lu,
Tao; Tang, Renhong; Chen, Yadong; Jiao, Yu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(1), 322-348

$RFMT $RIREG SCHEME183 STEP1
$RXN



  2  1
$MOL
1-Methyl-5-nitro-1H-indazole-3-carboxylic acid
C9H7N3O4
1363382-25-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5064 5.4210 0.0 0
M  V30 2 O 2.5369 6.5654 0.0 0
M  V30 3 O 0.0000 5.7411 0.0 0
M  V30 4 C 1.5064 0.0000 0.0 0
M  V30 5 N 7.4479 4.2504 0.0 0 VAL=5
M  V30 6 O 8.7817 3.4804 0.0 0
M  V30 7 O 7.4479 5.7904 0.0 0
M  V30 8 C 3.4470 3.4804 0.0 0
M  V30 9 C 3.4470 1.9404 0.0 0
M  V30 10 C 1.9823 3.9563 0.0 0
M  V30 11 C 4.7806 4.2504 0.0 0
M  V30 12 N 1.9823 1.4645 0.0 0
M  V30 13 C 4.7806 1.1704 0.0 0
M  V30 14 N 1.0771 2.7104 0.0 0
M  V30 15 C 6.1143 3.4804 0.0 0
M  V30 16 C 6.1143 1.9404 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 4 12
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 15
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 8 11
M  V30 11 1 9 12
M  V30 12 2 9 13
M  V30 13 2 10 14
M  V30 14 1 11 15
M  V30 15 1 12 14
M  V30 16 1 13 16
M  V30 17 2 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indazole-3-carboxamide, N,1-dimethyl-5-nitro-
C10H10N4O3
3050907-75-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.2708 4.6948 0.0 0
M  V30 2 N 8.7355 4.2189 0.0 0
M  V30 3 O 6.9506 6.2013 0.0 0
M  V30 4 C 9.8799 5.2495 0.0 0
M  V30 5 C 4.5603 0.0000 0.0 0
M  V30 6 N 1.5400 6.6520 0.0 0 VAL=5
M  V30 7 O 0.0000 6.6520 0.0 0
M  V30 8 O 2.3101 7.9857 0.0 0
M  V30 9 C 4.6201 3.9845 0.0 0
M  V30 10 C 3.8501 2.6509 0.0 0
M  V30 11 C 6.1264 3.6644 0.0 0
M  V30 12 C 3.8501 5.3182 0.0 0
M  V30 13 N 4.8805 1.5065 0.0 0
M  V30 14 C 2.3101 2.6509 0.0 0
M  V30 15 N 6.2873 2.1328 0.0 0
M  V30 16 C 2.3101 5.3182 0.0 0
M  V30 17 C 1.5400 3.9845 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 5 13
M  V30 6 2 6 7
M  V30 7 2 6 8
M  V30 8 1 6 16
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 9 12
M  V30 12 1 10 13
M  V30 13 2 10 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 13 15
M  V30 17 1 14 17
M  V30 18 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1363382-25-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3050907-75-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41431404
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of a series of potent, selective and orally bioavailable SYK
inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Grimster, Neil P.; Gingipalli, Lakshmaiah; Barlaam, Bernard; Su, Qibin;
Zheng, XiaoLan; Watson, David; Wang, Haixia; Simpson, Iain; Pike, Andy;
Balazs, Amber; Boiko, Scott; Ikeda, Timothy P.; Impastato, Anna C.;
Jones, Natalie H.; Kawatkar, Sameer; Kemmitt, Paul; Lamont, Scott; Patel,
Joe; Read, Jon; Sarkar, Ujjal; Sha, Li; Tomlinson, Ronald C.; Wang,
Haiyun; Wilson, David M.; Zehnder, Troy E.; Wang, Lianghe; Wang, Peng;
Goldberg, Frederick W.; Shao, Wenlin; Fawell, Stephen; Dry, Hannah;
Dowling, James E.; Edmondson, Scott D.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(19), 127433

$RFMT $RIREG SCHEME184 STEP1
$RXN



  2  1
$MOL
Diphenylacetic acid
C14H12O2
117-34-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 2.3100 0.0 0
M  V30 2 C 4.0011 0.7700 0.0 0
M  V30 3 O 2.6674 0.0000 0.0 0
M  V30 4 O 5.3347 0.0000 0.0 0
M  V30 5 C 2.6674 3.0800 0.0 0
M  V30 6 C 1.3336 2.3100 0.0 0
M  V30 7 C 2.6674 4.6200 0.0 0
M  V30 8 C 0.0000 3.0800 0.0 0
M  V30 9 C 1.3336 5.3900 0.0 0
M  V30 10 C 0.0000 4.6200 0.0 0
M  V30 11 C 5.3347 3.0800 0.0 0
M  V30 12 C 5.3347 4.6200 0.0 0
M  V30 13 C 6.6685 2.3100 0.0 0
M  V30 14 C 6.6685 5.3900 0.0 0
M  V30 15 C 8.0021 3.0800 0.0 0
M  V30 16 C 8.0021 4.6200 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 1 11
M  V30 4 1 2 3
M  V30 5 2 2 4
M  V30 6 2 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenepropanamide, -amino-N-(cyanomethyl)-3-methyl-, (S)-, 2,2,2-trifluoro...
C12H15N3O.C2HF3O2
3026372-58-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 6.7238 0.0 0
M  V30 2 C 6.6685 7.4938 0.0 0 CFG=2
M  V30 3 C 8.0022 6.7238 0.0 0
M  V30 4 N 6.6685 9.0338 0.0 0
M  V30 5 N 9.3360 7.4938 0.0 0
M  V30 6 O 8.0022 5.1837 0.0 0
M  V30 7 C 10.6697 6.7238 0.0 0
M  V30 8 C 12.0033 7.4938 0.0 0
M  V30 9 N 13.3370 8.2638 0.0 0
M  V30 10 C 0.0000 6.7238 0.0 0
M  V30 11 C 4.0010 7.4938 0.0 0
M  V30 12 C 2.6673 6.7238 0.0 0
M  V30 13 C 4.0010 9.0338 0.0 0
M  V30 14 C 1.3337 7.4938 0.0 0
M  V30 15 C 2.6673 9.8038 0.0 0
M  V30 16 C 1.3337 9.0338 0.0 0
M  V30 17 C 6.0017 2.3101 0.0 0
M  V30 18 C 7.3353 1.5400 0.0 0
M  V30 19 F 6.7717 3.6437 0.0 0
M  V30 20 F 4.6680 3.0801 0.0 0
M  V30 21 F 5.2316 0.9764 0.0 0
M  V30 22 O 8.6690 2.3101 0.0 0
M  V30 23 O 7.3353 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 3 8 9
M  V30 10 1 10 14
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 17 20
M  V30 20 1 17 21
M  V30 21 1 18 22
M  V30 22 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(S)-N-(Cyanomethyl)--[(2,2-diphenylacetyl)amino]-3-methylbenzenepropanamide
C26H25N3O2
225120-29-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 4.6201 0.0 0
M  V30 2 C 5.3348 5.3901 0.0 0
M  V30 3 N 5.3348 6.9302 0.0 0
M  V30 4 O 6.6685 4.6201 0.0 0
M  V30 5 C 6.6685 7.7002 0.0 0 CFG=2
M  V30 6 C 8.0022 6.9302 0.0 0
M  V30 7 C 6.6685 9.2402 0.0 0
M  V30 8 N 5.3348 10.0102 0.0 0
M  V30 9 O 8.0022 10.0102 0.0 0
M  V30 10 C 5.3348 11.5503 0.0 0
M  V30 11 C 4.0010 12.3203 0.0 0
M  V30 12 N 2.6673 13.0903 0.0 0
M  V30 13 C 13.3370 6.9302 0.0 0
M  V30 14 C 4.0010 3.0801 0.0 0
M  V30 15 C 5.3348 2.3101 0.0 0
M  V30 16 C 2.6673 2.3101 0.0 0
M  V30 17 C 5.3348 0.7700 0.0 0
M  V30 18 C 2.6673 0.7700 0.0 0
M  V30 19 C 4.0010 0.0000 0.0 0
M  V30 20 C 2.6673 5.3901 0.0 0
M  V30 21 C 1.3337 4.6201 0.0 0
M  V30 22 C 2.6673 6.9302 0.0 0
M  V30 23 C 0.0000 5.3901 0.0 0
M  V30 24 C 1.3337 7.7002 0.0 0
M  V30 25 C 0.0000 6.9302 0.0 0
M  V30 26 C 9.3360 7.7002 0.0 0
M  V30 27 C 10.6697 6.9302 0.0 0
M  V30 28 C 9.3360 9.2402 0.0 0
M  V30 29 C 12.0033 7.7002 0.0 0
M  V30 30 C 10.6697 10.0102 0.0 0
M  V30 31 C 12.0033 9.2402 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 1 20
M  V30 4 1 2 3
M  V30 5 2 2 4
M  V30 6 1 3 5
M  V30 7 1 5 6 CFG=3
M  V30 8 1 5 7
M  V30 9 1 6 26
M  V30 10 1 7 8
M  V30 11 2 7 9
M  V30 12 1 8 10
M  V30 13 1 10 11
M  V30 14 3 11 12
M  V30 15 1 13 29
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 2 28 30
M  V30 32 2 29 31
M  V30 33 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 5)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 117-34-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3026372-58-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 225120-29-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40676279
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dipeptide-derived alkynes as potent and selective irreversible inhibitors
of cysteine cathepsins
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Behring, Lydia; Ruiz-Gomez, Gloria; Trapp, Christian; Morales, Maryann;
Wodtke, Robert; Koeckerling, Martin; Kopka, Klaus; Pisabarro, M. Teresa;
Pietzsch, Jens; Loeser, Reik
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(6), 3818-3851

$RFMT $RIREG SCHEME185 STEP1
$RXN



  2  1
$MOL
Ketoprofen
C16H14O3
22071-15-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 O 4.0012 0.0000 0.0 0
M  V30 3 C 9.3360 1.5400 0.0 0
M  V30 4 C 10.6697 2.3101 0.0 0
M  V30 5 C 9.3360 0.0000 0.0 0
M  V30 6 O 10.6697 3.8501 0.0 0
M  V30 7 O 12.0033 1.5400 0.0 0
M  V30 8 C 5.3348 2.3101 0.0 0
M  V30 9 C 6.6685 1.5400 0.0 0
M  V30 10 C 5.3348 3.8501 0.0 0
M  V30 11 C 8.0022 2.3101 0.0 0
M  V30 12 C 6.6685 4.6201 0.0 0
M  V30 13 C 8.0022 3.8501 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 1.3337 1.5400 0.0 0
M  V30 16 C 2.6673 3.8501 0.0 0
M  V30 17 C 0.0000 2.3101 0.0 0
M  V30 18 C 1.3337 4.6201 0.0 0
M  V30 19 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 8
M  V30 3 1 1 14
M  V30 4 1 3 4
M  V30 5 1 3 5
M  V30 6 1 3 11
M  V30 7 1 4 6
M  V30 8 2 4 7
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1,N1-Didodecyl-N2-methyl-1,2-ethanediamine
C27H59N2.I
2128731-38-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 13.8600 5.3900 0.0 0 CHG=1 VAL=4
M  V30 2 C 12.3200 5.3900 0.0 0
M  V30 3 C 15.4000 5.3900 0.0 0
M  V30 4 C 13.8600 3.8500 0.0 0
M  V30 5 C 13.8600 6.9300 0.0 0
M  V30 6 C 11.5500 6.7236 0.0 0
M  V30 7 C 16.1700 6.7236 0.0 0
M  V30 8 C 12.5264 3.0800 0.0 0
M  V30 9 C 10.0100 6.7236 0.0 0
M  V30 10 C 17.7100 6.7236 0.0 0
M  V30 11 N 12.5264 1.5400 0.0 0
M  V30 12 C 9.2400 8.0574 0.0 0
M  V30 13 C 18.4800 8.0574 0.0 0
M  V30 14 C 7.7000 8.0574 0.0 0
M  V30 15 C 20.0200 8.0574 0.0 0
M  V30 16 C 6.9300 9.3911 0.0 0
M  V30 17 C 20.7900 9.3911 0.0 0
M  V30 18 C 5.3900 9.3911 0.0 0
M  V30 19 C 22.3300 9.3911 0.0 0
M  V30 20 C 4.6200 10.7247 0.0 0
M  V30 21 C 23.1000 10.7247 0.0 0
M  V30 22 C 3.0800 10.7247 0.0 0
M  V30 23 C 24.6400 10.7247 0.0 0
M  V30 24 C 2.3100 12.0585 0.0 0
M  V30 25 C 25.4100 12.0585 0.0 0
M  V30 26 C 0.7700 12.0585 0.0 0
M  V30 27 C 26.9500 12.0585 0.0 0
M  V30 28 C 0.0000 13.3921 0.0 0
M  V30 29 C 27.7200 13.3921 0.0 0
M  V30 30 I 13.8600 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 10 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Dodecanaminium, N-[2-[[2-(3-benzoylphenyl)-1-oxopropyl]amino]ethyl]-N-dodec...
C43H71N2O2.I
3055833-28-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  48 48 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 24.2130 0.0 0
M  V30 2 O 5.3901 25.5467 0.0 0
M  V30 3 C 9.2402 21.5457 0.0 0
M  V30 4 C 10.0102 20.2118 0.0 0
M  V30 5 C 10.0102 22.8793 0.0 0
M  V30 6 N 11.5503 20.2118 0.0 0
M  V30 7 O 9.2402 18.8782 0.0 0
M  V30 8 C 12.3203 18.8782 0.0 0
M  V30 9 C 13.8603 18.8782 0.0 0
M  V30 10 N 14.6303 17.5445 0.0 0 CHG=1 VAL=4
M  V30 11 C 15.4003 16.2108 0.0 0
M  V30 12 C 15.9641 18.3145 0.0 0
M  V30 13 C 13.2967 16.7745 0.0 0
M  V30 14 C 14.6303 14.8770 0.0 0
M  V30 15 C 17.2978 17.5445 0.0 0
M  V30 16 C 15.4003 13.5433 0.0 0
M  V30 17 C 18.6315 18.3145 0.0 0
M  V30 18 C 14.6303 12.2097 0.0 0
M  V30 19 C 19.9652 17.5445 0.0 0
M  V30 20 C 15.4003 10.8758 0.0 0
M  V30 21 C 21.2990 18.3145 0.0 0
M  V30 22 C 14.6303 9.5422 0.0 0
M  V30 23 C 22.6326 17.5445 0.0 0
M  V30 24 C 15.4003 8.2085 0.0 0
M  V30 25 C 23.9663 18.3145 0.0 0
M  V30 26 C 14.6303 6.8748 0.0 0
M  V30 27 C 25.3001 17.5445 0.0 0
M  V30 28 C 15.4003 5.5410 0.0 0
M  V30 29 C 26.6338 18.3145 0.0 0
M  V30 30 C 14.6303 4.2073 0.0 0
M  V30 31 C 27.9675 17.5445 0.0 0
M  V30 32 C 15.4003 2.8737 0.0 0
M  V30 33 C 29.3011 18.3145 0.0 0
M  V30 34 C 14.6303 1.5400 0.0 0
M  V30 35 C 30.6350 17.5445 0.0 0
M  V30 36 C 5.3901 22.8793 0.0 0
M  V30 37 C 6.9302 22.8793 0.0 0
M  V30 38 C 4.6201 21.5457 0.0 0
M  V30 39 C 7.7002 21.5457 0.0 0
M  V30 40 C 5.3901 20.2118 0.0 0
M  V30 41 C 6.9302 20.2118 0.0 0
M  V30 42 C 3.0801 24.2130 0.0 0
M  V30 43 C 2.3101 22.8793 0.0 0
M  V30 44 C 2.3101 25.5467 0.0 0
M  V30 45 C 0.7700 22.8793 0.0 0
M  V30 46 C 0.7700 25.5467 0.0 0
M  V30 47 C 0.0000 24.2130 0.0 0
M  V30 48 I 15.3175 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 36
M  V30 3 1 1 42
M  V30 4 1 3 4
M  V30 5 1 3 5
M  V30 6 1 3 39
M  V30 7 1 4 6
M  V30 8 2 4 7
M  V30 9 1 6 8
M  V30 10 1 8 9
M  V30 11 1 9 10
M  V30 12 1 10 11
M  V30 13 1 10 12
M  V30 14 1 10 13
M  V30 15 1 11 14
M  V30 16 1 12 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 1 28 30
M  V30 32 1 29 31
M  V30 33 1 30 32
M  V30 34 1 31 33
M  V30 35 1 32 34
M  V30 36 1 33 35
M  V30 37 2 36 37
M  V30 38 1 36 38
M  V30 39 1 37 39
M  V30 40 2 38 40
M  V30 41 2 39 41
M  V30 42 1 40 41
M  V30 43 2 42 43
M  V30 44 1 42 44
M  V30 45 1 43 45
M  V30 46 2 44 46
M  V30 47 2 45 47
M  V30 48 1 46 47
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 22071-15-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2128731-38-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3055833-28-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37275697
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM inert in stage 2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and Characterization of a New Cationic Lipid: Efficient siRNA
Delivery and Anticancer Activity of Survivin-siRNA Lipoplexes for the
Treatment of Lung and Breast Cancers
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Vaidya, Sandeep; Mohod, Annie; Eedara, Abhisheik Chowdary; Andugulapati,
Sai Balaji; Pabbaraja, Srihari
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(16), e202300097

$RFMT $RIREG SCHEME186 STEP1
$RXN



  2  1
$MOL
Benzoic acid, 3-bromo-4-(2,6-dimethylphenoxy)-
C15H13BrO3
2138863-08-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.0011 4.6200 0.0 0
M  V30 2 Br 6.6684 6.1600 0.0 0
M  V30 3 C 1.3336 6.1600 0.0 0
M  V30 4 C 4.0011 1.5400 0.0 0
M  V30 5 C 9.3358 1.5400 0.0 0
M  V30 6 O 10.6694 2.3100 0.0 0
M  V30 7 O 9.3358 0.0000 0.0 0
M  V30 8 C 5.3347 3.8500 0.0 0
M  V30 9 C 6.6684 4.6200 0.0 0
M  V30 10 C 5.3347 2.3100 0.0 0
M  V30 11 C 8.0021 3.8500 0.0 0
M  V30 12 C 6.6684 1.5400 0.0 0
M  V30 13 C 8.0021 2.3100 0.0 0
M  V30 14 C 2.6673 3.8500 0.0 0
M  V30 15 C 1.3336 4.6200 0.0 0
M  V30 16 C 2.6673 2.3100 0.0 0
M  V30 17 C 0.0000 3.8500 0.0 0
M  V30 18 C 1.3336 1.5400 0.0 0
M  V30 19 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 1 14
M  V30 3 1 2 9
M  V30 4 1 3 15
M  V30 5 1 4 16
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 13
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethylamine hydrochloride
C2H7N.ClH
557-66-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 0.0000 2.3100 0.0 0
M  V30 3 N 2.6673 2.3100 0.0 0
M  V30 4 Cl 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Bromo-4-(2,6-dimethylphenoxy)-N-ethylbenzamide
C17H18BrNO2
2702965-85-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.0010 1.5400 0.0 0
M  V30 2 Br 6.6685 0.0000 0.0 0
M  V30 3 C 1.3337 0.0000 0.0 0
M  V30 4 C 4.0010 4.6201 0.0 0
M  V30 5 C 9.3360 4.6201 0.0 0
M  V30 6 N 10.6697 3.8501 0.0 0
M  V30 7 O 9.3360 6.1601 0.0 0
M  V30 8 C 12.0033 4.6201 0.0 0
M  V30 9 C 13.3370 3.8501 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 6.6685 1.5400 0.0 0
M  V30 12 C 5.3348 3.8501 0.0 0
M  V30 13 C 8.0022 2.3101 0.0 0
M  V30 14 C 6.6685 4.6201 0.0 0
M  V30 15 C 8.0022 3.8501 0.0 0
M  V30 16 C 2.6673 2.3101 0.0 0
M  V30 17 C 1.3337 1.5400 0.0 0
M  V30 18 C 2.6673 3.8501 0.0 0
M  V30 19 C 0.0000 2.3101 0.0 0
M  V30 20 C 1.3337 4.6201 0.0 0
M  V30 21 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 1 16
M  V30 3 1 2 11
M  V30 4 1 3 17
M  V30 5 1 4 18
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 15
M  V30 9 1 6 8
M  V30 10 1 8 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2138863-08-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 557-66-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2702965-85-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24358150
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 110-54-3
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of
N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
(ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second
Bromodomain
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sheppard, George S.; Wang, Le; Fidanze, Steven D.; Hasvold, Lisa A.; Liu,
Dachun; Pratt, John K.; Park, Chang H.; Longenecker, Kenton; Qiu, Wei;
Torrent, Maricel; Kovar, Peter J.; Bui, Mai; Faivre, Emily; Huang,
Xiaoli; Lin, Xiaoyu; Wilcox, Denise; Zhang, Lu; Shen, Yu; Albert, Daniel
H.; Magoc, Terrance J.; Rajaraman, Ganesh; Kati, Warren M.; McDaniel,
Keith F.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(10), 5585-5623

$RFMT $RIREG SCHEME187 STEP1
$RXN



  2  1
$MOL
4-Pyridinecarboxylic acid
C6H5NO2
55-22-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 N 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethyl (S)--aminocyclohexanepropanoate
C11H21NO2
169961-66-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0 CFG=2
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 N 5.3348 3.8501 0.0 0
M  V30 5 O 8.0023 2.3101 0.0 0
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 C 9.3360 1.5400 0.0 0
M  V30 8 C 10.6697 2.3101 0.0 0
M  V30 9 C 2.6673 2.3101 0.0 0
M  V30 10 C 1.3337 1.5400 0.0 0
M  V30 11 C 2.6673 3.8501 0.0 0
M  V30 12 C 0.0000 2.3101 0.0 0
M  V30 13 C 1.3337 4.6201 0.0 0
M  V30 14 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Cyclohexanepropanoic acid, -[(4-pyridinylcarbonyl)amino]-, ethyl ester, (S)-
C17H24N2O3
3054992-08-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0 CFG=1
M  V30 2 C 4.6200 6.6685 0.0 0
M  V30 3 N 6.9300 5.3347 0.0 0
M  V30 4 C 4.6200 4.0011 0.0 0
M  V30 5 C 7.7000 6.6685 0.0 0
M  V30 6 O 5.3900 2.6674 0.0 0
M  V30 7 O 3.0800 4.0011 0.0 0
M  V30 8 O 6.9300 8.0021 0.0 0
M  V30 9 C 4.6200 1.3336 0.0 0
M  V30 10 C 5.3900 0.0000 0.0 0
M  V30 11 C 3.0800 6.6685 0.0 0
M  V30 12 C 2.3100 8.0021 0.0 0
M  V30 13 C 2.3100 5.3347 0.0 0
M  V30 14 C 0.7700 8.0021 0.0 0
M  V30 15 C 0.7700 5.3347 0.0 0
M  V30 16 C 0.0000 6.6685 0.0 0
M  V30 17 C 9.2400 6.6685 0.0 0
M  V30 18 C 10.0100 5.3347 0.0 0
M  V30 19 C 10.0100 8.0021 0.0 0
M  V30 20 C 11.5500 5.3347 0.0 0
M  V30 21 C 11.5500 8.0021 0.0 0
M  V30 22 N 12.3200 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 11
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 5 17
M  V30 10 1 6 9
M  V30 11 1 9 10
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 16
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 22
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 55-22-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 169961-66-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3054992-08-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36966239
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing
Covalent Reversible -Fluorovinylsulfones and -Sulfonates as Potential
Immunomodulators in Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fuchs, Natalie; Meta, Mergim; Lantzberg, Bellinda; Bros, Matthias; Ling
Kuan, Seah; Weil, Tanja; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(15), e202300160

$RFMT $RIREG SCHEME188 STEP1
$RXN



  2  1
$MOL
4-Cyanophenylacetic acid
C9H7NO2
5462-71-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 2.6673 0.0 0
M  V30 2 C 1.5400 1.3337 0.0 0
M  V30 3 O 2.3100 0.0000 0.0 0
M  V30 4 O 0.0000 1.3337 0.0 0
M  V30 5 C 8.4701 2.6673 0.0 0
M  V30 6 N 10.0101 2.6673 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 6.1601 4.0010 0.0 0
M  V30 11 C 6.1601 1.3337 0.0 0
M  V30 12 C 6.9301 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 3 5 6
M  V30 6 1 5 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-(4-amino-2-methyl[1,1-biphenyl]-2-yl)-
C16H16N2O
2983540-42-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 6.1600 0.0 0
M  V30 2 C 6.6684 6.9300 0.0 0
M  V30 3 C 8.0021 6.1600 0.0 0
M  V30 4 O 6.6684 8.4700 0.0 0
M  V30 5 C 9.3358 6.9300 0.0 0
M  V30 6 C 0.0000 4.6200 0.0 0
M  V30 7 N 2.6674 0.0000 0.0 0
M  V30 8 C 2.6674 6.1600 0.0 0
M  V30 9 C 4.0011 6.9300 0.0 0
M  V30 10 C 1.3336 6.9300 0.0 0
M  V30 11 C 4.0011 8.4700 0.0 0
M  V30 12 C 1.3336 8.4700 0.0 0
M  V30 13 C 2.6674 9.2400 0.0 0
M  V30 14 C 2.6674 4.6200 0.0 0
M  V30 15 C 1.3336 3.8500 0.0 0
M  V30 16 C 4.0011 3.8500 0.0 0
M  V30 17 C 1.3336 2.3100 0.0 0
M  V30 18 C 4.0011 2.3100 0.0 0
M  V30 19 C 2.6674 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 15
M  V30 7 1 7 19
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 14
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, 4-cyano-N-[2-methyl-2-[(1-oxo-2-propen-1-yl)amino][1,1-bi...
C25H21N3O2
2983540-46-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.8500 4.0011 0.0 0
M  V30 2 C 2.3100 4.0011 0.0 0
M  V30 3 C 1.5400 5.3347 0.0 0
M  V30 4 O 1.5400 2.6673 0.0 0
M  V30 5 C 0.0000 5.3347 0.0 0
M  V30 6 C 9.2400 2.6673 0.0 0
M  V30 7 N 9.2400 8.0020 0.0 0
M  V30 8 C 10.7800 8.0020 0.0 0
M  V30 9 C 11.5500 9.3358 0.0 0
M  V30 10 O 11.5500 6.6684 0.0 0
M  V30 11 C 17.7100 9.3358 0.0 0
M  V30 12 N 19.2500 9.3358 0.0 0
M  V30 13 C 6.1600 2.6673 0.0 0
M  V30 14 C 4.6200 2.6673 0.0 0
M  V30 15 C 6.9300 1.3336 0.0 0
M  V30 16 C 3.8500 1.3336 0.0 0
M  V30 17 C 6.1600 0.0000 0.0 0
M  V30 18 C 4.6200 0.0000 0.0 0
M  V30 19 C 6.9300 4.0011 0.0 0
M  V30 20 C 8.4700 4.0011 0.0 0
M  V30 21 C 6.1600 5.3347 0.0 0
M  V30 22 C 9.2400 5.3347 0.0 0
M  V30 23 C 6.9300 6.6684 0.0 0
M  V30 24 C 8.4700 6.6684 0.0 0
M  V30 25 C 13.0900 9.3358 0.0 0
M  V30 26 C 13.8600 10.6694 0.0 0
M  V30 27 C 13.8600 8.0021 0.0 0
M  V30 28 C 15.4000 10.6694 0.0 0
M  V30 29 C 15.4000 8.0020 0.0 0
M  V30 30 C 16.1700 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 20
M  V30 7 1 7 8
M  V30 8 1 7 24
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 25
M  V30 12 3 11 12
M  V30 13 1 11 30
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 13 19
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5462-71-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2983540-42-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-46-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256044
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME189 STEP1
$RXN



  2  1
$MOL
Monomethyl succinate
C5H8O4
3878-55-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 2.3100 0.0 0
M  V30 2 C 4.0011 1.5400 0.0 0
M  V30 3 O 6.6686 1.5400 0.0 0
M  V30 4 O 5.3348 3.8500 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 8.0022 2.3100 0.0 0
M  V30 7 C 1.3337 1.5400 0.0 0
M  V30 8 O 1.3337 0.0000 0.0 0
M  V30 9 O 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 3-amino-4-(methylamino)benzoate
C9H12N2O2
66315-16-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9302 2.6673 0.0 0
M  V30 2 O 7.7002 4.0010 0.0 0
M  V30 3 O 7.7002 1.3337 0.0 0
M  V30 4 C 9.2402 4.0010 0.0 0
M  V30 5 N 2.3101 0.0000 0.0 0
M  V30 6 N 0.7700 2.6673 0.0 0
M  V30 7 C 0.0000 4.0010 0.0 0
M  V30 8 C 5.3901 2.6673 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 3.0801 1.3337 0.0 0
M  V30 12 C 3.0801 4.0010 0.0 0
M  V30 13 C 2.3101 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 5 11
M  V30 6 1 6 7
M  V30 7 1 6 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 3-[(4-methoxy-1,4-dioxobutyl)amino]-4-(methylamino)benzoate
C14H18N2O5
2161389-27-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 4.0011 0.0 0
M  V30 2 C 7.7000 5.3347 0.0 0
M  V30 3 C 9.2400 5.3347 0.0 0
M  V30 4 O 6.9300 6.6685 0.0 0
M  V30 5 C 10.0100 6.6685 0.0 0
M  V30 6 C 11.5500 6.6685 0.0 0
M  V30 7 O 12.3200 8.0021 0.0 0
M  V30 8 O 12.3200 5.3347 0.0 0
M  V30 9 C 13.8600 8.0021 0.0 0
M  V30 10 N 5.3900 1.3336 0.0 0
M  V30 11 C 4.6200 0.0000 0.0 0
M  V30 12 C 2.3100 6.6685 0.0 0
M  V30 13 O 0.7700 6.6685 0.0 0
M  V30 14 O 3.0800 8.0021 0.0 0
M  V30 15 C 0.0000 8.0021 0.0 0
M  V30 16 C 5.3900 4.0011 0.0 0
M  V30 17 C 4.6200 2.6674 0.0 0
M  V30 18 C 4.6200 5.3347 0.0 0
M  V30 19 C 3.0800 2.6674 0.0 0
M  V30 20 C 3.0800 5.3347 0.0 0
M  V30 21 C 2.3100 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 10 11
M  V30 11 1 10 17
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 12 20
M  V30 15 1 13 15
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3878-55-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 66315-16-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2161389-27-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38825440
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bothe, Ulrich; Guenther, Judith; Nubbemeyer, Reinhard; Siebeneicher,
Holger; Ring, Sven; Boemer, Ulf; Peters, Michaele; Rausch, Alexandra;
Denner, Karsten; Himmel, Herbert; Sutter, Andreas; Terebesi, Ildiko;
Lange, Martin; Wengner, Antje M.; Guimond, Nicolas; Thaler, Tobias;
Platzek, Johannes; Eberspaecher, Uwe; Schaefer, Martina; Steuber, Holger;
Zollner, Thomas M.; Steinmeyer, Andreas; Schmidt, Nicole
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1225-1242

$RFMT $RIREG SCHEME190 STEP1
$RXN



  2  1
$MOL
5-Methyl-3-isoxazolecarboxylic acid
C5H5NO3
3405-77-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 N 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 O 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C7H14N2O3S.C2HF3O2
2760538-81-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 6.7238 0.0 0
M  V30 2 C 8.0022 7.4938 0.0 0 CFG=1
M  V30 3 N 5.3348 7.4938 0.0 0
M  V30 4 O 6.6685 5.1837 0.0 0
M  V30 5 C 9.3360 6.7238 0.0 0
M  V30 6 N 8.0022 9.0338 0.0 0
M  V30 7 C 4.0012 6.7238 0.0 0
M  V30 8 S 10.6697 7.4938 0.0 0
M  V30 9 C 2.6673 7.4938 0.0 0
M  V30 10 C 12.0033 6.7238 0.0 0
M  V30 11 O 1.3337 6.7238 0.0 0
M  V30 12 O 2.6673 9.0338 0.0 0
M  V30 13 C 0.0000 7.4938 0.0 0
M  V30 14 C 5.3348 2.3101 0.0 0
M  V30 15 C 6.6685 1.5400 0.0 0
M  V30 16 F 6.1048 3.6437 0.0 0
M  V30 17 F 4.0012 3.0801 0.0 0
M  V30 18 F 4.5648 0.9764 0.0 0
M  V30 19 O 8.0022 2.3101 0.0 0
M  V30 20 O 6.6685 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=1
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 9 12
M  V30 12 1 11 13
M  V30 13 1 14 15
M  V30 14 1 14 16
M  V30 15 1 14 17
M  V30 16 1 14 18
M  V30 17 1 15 19
M  V30 18 2 15 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C12H17N3O5S
2760538-92-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0287 5.3348 0.0 0
M  V30 2 N 5.5687 5.3348 0.0 0
M  V30 3 O 3.2587 4.0011 0.0 0
M  V30 4 C 6.3387 4.0011 0.0 0 CFG=1
M  V30 5 C 7.8788 4.0011 0.0 0
M  V30 6 C 5.5687 2.6673 0.0 0
M  V30 7 N 8.6488 5.3348 0.0 0
M  V30 8 O 8.6488 2.6673 0.0 0
M  V30 9 S 6.3387 1.3337 0.0 0
M  V30 10 C 10.1888 5.3348 0.0 0
M  V30 11 C 5.5687 0.0000 0.0 0
M  V30 12 C 10.9588 6.6684 0.0 0
M  V30 13 O 12.4988 6.6684 0.0 0
M  V30 14 O 10.1888 8.0023 0.0 0
M  V30 15 C 13.2688 8.0023 0.0 0
M  V30 16 C 0.0000 8.9622 0.0 0
M  V30 17 C 3.2587 6.6684 0.0 0
M  V30 18 C 1.7271 6.8295 0.0 0
M  V30 19 N 3.8850 8.0754 0.0 0
M  V30 20 C 1.4070 8.3358 0.0 0
M  V30 21 O 2.7406 9.1058 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 16 20
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3405-77-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-81-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-92-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545345
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME191 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(2-Aminoethyl)piperidine-1-carboxylic acid tert-butyl ester
C12H24N2O2
146093-46-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8736 0.0 0
M  V30 2 O 3.0800 1.5400 0.0 0
M  V30 3 O 3.0800 4.2073 0.0 0
M  V30 4 C 1.5400 1.5400 0.0 0
M  V30 5 C 1.5400 0.0000 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 1.5400 3.0800 0.0 0
M  V30 8 C 10.0100 2.8736 0.0 0
M  V30 9 C 10.7800 4.2073 0.0 0
M  V30 10 N 12.3200 4.2073 0.0 0
M  V30 11 N 5.3900 2.8736 0.0 0
M  V30 12 C 6.1600 1.5400 0.0 0
M  V30 13 C 6.1600 4.2073 0.0 0
M  V30 14 C 7.7000 1.5400 0.0 0
M  V30 15 C 7.7000 4.2073 0.0 0
M  V30 16 C 8.4700 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 1 8 16
M  V30 10 1 9 10
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Piperidinecarboxylic acid, 4-[2-[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]...
C20H29N3O3
3031471-30-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8738 0.0 0
M  V30 2 O 3.0800 1.5400 0.0 0
M  V30 3 O 3.0800 4.2074 0.0 0
M  V30 4 C 1.5400 1.5400 0.0 0
M  V30 5 C 1.5400 3.0800 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 1.5400 0.0000 0.0 0
M  V30 8 C 10.0100 2.8738 0.0 0
M  V30 9 C 10.7800 4.2074 0.0 0
M  V30 10 N 12.3200 4.2074 0.0 0
M  V30 11 C 13.0900 5.5411 0.0 0
M  V30 12 C 14.6300 5.5411 0.0 0
M  V30 13 O 12.3200 6.8747 0.0 0
M  V30 14 C 15.4000 6.8747 0.0 0
M  V30 15 N 5.3900 2.8738 0.0 0
M  V30 16 C 6.1600 1.5400 0.0 0
M  V30 17 C 6.1600 4.2074 0.0 0
M  V30 18 C 7.7000 1.5400 0.0 0
M  V30 19 C 7.7000 4.2074 0.0 0
M  V30 20 C 8.4700 2.8738 0.0 0
M  V30 21 C 16.9400 6.8747 0.0 0
M  V30 22 C 17.7100 8.2085 0.0 0
M  V30 23 C 17.7100 5.5411 0.0 0
M  V30 24 C 19.2500 8.2085 0.0 0
M  V30 25 N 19.2500 5.5411 0.0 0
M  V30 26 C 20.0200 6.8747 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 1 8 20
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 14 21
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 20
M  V30 22 1 21 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 2 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 146093-46-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031471-30-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131908
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME192 STEP1
$RXN



  2  1
$MOL
(4-Chlorophenyl)acetic acid
C8H7ClO2
1878-66-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6673 0.0 0
M  V30 2 C 6.9302 1.3337 0.0 0
M  V30 3 O 6.1601 0.0000 0.0 0
M  V30 4 O 8.4702 1.3337 0.0 0
M  V30 5 Cl 0.0000 2.6673 0.0 0
M  V30 6 C 4.6201 2.6673 0.0 0
M  V30 7 C 3.8501 4.0010 0.0 0
M  V30 8 C 3.8501 1.3337 0.0 0
M  V30 9 C 2.3101 4.0010 0.0 0
M  V30 10 C 2.3101 1.3337 0.0 0
M  V30 11 C 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Benzimidazole-2-ethanamine, hydrochloride (1:2)
C9H11N3.2ClH
4499-07-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.5772 3.0800 0.0 0
M  V30 2 C 7.3472 4.4137 0.0 0
M  V30 3 N 8.8872 4.4137 0.0 0
M  V30 4 C 2.6673 3.8501 0.0 0
M  V30 5 C 2.6673 2.3100 0.0 0
M  V30 6 N 4.1321 4.3259 0.0 0
M  V30 7 C 1.3337 4.6201 0.0 0
M  V30 8 N 4.1321 1.8341 0.0 0
M  V30 9 C 1.3337 1.5400 0.0 0
M  V30 10 C 5.0371 3.0800 0.0 0
M  V30 11 C 0.0000 3.8501 0.0 0
M  V30 12 C 0.0000 2.3100 0.0 0
M  V30 13 Cl 4.4436 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 1 5 8
M  V30 8 2 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 2 8 10
M  V30 12 1 9 12
M  V30 13 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(1H-Benzimidazol-2-yl)ethyl]-4-chlorobenzeneacetamide
C17H16ClN3O
448233-07-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.0811 3.9554 0.0 0
M  V30 2 C 7.4150 3.1854 0.0 0
M  V30 3 N 8.7486 3.9554 0.0 0
M  V30 4 C 10.0823 3.1854 0.0 0
M  V30 5 C 11.4161 3.9554 0.0 0
M  V30 6 O 10.0823 1.6454 0.0 0
M  V30 7 Cl 16.7509 0.8754 0.0 0
M  V30 8 C 2.3101 2.6673 0.0 0
M  V30 9 C 3.0801 1.3337 0.0 0
M  V30 10 N 3.3406 3.8119 0.0 0
M  V30 11 C 0.7700 2.6673 0.0 0
M  V30 12 N 4.5865 1.6538 0.0 0
M  V30 13 C 2.3101 0.0000 0.0 0
M  V30 14 C 4.7475 3.1854 0.0 0
M  V30 15 C 0.0000 1.3337 0.0 0
M  V30 16 C 0.7700 0.0000 0.0 0
M  V30 17 C 12.7498 3.1854 0.0 0
M  V30 18 C 14.0835 3.9554 0.0 0
M  V30 19 C 12.7498 1.6454 0.0 0
M  V30 20 C 15.4171 3.1854 0.0 0
M  V30 21 C 14.0835 0.8754 0.0 0
M  V30 22 C 15.4171 1.6454 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 5 17
M  V30 8 1 7 22
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 2 9 13
M  V30 14 1 10 14
M  V30 15 1 11 15
M  V30 16 2 12 14
M  V30 17 1 13 16
M  V30 18 2 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1878-66-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4499-07-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 448233-07-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35153686
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Hit-to-lead optimization of a 2-aminobenzimidazole series as new
candidates for chagas disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM de Oliveira Rezende, Celso Junior; Martinez, Pablo David Grigol;
Ferreira, Rafael Augusto Alves; Koovits, Paul John; Miranda Soares,
Bruna; Ferreira, Leonardo L. G.; Michelan-Duarte, Simone; Chelucci,
Rafael Consolin; Andricopulo, Adriano D.; Matheeussen, An; Van Pelt,
Natascha; Caljon, Guy; Maes, Louis; Campbell, Simon; Kratz, Jadel M.;
Mowbray, Charles E.; Dias, Luiz Carlos
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 246114925

$RFMT $RIREG SCHEME193 STEP1
$RXN



  2  1
$MOL
3-Aminopyridine
C5H6N2
462-08-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 N 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 2 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[[(4-Fluorobenzoyl)amino]methyl]benzoic acid
C15H12FNO3
925137-90-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 6.6685 2.3101 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 8.0022 1.5400 0.0 0
M  V30 5 F 0.0000 4.6201 0.0 0
M  V30 6 C 13.3370 4.6201 0.0 0
M  V30 7 O 14.6707 3.8501 0.0 0
M  V30 8 O 13.3370 6.1601 0.0 0
M  V30 9 C 4.0010 2.3101 0.0 0
M  V30 10 C 2.6673 1.5400 0.0 0
M  V30 11 C 4.0010 3.8501 0.0 0
M  V30 12 C 1.3337 2.3101 0.0 0
M  V30 13 C 2.6673 4.6201 0.0 0
M  V30 14 C 1.3337 3.8501 0.0 0
M  V30 15 C 9.3358 2.3101 0.0 0
M  V30 16 C 9.3358 3.8501 0.0 0
M  V30 17 C 10.6697 1.5400 0.0 0
M  V30 18 C 10.6697 4.6201 0.0 0
M  V30 19 C 12.0033 2.3101 0.0 0
M  V30 20 C 12.0033 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 15
M  V30 6 1 5 14
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 20
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C20H16FN3O2
2335006-47-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 4.6200 0.0 0
M  V30 2 N 4.0011 3.8500 0.0 0
M  V30 3 O 5.3347 6.1600 0.0 0
M  V30 4 C 10.6694 1.5400 0.0 0
M  V30 5 N 12.0031 2.3100 0.0 0
M  V30 6 C 13.3369 1.5400 0.0 0
M  V30 7 O 13.3369 0.0000 0.0 0
M  V30 8 F 18.6716 4.6200 0.0 0
M  V30 9 C 6.6684 3.8500 0.0 0
M  V30 10 C 6.6684 2.3100 0.0 0
M  V30 11 C 8.0021 4.6200 0.0 0
M  V30 12 C 8.0021 1.5400 0.0 0
M  V30 13 C 9.3358 3.8500 0.0 0
M  V30 14 C 9.3358 2.3100 0.0 0
M  V30 15 C 2.6674 4.6200 0.0 0
M  V30 16 C 1.3336 3.8500 0.0 0
M  V30 17 C 2.6674 6.1600 0.0 0
M  V30 18 C 0.0000 4.6200 0.0 0
M  V30 19 N 1.3336 6.9300 0.0 0
M  V30 20 C 0.0000 6.1600 0.0 0
M  V30 21 C 14.6705 2.3100 0.0 0
M  V30 22 C 16.0041 1.5400 0.0 0
M  V30 23 C 14.6705 3.8500 0.0 0
M  V30 24 C 17.3379 2.3100 0.0 0
M  V30 25 C 16.0041 4.6200 0.0 0
M  V30 26 C 17.3379 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 1 4 5
M  V30 6 1 4 14
M  V30 7 1 5 6
M  V30 8 2 6 7
M  V30 9 1 6 21
M  V30 10 1 8 26
M  V30 11 2 9 10
M  V30 12 1 9 11
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 14
M  V30 17 1 15 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 462-08-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 925137-90-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2335006-47-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23337821
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 127-19-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A new chemotype with promise against Trypanosoma cruzi
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Xiaofang; Cal, Monica; Kaiser, Marcel; Buckner, Frederick S.;
Lepesheva, Galina I.; Sanford, Austin G.; Wallick, Alexander I.; Davis,
Paul H.; Vennerstrom, Jonathan L.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(1), 126778

$RFMT $RIREG SCHEME194 STEP1
$RXN



  2  1
$MOL
3-Cyanobenzeneacetic acid
C9H7NO2
1878-71-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0801 0.0 0
M  V30 2 C 1.3337 2.3101 0.0 0
M  V30 3 O 1.3337 0.7700 0.0 0
M  V30 4 O 0.0000 3.0801 0.0 0
M  V30 5 C 8.0023 3.0801 0.0 0
M  V30 6 N 9.3360 3.8501 0.0 0
M  V30 7 C 4.0012 2.3101 0.0 0
M  V30 8 C 5.3348 3.0801 0.0 0
M  V30 9 C 4.0012 0.7700 0.0 0
M  V30 10 C 6.6685 2.3101 0.0 0
M  V30 11 C 5.3348 0.0000 0.0 0
M  V30 12 C 6.6685 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 3 5 6
M  V30 6 1 5 10
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-(4-amino-2-methyl[1,1-biphenyl]-2-yl)-
C16H16N2O
2983540-42-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 6.1600 0.0 0
M  V30 2 C 6.6684 6.9300 0.0 0
M  V30 3 C 8.0021 6.1600 0.0 0
M  V30 4 O 6.6684 8.4700 0.0 0
M  V30 5 C 9.3358 6.9300 0.0 0
M  V30 6 C 0.0000 4.6200 0.0 0
M  V30 7 N 2.6674 0.0000 0.0 0
M  V30 8 C 2.6674 6.1600 0.0 0
M  V30 9 C 4.0011 6.9300 0.0 0
M  V30 10 C 1.3336 6.9300 0.0 0
M  V30 11 C 4.0011 8.4700 0.0 0
M  V30 12 C 1.3336 8.4700 0.0 0
M  V30 13 C 2.6674 9.2400 0.0 0
M  V30 14 C 2.6674 4.6200 0.0 0
M  V30 15 C 1.3336 3.8500 0.0 0
M  V30 16 C 4.0011 3.8500 0.0 0
M  V30 17 C 1.3336 2.3100 0.0 0
M  V30 18 C 4.0011 2.3100 0.0 0
M  V30 19 C 2.6674 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 15
M  V30 7 1 7 19
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 14
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, 3-cyano-N-[2-methyl-2-[(1-oxo-2-propen-1-yl)amino][1,1-bi...
C25H21N3O2
2983540-50-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.6674 4.6200 0.0 0
M  V30 2 C 1.3336 5.3900 0.0 0
M  V30 3 C 1.3336 6.9300 0.0 0
M  V30 4 O 0.0000 4.6200 0.0 0
M  V30 5 C 0.0000 7.7000 0.0 0
M  V30 6 C 6.6684 0.7700 0.0 0
M  V30 7 N 9.3358 5.3900 0.0 0
M  V30 8 C 10.6694 4.6200 0.0 0
M  V30 9 C 12.0032 5.3900 0.0 0
M  V30 10 O 10.6694 3.0800 0.0 0
M  V30 11 C 17.3379 5.3900 0.0 0
M  V30 12 N 18.6716 6.1600 0.0 0
M  V30 13 C 4.0011 2.3100 0.0 0
M  V30 14 C 2.6674 3.0800 0.0 0
M  V30 15 C 4.0011 0.7700 0.0 0
M  V30 16 C 1.3336 2.3100 0.0 0
M  V30 17 C 2.6674 0.0000 0.0 0
M  V30 18 C 1.3336 0.7700 0.0 0
M  V30 19 C 5.3347 3.0800 0.0 0
M  V30 20 C 6.6684 2.3100 0.0 0
M  V30 21 C 5.3347 4.6200 0.0 0
M  V30 22 C 8.0021 3.0800 0.0 0
M  V30 23 C 6.6684 5.3900 0.0 0
M  V30 24 C 8.0021 4.6200 0.0 0
M  V30 25 C 13.3369 4.6200 0.0 0
M  V30 26 C 14.6705 5.3900 0.0 0
M  V30 27 C 13.3369 3.0800 0.0 0
M  V30 28 C 16.0041 4.6200 0.0 0
M  V30 29 C 14.6705 2.3100 0.0 0
M  V30 30 C 16.0041 3.0800 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 20
M  V30 7 1 7 8
M  V30 8 1 7 24
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 25
M  V30 12 3 11 12
M  V30 13 1 11 28
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 13 19
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1878-71-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2983540-42-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-50-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256047
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME195 STEP1
$RXN



  2  1
$MOL
4-Methoxy-3-nitrobenzoic acid
C8H7NO5
89-41-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 6.1601 0.0 0 VAL=5
M  V30 2 O 2.6675 6.9302 0.0 0
M  V30 3 O 5.3348 6.9302 0.0 0
M  V30 4 O 6.6687 4.6201 0.0 0
M  V30 5 C 8.0023 3.8501 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 O 1.3337 0.0000 0.0 0
M  V30 8 O 0.0000 2.3101 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 3.8501 0.0 0
M  V30 11 C 2.6675 3.8501 0.0 0
M  V30 12 C 5.3348 2.3101 0.0 0
M  V30 13 C 2.6675 2.3101 0.0 0
M  V30 14 C 4.0012 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 4 5
M  V30 5 1 4 10
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 6 13
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N,N-Dimethyl-p-phenylenediamine
C8H12N2
99-98-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.7700 1.3337 0.0 0
M  V30 2 C 0.0000 0.0000 0.0 0
M  V30 3 C 0.0000 2.6673 0.0 0
M  V30 4 N 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[4-(Dimethylamino)phenyl]-4-methoxy-3-nitrobenzamide
C16H17N3O4
349402-03-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 4.6201 0.0 0
M  V30 2 N 8.0021 3.8500 0.0 0
M  V30 3 O 6.6684 6.1601 0.0 0
M  V30 4 N 1.3337 4.6201 0.0 0 VAL=5
M  V30 5 O 0.0000 3.8500 0.0 0
M  V30 6 O 1.3337 6.1601 0.0 0
M  V30 7 O 1.3337 1.5400 0.0 0
M  V30 8 C 1.3337 0.0000 0.0 0
M  V30 9 N 13.3369 6.9301 0.0 0
M  V30 10 C 13.3369 8.4701 0.0 0
M  V30 11 C 14.6705 6.1601 0.0 0
M  V30 12 C 5.3348 3.8500 0.0 0
M  V30 13 C 4.0010 4.6201 0.0 0
M  V30 14 C 5.3348 2.3100 0.0 0
M  V30 15 C 2.6673 3.8500 0.0 0
M  V30 16 C 4.0010 1.5400 0.0 0
M  V30 17 C 2.6673 2.3100 0.0 0
M  V30 18 C 9.3357 4.6201 0.0 0
M  V30 19 C 9.3357 6.1601 0.0 0
M  V30 20 C 10.6695 3.8500 0.0 0
M  V30 21 C 10.6695 6.9301 0.0 0
M  V30 22 C 12.0032 4.6201 0.0 0
M  V30 23 C 12.0032 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 18
M  V30 5 2 4 5
M  V30 6 2 4 6
M  V30 7 1 4 15
M  V30 8 1 7 8
M  V30 9 1 7 17
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 23
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 89-41-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 99-98-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 349402-03-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40728145
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and structure-activity relationship study of new biaryl amide
derivatives and their inhibitory effects against hepatitis C virus
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liu, Yonghua; Li, Jianrui; Gu, Yuxi; Ma, Ling; Cen, Shan; Peng, Zonggen;
Hu, Laixing
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2022), 228114033

$RFMT $RIREG SCHEME196 STEP1
$RXN



  2  1
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Piperidineethanamine
C7H16N2
27578-60-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 5.3901 2.6673 0.0 0
M  V30 3 N 6.9302 2.6673 0.0 0
M  V30 4 N 3.0801 1.3337 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.7700 2.6673 0.0 0
M  V30 9 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 2 3
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-nitro-N-[2-(1-piperidinyl)ethyl]benzamide
C14H20N4O3
1455659-36-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 C 9.2400 5.3347 0.0 0
M  V30 6 N 4.6200 0.0000 0.0 0
M  V30 7 N 1.5400 5.3347 0.0 0 VAL=5
M  V30 8 O 0.0000 5.3347 0.0 0
M  V30 9 O 2.3100 6.6685 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.8500 4.0011 0.0 0
M  V30 12 C 3.8500 1.3338 0.0 0
M  V30 13 C 2.3100 4.0011 0.0 0
M  V30 14 C 2.3100 1.3338 0.0 0
M  V30 15 C 1.5400 2.6674 0.0 0
M  V30 16 N 10.7800 5.3347 0.0 0
M  V30 17 C 11.5500 6.6685 0.0 0
M  V30 18 C 11.5500 4.0011 0.0 0
M  V30 19 C 13.0900 6.6685 0.0 0
M  V30 20 C 13.0900 4.0011 0.0 0
M  V30 21 C 13.8600 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 16
M  V30 7 1 6 12
M  V30 8 2 7 8
M  V30 9 2 7 9
M  V30 10 1 7 13
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 27578-60-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1455659-36-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38624465
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of Quinazolinones and Quinazolinediones for
Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating
COP1-ATGL Axis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sarkar, Dipayan; Chowdhury, Saheli; Goon, Sunny; Sen, Abhishek; Dastidar,
Uddipta Ghosh; Mondal, Mohabul Alam; Chakrabarti, Partha; Talukdar,
Arindam
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(24), 16728-16761

$RFMT $RIREG SCHEME197 STEP1
$RXN



  2  1
$MOL
2-Propanol, 3-amino-1,1,1-trifluoro-, hydrochloride (1:1)
C3H6F3NO.ClH
3832-24-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 3.0800 0.0 0
M  V30 2 C 1.5400 3.0800 0.0 0
M  V30 3 C 3.8500 4.4136 0.0 0
M  V30 4 O 3.8500 1.7464 0.0 0
M  V30 5 F 1.5400 4.6200 0.0 0
M  V30 6 F 0.0000 3.0800 0.0 0
M  V30 7 F 1.5400 1.5400 0.0 0
M  V30 8 N 5.3900 4.4136 0.0 0
M  V30 9 Cl 2.6950 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 2 7
M  V30 7 1 3 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-5-bromo-2-pyridinecarboxylic acid
C6H5BrN2O2
870997-85-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 Br 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 N 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-5-bromo-N-(3,3,3-trifluoro-2-hydroxypropyl)-2-pyridinecarboxamide
C9H9BrF3N3O2
2055018-42-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 N 5.3900 4.0011 0.0 0
M  V30 3 O 5.3900 1.3338 0.0 0
M  V30 4 C 3.8500 4.0011 0.0 0
M  V30 5 C 3.0800 5.3349 0.0 0
M  V30 6 C 1.5400 5.3349 0.0 0
M  V30 7 O 3.8500 6.6685 0.0 0
M  V30 8 F 0.0000 5.3349 0.0 0
M  V30 9 F 1.5400 6.8749 0.0 0
M  V30 10 F 1.5400 3.7949 0.0 0
M  V30 11 N 7.7000 0.0000 0.0 0
M  V30 12 Br 12.3200 2.6674 0.0 0
M  V30 13 C 7.7000 2.6674 0.0 0
M  V30 14 C 8.4700 1.3338 0.0 0
M  V30 15 N 8.4700 4.0011 0.0 0
M  V30 16 C 10.0100 1.3338 0.0 0
M  V30 17 C 10.0100 4.0011 0.0 0
M  V30 18 C 10.7800 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 6 10
M  V30 11 1 11 14
M  V30 12 1 12 18
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3832-24-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 870997-85-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2055018-42-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23762826
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 872-50-4
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment
of Cystic Fibrosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Van der Plas, Steven E.; Kelgtermans, Hans; Mammoliti, Oscar; Menet,
Christel; Tricarico, Giovanni; De Blieck, Ann; Joannesse, Caroline; De
Munck, Tom; Lambin, Dominique; Cowart, Marlon; Dropsit, Sebastien;
Martina, Sebastien L. X.; Gees, Maarten; Wesse, Anne-Sophie; Conrath,
Katja; Andrews, Martin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(1), 343-353

$RFMT $RIREG SCHEME198 STEP1
$RXN



  2  1
$MOL
Phenylacetic acid
C8H8O2
103-82-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 C 5.3901 1.3337 0.0 0
M  V30 3 O 4.6201 0.0000 0.0 0
M  V30 4 O 6.9302 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 2.3101 4.0010 0.0 0
M  V30 7 C 2.3101 1.3337 0.0 0
M  V30 8 C 0.7700 4.0010 0.0 0
M  V30 9 C 0.7700 1.3337 0.0 0
M  V30 10 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethyl -amino-3-chlorobenzenepropanoate
C11H14ClNO2
498581-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.0801 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 N 5.3348 4.6201 0.0 0
M  V30 4 C 8.0022 3.0801 0.0 0
M  V30 5 O 9.3360 2.3101 0.0 0
M  V30 6 O 8.0022 4.6201 0.0 0
M  V30 7 C 10.6697 3.0801 0.0 0
M  V30 8 C 12.0033 2.3101 0.0 0
M  V30 9 Cl 0.0000 3.0801 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 3.0801 0.0 0
M  V30 12 C 4.0012 0.7700 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 0.0000 0.0 0
M  V30 15 C 1.3337 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 9 13
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenepropanoic acid, 3-chloro--[(2-phenylacetyl)amino]-, ethyl ester
C19H20ClNO3
3048689-43-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 6.6684 0.0 0
M  V30 2 N 5.3900 8.0021 0.0 0
M  V30 3 C 5.3900 5.3347 0.0 0
M  V30 4 C 6.9300 8.0021 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 7.7000 9.3358 0.0 0
M  V30 7 O 7.7000 6.6684 0.0 0
M  V30 8 O 5.3900 2.6673 0.0 0
M  V30 9 O 3.0800 4.0011 0.0 0
M  V30 10 C 4.6200 1.3336 0.0 0
M  V30 11 C 5.3900 0.0000 0.0 0
M  V30 12 Cl 0.0000 9.3358 0.0 0
M  V30 13 C 3.0800 6.6684 0.0 0
M  V30 14 C 2.3100 8.0021 0.0 0
M  V30 15 C 2.3100 5.3347 0.0 0
M  V30 16 C 0.7700 8.0021 0.0 0
M  V30 17 C 0.7700 5.3347 0.0 0
M  V30 18 C 0.0000 6.6684 0.0 0
M  V30 19 C 9.2400 9.3358 0.0 0
M  V30 20 C 10.0100 10.6694 0.0 0
M  V30 21 C 10.0100 8.0021 0.0 0
M  V30 22 C 11.5500 10.6694 0.0 0
M  V30 23 C 11.5500 8.0021 0.0 0
M  V30 24 C 12.3200 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 19
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 1 12 16
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 103-82-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 498581-88-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3048689-43-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40877747
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and biological characterization of an orally bioavailable
lactate dehydrogenase-A inhibitor against pancreatic cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sharma, Horrick; Mondal, Somrita; Urquiza, Uzziah; Esparza, Colter;
Bartlett, Seth; Santa-Pinter, Landon; Hill, Hanna; White, Madalyn;
Sharma, Pragya; Luckett-Chastain, Lerin; Cooper, Anne; Rasel, Mohammad;
Gao, Philip; Battaile, Kevin P.; Shukla, Surendra K.; Lovell, Scott;
Ihnat, Michael A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 275116598

$RFMT $RIREG SCHEME199 STEP1
$RXN



  2  1
$MOL
2-Methyl-5-thiazolecarboxylic acid
C5H5NO2S
40004-69-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 S 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 N 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C9H18N2O3S2.C2HF3O2
2760538-76-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 S 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 S 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H21N3O4S3
2760538-93-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 6.9302 0.0 0
M  V30 2 N 8.0023 6.1601 0.0 0
M  V30 3 O 9.3360 8.4702 0.0 0
M  V30 4 C 6.6685 6.9302 0.0 0 CFG=1
M  V30 5 C 5.3348 6.1601 0.0 0
M  V30 6 C 6.6685 8.4702 0.0 0
M  V30 7 N 5.3348 4.6201 0.0 0
M  V30 8 O 4.0012 6.9302 0.0 0
M  V30 9 S 5.3348 9.2402 0.0 0
M  V30 10 C 4.0012 3.8501 0.0 0 CFG=1
M  V30 11 C 5.3348 10.7802 0.0 0
M  V30 12 C 4.0012 2.3101 0.0 0
M  V30 13 C 2.6675 4.6201 0.0 0
M  V30 14 O 2.6675 1.5400 0.0 0
M  V30 15 O 5.3348 1.5400 0.0 0
M  V30 16 S 1.3337 3.8501 0.0 0
M  V30 17 C 2.6673 0.0000 0.0 0
M  V30 18 C 0.0000 4.6201 0.0 0
M  V30 19 C 14.6386 5.8030 0.0 0
M  V30 20 C 10.6697 6.1601 0.0 0
M  V30 21 S 12.0765 6.7865 0.0 0
M  V30 22 C 10.8306 4.6286 0.0 0
M  V30 23 C 13.1071 5.6421 0.0 0
M  V30 24 N 12.3371 4.3084 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 20
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 10 13 CFG=3
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 23
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 40004-69-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-76-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-93-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545344
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME200 STEP1
$RXN



  2  1
$MOL
1-Methyl-1H-pyrazole-4-carboxylic acid
C5H6N2O2
5952-92-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 N 5.1048 2.8281 0.0 0
M  V30 9 N 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indene-5-carbonitrile, 1-amino-2,3-dihydro-, (1R)-, 4-methylbenzenesulfona...
C10H10N2.C7H8O3S
2364561-76-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 7.8084 0.0 0
M  V30 2 C 7.2706 7.0982 0.0 0
M  V30 3 N 8.8106 7.0982 0.0 0
M  V30 4 C 2.6506 7.0982 0.0 0
M  V30 5 C 3.4206 5.7644 0.0 0
M  V30 6 C 1.1444 6.7780 0.0 0 CFG=2
M  V30 7 C 3.4206 8.4318 0.0 0
M  V30 8 C 4.9606 5.7644 0.0 0
M  V30 9 C 2.3902 4.6200 0.0 0
M  V30 10 C 0.9834 5.2463 0.0 0
M  V30 11 C 4.9606 8.4318 0.0 0
M  V30 12 C 5.7306 7.0982 0.0 0
M  V30 13 S 2.0953 1.5400 0.0 0 VAL=6
M  V30 14 O 2.0953 3.0800 0.0 0
M  V30 15 O 2.0953 0.0000 0.0 0
M  V30 16 O 0.5553 1.5400 0.0 0
M  V30 17 C 8.2553 1.5400 0.0 0
M  V30 18 C 3.6353 1.5400 0.0 0
M  V30 19 C 4.4053 0.2064 0.0 0
M  V30 20 C 4.4053 2.8736 0.0 0
M  V30 21 C 5.9453 0.2064 0.0 0
M  V30 22 C 5.9453 2.8736 0.0 0
M  V30 23 C 6.7153 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 6 1 CFG=1
M  V30 2 3 2 3
M  V30 3 1 2 12
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 2 5 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 10
M  V30 13 2 11 12
M  V30 14 2 13 14
M  V30 15 2 13 15
M  V30 16 1 13 16
M  V30 17 1 13 18
M  V30 18 1 17 23
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1R)-5-Cyano-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-pyrazole-4-carboxamide
C15H14N4O
2364561-64-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.4171 2.7126 0.0 0
M  V30 2 C 4.9524 3.1884 0.0 0
M  V30 3 O 4.6322 4.6949 0.0 0
M  V30 4 C 13.6879 3.4228 0.0 0
M  V30 5 N 15.2279 3.4228 0.0 0
M  V30 6 C 0.0000 0.9835 0.0 0
M  V30 7 C 9.0679 3.4228 0.0 0
M  V30 8 C 7.5615 3.7430 0.0 0 CFG=2
M  V30 9 C 9.8379 4.7565 0.0 0
M  V30 10 C 9.8379 2.0892 0.0 0
M  V30 11 C 7.4005 5.2745 0.0 0
M  V30 12 C 11.3779 4.7565 0.0 0
M  V30 13 C 8.8075 5.9010 0.0 0
M  V30 14 C 11.3779 2.0892 0.0 0
M  V30 15 C 12.1479 3.4228 0.0 0
M  V30 16 C 3.8080 2.1580 0.0 0
M  V30 17 C 2.3015 2.4782 0.0 0
M  V30 18 C 3.9689 0.6265 0.0 0
M  V30 19 N 1.5315 1.1445 0.0 0
M  V30 20 N 2.5621 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 8 1 CFG=3
M  V30 3 2 2 3
M  V30 4 1 2 16
M  V30 5 3 4 5
M  V30 6 1 4 15
M  V30 7 1 6 19
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 2 9 12
M  V30 13 1 9 13
M  V30 14 1 10 14
M  V30 15 1 11 13
M  V30 16 1 12 15
M  V30 17 2 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5952-92-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2364561-76-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2364561-64-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34638596
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 107-06-2
$DTYPE RXN:VAR(1):NOTES
$DATUM alternative preparation shown
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin
Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chuang, Chihyuan; Collibee, Scott; Ashcraft, Luke; Wang, Wenyue; Vander
Wal, Mark; Wang, Xiaolin; Hwee, Darren T.; Wu, Yangsong; Wang, Jingying;
Chin, Eva R.; Cremin, Peadar; Zamora, Jeanelle; Hartman, James;
Schaletzky, Julia; Wehri, Eddie; Robertson, Laura A.; Malik, Fady I.;
Morgan, Bradley P.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(19), 14142-14152

$RFMT $RIREG SCHEME201 STEP1
$RXN



  2  1
$MOL
1-Methyl-1H-pyrazole-4-carboxylic acid
C5H6N2O2
5952-92-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 N 5.1048 2.8281 0.0 0
M  V30 9 N 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indene-5-carbonitrile, 1-amino-2,3-dihydro-, hydrochloride (1:1), (1R)-
C10H10N2.ClH
903556-00-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 4.7284 0.0 0
M  V30 2 C 7.2706 4.0182 0.0 0
M  V30 3 N 8.8106 4.0182 0.0 0
M  V30 4 C 2.6506 4.0182 0.0 0
M  V30 5 C 3.4206 2.6844 0.0 0
M  V30 6 C 1.1444 3.6980 0.0 0 CFG=2
M  V30 7 C 3.4206 5.3518 0.0 0
M  V30 8 C 4.9606 2.6844 0.0 0
M  V30 9 C 2.3902 1.5400 0.0 0
M  V30 10 C 0.9834 2.1663 0.0 0
M  V30 11 C 4.9606 5.3518 0.0 0
M  V30 12 C 5.7306 4.0182 0.0 0
M  V30 13 Cl 4.4053 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 6 1 CFG=1
M  V30 2 3 2 3
M  V30 3 1 2 12
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 2 5 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 10
M  V30 13 2 11 12
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1R)-5-Cyano-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-pyrazole-4-carboxamide
C15H14N4O
2364561-64-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.4171 2.7126 0.0 0
M  V30 2 C 4.9524 3.1884 0.0 0
M  V30 3 O 4.6322 4.6949 0.0 0
M  V30 4 C 13.6879 3.4228 0.0 0
M  V30 5 N 15.2279 3.4228 0.0 0
M  V30 6 C 0.0000 0.9835 0.0 0
M  V30 7 C 9.0679 3.4228 0.0 0
M  V30 8 C 7.5615 3.7430 0.0 0 CFG=2
M  V30 9 C 9.8379 4.7565 0.0 0
M  V30 10 C 9.8379 2.0892 0.0 0
M  V30 11 C 7.4005 5.2745 0.0 0
M  V30 12 C 11.3779 4.7565 0.0 0
M  V30 13 C 8.8075 5.9010 0.0 0
M  V30 14 C 11.3779 2.0892 0.0 0
M  V30 15 C 12.1479 3.4228 0.0 0
M  V30 16 C 3.8080 2.1580 0.0 0
M  V30 17 C 2.3015 2.4782 0.0 0
M  V30 18 C 3.9689 0.6265 0.0 0
M  V30 19 N 1.5315 1.1445 0.0 0
M  V30 20 N 2.5621 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 8 1 CFG=3
M  V30 3 2 2 3
M  V30 4 1 2 16
M  V30 5 3 4 5
M  V30 6 1 4 15
M  V30 7 1 6 19
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 2 9 12
M  V30 13 1 9 13
M  V30 14 1 10 14
M  V30 15 1 11 13
M  V30 16 1 12 15
M  V30 17 2 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5952-92-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 903556-00-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2364561-64-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34638576
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM alternative preparation shown
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin
Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chuang, Chihyuan; Collibee, Scott; Ashcraft, Luke; Wang, Wenyue; Vander
Wal, Mark; Wang, Xiaolin; Hwee, Darren T.; Wu, Yangsong; Wang, Jingying;
Chin, Eva R.; Cremin, Peadar; Zamora, Jeanelle; Hartman, James;
Schaletzky, Julia; Wehri, Eddie; Robertson, Laura A.; Malik, Fady I.;
Morgan, Bradley P.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(19), 14142-14152

$RFMT $RIREG SCHEME202 STEP1
$RXN



  2  1
$MOL
2-Amino-N-methylbenzamide
C8H10N2O
4141-08-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 N 5.3901 4.0010 0.0 0
M  V30 3 O 5.3901 1.3337 0.0 0
M  V30 4 C 6.9302 4.0010 0.0 0
M  V30 5 N 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 2.3101 1.3337 0.0 0
M  V30 8 C 2.3101 4.0010 0.0 0
M  V30 9 C 0.7700 1.3337 0.0 0
M  V30 10 C 0.7700 4.0010 0.0 0
M  V30 11 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 4
M  V30 5 1 5 7
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C15H21N3O4
2998587-28-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 4.0012 0.0 0
M  V30 2 N 0.7700 4.0012 0.0 0
M  V30 3 O 3.0801 5.3348 0.0 0
M  V30 4 C 0.0000 5.3348 0.0 0
M  V30 5 N 5.3901 4.0012 0.0 0
M  V30 6 C 6.9302 4.0012 0.0 0
M  V30 7 C 7.7002 5.3348 0.0 0
M  V30 8 O 7.7002 2.6675 0.0 0
M  V30 9 N 9.2402 5.3348 0.0 0
M  V30 10 C 10.0102 6.6685 0.0 0
M  V30 11 O 11.5503 6.6685 0.0 0
M  V30 12 O 9.2402 8.0023 0.0 0
M  V30 13 C 12.3203 8.0023 0.0 0
M  V30 14 C 13.6539 7.2323 0.0 0
M  V30 15 C 13.0903 9.3360 0.0 0
M  V30 16 C 10.9866 8.7723 0.0 0
M  V30 17 C 3.0801 2.6675 0.0 0
M  V30 18 C 4.6201 2.6675 0.0 0
M  V30 19 C 2.3101 1.3337 0.0 0
M  V30 20 C 5.3901 1.3337 0.0 0
M  V30 21 C 3.0801 0.0000 0.0 0
M  V30 22 C 4.6201 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 18
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4141-08-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2998587-28-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40640859
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for
Platelet Degranulation Modulation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bayrak, Alp; Mohr, Florian; Kolb, Kyra; Szpakowska, Martyna; Shevchenko,
Ekaterina; Dicenta, Valerie; Rohlfing, Anne-Katrin; Kudolo, Mark;
Pantsar, Tatu; Guenther, Marcel; Kaczor, Agnieszka A.; Poso, Antti;
Chevigne, Andy; Pillaiyar, Thanigaimalai; Gawaz, Meinrad; Laufer, Stefan
A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(19), 13365-13384

$RFMT $RIREG SCHEME203 STEP1
$RXN



  2  1
$MOL
L-Serine, methyl ester
C4H9NO3
2788-84-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 7 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 2.3100 0.0 0 CFG=1
M  V30 2 C 4.0011 1.5400 0.0 0
M  V30 3 C 1.3338 1.5400 0.0 0
M  V30 4 N 2.6674 3.8500 0.0 0
M  V30 5 O 5.3347 2.3100 0.0 0
M  V30 6 O 4.0011 0.0000 0.0 0
M  V30 7 O 0.0000 2.3100 0.0 0
M  V30 8 C 6.6685 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
BOC-L-Phenylalanine
C14H19NO4
13734-34-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 2 C 4.6201 4.0012 0.0 0
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6766 6.1048 0.0 0
M  V30 14 C 3.0801 4.0012 0.0 0
M  V30 15 C 2.3101 5.3348 0.0 0
M  V30 16 C 2.3101 2.6675 0.0 0
M  V30 17 C 0.7700 5.3348 0.0 0
M  V30 18 C 0.7700 2.6675 0.0 0
M  V30 19 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 14
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-phenylalanyl-L-serine methyl ester
C18H26N2O6
34290-59-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 5.3347 0.0 0 CFG=2
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 C 5.3900 5.3347 0.0 0
M  V30 4 N 7.7000 6.6685 0.0 0
M  V30 5 N 4.6200 6.6685 0.0 0
M  V30 6 O 4.6200 4.0011 0.0 0
M  V30 7 C 9.2400 6.6685 0.0 0
M  V30 8 C 3.0800 6.6685 0.0 0 CFG=1
M  V30 9 O 10.0100 8.0021 0.0 0
M  V30 10 O 10.0100 5.3347 0.0 0
M  V30 11 C 2.3100 8.0021 0.0 0
M  V30 12 C 2.3100 5.3347 0.0 0
M  V30 13 C 11.5500 8.0021 0.0 0
M  V30 14 O 0.7700 8.0021 0.0 0
M  V30 15 O 3.0800 9.3358 0.0 0
M  V30 16 O 0.7700 5.3347 0.0 0
M  V30 17 C 11.5500 6.4621 0.0 0
M  V30 18 C 13.0900 8.0021 0.0 0
M  V30 19 C 11.5500 9.5421 0.0 0
M  V30 20 C 0.0000 9.3358 0.0 0
M  V30 21 C 6.9300 2.6674 0.0 0
M  V30 22 C 7.7000 1.3336 0.0 0
M  V30 23 C 5.3900 2.6674 0.0 0
M  V30 24 C 6.9300 0.0000 0.0 0
M  V30 25 C 4.6200 1.3336 0.0 0
M  V30 26 C 5.3900 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 21
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=1
M  V30 13 1 9 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 1 13 18
M  V30 19 1 13 19
M  V30 20 1 14 20
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 25
M  V30 25 2 24 26
M  V30 26 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2788-84-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13734-34-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 34290-59-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24281822
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM aerobic
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and Biological Evaluation of CF3Se-Substituted -Amino Acid
Derivatives
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Han, Zhou-Zhou; Dong, Tao; Ming, Xiao-Xia; Kuang, Fu; Zhang, Cheng-Pan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2021), 16(20), 3177-3180

$RFMT $RIREG SCHEME204 STEP1
$RXN



  2  1
$MOL
Benzocaine
C9H11NO2
94-09-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 O 6.6684 2.3100 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 8.0022 1.5400 0.0 0
M  V30 5 C 9.3359 2.3100 0.0 0
M  V30 6 N 0.0000 4.6201 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 2.6675 1.5400 0.0 0
M  V30 9 C 4.0011 3.8500 0.0 0
M  V30 10 C 1.3337 2.3100 0.0 0
M  V30 11 C 2.6675 4.6201 0.0 0
M  V30 12 C 1.3337 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(3-Phenylpropoxy)benzoic acid
C16H16O3
30762-07-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 8.0022 4.6201 0.0 0
M  V30 2 C 6.6685 3.8501 0.0 0
M  V30 3 C 5.3348 4.6201 0.0 0
M  V30 4 C 4.0010 3.8501 0.0 0
M  V30 5 C 13.3370 1.5400 0.0 0
M  V30 6 O 13.3370 0.0000 0.0 0
M  V30 7 O 14.6707 2.3101 0.0 0
M  V30 8 C 9.3358 3.8501 0.0 0
M  V30 9 C 9.3358 2.3101 0.0 0
M  V30 10 C 10.6697 4.6201 0.0 0
M  V30 11 C 10.6697 1.5400 0.0 0
M  V30 12 C 12.0033 3.8501 0.0 0
M  V30 13 C 12.0033 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 16 C 2.6673 6.1601 0.0 0
M  V30 17 C 0.0000 4.6201 0.0 0
M  V30 18 C 1.3337 6.9302 0.0 0
M  V30 19 C 0.0000 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 14
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 13
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethyl 4-[[4-(3-phenylpropoxy)benzoyl]amino]benzoate
C25H25NO4
2762795-95-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 14.6708 4.6201 0.0 0
M  V30 2 C 13.3370 3.8501 0.0 0
M  V30 3 O 13.3370 2.3101 0.0 0
M  V30 4 C 20.0057 1.5400 0.0 0
M  V30 5 O 21.3393 2.3101 0.0 0
M  V30 6 O 20.0057 0.0000 0.0 0
M  V30 7 C 22.6730 1.5400 0.0 0
M  V30 8 C 24.0067 2.3101 0.0 0
M  V30 9 O 8.0022 6.9302 0.0 0
M  V30 10 C 6.6685 6.1601 0.0 0
M  V30 11 C 5.3348 6.9302 0.0 0
M  V30 12 C 4.0010 6.1601 0.0 0
M  V30 13 C 16.0045 3.8501 0.0 0
M  V30 14 C 17.3382 4.6201 0.0 0
M  V30 15 C 16.0045 2.3101 0.0 0
M  V30 16 C 18.6718 3.8501 0.0 0
M  V30 17 C 17.3382 1.5400 0.0 0
M  V30 18 C 18.6718 2.3101 0.0 0
M  V30 19 C 12.0033 4.6201 0.0 0
M  V30 20 C 10.6697 3.8501 0.0 0
M  V30 21 C 12.0033 6.1601 0.0 0
M  V30 22 C 9.3358 4.6201 0.0 0
M  V30 23 C 10.6697 6.9302 0.0 0
M  V30 24 C 9.3358 6.1601 0.0 0
M  V30 25 C 2.6673 6.9302 0.0 0
M  V30 26 C 2.6673 8.4702 0.0 0
M  V30 27 C 1.3337 6.1601 0.0 0
M  V30 28 C 1.3337 9.2402 0.0 0
M  V30 29 C 0.0000 6.9302 0.0 0
M  V30 30 C 0.0000 8.4702 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 2 2 3
M  V30 4 1 2 19
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 18
M  V30 8 1 5 7
M  V30 9 1 7 8
M  V30 10 1 9 10
M  V30 11 1 9 24
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 12 25
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 94-09-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 30762-07-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2762795-95-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31490959
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-66-3
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development and in-vitro Profiling of Dual FXR/LTA4H Modulators
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Schierle, Simone; Brunst, Steffen; Helmstadter, Moritz; Ebert, Roland;
Kramer, Jan S.; Steinhilber, Dieter; Proschak, Ewgenij; Merk, Daniel
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2021), 16(15), 2366-2374

$RFMT $RIREG SCHEME205 STEP1
$RXN



  2  1
$MOL
3,4-Difluoroaniline
C6H5F2N
3863-11-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 1.5400 0.0000 0.0 0
M  V30 2 F 0.0000 2.6673 0.0 0
M  V30 3 N 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Methyl-1H-pyrrole-2-carboxylic acid
C6H7NO2
6973-60-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 1.5400 0.0 0
M  V30 2 O 5.1049 2.3100 0.0 0
M  V30 3 O 3.7711 0.0000 0.0 0
M  V30 4 C 0.7104 0.1773 0.0 0
M  V30 5 C 2.4374 2.3100 0.0 0
M  V30 6 N 1.0306 1.6836 0.0 0
M  V30 7 C 2.2765 3.8416 0.0 0
M  V30 8 C 0.0000 2.8281 0.0 0
M  V30 9 C 0.7700 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3,4-Difluorophenyl)-1-methyl-1H-pyrrole-2-carboxamide
C12H10F2N2O
1388765-64-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6798 2.6674 0.0 0
M  V30 2 C 3.9098 4.0011 0.0 0
M  V30 3 O 4.6798 5.3347 0.0 0
M  V30 4 F 9.2998 0.0000 0.0 0
M  V30 5 F 10.8398 2.6674 0.0 0
M  V30 6 C 1.9406 6.7117 0.0 0
M  V30 7 C 6.2198 2.6674 0.0 0
M  V30 8 C 6.9898 1.3338 0.0 0
M  V30 9 C 6.9898 4.0011 0.0 0
M  V30 10 C 8.5298 1.3338 0.0 0
M  V30 11 C 8.5298 4.0011 0.0 0
M  V30 12 C 9.2998 2.6674 0.0 0
M  V30 13 C 2.3698 4.0011 0.0 0
M  V30 14 N 1.4645 5.2470 0.0 0
M  V30 15 C 1.4645 2.7552 0.0 0
M  V30 16 C 0.0000 4.7711 0.0 0
M  V30 17 C 0.0000 3.2311 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 2 2 3
M  V30 4 1 2 13
M  V30 5 1 4 10
M  V30 6 1 5 12
M  V30 7 1 6 14
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3863-11-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6973-60-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1388765-64-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24782806
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 12125-02-9
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and structure activity relationship of glyoxamide derivatives
as anti-hepatitis B virus agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Amblard, Franck; Boucle, Sebastien; Bassit, Leda; Chen, Zhe; Sari, Ozkan;
Cox, Bryan; Verma, Kiran; Ozturk, Tugba; Ollinger-Russell, Olivia;
Schinazi, Raymond F.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 31115952

$RFMT $RIREG SCHEME206 STEP1
$RXN



  2  1
$MOL
Phenylacetic acid
C8H8O2
103-82-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 C 5.3901 1.3337 0.0 0
M  V30 3 O 4.6201 0.0000 0.0 0
M  V30 4 O 6.9302 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 2.3101 4.0010 0.0 0
M  V30 7 C 2.3101 1.3337 0.0 0
M  V30 8 C 0.7700 4.0010 0.0 0
M  V30 9 C 0.7700 1.3337 0.0 0
M  V30 10 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 3-[(5-amino-1,3,4-thiadiazol-2-yl)thio]propanoate
C9H15N3O2S2
1599822-92-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 8.0023 2.6218 0.0 0
M  V30 2 C 6.6685 1.8517 0.0 0
M  V30 3 C 5.3348 2.6218 0.0 0
M  V30 4 C 4.0012 1.8517 0.0 0
M  V30 5 O 2.6675 2.6218 0.0 0
M  V30 6 O 4.0012 0.3117 0.0 0
M  V30 7 C 1.3337 1.8517 0.0 0
M  V30 8 C 2.1037 0.5181 0.0 0
M  V30 9 C 0.0000 1.0817 0.0 0
M  V30 10 C 0.5637 3.1854 0.0 0
M  V30 11 N 13.3050 1.4946 0.0 0
M  V30 12 C 9.3360 1.8517 0.0 0
M  V30 13 N 9.4969 0.3202 0.0 0
M  V30 14 S 10.7428 2.4781 0.0 0
M  V30 15 N 11.0034 0.0000 0.0 0
M  V30 16 C 11.7734 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 1 11 16
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 3-[[5-[(2-phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]thio]pr...
C17H21N3O3S2
2484994-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3900 5.3347 0.0 0
M  V30 2 C 4.6200 4.0011 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 O 5.3900 2.6674 0.0 0
M  V30 5 S 10.5457 7.0100 0.0 0
M  V30 6 C 11.9526 6.3836 0.0 0
M  V30 7 C 13.1985 7.2887 0.0 0
M  V30 8 C 14.6053 6.6624 0.0 0
M  V30 9 O 15.8511 7.5676 0.0 0
M  V30 10 O 14.7664 5.1308 0.0 0
M  V30 11 C 17.2581 6.9413 0.0 0
M  V30 12 C 17.8844 8.3481 0.0 0
M  V30 13 C 18.6649 6.3148 0.0 0
M  V30 14 C 16.6318 5.5343 0.0 0
M  V30 15 C 6.9300 5.3347 0.0 0
M  V30 16 S 7.8351 6.5806 0.0 0
M  V30 17 N 7.8351 4.0889 0.0 0
M  V30 18 C 9.2998 6.1047 0.0 0
M  V30 19 N 9.2998 4.5647 0.0 0
M  V30 20 C 2.3100 2.6674 0.0 0
M  V30 21 C 0.7700 2.6674 0.0 0
M  V30 22 C 3.0800 1.3336 0.0 0
M  V30 23 C 0.0000 1.3336 0.0 0
M  V30 24 C 2.3100 0.0000 0.0 0
M  V30 25 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 20
M  V30 6 1 5 6
M  V30 7 1 5 18
M  V30 8 1 6 7
M  V30 9 1 7 8
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 9 11
M  V30 13 1 11 12
M  V30 14 1 11 13
M  V30 15 1 11 14
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 103-82-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1599822-92-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2484994-88-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22615131
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl
linker
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Duvall, Bridget; Zimmermann, Sarah C.; Gao, Run-Duo; Thomas, Ajit G.;
Kalcic, Filip; Veeravalli, Vijayabhaskar; Elgogary, Amira; Rais, Rana;
Rojas, Camilo; Le, Anne; Slusher, Barbara S.; Tsukamoto, Takashi
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2020), 28(20), 115698

$RFMT $RIREG SCHEME207 STEP1
$RXN



  2  1
$MOL
Benzenepropanoic acid
C9H10O2
501-52-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 C 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethyl -amino-3-chlorobenzenepropanoate
C11H14ClNO2
498581-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.0801 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 N 5.3348 4.6201 0.0 0
M  V30 4 C 8.0022 3.0801 0.0 0
M  V30 5 O 9.3360 2.3101 0.0 0
M  V30 6 O 8.0022 4.6201 0.0 0
M  V30 7 C 10.6697 3.0801 0.0 0
M  V30 8 C 12.0033 2.3101 0.0 0
M  V30 9 Cl 0.0000 3.0801 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 3.0801 0.0 0
M  V30 12 C 4.0012 0.7700 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 0.0000 0.0 0
M  V30 15 C 1.3337 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 9 13
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenepropanoic acid, 3-chloro--[(1-oxo-3-phenylpropyl)amino]-, ethyl ester
C20H22ClNO3
3048689-42-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0
M  V30 2 N 6.9300 5.3347 0.0 0
M  V30 3 C 4.6200 6.6684 0.0 0
M  V30 4 C 7.7000 6.6684 0.0 0
M  V30 5 C 3.0800 6.6684 0.0 0
M  V30 6 C 9.2400 6.6684 0.0 0
M  V30 7 O 6.9300 8.0021 0.0 0
M  V30 8 O 2.3100 8.0021 0.0 0
M  V30 9 O 2.3100 5.3347 0.0 0
M  V30 10 C 10.0100 8.0021 0.0 0
M  V30 11 C 0.7700 8.0021 0.0 0
M  V30 12 C 0.0000 9.3358 0.0 0
M  V30 13 Cl 5.3900 0.0000 0.0 0
M  V30 14 C 4.6200 4.0011 0.0 0
M  V30 15 C 5.3900 2.6674 0.0 0
M  V30 16 C 3.0800 4.0011 0.0 0
M  V30 17 C 4.6200 1.3336 0.0 0
M  V30 18 C 2.3100 2.6674 0.0 0
M  V30 19 C 3.0800 1.3336 0.0 0
M  V30 20 C 11.5500 8.0021 0.0 0
M  V30 21 C 12.3200 9.3358 0.0 0
M  V30 22 C 12.3200 6.6684 0.0 0
M  V30 23 C 13.8600 9.3358 0.0 0
M  V30 24 C 13.8600 6.6684 0.0 0
M  V30 25 C 14.6300 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 10 20
M  V30 13 1 11 12
M  V30 14 1 13 17
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 501-52-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 498581-88-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3048689-42-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40877745
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and biological characterization of an orally bioavailable
lactate dehydrogenase-A inhibitor against pancreatic cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sharma, Horrick; Mondal, Somrita; Urquiza, Uzziah; Esparza, Colter;
Bartlett, Seth; Santa-Pinter, Landon; Hill, Hanna; White, Madalyn;
Sharma, Pragya; Luckett-Chastain, Lerin; Cooper, Anne; Rasel, Mohammad;
Gao, Philip; Battaile, Kevin P.; Shukla, Surendra K.; Lovell, Scott;
Ihnat, Michael A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 275116598

$RFMT $RIREG SCHEME208 STEP1
$RXN



  2  1
$MOL
1-Adamantaneacetic acid
C12H18O2
4942-47-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5315 3.0177 0.0 0
M  V30 2 C 6.8679 2.2462 0.0 0
M  V30 3 O 6.8679 0.7033 0.0 0
M  V30 4 O 8.2040 3.0177 0.0 0
M  V30 5 C 4.1954 2.2462 0.0 0
M  V30 6 C 2.9049 3.0865 0.0 0
M  V30 7 C 4.2778 0.7085 0.0 0
M  V30 8 C 2.4985 2.2354 0.0 0
M  V30 9 C 1.6968 2.3889 0.0 0
M  V30 10 C 3.0696 0.0111 0.0 0
M  V30 11 C 1.2903 1.5378 0.0 0
M  V30 12 C 0.0000 2.3778 0.0 0
M  V30 13 C 1.7793 0.8512 0.0 0
M  V30 14 C 1.3729 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 9 13
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 1 11 12
M  V30 16 1 11 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
tert-Butyl [2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate
C11H24N2O4
153086-78-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 O 2.6675 2.3101 0.0 0
M  V30 4 O 4.0012 0.0000 0.0 0
M  V30 5 C 6.6687 1.5400 0.0 0
M  V30 6 C 1.3338 1.5400 0.0 0
M  V30 7 C 8.0023 2.3101 0.0 0
M  V30 8 C 2.1038 0.2064 0.0 0
M  V30 9 C 0.0000 0.7700 0.0 0
M  V30 10 C 0.5638 2.8737 0.0 0
M  V30 11 O 9.3360 1.5400 0.0 0
M  V30 12 C 10.6697 2.3101 0.0 0
M  V30 13 C 12.0035 1.5400 0.0 0
M  V30 14 O 13.3372 2.3101 0.0 0
M  V30 15 C 14.6708 1.5400 0.0 0
M  V30 16 C 16.0045 2.3101 0.0 0
M  V30 17 N 17.3383 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 12-oxo-13-tricyclo[3.3.1.13,7]dec-1-yl-5,8-dioxa-2,11-diaza...
C23H40N2O5
1263772-35-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5213 3.0120 0.0 0
M  V30 2 C 6.8550 2.2420 0.0 0
M  V30 3 N 8.1887 3.0120 0.0 0
M  V30 4 O 6.8550 0.7019 0.0 0
M  V30 5 C 9.5225 2.2420 0.0 0
M  V30 6 C 10.8562 3.0120 0.0 0
M  V30 7 O 12.1898 2.2420 0.0 0
M  V30 8 C 13.5235 3.0120 0.0 0
M  V30 9 C 14.8573 2.2420 0.0 0
M  V30 10 O 16.1910 3.0120 0.0 0
M  V30 11 C 17.5247 2.2420 0.0 0
M  V30 12 C 18.8583 3.0120 0.0 0
M  V30 13 N 20.1922 2.2420 0.0 0
M  V30 14 C 21.5258 3.0120 0.0 0
M  V30 15 O 22.8595 2.2420 0.0 0
M  V30 16 O 21.5258 4.5520 0.0 0
M  V30 17 C 24.1932 3.0120 0.0 0
M  V30 18 C 24.9632 1.6783 0.0 0
M  V30 19 C 25.5270 3.7820 0.0 0
M  V30 20 C 23.4231 4.3457 0.0 0
M  V30 21 C 4.1877 2.2420 0.0 0
M  V30 22 C 2.8994 3.0807 0.0 0
M  V30 23 C 4.2697 0.7072 0.0 0
M  V30 24 C 2.4938 2.2312 0.0 0
M  V30 25 C 1.6937 2.3844 0.0 0
M  V30 26 C 3.0641 0.0109 0.0 0
M  V30 27 C 1.2881 1.5350 0.0 0
M  V30 28 C 0.0000 2.3733 0.0 0
M  V30 29 C 1.7760 0.8496 0.0 0
M  V30 30 C 1.3703 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 21
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 17 20
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 21 24
M  V30 24 1 22 25
M  V30 25 1 23 26
M  V30 26 1 24 27
M  V30 27 1 25 28
M  V30 28 1 25 29
M  V30 29 1 26 29
M  V30 30 1 26 30
M  V30 31 1 27 28
M  V30 32 1 27 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4942-47-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 153086-78-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1263772-35-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31556162
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors
activating the ER stress pathway
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rastelli, Ettore J.; Sannino, Sara; Hart, Duncan J.; Sharlow, Elizabeth
R.; Lazo, John S.; Brodsky, Jeffrey L.; Wipf, Peter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2021), 46128167

$RFMT $RIREG SCHEME209 STEP1
$RXN



  2  1
$MOL
3-Nitrobenzoic acid
C7H5NO4
121-92-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.0800 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3337 4.6201 0.0 0
M  V30 4 N 6.6686 3.0800 0.0 0 VAL=5
M  V30 5 O 6.6686 4.6201 0.0 0
M  V30 6 O 8.0022 2.3100 0.0 0
M  V30 7 C 2.6675 2.3100 0.0 0
M  V30 8 C 4.0011 3.0800 0.0 0
M  V30 9 C 2.6675 0.7700 0.0 0
M  V30 10 C 5.3348 2.3100 0.0 0
M  V30 11 C 4.0011 0.0000 0.0 0
M  V30 12 C 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 10
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Amino-2-methoxypyridine
C6H8N2O
6628-77-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7700 1.3337 0.0 0
M  V30 2 C 0.0000 2.6673 0.0 0
M  V30 3 N 6.9302 1.3337 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 N 3.0801 0.0000 0.0 0
M  V30 7 C 4.6201 2.6673 0.0 0
M  V30 8 C 4.6201 0.0000 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(6-Methoxy-3-pyridinyl)-3-nitrobenzamide
C13H11N3O4
1181057-77-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 3.0801 0.0 0
M  V30 2 N 8.0022 2.3101 0.0 0
M  V30 3 O 6.6685 4.6201 0.0 0
M  V30 4 N 1.3337 3.0801 0.0 0 VAL=5
M  V30 5 O 1.3337 4.6201 0.0 0
M  V30 6 O 0.0000 2.3101 0.0 0
M  V30 7 O 13.3370 5.3901 0.0 0
M  V30 8 C 14.6707 4.6201 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 C 4.0010 3.0801 0.0 0
M  V30 11 C 5.3348 0.7700 0.0 0
M  V30 12 C 2.6673 2.3101 0.0 0
M  V30 13 C 4.0010 0.0000 0.0 0
M  V30 14 C 2.6673 0.7700 0.0 0
M  V30 15 C 9.3358 3.0801 0.0 0
M  V30 16 C 9.3358 4.6201 0.0 0
M  V30 17 C 10.6697 2.3101 0.0 0
M  V30 18 C 10.6697 5.3901 0.0 0
M  V30 19 N 12.0033 3.0801 0.0 0
M  V30 20 C 12.0033 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 15
M  V30 5 2 4 5
M  V30 6 2 4 6
M  V30 7 1 4 12
M  V30 8 1 7 8
M  V30 9 1 7 20
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 121-92-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6628-77-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1181057-77-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33822229
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM [11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin
Aggregates with Reduced Binding to AD Pathological Proteins
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liu, Longbin; Johnson, Peter D.; Prime, Michael E.; Khetarpal, Vinod;
Lee, Matthew R.; Brown, Christopher J.; Chen, Xuemei; Clark-Frew, Daniel;
Coe, Samuel; Conlon, Mike; Davis, Randall; Ensor, Samantha; Esposito,
Simone; Moren, Anton Forsberg; Gai, Xinjie; Green, Samantha; Greenaway,
Catherine; Haber, James; Halldin, Christer; Hayes, Sarah; Herbst, Todd;
Herrmann, Frank; Hessmann, Manuela; Hsai, Ming Min; Kotey, Adrian;
Mangette, John E.; Mills, Matthew R.; Monteagudo, Edith; Nag, Sangram;
Nibbio, Martina; Orsatti, Laura; Schaertl, Sabine; Scheich, Christoph;
Sproston, Joanne; Stepanov, Vladimir; Varnas, Katarina; Varrone, Andrea;
Wityak, John; Mrzljak, Ladislav; Munoz-Sanjuan, Ignacio; Bard, Jonathan
A.; Dominguez, Celia
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(16), 12003-12021

$RFMT $RIREG SCHEME210 STEP1
$RXN



  2  1
$MOL
5-Bromonicotinic acid
C6H4BrNO2
20826-04-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 Br 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 N 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Trifluoromethoxy)aniline
C7H6F3NO
461-82-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3101 1.3337 0.0 0
M  V30 2 C 1.5400 2.6673 0.0 0
M  V30 3 F 2.3101 4.0010 0.0 0
M  V30 4 F 0.7700 4.0010 0.0 0
M  V30 5 F 0.0000 2.6673 0.0 0
M  V30 6 N 8.4702 1.3337 0.0 0
M  V30 7 C 3.8501 1.3337 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 6.1601 2.6673 0.0 0
M  V30 11 C 6.1601 0.0000 0.0 0
M  V30 12 C 6.9302 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide
C13H8BrF3N2O2
388571-71-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.3358 3.0801 0.0 0
M  V30 2 N 8.0022 2.3101 0.0 0
M  V30 3 O 9.3358 4.6201 0.0 0
M  V30 4 Br 14.6707 3.0801 0.0 0
M  V30 5 O 2.6673 5.3901 0.0 0
M  V30 6 C 1.3337 4.6201 0.0 0
M  V30 7 F 0.0000 5.3901 0.0 0
M  V30 8 F 0.0000 3.8501 0.0 0
M  V30 9 F 1.3337 3.0801 0.0 0
M  V30 10 C 10.6697 2.3101 0.0 0
M  V30 11 C 12.0033 3.0801 0.0 0
M  V30 12 C 10.6697 0.7700 0.0 0
M  V30 13 C 13.3370 2.3101 0.0 0
M  V30 14 N 12.0033 0.0000 0.0 0
M  V30 15 C 13.3370 0.7700 0.0 0
M  V30 16 C 6.6685 3.0801 0.0 0
M  V30 17 C 6.6685 4.6201 0.0 0
M  V30 18 C 5.3348 2.3101 0.0 0
M  V30 19 C 5.3348 5.3901 0.0 0
M  V30 20 C 4.0010 3.0801 0.0 0
M  V30 21 C 4.0010 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 16
M  V30 5 1 4 13
M  V30 6 1 5 6
M  V30 7 1 5 21
M  V30 8 1 6 7
M  V30 9 1 6 8
M  V30 10 1 6 9
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 20826-04-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 461-82-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 388571-71-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33604392
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 108-88-3
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A kinase inhibitor which specifically targets the ABL myristate pocket
(STAMP), but unlike asciminib crosses the blood-brain barrier
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Manley, Paul W.; Huth, Felix; Moussaoui, Saliha; Schoepfer, Joseph
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2022), 59128577

$RFMT $RIREG SCHEME211 STEP1
$RXN



  2  1
$MOL
Urea
CH4N2O
57-13-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 N 0.0000 2.3101 0.0 0
M  V30 3 N 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(4-Hydroxybenzoyl)-1-piperidinepropanoic acid
C15H19NO4
2803886-08-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 O 5.3348 0.0000 0.0 0
M  V30 3 C 10.6697 4.6201 0.0 0
M  V30 4 C 12.0033 3.8501 0.0 0
M  V30 5 C 13.3370 4.6201 0.0 0
M  V30 6 O 14.6707 3.8501 0.0 0
M  V30 7 O 13.3370 6.1601 0.0 0
M  V30 8 O 0.0000 4.6201 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 6.6685 3.8501 0.0 0
M  V30 11 C 8.0022 1.5400 0.0 0
M  V30 12 C 8.0022 4.6201 0.0 0
M  V30 13 C 9.3358 2.3101 0.0 0
M  V30 14 N 9.3358 3.8501 0.0 0
M  V30 15 C 4.0010 2.3101 0.0 0
M  V30 16 C 4.0010 3.8501 0.0 0
M  V30 17 C 2.6673 1.5400 0.0 0
M  V30 18 C 2.6673 4.6201 0.0 0
M  V30 19 C 1.3337 2.3101 0.0 0
M  V30 20 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 9
M  V30 3 1 1 15
M  V30 4 1 3 4
M  V30 5 1 3 14
M  V30 6 1 4 5
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 1 8 20
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(Aminocarbonyl)-4-(4-hydroxybenzoyl)-1-piperidinepropanamide
C16H21N3O4
941068-17-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 O 5.3348 0.0000 0.0 0
M  V30 3 C 10.6697 4.6201 0.0 0
M  V30 4 C 12.0035 3.8501 0.0 0
M  V30 5 C 13.3372 4.6201 0.0 0
M  V30 6 N 14.6708 3.8501 0.0 0
M  V30 7 O 13.3372 6.1601 0.0 0
M  V30 8 C 16.0045 4.6201 0.0 0
M  V30 9 N 16.0045 6.1601 0.0 0
M  V30 10 O 17.3383 3.8501 0.0 0
M  V30 11 O 0.0000 4.6201 0.0 0
M  V30 12 C 6.6687 2.3101 0.0 0
M  V30 13 C 8.0023 1.5400 0.0 0
M  V30 14 C 6.6687 3.8501 0.0 0
M  V30 15 C 9.3360 2.3101 0.0 0
M  V30 16 C 8.0023 4.6201 0.0 0
M  V30 17 N 9.3360 3.8501 0.0 0
M  V30 18 C 4.0012 2.3101 0.0 0
M  V30 19 C 2.6675 1.5400 0.0 0
M  V30 20 C 4.0012 3.8501 0.0 0
M  V30 21 C 1.3338 2.3101 0.0 0
M  V30 22 C 2.6675 4.6201 0.0 0
M  V30 23 C 1.3338 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 12
M  V30 3 1 1 18
M  V30 4 1 3 4
M  V30 5 1 3 17
M  V30 6 1 4 5
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 1 6 8
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 11 23
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 57-13-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2803886-08-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 941068-17-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38145041
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 108-24-7
$DTYPE RXN:VAR(1):NOTES
$DATUM Ac2O also act as solvent
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structural and Functional Study of the Klebsiella pneumoniae VapBC
Toxin-Antitoxin System, Including the Development of an Inhibitor That
Activates VapC
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kang, Sung-Min; Jin, Chenglong; Kim, Do-Hee; Lee, Yuno; Lee, Bong-Jin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(22), 13669-13679

$RFMT $RIREG SCHEME212 STEP1
$RXN



  2  1
$MOL
Monomethyl succinate
C5H8O4
3878-55-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 2.3100 0.0 0
M  V30 2 C 4.0011 1.5400 0.0 0
M  V30 3 O 6.6686 1.5400 0.0 0
M  V30 4 O 5.3348 3.8500 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 8.0022 2.3100 0.0 0
M  V30 7 C 1.3337 1.5400 0.0 0
M  V30 8 O 1.3337 0.0000 0.0 0
M  V30 9 O 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 3-amino-4-(ethylamino)-, methyl ester
C10H14N2O2
343942-49-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 2.6673 0.0 0
M  V30 2 O 1.5400 4.0010 0.0 0
M  V30 3 O 1.5400 1.3337 0.0 0
M  V30 4 C 0.0000 4.0010 0.0 0
M  V30 5 N 6.9302 0.0000 0.0 0
M  V30 6 N 8.4702 2.6673 0.0 0
M  V30 7 C 9.2402 4.0010 0.0 0
M  V30 8 C 10.7802 4.0010 0.0 0
M  V30 9 C 3.8501 2.6673 0.0 0
M  V30 10 C 4.6201 1.3337 0.0 0
M  V30 11 C 4.6201 4.0010 0.0 0
M  V30 12 C 6.1601 1.3337 0.0 0
M  V30 13 C 6.1601 4.0010 0.0 0
M  V30 14 C 6.9302 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 5 12
M  V30 6 1 6 7
M  V30 7 1 6 14
M  V30 8 1 7 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-(ethylamino)-3-[(4-methoxy-1,4-dioxobutyl)amino]-, methyl ester
C15H20N2O5
3032481-80-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 5.3347 0.0 0
M  V30 2 C 7.7000 6.6684 0.0 0
M  V30 3 C 9.2400 6.6684 0.0 0
M  V30 4 O 6.9300 8.0021 0.0 0
M  V30 5 C 10.0100 8.0021 0.0 0
M  V30 6 C 11.5500 8.0021 0.0 0
M  V30 7 O 12.3200 9.3358 0.0 0
M  V30 8 O 12.3200 6.6684 0.0 0
M  V30 9 C 13.8600 9.3358 0.0 0
M  V30 10 N 5.3900 2.6674 0.0 0
M  V30 11 C 4.6200 1.3336 0.0 0
M  V30 12 C 5.3900 0.0000 0.0 0
M  V30 13 C 2.3100 8.0021 0.0 0
M  V30 14 O 0.7700 8.0021 0.0 0
M  V30 15 O 3.0800 9.3358 0.0 0
M  V30 16 C 0.0000 9.3358 0.0 0
M  V30 17 C 5.3900 5.3347 0.0 0
M  V30 18 C 4.6200 4.0011 0.0 0
M  V30 19 C 4.6200 6.6684 0.0 0
M  V30 20 C 3.0800 4.0011 0.0 0
M  V30 21 C 3.0800 6.6684 0.0 0
M  V30 22 C 2.3100 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 10 11
M  V30 11 1 10 18
M  V30 12 1 11 12
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 13 21
M  V30 16 1 14 16
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3878-55-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 343942-49-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3032481-80-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38825448
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bothe, Ulrich; Guenther, Judith; Nubbemeyer, Reinhard; Siebeneicher,
Holger; Ring, Sven; Boemer, Ulf; Peters, Michaele; Rausch, Alexandra;
Denner, Karsten; Himmel, Herbert; Sutter, Andreas; Terebesi, Ildiko;
Lange, Martin; Wengner, Antje M.; Guimond, Nicolas; Thaler, Tobias;
Platzek, Johannes; Eberspaecher, Uwe; Schaefer, Martina; Steuber, Holger;
Zollner, Thomas M.; Steinmeyer, Andreas; Schmidt, Nicole
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1225-1242

$RFMT $RIREG SCHEME213 STEP1
$RXN



  2  1
$MOL
4-[[(tert-butoxycarbonyl)amino]methyl]benzoic acid
C13H17NO4
33233-67-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 5.3348 3.8501 0.0 0
M  V30 3 C 4.0010 4.6201 0.0 0
M  V30 4 O 2.6673 3.8501 0.0 0
M  V30 5 O 4.0010 6.1601 0.0 0
M  V30 6 C 1.3337 4.6201 0.0 0
M  V30 7 C 0.5637 3.2864 0.0 0
M  V30 8 C 0.0000 5.3901 0.0 0
M  V30 9 C 2.1037 5.9538 0.0 0
M  V30 10 C 12.0033 1.5400 0.0 0
M  V30 11 O 12.0033 0.0000 0.0 0
M  V30 12 O 13.3370 2.3101 0.0 0
M  V30 13 C 8.0022 3.8501 0.0 0
M  V30 14 C 8.0022 2.3101 0.0 0
M  V30 15 C 9.3360 4.6201 0.0 0
M  V30 16 C 9.3360 1.5400 0.0 0
M  V30 17 C 10.6697 3.8501 0.0 0
M  V30 18 C 10.6697 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 10 18
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Methoxybenzylamine
C8H11NO
6850-57-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 4.0010 0.0 0
M  V30 2 N 0.0000 4.0010 0.0 0
M  V30 3 O 4.6201 4.0010 0.0 0
M  V30 4 C 6.1601 4.0010 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.8501 2.6673 0.0 0
M  V30 7 C 1.5400 1.3337 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 2.3101 0.0000 0.0 0
M  V30 10 C 3.8501 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 3 4
M  V30 4 1 3 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[[4-[[[(2-methoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]...
C21H26N2O4
2971723-52-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0011 0.0 0
M  V30 2 N 6.1600 4.0011 0.0 0
M  V30 3 C 6.9300 5.3347 0.0 0
M  V30 4 O 6.1600 6.6685 0.0 0
M  V30 5 O 1.5400 4.0011 0.0 0
M  V30 6 C 0.0000 4.0011 0.0 0
M  V30 7 C 13.0900 5.3347 0.0 0
M  V30 8 N 13.8600 6.6685 0.0 0
M  V30 9 C 15.4000 6.6685 0.0 0
M  V30 10 O 16.1700 8.0021 0.0 0
M  V30 11 O 16.1700 5.3347 0.0 0
M  V30 12 C 17.7100 8.0021 0.0 0
M  V30 13 C 17.7100 9.5421 0.0 0
M  V30 14 C 19.2500 8.0021 0.0 0
M  V30 15 C 17.7100 6.4621 0.0 0
M  V30 16 C 3.8500 2.6674 0.0 0
M  V30 17 C 2.3100 2.6674 0.0 0
M  V30 18 C 4.6200 1.3336 0.0 0
M  V30 19 C 1.5400 1.3336 0.0 0
M  V30 20 C 3.8500 0.0000 0.0 0
M  V30 21 C 2.3100 0.0000 0.0 0
M  V30 22 C 8.4700 5.3347 0.0 0
M  V30 23 C 9.2400 4.0011 0.0 0
M  V30 24 C 9.2400 6.6685 0.0 0
M  V30 25 C 10.7800 4.0011 0.0 0
M  V30 26 C 10.7800 6.6685 0.0 0
M  V30 27 C 11.5500 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 3 4
M  V30 5 1 3 22
M  V30 6 1 5 6
M  V30 7 1 5 17
M  V30 8 1 7 8
M  V30 9 1 7 27
M  V30 10 1 8 9
M  V30 11 1 9 10
M  V30 12 2 9 11
M  V30 13 1 10 12
M  V30 14 1 12 13
M  V30 15 1 12 14
M  V30 16 1 12 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 33233-67-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6850-57-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2971723-52-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41060792
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-14-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-Based Design and Synthesis of Covalent Inhibitors for
Deubiquitinase and Acetyltransferase ChlaDUB1 of Chlamydia trachomatis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zimmermann, Thomas; Feng, Jiachen; de Campos, Luana Janaina; Knight,
Lindsey A.; Schloetzer, Jan; Ramirez, Yesid A.; Schwickert, Kevin; Zehe,
Markus; Adler, Thomas B.; Schirmeister, Tanja; Kisker, Caroline;
Sotriffer, Christoph; Conda-Sheridan, Martin; Decker, Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(13), 10710-10742

$RFMT $RIREG SCHEME214 STEP1
$RXN



  2  1
$MOL
2,4-Dichloroaniline
C6H5Cl2N
554-00-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 1.5400 0.0000 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 Cl 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[(Phenylamino)sulfonyl]benzoic acid
C13H11NO4S
6314-72-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 5.3348 4.6201 0.0 0 VAL=6
M  V30 2 N 4.0012 5.3901 0.0 0
M  V30 3 O 6.1048 5.9538 0.0 0
M  V30 4 O 4.5648 3.2864 0.0 0
M  V30 5 C 10.6697 1.5400 0.0 0
M  V30 6 O 12.0033 2.3101 0.0 0
M  V30 7 O 10.6697 0.0000 0.0 0
M  V30 8 C 6.6685 3.8501 0.0 0
M  V30 9 C 8.0022 4.6201 0.0 0
M  V30 10 C 6.6685 2.3101 0.0 0
M  V30 11 C 9.3360 3.8501 0.0 0
M  V30 12 C 8.0022 1.5400 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 5.3901 0.0 0
M  V30 16 C 2.6673 3.0801 0.0 0
M  V30 17 C 0.0000 4.6201 0.0 0
M  V30 18 C 1.3337 2.3101 0.0 0
M  V30 19 C 0.0000 3.0801 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 8
M  V30 5 1 2 14
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 13
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(2,4-Dichlorophenyl)-4-[(phenylamino)sulfonyl]benzamide
C19H14Cl2N2O3S
2832987-89-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 4.6200 4.0011 0.0 0 VAL=6
M  V30 2 N 3.0800 4.0011 0.0 0
M  V30 3 O 4.6200 2.4611 0.0 0
M  V30 4 O 4.6200 5.5411 0.0 0
M  V30 5 C 10.7800 4.0011 0.0 0
M  V30 6 N 11.5500 2.6674 0.0 0
M  V30 7 O 11.5500 5.3347 0.0 0
M  V30 8 Cl 13.0900 0.0000 0.0 0
M  V30 9 Cl 17.7100 2.6674 0.0 0
M  V30 10 C 6.1600 4.0011 0.0 0
M  V30 11 C 6.9300 2.6674 0.0 0
M  V30 12 C 6.9300 5.3347 0.0 0
M  V30 13 C 8.4700 2.6674 0.0 0
M  V30 14 C 8.4700 5.3347 0.0 0
M  V30 15 C 9.2400 4.0011 0.0 0
M  V30 16 C 2.3100 5.3347 0.0 0
M  V30 17 C 0.7700 5.3347 0.0 0
M  V30 18 C 3.0800 6.6685 0.0 0
M  V30 19 C 0.0000 6.6685 0.0 0
M  V30 20 C 2.3100 8.0021 0.0 0
M  V30 21 C 0.7700 8.0021 0.0 0
M  V30 22 C 13.0900 2.6674 0.0 0
M  V30 23 C 13.8600 1.3336 0.0 0
M  V30 24 C 13.8600 4.0011 0.0 0
M  V30 25 C 15.4000 1.3336 0.0 0
M  V30 26 C 15.4000 4.0011 0.0 0
M  V30 27 C 16.1700 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 16
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 15
M  V30 9 1 6 22
M  V30 10 1 8 23
M  V30 11 1 9 27
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 2 12 14
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 554-00-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6314-72-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2832987-89-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32142486
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-activity relationships of agonists for the orphan G
protein-coupled receptor GPR27
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Pillaiyar, Thanigaimalai; Rosato, Francesca; Wozniak, Monika; Blavier,
Jeremy; Charles, Maelle; Laschet, Celine; Kronenberger, Thales; Mueller,
Christa E.; Hanson, Julien
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 225113777

$RFMT $RIREG SCHEME215 STEP1
$RXN



  2  1
$MOL
7-Benzofurancarboxylic acid, 5-bromo-2-methyl-
C10H7BrO3
2138475-12-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0.7700 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 4.0011 0.0000 0.0 0
M  V30 4 C 7.9110 3.8500 0.0 0
M  V30 5 Br 0.0000 5.3900 0.0 0
M  V30 6 C 4.0011 3.0800 0.0 0
M  V30 7 C 4.0011 4.6200 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 O 5.4658 2.6042 0.0 0
M  V30 10 C 5.4658 5.0959 0.0 0
M  V30 11 C 2.6674 5.3900 0.0 0
M  V30 12 C 1.3338 3.0800 0.0 0
M  V30 13 C 6.3710 3.8500 0.0 0
M  V30 14 C 1.3338 4.6200 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 13
M  V30 5 1 5 14
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 2 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N,2-dimethyl-7-benzofurancarboxamide
C11H10BrNO2
2138475-13-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 5.3347 0.0 0
M  V30 2 N 0.7700 5.3347 0.0 0
M  V30 3 O 3.0800 6.6685 0.0 0
M  V30 4 C 0.0000 6.6685 0.0 0
M  V30 5 Br 2.3100 0.0000 0.0 0
M  V30 6 C 8.3912 5.2891 0.0 0
M  V30 7 C 3.0800 4.0011 0.0 0
M  V30 8 C 4.6200 4.0011 0.0 0
M  V30 9 C 2.3100 2.6674 0.0 0
M  V30 10 C 5.3900 2.6674 0.0 0
M  V30 11 O 5.6506 5.1456 0.0 0
M  V30 12 C 3.0800 1.3338 0.0 0
M  V30 13 C 6.8964 2.9876 0.0 0
M  V30 14 C 4.6200 1.3338 0.0 0
M  V30 15 C 7.0574 4.5191 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 12
M  V30 6 1 6 15
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 8 11
M  V30 11 2 9 12
M  V30 12 1 10 13
M  V30 13 2 10 14
M  V30 14 1 11 15
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2138475-12-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2138475-13-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31168962
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):NOTES
$DATUM incremental addition of agent and catalyst in stage 1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Multigram Synthesis of Tetrasubstituted Dihydrobenzofuran GSK973 Enabled
by High-Throughput Experimentation and a Claisen Rearrangement in Flow
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Alder, Catherine M.; Gray, Matthew; Huff, Chelsea A.; Manning, Calvin O.;
Preston, Alex; Rushworth, Philip; Shuster, Leanna E.; Watson, Robert J.;
Wheelhouse, Katherine M. P.; Williams, Glynn D.; Demont, Emmanuel H.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2022), 26(2), 365-379

$RFMT $RIREG SCHEME216 STEP1
$RXN



  2  1
$MOL
1-Methyl dodecanedioate
C13H24O4
3903-40-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 16.0045 2.3101 0.0 0
M  V30 2 C 14.6708 1.5400 0.0 0
M  V30 3 O 17.3383 1.5400 0.0 0
M  V30 4 O 16.0045 3.8501 0.0 0
M  V30 5 C 13.3372 2.3101 0.0 0
M  V30 6 C 18.6720 2.3101 0.0 0
M  V30 7 C 12.0035 1.5400 0.0 0
M  V30 8 C 10.6697 2.3101 0.0 0
M  V30 9 C 9.3360 1.5400 0.0 0
M  V30 10 C 8.0023 2.3101 0.0 0
M  V30 11 C 6.6685 1.5400 0.0 0
M  V30 12 C 5.3348 2.3101 0.0 0
M  V30 13 C 4.0012 1.5400 0.0 0
M  V30 14 C 2.6675 2.3101 0.0 0
M  V30 15 C 1.3337 1.5400 0.0 0
M  V30 16 O 1.3337 0.0000 0.0 0
M  V30 17 O 0.0000 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Bis(1,1-dimethylethyl) 3,3-[[2-amino-2-[[3-(1,1-dimethylethoxy)-3-oxopr...
C25H47NO9
175724-30-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.0100 10.0100 0.0 0
M  V30 2 C 10.0100 8.4700 0.0 0
M  V30 3 C 8.4700 10.0100 0.0 0
M  V30 4 C 11.5500 10.0100 0.0 0
M  V30 5 N 10.0100 11.5500 0.0 0
M  V30 6 O 8.6764 7.7000 0.0 0
M  V30 7 O 7.7000 11.3436 0.0 0
M  V30 8 O 12.3200 11.3436 0.0 0
M  V30 9 C 8.6764 6.1600 0.0 0
M  V30 10 C 6.1600 11.3436 0.0 0
M  V30 11 C 13.8600 11.3436 0.0 0
M  V30 12 C 7.3426 5.3900 0.0 0
M  V30 13 C 5.3900 12.6773 0.0 0
M  V30 14 C 14.6300 12.6773 0.0 0
M  V30 15 C 7.3426 3.8500 0.0 0
M  V30 16 C 3.8500 12.6773 0.0 0
M  V30 17 C 16.1700 12.6773 0.0 0
M  V30 18 O 6.0089 3.0800 0.0 0
M  V30 19 O 8.6764 3.0800 0.0 0
M  V30 20 O 3.0800 14.0109 0.0 0
M  V30 21 O 3.0800 11.3436 0.0 0
M  V30 22 O 16.9400 14.0109 0.0 0
M  V30 23 O 16.9400 11.3436 0.0 0
M  V30 24 C 6.0089 1.5400 0.0 0
M  V30 25 C 1.5400 14.0109 0.0 0
M  V30 26 C 18.4800 14.0109 0.0 0
M  V30 27 C 4.4689 1.5400 0.0 0
M  V30 28 C 6.0089 0.0000 0.0 0
M  V30 29 C 7.5489 1.5400 0.0 0
M  V30 30 C 1.5400 15.5509 0.0 0
M  V30 31 C 0.0000 14.0109 0.0 0
M  V30 32 C 1.5400 12.4709 0.0 0
M  V30 33 C 18.4800 15.5509 0.0 0
M  V30 34 C 20.0200 14.0109 0.0 0
M  V30 35 C 18.4800 12.4709 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 10 13
M  V30 13 1 11 14
M  V30 14 1 12 15
M  V30 15 1 13 16
M  V30 16 1 14 17
M  V30 17 1 15 18
M  V30 18 2 15 19
M  V30 19 1 16 20
M  V30 20 2 16 21
M  V30 21 1 17 22
M  V30 22 2 17 23
M  V30 23 1 18 24
M  V30 24 1 20 25
M  V30 25 1 22 26
M  V30 26 1 24 27
M  V30 27 1 24 28
M  V30 28 1 24 29
M  V30 29 1 25 30
M  V30 30 1 25 31
M  V30 31 1 25 32
M  V30 32 1 26 33
M  V30 33 1 26 34
M  V30 34 1 26 35
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 12-[[2-[3-(1,1-dimethylethoxy)-3-oxopropoxy]-1,1-bis[[3-(1,1-dimethyle...
C38H69NO12
1551527-33-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  51 50 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 10.6697 0.0 0
M  V30 2 N 12.0033 9.8996 0.0 0
M  V30 3 C 9.8996 9.3360 0.0 0
M  V30 4 C 11.4397 12.0033 0.0 0
M  V30 5 C 9.3360 11.4397 0.0 0
M  V30 6 C 13.3372 10.6697 0.0 0
M  V30 7 O 10.6697 8.0022 0.0 0
M  V30 8 O 10.6697 13.3372 0.0 0
M  V30 9 O 8.0023 10.6697 0.0 0
M  V30 10 C 14.6708 9.8996 0.0 0
M  V30 11 O 13.3372 12.2097 0.0 0
M  V30 12 C 9.8996 6.6685 0.0 0
M  V30 13 C 11.4397 14.6708 0.0 0
M  V30 14 C 6.6685 11.4397 0.0 0
M  V30 15 C 16.0045 10.6697 0.0 0
M  V30 16 C 10.6697 5.3348 0.0 0
M  V30 17 C 10.6697 16.0045 0.0 0
M  V30 18 C 5.3348 10.6697 0.0 0
M  V30 19 C 17.3382 9.8996 0.0 0
M  V30 20 C 9.8996 4.0012 0.0 0
M  V30 21 C 11.4397 17.3382 0.0 0
M  V30 22 C 4.0012 11.4397 0.0 0
M  V30 23 C 18.6720 10.6697 0.0 0
M  V30 24 O 10.6697 2.6673 0.0 0
M  V30 25 O 8.3596 4.0012 0.0 0
M  V30 26 O 10.6697 18.6720 0.0 0
M  V30 27 O 12.9797 17.3382 0.0 0
M  V30 28 O 2.6675 10.6697 0.0 0
M  V30 29 O 4.0012 12.9797 0.0 0
M  V30 30 C 20.0057 9.8996 0.0 0
M  V30 31 C 9.8996 1.3337 0.0 0
M  V30 32 C 11.4397 20.0057 0.0 0
M  V30 33 C 1.3337 11.4397 0.0 0
M  V30 34 C 21.3393 10.6697 0.0 0
M  V30 35 C 8.5660 2.1037 0.0 0
M  V30 36 C 9.1296 0.0000 0.0 0
M  V30 37 C 11.2333 0.5637 0.0 0
M  V30 38 C 12.7733 19.2356 0.0 0
M  V30 39 C 12.2097 21.3393 0.0 0
M  V30 40 C 10.1060 20.7757 0.0 0
M  V30 41 C 2.1037 12.7733 0.0 0
M  V30 42 C 0.0000 12.2097 0.0 0
M  V30 43 C 0.5637 10.1060 0.0 0
M  V30 44 C 22.6730 9.8996 0.0 0
M  V30 45 C 24.0068 10.6697 0.0 0
M  V30 46 C 25.3405 9.8996 0.0 0
M  V30 47 C 26.6742 10.6697 0.0 0
M  V30 48 C 28.0078 9.8996 0.0 0
M  V30 49 O 29.3416 10.6697 0.0 0
M  V30 50 O 28.0078 8.3596 0.0 0
M  V30 51 C 30.6753 9.8996 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 2 6 11
M  V30 11 1 7 12
M  V30 12 1 8 13
M  V30 13 1 9 14
M  V30 14 1 10 15
M  V30 15 1 12 16
M  V30 16 1 13 17
M  V30 17 1 14 18
M  V30 18 1 15 19
M  V30 19 1 16 20
M  V30 20 1 17 21
M  V30 21 1 18 22
M  V30 22 1 19 23
M  V30 23 1 20 24
M  V30 24 2 20 25
M  V30 25 1 21 26
M  V30 26 2 21 27
M  V30 27 1 22 28
M  V30 28 2 22 29
M  V30 29 1 23 30
M  V30 30 1 24 31
M  V30 31 1 26 32
M  V30 32 1 28 33
M  V30 33 1 30 34
M  V30 34 1 31 35
M  V30 35 1 31 36
M  V30 36 1 31 37
M  V30 37 1 32 38
M  V30 38 1 32 39
M  V30 39 1 32 40
M  V30 40 1 33 41
M  V30 41 1 33 42
M  V30 42 1 33 43
M  V30 43 1 34 44
M  V30 44 1 44 45
M  V30 45 1 45 46
M  V30 46 1 46 47
M  V30 47 1 47 48
M  V30 48 1 48 49
M  V30 49 2 48 50
M  V30 50 1 49 51
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3903-40-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 175724-30-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1551527-33-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39012245
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA
Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kandasamy, Pachamuthu; Mori, Shohei; Matsuda, Shigeo; Erande, Namrata;
Datta, Dhrubajyoti; Willoughby, Jennifer L. S.; Taneja, Nate; O'Shea,
Jonathan; Bisbe, Anna; Manoharan, Rajar M.; Yucius, Kristina; Nguyen,
Tuyen; Indrakanti, Ramesh; Gupta, Swati; Gilbert, Jason A.; Racie, Tim;
Chan, Amy; Liu, Ju; Hutabarat, Renta; Nair, Jayaprakash K.; Charisse,
Klaus; Maier, Martin A.; Rajeev, Kallanthottathil G.; Egli, Martin;
Manoharan, Muthiah
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(4), 2506-2523

$RFMT $RIREG SCHEME217 STEP1
$RXN



  2  1
$MOL
3-Methoxyaniline
C7H9NO
536-90-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3348 3.0801 0.0 0
M  V30 2 C 6.6687 2.3101 0.0 0
M  V30 3 N 0.0000 3.0801 0.0 0
M  V30 4 C 4.0012 2.3101 0.0 0
M  V30 5 C 2.6675 3.0801 0.0 0
M  V30 6 C 4.0012 0.7700 0.0 0
M  V30 7 C 1.3338 2.3101 0.0 0
M  V30 8 C 2.6675 0.0000 0.0 0
M  V30 9 C 1.3338 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 7
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-(3-methoxyphenyl)-5-nitrobenzamide
C14H13N3O4
1442089-40-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6675 0.0 0
M  V30 2 N 6.9301 4.0011 0.0 0
M  V30 3 O 6.9301 1.3338 0.0 0
M  V30 4 N 4.6201 0.0000 0.0 0
M  V30 5 N 1.5400 5.3348 0.0 0 VAL=5
M  V30 6 O 0.0000 5.3348 0.0 0
M  V30 7 O 2.3100 6.6686 0.0 0
M  V30 8 O 11.5501 6.6686 0.0 0
M  V30 9 C 13.0901 6.6686 0.0 0
M  V30 10 C 4.6201 2.6675 0.0 0
M  V30 11 C 3.8500 4.0011 0.0 0
M  V30 12 C 3.8500 1.3338 0.0 0
M  V30 13 C 2.3100 4.0011 0.0 0
M  V30 14 C 2.3100 1.3338 0.0 0
M  V30 15 C 1.5400 2.6675 0.0 0
M  V30 16 C 8.4701 4.0011 0.0 0
M  V30 17 C 9.2401 5.3348 0.0 0
M  V30 18 C 9.2401 2.6675 0.0 0
M  V30 19 C 10.7801 5.3348 0.0 0
M  V30 20 C 10.7801 2.6675 0.0 0
M  V30 21 C 11.5501 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 16
M  V30 5 1 4 12
M  V30 6 2 5 6
M  V30 7 2 5 7
M  V30 8 1 5 13
M  V30 9 1 8 9
M  V30 10 1 8 19
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 536-90-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1442089-40-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31626786
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Piperazinobenzodiazepinones: New Encephalitic Alphavirus Inhibitors via
Ring Expansion of 2-Dichloromethylquinazolinones
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ryan, Michael C.; Kim, Eunjung; Cao, Xufeng; Reichard, Walter; Ogorek,
Tyler J.; Das, Pronay; Jonsson, Colleen B.; Baudry, Jerome; Chung,
Donghoon; Golden, Jennifer E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(4), 546-553

$RFMT $RIREG SCHEME218 STEP1
$RXN



  2  1
$MOL
Cyanoacetic acid
C3H3NO2
372-09-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 2.6673 0.0 0
M  V30 2 C 1.5400 1.3336 0.0 0
M  V30 3 C 3.8500 2.6673 0.0 0
M  V30 4 O 2.3100 0.0000 0.0 0
M  V30 5 O 0.0000 1.3336 0.0 0
M  V30 6 N 5.3900 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 3 3 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(2,4-Dimethoxyphenyl)methyl]urea
C10H14N2O3
296277-76-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0801 4.0012 0.0 0
M  V30 2 N 2.3101 5.3348 0.0 0
M  V30 3 C 0.7700 5.3348 0.0 0
M  V30 4 N 0.0000 6.6687 0.0 0
M  V30 5 O 0.0000 4.0012 0.0 0
M  V30 6 O 4.6201 1.3338 0.0 0
M  V30 7 C 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 C 10.0102 5.3348 0.0 0
M  V30 10 C 4.6201 4.0012 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 12 C 5.3901 5.3348 0.0 0
M  V30 13 C 6.9302 2.6675 0.0 0
M  V30 14 C 6.9302 5.3348 0.0 0
M  V30 15 C 7.7002 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 11
M  V30 8 1 8 9
M  V30 9 1 8 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Cyano-N-[[[(2,4-dimethoxyphenyl)methyl]amino]carbonyl]acetamide
C13H15N3O4
1187960-54-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 4.0011 0.0 0
M  V30 2 N 7.7000 5.3347 0.0 0
M  V30 3 C 9.2400 5.3347 0.0 0
M  V30 4 N 10.0100 6.6685 0.0 0
M  V30 5 O 10.0100 4.0011 0.0 0
M  V30 6 C 11.5500 6.6685 0.0 0
M  V30 7 C 12.3200 8.0021 0.0 0
M  V30 8 O 12.3200 5.3347 0.0 0
M  V30 9 C 13.8600 8.0021 0.0 0
M  V30 10 N 15.4000 8.0021 0.0 0
M  V30 11 O 5.3900 1.3336 0.0 0
M  V30 12 C 4.6200 0.0000 0.0 0
M  V30 13 O 0.7700 4.0011 0.0 0
M  V30 14 C 0.0000 5.3347 0.0 0
M  V30 15 C 5.3900 4.0011 0.0 0
M  V30 16 C 4.6200 2.6674 0.0 0
M  V30 17 C 4.6200 5.3347 0.0 0
M  V30 18 C 3.0800 2.6674 0.0 0
M  V30 19 C 3.0800 5.3347 0.0 0
M  V30 20 C 2.3100 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 3 9 10
M  V30 11 1 11 12
M  V30 12 1 11 16
M  V30 13 1 13 14
M  V30 14 1 13 20
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 372-09-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 296277-76-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1187960-54-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40275737
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 108-24-7
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of Covalent, Clickable Probes for Adenosine A1 and A3
Receptors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Trinh, Phuc N. H.; Chong, Daniel J. W.; Leach, Katie; Hill, Stephen J.;
Tyndall, Joel D. A.; May, Lauren T.; Vernall, Andrea J.; Gregory, Karen
J.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(12), 8161-8178

$RFMT $RIREG SCHEME219 STEP1
$RXN



  2  1
$MOL
Benzoic acid, 4-(aminomethyl)-, methyl ester, hydrochloride (1:1)
C9H11NO2.ClH
6232-11-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0800 0.0 0
M  V30 2 O 1.3337 3.8501 0.0 0
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 C 0.0000 3.0800 0.0 0
M  V30 5 C 8.0023 6.1601 0.0 0
M  V30 6 N 9.3360 5.3901 0.0 0
M  V30 7 C 4.0012 3.8501 0.0 0
M  V30 8 C 4.0012 5.3901 0.0 0
M  V30 9 C 5.3348 3.0800 0.0 0
M  V30 10 C 5.3348 6.1601 0.0 0
M  V30 11 C 6.6685 3.8501 0.0 0
M  V30 12 C 6.6685 5.3901 0.0 0
M  V30 13 Cl 4.6680 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[[(1,1-Dimethylethoxy)carbonyl]amino]cyclohexanecarboxylic acid
C12H21NO4
130309-46-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 1.5400 0.0 0
M  V30 2 O 12.0033 2.3101 0.0 0
M  V30 3 O 10.6697 0.0000 0.0 0
M  V30 4 N 5.3348 4.6201 0.0 0
M  V30 5 C 4.0012 3.8501 0.0 0
M  V30 6 O 2.6673 4.6201 0.0 0
M  V30 7 O 4.0012 2.3101 0.0 0
M  V30 8 C 1.3337 3.8501 0.0 0
M  V30 9 C 0.5637 5.1838 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 2.1037 2.5164 0.0 0
M  V30 12 C 9.3360 2.3101 0.0 0
M  V30 13 C 8.0022 1.5400 0.0 0
M  V30 14 C 9.3360 3.8501 0.0 0
M  V30 15 C 6.6685 2.3101 0.0 0
M  V30 16 C 8.0022 4.6201 0.0 0
M  V30 17 C 6.6685 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 4 5
M  V30 5 1 4 17
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 8 11
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]cyclohexyl]carbonyl]amino...
C21H30N2O5
2760730-69-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 1.5400 0.0 0
M  V30 2 N 12.0033 2.3101 0.0 0
M  V30 3 O 10.6697 0.0000 0.0 0
M  V30 4 C 13.3372 1.5400 0.0 0
M  V30 5 N 5.3348 4.6201 0.0 0
M  V30 6 C 4.0012 3.8501 0.0 0
M  V30 7 O 2.6673 4.6201 0.0 0
M  V30 8 O 4.0012 2.3101 0.0 0
M  V30 9 C 1.3337 3.8501 0.0 0
M  V30 10 C 2.1037 2.5164 0.0 0
M  V30 11 C 0.0000 3.0801 0.0 0
M  V30 12 C 0.5637 5.1838 0.0 0
M  V30 13 C 18.6720 4.6201 0.0 0
M  V30 14 O 20.0057 3.8501 0.0 0
M  V30 15 O 18.6720 6.1601 0.0 0
M  V30 16 C 21.3393 4.6201 0.0 0
M  V30 17 C 9.3360 2.3101 0.0 0
M  V30 18 C 8.0022 1.5400 0.0 0
M  V30 19 C 9.3360 3.8501 0.0 0
M  V30 20 C 6.6685 2.3101 0.0 0
M  V30 21 C 8.0022 4.6201 0.0 0
M  V30 22 C 6.6685 3.8501 0.0 0
M  V30 23 C 14.6708 2.3101 0.0 0
M  V30 24 C 16.0045 1.5400 0.0 0
M  V30 25 C 14.6708 3.8501 0.0 0
M  V30 26 C 17.3382 2.3101 0.0 0
M  V30 27 C 16.0045 4.6201 0.0 0
M  V30 28 C 17.3382 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 23
M  V30 6 1 5 6
M  V30 7 1 5 22
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 7 9
M  V30 11 1 9 10
M  V30 12 1 9 11
M  V30 13 1 9 12
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 13 28
M  V30 17 1 14 16
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 22
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 2 25 27
M  V30 28 2 26 28
M  V30 29 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6232-11-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 130309-46-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760730-69-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31382127
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded
library technology (ELT)
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ding, Yun; Belyanskaya, Svetlana; DeLorey, Jennifer L.; Messer, Jeffrey
A.; Joseph Franklin, G.; Centrella, Paolo A.; Morgan, Barry A.; Clark,
Matthew A.; Skinner, Steven R.; Dodson, Jason W.; Li, Peng; Marino,
Joseph P. Jr.; Israel, David I.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 41116216

$RFMT $RIREG SCHEME220 STEP1
$RXN



  2  1
$MOL
3-Iodobenzoic acid
C7H5IO2
618-51-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 I 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-Phenyl-4-(trifluoromethoxy)benzenepropanamine
C16H16F3NO
2709014-52-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.8501 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 2.6673 1.5400 0.0 0
M  V30 4 N 2.6673 0.0000 0.0 0
M  V30 5 O 9.3360 6.9302 0.0 0
M  V30 6 C 10.6697 6.1601 0.0 0
M  V30 7 F 10.6697 4.6201 0.0 0
M  V30 8 F 12.0033 5.3901 0.0 0
M  V30 9 F 12.0033 6.9302 0.0 0
M  V30 10 C 5.3348 4.6201 0.0 0
M  V30 11 C 6.6685 3.8501 0.0 0
M  V30 12 C 5.3348 6.1601 0.0 0
M  V30 13 C 8.0022 4.6201 0.0 0
M  V30 14 C 6.6685 6.9302 0.0 0
M  V30 15 C 8.0022 6.1601 0.0 0
M  V30 16 C 2.6673 4.6201 0.0 0
M  V30 17 C 2.6673 6.1601 0.0 0
M  V30 18 C 1.3337 3.8501 0.0 0
M  V30 19 C 1.3337 6.9302 0.0 0
M  V30 20 C 0.0000 4.6201 0.0 0
M  V30 21 C 0.0000 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 1 16
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 5 6
M  V30 7 1 5 15
M  V30 8 1 6 7
M  V30 9 1 6 8
M  V30 10 1 6 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Iodo-N-[3-phenyl-3-[4-(trifluoromethoxy)phenyl]propyl]benzamide
C23H19F3INO2
2709014-24-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.2401 6.6684 0.0 0
M  V30 2 C 8.4701 5.3348 0.0 0
M  V30 3 C 6.9301 5.3348 0.0 0
M  V30 4 N 6.1601 4.0011 0.0 0
M  V30 5 C 4.6201 4.0011 0.0 0
M  V30 6 O 3.8500 5.3348 0.0 0
M  V30 7 O 15.4002 6.6684 0.0 0
M  V30 8 C 16.1702 5.3348 0.0 0
M  V30 9 F 15.4002 4.0011 0.0 0
M  V30 10 F 16.9402 4.0011 0.0 0
M  V30 11 F 17.7102 5.3348 0.0 0
M  V30 12 I 0.0000 1.3337 0.0 0
M  V30 13 C 10.7801 6.6684 0.0 0
M  V30 14 C 11.5501 5.3348 0.0 0
M  V30 15 C 11.5501 8.0022 0.0 0
M  V30 16 C 13.0901 5.3348 0.0 0
M  V30 17 C 13.0901 8.0022 0.0 0
M  V30 18 C 13.8602 6.6684 0.0 0
M  V30 19 C 8.4701 8.0022 0.0 0
M  V30 20 C 6.9301 8.0022 0.0 0
M  V30 21 C 9.2401 9.3359 0.0 0
M  V30 22 C 6.1601 9.3359 0.0 0
M  V30 23 C 8.4701 10.6695 0.0 0
M  V30 24 C 6.9301 10.6695 0.0 0
M  V30 25 C 3.8500 2.6673 0.0 0
M  V30 26 C 2.3100 2.6673 0.0 0
M  V30 27 C 4.6201 1.3337 0.0 0
M  V30 28 C 1.5400 1.3337 0.0 0
M  V30 29 C 3.8500 0.0000 0.0 0
M  V30 30 C 2.3100 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 1 19
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 4 5
M  V30 7 2 5 6
M  V30 8 1 5 25
M  V30 9 1 7 8
M  V30 10 1 7 18
M  V30 11 1 8 9
M  V30 12 1 8 10
M  V30 13 1 8 11
M  V30 14 1 12 28
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 618-51-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2709014-52-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2709014-24-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24414244
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 108-18-9
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Structure-Activity Relationship Studies of Dual
Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hiesinger, Kerstin; Kramer, Jan S.; Beyer, Sandra; Eckes, Timon; Brunst,
Steffen; Flauaus, Cathrin; Wittmann, Sandra K.; Weizel, Lilia; Kaiser,
Astrid; Kretschmer, Simon B. M.; George, Sven; Angioni, Carlo; Heering,
Jan; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred; Schmidtko, Achim;
Pogoryelov, Denys; Pfeilschifter, Josef; Hofmann, Bettina; Steinhilber,
Dieter; Schwalm, Stephanie; Proschak, Ewgenij
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 11498-11521

$RFMT $RIREG SCHEME221 STEP1
$RXN



  2  1
$MOL
4-Methoxyaniline
C7H9NO
104-94-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7700 1.3337 0.0 0
M  V30 2 C 0.0000 2.6673 0.0 0
M  V30 3 N 6.9302 1.3337 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 3.0801 0.0000 0.0 0
M  V30 7 C 4.6201 2.6673 0.0 0
M  V30 8 C 4.6201 0.0000 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-cyanobenzoic acid
C8H6N2O2
99767-45-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 N 1.3337 4.6201 0.0 0
M  V30 5 C 6.6686 1.5400 0.0 0
M  V30 6 N 8.0022 0.7700 0.0 0
M  V30 7 C 2.6675 2.3100 0.0 0
M  V30 8 C 4.0011 1.5400 0.0 0
M  V30 9 C 2.6675 3.8500 0.0 0
M  V30 10 C 5.3348 2.3100 0.0 0
M  V30 11 C 4.0011 4.6201 0.0 0
M  V30 12 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 9
M  V30 5 3 5 6
M  V30 6 1 5 10
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-cyano-N-(3-fluoro-4-methoxyphenyl)benzamide
C15H12FN3O2
2765056-71-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 6.1601 0.0 0
M  V30 2 N 6.6685 4.6201 0.0 0
M  V30 3 O 5.3348 6.9302 0.0 0
M  V30 4 N 6.6685 9.2402 0.0 0
M  V30 5 C 12.0033 6.1601 0.0 0
M  V30 6 N 13.3370 5.3901 0.0 0
M  V30 7 F 4.0010 0.0000 0.0 0
M  V30 8 O 1.3337 1.5400 0.0 0
M  V30 9 C 0.0000 2.3101 0.0 0
M  V30 10 C 8.0022 6.9302 0.0 0
M  V30 11 C 9.3360 6.1601 0.0 0
M  V30 12 C 8.0022 8.4702 0.0 0
M  V30 13 C 10.6697 6.9302 0.0 0
M  V30 14 C 9.3360 9.2402 0.0 0
M  V30 15 C 10.6697 8.4702 0.0 0
M  V30 16 C 5.3348 3.8501 0.0 0
M  V30 17 C 5.3348 2.3101 0.0 0
M  V30 18 C 4.0010 4.6201 0.0 0
M  V30 19 C 4.0010 1.5400 0.0 0
M  V30 20 C 2.6673 3.8501 0.0 0
M  V30 21 C 2.6673 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 16
M  V30 5 1 4 12
M  V30 6 3 5 6
M  V30 7 1 5 13
M  V30 8 1 7 19
M  V30 9 1 8 9
M  V30 10 1 8 21
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 104-94-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 99767-45-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2765056-71-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31626793
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Piperazinobenzodiazepinones: New Encephalitic Alphavirus Inhibitors via
Ring Expansion of 2-Dichloromethylquinazolinones
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ryan, Michael C.; Kim, Eunjung; Cao, Xufeng; Reichard, Walter; Ogorek,
Tyler J.; Das, Pronay; Jonsson, Colleen B.; Baudry, Jerome; Chung,
Donghoon; Golden, Jennifer E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(4), 546-553

$RFMT $RIREG SCHEME222 STEP1
$RXN



  2  1
$MOL
2,3-Dimethoxybenzoic acid
C9H10O4
1521-38-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.0012 0.7700 0.0 0
M  V30 2 C 5.3348 0.0000 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 O 0.0000 3.0801 0.0 0
M  V30 5 O 1.3337 0.7700 0.0 0
M  V30 6 O 6.6687 2.3101 0.0 0
M  V30 7 C 8.0023 3.0801 0.0 0
M  V30 8 C 4.0012 2.3101 0.0 0
M  V30 9 C 2.6675 3.0801 0.0 0
M  V30 10 C 5.3348 3.0801 0.0 0
M  V30 11 C 2.6675 4.6201 0.0 0
M  V30 12 C 5.3348 4.6201 0.0 0
M  V30 13 C 4.0012 5.3901 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 9
M  V30 6 1 6 7
M  V30 7 1 6 10
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Aminoacetaldehyde diethyl acetal
C6H15NO2
645-36-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 2.6674 0.0 0
M  V30 2 O 4.6200 2.6674 0.0 0
M  V30 3 O 2.3100 4.0011 0.0 0
M  V30 4 C 2.3100 1.3338 0.0 0
M  V30 5 C 5.3900 4.0011 0.0 0
M  V30 6 C 0.7700 4.0011 0.0 0
M  V30 7 N 3.0800 0.0000 0.0 0
M  V30 8 C 6.9300 4.0011 0.0 0
M  V30 9 C 0.0000 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(2,2-Diethoxyethyl)-2,3-dimethoxybenzamide
C15H23NO5
1494575-28-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 5.3348 3.8501 0.0 0
M  V30 3 O 6.6685 6.1601 0.0 0
M  V30 4 C 4.0010 4.6201 0.0 0
M  V30 5 C 2.6673 3.8501 0.0 0
M  V30 6 O 2.6673 2.3101 0.0 0
M  V30 7 O 1.3337 4.6201 0.0 0
M  V30 8 C 1.3337 1.5400 0.0 0
M  V30 9 C 1.3337 6.1601 0.0 0
M  V30 10 C 1.3337 0.0000 0.0 0
M  V30 11 C 0.0000 6.9302 0.0 0
M  V30 12 O 9.3360 6.1601 0.0 0
M  V30 13 C 10.6697 6.9302 0.0 0
M  V30 14 O 12.0033 4.6201 0.0 0
M  V30 15 C 13.3370 3.8501 0.0 0
M  V30 16 C 8.0022 3.8501 0.0 0
M  V30 17 C 9.3360 4.6201 0.0 0
M  V30 18 C 8.0022 2.3101 0.0 0
M  V30 19 C 10.6697 3.8501 0.0 0
M  V30 20 C 9.3360 1.5400 0.0 0
M  V30 21 C 10.6697 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 1 12 13
M  V30 13 1 12 17
M  V30 14 1 14 15
M  V30 15 1 14 19
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1521-38-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 645-36-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1494575-28-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23515650
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM The total synthesis of berberine and selected analogues, and their
evaluation as amyloid beta aggregation inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tajiri, Misato; Yamada, Ryo; Hotsumi, Mayumi; Makabe, Koki; Konno,
Hiroyuki
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 215113289

$RFMT $RIREG SCHEME223 STEP1
$RXN



  2  1
$MOL
-Alanine, methyl ester, hydrochloride
C4H9NO2.ClH
3196-73-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0800 0.0 0
M  V30 2 C 4.0011 3.8500 0.0 0
M  V30 3 O 1.3338 3.8500 0.0 0
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 C 5.3348 3.0800 0.0 0
M  V30 6 C 0.0000 3.0800 0.0 0
M  V30 7 N 6.6686 3.8500 0.0 0
M  V30 8 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-(5-Methyl-1,2,4-oxadiazol-3-yl)benzoic acid
C10H8N2O3
264264-32-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 3.0801 0.0 0
M  V30 2 O 1.3338 4.6201 0.0 0
M  V30 3 O 0.0000 2.3100 0.0 0
M  V30 4 C 10.6376 3.4372 0.0 0
M  V30 5 C 5.3348 2.3100 0.0 0
M  V30 6 C 4.0011 3.0801 0.0 0
M  V30 7 C 5.3348 0.7700 0.0 0
M  V30 8 C 2.6675 2.3100 0.0 0
M  V30 9 C 4.0011 0.0000 0.0 0
M  V30 10 C 2.6675 0.7700 0.0 0
M  V30 11 C 6.6686 3.0801 0.0 0
M  V30 12 N 6.8296 4.6116 0.0 0
M  V30 13 N 8.0755 2.4536 0.0 0
M  V30 14 O 8.3359 4.9318 0.0 0
M  V30 15 C 9.1059 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 15
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 5 11
M  V30 8 1 6 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-Alanine, N-[3-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]-, methyl ester
C14H15N3O4
2902671-83-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.3038 3.0801 0.0 0
M  V30 2 N 10.6375 2.3101 0.0 0
M  V30 3 O 9.3038 4.6201 0.0 0
M  V30 4 C 11.9711 3.0801 0.0 0
M  V30 5 C 13.3050 2.3101 0.0 0
M  V30 6 C 14.6386 3.0801 0.0 0
M  V30 7 O 15.9723 2.3101 0.0 0
M  V30 8 O 14.6386 4.6201 0.0 0
M  V30 9 C 17.3060 3.0801 0.0 0
M  V30 10 C 0.0000 3.4372 0.0 0
M  V30 11 C 5.3026 2.3101 0.0 0
M  V30 12 C 6.6363 3.0801 0.0 0
M  V30 13 C 5.3026 0.7700 0.0 0
M  V30 14 C 7.9700 2.3101 0.0 0
M  V30 15 C 6.6363 0.0000 0.0 0
M  V30 16 C 7.9700 0.7700 0.0 0
M  V30 17 C 3.9690 3.0801 0.0 0
M  V30 18 N 2.5620 2.4536 0.0 0
M  V30 19 N 3.8079 4.6116 0.0 0
M  V30 20 C 1.5316 3.5981 0.0 0
M  V30 21 O 2.3016 4.9318 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 10 20
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 11 17
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3196-73-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 264264-32-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2902671-83-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35473530
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of 2-(3-Benzamidopropanamido)thiazole-5-carboxylate Inhibitors
of the Kinesin HSET (KIFC1) and the Development of Cellular Target
Engagement Probes
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Saint-Dizier, Francois; Matthews, Thomas P.; Gregson, Aaron M.; Prevet,
Hugues; McHardy, Tatiana; Colombano, Giampiero; Saville, Harry; Rowlands,
Martin; Ewens, Caroline; McAndrew, P. Craig; Tomlin, Kathy; Guillotin,
Delphine; Mak, Grace Wing-Yan; Drosopoulos, Konstantinos; Poursaitidis,
Ioannis; Burke, Rosemary; van Montfort, Rob; Linardopoulos, Spiros;
Collins, Ian
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(4), 2622-2645

$RFMT $RIREG SCHEME224 STEP1
$RXN



  2  1
$MOL
4-Aminobenzyl alcohol
C7H9NO
623-04-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 N 6.9302 1.3337 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 3.0801 0.0000 0.0 0
M  V30 7 C 4.6201 2.6673 0.0 0
M  V30 8 C 4.6201 0.0000 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-valyl-L-alanine
C13H24N2O5
70396-18-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0 CFG=2
M  V30 2 C 7.7000 2.6674 0.0 0
M  V30 3 N 5.3900 4.0011 0.0 0
M  V30 4 C 5.3900 1.3338 0.0 0
M  V30 5 N 8.4700 4.0011 0.0 0
M  V30 6 O 8.4700 1.3338 0.0 0
M  V30 7 C 3.8500 4.0011 0.0 0
M  V30 8 C 3.8500 1.3338 0.0 0
M  V30 9 C 6.1600 0.0000 0.0 0
M  V30 10 C 10.0100 4.0011 0.0 0 CFG=1
M  V30 11 O 3.0800 5.3349 0.0 0
M  V30 12 O 3.0800 2.6674 0.0 0
M  V30 13 C 10.7800 5.3349 0.0 0
M  V30 14 C 10.7800 2.6674 0.0 0
M  V30 15 C 1.5400 5.3349 0.0 0
M  V30 16 O 12.3200 5.3349 0.0 0
M  V30 17 O 10.0100 6.6685 0.0 0
M  V30 18 C 1.5400 6.8749 0.0 0
M  V30 19 C 0.0000 5.3349 0.0 0
M  V30 20 C 1.5400 3.7949 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 4 9
M  V30 9 1 5 10
M  V30 10 1 7 11
M  V30 11 2 7 12
M  V30 12 1 10 13
M  V30 13 1 10 14 CFG=3
M  V30 14 1 11 15
M  V30 15 1 13 16
M  V30 16 2 13 17
M  V30 17 1 15 18
M  V30 18 1 15 19
M  V30 19 1 15 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-valyl-N-[4-(hydroxymethyl)phenyl]-L-alanin...
C20H31N3O5
1884577-99-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 5.9538 0.0 0 CFG=1
M  V30 2 N 4.0012 4.4137 0.0 0
M  V30 3 C 5.3348 6.7238 0.0 0
M  V30 4 C 2.6675 6.7238 0.0 0
M  V30 5 C 2.6675 3.6437 0.0 0
M  V30 6 N 6.6687 5.9538 0.0 0
M  V30 7 O 5.3348 8.2638 0.0 0
M  V30 8 C 2.6675 8.2638 0.0 0
M  V30 9 C 1.3338 5.9538 0.0 0
M  V30 10 O 2.6675 2.1037 0.0 0
M  V30 11 O 1.3338 4.4137 0.0 0
M  V30 12 C 8.0023 6.7238 0.0 0 CFG=1
M  V30 13 C 1.3338 1.3337 0.0 0
M  V30 14 C 9.3360 5.9538 0.0 0
M  V30 15 C 8.0023 8.2638 0.0 0
M  V30 16 C 2.1038 0.0000 0.0 0
M  V30 17 C 0.0000 0.5637 0.0 0
M  V30 18 C 0.5638 2.6673 0.0 0
M  V30 19 N 10.6697 6.7238 0.0 0
M  V30 20 O 9.3360 4.4137 0.0 0
M  V30 21 C 16.0045 3.6437 0.0 0
M  V30 22 O 17.3383 4.4137 0.0 0
M  V30 23 C 12.0035 5.9538 0.0 0
M  V30 24 C 12.0035 4.4137 0.0 0
M  V30 25 C 13.3372 6.7238 0.0 0
M  V30 26 C 13.3372 3.6437 0.0 0
M  V30 27 C 14.6708 5.9538 0.0 0
M  V30 28 C 14.6708 4.4137 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 4 9
M  V30 9 1 5 10
M  V30 10 2 5 11
M  V30 11 1 6 12
M  V30 12 1 10 13
M  V30 13 1 12 14
M  V30 14 1 12 15 CFG=1
M  V30 15 1 13 16
M  V30 16 1 13 17
M  V30 17 1 13 18
M  V30 18 1 14 19
M  V30 19 2 14 20
M  V30 20 1 19 23
M  V30 21 1 21 22
M  V30 22 1 21 28
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 2 25 27
M  V30 27 2 26 28
M  V30 28 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 12)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 623-04-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 70396-18-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1884577-99-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37713121
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 16357-59-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):NOTES
$DATUM in the dark
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Enhancing the Pharmacokinetics and Antitumor Activity of an
-Amanitin-Based Small-Molecule Drug Conjugate via Conjugation with an Fc
Domain
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Gallo, Francesca; Korsak, Barbara; Mueller, Christoph; Hechler, Torsten;
Yanakieva, Desislava; Avrutina, Olga; Kolmar, Harald; Pahl, Andreas
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(7), 4117-4129

$RFMT $RIREG SCHEME225 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Aminomethylpiperidine-1-carboxylic acid tert-butyl ester
C11H22N2O2
144222-22-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8736 0.0 0
M  V30 2 O 3.0800 1.5400 0.0 0
M  V30 3 O 3.0800 4.2073 0.0 0
M  V30 4 C 1.5400 1.5400 0.0 0
M  V30 5 C 1.5400 3.0800 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 1.5400 0.0000 0.0 0
M  V30 8 C 10.0100 2.8736 0.0 0
M  V30 9 N 10.7800 4.2073 0.0 0
M  V30 10 N 5.3900 2.8736 0.0 0
M  V30 11 C 6.1600 4.2073 0.0 0
M  V30 12 C 6.1600 1.5400 0.0 0
M  V30 13 C 7.7000 4.2073 0.0 0
M  V30 14 C 7.7000 1.5400 0.0 0
M  V30 15 C 8.4700 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 1 8 15
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Piperidinecarboxylic acid, 4-[[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]am...
C19H27N3O3
3031471-29-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 4.6201 0.0 0
M  V30 2 O 2.6675 3.8501 0.0 0
M  V30 3 O 4.0012 6.1601 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 2.1037 5.9538 0.0 0
M  V30 6 C 0.0000 5.3901 0.0 0
M  V30 7 C 0.5637 3.2864 0.0 0
M  V30 8 C 9.3360 1.5400 0.0 0
M  V30 9 N 10.6697 2.3101 0.0 0
M  V30 10 C 12.0035 1.5400 0.0 0
M  V30 11 C 13.3372 2.3101 0.0 0
M  V30 12 O 12.0035 0.0000 0.0 0
M  V30 13 C 14.6708 1.5400 0.0 0
M  V30 14 N 5.3348 3.8501 0.0 0
M  V30 15 C 5.3348 2.3101 0.0 0
M  V30 16 C 6.6685 4.6201 0.0 0
M  V30 17 C 6.6685 1.5400 0.0 0
M  V30 18 C 8.0023 3.8501 0.0 0
M  V30 19 C 8.0023 2.3101 0.0 0
M  V30 20 C 16.0045 2.3101 0.0 0
M  V30 21 C 17.3383 1.5400 0.0 0
M  V30 22 C 16.0045 3.8501 0.0 0
M  V30 23 C 18.6720 2.3101 0.0 0
M  V30 24 N 17.3383 4.6201 0.0 0
M  V30 25 C 18.6720 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 1 8 19
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 13 20
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 19
M  V30 21 1 20 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 144222-22-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031471-29-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131897
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME226 STEP1
$RXN



  2  1
$MOL
(+)-2-Phenylpropionic acid
C9H10O2
7782-24-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0 CFG=2
M  V30 2 C 5.3901 1.3337 0.0 0
M  V30 3 C 5.3901 4.0010 0.0 0
M  V30 4 O 4.6201 0.0000 0.0 0
M  V30 5 O 6.9302 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 2.3101 1.3337 0.0 0
M  V30 9 C 0.7700 4.0010 0.0 0
M  V30 10 C 0.7700 1.3337 0.0 0
M  V30 11 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 6
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzenemethanamine, -(azidomethyl)-4-[(2S)-2-methylbutoxy]-, hydrochloride (...
C13H20N4O.ClH
2821859-79-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6698 3.0800 0.0 0 CFG=1
M  V30 2 C 12.0035 3.8501 0.0 0
M  V30 3 N 10.6698 1.5400 0.0 0
M  V30 4 N 13.3372 3.0800 0.0 0
M  V30 5 N 14.6708 3.8501 0.0 0 CHG=1 VAL=4
M  V30 6 N 16.0046 4.6201 0.0 0 CHG=-1
M  V30 7 O 5.3348 6.1601 0.0 0
M  V30 8 C 4.0012 5.3901 0.0 0
M  V30 9 C 2.6675 6.1601 0.0 0 CFG=1
M  V30 10 C 1.3338 5.3901 0.0 0
M  V30 11 C 2.6675 7.7001 0.0 0
M  V30 12 C 0.0000 6.1601 0.0 0
M  V30 13 C 9.3360 3.8501 0.0 0
M  V30 14 C 8.0023 3.0800 0.0 0
M  V30 15 C 9.3360 5.3901 0.0 0
M  V30 16 C 6.6687 3.8501 0.0 0
M  V30 17 C 8.0023 6.1601 0.0 0
M  V30 18 C 6.6687 5.3901 0.0 0
M  V30 19 Cl 8.0023 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 2 4 5
M  V30 6 2 5 6
M  V30 7 1 7 8
M  V30 8 1 7 18
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 9 11 CFG=3
M  V30 12 1 10 12
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, N-[(1R)-2-azido-1-[4-[(2S)-2-methylbutoxy]phenyl]ethyl]--m...
C22H28N4O2
2821859-81-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7000 5.3347 0.0 0 CFG=2
M  V30 2 N 6.9300 6.6684 0.0 0
M  V30 3 C 6.9300 4.0011 0.0 0
M  V30 4 C 5.3900 6.6684 0.0 0
M  V30 5 N 7.7000 2.6674 0.0 0
M  V30 6 C 4.6200 8.0021 0.0 0 CFG=2
M  V30 7 O 4.6200 5.3347 0.0 0
M  V30 8 N 6.9300 1.3336 0.0 0 CHG=1 VAL=4
M  V30 9 C 5.3900 9.3358 0.0 0
M  V30 10 N 6.1600 0.0000 0.0 0 CHG=-1
M  V30 11 O 13.8600 5.3347 0.0 0
M  V30 12 C 14.6300 6.6684 0.0 0
M  V30 13 C 16.1700 6.6684 0.0 0 CFG=1
M  V30 14 C 16.9400 8.0021 0.0 0
M  V30 15 C 16.9400 5.3347 0.0 0
M  V30 16 C 18.4800 8.0021 0.0 0
M  V30 17 C 9.2400 5.3347 0.0 0
M  V30 18 C 10.0100 4.0011 0.0 0
M  V30 19 C 10.0100 6.6684 0.0 0
M  V30 20 C 11.5500 4.0011 0.0 0
M  V30 21 C 11.5500 6.6684 0.0 0
M  V30 22 C 12.3200 5.3347 0.0 0
M  V30 23 C 3.0800 8.0021 0.0 0
M  V30 24 C 2.3100 9.3358 0.0 0
M  V30 25 C 2.3100 6.6684 0.0 0
M  V30 26 C 0.7700 9.3358 0.0 0
M  V30 27 C 0.7700 6.6684 0.0 0
M  V30 28 C 0.0000 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 6 9 CFG=3
M  V30 10 1 6 23
M  V30 11 2 8 10
M  V30 12 1 11 12
M  V30 13 1 11 22
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 13 15 CFG=3
M  V30 17 1 14 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 2 25 27
M  V30 28 2 26 28
M  V30 29 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 1 6 13)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7782-24-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2821859-79-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2821859-81-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36136965
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-05-8
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Evaluation of Amide Bioisosteres Leading to 1,2,3-Triazole Containing
Compounds as GPR88 Agonists: Design, Synthesis, and Structure-Activity
Relationship Studies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rahman, Toufiqur Md; Decker, Ann M.; Laudermilk, Lucas; Maitra, Rangan;
Ma, Weiya; Ben Hamida, Sami; Darcq, Emmanuel; Kieffer, Brigitte L.; Jin,
Chunyang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(16), 12397-12413

$RFMT $RIREG SCHEME227 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Methoxy-3-benzofurancarboxylic acid
C10H8O4
23455-49-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5064 1.1444 0.0 0
M  V30 2 O 0.0000 0.8242 0.0 0
M  V30 3 O 2.5369 0.0000 0.0 0
M  V30 4 O 7.4479 2.3149 0.0 0
M  V30 5 C 8.7817 3.0849 0.0 0
M  V30 6 C 3.4470 3.0849 0.0 0
M  V30 7 C 3.4470 4.6250 0.0 0
M  V30 8 C 1.9823 2.6091 0.0 0
M  V30 9 C 4.7806 2.3149 0.0 0
M  V30 10 O 1.9823 5.1008 0.0 0
M  V30 11 C 4.7806 5.3950 0.0 0
M  V30 12 C 1.0771 3.8549 0.0 0
M  V30 13 C 6.1143 3.0849 0.0 0
M  V30 14 C 6.1143 4.6250 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 5
M  V30 5 1 4 13
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 12
M  V30 14 1 11 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Boronic acid, B-[5-methoxy-3-[(methylamino)carbonyl]-2-benzofuranyl]-
C11H12BNO5
3036029-28-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.7394 2.6091 0.0 0
M  V30 2 N 3.7698 1.4645 0.0 0
M  V30 3 O 1.2329 2.2889 0.0 0
M  V30 4 C 3.2939 0.0000 0.0 0
M  V30 5 B 0.7700 5.3195 0.0 0
M  V30 6 O 0.0000 6.6533 0.0 0
M  V30 7 O 0.0000 3.9858 0.0 0
M  V30 8 O 8.6808 3.7795 0.0 0
M  V30 9 C 10.0146 4.5495 0.0 0
M  V30 10 C 4.6799 4.5495 0.0 0
M  V30 11 C 3.2152 4.0736 0.0 0
M  V30 12 C 4.6799 6.0895 0.0 0
M  V30 13 C 6.0135 3.7795 0.0 0
M  V30 14 C 2.3100 5.3195 0.0 0
M  V30 15 O 3.2152 6.5655 0.0 0
M  V30 16 C 6.0135 6.8595 0.0 0
M  V30 17 C 7.3472 4.5495 0.0 0
M  V30 18 C 7.3472 6.0895 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 14
M  V30 8 1 8 9
M  V30 9 1 8 17
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 10 13
M  V30 13 2 11 14
M  V30 14 1 12 15
M  V30 15 2 12 16
M  V30 16 1 13 17
M  V30 17 1 14 15
M  V30 18 1 16 18
M  V30 19 2 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 23455-49-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3036029-28-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40724155
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 4
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 121-43-7
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 4111-54-0
$DTYPE RXN:VAR(1):RGT(5):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):NOTES
$DATUM pyridine also used as a solvent in stage 1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase
Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel
Antituberculosis Clinical Target
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wilson, Caroline; Ray, Peter; Zuccotto, Fabio; Hernandez, Jorge;
Aggarwal, Anup; Mackenzie, Claire; Caldwell, Nicola; Taylor, Malcolm;
Huggett, Margaret; Mathieson, Michael; Murugesan, Dinakaran; Smith,
Alasdair; Davis, Susan; Cocco, Mattia; Parai, Maloy K.; Acharya, Arjun;
Tamaki, Fabio; Scullion, Paul; Epemolu, Ola; Riley, Jennifer;
Stojanovski, Laste; Lopez-Roman, Eva Maria; Torres-Gomez, Pedro Alfonso;
Toledo, Ana Maria; Guijarro-Lopez, Laura; Camino, Isabel; Engelhart,
Curtis A.; Schnappinger, Dirk; Massoudi, Lisa M.; Lenaerts, Anne;
Robertson, Gregory T.; Walpole, Chris; Matthews, David; Floyd, David;
Sacchettini, James C.; Read, Kevin D.; Encinas, Lourdes; Bates, Robert
H.; Green, Simon R.; Wyatt, Paul G.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(1), 409-423

$RFMT $RIREG SCHEME228 STEP1
$RXN



  2  1
$MOL
1H-Indole-3-propanoic acid
C11H11NO2
830-96-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7533 2.6218 0.0 0
M  V30 2 C 7.0869 1.8518 0.0 0
M  V30 3 C 8.4206 2.6218 0.0 0
M  V30 4 O 9.7544 1.8518 0.0 0
M  V30 5 O 8.4206 4.1618 0.0 0
M  V30 6 C 3.0127 2.4782 0.0 0
M  V30 7 C 4.4196 1.8518 0.0 0
M  V30 8 C 1.9823 1.3338 0.0 0
M  V30 9 C 2.5368 3.9429 0.0 0
M  V30 10 C 4.2586 0.3202 0.0 0
M  V30 11 N 2.7523 0.0000 0.0 0
M  V30 12 C 0.4759 1.6540 0.0 0
M  V30 13 C 1.0306 4.2630 0.0 0
M  V30 14 C 0.0000 3.1185 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 2 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 11
M  V30 14 1 12 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Alanine, methyl ester, hydrochloride (1:1)
C4H9NO2.ClH
13515-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.8500 0.0 0
M  V30 2 C 1.3338 3.0800 0.0 0
M  V30 3 O 4.0011 3.0800 0.0 0
M  V30 4 O 2.6674 5.3900 0.0 0
M  V30 5 C 0.0000 3.8500 0.0 0
M  V30 6 N 1.3338 1.5400 0.0 0
M  V30 7 C 5.3349 3.8500 0.0 0
M  V30 8 Cl 2.6674 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Alanine, N-[3-(1H-indol-3-yl)-1-oxopropyl]-, methyl ester
C15H18N2O3
3007690-42-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7531 2.6218 0.0 0
M  V30 2 C 7.0869 1.8518 0.0 0
M  V30 3 C 8.4206 2.6218 0.0 0
M  V30 4 N 9.7542 1.8518 0.0 0
M  V30 5 O 8.4206 4.1618 0.0 0
M  V30 6 C 11.0878 2.6218 0.0 0
M  V30 7 C 12.4216 1.8518 0.0 0
M  V30 8 C 11.0878 4.1618 0.0 0
M  V30 9 O 13.7553 2.6218 0.0 0
M  V30 10 O 12.4216 0.3118 0.0 0
M  V30 11 C 15.0889 1.8518 0.0 0
M  V30 12 C 3.0127 2.4782 0.0 0
M  V30 13 C 4.4195 1.8518 0.0 0
M  V30 14 C 1.9821 1.3338 0.0 0
M  V30 15 C 2.5368 3.9429 0.0 0
M  V30 16 C 4.2586 0.3202 0.0 0
M  V30 17 N 2.7521 0.0000 0.0 0
M  V30 18 C 0.4759 1.6540 0.0 0
M  V30 19 C 1.0304 4.2630 0.0 0
M  V30 20 C 0.0000 3.1185 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 9 11
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 2 12 15
M  V30 15 2 13 16
M  V30 16 1 14 17
M  V30 17 2 14 18
M  V30 18 1 15 19
M  V30 19 1 16 17
M  V30 20 1 18 20
M  V30 21 2 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 830-96-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13515-97-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3007690-42-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37335626
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 3282-30-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Nonpeptidic Oxazole Based Prolyl Oligopeptidase Ligands with Disease
Modifying Effects on alpha Synuclein Mouse Models of Parkinson Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kilpelainen, Tommi P.; Patsi, Henri T.; Svarcbahs, Reinis; Julku, Ulrika
H.; Etelainen, Tony S.; Cui, Hengjing; Auno, Samuli; Sipari, Nina;
Norrbacka, Susanna; Leino, Teppo O.; Jantti, Maria; Myohanen, Timo T.;
Wallen, Erik A. A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(11), 7475-7496

$RFMT $RIREG SCHEME229 STEP1
$RXN



  2  1
$MOL
L-Tyrosine, methyl ester
C10H13NO3
1080-06-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 3.8501 2.6673 0.0 0 CFG=2
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 N 4.6201 4.0010 0.0 0
M  V30 5 O 1.5400 4.0010 0.0 0
M  V30 6 O 1.5400 1.3337 0.0 0
M  V30 7 C 0.0000 4.0010 0.0 0
M  V30 8 O 10.7802 1.3337 0.0 0
M  V30 9 C 6.1601 1.3337 0.0 0
M  V30 10 C 6.9302 0.0000 0.0 0
M  V30 11 C 6.9302 2.6673 0.0 0
M  V30 12 C 8.4702 0.0000 0.0 0
M  V30 13 C 8.4702 2.6673 0.0 0
M  V30 14 C 9.2402 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]glycyl-L-tyrosine methyl ester
C17H24N2O6
65160-62-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 5.3347 0.0 0
M  V30 2 C 6.9300 4.0011 0.0 0 CFG=1
M  V30 3 N 8.4700 4.0011 0.0 0
M  V30 4 C 6.1600 2.6674 0.0 0
M  V30 5 C 9.2400 5.3347 0.0 0
M  V30 6 O 6.9300 1.3336 0.0 0
M  V30 7 O 4.6200 2.6674 0.0 0
M  V30 8 C 10.7800 5.3347 0.0 0
M  V30 9 O 8.4700 6.6685 0.0 0
M  V30 10 C 6.1600 0.0000 0.0 0
M  V30 11 N 11.5500 6.6685 0.0 0
M  V30 12 C 13.0900 6.6685 0.0 0
M  V30 13 O 13.8600 8.0021 0.0 0
M  V30 14 O 13.8600 5.3347 0.0 0
M  V30 15 C 15.4000 8.0021 0.0 0
M  V30 16 C 15.4000 9.5421 0.0 0
M  V30 17 C 16.9400 8.0021 0.0 0
M  V30 18 C 15.4000 6.4621 0.0 0
M  V30 19 O 0.0000 5.3347 0.0 0
M  V30 20 C 4.6200 5.3347 0.0 0
M  V30 21 C 3.8500 6.6685 0.0 0
M  V30 22 C 3.8500 4.0011 0.0 0
M  V30 23 C 2.3100 6.6685 0.0 0
M  V30 24 C 2.3100 4.0011 0.0 0
M  V30 25 C 1.5400 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 1 19 25
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 2 22 24
M  V30 24 2 23 25
M  V30 25 1 24 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1080-06-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 65160-62-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31824053
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine
structures to inhibit A oligomerisation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Falkenstein, Markus; Reiner-Link, David; Zivkovic, Aleksandra; Gering,
Ian; Willbold, Dieter; Stark, Holger
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 50116462

$RFMT $RIREG SCHEME230 STEP1
$RXN



  2  1
$MOL
D-Tyrosine, methyl ester
C10H13NO3
3410-66-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 3.8501 2.6673 0.0 0 CFG=1
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 N 4.6201 4.0010 0.0 0
M  V30 5 O 1.5400 4.0010 0.0 0
M  V30 6 O 1.5400 1.3337 0.0 0
M  V30 7 C 0.0000 4.0010 0.0 0
M  V30 8 O 10.7802 1.3337 0.0 0
M  V30 9 C 6.1601 1.3337 0.0 0
M  V30 10 C 6.9302 0.0000 0.0 0
M  V30 11 C 6.9302 2.6673 0.0 0
M  V30 12 C 8.4702 0.0000 0.0 0
M  V30 13 C 8.4702 2.6673 0.0 0
M  V30 14 C 9.2402 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C17H24N2O6
2413848-30-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 5.3347 0.0 0
M  V30 2 C 6.9300 4.0011 0.0 0 CFG=2
M  V30 3 N 8.4700 4.0011 0.0 0
M  V30 4 C 6.1600 2.6674 0.0 0
M  V30 5 C 9.2400 5.3347 0.0 0
M  V30 6 O 6.9300 1.3336 0.0 0
M  V30 7 O 4.6200 2.6674 0.0 0
M  V30 8 C 10.7800 5.3347 0.0 0
M  V30 9 O 8.4700 6.6685 0.0 0
M  V30 10 C 6.1600 0.0000 0.0 0
M  V30 11 N 11.5500 6.6685 0.0 0
M  V30 12 C 13.0900 6.6685 0.0 0
M  V30 13 O 13.8600 8.0021 0.0 0
M  V30 14 O 13.8600 5.3347 0.0 0
M  V30 15 C 15.4000 8.0021 0.0 0
M  V30 16 C 15.4000 9.5421 0.0 0
M  V30 17 C 16.9400 8.0021 0.0 0
M  V30 18 C 15.4000 6.4621 0.0 0
M  V30 19 O 0.0000 5.3347 0.0 0
M  V30 20 C 4.6200 5.3347 0.0 0
M  V30 21 C 3.8500 6.6685 0.0 0
M  V30 22 C 3.8500 4.0011 0.0 0
M  V30 23 C 2.3100 6.6685 0.0 0
M  V30 24 C 2.3100 4.0011 0.0 0
M  V30 25 C 1.5400 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 1 19 25
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 2 22 24
M  V30 24 2 23 25
M  V30 25 1 24 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3410-66-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2413848-30-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31824047
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine
structures to inhibit A oligomerisation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Falkenstein, Markus; Reiner-Link, David; Zivkovic, Aleksandra; Gering,
Ian; Willbold, Dieter; Stark, Holger
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 50116462

$RFMT $RIREG SCHEME231 STEP1
$RXN



  2  1
$MOL
2-Bromo-4-(2-methylpropyl)-5-thiazolecarboxylic acid
C8H10BrNO2S
1780825-95-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.1864 1.1444 0.0 0
M  V30 2 O 4.6927 0.8242 0.0 0
M  V30 3 O 2.1559 0.0000 0.0 0
M  V30 4 C 5.1556 3.8549 0.0 0
M  V30 5 C 5.9256 5.1886 0.0 0
M  V30 6 C 5.1556 6.5222 0.0 0
M  V30 7 C 7.4656 5.1886 0.0 0
M  V30 8 Br 0.0000 5.5302 0.0 0
M  V30 9 C 2.7104 2.6091 0.0 0
M  V30 10 C 3.6156 3.8549 0.0 0
M  V30 11 S 1.2459 3.0849 0.0 0
M  V30 12 N 2.7104 5.1008 0.0 0
M  V30 13 C 1.2459 4.6250 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 4 5
M  V30 5 1 4 10
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 8 13
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluorobenzylamine
C7H8FN
140-75-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 F 6.9302 1.3337 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 3.0801 0.0000 0.0 0
M  V30 7 C 4.6201 2.6673 0.0 0
M  V30 8 C 4.6201 0.0000 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Bromo-N-[(4-fluorophenyl)methyl]-4-(2-methylpropyl)-5-thiazolecarboxamide
C15H16BrFN2OS
2460957-62-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.8690 5.3026 0.0 0
M  V30 2 N 7.4090 5.3026 0.0 0
M  V30 3 O 5.0990 6.6362 0.0 0
M  V30 4 C 8.1790 6.6362 0.0 0
M  V30 5 C 2.5369 4.9524 0.0 0
M  V30 6 C 1.0306 4.6322 0.0 0
M  V30 7 C 0.5546 3.1675 0.0 0
M  V30 8 C 0.0000 5.7766 0.0 0
M  V30 9 Br 4.7419 0.0000 0.0 0
M  V30 10 F 14.3391 6.6362 0.0 0
M  V30 11 C 5.0990 3.9689 0.0 0
M  V30 12 C 3.5673 3.8078 0.0 0
M  V30 13 S 5.7253 2.5620 0.0 0
M  V30 14 N 3.2471 2.3016 0.0 0
M  V30 15 C 4.5809 1.5315 0.0 0
M  V30 16 C 9.7190 6.6362 0.0 0
M  V30 17 C 10.4891 7.9699 0.0 0
M  V30 18 C 10.4891 5.3026 0.0 0
M  V30 19 C 12.0291 7.9699 0.0 0
M  V30 20 C 12.0291 5.3026 0.0 0
M  V30 21 C 12.7991 6.6362 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 16
M  V30 6 1 5 6
M  V30 7 1 5 12
M  V30 8 1 6 7
M  V30 9 1 6 8
M  V30 10 1 9 15
M  V30 11 1 10 21
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1780825-95-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 140-75-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2460957-62-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22493175
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, diversity-oriented synthesis and biological evaluation of novel
heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Jia, Haiyong; Yu, Ji; Du, Xianhong; Cherukupalli, Srinivasulu; Zhan,
Peng; Liu, Xinyong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 202112495

$RFMT $RIREG SCHEME232 STEP1
$RXN



  2  1
$MOL
Hydroxyphenylacetic acid
C8H8O3
156-38-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6673 0.0 0
M  V30 2 C 6.9302 1.3337 0.0 0
M  V30 3 O 6.1601 0.0000 0.0 0
M  V30 4 O 8.4702 1.3337 0.0 0
M  V30 5 O 0.0000 2.6673 0.0 0
M  V30 6 C 4.6201 2.6673 0.0 0
M  V30 7 C 3.8501 4.0010 0.0 0
M  V30 8 C 3.8501 1.3337 0.0 0
M  V30 9 C 2.3101 4.0010 0.0 0
M  V30 10 C 2.3101 1.3337 0.0 0
M  V30 11 C 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Aspartic acid, 1,4-bis(1,1-dimethylethyl) ester, hydrochloride (1:1)
C12H23NO4.ClH
1791-13-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 3.0800 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0 CFG=2
M  V30 3 C 8.0022 3.8501 0.0 0
M  V30 4 C 4.0012 3.0800 0.0 0
M  V30 5 N 5.3348 5.3901 0.0 0
M  V30 6 O 9.3360 3.0800 0.0 0
M  V30 7 O 8.0022 5.3901 0.0 0
M  V30 8 O 2.6673 3.8501 0.0 0
M  V30 9 O 4.0012 1.5400 0.0 0
M  V30 10 C 10.6697 3.8501 0.0 0
M  V30 11 C 1.3337 3.0800 0.0 0
M  V30 12 C 11.4397 2.5164 0.0 0
M  V30 13 C 12.0033 4.6201 0.0 0
M  V30 14 C 9.8996 5.1837 0.0 0
M  V30 15 C 0.5637 4.4137 0.0 0
M  V30 16 C 0.0000 2.3100 0.0 0
M  V30 17 C 2.1037 1.7464 0.0 0
M  V30 18 Cl 6.0017 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 2 5 CFG=1
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 1 6 10
M  V30 10 1 8 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 13 1 10 14
M  V30 14 1 11 15
M  V30 15 1 11 16
M  V30 16 1 11 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Aspartic acid, N-[2-(4-hydroxyphenyl)acetyl]-, 1,4-bis(1,1-dimethylethyl) e...
C20H29NO6
3031537-44-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 6.6684 0.0 0 CFG=1
M  V30 2 C 6.1600 5.3347 0.0 0
M  V30 3 N 6.1600 8.0021 0.0 0
M  V30 4 C 3.8500 6.6684 0.0 0
M  V30 5 C 5.3900 4.0011 0.0 0
M  V30 6 C 7.7000 8.0021 0.0 0
M  V30 7 O 3.0800 8.0021 0.0 0
M  V30 8 O 3.0800 5.3347 0.0 0
M  V30 9 O 6.1600 2.6673 0.0 0
M  V30 10 O 3.8500 4.0011 0.0 0
M  V30 11 C 8.4700 9.3358 0.0 0
M  V30 12 O 8.4700 6.6684 0.0 0
M  V30 13 C 1.5400 8.0021 0.0 0
M  V30 14 C 5.3900 1.3336 0.0 0
M  V30 15 C 1.5400 9.5421 0.0 0
M  V30 16 C 0.0000 8.0021 0.0 0
M  V30 17 C 1.5400 6.4621 0.0 0
M  V30 18 C 6.7236 0.5636 0.0 0
M  V30 19 C 4.6200 0.0000 0.0 0
M  V30 20 C 4.0564 2.1036 0.0 0
M  V30 21 O 14.6300 9.3358 0.0 0
M  V30 22 C 10.0100 9.3358 0.0 0
M  V30 23 C 10.7800 8.0021 0.0 0
M  V30 24 C 10.7800 10.6694 0.0 0
M  V30 25 C 12.3200 8.0020 0.0 0
M  V30 26 C 12.3200 10.6694 0.0 0
M  V30 27 C 13.0900 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 2 6 12
M  V30 12 1 7 13
M  V30 13 1 9 14
M  V30 14 1 11 22
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 14 19
M  V30 20 1 14 20
M  V30 21 1 21 27
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 156-38-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1791-13-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031537-44-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131686
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of a Novel Series of
4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low
Systemic Exposure for the Treatment of Obesity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ikeda, Zenichi; Kakegawa, Keiko; Kikuchi, Fumiaki; Itono, Sachiko; Oki,
Hideyuki; Yashiro, Hiroaki; Hiyoshi, Hideyuki; Tsuchimori, Kazue;
Hamagami, Kenichi; Watanabe, Masanori; Sasaki, Masako; Ishihara, Youko;
Tohyama, Kimio; Kitazaki, Tomoyuki; Maekawa, Tsuyoshi; Sasaki, Minoru
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(12), 8456-8477

$RFMT $RIREG SCHEME233 STEP1
$RXN



  2  1
$MOL
()-Tropic acid
C9H10O3
552-63-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 2.6673 0.0 0
M  V30 2 C 1.5400 1.3337 0.0 0
M  V30 3 C 1.5400 4.0010 0.0 0
M  V30 4 O 2.3101 0.0000 0.0 0
M  V30 5 O 0.0000 1.3337 0.0 0
M  V30 6 O 0.0000 4.0010 0.0 0
M  V30 7 C 3.8501 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 6.1601 1.3337 0.0 0
M  V30 11 C 6.1601 4.0010 0.0 0
M  V30 12 C 6.9302 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 3 6
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenesulfonamide, N-[4-(aminomethyl)phenyl]-4-methoxy-, 2,2,2-trifluoroacet...
C14H16N2O3S.C2HF3O2
2494197-42-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 6.6685 6.5174 0.0 0 VAL=6
M  V30 2 N 8.0022 5.7474 0.0 0
M  V30 3 O 7.4385 7.8511 0.0 0
M  V30 4 O 5.8985 5.1837 0.0 0
M  V30 5 O 1.3337 9.5975 0.0 0
M  V30 6 C 0.0000 8.8274 0.0 0
M  V30 7 C 13.3370 8.8274 0.0 0
M  V30 8 N 14.6707 8.0574 0.0 0
M  V30 9 C 5.3348 7.2874 0.0 0
M  V30 10 C 5.3348 8.8274 0.0 0
M  V30 11 C 4.0010 6.5174 0.0 0
M  V30 12 C 4.0010 9.5975 0.0 0
M  V30 13 C 2.6673 7.2874 0.0 0
M  V30 14 C 2.6673 8.8274 0.0 0
M  V30 15 C 9.3358 6.5174 0.0 0
M  V30 16 C 10.6697 5.7474 0.0 0
M  V30 17 C 9.3358 8.0574 0.0 0
M  V30 18 C 12.0033 6.5174 0.0 0
M  V30 19 C 10.6697 8.8274 0.0 0
M  V30 20 C 12.0033 8.0574 0.0 0
M  V30 21 C 6.6685 2.3101 0.0 0
M  V30 22 C 8.0022 1.5400 0.0 0
M  V30 23 F 7.4385 3.6437 0.0 0
M  V30 24 F 5.3348 3.0801 0.0 0
M  V30 25 F 5.8985 0.9764 0.0 0
M  V30 26 O 9.3358 2.3101 0.0 0
M  V30 27 O 8.0022 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 9
M  V30 5 1 2 15
M  V30 6 1 5 6
M  V30 7 1 5 14
M  V30 8 1 7 8
M  V30 9 1 7 20
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 22 1 21 22
M  V30 23 1 21 23
M  V30 24 1 21 24
M  V30 25 1 21 25
M  V30 26 1 22 26
M  V30 27 2 22 27
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-(Hydroxymethyl)-N-[[4-[[(4-methoxyphenyl)sulfonyl]amino]phenyl]methyl]benze...
C23H24N2O5S
2494197-33-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 4.0012 4.6201 0.0 0
M  V30 4 N 6.6685 3.0801 0.0 0
M  V30 5 O 5.3348 0.7700 0.0 0
M  V30 6 O 2.6673 5.3901 0.0 0
M  V30 7 C 8.0022 2.3101 0.0 0
M  V30 8 N 13.3370 5.3901 0.0 0
M  V30 9 S 14.6708 4.6201 0.0 0 VAL=6
M  V30 10 O 13.9008 3.2864 0.0 0
M  V30 11 O 15.4408 5.9538 0.0 0
M  V30 12 O 20.0057 1.5400 0.0 0
M  V30 13 C 21.3393 2.3101 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 1.3337 3.0801 0.0 0
M  V30 16 C 2.6673 0.7700 0.0 0
M  V30 17 C 0.0000 2.3101 0.0 0
M  V30 18 C 1.3337 0.0000 0.0 0
M  V30 19 C 0.0000 0.7700 0.0 0
M  V30 20 C 9.3360 3.0801 0.0 0
M  V30 21 C 9.3360 4.6201 0.0 0
M  V30 22 C 10.6697 2.3101 0.0 0
M  V30 23 C 10.6697 5.3901 0.0 0
M  V30 24 C 12.0033 3.0801 0.0 0
M  V30 25 C 12.0033 4.6201 0.0 0
M  V30 26 C 16.0045 3.8501 0.0 0
M  V30 27 C 17.3382 4.6201 0.0 0
M  V30 28 C 16.0045 2.3101 0.0 0
M  V30 29 C 18.6720 3.8501 0.0 0
M  V30 30 C 17.3382 1.5400 0.0 0
M  V30 31 C 18.6718 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 3 6
M  V30 7 1 4 7
M  V30 8 1 7 20
M  V30 9 1 8 9
M  V30 10 1 8 25
M  V30 11 2 9 10
M  V30 12 2 9 11
M  V30 13 1 9 26
M  V30 14 1 12 13
M  V30 15 1 12 31
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 2 28 30
M  V30 32 2 29 31
M  V30 33 1 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 552-63-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2494197-42-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2494197-33-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22829000
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):NOTES
$DATUM stages 1 and 2 combined after 30 minutes (stage 2)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Small-Molecule Inhibitors Targeting Sterol 14-Demethylase (CYP51):
Synthesis, Molecular Modelling and Evaluation Against Candida albicans
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Binjubair, Faizah A.; Parker, Josie E.; Warrilow, Andrew G.; Puri,
Kalika; Braidley, Peter J.; Tatar, Esra; Kelly, Steven L.; Kelly, Diane
E.; Simons, Claire
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2020), 15(14), 1294-1309

$RFMT $RIREG SCHEME234 STEP1
$RXN



  2  1
$MOL
4-(Ethylsulfonyl)benzeneacetic acid
C10H12O4S
383135-47-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 2.3100 2.6673 0.0 0 VAL=6
M  V30 2 C 0.7700 2.6673 0.0 0
M  V30 3 O 2.3100 1.1273 0.0 0
M  V30 4 O 2.3100 4.2073 0.0 0
M  V30 5 C 0.0000 4.0011 0.0 0
M  V30 6 C 8.4700 2.6673 0.0 0
M  V30 7 C 9.2400 1.3336 0.0 0
M  V30 8 O 10.7800 1.3336 0.0 0
M  V30 9 O 8.4700 0.0000 0.0 0
M  V30 10 C 3.8500 2.6673 0.0 0
M  V30 11 C 4.6200 1.3336 0.0 0
M  V30 12 C 4.6200 4.0011 0.0 0
M  V30 13 C 6.1600 1.3336 0.0 0
M  V30 14 C 6.1600 4.0011 0.0 0
M  V30 15 C 6.9300 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 6 7
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-(4-amino[1,1-biphenyl]-2-yl)-
C15H14N2O
3032933-03-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.6674 3.0800 0.0 0
M  V30 2 C 1.3336 2.3100 0.0 0
M  V30 3 C 1.3336 0.7700 0.0 0
M  V30 4 O 0.0000 3.0800 0.0 0
M  V30 5 C 0.0000 0.0000 0.0 0
M  V30 6 N 9.3358 2.3100 0.0 0
M  V30 7 C 4.0011 5.3900 0.0 0
M  V30 8 C 2.6674 4.6200 0.0 0
M  V30 9 C 4.0011 6.9300 0.0 0
M  V30 10 C 1.3336 5.3900 0.0 0
M  V30 11 C 2.6674 7.7000 0.0 0
M  V30 12 C 1.3336 6.9300 0.0 0
M  V30 13 C 5.3347 4.6200 0.0 0
M  V30 14 C 6.6684 5.3900 0.0 0
M  V30 15 C 5.3347 3.0800 0.0 0
M  V30 16 C 8.0021 4.6200 0.0 0
M  V30 17 C 6.6684 2.3100 0.0 0
M  V30 18 C 8.0021 3.0800 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 18
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 7 13
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, 4-(ethylsulfonyl)-N-[2-[(1-oxo-2-propen-1-yl)amino][1,1-b...
C25H24N2O4S
2983540-53-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.8500 4.0011 0.0 0
M  V30 2 C 2.3100 4.0011 0.0 0
M  V30 3 C 1.5400 5.3347 0.0 0
M  V30 4 O 1.5400 2.6674 0.0 0
M  V30 5 C 0.0000 5.3347 0.0 0
M  V30 6 N 9.2400 8.0021 0.0 0
M  V30 7 C 10.7800 8.0021 0.0 0
M  V30 8 C 11.5500 9.3358 0.0 0
M  V30 9 O 11.5500 6.6684 0.0 0
M  V30 10 S 17.7100 9.3358 0.0 0 VAL=6
M  V30 11 C 19.2500 9.3358 0.0 0
M  V30 12 O 17.7100 7.7958 0.0 0
M  V30 13 O 17.7100 10.8758 0.0 0
M  V30 14 C 20.0200 10.6694 0.0 0
M  V30 15 C 6.1600 2.6674 0.0 0
M  V30 16 C 4.6200 2.6674 0.0 0
M  V30 17 C 6.9300 1.3336 0.0 0
M  V30 18 C 3.8500 1.3336 0.0 0
M  V30 19 C 6.1600 0.0000 0.0 0
M  V30 20 C 4.6200 0.0000 0.0 0
M  V30 21 C 6.9300 4.0011 0.0 0
M  V30 22 C 8.4700 4.0011 0.0 0
M  V30 23 C 6.1600 5.3347 0.0 0
M  V30 24 C 9.2400 5.3347 0.0 0
M  V30 25 C 6.9300 6.6684 0.0 0
M  V30 26 C 8.4700 6.6684 0.0 0
M  V30 27 C 13.0900 9.3358 0.0 0
M  V30 28 C 13.8600 10.6694 0.0 0
M  V30 29 C 13.8600 8.0021 0.0 0
M  V30 30 C 15.4000 10.6694 0.0 0
M  V30 31 C 15.4000 8.0021 0.0 0
M  V30 32 C 16.1700 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 26
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 27
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 10 13
M  V30 14 1 10 32
M  V30 15 1 11 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 15 21
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 1 28 30
M  V30 32 2 29 31
M  V30 33 2 30 32
M  V30 34 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 383135-47-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3032933-03-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-53-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256072
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME235 STEP1
$RXN



  2  1
$MOL
5-Bromo-2-furancarboxylic acid
C5H3BrO3
585-70-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 Br 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 O 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 C 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluoro-2-methylaniline
C7H8FN
452-71-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 0.0000 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 F 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N-(4-fluoro-2-methylphenyl)-2-furancarboxamide
C12H9BrFNO2
895665-61-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.9256 2.6673 0.0 0
M  V30 2 C 5.1556 4.0009 0.0 0
M  V30 3 O 5.9256 5.3347 0.0 0
M  V30 4 C 7.4657 0.0000 0.0 0
M  V30 5 F 12.0857 2.6673 0.0 0
M  V30 6 Br 0.0000 5.6762 0.0 0
M  V30 7 C 7.4657 2.6673 0.0 0
M  V30 8 C 8.2357 1.3336 0.0 0
M  V30 9 C 8.2357 4.0009 0.0 0
M  V30 10 C 9.7757 1.3336 0.0 0
M  V30 11 C 9.7757 4.0009 0.0 0
M  V30 12 C 10.5457 2.6673 0.0 0
M  V30 13 C 3.6156 4.0009 0.0 0
M  V30 14 O 2.7104 5.2470 0.0 0
M  V30 15 C 2.7104 2.7551 0.0 0
M  V30 16 C 1.2459 4.7709 0.0 0
M  V30 17 C 1.2459 3.2309 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 2 2 3
M  V30 4 1 2 13
M  V30 5 1 4 8
M  V30 6 1 5 12
M  V30 7 1 6 16
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 585-70-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 452-71-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 895665-61-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38145487
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 108-88-3
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dual Targeting of Steroid Sulfatase and 17-Hydroxysteroid Dehydrogenase
Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option
for the Treatment of Endometriosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Mohamed, Abdelrahman; Salah, Mohamed; Tahoun, Mariam; Hawner, Manuel;
Abdelsamie, Ahmed S.; Frotscher, Martin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(17), 11726-11744

$RFMT $RIREG SCHEME236 STEP1
$RXN



  2  1
$MOL
4-Chloro-3-nitrobenzoic acid
C7H4ClNO4
96-99-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3336 1.5400 0.0 0 VAL=5
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 Cl 1.3336 4.6200 0.0 0
M  V30 5 C 6.6685 1.5400 0.0 0
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phosphonium, (5-aminopentyl)triphenyl-, bromide, hydrobromide (1:1:1)
C23H27NP.BrH.Br
73648-11-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 P 4.0012 7.0812 0.0 0 CHG=1 VAL=4
M  V30 2 C 5.3348 6.3111 0.0 0
M  V30 3 C 6.6685 7.0812 0.0 0
M  V30 4 C 8.0022 6.3111 0.0 0
M  V30 5 C 9.3360 7.0812 0.0 0
M  V30 6 C 10.6697 6.3111 0.0 0
M  V30 7 N 12.0033 7.0812 0.0 0
M  V30 8 C 2.6673 7.8512 0.0 0
M  V30 9 C 1.3337 7.0812 0.0 0
M  V30 10 C 2.6673 9.3912 0.0 0
M  V30 11 C 0.0000 7.8512 0.0 0
M  V30 12 C 1.3337 10.1612 0.0 0
M  V30 13 C 0.0000 9.3912 0.0 0
M  V30 14 C 3.2311 5.7475 0.0 0
M  V30 15 C 1.6911 5.7475 0.0 0
M  V30 16 C 4.0012 4.4137 0.0 0
M  V30 17 C 0.9211 4.4137 0.0 0
M  V30 18 C 3.2311 3.0800 0.0 0
M  V30 19 C 1.6911 3.0800 0.0 0
M  V30 20 C 4.7712 8.4148 0.0 0
M  V30 21 C 6.3112 8.4148 0.0 0
M  V30 22 C 4.0012 9.7487 0.0 0
M  V30 23 C 7.0812 9.7487 0.0 0
M  V30 24 C 4.7712 11.0823 0.0 0
M  V30 25 C 6.3112 11.0823 0.0 0
M  V30 26 Br 6.0017 1.5400 0.0 0 CHG=-1
M  V30 27 Br 6.0017 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 1 14
M  V30 4 1 1 20
M  V30 5 1 2 3
M  V30 6 1 3 4
M  V30 7 1 4 5
M  V30 8 1 5 6
M  V30 9 1 6 7
M  V30 10 2 8 9
M  V30 11 1 8 10
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 14 2 11 13
M  V30 15 1 12 13
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phosphonium, [5-[(4-chloro-3-nitrobenzoyl)amino]pentyl]triphenyl-, chloride (...
C30H29ClN2O3P.Cl
3063821-91-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  38 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 P 4.0011 5.5411 0.0 0 CHG=1 VAL=4
M  V30 2 C 5.3348 4.7711 0.0 0
M  V30 3 C 6.6684 5.5411 0.0 0
M  V30 4 C 8.0022 4.7711 0.0 0
M  V30 5 C 9.3359 5.5411 0.0 0
M  V30 6 C 10.6695 4.7711 0.0 0
M  V30 7 N 12.0032 5.5411 0.0 0
M  V30 8 C 13.3370 4.7711 0.0 0
M  V30 9 O 13.3370 3.2311 0.0 0
M  V30 10 N 18.6718 4.7711 0.0 0 VAL=5
M  V30 11 O 18.6718 3.2311 0.0 0
M  V30 12 O 20.0054 5.5411 0.0 0
M  V30 13 Cl 18.6718 7.8511 0.0 0
M  V30 14 C 2.6675 6.3111 0.0 0
M  V30 15 C 2.6675 7.8511 0.0 0
M  V30 16 C 1.3337 5.5411 0.0 0
M  V30 17 C 1.3337 8.6212 0.0 0
M  V30 18 C 0.0000 6.3111 0.0 0
M  V30 19 C 0.0000 7.8511 0.0 0
M  V30 20 C 4.7711 6.8748 0.0 0
M  V30 21 C 4.0011 8.2086 0.0 0
M  V30 22 C 6.3111 6.8748 0.0 0
M  V30 23 C 4.7711 9.5422 0.0 0
M  V30 24 C 7.0812 8.2086 0.0 0
M  V30 25 C 6.3111 9.5422 0.0 0
M  V30 26 C 3.2311 4.2075 0.0 0
M  V30 27 C 4.0011 2.8737 0.0 0
M  V30 28 C 1.6911 4.2075 0.0 0
M  V30 29 C 3.2311 1.5400 0.0 0
M  V30 30 C 0.9211 2.8737 0.0 0
M  V30 31 C 1.6911 1.5400 0.0 0
M  V30 32 C 14.6707 5.5411 0.0 0
M  V30 33 C 16.0043 4.7711 0.0 0
M  V30 34 C 14.6707 7.0811 0.0 0
M  V30 35 C 17.3380 5.5411 0.0 0
M  V30 36 C 16.0043 7.8511 0.0 0
M  V30 37 C 17.3380 7.0811 0.0 0
M  V30 38 Cl 10.0027 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 1 20
M  V30 4 1 1 26
M  V30 5 1 2 3
M  V30 6 1 3 4
M  V30 7 1 4 5
M  V30 8 1 5 6
M  V30 9 1 6 7
M  V30 10 1 7 8
M  V30 11 2 8 9
M  V30 12 1 8 32
M  V30 13 2 10 11
M  V30 14 2 10 12
M  V30 15 1 10 35
M  V30 16 1 13 37
M  V30 17 2 14 15
M  V30 18 1 14 16
M  V30 19 1 15 17
M  V30 20 2 16 18
M  V30 21 2 17 19
M  V30 22 1 18 19
M  V30 23 2 20 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 2 22 24
M  V30 27 2 23 25
M  V30 28 1 24 25
M  V30 29 2 26 27
M  V30 30 1 26 28
M  V30 31 1 27 29
M  V30 32 2 28 30
M  V30 33 2 29 31
M  V30 34 1 30 31
M  V30 35 2 32 33
M  V30 36 1 32 34
M  V30 37 1 33 35
M  V30 38 2 34 36
M  V30 39 2 35 37
M  V30 40 1 36 37
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 96-99-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 73648-11-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3063821-91-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40472116
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 6066-82-6
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Human mitochondrial glutathione transferases: Kinetic parameters and
accommodation of a mitochondria-targeting group in substrates
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Cardwell, Patrick A.; Del Moro, Carlo; Murphy, Michael P.; Lapthorn,
Adrian J.; Hartley, Richard C.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2024), 104117712

$RFMT $RIREG SCHEME237 STEP1
$RXN



  2  1
$MOL
trans-3-(3-Pyridyl)acrylic acid
C8H7NO2
19337-97-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0
M  V30 2 C 5.3347 2.3100 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 8.0021 2.3100 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 2.6674 2.3100 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 1.3336 1.5400 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 N 0.0000 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
tert-Butyl 4-aminopiperidine-1-carboxylate
C10H20N2O2
87120-72-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8736 0.0 0
M  V30 2 O 3.0800 1.5400 0.0 0
M  V30 3 O 3.0800 4.2073 0.0 0
M  V30 4 C 1.5400 1.5400 0.0 0
M  V30 5 C 1.5400 0.0000 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 1.5400 3.0800 0.0 0
M  V30 8 N 10.0100 2.8736 0.0 0
M  V30 9 N 5.3900 2.8736 0.0 0
M  V30 10 C 6.1600 1.5400 0.0 0
M  V30 11 C 6.1600 4.2073 0.0 0
M  V30 12 C 7.7000 1.5400 0.0 0
M  V30 13 C 7.7000 4.2073 0.0 0
M  V30 14 C 8.4700 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 14
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Piperidinecarboxylic acid, 4-[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]ami...
C18H25N3O3
3031471-28-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8738 0.0 0
M  V30 2 O 3.0800 1.5400 0.0 0
M  V30 3 O 3.0800 4.2074 0.0 0
M  V30 4 C 1.5400 1.5400 0.0 0
M  V30 5 C 1.5400 3.0800 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 1.5400 0.0000 0.0 0
M  V30 8 N 10.0100 2.8738 0.0 0
M  V30 9 C 10.7800 4.2074 0.0 0
M  V30 10 C 12.3200 4.2074 0.0 0
M  V30 11 O 10.0100 5.5411 0.0 0
M  V30 12 C 13.0900 5.5411 0.0 0
M  V30 13 N 5.3900 2.8738 0.0 0
M  V30 14 C 6.1600 4.2074 0.0 0
M  V30 15 C 6.1600 1.5400 0.0 0
M  V30 16 C 7.7000 4.2074 0.0 0
M  V30 17 C 7.7000 1.5400 0.0 0
M  V30 18 C 8.4700 2.8738 0.0 0
M  V30 19 C 14.6300 5.5411 0.0 0
M  V30 20 C 15.4000 6.8749 0.0 0
M  V30 21 C 15.4000 4.2074 0.0 0
M  V30 22 C 16.9400 6.8749 0.0 0
M  V30 23 N 16.9400 4.2074 0.0 0
M  V30 24 C 17.7100 5.5411 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 1 8 18
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 12 19
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 18
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19337-97-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 87120-72-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031471-28-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131898
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone
Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of
Drug-Resistant Non-small-Cell Lung Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Kuojun; Wang, Kaizhen; Zhang, Xiangyu; Qian, Zhenlong; Zhang,
Wenbo; Zheng, Xiao; Wang, Jiaying; Jiang, Yin; Zhang, Wanheng; Lu, Zhiyu;
Hao, Haiping; Jiang, Sheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(11), 7746-7769

$RFMT $RIREG SCHEME238 STEP1
$RXN



  2  1
$MOL
Nicotinic acid
C6H5NO2
59-67-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 N 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1,N1-Dimethyl-4-nitro-1,2-benzenediamine
C8H11N3O2
5367-52-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 4.6200 0.0 0 VAL=5
M  V30 2 O 8.0021 3.8500 0.0 0
M  V30 3 O 6.6685 6.1600 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 1.3336 1.5400 0.0 0
M  V30 6 C 0.0000 2.3100 0.0 0
M  V30 7 C 1.3336 0.0000 0.0 0
M  V30 8 C 5.3347 3.8500 0.0 0
M  V30 9 C 4.0011 4.6200 0.0 0
M  V30 10 C 5.3347 2.3100 0.0 0
M  V30 11 C 2.6674 3.8500 0.0 0
M  V30 12 C 4.0011 1.5400 0.0 0
M  V30 13 C 2.6674 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 11
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(Dimethylamino)-5-nitrophenyl]-3-pyridinecarboxamide
C14H14N4O3
2485702-39-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1600 4.0011 0.0 0
M  V30 2 C 6.9300 5.3347 0.0 0
M  V30 3 O 6.1600 6.6685 0.0 0
M  V30 4 N 4.6200 1.3336 0.0 0
M  V30 5 C 6.1600 1.3336 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 N 1.5400 6.6685 0.0 0 VAL=5
M  V30 8 O 0.0000 6.6685 0.0 0
M  V30 9 O 2.3100 8.0021 0.0 0
M  V30 10 C 4.6200 4.0011 0.0 0
M  V30 11 C 3.8500 2.6674 0.0 0
M  V30 12 C 3.8500 5.3347 0.0 0
M  V30 13 C 2.3100 2.6674 0.0 0
M  V30 14 C 2.3100 5.3347 0.0 0
M  V30 15 C 1.5400 4.0011 0.0 0
M  V30 16 C 8.4700 5.3347 0.0 0
M  V30 17 C 9.2400 6.6685 0.0 0
M  V30 18 C 9.2400 4.0011 0.0 0
M  V30 19 C 10.7800 6.6685 0.0 0
M  V30 20 N 10.7800 4.0011 0.0 0
M  V30 21 C 11.5500 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 2 2 3
M  V30 4 1 2 16
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 11
M  V30 8 2 7 8
M  V30 9 2 7 9
M  V30 10 1 7 14
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 59-67-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5367-52-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2485702-39-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22866626
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM key intermediate
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel TNNI3K inhibitor suppresses pyroptosis and apoptosis
in murine myocardial infarction injury
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Pang, Haiying; Wang, Ning; Chai, Jinlong; Wang, Xiaoyun; Zhang, Yuehua;
Bi, Zhiang; Wu, Wenbin; He, Gu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 197112314

$RFMT $RIREG SCHEME239 STEP1
$RXN



  2  1
$MOL
5-Bromo-2-furancarboxylic acid
C5H3BrO3
585-70-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 Br 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 O 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 C 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-2-methylpyridine
C6H8N2
3430-10-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 2.6673 0.0 0
M  V30 2 C 3.0801 0.0000 0.0 0
M  V30 3 C 3.0801 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 2.3101 4.0010 0.0 0
M  V30 6 N 0.7700 1.3337 0.0 0
M  V30 7 C 0.7700 4.0010 0.0 0
M  V30 8 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 4
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N-(2-methyl-3-pyridinyl)-2-furancarboxamide
C11H9BrN2O2
1519619-65-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 2.3100 0.0 0
M  V30 2 N 4.0011 3.0800 0.0 0
M  V30 3 O 5.3347 0.7700 0.0 0
M  V30 4 Br 10.6374 3.4371 0.0 0
M  V30 5 C 1.3338 4.6200 0.0 0
M  V30 6 C 6.6685 3.0800 0.0 0
M  V30 7 C 6.8294 4.6115 0.0 0
M  V30 8 O 8.0753 2.4535 0.0 0
M  V30 9 C 8.3357 4.9317 0.0 0
M  V30 10 C 9.1057 3.5981 0.0 0
M  V30 11 C 2.6674 2.3100 0.0 0
M  V30 12 C 1.3338 3.0800 0.0 0
M  V30 13 C 2.6674 0.7700 0.0 0
M  V30 14 N 0.0000 2.3100 0.0 0
M  V30 15 C 1.3338 0.0000 0.0 0
M  V30 16 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 11
M  V30 5 1 4 10
M  V30 6 1 5 12
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 585-70-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3430-10-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1519619-65-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38145506
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dual Targeting of Steroid Sulfatase and 17-Hydroxysteroid Dehydrogenase
Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option
for the Treatment of Endometriosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Mohamed, Abdelrahman; Salah, Mohamed; Tahoun, Mariam; Hawner, Manuel;
Abdelsamie, Ahmed S.; Frotscher, Martin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(17), 11726-11744

$RFMT $RIREG SCHEME240 STEP1
$RXN



  2  1
$MOL
-Lipoic acid
C8H14O2S2
1200-22-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.7711 1.5400 0.0 0
M  V30 2 C 5.1048 2.3101 0.0 0
M  V30 3 C 6.4384 1.5400 0.0 0
M  V30 4 C 7.7722 2.3101 0.0 0
M  V30 5 C 9.1059 1.5400 0.0 0
M  V30 6 O 9.1059 0.0000 0.0 0
M  V30 7 O 10.4396 2.3101 0.0 0
M  V30 8 C 2.4374 2.3101 0.0 0 CFG=1
M  V30 9 C 1.0304 1.6836 0.0 0
M  V30 10 S 2.2763 3.8416 0.0 0
M  V30 11 C 0.0000 2.8281 0.0 0
M  V30 12 S 0.7700 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 8 1 CFG=3
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Methyl (2Z)-4-(4-aminophenyl)-2-hydroxy-4-oxo-2-butenoate
C11H11NO4
2418023-78-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 C 6.6684 2.3100 0.0 0
M  V30 3 O 5.3348 0.0000 0.0 0
M  V30 4 C 8.0021 1.5400 0.0 0
M  V30 5 C 9.3359 2.3100 0.0 0
M  V30 6 O 8.0021 0.0000 0.0 0
M  V30 7 O 10.6695 1.5400 0.0 0
M  V30 8 O 9.3359 3.8500 0.0 0
M  V30 9 C 12.0032 2.3100 0.0 0
M  V30 10 N 0.0000 4.6201 0.0 0
M  V30 11 C 4.0011 2.3100 0.0 0
M  V30 12 C 4.0011 3.8500 0.0 0
M  V30 13 C 2.6673 1.5400 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 2.3100 0.0 0
M  V30 16 C 1.3337 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 2 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 7 9
M  V30 10 1 10 16
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl (2Z)-4-[4-[[5-(3S)-1,2-dithiolan-3-yl-1-oxopentyl]amino]phenyl]-2-hydr...
C19H23NO5S2
2418022-46-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 12.0033 4.6201 0.0 0
M  V30 2 C 13.3370 3.8501 0.0 0
M  V30 3 C 14.6708 4.6201 0.0 0
M  V30 4 O 13.3370 2.3101 0.0 0
M  V30 5 C 16.0045 3.8501 0.0 0
M  V30 6 C 17.3382 4.6201 0.0 0
M  V30 7 C 18.6718 3.8501 0.0 0
M  V30 8 C 6.6685 1.5400 0.0 0
M  V30 9 C 5.3348 2.3101 0.0 0
M  V30 10 O 6.6685 0.0000 0.0 0
M  V30 11 C 4.0010 1.5400 0.0 0
M  V30 12 C 2.6673 2.3101 0.0 0
M  V30 13 O 4.0010 0.0000 0.0 0
M  V30 14 O 1.3337 1.5400 0.0 0
M  V30 15 O 2.6673 3.8501 0.0 0
M  V30 16 C 0.0000 2.3101 0.0 0
M  V30 17 C 10.6697 3.8501 0.0 0
M  V30 18 C 10.6697 2.3101 0.0 0
M  V30 19 C 9.3358 4.6201 0.0 0
M  V30 20 C 9.3358 1.5400 0.0 0
M  V30 21 C 8.0022 3.8501 0.0 0
M  V30 22 C 8.0022 2.3101 0.0 0
M  V30 23 C 20.0057 4.6201 0.0 0 CFG=2
M  V30 24 C 21.4125 3.9936 0.0 0
M  V30 25 S 20.1666 6.1517 0.0 0
M  V30 26 C 22.4429 5.1382 0.0 0
M  V30 27 S 21.6729 6.4718 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 23 7 CFG=3
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 8 22
M  V30 12 2 9 11
M  V30 13 1 11 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 2 12 15
M  V30 17 1 14 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 24 1 23 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 23)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1200-22-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2418023-78-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2418022-46-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23231473
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 127-19-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Inhibition of Human Immunodeficiency Virus-1 Integrase by -Diketo Acid
Coated Gold Nanoparticles
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sanna, Vanna; Youssef, Mohamed Fathy; Pala, Nicolino; Rogolino, Dominga;
Carcelli, Mauro; Singh, Pankaj Kumar; Sanchez, Tino; Neamati, Nouri;
Sechi, Mario
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2020), 11(5), 857-861

$RFMT $RIREG SCHEME241 STEP1
$RXN



  2  1
$MOL
Cyclopentylamine
C5H11N
1003-03-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.9098 1.2459 0.0 0
M  V30 2 C 2.3698 1.2459 0.0 0
M  V30 3 C 1.4645 2.4917 0.0 0
M  V30 4 C 1.4645 0.0000 0.0 0
M  V30 5 C 0.0000 2.0159 0.0 0
M  V30 6 C 0.0000 0.4759 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Hydroxy-N-[(phenylmethoxy)carbonyl]-L-norleucine
C14H19NO5
102922-72-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.2400 2.6674 0.0 0 CFG=2
M  V30 2 N 7.7000 2.6674 0.0 0
M  V30 3 C 10.0100 4.0011 0.0 0
M  V30 4 C 10.0100 1.3338 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 11.5500 4.0011 0.0 0
M  V30 7 O 11.5500 1.3338 0.0 0
M  V30 8 O 9.2400 0.0000 0.0 0
M  V30 9 O 5.3900 4.0011 0.0 0
M  V30 10 O 7.7000 5.3347 0.0 0
M  V30 11 C 12.3200 5.3347 0.0 0
M  V30 12 C 4.6200 5.3347 0.0 0
M  V30 13 C 13.8600 5.3347 0.0 0
M  V30 14 O 14.6300 6.6685 0.0 0
M  V30 15 C 3.0800 5.3347 0.0 0
M  V30 16 C 2.3100 6.6685 0.0 0
M  V30 17 C 2.3100 4.0011 0.0 0
M  V30 18 C 0.7700 6.6685 0.0 0
M  V30 19 C 0.7700 4.0011 0.0 0
M  V30 20 C 0.0000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 9 12
M  V30 12 1 11 13
M  V30 13 1 12 15
M  V30 14 1 13 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C19H28N2O4
2307268-42-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.1048 6.1600 0.0 0 CFG=2
M  V30 2 C 3.7710 6.9300 0.0 0
M  V30 3 N 6.4384 6.9300 0.0 0
M  V30 4 C 5.1048 4.6200 0.0 0
M  V30 5 N 3.7710 8.4700 0.0 0
M  V30 6 O 2.4374 6.1600 0.0 0
M  V30 7 C 7.7721 6.1600 0.0 0
M  V30 8 C 3.7710 3.8500 0.0 0
M  V30 9 O 9.1059 6.9300 0.0 0
M  V30 10 O 7.7721 4.6200 0.0 0
M  V30 11 C 3.7710 2.3100 0.0 0
M  V30 12 C 10.4395 6.1600 0.0 0
M  V30 13 C 2.4374 1.5400 0.0 0
M  V30 14 O 2.4374 0.0000 0.0 0
M  V30 15 C 2.4374 9.2400 0.0 0
M  V30 16 C 1.0306 8.6135 0.0 0
M  V30 17 C 2.2764 10.7715 0.0 0
M  V30 18 C 0.0000 9.7581 0.0 0
M  V30 19 C 0.7700 11.0917 0.0 0
M  V30 20 C 11.7731 6.9300 0.0 0
M  V30 21 C 13.1068 6.1600 0.0 0
M  V30 22 C 11.7731 8.4700 0.0 0
M  V30 23 C 14.4406 6.9300 0.0 0
M  V30 24 C 13.1068 9.2400 0.0 0
M  V30 25 C 14.4406 8.4700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 15
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 20
M  V30 15 1 13 14
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1003-03-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 102922-72-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2307268-42-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36137379
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM alternate reaction conditions also shown
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and optimization of macrocyclic peptides as
species-selective antimalaria proteasome inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Hao; Ginn, John; Zhan, Wenhu; Liu, Yi J.; Leung, Annie; Toita,
Akinori; Okamoto, Rei; Wong, Tzu-Tshin; Imaeda, Toshihiro; Hara, Ryoma;
Yukawa, Takafumi; Michino, Mayako; Vendome, Jeremie; Beuming, Thijs;
Sato, Kenjiro; Aso, Kazuyoshi; Meinke, Peter T.; Nathan, Carl F.;
Kirkman, Laura A.; Lin, Gang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(13), 9350-9375

$RFMT $RIREG SCHEME242 STEP1
$RXN



  2  1
$MOL
()-Tropic acid
C9H10O3
552-63-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 2.6673 0.0 0
M  V30 2 C 1.5400 1.3337 0.0 0
M  V30 3 C 1.5400 4.0010 0.0 0
M  V30 4 O 2.3101 0.0000 0.0 0
M  V30 5 O 0.0000 1.3337 0.0 0
M  V30 6 O 0.0000 4.0010 0.0 0
M  V30 7 C 3.8501 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 6.1601 1.3337 0.0 0
M  V30 11 C 6.1601 4.0010 0.0 0
M  V30 12 C 6.9302 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 3 6
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenesulfonamide, N-[4-(aminomethyl)phenyl]-4-chloro-, 2,2,2-trifluoroaceta...
C13H13ClN2O2S.C2HF3O2
2503233-54-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 5.3348 6.5174 0.0 0 VAL=6
M  V30 2 N 6.6685 5.7474 0.0 0
M  V30 3 O 6.1048 7.8511 0.0 0
M  V30 4 O 4.5648 5.1837 0.0 0
M  V30 5 Cl 0.0000 9.5975 0.0 0
M  V30 6 C 12.0033 8.8274 0.0 0
M  V30 7 N 13.3370 8.0574 0.0 0
M  V30 8 C 4.0010 7.2874 0.0 0
M  V30 9 C 2.6673 6.5174 0.0 0
M  V30 10 C 4.0010 8.8274 0.0 0
M  V30 11 C 1.3337 7.2874 0.0 0
M  V30 12 C 2.6673 9.5975 0.0 0
M  V30 13 C 1.3337 8.8274 0.0 0
M  V30 14 C 8.0022 6.5174 0.0 0
M  V30 15 C 9.3360 5.7474 0.0 0
M  V30 16 C 8.0022 8.0574 0.0 0
M  V30 17 C 10.6697 6.5174 0.0 0
M  V30 18 C 9.3360 8.8274 0.0 0
M  V30 19 C 10.6697 8.0574 0.0 0
M  V30 20 C 6.0017 2.3101 0.0 0
M  V30 21 C 7.3353 1.5400 0.0 0
M  V30 22 F 6.7717 3.6437 0.0 0
M  V30 23 F 4.6680 3.0801 0.0 0
M  V30 24 F 5.2316 0.9764 0.0 0
M  V30 25 O 8.6690 2.3101 0.0 0
M  V30 26 O 7.3353 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 8
M  V30 5 1 2 14
M  V30 6 1 5 13
M  V30 7 1 6 7
M  V30 8 1 6 19
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 1 20 23
M  V30 24 1 20 24
M  V30 25 1 21 25
M  V30 26 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[[4-[[(4-Chlorophenyl)sulfonyl]amino]phenyl]methyl]--(hydroxymethyl)benzen...
C22H21ClN2O4S
2503233-56-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 14.6708 4.6201 0.0 0 VAL=6
M  V30 2 N 13.3372 5.3901 0.0 0
M  V30 3 O 13.9008 3.2864 0.0 0
M  V30 4 O 15.4408 5.9538 0.0 0
M  V30 5 Cl 20.0057 1.5400 0.0 0
M  V30 6 C 8.0023 2.3101 0.0 0
M  V30 7 N 6.6685 3.0801 0.0 0
M  V30 8 C 5.3348 2.3101 0.0 0
M  V30 9 C 4.0012 3.0801 0.0 0
M  V30 10 O 5.3348 0.7700 0.0 0
M  V30 11 C 4.0012 4.6201 0.0 0
M  V30 12 O 2.6675 5.3901 0.0 0
M  V30 13 C 16.0045 3.8501 0.0 0
M  V30 14 C 17.3382 4.6201 0.0 0
M  V30 15 C 16.0045 2.3101 0.0 0
M  V30 16 C 18.6720 3.8501 0.0 0
M  V30 17 C 17.3382 1.5400 0.0 0
M  V30 18 C 18.6720 2.3101 0.0 0
M  V30 19 C 12.0033 4.6201 0.0 0
M  V30 20 C 12.0033 3.0801 0.0 0
M  V30 21 C 10.6697 5.3901 0.0 0
M  V30 22 C 10.6697 2.3101 0.0 0
M  V30 23 C 9.3360 4.6201 0.0 0
M  V30 24 C 9.3360 3.0801 0.0 0
M  V30 25 C 2.6675 2.3101 0.0 0
M  V30 26 C 1.3337 3.0801 0.0 0
M  V30 27 C 2.6675 0.7700 0.0 0
M  V30 28 C 0.0000 2.3101 0.0 0
M  V30 29 C 1.3337 0.0000 0.0 0
M  V30 30 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 13
M  V30 5 1 2 19
M  V30 6 1 5 18
M  V30 7 1 6 7
M  V30 8 1 6 24
M  V30 9 1 7 8
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 9 11
M  V30 13 1 9 25
M  V30 14 1 11 12
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 552-63-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2503233-54-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2503233-56-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22827989
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):NOTES
$DATUM stages 1 and 2 combined after 30 minutes (stage 2)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Small-Molecule Inhibitors Targeting Sterol 14-Demethylase (CYP51):
Synthesis, Molecular Modelling and Evaluation Against Candida albicans
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Binjubair, Faizah A.; Parker, Josie E.; Warrilow, Andrew G.; Puri,
Kalika; Braidley, Peter J.; Tatar, Esra; Kelly, Steven L.; Kelly, Diane
E.; Simons, Claire
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2020), 15(14), 1294-1309

$RFMT $RIREG SCHEME243 STEP1
$RXN



  2  1
$MOL
Hydroxyphenylacetic acid
C8H8O3
156-38-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 2.6673 0.0 0
M  V30 2 C 6.9302 1.3337 0.0 0
M  V30 3 O 6.1601 0.0000 0.0 0
M  V30 4 O 8.4702 1.3337 0.0 0
M  V30 5 O 0.0000 2.6673 0.0 0
M  V30 6 C 4.6201 2.6673 0.0 0
M  V30 7 C 3.8501 4.0010 0.0 0
M  V30 8 C 3.8501 1.3337 0.0 0
M  V30 9 C 2.3101 4.0010 0.0 0
M  V30 10 C 2.3101 1.3337 0.0 0
M  V30 11 C 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
D-Glutamic acid, 1,5-bis(1,1-dimethylethyl) ester, hydrochloride (1:1)
C13H25NO4.ClH
172793-31-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 3.8501 0.0 0
M  V30 2 C 5.3348 3.0800 0.0 0 CFG=2
M  V30 3 O 2.6673 3.0800 0.0 0
M  V30 4 O 4.0010 5.3901 0.0 0
M  V30 5 C 6.6685 3.8501 0.0 0
M  V30 6 N 5.3348 1.5400 0.0 0
M  V30 7 C 1.3337 3.8501 0.0 0
M  V30 8 C 8.0022 3.0800 0.0 0
M  V30 9 C 0.5637 2.5164 0.0 0
M  V30 10 C 0.0000 4.6201 0.0 0
M  V30 11 C 2.1037 5.1837 0.0 0
M  V30 12 C 9.3360 3.8501 0.0 0
M  V30 13 O 10.6697 3.0800 0.0 0
M  V30 14 O 9.3360 5.3901 0.0 0
M  V30 15 C 12.0033 3.8501 0.0 0
M  V30 16 C 12.7733 2.5164 0.0 0
M  V30 17 C 13.3370 4.6201 0.0 0
M  V30 18 C 11.2333 5.1837 0.0 0
M  V30 19 Cl 6.6685 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=1
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 15 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Glutamic acid, N-[2-(4-hydroxyphenyl)acetyl]-, 1,5-bis(1,1-dimethylethyl) e...
C21H31NO6
3031537-46-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7000 5.3347 0.0 0 CFG=1
M  V30 2 C 8.4700 4.0011 0.0 0
M  V30 3 C 6.1600 5.3347 0.0 0
M  V30 4 N 8.4700 6.6685 0.0 0
M  V30 5 O 7.7000 2.6674 0.0 0
M  V30 6 O 10.0100 4.0011 0.0 0
M  V30 7 C 5.3900 6.6685 0.0 0
M  V30 8 C 10.0100 6.6685 0.0 0
M  V30 9 C 8.4700 1.3336 0.0 0
M  V30 10 C 3.8500 6.6685 0.0 0
M  V30 11 C 10.7800 8.0021 0.0 0
M  V30 12 O 10.7800 5.3347 0.0 0
M  V30 13 C 7.1364 0.5636 0.0 0
M  V30 14 C 9.2400 0.0000 0.0 0
M  V30 15 C 9.8036 2.1036 0.0 0
M  V30 16 O 3.0800 8.0021 0.0 0
M  V30 17 O 3.0800 5.3347 0.0 0
M  V30 18 C 1.5400 8.0021 0.0 0
M  V30 19 C 1.5400 9.5421 0.0 0
M  V30 20 C 0.0000 8.0021 0.0 0
M  V30 21 C 1.5400 6.4621 0.0 0
M  V30 22 O 16.9400 8.0021 0.0 0
M  V30 23 C 12.3200 8.0021 0.0 0
M  V30 24 C 13.0900 6.6685 0.0 0
M  V30 25 C 13.0900 9.3358 0.0 0
M  V30 26 C 14.6300 6.6685 0.0 0
M  V30 27 C 14.6300 9.3358 0.0 0
M  V30 28 C 15.4000 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14
M  V30 14 1 9 15
M  V30 15 1 10 16
M  V30 16 2 10 17
M  V30 17 1 11 23
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 1 22 28
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 2 25 27
M  V30 27 2 26 28
M  V30 28 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 156-38-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 172793-31-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031537-46-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40131683
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of a Novel Series of
4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low
Systemic Exposure for the Treatment of Obesity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ikeda, Zenichi; Kakegawa, Keiko; Kikuchi, Fumiaki; Itono, Sachiko; Oki,
Hideyuki; Yashiro, Hiroaki; Hiyoshi, Hideyuki; Tsuchimori, Kazue;
Hamagami, Kenichi; Watanabe, Masanori; Sasaki, Masako; Ishihara, Youko;
Tohyama, Kimio; Kitazaki, Tomoyuki; Maekawa, Tsuyoshi; Sasaki, Minoru
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(12), 8456-8477

$RFMT $RIREG SCHEME244 STEP1
$RXN



  2  1
$MOL
Aminoacetonitrile
C2H4N2
540-61-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 0.0000 0.0 0
M  V30 2 C 1.3337 0.7700 0.0 0
M  V30 3 N 4.0010 0.7700 0.0 0
M  V30 4 N 0.0000 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 3 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(4-Methoxy[1,1-biphenyl]-4-yl)carbonyl]-N-(phenylmethyl)glycine
C23H21NO4
2759356-75-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0
M  V30 2 N 4.6200 4.0011 0.0 0
M  V30 3 O 4.6200 6.6685 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 5.3900 2.6674 0.0 0
M  V30 6 C 4.6200 1.3336 0.0 0
M  V30 7 O 5.3900 0.0000 0.0 0
M  V30 8 O 3.0800 1.3336 0.0 0
M  V30 9 O 16.1700 5.3347 0.0 0
M  V30 10 C 16.9400 6.6685 0.0 0
M  V30 11 C 10.0100 5.3347 0.0 0
M  V30 12 C 9.2400 4.0011 0.0 0
M  V30 13 C 9.2400 6.6685 0.0 0
M  V30 14 C 7.7000 4.0011 0.0 0
M  V30 15 C 7.7000 6.6685 0.0 0
M  V30 16 C 6.9300 5.3347 0.0 0
M  V30 17 C 11.5500 5.3347 0.0 0
M  V30 18 C 12.3200 6.6685 0.0 0
M  V30 19 C 12.3200 4.0011 0.0 0
M  V30 20 C 13.8600 6.6685 0.0 0
M  V30 21 C 13.8600 4.0011 0.0 0
M  V30 22 C 14.6300 5.3347 0.0 0
M  V30 23 C 2.3100 5.3347 0.0 0
M  V30 24 C 3.0800 6.6685 0.0 0
M  V30 25 C 0.7700 5.3347 0.0 0
M  V30 26 C 2.3100 8.0021 0.0 0
M  V30 27 C 0.0000 6.6685 0.0 0
M  V30 28 C 0.7700 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 4 23
M  V30 7 1 5 6
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 9 10
M  V30 11 1 9 22
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 11 17
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 22
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 2 25 27
M  V30 29 2 26 28
M  V30 30 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-[(Cyanomethyl)amino]-2-oxoethyl]-4-methoxy-N-(phenylmethyl)[1,1-biphen...
C25H23N3O3
2760280-59-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 9.3358 0.0 0
M  V30 2 N 4.6200 8.0020 0.0 0
M  V30 3 O 4.6200 10.6694 0.0 0
M  V30 4 C 3.0800 8.0020 0.0 0
M  V30 5 C 5.3900 6.6684 0.0 0
M  V30 6 C 4.6200 5.3347 0.0 0
M  V30 7 N 5.3900 4.0011 0.0 0
M  V30 8 O 3.0800 5.3347 0.0 0
M  V30 9 C 4.6200 2.6673 0.0 0
M  V30 10 C 5.3900 1.3336 0.0 0
M  V30 11 N 6.1600 0.0000 0.0 0
M  V30 12 O 16.1700 9.3358 0.0 0
M  V30 13 C 16.9400 10.6694 0.0 0
M  V30 14 C 10.0100 9.3358 0.0 0
M  V30 15 C 9.2400 8.0020 0.0 0
M  V30 16 C 9.2400 10.6694 0.0 0
M  V30 17 C 7.7000 8.0020 0.0 0
M  V30 18 C 7.7000 10.6694 0.0 0
M  V30 19 C 6.9300 9.3358 0.0 0
M  V30 20 C 11.5500 9.3358 0.0 0
M  V30 21 C 12.3200 8.0020 0.0 0
M  V30 22 C 12.3200 10.6694 0.0 0
M  V30 23 C 13.8600 8.0020 0.0 0
M  V30 24 C 13.8600 10.6694 0.0 0
M  V30 25 C 14.6300 9.3358 0.0 0
M  V30 26 C 2.3100 9.3358 0.0 0
M  V30 27 C 3.0800 10.6694 0.0 0
M  V30 28 C 0.7700 9.3358 0.0 0
M  V30 29 C 2.3100 12.0031 0.0 0
M  V30 30 C 0.0000 10.6694 0.0 0
M  V30 31 C 0.7700 12.0031 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 19
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 4 26
M  V30 7 1 5 6
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 7 9
M  V30 11 1 9 10
M  V30 12 3 10 11
M  V30 13 1 12 13
M  V30 14 1 12 25
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 14 20
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 2 28 30
M  V30 32 2 29 31
M  V30 33 1 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 540-61-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2759356-75-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760280-59-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31510779
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Nitrile-based peptoids as cysteine protease inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Alves, Luana; Santos, Deborah A.; Cendron, Rodrigo; Rocho, Fernanda R.;
Matos, Thiago K. B.; Leitao, Andrei; Montanari, Carlos A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 41116211

$RFMT $RIREG SCHEME245 STEP1
$RXN



  2  1
$MOL
4-Fluoroaniline
C6H6FN
371-40-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 0.0000 1.3337 0.0 0
M  V30 2 N 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-(4-Bromophenyl)-3-oxetanecarboxylic acid
C10H9BrO3
1393585-20-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 0.7700 0.0 0
M  V30 2 O 0.2064 0.0000 0.0 0
M  V30 3 O 2.8736 0.0000 0.0 0
M  V30 4 Br 7.7000 2.3100 0.0 0
M  V30 5 C 1.5400 2.3100 0.0 0
M  V30 6 C 1.5400 3.8500 0.0 0
M  V30 7 C 0.0000 2.3100 0.0 0
M  V30 8 O 0.0000 3.8500 0.0 0
M  V30 9 C 3.0800 2.3100 0.0 0
M  V30 10 C 3.8500 3.6436 0.0 0
M  V30 11 C 3.8500 0.9764 0.0 0
M  V30 12 C 5.3900 3.6436 0.0 0
M  V30 13 C 5.3900 0.9764 0.0 0
M  V30 14 C 6.1600 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 14
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 9
M  V30 8 1 6 8
M  V30 9 1 7 8
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-(4-Bromophenyl)-N-(4-fluorophenyl)-3-oxetanecarboxamide
C16H13BrFNO2
2306411-45-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.4137 4.5648 0.0 0
M  V30 2 N 5.7476 5.3348 0.0 0
M  V30 3 O 4.4137 3.0248 0.0 0
M  V30 4 Br 0.0000 0.0000 0.0 0
M  V30 5 F 11.0824 2.2548 0.0 0
M  V30 6 C 3.0801 5.3348 0.0 0
M  V30 7 C 3.8501 6.6687 0.0 0
M  V30 8 C 1.7464 6.1048 0.0 0
M  V30 9 O 2.5164 7.4387 0.0 0
M  V30 10 C 2.3101 4.0012 0.0 0
M  V30 11 C 0.7700 4.0012 0.0 0
M  V30 12 C 3.0801 2.6675 0.0 0
M  V30 13 C 0.0000 2.6675 0.0 0
M  V30 14 C 2.3101 1.3338 0.0 0
M  V30 15 C 0.7700 1.3338 0.0 0
M  V30 16 C 7.0812 4.5648 0.0 0
M  V30 17 C 8.4149 5.3348 0.0 0
M  V30 18 C 7.0812 3.0248 0.0 0
M  V30 19 C 9.7487 4.5648 0.0 0
M  V30 20 C 8.4149 2.2548 0.0 0
M  V30 21 C 9.7487 3.0248 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 16
M  V30 5 1 4 15
M  V30 6 1 5 21
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 10
M  V30 10 1 7 9
M  V30 11 1 8 9
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 2 12 14
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 371-40-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1393585-20-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2306411-45-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32085759
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM alternate reaction conditions gave 75% yield
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors
Suitable for Q3W Oral or Parenteral Dosing
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Derun; Sloman, David L.; Achab, Abdelghani; Zhou, Hua; McGowan,
Meredeth A.; White, Catherine; Gibeau, Craig; Zhang, Hongjun; Pu,
Qinglin; Bharathan, Indu; Hopkins, Brett; Liu, Kun; Ferguson, Heidi;
Fradera, Xavier; Lesburg, Charles A.; Martinot, Theodore A.; Qi, Ji;
Song, Zhiguo J.; Yin, Jingjun; Zhang, Huangguang; Song, Licheng; Wan,
Baoqiang; D'Addio, Suzanne; Solban, Nicolas; Miller, J. Richard;
Zamlynny, Beata; Bass, Alan; Freeland, Elizabeth; Ykoruk, Bridget;
Hilliard, Catherine; Ferraro, Jude; Zhai, Jin; Knemeyer, Ian; Otte, Karin
M.; Vincent, Stella; Sciammetta, Nunzio; Pasternak, Alexander; Bennett,
David Jonathan; Han, Yongxin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(8), 6001-6016

$RFMT $RIREG SCHEME246 STEP1
$RXN



  2  1
$MOL
3-(1-Cyano-1-methylethyl)benzoic acid
C11H11NO2
872091-00-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0800 0.0 0
M  V30 2 C 1.3337 2.3100 0.0 0
M  V30 3 C 1.3337 3.8500 0.0 0
M  V30 4 C 2.6675 4.6201 0.0 0
M  V30 5 N 0.0000 1.5400 0.0 0
M  V30 6 C 8.0022 3.0800 0.0 0
M  V30 7 O 8.0022 4.6201 0.0 0
M  V30 8 O 9.3359 2.3100 0.0 0
M  V30 9 C 4.0011 2.3100 0.0 0
M  V30 10 C 5.3348 3.0800 0.0 0
M  V30 11 C 4.0011 0.7700 0.0 0
M  V30 12 C 6.6684 2.3100 0.0 0
M  V30 13 C 5.3348 0.0000 0.0 0
M  V30 14 C 6.6684 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 9
M  V30 5 3 2 5
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 6 12
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-2-fluoro-4-methylbenzenamine
C7H7BrFN
945244-29-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0.0000 2.6674 0.0 0
M  V30 2 C 1.5400 0.0000 0.0 0
M  V30 3 N 4.6200 5.3349 0.0 0
M  V30 4 F 6.1600 2.6674 0.0 0
M  V30 5 C 1.5400 2.6674 0.0 0
M  V30 6 C 2.3100 1.3338 0.0 0
M  V30 7 C 2.3100 4.0011 0.0 0
M  V30 8 C 3.8500 1.3338 0.0 0
M  V30 9 C 3.8500 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 5
M  V30 2 1 2 6
M  V30 3 1 3 9
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(5-Bromo-2-fluoro-4-methylphenyl)-3-(1-cyano-1-methylethyl)benzamide
C18H16BrFN2O
2729996-48-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 4.6201 0.0 0
M  V30 2 C 6.6685 3.8501 0.0 0
M  V30 3 O 6.6685 2.3101 0.0 0
M  V30 4 F 2.6673 6.1601 0.0 0
M  V30 5 Br 2.6673 0.0000 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 12.0033 3.8501 0.0 0
M  V30 8 C 13.3370 4.6201 0.0 0
M  V30 9 C 13.3370 3.0801 0.0 0
M  V30 10 C 12.0033 2.3101 0.0 0
M  V30 11 N 14.6707 5.3901 0.0 0
M  V30 12 C 4.0010 3.8501 0.0 0
M  V30 13 C 2.6673 4.6201 0.0 0
M  V30 14 C 4.0010 2.3101 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 16 C 2.6673 1.5400 0.0 0
M  V30 17 C 1.3337 2.3101 0.0 0
M  V30 18 C 8.0022 4.6201 0.0 0
M  V30 19 C 9.3358 3.8501 0.0 0
M  V30 20 C 8.0022 6.1601 0.0 0
M  V30 21 C 10.6697 4.6201 0.0 0
M  V30 22 C 9.3358 6.9302 0.0 0
M  V30 23 C 10.6697 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 2 2 3
M  V30 4 1 2 18
M  V30 5 1 4 13
M  V30 6 1 5 16
M  V30 7 1 6 17
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 1 7 21
M  V30 12 3 8 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 872091-00-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 945244-29-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2729996-48-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24719966
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a
Pyridopyridazinone pan-RAF Kinase Inhibitor
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Huestis, Malcolm P.; Durk, Matthew R.; Eigenbrot, Charles; Gibbons, Paul;
Hunsaker, Thomas L.; La, Hank; Leung, Dennis H.; Liu, Wendy; Malek,
Shiva; Merchant, Mark; Moffat, John G.; Muli, Christine S.; Orr,
Christine J.; Parr, Brendan T.; Shanahan, Frances; Sneeringer,
Christopher J.; Wang, Weiru; Yen, Ivana; Yin, Jianping; Rudolph, Joachim;
Siu, Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2021), 12(5), 791-797

$RFMT $RIREG SCHEME247 STEP1
$RXN



  2  1
$MOL
(2S)-2-Hydroxypentanoic acid
C5H10O3
41014-93-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 7 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 2.3100 0.0 0 CFG=2
M  V30 2 C 4.0011 1.5400 0.0 0
M  V30 3 C 1.3338 1.5400 0.0 0
M  V30 4 O 2.6674 3.8500 0.0 0
M  V30 5 C 5.3347 2.3100 0.0 0
M  V30 6 O 0.0000 2.3100 0.0 0
M  V30 7 O 1.3338 0.0000 0.0 0
M  V30 8 C 6.6685 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 5 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
2-Amino-5-bromo-N-ethylbenzamide
C9H11BrN2O
1263377-68-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 4.6200 0.0 0
M  V30 2 N 5.3347 3.8500 0.0 0
M  V30 3 O 4.0011 6.1600 0.0 0
M  V30 4 C 6.6685 4.6200 0.0 0
M  V30 5 C 8.0021 3.8500 0.0 0
M  V30 6 N 1.3336 6.1600 0.0 0
M  V30 7 Br 1.3336 0.0000 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 C 2.6674 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 1.5400 0.0 0
M  V30 13 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 6 9
M  V30 7 1 7 12
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N-ethyl-2-[[(2S)-2-hydroxy-1-oxopentyl]amino]benzamide
C14H19BrN2O3
2730115-19-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 5.3347 0.0 0
M  V30 2 C 8.4700 5.3347 0.0 0
M  V30 3 C 9.2400 6.6685 0.0 0 CFG=1
M  V30 4 O 9.2400 4.0011 0.0 0
M  V30 5 C 10.7800 6.6685 0.0 0
M  V30 6 O 8.4700 8.0021 0.0 0
M  V30 7 C 11.5500 8.0021 0.0 0
M  V30 8 C 13.0900 8.0021 0.0 0
M  V30 9 C 3.8500 5.3347 0.0 0
M  V30 10 N 2.3100 5.3347 0.0 0
M  V30 11 O 4.6200 6.6685 0.0 0
M  V30 12 C 1.5400 6.6685 0.0 0
M  V30 13 C 0.0000 6.6685 0.0 0
M  V30 14 Br 3.8500 0.0000 0.0 0
M  V30 15 C 6.1600 4.0011 0.0 0
M  V30 16 C 4.6200 4.0011 0.0 0
M  V30 17 C 6.9300 2.6674 0.0 0
M  V30 18 C 3.8500 2.6674 0.0 0
M  V30 19 C 6.1600 1.3336 0.0 0
M  V30 20 C 4.6200 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 3 6 CFG=1
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 9 16
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 14 20
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 41014-93-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1263377-68-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2730115-19-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24398168
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM incremental addition (HATU)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Piperazinyl Bicyclic Derivatives as Selective Ligands of the 2-1
Subunit of Voltage-Gated Calcium Channels
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fernandez, Ariadna; Diaz, Jose Luis; Garcia, Monica; Rodriguez-Escrich,
Sergi; Lorente, Adriana; Enrech, Raquel; Dordal, Albert; Portillo-Salido,
Enrique; Porras, Monica; Fernandez, Begona; Reinoso, Raquel F.; Vela,
Jose Miguel; Almansa, Carmen
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2021), 12(11), 1802-1809

$RFMT $RIREG SCHEME248 STEP1
$RXN



  2  1
$MOL
4-Fluoroaniline
C6H6FN
371-40-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 0.0000 1.3337 0.0 0
M  V30 2 N 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C13H21NO4
2379569-54-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 1.5400 0.0 0
M  V30 2 C 1.3337 2.3101 0.0 0
M  V30 3 C 2.6673 0.0000 0.0 0
M  V30 4 O 1.3337 3.8501 0.0 0
M  V30 5 O 0.0000 1.5400 0.0 0
M  V30 6 N 7.2198 4.1684 0.0 0
M  V30 7 C 8.5535 3.3984 0.0 0
M  V30 8 O 9.8873 4.1684 0.0 0
M  V30 9 O 8.5535 1.8584 0.0 0
M  V30 10 C 11.2210 3.3984 0.0 0
M  V30 11 C 10.4510 2.0647 0.0 0
M  V30 12 C 12.5547 2.6284 0.0 0
M  V30 13 C 11.9910 4.7322 0.0 0
M  V30 14 C 4.0012 2.3101 0.0 0
M  V30 15 C 5.4878 1.9118 0.0 0
M  V30 16 C 4.3994 3.7968 0.0 0
M  V30 17 C 4.7273 3.0850 0.0 0
M  V30 18 C 5.8862 3.3984 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 6 7
M  V30 7 1 6 18
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 15 18
M  V30 18 1 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C19H25FN2O3
2379569-61-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.8873 1.5400 0.0 0
M  V30 2 C 11.2210 2.3101 0.0 0
M  V30 3 C 9.8873 0.0000 0.0 0
M  V30 4 N 12.5548 1.5400 0.0 0
M  V30 5 O 11.2210 3.8501 0.0 0
M  V30 6 N 5.3348 4.1684 0.0 0
M  V30 7 C 4.0012 3.3984 0.0 0
M  V30 8 O 2.6675 4.1684 0.0 0
M  V30 9 O 4.0012 1.8584 0.0 0
M  V30 10 C 1.3338 3.3984 0.0 0
M  V30 11 C 0.5638 4.7322 0.0 0
M  V30 12 C 0.0000 2.6284 0.0 0
M  V30 13 C 2.1038 2.0647 0.0 0
M  V30 14 F 17.8896 4.6201 0.0 0
M  V30 15 C 8.5537 2.3101 0.0 0
M  V30 16 C 7.0669 1.9118 0.0 0
M  V30 17 C 8.1552 3.7968 0.0 0
M  V30 18 C 7.7028 3.1569 0.0 0
M  V30 19 C 6.6687 3.3984 0.0 0
M  V30 20 C 13.8885 2.3101 0.0 0
M  V30 21 C 13.8885 3.8501 0.0 0
M  V30 22 C 15.2222 1.5400 0.0 0
M  V30 23 C 15.2222 4.6201 0.0 0
M  V30 24 C 16.5558 2.3101 0.0 0
M  V30 25 C 16.5558 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 15
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 4 20
M  V30 7 1 6 7
M  V30 8 1 6 19
M  V30 9 1 7 8
M  V30 10 2 7 9
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 1 10 12
M  V30 14 1 10 13
M  V30 15 1 14 25
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 1 16 19
M  V30 20 1 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 371-40-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2379569-54-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2379569-61-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23349010
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived
Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Pu, Qinglin; Zhang, Hongjun; Guo, Liangqin; Cheng, Mangeng; Doty, Amy C.;
Ferguson, Heidi; Fradera, Xavier; Lesburg, Charles A.; McGowan, Meredeth
A.; Miller, J. Richard; Geda, Prasanthi; Song, Xuelei; Otte, Karin;
Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Sloman, David L.;
Zhou, Hua; Lammens, Alfred; Neumann, Lars; Bennett, David Jonathan;
Pasternak, Alexander; Han, Yongxin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2020), 11(8), 1548-1554

$RFMT $RIREG SCHEME249 STEP1
$RXN



  2  1
$MOL
2-Amino-N-methylbenzamide
C8H10N2O
4141-08-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 N 5.3901 4.0010 0.0 0
M  V30 3 O 5.3901 1.3337 0.0 0
M  V30 4 C 6.9302 4.0010 0.0 0
M  V30 5 N 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 2.3101 1.3337 0.0 0
M  V30 8 C 2.3101 4.0010 0.0 0
M  V30 9 C 0.7700 1.3337 0.0 0
M  V30 10 C 0.7700 4.0010 0.0 0
M  V30 11 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 4
M  V30 5 1 5 7
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
[(tert-Butoxycarbonyl)(methyl)amino]acetic acid
C8H15NO4
13734-36-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 2.3101 0.0 0
M  V30 2 N 5.3348 1.5400 0.0 0
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 6.6685 2.3101 0.0 0
M  V30 6 C 5.3348 0.0000 0.0 0
M  V30 7 C 1.3337 2.3101 0.0 0
M  V30 8 C 8.0023 1.5400 0.0 0
M  V30 9 C 0.5637 0.9764 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 2.1037 3.6437 0.0 0
M  V30 12 O 8.0023 0.0000 0.0 0
M  V30 13 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C16H23N3O4
2998587-29-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.3439 5.3348 0.0 0
M  V30 2 N 12.8839 5.3348 0.0 0
M  V30 3 O 10.5739 4.0012 0.0 0
M  V30 4 C 13.6539 4.0012 0.0 0
M  V30 5 N 8.2638 5.3348 0.0 0
M  V30 6 C 6.7238 5.3348 0.0 0
M  V30 7 C 5.9538 4.0012 0.0 0
M  V30 8 O 5.9538 6.6685 0.0 0
M  V30 9 N 4.4137 4.0012 0.0 0
M  V30 10 C 3.6437 2.6675 0.0 0
M  V30 11 C 3.6437 5.3348 0.0 0
M  V30 12 O 2.1037 2.6675 0.0 0
M  V30 13 O 4.4137 1.3337 0.0 0
M  V30 14 C 1.3337 1.3337 0.0 0
M  V30 15 C 2.6673 0.5637 0.0 0
M  V30 16 C 0.5637 0.0000 0.0 0
M  V30 17 C 0.0000 2.1037 0.0 0
M  V30 18 C 10.5739 6.6685 0.0 0
M  V30 19 C 9.0338 6.6685 0.0 0
M  V30 20 C 11.3439 8.0023 0.0 0
M  V30 21 C 8.2638 8.0023 0.0 0
M  V30 22 C 10.5739 9.3360 0.0 0
M  V30 23 C 9.0338 9.3360 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 18
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 19
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4141-08-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13734-36-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2998587-29-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40640858
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for
Platelet Degranulation Modulation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bayrak, Alp; Mohr, Florian; Kolb, Kyra; Szpakowska, Martyna; Shevchenko,
Ekaterina; Dicenta, Valerie; Rohlfing, Anne-Katrin; Kudolo, Mark;
Pantsar, Tatu; Guenther, Marcel; Kaczor, Agnieszka A.; Poso, Antti;
Chevigne, Andy; Pillaiyar, Thanigaimalai; Gawaz, Meinrad; Laufer, Stefan
A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(19), 13365-13384

$RFMT $RIREG SCHEME250 STEP1
$RXN



  2  1
$MOL
L-Phenylalanine, methyl ester, hydrochloride
C10H13NO2.ClH
7524-50-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0 CFG=2
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 N 5.3347 5.3900 0.0 0
M  V30 5 O 8.0021 3.8500 0.0 0
M  V30 6 O 6.6684 1.5400 0.0 0
M  V30 7 C 9.3358 3.0800 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 3.0800 0.0 0
M  V30 10 C 2.6674 5.3900 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 6.1600 0.0 0
M  V30 13 C 0.0000 5.3900 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Boc-L-valine
C10H19NO4
13734-41-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 2.3101 0.0 0 CFG=2
M  V30 2 N 4.0012 1.5400 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 C 2.6675 3.8501 0.0 0
M  V30 5 C 5.3348 2.3101 0.0 0
M  V30 6 C 0.0000 2.3101 0.0 0
M  V30 7 C 1.3337 0.0000 0.0 0
M  V30 8 O 1.3337 4.6201 0.0 0
M  V30 9 O 4.0012 4.6201 0.0 0
M  V30 10 O 6.6685 1.5400 0.0 0
M  V30 11 O 5.3348 3.8501 0.0 0
M  V30 12 C 8.0023 2.3101 0.0 0
M  V30 13 C 8.7723 0.9764 0.0 0
M  V30 14 C 9.3360 3.0801 0.0 0
M  V30 15 C 7.2323 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 1 5 10
M  V30 10 2 5 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-valyl-L-phenylalanine methyl ester
C20H30N2O5
20902-47-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 4.0011 0.0 0 CFG=2
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 C 4.6200 5.3347 0.0 0
M  V30 4 C 4.6200 2.6674 0.0 0
M  V30 5 C 7.7000 5.3347 0.0 0
M  V30 6 O 5.3900 1.3336 0.0 0
M  V30 7 O 3.0800 2.6674 0.0 0
M  V30 8 C 9.2400 5.3347 0.0 0 CFG=2
M  V30 9 O 6.9300 6.6685 0.0 0
M  V30 10 C 4.6200 0.0000 0.0 0
M  V30 11 N 10.0100 4.0011 0.0 0
M  V30 12 C 10.0100 6.6685 0.0 0
M  V30 13 C 11.5500 4.0011 0.0 0
M  V30 14 C 9.2400 8.0021 0.0 0
M  V30 15 C 11.5500 6.6685 0.0 0
M  V30 16 O 12.3200 2.6674 0.0 0
M  V30 17 O 12.3200 5.3347 0.0 0
M  V30 18 C 13.8600 2.6674 0.0 0
M  V30 19 C 13.8600 1.1274 0.0 0
M  V30 20 C 15.4000 2.6674 0.0 0
M  V30 21 C 13.8600 4.2074 0.0 0
M  V30 22 C 3.0800 5.3347 0.0 0
M  V30 23 C 2.3100 4.0011 0.0 0
M  V30 24 C 2.3100 6.6685 0.0 0
M  V30 25 C 0.7700 4.0011 0.0 0
M  V30 26 C 0.7700 6.6685 0.0 0
M  V30 27 C 0.0000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 22
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=3
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7524-50-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13734-41-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 20902-47-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39179136
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 693-13-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of
3-Chymotrypsin-like Protease of SARS-CoV-2
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Grifagni, Deborah; Lenci, Elena; De Santis, Alessia; Orsetti, Andrea;
Barracchia, Carlo Giorgio; Tedesco, Filomena; Bellini Puglielli,
Raffaele; Lucarelli, Francesca; Lauriola, Angela; Assfalg, Michael;
Cantini, Francesca; Calderone, Vito; Guardavaccaro, Daniele; Trabocchi,
Andrea; DOnofrio, Mariapina; Ciofi-Baffoni, Simone
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2024), 15(2), 250-257

$RFMT $RIREG SCHEME251 STEP1
$RXN



  2  1
$MOL
1,6-Dihydro-1,5-dimethyl-6-oxo-3-pyridinecarboxylic acid
C8H9NO3
677762-39-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 4.0011 0.0 0
M  V30 3 O 0.0000 1.3338 0.0 0
M  V30 4 C 5.3901 0.0000 0.0 0
M  V30 5 C 5.3901 5.3349 0.0 0
M  V30 6 O 6.9301 2.6675 0.0 0
M  V30 7 C 2.3100 2.6675 0.0 0
M  V30 8 C 3.0800 1.3338 0.0 0
M  V30 9 C 3.0800 4.0011 0.0 0
M  V30 10 C 4.6201 1.3338 0.0 0
M  V30 11 N 4.6201 4.0011 0.0 0
M  V30 12 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 10
M  V30 5 1 5 11
M  V30 6 2 6 12
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2,2-Diphenylethylamine
C14H15N
3963-62-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 2.3100 0.0 0
M  V30 2 C 4.0011 0.7700 0.0 0
M  V30 3 N 2.6674 0.0000 0.0 0
M  V30 4 C 2.6674 3.0800 0.0 0
M  V30 5 C 2.6674 4.6200 0.0 0
M  V30 6 C 1.3336 2.3100 0.0 0
M  V30 7 C 1.3336 5.3900 0.0 0
M  V30 8 C 0.0000 3.0800 0.0 0
M  V30 9 C 0.0000 4.6200 0.0 0
M  V30 10 C 5.3347 3.0800 0.0 0
M  V30 11 C 5.3347 4.6200 0.0 0
M  V30 12 C 6.6685 2.3100 0.0 0
M  V30 13 C 6.6685 5.3900 0.0 0
M  V30 14 C 8.0021 3.0800 0.0 0
M  V30 15 C 8.0021 4.6200 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 1 10
M  V30 4 1 2 3
M  V30 5 2 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 8 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(2,2-Diphenylethyl)-1,6-dihydro-1,5-dimethyl-6-oxo-3-pyridinecarboxamide
C22H22N2O2
2752331-29-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.2400 4.0011 0.0 0
M  V30 2 C 8.4700 5.3347 0.0 0
M  V30 3 N 6.9300 5.3347 0.0 0
M  V30 4 C 6.1600 6.6684 0.0 0
M  V30 5 O 6.9300 8.0021 0.0 0
M  V30 6 C 1.5400 9.3358 0.0 0
M  V30 7 C 1.5400 4.0011 0.0 0
M  V30 8 O 0.0000 6.6684 0.0 0
M  V30 9 C 10.7800 4.0011 0.0 0
M  V30 10 C 11.5500 2.6674 0.0 0
M  V30 11 C 11.5500 5.3347 0.0 0
M  V30 12 C 13.0900 2.6674 0.0 0
M  V30 13 C 13.0900 5.3347 0.0 0
M  V30 14 C 13.8600 4.0011 0.0 0
M  V30 15 C 8.4700 2.6674 0.0 0
M  V30 16 C 9.2400 1.3336 0.0 0
M  V30 17 C 6.9300 2.6674 0.0 0
M  V30 18 C 8.4700 0.0000 0.0 0
M  V30 19 C 6.1600 1.3336 0.0 0
M  V30 20 C 6.9300 0.0000 0.0 0
M  V30 21 C 4.6200 6.6684 0.0 0
M  V30 22 C 3.8500 8.0021 0.0 0
M  V30 23 C 3.8500 5.3347 0.0 0
M  V30 24 C 2.3100 8.0021 0.0 0
M  V30 25 N 2.3100 5.3347 0.0 0
M  V30 26 C 1.5400 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 1 15
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 2 4 5
M  V30 7 1 4 21
M  V30 8 1 6 24
M  V30 9 1 7 25
M  V30 10 2 8 26
M  V30 11 2 9 10
M  V30 12 1 9 11
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 1 21 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 677762-39-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3963-62-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2752331-29-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31186652
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded
Library Technology Screening Hit
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rianjongdee, Francesco; Atkinson, Stephen J.; Chung, Chun-wa; Grandi,
Paola; Gray, James R. J.; Kaushansky, Laura J.; Medeiros, Patricia;
Messenger, Cassie; Phillipou, Alex; Preston, Alex; Prinjha, Rab K.;
Rioja, Inmaculada; Satz, Alexander L.; Taylor, Simon; Wall, Ian D.;
Watson, Robert J.; Yao, Gang; Demont, Emmanuel H.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(15), 10806-10833

$RFMT $RIREG SCHEME252 STEP1
$RXN



  2  1
$MOL
3-Nitroaniline
C6H6N2O2
99-09-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3338 1.5400 0.0 0 VAL=5
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 N 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(3-Phenylpropoxy)benzoic acid
C16H16O3
30762-07-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 8.0022 4.6201 0.0 0
M  V30 2 C 6.6685 3.8501 0.0 0
M  V30 3 C 5.3348 4.6201 0.0 0
M  V30 4 C 4.0010 3.8501 0.0 0
M  V30 5 C 13.3370 1.5400 0.0 0
M  V30 6 O 13.3370 0.0000 0.0 0
M  V30 7 O 14.6707 2.3101 0.0 0
M  V30 8 C 9.3358 3.8501 0.0 0
M  V30 9 C 9.3358 2.3101 0.0 0
M  V30 10 C 10.6697 4.6201 0.0 0
M  V30 11 C 10.6697 1.5400 0.0 0
M  V30 12 C 12.0033 3.8501 0.0 0
M  V30 13 C 12.0033 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 16 C 2.6673 6.1601 0.0 0
M  V30 17 C 0.0000 4.6201 0.0 0
M  V30 18 C 1.3337 6.9302 0.0 0
M  V30 19 C 0.0000 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 14
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 13
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3-Nitrophenyl)-4-(3-phenylpropoxy)benzamide
C22H20N2O4
2762795-92-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 4.6201 0.0 0
M  V30 2 C 8.0022 5.3901 0.0 0
M  V30 3 O 8.0022 6.9302 0.0 0
M  V30 4 N 1.3337 4.6201 0.0 0 VAL=5
M  V30 5 O 0.0000 5.3901 0.0 0
M  V30 6 O 1.3337 3.0801 0.0 0
M  V30 7 O 13.3372 2.3101 0.0 0
M  V30 8 C 14.6708 3.0801 0.0 0
M  V30 9 C 16.0045 2.3101 0.0 0
M  V30 10 C 17.3382 3.0801 0.0 0
M  V30 11 C 5.3348 5.3901 0.0 0
M  V30 12 C 4.0012 4.6201 0.0 0
M  V30 13 C 5.3348 6.9302 0.0 0
M  V30 14 C 2.6673 5.3901 0.0 0
M  V30 15 C 4.0012 7.7002 0.0 0
M  V30 16 C 2.6673 6.9302 0.0 0
M  V30 17 C 9.3360 4.6201 0.0 0
M  V30 18 C 9.3360 3.0801 0.0 0
M  V30 19 C 10.6697 5.3901 0.0 0
M  V30 20 C 10.6697 2.3101 0.0 0
M  V30 21 C 12.0033 4.6201 0.0 0
M  V30 22 C 12.0033 3.0801 0.0 0
M  V30 23 C 18.6720 2.3101 0.0 0
M  V30 24 C 20.0057 3.0801 0.0 0
M  V30 25 C 18.6720 0.7700 0.0 0
M  V30 26 C 21.3393 2.3101 0.0 0
M  V30 27 C 20.0057 0.0000 0.0 0
M  V30 28 C 21.3393 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 2 2 3
M  V30 4 1 2 17
M  V30 5 2 4 5
M  V30 6 2 4 6
M  V30 7 1 4 14
M  V30 8 1 7 8
M  V30 9 1 7 22
M  V30 10 1 8 9
M  V30 11 1 9 10
M  V30 12 1 10 23
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 22
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 2 25 27
M  V30 29 2 26 28
M  V30 30 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 99-09-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 30762-07-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2762795-92-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31490957
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-66-3
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development and in-vitro Profiling of Dual FXR/LTA4H Modulators
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Schierle, Simone; Brunst, Steffen; Helmstadter, Moritz; Ebert, Roland;
Kramer, Jan S.; Steinhilber, Dieter; Proschak, Ewgenij; Merk, Daniel
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2021), 16(15), 2366-2374

$RFMT $RIREG SCHEME253 STEP1
$RXN



  2  1
$MOL
5-Methyl-3-isoxazolecarboxylic acid
C5H5NO3
3405-77-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 N 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 O 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C9H18N2O4S.C2HF3O2
2760538-75-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 O 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 S 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H21N3O6S
2760538-88-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 6.9302 0.0 0
M  V30 2 N 8.0023 6.1601 0.0 0
M  V30 3 O 9.3360 8.4702 0.0 0
M  V30 4 C 6.6685 6.9302 0.0 0 CFG=1
M  V30 5 C 5.3348 6.1601 0.0 0
M  V30 6 C 6.6685 8.4702 0.0 0
M  V30 7 N 5.3348 4.6201 0.0 0
M  V30 8 O 4.0012 6.9302 0.0 0
M  V30 9 S 5.3348 9.2402 0.0 0
M  V30 10 C 4.0012 3.8501 0.0 0 CFG=1
M  V30 11 C 5.3348 10.7802 0.0 0
M  V30 12 C 4.0012 2.3101 0.0 0
M  V30 13 C 2.6675 4.6201 0.0 0
M  V30 14 O 2.6673 1.5400 0.0 0
M  V30 15 O 5.3348 1.5400 0.0 0
M  V30 16 O 1.3337 3.8501 0.0 0
M  V30 17 C 2.6673 0.0000 0.0 0
M  V30 18 C 0.0000 4.6201 0.0 0
M  V30 19 C 14.6386 5.8030 0.0 0
M  V30 20 C 10.6697 6.1601 0.0 0
M  V30 21 C 12.0765 6.7865 0.0 0
M  V30 22 N 10.8306 4.6286 0.0 0
M  V30 23 C 13.1071 5.6421 0.0 0
M  V30 24 O 12.3371 4.3084 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 20
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 10 13 CFG=3
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 23
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3405-77-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-75-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-88-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545325
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME254 STEP1
$RXN



  2  1
$MOL
5-Methyl-3-isoxazolecarboxylic acid
C5H5NO3
3405-77-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 N 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 O 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C9H18N2O3S2.C2HF3O2
2760538-76-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 S 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 S 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H21N3O5S2
2760538-89-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 6.9302 0.0 0
M  V30 2 N 8.0023 6.1601 0.0 0
M  V30 3 O 9.3360 8.4702 0.0 0
M  V30 4 C 6.6685 6.9302 0.0 0 CFG=1
M  V30 5 C 5.3348 6.1601 0.0 0
M  V30 6 C 6.6685 8.4702 0.0 0
M  V30 7 N 5.3348 4.6201 0.0 0
M  V30 8 O 4.0012 6.9302 0.0 0
M  V30 9 S 5.3348 9.2402 0.0 0
M  V30 10 C 4.0012 3.8501 0.0 0 CFG=1
M  V30 11 C 5.3348 10.7802 0.0 0
M  V30 12 C 4.0012 2.3101 0.0 0
M  V30 13 C 2.6675 4.6201 0.0 0
M  V30 14 O 2.6673 1.5400 0.0 0
M  V30 15 O 5.3348 1.5400 0.0 0
M  V30 16 S 1.3337 3.8501 0.0 0
M  V30 17 C 2.6673 0.0000 0.0 0
M  V30 18 C 0.0000 4.6201 0.0 0
M  V30 19 C 14.6386 5.8030 0.0 0
M  V30 20 C 10.6697 6.1601 0.0 0
M  V30 21 C 12.0765 6.7865 0.0 0
M  V30 22 N 10.8306 4.6286 0.0 0
M  V30 23 C 13.1071 5.6421 0.0 0
M  V30 24 O 12.3371 4.3084 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 20
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 10 13 CFG=3
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 23
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3405-77-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-76-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-89-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545336
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME255 STEP1
$RXN



  2  1
$MOL
4-Phenylbutyric acid
C10H12O2
1821-12-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3348 2.3100 0.0 0
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 C 8.0022 2.3100 0.0 0
M  V30 5 O 9.3359 3.0800 0.0 0
M  V30 6 O 8.0022 0.7700 0.0 0
M  V30 7 C 2.6675 2.3100 0.0 0
M  V30 8 C 2.6675 0.7700 0.0 0
M  V30 9 C 1.3337 3.0800 0.0 0
M  V30 10 C 1.3337 0.0000 0.0 0
M  V30 11 C 0.0000 2.3100 0.0 0
M  V30 12 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[2-amino-1,1-bis(aminomethyl)ethyl]carbamate
C9H22N4O2
1345700-41-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 2.6675 0.0 0
M  V30 2 N 4.0012 1.8975 0.0 0
M  V30 3 C 3.4375 4.0012 0.0 0
M  V30 4 C 1.3337 3.4375 0.0 0
M  V30 5 C 1.8975 1.3338 0.0 0
M  V30 6 C 5.3348 2.6675 0.0 0
M  V30 7 N 2.6675 5.3350 0.0 0
M  V30 8 N 0.0000 2.6675 0.0 0
M  V30 9 N 2.6675 0.0000 0.0 0
M  V30 10 O 6.6685 1.8975 0.0 0
M  V30 11 O 5.3348 4.2075 0.0 0
M  V30 12 C 8.0023 2.6675 0.0 0
M  V30 13 C 8.7723 1.3338 0.0 0
M  V30 14 C 9.3360 3.4375 0.0 0
M  V30 15 C 7.2323 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 2 6 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C39H52N4O5
2820146-39-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  48 50 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 12.0033 12.0035 0.0 0
M  V30 2 C 13.3370 11.2335 0.0 0
M  V30 3 C 11.2333 10.6697 0.0 0
M  V30 4 C 10.6697 12.7735 0.0 0
M  V30 5 N 12.7733 13.3372 0.0 0
M  V30 6 N 14.6708 12.0035 0.0 0
M  V30 7 N 12.0033 9.3360 0.0 0
M  V30 8 N 9.3358 12.0035 0.0 0
M  V30 9 C 12.0033 14.6708 0.0 0
M  V30 10 C 16.0045 11.2335 0.0 0
M  V30 11 C 11.2333 8.0023 0.0 0
M  V30 12 C 8.0022 12.7735 0.0 0
M  V30 13 O 12.7733 16.0045 0.0 0
M  V30 14 O 10.4633 14.6708 0.0 0
M  V30 15 C 17.3382 12.0035 0.0 0
M  V30 16 O 16.0045 9.6934 0.0 0
M  V30 17 C 12.0033 6.6685 0.0 0
M  V30 18 O 9.6933 8.0023 0.0 0
M  V30 19 C 6.6685 12.0035 0.0 0
M  V30 20 O 8.0022 14.3135 0.0 0
M  V30 21 C 12.0033 17.3383 0.0 0
M  V30 22 C 18.6718 11.2335 0.0 0
M  V30 23 C 11.2333 5.3348 0.0 0
M  V30 24 C 5.3348 12.7735 0.0 0
M  V30 25 C 13.3370 18.1083 0.0 0
M  V30 26 C 11.2333 18.6720 0.0 0
M  V30 27 C 10.6697 16.5683 0.0 0
M  V30 28 C 20.0057 12.0035 0.0 0
M  V30 29 C 12.0033 4.0012 0.0 0
M  V30 30 C 4.0010 12.0035 0.0 0
M  V30 31 C 21.3393 11.2335 0.0 0
M  V30 32 C 21.3393 9.6934 0.0 0
M  V30 33 C 22.6730 12.0035 0.0 0
M  V30 34 C 22.6730 8.9234 0.0 0
M  V30 35 C 24.0067 11.2335 0.0 0
M  V30 36 C 24.0067 9.6934 0.0 0
M  V30 37 C 11.2333 2.6675 0.0 0
M  V30 38 C 12.0033 1.3337 0.0 0
M  V30 39 C 9.6933 2.6675 0.0 0
M  V30 40 C 11.2333 0.0000 0.0 0
M  V30 41 C 8.9233 1.3337 0.0 0
M  V30 42 C 9.6933 0.0000 0.0 0
M  V30 43 C 2.6673 12.7735 0.0 0
M  V30 44 C 1.3337 12.0035 0.0 0
M  V30 45 C 2.6673 14.3135 0.0 0
M  V30 46 C 0.0000 12.7735 0.0 0
M  V30 47 C 1.3337 15.0836 0.0 0
M  V30 48 C 0.0000 14.3135 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 2 9 14
M  V30 14 1 10 15
M  V30 15 2 10 16
M  V30 16 1 11 17
M  V30 17 2 11 18
M  V30 18 1 12 19
M  V30 19 2 12 20
M  V30 20 1 13 21
M  V30 21 1 15 22
M  V30 22 1 17 23
M  V30 23 1 19 24
M  V30 24 1 21 25
M  V30 25 1 21 26
M  V30 26 1 21 27
M  V30 27 1 22 28
M  V30 28 1 23 29
M  V30 29 1 24 30
M  V30 30 1 28 31
M  V30 31 1 29 37
M  V30 32 1 30 43
M  V30 33 2 31 32
M  V30 34 1 31 33
M  V30 35 1 32 34
M  V30 36 2 33 35
M  V30 37 2 34 36
M  V30 38 1 35 36
M  V30 39 2 37 38
M  V30 40 1 37 39
M  V30 41 1 38 40
M  V30 42 2 39 41
M  V30 43 2 40 42
M  V30 44 1 41 42
M  V30 45 2 43 44
M  V30 46 1 43 45
M  V30 47 1 44 46
M  V30 48 2 45 47
M  V30 49 2 46 48
M  V30 50 1 47 48
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1821-12-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1345700-41-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2820146-39-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34105968
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A Mitochondria-Targeted Phenylbutyric Acid Prodrug Confers Drastically
Improved Anticancer Activities
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Huang, Ding; Liu, Qingwang; Zhang, Maojie; Guo, Yizhen; Cui, Zhiying; Li,
Tao; Luo, Dong; Xu, Biao; Huang, Chao; Guo, Jian; Tam, Kin Yip; Zhang,
Min; Zhang, Shao-Lin; He, Yun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(14), 9955-9973

$RFMT $RIREG SCHEME256 STEP1
$RXN



  2  1
$MOL
3,4,5-Trimethoxybenzoic acid
C10H12O5
118-41-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3336 2.3100 0.0 0
M  V30 2 C 0.0000 3.0800 0.0 0
M  V30 3 O 4.0011 0.7700 0.0 0
M  V30 4 C 5.3347 0.0000 0.0 0
M  V30 5 O 1.3336 5.3900 0.0 0
M  V30 6 C 1.3336 6.9300 0.0 0
M  V30 7 C 6.6685 5.3900 0.0 0
M  V30 8 O 8.0021 4.6200 0.0 0
M  V30 9 O 6.6685 6.9300 0.0 0
M  V30 10 C 2.6674 3.0800 0.0 0
M  V30 11 C 4.0011 2.3100 0.0 0
M  V30 12 C 2.6674 4.6200 0.0 0
M  V30 13 C 5.3347 3.0800 0.0 0
M  V30 14 C 4.0011 5.3900 0.0 0
M  V30 15 C 5.3347 4.6200 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 3 4
M  V30 4 1 3 11
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 7 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetic acid, 4-amino-, methyl ester
C9H11NO2
39552-81-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.0800 0.0 0
M  V30 2 C 6.6684 2.3100 0.0 0
M  V30 3 O 8.0022 3.0800 0.0 0
M  V30 4 O 6.6684 0.7700 0.0 0
M  V30 5 C 9.3359 2.3100 0.0 0
M  V30 6 N 0.0000 0.0000 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 4.0011 0.7700 0.0 0
M  V30 9 C 2.6675 3.0800 0.0 0
M  V30 10 C 2.6675 0.0000 0.0 0
M  V30 11 C 1.3337 2.3100 0.0 0
M  V30 12 C 1.3337 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[(3,4,5-trimethoxybenzoyl)amino]benzeneacetate
C19H21NO6
690987-99-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6687 5.3901 0.0 0
M  V30 2 N 8.0023 4.6201 0.0 0
M  V30 3 O 6.6687 6.9302 0.0 0
M  V30 4 O 1.3338 5.3901 0.0 0
M  V30 5 C 1.3338 6.9302 0.0 0
M  V30 6 O 4.0012 0.7700 0.0 0
M  V30 7 C 5.3348 0.0000 0.0 0
M  V30 8 O 1.3338 2.3101 0.0 0
M  V30 9 C 0.0000 3.0801 0.0 0
M  V30 10 C 13.3372 7.7002 0.0 0
M  V30 11 C 14.6708 6.9302 0.0 0
M  V30 12 O 16.0045 7.7002 0.0 0
M  V30 13 O 14.6708 5.3901 0.0 0
M  V30 14 C 17.3383 6.9302 0.0 0
M  V30 15 C 5.3348 4.6201 0.0 0
M  V30 16 C 4.0012 5.3901 0.0 0
M  V30 17 C 5.3348 3.0801 0.0 0
M  V30 18 C 2.6675 4.6201 0.0 0
M  V30 19 C 4.0012 2.3101 0.0 0
M  V30 20 C 2.6675 3.0801 0.0 0
M  V30 21 C 9.3360 5.3901 0.0 0
M  V30 22 C 9.3360 6.9302 0.0 0
M  V30 23 C 10.6697 4.6201 0.0 0
M  V30 24 C 10.6697 7.7002 0.0 0
M  V30 25 C 12.0035 5.3901 0.0 0
M  V30 26 C 12.0035 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 21
M  V30 5 1 4 5
M  V30 6 1 4 18
M  V30 7 1 6 7
M  V30 8 1 6 19
M  V30 9 1 8 9
M  V30 10 1 8 20
M  V30 11 1 10 11
M  V30 12 1 10 26
M  V30 13 1 11 12
M  V30 14 2 11 13
M  V30 15 1 12 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 25
M  V30 26 2 24 26
M  V30 27 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 118-41-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 39552-81-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 690987-99-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37616116
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-66-3
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and
elacridar: New potent P-gp modulators acting as MDR reversers
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Braconi, Laura; Dei, Silvia; Contino, Marialessandra; Riganti, Chiara;
Bartolucci, Gianluca; Manetti, Dina; Romanelli, Maria Novella; Perrone,
Maria Grazia; Colabufo, Nicola Antonio; Guglielmo, Stefano; Teodori,
Elisabetta
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 259115716

$RFMT $RIREG SCHEME257 STEP1
$RXN



  2  1
$MOL
2-Methyl-6-quinolinecarboxylic acid
C11H9NO2
635-80-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0023 1.5400 0.0 0
M  V30 2 O 8.0023 0.0000 0.0 0
M  V30 3 O 9.3360 2.3101 0.0 0
M  V30 4 C 0.0000 4.6201 0.0 0
M  V30 5 C 4.0012 2.3101 0.0 0
M  V30 6 C 4.0012 3.8501 0.0 0
M  V30 7 C 5.3348 1.5400 0.0 0
M  V30 8 C 2.6675 1.5400 0.0 0
M  V30 9 N 2.6675 4.6201 0.0 0
M  V30 10 C 5.3348 4.6201 0.0 0
M  V30 11 C 6.6685 2.3101 0.0 0
M  V30 12 C 1.3337 2.3101 0.0 0
M  V30 13 C 1.3337 3.8501 0.0 0
M  V30 14 C 6.6685 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 4 13
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 2 9 13
M  V30 13 2 10 14
M  V30 14 1 11 14
M  V30 15 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Methyl-5-nitroaniline
C7H8N2O2
99-55-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.7700 2.6673 0.0 0 VAL=5
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 5.3901 0.0000 0.0 0
M  V30 5 C 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Methyl-N-(2-methyl-5-nitrophenyl)-6-quinolinecarboxamide
C18H15N3O3
2015952-91-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 4.0011 0.0 0
M  V30 2 N 6.1600 2.6674 0.0 0
M  V30 3 O 6.1600 5.3347 0.0 0
M  V30 4 C 15.4000 5.3347 0.0 0
M  V30 5 C 4.6200 0.0000 0.0 0
M  V30 6 N 1.5400 5.3347 0.0 0 VAL=5
M  V30 7 O 2.3100 6.6685 0.0 0
M  V30 8 O 0.0000 5.3347 0.0 0
M  V30 9 C 10.7800 5.3347 0.0 0
M  V30 10 C 11.5500 4.0011 0.0 0
M  V30 11 C 9.2400 5.3347 0.0 0
M  V30 12 C 11.5500 6.6685 0.0 0
M  V30 13 C 10.7800 2.6674 0.0 0
M  V30 14 N 13.0900 4.0011 0.0 0
M  V30 15 C 8.4700 4.0011 0.0 0
M  V30 16 C 13.0900 6.6685 0.0 0
M  V30 17 C 9.2400 2.6674 0.0 0
M  V30 18 C 13.8600 5.3347 0.0 0
M  V30 19 C 4.6200 2.6674 0.0 0
M  V30 20 C 3.8500 4.0011 0.0 0
M  V30 21 C 3.8500 1.3338 0.0 0
M  V30 22 C 2.3100 4.0011 0.0 0
M  V30 23 C 2.3100 1.3338 0.0 0
M  V30 24 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 19
M  V30 5 1 4 18
M  V30 6 1 5 21
M  V30 7 2 6 7
M  V30 8 2 6 8
M  V30 9 1 6 22
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 2 11 15
M  V30 16 2 12 16
M  V30 17 2 13 17
M  V30 18 2 14 18
M  V30 19 1 15 17
M  V30 20 1 16 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 635-80-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 99-55-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2015952-91-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40578368
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM pyridine also used as a solvent in stage 2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed
from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian
Cancer and Other Malignancies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Pasqua, A. Elisa; Sharp, Swee Y.; Chessum, Nicola E. A.; Hayes, Angela;
Pellegrino, Loredana; Tucker, Michael J.; Miah, Asadh; Wilding, Birgit;
Evans, Lindsay E.; Rye, Carl S.; Mok, N. Yi; Liu, Manjuan; Henley, Alan
T.; Gowan, Sharon; De Billy, Emmanuel; te Poele, Robert; Powers, Marissa;
Eccles, Suzanne A.; Clarke, Paul A.; Raynaud, Florence I.; Workman, Paul;
Jones, Keith; Cheeseman, Matthew D.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(8), 5907-5936

$RFMT $RIREG SCHEME258 STEP1
$RXN



  2  1
$MOL
4-Chloro[1,1-biphenyl]-3-carboxylic acid
C13H9ClO2
4655-10-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 1.3338 0.0 0
M  V30 2 O 0.0000 1.3338 0.0 0
M  V30 3 O 2.3100 0.0000 0.0 0
M  V30 4 Cl 10.7800 4.0011 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 3.8500 2.6674 0.0 0
M  V30 7 C 3.8500 5.3349 0.0 0
M  V30 8 C 2.3100 2.6674 0.0 0
M  V30 9 C 2.3100 5.3349 0.0 0
M  V30 10 C 1.5400 4.0011 0.0 0
M  V30 11 C 6.1600 4.0011 0.0 0
M  V30 12 C 6.9300 5.3349 0.0 0
M  V30 13 C 6.9300 2.6674 0.0 0
M  V30 14 C 8.4700 5.3349 0.0 0
M  V30 15 C 8.4700 2.6674 0.0 0
M  V30 16 C 9.2400 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 16
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 5 11
M  V30 8 1 6 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl anthranilate
C8H9NO2
134-20-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0
M  V30 2 O 5.3901 4.0010 0.0 0
M  V30 3 O 5.3901 1.3337 0.0 0
M  V30 4 C 6.9302 4.0010 0.0 0
M  V30 5 N 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 2.3101 1.3337 0.0 0
M  V30 8 C 2.3101 4.0010 0.0 0
M  V30 9 C 0.7700 1.3337 0.0 0
M  V30 10 C 0.7700 4.0010 0.0 0
M  V30 11 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 2 4
M  V30 5 1 5 7
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 2-[[(4-chloro[1,1-biphenyl]-3-yl)carbonyl]amino]benzoate
C21H16ClNO3
2711750-25-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 4.0011 0.0 0
M  V30 2 N 5.3900 4.0011 0.0 0
M  V30 3 O 7.7000 2.6674 0.0 0
M  V30 4 Cl 16.1700 6.6685 0.0 0
M  V30 5 C 2.3100 4.0011 0.0 0
M  V30 6 O 0.7700 4.0011 0.0 0
M  V30 7 O 3.0800 5.3347 0.0 0
M  V30 8 C 0.0000 5.3347 0.0 0
M  V30 9 C 10.0100 6.6685 0.0 0
M  V30 10 C 9.2400 5.3347 0.0 0
M  V30 11 C 9.2400 8.0021 0.0 0
M  V30 12 C 7.7000 5.3347 0.0 0
M  V30 13 C 7.7000 8.0021 0.0 0
M  V30 14 C 6.9300 6.6685 0.0 0
M  V30 15 C 11.5500 6.6685 0.0 0
M  V30 16 C 12.3200 5.3347 0.0 0
M  V30 17 C 12.3200 8.0021 0.0 0
M  V30 18 C 13.8600 5.3347 0.0 0
M  V30 19 C 13.8600 8.0021 0.0 0
M  V30 20 C 14.6300 6.6685 0.0 0
M  V30 21 C 4.6200 2.6674 0.0 0
M  V30 22 C 3.0800 2.6674 0.0 0
M  V30 23 C 5.3900 1.3336 0.0 0
M  V30 24 C 2.3100 1.3336 0.0 0
M  V30 25 C 4.6200 0.0000 0.0 0
M  V30 26 C 3.0800 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 21
M  V30 5 1 4 20
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 22
M  V30 9 1 6 8
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 9 15
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4655-10-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 134-20-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2711750-25-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24494512
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of
Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral
Exposure
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Velcicky, Juraj; Wilcken, Rainer; Cotesta, Simona; Janser, Philipp;
Schlapbach, Achim; Wagner, Trixie; Piechon, Philippe; Villard, Frederic;
Bouhelal, Rochdi; Piller, Fabian; Harlfinger, Stephanie; Stringer, Rowan;
Fehlmann, Dominique; Kaupmann, Klemens; Littlewood-Evans, Amanda; Haffke,
Matthias; Gommermann, Nina
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(17), 9856-9875

$RFMT $RIREG SCHEME259 STEP1
$RXN



  2  1
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Morpholineethanamine
C6H14N2O
2038-03-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 5.3901 2.6673 0.0 0
M  V30 3 N 6.9302 2.6673 0.0 0
M  V30 4 N 3.0801 1.3337 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.7700 2.6673 0.0 0
M  V30 9 O 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 2 3
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-[2-(4-morpholinyl)ethyl]-5-nitrobenzamide
C13H18N4O4
1442094-57-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 C 9.2400 5.3347 0.0 0
M  V30 6 N 4.6200 0.0000 0.0 0
M  V30 7 N 1.5400 5.3347 0.0 0 VAL=5
M  V30 8 O 0.0000 5.3347 0.0 0
M  V30 9 O 2.3100 6.6685 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.8500 4.0011 0.0 0
M  V30 12 C 3.8500 1.3338 0.0 0
M  V30 13 C 2.3100 4.0011 0.0 0
M  V30 14 C 2.3100 1.3338 0.0 0
M  V30 15 C 1.5400 2.6674 0.0 0
M  V30 16 N 10.7800 5.3347 0.0 0
M  V30 17 C 11.5500 6.6685 0.0 0
M  V30 18 C 11.5500 4.0011 0.0 0
M  V30 19 C 13.0900 6.6685 0.0 0
M  V30 20 C 13.0900 4.0011 0.0 0
M  V30 21 O 13.8600 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 16
M  V30 7 1 6 12
M  V30 8 2 7 8
M  V30 9 2 7 9
M  V30 10 1 7 13
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2038-03-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1442094-57-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38624468
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of Quinazolinones and Quinazolinediones for
Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating
COP1-ATGL Axis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sarkar, Dipayan; Chowdhury, Saheli; Goon, Sunny; Sen, Abhishek; Dastidar,
Uddipta Ghosh; Mondal, Mohabul Alam; Chakrabarti, Partha; Talukdar,
Arindam
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(24), 16728-16761

$RFMT $RIREG SCHEME260 STEP1
$RXN



  2  1
$MOL
N,N-Dimethyl-p-phenylenediamine
C8H12N2
99-98-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.7700 1.3337 0.0 0
M  V30 2 C 0.0000 0.0000 0.0 0
M  V30 3 C 0.0000 2.6673 0.0 0
M  V30 4 N 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(1-Methylethoxy)-3-nitrobenzoic acid
C10H11NO5
156629-52-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 6.1601 0.0 0 VAL=5
M  V30 2 O 5.3348 6.9302 0.0 0
M  V30 3 O 2.6675 6.9302 0.0 0
M  V30 4 O 6.6685 4.6201 0.0 0
M  V30 5 C 8.0023 3.8501 0.0 0
M  V30 6 C 9.3360 4.6201 0.0 0
M  V30 7 C 8.0023 2.3101 0.0 0
M  V30 8 C 1.3337 1.5400 0.0 0
M  V30 9 O 1.3337 0.0000 0.0 0
M  V30 10 O 0.0000 2.3101 0.0 0
M  V30 11 C 4.0012 4.6201 0.0 0
M  V30 12 C 5.3348 3.8501 0.0 0
M  V30 13 C 2.6675 3.8501 0.0 0
M  V30 14 C 5.3348 2.3101 0.0 0
M  V30 15 C 2.6675 2.3101 0.0 0
M  V30 16 C 4.0012 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 4 5
M  V30 5 1 4 12
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 15
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzamide, N-[4-(dimethylamino)phenyl]-4-(1-methylethoxy)-3-nitro-
C18H21N3O4
3035807-27-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.8500 1.3338 0.0 0 VAL=5
M  V30 2 O 2.3100 1.3338 0.0 0
M  V30 3 O 4.6200 0.0000 0.0 0
M  V30 4 O 2.3100 4.0011 0.0 0
M  V30 5 C 1.5400 5.3347 0.0 0
M  V30 6 C 2.3100 6.6685 0.0 0
M  V30 7 C 0.0000 5.3347 0.0 0
M  V30 8 C 8.4700 4.0011 0.0 0
M  V30 9 N 9.2400 5.3347 0.0 0
M  V30 10 O 9.2400 2.6674 0.0 0
M  V30 11 N 15.4000 5.3347 0.0 0
M  V30 12 C 16.1700 4.0011 0.0 0
M  V30 13 C 16.1700 6.6685 0.0 0
M  V30 14 C 4.6200 2.6674 0.0 0
M  V30 15 C 3.8500 4.0011 0.0 0
M  V30 16 C 6.1600 2.6674 0.0 0
M  V30 17 C 4.6200 5.3347 0.0 0
M  V30 18 C 6.9300 4.0011 0.0 0
M  V30 19 C 6.1600 5.3347 0.0 0
M  V30 20 C 10.7800 5.3347 0.0 0
M  V30 21 C 11.5500 6.6685 0.0 0
M  V30 22 C 11.5500 4.0011 0.0 0
M  V30 23 C 13.0900 6.6685 0.0 0
M  V30 24 C 13.0900 4.0011 0.0 0
M  V30 25 C 13.8600 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 4 5
M  V30 5 1 4 15
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 18
M  V30 11 1 9 20
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 25
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 99-98-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 156629-52-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3035807-27-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40728186
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and structure-activity relationship study of new biaryl amide
derivatives and their inhibitory effects against hepatitis C virus
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liu, Yonghua; Li, Jianrui; Gu, Yuxi; Ma, Ling; Cen, Shan; Peng, Zonggen;
Hu, Laixing
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2022), 228114033

$RFMT $RIREG SCHEME261 STEP1
$RXN



  2  1
$MOL
Sulindac
C20H17FO3S
38194-50-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.4607 6.6956 0.0 0
M  V30 2 C 2.1580 5.5685 0.0 0
M  V30 3 C 1.5316 6.9754 0.0 0
M  V30 4 O 0.0000 7.1364 0.0 0
M  V30 5 O 2.4368 8.2213 0.0 0
M  V30 6 C 4.3999 8.0584 0.0 0
M  V30 7 F 4.5383 0.0000 0.0 0
M  V30 8 S 12.7955 3.6155 0.0 0 CFG=3 VAL=4
M  V30 9 C 12.7955 2.0755 0.0 0
M  V30 10 O 14.1292 4.3856 0.0 0
M  V30 11 C 5.9659 4.3940 0.0 0
M  V30 12 C 4.4596 4.0739 0.0 0
M  V30 13 C 6.1270 5.9256 0.0 0
M  V30 14 C 6.9965 3.2495 0.0 0
M  V30 15 C 3.6896 5.4075 0.0 0
M  V30 16 C 3.9838 2.6091 0.0 0
M  V30 17 C 4.7200 6.5519 0.0 0
M  V30 18 C 6.5205 1.7849 0.0 0
M  V30 19 C 5.0142 1.4647 0.0 0
M  V30 20 C 8.7944 5.9256 0.0 0
M  V30 21 C 10.1280 6.6956 0.0 0
M  V30 22 C 8.7944 4.3856 0.0 0
M  V30 23 C 11.4619 5.9256 0.0 0
M  V30 24 C 10.1280 3.6155 0.0 0
M  V30 25 C 11.4619 4.3856 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 13
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 1 2 15
M  V30 5 1 3 4
M  V30 6 2 3 5
M  V30 7 1 6 17
M  V30 8 1 7 19
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 8 25
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 2 15 17
M  V30 20 1 16 19
M  V30 21 2 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indene-3-acetamide, 5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methyle...
C23H20FNO2S
3033692-54-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.7758 4.9933 0.0 0
M  V30 2 C 11.1826 5.6196 0.0 0
M  V30 3 N 12.4285 4.7144 0.0 0
M  V30 4 O 11.3435 7.1512 0.0 0
M  V30 5 C 13.8354 5.3409 0.0 0
M  V30 6 C 15.0813 4.4357 0.0 0
M  V30 7 C 16.3272 3.5305 0.0 0
M  V30 8 C 4.6200 6.6685 0.0 0
M  V30 9 C 6.5894 3.9580 0.0 0
M  V30 10 F 10.4985 11.0058 0.0 0
M  V30 11 S 1.5400 1.3338 0.0 0 VAL=4
M  V30 12 C 0.0000 1.3338 0.0 0
M  V30 13 O 2.3100 0.0000 0.0 0
M  V30 14 C 8.5298 7.4385 0.0 0
M  V30 15 C 7.0652 7.9144 0.0 0
M  V30 16 C 8.5298 5.8985 0.0 0
M  V30 17 C 9.6743 8.4690 0.0 0
M  V30 18 C 6.1600 6.6685 0.0 0
M  V30 19 C 6.7451 9.4207 0.0 0
M  V30 20 C 7.0652 5.4225 0.0 0
M  V30 21 C 9.3542 9.9752 0.0 0
M  V30 22 C 7.8895 10.4513 0.0 0
M  V30 23 C 3.8500 5.3347 0.0 0
M  V30 24 C 4.6200 4.0011 0.0 0
M  V30 25 C 2.3100 5.3347 0.0 0
M  V30 26 C 3.8500 2.6674 0.0 0
M  V30 27 C 1.5400 4.0011 0.0 0
M  V30 28 C 2.3100 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 3 6 7
M  V30 8 2 8 18 CFG=2
M  V30 9 1 8 23
M  V30 10 1 9 20
M  V30 11 1 10 21
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 11 28
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 14 17
M  V30 18 1 15 18
M  V30 19 2 15 19
M  V30 20 2 16 20
M  V30 21 1 17 21
M  V30 22 1 18 20
M  V30 23 1 19 22
M  V30 24 2 21 22
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 2 25 27
M  V30 29 2 26 28
M  V30 30 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 38194-50-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3033692-54-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37043005
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM NSAID-Au(I) Complexes Induce ROS-Driven DAMPs and Interpose Inflammation
to Stimulate the Immune Response against Ovarian Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Xu, Zhongren; Lu, Qiuyue; Shan, Min; Jiang, Guizhi; Liu, Yuanhao; Yang,
Zhibin; Lu, Yunlong; Liu, Wukun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(12), 7813-7833

$RFMT $RIREG SCHEME262 STEP1
$RXN



  2  1
$MOL
(2-Nitrophenyl)acetic acid
C8H7NO4
3740-52-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3900 4.0011 0.0 0 VAL=5
M  V30 2 O 6.9300 4.0011 0.0 0
M  V30 3 O 4.6200 5.3349 0.0 0
M  V30 4 C 2.3100 4.0011 0.0 0
M  V30 5 C 0.7700 4.0011 0.0 0
M  V30 6 O 0.0000 5.3349 0.0 0
M  V30 7 O 0.0000 2.6674 0.0 0
M  V30 8 C 4.6200 2.6674 0.0 0
M  V30 9 C 3.0800 2.6674 0.0 0
M  V30 10 C 5.3900 1.3338 0.0 0
M  V30 11 C 2.3100 1.3338 0.0 0
M  V30 12 C 4.6200 0.0000 0.0 0
M  V30 13 C 3.0800 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 5
M  V30 5 1 4 9
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-(4-amino-2-methyl[1,1-biphenyl]-2-yl)-
C16H16N2O
2983540-42-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 6.1600 0.0 0
M  V30 2 C 6.6684 6.9300 0.0 0
M  V30 3 C 8.0021 6.1600 0.0 0
M  V30 4 O 6.6684 8.4700 0.0 0
M  V30 5 C 9.3358 6.9300 0.0 0
M  V30 6 C 0.0000 4.6200 0.0 0
M  V30 7 N 2.6674 0.0000 0.0 0
M  V30 8 C 2.6674 6.1600 0.0 0
M  V30 9 C 4.0011 6.9300 0.0 0
M  V30 10 C 1.3336 6.9300 0.0 0
M  V30 11 C 4.0011 8.4700 0.0 0
M  V30 12 C 1.3336 8.4700 0.0 0
M  V30 13 C 2.6674 9.2400 0.0 0
M  V30 14 C 2.6674 4.6200 0.0 0
M  V30 15 C 1.3336 3.8500 0.0 0
M  V30 16 C 4.0011 3.8500 0.0 0
M  V30 17 C 1.3336 2.3100 0.0 0
M  V30 18 C 4.0011 2.3100 0.0 0
M  V30 19 C 2.6674 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 15
M  V30 7 1 7 19
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 14
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, N-[2-methyl-2-[(1-oxo-2-propen-1-yl)amino][1,1-biphenyl]-...
C24H21N3O4
2983540-43-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 12.3200 9.3358 0.0 0
M  V30 2 C 13.8600 9.3358 0.0 0
M  V30 3 C 14.6300 8.0020 0.0 0
M  V30 4 O 14.6300 10.6694 0.0 0
M  V30 5 C 16.1700 8.0020 0.0 0
M  V30 6 C 6.9300 10.6694 0.0 0
M  V30 7 N 6.9300 5.3347 0.0 0
M  V30 8 C 5.3900 5.3347 0.0 0
M  V30 9 C 4.6200 4.0009 0.0 0
M  V30 10 O 4.6200 6.6684 0.0 0
M  V30 11 N 3.0800 1.3336 0.0 0 VAL=5
M  V30 12 O 2.3100 0.0000 0.0 0
M  V30 13 O 4.6200 1.3336 0.0 0
M  V30 14 C 10.0100 10.6694 0.0 0
M  V30 15 C 11.5500 10.6694 0.0 0
M  V30 16 C 9.2400 12.0031 0.0 0
M  V30 17 C 12.3200 12.0031 0.0 0
M  V30 18 C 10.0100 13.3367 0.0 0
M  V30 19 C 11.5500 13.3367 0.0 0
M  V30 20 C 9.2400 9.3358 0.0 0
M  V30 21 C 7.7000 9.3358 0.0 0
M  V30 22 C 10.0100 8.0020 0.0 0
M  V30 23 C 6.9300 8.0020 0.0 0
M  V30 24 C 9.2400 6.6684 0.0 0
M  V30 25 C 7.7000 6.6684 0.0 0
M  V30 26 C 3.0800 4.0009 0.0 0
M  V30 27 C 2.3100 2.6673 0.0 0
M  V30 28 C 2.3100 5.3347 0.0 0
M  V30 29 C 0.7700 2.6673 0.0 0
M  V30 30 C 0.7700 5.3347 0.0 0
M  V30 31 C 0.0000 4.0009 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 21
M  V30 7 1 7 8
M  V30 8 1 7 25
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 26
M  V30 12 2 11 12
M  V30 13 2 11 13
M  V30 14 1 11 27
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 14 20
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 2 28 30
M  V30 32 2 29 31
M  V30 33 1 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3740-52-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2983540-42-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-43-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256049
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME263 STEP1
$RXN



  2  1
$MOL
Ethyl (R)-4-bromo--[[(1,1-dimethylethoxy)carbonyl]amino]benzenebutanoate
C17H24BrNO4
1257446-29-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.9536 6.6684 0.0 0 CFG=2
M  V30 2 C 6.7236 8.0021 0.0 0
M  V30 3 N 4.4136 6.6684 0.0 0
M  V30 4 C 6.7236 5.3347 0.0 0
M  V30 5 C 3.6436 8.0021 0.0 0
M  V30 6 C 5.9536 4.0011 0.0 0
M  V30 7 O 2.1036 8.0021 0.0 0
M  V30 8 O 4.4136 9.3358 0.0 0
M  V30 9 O 6.7236 2.6673 0.0 0
M  V30 10 O 4.4136 4.0011 0.0 0
M  V30 11 C 1.3336 9.3358 0.0 0
M  V30 12 C 5.9536 1.3336 0.0 0
M  V30 13 C 2.6673 10.1058 0.0 0
M  V30 14 C 0.5636 10.6694 0.0 0
M  V30 15 C 0.0000 8.5658 0.0 0
M  V30 16 C 6.7236 0.0000 0.0 0
M  V30 17 Br 12.8836 8.0021 0.0 0
M  V30 18 C 8.2636 8.0021 0.0 0
M  V30 19 C 9.0336 9.3358 0.0 0
M  V30 20 C 9.0336 6.6684 0.0 0
M  V30 21 C 10.5736 9.3358 0.0 0
M  V30 22 C 10.5736 6.6684 0.0 0
M  V30 23 C 11.3436 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 18
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 2 6 10
M  V30 11 1 7 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 17 23
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) butanedioate
C8H14O4
15026-17-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 C 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethyl (R)-4-bromo--[[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]amino]benzenebut...
C20H28BrNO5
1257443-64-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 6.6684 0.0 0 CFG=2
M  V30 2 C 6.1600 8.0021 0.0 0
M  V30 3 N 8.4700 6.6684 0.0 0
M  V30 4 C 6.1600 5.3347 0.0 0
M  V30 5 C 9.2400 8.0021 0.0 0
M  V30 6 C 6.9300 4.0011 0.0 0
M  V30 7 C 10.7800 8.0021 0.0 0
M  V30 8 O 8.4700 9.3358 0.0 0
M  V30 9 O 6.1600 2.6673 0.0 0
M  V30 10 O 8.4700 4.0011 0.0 0
M  V30 11 C 11.5500 9.3358 0.0 0
M  V30 12 C 6.9300 1.3336 0.0 0
M  V30 13 C 13.0900 9.3358 0.0 0
M  V30 14 C 6.1600 0.0000 0.0 0
M  V30 15 O 13.8600 10.6694 0.0 0
M  V30 16 O 13.8600 8.0021 0.0 0
M  V30 17 C 15.4000 10.6694 0.0 0
M  V30 18 C 15.4000 9.1294 0.0 0
M  V30 19 C 16.9400 10.6694 0.0 0
M  V30 20 C 15.4000 12.2094 0.0 0
M  V30 21 Br 0.0000 8.0021 0.0 0
M  V30 22 C 4.6200 8.0021 0.0 0
M  V30 23 C 3.8500 6.6684 0.0 0
M  V30 24 C 3.8500 9.3358 0.0 0
M  V30 25 C 2.3100 6.6684 0.0 0
M  V30 26 C 2.3100 9.3358 0.0 0
M  V30 27 C 1.5400 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 22
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 2 6 10
M  V30 11 1 7 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 17 20
M  V30 21 1 21 27
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1257446-29-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 15026-17-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1257443-64-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24120096
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 39968-33-7
$DTYPE RXN:VAR(1):RGT(5):CAS_RN
$DATUM 7664-41-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 123-91-1
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives
as Neprilysin Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kawanami, Toshio; Karki, Rajeshri G.; Cody, Emma; Liu, Qian; Liang,
Guiqing; Ksander, Gary M.; Rigel, Dean F.; Schiering, Nikolaus; Gong,
Yongjin; Coppola, Gary M.; Iwaki, Yuki; Sun, Robert; Neubert, Alan; Fan,
Li; Ingles, Sara; D'Arcy, Allan; Villard, Frederic; Ramage, Paul; Jeng,
Arco Y.; Leung-Chu, Jennifer; Liu, Jing; Beil, Michael; Fu, Fumin; Chen,
Wei; Cumin, Frederic; Wiesmann, Christian; Mogi, Muneto
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2020), 11(2), 188-194

$RFMT $RIREG SCHEME264 STEP1
$RXN



  2  1
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-(Ethoxycarbonyl)-1,2,4-trimethyl--oxo-1H-pyrrole-3-acetic acid
C12H15NO5
1644485-94-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 3.2068 0.0 0
M  V30 2 C 1.5400 4.5404 0.0 0
M  V30 3 O 1.5400 1.8731 0.0 0
M  V30 4 O 0.0000 4.5404 0.0 0
M  V30 5 O 2.3100 5.8742 0.0 0
M  V30 6 C 4.2794 0.4962 0.0 0
M  V30 7 C 4.2794 5.9173 0.0 0
M  V30 8 C 7.4658 1.5315 0.0 0
M  V30 9 O 8.8726 2.1580 0.0 0
M  V30 10 O 7.3047 0.0000 0.0 0
M  V30 11 C 10.1184 1.2528 0.0 0
M  V30 12 C 11.5254 1.8791 0.0 0
M  V30 13 C 7.4658 4.8820 0.0 0
M  V30 14 C 3.8500 3.2068 0.0 0
M  V30 15 C 4.7552 1.9609 0.0 0
M  V30 16 C 4.7552 4.4526 0.0 0
M  V30 17 C 6.2199 2.4367 0.0 0
M  V30 18 N 6.2199 3.9768 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 6 15
M  V30 7 1 7 16
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 17
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 13 18
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,3,5-Trimethyl-4-[2-oxo-2-(2-propyn-1-ylamino)acetyl]-1H-pyrrole-2-carboxyli...
C13H14N2O4
2133017-35-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.2077 4.0286 0.0 0
M  V30 2 C 7.5415 3.2586 0.0 0
M  V30 3 O 6.2077 5.5686 0.0 0
M  V30 4 N 8.8752 4.0286 0.0 0
M  V30 5 O 7.5415 1.7186 0.0 0
M  V30 6 C 10.2088 3.2586 0.0 0
M  V30 7 C 11.5425 4.0286 0.0 0
M  V30 8 C 12.8762 4.7986 0.0 0
M  V30 9 C 3.1471 5.3914 0.0 0
M  V30 10 C 5.8575 0.6965 0.0 0
M  V30 11 C 0.9052 2.9015 0.0 0
M  V30 12 O 0.0000 1.6557 0.0 0
M  V30 13 O 0.2789 4.3085 0.0 0
M  V30 14 C 2.5804 0.0000 0.0 0
M  V30 15 C 4.8741 3.2586 0.0 0
M  V30 16 C 3.4673 3.8850 0.0 0
M  V30 17 C 4.7132 1.7271 0.0 0
M  V30 18 C 2.4367 2.7406 0.0 0
M  V30 19 N 3.2067 1.4069 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 3 7 8
M  V30 9 1 9 16
M  V30 10 1 10 17
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 11 18
M  V30 14 1 14 19
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1644485-94-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2133017-35-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24782838
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 4
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 12125-02-9
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 1310-73-2
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(4):CAS_RN
$DATUM 67-56-1
$DTYPE RXN:VAR(1):SOL(5):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and structure activity relationship of glyoxamide derivatives
as anti-hepatitis B virus agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Amblard, Franck; Boucle, Sebastien; Bassit, Leda; Chen, Zhe; Sari, Ozkan;
Cox, Bryan; Verma, Kiran; Ozturk, Tugba; Ollinger-Russell, Olivia;
Schinazi, Raymond F.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 31115952

$RFMT $RIREG SCHEME265 STEP1
$RXN



  2  1
$MOL
(+)-2-Phenylpropionic acid
C9H10O2
7782-24-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6673 0.0 0 CFG=2
M  V30 2 C 5.3901 1.3337 0.0 0
M  V30 3 C 5.3901 4.0010 0.0 0
M  V30 4 O 4.6201 0.0000 0.0 0
M  V30 5 O 6.9302 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 2.3101 1.3337 0.0 0
M  V30 9 C 0.7700 4.0010 0.0 0
M  V30 10 C 0.7700 1.3337 0.0 0
M  V30 11 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 6
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzenemethanamine, -(azidomethyl)-4-(cyclobutylmethoxy)-, hydrochloride (1:...
C13H18N4O.ClH
2821859-77-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.8884 3.0800 0.0 0 CFG=1
M  V30 2 C 11.2221 3.8501 0.0 0
M  V30 3 N 9.8884 1.5400 0.0 0
M  V30 4 N 12.5557 3.0800 0.0 0
M  V30 5 N 13.8896 3.8501 0.0 0 CHG=1 VAL=4
M  V30 6 N 15.2232 4.6201 0.0 0 CHG=-1
M  V30 7 O 4.5536 6.1601 0.0 0
M  V30 8 C 3.2199 5.3901 0.0 0
M  V30 9 C 8.5547 3.8501 0.0 0
M  V30 10 C 8.5547 5.3901 0.0 0
M  V30 11 C 7.2209 3.0800 0.0 0
M  V30 12 C 7.2209 6.1601 0.0 0
M  V30 13 C 5.8872 3.8501 0.0 0
M  V30 14 C 5.8872 5.3901 0.0 0
M  V30 15 C 1.8861 6.1601 0.0 0
M  V30 16 C 0.3986 5.7615 0.0 0
M  V30 17 C 1.4875 7.6478 0.0 0
M  V30 18 C 0.0000 7.2491 0.0 0
M  V30 19 Cl 7.6116 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 2 4 5
M  V30 6 2 5 6
M  V30 7 1 7 8
M  V30 8 1 7 14
M  V30 9 1 8 15
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(S)-N-[(1R)-2-Azido-1-[4-(cyclobutylmethoxy)phenyl]ethyl]--methylbenzeneace...
C22H26N4O2
2821859-80-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7001 5.3348 0.0 0 CFG=2
M  V30 2 N 6.9301 6.6684 0.0 0
M  V30 3 C 6.9301 4.0011 0.0 0
M  V30 4 C 5.3901 6.6684 0.0 0
M  V30 5 N 7.7001 2.6675 0.0 0
M  V30 6 C 4.6200 8.0022 0.0 0 CFG=2
M  V30 7 O 4.6200 5.3348 0.0 0
M  V30 8 N 6.9301 1.3337 0.0 0 CHG=1 VAL=4
M  V30 9 C 5.3901 9.3359 0.0 0
M  V30 10 N 6.1601 0.0000 0.0 0 CHG=-1
M  V30 11 O 13.8601 5.3348 0.0 0
M  V30 12 C 14.6301 6.6684 0.0 0
M  V30 13 C 9.2401 5.3348 0.0 0
M  V30 14 C 10.0101 6.6684 0.0 0
M  V30 15 C 10.0101 4.0011 0.0 0
M  V30 16 C 11.5501 6.6684 0.0 0
M  V30 17 C 11.5501 4.0011 0.0 0
M  V30 18 C 12.3201 5.3348 0.0 0
M  V30 19 C 3.0800 8.0022 0.0 0
M  V30 20 C 2.3100 6.6684 0.0 0
M  V30 21 C 2.3100 9.3359 0.0 0
M  V30 22 C 0.7700 6.6684 0.0 0
M  V30 23 C 0.7700 9.3359 0.0 0
M  V30 24 C 0.0000 8.0022 0.0 0
M  V30 25 C 16.1702 6.6684 0.0 0
M  V30 26 C 17.2591 5.5795 0.0 0
M  V30 27 C 17.2591 7.7574 0.0 0
M  V30 28 C 18.3480 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 6 9 CFG=3
M  V30 10 1 6 19
M  V30 11 2 8 10
M  V30 12 1 11 12
M  V30 13 1 11 18
M  V30 14 1 12 25
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 1 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7782-24-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2821859-77-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2821859-80-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36136857
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-05-8
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Evaluation of Amide Bioisosteres Leading to 1,2,3-Triazole Containing
Compounds as GPR88 Agonists: Design, Synthesis, and Structure-Activity
Relationship Studies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Rahman, Toufiqur Md; Decker, Ann M.; Laudermilk, Lucas; Maitra, Rangan;
Ma, Weiya; Ben Hamida, Sami; Darcq, Emmanuel; Kieffer, Brigitte L.; Jin,
Chunyang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(16), 12397-12413

$RFMT $RIREG SCHEME266 STEP1
$RXN



  2  1
$MOL
4-[[(tert-butoxycarbonyl)amino]methyl]benzoic acid
C13H17NO4
33233-67-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 5.3348 3.8501 0.0 0
M  V30 3 C 4.0010 4.6201 0.0 0
M  V30 4 O 2.6673 3.8501 0.0 0
M  V30 5 O 4.0010 6.1601 0.0 0
M  V30 6 C 1.3337 4.6201 0.0 0
M  V30 7 C 0.5637 3.2864 0.0 0
M  V30 8 C 0.0000 5.3901 0.0 0
M  V30 9 C 2.1037 5.9538 0.0 0
M  V30 10 C 12.0033 1.5400 0.0 0
M  V30 11 O 12.0033 0.0000 0.0 0
M  V30 12 O 13.3370 2.3101 0.0 0
M  V30 13 C 8.0022 3.8501 0.0 0
M  V30 14 C 8.0022 2.3101 0.0 0
M  V30 15 C 9.3360 4.6201 0.0 0
M  V30 16 C 9.3360 1.5400 0.0 0
M  V30 17 C 10.6697 3.8501 0.0 0
M  V30 18 C 10.6697 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 10 18
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Ethoxybenzenemethanamine
C9H13NO
37806-29-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.6200 4.0011 0.0 0
M  V30 2 C 6.1600 4.0011 0.0 0
M  V30 3 C 6.9300 5.3349 0.0 0
M  V30 4 C 1.5400 4.0011 0.0 0
M  V30 5 N 0.0000 4.0011 0.0 0
M  V30 6 C 3.8500 2.6674 0.0 0
M  V30 7 C 2.3100 2.6674 0.0 0
M  V30 8 C 4.6200 1.3338 0.0 0
M  V30 9 C 1.5400 1.3338 0.0 0
M  V30 10 C 3.8500 0.0000 0.0 0
M  V30 11 C 2.3100 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 4 5
M  V30 5 1 4 7
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[[4-[[[(2-ethoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]-...
C22H28N2O4
3052553-63-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 4.0011 0.0 0
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 C 7.7000 5.3347 0.0 0
M  V30 4 O 6.9300 6.6685 0.0 0
M  V30 5 O 2.3100 4.0011 0.0 0
M  V30 6 C 0.7700 4.0011 0.0 0
M  V30 7 C 0.0000 5.3347 0.0 0
M  V30 8 C 13.8600 5.3347 0.0 0
M  V30 9 N 14.6300 6.6685 0.0 0
M  V30 10 C 16.1700 6.6685 0.0 0
M  V30 11 O 16.9400 8.0021 0.0 0
M  V30 12 O 16.9400 5.3347 0.0 0
M  V30 13 C 18.4800 8.0021 0.0 0
M  V30 14 C 18.4800 6.4621 0.0 0
M  V30 15 C 20.0200 8.0021 0.0 0
M  V30 16 C 18.4800 9.5421 0.0 0
M  V30 17 C 4.6200 2.6674 0.0 0
M  V30 18 C 3.0800 2.6674 0.0 0
M  V30 19 C 5.3900 1.3336 0.0 0
M  V30 20 C 2.3100 1.3336 0.0 0
M  V30 21 C 4.6200 0.0000 0.0 0
M  V30 22 C 3.0800 0.0000 0.0 0
M  V30 23 C 9.2400 5.3347 0.0 0
M  V30 24 C 10.0100 4.0011 0.0 0
M  V30 25 C 10.0100 6.6685 0.0 0
M  V30 26 C 11.5500 4.0011 0.0 0
M  V30 27 C 11.5500 6.6685 0.0 0
M  V30 28 C 12.3200 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 3 4
M  V30 5 1 3 23
M  V30 6 1 5 6
M  V30 7 1 5 18
M  V30 8 1 6 7
M  V30 9 1 8 9
M  V30 10 1 8 28
M  V30 11 1 9 10
M  V30 12 1 10 11
M  V30 13 2 10 12
M  V30 14 1 11 13
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 1 13 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 2 25 27
M  V30 28 2 26 28
M  V30 29 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 33233-67-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 37806-29-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3052553-63-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41060811
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-14-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-Based Design and Synthesis of Covalent Inhibitors for
Deubiquitinase and Acetyltransferase ChlaDUB1 of Chlamydia trachomatis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zimmermann, Thomas; Feng, Jiachen; de Campos, Luana Janaina; Knight,
Lindsey A.; Schloetzer, Jan; Ramirez, Yesid A.; Schwickert, Kevin; Zehe,
Markus; Adler, Thomas B.; Schirmeister, Tanja; Kisker, Caroline;
Sotriffer, Christoph; Conda-Sheridan, Martin; Decker, Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(13), 10710-10742

$RFMT $RIREG SCHEME267 STEP1
$RXN



  2  1
$MOL
4-Chlorobenzoic acid
C7H5ClO2
74-11-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 0.0000 0.0 0
M  V30 3 O 0.0000 2.6673 0.0 0
M  V30 4 Cl 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-[[(1,1-Dimethylethyl)diphenylsilyl]oxy]-,-dimethylbicyclo[3.1.0]hexane-6-...
C25H35NOSi
2760687-93-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Si 4.0011 4.0009 0.0 0
M  V30 2 O 4.7711 5.3347 0.0 0
M  V30 3 C 5.3347 3.2309 0.0 0
M  V30 4 C 4.5647 1.8973 0.0 0
M  V30 5 C 6.6685 2.4609 0.0 0
M  V30 6 C 6.1047 4.5647 0.0 0
M  V30 7 C 11.5546 5.3347 0.0 0
M  V30 8 C 11.5546 6.8747 0.0 0
M  V30 9 C 13.0946 5.3347 0.0 0
M  V30 10 N 11.5546 3.7947 0.0 0
M  V30 11 C 3.2311 2.6673 0.0 0
M  V30 12 C 1.6911 2.6673 0.0 0
M  V30 13 C 4.0011 1.3336 0.0 0
M  V30 14 C 0.9211 1.3336 0.0 0
M  V30 15 C 3.2311 0.0000 0.0 0
M  V30 16 C 1.6911 0.0000 0.0 0
M  V30 17 C 2.6674 4.7709 0.0 0
M  V30 18 C 1.3338 4.0009 0.0 0
M  V30 19 C 2.6674 6.3109 0.0 0
M  V30 20 C 0.0000 4.7709 0.0 0
M  V30 21 C 1.3338 7.0809 0.0 0
M  V30 22 C 0.0000 6.3109 0.0 0
M  V30 23 C 6.3111 5.3347 0.0 0
M  V30 24 C 7.2163 6.5806 0.0 0
M  V30 25 C 7.2163 4.0887 0.0 0
M  V30 26 C 8.6808 6.1047 0.0 0
M  V30 27 C 8.6808 4.5647 0.0 0
M  V30 28 C 10.0146 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 11
M  V30 4 1 1 17
M  V30 5 1 2 23
M  V30 6 1 3 4
M  V30 7 1 3 5
M  V30 8 1 3 6
M  V30 9 1 7 8
M  V30 10 1 7 9
M  V30 11 1 7 10
M  V30 12 1 7 28
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 22
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 1 26 27
M  V30 30 1 26 28
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Chloro-N-[1-[3-[[(1,1-dimethylethyl)diphenylsilyl]oxy]bicyclo[3.1.0]hex-6-y...
C32H38ClNO2Si
2760687-94-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  37 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Si 4.6200 4.6200 0.0 0
M  V30 2 O 6.1600 4.6200 0.0 0
M  V30 3 C 4.6200 6.1600 0.0 0
M  V30 4 C 6.1600 6.1600 0.0 0
M  V30 5 C 4.6200 7.7000 0.0 0
M  V30 6 C 3.0800 6.1600 0.0 0
M  V30 7 C 9.5517 10.4948 0.0 0
M  V30 8 N 10.8855 9.7248 0.0 0
M  V30 9 C 10.3217 11.8284 0.0 0
M  V30 10 C 8.2181 11.2648 0.0 0
M  V30 11 C 12.2191 10.4948 0.0 0
M  V30 12 O 12.2191 12.0348 0.0 0
M  V30 13 Cl 17.5538 7.4148 0.0 0
M  V30 14 C 3.0800 4.6200 0.0 0
M  V30 15 C 2.3100 5.9538 0.0 0
M  V30 16 C 2.3100 3.2864 0.0 0
M  V30 17 C 0.7700 5.9538 0.0 0
M  V30 18 C 0.7700 3.2864 0.0 0
M  V30 19 C 0.0000 4.6200 0.0 0
M  V30 20 C 4.6200 3.0800 0.0 0
M  V30 21 C 3.2864 2.3100 0.0 0
M  V30 22 C 5.9536 2.3100 0.0 0
M  V30 23 C 3.2864 0.7700 0.0 0
M  V30 24 C 5.9536 0.7700 0.0 0
M  V30 25 C 4.6200 0.0000 0.0 0
M  V30 26 C 6.9300 5.9538 0.0 0
M  V30 27 C 8.4615 6.1147 0.0 0
M  V30 28 C 6.3037 7.3606 0.0 0
M  V30 29 C 8.7817 7.6210 0.0 0
M  V30 30 C 7.4481 8.3910 0.0 0
M  V30 31 C 8.7817 9.1610 0.0 0
M  V30 32 C 13.5528 9.7248 0.0 0
M  V30 33 C 13.5528 8.1848 0.0 0
M  V30 34 C 14.8864 10.4948 0.0 0
M  V30 35 C 14.8864 7.4148 0.0 0
M  V30 36 C 16.2202 9.7248 0.0 0
M  V30 37 C 16.2202 8.1848 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 14
M  V30 4 1 1 20
M  V30 5 1 2 26
M  V30 6 1 3 4
M  V30 7 1 3 5
M  V30 8 1 3 6
M  V30 9 1 7 8
M  V30 10 1 7 9
M  V30 11 1 7 10
M  V30 12 1 7 31
M  V30 13 1 8 11
M  V30 14 2 11 12
M  V30 15 1 11 32
M  V30 16 1 13 37
M  V30 17 2 14 15
M  V30 18 1 14 16
M  V30 19 1 15 17
M  V30 20 2 16 18
M  V30 21 2 17 19
M  V30 22 1 18 19
M  V30 23 2 20 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 2 22 24
M  V30 27 2 23 25
M  V30 28 1 24 25
M  V30 29 1 26 27
M  V30 30 1 26 28
M  V30 31 1 27 29
M  V30 32 1 28 30
M  V30 33 1 29 30
M  V30 34 1 29 31
M  V30 35 1 30 31
M  V30 36 2 32 33
M  V30 37 1 32 34
M  V30 38 1 33 35
M  V30 39 2 34 36
M  V30 40 2 35 37
M  V30 41 1 36 37
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 74-11-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760687-93-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760687-94-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31542881
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting
Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hamilton, Matthew M.; Mseeh, Faika; McAfoos, Timothy J.; Leonard, Paul
G.; Reyna, Naphtali J.; Harris, Angela L.; Xu, Alan; Han, Michelle; Soth,
Michael J.; Czako, Barbara; Theroff, Jay P.; Mandal, Pijus K.; Burke,
Jason P.; Virgin-Downey, Brett; Petrocchi, Alessia; Pfaffinger, Dana;
Rogers, Norma E.; Parker, Connor A.; Yu, Simon S.; Jiang, Yongying;
Krapp, Stephan; Lammens, Alfred; Trevitt, Graham; Tremblay, Martin R.;
Mikule, Keith; Wilcoxen, Keith; Cross, Jason B.; Jones, Philip;
Marszalek, Joseph R.; Lewis, Richard T.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(15), 11302-11329

$RFMT $RIREG SCHEME268 STEP1
$RXN



  2  1
$MOL
2-Aminoadamantane
C10H17N
13074-39-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.0459 1.0341 0.0 0
M  V30 2 C 3.0745 2.2371 0.0 0
M  V30 3 C 4.5441 1.3886 0.0 0
M  V30 4 C 2.2427 0.9411 0.0 0
M  V30 5 C 2.3690 3.4407 0.0 0
M  V30 6 C 3.0071 1.2963 0.0 0
M  V30 7 C 0.7055 0.8485 0.0 0
M  V30 8 C 0.8319 3.3481 0.0 0
M  V30 9 C 2.3016 2.4999 0.0 0
M  V30 10 C 2.1752 0.0000 0.0 0
M  V30 11 C 0.0000 2.0519 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 1 7 10
M  V30 11 1 7 11
M  V30 12 1 8 9
M  V30 13 1 8 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromo-1H-pyrrole-2-carboxylic acid
C5H4BrNO2
27746-02-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 Br 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 N 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 C 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromo-N-tricyclo[3.3.1.13,7]dec-2-yl-1H-pyrrole-2-carboxamide
C15H19BrN2O
1183504-44-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.4868 1.8517 0.0 0
M  V30 2 C 6.8205 2.6218 0.0 0
M  V30 3 O 6.8205 4.1618 0.0 0
M  V30 4 Br 12.1231 1.4948 0.0 0
M  V30 5 C 2.9920 3.8547 0.0 0
M  V30 6 C 4.1530 2.6218 0.0 0
M  V30 7 C 1.8248 2.8548 0.0 0
M  V30 8 C 2.6632 5.2078 0.0 0
M  V30 9 C 2.6573 2.9749 0.0 0
M  V30 10 C 0.3288 3.2076 0.0 0
M  V30 11 C 1.1672 5.5608 0.0 0
M  V30 12 C 2.3285 4.3278 0.0 0
M  V30 13 C 1.4900 1.9748 0.0 0
M  V30 14 C 0.0000 4.5607 0.0 0
M  V30 15 C 8.1542 1.8517 0.0 0
M  V30 16 N 8.3151 0.3202 0.0 0
M  V30 17 C 9.5610 2.4782 0.0 0
M  V30 18 C 9.8216 0.0000 0.0 0
M  V30 19 C 10.5916 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 2 2 3
M  V30 4 1 2 15
M  V30 5 1 4 19
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 9 13
M  V30 14 1 10 13
M  V30 15 1 10 14
M  V30 16 1 11 12
M  V30 17 1 11 14
M  V30 18 1 15 16
M  V30 19 2 15 17
M  V30 20 1 16 18
M  V30 21 1 17 19
M  V30 22 2 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 13074-39-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 27746-02-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1183504-44-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39885681
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide
Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for
Treating Drug-Resistant Tuberculosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhao, Hongyi; Gao, Yongxin; Li, Wei; Sheng, Li; Cui, Keli; Wang, Bin; Fu,
Lei; Gao, Meng; Lin, Ziyun; Zou, Xiaowen; Jackson, Mary; Huang, Haihong;
Lu, Yu; Zhang, Dongfeng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(15), 10534-10553

$RFMT $RIREG SCHEME269 STEP1
$RXN



  2  1
$MOL
L-Alanine, phenylmethyl ester, hydrochloride (1:1)
C10H13NO2.ClH
5557-83-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 O 5.3347 3.8500 0.0 0
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 C 8.0021 3.8500 0.0 0 CFG=1
M  V30 5 O 6.6684 1.5400 0.0 0
M  V30 6 C 9.3358 3.0800 0.0 0
M  V30 7 N 8.0021 5.3900 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 2.6674 5.3900 0.0 0
M  V30 10 C 1.3336 3.0800 0.0 0
M  V30 11 C 1.3336 6.1600 0.0 0
M  V30 12 C 0.0000 3.8500 0.0 0
M  V30 13 C 0.0000 5.3900 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 4 7 CFG=1
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
BOC-L-leucine
C11H21NO4
13139-15-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8501 0.0 0 CFG=2
M  V30 2 N 4.0012 4.6201 0.0 0
M  V30 3 C 2.6675 2.3101 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8501 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 O 0.0000 3.8501 0.0 0
M  V30 8 O 1.3337 6.1601 0.0 0
M  V30 9 O 6.6685 4.6201 0.0 0
M  V30 10 O 5.3348 2.3101 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 2.3101 0.0 0
M  V30 13 C 8.0023 3.8501 0.0 0
M  V30 14 C 7.2323 2.5164 0.0 0
M  V30 15 C 9.3360 3.0801 0.0 0
M  V30 16 C 8.7723 5.1838 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 6 12
M  V30 12 1 9 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-leucyl-L-alanine phenylmethyl ester
C21H32N2O5
66415-01-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 4.0011 0.0 0 CFG=2
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 N 5.3900 5.3347 0.0 0
M  V30 4 C 5.3900 2.6674 0.0 0
M  V30 5 N 8.4700 5.3347 0.0 0
M  V30 6 O 8.4700 2.6674 0.0 0
M  V30 7 C 3.8500 5.3347 0.0 0
M  V30 8 C 6.1600 1.3336 0.0 0
M  V30 9 C 10.0100 5.3347 0.0 0 CFG=1
M  V30 10 O 3.0800 6.6684 0.0 0
M  V30 11 O 3.0800 4.0011 0.0 0
M  V30 12 C 7.7000 1.3336 0.0 0
M  V30 13 C 5.3900 0.0000 0.0 0
M  V30 14 C 10.7800 6.6684 0.0 0
M  V30 15 C 10.7800 4.0011 0.0 0
M  V30 16 C 1.5400 6.6684 0.0 0
M  V30 17 O 12.3200 6.6684 0.0 0
M  V30 18 O 10.0100 8.0021 0.0 0
M  V30 19 C 1.5400 5.1284 0.0 0
M  V30 20 C 0.0000 6.6684 0.0 0
M  V30 21 C 1.5400 8.2084 0.0 0
M  V30 22 C 13.0900 8.0021 0.0 0
M  V30 23 C 14.6300 8.0021 0.0 0
M  V30 24 C 15.4000 9.3358 0.0 0
M  V30 25 C 15.4000 6.6684 0.0 0
M  V30 26 C 16.9400 9.3358 0.0 0
M  V30 27 C 16.9400 6.6684 0.0 0
M  V30 28 C 17.7100 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 13 1 9 14
M  V30 14 1 9 15 CFG=3
M  V30 15 1 10 16
M  V30 16 1 14 17
M  V30 17 2 14 18
M  V30 18 1 16 19
M  V30 19 1 16 20
M  V30 20 1 16 21
M  V30 21 1 17 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 2 25 27
M  V30 27 2 26 28
M  V30 28 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5557-83-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13139-15-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 66415-01-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35038130
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Lectin-Targeted Prodrugs Activated by Pseudomonas aeruginosa for
Self-Destructive Antibiotic Release
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Meiers, Joscha; Rox, Katharina; Titz, Alexander
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(20), 13988-14014

$RFMT $RIREG SCHEME270 STEP1
$RXN



  2  1
$MOL
3-Iodobenzoic acid
C7H5IO2
618-51-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 I 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-(4-Fluorophenyl)-4-(trifluoromethoxy)benzenepropanamine
C16H15F4NO
2709014-55-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.8501 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 4.0010 1.5400 0.0 0
M  V30 4 N 4.0010 0.0000 0.0 0
M  V30 5 O 10.6697 6.9302 0.0 0
M  V30 6 C 12.0033 6.1601 0.0 0
M  V30 7 F 12.0033 4.6201 0.0 0
M  V30 8 F 13.3370 5.3901 0.0 0
M  V30 9 F 13.3370 6.9302 0.0 0
M  V30 10 F 0.0000 6.9302 0.0 0
M  V30 11 C 6.6685 4.6201 0.0 0
M  V30 12 C 8.0022 3.8501 0.0 0
M  V30 13 C 6.6685 6.1601 0.0 0
M  V30 14 C 9.3358 4.6201 0.0 0
M  V30 15 C 8.0022 6.9302 0.0 0
M  V30 16 C 9.3360 6.1601 0.0 0
M  V30 17 C 4.0010 4.6201 0.0 0
M  V30 18 C 4.0010 6.1601 0.0 0
M  V30 19 C 2.6673 3.8501 0.0 0
M  V30 20 C 2.6673 6.9302 0.0 0
M  V30 21 C 1.3337 4.6201 0.0 0
M  V30 22 C 1.3337 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 1 17
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 5 6
M  V30 7 1 5 16
M  V30 8 1 6 7
M  V30 9 1 6 8
M  V30 10 1 6 9
M  V30 11 1 10 22
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[3-(4-Fluorophenyl)-3-[4-(trifluoromethoxy)phenyl]propyl]-3-iodobenzamide
C23H18F4INO2
2709014-31-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.2402 5.3348 0.0 0
M  V30 2 C 8.4702 6.6685 0.0 0
M  V30 3 C 6.9302 6.6685 0.0 0
M  V30 4 N 6.1601 8.0022 0.0 0
M  V30 5 C 4.6201 8.0022 0.0 0
M  V30 6 O 3.8501 6.6685 0.0 0
M  V30 7 O 15.4003 5.3348 0.0 0
M  V30 8 C 16.1704 6.6685 0.0 0
M  V30 9 F 17.7104 6.6685 0.0 0
M  V30 10 F 16.9404 8.0022 0.0 0
M  V30 11 F 15.4003 8.0022 0.0 0
M  V30 12 F 6.1601 0.0000 0.0 0
M  V30 13 I 0.0000 10.6697 0.0 0
M  V30 14 C 10.7802 5.3348 0.0 0
M  V30 15 C 11.5503 4.0012 0.0 0
M  V30 16 C 11.5503 6.6685 0.0 0
M  V30 17 C 13.0903 4.0012 0.0 0
M  V30 18 C 13.0903 6.6685 0.0 0
M  V30 19 C 13.8603 5.3348 0.0 0
M  V30 20 C 8.4702 4.0012 0.0 0
M  V30 21 C 9.2402 2.6673 0.0 0
M  V30 22 C 6.9302 4.0012 0.0 0
M  V30 23 C 8.4702 1.3337 0.0 0
M  V30 24 C 6.1601 2.6673 0.0 0
M  V30 25 C 6.9302 1.3337 0.0 0
M  V30 26 C 3.8501 9.3360 0.0 0
M  V30 27 C 2.3101 9.3360 0.0 0
M  V30 28 C 4.6201 10.6697 0.0 0
M  V30 29 C 1.5400 10.6697 0.0 0
M  V30 30 C 3.8501 12.0033 0.0 0
M  V30 31 C 2.3101 12.0033 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 1 20
M  V30 4 1 2 3
M  V30 5 1 3 4
M  V30 6 1 4 5
M  V30 7 2 5 6
M  V30 8 1 5 26
M  V30 9 1 7 8
M  V30 10 1 7 19
M  V30 11 1 8 9
M  V30 12 1 8 10
M  V30 13 1 8 11
M  V30 14 1 12 25
M  V30 15 1 13 29
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 2 28 30
M  V30 32 2 29 31
M  V30 33 1 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 618-51-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2709014-55-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2709014-31-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24414256
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):NOTES
$DATUM microwave irradiation
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Structure-Activity Relationship Studies of Dual
Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hiesinger, Kerstin; Kramer, Jan S.; Beyer, Sandra; Eckes, Timon; Brunst,
Steffen; Flauaus, Cathrin; Wittmann, Sandra K.; Weizel, Lilia; Kaiser,
Astrid; Kretschmer, Simon B. M.; George, Sven; Angioni, Carlo; Heering,
Jan; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred; Schmidtko, Achim;
Pogoryelov, Denys; Pfeilschifter, Josef; Hofmann, Bettina; Steinhilber,
Dieter; Schwalm, Stephanie; Proschak, Ewgenij
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(20), 11498-11521

$RFMT $RIREG SCHEME271 STEP1
$RXN



  2  1
$MOL
2-Amino-5-nitrobenzoic acid
C7H6N2O4
616-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 0.0000 0.0 0
M  V30 4 N 1.3336 4.6200 0.0 0
M  V30 5 N 6.6685 1.5400 0.0 0 VAL=5
M  V30 6 O 6.6685 0.0000 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 1.5400 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 4.6200 0.0 0
M  V30 13 C 5.3347 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(3-Aminopropyl)morpholine
C7H16N2O
123-00-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3348 2.3100 0.0 0
M  V30 3 C 6.6686 3.0800 0.0 0
M  V30 4 N 8.0022 2.3100 0.0 0
M  V30 5 N 2.6675 2.3100 0.0 0
M  V30 6 C 1.3337 3.0800 0.0 0
M  V30 7 C 2.6675 0.7700 0.0 0
M  V30 8 C 0.0000 2.3100 0.0 0
M  V30 9 C 1.3337 0.0000 0.0 0
M  V30 10 O 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-[3-(4-morpholinyl)propyl]-5-nitrobenzamide
C14H20N4O4
1442107-58-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 N 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3336 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 C 9.2400 5.3347 0.0 0
M  V30 6 C 10.7800 5.3347 0.0 0
M  V30 7 N 4.6200 0.0000 0.0 0
M  V30 8 N 1.5400 5.3347 0.0 0 VAL=5
M  V30 9 O 0.0000 5.3347 0.0 0
M  V30 10 O 2.3100 6.6684 0.0 0
M  V30 11 C 4.6200 2.6674 0.0 0
M  V30 12 C 3.8500 4.0011 0.0 0
M  V30 13 C 3.8500 1.3336 0.0 0
M  V30 14 C 2.3100 4.0011 0.0 0
M  V30 15 C 2.3100 1.3336 0.0 0
M  V30 16 C 1.5400 2.6674 0.0 0
M  V30 17 N 11.5500 6.6684 0.0 0
M  V30 18 C 13.0900 6.6684 0.0 0
M  V30 19 C 10.7800 8.0021 0.0 0
M  V30 20 C 13.8600 8.0021 0.0 0
M  V30 21 C 11.5500 9.3358 0.0 0
M  V30 22 O 13.0900 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 17
M  V30 8 1 7 13
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 14
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 616-79-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 123-00-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1442107-58-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38624469
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Development of Quinazolinones and Quinazolinediones for
Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating
COP1-ATGL Axis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sarkar, Dipayan; Chowdhury, Saheli; Goon, Sunny; Sen, Abhishek; Dastidar,
Uddipta Ghosh; Mondal, Mohabul Alam; Chakrabarti, Partha; Talukdar,
Arindam
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(24), 16728-16761

$RFMT $RIREG SCHEME272 STEP1
$RXN



  2  1
$MOL
4-Chloroaniline
C6H6ClN
106-47-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0.0000 1.3337 0.0 0
M  V30 2 N 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
cis-(R)-4-(6-Fluoro-4-quinolinyl)--methylcyclohexaneacetic acid
C18H20FNO2
1923836-34-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 F 1.3336 6.9300 0.0 0
M  V30 2 C 9.5187 4.3525 0.0 0 CFG=1
M  V30 3 C 10.5087 5.5323 0.0 0
M  V30 4 C 10.0454 2.9054 0.0 0
M  V30 5 O 12.0252 5.2648 0.0 0
M  V30 6 O 9.9820 6.9793 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 2.6674 3.0800 0.0 0
M  V30 9 C 4.0011 0.7700 0.0 0
M  V30 10 C 1.3336 2.3100 0.0 0
M  V30 11 C 2.6674 4.6200 0.0 0
M  V30 12 C 2.6674 0.0000 0.0 0
M  V30 13 N 1.3336 0.7700 0.0 0
M  V30 14 C 0.0000 3.0800 0.0 0
M  V30 15 C 1.3336 5.3900 0.0 0
M  V30 16 C 0.0000 4.6200 0.0 0
M  V30 17 C 5.3347 3.0800 0.0 0 CFG=2
M  V30 18 C 5.3347 4.6200 0.0 0
M  V30 19 C 6.6684 2.3100 0.0 0
M  V30 20 C 6.6684 5.3900 0.0 0
M  V30 21 C 8.0021 3.0800 0.0 0
M  V30 22 C 8.0021 4.6200 0.0 0 CFG=1
M  V30 23 H 8.5288 6.0670 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 15
M  V30 2 1 2 3
M  V30 3 1 2 4 CFG=3
M  V30 4 1 2 22
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 17 7 CFG=1
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 2 11 15
M  V30 16 2 12 13
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 1 21 22
M  V30 25 1 22 23 CFG=3
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 2 17 22)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
cis-(R)-N-(4-Chlorophenyl)-4-(6-fluoro-4-quinolinyl)--methylcyclohexaneacet...
C24H24ClFN2O
1923833-60-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 F 3.0800 0.0000 0.0 0
M  V30 2 C 8.8798 6.3245 0.0 0 CFG=1
M  V30 3 C 10.3269 5.7978 0.0 0
M  V30 4 C 8.6123 7.8411 0.0 0
M  V30 5 N 11.5066 6.7877 0.0 0
M  V30 6 O 10.5943 4.2812 0.0 0
M  V30 7 Cl 17.2951 4.6808 0.0 0
M  V30 8 C 2.3100 4.0009 0.0 0
M  V30 9 C 3.0800 5.3347 0.0 0
M  V30 10 C 0.7700 4.0009 0.0 0
M  V30 11 C 3.0800 2.6673 0.0 0
M  V30 12 C 2.3100 6.6684 0.0 0
M  V30 13 N 0.0000 5.3347 0.0 0
M  V30 14 C 0.0000 2.6673 0.0 0
M  V30 15 C 2.3100 1.3336 0.0 0
M  V30 16 C 0.7700 6.6684 0.0 0
M  V30 17 C 0.7700 1.3336 0.0 0
M  V30 18 C 4.6200 5.3347 0.0 0 CFG=1
M  V30 19 C 5.3900 4.0009 0.0 0
M  V30 20 C 5.3900 6.6684 0.0 0
M  V30 21 C 6.9300 4.0009 0.0 0
M  V30 22 C 6.9300 6.6684 0.0 0
M  V30 23 C 7.7000 5.3347 0.0 0 CFG=2
M  V30 24 C 12.9537 6.2610 0.0 0
M  V30 25 C 13.2211 4.7444 0.0 0
M  V30 26 C 14.1334 7.2509 0.0 0
M  V30 27 C 14.6682 4.2178 0.0 0
M  V30 28 C 15.5805 6.7243 0.0 0
M  V30 29 C 15.8480 5.2075 0.0 0
M  V30 30 H 8.8798 4.3448 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 15
M  V30 2 1 2 3
M  V30 3 1 2 4 CFG=1
M  V30 4 1 2 23
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 24
M  V30 8 1 7 29
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 2 9 12
M  V30 13 1 18 9 CFG=1
M  V30 14 1 10 13
M  V30 15 1 10 14
M  V30 16 2 11 15
M  V30 17 1 12 16
M  V30 18 2 13 16
M  V30 19 2 14 17
M  V30 20 1 15 17
M  V30 21 1 18 19
M  V30 22 1 18 20
M  V30 23 1 19 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 1 22 23
M  V30 27 1 23 30 CFG=3
M  V30 28 2 24 25
M  V30 29 1 24 26
M  V30 30 1 25 27
M  V30 31 2 26 28
M  V30 32 2 27 29
M  V30 33 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 2 18 23)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 106-47-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1923836-34-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1923833-60-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35008193
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Identification and Characterization of a Novel Indoleamine
2,3-Dioxygenase 1 Protein Degrader for Glioblastoma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bollu, Lakshmi R.; Bommi, Prashant V.; Monsen, Paige J.; Zhai, Lijie;
Lauing, Kristen L.; Bell, April; Kim, Miri; Ladomersky, Erik; Yang,
Xinyu; Platanias, Leonidas C.; Matei, Daniela E.; Bonini, Marcelo G.;
Munshi, Hidayatullah G.; Hashizume, Rintaro; Wu, Jennifer D.; Zhang, Bin;
James, Charles David; Chen, Peiwen; Kocherginsky, Masha; Horbinski,
Craig; Cameron, Michael D.; Grigorescu, Arabela A.; Yamini, Bakhtiar;
Lukas, Rimas V.; Schiltz, Gary E.; Wainwright, Derek A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(23), 15642-15662

$RFMT $RIREG SCHEME273 STEP1
$RXN



  2  1
$MOL
D-Norleucine, methyl ester, hydrochloride (1:1)
C7H15NO2.ClH
60687-33-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.8501 0.0 0 CFG=2
M  V30 2 C 2.6675 3.0800 0.0 0
M  V30 3 C 5.3348 3.0800 0.0 0
M  V30 4 N 4.0012 5.3901 0.0 0
M  V30 5 O 1.3337 3.8501 0.0 0
M  V30 6 O 2.6675 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 0.0000 3.0800 0.0 0
M  V30 9 C 8.0023 3.0800 0.0 0
M  V30 10 C 9.3360 3.8501 0.0 0
M  V30 11 Cl 4.6680 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(4E)-3-Hydroxy-7-[(triphenylmethyl)thio]-4-heptenoic acid
C26H26O3S
2088322-33-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 4.0011 0.0 0
M  V30 2 S 5.3347 3.2311 0.0 0
M  V30 3 C 6.6685 4.0011 0.0 0
M  V30 4 C 8.0021 3.2311 0.0 0
M  V30 5 C 9.3358 4.0011 0.0 0
M  V30 6 C 10.6696 3.2311 0.0 0
M  V30 7 C 12.0032 4.0011 0.0 0 CFG=3
M  V30 8 C 13.3369 3.2311 0.0 0
M  V30 9 O 12.0032 5.5411 0.0 0
M  V30 10 C 14.6705 4.0011 0.0 0
M  V30 11 O 14.6705 5.5411 0.0 0
M  V30 12 O 16.0043 3.2311 0.0 0
M  V30 13 C 3.2311 2.6674 0.0 0
M  V30 14 C 1.6911 2.6674 0.0 0
M  V30 15 C 4.0011 1.3336 0.0 0
M  V30 16 C 0.9211 1.3336 0.0 0
M  V30 17 C 3.2311 0.0000 0.0 0
M  V30 18 C 1.6911 0.0000 0.0 0
M  V30 19 C 2.6674 4.7711 0.0 0
M  V30 20 C 2.6674 6.3111 0.0 0
M  V30 21 C 1.3338 4.0011 0.0 0
M  V30 22 C 1.3338 7.0811 0.0 0
M  V30 23 C 0.0000 4.7711 0.0 0
M  V30 24 C 0.0000 6.3111 0.0 0
M  V30 25 C 4.7711 5.3347 0.0 0
M  V30 26 C 6.3111 5.3347 0.0 0
M  V30 27 C 4.0011 6.6685 0.0 0
M  V30 28 C 7.0811 6.6685 0.0 0
M  V30 29 C 4.7711 8.0021 0.0 0
M  V30 30 C 6.3111 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 1 19
M  V30 4 1 1 25
M  V30 5 1 2 3
M  V30 6 1 3 4
M  V30 7 1 4 5
M  V30 8 2 5 6
M  V30 9 1 6 7
M  V30 10 1 7 8
M  V30 11 1 7 9
M  V30 12 1 8 10
M  V30 13 1 10 11
M  V30 14 2 10 12
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Norleucine, N-[(4E)-3-hydroxy-1-oxo-7-[(triphenylmethyl)thio]-4-hepten-1-yl...
C33H39NO4S
3035200-66-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  39 41 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 12.0033 0.0 0
M  V30 2 S 6.1601 12.0033 0.0 0
M  V30 3 C 6.9302 10.6697 0.0 0
M  V30 4 C 8.4702 10.6697 0.0 0
M  V30 5 C 9.2402 9.3360 0.0 0
M  V30 6 C 10.7802 9.3360 0.0 0
M  V30 7 C 11.5503 8.0022 0.0 0 CFG=3
M  V30 8 C 13.0903 8.0022 0.0 0
M  V30 9 O 10.7802 6.6685 0.0 0
M  V30 10 C 13.8603 6.6685 0.0 0
M  V30 11 N 15.4003 6.6685 0.0 0
M  V30 12 O 13.0903 5.3348 0.0 0
M  V30 13 C 16.1704 5.3348 0.0 0 CFG=2
M  V30 14 C 15.4003 4.0012 0.0 0
M  V30 15 C 17.7104 5.3348 0.0 0
M  V30 16 C 16.1704 2.6673 0.0 0
M  V30 17 O 18.4804 6.6685 0.0 0
M  V30 18 O 18.4804 4.0012 0.0 0
M  V30 19 C 15.4003 1.3337 0.0 0
M  V30 20 C 20.0204 6.6685 0.0 0
M  V30 21 C 16.1704 0.0000 0.0 0
M  V30 22 C 4.6201 13.5434 0.0 0
M  V30 23 C 3.2864 14.3134 0.0 0
M  V30 24 C 5.9538 14.3134 0.0 0
M  V30 25 C 3.2864 15.8534 0.0 0
M  V30 26 C 5.9538 15.8534 0.0 0
M  V30 27 C 4.6201 16.6234 0.0 0
M  V30 28 C 3.0801 12.0033 0.0 0
M  V30 29 C 2.3101 13.3370 0.0 0
M  V30 30 C 2.3101 10.6697 0.0 0
M  V30 31 C 0.7700 13.3370 0.0 0
M  V30 32 C 0.7700 10.6697 0.0 0
M  V30 33 C 0.0000 12.0033 0.0 0
M  V30 34 C 4.6201 10.4633 0.0 0
M  V30 35 C 3.2864 9.6933 0.0 0
M  V30 36 C 5.9538 9.6933 0.0 0
M  V30 37 C 3.2864 8.1532 0.0 0
M  V30 38 C 5.9538 8.1532 0.0 0
M  V30 39 C 4.6201 7.3832 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 22
M  V30 3 1 1 28
M  V30 4 1 1 34
M  V30 5 1 2 3
M  V30 6 1 3 4
M  V30 7 1 4 5
M  V30 8 2 5 6
M  V30 9 1 6 7
M  V30 10 1 7 8
M  V30 11 1 7 9
M  V30 12 1 8 10
M  V30 13 1 10 11
M  V30 14 2 10 12
M  V30 15 1 11 13
M  V30 16 1 13 14 CFG=3
M  V30 17 1 13 15
M  V30 18 1 14 16
M  V30 19 1 15 17
M  V30 20 2 15 18
M  V30 21 1 16 19
M  V30 22 1 17 20
M  V30 23 1 19 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 1 29 31
M  V30 33 2 30 32
M  V30 34 2 31 33
M  V30 35 1 32 33
M  V30 36 2 34 35
M  V30 37 1 34 36
M  V30 38 1 35 37
M  V30 39 2 36 38
M  V30 40 2 37 39
M  V30 41 1 38 39
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 13)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 60687-33-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2088322-33-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3035200-66-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40890886
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 12125-02-9
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of a Novel, Small-Molecule Brain-Penetrant Histone
Deacetylase Inhibitor That Enhances Spatial Memory Formation in Mice
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Belayet, Jawad B.; Beamish, Sarah; Rahaman, Mizzanoor; Alanani, Samer;
Virdi, Rajdeep S.; Frick, David N.; Rahman, A. F. M. Towheedur; Ulicki,
Joseph S.; Biswas, Sreya; Arnold, Leggy A.; Roni, M. S. Rashid; Cheng,
Eric Y.; Steeber, Douglas A.; Frick, Karyn M.; Hossain, M. Mahmun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(4), 3388-3403

$RFMT $RIREG SCHEME274 STEP1
$RXN



  2  1
$MOL
Nicotinic acid
C6H5NO2
59-67-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 N 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(4-Pyridinyl)-2-thiazolamine
C8H7N3S
30235-28-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 8.2357 0.0000 0.0 0
M  V30 2 C 4.6200 1.6752 0.0 0
M  V30 3 N 5.5252 0.4294 0.0 0
M  V30 4 C 5.5252 2.9211 0.0 0
M  V30 5 C 6.9898 0.9052 0.0 0
M  V30 6 S 6.9898 2.4452 0.0 0
M  V30 7 C 3.0800 1.6752 0.0 0
M  V30 8 C 2.3100 3.0089 0.0 0
M  V30 9 C 2.3100 0.3416 0.0 0
M  V30 10 C 0.7700 3.0089 0.0 0
M  V30 11 C 0.7700 0.3416 0.0 0
M  V30 12 N 0.0000 1.6752 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 5
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 7
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 5 6
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[4-(4-Pyridinyl)-2-thiazolyl]-3-pyridinecarboxamide
C14H10N4OS
1328467-31-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 2.3100 0.0 0
M  V30 2 C 4.0011 3.0800 0.0 0
M  V30 3 O 4.0011 4.6200 0.0 0
M  V30 4 C 9.1058 3.5981 0.0 0
M  V30 5 N 8.0754 2.4536 0.0 0
M  V30 6 C 8.3358 4.9317 0.0 0
M  V30 7 C 6.6684 3.0800 0.0 0
M  V30 8 S 6.8295 4.6116 0.0 0
M  V30 9 C 10.6373 3.4372 0.0 0
M  V30 10 C 11.5426 4.6830 0.0 0
M  V30 11 C 11.2638 2.0302 0.0 0
M  V30 12 C 13.0741 4.5221 0.0 0
M  V30 13 C 12.7954 1.8693 0.0 0
M  V30 14 N 13.7006 3.1151 0.0 0
M  V30 15 C 2.6675 2.3100 0.0 0
M  V30 16 C 2.6675 0.7700 0.0 0
M  V30 17 C 1.3337 3.0800 0.0 0
M  V30 18 C 1.3337 0.0000 0.0 0
M  V30 19 N 0.0000 2.3100 0.0 0
M  V30 20 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 2 2 3
M  V30 4 1 2 15
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 9
M  V30 8 2 5 7
M  V30 9 1 6 8
M  V30 10 1 7 8
M  V30 11 1 9 10
M  V30 12 2 9 11
M  V30 13 2 10 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 2 13 14
M  V30 17 1 15 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 59-67-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 30235-28-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1328467-31-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22629929
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of
4-aryl-5-aminoalkyl-thiazole-2-amines derivatives as ROCK II inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ma, Shuchao; Wang, Linan; Ouyang, Ben; Fan, Meixia; Qi, Junhui; Yao, Lei
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2020), 28(19), 115683

$RFMT $RIREG SCHEME275 STEP1
$RXN



  2  1
$MOL
(E)-3,4,5-Trimethoxycinnamic acid
C12H14O5
20329-98-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 5.3901 0.0 0
M  V30 2 C 1.3337 6.9302 0.0 0
M  V30 3 O 1.3337 2.3101 0.0 0
M  V30 4 C 0.0000 3.0801 0.0 0
M  V30 5 O 4.0012 0.7700 0.0 0
M  V30 6 C 5.3348 0.0000 0.0 0
M  V30 7 C 6.6685 5.3901 0.0 0
M  V30 8 C 8.0023 4.6201 0.0 0
M  V30 9 C 9.3360 5.3901 0.0 0
M  V30 10 O 9.3360 6.9302 0.0 0
M  V30 11 O 10.6697 4.6201 0.0 0
M  V30 12 C 2.6673 4.6201 0.0 0
M  V30 13 C 2.6673 3.0801 0.0 0
M  V30 14 C 4.0012 5.3901 0.0 0
M  V30 15 C 4.0012 2.3101 0.0 0
M  V30 16 C 5.3348 4.6201 0.0 0
M  V30 17 C 5.3348 3.0801 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 3 4
M  V30 4 1 3 13
M  V30 5 1 5 6
M  V30 6 1 5 15
M  V30 7 2 7 8
M  V30 8 1 7 16
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetic acid, 4-amino-, methyl ester
C9H11NO2
39552-81-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 3.0800 0.0 0
M  V30 2 C 6.6684 2.3100 0.0 0
M  V30 3 O 8.0022 3.0800 0.0 0
M  V30 4 O 6.6684 0.7700 0.0 0
M  V30 5 C 9.3359 2.3100 0.0 0
M  V30 6 N 0.0000 0.0000 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 4.0011 0.7700 0.0 0
M  V30 9 C 2.6675 3.0800 0.0 0
M  V30 10 C 2.6675 0.0000 0.0 0
M  V30 11 C 1.3337 2.3100 0.0 0
M  V30 12 C 1.3337 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetic acid, 4-[[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]a...
C21H23NO6
3052839-58-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 2.3101 0.0 0
M  V30 2 C 0.0000 3.0801 0.0 0
M  V30 3 O 1.3337 5.3901 0.0 0
M  V30 4 C 1.3337 6.9302 0.0 0
M  V30 5 O 4.0012 0.7700 0.0 0
M  V30 6 C 5.3348 0.0000 0.0 0
M  V30 7 C 6.6685 5.3901 0.0 0
M  V30 8 C 8.0023 4.6201 0.0 0
M  V30 9 C 9.3360 5.3901 0.0 0
M  V30 10 N 10.6697 4.6201 0.0 0
M  V30 11 O 9.3360 6.9302 0.0 0
M  V30 12 C 16.0045 7.7002 0.0 0
M  V30 13 C 17.3382 6.9302 0.0 0
M  V30 14 O 18.6720 7.7002 0.0 0
M  V30 15 O 17.3382 5.3901 0.0 0
M  V30 16 C 20.0057 6.9302 0.0 0
M  V30 17 C 2.6675 3.0801 0.0 0
M  V30 18 C 2.6675 4.6201 0.0 0
M  V30 19 C 4.0012 2.3101 0.0 0
M  V30 20 C 4.0012 5.3901 0.0 0
M  V30 21 C 5.3348 3.0801 0.0 0
M  V30 22 C 5.3348 4.6201 0.0 0
M  V30 23 C 12.0033 5.3901 0.0 0
M  V30 24 C 13.3372 4.6201 0.0 0
M  V30 25 C 12.0033 6.9302 0.0 0
M  V30 26 C 14.6708 5.3901 0.0 0
M  V30 27 C 13.3372 7.7002 0.0 0
M  V30 28 C 14.6708 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 3 4
M  V30 4 1 3 18
M  V30 5 1 5 6
M  V30 6 1 5 19
M  V30 7 2 7 8
M  V30 8 1 7 22
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 1 10 23
M  V30 13 1 12 13
M  V30 14 1 12 28
M  V30 15 1 13 14
M  V30 16 2 13 15
M  V30 17 1 14 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 2 25 27
M  V30 28 2 26 28
M  V30 29 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 20329-98-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 39552-81-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3052839-58-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37616100
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-66-3
$DTYPE RXN:VAR(1):NOTES
$DATUM stereoselective
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and
elacridar: New potent P-gp modulators acting as MDR reversers
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Braconi, Laura; Dei, Silvia; Contino, Marialessandra; Riganti, Chiara;
Bartolucci, Gianluca; Manetti, Dina; Romanelli, Maria Novella; Perrone,
Maria Grazia; Colabufo, Nicola Antonio; Guglielmo, Stefano; Teodori,
Elisabetta
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 259115716

$RFMT $RIREG SCHEME276 STEP1
$RXN



  2  1
$MOL
Cyclopropanecarboxylic acid
C4H6O2
1759-53-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8737 1.5400 0.0 0
M  V30 2 O 4.2074 2.3101 0.0 0
M  V30 3 O 2.8737 0.0000 0.0 0
M  V30 4 C 1.5400 2.3101 0.0 0
M  V30 5 C 0.0000 2.3101 0.0 0
M  V30 6 C 0.7700 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanine methyl ester
C15H22N2O4
65615-90-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.9536 4.0011 0.0 0 CFG=1
M  V30 2 C 6.7236 5.3347 0.0 0
M  V30 3 N 4.4136 4.0011 0.0 0
M  V30 4 C 6.7236 2.6674 0.0 0
M  V30 5 C 3.6436 5.3347 0.0 0
M  V30 6 O 5.9536 1.3336 0.0 0
M  V30 7 O 8.2636 2.6674 0.0 0
M  V30 8 O 2.1036 5.3347 0.0 0
M  V30 9 O 4.4136 6.6685 0.0 0
M  V30 10 C 6.7236 0.0000 0.0 0
M  V30 11 C 1.3336 6.6685 0.0 0
M  V30 12 C 2.6673 7.4385 0.0 0
M  V30 13 C 0.5636 8.0021 0.0 0
M  V30 14 C 0.0000 5.8985 0.0 0
M  V30 15 N 12.8836 5.3347 0.0 0
M  V30 16 C 8.2636 5.3347 0.0 0
M  V30 17 C 9.0336 4.0011 0.0 0
M  V30 18 C 9.0336 6.6685 0.0 0
M  V30 19 C 10.5736 4.0011 0.0 0
M  V30 20 C 10.5736 6.6685 0.0 0
M  V30 21 C 11.3436 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 16
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 15 21
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Phenylalanine, 4-[(cyclopropylcarbonyl)amino]-N-[(1,1-dimethylethoxy)carbon...
C19H26N2O5
2423992-73-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.9536 4.0011 0.0 0 CFG=1
M  V30 2 C 6.7236 5.3347 0.0 0
M  V30 3 N 4.4136 4.0011 0.0 0
M  V30 4 C 6.7236 2.6674 0.0 0
M  V30 5 C 3.6436 5.3347 0.0 0
M  V30 6 O 5.9536 1.3336 0.0 0
M  V30 7 O 8.2636 2.6674 0.0 0
M  V30 8 O 2.1036 5.3347 0.0 0
M  V30 9 O 4.4136 6.6685 0.0 0
M  V30 10 C 6.7236 0.0000 0.0 0
M  V30 11 C 1.3336 6.6685 0.0 0
M  V30 12 C 2.6673 7.4385 0.0 0
M  V30 13 C 0.5636 8.0021 0.0 0
M  V30 14 C 0.0000 5.8985 0.0 0
M  V30 15 N 12.8836 5.3347 0.0 0
M  V30 16 C 13.6536 6.6685 0.0 0
M  V30 17 O 12.8836 8.0021 0.0 0
M  V30 18 C 8.2636 5.3347 0.0 0
M  V30 19 C 9.0336 6.6685 0.0 0
M  V30 20 C 9.0336 4.0011 0.0 0
M  V30 21 C 10.5736 6.6685 0.0 0
M  V30 22 C 10.5736 4.0011 0.0 0
M  V30 23 C 11.3436 5.3347 0.0 0
M  V30 24 C 15.1936 6.6685 0.0 0
M  V30 25 C 16.5273 5.8985 0.0 0
M  V30 26 C 16.5273 7.4385 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 18
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 15 16
M  V30 16 1 15 23
M  V30 17 2 16 17
M  V30 18 1 16 24
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1759-53-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 65615-90-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2423992-73-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39656177
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 128625-52-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of 6-chloro-quinolin-2-one
derivatives as novel FXIa inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Yanshi; Yuan, Jianglin; Yan, Sida; Liu, Peng; Zheng, Zhichao;
Zhang, Shijun; Meng, Fancui; Liu, Wei; Huang, Changjiang; Wei, Qunchao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2024), 99129610

$RFMT $RIREG SCHEME277 STEP1
$RXN



  2  1
$MOL
2-Methoxypyridin-4-amine
C6H8N2O
20265-39-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3348 3.0801 0.0 0
M  V30 2 C 6.6687 2.3101 0.0 0
M  V30 3 N 0.0000 3.0801 0.0 0
M  V30 4 C 4.0012 2.3101 0.0 0
M  V30 5 C 2.6675 3.0801 0.0 0
M  V30 6 N 4.0012 0.7700 0.0 0
M  V30 7 C 1.3338 2.3101 0.0 0
M  V30 8 C 2.6675 0.0000 0.0 0
M  V30 9 C 1.3338 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 7
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Fluoro-4-(trifluoromethyl)benzoic acid
C8H4F4O2
115029-24-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 2.6673 0.0 0
M  V30 2 F 6.9300 4.2073 0.0 0
M  V30 3 F 8.4700 2.6673 0.0 0
M  V30 4 F 6.9300 1.1273 0.0 0
M  V30 5 F 2.3100 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 O 0.0000 4.0011 0.0 0
M  V30 8 O 0.0000 1.3336 0.0 0
M  V30 9 C 5.3900 2.6673 0.0 0
M  V30 10 C 4.6200 1.3336 0.0 0
M  V30 11 C 4.6200 4.0011 0.0 0
M  V30 12 C 3.0800 1.3336 0.0 0
M  V30 13 C 3.0800 4.0011 0.0 0
M  V30 14 C 2.3100 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 9
M  V30 5 1 5 12
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 6 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Fluoro-N-(2-methoxy-4-pyridinyl)-4-(trifluoromethyl)benzamide
C14H10F4N2O2
1620847-67-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.4137 0.0 0
M  V30 2 N 8.0022 3.6437 0.0 0
M  V30 3 O 6.6685 5.9538 0.0 0
M  V30 4 F 4.0010 5.9538 0.0 0
M  V30 5 C 1.3337 1.3337 0.0 0
M  V30 6 F 2.1037 0.0000 0.0 0
M  V30 7 F 0.0000 0.5637 0.0 0
M  V30 8 F 0.5637 2.6673 0.0 0
M  V30 9 O 13.3370 3.6437 0.0 0
M  V30 10 C 14.6707 4.4137 0.0 0
M  V30 11 C 5.3348 3.6437 0.0 0
M  V30 12 C 4.0010 4.4137 0.0 0
M  V30 13 C 5.3348 2.1037 0.0 0
M  V30 14 C 2.6673 3.6437 0.0 0
M  V30 15 C 4.0010 1.3337 0.0 0
M  V30 16 C 2.6673 2.1037 0.0 0
M  V30 17 C 9.3358 4.4137 0.0 0
M  V30 18 C 10.6697 3.6437 0.0 0
M  V30 19 C 9.3358 5.9538 0.0 0
M  V30 20 C 12.0033 4.4137 0.0 0
M  V30 21 C 10.6697 6.7238 0.0 0
M  V30 22 N 12.0033 5.9538 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 17
M  V30 5 1 4 12
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 5 16
M  V30 10 1 9 10
M  V30 11 1 9 20
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 20265-39-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 115029-24-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1620847-67-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39636683
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 96-47-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a novel series of pyridone amides as NaV1.8 inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Yanfang; Hu, Shilong; Chen, Yuhao; Chen, Meiyuan; Zhang, Di; Liu,
Wencheng; Chen, Chunxia; Gan, Yu; Luo, Menglan; Ke, Bowen
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2024), 101129655

$RFMT $RIREG SCHEME278 STEP1
$RXN



  2  1
$MOL
BOC--alanine
C8H15NO4
3303-84-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 O 2.6673 2.3101 0.0 0
M  V30 3 N 5.3348 2.3101 0.0 0
M  V30 4 O 4.0012 0.0000 0.0 0
M  V30 5 C 1.3337 1.5400 0.0 0
M  V30 6 C 6.6685 1.5400 0.0 0
M  V30 7 C 2.1037 0.2064 0.0 0
M  V30 8 C 0.0000 0.7700 0.0 0
M  V30 9 C 0.5637 2.8737 0.0 0
M  V30 10 C 8.0023 2.3101 0.0 0
M  V30 11 C 9.3360 1.5400 0.0 0
M  V30 12 O 10.6697 2.3101 0.0 0
M  V30 13 O 9.3360 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Thiazolecarboxylic acid, 2-amino-4-methyl-, ethyl ester
C7H10N2O2S
7210-76-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.1556 2.7106 0.0 0
M  V30 2 O 5.9256 4.0442 0.0 0
M  V30 3 O 5.9256 1.3769 0.0 0
M  V30 4 C 7.4656 4.0442 0.0 0
M  V30 5 C 8.2357 5.3780 0.0 0
M  V30 6 C 3.1864 0.0000 0.0 0
M  V30 7 N 0.0000 4.3858 0.0 0
M  V30 8 C 3.6156 2.7106 0.0 0
M  V30 9 C 2.7104 1.4647 0.0 0
M  V30 10 S 2.7104 3.9564 0.0 0
M  V30 11 N 1.2459 1.9406 0.0 0
M  V30 12 C 1.2459 3.4806 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 6 9
M  V30 7 1 7 12
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethyl 2-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-4-methyl...
C15H23N3O5S
2864201-16-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 8.0870 4.0287 0.0 0
M  V30 2 C 9.4207 3.2587 0.0 0
M  V30 3 C 10.7545 4.0287 0.0 0
M  V30 4 O 9.4207 1.7187 0.0 0
M  V30 5 C 12.0882 3.2587 0.0 0
M  V30 6 N 13.4219 4.0287 0.0 0
M  V30 7 C 14.7555 3.2587 0.0 0
M  V30 8 O 16.0893 4.0287 0.0 0
M  V30 9 O 14.7555 1.7187 0.0 0
M  V30 10 C 17.4230 3.2587 0.0 0
M  V30 11 C 18.1930 4.5924 0.0 0
M  V30 12 C 18.7567 2.4887 0.0 0
M  V30 13 C 16.6530 1.9250 0.0 0
M  V30 14 C 2.7844 2.9016 0.0 0
M  V30 15 O 2.1579 4.3086 0.0 0
M  V30 16 O 1.8791 1.6557 0.0 0
M  V30 17 C 0.6263 4.4695 0.0 0
M  V30 18 C 0.0000 5.8765 0.0 0
M  V30 19 C 4.4596 0.0000 0.0 0
M  V30 20 C 6.7534 3.2587 0.0 0
M  V30 21 S 5.3464 3.8852 0.0 0
M  V30 22 N 6.5924 1.7271 0.0 0
M  V30 23 C 4.3159 2.7406 0.0 0
M  V30 24 C 5.0860 1.4070 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 14 23
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 19 24
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3303-84-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7210-76-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2864201-16-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35473515
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of 2-(3-Benzamidopropanamido)thiazole-5-carboxylate Inhibitors
of the Kinesin HSET (KIFC1) and the Development of Cellular Target
Engagement Probes
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Saint-Dizier, Francois; Matthews, Thomas P.; Gregson, Aaron M.; Prevet,
Hugues; McHardy, Tatiana; Colombano, Giampiero; Saville, Harry; Rowlands,
Martin; Ewens, Caroline; McAndrew, P. Craig; Tomlin, Kathy; Guillotin,
Delphine; Mak, Grace Wing-Yan; Drosopoulos, Konstantinos; Poursaitidis,
Ioannis; Burke, Rosemary; van Montfort, Rob; Linardopoulos, Spiros;
Collins, Ian
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(4), 2622-2645

$RFMT $RIREG SCHEME279 STEP1
$RXN



  2  1
$MOL
tert-Butylamine
C4H11N
75-64-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 1.5400 0.0 0
M  V30 2 C 0.0000 1.5400 0.0 0
M  V30 3 C 1.5400 3.0800 0.0 0
M  V30 4 C 3.0800 1.5400 0.0 0
M  V30 5 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)aspartic acid benzyl ester
C16H21NO6
30925-18-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 4.0011 0.0 0 CFG=2
M  V30 2 C 5.3900 4.0011 0.0 0
M  V30 3 N 7.7000 5.3347 0.0 0
M  V30 4 C 7.7000 2.6674 0.0 0
M  V30 5 O 4.6200 5.3347 0.0 0
M  V30 6 O 4.6200 2.6674 0.0 0
M  V30 7 C 9.2400 5.3347 0.0 0
M  V30 8 C 6.9300 1.3336 0.0 0
M  V30 9 C 3.0800 5.3347 0.0 0
M  V30 10 O 10.0100 6.6684 0.0 0
M  V30 11 O 10.0100 4.0011 0.0 0
M  V30 12 O 5.3900 1.3336 0.0 0
M  V30 13 O 7.7000 0.0000 0.0 0
M  V30 14 C 11.5500 6.6684 0.0 0
M  V30 15 C 11.5500 8.2084 0.0 0
M  V30 16 C 13.0900 6.6684 0.0 0
M  V30 17 C 11.5500 5.1284 0.0 0
M  V30 18 C 2.3100 6.6684 0.0 0
M  V30 19 C 3.0800 8.0021 0.0 0
M  V30 20 C 0.7700 6.6684 0.0 0
M  V30 21 C 2.3100 9.3358 0.0 0
M  V30 22 C 0.0000 8.0021 0.0 0
M  V30 23 C 0.7700 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 2 8 13
M  V30 13 1 9 18
M  V30 14 1 10 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N2-[(1,1-Dimethylethoxy)carbonyl]-N-(1,1-dimethylethyl)-L-asparagine phenylme...
C20H30N2O5
1185984-32-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.9538 6.6685 0.0 0 CFG=1
M  V30 2 C 6.7238 8.0023 0.0 0
M  V30 3 C 4.4137 6.6685 0.0 0
M  V30 4 N 6.7238 5.3348 0.0 0
M  V30 5 O 8.2638 8.0022 0.0 0
M  V30 6 O 5.9538 9.3360 0.0 0
M  V30 7 C 3.6437 8.0023 0.0 0
M  V30 8 C 5.9538 4.0012 0.0 0
M  V30 9 C 9.0338 9.3360 0.0 0
M  V30 10 N 2.1037 8.0023 0.0 0
M  V30 11 O 4.4137 9.3360 0.0 0
M  V30 12 O 6.7238 2.6673 0.0 0
M  V30 13 O 4.4137 4.0012 0.0 0
M  V30 14 C 1.3337 9.3360 0.0 0
M  V30 15 C 5.9538 1.3337 0.0 0
M  V30 16 C 0.0000 8.5660 0.0 0
M  V30 17 C 0.5637 10.6697 0.0 0
M  V30 18 C 2.6673 10.1060 0.0 0
M  V30 19 C 4.6201 2.1037 0.0 0
M  V30 20 C 5.1838 0.0000 0.0 0
M  V30 21 C 7.2874 0.5637 0.0 0
M  V30 22 C 10.5739 9.3360 0.0 0
M  V30 23 C 11.3439 8.0022 0.0 0
M  V30 24 C 11.3439 10.6697 0.0 0
M  V30 25 C 12.8839 8.0022 0.0 0
M  V30 26 C 12.8839 10.6697 0.0 0
M  V30 27 C 13.6539 9.3360 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 2 8 13
M  V30 13 1 9 22
M  V30 14 1 10 14
M  V30 15 1 12 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 15 20
M  V30 21 1 15 21
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-64-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 30925-18-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1185984-32-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39628847
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Highly Selective Inhibitors of the Human Constitutive
Proteasome 5c Chymotryptic Subunit
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhan, Wenhu; Li, Daqiang; Saha, Priya; Wang, Rong; Zhang, Hao; Ajay,
Amrendra K.; Deban, Christa; Sukenick, George; Azzi, Jamil; Lin, Gang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(2), 1172-1185

$RFMT $RIREG SCHEME280 STEP1
$RXN



  2  1
$MOL
5-Methyl-3-isoxazolecarboxylic acid
C5H5NO3
3405-77-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 N 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 O 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Cysteine, O-methyl-L-seryl-S-methyl-, methyl ester, 2,2,2-trifluoroacetate ...
C9H18N2O4S.C2HF3O2
2387522-87-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 S 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 O 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C14H21N3O6S
2760538-87-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 6.9302 0.0 0
M  V30 2 N 8.0023 6.1601 0.0 0
M  V30 3 O 9.3360 8.4702 0.0 0
M  V30 4 C 6.6685 6.9302 0.0 0 CFG=1
M  V30 5 C 5.3348 6.1601 0.0 0
M  V30 6 C 6.6685 8.4702 0.0 0
M  V30 7 N 5.3348 4.6201 0.0 0
M  V30 8 O 4.0012 6.9302 0.0 0
M  V30 9 O 5.3348 9.2402 0.0 0
M  V30 10 C 4.0012 3.8501 0.0 0 CFG=1
M  V30 11 C 5.3348 10.7802 0.0 0
M  V30 12 C 4.0012 2.3101 0.0 0
M  V30 13 C 2.6675 4.6201 0.0 0
M  V30 14 O 2.6673 1.5400 0.0 0
M  V30 15 O 5.3348 1.5400 0.0 0
M  V30 16 S 1.3337 3.8501 0.0 0
M  V30 17 C 2.6673 0.0000 0.0 0
M  V30 18 C 0.0000 4.6201 0.0 0
M  V30 19 C 14.6386 5.8030 0.0 0
M  V30 20 C 10.6697 6.1601 0.0 0
M  V30 21 C 12.0765 6.7865 0.0 0
M  V30 22 N 10.8306 4.6286 0.0 0
M  V30 23 C 13.1071 5.6421 0.0 0
M  V30 24 O 12.3371 4.3084 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 20
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 10 13 CFG=3
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 23
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 2 21 23
M  V30 23 1 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3405-77-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2387522-87-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-87-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545329
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME281 STEP1
$RXN



  2  1
$MOL
D-Glutamic acid, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-, 21,25-diethyl ester
C19H34N2O7
2289702-51-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 4.6201 0.0 0 CFG=1
M  V30 2 N 8.0023 5.3901 0.0 0
M  V30 3 C 10.6697 5.3901 0.0 0
M  V30 4 C 9.3360 3.0801 0.0 0
M  V30 5 C 8.0023 6.9302 0.0 0
M  V30 6 C 12.0035 4.6201 0.0 0
M  V30 7 O 8.0023 2.3101 0.0 0
M  V30 8 O 10.6697 2.3101 0.0 0
M  V30 9 C 6.6687 7.7002 0.0 0 CFG=2
M  V30 10 O 9.3360 7.7002 0.0 0
M  V30 11 C 13.3372 5.3901 0.0 0
M  V30 12 C 8.0023 0.7700 0.0 0
M  V30 13 N 5.3348 6.9302 0.0 0
M  V30 14 C 6.6687 9.2402 0.0 0
M  V30 15 O 14.6708 4.6201 0.0 0
M  V30 16 O 13.3372 6.9302 0.0 0
M  V30 17 C 6.6687 0.0000 0.0 0
M  V30 18 C 4.0012 7.7002 0.0 0
M  V30 19 C 5.3348 10.0102 0.0 0
M  V30 20 C 8.0023 10.0102 0.0 0
M  V30 21 C 16.0045 5.3901 0.0 0
M  V30 22 O 2.6675 6.9302 0.0 0
M  V30 23 O 4.0012 9.2402 0.0 0
M  V30 24 C 17.3383 4.6201 0.0 0
M  V30 25 C 1.3338 7.7002 0.0 0
M  V30 26 C 2.1038 9.0338 0.0 0
M  V30 27 C 0.0000 8.4702 0.0 0
M  V30 28 C 0.5638 6.3665 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 11 15
M  V30 15 2 11 16
M  V30 16 1 12 17
M  V30 17 1 13 18
M  V30 18 1 14 19
M  V30 19 1 14 20
M  V30 20 1 15 21
M  V30 21 1 18 22
M  V30 22 2 18 23
M  V30 23 1 21 24
M  V30 24 1 22 25
M  V30 25 1 25 26
M  V30 26 1 25 27
M  V30 27 1 25 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C21H37N3O8
2289702-52-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 12.8839 5.3348 0.0 0 CFG=1
M  V30 2 N 11.3439 5.3348 0.0 0
M  V30 3 C 13.6539 6.6685 0.0 0
M  V30 4 C 13.6539 4.0010 0.0 0
M  V30 5 C 10.5739 6.6685 0.0 0
M  V30 6 C 15.1940 6.6685 0.0 0
M  V30 7 O 12.8839 2.6673 0.0 0
M  V30 8 O 15.1940 4.0010 0.0 0
M  V30 9 C 9.0338 6.6685 0.0 0 CFG=2
M  V30 10 O 11.3439 8.0022 0.0 0
M  V30 11 C 15.9640 8.0022 0.0 0
M  V30 12 C 13.6539 1.3337 0.0 0
M  V30 13 N 8.2638 8.0022 0.0 0
M  V30 14 C 8.2638 5.3348 0.0 0
M  V30 15 O 17.5040 8.0022 0.0 0
M  V30 16 O 15.1940 9.3360 0.0 0
M  V30 17 C 12.8839 0.0000 0.0 0
M  V30 18 C 6.7238 8.0022 0.0 0
M  V30 19 C 6.7238 5.3348 0.0 0
M  V30 20 C 9.0338 4.0010 0.0 0
M  V30 21 C 18.2740 9.3360 0.0 0
M  V30 22 C 5.9538 9.3360 0.0 0
M  V30 23 O 5.9538 6.6685 0.0 0
M  V30 24 C 19.8141 9.3360 0.0 0
M  V30 25 N 4.4137 9.3360 0.0 0
M  V30 26 C 3.6437 10.6697 0.0 0
M  V30 27 O 2.1037 10.6697 0.0 0
M  V30 28 O 4.4137 12.0033 0.0 0
M  V30 29 C 1.3337 12.0033 0.0 0
M  V30 30 C 2.6673 12.7733 0.0 0
M  V30 31 C 0.5637 13.3370 0.0 0
M  V30 32 C 0.0000 11.2333 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=3
M  V30 14 1 11 15
M  V30 15 2 11 16
M  V30 16 1 12 17
M  V30 17 1 13 18
M  V30 18 1 14 19
M  V30 19 1 14 20
M  V30 20 1 15 21
M  V30 21 1 18 22
M  V30 22 2 18 23
M  V30 23 1 21 24
M  V30 24 1 22 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 2 26 28
M  V30 28 1 27 29
M  V30 29 1 29 30
M  V30 30 1 29 31
M  V30 31 1 29 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2289702-51-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2289702-52-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34998057
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 76-05-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune
Potentiators
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guzelj, Samo; Weiss, Matjaz; Slutter, Bram; Frkanec, Ruza; Jakopin, Ziga
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(22), 15085-15101

$RFMT $RIREG SCHEME282 STEP1
$RXN



  2  1
$MOL
o-Phenylenediamine
C6H8N2
95-54-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 2.6673 0.0 0
M  V30 2 N 3.0801 0.0000 0.0 0
M  V30 3 C 3.0801 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 2.3101 4.0010 0.0 0
M  V30 6 C 0.7700 1.3337 0.0 0
M  V30 7 C 0.7700 4.0010 0.0 0
M  V30 8 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 4
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Sodium pyruvate
C3H4O3.Na
113-24-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 3.0800 0.0 0
M  V30 2 C 1.3337 3.8501 0.0 0
M  V30 3 C 4.0010 3.8501 0.0 0
M  V30 4 O 2.6673 1.5400 0.0 0
M  V30 5 O 1.3337 5.3901 0.0 0
M  V30 6 O 0.0000 3.0800 0.0 0
M  V30 7 Na 2.0005 0.0000 0.0 0 VAL=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Methyl-2(1H)-quinoxalinone
C9H8N2O
14003-34-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 N 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 2 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 95-54-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 113-24-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 14003-34-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39174753
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Exploring the Dispersion and Electrostatic Components in Arene-Arene
Interactions between Ligands and G4 DNA to Develop G4-Ligands
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Andreasson, Maans; Donzel, Maxime; Abrahamsson, Alva; Berner, Andreas;
Doimo, Mara; Quiroga, Anna; Eriksson, Anna; Chao, Yu-Kai; Overman,
Jeroen; Pemberton, Nils; Wanrooij, Sjoerd; Chorell, Erik
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(3), 2202-2219

$RFMT $RIREG SCHEME283 STEP1
$RXN



  2  1
$MOL
Methyl 2-[[[(2S)-3-(dimethylamino)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-...
C19H28N2O5S
2696272-82-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 13.0900 5.3347 0.0 0
M  V30 2 O 14.6300 5.3347 0.0 0
M  V30 3 O 12.3200 4.0011 0.0 0
M  V30 4 C 15.4000 4.0011 0.0 0
M  V30 5 C 10.0100 5.3347 0.0 0
M  V30 6 S 8.4700 5.3347 0.0 0
M  V30 7 C 7.7000 4.0011 0.0 0
M  V30 8 C 6.1600 4.0011 0.0 0 CFG=2
M  V30 9 N 5.3900 5.3347 0.0 0
M  V30 10 C 5.3900 2.6674 0.0 0
M  V30 11 C 3.8500 5.3347 0.0 0
M  V30 12 N 6.1600 1.3336 0.0 0
M  V30 13 O 3.8500 2.6674 0.0 0
M  V30 14 O 3.0800 6.6684 0.0 0
M  V30 15 O 3.0800 4.0011 0.0 0
M  V30 16 C 7.7000 1.3336 0.0 0
M  V30 17 C 5.3900 0.0000 0.0 0
M  V30 18 C 1.5400 6.6684 0.0 0
M  V30 19 C 1.5400 5.1284 0.0 0
M  V30 20 C 0.0000 6.6684 0.0 0
M  V30 21 C 1.5400 8.2084 0.0 0
M  V30 22 C 12.3200 6.6684 0.0 0
M  V30 23 C 10.7800 6.6684 0.0 0
M  V30 24 C 13.0900 8.0021 0.0 0
M  V30 25 C 10.0100 8.0021 0.0 0
M  V30 26 C 12.3200 9.3358 0.0 0
M  V30 27 C 10.7800 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 22
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 23
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9 CFG=3
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 1 12 17
M  V30 18 1 14 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C21H31N3O6S
2696272-86-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0801 0.0 0
M  V30 2 O 1.3337 2.3101 0.0 0
M  V30 3 O 2.6675 4.6201 0.0 0
M  V30 4 C 0.0000 3.0801 0.0 0
M  V30 5 C 5.3348 4.6201 0.0 0
M  V30 6 S 6.6685 5.3901 0.0 0
M  V30 7 C 6.6685 6.9302 0.0 0
M  V30 8 C 8.0023 7.7002 0.0 0 CFG=2
M  V30 9 N 9.3360 6.9302 0.0 0
M  V30 10 C 8.0023 9.2402 0.0 0
M  V30 11 C 10.6697 7.7002 0.0 0
M  V30 12 N 6.6685 10.0102 0.0 0
M  V30 13 O 9.3360 10.0102 0.0 0
M  V30 14 C 12.0035 6.9302 0.0 0
M  V30 15 O 10.6697 9.2402 0.0 0
M  V30 16 C 5.3348 9.2402 0.0 0
M  V30 17 C 6.6685 11.5503 0.0 0
M  V30 18 N 13.3372 7.7002 0.0 0
M  V30 19 C 14.6708 6.9302 0.0 0
M  V30 20 O 16.0045 7.7002 0.0 0
M  V30 21 O 14.6708 5.3901 0.0 0
M  V30 22 C 17.3383 6.9302 0.0 0
M  V30 23 C 18.1083 8.2638 0.0 0
M  V30 24 C 18.6720 6.1601 0.0 0
M  V30 25 C 16.5683 5.5965 0.0 0
M  V30 26 C 4.0012 2.3101 0.0 0
M  V30 27 C 5.3348 3.0801 0.0 0
M  V30 28 C 4.0012 0.7700 0.0 0
M  V30 29 C 6.6685 2.3101 0.0 0
M  V30 30 C 5.3348 0.0000 0.0 0
M  V30 31 C 6.6685 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 26
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 27
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9 CFG=3
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 1 12 17
M  V30 18 1 14 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 1 22 25
M  V30 26 2 26 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 29 2 28 30
M  V30 30 2 29 31
M  V30 31 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2696272-82-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2696272-86-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24176908
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 123-91-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Mining Natural Products for Macrocycles to Drug Difficult Targets
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Begnini, Fabio; Poongavanam, Vasanthanathan; Over, Bjoern; Castaldo,
Marie; Geschwindner, Stefan; Johansson, Patrik; Tyagi, Mohit; Tyrchan,
Christian; Wissler, Lisa; Sjoe, Peter; Schiesser, Stefan; Kihlberg, Jan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(2), 1054-1072

$RFMT $RIREG SCHEME284 STEP1
$RXN



  2  1
$MOL
2-Methyl-5-pyrimidinecarboxylic acid
C6H6N2O2
5194-32-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 0.0000 0.0 0
M  V30 3 O 0.0000 2.6673 0.0 0
M  V30 4 C 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 N 4.6201 2.6673 0.0 0
M  V30 9 N 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-(4-amino-2-methyl[1,1-biphenyl]-2-yl)-
C16H16N2O
2983540-42-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 6.1600 0.0 0
M  V30 2 C 6.6684 6.9300 0.0 0
M  V30 3 C 8.0021 6.1600 0.0 0
M  V30 4 O 6.6684 8.4700 0.0 0
M  V30 5 C 9.3358 6.9300 0.0 0
M  V30 6 C 0.0000 4.6200 0.0 0
M  V30 7 N 2.6674 0.0000 0.0 0
M  V30 8 C 2.6674 6.1600 0.0 0
M  V30 9 C 4.0011 6.9300 0.0 0
M  V30 10 C 1.3336 6.9300 0.0 0
M  V30 11 C 4.0011 8.4700 0.0 0
M  V30 12 C 1.3336 8.4700 0.0 0
M  V30 13 C 2.6674 9.2400 0.0 0
M  V30 14 C 2.6674 4.6200 0.0 0
M  V30 15 C 1.3336 3.8500 0.0 0
M  V30 16 C 4.0011 3.8500 0.0 0
M  V30 17 C 1.3336 2.3100 0.0 0
M  V30 18 C 4.0011 2.3100 0.0 0
M  V30 19 C 2.6674 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 15
M  V30 7 1 7 19
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 14
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Pyrimidinecarboxamide, 2-methyl-N-[2-methyl-2-[(1-oxo-2-propen-1-yl)amino]...
C22H20N4O2
2983540-45-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.6674 4.6200 0.0 0
M  V30 2 C 1.3338 5.3900 0.0 0
M  V30 3 C 1.3338 6.9300 0.0 0
M  V30 4 O 0.0000 4.6200 0.0 0
M  V30 5 C 0.0000 7.7000 0.0 0
M  V30 6 C 6.6685 0.7700 0.0 0
M  V30 7 N 9.3358 5.3900 0.0 0
M  V30 8 C 10.6694 4.6200 0.0 0
M  V30 9 O 10.6696 3.0800 0.0 0
M  V30 10 C 16.0043 7.7000 0.0 0
M  V30 11 C 4.0011 2.3100 0.0 0
M  V30 12 C 2.6674 3.0800 0.0 0
M  V30 13 C 4.0011 0.7700 0.0 0
M  V30 14 C 1.3338 2.3100 0.0 0
M  V30 15 C 2.6674 0.0000 0.0 0
M  V30 16 C 1.3338 0.7700 0.0 0
M  V30 17 C 5.3347 3.0800 0.0 0
M  V30 18 C 6.6685 2.3100 0.0 0
M  V30 19 C 5.3347 4.6200 0.0 0
M  V30 20 C 8.0021 3.0800 0.0 0
M  V30 21 C 6.6685 5.3900 0.0 0
M  V30 22 C 8.0021 4.6200 0.0 0
M  V30 23 C 12.0032 5.3900 0.0 0
M  V30 24 C 12.0032 6.9300 0.0 0
M  V30 25 C 13.3369 4.6200 0.0 0
M  V30 26 N 13.3369 7.7000 0.0 0
M  V30 27 N 14.6705 5.3900 0.0 0
M  V30 28 C 14.6705 6.9300 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 18
M  V30 7 1 7 8
M  V30 8 1 7 22
M  V30 9 2 8 9
M  V30 10 1 8 23
M  V30 11 1 10 28
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 11 17
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 22
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5194-32-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2983540-42-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-45-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256065
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME285 STEP1
$RXN



  2  1
$MOL
4-Bromobenzoic acid
C7H5BrO2
586-76-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 0.0000 0.0 0
M  V30 3 O 0.0000 2.6673 0.0 0
M  V30 4 Br 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenamine, 2,6-dimethoxy-4-pentyl-
C13H21NO2
3019990-12-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.5400 6.6685 0.0 0
M  V30 2 C 2.3100 8.0021 0.0 0
M  V30 3 N 0.0000 4.0011 0.0 0
M  V30 4 O 1.5400 1.3336 0.0 0
M  V30 5 C 2.3100 0.0000 0.0 0
M  V30 6 C 6.1600 4.0011 0.0 0
M  V30 7 C 6.9300 5.3347 0.0 0
M  V30 8 C 8.4700 5.3347 0.0 0
M  V30 9 C 9.2400 6.6685 0.0 0
M  V30 10 C 10.7800 6.6685 0.0 0
M  V30 11 C 2.3100 5.3347 0.0 0
M  V30 12 C 1.5400 4.0011 0.0 0
M  V30 13 C 3.8500 5.3347 0.0 0
M  V30 14 C 2.3100 2.6674 0.0 0
M  V30 15 C 4.6200 4.0011 0.0 0
M  V30 16 C 3.8500 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 3 12
M  V30 4 1 4 5
M  V30 5 1 4 14
M  V30 6 1 6 7
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzamide, 4-bromo-N-(2,6-dimethoxy-4-pentylphenyl)-
C20H24BrNO3
3049477-28-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 4.0011 0.0 0
M  V30 2 C 6.1600 5.3347 0.0 0
M  V30 3 O 6.9300 6.6685 0.0 0
M  V30 4 O 8.4700 1.3336 0.0 0
M  V30 5 C 9.2400 0.0000 0.0 0
M  V30 6 O 8.4700 6.6685 0.0 0
M  V30 7 C 9.2400 8.0021 0.0 0
M  V30 8 C 13.0900 4.0011 0.0 0
M  V30 9 C 13.8600 2.6674 0.0 0
M  V30 10 C 15.4000 2.6674 0.0 0
M  V30 11 C 16.1700 1.3336 0.0 0
M  V30 12 C 17.7100 1.3336 0.0 0
M  V30 13 Br 0.0000 5.3347 0.0 0
M  V30 14 C 8.4700 4.0011 0.0 0
M  V30 15 C 9.2400 2.6674 0.0 0
M  V30 16 C 9.2400 5.3347 0.0 0
M  V30 17 C 10.7800 2.6674 0.0 0
M  V30 18 C 10.7800 5.3347 0.0 0
M  V30 19 C 11.5500 4.0011 0.0 0
M  V30 20 C 4.6200 5.3347 0.0 0
M  V30 21 C 3.8500 4.0011 0.0 0
M  V30 22 C 3.8500 6.6685 0.0 0
M  V30 23 C 2.3100 4.0011 0.0 0
M  V30 24 C 2.3100 6.6685 0.0 0
M  V30 25 C 1.5400 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 2 2 3
M  V30 4 1 2 20
M  V30 5 1 4 5
M  V30 6 1 4 15
M  V30 7 1 6 7
M  V30 8 1 6 16
M  V30 9 1 8 9
M  V30 10 1 8 19
M  V30 11 1 9 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 13 25
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 586-76-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3019990-12-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3049477-28-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37102940
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and analgesia evaluation of novel Transient Receptor
Potential Vanilloid 1 (TRPV1) agonists modified from Cannabidiol (CBD)
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Jin, Fangjie; Wen, Yuting; Lin, Guoqiang; Yu, Shaopeng; Wang, Chao; Ye,
Wenbo; Zhang, Jiange
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2023), 90117379

$RFMT $RIREG SCHEME286 STEP1
$RXN



  2  1
$MOL
tert-Butylamine
C4H11N
75-64-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 1.5400 0.0 0
M  V30 2 C 0.0000 1.5400 0.0 0
M  V30 3 C 1.5400 3.0800 0.0 0
M  V30 4 C 3.0800 1.5400 0.0 0
M  V30 5 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(Phenylmethyl) hydrogen N-[(1,1-dimethylethoxy)carbonyl]-L-glutamate
C17H23NO6
30924-93-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 5.3347 0.0 0 CFG=2
M  V30 2 C 5.3900 5.3347 0.0 0
M  V30 3 N 7.7000 6.6684 0.0 0
M  V30 4 C 7.7000 4.0011 0.0 0
M  V30 5 O 4.6200 6.6684 0.0 0
M  V30 6 O 4.6200 4.0011 0.0 0
M  V30 7 C 9.2400 6.6684 0.0 0
M  V30 8 C 6.9300 2.6673 0.0 0
M  V30 9 C 3.0800 6.6684 0.0 0
M  V30 10 O 10.0100 8.0021 0.0 0
M  V30 11 O 10.0100 5.3347 0.0 0
M  V30 12 C 7.7000 1.3336 0.0 0
M  V30 13 C 11.5500 8.0021 0.0 0
M  V30 14 O 9.2400 1.3336 0.0 0
M  V30 15 O 6.9300 0.0000 0.0 0
M  V30 16 C 11.5500 9.5421 0.0 0
M  V30 17 C 13.0900 8.0021 0.0 0
M  V30 18 C 11.5500 6.4621 0.0 0
M  V30 19 C 2.3100 8.0021 0.0 0
M  V30 20 C 3.0800 9.3358 0.0 0
M  V30 21 C 0.7700 8.0021 0.0 0
M  V30 22 C 2.3100 10.6694 0.0 0
M  V30 23 C 0.0000 9.3358 0.0 0
M  V30 24 C 0.7700 10.6694 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 19
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 13 17
M  V30 18 1 13 18
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 23
M  V30 23 2 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N2-[(1,1-Dimethylethoxy)carbonyl]-N-(1,1-dimethylethyl)-L-glutamine phenylmet...
C21H32N2O5
102651-05-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7000 6.6684 0.0 0 CFG=1
M  V30 2 C 8.4700 8.0021 0.0 0
M  V30 3 C 6.1600 6.6684 0.0 0
M  V30 4 N 8.4700 5.3347 0.0 0
M  V30 5 O 10.0100 8.0021 0.0 0
M  V30 6 O 7.7000 9.3358 0.0 0
M  V30 7 C 5.3900 8.0021 0.0 0
M  V30 8 C 7.7000 4.0011 0.0 0
M  V30 9 C 10.7800 9.3358 0.0 0
M  V30 10 C 3.8500 8.0021 0.0 0
M  V30 11 O 8.4700 2.6674 0.0 0
M  V30 12 O 6.1600 4.0011 0.0 0
M  V30 13 N 3.0800 9.3358 0.0 0
M  V30 14 O 3.0800 6.6684 0.0 0
M  V30 15 C 7.7000 1.3336 0.0 0
M  V30 16 C 1.5400 9.3358 0.0 0
M  V30 17 C 6.3664 2.1036 0.0 0
M  V30 18 C 6.9300 0.0000 0.0 0
M  V30 19 C 9.0336 0.5636 0.0 0
M  V30 20 C 1.5400 10.8758 0.0 0
M  V30 21 C 0.0000 9.3358 0.0 0
M  V30 22 C 1.5400 7.7958 0.0 0
M  V30 23 C 12.3200 9.3358 0.0 0
M  V30 24 C 13.0900 8.0021 0.0 0
M  V30 25 C 13.0900 10.6694 0.0 0
M  V30 26 C 14.6300 8.0021 0.0 0
M  V30 27 C 14.6300 10.6694 0.0 0
M  V30 28 C 15.4000 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 23
M  V30 13 1 10 13
M  V30 14 2 10 14
M  V30 15 1 11 15
M  V30 16 1 13 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 16 21
M  V30 22 1 16 22
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 2 25 27
M  V30 27 2 26 28
M  V30 28 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-64-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 30924-93-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 102651-05-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39975902
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Highly Selective Inhibitors of the Human Constitutive
Proteasome 5c Chymotryptic Subunit
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhan, Wenhu; Li, Daqiang; Saha, Priya; Wang, Rong; Zhang, Hao; Ajay,
Amrendra K.; Deban, Christa; Sukenick, George; Azzi, Jamil; Lin, Gang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(2), 1172-1185

$RFMT $RIREG SCHEME287 STEP1
$RXN



  2  1
$MOL
Boronic acid, B-[3-(aminomethyl)phenyl]-, hydrochloride (1:1)
C7H10BNO2.ClH
352525-94-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 B 1.3337 3.0800 0.0 0
M  V30 2 O 1.3337 1.5400 0.0 0
M  V30 3 O 0.0000 3.8501 0.0 0
M  V30 4 C 6.6687 3.0800 0.0 0
M  V30 5 N 8.0023 3.8501 0.0 0
M  V30 6 C 2.6675 3.8501 0.0 0
M  V30 7 C 4.0012 3.0800 0.0 0
M  V30 8 C 2.6675 5.3901 0.0 0
M  V30 9 C 5.3348 3.8501 0.0 0
M  V30 10 C 4.0012 6.1601 0.0 0
M  V30 11 C 5.3348 5.3901 0.0 0
M  V30 12 Cl 4.0012 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 6
M  V30 4 1 4 5
M  V30 5 1 4 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N2-[(1,1-Dimethylethoxy)carbonyl]-N-(1,1-dimethylethyl)-L-asparagine
C13H24N2O5
2095522-71-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0 CFG=1
M  V30 2 C 7.7000 2.6674 0.0 0
M  V30 3 N 5.3900 4.0011 0.0 0
M  V30 4 C 5.3900 1.3338 0.0 0
M  V30 5 C 8.4700 4.0011 0.0 0
M  V30 6 C 3.8500 4.0011 0.0 0
M  V30 7 O 6.1600 0.0000 0.0 0
M  V30 8 O 3.8500 1.3338 0.0 0
M  V30 9 N 10.0100 4.0011 0.0 0
M  V30 10 O 7.7000 5.3349 0.0 0
M  V30 11 O 3.0800 5.3349 0.0 0
M  V30 12 O 3.0800 2.6674 0.0 0
M  V30 13 C 10.7800 5.3349 0.0 0
M  V30 14 C 1.5400 5.3349 0.0 0
M  V30 15 C 12.1136 4.5649 0.0 0
M  V30 16 C 11.5500 6.6685 0.0 0
M  V30 17 C 9.4464 6.1049 0.0 0
M  V30 18 C 1.5400 6.8749 0.0 0
M  V30 19 C 0.0000 5.3349 0.0 0
M  V30 20 C 1.5400 3.7949 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 2 6 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 16 1 13 17
M  V30 17 1 14 18
M  V30 18 1 14 19
M  V30 19 1 14 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C20H32BN3O6
2892822-10-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 6.6685 0.0 0 CFG=1
M  V30 2 C 7.7002 6.6685 0.0 0
M  V30 3 C 5.3901 5.3348 0.0 0
M  V30 4 N 5.3901 8.0022 0.0 0
M  V30 5 N 8.4702 8.0022 0.0 0
M  V30 6 O 8.4702 5.3348 0.0 0
M  V30 7 C 6.1601 4.0012 0.0 0
M  V30 8 C 3.8501 8.0022 0.0 0
M  V30 9 C 10.0102 8.0022 0.0 0
M  V30 10 N 5.3901 2.6673 0.0 0
M  V30 11 O 7.7002 4.0012 0.0 0
M  V30 12 O 3.0801 9.3360 0.0 0
M  V30 13 O 3.0801 6.6685 0.0 0
M  V30 14 C 6.1601 1.3337 0.0 0
M  V30 15 C 1.5400 9.3360 0.0 0
M  V30 16 C 7.4938 2.1037 0.0 0
M  V30 17 C 6.9302 0.0000 0.0 0
M  V30 18 C 4.8265 0.5637 0.0 0
M  V30 19 C 1.5400 10.8760 0.0 0
M  V30 20 C 0.0000 9.3360 0.0 0
M  V30 21 C 1.5400 7.7960 0.0 0
M  V30 22 B 14.6303 10.6697 0.0 0
M  V30 23 O 15.4003 9.3360 0.0 0
M  V30 24 O 15.4003 12.0033 0.0 0
M  V30 25 C 10.7802 9.3360 0.0 0
M  V30 26 C 12.3203 9.3360 0.0 0
M  V30 27 C 10.0102 10.6697 0.0 0
M  V30 28 C 13.0903 10.6697 0.0 0
M  V30 29 C 10.7802 12.0033 0.0 0
M  V30 30 C 12.3203 12.0033 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 2 8 13
M  V30 13 1 9 25
M  V30 14 1 10 14
M  V30 15 1 12 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 15 20
M  V30 21 1 15 21
M  V30 22 1 22 23
M  V30 23 1 22 24
M  V30 24 1 22 28
M  V30 25 2 25 26
M  V30 26 1 25 27
M  V30 27 1 26 28
M  V30 28 2 27 29
M  V30 29 2 28 30
M  V30 30 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 352525-94-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2095522-71-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2892822-10-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39975883
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Highly Selective Inhibitors of the Human Constitutive
Proteasome 5c Chymotryptic Subunit
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhan, Wenhu; Li, Daqiang; Saha, Priya; Wang, Rong; Zhang, Hao; Ajay,
Amrendra K.; Deban, Christa; Sukenick, George; Azzi, Jamil; Lin, Gang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(2), 1172-1185

$RFMT $RIREG SCHEME288 STEP1
$RXN



  2  1
$MOL
4-[[[(Phenylmethoxy)carbonyl]amino]methyl]benzoic acid
C16H15NO4
58933-52-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.3359 4.6201 0.0 0
M  V30 2 N 8.0022 3.8500 0.0 0
M  V30 3 C 6.6686 4.6201 0.0 0
M  V30 4 O 5.3348 3.8500 0.0 0
M  V30 5 O 6.6686 6.1601 0.0 0
M  V30 6 C 4.0011 4.6201 0.0 0
M  V30 7 C 14.6707 1.5400 0.0 0
M  V30 8 O 14.6707 0.0000 0.0 0
M  V30 9 O 16.0045 2.3100 0.0 0
M  V30 10 C 10.6697 3.8500 0.0 0
M  V30 11 C 10.6697 2.3100 0.0 0
M  V30 12 C 12.0034 4.6201 0.0 0
M  V30 13 C 12.0034 1.5400 0.0 0
M  V30 14 C 13.3370 3.8500 0.0 0
M  V30 15 C 13.3370 2.3100 0.0 0
M  V30 16 C 2.6675 3.8500 0.0 0
M  V30 17 C 1.3338 4.6201 0.0 0
M  V30 18 C 2.6675 2.3100 0.0 0
M  V30 19 C 0.0000 3.8500 0.0 0
M  V30 20 C 1.3338 1.5400 0.0 0
M  V30 21 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 16
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 15
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Aminopyridine
C5H6N2
462-08-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 N 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 2 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phenylmethyl N-[[4-[(3-pyridinylamino)carbonyl]phenyl]methyl]carbamate
C21H19N3O3
1262991-47-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 2.3100 0.0 0
M  V30 2 N 4.0011 3.0800 0.0 0
M  V30 3 O 5.3347 0.7700 0.0 0
M  V30 4 C 10.6694 5.3900 0.0 0
M  V30 5 N 12.0031 4.6200 0.0 0
M  V30 6 C 13.3369 5.3900 0.0 0
M  V30 7 O 14.6705 4.6200 0.0 0
M  V30 8 O 13.3369 6.9300 0.0 0
M  V30 9 C 16.0041 5.3900 0.0 0
M  V30 10 C 6.6684 3.0800 0.0 0
M  V30 11 C 6.6684 4.6200 0.0 0
M  V30 12 C 8.0021 2.3100 0.0 0
M  V30 13 C 8.0021 5.3900 0.0 0
M  V30 14 C 9.3358 3.0800 0.0 0
M  V30 15 C 9.3358 4.6200 0.0 0
M  V30 16 C 2.6674 2.3100 0.0 0
M  V30 17 C 1.3336 3.0800 0.0 0
M  V30 18 C 2.6674 0.7700 0.0 0
M  V30 19 C 0.0000 2.3100 0.0 0
M  V30 20 N 1.3336 0.0000 0.0 0
M  V30 21 C 0.0000 0.7700 0.0 0
M  V30 22 C 17.3378 4.6200 0.0 0
M  V30 23 C 17.3378 3.0800 0.0 0
M  V30 24 C 18.6716 5.3900 0.0 0
M  V30 25 C 18.6716 2.3100 0.0 0
M  V30 26 C 20.0052 4.6200 0.0 0
M  V30 27 C 20.0052 3.0800 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 16
M  V30 5 1 4 5
M  V30 6 1 4 15
M  V30 7 1 5 6
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 7 9
M  V30 11 1 9 22
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 2 12 14
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 1 16 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 58933-52-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 462-08-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1262991-47-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40620103
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Oxygen-Dependent Interactions between the Ruthenium Cage and the
Photoreleased Inhibitor in NAMPT-Targeted Photoactivated Chemotherapy
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Abyar, Selda; Huang, Luojiao; Husiev, Yurii; Bretin, Ludovic; Chau,
Bobby; Ramu, Vadde; Wildeman, Jacob Hendricus; Belfor, Kimberley; Wijaya,
Lukas S.; van der Noord, Vera E.; Harms, Amy C.; Siegler, Maxime A.; Le
Devedec, Sylvia E.; Bonnet, Sylvestre
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(13), 11086-11102

$RFMT $RIREG SCHEME289 STEP1
$RXN



  2  1
$MOL
3-Aminopyridine
C5H6N2
462-08-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 N 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 2 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
trans-4-[[[(4-Fluorophenyl)sulfonyl]amino]methyl]cyclohexanecarboxylic acid
C14H18FNO4S
744248-54-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 9.2400 1.5400 0.0 0 VAL=6
M  V30 2 N 7.7000 1.5400 0.0 0
M  V30 3 O 9.2400 3.0800 0.0 0
M  V30 4 O 9.2400 0.0000 0.0 0
M  V30 5 C 6.9300 2.8736 0.0 0
M  V30 6 F 15.4000 1.5400 0.0 0
M  V30 7 C 0.7700 2.8736 0.0 0
M  V30 8 O 0.0000 4.2073 0.0 0
M  V30 9 O 0.0000 1.5400 0.0 0
M  V30 10 C 10.7800 1.5400 0.0 0
M  V30 11 C 11.5500 0.2062 0.0 0
M  V30 12 C 11.5500 2.8736 0.0 0
M  V30 13 C 13.0900 0.2062 0.0 0
M  V30 14 C 13.0900 2.8736 0.0 0
M  V30 15 C 13.8600 1.5400 0.0 0
M  V30 16 C 5.3900 2.8736 0.0 0 CFG=1
M  V30 17 C 4.6200 4.2073 0.0 0
M  V30 18 C 4.6200 1.5400 0.0 0
M  V30 19 C 3.0800 4.2073 0.0 0
M  V30 20 C 3.0800 1.5400 0.0 0
M  V30 21 C 2.3100 2.8736 0.0 0 CFG=1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 16 5 CFG=1
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 21 7 CFG=3
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(2 16 21)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
trans-4-[[[(4-Fluorophenyl)sulfonyl]amino]methyl]-N-3-pyridinylcyclohexanecar...
C19H22FN3O3S
2581115-34-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 13.8600 4.0009 0.0 0 VAL=6
M  V30 2 N 12.3200 4.0009 0.0 0
M  V30 3 O 13.8600 5.5409 0.0 0
M  V30 4 O 13.8600 2.4609 0.0 0
M  V30 5 C 11.5500 2.6673 0.0 0
M  V30 6 F 20.0200 4.0009 0.0 0
M  V30 7 C 5.3900 2.6673 0.0 0
M  V30 8 N 4.6200 1.3336 0.0 0
M  V30 9 O 4.6200 4.0009 0.0 0
M  V30 10 C 15.4000 4.0009 0.0 0
M  V30 11 C 16.1700 5.3347 0.0 0
M  V30 12 C 16.1700 2.6673 0.0 0
M  V30 13 C 17.7100 5.3347 0.0 0
M  V30 14 C 17.7100 2.6673 0.0 0
M  V30 15 C 18.4800 4.0009 0.0 0
M  V30 16 C 10.0100 2.6673 0.0 0 CFG=2
M  V30 17 C 9.2400 1.3336 0.0 0
M  V30 18 C 9.2400 4.0009 0.0 0
M  V30 19 C 7.7000 1.3336 0.0 0
M  V30 20 C 7.7000 4.0009 0.0 0
M  V30 21 C 6.9300 2.6673 0.0 0 CFG=2
M  V30 22 C 3.0800 1.3336 0.0 0
M  V30 23 C 2.3100 2.6673 0.0 0
M  V30 24 C 2.3100 0.0000 0.0 0
M  V30 25 C 0.7700 2.6673 0.0 0
M  V30 26 N 0.7700 0.0000 0.0 0
M  V30 27 C 0.0000 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 16 5 CFG=1
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 21 7 CFG=3
M  V30 11 1 8 22
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 2 12 14
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 21
M  V30 24 1 22 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 2 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(2 16 21)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 462-08-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 744248-54-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2581115-34-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23338374
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 127-19-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A new chemotype with promise against Trypanosoma cruzi
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Xiaofang; Cal, Monica; Kaiser, Marcel; Buckner, Frederick S.;
Lepesheva, Galina I.; Sanford, Austin G.; Wallick, Alexander I.; Davis,
Paul H.; Vennerstrom, Jonathan L.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(1), 126778

$RFMT $RIREG SCHEME290 STEP1
$RXN



  2  1
$MOL
5-Amino-2-methylpyridine
C6H8N2
3430-14-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 1.3337 0.0 0
M  V30 2 C 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 N 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 2 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[[[(4-Fluorophenyl)sulfonyl]amino]methyl]benzoic acid
C14H12FNO4S
438575-58-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 9.2400 1.5400 0.0 0 VAL=6
M  V30 2 N 7.7000 1.5400 0.0 0
M  V30 3 O 9.2400 3.0800 0.0 0
M  V30 4 O 9.2400 0.0000 0.0 0
M  V30 5 C 6.9300 2.8736 0.0 0
M  V30 6 F 15.4000 1.5400 0.0 0
M  V30 7 C 0.7700 2.8736 0.0 0
M  V30 8 O 0.0000 4.2073 0.0 0
M  V30 9 O 0.0000 1.5400 0.0 0
M  V30 10 C 10.7800 1.5400 0.0 0
M  V30 11 C 11.5500 0.2062 0.0 0
M  V30 12 C 11.5500 2.8736 0.0 0
M  V30 13 C 13.0900 0.2062 0.0 0
M  V30 14 C 13.0900 2.8736 0.0 0
M  V30 15 C 13.8600 1.5400 0.0 0
M  V30 16 C 5.3900 2.8736 0.0 0
M  V30 17 C 4.6200 4.2073 0.0 0
M  V30 18 C 4.6200 1.5400 0.0 0
M  V30 19 C 3.0800 4.2073 0.0 0
M  V30 20 C 3.0800 1.5400 0.0 0
M  V30 21 C 2.3100 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 5 16
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 21
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[[[(4-Fluorophenyl)sulfonyl]amino]methyl]-N-(6-methyl-3-pyridinyl)benzamide
C20H18FN3O3S
2581111-05-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 6.1600 4.0009 0.0 0 VAL=6
M  V30 2 N 7.7000 4.0009 0.0 0
M  V30 3 O 6.1600 5.5409 0.0 0
M  V30 4 O 6.1600 2.4609 0.0 0
M  V30 5 C 8.4700 2.6673 0.0 0
M  V30 6 F 0.0000 4.0009 0.0 0
M  V30 7 C 14.6300 2.6673 0.0 0
M  V30 8 N 15.4000 1.3336 0.0 0
M  V30 9 O 15.4000 4.0009 0.0 0
M  V30 10 C 21.5600 1.3336 0.0 0
M  V30 11 C 4.6200 4.0009 0.0 0
M  V30 12 C 3.8500 5.3347 0.0 0
M  V30 13 C 3.8500 2.6673 0.0 0
M  V30 14 C 2.3100 5.3347 0.0 0
M  V30 15 C 2.3100 2.6673 0.0 0
M  V30 16 C 1.5400 4.0009 0.0 0
M  V30 17 C 10.0100 2.6673 0.0 0
M  V30 18 C 10.7800 1.3336 0.0 0
M  V30 19 C 10.7800 4.0009 0.0 0
M  V30 20 C 12.3200 1.3336 0.0 0
M  V30 21 C 12.3200 4.0009 0.0 0
M  V30 22 C 13.0900 2.6673 0.0 0
M  V30 23 C 16.9400 1.3336 0.0 0
M  V30 24 C 17.7100 2.6673 0.0 0
M  V30 25 C 17.7100 0.0000 0.0 0
M  V30 26 C 19.2500 2.6673 0.0 0
M  V30 27 N 19.2500 0.0000 0.0 0
M  V30 28 C 20.0200 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 11
M  V30 5 1 2 5
M  V30 6 1 5 17
M  V30 7 1 6 16
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 22
M  V30 11 1 8 23
M  V30 12 1 10 28
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 22
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3430-14-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 438575-58-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2581111-05-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23338923
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 127-19-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A new chemotype with promise against Trypanosoma cruzi
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Xiaofang; Cal, Monica; Kaiser, Marcel; Buckner, Frederick S.;
Lepesheva, Galina I.; Sanford, Austin G.; Wallick, Alexander I.; Davis,
Paul H.; Vennerstrom, Jonathan L.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(1), 126778

$RFMT $RIREG SCHEME291 STEP1
$RXN



  2  1
$MOL
[1,1-Biphenyl]-4-carboxylic acid
C13H10O2
92-92-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 5.3901 1.3337 0.0 0
M  V30 5 C 4.6201 0.0000 0.0 0
M  V30 6 C 4.6201 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 C 3.0801 2.6673 0.0 0
M  V30 9 C 2.3101 1.3337 0.0 0
M  V30 10 C 6.9302 1.3337 0.0 0
M  V30 11 C 7.7002 2.6673 0.0 0
M  V30 12 C 7.7002 0.0000 0.0 0
M  V30 13 C 9.2402 2.6673 0.0 0
M  V30 14 C 9.2402 0.0000 0.0 0
M  V30 15 C 10.0102 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 4 10
M  V30 7 1 5 7
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 8 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Butanoic acid, 2-amino-4-[[(1,1-dimethylethoxy)carbonyl]amino]-, methyl ester...
C10H20N2O4.ClH
3350-15-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 3.8501 0.0 0
M  V30 2 O 2.6673 3.0800 0.0 0
M  V30 3 N 5.3348 3.0800 0.0 0
M  V30 4 O 4.0010 5.3901 0.0 0
M  V30 5 C 1.3337 3.8501 0.0 0
M  V30 6 C 6.6685 3.8501 0.0 0
M  V30 7 C 2.1037 5.1837 0.0 0
M  V30 8 C 0.0000 4.6201 0.0 0
M  V30 9 C 0.5637 2.5164 0.0 0
M  V30 10 C 8.0022 3.0800 0.0 0
M  V30 11 C 9.3360 3.8501 0.0 0 CFG=2
M  V30 12 C 10.6697 3.0800 0.0 0
M  V30 13 N 9.3360 5.3901 0.0 0
M  V30 14 O 12.0033 3.8501 0.0 0
M  V30 15 O 10.6697 1.5400 0.0 0
M  V30 16 C 13.3370 3.0800 0.0 0
M  V30 17 Cl 6.6685 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13 CFG=3
M  V30 13 1 12 14
M  V30 14 2 12 15
M  V30 15 1 14 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 11)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Methyl (2S)-2-[([1,1-biphenyl]-4-ylcarbonyl)amino]-4-[[(1,1-dimethylethoxy)c...
C23H28N2O5
2682842-26-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.7800 5.3347 0.0 0
M  V30 2 N 10.0100 4.0011 0.0 0
M  V30 3 O 10.0100 6.6685 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0 CFG=2
M  V30 5 C 7.7000 5.3347 0.0 0
M  V30 6 C 7.7000 2.6674 0.0 0
M  V30 7 C 6.1600 5.3347 0.0 0
M  V30 8 O 8.4700 1.3336 0.0 0
M  V30 9 O 6.1600 2.6674 0.0 0
M  V30 10 N 5.3900 6.6685 0.0 0
M  V30 11 C 7.7000 0.0000 0.0 0
M  V30 12 C 3.8500 6.6685 0.0 0
M  V30 13 O 3.0800 8.0021 0.0 0
M  V30 14 O 3.0800 5.3347 0.0 0
M  V30 15 C 1.5400 8.0021 0.0 0
M  V30 16 C 1.5400 9.5421 0.0 0
M  V30 17 C 0.0000 8.0021 0.0 0
M  V30 18 C 1.5400 6.4621 0.0 0
M  V30 19 C 15.4000 5.3347 0.0 0
M  V30 20 C 14.6300 6.6685 0.0 0
M  V30 21 C 14.6300 4.0011 0.0 0
M  V30 22 C 13.0900 6.6685 0.0 0
M  V30 23 C 13.0900 4.0011 0.0 0
M  V30 24 C 12.3200 5.3347 0.0 0
M  V30 25 C 16.9400 5.3347 0.0 0
M  V30 26 C 17.7100 4.0011 0.0 0
M  V30 27 C 17.7100 6.6685 0.0 0
M  V30 28 C 19.2500 4.0011 0.0 0
M  V30 29 C 19.2500 6.6685 0.0 0
M  V30 30 C 20.0200 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 24
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=3
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 19 25
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 92-92-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3350-15-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2682842-26-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-23939232
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with
Antibacterial Activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yamada, Yousuke; Takashima, Hajime; Walmsley, David Lee; Ushiyama,
Fumihito; Matsuda, Yohei; Kanazawa, Harumi; Yamaguchi-Sasaki, Toru;
Tanaka-Yamamoto, Nozomi; Yamagishi, Junya; Kurimoto-Tsuruta, Risa; Ogata,
Yuya; Ohtake, Norikazu; Angove, Hayley; Baker, Lisa; Harris, Richard;
Macias, Alba; Robertson, Alan; Surgenor, Allan; Watanabe, Hayato; Nakano,
Koichiro; Mima, Masashi; Iwamoto, Kunihiko; Okada, Atsushi; Takata,
Iichiro; Hitaka, Kosuke; Tanaka, Akihiro; Fujita, Kiyoko; Sugiyama,
Hiroyuki; Hubbard, Roderick E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(23), 14805-14820

$RFMT $RIREG SCHEME292 STEP1
$RXN



  2  1
$MOL
Aminoacetaldehyde diethyl acetal
C6H15NO2
645-36-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 2.6674 0.0 0
M  V30 2 O 4.6200 2.6674 0.0 0
M  V30 3 O 2.3100 4.0011 0.0 0
M  V30 4 C 2.3100 1.3338 0.0 0
M  V30 5 C 5.3900 4.0011 0.0 0
M  V30 6 C 0.7700 4.0011 0.0 0
M  V30 7 N 3.0800 0.0000 0.0 0
M  V30 8 C 6.9300 4.0011 0.0 0
M  V30 9 C 0.0000 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-BOC-4-Chloro-L-phenylalanine
C14H18ClNO4
68090-88-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.7238 4.0012 0.0 0
M  V30 2 C 5.9538 2.6675 0.0 0 CFG=1
M  V30 3 N 4.4137 2.6675 0.0 0
M  V30 4 C 6.7238 1.3338 0.0 0
M  V30 5 C 3.6437 4.0012 0.0 0
M  V30 6 O 8.2638 1.3338 0.0 0
M  V30 7 O 5.9538 0.0000 0.0 0
M  V30 8 O 2.1037 4.0012 0.0 0
M  V30 9 O 4.4137 5.3348 0.0 0
M  V30 10 C 1.3337 5.3348 0.0 0
M  V30 11 C 0.0000 4.5648 0.0 0
M  V30 12 C 0.5637 6.6687 0.0 0
M  V30 13 C 2.6673 6.1048 0.0 0
M  V30 14 Cl 12.8839 4.0012 0.0 0
M  V30 15 C 8.2638 4.0012 0.0 0
M  V30 16 C 9.0338 5.3348 0.0 0
M  V30 17 C 9.0338 2.6675 0.0 0
M  V30 18 C 10.5739 5.3348 0.0 0
M  V30 19 C 10.5739 2.6675 0.0 0
M  V30 20 C 11.3439 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3 CFG=1
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 20
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[(1S)-1-[(4-chlorophenyl)methyl]-2-[(2,2-diethoxyethyl)am...
C20H31ClN2O5
2088455-53-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 6.6684 0.0 0 CFG=2
M  V30 2 C 5.3900 5.3347 0.0 0
M  V30 3 C 7.7000 6.6684 0.0 0
M  V30 4 N 5.3900 8.0020 0.0 0
M  V30 5 N 8.4700 8.0020 0.0 0
M  V30 6 O 8.4700 5.3347 0.0 0
M  V30 7 C 3.8500 8.0020 0.0 0
M  V30 8 C 10.0100 8.0020 0.0 0
M  V30 9 O 3.0800 9.3358 0.0 0
M  V30 10 O 3.0800 6.6684 0.0 0
M  V30 11 C 10.7800 9.3358 0.0 0
M  V30 12 C 1.5400 9.3358 0.0 0
M  V30 13 O 10.0100 10.6694 0.0 0
M  V30 14 O 12.3200 9.3358 0.0 0
M  V30 15 C 1.5400 7.7958 0.0 0
M  V30 16 C 0.0000 9.3358 0.0 0
M  V30 17 C 1.5400 10.8758 0.0 0
M  V30 18 C 10.7800 12.0031 0.0 0
M  V30 19 C 13.0900 8.0020 0.0 0
M  V30 20 C 10.0100 13.3367 0.0 0
M  V30 21 C 14.6300 8.0020 0.0 0
M  V30 22 Cl 8.4700 0.0000 0.0 0
M  V30 23 C 6.1600 4.0009 0.0 0
M  V30 24 C 7.7000 4.0009 0.0 0
M  V30 25 C 5.3900 2.6673 0.0 0
M  V30 26 C 8.4700 2.6673 0.0 0
M  V30 27 C 6.1600 1.3336 0.0 0
M  V30 28 C 7.7000 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 23
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 12 15
M  V30 16 1 12 16
M  V30 17 1 12 17
M  V30 18 1 13 18
M  V30 19 1 14 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 22 28
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 2 25 27
M  V30 27 2 26 28
M  V30 28 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 645-36-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 68090-88-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2088455-53-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23761770
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential
New Therapeutics for Idiopathic Pulmonary Fibrosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Koralewski, Robert; Dymek, Barbara; Mazur, Marzena; Sklepkiewicz, Piotr;
Olejniczak, Sylwia; Czestkowski, Wojciech; Matyszewski, Krzysztof;
Andryianau, Gleb; Niedziejko, Piotr; Kowalski, Michal; Gruza, Mariusz;
Borek, Bartlomiej; Jedrzejczak, Karol; Bartoszewicz, Agnieszka; Pluta,
Elzbieta; Rymaszewska, Aleksandra; Kania, Magdalena; Rejczak, Tomasz;
Piasecka, Sylwia; Mlacki, Michal; Mazurkiewicz, Marcin; Piotrowicz,
Michal; Salamon, Magdalena; Zagozdzon, Agnieszka; Napiorkowska-Gromadzka,
Agnieszka; Bartlomiejczak, Aneta; Mozga, Witold; Dobrzanski, Pawel;
Dzwonek, Karolina; Golab, Jakub; Nowotny, Marcin; Olczak, Jacek;
Golebiowski, Adam
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(24), 15527-15540

$RFMT $RIREG SCHEME293 STEP1
$RXN



  2  1
$MOL
2-Methoxyethylamine
C3H9NO
109-85-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0.7700 0.0 0
M  V30 2 C 1.3338 0.0000 0.0 0
M  V30 3 O 4.0010 0.0000 0.0 0
M  V30 4 N 0.0000 0.7700 0.0 0
M  V30 5 C 5.3348 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-[[(4-Chloro-3-hydroxyphenyl)amino]methyl]-5-iodobenzoic acid
C14H11ClINO3
2867540-40-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 5.3348 3.8501 0.0 0
M  V30 3 C 12.0033 4.6201 0.0 0
M  V30 4 O 12.0033 6.1601 0.0 0
M  V30 5 O 13.3370 3.8501 0.0 0
M  V30 6 I 9.3360 0.0000 0.0 0
M  V30 7 O 0.0000 3.8501 0.0 0
M  V30 8 Cl 0.0000 6.9302 0.0 0
M  V30 9 C 8.0022 3.8501 0.0 0
M  V30 10 C 9.3360 4.6201 0.0 0
M  V30 11 C 8.0022 2.3101 0.0 0
M  V30 12 C 10.6697 3.8501 0.0 0
M  V30 13 C 9.3360 1.5400 0.0 0
M  V30 14 C 10.6697 2.3101 0.0 0
M  V30 15 C 4.0010 4.6201 0.0 0
M  V30 16 C 2.6673 3.8501 0.0 0
M  V30 17 C 4.0010 6.1601 0.0 0
M  V30 18 C 1.3337 4.6201 0.0 0
M  V30 19 C 2.6673 6.9302 0.0 0
M  V30 20 C 1.3337 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 15
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 3 12
M  V30 7 1 6 13
M  V30 8 1 7 18
M  V30 9 1 8 20
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-[[(4-Chloro-3-hydroxyphenyl)amino]methyl]-5-iodo-N-(2-methoxyethyl)benzamide
C17H18ClIN2O3
2867540-41-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 12.0035 4.6201 0.0 0
M  V30 2 N 13.3372 3.8501 0.0 0
M  V30 3 O 12.0035 6.1601 0.0 0
M  V30 4 C 14.6708 4.6201 0.0 0
M  V30 5 C 16.0045 3.8501 0.0 0
M  V30 6 O 17.3383 4.6201 0.0 0
M  V30 7 C 18.6720 3.8501 0.0 0
M  V30 8 C 6.6685 4.6201 0.0 0
M  V30 9 N 5.3348 3.8501 0.0 0
M  V30 10 I 9.3360 0.0000 0.0 0
M  V30 11 O 0.0000 3.8501 0.0 0
M  V30 12 Cl 0.0000 6.9302 0.0 0
M  V30 13 C 10.6697 3.8501 0.0 0
M  V30 14 C 9.3360 4.6201 0.0 0
M  V30 15 C 10.6697 2.3101 0.0 0
M  V30 16 C 8.0023 3.8501 0.0 0
M  V30 17 C 9.3360 1.5400 0.0 0
M  V30 18 C 8.0023 2.3101 0.0 0
M  V30 19 C 4.0012 4.6201 0.0 0
M  V30 20 C 2.6675 3.8501 0.0 0
M  V30 21 C 4.0012 6.1601 0.0 0
M  V30 22 C 1.3337 4.6201 0.0 0
M  V30 23 C 2.6675 6.9302 0.0 0
M  V30 24 C 1.3337 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 8 9
M  V30 9 1 8 16
M  V30 10 1 9 19
M  V30 11 1 10 17
M  V30 12 1 11 22
M  V30 13 1 12 24
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 109-85-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2867540-40-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2867540-41-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35191378
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM incremental addition of 2-methoxyethylamine after 30 minutes
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM DNA-Encoded Library Hit Confirmation: Bridging the Gap Between On-DNA and
Off-DNA Chemistry
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Xia, Bing; Franklin, G. Joseph; Lu, Xiaojie; Bedard, Katie L.; Grady,
LaShadric C.; Summerfield, Jennifer D.; Shi, Eric X.; King, Bryan W.;
Lind, Kenneth E.; Chiu, Cynthia; Watts, Eleanor; Bodmer, Vera; Bai,
Xiaopeng; Marcaurelle, Lisa A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2021), 12(7), 1166-1172

$RFMT $RIREG SCHEME294 STEP1
$RXN



  2  1
$MOL
4-(Trifluoroacetylamino)benzoic acid
C9H6F3NO3
404-26-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.8736 0.0 0
M  V30 2 C 7.7000 1.5400 0.0 0
M  V30 3 C 9.2400 1.5400 0.0 0
M  V30 4 O 6.9300 0.2062 0.0 0
M  V30 5 F 9.2400 0.0000 0.0 0
M  V30 6 F 10.7800 1.5400 0.0 0
M  V30 7 F 9.2400 3.0800 0.0 0
M  V30 8 C 0.7700 2.8736 0.0 0
M  V30 9 O 0.0000 1.5400 0.0 0
M  V30 10 O 0.0000 4.2073 0.0 0
M  V30 11 C 5.3900 2.8736 0.0 0
M  V30 12 C 4.6200 1.5400 0.0 0
M  V30 13 C 4.6200 4.2073 0.0 0
M  V30 14 C 3.0800 1.5400 0.0 0
M  V30 15 C 3.0800 4.2073 0.0 0
M  V30 16 C 2.3100 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 3 6
M  V30 7 1 3 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 16
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluoro-3-nitroaniline
C6H5FN2O2
364-76-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3338 1.5400 0.0 0 VAL=5
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 F 1.3338 4.6201 0.0 0
M  V30 5 N 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzamide, N-(4-fluoro-3-nitrophenyl)-4-[(2,2,2-trifluoroacetyl)amino]-
C15H9F4N3O4
3033385-12-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6687 3.6437 0.0 0
M  V30 2 C 8.0023 4.4137 0.0 0
M  V30 3 O 8.0023 5.9538 0.0 0
M  V30 4 N 1.3338 3.6437 0.0 0 VAL=5
M  V30 5 O 1.3338 2.1037 0.0 0
M  V30 6 O 0.0000 4.4137 0.0 0
M  V30 7 F 1.3338 6.7238 0.0 0
M  V30 8 N 13.3372 1.3337 0.0 0
M  V30 9 C 14.6708 2.1037 0.0 0
M  V30 10 C 16.0045 1.3337 0.0 0
M  V30 11 O 14.6708 3.6437 0.0 0
M  V30 12 F 16.7745 2.6673 0.0 0
M  V30 13 F 17.3383 0.5637 0.0 0
M  V30 14 F 15.2345 0.0000 0.0 0
M  V30 15 C 5.3348 4.4137 0.0 0
M  V30 16 C 4.0012 3.6437 0.0 0
M  V30 17 C 5.3348 5.9538 0.0 0
M  V30 18 C 2.6675 4.4137 0.0 0
M  V30 19 C 4.0012 6.7238 0.0 0
M  V30 20 C 2.6675 5.9538 0.0 0
M  V30 21 C 9.3360 3.6437 0.0 0
M  V30 22 C 10.6697 4.4137 0.0 0
M  V30 23 C 9.3360 2.1037 0.0 0
M  V30 24 C 12.0035 3.6437 0.0 0
M  V30 25 C 10.6697 1.3337 0.0 0
M  V30 26 C 12.0035 2.1037 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 2 2 3
M  V30 4 1 2 21
M  V30 5 2 4 5
M  V30 6 2 4 6
M  V30 7 1 4 18
M  V30 8 1 7 20
M  V30 9 1 8 9
M  V30 10 1 8 26
M  V30 11 1 9 10
M  V30 12 2 9 11
M  V30 13 1 10 12
M  V30 14 1 10 13
M  V30 15 1 10 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 25
M  V30 26 2 24 26
M  V30 27 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 404-26-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 364-76-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3033385-12-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38259318
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Insight from Linker Investigations: Discovery of a Novel
Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting
Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual
RIPK1/3 Targeting Activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Jing-jie; Yao, Hou-Zong; Zhuang, Chunlin; Chen, Fen-Er
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(22), 15288-15308

$RFMT $RIREG SCHEME295 STEP1
$RXN



  2  1
$MOL
Boc-L-alanine
C8H15NO4
15761-38-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0 CFG=1
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 8.0023 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 1.3337 2.3101 0.0 0
M  V30 9 O 8.0023 0.0000 0.0 0
M  V30 10 O 9.3360 2.3101 0.0 0
M  V30 11 C 0.5637 0.9764 0.0 0
M  V30 12 C 0.0000 3.0801 0.0 0
M  V30 13 C 2.1037 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7 CFG=1
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
O-Methyl-L-tyrosine methyl ester
C11H15NO3
17355-19-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 1.5400 0.0 0
M  V30 2 C 8.0022 2.3101 0.0 0 CFG=2
M  V30 3 C 9.3360 1.5400 0.0 0
M  V30 4 N 8.0022 3.8501 0.0 0
M  V30 5 O 10.6697 2.3101 0.0 0
M  V30 6 O 9.3360 0.0000 0.0 0
M  V30 7 C 12.0033 1.5400 0.0 0
M  V30 8 O 1.3337 4.6201 0.0 0
M  V30 9 C 0.0000 3.8501 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 12 C 4.0012 1.5400 0.0 0
M  V30 13 C 4.0012 4.6201 0.0 0
M  V30 14 C 2.6673 2.3101 0.0 0
M  V30 15 C 2.6673 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 9
M  V30 9 1 8 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-alanyl-O-methyl-L-tyrosine methyl ester
C19H28N2O6
1263359-83-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.7800 5.3347 0.0 0
M  V30 2 C 10.0100 4.0011 0.0 0 CFG=1
M  V30 3 N 8.4700 4.0011 0.0 0
M  V30 4 C 10.7800 2.6674 0.0 0
M  V30 5 C 7.7000 5.3347 0.0 0
M  V30 6 O 10.0100 1.3336 0.0 0
M  V30 7 O 12.3200 2.6674 0.0 0
M  V30 8 C 6.1600 5.3347 0.0 0 CFG=2
M  V30 9 O 8.4700 6.6685 0.0 0
M  V30 10 C 10.7800 0.0000 0.0 0
M  V30 11 N 5.3900 6.6685 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 3.8500 6.6685 0.0 0
M  V30 14 O 3.0800 8.0021 0.0 0
M  V30 15 O 3.0800 5.3347 0.0 0
M  V30 16 C 1.5400 8.0021 0.0 0
M  V30 17 C 1.5400 6.4621 0.0 0
M  V30 18 C 0.0000 8.0021 0.0 0
M  V30 19 C 1.5400 9.5421 0.0 0
M  V30 20 O 16.9400 5.3347 0.0 0
M  V30 21 C 17.7100 6.6685 0.0 0
M  V30 22 C 12.3200 5.3347 0.0 0
M  V30 23 C 13.0900 6.6685 0.0 0
M  V30 24 C 13.0900 4.0011 0.0 0
M  V30 25 C 14.6300 6.6685 0.0 0
M  V30 26 C 14.6300 4.0011 0.0 0
M  V30 27 C 15.4000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 1 22
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=3
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 16 19
M  V30 20 1 20 21
M  V30 21 1 20 27
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 15761-38-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 17355-19-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1263359-83-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41063829
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):NOTES
$DATUM alternate reaction conditions also shown
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A new class of -ketoamide derivatives with potent anticancer and
anti-SARS-CoV-2 activities
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Juan; Liang, Boqiang; Chen, Yiling; Fuk-Woo Chan, Jasper; Yuan,
Shuofeng; Ye, Hui; Nie, Linlin; Zhou, Jiao; Wu, Yi; Wu, Meixian; Huang,
Lina S.; An, Jing; Warshel, Arieh; Yuen, Kwok-Yung; Ciechanover, Aaron;
Huang, Ziwei; Xu, Yan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 215113267

$RFMT $RIREG SCHEME296 STEP1
$RXN



  2  1
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(3,5)-3-(Acetyloxy)cholan-24-oic acid
C26H42O4
4057-84-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.8305 6.9215 0.0 0
M  V30 2 C 13.4678 6.6359 0.0 0 CFG=2
M  V30 3 C 13.4678 8.1759 0.0 0
M  V30 4 C 14.8014 5.8659 0.0 0
M  V30 5 C 14.8014 8.9459 0.0 0
M  V30 6 C 14.8014 10.4859 0.0 0
M  V30 7 O 16.1352 11.2559 0.0 0
M  V30 8 O 13.4678 11.2559 0.0 0
M  V30 9 C 6.0176 4.4757 0.0 0
M  V30 10 O 2.6674 0.7700 0.0 0
M  V30 11 C 1.3338 1.5400 0.0 0
M  V30 12 C 0.0000 0.7700 0.0 0
M  V30 13 O 1.3338 3.0800 0.0 0
M  V30 14 C 10.6695 3.8500 0.0 0 CFG=2
M  V30 15 C 9.3358 3.0800 0.0 0 CFG=2
M  V30 16 C 10.6695 5.3900 0.0 0 CFG=1
M  V30 17 C 12.1342 3.3741 0.0 0
M  V30 18 C 8.0022 3.8500 0.0 0 CFG=2
M  V30 19 C 9.3358 1.5400 0.0 0
M  V30 20 C 12.1342 5.8659 0.0 0 CFG=1
M  V30 21 C 9.3358 6.1600 0.0 0
M  V30 22 C 13.0394 4.6200 0.0 0
M  V30 23 C 6.6685 3.0800 0.0 0 CFG=2
M  V30 24 C 8.0022 5.3900 0.0 0
M  V30 25 C 8.0022 0.7700 0.0 0
M  V30 26 C 6.6685 1.5400 0.0 0 CFG=1
M  V30 27 C 5.3347 3.8500 0.0 0
M  V30 28 C 5.3347 0.7700 0.0 0
M  V30 29 C 4.0011 3.0800 0.0 0
M  V30 30 C 4.0011 1.5400 0.0 0 CFG=2
M  V30 31 H 11.4627 2.5299 0.0 0
M  V30 32 H 10.2192 1.8184 0.0 0
M  V30 33 H 7.1188 5.1114 0.0 0
M  V30 34 H 11.5078 7.2728 0.0 0
M  V30 35 H 6.6685 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 16 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 2 4 CFG=1
M  V30 4 1 2 20
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 23 9 CFG=1
M  V30 10 1 10 11
M  V30 11 1 30 10 CFG=3
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 14 31 CFG=3
M  V30 18 1 15 18
M  V30 19 1 15 19
M  V30 20 1 15 32 CFG=1
M  V30 21 1 16 20
M  V30 22 1 16 21
M  V30 23 1 17 22
M  V30 24 1 18 23
M  V30 25 1 18 24
M  V30 26 1 18 33 CFG=3
M  V30 27 1 19 25
M  V30 28 1 20 22
M  V30 29 1 20 34 CFG=3
M  V30 30 1 21 24
M  V30 31 1 23 26
M  V30 32 1 23 27
M  V30 33 1 25 26
M  V30 34 1 26 28
M  V30 35 1 26 35 CFG=1
M  V30 36 1 27 29
M  V30 37 1 28 30
M  V30 38 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(9 2 14 15 16 18 20 23 26 30)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(3,5)-3-(Acetyloxy)-N-2-propyn-1-ylcholan-24-amide
C29H45NO3
1801369-46-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  38 41 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.8305 6.9216 0.0 0
M  V30 2 C 13.4679 6.6359 0.0 0 CFG=2
M  V30 3 C 13.4679 8.1759 0.0 0
M  V30 4 C 14.8015 5.8659 0.0 0
M  V30 5 C 14.8015 8.9459 0.0 0
M  V30 6 C 14.8015 10.4860 0.0 0
M  V30 7 N 16.1352 11.2560 0.0 0
M  V30 8 O 13.4679 11.2560 0.0 0
M  V30 9 C 16.1352 12.7960 0.0 0
M  V30 10 C 17.4690 13.5660 0.0 0
M  V30 11 C 18.8027 14.3360 0.0 0
M  V30 12 C 6.2699 4.5675 0.0 0
M  V30 13 O 2.6675 0.7700 0.0 0
M  V30 14 C 1.3337 1.5400 0.0 0
M  V30 15 C 0.0000 0.7700 0.0 0
M  V30 16 O 1.3337 3.0800 0.0 0
M  V30 17 C 10.6695 3.8500 0.0 0 CFG=2
M  V30 18 C 9.3359 3.0800 0.0 0 CFG=2
M  V30 19 C 10.6695 5.3901 0.0 0 CFG=1
M  V30 20 C 12.1342 3.3742 0.0 0
M  V30 21 C 8.0022 3.8500 0.0 0 CFG=2
M  V30 22 C 9.3359 1.5400 0.0 0
M  V30 23 C 12.1342 5.8659 0.0 0 CFG=1
M  V30 24 C 9.3359 6.1601 0.0 0
M  V30 25 C 13.0395 4.6200 0.0 0
M  V30 26 C 6.6684 3.0800 0.0 0 CFG=2
M  V30 27 C 8.0022 5.3901 0.0 0
M  V30 28 C 8.0022 0.7700 0.0 0
M  V30 29 C 6.6684 1.5400 0.0 0 CFG=1
M  V30 30 C 5.3348 3.8500 0.0 0
M  V30 31 C 5.3348 0.7700 0.0 0
M  V30 32 C 4.0011 3.0800 0.0 0
M  V30 33 C 4.0011 1.5400 0.0 0 CFG=2
M  V30 34 H 11.2215 2.4123 0.0 0
M  V30 35 H 10.4248 1.9911 0.0 0
M  V30 36 H 7.1189 5.1115 0.0 0
M  V30 37 H 11.5078 7.2729 0.0 0
M  V30 38 H 6.6684 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 19 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 2 4 CFG=1
M  V30 4 1 2 23
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 3 10 11
M  V30 12 1 26 12 CFG=1
M  V30 13 1 13 14
M  V30 14 1 33 13 CFG=3
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 17 20
M  V30 20 1 17 34 CFG=3
M  V30 21 1 18 21
M  V30 22 1 18 22
M  V30 23 1 18 35 CFG=1
M  V30 24 1 19 23
M  V30 25 1 19 24
M  V30 26 1 20 25
M  V30 27 1 21 26
M  V30 28 1 21 27
M  V30 29 1 21 36 CFG=3
M  V30 30 1 22 28
M  V30 31 1 23 25
M  V30 32 1 23 37 CFG=3
M  V30 33 1 24 27
M  V30 34 1 26 29
M  V30 35 1 26 30
M  V30 36 1 28 29
M  V30 37 1 29 31
M  V30 38 1 29 38 CFG=1
M  V30 39 1 30 32
M  V30 40 1 31 33
M  V30 41 1 32 33
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(9 2 17 18 19 21 23 26 29 33)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4057-84-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1801369-46-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44299839
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV-2
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chhabra, Mohit; Shanthamurthy, Chethan D.; Kumar, Nanjudaswamy Vijendra;
Mardhekar, Sandhya; Vishweshwara, Sharath S.; Wimmer, Norbert; Modhiran,
Naphak; Watterson, Daniel; Amarilla, Alberto A.; Cha, Jonathan S.;
Beckett, James R.; De Voss, James J.; Kayal, Yasmin; Vlodavsky, Israel;
Dorsett, Lauren R.; Smith, Raymond A. A.; Gandhi, Neha S.; Kikkeri,
Raghavendra; Ferro, Vito
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(14), 11885-11916

$RFMT $RIREG SCHEME297 STEP1
$RXN



  2  1
$MOL

C23H28N2O3
2965359-39-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 5.3901 0.0 0
M  V30 2 C 2.6675 4.6201 0.0 0
M  V30 3 C 4.0012 6.9302 0.0 0
M  V30 4 C 5.3348 4.6201 0.0 0
M  V30 5 C 6.6687 5.3901 0.0 0
M  V30 6 O 5.3348 3.0801 0.0 0
M  V30 7 C 8.0023 4.6201 0.0 0
M  V30 8 C 9.3360 5.3901 0.0 0
M  V30 9 N 10.6698 4.6201 0.0 0
M  V30 10 C 12.0035 5.3901 0.0 0
M  V30 11 O 13.3372 4.6201 0.0 0
M  V30 12 O 12.0035 6.9302 0.0 0
M  V30 13 C 14.6708 5.3901 0.0 0
M  V30 14 C 13.9008 6.7238 0.0 0
M  V30 15 C 16.0046 6.1601 0.0 0
M  V30 16 C 15.4408 4.0564 0.0 0
M  V30 17 C 2.6675 3.0801 0.0 0
M  V30 18 C 1.3338 2.3101 0.0 0
M  V30 19 C 4.0012 2.3101 0.0 0
M  V30 20 C 1.3338 0.7700 0.0 0
M  V30 21 C 4.0012 0.7700 0.0 0
M  V30 22 C 2.6675 0.0000 0.0 0
M  V30 23 C 2.6675 7.7002 0.0 0
M  V30 24 C 2.6675 9.2402 0.0 0
M  V30 25 C 1.3338 6.9302 0.0 0
M  V30 26 C 1.3338 10.0102 0.0 0
M  V30 27 C 0.0000 7.7002 0.0 0
M  V30 28 C 0.0000 9.2402 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 17
M  V30 5 1 3 23
M  V30 6 1 4 5
M  V30 7 2 4 6
M  V30 8 2 5 7
M  V30 9 1 7 8
M  V30 10 1 8 9
M  V30 11 1 9 10
M  V30 12 1 10 11
M  V30 13 2 10 12
M  V30 14 1 11 13
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 1 13 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 2 25 27
M  V30 28 2 26 28
M  V30 29 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
BOC-L-leucine
C11H21NO4
13139-15-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8501 0.0 0 CFG=2
M  V30 2 N 4.0012 4.6201 0.0 0
M  V30 3 C 2.6675 2.3101 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8501 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 O 0.0000 3.8501 0.0 0
M  V30 8 O 1.3337 6.1601 0.0 0
M  V30 9 O 6.6685 4.6201 0.0 0
M  V30 10 O 5.3348 2.3101 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 2.3101 0.0 0
M  V30 13 C 8.0023 3.8501 0.0 0
M  V30 14 C 7.2323 2.5164 0.0 0
M  V30 15 C 9.3360 3.0801 0.0 0
M  V30 16 C 8.7723 5.1838 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 6 12
M  V30 12 1 9 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C29H39N3O4
2965359-40-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  36 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3900 8.0020 0.0 0
M  V30 2 C 4.6200 6.6684 0.0 0
M  V30 3 C 4.6200 9.3358 0.0 0
M  V30 4 C 6.9300 8.0020 0.0 0
M  V30 5 C 7.7000 6.6684 0.0 0
M  V30 6 O 7.7000 9.3358 0.0 0
M  V30 7 C 9.2400 6.6684 0.0 0
M  V30 8 C 10.0100 5.3347 0.0 0
M  V30 9 N 11.5500 5.3347 0.0 0
M  V30 10 C 12.3200 4.0009 0.0 0
M  V30 11 C 13.8600 4.0009 0.0 0 CFG=2
M  V30 12 O 11.5500 2.6673 0.0 0
M  V30 13 N 14.6300 5.3347 0.0 0
M  V30 14 C 14.6300 2.6673 0.0 0
M  V30 15 C 16.1700 5.3347 0.0 0
M  V30 16 C 13.8600 1.3336 0.0 0
M  V30 17 O 16.9400 6.6684 0.0 0
M  V30 18 O 16.9400 4.0009 0.0 0
M  V30 19 C 14.6300 0.0000 0.0 0
M  V30 20 C 12.3200 1.3336 0.0 0
M  V30 21 C 18.4800 6.6684 0.0 0
M  V30 22 C 18.4800 8.2084 0.0 0
M  V30 23 C 20.0200 6.6684 0.0 0
M  V30 24 C 18.4800 5.1284 0.0 0
M  V30 25 C 3.0800 6.6684 0.0 0
M  V30 26 C 2.3100 8.0020 0.0 0
M  V30 27 C 2.3100 5.3347 0.0 0
M  V30 28 C 0.7700 8.0020 0.0 0
M  V30 29 C 0.7700 5.3347 0.0 0
M  V30 30 C 0.0000 6.6684 0.0 0
M  V30 31 C 5.3900 10.6694 0.0 0
M  V30 32 C 4.6200 12.0031 0.0 0
M  V30 33 C 6.9300 10.6694 0.0 0
M  V30 34 C 5.3900 13.3367 0.0 0
M  V30 35 C 7.7000 12.0031 0.0 0
M  V30 36 C 6.9300 13.3367 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 25
M  V30 5 1 3 31
M  V30 6 1 4 5
M  V30 7 2 4 6
M  V30 8 2 5 7
M  V30 9 1 7 8
M  V30 10 1 8 9
M  V30 11 1 9 10
M  V30 12 1 10 11
M  V30 13 2 10 12
M  V30 14 1 11 13
M  V30 15 1 11 14 CFG=1
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 15 18
M  V30 20 1 16 19
M  V30 21 1 16 20
M  V30 22 1 17 21
M  V30 23 1 21 22
M  V30 24 1 21 23
M  V30 25 1 21 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 32 2 31 32
M  V30 33 1 31 33
M  V30 34 1 32 34
M  V30 35 2 33 35
M  V30 36 2 34 36
M  V30 37 1 35 36
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 11)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2965359-39-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13139-15-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2965359-40-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34955247
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 76-05-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM stage 2 and stage 3 combined at room temperature for 16 hours (stage 3)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM An Activity-Based Probe for Cathepsin K Imaging with Excellent Potency
and Selectivity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Lemke, Carina; Benysek, Jakub; Brajtenbach, Dominik; Breuer, Christian;
Jilkova, Adela; Horn, Martin; Busa, Michal; Ulrychova, Lenka; Illies,
Annika; Kubatzky, Katharina F.; Bartz, Ulrike; Mares, Michael; Guetschow,
Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(18), 13793-13806

$RFMT $RIREG SCHEME298 STEP1
$RXN



  2  1
$MOL
Phenylmethyl (4R)-5-amino-4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentan...
C17H24N2O5
19238-66-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 11.3436 6.6685 0.0 0
M  V30 2 O 10.5736 5.3347 0.0 0
M  V30 3 C 9.0336 5.3347 0.0 0
M  V30 4 C 8.2636 4.0011 0.0 0
M  V30 5 O 8.2636 6.6685 0.0 0
M  V30 6 C 6.7236 4.0011 0.0 0
M  V30 7 C 5.9536 2.6674 0.0 0 CFG=2
M  V30 8 N 4.4136 2.6674 0.0 0
M  V30 9 C 6.7236 1.3336 0.0 0
M  V30 10 C 3.6436 4.0011 0.0 0
M  V30 11 N 8.2636 1.3336 0.0 0
M  V30 12 O 5.9536 0.0000 0.0 0
M  V30 13 O 2.1036 4.0011 0.0 0
M  V30 14 O 4.4136 5.3347 0.0 0
M  V30 15 C 1.3336 5.3347 0.0 0
M  V30 16 C 2.6673 6.1047 0.0 0
M  V30 17 C 0.5636 6.6685 0.0 0
M  V30 18 C 0.0000 4.5647 0.0 0
M  V30 19 C 12.8836 6.6685 0.0 0
M  V30 20 C 13.6536 5.3347 0.0 0
M  V30 21 C 13.6536 8.0021 0.0 0
M  V30 22 C 15.1936 5.3347 0.0 0
M  V30 23 C 15.1936 8.0021 0.0 0
M  V30 24 C 15.9636 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8 CFG=3
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 10 13
M  V30 14 2 10 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 23
M  V30 23 2 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 7)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Boc-L-alanine
C8H15NO4
15761-38-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0 CFG=1
M  V30 4 O 2.6675 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 8.0023 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 1.3337 2.3101 0.0 0
M  V30 9 O 8.0023 0.0000 0.0 0
M  V30 10 O 9.3360 2.3101 0.0 0
M  V30 11 C 0.5637 0.9764 0.0 0
M  V30 12 C 0.0000 3.0801 0.0 0
M  V30 13 C 2.1037 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7 CFG=1
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 1 8 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-alanyl-D--glutamine phenylmethyl ester
C20H29N3O6
18814-49-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 15.4000 6.6685 0.0 0
M  V30 2 O 14.6300 5.3347 0.0 0
M  V30 3 C 13.0900 5.3347 0.0 0
M  V30 4 C 12.3200 4.0011 0.0 0
M  V30 5 O 12.3200 6.6685 0.0 0
M  V30 6 C 10.7800 4.0011 0.0 0
M  V30 7 C 10.0100 2.6674 0.0 0 CFG=2
M  V30 8 N 8.4700 2.6674 0.0 0
M  V30 9 C 10.7800 1.3338 0.0 0
M  V30 10 C 7.7000 4.0011 0.0 0
M  V30 11 N 12.3200 1.3338 0.0 0
M  V30 12 O 10.0100 0.0000 0.0 0
M  V30 13 C 6.1600 4.0011 0.0 0 CFG=2
M  V30 14 O 8.4700 5.3347 0.0 0
M  V30 15 N 5.3900 5.3347 0.0 0
M  V30 16 C 5.3900 2.6674 0.0 0
M  V30 17 C 3.8500 5.3347 0.0 0
M  V30 18 O 3.0800 6.6685 0.0 0
M  V30 19 O 3.0800 4.0011 0.0 0
M  V30 20 C 1.5400 6.6685 0.0 0
M  V30 21 C 1.5400 8.2085 0.0 0
M  V30 22 C 0.0000 6.6685 0.0 0
M  V30 23 C 1.5400 5.1285 0.0 0
M  V30 24 C 16.9400 6.6685 0.0 0
M  V30 25 C 17.7100 8.0021 0.0 0
M  V30 26 C 17.7100 5.3347 0.0 0
M  V30 27 C 19.2500 8.0021 0.0 0
M  V30 28 C 19.2500 5.3347 0.0 0
M  V30 29 C 20.0200 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 24
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 7 6 CFG=3
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 10 13
M  V30 14 2 10 14
M  V30 15 1 13 15
M  V30 16 1 13 16 CFG=3
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 1 20 23
M  V30 24 2 24 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 2 26 28
M  V30 28 2 27 29
M  V30 29 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 7 13)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19238-66-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 15761-38-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 18814-49-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44479962
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 76-05-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):NOTES
$DATUM intermediate from stage 1 added in stage 3 (stage 3)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel lipophilic 2,
5-disubstituted tetrazole analogues of muramyl dipeptide as NOD2 agonists
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Mhamane, Tukaram B.; Sambyal, Shainy; Vemireddy, Sravanthi; Paturu, Rama
Subba Reddy; Katragadda, Suresh Babu; Syed, Shafi; Khan, Arif; Halmuthur
M., Sampath Kumar
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2023), 88-89117296

$RFMT $RIREG SCHEME299 STEP1
$RXN



  2  1
$MOL
3,5-Dimethylaniline
C8H11N
108-69-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 4.6200 0.0 0
M  V30 2 C 5.3349 4.6200 0.0 0
M  V30 3 N 2.6674 0.0000 0.0 0
M  V30 4 C 2.6674 4.6200 0.0 0
M  V30 5 C 1.3338 3.8500 0.0 0
M  V30 6 C 4.0011 3.8500 0.0 0
M  V30 7 C 1.3338 2.3100 0.0 0
M  V30 8 C 4.0011 2.3100 0.0 0
M  V30 9 C 2.6674 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 5
M  V30 2 1 2 6
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
BOC-L-Proline
C10H17NO4
15761-39-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.5254 2.6218 0.0 0
M  V30 2 O 5.8592 1.8517 0.0 0
M  V30 3 O 4.5254 4.1618 0.0 0
M  V30 4 C 7.1929 2.6218 0.0 0
M  V30 5 C 6.4229 3.9554 0.0 0
M  V30 6 C 8.5266 3.3918 0.0 0
M  V30 7 C 7.9629 1.2881 0.0 0
M  V30 8 C 1.4646 3.9845 0.0 0
M  V30 9 O 2.6091 5.0150 0.0 0
M  V30 10 O 0.0000 4.4604 0.0 0
M  V30 11 N 3.1917 1.8517 0.0 0
M  V30 12 C 1.7849 2.4781 0.0 0 CFG=2
M  V30 13 C 3.0308 0.3202 0.0 0
M  V30 14 C 0.7543 1.3337 0.0 0
M  V30 15 C 1.5243 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 12 8 CFG=1
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 12)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl (2S)-2-[[(3,5-dimethylphenyl)amino]carbonyl]-1-pyrrolidinec...
C18H26N2O3
137496-70-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.0132 5.3348 0.0 0
M  V30 2 N 8.5532 5.3348 0.0 0
M  V30 3 O 6.2432 4.0011 0.0 0
M  V30 4 C 3.6812 5.6850 0.0 0
M  V30 5 O 2.1748 6.0051 0.0 0
M  V30 6 O 4.1571 4.2204 0.0 0
M  V30 7 C 1.1444 4.8607 0.0 0
M  V30 8 C 0.0000 5.8912 0.0 0
M  V30 9 C 0.1140 3.7162 0.0 0
M  V30 10 C 2.2889 3.8302 0.0 0
M  V30 11 C 8.5532 0.0000 0.0 0
M  V30 12 C 13.1733 2.6673 0.0 0
M  V30 13 C 6.2432 6.6684 0.0 0 CFG=2
M  V30 14 N 4.7117 6.8295 0.0 0
M  V30 15 C 6.8697 8.0754 0.0 0
M  V30 16 C 4.3915 8.3358 0.0 0
M  V30 17 C 5.7251 9.1058 0.0 0
M  V30 18 C 9.3232 4.0011 0.0 0
M  V30 19 C 8.5532 2.6673 0.0 0
M  V30 20 C 10.8632 4.0011 0.0 0
M  V30 21 C 9.3232 1.3336 0.0 0
M  V30 22 C 11.6332 2.6673 0.0 0
M  V30 23 C 10.8632 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 13 1 CFG=1
M  V30 4 1 2 18
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 14
M  V30 8 1 5 7
M  V30 9 1 7 8
M  V30 10 1 7 9
M  V30 11 1 7 10
M  V30 12 1 11 21
M  V30 13 1 12 22
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 13)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 108-69-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 15761-39-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 137496-70-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-29435454
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 2135447-74-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM sealed flask used, multi-gram scale
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Insights into Fast Amide Couplings in Aqueous Nanomicelles
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sharma, Sudripet; Kaur, Gaganpreet; Handa, Sachin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(8), 1960-1965

$RFMT $RIREG SCHEME300 STEP1
$RXN



  2  1
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-O-methyl-D-serine
C9H17NO5
86123-95-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8500 0.0 0 CFG=1
M  V30 2 N 4.0011 4.6201 0.0 0
M  V30 3 C 2.6675 2.3100 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8500 0.0 0
M  V30 6 O 1.3337 1.5400 0.0 0
M  V30 7 O 1.3337 6.1601 0.0 0
M  V30 8 O 0.0000 3.8500 0.0 0
M  V30 9 O 6.6684 4.6201 0.0 0
M  V30 10 O 5.3348 2.3100 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 8.0022 3.8500 0.0 0
M  V30 13 C 8.7722 5.1837 0.0 0
M  V30 14 C 9.3359 3.0800 0.0 0
M  V30 15 C 7.2322 2.5164 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-[(5-Amino-1,3,4-thiadiazol-2-yl)methyl]benzonitrile
C10H8N4S
2159560-75-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6687 3.8501 0.0 0
M  V30 2 N 11.9713 2.7229 0.0 0
M  V30 3 C 1.3338 0.7700 0.0 0
M  V30 4 N 0.0000 0.0000 0.0 0
M  V30 5 C 8.0023 3.0801 0.0 0
M  V30 6 N 8.1633 1.5485 0.0 0
M  V30 7 S 9.4091 3.7064 0.0 0
M  V30 8 N 9.6697 1.2283 0.0 0
M  V30 9 C 10.4397 2.5620 0.0 0
M  V30 10 C 5.3348 3.0801 0.0 0
M  V30 11 C 5.3348 1.5400 0.0 0
M  V30 12 C 4.0012 3.8501 0.0 0
M  V30 13 C 4.0012 0.7700 0.0 0
M  V30 14 C 2.6675 3.0801 0.0 0
M  V30 15 C 2.6675 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 5
M  V30 2 1 1 10
M  V30 3 1 2 9
M  V30 4 3 3 4
M  V30 5 1 3 15
M  V30 6 2 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 8 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[(1R)-2-[[5-[(4-cyanophenyl)methyl]-1,3,4-thiadiazol-2-yl]am...
C19H23N5O4S
3042818-59-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 13.6258 7.0099 0.0 0
M  V30 2 N 8.4700 5.3347 0.0 0
M  V30 3 C 7.7000 4.0011 0.0 0
M  V30 4 C 6.1600 4.0011 0.0 0 CFG=1
M  V30 5 O 8.4700 2.6674 0.0 0
M  V30 6 N 5.3900 5.3347 0.0 0
M  V30 7 C 5.3900 2.6674 0.0 0
M  V30 8 C 3.8500 5.3347 0.0 0
M  V30 9 O 6.1600 1.3338 0.0 0
M  V30 10 O 3.0800 6.6685 0.0 0
M  V30 11 O 3.0800 4.0011 0.0 0
M  V30 12 C 5.3900 0.0000 0.0 0
M  V30 13 C 1.5400 6.6685 0.0 0
M  V30 14 C 1.5400 5.1285 0.0 0
M  V30 15 C 0.0000 6.6685 0.0 0
M  V30 16 C 1.5400 8.2085 0.0 0
M  V30 17 C 19.2531 4.5045 0.0 0
M  V30 18 N 20.6601 3.8780 0.0 0
M  V30 19 C 12.3798 6.1047 0.0 0
M  V30 20 S 10.9152 6.5807 0.0 0
M  V30 21 N 12.3798 4.5647 0.0 0
M  V30 22 C 10.0100 5.3347 0.0 0
M  V30 23 N 10.9152 4.0889 0.0 0
M  V30 24 C 15.0326 6.3836 0.0 0
M  V30 25 C 16.2785 7.2888 0.0 0
M  V30 26 C 15.1935 4.8521 0.0 0
M  V30 27 C 17.6854 6.6624 0.0 0
M  V30 28 C 16.6005 4.2256 0.0 0
M  V30 29 C 17.8463 5.1308 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 19
M  V30 2 1 1 24
M  V30 3 1 2 3
M  V30 4 1 2 22
M  V30 5 1 3 4
M  V30 6 2 3 5
M  V30 7 1 4 6
M  V30 8 1 4 7 CFG=1
M  V30 9 1 6 8
M  V30 10 1 7 9
M  V30 11 1 8 10
M  V30 12 2 8 11
M  V30 13 1 9 12
M  V30 14 1 10 13
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 1 13 16
M  V30 18 3 17 18
M  V30 19 1 17 29
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 23
M  V30 25 2 24 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 2 26 28
M  V30 29 2 27 29
M  V30 30 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 86123-95-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2159560-75-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3042818-59-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40576505
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and characterization of BAY-805, a potent and selective
inhibitor of ubiquitin-specific protease USP21
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Goericke, Fabian; Vu, Victoria; Smith, Leanna; Scheib, Ulrike; Boehm,
Raphael; Akkilic, Namik; Wohlfahrt, Gerd; Weiske, Joerg; Boemer, Ulf;
Brzezinka, Krzysztof; Lindner, Niels; Lienau, Philip; Gradl, Stefan;
Beck, Hartmut; Brown, Peter J.; Santhakumar, Vijayaratnam; Vedadi,
Masoud; Barsyte-Lovejoy, Dalia; Arrowsmith, Cheryl H.; Schmees, Norbert;
Petersen, Kirstin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3431-3447

$RFMT $RIREG SCHEME301 STEP1
$RXN



  2  1
$MOL
5-Phenyl-1H-pyrazole-3-carboxylic acid
C10H8N2O2
5071-61-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.2358 1.5317 0.0 0
M  V30 2 O 9.6426 2.1580 0.0 0
M  V30 3 O 8.0747 0.0000 0.0 0
M  V30 4 C 4.6200 3.2067 0.0 0
M  V30 5 C 5.5252 1.9609 0.0 0
M  V30 6 N 5.5252 4.4528 0.0 0
M  V30 7 C 6.9898 2.4367 0.0 0
M  V30 8 N 6.9898 3.9767 0.0 0
M  V30 9 C 3.0800 3.2067 0.0 0
M  V30 10 C 2.3100 4.5405 0.0 0
M  V30 11 C 2.3100 1.8731 0.0 0
M  V30 12 C 0.7700 4.5405 0.0 0
M  V30 13 C 0.7700 1.8731 0.0 0
M  V30 14 C 0.0000 3.2067 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 4 9
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 7 8
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-(1-aminoethyl)-, methyl ester, hydrochloride (1:1)
C10H13NO2.ClH
934388-45-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 6.1601 0.0 0
M  V30 2 O 8.0023 5.3901 0.0 0
M  V30 3 O 6.6685 7.7001 0.0 0
M  V30 4 C 9.3360 6.1601 0.0 0
M  V30 5 C 1.3337 3.0800 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 N 0.0000 3.8501 0.0 0
M  V30 8 C 5.3348 5.3901 0.0 0
M  V30 9 C 4.0012 6.1601 0.0 0
M  V30 10 C 5.3348 3.8501 0.0 0
M  V30 11 C 2.6675 5.3901 0.0 0
M  V30 12 C 4.0012 3.0800 0.0 0
M  V30 13 C 2.6675 3.8501 0.0 0
M  V30 14 Cl 4.6680 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[1-[[(3-phenyl-1H-pyrazol-5-yl)carbonyl]amino]ethyl]benzoate
C20H19N3O3
2837055-71-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.3657 4.6201 0.0 0
M  V30 2 N 9.6995 3.8501 0.0 0
M  V30 3 O 8.3657 6.1601 0.0 0
M  V30 4 C 11.0332 4.6201 0.0 0
M  V30 5 C 11.0332 6.1601 0.0 0
M  V30 6 C 16.3680 1.5400 0.0 0
M  V30 7 O 17.7016 2.3100 0.0 0
M  V30 8 O 16.3680 0.0000 0.0 0
M  V30 9 C 19.0353 1.5400 0.0 0
M  V30 10 C 4.5947 3.3320 0.0 0
M  V30 11 C 5.6252 4.4764 0.0 0
M  V30 12 N 5.3647 1.9983 0.0 0
M  V30 13 C 7.0320 3.8501 0.0 0
M  V30 14 N 6.8711 2.3185 0.0 0
M  V30 15 C 3.0631 3.4929 0.0 0
M  V30 16 C 2.4368 4.8999 0.0 0
M  V30 17 C 2.1579 2.2470 0.0 0
M  V30 18 C 0.9051 5.0608 0.0 0
M  V30 19 C 0.6263 2.4080 0.0 0
M  V30 20 C 0.0000 3.8149 0.0 0
M  V30 21 C 12.3668 3.8501 0.0 0
M  V30 22 C 12.3668 2.3100 0.0 0
M  V30 23 C 13.7005 4.6201 0.0 0
M  V30 24 C 13.7005 1.5400 0.0 0
M  V30 25 C 15.0343 3.8501 0.0 0
M  V30 26 C 15.0343 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 21
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 26
M  V30 10 1 7 9
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 10 15
M  V30 14 2 11 13
M  V30 15 1 12 14
M  V30 16 1 13 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5071-61-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 934388-45-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2837055-71-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34491577
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38
Kinase Chemical Probe
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Roehm, Sandra; Berger, Benedict-Tilman; Schroeder, Martin; Chatterjee,
Deep; Mathea, Sebastian; Joerger, Andreas C.; Pinkas, Daniel M.; Bufton,
Joshua C.; Tjaden, Amelie; Kovooru, Lohitesh; Kudolo, Mark; Pohl,
Christian; Bullock, Alex N.; Mueller, Susanne; Laufer, Stefan; Knapp,
Stefan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(18), 13451-13474

$RFMT $RIREG SCHEME302 STEP1
$RXN



  2  1
$MOL
4-Chlorobenzo[b]thiophene-2-carboxylic acid
C9H5ClO2S
23967-57-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0.0000 1.4944 0.0 0
M  V30 2 C 6.0811 1.5400 0.0 0
M  V30 3 O 6.0811 0.0000 0.0 0
M  V30 4 O 7.4149 2.3100 0.0 0
M  V30 5 C 3.0801 4.1618 0.0 0
M  V30 6 C 2.3100 2.8281 0.0 0
M  V30 7 S 4.5865 3.8416 0.0 0
M  V30 8 C 2.3100 5.4954 0.0 0
M  V30 9 C 3.3406 1.6836 0.0 0
M  V30 10 C 0.7700 2.8281 0.0 0
M  V30 11 C 4.7474 2.3100 0.0 0
M  V30 12 C 0.7700 5.4954 0.0 0
M  V30 13 C 0.0000 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 11
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 11
M  V30 13 1 10 13
M  V30 14 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Piperidinamine, 1-methyl-, hydrochloride (1:2), (3R)-
C6H14N2.2ClH
1157849-50-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 4.6200 0.0 0
M  V30 2 C 5.3349 4.6200 0.0 0
M  V30 3 C 2.6675 4.6200 0.0 0
M  V30 4 C 1.3338 3.8500 0.0 0 CFG=2
M  V30 5 N 4.0011 3.8500 0.0 0
M  V30 6 C 1.3338 2.3100 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 2.6675 1.5400 0.0 0
M  V30 9 Cl 2.6675 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 1 CFG=1
M  V30 2 1 2 5
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-Chloro-N-[(3R)-1-methyl-3-piperidinyl]benzo[b]thiophene-2-carboxamide
C15H17ClN2OS
2053549-47-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0.0000 4.0010 0.0 0
M  V30 2 C 6.0811 3.9554 0.0 0
M  V30 3 N 7.4148 3.1854 0.0 0
M  V30 4 O 6.0811 5.4955 0.0 0
M  V30 5 C 12.7496 3.1854 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 2.3101 2.6673 0.0 0
M  V30 8 S 4.5864 1.6538 0.0 0
M  V30 9 C 2.3101 0.0000 0.0 0
M  V30 10 C 3.3405 3.8119 0.0 0
M  V30 11 C 0.7700 2.6673 0.0 0
M  V30 12 C 4.7475 3.1854 0.0 0
M  V30 13 C 0.7700 0.0000 0.0 0
M  V30 14 C 0.0000 1.3337 0.0 0
M  V30 15 C 8.7485 3.9554 0.0 0 CFG=2
M  V30 16 C 10.0823 3.1854 0.0 0
M  V30 17 C 8.7485 5.4955 0.0 0
M  V30 18 N 11.4160 3.9554 0.0 0
M  V30 19 C 10.0823 6.2655 0.0 0
M  V30 20 C 11.4160 5.4955 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 12
M  V30 5 1 15 3 CFG=3
M  V30 6 1 5 18
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 2 7 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 2 10 12
M  V30 15 1 11 14
M  V30 16 2 13 14
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 15)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 23967-57-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1157849-50-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2053549-47-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33998211
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM product further converted into HCl salt
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Preparation of Enantiopure 3-Aminopiperidine and 3-Aminoazepane
Derivatives from Ornithine and Lysine. Consecutive Syntheses of
Pharmacologically Active Analogs, Such as Besifloxacin
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Schiffers, Ingo; Frings, Marcus; Kuebber, Britta Maria; Truong,
Khai-Nghi; Rissanen, Kari; Bolm, Carsten
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2022), 26(10), 2811-2822

$RFMT $RIREG SCHEME303 STEP1
$RXN



  2  1
$MOL
3-Methoxyphenethylamine
C9H13NO
2039-67-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 3.0801 0.0 0
M  V30 2 C 8.0023 2.3101 0.0 0
M  V30 3 N 9.3360 3.0801 0.0 0
M  V30 4 O 1.3337 3.0801 0.0 0
M  V30 5 C 0.0000 2.3101 0.0 0
M  V30 6 C 5.3348 2.3101 0.0 0
M  V30 7 C 4.0012 3.0801 0.0 0
M  V30 8 C 5.3348 0.7700 0.0 0
M  V30 9 C 2.6675 2.3101 0.0 0
M  V30 10 C 4.0012 0.0000 0.0 0
M  V30 11 C 2.6675 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 4 5
M  V30 5 1 4 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Methoxy-,-dimethyl-2-nitrobenzeneacetic acid
C11H13NO5
1800474-32-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 4.0011 0.0 0
M  V30 2 C 1.5400 5.3347 0.0 0
M  V30 3 C 0.7700 4.0011 0.0 0
M  V30 4 C 1.5400 2.6674 0.0 0
M  V30 5 O 0.0000 5.3347 0.0 0
M  V30 6 O 2.3100 6.6685 0.0 0
M  V30 7 N 3.8500 1.3338 0.0 0 VAL=5
M  V30 8 O 4.6200 0.0000 0.0 0
M  V30 9 O 2.3100 1.3338 0.0 0
M  V30 10 O 6.9300 6.6685 0.0 0
M  V30 11 C 8.4700 6.6685 0.0 0
M  V30 12 C 3.8500 4.0011 0.0 0
M  V30 13 C 4.6200 2.6674 0.0 0
M  V30 14 C 4.6200 5.3347 0.0 0
M  V30 15 C 6.1600 2.6674 0.0 0
M  V30 16 C 6.1600 5.3347 0.0 0
M  V30 17 C 6.9300 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 12
M  V30 5 1 2 5
M  V30 6 2 2 6
M  V30 7 2 7 8
M  V30 8 2 7 9
M  V30 9 1 7 13
M  V30 10 1 10 11
M  V30 11 1 10 16
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, 5-methoxy-N-[2-(3-methoxyphenyl)ethyl]-,-dimethyl-2-nitro-
C20H24N2O5
3049081-25-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 4.0011 0.0 0
M  V30 2 C 6.9300 5.3347 0.0 0
M  V30 3 C 7.7000 4.0011 0.0 0
M  V30 4 C 6.9300 2.6673 0.0 0
M  V30 5 N 8.4700 5.3347 0.0 0
M  V30 6 O 6.1600 6.6684 0.0 0
M  V30 7 C 9.2400 6.6684 0.0 0
M  V30 8 C 10.7800 6.6684 0.0 0
M  V30 9 N 4.6200 1.3336 0.0 0 VAL=5
M  V30 10 O 3.8500 0.0000 0.0 0
M  V30 11 O 6.1600 1.3336 0.0 0
M  V30 12 O 1.5400 6.6684 0.0 0
M  V30 13 C 0.0000 6.6684 0.0 0
M  V30 14 O 15.4000 9.3358 0.0 0
M  V30 15 C 16.1700 10.6694 0.0 0
M  V30 16 C 4.6200 4.0011 0.0 0
M  V30 17 C 3.8500 2.6673 0.0 0
M  V30 18 C 3.8500 5.3347 0.0 0
M  V30 19 C 2.3100 2.6673 0.0 0
M  V30 20 C 2.3100 5.3347 0.0 0
M  V30 21 C 1.5400 4.0011 0.0 0
M  V30 22 C 11.5500 8.0021 0.0 0
M  V30 23 C 13.0900 8.0021 0.0 0
M  V30 24 C 10.7800 9.3358 0.0 0
M  V30 25 C 13.8600 9.3358 0.0 0
M  V30 26 C 11.5500 10.6694 0.0 0
M  V30 27 C 13.0900 10.6694 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 16
M  V30 5 1 2 5
M  V30 6 2 2 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 8 22
M  V30 10 2 9 10
M  V30 11 2 9 11
M  V30 12 1 9 17
M  V30 13 1 12 13
M  V30 14 1 12 20
M  V30 15 1 14 15
M  V30 16 1 14 25
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2039-67-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1800474-32-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3049081-25-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34871213
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 20734-58-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 39968-33-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-activity relationship study of 4,5-didehydroguadiscine, an
aporphine alkaloid showing potent melanogenesis-inhibitory activity in
B16 melanoma cells
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Takashima, Katsuki; Teramachi, Miyu; Marumoto, Shinsuke; Ishikawa,
Fumihiro; Manse, Yoshiaki; Morikawa, Toshio; Tanabe, Genzoh
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2022), 78129034

$RFMT $RIREG SCHEME304 STEP1
$RXN



  2  1
$MOL
10,11-Dihydro-8-[(2-nitrophenyl)amino]-5-oxo-5H-dibenzo[a,d]cycloheptene-3-ca...
C22H16N2O5
2614241-26-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 11.2167 2.3000 0.0 0
M  V30 2 C 15.9391 4.3502 0.0 0
M  V30 3 O 17.2115 5.2177 0.0 0
M  V30 4 O 16.0541 2.8145 0.0 0
M  V30 5 N 4.6200 4.0011 0.0 0
M  V30 6 N 1.5400 4.0011 0.0 0 VAL=5
M  V30 7 O 0.0000 4.0011 0.0 0
M  V30 8 O 2.3100 5.3347 0.0 0
M  V30 9 C 11.8916 4.8190 0.0 0
M  V30 10 C 11.7766 6.3547 0.0 0
M  V30 11 C 10.7628 3.7716 0.0 0
M  V30 12 C 13.2792 4.1509 0.0 0
M  V30 13 C 10.5042 7.2223 0.0 0
M  V30 14 C 13.0490 7.2223 0.0 0
M  V30 15 C 9.2401 4.0011 0.0 0
M  V30 16 C 14.5515 5.0184 0.0 0
M  V30 17 C 9.0326 6.7683 0.0 0
M  V30 18 C 14.4365 6.5541 0.0 0
M  V30 19 C 8.4701 5.3347 0.0 0
M  V30 20 C 8.4701 2.6674 0.0 0
M  V30 21 C 6.9300 5.3347 0.0 0
M  V30 22 C 6.9300 2.6674 0.0 0
M  V30 23 C 6.1600 4.0011 0.0 0
M  V30 24 C 3.8500 2.6674 0.0 0
M  V30 25 C 2.3100 2.6674 0.0 0
M  V30 26 C 4.6200 1.3338 0.0 0
M  V30 27 C 1.5400 1.3338 0.0 0
M  V30 28 C 3.8500 0.0000 0.0 0
M  V30 29 C 2.3100 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 11
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 16
M  V30 5 1 5 23
M  V30 6 1 5 24
M  V30 7 2 6 7
M  V30 8 2 6 8
M  V30 9 1 6 25
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 10 13
M  V30 14 2 10 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 2 15 20
M  V30 21 2 16 18
M  V30 22 1 17 19
M  V30 23 2 19 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 2 22 23
M  V30 27 2 24 25
M  V30 28 1 24 26
M  V30 29 1 25 27
M  V30 30 2 26 28
M  V30 31 2 27 29
M  V30 32 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
10,11-Dihydro-N-methyl-8-[(2-nitrophenyl)amino]-5-oxo-5H-dibenzo[a,d]cyclohep...
C23H19N3O4
2614243-24-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 11.2167 2.3000 0.0 0
M  V30 2 C 15.9390 4.3502 0.0 0
M  V30 3 N 17.2115 5.2177 0.0 0
M  V30 4 O 16.0542 2.8145 0.0 0
M  V30 5 C 18.5989 4.5495 0.0 0
M  V30 6 N 4.6200 4.0011 0.0 0
M  V30 7 N 1.5400 4.0011 0.0 0 VAL=5
M  V30 8 O 0.0000 4.0011 0.0 0
M  V30 9 O 2.3100 5.3347 0.0 0
M  V30 10 C 11.8916 4.8190 0.0 0
M  V30 11 C 11.7765 6.3547 0.0 0
M  V30 12 C 10.7628 3.7716 0.0 0
M  V30 13 C 13.2791 4.1509 0.0 0
M  V30 14 C 10.5042 7.2223 0.0 0
M  V30 15 C 13.0490 7.2223 0.0 0
M  V30 16 C 9.2400 4.0011 0.0 0
M  V30 17 C 14.5516 5.0184 0.0 0
M  V30 18 C 9.0326 6.7683 0.0 0
M  V30 19 C 14.4364 6.5541 0.0 0
M  V30 20 C 8.4700 5.3347 0.0 0
M  V30 21 C 8.4700 2.6674 0.0 0
M  V30 22 C 6.9300 5.3347 0.0 0
M  V30 23 C 6.9300 2.6674 0.0 0
M  V30 24 C 6.1600 4.0011 0.0 0
M  V30 25 C 3.8500 2.6674 0.0 0
M  V30 26 C 2.3100 2.6674 0.0 0
M  V30 27 C 4.6200 1.3338 0.0 0
M  V30 28 C 1.5400 1.3338 0.0 0
M  V30 29 C 3.8500 0.0000 0.0 0
M  V30 30 C 2.3100 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 12
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 17
M  V30 5 1 3 5
M  V30 6 1 6 24
M  V30 7 1 6 25
M  V30 8 2 7 8
M  V30 9 2 7 9
M  V30 10 1 7 26
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 2 16 21
M  V30 22 2 17 19
M  V30 23 1 18 20
M  V30 24 2 20 22
M  V30 25 1 21 23
M  V30 26 1 22 24
M  V30 27 2 23 24
M  V30 28 2 25 26
M  V30 29 1 25 27
M  V30 30 1 26 28
M  V30 31 2 27 29
M  V30 32 2 28 30
M  V30 33 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2614241-26-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2614243-24-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31188048
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Synthesis of Highly Selective Brain Penetrant p38
Mitogen-Activated Protein Kinase Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tormaehlen, Niklas M.; Martorelli, Mariella; Kuhn, Annette; Maier,
Florian; Guezguez, Jamil; Burnet, Michael; Albrecht, Wolfgang; Laufer,
Stefan A.; Koch, Pierre
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(2), 1225-1242

$RFMT $RIREG SCHEME305 STEP1
$RXN



  2  1
$MOL
6-Methoxy-2-benzofurancarboxylic acid
C10H8O4
50551-61-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.5400 0.0 0
M  V30 2 O 0.0000 0.2064 0.0 0
M  V30 3 O 0.0000 2.8737 0.0 0
M  V30 4 O 8.6809 3.0800 0.0 0
M  V30 5 C 10.0147 2.3100 0.0 0
M  V30 6 C 4.6799 2.3100 0.0 0
M  V30 7 C 4.6799 0.7700 0.0 0
M  V30 8 O 3.2152 2.7859 0.0 0
M  V30 9 C 6.0136 3.0800 0.0 0
M  V30 10 C 3.2152 0.2941 0.0 0
M  V30 11 C 6.0136 0.0000 0.0 0
M  V30 12 C 2.3100 1.5400 0.0 0
M  V30 13 C 7.3472 2.3100 0.0 0
M  V30 14 C 7.3472 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 4 5
M  V30 5 1 4 13
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 2 10 12
M  V30 14 1 11 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Glycine
C2H5NO2
56-40-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 O 1.3337 2.3101 0.0 0
M  V30 5 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(6-Methoxy-2-benzofuranyl)carbonyl]glycine
C12H11NO5
2339980-44-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0009 0.0 0
M  V30 2 N 3.8500 2.6673 0.0 0
M  V30 3 O 3.8500 5.3347 0.0 0
M  V30 4 C 2.3100 2.6673 0.0 0
M  V30 5 C 1.5400 1.3336 0.0 0
M  V30 6 O 0.0000 1.3336 0.0 0
M  V30 7 O 2.3100 0.0000 0.0 0
M  V30 8 O 12.5308 5.5409 0.0 0
M  V30 9 C 13.8646 4.7709 0.0 0
M  V30 10 C 8.5299 4.7709 0.0 0
M  V30 11 C 8.5299 3.2309 0.0 0
M  V30 12 O 7.0652 5.2469 0.0 0
M  V30 13 C 9.8635 5.5409 0.0 0
M  V30 14 C 7.0652 2.7551 0.0 0
M  V30 15 C 9.8635 2.4609 0.0 0
M  V30 16 C 6.1600 4.0009 0.0 0
M  V30 17 C 11.1972 4.7709 0.0 0
M  V30 18 C 11.1972 3.2309 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 8 9
M  V30 9 1 8 17
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 10 13
M  V30 13 1 11 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 13 17
M  V30 17 2 14 16
M  V30 18 1 15 18
M  V30 19 2 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 50551-61-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 56-40-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2339980-44-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38408158
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Efficacy, Mechanism, and Structure-Activity Relationship of 6-Methoxy
Benzofuran Derivatives as a Useful Tool for Senile Osteoporosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhou, Zi-ying; Sun, Lian-qi; Han, Xiao-yang; Wang, Yong-jian; Xie,
Zhuo-song; Xue, Si-tu; Li, Zhuo-rong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(3), 1742-1760

$RFMT $RIREG SCHEME306 STEP1
$RXN



  2  1
$MOL
Benzeneethanamine
C8H11N
64-04-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 5.3901 2.6673 0.0 0
M  V30 3 N 6.9302 2.6673 0.0 0
M  V30 4 C 3.0801 1.3337 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.7700 2.6673 0.0 0
M  V30 9 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 2 3
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-(3,4-Dichlorophenyl)-1H-pyrazole-4-carboxylic acid
C10H6Cl2N2O2
1152543-93-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.1821 4.3513 0.0 0
M  V30 2 O 8.6884 4.6714 0.0 0
M  V30 3 O 6.7061 2.8866 0.0 0
M  V30 4 Cl 0.0000 2.6674 0.0 0
M  V30 5 Cl 1.5400 0.0000 0.0 0
M  V30 6 C 4.6200 5.3347 0.0 0
M  V30 7 C 6.1515 5.4956 0.0 0
M  V30 8 N 3.9937 6.7417 0.0 0
M  V30 9 C 6.4717 7.0021 0.0 0
M  V30 10 N 5.1381 7.7721 0.0 0
M  V30 11 C 3.8500 4.0011 0.0 0
M  V30 12 C 2.3100 4.0011 0.0 0
M  V30 13 C 4.6200 2.6674 0.0 0
M  V30 14 C 1.5400 2.6674 0.0 0
M  V30 15 C 3.8500 1.3336 0.0 0
M  V30 16 C 2.3100 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 14
M  V30 5 1 5 16
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 6 11
M  V30 9 2 7 9
M  V30 10 1 8 10
M  V30 11 1 9 10
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-(3,4-Dichlorophenyl)-N-(2-phenylethyl)-1H-pyrazole-4-carboxamide
C18H15Cl2N3O
2763775-65-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.3103 5.8819 0.0 0
M  V30 2 N 7.6440 6.6519 0.0 0
M  V30 3 O 6.3103 4.3418 0.0 0
M  V30 4 C 8.9776 5.8819 0.0 0
M  V30 5 C 10.3114 6.6519 0.0 0
M  V30 6 Cl 0.0000 2.0610 0.0 0
M  V30 7 Cl 2.2890 0.0000 0.0 0
M  V30 8 C 3.5696 6.0255 0.0 0
M  V30 9 C 4.9766 6.6519 0.0 0
M  V30 10 N 2.5392 7.1701 0.0 0
M  V30 11 C 4.8155 8.1836 0.0 0
M  V30 12 N 3.3092 8.5038 0.0 0
M  V30 13 C 3.2495 4.5192 0.0 0
M  V30 14 C 1.7847 4.0432 0.0 0
M  V30 15 C 4.3939 3.4886 0.0 0
M  V30 16 C 1.4646 2.5369 0.0 0
M  V30 17 C 4.0737 1.9823 0.0 0
M  V30 18 C 2.6091 1.5065 0.0 0
M  V30 19 C 11.6451 5.8819 0.0 0
M  V30 20 C 12.9788 6.6519 0.0 0
M  V30 21 C 11.6451 4.3418 0.0 0
M  V30 22 C 14.3125 5.8819 0.0 0
M  V30 23 C 12.9788 3.5718 0.0 0
M  V30 24 C 14.3125 4.3418 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 19
M  V30 7 1 6 16
M  V30 8 1 7 18
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 8 13
M  V30 12 2 9 11
M  V30 13 1 10 12
M  V30 14 1 11 12
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 64-04-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1152543-93-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2763775-65-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31828433
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a cryptic site at the interface 2 of TEAD - Towards a new
family of YAP/TAZ-TEAD inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sturbaut, Manon; Bailly, Fabrice; Coevoet, Mathilde; Sileo, Pasquale;
Pugniere, Martine; Liberelle, Maxime; Magnez, Romain; Thuru, Xavier;
Chartier-Harlin, Marie-Christine; Melnyk, Patricia; Gelin, Muriel;
Allemand, Frederic; Guichou, Jean-Francois; Cotelle, Philippe
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 226113835

$RFMT $RIREG SCHEME307 STEP1
$RXN



  2  1
$MOL
5-Bromo-6-chloronicotinic acid
C6H3BrClNO2
29241-62-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 Br 5.3901 0.0000 0.0 0
M  V30 5 Cl 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 N 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 11
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Chlorodifluoromethoxy)benzenamine
C7H6ClF2NO
39065-95-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3101 2.6673 0.0 0
M  V30 2 C 1.5400 1.3337 0.0 0
M  V30 3 Cl 0.0000 1.3337 0.0 0
M  V30 4 F 0.7700 0.0000 0.0 0
M  V30 5 F 2.3101 0.0000 0.0 0
M  V30 6 N 8.4702 2.6673 0.0 0
M  V30 7 C 3.8501 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 6.1601 1.3337 0.0 0
M  V30 11 C 6.1601 4.0010 0.0 0
M  V30 12 C 6.9302 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 6 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-6-chloro-N-[4-(chlorodifluoromethoxy)phenyl]-3-pyridinecarboxamide
C13H7BrCl2F2N2O2
1491150-22-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.2400 2.6674 0.0 0
M  V30 2 N 8.4700 4.0011 0.0 0
M  V30 3 O 8.4700 1.3338 0.0 0
M  V30 4 Br 13.8600 0.0000 0.0 0
M  V30 5 Cl 15.4000 2.6674 0.0 0
M  V30 6 O 2.3100 4.0011 0.0 0
M  V30 7 C 1.5400 5.3347 0.0 0
M  V30 8 Cl 0.0000 5.3347 0.0 0
M  V30 9 F 0.7700 6.6685 0.0 0
M  V30 10 F 2.3100 6.6685 0.0 0
M  V30 11 C 10.7800 2.6674 0.0 0
M  V30 12 C 11.5500 1.3338 0.0 0
M  V30 13 C 11.5500 4.0011 0.0 0
M  V30 14 C 13.0900 1.3338 0.0 0
M  V30 15 N 13.0900 4.0011 0.0 0
M  V30 16 C 13.8600 2.6674 0.0 0
M  V30 17 C 6.9300 4.0011 0.0 0
M  V30 18 C 6.1600 2.6674 0.0 0
M  V30 19 C 6.1600 5.3347 0.0 0
M  V30 20 C 4.6200 2.6674 0.0 0
M  V30 21 C 4.6200 5.3347 0.0 0
M  V30 22 C 3.8500 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 17
M  V30 5 1 4 14
M  V30 6 1 5 16
M  V30 7 1 6 7
M  V30 8 1 6 22
M  V30 9 1 7 8
M  V30 10 1 7 9
M  V30 11 1 7 10
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 29241-62-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 39065-95-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1491150-22-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34628433
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 108-88-3
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and characterization of novel potent BCR-ABL degraders by
conjugating allosteric inhibitor
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liu, Haixia; Mi, Qianglong; Ding, Xinyu; Lin, Chencen; Liu, Linyi; Ren,
Chaowei; Shen, ShuTing; Shao, YuBao; Chen, Jinju; Zhou, Yongqi; Ji,
Liting; Zhang, Heqiao; Bai, Fang; Yang, Xiaobao; Yin, Qianqian; Jiang,
Biao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2022), 244114810

$RFMT $RIREG SCHEME308 STEP1
$RXN



  2  1
$MOL
L-Tyrosine, methyl ester
C10H13NO3
1080-06-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 3.8501 2.6673 0.0 0 CFG=2
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 N 4.6201 4.0010 0.0 0
M  V30 5 O 1.5400 4.0010 0.0 0
M  V30 6 O 1.5400 1.3337 0.0 0
M  V30 7 C 0.0000 4.0010 0.0 0
M  V30 8 O 10.7802 1.3337 0.0 0
M  V30 9 C 6.1601 1.3337 0.0 0
M  V30 10 C 6.9302 0.0000 0.0 0
M  V30 11 C 6.9302 2.6673 0.0 0
M  V30 12 C 8.4702 0.0000 0.0 0
M  V30 13 C 8.4702 2.6673 0.0 0
M  V30 14 C 9.2402 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Boc-L-valine
C10H19NO4
13734-41-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 2.3101 0.0 0 CFG=2
M  V30 2 N 4.0012 1.5400 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 C 2.6675 3.8501 0.0 0
M  V30 5 C 5.3348 2.3101 0.0 0
M  V30 6 C 0.0000 2.3101 0.0 0
M  V30 7 C 1.3337 0.0000 0.0 0
M  V30 8 O 1.3337 4.6201 0.0 0
M  V30 9 O 4.0012 4.6201 0.0 0
M  V30 10 O 6.6685 1.5400 0.0 0
M  V30 11 O 5.3348 3.8501 0.0 0
M  V30 12 C 8.0023 2.3101 0.0 0
M  V30 13 C 8.7723 0.9764 0.0 0
M  V30 14 C 9.3360 3.0801 0.0 0
M  V30 15 C 7.2323 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 1 5 10
M  V30 10 2 5 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-valyl-L-tyrosine methyl ester
C20H30N2O6
25518-33-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.0100 4.0011 0.0 0 CFG=1
M  V30 2 C 10.7800 5.3347 0.0 0
M  V30 3 N 8.4700 4.0011 0.0 0
M  V30 4 C 10.7800 2.6674 0.0 0
M  V30 5 C 7.7000 5.3347 0.0 0
M  V30 6 O 10.0100 1.3336 0.0 0
M  V30 7 O 12.3200 2.6674 0.0 0
M  V30 8 C 6.1600 5.3347 0.0 0 CFG=2
M  V30 9 O 8.4700 6.6685 0.0 0
M  V30 10 C 10.7800 0.0000 0.0 0
M  V30 11 N 5.3900 4.0011 0.0 0
M  V30 12 C 5.3900 6.6685 0.0 0
M  V30 13 C 3.8500 4.0011 0.0 0
M  V30 14 C 6.1600 8.0021 0.0 0
M  V30 15 C 3.8500 6.6685 0.0 0
M  V30 16 O 3.0800 2.6674 0.0 0
M  V30 17 O 3.0800 5.3347 0.0 0
M  V30 18 C 1.5400 2.6674 0.0 0
M  V30 19 C 1.5400 1.1274 0.0 0
M  V30 20 C 0.0000 2.6674 0.0 0
M  V30 21 C 1.5400 4.2074 0.0 0
M  V30 22 O 16.9400 5.3347 0.0 0
M  V30 23 C 12.3200 5.3347 0.0 0
M  V30 24 C 13.0900 4.0011 0.0 0
M  V30 25 C 13.0900 6.6685 0.0 0
M  V30 26 C 14.6300 4.0011 0.0 0
M  V30 27 C 14.6300 6.6685 0.0 0
M  V30 28 C 15.4000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 23
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=1
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 1 22 28
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 2 25 27
M  V30 27 2 26 28
M  V30 28 1 27 28
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1080-06-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13734-41-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 25518-33-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31824054
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine
structures to inhibit A oligomerisation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Falkenstein, Markus; Reiner-Link, David; Zivkovic, Aleksandra; Gering,
Ian; Willbold, Dieter; Stark, Holger
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 50116462

$RFMT $RIREG SCHEME309 STEP1
$RXN



  2  1
$MOL
2-Pyridinebutanoic acid
C9H11NO2
102879-51-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3348 2.3100 0.0 0
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 C 8.0022 2.3100 0.0 0
M  V30 5 O 9.3359 3.0800 0.0 0
M  V30 6 O 8.0022 0.7700 0.0 0
M  V30 7 C 2.6675 2.3100 0.0 0
M  V30 8 C 2.6675 0.7700 0.0 0
M  V30 9 N 1.3337 3.0800 0.0 0
M  V30 10 C 1.3337 0.0000 0.0 0
M  V30 11 C 0.0000 2.3100 0.0 0
M  V30 12 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Prolinamide, L-alanyl-, 2,2,2-trifluoroacetate (1:1)
C8H15N3O2.C2HF3O2
204503-00-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.5253 7.5769 0.0 0
M  V30 2 C 5.8591 8.3469 0.0 0 CFG=1
M  V30 3 O 4.5253 6.0369 0.0 0
M  V30 4 C 5.8591 9.8869 0.0 0
M  V30 5 N 7.1927 7.5769 0.0 0
M  V30 6 C 1.4647 6.2141 0.0 0
M  V30 7 N 0.0000 5.7383 0.0 0
M  V30 8 O 2.6091 5.1837 0.0 0
M  V30 9 N 3.1917 8.3469 0.0 0
M  V30 10 C 1.7849 7.7206 0.0 0 CFG=2
M  V30 11 C 3.0307 9.8784 0.0 0
M  V30 12 C 0.7543 8.8649 0.0 0
M  V30 13 C 1.5243 10.1986 0.0 0
M  V30 14 C 2.9295 2.3101 0.0 0
M  V30 15 C 4.2632 1.5400 0.0 0
M  V30 16 F 3.6995 3.6437 0.0 0
M  V30 17 F 1.5959 3.0801 0.0 0
M  V30 18 F 2.1595 0.9764 0.0 0
M  V30 19 O 5.5969 2.3101 0.0 0
M  V30 20 O 4.2632 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=3
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 10 6 CFG=3
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 13
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 14 18
M  V30 18 1 15 19
M  V30 19 2 15 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C17H24N4O3
3007690-73-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.5255 2.3932 0.0 0
M  V30 2 C 5.8592 3.1632 0.0 0 CFG=2
M  V30 3 O 4.5255 0.8532 0.0 0
M  V30 4 N 7.1929 2.3932 0.0 0
M  V30 5 C 5.8592 4.7033 0.0 0
M  V30 6 C 8.5266 3.1632 0.0 0
M  V30 7 C 9.8604 2.3932 0.0 0
M  V30 8 O 8.5266 4.7033 0.0 0
M  V30 9 C 11.1940 3.1632 0.0 0
M  V30 10 C 12.5277 2.3932 0.0 0
M  V30 11 C 1.4647 1.0304 0.0 0
M  V30 12 N 0.0000 0.5546 0.0 0
M  V30 13 O 2.6091 0.0000 0.0 0
M  V30 14 N 3.1917 3.1632 0.0 0
M  V30 15 C 1.7849 2.5369 0.0 0 CFG=2
M  V30 16 C 3.0308 4.6948 0.0 0
M  V30 17 C 0.7545 3.6813 0.0 0
M  V30 18 C 1.5245 5.0150 0.0 0
M  V30 19 C 13.8614 3.1632 0.0 0
M  V30 20 C 15.1952 2.3932 0.0 0
M  V30 21 N 13.8614 4.7033 0.0 0
M  V30 22 C 16.5289 3.1632 0.0 0
M  V30 23 C 15.1952 5.4733 0.0 0
M  V30 24 C 16.5289 4.7033 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=3
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 19
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 15 11 CFG=3
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 15)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 102879-51-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 204503-00-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3007690-73-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37335664
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Nonpeptidic Oxazole Based Prolyl Oligopeptidase Ligands with Disease
Modifying Effects on alpha Synuclein Mouse Models of Parkinson Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kilpelainen, Tommi P.; Patsi, Henri T.; Svarcbahs, Reinis; Julku, Ulrika
H.; Etelainen, Tony S.; Cui, Hengjing; Auno, Samuli; Sipari, Nina;
Norrbacka, Susanna; Leino, Teppo O.; Jantti, Maria; Myohanen, Timo T.;
Wallen, Erik A. A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(11), 7475-7496

$RFMT $RIREG SCHEME310 STEP1
$RXN



  2  1
$MOL
2,6-Difluoronicotinic acid
C6H3F2NO2
171178-50-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 F 2.3101 0.0000 0.0 0
M  V30 5 F 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 N 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-N-tert-butylbenzenesulfonamide
C10H16N2O2S
608523-94-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 4.0012 3.0801 0.0 0 VAL=6
M  V30 2 N 2.6675 3.8501 0.0 0
M  V30 3 O 4.7712 4.4137 0.0 0
M  V30 4 O 3.2311 1.7464 0.0 0
M  V30 5 C 1.3337 3.0801 0.0 0
M  V30 6 C 0.5637 4.4137 0.0 0
M  V30 7 C 0.0000 2.3101 0.0 0
M  V30 8 C 2.1037 1.7464 0.0 0
M  V30 9 N 9.3360 3.0801 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 6.6685 3.0801 0.0 0
M  V30 12 C 5.3348 0.7700 0.0 0
M  V30 13 C 8.0023 2.3101 0.0 0
M  V30 14 C 6.6685 0.0000 0.0 0
M  V30 15 C 8.0023 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 13
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[3-[[(1,1-Dimethylethyl)amino]sulfonyl]phenyl]-2,6-difluoro-3-pyridinecarbo...
C16H17F2N3O3S
2820400-44-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 4.0012 3.0801 0.0 0 VAL=6
M  V30 2 N 2.6675 3.8501 0.0 0
M  V30 3 O 4.7712 4.4137 0.0 0
M  V30 4 O 3.2311 1.7464 0.0 0
M  V30 5 C 1.3338 3.0801 0.0 0
M  V30 6 C 0.5638 4.4137 0.0 0
M  V30 7 C 0.0000 2.3101 0.0 0
M  V30 8 C 2.1038 1.7464 0.0 0
M  V30 9 N 9.3360 3.0801 0.0 0
M  V30 10 C 10.6698 2.3101 0.0 0
M  V30 11 O 10.6698 0.7700 0.0 0
M  V30 12 F 13.3372 0.7700 0.0 0
M  V30 13 F 16.0046 5.3901 0.0 0
M  V30 14 C 5.3348 2.3101 0.0 0
M  V30 15 C 6.6687 3.0801 0.0 0
M  V30 16 C 5.3348 0.7700 0.0 0
M  V30 17 C 8.0023 2.3101 0.0 0
M  V30 18 C 6.6687 0.0000 0.0 0
M  V30 19 C 8.0023 0.7700 0.0 0
M  V30 20 C 12.0035 3.0801 0.0 0
M  V30 21 C 13.3372 2.3101 0.0 0
M  V30 22 C 12.0035 4.6201 0.0 0
M  V30 23 N 14.6708 3.0801 0.0 0
M  V30 24 C 13.3372 5.3901 0.0 0
M  V30 25 C 14.6708 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 14
M  V30 5 1 2 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 10
M  V30 10 1 9 17
M  V30 11 2 10 11
M  V30 12 1 10 20
M  V30 13 1 12 21
M  V30 14 1 13 25
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 171178-50-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 608523-94-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2820400-44-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34105800
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers:
Hit Optimization Toward an In Vivo Chemical Probe
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tamayo, Nuria A.; Bourbeau, Matthew P.; Allen, Jennifer R.; Ashton, Kate
S.; Chen, Jian Jeffrey; Kaller, Matthew R.; Nguyen, Thomas T.; Nishimura,
Nobuko; Pettus, Liping H.; Walton, Mary; Belmontes, Brian; Moriguchi,
Jodi; Chen, Kui; McCarter, John D.; Hanestad, Kelly; Chung, Grace;
Ninniri, Maria Stefania S.; Sun, Jan; Poppe, Leszek; Spahr, Chris; Hui,
John; Jia, Lei; Wu, Tian; Dahal, Upendra P.; Edson, Katheryne Z.; Payton,
Marc
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(6), 4972-4990

$RFMT $RIREG SCHEME311 STEP1
$RXN



  2  1
$MOL
(3,4-Dimethoxyphenyl)acetic acid
C10H12O4
93-40-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7700 4.0011 0.0 0
M  V30 2 C 0.0000 5.3348 0.0 0
M  V30 3 O 2.3100 1.3338 0.0 0
M  V30 4 C 3.0800 0.0000 0.0 0
M  V30 5 C 6.9301 4.0011 0.0 0
M  V30 6 C 7.7001 5.3348 0.0 0
M  V30 7 O 6.9301 6.6686 0.0 0
M  V30 8 O 9.2401 5.3348 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 3.0800 2.6675 0.0 0
M  V30 11 C 3.0800 5.3348 0.0 0
M  V30 12 C 4.6201 2.6675 0.0 0
M  V30 13 C 4.6201 5.3348 0.0 0
M  V30 14 C 5.3901 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 3 4
M  V30 4 1 3 10
M  V30 5 1 5 6
M  V30 6 1 5 14
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Methoxy-O-methyl-L-tyrosine methyl ester
C12H17NO4
78083-80-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3347 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3347 0.0 0 CFG=2
M  V30 7 C 9.2400 5.3347 0.0 0
M  V30 8 N 6.9300 6.6685 0.0 0
M  V30 9 O 10.0100 6.6685 0.0 0
M  V30 10 O 10.0100 4.0011 0.0 0
M  V30 11 C 11.5500 6.6685 0.0 0
M  V30 12 C 3.0800 2.6674 0.0 0
M  V30 13 C 2.3100 4.0011 0.0 0
M  V30 14 C 4.6200 2.6674 0.0 0
M  V30 15 C 3.0800 5.3347 0.0 0
M  V30 16 C 5.3900 4.0011 0.0 0
M  V30 17 C 4.6200 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 3 4
M  V30 4 1 3 13
M  V30 5 1 5 6
M  V30 6 1 5 16
M  V30 7 1 6 7
M  V30 8 1 6 8 CFG=3
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 9 11
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)acetyl]-3-methoxy-O-methyl-L-tyrosine methyl ester
C22H27NO7
1089721-60-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9302 5.3348 0.0 0
M  V30 2 C 7.7002 4.0012 0.0 0 CFG=1
M  V30 3 N 9.2402 4.0012 0.0 0
M  V30 4 C 6.9302 2.6673 0.0 0
M  V30 5 C 10.0102 5.3348 0.0 0
M  V30 6 O 7.7002 1.3337 0.0 0
M  V30 7 O 5.3901 2.6673 0.0 0
M  V30 8 C 11.5503 5.3348 0.0 0
M  V30 9 O 9.2402 6.6685 0.0 0
M  V30 10 C 6.9302 0.0000 0.0 0
M  V30 11 O 2.3101 8.0022 0.0 0
M  V30 12 C 3.0801 9.3360 0.0 0
M  V30 13 O 0.7700 5.3348 0.0 0
M  V30 14 C 0.0000 4.0012 0.0 0
M  V30 15 O 16.1704 8.0022 0.0 0
M  V30 16 C 16.9404 6.6685 0.0 0
M  V30 17 O 14.6303 10.6697 0.0 0
M  V30 18 C 13.8603 12.0033 0.0 0
M  V30 19 C 5.3901 5.3348 0.0 0
M  V30 20 C 4.6201 6.6685 0.0 0
M  V30 21 C 4.6201 4.0012 0.0 0
M  V30 22 C 3.0801 6.6685 0.0 0
M  V30 23 C 3.0801 4.0012 0.0 0
M  V30 24 C 2.3101 5.3348 0.0 0
M  V30 25 C 12.3203 6.6685 0.0 0
M  V30 26 C 13.8603 6.6685 0.0 0
M  V30 27 C 11.5503 8.0022 0.0 0
M  V30 28 C 14.6303 8.0022 0.0 0
M  V30 29 C 12.3203 9.3360 0.0 0
M  V30 30 C 13.8603 9.3360 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 25
M  V30 12 1 11 12
M  V30 13 1 11 22
M  V30 14 1 13 14
M  V30 15 1 13 24
M  V30 16 1 15 16
M  V30 17 1 15 28
M  V30 18 1 17 18
M  V30 19 1 17 30
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 93-40-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 78083-80-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1089721-60-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32532467
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and optimization of new 6, 7-dihydroxy-1, 2, 3,
4-tetrahydroisoquinoline derivatives as potent influenza virus PAN
inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Liu, Zhihao; Gu, Shuyin; Zhu, Xiang; Liu, Mingjian; Cao, Zhenqing; Qiu,
Pengsen; Li, Sumei; Liu, Shuwen; Song, Gaopeng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2022), 227113929

$RFMT $RIREG SCHEME312 STEP1
$RXN



  2  1
$MOL
L-Tyrosine, methyl ester
C10H13NO3
1080-06-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 3.8501 2.6673 0.0 0 CFG=2
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 N 4.6201 4.0010 0.0 0
M  V30 5 O 1.5400 4.0010 0.0 0
M  V30 6 O 1.5400 1.3337 0.0 0
M  V30 7 C 0.0000 4.0010 0.0 0
M  V30 8 O 10.7802 1.3337 0.0 0
M  V30 9 C 6.1601 1.3337 0.0 0
M  V30 10 C 6.9302 0.0000 0.0 0
M  V30 11 C 6.9302 2.6673 0.0 0
M  V30 12 C 8.4702 0.0000 0.0 0
M  V30 13 C 8.4702 2.6673 0.0 0
M  V30 14 C 9.2402 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
BOC-L-leucine
C11H21NO4
13139-15-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8501 0.0 0 CFG=2
M  V30 2 N 4.0012 4.6201 0.0 0
M  V30 3 C 2.6675 2.3101 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8501 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 O 0.0000 3.8501 0.0 0
M  V30 8 O 1.3337 6.1601 0.0 0
M  V30 9 O 6.6685 4.6201 0.0 0
M  V30 10 O 5.3348 2.3101 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 2.3101 0.0 0
M  V30 13 C 8.0023 3.8501 0.0 0
M  V30 14 C 7.2323 2.5164 0.0 0
M  V30 15 C 9.3360 3.0801 0.0 0
M  V30 16 C 8.7723 5.1838 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 6 12
M  V30 12 1 9 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-leucyl-L-tyrosine methyl ester
C21H32N2O6
18658-65-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.0100 5.3347 0.0 0 CFG=1
M  V30 2 C 10.7800 4.0011 0.0 0
M  V30 3 N 8.4700 5.3347 0.0 0
M  V30 4 C 10.7800 6.6684 0.0 0
M  V30 5 C 7.7000 4.0011 0.0 0
M  V30 6 O 10.0100 8.0021 0.0 0
M  V30 7 O 12.3200 6.6684 0.0 0
M  V30 8 C 6.1600 4.0011 0.0 0 CFG=2
M  V30 9 O 8.4700 2.6674 0.0 0
M  V30 10 C 10.7800 9.3358 0.0 0
M  V30 11 N 5.3900 5.3347 0.0 0
M  V30 12 C 5.3900 2.6674 0.0 0
M  V30 13 C 3.8500 5.3347 0.0 0
M  V30 14 C 6.1600 1.3336 0.0 0
M  V30 15 O 3.0800 6.6684 0.0 0
M  V30 16 O 3.0800 4.0011 0.0 0
M  V30 17 C 5.3900 0.0000 0.0 0
M  V30 18 C 7.7000 1.3336 0.0 0
M  V30 19 C 1.5400 6.6684 0.0 0
M  V30 20 C 1.5400 5.1284 0.0 0
M  V30 21 C 0.0000 6.6684 0.0 0
M  V30 22 C 1.5400 8.2084 0.0 0
M  V30 23 O 16.9400 4.0011 0.0 0
M  V30 24 C 12.3200 4.0011 0.0 0
M  V30 25 C 13.0900 2.6674 0.0 0
M  V30 26 C 13.0900 5.3347 0.0 0
M  V30 27 C 14.6300 2.6674 0.0 0
M  V30 28 C 14.6300 5.3347 0.0 0
M  V30 29 C 15.4000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 24
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=3
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 19 22
M  V30 23 1 23 29
M  V30 24 2 24 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 2 26 28
M  V30 28 2 27 29
M  V30 29 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1080-06-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13139-15-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 18658-65-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39925599
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Macrocyclic Oxindole Peptide Epoxyketones-A Comparative Study of
Macrocyclic Inhibitors of the 20S Proteasome
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Gotz, Marion G.; Godwin, Kacey; Price, Rachel; Dorn, Robert;
Merrill-Steskal, Gabriel; Klemmer, William; Hansen, Hunter; Produturi,
Gautam; Rocha, Megan; Palmer, Mathias; Molacek, Lea; Strater, Zack;
Groll, Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2024), 15(4), 533-539

$RFMT $RIREG SCHEME313 STEP1
$RXN



  2  1
$MOL
5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid
C10H9N3O2
51649-80-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.0494 0.4963 0.0 0
M  V30 2 C 8.2358 1.5317 0.0 0
M  V30 3 O 9.6426 2.1580 0.0 0
M  V30 4 O 8.0747 0.0000 0.0 0
M  V30 5 N 4.6200 3.2067 0.0 0
M  V30 6 C 5.5252 1.9609 0.0 0
M  V30 7 N 5.5252 4.4528 0.0 0
M  V30 8 C 6.9898 2.4367 0.0 0
M  V30 9 C 6.9898 3.9767 0.0 0
M  V30 10 C 3.0800 3.2067 0.0 0
M  V30 11 C 2.3100 4.5405 0.0 0
M  V30 12 C 2.3100 1.8731 0.0 0
M  V30 13 C 0.7700 4.5405 0.0 0
M  V30 14 C 0.7700 1.8731 0.0 0
M  V30 15 C 0.0000 3.2067 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 6
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 8
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 10
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 8 9
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-(aminomethyl)-, methyl ester, hydrochloride (1:1)
C9H11NO2.ClH
6232-11-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.0800 0.0 0
M  V30 2 O 1.3337 3.8501 0.0 0
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 C 0.0000 3.0800 0.0 0
M  V30 5 C 8.0023 6.1601 0.0 0
M  V30 6 N 9.3360 5.3901 0.0 0
M  V30 7 C 4.0012 3.8501 0.0 0
M  V30 8 C 4.0012 5.3901 0.0 0
M  V30 9 C 5.3348 3.0800 0.0 0
M  V30 10 C 5.3348 6.1601 0.0 0
M  V30 11 C 6.6685 3.8501 0.0 0
M  V30 12 C 6.6685 5.3901 0.0 0
M  V30 13 Cl 4.6680 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[[[(5-amino-1-phenyl-1H-pyrazol-4-yl)carbonyl]amino]methyl]benzoate
C19H18N4O3
2410792-53-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3049 5.9828 0.0 0
M  V30 2 C 8.3657 4.6201 0.0 0
M  V30 3 N 9.6995 3.8501 0.0 0
M  V30 4 O 8.3657 6.1601 0.0 0
M  V30 5 C 11.0332 4.6201 0.0 0
M  V30 6 C 16.3680 1.5400 0.0 0
M  V30 7 O 17.7016 2.3100 0.0 0
M  V30 8 O 16.3680 0.0000 0.0 0
M  V30 9 C 19.0353 1.5400 0.0 0
M  V30 10 N 4.5947 3.3320 0.0 0
M  V30 11 C 5.6252 4.4764 0.0 0
M  V30 12 N 5.3647 1.9983 0.0 0
M  V30 13 C 7.0320 3.8501 0.0 0
M  V30 14 C 6.8711 2.3185 0.0 0
M  V30 15 C 3.0631 3.4929 0.0 0
M  V30 16 C 2.4368 4.8999 0.0 0
M  V30 17 C 2.1579 2.2470 0.0 0
M  V30 18 C 0.9051 5.0608 0.0 0
M  V30 19 C 0.6263 2.4080 0.0 0
M  V30 20 C 0.0000 3.8149 0.0 0
M  V30 21 C 12.3668 3.8501 0.0 0
M  V30 22 C 12.3668 2.3100 0.0 0
M  V30 23 C 13.7005 4.6201 0.0 0
M  V30 24 C 13.7005 1.5400 0.0 0
M  V30 25 C 15.0343 3.8501 0.0 0
M  V30 26 C 15.0343 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 13
M  V30 5 1 3 5
M  V30 6 1 5 21
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 26
M  V30 10 1 7 9
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 15
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 51649-80-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6232-11-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2410792-53-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38164670
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 67-68-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Selective targeting of the C and DFG-out pocket in p38 MAPK
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Roehm, Sandra; Schroeder, Martin; Dwyer, Jessica E.; Widdowson, Caroline
S.; Chaikuad, Apirat; Berger, Benedict-Tilman; Joerger, Andreas C.;
Kraemer, Andreas; Harbig, Jule; Dauch, Daniel; Kudolo, Mark; Laufer,
Stefan; Bagley, Mark C.; Knapp, Stefan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 208112721

$RFMT $RIREG SCHEME314 STEP1
$RXN



  2  1
$MOL
3-(Trifluoromethoxy)aniline
C7H6F3NO
1535-73-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 3.0800 0.0 0
M  V30 2 C 1.3337 2.3100 0.0 0
M  V30 3 F 1.3337 0.7700 0.0 0
M  V30 4 F 0.0000 1.5400 0.0 0
M  V30 5 F 0.0000 3.0800 0.0 0
M  V30 6 N 8.0022 3.0800 0.0 0
M  V30 7 C 4.0011 2.3100 0.0 0
M  V30 8 C 5.3348 3.0800 0.0 0
M  V30 9 C 4.0011 0.7700 0.0 0
M  V30 10 C 6.6686 2.3100 0.0 0
M  V30 11 C 5.3348 0.0000 0.0 0
M  V30 12 C 6.6686 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 6 10
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(tert-Butyloxycarbonyl)-D-methionine
C10H19NO4S
5241-66-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.9538 2.6675 0.0 0 CFG=1
M  V30 2 N 4.4137 2.6675 0.0 0
M  V30 3 C 6.7238 4.0012 0.0 0
M  V30 4 C 6.7238 1.3338 0.0 0
M  V30 5 C 3.6437 4.0012 0.0 0
M  V30 6 C 8.2638 4.0012 0.0 0
M  V30 7 O 5.9538 0.0000 0.0 0
M  V30 8 O 8.2638 1.3338 0.0 0
M  V30 9 O 2.1037 4.0012 0.0 0
M  V30 10 O 4.4137 5.3348 0.0 0
M  V30 11 S 9.0338 5.3348 0.0 0
M  V30 12 C 1.3337 5.3348 0.0 0
M  V30 13 C 10.5739 5.3348 0.0 0
M  V30 14 C 0.0000 4.5648 0.0 0
M  V30 15 C 0.5637 6.6687 0.0 0
M  V30 16 C 2.6673 6.1048 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 9 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 15 1 12 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C17H23F3N2O4S
2682842-39-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 8.4700 6.6684 0.0 0
M  V30 2 C 7.7000 5.3347 0.0 0
M  V30 3 C 6.1600 5.3347 0.0 0 CFG=1
M  V30 4 O 8.4700 4.0011 0.0 0
M  V30 5 N 5.3900 6.6684 0.0 0
M  V30 6 C 5.3900 4.0011 0.0 0
M  V30 7 C 3.8500 6.6684 0.0 0
M  V30 8 C 6.1600 2.6673 0.0 0
M  V30 9 O 3.0800 8.0021 0.0 0
M  V30 10 O 3.0800 5.3347 0.0 0
M  V30 11 S 5.3900 1.3336 0.0 0
M  V30 12 C 1.5400 8.0021 0.0 0
M  V30 13 C 6.1600 0.0000 0.0 0
M  V30 14 C 1.5400 9.5421 0.0 0
M  V30 15 C 0.0000 8.0021 0.0 0
M  V30 16 C 1.5400 6.4621 0.0 0
M  V30 17 O 13.0900 9.3358 0.0 0
M  V30 18 C 14.6300 9.3358 0.0 0
M  V30 19 F 15.4000 8.0021 0.0 0
M  V30 20 F 16.1700 9.3358 0.0 0
M  V30 21 F 15.4000 10.6694 0.0 0
M  V30 22 C 10.0100 6.6684 0.0 0
M  V30 23 C 10.7800 8.0021 0.0 0
M  V30 24 C 10.7800 5.3347 0.0 0
M  V30 25 C 12.3200 8.0021 0.0 0
M  V30 26 C 12.3200 5.3347 0.0 0
M  V30 27 C 13.0900 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 22
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 3 6 CFG=1
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 1 12 16
M  V30 17 1 17 18
M  V30 18 1 17 25
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1535-73-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5241-66-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2682842-39-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-23939242
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with
Antibacterial Activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yamada, Yousuke; Takashima, Hajime; Walmsley, David Lee; Ushiyama,
Fumihito; Matsuda, Yohei; Kanazawa, Harumi; Yamaguchi-Sasaki, Toru;
Tanaka-Yamamoto, Nozomi; Yamagishi, Junya; Kurimoto-Tsuruta, Risa; Ogata,
Yuya; Ohtake, Norikazu; Angove, Hayley; Baker, Lisa; Harris, Richard;
Macias, Alba; Robertson, Alan; Surgenor, Allan; Watanabe, Hayato; Nakano,
Koichiro; Mima, Masashi; Iwamoto, Kunihiko; Okada, Atsushi; Takata,
Iichiro; Hitaka, Kosuke; Tanaka, Akihiro; Fujita, Kiyoko; Sugiyama,
Hiroyuki; Hubbard, Roderick E.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(23), 14805-14820

$RFMT $RIREG SCHEME315 STEP1
$RXN



  2  1
$MOL
Cholic acid
C24H40O5
81-25-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 8.0020 0.7700 0.0 0
M  V30 2 C 8.1631 6.9216 0.0 0
M  V30 3 C 3.3501 4.4757 0.0 0
M  V30 4 C 8.8404 7.2727 0.0 0 CFG=2
M  V30 5 C 9.7455 8.5186 0.0 0
M  V30 6 C 7.3087 7.4336 0.0 0
M  V30 7 C 9.1192 9.9255 0.0 0
M  V30 8 C 10.0244 11.1714 0.0 0
M  V30 9 O 9.3981 12.5782 0.0 0
M  V30 10 O 11.5559 11.0104 0.0 0
M  V30 11 O 6.6684 7.7000 0.0 0
M  V30 12 O 0.0000 0.7700 0.0 0
M  V30 13 C 6.6684 3.0800 0.0 0 CFG=2
M  V30 14 C 8.0020 3.8500 0.0 0 CFG=2
M  V30 15 C 5.3347 3.8500 0.0 0 CFG=2
M  V30 16 C 6.6684 1.5400 0.0 0 CFG=2
M  V30 17 C 8.0020 5.3900 0.0 0 CFG=1
M  V30 18 C 9.4667 3.3740 0.0 0
M  V30 19 C 4.0011 3.0800 0.0 0 CFG=2
M  V30 20 C 5.3347 5.3900 0.0 0
M  V30 21 C 5.3347 0.7700 0.0 0
M  V30 22 C 9.4667 5.8659 0.0 0 CFG=1
M  V30 23 C 6.6684 6.1600 0.0 0 CFG=1
M  V30 24 C 10.3720 4.6200 0.0 0
M  V30 25 C 4.0011 1.5400 0.0 0 CFG=1
M  V30 26 C 2.6673 3.8500 0.0 0
M  V30 27 C 2.6673 0.7700 0.0 0
M  V30 28 C 1.3336 3.0800 0.0 0
M  V30 29 C 1.3336 1.5400 0.0 0 CFG=2
M  V30 30 H 7.7573 1.9909 0.0 0
M  V30 31 H 8.7953 2.5299 0.0 0
M  V30 32 H 4.2458 4.9390 0.0 0
M  V30 33 H 10.8004 6.6359 0.0 0
M  V30 34 H 4.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 16 1 CFG=3
M  V30 2 1 17 2 CFG=1
M  V30 3 1 19 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 4 6 CFG=3
M  V30 6 1 4 22
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 23 11 CFG=3
M  V30 12 1 29 12 CFG=3
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 16 1 13 30 CFG=1
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 1 14 31 CFG=3
M  V30 20 1 15 19
M  V30 21 1 15 20
M  V30 22 1 15 32 CFG=3
M  V30 23 1 16 21
M  V30 24 1 17 22
M  V30 25 1 17 23
M  V30 26 1 18 24
M  V30 27 1 19 25
M  V30 28 1 19 26
M  V30 29 1 20 23
M  V30 30 1 21 25
M  V30 31 1 22 24
M  V30 32 1 22 33 CFG=3
M  V30 33 1 25 27
M  V30 34 1 25 34 CFG=1
M  V30 35 1 26 28
M  V30 36 1 27 29
M  V30 37 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(11 4 13 14 15 16 17 19 22 23 25 29)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(3,5,7,12)-3,7,12-Trihydroxy-N-2-propyn-1-ylcholan-24-amide
C27H43NO4
1021182-35-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  37 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 8.0021 0.7700 0.0 0
M  V30 2 C 8.1631 6.9216 0.0 0
M  V30 3 C 3.3501 4.4757 0.0 0
M  V30 4 C 8.8404 7.2729 0.0 0 CFG=2
M  V30 5 C 9.7455 8.5187 0.0 0
M  V30 6 C 7.3087 7.4338 0.0 0
M  V30 7 C 9.1192 9.9255 0.0 0
M  V30 8 C 10.0244 11.1714 0.0 0
M  V30 9 N 9.3981 12.5783 0.0 0
M  V30 10 O 11.5559 11.0105 0.0 0
M  V30 11 C 10.3031 13.8242 0.0 0
M  V30 12 C 9.6768 15.2312 0.0 0
M  V30 13 C 9.0505 16.6380 0.0 0
M  V30 14 O 6.6684 7.7001 0.0 0
M  V30 15 O 0.0000 0.7700 0.0 0
M  V30 16 C 6.6684 3.0800 0.0 0 CFG=2
M  V30 17 C 8.0021 3.8500 0.0 0 CFG=2
M  V30 18 C 5.3348 3.8500 0.0 0 CFG=2
M  V30 19 C 6.6684 1.5400 0.0 0 CFG=2
M  V30 20 C 8.0021 5.3900 0.0 0 CFG=1
M  V30 21 C 9.4668 3.3742 0.0 0
M  V30 22 C 4.0011 3.0800 0.0 0 CFG=2
M  V30 23 C 5.3348 5.3900 0.0 0
M  V30 24 C 5.3348 0.7700 0.0 0
M  V30 25 C 9.4668 5.8659 0.0 0 CFG=1
M  V30 26 C 6.6684 6.1600 0.0 0 CFG=1
M  V30 27 C 10.3720 4.6200 0.0 0
M  V30 28 C 4.0011 1.5400 0.0 0 CFG=1
M  V30 29 C 2.6673 3.8500 0.0 0
M  V30 30 C 2.6673 0.7700 0.0 0
M  V30 31 C 1.3336 3.0800 0.0 0
M  V30 32 C 1.3336 1.5400 0.0 0 CFG=2
M  V30 33 H 7.7573 1.9911 0.0 0
M  V30 34 H 8.5540 2.4123 0.0 0
M  V30 35 H 4.2458 4.9390 0.0 0
M  V30 36 H 10.8004 6.6359 0.0 0
M  V30 37 H 4.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 19 1 CFG=3
M  V30 2 1 20 2 CFG=1
M  V30 3 1 22 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 4 6 CFG=3
M  V30 6 1 4 25
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 3 12 13
M  V30 14 1 26 14 CFG=3
M  V30 15 1 32 15 CFG=3
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 16 19
M  V30 19 1 16 33 CFG=1
M  V30 20 1 17 20
M  V30 21 1 17 21
M  V30 22 1 17 34 CFG=3
M  V30 23 1 18 22
M  V30 24 1 18 23
M  V30 25 1 18 35 CFG=3
M  V30 26 1 19 24
M  V30 27 1 20 25
M  V30 28 1 20 26
M  V30 29 1 21 27
M  V30 30 1 22 28
M  V30 31 1 22 29
M  V30 32 1 23 26
M  V30 33 1 24 28
M  V30 34 1 25 27
M  V30 35 1 25 36 CFG=3
M  V30 36 1 28 30
M  V30 37 1 28 37 CFG=1
M  V30 38 1 29 31
M  V30 39 1 30 32
M  V30 40 1 31 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(11 4 16 17 18 19 20 22 25 26 28 32)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 81-25-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1021182-35-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35275925
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Targeting Vancomycin-Resistant Enterococci (VRE) Infections and Van
Operon-Mediated Drug Resistance Using Dimeric Cholic Acid-Peptide
Conjugates
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Saini, Varsha; Mehta, Devashish; Gupta, Siddhi; Kumar, Sandeep; Rani,
Parul; Rana, Kajal; Rajput, Kajal; Jain, Dolly; Pal, Garima; Aggarwal,
Bharti; Pal, Sanjay; Gupta, Sonu K.; Kumar, Yashwant; Ramu, Vemanna S.;
Bajaj, Avinash
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(22), 15312-15326

$RFMT $RIREG SCHEME316 STEP1
$RXN



  2  1
$MOL
4,5-Dibromo-2-thiophenecarboxylic acid
C5H2Br2O2S
6324-10-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3026 4.0287 0.0 0
M  V30 2 O 6.6363 3.2587 0.0 0
M  V30 3 O 5.3026 5.5688 0.0 0
M  V30 4 Br 0.0000 2.9016 0.0 0
M  V30 5 Br 1.6752 0.0000 0.0 0
M  V30 6 C 3.9690 3.2587 0.0 0
M  V30 7 C 2.5620 3.8850 0.0 0
M  V30 8 S 3.8079 1.7271 0.0 0
M  V30 9 C 1.5316 2.7406 0.0 0
M  V30 10 C 2.3016 1.4070 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Aminomethylpiperidine-1-carboxylic acid tert-butyl ester
C11H22N2O2
144222-22-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8736 0.0 0
M  V30 2 O 3.0800 1.5400 0.0 0
M  V30 3 O 3.0800 4.2073 0.0 0
M  V30 4 C 1.5400 1.5400 0.0 0
M  V30 5 C 1.5400 3.0800 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 1.5400 0.0000 0.0 0
M  V30 8 C 10.0100 2.8736 0.0 0
M  V30 9 N 10.7800 4.2073 0.0 0
M  V30 10 N 5.3900 2.8736 0.0 0
M  V30 11 C 6.1600 4.2073 0.0 0
M  V30 12 C 6.1600 1.5400 0.0 0
M  V30 13 C 7.7000 4.2073 0.0 0
M  V30 14 C 7.7000 1.5400 0.0 0
M  V30 15 C 8.4700 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 1 8 15
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 4-[[[(4,5-dibromo-2-thienyl)carbonyl]amino]methyl]-1-piperi...
C16H22Br2N2O3S
2416928-81-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 4.6201 0.0 0
M  V30 2 O 2.6673 3.8501 0.0 0
M  V30 3 O 4.0010 6.1601 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 0.5637 3.2864 0.0 0
M  V30 6 C 0.0000 5.3901 0.0 0
M  V30 7 C 2.1037 5.9538 0.0 0
M  V30 8 C 9.3360 1.5400 0.0 0
M  V30 9 N 10.6697 2.3101 0.0 0
M  V30 10 C 12.0033 1.5400 0.0 0
M  V30 11 O 12.0033 0.0000 0.0 0
M  V30 12 Br 15.6307 5.5688 0.0 0
M  V30 13 Br 17.3060 2.6672 0.0 0
M  V30 14 N 5.3348 3.8501 0.0 0
M  V30 15 C 5.3348 2.3101 0.0 0
M  V30 16 C 6.6685 4.6201 0.0 0
M  V30 17 C 6.6685 1.5400 0.0 0
M  V30 18 C 8.0022 3.8501 0.0 0
M  V30 19 C 8.0022 2.3101 0.0 0
M  V30 20 C 13.3370 2.3101 0.0 0
M  V30 21 C 13.4981 3.8416 0.0 0
M  V30 22 S 14.7440 1.6837 0.0 0
M  V30 23 C 15.0044 4.1618 0.0 0
M  V30 24 C 15.7744 2.8281 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 1 8 19
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 20
M  V30 13 1 12 23
M  V30 14 1 13 24
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6324-10-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 144222-22-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416928-81-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21945245
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery, Structure-Activity Relationship, and Biological Activity of
Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wu, Fangrui; Hua, Yuanda; Kaochar, Salma; Nie, Shenyou; Lin, Yi-Lun; Yao,
Yuan; Wu, Jingyu; Wu, Xiaowei; Fu, Xiaoyong; Schiff, Rachel; Davis,
Christel M.; Robertson, Matthew; Ehli, Erik A.; Coarfa, Cristian;
Mitsiades, Nicholas; Song, Yongcheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(9), 4716-4731

$RFMT $RIREG SCHEME317 STEP1
$RXN



  2  1
$MOL
4-(Cyclopentylamino)-2-(methylthio)-5-pyrimidinecarboxylic acid
C11H15N3O2S
1065075-68-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.6217 4.0011 0.0 0
M  V30 2 C 4.1617 1.3337 0.0 0
M  V30 3 O 2.6217 1.3337 0.0 0
M  V30 4 O 4.9318 0.0000 0.0 0
M  V30 5 S 7.2418 6.6684 0.0 0
M  V30 6 C 8.7818 6.6684 0.0 0
M  V30 7 C 4.1617 4.0011 0.0 0
M  V30 8 C 4.9318 2.6675 0.0 0
M  V30 9 N 4.9318 5.3348 0.0 0
M  V30 10 C 6.4718 2.6675 0.0 0
M  V30 11 C 6.4718 5.3348 0.0 0
M  V30 12 N 7.2418 4.0011 0.0 0
M  V30 13 C 1.8517 5.3348 0.0 0
M  V30 14 C 0.3202 5.4957 0.0 0
M  V30 15 C 2.4782 6.7417 0.0 0
M  V30 16 C 0.0000 7.0021 0.0 0
M  V30 17 C 1.3337 7.7722 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 7
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 8
M  V30 6 1 5 6
M  V30 7 1 5 11
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 12
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(3-Aminopropyl)-2-pyrrolidinone
C7H14N2O
7663-77-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7710 1.3627 0.0 0
M  V30 2 C 5.1046 2.1327 0.0 0
M  V30 3 C 6.4384 1.3627 0.0 0
M  V30 4 N 7.7720 2.1327 0.0 0
M  V30 5 O 0.7102 0.0000 0.0 0
M  V30 6 N 2.4373 2.1327 0.0 0
M  V30 7 C 1.0304 1.5064 0.0 0
M  V30 8 C 2.2764 3.6643 0.0 0
M  V30 9 C 0.0000 2.6508 0.0 0
M  V30 10 C 0.7700 3.9846 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 5 7
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Cyclopentylamino)-2-(methylthio)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-5-pyri...
C18H27N5O2S
1421367-69-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.7711 2.6217 0.0 0
M  V30 2 C 6.4386 4.1618 0.0 0
M  V30 3 N 7.7722 4.9318 0.0 0
M  V30 4 O 6.4386 2.6217 0.0 0
M  V30 5 C 9.1059 4.1618 0.0 0
M  V30 6 C 10.4397 4.9318 0.0 0
M  V30 7 C 11.7734 4.1618 0.0 0
M  V30 8 S 1.1037 7.2418 0.0 0
M  V30 9 C 1.1037 8.7819 0.0 0
M  V30 10 O 14.8342 2.7990 0.0 0
M  V30 11 C 3.7711 4.1618 0.0 0
M  V30 12 C 5.1047 4.9318 0.0 0
M  V30 13 N 2.4374 4.9318 0.0 0
M  V30 14 C 5.1047 6.4718 0.0 0
M  V30 15 C 2.4374 6.4718 0.0 0
M  V30 16 N 3.7711 7.2418 0.0 0
M  V30 17 C 2.4374 1.8517 0.0 0
M  V30 18 C 1.0306 2.4782 0.0 0
M  V30 19 C 2.2765 0.3202 0.0 0
M  V30 20 C 0.0000 1.3337 0.0 0
M  V30 21 C 0.7700 0.0000 0.0 0
M  V30 22 N 13.1070 4.9318 0.0 0
M  V30 23 C 14.5138 4.3055 0.0 0
M  V30 24 C 13.2680 6.4633 0.0 0
M  V30 25 C 15.5444 5.4499 0.0 0
M  V30 26 C 14.7744 6.7837 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 12
M  V30 6 1 3 5
M  V30 7 1 5 6
M  V30 8 1 6 7
M  V30 9 1 7 22
M  V30 10 1 8 9
M  V30 11 1 8 15
M  V30 12 2 10 23
M  V30 13 1 11 12
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 16
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 21
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1065075-68-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7663-77-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1421367-69-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31592699
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Development of a Chemical Probe for Pseudokinase
Ca2+/calmodulin-Dependent Ser/Thr Kinase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Russ, Nadine; Schroeder, Martin; Berger, Benedict-Tilman; Mandel,
Sebastian; Aydogan, Yagmur; Mauer, Sandy; Pohl, Christian; Drewry, David
H.; Chaikuad, Apirat; Mueller, Susanne; Knapp, Stefan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(19), 14358-14376

$RFMT $RIREG SCHEME318 STEP1
$RXN



  2  1
$MOL
Acetic acid
C2H4O2
64-19-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 0.0000 2.3101 0.0 0
M  V30 3 O 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-2-[[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]meth...
C30H35N3O
2648234-33-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2066 5.3084 0.0 0
M  V30 2 C 6.5402 4.5384 0.0 0
M  V30 3 C 7.8740 5.3084 0.0 0
M  V30 4 N 9.2077 4.5384 0.0 0
M  V30 5 C 10.5413 5.3084 0.0 0
M  V30 6 C 9.2077 2.9984 0.0 0
M  V30 7 C 11.8749 4.5384 0.0 0
M  V30 8 C 10.5413 6.8484 0.0 0
M  V30 9 N 13.2087 5.3084 0.0 0
M  V30 10 O 11.8749 2.9984 0.0 0
M  V30 11 C 11.8749 7.6184 0.0 0
M  V30 12 C 14.5424 4.5384 0.0 0
M  V30 13 N 11.8749 9.1584 0.0 0
M  V30 14 C 3.8729 4.5384 0.0 0
M  V30 15 C 3.9880 3.0027 0.0 0
M  V30 16 C 2.6006 5.4060 0.0 0
M  V30 17 C 2.8592 1.9553 0.0 0
M  V30 18 C 5.4596 2.5489 0.0 0
M  V30 19 C 1.1290 4.9520 0.0 0
M  V30 20 C 2.9432 6.9074 0.0 0
M  V30 21 C 1.3363 2.1848 0.0 0
M  V30 22 C 3.2018 0.4538 0.0 0
M  V30 23 C 5.8023 1.0474 0.0 0
M  V30 24 C 0.5663 3.5184 0.0 0
M  V30 25 C 0.0000 5.9995 0.0 0
M  V30 26 C 1.8143 7.9549 0.0 0
M  V30 27 C 4.6734 0.0000 0.0 0
M  V30 28 C 0.3426 7.5009 0.0 0
M  V30 29 C 15.8760 5.3084 0.0 0
M  V30 30 C 17.2097 4.5384 0.0 0
M  V30 31 C 15.8760 6.8484 0.0 0
M  V30 32 C 18.5434 5.3084 0.0 0
M  V30 33 C 17.2097 7.6184 0.0 0
M  V30 34 C 18.5434 6.8484 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 14
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 29
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 15 18
M  V30 19 1 16 19
M  V30 20 2 16 20
M  V30 21 1 17 21
M  V30 22 2 17 22
M  V30 23 1 18 23
M  V30 24 1 19 24
M  V30 25 2 19 25
M  V30 26 1 20 26
M  V30 27 1 21 24
M  V30 28 1 22 27
M  V30 29 2 23 27
M  V30 30 1 25 28
M  V30 31 2 26 28
M  V30 32 2 29 30
M  V30 33 1 29 31
M  V30 34 1 30 32
M  V30 35 2 31 33
M  V30 36 2 32 34
M  V30 37 1 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Acetylamino)-2-[[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)pro...
C32H37N3O2
2648234-38-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3085 9.3358 0.0 0
M  V30 2 C 6.8485 9.3358 0.0 0
M  V30 3 C 7.6185 8.0021 0.0 0
M  V30 4 N 9.1585 8.0021 0.0 0
M  V30 5 C 9.9285 6.6684 0.0 0
M  V30 6 C 9.9285 9.3358 0.0 0
M  V30 7 C 11.4685 6.6684 0.0 0
M  V30 8 C 9.1585 5.3348 0.0 0
M  V30 9 N 12.2386 8.0021 0.0 0
M  V30 10 O 12.2386 5.3348 0.0 0
M  V30 11 C 9.9285 4.0010 0.0 0
M  V30 12 C 13.7786 8.0021 0.0 0
M  V30 13 N 9.1585 2.6673 0.0 0
M  V30 14 C 9.9285 1.3337 0.0 0
M  V30 15 C 11.4685 1.3337 0.0 0
M  V30 16 O 9.1585 0.0000 0.0 0
M  V30 17 C 4.5384 10.6696 0.0 0
M  V30 18 C 5.4059 11.9419 0.0 0
M  V30 19 C 3.0027 10.5544 0.0 0
M  V30 20 C 4.9521 13.4136 0.0 0
M  V30 21 C 6.9075 11.5993 0.0 0
M  V30 22 C 1.9554 11.6834 0.0 0
M  V30 23 C 2.5489 9.0829 0.0 0
M  V30 24 C 3.5185 13.9762 0.0 0
M  V30 25 C 5.9996 14.5424 0.0 0
M  V30 26 C 7.9548 12.7281 0.0 0
M  V30 27 C 2.1848 13.2061 0.0 0
M  V30 28 C 0.4538 11.3407 0.0 0
M  V30 29 C 1.0474 8.7401 0.0 0
M  V30 30 C 7.5010 14.1998 0.0 0
M  V30 31 C 0.0000 9.8691 0.0 0
M  V30 32 C 14.5486 9.3358 0.0 0
M  V30 33 C 16.0886 9.3358 0.0 0
M  V30 34 C 13.7786 10.6696 0.0 0
M  V30 35 C 16.8586 10.6696 0.0 0
M  V30 36 C 14.5486 12.0032 0.0 0
M  V30 37 C 16.0886 12.0032 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 17
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 32
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 14 16
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 18 21
M  V30 22 1 19 22
M  V30 23 2 19 23
M  V30 24 1 20 24
M  V30 25 2 20 25
M  V30 26 1 21 26
M  V30 27 1 22 27
M  V30 28 2 22 28
M  V30 29 1 23 29
M  V30 30 1 24 27
M  V30 31 1 25 30
M  V30 32 2 26 30
M  V30 33 1 28 31
M  V30 34 2 29 31
M  V30 35 2 32 33
M  V30 36 1 32 34
M  V30 37 1 33 35
M  V30 38 2 34 36
M  V30 39 2 35 37
M  V30 40 1 36 37
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2648234-33-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2648234-38-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23748721
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as
inhibitors of GABA transporters mGAT1-4 with anticonvulsant,
antinociceptive, and antidepressant activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zareba, Paula; Salat, Kinga; Hofner, Georg C.; Latka, Kamil; Bajda,
Marek; Latacz, Gniewomir; Kotniewicz, Krzysztof; Rapacz, Anna; Podkowa,
Adrian; Maj, Maciej; Jozwiak, Krzysztof; Filipek, Barbara; Wanner, Klaus
T.; Malawska, Barbara; Kulig, Katarzyna
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 221113512

$RFMT $RIREG SCHEME319 STEP1
$RXN



  2  1
$MOL
2,3-Dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazole-4-carboxylic acid
C12H12N2O3
83-10-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.5932 5.4211 0.0 0
M  V30 2 C 4.5932 0.0000 0.0 0
M  V30 3 C 1.4068 4.3858 0.0 0
M  V30 4 O 0.0000 3.7593 0.0 0
M  V30 5 O 1.5679 5.9173 0.0 0
M  V30 6 C 1.4068 1.0353 0.0 0
M  V30 7 N 5.0226 2.7106 0.0 0
M  V30 8 C 4.1174 3.9564 0.0 0
M  V30 9 N 4.1174 1.4647 0.0 0
M  V30 10 C 2.6528 3.4806 0.0 0
M  V30 11 C 2.6528 1.9406 0.0 0
M  V30 12 C 6.5626 2.7106 0.0 0
M  V30 13 C 7.3326 1.3769 0.0 0
M  V30 14 C 7.3326 4.0442 0.0 0
M  V30 15 C 8.8726 1.3769 0.0 0
M  V30 16 C 8.8726 4.0442 0.0 0
M  V30 17 C 9.6426 2.7106 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 8
M  V30 2 1 2 9
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 10
M  V30 6 1 6 11
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 7 12
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Aminophenol
C6H7NO
123-30-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 1.3337 0.0 0
M  V30 2 O 6.1601 1.3337 0.0 0
M  V30 3 C 1.5400 1.3337 0.0 0
M  V30 4 C 2.3100 0.0000 0.0 0
M  V30 5 C 2.3100 2.6673 0.0 0
M  V30 6 C 3.8500 0.0000 0.0 0
M  V30 7 C 3.8500 2.6673 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 8
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2,3-Dihydro-N-(4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazole-4-car...
C18H17N3O3
1552280-87-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3050 5.3914 0.0 0
M  V30 2 C 4.7383 0.0000 0.0 0
M  V30 3 C 8.3658 4.0287 0.0 0
M  V30 4 N 9.6994 3.2586 0.0 0
M  V30 5 O 8.3658 5.5687 0.0 0
M  V30 6 C 8.0156 0.6965 0.0 0
M  V30 7 O 15.0341 6.3387 0.0 0
M  V30 8 N 4.5948 2.7406 0.0 0
M  V30 9 C 5.6252 3.8850 0.0 0
M  V30 10 N 5.3648 1.4069 0.0 0
M  V30 11 C 7.0320 3.2586 0.0 0
M  V30 12 C 6.8710 1.7271 0.0 0
M  V30 13 C 3.0631 2.9015 0.0 0
M  V30 14 C 2.4367 4.3085 0.0 0
M  V30 15 C 2.1580 1.6557 0.0 0
M  V30 16 C 0.9052 4.4694 0.0 0
M  V30 17 C 0.6263 1.8166 0.0 0
M  V30 18 C 0.0000 3.2235 0.0 0
M  V30 19 C 11.0330 4.0287 0.0 0
M  V30 20 C 12.3667 3.2586 0.0 0
M  V30 21 C 11.0330 5.5687 0.0 0
M  V30 22 C 13.7005 4.0287 0.0 0
M  V30 23 C 12.3667 6.3387 0.0 0
M  V30 24 C 13.7005 5.5687 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 9
M  V30 2 1 2 10
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 11
M  V30 6 1 4 19
M  V30 7 1 6 12
M  V30 8 1 7 24
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 8 13
M  V30 12 1 9 11
M  V30 13 1 10 12
M  V30 14 2 11 12
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 83-10-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 123-30-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1552280-87-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31703039
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-guided design and development of novel
N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Huang, Daowei; Yang, Jixia; Zhang, Qingwei; Wang, Guan; Zhang, Zixue;
Zhang, Yue; Li, Jianqi
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 223113648

$RFMT $RIREG SCHEME320 STEP1
$RXN



  2  1
$MOL
3-[[(1,1-Dimethylethoxy)carbonyl]amino]-N-[(phenylmethoxy)carbonyl]-L-alanine
C16H22N2O6
16947-84-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 11.3436 5.3347 0.0 0
M  V30 2 O 10.5736 4.0011 0.0 0
M  V30 3 C 9.0336 4.0011 0.0 0
M  V30 4 N 8.2636 2.6674 0.0 0
M  V30 5 O 8.2636 5.3347 0.0 0
M  V30 6 C 6.7236 2.6674 0.0 0 CFG=2
M  V30 7 C 5.9536 4.0011 0.0 0
M  V30 8 C 5.9536 1.3336 0.0 0
M  V30 9 N 4.4136 4.0011 0.0 0
M  V30 10 O 4.4136 1.3336 0.0 0
M  V30 11 O 6.7236 0.0000 0.0 0
M  V30 12 C 3.6436 5.3347 0.0 0
M  V30 13 O 2.1036 5.3347 0.0 0
M  V30 14 O 4.4136 6.6685 0.0 0
M  V30 15 C 1.3336 6.6685 0.0 0
M  V30 16 C 2.6673 7.4385 0.0 0
M  V30 17 C 0.5636 8.0021 0.0 0
M  V30 18 C 0.0000 5.8985 0.0 0
M  V30 19 C 12.8836 5.3347 0.0 0
M  V30 20 C 13.6536 4.0011 0.0 0
M  V30 21 C 13.6536 6.6685 0.0 0
M  V30 22 C 15.1936 4.0011 0.0 0
M  V30 23 C 15.1936 6.6685 0.0 0
M  V30 24 C 15.9636 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7 CFG=3
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 23
M  V30 23 2 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Norvaline, methyl ester
C6H13NO2
29582-96-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 1.5400 0.0 0 CFG=1
M  V30 2 C 2.6675 2.3100 0.0 0
M  V30 3 C 5.3348 2.3100 0.0 0
M  V30 4 N 4.0011 0.0000 0.0 0
M  V30 5 O 1.3337 1.5400 0.0 0
M  V30 6 O 2.6675 3.8500 0.0 0
M  V30 7 C 6.6686 1.5400 0.0 0
M  V30 8 C 0.0000 2.3100 0.0 0
M  V30 9 C 8.0022 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C22H33N3O7
2757278-18-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 7.7000 0.0 0 CFG=2
M  V30 2 C 5.3347 8.4700 0.0 0
M  V30 3 N 8.0021 8.4700 0.0 0
M  V30 4 C 6.6685 6.1600 0.0 0
M  V30 5 N 5.3347 10.0100 0.0 0
M  V30 6 O 4.0011 7.7000 0.0 0
M  V30 7 C 9.3358 7.7000 0.0 0
M  V30 8 N 5.3347 5.3900 0.0 0
M  V30 9 C 4.0011 10.7800 0.0 0 CFG=1
M  V30 10 O 10.6696 8.4700 0.0 0
M  V30 11 O 9.3358 6.1600 0.0 0
M  V30 12 C 5.3347 3.8500 0.0 0
M  V30 13 C 4.0011 12.3200 0.0 0
M  V30 14 C 2.6674 10.0100 0.0 0
M  V30 15 C 12.0032 7.7000 0.0 0
M  V30 16 O 4.0011 3.0800 0.0 0
M  V30 17 O 6.6685 3.0800 0.0 0
M  V30 18 O 2.6674 13.0900 0.0 0
M  V30 19 O 5.3347 13.0900 0.0 0
M  V30 20 C 1.3338 10.7800 0.0 0
M  V30 21 C 4.0011 1.5400 0.0 0
M  V30 22 C 2.6674 14.6300 0.0 0
M  V30 23 C 0.0000 10.0100 0.0 0
M  V30 24 C 2.4611 1.5400 0.0 0
M  V30 25 C 4.0011 0.0000 0.0 0
M  V30 26 C 5.5411 1.5400 0.0 0
M  V30 27 C 13.3369 8.4700 0.0 0
M  V30 28 C 14.6705 7.7000 0.0 0
M  V30 29 C 13.3369 10.0100 0.0 0
M  V30 30 C 16.0043 8.4700 0.0 0
M  V30 31 C 14.6705 10.7800 0.0 0
M  V30 32 C 16.0043 10.0100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 10 15
M  V30 15 1 12 16
M  V30 16 2 12 17
M  V30 17 1 13 18
M  V30 18 2 13 19
M  V30 19 1 14 20
M  V30 20 1 15 27
M  V30 21 1 16 21
M  V30 22 1 18 22
M  V30 23 1 20 23
M  V30 24 1 21 24
M  V30 25 1 21 25
M  V30 26 1 21 26
M  V30 27 2 27 28
M  V30 28 1 27 29
M  V30 29 1 28 30
M  V30 30 2 29 31
M  V30 31 2 30 32
M  V30 32 1 31 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 16947-84-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 29582-96-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2757278-18-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35054318
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Elastase inhibitor cyclotheonellazole A: Total synthesis and in vivo
biological evaluation for acute lung injury
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Cui, Yingjun; Zhang, Mengyi; Xu, Honglei; Zhang, Tingrong; Zhang,
Songming; Zhao, Xiuhe; Jiang, Peng; Li, Jing; Ye, Baijun; Sun, Yuanjun;
Wang, Mukuo; Deng, Yangping; Meng, Qing; Liu, Yang; Fu, Qiang; Lin,
Jianping; Wang, Liang; Chen, Yue
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(4), 2971-2987

$RFMT $RIREG SCHEME321 STEP1
$RXN



  2  1
$MOL
3-Hydroxy-2-methylbenzoic acid
C8H8O3
603-80-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 3.0800 0.0 0
M  V30 2 O 6.6685 2.3100 0.0 0
M  V30 3 O 5.3347 4.6200 0.0 0
M  V30 4 C 2.6674 4.6200 0.0 0
M  V30 5 O 0.0000 3.0800 0.0 0
M  V30 6 C 4.0011 2.3100 0.0 0
M  V30 7 C 2.6674 3.0800 0.0 0
M  V30 8 C 4.0011 0.7700 0.0 0
M  V30 9 C 1.3338 2.3100 0.0 0
M  V30 10 C 2.6674 0.0000 0.0 0
M  V30 11 C 1.3338 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Aspartic acid, 1,4-bis(1,1-dimethylethyl) ester, hydrochloride (1:1)
C12H23NO4.ClH
1791-13-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 3.0800 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0 CFG=2
M  V30 3 C 8.0022 3.8501 0.0 0
M  V30 4 C 4.0012 3.0800 0.0 0
M  V30 5 N 5.3348 5.3901 0.0 0
M  V30 6 O 9.3360 3.0800 0.0 0
M  V30 7 O 8.0022 5.3901 0.0 0
M  V30 8 O 2.6673 3.8501 0.0 0
M  V30 9 O 4.0012 1.5400 0.0 0
M  V30 10 C 10.6697 3.8501 0.0 0
M  V30 11 C 1.3337 3.0800 0.0 0
M  V30 12 C 11.4397 2.5164 0.0 0
M  V30 13 C 12.0033 4.6201 0.0 0
M  V30 14 C 9.8996 5.1837 0.0 0
M  V30 15 C 0.5637 4.4137 0.0 0
M  V30 16 C 0.0000 2.3100 0.0 0
M  V30 17 C 2.1037 1.7464 0.0 0
M  V30 18 Cl 6.0017 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 2 5 CFG=1
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 1 6 10
M  V30 10 1 8 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 13 1 10 14
M  V30 14 1 11 15
M  V30 15 1 11 16
M  V30 16 1 11 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Aspartic acid, N-(3-hydroxy-2-methylbenzoyl)-, 1,4-bis(1,1-dimethylethyl) e...
C20H29NO6
3070238-05-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 5.3347 0.0 0 CFG=1
M  V30 2 N 5.3900 5.3347 0.0 0
M  V30 3 C 7.7000 4.0011 0.0 0
M  V30 4 C 7.7000 6.6685 0.0 0
M  V30 5 C 4.6200 6.6685 0.0 0
M  V30 6 O 6.9300 2.6674 0.0 0
M  V30 7 O 9.2400 4.0011 0.0 0
M  V30 8 C 9.2400 6.6685 0.0 0
M  V30 9 O 5.3900 8.0021 0.0 0
M  V30 10 C 7.7000 1.3336 0.0 0
M  V30 11 O 10.0100 8.0021 0.0 0
M  V30 12 O 10.0100 5.3347 0.0 0
M  V30 13 C 9.0336 2.1036 0.0 0
M  V30 14 C 8.4700 0.0000 0.0 0
M  V30 15 C 6.3664 0.5636 0.0 0
M  V30 16 C 11.5500 8.0021 0.0 0
M  V30 17 C 11.5500 6.4621 0.0 0
M  V30 18 C 13.0900 8.0021 0.0 0
M  V30 19 C 11.5500 9.5421 0.0 0
M  V30 20 C 3.0800 9.3358 0.0 0
M  V30 21 O 0.0000 9.3358 0.0 0
M  V30 22 C 3.0800 6.6685 0.0 0
M  V30 23 C 2.3100 8.0021 0.0 0
M  V30 24 C 2.3100 5.3347 0.0 0
M  V30 25 C 0.7700 8.0021 0.0 0
M  V30 26 C 0.7700 5.3347 0.0 0
M  V30 27 C 0.0000 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 2 5 9
M  V30 9 1 5 22
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 2 8 12
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 1 10 15
M  V30 16 1 11 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 16 19
M  V30 20 1 20 23
M  V30 21 1 21 25
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 603-80-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1791-13-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3070238-05-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37842851
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a novel series of medium-sized cyclic enteropeptidase
inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kikuchi, Fumiaki; Ikeda, Zenichi; Kakegawa, Keiko; Nishikawa, Youichi;
Sasaki, Shigekazu; Fukuda, Koichiro; Takami, Kazuaki; Banno, Yoshihiro;
Nishikawa, Hitoaki; Taya, Naohiro; Nakahata, Takashi; Itono, Sachiko;
Yashiro, Hiroaki; Tsuchimori, Kazue; Hiyoshi, Hideyuki; Sasaki, Masako;
Tohyama, Kimio; Matsumiya, Kouta; Ishihara, Youko; Kawamoto, Tetsuji;
Kamaura, Masahiro; Watanabe, Masanori; Kitazaki, Tomoyuki; Maekawa,
Tsuyoshi; Sasaki, Minoru
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2023), 93117462

$RFMT $RIREG SCHEME322 STEP1
$RXN



  2  1
$MOL
1-(Phenylmethyl) hydrogen N-[(phenylmethoxy)carbonyl]-L-glutamate
C20H21NO6
3705-42-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7002 5.3348 0.0 0 CFG=2
M  V30 2 C 9.2402 5.3348 0.0 0
M  V30 3 N 6.9302 6.6685 0.0 0
M  V30 4 C 6.9302 4.0012 0.0 0
M  V30 5 O 10.0102 6.6685 0.0 0
M  V30 6 O 10.0102 4.0012 0.0 0
M  V30 7 C 5.3901 6.6685 0.0 0
M  V30 8 C 7.7002 2.6673 0.0 0
M  V30 9 C 11.5503 6.6685 0.0 0
M  V30 10 O 4.6201 8.0022 0.0 0
M  V30 11 O 4.6201 5.3348 0.0 0
M  V30 12 C 6.9302 1.3337 0.0 0
M  V30 13 C 3.0801 8.0022 0.0 0
M  V30 14 O 7.7002 0.0000 0.0 0
M  V30 15 O 5.3901 1.3337 0.0 0
M  V30 16 C 12.3203 8.0022 0.0 0
M  V30 17 C 13.8603 8.0022 0.0 0
M  V30 18 C 11.5503 9.3360 0.0 0
M  V30 19 C 14.6303 9.3360 0.0 0
M  V30 20 C 12.3203 10.6697 0.0 0
M  V30 21 C 13.8603 10.6697 0.0 0
M  V30 22 C 2.3101 9.3360 0.0 0
M  V30 23 C 3.0801 10.6697 0.0 0
M  V30 24 C 0.7700 9.3360 0.0 0
M  V30 25 C 2.3101 12.0033 0.0 0
M  V30 26 C 0.0000 10.6697 0.0 0
M  V30 27 C 0.7700 12.0033 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 16
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 22
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
2-Propanamine, hydrochloride (1:1)
C3H9N.ClH
15572-56-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.0800 0.0 0
M  V30 2 C 0.0000 3.8501 0.0 0
M  V30 3 C 2.6673 3.8501 0.0 0
M  V30 4 N 1.3337 1.5400 0.0 0
M  V30 5 Cl 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(1-Methylethyl)-N2-[(phenylmethoxy)carbonyl]-L-glutamine phenylmethyl ester
C23H28N2O5
138594-81-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9302 8.0022 0.0 0 CFG=2
M  V30 2 C 6.1601 6.6685 0.0 0
M  V30 3 N 8.4702 8.0022 0.0 0
M  V30 4 C 6.1601 9.3360 0.0 0
M  V30 5 O 6.9302 5.3348 0.0 0
M  V30 6 O 4.6201 6.6685 0.0 0
M  V30 7 C 9.2402 9.3360 0.0 0
M  V30 8 C 4.6201 9.3360 0.0 0
M  V30 9 C 6.1601 4.0010 0.0 0
M  V30 10 O 10.7802 9.3360 0.0 0
M  V30 11 O 8.4702 10.6697 0.0 0
M  V30 12 C 3.8501 10.6697 0.0 0
M  V30 13 C 11.5503 10.6697 0.0 0
M  V30 14 N 2.3101 10.6697 0.0 0
M  V30 15 O 4.6201 12.0033 0.0 0
M  V30 16 C 1.5400 12.0033 0.0 0
M  V30 17 C 0.0000 12.0033 0.0 0
M  V30 18 C 2.3101 13.3370 0.0 0
M  V30 19 C 6.9302 2.6673 0.0 0
M  V30 20 C 8.4702 2.6673 0.0 0
M  V30 21 C 6.1601 1.3337 0.0 0
M  V30 22 C 9.2402 1.3337 0.0 0
M  V30 23 C 6.9302 0.0000 0.0 0
M  V30 24 C 8.4702 0.0000 0.0 0
M  V30 25 C 13.0903 10.6697 0.0 0
M  V30 26 C 13.8603 9.3360 0.0 0
M  V30 27 C 13.8603 12.0033 0.0 0
M  V30 28 C 15.4003 9.3360 0.0 0
M  V30 29 C 15.4003 12.0033 0.0 0
M  V30 30 C 16.1704 10.6697 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 19
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 25
M  V30 17 1 14 16
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3705-42-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 15572-56-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 138594-81-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37376187
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhu, Junjie; Lei, Saifei; Lu, Jie; Hao, Yixuan; Qian, Qi; Devanathan,
Aaron S.; Feng, Zhiwei; Xie, Xiang-Qun; Wipf, Peter; Ma, Xiaochao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 259115666

$RFMT $RIREG SCHEME323 STEP1
$RXN



  2  1
$MOL
Fluorenone-4-carboxylic acid
C14H8O3
6223-83-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6520 4.3201 0.0 0
M  V30 2 O 7.9856 5.0901 0.0 0
M  V30 3 O 6.6520 2.7800 0.0 0
M  V30 4 O 0.0000 4.3798 0.0 0
M  V30 5 C 3.9845 4.3201 0.0 0
M  V30 6 C 3.6643 2.8138 0.0 0
M  V30 7 C 2.6508 5.0901 0.0 0
M  V30 8 C 5.3182 5.0901 0.0 0
M  V30 9 C 2.1328 2.6527 0.0 0
M  V30 10 C 4.5696 1.5679 0.0 0
M  V30 11 C 1.5064 4.0597 0.0 0
M  V30 12 C 2.6508 6.6301 0.0 0
M  V30 13 C 5.3182 6.6301 0.0 0
M  V30 14 C 1.5064 1.2459 0.0 0
M  V30 15 C 3.9432 0.1609 0.0 0
M  V30 16 C 3.9845 7.4001 0.0 0
M  V30 17 C 2.4115 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 2 4 11
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 2 7 12
M  V30 12 1 8 13
M  V30 13 1 9 11
M  V30 14 2 9 14
M  V30 15 1 10 15
M  V30 16 1 12 16
M  V30 17 2 13 16
M  V30 18 1 14 17
M  V30 19 2 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenebutanoic acid, -amino-, methyl ester, hydrochloride (1:1)
C11H15NO2.ClH
1001427-55-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 4.6201 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0
M  V30 3 C 6.6685 4.6201 0.0 0
M  V30 4 N 5.3348 2.3100 0.0 0
M  V30 5 C 8.0023 3.8501 0.0 0
M  V30 6 O 9.3360 4.6201 0.0 0
M  V30 7 O 8.0023 2.3100 0.0 0
M  V30 8 C 10.6697 3.8501 0.0 0
M  V30 9 C 2.6673 3.8501 0.0 0
M  V30 10 C 1.3337 4.6201 0.0 0
M  V30 11 C 2.6673 2.3100 0.0 0
M  V30 12 C 0.0000 3.8501 0.0 0
M  V30 13 C 1.3337 1.5400 0.0 0
M  V30 14 C 0.0000 2.3100 0.0 0
M  V30 15 Cl 5.3348 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenebutanoic acid, -[[(9-oxo-9H-fluoren-4-yl)carbonyl]amino]-, methyl ester
C25H21NO4
3031559-99-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7905 6.6685 0.0 0
M  V30 2 N 6.5605 5.3348 0.0 0
M  V30 3 O 6.5605 8.0022 0.0 0
M  V30 4 C 8.1006 5.3348 0.0 0
M  V30 5 C 8.8706 6.6685 0.0 0
M  V30 6 C 8.8706 4.0012 0.0 0
M  V30 7 C 8.1006 2.6673 0.0 0
M  V30 8 O 8.8706 1.3337 0.0 0
M  V30 9 O 6.5605 2.6673 0.0 0
M  V30 10 C 8.1006 0.0000 0.0 0
M  V30 11 O 0.0000 9.9428 0.0 0
M  V30 12 C 3.4805 8.0022 0.0 0
M  V30 13 C 3.9565 9.4669 0.0 0
M  V30 14 C 1.9404 8.0022 0.0 0
M  V30 15 C 4.2505 6.6685 0.0 0
M  V30 16 C 2.7105 10.3721 0.0 0
M  V30 17 C 5.3633 10.0932 0.0 0
M  V30 18 C 1.4646 9.4669 0.0 0
M  V30 19 C 1.1704 6.6685 0.0 0
M  V30 20 C 3.4805 5.3348 0.0 0
M  V30 21 C 2.8715 11.9037 0.0 0
M  V30 22 C 5.5243 11.6248 0.0 0
M  V30 23 C 1.9404 5.3348 0.0 0
M  V30 24 C 4.2784 12.5300 0.0 0
M  V30 25 C 10.4106 6.6685 0.0 0
M  V30 26 C 11.1806 5.3348 0.0 0
M  V30 27 C 11.1806 8.0022 0.0 0
M  V30 28 C 12.7207 5.3348 0.0 0
M  V30 29 C 12.7207 8.0022 0.0 0
M  V30 30 C 13.4907 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 25
M  V30 8 1 6 7
M  V30 9 1 7 8
M  V30 10 2 7 9
M  V30 11 1 8 10
M  V30 12 2 11 18
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 2 14 19
M  V30 20 1 15 20
M  V30 21 1 16 18
M  V30 22 2 16 21
M  V30 23 1 17 22
M  V30 24 1 19 23
M  V30 25 2 20 23
M  V30 26 1 21 24
M  V30 27 2 22 24
M  V30 28 2 25 26
M  V30 29 1 25 27
M  V30 30 1 26 28
M  V30 31 2 27 29
M  V30 32 2 28 30
M  V30 33 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6223-83-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1001427-55-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031559-99-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40678197
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by
Fragment-Based Drug Discovery
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Narayanan, Dilip; Tran, Kim T.; Pallesen, Jakob S.; Solbak, Sara M. Oe.;
Qin, Yuting; Mukminova, Elina; Luchini, Martina; Vasilyeva, Kristina O.;
Gonzalez Chichon, Dorleta; Goutsiou, Georgia; Poulsen, Cecilie; Haapanen,
Nanna; Popowicz, Grzegorz M.; Sattler, Michael; Olagnier, David; Gajhede,
Michael; Bach, Anders
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(21), 14481-14526

$RFMT $RIREG SCHEME324 STEP1
$RXN



  2  1
$MOL
1,1-Dimethylethyl 2-amino-5-chlorobenzoate
C11H14ClNO2
871124-99-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 2.6673 0.0 0
M  V30 2 O 5.3900 4.0009 0.0 0
M  V30 3 O 5.3900 1.3336 0.0 0
M  V30 4 C 6.9300 4.0009 0.0 0
M  V30 5 C 6.9300 5.5409 0.0 0
M  V30 6 C 8.4700 4.0009 0.0 0
M  V30 7 C 6.9300 2.4609 0.0 0
M  V30 8 N 3.0800 0.0000 0.0 0
M  V30 9 Cl 0.0000 5.3347 0.0 0
M  V30 10 C 3.0800 2.6673 0.0 0
M  V30 11 C 2.3100 1.3336 0.0 0
M  V30 12 C 2.3100 4.0009 0.0 0
M  V30 13 C 0.7700 1.3336 0.0 0
M  V30 14 C 0.7700 4.0009 0.0 0
M  V30 15 C 0.0000 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 11
M  V30 9 1 9 14
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Acetic acid, 2-[[[3,5-bis(trifluoromethyl)phenyl]methyl]thio]-
C11H8F6O2S
3087166-25-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 6.1601 0.0 0
M  V30 2 F 2.1037 7.4937 0.0 0
M  V30 3 F 0.0000 6.9301 0.0 0
M  V30 4 F 0.5636 4.8264 0.0 0
M  V30 5 C 4.0011 1.5400 0.0 0
M  V30 6 F 2.4611 1.5400 0.0 0
M  V30 7 F 4.0011 0.0000 0.0 0
M  V30 8 F 5.5411 1.5400 0.0 0
M  V30 9 C 6.6684 6.1601 0.0 0
M  V30 10 S 8.0021 5.3901 0.0 0
M  V30 11 C 9.3359 6.1601 0.0 0
M  V30 12 C 10.6695 5.3901 0.0 0
M  V30 13 O 12.0032 6.1601 0.0 0
M  V30 14 O 10.6695 3.8500 0.0 0
M  V30 15 C 2.6673 5.3901 0.0 0
M  V30 16 C 2.6673 3.8500 0.0 0
M  V30 17 C 4.0011 6.1601 0.0 0
M  V30 18 C 4.0011 3.0800 0.0 0
M  V30 19 C 5.3348 5.3901 0.0 0
M  V30 20 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 15
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 5 18
M  V30 9 1 9 10
M  V30 10 1 9 19
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 2-[[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl]thio]acetyl]amin...
C22H21F6NO3S
3087166-26-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5409 5.3900 0.0 0
M  V30 2 C 6.8747 6.1600 0.0 0
M  V30 3 C 8.2084 5.3900 0.0 0
M  V30 4 O 6.8747 7.7000 0.0 0
M  V30 5 S 8.2084 3.8500 0.0 0
M  V30 6 C 9.5420 3.0800 0.0 0
M  V30 7 C 2.8736 3.8500 0.0 0
M  V30 8 O 1.5400 3.0800 0.0 0
M  V30 9 O 4.2073 3.0800 0.0 0
M  V30 10 C 1.5400 1.5400 0.0 0
M  V30 11 C 3.0800 1.5400 0.0 0
M  V30 12 C 1.5400 0.0000 0.0 0
M  V30 13 C 0.0000 1.5400 0.0 0
M  V30 14 C 12.2094 7.7000 0.0 0
M  V30 15 F 13.7494 7.7000 0.0 0
M  V30 16 F 12.2094 9.2400 0.0 0
M  V30 17 F 10.6694 7.7000 0.0 0
M  V30 18 C 14.8767 3.0800 0.0 0
M  V30 19 F 14.1067 1.7464 0.0 0
M  V30 20 F 16.2103 2.3100 0.0 0
M  V30 21 F 15.6467 4.4136 0.0 0
M  V30 22 C 4.2073 6.1600 0.0 0
M  V30 23 C 2.8736 5.3900 0.0 0
M  V30 24 C 4.2073 7.7000 0.0 0
M  V30 25 C 1.5400 6.1600 0.0 0
M  V30 26 C 2.8736 8.4700 0.0 0
M  V30 27 C 1.5400 7.7000 0.0 0
M  V30 28 C 10.8756 3.8500 0.0 0
M  V30 29 C 10.8756 5.3900 0.0 0
M  V30 30 C 12.2094 3.0800 0.0 0
M  V30 31 C 12.2094 6.1600 0.0 0
M  V30 32 C 13.5431 3.8500 0.0 0
M  V30 33 C 13.5431 5.3900 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 22
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 28
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 23
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 1 10 12
M  V30 14 1 10 13
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 1 14 31
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 1 18 32
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 29 31
M  V30 32 2 30 32
M  V30 33 2 31 33
M  V30 34 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 871124-99-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3087166-25-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3087166-26-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40093181
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Identification of ss-Glucocerebrosidase Activators for Glucosylceramide
hydrolysis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Schulze, Monika-Sarah E. D.; Scholz, Diana; Jnoff, Eric; Hall, Adrian;
Melin, Jonathan; Sands, Zara A.; Rodriguez, Elizabeth; Andre, Veronique
M.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2024), 19(7), e202300548

$RFMT $RIREG SCHEME325 STEP1
$RXN



  2  1
$MOL
Mefenamic acid
C15H15NO2
61-68-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0011 2.3100 0.0 0
M  V30 2 C 1.3336 0.7700 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 O 2.6674 0.0000 0.0 0
M  V30 5 C 6.6684 0.7700 0.0 0
M  V30 6 C 9.3358 2.3100 0.0 0
M  V30 7 C 2.6674 3.0800 0.0 0
M  V30 8 C 1.3336 2.3100 0.0 0
M  V30 9 C 2.6674 4.6200 0.0 0
M  V30 10 C 0.0000 3.0800 0.0 0
M  V30 11 C 1.3336 5.3900 0.0 0
M  V30 12 C 0.0000 4.6200 0.0 0
M  V30 13 C 5.3347 3.0800 0.0 0
M  V30 14 C 6.6684 2.3100 0.0 0
M  V30 15 C 5.3347 4.6200 0.0 0
M  V30 16 C 8.0021 3.0800 0.0 0
M  V30 17 C 6.6684 5.3900 0.0 0
M  V30 18 C 8.0021 4.6200 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 7
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 8
M  V30 6 1 5 14
M  V30 7 1 6 16
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1,N1-Didodecyl-N2-methyl-1,2-ethanediamine
C27H59N2.I
2128731-38-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 13.8600 5.3900 0.0 0 CHG=1 VAL=4
M  V30 2 C 12.3200 5.3900 0.0 0
M  V30 3 C 15.4000 5.3900 0.0 0
M  V30 4 C 13.8600 3.8500 0.0 0
M  V30 5 C 13.8600 6.9300 0.0 0
M  V30 6 C 11.5500 6.7236 0.0 0
M  V30 7 C 16.1700 6.7236 0.0 0
M  V30 8 C 12.5264 3.0800 0.0 0
M  V30 9 C 10.0100 6.7236 0.0 0
M  V30 10 C 17.7100 6.7236 0.0 0
M  V30 11 N 12.5264 1.5400 0.0 0
M  V30 12 C 9.2400 8.0574 0.0 0
M  V30 13 C 18.4800 8.0574 0.0 0
M  V30 14 C 7.7000 8.0574 0.0 0
M  V30 15 C 20.0200 8.0574 0.0 0
M  V30 16 C 6.9300 9.3911 0.0 0
M  V30 17 C 20.7900 9.3911 0.0 0
M  V30 18 C 5.3900 9.3911 0.0 0
M  V30 19 C 22.3300 9.3911 0.0 0
M  V30 20 C 4.6200 10.7247 0.0 0
M  V30 21 C 23.1000 10.7247 0.0 0
M  V30 22 C 3.0800 10.7247 0.0 0
M  V30 23 C 24.6400 10.7247 0.0 0
M  V30 24 C 2.3100 12.0585 0.0 0
M  V30 25 C 25.4100 12.0585 0.0 0
M  V30 26 C 0.7700 12.0585 0.0 0
M  V30 27 C 26.9500 12.0585 0.0 0
M  V30 28 C 0.0000 13.3921 0.0 0
M  V30 29 C 27.7200 13.3921 0.0 0
M  V30 30 I 13.8600 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 10 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Dodecanaminium, N-[2-[[2-[(2,3-dimethylphenyl)amino]benzoyl]amino]ethyl]-N-...
C42H72N3O.I
3055833-26-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  47 47 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.7002 20.2118 0.0 0
M  V30 2 N 9.2402 20.2118 0.0 0
M  V30 3 O 6.9302 18.8782 0.0 0
M  V30 4 C 10.0102 18.8782 0.0 0
M  V30 5 C 11.5503 18.8782 0.0 0
M  V30 6 N 12.3203 17.5445 0.0 0 CHG=1 VAL=4
M  V30 7 C 13.0903 16.2108 0.0 0
M  V30 8 C 13.6541 18.3145 0.0 0
M  V30 9 C 10.9866 16.7745 0.0 0
M  V30 10 C 12.3203 14.8770 0.0 0
M  V30 11 C 14.9878 17.5445 0.0 0
M  V30 12 C 13.0903 13.5433 0.0 0
M  V30 13 C 16.3214 18.3145 0.0 0
M  V30 14 C 12.3203 12.2097 0.0 0
M  V30 15 C 17.6551 17.5445 0.0 0
M  V30 16 C 13.0903 10.8760 0.0 0
M  V30 17 C 18.9889 18.3145 0.0 0
M  V30 18 C 12.3203 9.5422 0.0 0
M  V30 19 C 20.3226 17.5445 0.0 0
M  V30 20 C 13.0903 8.2085 0.0 0
M  V30 21 C 21.6563 18.3145 0.0 0
M  V30 22 C 12.3203 6.8748 0.0 0
M  V30 23 C 22.9899 17.5445 0.0 0
M  V30 24 C 13.0903 5.5412 0.0 0
M  V30 25 C 24.3238 18.3145 0.0 0
M  V30 26 C 12.3203 4.2073 0.0 0
M  V30 27 C 25.6574 17.5445 0.0 0
M  V30 28 C 13.0903 2.8737 0.0 0
M  V30 29 C 26.9911 18.3145 0.0 0
M  V30 30 C 12.3203 1.5400 0.0 0
M  V30 31 C 28.3249 17.5445 0.0 0
M  V30 32 N 4.6201 20.2118 0.0 0
M  V30 33 C 3.0801 17.5445 0.0 0
M  V30 34 C 0.0000 17.5445 0.0 0
M  V30 35 C 6.9302 21.5457 0.0 0
M  V30 36 C 5.3901 21.5457 0.0 0
M  V30 37 C 7.7002 22.8793 0.0 0
M  V30 38 C 4.6201 22.8793 0.0 0
M  V30 39 C 6.9302 24.2130 0.0 0
M  V30 40 C 5.3901 24.2130 0.0 0
M  V30 41 C 3.0801 20.2118 0.0 0
M  V30 42 C 2.3101 18.8782 0.0 0
M  V30 43 C 2.3101 21.5457 0.0 0
M  V30 44 C 0.7700 18.8782 0.0 0
M  V30 45 C 0.7700 21.5457 0.0 0
M  V30 46 C 0.0000 20.2118 0.0 0
M  V30 47 I 14.1625 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 35
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 1 29 31
M  V30 32 1 32 36
M  V30 33 1 32 41
M  V30 34 1 33 42
M  V30 35 1 34 44
M  V30 36 2 35 36
M  V30 37 1 35 37
M  V30 38 1 36 38
M  V30 39 2 37 39
M  V30 40 2 38 40
M  V30 41 1 39 40
M  V30 42 2 41 42
M  V30 43 1 41 43
M  V30 44 1 42 44
M  V30 45 2 43 45
M  V30 46 2 44 46
M  V30 47 1 45 46
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 61-68-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2128731-38-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3055833-26-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37275693
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM inert in stage 2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and Characterization of a New Cationic Lipid: Efficient siRNA
Delivery and Anticancer Activity of Survivin-siRNA Lipoplexes for the
Treatment of Lung and Breast Cancers
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Vaidya, Sandeep; Mohod, Annie; Eedara, Abhisheik Chowdary; Andugulapati,
Sai Balaji; Pabbaraja, Srihari
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(16), e202300097

$RFMT $RIREG SCHEME326 STEP1
$RXN



  2  1
$MOL
Fluorenone-4-carboxylic acid
C14H8O3
6223-83-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6520 4.3201 0.0 0
M  V30 2 O 7.9856 5.0901 0.0 0
M  V30 3 O 6.6520 2.7800 0.0 0
M  V30 4 O 0.0000 4.3798 0.0 0
M  V30 5 C 3.9845 4.3201 0.0 0
M  V30 6 C 3.6643 2.8138 0.0 0
M  V30 7 C 2.6508 5.0901 0.0 0
M  V30 8 C 5.3182 5.0901 0.0 0
M  V30 9 C 2.1328 2.6527 0.0 0
M  V30 10 C 4.5696 1.5679 0.0 0
M  V30 11 C 1.5064 4.0597 0.0 0
M  V30 12 C 2.6508 6.6301 0.0 0
M  V30 13 C 5.3182 6.6301 0.0 0
M  V30 14 C 1.5064 1.2459 0.0 0
M  V30 15 C 3.9432 0.1609 0.0 0
M  V30 16 C 3.9845 7.4001 0.0 0
M  V30 17 C 2.4115 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 2 4 11
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 2 7 12
M  V30 12 1 8 13
M  V30 13 1 9 11
M  V30 14 2 9 14
M  V30 15 1 10 15
M  V30 16 1 12 16
M  V30 17 2 13 16
M  V30 18 1 14 17
M  V30 19 2 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenepropanoic acid, -amino-, methyl ester, hydrochloride (1:1)
C10H13NO2.ClH
88831-43-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 4.6200 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0
M  V30 3 N 4.0011 6.1600 0.0 0
M  V30 4 C 6.6684 4.6200 0.0 0
M  V30 5 O 8.0021 3.8500 0.0 0
M  V30 6 O 6.6684 6.1600 0.0 0
M  V30 7 C 9.3358 4.6200 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 4.6200 0.0 0
M  V30 10 C 2.6674 2.3100 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 1.5400 0.0 0
M  V30 13 C 0.0000 2.3100 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 5 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenepropanoic acid, -[[(9-oxo-9H-fluoren-4-yl)carbonyl]amino]-, methyl ester
C24H19NO4
3031559-98-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 5.3348 5.3901 0.0 0
M  V30 3 O 6.6685 3.0801 0.0 0
M  V30 4 C 4.0010 4.6201 0.0 0
M  V30 5 C 4.0010 3.0801 0.0 0
M  V30 6 C 2.6673 2.3101 0.0 0
M  V30 7 O 2.6673 0.7700 0.0 0
M  V30 8 O 1.3337 3.0801 0.0 0
M  V30 9 C 1.3337 0.0000 0.0 0
M  V30 10 O 13.3204 4.6799 0.0 0
M  V30 11 C 9.3358 4.6201 0.0 0
M  V30 12 C 9.6560 3.1138 0.0 0
M  V30 13 C 10.6697 5.3901 0.0 0
M  V30 14 C 8.0022 5.3901 0.0 0
M  V30 15 C 11.1877 2.9527 0.0 0
M  V30 16 C 8.7509 1.8678 0.0 0
M  V30 17 C 11.8141 4.3597 0.0 0
M  V30 18 C 10.6697 6.9302 0.0 0
M  V30 19 C 8.0022 6.9302 0.0 0
M  V30 20 C 11.8141 1.5459 0.0 0
M  V30 21 C 9.3773 0.4609 0.0 0
M  V30 22 C 9.3358 7.7002 0.0 0
M  V30 23 C 10.9088 0.3000 0.0 0
M  V30 24 C 2.6673 5.3901 0.0 0
M  V30 25 C 1.3337 4.6201 0.0 0
M  V30 26 C 2.6673 6.9302 0.0 0
M  V30 27 C 0.0000 5.3901 0.0 0
M  V30 28 C 1.3337 7.7002 0.0 0
M  V30 29 C 0.0000 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 24
M  V30 7 1 5 6
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 7 9
M  V30 11 2 10 17
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 2 13 18
M  V30 19 1 14 19
M  V30 20 1 15 17
M  V30 21 2 15 20
M  V30 22 1 16 21
M  V30 23 1 18 22
M  V30 24 2 19 22
M  V30 25 1 20 23
M  V30 26 2 21 23
M  V30 27 2 24 25
M  V30 28 1 24 26
M  V30 29 1 25 27
M  V30 30 2 26 28
M  V30 31 2 27 29
M  V30 32 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6223-83-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 88831-43-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031559-98-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40678201
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by
Fragment-Based Drug Discovery
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Narayanan, Dilip; Tran, Kim T.; Pallesen, Jakob S.; Solbak, Sara M. Oe.;
Qin, Yuting; Mukminova, Elina; Luchini, Martina; Vasilyeva, Kristina O.;
Gonzalez Chichon, Dorleta; Goutsiou, Georgia; Poulsen, Cecilie; Haapanen,
Nanna; Popowicz, Grzegorz M.; Sattler, Michael; Olagnier, David; Gajhede,
Michael; Bach, Anders
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(21), 14481-14526

$RFMT $RIREG SCHEME327 STEP1
$RXN



  2  1
$MOL
2,6-Dimethyl-3-pyridinamine
C7H10N2
3430-33-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 0.0000 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 C 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 N 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[[[(4-Fluorophenyl)sulfonyl]amino]methyl]benzoic acid
C14H12FNO4S
438575-58-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 9.2400 1.5400 0.0 0 VAL=6
M  V30 2 N 7.7000 1.5400 0.0 0
M  V30 3 O 9.2400 3.0800 0.0 0
M  V30 4 O 9.2400 0.0000 0.0 0
M  V30 5 C 6.9300 2.8736 0.0 0
M  V30 6 F 15.4000 1.5400 0.0 0
M  V30 7 C 0.7700 2.8736 0.0 0
M  V30 8 O 0.0000 4.2073 0.0 0
M  V30 9 O 0.0000 1.5400 0.0 0
M  V30 10 C 10.7800 1.5400 0.0 0
M  V30 11 C 11.5500 0.2062 0.0 0
M  V30 12 C 11.5500 2.8736 0.0 0
M  V30 13 C 13.0900 0.2062 0.0 0
M  V30 14 C 13.0900 2.8736 0.0 0
M  V30 15 C 13.8600 1.5400 0.0 0
M  V30 16 C 5.3900 2.8736 0.0 0
M  V30 17 C 4.6200 4.2073 0.0 0
M  V30 18 C 4.6200 1.5400 0.0 0
M  V30 19 C 3.0800 4.2073 0.0 0
M  V30 20 C 3.0800 1.5400 0.0 0
M  V30 21 C 2.3100 2.8736 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 5 16
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 21
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(2,6-Dimethyl-3-pyridinyl)-4-[[[(4-fluorophenyl)sulfonyl]amino]methyl]benza...
C21H20FN3O3S
2581109-86-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 4.0011 0.0 0
M  V30 2 N 6.1600 2.6674 0.0 0
M  V30 3 O 6.1600 5.3349 0.0 0
M  V30 4 C 13.0900 4.0011 0.0 0
M  V30 5 N 13.8600 5.3349 0.0 0
M  V30 6 S 15.4000 5.3349 0.0 0 VAL=6
M  V30 7 O 15.4000 6.8749 0.0 0
M  V30 8 O 15.4000 3.7949 0.0 0
M  V30 9 C 4.6200 0.0000 0.0 0
M  V30 10 C 0.0000 2.6674 0.0 0
M  V30 11 F 21.5600 5.3349 0.0 0
M  V30 12 C 8.4700 4.0011 0.0 0
M  V30 13 C 9.2400 2.6674 0.0 0
M  V30 14 C 9.2400 5.3349 0.0 0
M  V30 15 C 10.7800 2.6674 0.0 0
M  V30 16 C 10.7800 5.3349 0.0 0
M  V30 17 C 11.5500 4.0011 0.0 0
M  V30 18 C 4.6200 2.6674 0.0 0
M  V30 19 C 3.8500 1.3338 0.0 0
M  V30 20 C 3.8500 4.0011 0.0 0
M  V30 21 N 2.3100 1.3338 0.0 0
M  V30 22 C 2.3100 4.0011 0.0 0
M  V30 23 C 1.5400 2.6674 0.0 0
M  V30 24 C 16.9400 5.3349 0.0 0
M  V30 25 C 17.7100 4.0011 0.0 0
M  V30 26 C 17.7100 6.6685 0.0 0
M  V30 27 C 19.2500 4.0011 0.0 0
M  V30 28 C 19.2500 6.6685 0.0 0
M  V30 29 C 20.0200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 18
M  V30 5 1 4 5
M  V30 6 1 4 17
M  V30 7 1 5 6
M  V30 8 2 6 7
M  V30 9 2 6 8
M  V30 10 1 6 24
M  V30 11 1 9 19
M  V30 12 1 10 23
M  V30 13 1 11 29
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 1 13 15
M  V30 17 2 14 16
M  V30 18 2 15 17
M  V30 19 1 16 17
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 20 22
M  V30 24 2 21 23
M  V30 25 1 22 23
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 2 26 28
M  V30 30 2 27 29
M  V30 31 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3430-33-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 438575-58-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2581109-86-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23338306
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 127-19-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A new chemotype with promise against Trypanosoma cruzi
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Xiaofang; Cal, Monica; Kaiser, Marcel; Buckner, Frederick S.;
Lepesheva, Galina I.; Sanford, Austin G.; Wallick, Alexander I.; Davis,
Paul H.; Vennerstrom, Jonathan L.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(1), 126778

$RFMT $RIREG SCHEME328 STEP1
$RXN



  2  1
$MOL
2-Pyridinemethanamine, 6-bromo--methyl-, hydrochloride (1:1), (S)-
C7H9BrN2.ClH
1415303-42-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 3.0800 0.0 0 CFG=1
M  V30 2 C 0.0000 3.8500 0.0 0
M  V30 3 N 1.3338 1.5400 0.0 0
M  V30 4 Br 6.6686 3.0800 0.0 0
M  V30 5 C 2.6675 3.8500 0.0 0
M  V30 6 N 4.0011 3.0800 0.0 0
M  V30 7 C 2.6675 5.3900 0.0 0
M  V30 8 C 5.3348 3.8500 0.0 0
M  V30 9 C 4.0011 6.1601 0.0 0
M  V30 10 C 5.3348 5.3900 0.0 0
M  V30 11 Cl 3.3343 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
5-[4-(Trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid
C18H11F3O2
2417720-65-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 12.0033 5.3901 0.0 0
M  V30 2 O 12.0033 6.9302 0.0 0
M  V30 3 O 13.3370 4.6201 0.0 0
M  V30 4 C 1.3337 5.3901 0.0 0
M  V30 5 F 2.1037 6.7238 0.0 0
M  V30 6 F 0.0000 6.1601 0.0 0
M  V30 7 F 0.5637 4.0564 0.0 0
M  V30 8 C 8.0022 3.0801 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 9.3360 2.3101 0.0 0
M  V30 11 C 8.0022 4.6201 0.0 0
M  V30 12 C 6.6685 0.7700 0.0 0
M  V30 13 C 10.6697 3.0801 0.0 0
M  V30 14 C 9.3360 0.7700 0.0 0
M  V30 15 C 9.3360 5.3901 0.0 0
M  V30 16 C 8.0022 0.0000 0.0 0
M  V30 17 C 10.6697 4.6201 0.0 0
M  V30 18 C 5.3348 3.0801 0.0 0
M  V30 19 C 4.0010 2.3101 0.0 0
M  V30 20 C 5.3348 4.6201 0.0 0
M  V30 21 C 2.6673 3.0801 0.0 0
M  V30 22 C 4.0010 5.3901 0.0 0
M  V30 23 C 2.6673 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 4 7
M  V30 7 1 4 23
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 11
M  V30 11 2 9 12
M  V30 12 1 9 18
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 2 13 17
M  V30 18 2 14 16
M  V30 19 1 15 17
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 20 22
M  V30 24 2 21 23
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Naphthalenecarboxamide, N-[(1S)-1-(6-bromo-2-pyridinyl)ethyl]-5-[4-(trifluo...
C25H18BrF3N2O
2971850-47-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 12.0033 5.3901 0.0 0
M  V30 2 N 13.3372 4.6201 0.0 0
M  V30 3 O 12.0033 6.9302 0.0 0
M  V30 4 C 14.6708 5.3901 0.0 0 CFG=2
M  V30 5 C 14.6708 6.9302 0.0 0
M  V30 6 C 1.3337 5.3901 0.0 0
M  V30 7 F 2.1037 6.7238 0.0 0
M  V30 8 F 0.0000 6.1601 0.0 0
M  V30 9 F 0.5637 4.0564 0.0 0
M  V30 10 Br 20.0057 5.3901 0.0 0
M  V30 11 C 8.0023 3.0801 0.0 0
M  V30 12 C 6.6685 2.3101 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 14 C 8.0023 4.6201 0.0 0
M  V30 15 C 6.6685 0.7700 0.0 0
M  V30 16 C 10.6697 3.0801 0.0 0
M  V30 17 C 9.3360 0.7700 0.0 0
M  V30 18 C 9.3360 5.3901 0.0 0
M  V30 19 C 8.0023 0.0000 0.0 0
M  V30 20 C 10.6697 4.6201 0.0 0
M  V30 21 C 5.3348 3.0801 0.0 0
M  V30 22 C 4.0012 2.3101 0.0 0
M  V30 23 C 5.3348 4.6201 0.0 0
M  V30 24 C 2.6675 3.0801 0.0 0
M  V30 25 C 4.0012 5.3901 0.0 0
M  V30 26 C 2.6675 4.6201 0.0 0
M  V30 27 C 16.0045 4.6201 0.0 0
M  V30 28 N 17.3382 5.3901 0.0 0
M  V30 29 C 16.0045 3.0801 0.0 0
M  V30 30 C 18.6720 4.6201 0.0 0
M  V30 31 C 17.3382 2.3101 0.0 0
M  V30 32 C 18.6720 3.0801 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 20
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=1
M  V30 6 1 4 27
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 6 26
M  V30 11 1 10 30
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 11 14
M  V30 15 2 12 15
M  V30 16 1 12 21
M  V30 17 1 13 16
M  V30 18 1 13 17
M  V30 19 2 14 18
M  V30 20 1 15 19
M  V30 21 2 16 20
M  V30 22 2 17 19
M  V30 23 1 18 20
M  V30 24 2 21 22
M  V30 25 1 21 23
M  V30 26 1 22 24
M  V30 27 2 23 25
M  V30 28 2 24 26
M  V30 29 1 25 26
M  V30 30 1 27 28
M  V30 31 2 27 29
M  V30 32 2 28 30
M  V30 33 1 29 31
M  V30 34 1 30 32
M  V30 35 2 31 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1415303-42-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2417720-65-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2971850-47-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40459765
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Bioevaluation of Transcriptional Enhanced
Assocciated Domain (TEAD) PROTAC Degraders
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Huajie; Ge, Zhiming; Lin, Kexin; He, Wei; Chu, Qinyu; Zheng, Mingyue;
Zhang, Sulin; Xu, Tianfeng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2024), 15(5), 631-639

$RFMT $RIREG SCHEME329 STEP1
$RXN



  2  1
$MOL
(R)-Chroman-2-carboxylic acid
C10H10O3
83780-47-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6686 1.5400 0.0 0
M  V30 2 O 8.0022 2.3100 0.0 0
M  V30 3 O 6.6686 0.0000 0.0 0
M  V30 4 C 2.6675 2.3100 0.0 0
M  V30 5 C 2.6675 3.8500 0.0 0
M  V30 6 O 4.0011 1.5400 0.0 0
M  V30 7 C 1.3337 1.5400 0.0 0
M  V30 8 C 4.0011 4.6201 0.0 0
M  V30 9 C 1.3337 4.6201 0.0 0
M  V30 10 C 5.3348 2.3100 0.0 0 CFG=1
M  V30 11 C 0.0000 2.3100 0.0 0
M  V30 12 C 5.3348 3.8500 0.0 0
M  V30 13 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 10 1 CFG=3
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 1 5 8
M  V30 8 2 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(+)-1-(1-Naphthyl)ethylamine
C12H13N
3886-70-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 1.3338 0.0 0 CFG=2
M  V30 2 C 6.9300 1.3338 0.0 0
M  V30 3 N 4.6200 0.0000 0.0 0
M  V30 4 C 3.0800 2.6674 0.0 0
M  V30 5 C 2.3100 4.0011 0.0 0
M  V30 6 C 4.6200 2.6674 0.0 0
M  V30 7 C 2.3100 1.3338 0.0 0
M  V30 8 C 3.0800 5.3349 0.0 0
M  V30 9 C 0.7700 4.0011 0.0 0
M  V30 10 C 5.3900 4.0011 0.0 0
M  V30 11 C 0.7700 1.3338 0.0 0
M  V30 12 C 4.6200 5.3349 0.0 0
M  V30 13 C 0.0000 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 6
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 4 7
M  V30 7 1 5 8
M  V30 8 1 5 9
M  V30 9 2 6 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 2 9 13
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(2R)-3,4-Dihydro-N-[(1R)-1-(1-naphthalenyl)ethyl]-2H-1-benzopyran-2-carboxamide
C22H21NO2
1451373-92-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 2.3101 0.0 0 CFG=1
M  V30 2 N 6.6685 3.0801 0.0 0
M  V30 3 C 5.3348 0.7700 0.0 0
M  V30 4 C 8.0022 2.3101 0.0 0
M  V30 5 O 8.0022 0.7700 0.0 0
M  V30 6 C 2.6673 2.3101 0.0 0
M  V30 7 C 4.0010 3.0801 0.0 0
M  V30 8 C 1.3337 3.0801 0.0 0
M  V30 9 C 2.6673 0.7700 0.0 0
M  V30 10 C 4.0010 4.6201 0.0 0
M  V30 11 C 1.3337 4.6201 0.0 0
M  V30 12 C 0.0000 2.3101 0.0 0
M  V30 13 C 1.3337 0.0000 0.0 0
M  V30 14 C 2.6673 5.3901 0.0 0
M  V30 15 C 0.0000 0.7700 0.0 0
M  V30 16 C 9.3358 3.0801 0.0 0 CFG=1
M  V30 17 O 10.6697 2.3101 0.0 0
M  V30 18 C 9.3358 4.6201 0.0 0
M  V30 19 C 12.0033 3.0801 0.0 0
M  V30 20 C 10.6697 5.3901 0.0 0
M  V30 21 C 12.0033 4.6201 0.0 0
M  V30 22 C 13.3370 2.3101 0.0 0
M  V30 23 C 13.3370 5.3901 0.0 0
M  V30 24 C 14.6707 3.0801 0.0 0
M  V30 25 C 14.6707 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 2 4 5
M  V30 6 1 16 4 CFG=1
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 2 9 13
M  V30 14 1 10 14
M  V30 15 2 11 14
M  V30 16 2 12 15
M  V30 17 1 13 15
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 19 22
M  V30 24 1 20 21
M  V30 25 2 21 23
M  V30 26 1 22 24
M  V30 27 1 23 25
M  V30 28 2 24 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 16)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 83780-47-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3886-70-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1451373-92-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37200035
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 107-06-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of LNP1892: A Precision Calcimimetic for the Treatment of
Secondary Hyperparathyroidism
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Shukla, Manojkumar R.; Sadasivam, Gayathri; Sarde, Ankush; Sayyed, Majid;
Pachpute, Vipul; Phadtare, Ramesh; Walke, Navanath; Chaudhari, Vinod D.;
Loriya, Rajesh; Khan, Talha; Gote, Ganesh; Pawar, Chetan; Tryambake,
Mahadeo; Mahajan, Nilesh; Gandhe, Amruta; Sabde, Sudeep; Pawar,
Shashikant; Patil, Vinod; Modi, Dipak; Mehta, Maneesh; Nigade, Prashant;
Modak, Vijay; Ghodke, Ravindra; Narasimham, Lakshmi; Bhonde, Mandar;
Gundu, Jayasagar; Goel, Rajan; Shah, Chirag; Kulkarni, Sanjeev; Sharma,
Sharad; Bakhle, Dhananjay; Kamboj, Rajender Kumar; Palle, Venkata P.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(14), 9418-9444

$RFMT $RIREG SCHEME330 STEP1
$RXN



  2  1
$MOL
1-Aminocyclopropanecarbonitrile
C4H6N2
196311-65-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.9871 2.0433 0.0 0
M  V30 2 N 4.4343 2.5700 0.0 0
M  V30 3 N 1.8075 0.0000 0.0 0
M  V30 4 C 1.5400 1.5166 0.0 0
M  V30 5 C 0.7700 2.8502 0.0 0
M  V30 6 C 0.0000 1.5166 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 3 1 2
M  V30 2 1 1 4
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(4-Methoxy[1,1-biphenyl]-4-yl)carbonyl]-N-(phenylmethyl)glycine
C23H21NO4
2759356-75-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3900 5.3347 0.0 0
M  V30 2 N 4.6200 4.0011 0.0 0
M  V30 3 O 4.6200 6.6685 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 5.3900 2.6674 0.0 0
M  V30 6 C 4.6200 1.3336 0.0 0
M  V30 7 O 5.3900 0.0000 0.0 0
M  V30 8 O 3.0800 1.3336 0.0 0
M  V30 9 O 16.1700 5.3347 0.0 0
M  V30 10 C 16.9400 6.6685 0.0 0
M  V30 11 C 10.0100 5.3347 0.0 0
M  V30 12 C 9.2400 4.0011 0.0 0
M  V30 13 C 9.2400 6.6685 0.0 0
M  V30 14 C 7.7000 4.0011 0.0 0
M  V30 15 C 7.7000 6.6685 0.0 0
M  V30 16 C 6.9300 5.3347 0.0 0
M  V30 17 C 11.5500 5.3347 0.0 0
M  V30 18 C 12.3200 6.6685 0.0 0
M  V30 19 C 12.3200 4.0011 0.0 0
M  V30 20 C 13.8600 6.6685 0.0 0
M  V30 21 C 13.8600 4.0011 0.0 0
M  V30 22 C 14.6300 5.3347 0.0 0
M  V30 23 C 2.3100 5.3347 0.0 0
M  V30 24 C 3.0800 6.6685 0.0 0
M  V30 25 C 0.7700 5.3347 0.0 0
M  V30 26 C 2.3100 8.0021 0.0 0
M  V30 27 C 0.0000 6.6685 0.0 0
M  V30 28 C 0.7700 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 4 23
M  V30 7 1 5 6
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 9 10
M  V30 11 1 9 22
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 11 17
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 22
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 2 25 27
M  V30 29 2 26 28
M  V30 30 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-[(1-Cyanocyclopropyl)amino]-2-oxoethyl]-4-methoxy-N-(phenylmethyl)[1,1...
C27H25N3O3
2760280-60-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.6643 6.6684 0.0 0
M  V30 2 C 5.2043 6.6684 0.0 0
M  V30 3 C 5.9743 5.3347 0.0 0
M  V30 4 O 5.9743 8.0021 0.0 0
M  V30 5 N 7.5143 5.3347 0.0 0
M  V30 6 C 8.2843 6.6684 0.0 0
M  V30 7 C 8.2843 4.0011 0.0 0
M  V30 8 O 7.5143 8.0021 0.0 0
M  V30 9 C 1.4471 7.4755 0.0 0
M  V30 10 N 0.0000 6.9486 0.0 0
M  V30 11 O 19.0643 6.6684 0.0 0
M  V30 12 C 19.8343 8.0021 0.0 0
M  V30 13 C 2.8943 8.0021 0.0 0
M  V30 14 C 4.0739 8.9921 0.0 0
M  V30 15 C 2.6268 9.5187 0.0 0
M  V30 16 C 9.8243 6.6684 0.0 0
M  V30 17 C 10.5943 5.3347 0.0 0
M  V30 18 C 10.5943 8.0021 0.0 0
M  V30 19 C 12.1343 5.3347 0.0 0
M  V30 20 C 12.1343 8.0021 0.0 0
M  V30 21 C 12.9043 6.6684 0.0 0
M  V30 22 C 7.5143 2.6674 0.0 0
M  V30 23 C 5.9743 2.6674 0.0 0
M  V30 24 C 8.2843 1.3336 0.0 0
M  V30 25 C 5.2043 1.3336 0.0 0
M  V30 26 C 7.5143 0.0000 0.0 0
M  V30 27 C 5.9743 0.0000 0.0 0
M  V30 28 C 14.4443 6.6684 0.0 0
M  V30 29 C 15.2143 5.3347 0.0 0
M  V30 30 C 15.2143 8.0021 0.0 0
M  V30 31 C 16.7543 5.3347 0.0 0
M  V30 32 C 16.7543 8.0021 0.0 0
M  V30 33 C 17.5243 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 2 6 8
M  V30 9 1 6 16
M  V30 10 1 7 22
M  V30 11 3 9 10
M  V30 12 1 9 13
M  V30 13 1 11 12
M  V30 14 1 11 33
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 1 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 1 21 28
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 23 25
M  V30 28 2 24 26
M  V30 29 2 25 27
M  V30 30 1 26 27
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 29 31
M  V30 34 2 30 32
M  V30 35 2 31 33
M  V30 36 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 196311-65-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2759356-75-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760280-60-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31510782
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Nitrile-based peptoids as cysteine protease inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Alves, Luana; Santos, Deborah A.; Cendron, Rodrigo; Rocho, Fernanda R.;
Matos, Thiago K. B.; Leitao, Andrei; Montanari, Carlos A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 41116211

$RFMT $RIREG SCHEME331 STEP1
$RXN



  2  1
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Methyl-9H-pyrido[2,3-b]indole-3-carboxylic acid
C13H10N2O2
2240180-14-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.5288 1.5400 0.0 0
M  V30 2 O 9.8625 2.3100 0.0 0
M  V30 3 O 8.5288 0.0000 0.0 0
M  V30 4 C 8.5288 4.6200 0.0 0
M  V30 5 C 4.5278 2.3100 0.0 0
M  V30 6 C 3.0631 1.8341 0.0 0
M  V30 7 C 4.5278 3.8500 0.0 0
M  V30 8 C 5.8614 1.5400 0.0 0
M  V30 9 C 2.1580 3.0800 0.0 0
M  V30 10 C 2.4367 0.4272 0.0 0
M  V30 11 N 3.0631 4.3259 0.0 0
M  V30 12 N 5.8614 4.6200 0.0 0
M  V30 13 C 7.1952 2.3100 0.0 0
M  V30 14 C 0.6263 2.9191 0.0 0
M  V30 15 C 0.9052 0.2663 0.0 0
M  V30 16 C 7.1952 3.8500 0.0 0
M  V30 17 C 0.0000 1.5121 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 4 16
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 2 7 12
M  V30 12 1 8 13
M  V30 13 1 9 11
M  V30 14 2 9 14
M  V30 15 1 10 15
M  V30 16 1 12 16
M  V30 17 2 13 16
M  V30 18 1 14 17
M  V30 19 2 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N,2-Dimethyl-9H-pyrido[2,3-b]indole-3-carboxamide
C14H13N3O
2775380-44-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 2.3100 0.0 0
M  V30 2 N 1.3336 0.7700 0.0 0
M  V30 3 O 0.0000 3.0800 0.0 0
M  V30 4 C 0.0000 0.0000 0.0 0
M  V30 5 C 1.3336 5.3900 0.0 0
M  V30 6 C 5.3347 3.0800 0.0 0
M  V30 7 C 6.7994 2.6041 0.0 0
M  V30 8 C 5.3347 4.6200 0.0 0
M  V30 9 C 4.0011 2.3100 0.0 0
M  V30 10 C 7.7045 3.8500 0.0 0
M  V30 11 C 7.4257 1.1972 0.0 0
M  V30 12 N 6.7994 5.0959 0.0 0
M  V30 13 N 4.0011 5.3900 0.0 0
M  V30 14 C 2.6673 3.0800 0.0 0
M  V30 15 C 9.2362 3.6891 0.0 0
M  V30 16 C 8.9573 1.0363 0.0 0
M  V30 17 C 2.6673 4.6200 0.0 0
M  V30 18 C 9.8625 2.2821 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 5 17
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 2 8 13
M  V30 13 1 9 14
M  V30 14 1 10 12
M  V30 15 2 10 15
M  V30 16 1 11 16
M  V30 17 1 13 17
M  V30 18 2 14 17
M  V30 19 1 15 18
M  V30 20 2 16 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2240180-14-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2775380-44-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32260332
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 56602-33-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and in vitro protective effect evaluation of
-carboline derivatives against H2O2-induced cardiomyocyte injury
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rong-Hong; Yang, Dan; Liao, Xiang-Ming; Zhang, Hong; Chen, Guo-Qi;
Zhang, Wen-Li; Wang, Yu-Chan; Wang, Cong; Liao, Shang-Gao; Zhou, Meng;
Wang, Yong-Lin; Li, Yong-Jun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2022), 238114469

$RFMT $RIREG SCHEME332 STEP1
$RXN



  2  1
$MOL
3,5-Dimethoxyaniline
C8H11NO2
10272-07-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 4.6201 0.0 0
M  V30 2 C 0.0000 3.8501 0.0 0
M  V30 3 O 6.6687 4.6201 0.0 0
M  V30 4 C 8.0023 3.8501 0.0 0
M  V30 5 N 4.0012 0.0000 0.0 0
M  V30 6 C 2.6675 3.8501 0.0 0
M  V30 7 C 4.0012 4.6201 0.0 0
M  V30 8 C 2.6675 2.3101 0.0 0
M  V30 9 C 5.3348 3.8501 0.0 0
M  V30 10 C 4.0012 1.5400 0.0 0
M  V30 11 C 5.3348 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-6-bromo-2-pyrazinecarboxylic acid
C5H4BrN3O2
486424-37-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 Br 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 N 4.0012 1.5400 0.0 0
M  V30 9 N 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Pyrazinecarboxamide, 3-amino-6-bromo-N-(3,5-dimethoxyphenyl)-
C13H13BrN4O3
3062364-97-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 3.8500 0.0 0
M  V30 2 C 4.0011 4.6200 0.0 0
M  V30 3 O 4.0011 6.1600 0.0 0
M  V30 4 O 8.0020 8.4700 0.0 0
M  V30 5 C 9.3358 9.2400 0.0 0
M  V30 6 O 10.6694 3.8500 0.0 0
M  V30 7 C 12.0031 4.6200 0.0 0
M  V30 8 N 1.3336 6.1600 0.0 0
M  V30 9 Br 1.3336 0.0000 0.0 0
M  V30 10 C 6.6684 4.6200 0.0 0
M  V30 11 C 6.6684 6.1600 0.0 0
M  V30 12 C 8.0020 3.8500 0.0 0
M  V30 13 C 8.0020 6.9300 0.0 0
M  V30 14 C 9.3358 4.6200 0.0 0
M  V30 15 C 9.3358 6.1600 0.0 0
M  V30 16 C 2.6673 3.8500 0.0 0
M  V30 17 C 1.3336 4.6200 0.0 0
M  V30 18 N 2.6673 2.3100 0.0 0
M  V30 19 N 0.0000 3.8500 0.0 0
M  V30 20 C 1.3336 1.5400 0.0 0
M  V30 21 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 2 2 3
M  V30 4 1 2 16
M  V30 5 1 4 5
M  V30 6 1 4 13
M  V30 7 1 6 7
M  V30 8 1 6 14
M  V30 9 1 8 17
M  V30 10 1 9 20
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 10272-07-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 486424-37-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3062364-97-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-43646483
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of
3-Amino-pyrazine-2-carboxamide Derivatives as Novel FGFR Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zheng, Jia; Zhang, Wei; Ni, Dan; Zhao, Shuang; He, Yi; Hu, Junchi; Li,
Linfeng; Dang, Yongjun; Guo, Zufeng; Nie, Shenyou
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2024), 15(11), 2019-2031

$RFMT $RIREG SCHEME333 STEP1
$RXN



  2  1
$MOL
2-Methyl-6-quinolinecarboxylic acid
C11H9NO2
635-80-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0023 1.5400 0.0 0
M  V30 2 O 8.0023 0.0000 0.0 0
M  V30 3 O 9.3360 2.3101 0.0 0
M  V30 4 C 0.0000 4.6201 0.0 0
M  V30 5 C 4.0012 2.3101 0.0 0
M  V30 6 C 4.0012 3.8501 0.0 0
M  V30 7 C 5.3348 1.5400 0.0 0
M  V30 8 C 2.6675 1.5400 0.0 0
M  V30 9 N 2.6675 4.6201 0.0 0
M  V30 10 C 5.3348 4.6201 0.0 0
M  V30 11 C 6.6685 2.3101 0.0 0
M  V30 12 C 1.3337 2.3101 0.0 0
M  V30 13 C 1.3337 3.8501 0.0 0
M  V30 14 C 6.6685 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 4 13
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 2 9 13
M  V30 13 2 10 14
M  V30 14 1 11 14
M  V30 15 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Chloro-5-nitroaniline
C6H5ClN2O2
6283-25-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.7700 2.6673 0.0 0 VAL=5
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 5.3901 0.0000 0.0 0
M  V30 5 Cl 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Quinolinecarboxamide, N-(2-chloro-5-nitrophenyl)-2-methyl-
C17H12ClN3O3
1693735-05-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 4.0011 0.0 0
M  V30 2 N 6.1600 2.6674 0.0 0
M  V30 3 O 6.1600 5.3347 0.0 0
M  V30 4 C 15.4000 5.3347 0.0 0
M  V30 5 Cl 4.6200 0.0000 0.0 0
M  V30 6 N 1.5400 5.3347 0.0 0 VAL=5
M  V30 7 O 2.3100 6.6685 0.0 0
M  V30 8 O 0.0000 5.3347 0.0 0
M  V30 9 C 10.7800 5.3347 0.0 0
M  V30 10 C 11.5500 4.0011 0.0 0
M  V30 11 C 9.2400 5.3347 0.0 0
M  V30 12 C 11.5500 6.6685 0.0 0
M  V30 13 C 10.7800 2.6674 0.0 0
M  V30 14 N 13.0900 4.0011 0.0 0
M  V30 15 C 8.4700 4.0011 0.0 0
M  V30 16 C 13.0900 6.6685 0.0 0
M  V30 17 C 9.2400 2.6674 0.0 0
M  V30 18 C 13.8600 5.3347 0.0 0
M  V30 19 C 4.6200 2.6674 0.0 0
M  V30 20 C 3.8500 4.0011 0.0 0
M  V30 21 C 3.8500 1.3338 0.0 0
M  V30 22 C 2.3100 4.0011 0.0 0
M  V30 23 C 2.3100 1.3338 0.0 0
M  V30 24 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 19
M  V30 5 1 4 18
M  V30 6 1 5 21
M  V30 7 2 6 7
M  V30 8 2 6 8
M  V30 9 1 6 22
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 2 11 15
M  V30 16 2 12 16
M  V30 17 2 13 17
M  V30 18 2 14 18
M  V30 19 1 15 17
M  V30 20 1 16 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 635-80-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 6283-25-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1693735-05-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40578370
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed
from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian
Cancer and Other Malignancies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Pasqua, A. Elisa; Sharp, Swee Y.; Chessum, Nicola E. A.; Hayes, Angela;
Pellegrino, Loredana; Tucker, Michael J.; Miah, Asadh; Wilding, Birgit;
Evans, Lindsay E.; Rye, Carl S.; Mok, N. Yi; Liu, Manjuan; Henley, Alan
T.; Gowan, Sharon; De Billy, Emmanuel; te Poele, Robert; Powers, Marissa;
Eccles, Suzanne A.; Clarke, Paul A.; Raynaud, Florence I.; Workman, Paul;
Jones, Keith; Cheeseman, Matthew D.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(8), 5907-5936

$RFMT $RIREG SCHEME334 STEP1
$RXN



  2  1
$MOL
4-Bromo-6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid
C9H7BrN2O3
1622303-52-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 4.6200 0.0000 0.0 0
M  V30 2 O 1.5400 5.3348 0.0 0
M  V30 3 C 7.6211 5.2890 0.0 0
M  V30 4 O 8.9549 4.5190 0.0 0
M  V30 5 O 7.6211 6.8290 0.0 0
M  V30 6 C 0.0000 2.6673 0.0 0
M  V30 7 C 4.6200 2.6673 0.0 0
M  V30 8 C 3.8500 4.0010 0.0 0
M  V30 9 C 6.1265 2.9875 0.0 0
M  V30 10 C 3.8500 1.3337 0.0 0
M  V30 11 N 4.8806 5.1455 0.0 0
M  V30 12 C 2.3100 4.0010 0.0 0
M  V30 13 C 6.2874 4.5190 0.0 0
M  V30 14 C 2.3100 1.3337 0.0 0
M  V30 15 N 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 2 2 12
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 13
M  V30 6 1 6 15
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 2 9 13
M  V30 13 2 10 14
M  V30 14 1 11 13
M  V30 15 1 12 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methylamine
CH5N
74-89-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromo-6,7-dihydro-N,6-dimethyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
C10H10BrN3O2
2138864-22-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 4.6201 0.0000 0.0 0
M  V30 2 O 1.5400 5.3348 0.0 0
M  V30 3 C 7.6211 5.2891 0.0 0
M  V30 4 N 8.9549 4.5190 0.0 0
M  V30 5 O 7.6211 6.8291 0.0 0
M  V30 6 C 10.2886 5.2891 0.0 0
M  V30 7 C 0.0000 2.6673 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 10 C 6.1265 2.9875 0.0 0
M  V30 11 C 3.8501 1.3337 0.0 0
M  V30 12 N 4.8806 5.1455 0.0 0
M  V30 13 C 2.3100 4.0010 0.0 0
M  V30 14 C 6.2875 4.5190 0.0 0
M  V30 15 C 2.3100 1.3337 0.0 0
M  V30 16 N 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 2 2 13
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 14
M  V30 6 1 4 6
M  V30 7 1 7 16
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 9 13
M  V30 13 2 10 14
M  V30 14 2 11 15
M  V30 15 1 12 14
M  V30 16 1 13 16
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1622303-52-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 74-89-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2138864-22-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24358052
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of
N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
(ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second
Bromodomain
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sheppard, George S.; Wang, Le; Fidanze, Steven D.; Hasvold, Lisa A.; Liu,
Dachun; Pratt, John K.; Park, Chang H.; Longenecker, Kenton; Qiu, Wei;
Torrent, Maricel; Kovar, Peter J.; Bui, Mai; Faivre, Emily; Huang,
Xiaoli; Lin, Xiaoyu; Wilcox, Denise; Zhang, Lu; Shen, Yu; Albert, Daniel
H.; Magoc, Terrance J.; Rajaraman, Ganesh; Kati, Warren M.; McDaniel,
Keith F.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(10), 5585-5623

$RFMT $RIREG SCHEME335 STEP1
$RXN



  2  1
$MOL
Fluorenone-4-carboxylic acid
C14H8O3
6223-83-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6520 4.3201 0.0 0
M  V30 2 O 7.9856 5.0901 0.0 0
M  V30 3 O 6.6520 2.7800 0.0 0
M  V30 4 O 0.0000 4.3798 0.0 0
M  V30 5 C 3.9845 4.3201 0.0 0
M  V30 6 C 3.6643 2.8138 0.0 0
M  V30 7 C 2.6508 5.0901 0.0 0
M  V30 8 C 5.3182 5.0901 0.0 0
M  V30 9 C 2.1328 2.6527 0.0 0
M  V30 10 C 4.5696 1.5679 0.0 0
M  V30 11 C 1.5064 4.0597 0.0 0
M  V30 12 C 2.6508 6.6301 0.0 0
M  V30 13 C 5.3182 6.6301 0.0 0
M  V30 14 C 1.5064 1.2459 0.0 0
M  V30 15 C 3.9432 0.1609 0.0 0
M  V30 16 C 3.9845 7.4001 0.0 0
M  V30 17 C 2.4115 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 2 4 11
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 2 7 12
M  V30 12 1 8 13
M  V30 13 1 9 11
M  V30 14 2 9 14
M  V30 15 1 10 15
M  V30 16 1 12 16
M  V30 17 2 13 16
M  V30 18 1 14 17
M  V30 19 2 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetic acid, -amino-, methyl ester, hydrochloride (1:1)
C9H11NO2.ClH
15028-40-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0
M  V30 3 N 4.0011 1.5400 0.0 0
M  V30 4 O 6.6685 3.0800 0.0 0
M  V30 5 O 5.3347 5.3900 0.0 0
M  V30 6 C 8.0021 3.8500 0.0 0
M  V30 7 C 2.6674 3.8500 0.0 0
M  V30 8 C 2.6674 5.3900 0.0 0
M  V30 9 C 1.3336 3.0800 0.0 0
M  V30 10 C 1.3336 6.1600 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 0.0000 5.3900 0.0 0
M  V30 13 Cl 4.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 4 6
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetic acid, -[[(9-oxo-9H-fluoren-4-yl)carbonyl]amino]-, methyl ester
C23H17NO4
3031559-89-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6519 4.3201 0.0 0
M  V30 2 N 7.9855 5.0901 0.0 0
M  V30 3 O 6.6519 2.7801 0.0 0
M  V30 4 C 9.3194 4.3201 0.0 0
M  V30 5 C 9.3194 2.7801 0.0 0
M  V30 6 O 10.6530 2.0101 0.0 0
M  V30 7 O 7.9855 2.0101 0.0 0
M  V30 8 C 10.6530 0.4700 0.0 0
M  V30 9 O 0.0000 4.3799 0.0 0
M  V30 10 C 3.9845 4.3201 0.0 0
M  V30 11 C 3.6644 2.8138 0.0 0
M  V30 12 C 2.6507 5.0901 0.0 0
M  V30 13 C 5.3182 5.0901 0.0 0
M  V30 14 C 2.1326 2.6527 0.0 0
M  V30 15 C 4.5694 1.5679 0.0 0
M  V30 16 C 1.5063 4.0597 0.0 0
M  V30 17 C 2.6507 6.6302 0.0 0
M  V30 18 C 5.3182 6.6302 0.0 0
M  V30 19 C 1.5063 1.2459 0.0 0
M  V30 20 C 3.9431 0.1609 0.0 0
M  V30 21 C 3.9845 7.4002 0.0 0
M  V30 22 C 2.4115 0.0000 0.0 0
M  V30 23 C 10.6530 5.0901 0.0 0
M  V30 24 C 10.6530 6.6302 0.0 0
M  V30 25 C 11.9867 4.3201 0.0 0
M  V30 26 C 11.9867 7.4002 0.0 0
M  V30 27 C 13.3204 5.0901 0.0 0
M  V30 28 C 13.3204 6.6302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 13
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 23
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 1 6 8
M  V30 10 2 9 16
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 2 12 17
M  V30 18 1 13 18
M  V30 19 1 14 16
M  V30 20 2 14 19
M  V30 21 1 15 20
M  V30 22 1 17 21
M  V30 23 2 18 21
M  V30 24 1 19 22
M  V30 25 2 20 22
M  V30 26 2 23 24
M  V30 27 1 23 25
M  V30 28 1 24 26
M  V30 29 2 25 27
M  V30 30 2 26 28
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6223-83-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 15028-40-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031559-89-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40678191
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by
Fragment-Based Drug Discovery
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Narayanan, Dilip; Tran, Kim T.; Pallesen, Jakob S.; Solbak, Sara M. Oe.;
Qin, Yuting; Mukminova, Elina; Luchini, Martina; Vasilyeva, Kristina O.;
Gonzalez Chichon, Dorleta; Goutsiou, Georgia; Poulsen, Cecilie; Haapanen,
Nanna; Popowicz, Grzegorz M.; Sattler, Michael; Olagnier, David; Gajhede,
Michael; Bach, Anders
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(21), 14481-14526

$RFMT $RIREG SCHEME336 STEP1
$RXN



  2  1
$MOL
Fluorenone-4-carboxylic acid
C14H8O3
6223-83-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6520 4.3201 0.0 0
M  V30 2 O 7.9856 5.0901 0.0 0
M  V30 3 O 6.6520 2.7800 0.0 0
M  V30 4 O 0.0000 4.3798 0.0 0
M  V30 5 C 3.9845 4.3201 0.0 0
M  V30 6 C 3.6643 2.8138 0.0 0
M  V30 7 C 2.6508 5.0901 0.0 0
M  V30 8 C 5.3182 5.0901 0.0 0
M  V30 9 C 2.1328 2.6527 0.0 0
M  V30 10 C 4.5696 1.5679 0.0 0
M  V30 11 C 1.5064 4.0597 0.0 0
M  V30 12 C 2.6508 6.6301 0.0 0
M  V30 13 C 5.3182 6.6301 0.0 0
M  V30 14 C 1.5064 1.2459 0.0 0
M  V30 15 C 3.9432 0.1609 0.0 0
M  V30 16 C 3.9845 7.4001 0.0 0
M  V30 17 C 2.4115 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 2 4 11
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 2 7 12
M  V30 12 1 8 13
M  V30 13 1 9 11
M  V30 14 2 9 14
M  V30 15 1 10 15
M  V30 16 1 12 16
M  V30 17 2 13 16
M  V30 18 1 14 17
M  V30 19 2 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Phenylalanine, methyl ester, hydrochloride
C10H13NO2.ClH
7524-50-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0 CFG=2
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 N 5.3347 5.3900 0.0 0
M  V30 5 O 8.0021 3.8500 0.0 0
M  V30 6 O 6.6684 1.5400 0.0 0
M  V30 7 C 9.3358 3.0800 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 3.0800 0.0 0
M  V30 10 C 2.6674 5.3900 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 6.1600 0.0 0
M  V30 13 C 0.0000 5.3900 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Phenylalanine, N-[(9-oxo-9H-fluoren-4-yl)carbonyl]-, methyl ester
C24H19NO4
3031559-90-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.9932 5.3348 0.0 0
M  V30 2 N 7.5332 5.3348 0.0 0
M  V30 3 O 5.2232 4.0012 0.0 0
M  V30 4 C 8.3032 4.0012 0.0 0
M  V30 5 C 9.8433 4.0012 0.0 0
M  V30 6 C 7.5332 2.6675 0.0 0
M  V30 7 O 8.3032 1.3337 0.0 0
M  V30 8 O 5.9932 2.6675 0.0 0
M  V30 9 C 7.5332 0.0000 0.0 0
M  V30 10 O 0.2624 8.7126 0.0 0
M  V30 11 C 3.6831 6.6685 0.0 0
M  V30 12 C 2.6527 5.5241 0.0 0
M  V30 13 C 2.9131 8.0023 0.0 0
M  V30 14 C 5.2232 6.6685 0.0 0
M  V30 15 C 1.2459 6.1504 0.0 0
M  V30 16 C 2.8136 3.9925 0.0 0
M  V30 17 C 1.4068 7.6822 0.0 0
M  V30 18 C 3.6831 9.3360 0.0 0
M  V30 19 C 5.9932 8.0023 0.0 0
M  V30 20 C 0.0000 5.2452 0.0 0
M  V30 21 C 1.5678 3.0873 0.0 0
M  V30 22 C 5.2232 9.3360 0.0 0
M  V30 23 C 0.1609 3.7136 0.0 0
M  V30 24 C 10.6133 5.3348 0.0 0
M  V30 25 C 12.1533 5.3348 0.0 0
M  V30 26 C 9.8433 6.6685 0.0 0
M  V30 27 C 12.9233 6.6685 0.0 0
M  V30 28 C 10.6133 8.0023 0.0 0
M  V30 29 C 12.1533 8.0023 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 24
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 7 9
M  V30 11 2 10 17
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 2 13 18
M  V30 19 1 14 19
M  V30 20 1 15 17
M  V30 21 2 15 20
M  V30 22 1 16 21
M  V30 23 1 18 22
M  V30 24 2 19 22
M  V30 25 1 20 23
M  V30 26 2 21 23
M  V30 27 2 24 25
M  V30 28 1 24 26
M  V30 29 1 25 27
M  V30 30 2 26 28
M  V30 31 2 27 29
M  V30 32 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 6223-83-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7524-50-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031559-90-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40678189
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by
Fragment-Based Drug Discovery
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Narayanan, Dilip; Tran, Kim T.; Pallesen, Jakob S.; Solbak, Sara M. Oe.;
Qin, Yuting; Mukminova, Elina; Luchini, Martina; Vasilyeva, Kristina O.;
Gonzalez Chichon, Dorleta; Goutsiou, Georgia; Poulsen, Cecilie; Haapanen,
Nanna; Popowicz, Grzegorz M.; Sattler, Michael; Olagnier, David; Gajhede,
Michael; Bach, Anders
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(21), 14481-14526

$RFMT $RIREG SCHEME337 STEP1
$RXN



  2  1
$MOL
N-tert-Butoxycarbonyl-D-phenylalanine
C14H19NO4
18942-49-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=2
M  V30 2 C 4.6201 4.0012 0.0 0
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6766 6.1048 0.0 0
M  V30 14 C 3.0801 4.0012 0.0 0
M  V30 15 C 2.3101 5.3348 0.0 0
M  V30 16 C 2.3101 2.6675 0.0 0
M  V30 17 C 0.7700 5.3348 0.0 0
M  V30 18 C 0.7700 2.6675 0.0 0
M  V30 19 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 14
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-(Phenylmethoxy)benzeneethanamine
C15H17NO
51179-05-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3901 2.6673 0.0 0
M  V30 2 C 4.6201 1.3337 0.0 0
M  V30 3 C 11.5503 2.6673 0.0 0
M  V30 4 C 12.3203 4.0010 0.0 0
M  V30 5 N 13.8603 4.0010 0.0 0
M  V30 6 C 6.9302 2.6673 0.0 0
M  V30 7 C 7.7002 4.0010 0.0 0
M  V30 8 C 7.7002 1.3337 0.0 0
M  V30 9 C 9.2402 4.0010 0.0 0
M  V30 10 C 9.2402 1.3337 0.0 0
M  V30 11 C 10.0102 2.6673 0.0 0
M  V30 12 C 3.0801 1.3337 0.0 0
M  V30 13 C 2.3101 2.6673 0.0 0
M  V30 14 C 2.3101 0.0000 0.0 0
M  V30 15 C 0.7700 2.6673 0.0 0
M  V30 16 C 0.7700 0.0000 0.0 0
M  V30 17 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 12
M  V30 4 1 3 4
M  V30 5 1 3 11
M  V30 6 1 4 5
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 8 10
M  V30 11 2 9 11
M  V30 12 1 10 11
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C29H34N2O4
3076055-71-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 5.3347 0.0 0 CFG=1
M  V30 2 C 5.3900 4.0011 0.0 0
M  V30 3 C 7.7000 5.3347 0.0 0
M  V30 4 N 5.3900 6.6684 0.0 0
M  V30 5 N 8.4700 6.6684 0.0 0
M  V30 6 O 8.4700 4.0011 0.0 0
M  V30 7 C 3.8500 6.6684 0.0 0
M  V30 8 C 10.0100 6.6684 0.0 0
M  V30 9 O 3.0800 8.0021 0.0 0
M  V30 10 O 3.0800 5.3347 0.0 0
M  V30 11 C 10.7800 8.0021 0.0 0
M  V30 12 C 1.5400 8.0021 0.0 0
M  V30 13 C 1.5400 6.4621 0.0 0
M  V30 14 C 0.0000 8.0021 0.0 0
M  V30 15 C 1.5400 9.5421 0.0 0
M  V30 16 O 16.9400 8.0021 0.0 0
M  V30 17 C 17.7100 9.3358 0.0 0
M  V30 18 C 6.1600 2.6673 0.0 0
M  V30 19 C 5.3900 1.3336 0.0 0
M  V30 20 C 7.7000 2.6673 0.0 0
M  V30 21 C 6.1600 0.0000 0.0 0
M  V30 22 C 8.4700 1.3336 0.0 0
M  V30 23 C 7.7000 0.0000 0.0 0
M  V30 24 C 12.3200 8.0021 0.0 0
M  V30 25 C 13.0900 9.3358 0.0 0
M  V30 26 C 13.0900 6.6684 0.0 0
M  V30 27 C 14.6300 9.3358 0.0 0
M  V30 28 C 14.6300 6.6684 0.0 0
M  V30 29 C 15.4000 8.0021 0.0 0
M  V30 30 C 19.2500 9.3358 0.0 0
M  V30 31 C 20.0200 8.0021 0.0 0
M  V30 32 C 20.0200 10.6694 0.0 0
M  V30 33 C 21.5600 8.0021 0.0 0
M  V30 34 C 21.5600 10.6694 0.0 0
M  V30 35 C 22.3300 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 18
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 24
M  V30 14 1 12 13
M  V30 15 1 12 14
M  V30 16 1 12 15
M  V30 17 1 16 17
M  V30 18 1 16 29
M  V30 19 1 17 30
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 20 22
M  V30 24 2 21 23
M  V30 25 1 22 23
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 2 26 28
M  V30 30 2 27 29
M  V30 31 1 28 29
M  V30 32 2 30 31
M  V30 33 1 30 32
M  V30 34 1 31 33
M  V30 35 2 32 34
M  V30 36 2 33 35
M  V30 37 1 34 35
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 18942-49-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 51179-05-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3076055-71-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44725301
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of Potent Mcl-1 Inhibitors: Structural Investigations on
Macrocycles Originating from a DNA-Encoded Chemical Library Screen
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hekking, Koen F. W.; Maroto, Sergio; van Kekem, Kees; Haasjes, Frank S.;
Slootweg, Jack C.; Oude Alink, Patrick G. B.; Dirks, Ron; Sardana,
Malvika; Bolster, Marjon G.; Kuijpers, Brian; Smith, Dennis; Doodeman,
Robin; Scheepstra, Marcel; Zech, Birgit; Mulvihill, Mark; Renzetti, Louis
M.; Babiss, Lee; Centrella, Paolo A.; Clark, Matthew A.; Cuozzo, John W.;
Guie, Marie-Aude; Sigel, Eric; Habeshian, Sevan; Hupp, Christopher D.;
Liu, Julie; Thomson, Heather A.; Zhang, Ying; Keefe, Anthony D.; Mueller,
Gerhard; Gremmen, Stijn
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(4), 3039-3065

$RFMT $RIREG SCHEME338 STEP1
$RXN



  2  1
$MOL
N2-[(1,1-Dimethylethoxy)carbonyl]-N5-[(phenylmethoxy)carbonyl]-L-ornithine
C18H26N2O6
2480-93-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 13.6536 8.0021 0.0 0
M  V30 2 O 12.8836 6.6684 0.0 0
M  V30 3 C 11.3436 6.6684 0.0 0
M  V30 4 N 10.5736 5.3347 0.0 0
M  V30 5 O 10.5736 8.0021 0.0 0
M  V30 6 C 9.0336 5.3347 0.0 0
M  V30 7 C 8.2636 4.0011 0.0 0
M  V30 8 C 6.7236 4.0011 0.0 0
M  V30 9 C 5.9536 2.6674 0.0 0 CFG=1
M  V30 10 N 4.4136 2.6674 0.0 0
M  V30 11 C 6.7236 1.3336 0.0 0
M  V30 12 C 3.6436 4.0011 0.0 0
M  V30 13 O 5.9536 0.0000 0.0 0
M  V30 14 O 8.2636 1.3336 0.0 0
M  V30 15 O 2.1036 4.0011 0.0 0
M  V30 16 O 4.4136 5.3347 0.0 0
M  V30 17 C 1.3336 5.3347 0.0 0
M  V30 18 C 2.6673 6.1047 0.0 0
M  V30 19 C 0.5636 6.6684 0.0 0
M  V30 20 C 0.0000 4.5647 0.0 0
M  V30 21 C 15.1936 8.0021 0.0 0
M  V30 22 C 15.9636 9.3358 0.0 0
M  V30 23 C 15.9636 6.6684 0.0 0
M  V30 24 C 17.5036 9.3358 0.0 0
M  V30 25 C 17.5036 6.6684 0.0 0
M  V30 26 C 18.2736 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 21
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10 CFG=1
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 17 20
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 25
M  V30 25 2 24 26
M  V30 26 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzylamine
C7H9N
100-46-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 N 5.3901 2.6673 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 2.3101 2.6673 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Phenylmethyl N-[(4S)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxo-5-[(phenyl...
C25H33N3O5
1374311-23-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7002 6.6685 0.0 0 CFG=2
M  V30 2 C 6.9302 8.0022 0.0 0
M  V30 3 N 6.9302 5.3348 0.0 0
M  V30 4 C 9.2402 6.6685 0.0 0
M  V30 5 N 5.3901 8.0022 0.0 0
M  V30 6 O 7.7002 9.3358 0.0 0
M  V30 7 C 7.7002 4.0010 0.0 0
M  V30 8 C 10.0102 8.0022 0.0 0
M  V30 9 C 4.6201 9.3358 0.0 0
M  V30 10 O 6.9302 2.6673 0.0 0
M  V30 11 O 9.2402 4.0010 0.0 0
M  V30 12 C 11.5503 8.0022 0.0 0
M  V30 13 C 7.7002 1.3337 0.0 0
M  V30 14 N 12.3203 9.3358 0.0 0
M  V30 15 C 6.3665 0.5637 0.0 0
M  V30 16 C 8.4702 0.0000 0.0 0
M  V30 17 C 9.0338 2.1037 0.0 0
M  V30 18 C 13.8603 9.3358 0.0 0
M  V30 19 O 14.6303 10.6697 0.0 0
M  V30 20 O 14.6303 8.0022 0.0 0
M  V30 21 C 16.1704 10.6697 0.0 0
M  V30 22 C 3.0801 9.3358 0.0 0
M  V30 23 C 2.3101 8.0022 0.0 0
M  V30 24 C 2.3101 10.6697 0.0 0
M  V30 25 C 0.7700 8.0022 0.0 0
M  V30 26 C 0.7700 10.6697 0.0 0
M  V30 27 C 0.0000 9.3358 0.0 0
M  V30 28 C 16.9404 12.0033 0.0 0
M  V30 29 C 16.1704 13.3370 0.0 0
M  V30 30 C 18.4804 12.0033 0.0 0
M  V30 31 C 16.9404 14.6707 0.0 0
M  V30 32 C 19.2504 13.3370 0.0 0
M  V30 33 C 18.4804 14.6707 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 22
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 19 21
M  V30 22 1 21 28
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 29 31
M  V30 32 2 30 32
M  V30 33 2 31 33
M  V30 34 1 32 33
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2480-93-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 100-46-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1374311-23-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37268467
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Highly-tumor-targeted PAD4 inhibitors with PBA modification inhibit
tumors in vivo by specifically inhibiting the PAD4-H3cit-NETs pathway in
neutrophils
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhu, Di; Lu, Yu; Hu, Bo; Pang, Yuheng; Liu, Bingru; Zhang, Miao; Wang,
Wenjing; Wang, Yuji
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 258115619

$RFMT $RIREG SCHEME339 STEP1
$RXN



  2  1
$MOL
4-Methoxy-5-nitro-1,2-benzenediamine
C7H9N3O3
69399-59-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.7700 4.0012 0.0 0 VAL=5
M  V30 2 O 0.0000 2.6675 0.0 0
M  V30 3 O 0.0000 5.3348 0.0 0
M  V30 4 O 2.3101 1.3338 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 N 5.3901 6.6687 0.0 0
M  V30 7 N 6.9302 4.0012 0.0 0
M  V30 8 C 2.3101 4.0012 0.0 0
M  V30 9 C 3.0801 2.6675 0.0 0
M  V30 10 C 3.0801 5.3348 0.0 0
M  V30 11 C 4.6201 2.6675 0.0 0
M  V30 12 C 4.6201 5.3348 0.0 0
M  V30 13 C 5.3901 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 5
M  V30 5 1 4 9
M  V30 6 1 6 12
M  V30 7 1 7 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2H-Thiopyran-3-carboxylic acid, tetrahydro-, 1,1-dioxide
C6H10O4S
167011-35-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5177 1.5400 0.0 0
M  V30 2 O 5.5177 0.0000 0.0 0
M  V30 3 O 6.8515 2.3100 0.0 0
M  V30 4 O 0.0000 2.5773 0.0 0
M  V30 5 O 0.9899 0.8629 0.0 0
M  V30 6 C 4.1840 2.3100 0.0 0
M  V30 7 C 2.8504 1.5400 0.0 0
M  V30 8 C 4.1840 3.8500 0.0 0
M  V30 9 S 1.5167 2.3100 0.0 0 VAL=6
M  V30 10 C 2.8504 4.6200 0.0 0
M  V30 11 C 1.5167 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 2 4 9
M  V30 5 2 5 9
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2H-Thiopyran-3-carboxamide, N-(2-amino-5-methoxy-4-nitrophenyl)tetrahydro-, 1...
C13H17N3O6S
3032481-75-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6684 5.3900 0.0 0
M  V30 2 C 8.0021 4.6200 0.0 0
M  V30 3 O 8.0021 3.0800 0.0 0
M  V30 4 N 4.0011 6.9301 0.0 0
M  V30 5 O 4.0011 0.7700 0.0 0
M  V30 6 C 5.3348 0.0000 0.0 0
M  V30 7 N 1.3337 2.3100 0.0 0 VAL=5
M  V30 8 O 1.3337 0.7700 0.0 0
M  V30 9 O 0.0000 3.0800 0.0 0
M  V30 10 O 13.5198 5.6574 0.0 0
M  V30 11 O 12.5298 3.9429 0.0 0
M  V30 12 C 5.3348 4.6200 0.0 0
M  V30 13 C 5.3348 3.0800 0.0 0
M  V30 14 C 4.0011 5.3900 0.0 0
M  V30 15 C 4.0011 2.3100 0.0 0
M  V30 16 C 2.6673 4.6200 0.0 0
M  V30 17 C 2.6673 3.0800 0.0 0
M  V30 18 C 9.3359 5.3900 0.0 0
M  V30 19 C 10.6695 4.6200 0.0 0
M  V30 20 C 9.3359 6.9301 0.0 0
M  V30 21 S 12.0032 5.3900 0.0 0 VAL=6
M  V30 22 C 10.6695 7.7001 0.0 0
M  V30 23 C 12.0032 6.9301 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 2 2 3
M  V30 4 1 2 18
M  V30 5 1 4 14
M  V30 6 1 5 6
M  V30 7 1 5 15
M  V30 8 2 7 8
M  V30 9 2 7 9
M  V30 10 1 7 17
M  V30 11 2 10 21
M  V30 12 2 11 21
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 69399-59-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 167011-35-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3032481-75-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38825401
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bothe, Ulrich; Guenther, Judith; Nubbemeyer, Reinhard; Siebeneicher,
Holger; Ring, Sven; Boemer, Ulf; Peters, Michaele; Rausch, Alexandra;
Denner, Karsten; Himmel, Herbert; Sutter, Andreas; Terebesi, Ildiko;
Lange, Martin; Wengner, Antje M.; Guimond, Nicolas; Thaler, Tobias;
Platzek, Johannes; Eberspaecher, Uwe; Schaefer, Martina; Steuber, Holger;
Zollner, Thomas M.; Steinmeyer, Andreas; Schmidt, Nicole
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1225-1242

$RFMT $RIREG SCHEME340 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-7a,8,8-trimethyl-...
C15H28BNO2.C2HF3O2
2415205-36-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.9308 5.1837 0.0 0
M  V30 2 C 1.5402 9.3367 0.0 0
M  V30 3 C 0.0000 7.4197 0.0 0
M  V30 4 C 8.0301 9.3424 0.0 0 CFG=1
M  V30 5 C 9.3638 8.5724 0.0 0
M  V30 6 N 8.0301 10.8824 0.0 0
M  V30 7 C 10.6974 9.3424 0.0 0
M  V30 8 C 10.6974 10.8824 0.0 0
M  V30 9 C 12.0312 8.5724 0.0 0
M  V30 10 C 4.2591 8.0543 0.0 0 CFG=1
M  V30 11 C 2.7187 7.4060 0.0 0 CFG=2
M  V30 12 C 5.0291 6.7207 0.0 0 CFG=2
M  V30 13 O 5.2895 9.1987 0.0 0
M  V30 14 C 1.4930 7.7974 0.0 0
M  V30 15 C 2.5438 5.2777 0.0 0
M  V30 16 C 3.8856 7.1212 0.0 0
M  V30 17 O 6.5354 7.0408 0.0 0
M  V30 18 B 6.6963 8.5724 0.0 0
M  V30 19 C 2.2413 6.5095 0.0 0 CFG=1
M  V30 20 H 3.3666 9.3094 0.0 0
M  V30 21 H 2.6499 8.9444 0.0 0
M  V30 22 H 0.8131 5.9332 0.0 0
M  V30 23 C 5.3488 2.3101 0.0 0
M  V30 24 C 6.6824 1.5400 0.0 0
M  V30 25 F 6.1188 3.6437 0.0 0
M  V30 26 F 4.0151 3.0801 0.0 0
M  V30 27 F 4.5788 0.9764 0.0 0
M  V30 28 O 8.0161 2.3101 0.0 0
M  V30 29 O 6.6824 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 12 1 CFG=3
M  V30 2 1 2 14
M  V30 3 1 3 14
M  V30 4 1 4 5
M  V30 5 1 4 6 CFG=1
M  V30 6 1 4 18
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 13 1 10 20 CFG=3
M  V30 14 1 11 14
M  V30 15 1 11 15
M  V30 16 1 11 21 CFG=1
M  V30 17 1 12 16 CFG=1
M  V30 18 1 12 17
M  V30 19 1 13 18
M  V30 20 1 14 19
M  V30 21 1 15 19
M  V30 22 1 16 19
M  V30 23 1 17 18
M  V30 24 1 19 22 CFG=3
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 1 23 26
M  V30 28 1 23 27
M  V30 29 1 24 28
M  V30 30 2 24 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(5 4 10 11 12 19)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C22H39BN2O5
2415205-25-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.4097 4.4547 0.0 0
M  V30 2 C 3.3111 9.4677 0.0 0
M  V30 3 C 0.8806 9.8430 0.0 0
M  V30 4 C 6.5609 3.8501 0.0 0 CFG=2
M  V30 5 N 7.8947 4.6201 0.0 0
M  V30 6 C 6.5609 2.3101 0.0 0
M  V30 7 C 9.2283 3.8501 0.0 0
M  V30 8 C 5.2272 1.5400 0.0 0
M  V30 9 C 10.5620 4.6201 0.0 0
M  V30 10 O 9.2283 2.3101 0.0 0
M  V30 11 C 5.2272 0.0000 0.0 0
M  V30 12 C 3.8935 2.3101 0.0 0
M  V30 13 N 11.8957 3.8501 0.0 0
M  V30 14 C 13.2295 4.6201 0.0 0
M  V30 15 O 14.5632 3.8501 0.0 0
M  V30 16 O 13.2295 6.1601 0.0 0
M  V30 17 C 15.8968 4.6201 0.0 0
M  V30 18 C 16.6669 3.2864 0.0 0
M  V30 19 C 17.2305 5.3901 0.0 0
M  V30 20 C 15.1268 5.9538 0.0 0
M  V30 21 C 3.5598 6.4718 0.0 0 CFG=1
M  V30 22 C 2.2281 7.4818 0.0 0 CFG=2
M  V30 23 C 2.7898 5.1382 0.0 0 CFG=2
M  V30 24 O 5.0662 6.1517 0.0 0
M  V30 25 C 1.9543 8.7389 0.0 0
M  V30 26 C 0.2975 6.5690 0.0 0
M  V30 27 C 2.5651 6.3288 0.0 0
M  V30 28 O 3.8204 3.9938 0.0 0
M  V30 29 B 5.2272 4.6201 0.0 0
M  V30 30 C 1.2131 7.4470 0.0 0 CFG=1
M  V30 31 H 4.2006 7.8723 0.0 0
M  V30 32 H 3.5262 8.3105 0.0 0
M  V30 33 H 0.0000 8.3956 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 23 1 CFG=3
M  V30 2 1 2 25
M  V30 3 1 3 25
M  V30 4 1 4 5
M  V30 5 1 4 6 CFG=1
M  V30 6 1 4 29
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 17 20
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 21 24
M  V30 24 1 21 31 CFG=3
M  V30 25 1 22 25
M  V30 26 1 22 26
M  V30 27 1 22 32 CFG=1
M  V30 28 1 23 27 CFG=1
M  V30 29 1 23 28
M  V30 30 1 24 29
M  V30 31 1 25 30
M  V30 32 1 26 30
M  V30 33 1 27 30
M  V30 34 1 28 29
M  V30 35 1 30 33 CFG=3
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(5 4 21 22 23 30)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2415205-36-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2415205-25-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22020120
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Peptide Boronate Derivatives as Histone Deacetylase and
Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of
Multiple Myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhou, Yi; Liu, Xiaoting; Xue, Junxin; Liu, Lulu; Liang, Tao; Li, Wen;
Yang, Xinying; Hou, Xuben; Fang, Hao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(9), 4701-4715

$RFMT $RIREG SCHEME340 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-7a,8,8-trimethyl-...
C15H28BNO2.C2HF3O2
2415205-36-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.9308 5.1837 0.0 0
M  V30 2 C 1.5402 9.3367 0.0 0
M  V30 3 C 0.0000 7.4197 0.0 0
M  V30 4 C 8.0301 9.3424 0.0 0 CFG=1
M  V30 5 C 9.3638 8.5724 0.0 0
M  V30 6 N 8.0301 10.8824 0.0 0
M  V30 7 C 10.6974 9.3424 0.0 0
M  V30 8 C 10.6974 10.8824 0.0 0
M  V30 9 C 12.0312 8.5724 0.0 0
M  V30 10 C 4.2591 8.0543 0.0 0 CFG=1
M  V30 11 C 2.7187 7.4060 0.0 0 CFG=2
M  V30 12 C 5.0291 6.7207 0.0 0 CFG=2
M  V30 13 O 5.2895 9.1987 0.0 0
M  V30 14 C 1.4930 7.7974 0.0 0
M  V30 15 C 2.5438 5.2777 0.0 0
M  V30 16 C 3.8856 7.1212 0.0 0
M  V30 17 O 6.5354 7.0408 0.0 0
M  V30 18 B 6.6963 8.5724 0.0 0
M  V30 19 C 2.2413 6.5095 0.0 0 CFG=1
M  V30 20 H 3.3666 9.3094 0.0 0
M  V30 21 H 2.6499 8.9444 0.0 0
M  V30 22 H 0.8131 5.9332 0.0 0
M  V30 23 C 5.3488 2.3101 0.0 0
M  V30 24 C 6.6824 1.5400 0.0 0
M  V30 25 F 6.1188 3.6437 0.0 0
M  V30 26 F 4.0151 3.0801 0.0 0
M  V30 27 F 4.5788 0.9764 0.0 0
M  V30 28 O 8.0161 2.3101 0.0 0
M  V30 29 O 6.6824 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 12 1 CFG=3
M  V30 2 1 2 14
M  V30 3 1 3 14
M  V30 4 1 4 5
M  V30 5 1 4 6 CFG=1
M  V30 6 1 4 18
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 13 1 10 20 CFG=3
M  V30 14 1 11 14
M  V30 15 1 11 15
M  V30 16 1 11 21 CFG=1
M  V30 17 1 12 16 CFG=1
M  V30 18 1 12 17
M  V30 19 1 13 18
M  V30 20 1 14 19
M  V30 21 1 15 19
M  V30 22 1 16 19
M  V30 23 1 17 18
M  V30 24 1 19 22 CFG=3
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 1 23 26
M  V30 28 1 23 27
M  V30 29 1 24 28
M  V30 30 2 24 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(5 4 10 11 12 19)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C22H39BN2O5
2415205-25-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.4097 4.4547 0.0 0
M  V30 2 C 3.3111 9.4677 0.0 0
M  V30 3 C 0.8806 9.8430 0.0 0
M  V30 4 C 6.5609 3.8501 0.0 0 CFG=2
M  V30 5 N 7.8947 4.6201 0.0 0
M  V30 6 C 6.5609 2.3101 0.0 0
M  V30 7 C 9.2283 3.8501 0.0 0
M  V30 8 C 5.2272 1.5400 0.0 0
M  V30 9 C 10.5620 4.6201 0.0 0
M  V30 10 O 9.2283 2.3101 0.0 0
M  V30 11 C 5.2272 0.0000 0.0 0
M  V30 12 C 3.8935 2.3101 0.0 0
M  V30 13 N 11.8957 3.8501 0.0 0
M  V30 14 C 13.2295 4.6201 0.0 0
M  V30 15 O 14.5632 3.8501 0.0 0
M  V30 16 O 13.2295 6.1601 0.0 0
M  V30 17 C 15.8968 4.6201 0.0 0
M  V30 18 C 16.6669 3.2864 0.0 0
M  V30 19 C 17.2305 5.3901 0.0 0
M  V30 20 C 15.1268 5.9538 0.0 0
M  V30 21 C 3.5598 6.4718 0.0 0 CFG=1
M  V30 22 C 2.2281 7.4818 0.0 0 CFG=2
M  V30 23 C 2.7898 5.1382 0.0 0 CFG=2
M  V30 24 O 5.0662 6.1517 0.0 0
M  V30 25 C 1.9543 8.7389 0.0 0
M  V30 26 C 0.2975 6.5690 0.0 0
M  V30 27 C 2.5651 6.3288 0.0 0
M  V30 28 O 3.8204 3.9938 0.0 0
M  V30 29 B 5.2272 4.6201 0.0 0
M  V30 30 C 1.2131 7.4470 0.0 0 CFG=1
M  V30 31 H 4.2006 7.8723 0.0 0
M  V30 32 H 3.5262 8.3105 0.0 0
M  V30 33 H 0.0000 8.3956 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 23 1 CFG=3
M  V30 2 1 2 25
M  V30 3 1 3 25
M  V30 4 1 4 5
M  V30 5 1 4 6 CFG=1
M  V30 6 1 4 29
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 17 20
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 21 24
M  V30 24 1 21 31 CFG=3
M  V30 25 1 22 25
M  V30 26 1 22 26
M  V30 27 1 22 32 CFG=1
M  V30 28 1 23 27 CFG=1
M  V30 29 1 23 28
M  V30 30 1 24 29
M  V30 31 1 25 30
M  V30 32 1 26 30
M  V30 33 1 27 30
M  V30 34 1 28 29
M  V30 35 1 30 33 CFG=3
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(5 4 21 22 23 30)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2415205-36-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2415205-25-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36054210
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and discovery of novel dipeptide boronic acid ester proteasome
inhibitors, an oral slowly-released prodrug for the treatment of multiple
myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Xueyuan; Zhang, Wen; Wen, Tiantian; Miao, Hang; Hu, Wenjiao; Liu,
Hailong; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 250115187

$RFMT $RIREG SCHEME341 STEP1
$RXN



  2  1
$MOL
Urea
CH4N2O
57-13-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 N 0.0000 2.3101 0.0 0
M  V30 3 N 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Anthranilic acid
C7H7NO2
118-92-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 3.0801 4.0010 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Quinazolinedione
C8H6N2O2
86-96-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 0.0000 0.0 0
M  V30 2 O 6.9300 2.6674 0.0 0
M  V30 3 C 2.3100 2.6674 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 3.0800 1.3338 0.0 0
M  V30 6 C 0.7700 2.6674 0.0 0
M  V30 7 N 4.6200 4.0011 0.0 0
M  V30 8 C 2.3100 5.3349 0.0 0
M  V30 9 N 4.6200 1.3338 0.0 0
M  V30 10 C 0.0000 4.0011 0.0 0
M  V30 11 C 5.3900 2.6674 0.0 0
M  V30 12 C 0.7700 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 57-13-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 118-92-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 86-96-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34513955
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM High ligand efficiency quinazoline compounds as novel A2A adenosine
receptor antagonists
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bolteau, Raphael; Duroux, Romain; Laversin, Amelie; Vreulz, Brandon;
Shiriaeva, Anna; Stauch, Benjamin; Han, Gye Won; Cherezov, Vadim;
Renault, Nicolas; Barczyk, Amelie; Ravez, Severine; Coevoet, Mathilde;
Melnyk, Patricia; Liberelle, Maxime; Yous, Said
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2022), 241114620

$RFMT $RIREG SCHEME341 STEP1
$RXN



  2  1
$MOL
Urea
CH4N2O
57-13-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 N 0.0000 2.3101 0.0 0
M  V30 3 N 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Anthranilic acid
C7H7NO2
118-92-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 3.0801 4.0010 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Quinazolinedione
C8H6N2O2
86-96-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 0.0000 0.0 0
M  V30 2 O 6.9300 2.6674 0.0 0
M  V30 3 C 2.3100 2.6674 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 3.0800 1.3338 0.0 0
M  V30 6 C 0.7700 2.6674 0.0 0
M  V30 7 N 4.6200 4.0011 0.0 0
M  V30 8 C 2.3100 5.3349 0.0 0
M  V30 9 N 4.6200 1.3338 0.0 0
M  V30 10 C 0.0000 4.0011 0.0 0
M  V30 11 C 5.3900 2.6674 0.0 0
M  V30 12 C 0.7700 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 57-13-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 118-92-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 86-96-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32762773
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 4
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1310-73-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis of acyclic nucleoside phosphonates targeting flavin-dependent
thymidylate synthase in Mycobacterium tuberculosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Biteau, Nicolas G.; Roy, Vincent; Lambry, Jean-Christophe; Becker, Hubert
F.; Myllykallio, Hannu; Agrofoglio, Luigi A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 46116351

$RFMT $RIREG SCHEME342 STEP1
$RXN



  2  1
$MOL
Leucine methyl ester hydrochloride
C7H15NO2.ClH
7517-19-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.8500 0.0 0 CFG=1
M  V30 2 C 5.3347 3.0800 0.0 0
M  V30 3 C 2.6674 3.0800 0.0 0
M  V30 4 N 4.0011 5.3900 0.0 0
M  V30 5 O 6.6685 3.8500 0.0 0
M  V30 6 O 5.3347 1.5400 0.0 0
M  V30 7 C 1.3336 3.8500 0.0 0
M  V30 8 C 8.0021 3.0800 0.0 0
M  V30 9 C 1.3336 5.3900 0.0 0
M  V30 10 C 0.0000 3.0800 0.0 0
M  V30 11 Cl 4.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
3-Chloro-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanine
C14H18ClNO4
114873-03-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 4.0012 0.0 0
M  V30 2 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 8.6765 6.1048 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 11.3439 4.5648 0.0 0
M  V30 14 Cl 0.0000 6.6687 0.0 0
M  V30 15 C 3.0801 4.0012 0.0 0
M  V30 16 C 2.3101 5.3348 0.0 0
M  V30 17 C 2.3101 2.6675 0.0 0
M  V30 18 C 0.7700 5.3348 0.0 0
M  V30 19 C 0.7700 2.6675 0.0 0
M  V30 20 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3 CFG=3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 18
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C21H31ClN2O5
3052551-80-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 6.1600 0.0 0 CFG=2
M  V30 2 C 6.6684 4.6200 0.0 0
M  V30 3 C 5.3347 6.9300 0.0 0
M  V30 4 N 8.0020 6.9300 0.0 0
M  V30 5 N 5.3347 8.4700 0.0 0
M  V30 6 O 4.0009 6.1600 0.0 0
M  V30 7 C 9.3358 6.1600 0.0 0
M  V30 8 C 4.0009 9.2400 0.0 0 CFG=1
M  V30 9 O 10.6694 6.9300 0.0 0
M  V30 10 O 9.3358 4.6200 0.0 0
M  V30 11 C 4.0009 10.7800 0.0 0
M  V30 12 C 2.6673 8.4700 0.0 0
M  V30 13 C 12.0031 6.1600 0.0 0
M  V30 14 O 5.3347 11.5500 0.0 0
M  V30 15 O 2.6673 11.5500 0.0 0
M  V30 16 C 1.3336 9.2400 0.0 0
M  V30 17 C 11.2331 4.8264 0.0 0
M  V30 18 C 13.3367 5.3900 0.0 0
M  V30 19 C 12.7731 7.4936 0.0 0
M  V30 20 C 5.3347 13.0900 0.0 0
M  V30 21 C 1.3336 10.7800 0.0 0
M  V30 22 C 0.0000 8.4700 0.0 0
M  V30 23 Cl 4.0009 0.0000 0.0 0
M  V30 24 C 5.3347 3.8500 0.0 0
M  V30 25 C 5.3347 2.3100 0.0 0
M  V30 26 C 4.0009 4.6200 0.0 0
M  V30 27 C 4.0009 1.5400 0.0 0
M  V30 28 C 2.6673 3.8500 0.0 0
M  V30 29 C 2.6673 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 24
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=1
M  V30 13 1 9 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 1 13 18
M  V30 19 1 13 19
M  V30 20 1 14 20
M  V30 21 1 16 21
M  V30 22 1 16 22
M  V30 23 1 23 27
M  V30 24 2 24 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 2 26 28
M  V30 28 2 27 29
M  V30 29 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7517-19-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 114873-03-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3052551-80-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41035940
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Identification of highly potent and selective HTRA1 inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Dennis, David G.; Joo Sun, Young; Parsons, Dylan E.; Mahajan, Vinit B.;
Smith, Mark
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2024), 109129814

$RFMT $RIREG SCHEME343 STEP1
$RXN



  2  1
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-O-methylserine
C9H17NO5
856417-65-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8500 0.0 0
M  V30 2 N 4.0011 4.6201 0.0 0
M  V30 3 C 2.6675 2.3100 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8500 0.0 0
M  V30 6 O 1.3337 1.5400 0.0 0
M  V30 7 O 1.3337 6.1601 0.0 0
M  V30 8 O 0.0000 3.8500 0.0 0
M  V30 9 O 6.6684 4.6201 0.0 0
M  V30 10 O 5.3348 2.3100 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 8.0022 3.8500 0.0 0
M  V30 13 C 8.7722 5.1837 0.0 0
M  V30 14 C 9.3359 3.0800 0.0 0
M  V30 15 C 7.2322 2.5164 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-[(4-Nitrophenyl)methyl]-1,3,4-thiadiazol-2-amine
C9H8N4O2S
247225-84-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6687 4.6201 0.0 0
M  V30 2 N 1.3338 1.5400 0.0 0 VAL=5
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 O 1.3338 0.0000 0.0 0
M  V30 5 N 11.9713 3.4930 0.0 0
M  V30 6 C 5.3348 3.8501 0.0 0
M  V30 7 C 5.3348 2.3101 0.0 0
M  V30 8 C 4.0012 4.6201 0.0 0
M  V30 9 C 4.0012 1.5400 0.0 0
M  V30 10 C 2.6675 3.8501 0.0 0
M  V30 11 C 2.6675 2.3101 0.0 0
M  V30 12 C 8.0023 3.8501 0.0 0
M  V30 13 S 9.4091 4.4764 0.0 0
M  V30 14 N 8.1633 2.3185 0.0 0
M  V30 15 C 10.4397 3.3320 0.0 0
M  V30 16 N 9.6697 1.9983 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 6
M  V30 2 1 1 12
M  V30 3 2 2 3
M  V30 4 2 2 4
M  V30 5 1 2 11
M  V30 6 1 5 15
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 8 10
M  V30 11 2 9 11
M  V30 12 1 10 11
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[1-(methoxymethyl)-2-[[5-[(4-nitrophenyl)methyl]-1,3,4-thiad...
C18H23N5O6S
3042818-51-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 13.6257 7.0100 0.0 0
M  V30 2 N 8.4700 5.3347 0.0 0
M  V30 3 C 7.7000 4.0011 0.0 0
M  V30 4 C 6.1600 4.0011 0.0 0
M  V30 5 O 8.4700 2.6674 0.0 0
M  V30 6 N 5.3900 5.3347 0.0 0
M  V30 7 C 5.3900 2.6674 0.0 0
M  V30 8 C 3.8500 5.3347 0.0 0
M  V30 9 O 6.1600 1.3338 0.0 0
M  V30 10 O 3.0800 6.6685 0.0 0
M  V30 11 O 3.0800 4.0011 0.0 0
M  V30 12 C 5.3900 0.0000 0.0 0
M  V30 13 C 1.5400 6.6685 0.0 0
M  V30 14 C 1.5400 5.1285 0.0 0
M  V30 15 C 0.0000 6.6685 0.0 0
M  V30 16 C 1.5400 8.2085 0.0 0
M  V30 17 N 19.2532 4.5045 0.0 0 VAL=5
M  V30 18 O 19.4141 2.9730 0.0 0
M  V30 19 O 20.4990 5.4097 0.0 0
M  V30 20 C 12.3798 6.1047 0.0 0
M  V30 21 S 10.9153 6.5808 0.0 0
M  V30 22 N 12.3798 4.5647 0.0 0
M  V30 23 C 10.0101 5.3347 0.0 0
M  V30 24 N 10.9153 4.0889 0.0 0
M  V30 25 C 15.0326 6.3836 0.0 0
M  V30 26 C 16.2785 7.2889 0.0 0
M  V30 27 C 15.1936 4.8521 0.0 0
M  V30 28 C 17.6853 6.6624 0.0 0
M  V30 29 C 16.6004 4.2256 0.0 0
M  V30 30 C 17.8464 5.1308 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 20
M  V30 2 1 1 25
M  V30 3 1 2 3
M  V30 4 1 2 23
M  V30 5 1 3 4
M  V30 6 2 3 5
M  V30 7 1 4 6
M  V30 8 1 4 7
M  V30 9 1 6 8
M  V30 10 1 7 9
M  V30 11 1 8 10
M  V30 12 2 8 11
M  V30 13 1 9 12
M  V30 14 1 10 13
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 1 13 16
M  V30 18 2 17 18
M  V30 19 2 17 19
M  V30 20 1 17 30
M  V30 21 1 20 21
M  V30 22 2 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 856417-65-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 247225-84-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3042818-51-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40576482
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and characterization of BAY-805, a potent and selective
inhibitor of ubiquitin-specific protease USP21
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Goericke, Fabian; Vu, Victoria; Smith, Leanna; Scheib, Ulrike; Boehm,
Raphael; Akkilic, Namik; Wohlfahrt, Gerd; Weiske, Joerg; Boemer, Ulf;
Brzezinka, Krzysztof; Lindner, Niels; Lienau, Philip; Gradl, Stefan;
Beck, Hartmut; Brown, Peter J.; Santhakumar, Vijayaratnam; Vedadi,
Masoud; Barsyte-Lovejoy, Dalia; Arrowsmith, Cheryl H.; Schmees, Norbert;
Petersen, Kirstin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3431-3447

$RFMT $RIREG SCHEME344 STEP1
$RXN



  2  1
$MOL
Acetic acid
C2H4O2
64-19-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 0.0000 2.3101 0.0 0
M  V30 3 O 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-2-[[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]meth...
C31H37N3O
2648234-37-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2066 5.3084 0.0 0
M  V30 2 C 6.5402 4.5384 0.0 0
M  V30 3 C 7.8740 5.3084 0.0 0
M  V30 4 N 9.2077 4.5384 0.0 0
M  V30 5 C 10.5413 5.3084 0.0 0
M  V30 6 C 9.2077 2.9984 0.0 0
M  V30 7 C 11.8750 4.5384 0.0 0
M  V30 8 C 10.5413 6.8484 0.0 0
M  V30 9 N 13.2088 5.3084 0.0 0
M  V30 10 O 11.8750 2.9984 0.0 0
M  V30 11 C 11.8750 7.6184 0.0 0
M  V30 12 C 14.5424 4.5384 0.0 0
M  V30 13 N 11.8750 9.1584 0.0 0
M  V30 14 C 19.8771 7.6184 0.0 0
M  V30 15 C 3.8730 4.5384 0.0 0
M  V30 16 C 3.9880 3.0027 0.0 0
M  V30 17 C 2.6005 5.4060 0.0 0
M  V30 18 C 2.8592 1.9553 0.0 0
M  V30 19 C 5.4596 2.5489 0.0 0
M  V30 20 C 1.1290 4.9520 0.0 0
M  V30 21 C 2.9433 6.9074 0.0 0
M  V30 22 C 1.3363 2.1848 0.0 0
M  V30 23 C 3.2018 0.4538 0.0 0
M  V30 24 C 5.8023 1.0474 0.0 0
M  V30 25 C 0.5663 3.5184 0.0 0
M  V30 26 C 0.0000 5.9996 0.0 0
M  V30 27 C 1.8143 7.9549 0.0 0
M  V30 28 C 4.6733 0.0000 0.0 0
M  V30 29 C 0.3427 7.5009 0.0 0
M  V30 30 C 15.8761 5.3084 0.0 0
M  V30 31 C 17.2097 4.5384 0.0 0
M  V30 32 C 15.8761 6.8484 0.0 0
M  V30 33 C 18.5435 5.3084 0.0 0
M  V30 34 C 17.2097 7.6184 0.0 0
M  V30 35 C 18.5435 6.8484 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 30
M  V30 15 1 14 35
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 16 19
M  V30 20 1 17 20
M  V30 21 2 17 21
M  V30 22 1 18 22
M  V30 23 2 18 23
M  V30 24 1 19 24
M  V30 25 1 20 25
M  V30 26 2 20 26
M  V30 27 1 21 27
M  V30 28 1 22 25
M  V30 29 1 23 28
M  V30 30 2 24 28
M  V30 31 1 26 29
M  V30 32 2 27 29
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 31 33
M  V30 36 2 32 34
M  V30 37 2 33 35
M  V30 38 1 34 35
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Acetylamino)-2-[[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)pro...
C33H39N3O2
2648234-42-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  38 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.5502 9.3358 0.0 0
M  V30 2 C 10.0101 9.3358 0.0 0
M  V30 3 C 9.2401 8.0021 0.0 0
M  V30 4 N 7.7001 8.0021 0.0 0
M  V30 5 C 6.9301 6.6684 0.0 0
M  V30 6 C 6.9301 9.3358 0.0 0
M  V30 7 C 5.3901 6.6684 0.0 0
M  V30 8 C 7.7001 5.3348 0.0 0
M  V30 9 N 4.6201 8.0021 0.0 0
M  V30 10 O 4.6201 5.3348 0.0 0
M  V30 11 C 6.9301 4.0010 0.0 0
M  V30 12 C 3.0800 8.0021 0.0 0
M  V30 13 N 7.7001 2.6673 0.0 0
M  V30 14 C 6.9301 1.3337 0.0 0
M  V30 15 C 5.3901 1.3337 0.0 0
M  V30 16 O 7.7001 0.0000 0.0 0
M  V30 17 C 0.0000 13.3369 0.0 0
M  V30 18 C 12.3202 10.6696 0.0 0
M  V30 19 C 11.4527 11.9419 0.0 0
M  V30 20 C 13.8559 10.5544 0.0 0
M  V30 21 C 11.9065 13.4136 0.0 0
M  V30 22 C 9.9512 11.5993 0.0 0
M  V30 23 C 14.9033 11.6834 0.0 0
M  V30 24 C 14.3097 9.0829 0.0 0
M  V30 25 C 13.3401 13.9762 0.0 0
M  V30 26 C 10.8590 14.5424 0.0 0
M  V30 27 C 8.9038 12.7281 0.0 0
M  V30 28 C 14.6738 13.2061 0.0 0
M  V30 29 C 16.4048 11.3407 0.0 0
M  V30 30 C 15.8113 8.7401 0.0 0
M  V30 31 C 9.3576 14.1998 0.0 0
M  V30 32 C 16.8586 9.8691 0.0 0
M  V30 33 C 2.3100 9.3358 0.0 0
M  V30 34 C 0.7700 9.3358 0.0 0
M  V30 35 C 3.0800 10.6696 0.0 0
M  V30 36 C 0.0000 10.6696 0.0 0
M  V30 37 C 2.3100 12.0032 0.0 0
M  V30 38 C 0.7700 12.0032 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 18
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 33
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 14 16
M  V30 18 1 17 38
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 19 22
M  V30 23 1 20 23
M  V30 24 2 20 24
M  V30 25 1 21 25
M  V30 26 2 21 26
M  V30 27 1 22 27
M  V30 28 1 23 28
M  V30 29 2 23 29
M  V30 30 1 24 30
M  V30 31 1 25 28
M  V30 32 1 26 31
M  V30 33 2 27 31
M  V30 34 1 29 32
M  V30 35 2 30 32
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 34 36
M  V30 39 2 35 37
M  V30 40 2 36 38
M  V30 41 1 37 38
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2648234-37-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2648234-42-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23747861
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as
inhibitors of GABA transporters mGAT1-4 with anticonvulsant,
antinociceptive, and antidepressant activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zareba, Paula; Salat, Kinga; Hofner, Georg C.; Latka, Kamil; Bajda,
Marek; Latacz, Gniewomir; Kotniewicz, Krzysztof; Rapacz, Anna; Podkowa,
Adrian; Maj, Maciej; Jozwiak, Krzysztof; Filipek, Barbara; Wanner, Klaus
T.; Malawska, Barbara; Kulig, Katarzyna
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 221113512

$RFMT $RIREG SCHEME345 STEP1
$RXN



  2  1
$MOL
Benzyloxycarbonyl-L-valine
C13H17NO4
1149-26-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 3.0801 0.0 0 CFG=2
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 C 2.6673 4.6201 0.0 0
M  V30 5 C 5.3348 3.0801 0.0 0
M  V30 6 C 0.0000 3.0801 0.0 0
M  V30 7 C 1.3337 0.7700 0.0 0
M  V30 8 O 1.3337 5.3901 0.0 0
M  V30 9 O 4.0012 5.3901 0.0 0
M  V30 10 O 6.6685 2.3101 0.0 0
M  V30 11 O 5.3348 4.6201 0.0 0
M  V30 12 C 8.0022 3.0801 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 14 C 9.3360 0.7700 0.0 0
M  V30 15 C 10.6697 3.0801 0.0 0
M  V30 16 C 10.6697 0.0000 0.0 0
M  V30 17 C 12.0033 2.3101 0.0 0
M  V30 18 C 12.0033 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 1 5 10
M  V30 10 2 5 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Cyclohexanepropanoic acid, -amino-, methyl ester, hydrochloride (1:1), (S)-
C10H19NO2.ClH
17193-39-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 C 5.3347 3.8500 0.0 0 CFG=2
M  V30 3 C 6.6684 3.0800 0.0 0
M  V30 4 N 5.3347 5.3900 0.0 0
M  V30 5 O 8.0021 3.8500 0.0 0
M  V30 6 O 6.6684 1.5400 0.0 0
M  V30 7 C 9.3358 3.0800 0.0 0
M  V30 8 C 2.6674 3.8500 0.0 0
M  V30 9 C 1.3336 3.0800 0.0 0
M  V30 10 C 2.6674 5.3900 0.0 0
M  V30 11 C 0.0000 3.8500 0.0 0
M  V30 12 C 1.3336 6.1600 0.0 0
M  V30 13 C 0.0000 5.3900 0.0 0
M  V30 14 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C23H34N2O5
2481133-92-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 4.6201 0.0 0 CFG=1
M  V30 2 C 4.0012 3.0801 0.0 0
M  V30 3 N 5.3348 5.3901 0.0 0
M  V30 4 C 2.6675 5.3901 0.0 0
M  V30 5 C 6.6687 4.6201 0.0 0
M  V30 6 O 2.6675 6.9302 0.0 0
M  V30 7 O 1.3338 4.6201 0.0 0
M  V30 8 C 8.0023 5.3901 0.0 0 CFG=2
M  V30 9 O 6.6687 3.0801 0.0 0
M  V30 10 C 1.3338 7.7002 0.0 0
M  V30 11 N 9.3360 4.6201 0.0 0
M  V30 12 C 8.0023 6.9302 0.0 0
M  V30 13 C 10.6697 5.3901 0.0 0
M  V30 14 C 6.6687 7.7002 0.0 0
M  V30 15 C 9.3360 7.7002 0.0 0
M  V30 16 O 12.0035 4.6201 0.0 0
M  V30 17 O 10.6697 6.9302 0.0 0
M  V30 18 C 13.3372 5.3901 0.0 0
M  V30 19 C 2.6675 2.3101 0.0 0
M  V30 20 C 1.3338 3.0801 0.0 0
M  V30 21 C 2.6675 0.7700 0.0 0
M  V30 22 C 0.0000 2.3101 0.0 0
M  V30 23 C 1.3338 0.0000 0.0 0
M  V30 24 C 0.0000 0.7700 0.0 0
M  V30 25 C 14.6708 4.6201 0.0 0
M  V30 26 C 14.6708 3.0801 0.0 0
M  V30 27 C 16.0045 5.3901 0.0 0
M  V30 28 C 16.0045 2.3101 0.0 0
M  V30 29 C 17.3383 4.6201 0.0 0
M  V30 30 C 17.3383 3.0801 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 19
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=3
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 16 18
M  V30 19 1 18 25
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 1 23 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1149-26-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 17193-39-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2481133-92-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23309934
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A quick route to multiple highly potent SARS-CoV-2 main protease
inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yang, Kai S.; Ma, Xinyu R.; Ma, Yuying; Alugubelli, Yugendar R.; Scott,
Danielle A.; Vatansever, Erol C.; Drelich, Aleksandra K.; Sankaran,
Banumathi; Geng, Zhi Z.; Blankenship, Lauren R.; Ward, Hannah E.; Sheng,
Yan J.; Hsu, Jason C.; Kratch, Kaci C.; Zhao, Baoyu; Hayatshahi, Hamed
S.; Liu, Jin; Li, Pingwei; Fierke, Carol A.; Tseng, Chien-Te K.; Xu,
Shiqing; Liu, Wenshe Ray
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2021), 16(6), 942-948

$RFMT $RIREG SCHEME346 STEP1
$RXN



  2  1
$MOL
tert-Butylamine
C4H11N
75-64-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 1.5400 0.0 0
M  V30 2 C 0.0000 1.5400 0.0 0
M  V30 3 C 1.5400 3.0800 0.0 0
M  V30 4 C 3.0800 1.5400 0.0 0
M  V30 5 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(Phenylmethyl) hydrogen N-[(phenylmethoxy)carbonyl]-L-glutamate
C20H21NO6
3705-42-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7002 5.3348 0.0 0 CFG=2
M  V30 2 C 9.2402 5.3348 0.0 0
M  V30 3 N 6.9302 6.6685 0.0 0
M  V30 4 C 6.9302 4.0012 0.0 0
M  V30 5 O 10.0102 6.6685 0.0 0
M  V30 6 O 10.0102 4.0012 0.0 0
M  V30 7 C 5.3901 6.6685 0.0 0
M  V30 8 C 7.7002 2.6673 0.0 0
M  V30 9 C 11.5503 6.6685 0.0 0
M  V30 10 O 4.6201 8.0022 0.0 0
M  V30 11 O 4.6201 5.3348 0.0 0
M  V30 12 C 6.9302 1.3337 0.0 0
M  V30 13 C 3.0801 8.0022 0.0 0
M  V30 14 O 7.7002 0.0000 0.0 0
M  V30 15 O 5.3901 1.3337 0.0 0
M  V30 16 C 12.3203 8.0022 0.0 0
M  V30 17 C 13.8603 8.0022 0.0 0
M  V30 18 C 11.5503 9.3360 0.0 0
M  V30 19 C 14.6303 9.3360 0.0 0
M  V30 20 C 12.3203 10.6697 0.0 0
M  V30 21 C 13.8603 10.6697 0.0 0
M  V30 22 C 2.3101 9.3360 0.0 0
M  V30 23 C 3.0801 10.6697 0.0 0
M  V30 24 C 0.7700 9.3360 0.0 0
M  V30 25 C 2.3101 12.0033 0.0 0
M  V30 26 C 0.0000 10.6697 0.0 0
M  V30 27 C 0.7700 12.0033 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 16
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 22
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(1,1-Dimethylethyl)-N2-[(phenylmethoxy)carbonyl]-L-glutamine phenylmethyl e...
C24H30N2O5
39538-24-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.7238 8.0022 0.0 0 CFG=2
M  V30 2 C 5.9538 6.6685 0.0 0
M  V30 3 N 8.2638 8.0022 0.0 0
M  V30 4 C 5.9538 9.3360 0.0 0
M  V30 5 O 6.7238 5.3348 0.0 0
M  V30 6 O 4.4137 6.6685 0.0 0
M  V30 7 C 9.0338 9.3360 0.0 0
M  V30 8 C 4.4137 9.3360 0.0 0
M  V30 9 C 5.9538 4.0010 0.0 0
M  V30 10 O 10.5739 9.3360 0.0 0
M  V30 11 O 8.2638 10.6697 0.0 0
M  V30 12 C 3.6437 10.6697 0.0 0
M  V30 13 C 11.3439 10.6697 0.0 0
M  V30 14 N 2.1037 10.6697 0.0 0
M  V30 15 O 4.4137 12.0033 0.0 0
M  V30 16 C 1.3337 12.0033 0.0 0
M  V30 17 C 0.0000 11.2333 0.0 0
M  V30 18 C 0.5637 13.3370 0.0 0
M  V30 19 C 2.6673 12.7733 0.0 0
M  V30 20 C 6.7238 2.6673 0.0 0
M  V30 21 C 8.2638 2.6673 0.0 0
M  V30 22 C 5.9538 1.3337 0.0 0
M  V30 23 C 9.0338 1.3337 0.0 0
M  V30 24 C 6.7238 0.0000 0.0 0
M  V30 25 C 8.2638 0.0000 0.0 0
M  V30 26 C 12.8839 10.6697 0.0 0
M  V30 27 C 13.6539 9.3360 0.0 0
M  V30 28 C 13.6539 12.0033 0.0 0
M  V30 29 C 15.1940 9.3360 0.0 0
M  V30 30 C 15.1940 12.0033 0.0 0
M  V30 31 C 15.9640 10.6697 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 20
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 26
M  V30 17 1 14 16
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 16 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 2 28 30
M  V30 31 2 29 31
M  V30 32 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-64-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3705-42-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 39538-24-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37376180
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhu, Junjie; Lei, Saifei; Lu, Jie; Hao, Yixuan; Qian, Qi; Devanathan,
Aaron S.; Feng, Zhiwei; Xie, Xiang-Qun; Wipf, Peter; Ma, Xiaochao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 259115666

$RFMT $RIREG SCHEME347 STEP1
$RXN



  2  1
$MOL
-Alanine, phenylmethyl ester, 4-methylbenzenesulfonate (1:1)
C10H13NO2.C7H8O3S
27019-47-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 6.1600 0.0 0
M  V30 2 O 5.3348 6.9301 0.0 0
M  V30 3 C 6.6685 6.1600 0.0 0
M  V30 4 C 8.0023 6.9301 0.0 0
M  V30 5 O 6.6685 4.6200 0.0 0
M  V30 6 C 9.3360 6.1600 0.0 0
M  V30 7 N 10.6697 6.9301 0.0 0
M  V30 8 C 2.6673 6.9301 0.0 0
M  V30 9 C 1.3337 6.1600 0.0 0
M  V30 10 C 2.6673 8.4701 0.0 0
M  V30 11 C 0.0000 6.9301 0.0 0
M  V30 12 C 1.3337 9.2401 0.0 0
M  V30 13 C 0.0000 8.4701 0.0 0
M  V30 14 S 3.0248 1.5400 0.0 0 VAL=6
M  V30 15 O 3.0248 3.0800 0.0 0
M  V30 16 O 3.0248 0.0000 0.0 0
M  V30 17 O 1.4848 1.5400 0.0 0
M  V30 18 C 9.1848 1.5400 0.0 0
M  V30 19 C 4.5648 1.5400 0.0 0
M  V30 20 C 5.3348 0.2064 0.0 0
M  V30 21 C 5.3348 2.8736 0.0 0
M  V30 22 C 6.8748 0.2064 0.0 0
M  V30 23 C 6.8748 2.8736 0.0 0
M  V30 24 C 7.6448 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 14 2 14 15
M  V30 15 2 14 16
M  V30 16 1 14 17
M  V30 17 1 14 19
M  V30 18 1 18 24
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 2 21 23
M  V30 23 2 22 24
M  V30 24 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-[(tert-Butoxycarbonyl)amino]benzoic acid
C12H15NO4
111331-82-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 O 2.6673 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 1.3337 2.3101 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 10.6697 1.5400 0.0 0
M  V30 10 O 12.0033 2.3101 0.0 0
M  V30 11 O 10.6697 0.0000 0.0 0
M  V30 12 C 6.6685 2.3101 0.0 0
M  V30 13 C 8.0022 1.5400 0.0 0
M  V30 14 C 6.6685 3.8501 0.0 0
M  V30 15 C 9.3360 2.3101 0.0 0
M  V30 16 C 8.0022 4.6201 0.0 0
M  V30 17 C 9.3360 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 9 15
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[3-[[(1,1-Dimethylethoxy)carbonyl]amino]benzoyl]--alanine phenylmethyl ester
C22H26N2O5
135321-13-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 O 2.6673 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 1.3337 2.3101 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 10.6697 1.5400 0.0 0
M  V30 10 N 12.0033 2.3101 0.0 0
M  V30 11 O 10.6697 0.0000 0.0 0
M  V30 12 C 13.3370 1.5400 0.0 0
M  V30 13 C 14.6708 2.3101 0.0 0
M  V30 14 C 16.0045 1.5400 0.0 0
M  V30 15 O 17.3382 2.3101 0.0 0
M  V30 16 O 16.0045 0.0000 0.0 0
M  V30 17 C 18.6718 1.5400 0.0 0
M  V30 18 C 6.6685 2.3101 0.0 0
M  V30 19 C 8.0022 1.5400 0.0 0
M  V30 20 C 6.6685 3.8501 0.0 0
M  V30 21 C 9.3360 2.3101 0.0 0
M  V30 22 C 8.0022 4.6201 0.0 0
M  V30 23 C 9.3360 3.8501 0.0 0
M  V30 24 C 20.0057 2.3101 0.0 0
M  V30 25 C 20.0057 3.8501 0.0 0
M  V30 26 C 21.3393 1.5400 0.0 0
M  V30 27 C 21.3393 4.6201 0.0 0
M  V30 28 C 22.6730 2.3101 0.0 0
M  V30 29 C 22.6730 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 18
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 9 21
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 15 17
M  V30 18 1 17 24
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 25 2 24 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 2 26 28
M  V30 29 2 27 29
M  V30 30 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 27019-47-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 111331-82-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 135321-13-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36693522
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the
relationship between linker length, properties, and selective protein
degradation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tokarski, Robert J. II; Sharpe, Chia M.; Huntsman, Andrew C.; Mize,
Brittney K.; Ayinde, Oluwatosin R.; Stahl, Emily H.; Lerma, James R.;
Reed, Andrew; Carmichael, Bridget; Muthusamy, Natarajan; Byrd, John C.;
Fuchs, James R.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 254115342

$RFMT $RIREG SCHEME348 STEP1
$RXN



  2  1
$MOL
4-(tert-Butoxycarbonylamino)benzoic acid
C12H15NO4
66493-39-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 1.5400 0.0 0
M  V30 2 O 12.0033 2.3101 0.0 0
M  V30 3 O 10.6697 0.0000 0.0 0
M  V30 4 N 5.3348 4.6201 0.0 0
M  V30 5 C 4.0012 3.8501 0.0 0
M  V30 6 O 2.6673 4.6201 0.0 0
M  V30 7 O 4.0012 2.3101 0.0 0
M  V30 8 C 1.3337 3.8501 0.0 0
M  V30 9 C 2.1037 2.5164 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 0.5637 5.1838 0.0 0
M  V30 12 C 9.3360 2.3101 0.0 0
M  V30 13 C 9.3360 3.8501 0.0 0
M  V30 14 C 8.0022 1.5400 0.0 0
M  V30 15 C 8.0022 4.6201 0.0 0
M  V30 16 C 6.6685 2.3101 0.0 0
M  V30 17 C 6.6685 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 4 5
M  V30 5 1 4 17
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 8 11
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Cyclohexanepropanoic acid, -amino-, ethyl ester, hydrochloride, (S)-
C11H21NO2.ClH
60025-25-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0800 0.0 0
M  V30 2 C 5.3348 3.8501 0.0 0 CFG=2
M  V30 3 C 6.6685 3.0800 0.0 0
M  V30 4 N 5.3348 5.3901 0.0 0
M  V30 5 O 8.0023 3.8501 0.0 0
M  V30 6 O 6.6685 1.5400 0.0 0
M  V30 7 C 9.3360 3.0800 0.0 0
M  V30 8 C 10.6697 3.8501 0.0 0
M  V30 9 C 2.6673 3.8501 0.0 0
M  V30 10 C 1.3337 3.0800 0.0 0
M  V30 11 C 2.6673 5.3901 0.0 0
M  V30 12 C 0.0000 3.8501 0.0 0
M  V30 13 C 1.3337 6.1601 0.0 0
M  V30 14 C 0.0000 5.3901 0.0 0
M  V30 15 Cl 5.3348 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Cyclohexanepropanoic acid, -[[4-[[(1,1-dimethylethoxy)carbonyl]amino]benzoyl...
C23H34N2O5
3054992-14-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7000 6.6684 0.0 0
M  V30 2 N 6.9300 5.3347 0.0 0
M  V30 3 O 6.9300 8.0021 0.0 0
M  V30 4 C 5.3900 5.3347 0.0 0 CFG=2
M  V30 5 C 4.6200 6.6684 0.0 0
M  V30 6 C 4.6200 4.0011 0.0 0
M  V30 7 O 5.3900 2.6673 0.0 0
M  V30 8 O 3.0800 4.0011 0.0 0
M  V30 9 C 4.6200 1.3336 0.0 0
M  V30 10 C 5.3900 0.0000 0.0 0
M  V30 11 N 13.8600 6.6684 0.0 0
M  V30 12 C 14.6300 8.0021 0.0 0
M  V30 13 O 16.1700 8.0021 0.0 0
M  V30 14 O 13.8600 9.3358 0.0 0
M  V30 15 C 16.9400 9.3358 0.0 0
M  V30 16 C 15.6064 10.1058 0.0 0
M  V30 17 C 17.7100 10.6694 0.0 0
M  V30 18 C 18.2736 8.5658 0.0 0
M  V30 19 C 9.2400 6.6684 0.0 0
M  V30 20 C 10.0100 5.3347 0.0 0
M  V30 21 C 10.0100 8.0021 0.0 0
M  V30 22 C 11.5500 5.3347 0.0 0
M  V30 23 C 11.5500 8.0021 0.0 0
M  V30 24 C 12.3200 6.6684 0.0 0
M  V30 25 C 3.0800 6.6684 0.0 0
M  V30 26 C 2.3100 5.3347 0.0 0
M  V30 27 C 2.3100 8.0021 0.0 0
M  V30 28 C 0.7700 5.3347 0.0 0
M  V30 29 C 0.7700 8.0021 0.0 0
M  V30 30 C 0.0000 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 19
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=3
M  V30 6 1 4 6
M  V30 7 1 5 25
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 7 9
M  V30 11 1 9 10
M  V30 12 1 11 12
M  V30 13 1 11 24
M  V30 14 1 12 13
M  V30 15 2 12 14
M  V30 16 1 13 15
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 1 15 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 66493-39-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 60025-25-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3054992-14-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36966246
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing
Covalent Reversible -Fluorovinylsulfones and -Sulfonates as Potential
Immunomodulators in Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fuchs, Natalie; Meta, Mergim; Lantzberg, Bellinda; Bros, Matthias; Ling
Kuan, Seah; Weil, Tanja; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(15), e202300160

$RFMT $RIREG SCHEME349 STEP1
$RXN



  2  1
$MOL
D-Alaninol
C3H9NO
35320-23-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0 CFG=2
M  V30 2 C 2.6673 2.3101 0.0 0
M  V30 3 C 1.3337 0.0000 0.0 0
M  V30 4 N 0.0000 2.3101 0.0 0
M  V30 5 O 4.0010 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
FMOC-L-phenylalanine
C24H21NO4
35661-40-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 5.2309 0.0 0
M  V30 2 O 8.0021 4.4608 0.0 0
M  V30 3 C 6.6685 5.2309 0.0 0
M  V30 4 N 5.3348 4.4608 0.0 0
M  V30 5 O 6.6685 6.7709 0.0 0
M  V30 6 C 4.0011 5.2309 0.0 0 CFG=2
M  V30 7 C 4.0011 6.7709 0.0 0
M  V30 8 C 2.6673 4.4608 0.0 0
M  V30 9 O 1.3337 5.2309 0.0 0
M  V30 10 O 2.6673 2.9208 0.0 0
M  V30 11 C 10.6696 4.4608 0.0 0
M  V30 12 C 10.8306 2.9293 0.0 0
M  V30 13 C 12.0764 5.0873 0.0 0
M  V30 14 C 12.3370 2.6091 0.0 0
M  V30 15 C 9.8001 1.7849 0.0 0
M  V30 16 C 13.1070 3.9428 0.0 0
M  V30 17 C 12.5523 6.5519 0.0 0
M  V30 18 C 12.8129 1.1444 0.0 0
M  V30 19 C 10.2760 0.3202 0.0 0
M  V30 20 C 14.6133 4.2630 0.0 0
M  V30 21 C 14.0588 6.8721 0.0 0
M  V30 22 C 11.7823 0.0000 0.0 0
M  V30 23 C 15.0892 5.7277 0.0 0
M  V30 24 C 2.6673 7.5409 0.0 0
M  V30 25 C 1.3337 6.7709 0.0 0
M  V30 26 C 2.6673 9.0809 0.0 0
M  V30 27 C 0.0000 7.5409 0.0 0
M  V30 28 C 1.3337 9.8509 0.0 0
M  V30 29 C 0.0000 9.0809 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7 CFG=3
M  V30 8 1 6 8
M  V30 9 1 7 24
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 16
M  V30 19 2 14 18
M  V30 20 1 15 19
M  V30 21 2 16 20
M  V30 22 1 17 21
M  V30 23 1 18 22
M  V30 24 2 19 22
M  V30 25 1 20 23
M  V30 26 2 21 23
M  V30 27 2 24 25
M  V30 28 1 24 26
M  V30 29 1 25 27
M  V30 30 2 26 28
M  V30 31 2 27 29
M  V30 32 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C27H28N2O4
3037043-04-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.2309 8.0022 0.0 0
M  V30 2 O 6.7709 8.0022 0.0 0
M  V30 3 C 7.5409 6.6685 0.0 0
M  V30 4 N 9.0810 6.6685 0.0 0
M  V30 5 O 6.7709 5.3348 0.0 0
M  V30 6 C 9.8510 5.3348 0.0 0 CFG=2
M  V30 7 C 9.0810 4.0012 0.0 0
M  V30 8 C 11.3910 5.3348 0.0 0
M  V30 9 N 12.1610 6.6685 0.0 0
M  V30 10 O 12.1610 4.0012 0.0 0
M  V30 11 C 13.7011 6.6685 0.0 0 CFG=2
M  V30 12 C 14.4711 8.0022 0.0 0
M  V30 13 C 14.4711 5.3348 0.0 0
M  V30 14 O 16.0111 8.0022 0.0 0
M  V30 15 C 4.4609 9.3360 0.0 0
M  V30 16 C 5.0873 10.7428 0.0 0
M  V30 17 C 2.9293 9.4969 0.0 0
M  V30 18 C 3.9428 11.7732 0.0 0
M  V30 19 C 6.5519 11.2187 0.0 0
M  V30 20 C 2.6091 11.0032 0.0 0
M  V30 21 C 1.7849 8.4665 0.0 0
M  V30 22 C 4.2630 13.2797 0.0 0
M  V30 23 C 6.8721 12.7251 0.0 0
M  V30 24 C 1.1444 11.4793 0.0 0
M  V30 25 C 0.3202 8.9424 0.0 0
M  V30 26 C 5.7277 13.7556 0.0 0
M  V30 27 C 0.0000 10.4487 0.0 0
M  V30 28 C 9.8510 2.6673 0.0 0
M  V30 29 C 9.0810 1.3337 0.0 0
M  V30 30 C 11.3910 2.6673 0.0 0
M  V30 31 C 9.8510 0.0000 0.0 0
M  V30 32 C 12.1610 1.3337 0.0 0
M  V30 33 C 11.3910 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7 CFG=3
M  V30 8 1 6 8
M  V30 9 1 7 28
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 9 11
M  V30 13 1 11 12
M  V30 14 1 11 13 CFG=1
M  V30 15 1 12 14
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 16 19
M  V30 20 1 17 20
M  V30 21 2 17 21
M  V30 22 1 18 20
M  V30 23 2 18 22
M  V30 24 1 19 23
M  V30 25 2 20 24
M  V30 26 1 21 25
M  V30 27 1 22 26
M  V30 28 2 23 26
M  V30 29 1 24 27
M  V30 30 2 25 27
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 29 31
M  V30 34 2 30 32
M  V30 35 2 31 33
M  V30 36 1 32 33
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 6 11)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 35320-23-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 35661-40-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3037043-04-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40804610
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with
Antiproliferative Activity in Breast Cancer Models
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Winter-Holt, Jon J.; Bardelle, Catherine; Chiarparin, Elisabetta; Dale,
Ian L.; Davey, Paul R. J.; Davies, Nichola L.; Denz, Christopher;
Fillery, Shaun M.; Guerot, Carine M.; Han, Fujin; Hughes, Samantha J.;
Kulkarni, Meghana; Liu, Zhaoqun; Milbradt, Alexander; Moss, Thomas A.;
Niu, Huijun; Patel, Joe; Rabow, Alfred A.; Schimpl, Marianne; Shi,
Junjie; Sun, Dongqing; Yang, Dejian; Guichard, Sylvie
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(4), 3306-3331

$RFMT $RIREG SCHEME350 STEP1
$RXN



  2  1
$MOL
4-Methoxyaniline
C7H9NO
104-94-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7700 1.3337 0.0 0
M  V30 2 C 0.0000 2.6673 0.0 0
M  V30 3 N 6.9302 1.3337 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 3.0801 0.0000 0.0 0
M  V30 7 C 4.6201 2.6673 0.0 0
M  V30 8 C 4.6201 0.0000 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
tert-Butoxycarbonyl-D-proline
C10H17NO4
37784-17-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.5254 2.6218 0.0 0
M  V30 2 O 5.8592 1.8517 0.0 0
M  V30 3 O 4.5254 4.1618 0.0 0
M  V30 4 C 7.1929 2.6218 0.0 0
M  V30 5 C 6.4229 3.9554 0.0 0
M  V30 6 C 8.5266 3.3918 0.0 0
M  V30 7 C 7.9629 1.2881 0.0 0
M  V30 8 C 1.4646 3.9845 0.0 0
M  V30 9 O 2.6091 5.0150 0.0 0
M  V30 10 O 0.0000 4.4604 0.0 0
M  V30 11 N 3.1917 1.8517 0.0 0
M  V30 12 C 1.7849 2.4781 0.0 0 CFG=1
M  V30 13 C 3.0308 0.3202 0.0 0
M  V30 14 C 0.7543 1.3337 0.0 0
M  V30 15 C 1.5243 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 12 8 CFG=3
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 12)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl (2R)-2-[[(4-methoxyphenyl)amino]carbonyl]-1-pyrrolidinecarb...
C17H24N2O4
877594-22-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.3520 4.8514 0.0 0
M  V30 2 N 7.6857 5.6214 0.0 0
M  V30 3 O 6.3520 3.3114 0.0 0
M  V30 4 C 3.2912 3.4886 0.0 0
M  V30 5 O 1.8266 3.0128 0.0 0
M  V30 6 O 4.4358 2.4582 0.0 0
M  V30 7 C 1.5065 1.5063 0.0 0
M  V30 8 C 0.0000 1.8265 0.0 0
M  V30 9 C 1.1863 0.0000 0.0 0
M  V30 10 C 3.0128 1.1861 0.0 0
M  V30 11 O 13.0207 2.5414 0.0 0
M  V30 12 C 14.3543 3.3114 0.0 0
M  V30 13 C 5.0184 5.6214 0.0 0 CFG=1
M  V30 14 N 3.6115 4.9949 0.0 0
M  V30 15 C 4.8574 7.1530 0.0 0
M  V30 16 C 2.5809 6.1395 0.0 0
M  V30 17 C 3.3510 7.4732 0.0 0
M  V30 18 C 9.0195 4.8514 0.0 0
M  V30 19 C 9.0195 3.3114 0.0 0
M  V30 20 C 10.3532 5.6214 0.0 0
M  V30 21 C 10.3532 2.5414 0.0 0
M  V30 22 C 11.6869 4.8514 0.0 0
M  V30 23 C 11.6869 3.3114 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 13 1 CFG=3
M  V30 4 1 2 18
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 14
M  V30 8 1 5 7
M  V30 9 1 7 8
M  V30 10 1 7 9
M  V30 11 1 7 10
M  V30 12 1 11 12
M  V30 13 1 11 23
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 13)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 104-94-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 37784-17-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 877594-22-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38128116
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 39968-33-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-68-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library
Technology in Combination with High-Throughput Screening
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tian, Xinrong; Suarez, Dominic; Thomson, Douglas; Li, William; King,
Elizabeth A.; LaFrance, Louis; Boehm, Jeffrey; Barton, Linda; Di Marco,
Christina; Martyr, Cuthbert; Thalji, Reema; Medina, Jesus; Knight,
Steven; Heerding, Dirk; Gao, Enoch; Nartey, Eldridge; Cecconie, Ted;
Nixon, Christopher; Zhang, Guofeng; Berrodin, Thomas J.; Phelps,
Christopher; Patel, Amish; Bai, Xiaopeng; Lind, Ken; Prabhu, Ninad;
Messer, Jeffrey; Zhu, Zhengrong; Shewchuk, Lisa; Reid, Rob; Graves, Alan
P.; McHugh, Charles; Mangatt, Biju
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(21), 14391-14408

$RFMT $RIREG SCHEME351 STEP1
$RXN



  2  1
$MOL
4-Oxo-4-(phenylamino)-2-butenoic acid
C10H9NO3
37902-58-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 1.5400 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 O 5.3348 3.8501 0.0 0
M  V30 5 C 8.0023 2.3101 0.0 0
M  V30 6 C 9.3360 1.5400 0.0 0
M  V30 7 O 9.3360 0.0000 0.0 0
M  V30 8 O 10.6697 2.3101 0.0 0
M  V30 9 C 2.6673 2.3101 0.0 0
M  V30 10 C 2.6673 3.8501 0.0 0
M  V30 11 C 1.3337 1.5400 0.0 0
M  V30 12 C 1.3337 4.6201 0.0 0
M  V30 13 C 0.0000 2.3101 0.0 0
M  V30 14 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-Phenyl-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H17N3O3
2416338-39-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 C 9.2400 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 10.0100 5.3347 0.0 0
M  V30 6 C 11.5500 5.3347 0.0 0
M  V30 7 N 12.3200 6.6685 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 O 5.3900 0.0000 0.0 0
M  V30 10 C 3.0800 4.0011 0.0 0
M  V30 11 C 2.3100 2.6674 0.0 0
M  V30 12 C 4.6200 4.0011 0.0 0
M  V30 13 C 2.3100 5.3347 0.0 0
M  V30 14 N 3.0800 1.3336 0.0 0
M  V30 15 C 0.7700 2.6674 0.0 0
M  V30 16 C 5.3900 2.6674 0.0 0
M  V30 17 C 0.7700 5.3347 0.0 0
M  V30 18 C 4.6200 1.3336 0.0 0
M  V30 19 C 0.0000 4.0011 0.0 0
M  V30 20 C 13.8600 6.6685 0.0 0
M  V30 21 C 14.6300 8.0021 0.0 0
M  V30 22 C 14.6300 5.3347 0.0 0
M  V30 23 C 16.1700 8.0021 0.0 0
M  V30 24 C 16.1700 5.3347 0.0 0
M  V30 25 C 16.9400 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 20
M  V30 10 2 9 18
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 18
M  V30 21 2 17 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 37902-58-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-39-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822021
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME352 STEP1
$RXN



  2  1
$MOL
3,4-Dimethoxyphenethylamine
C10H15NO2
120-20-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3349 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3349 0.0 0
M  V30 7 N 9.2400 5.3349 0.0 0
M  V30 8 C 3.0800 2.6674 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.0800 5.3349 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 4.6200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indole-3-propanoic acid
C11H11NO2
830-96-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7533 2.6218 0.0 0
M  V30 2 C 7.0869 1.8518 0.0 0
M  V30 3 C 8.4206 2.6218 0.0 0
M  V30 4 O 9.7544 1.8518 0.0 0
M  V30 5 O 8.4206 4.1618 0.0 0
M  V30 6 C 3.0127 2.4782 0.0 0
M  V30 7 C 4.4196 1.8518 0.0 0
M  V30 8 C 1.9823 1.3338 0.0 0
M  V30 9 C 2.5368 3.9429 0.0 0
M  V30 10 C 4.2586 0.3202 0.0 0
M  V30 11 N 2.7523 0.0000 0.0 0
M  V30 12 C 0.4759 1.6540 0.0 0
M  V30 13 C 1.0306 4.2630 0.0 0
M  V30 14 C 0.0000 3.1185 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 2 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 11
M  V30 14 1 12 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)ethyl]-1H-indole-3-propanamide
C21H24N2O3
929809-53-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 12.0033 3.8501 0.0 0
M  V30 2 C 10.6697 4.6201 0.0 0
M  V30 3 C 9.3358 3.8501 0.0 0
M  V30 4 N 8.0022 4.6201 0.0 0
M  V30 5 O 9.3358 2.3101 0.0 0
M  V30 6 C 6.6685 3.8501 0.0 0
M  V30 7 C 5.3348 4.6201 0.0 0
M  V30 8 O 0.0000 4.6201 0.0 0
M  V30 9 C 0.0000 6.1601 0.0 0
M  V30 10 O 0.0000 1.5400 0.0 0
M  V30 11 C 0.0000 0.0000 0.0 0
M  V30 12 C 14.7440 3.9936 0.0 0
M  V30 13 C 13.3370 4.6201 0.0 0
M  V30 14 C 15.7744 5.1382 0.0 0
M  V30 15 C 15.2198 2.5290 0.0 0
M  V30 16 C 13.4979 6.1517 0.0 0
M  V30 17 N 15.0044 6.4718 0.0 0
M  V30 18 C 17.2807 4.8180 0.0 0
M  V30 19 C 16.7262 2.2089 0.0 0
M  V30 20 C 17.7566 3.3533 0.0 0
M  V30 21 C 4.0010 3.8501 0.0 0
M  V30 22 C 2.6673 4.6201 0.0 0
M  V30 23 C 4.0010 2.3101 0.0 0
M  V30 24 C 1.3337 3.8501 0.0 0
M  V30 25 C 2.6673 1.5400 0.0 0
M  V30 26 C 1.3337 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 21
M  V30 9 1 8 9
M  V30 10 1 8 24
M  V30 11 1 10 11
M  V30 12 1 10 26
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 1 15 19
M  V30 20 1 16 17
M  V30 21 1 18 20
M  V30 22 2 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 120-20-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 830-96-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 929809-53-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40818679
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Optimization of Tetrahydroisoquinoline Derivatives To
Enhance Lysosome Biogenesis as Preclinical Candidates for the Treatment
of Alzheimer's Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhou, Jianhui; Wang, Ning; Wang, Mengxue; Hu, Yuting; Zhang, Zhenwei; Gu,
Zhiyong; Wang, Jing; Shou, Haowen; Cheng, Xi; Liu, Hong; Li, Yang; Zhou,
Yu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(11), 8836-8861

$RFMT $RIREG SCHEME353 STEP1
$RXN



  2  1
$MOL
8-[(2,4-Difluorophenyl)amino]-10,11-dihydro-5-oxo-5H-dibenzo[a,d]cycloheptene...
C22H15F2NO3
1417404-28-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.6505 1.9730 0.0 0
M  V30 2 C 1.5357 1.3874 0.0 0
M  V30 3 O 0.0000 1.5026 0.0 0
M  V30 4 O 2.2039 0.0000 0.0 0
M  V30 5 N 11.5129 6.7446 0.0 0
M  V30 6 F 14.1802 8.2846 0.0 0
M  V30 7 F 16.8476 3.6646 0.0 0
M  V30 8 C 4.8065 3.8172 0.0 0
M  V30 9 C 4.1383 5.2046 0.0 0
M  V30 10 C 6.3078 3.4745 0.0 0
M  V30 11 C 3.9389 2.5447 0.0 0
M  V30 12 C 4.8065 6.5921 0.0 0
M  V30 13 C 2.6026 5.3198 0.0 0
M  V30 14 C 7.5118 4.4346 0.0 0
M  V30 15 C 2.4032 2.6599 0.0 0
M  V30 16 C 6.3078 6.9348 0.0 0
M  V30 17 C 1.7350 4.0473 0.0 0
M  V30 18 C 7.5118 5.9746 0.0 0
M  V30 19 C 8.8455 3.6646 0.0 0
M  V30 20 C 8.8455 6.7446 0.0 0
M  V30 21 C 10.1792 4.4346 0.0 0
M  V30 22 C 10.1792 5.9746 0.0 0
M  V30 23 C 12.8465 5.9746 0.0 0
M  V30 24 C 14.1802 6.7446 0.0 0
M  V30 25 C 12.8465 4.4346 0.0 0
M  V30 26 C 15.5140 5.9746 0.0 0
M  V30 27 C 14.1802 3.6646 0.0 0
M  V30 28 C 15.5140 4.4346 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 10
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 15
M  V30 5 1 5 22
M  V30 6 1 5 23
M  V30 7 1 6 24
M  V30 8 1 7 28
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 2 9 13
M  V30 14 1 10 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 2 14 19
M  V30 20 2 15 17
M  V30 21 1 16 18
M  V30 22 2 18 20
M  V30 23 1 19 21
M  V30 24 1 20 22
M  V30 25 2 21 22
M  V30 26 2 23 24
M  V30 27 1 23 25
M  V30 28 1 24 26
M  V30 29 2 25 27
M  V30 30 2 26 28
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
8-[(2,4-Difluorophenyl)amino]-10,11-dihydro-5-oxo-N-phenyl-5H-dibenzo[a,d]cyc...
C28H20F2N2O2
2614241-99-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 9.9212 2.9003 0.0 0
M  V30 2 C 14.7836 4.5918 0.0 0
M  V30 3 N 16.1173 5.3619 0.0 0
M  V30 4 O 14.7836 3.0518 0.0 0
M  V30 5 N 3.4701 5.0896 0.0 0
M  V30 6 F 0.3987 5.3198 0.0 0
M  V30 7 F 0.0000 0.0000 0.0 0
M  V30 8 C 10.7825 5.3619 0.0 0
M  V30 9 C 10.7825 6.9019 0.0 0
M  V30 10 C 9.5785 4.4017 0.0 0
M  V30 11 C 12.1163 4.5918 0.0 0
M  V30 12 C 9.5785 7.8621 0.0 0
M  V30 13 C 12.1163 7.6719 0.0 0
M  V30 14 C 8.0772 4.7445 0.0 0
M  V30 15 C 13.4500 5.3619 0.0 0
M  V30 16 C 8.0772 7.5194 0.0 0
M  V30 17 C 13.4500 6.9019 0.0 0
M  V30 18 C 7.4090 6.1319 0.0 0
M  V30 19 C 7.2097 3.4720 0.0 0
M  V30 20 C 5.8733 6.2470 0.0 0
M  V30 21 C 5.6740 3.5870 0.0 0
M  V30 22 C 5.0058 4.9745 0.0 0
M  V30 23 C 17.4511 4.5918 0.0 0
M  V30 24 C 18.7847 5.3619 0.0 0
M  V30 25 C 17.4511 3.0518 0.0 0
M  V30 26 C 20.1184 4.5918 0.0 0
M  V30 27 C 18.7847 2.2818 0.0 0
M  V30 28 C 20.1184 3.0518 0.0 0
M  V30 29 C 2.6025 3.8172 0.0 0
M  V30 30 C 1.0668 3.9323 0.0 0
M  V30 31 C 3.2707 2.4297 0.0 0
M  V30 32 C 0.1993 2.6599 0.0 0
M  V30 33 C 2.4032 1.1573 0.0 0
M  V30 34 C 0.8675 1.2724 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 10
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 15
M  V30 5 1 3 23
M  V30 6 1 5 22
M  V30 7 1 5 29
M  V30 8 1 6 30
M  V30 9 1 7 34
M  V30 10 1 8 9
M  V30 11 1 8 10
M  V30 12 2 8 11
M  V30 13 1 9 12
M  V30 14 2 9 13
M  V30 15 1 10 14
M  V30 16 1 11 15
M  V30 17 1 12 16
M  V30 18 1 13 17
M  V30 19 1 14 18
M  V30 20 2 14 19
M  V30 21 2 15 17
M  V30 22 1 16 18
M  V30 23 2 18 20
M  V30 24 1 19 21
M  V30 25 1 20 22
M  V30 26 2 21 22
M  V30 27 2 23 24
M  V30 28 1 23 25
M  V30 29 1 24 26
M  V30 30 2 25 27
M  V30 31 2 26 28
M  V30 32 1 27 28
M  V30 33 2 29 30
M  V30 34 1 29 31
M  V30 35 1 30 32
M  V30 36 2 31 33
M  V30 37 2 32 34
M  V30 38 1 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1417404-28-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2614241-99-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31188001
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Synthesis of Highly Selective Brain Penetrant p38
Mitogen-Activated Protein Kinase Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tormaehlen, Niklas M.; Martorelli, Mariella; Kuhn, Annette; Maier,
Florian; Guezguez, Jamil; Burnet, Michael; Albrecht, Wolfgang; Laufer,
Stefan A.; Koch, Pierre
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(2), 1225-1242

$RFMT $RIREG SCHEME354 STEP1
$RXN



  2  1
$MOL
Amantadine
C10H17N
768-94-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5321 3.0179 0.0 0
M  V30 2 C 4.1957 2.2463 0.0 0
M  V30 3 C 2.9051 3.0867 0.0 0
M  V30 4 C 4.2781 0.7086 0.0 0
M  V30 5 C 2.4986 2.2355 0.0 0
M  V30 6 C 1.6969 2.3891 0.0 0
M  V30 7 C 3.0699 0.0111 0.0 0
M  V30 8 C 1.2906 1.5379 0.0 0
M  V30 9 C 0.0000 2.3780 0.0 0
M  V30 10 C 1.7794 0.8513 0.0 0
M  V30 11 C 1.3730 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 6 10
M  V30 10 1 7 10
M  V30 11 1 7 11
M  V30 12 1 8 9
M  V30 13 1 8 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-(3,5-Dimethyl-1H-pyrazol-1-yl)-3,5-dimethyl-1H-pyrazole-1-acetic acid
C12H16N4O2
331943-38-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.3322 5.3026 0.0 0
M  V30 2 C 2.5622 6.6363 0.0 0
M  V30 3 O 1.0221 6.6363 0.0 0
M  V30 4 O 3.3322 7.9700 0.0 0
M  V30 5 C 0.0000 4.9524 0.0 0
M  V30 6 C 5.3016 8.0131 0.0 0
M  V30 7 C 2.2050 0.0000 0.0 0
M  V30 8 C 8.4881 3.6274 0.0 0
M  V30 9 N 2.5622 3.9688 0.0 0
M  V30 10 C 1.0306 3.8079 0.0 0
M  V30 11 N 3.1885 2.5620 0.0 0
M  V30 12 C 0.7104 2.3016 0.0 0
M  V30 13 C 2.0441 1.5316 0.0 0
M  V30 14 N 4.8722 5.3026 0.0 0
M  V30 15 C 5.7774 6.5485 0.0 0
M  V30 16 N 5.7774 4.0568 0.0 0
M  V30 17 C 7.2420 6.0727 0.0 0
M  V30 18 C 7.2420 4.5326 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 1 14
M  V30 4 1 2 3
M  V30 5 2 2 4
M  V30 6 1 5 10
M  V30 7 1 6 15
M  V30 8 1 7 13
M  V30 9 1 8 18
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-(3,5-Dimethyl-1H-pyrazol-1-yl)-3,5-dimethyl-N-tricyclo[3.3.1.13,7]dec-1-yl-...
C22H31N5O
2820409-56-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5212 5.1559 0.0 0
M  V30 2 C 6.8550 5.9259 0.0 0
M  V30 3 C 8.1887 5.1559 0.0 0
M  V30 4 O 6.8550 7.4659 0.0 0
M  V30 5 C 10.8993 3.1865 0.0 0
M  V30 6 C 8.5389 8.4881 0.0 0
M  V30 7 C 6.5134 0.0000 0.0 0
M  V30 8 C 13.4913 6.2830 0.0 0
M  V30 9 C 4.1875 5.9259 0.0 0
M  V30 10 C 2.8994 5.0873 0.0 0
M  V30 11 C 4.2697 7.4607 0.0 0
M  V30 12 C 2.4938 5.9368 0.0 0
M  V30 13 C 1.6936 5.7834 0.0 0
M  V30 14 C 3.0639 8.1569 0.0 0
M  V30 15 C 1.2879 6.6329 0.0 0
M  V30 16 C 0.0000 5.7945 0.0 0
M  V30 17 C 1.7760 7.3182 0.0 0
M  V30 18 C 1.3702 8.1679 0.0 0
M  V30 19 N 8.1887 3.6158 0.0 0
M  V30 20 C 9.4346 2.7106 0.0 0
M  V30 21 N 6.9428 2.7106 0.0 0
M  V30 22 C 8.9587 1.2460 0.0 0
M  V30 23 C 7.4187 1.2460 0.0 0
M  V30 24 N 9.5223 5.9259 0.0 0
M  V30 25 C 9.6833 7.4575 0.0 0
M  V30 26 N 10.9293 5.2996 0.0 0
M  V30 27 C 11.1897 7.7776 0.0 0
M  V30 28 C 11.9597 6.4440 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 19
M  V30 6 1 3 24
M  V30 7 1 5 20
M  V30 8 1 6 25
M  V30 9 1 7 23
M  V30 10 1 8 28
M  V30 11 1 9 10
M  V30 12 1 9 11
M  V30 13 1 9 12
M  V30 14 1 10 13
M  V30 15 1 11 14
M  V30 16 1 12 15
M  V30 17 1 13 16
M  V30 18 1 13 17
M  V30 19 1 14 17
M  V30 20 1 14 18
M  V30 21 1 15 16
M  V30 22 1 15 18
M  V30 23 1 19 20
M  V30 24 1 19 21
M  V30 25 2 20 22
M  V30 26 2 21 23
M  V30 27 1 22 23
M  V30 28 1 24 25
M  V30 29 1 24 26
M  V30 30 2 25 27
M  V30 31 2 26 28
M  V30 32 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 768-94-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 331943-38-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2820409-56-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40920475
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Copper-Based Complexes with Adamantane Ring-Conjugated
bis(3,5-Dimethyl-pyrazol-1-yl)acetate Ligand as Promising Agents for the
Treatment of Glioblastoma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Morelli, Maria Beatrice; Caviglia, Miriam; Santini, Carlo; Del Gobbo,
Jo'; Zeppa, Laura; Del Bello, Fabio; Giorgioni, Gianfabio; Piergentili,
Alessandro; Quaglia, Wilma; Battocchio, Chiara; Bertela, Federica;
Amatori, Simone; Meneghini, Carlo; Iucci, Giovanna; Venditti, Iole;
Dolmella, Alessandro; Di Palma, Michele; Pellei, Maura
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(11), 9662-9685

$RFMT $RIREG SCHEME355 STEP1
$RXN



  2  1
$MOL
tert-Butoxycarbonyl-D-leucine
C11H21NO4
16937-99-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8501 0.0 0 CFG=1
M  V30 2 N 4.0012 4.6201 0.0 0
M  V30 3 C 2.6675 2.3101 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 5.3348 3.8501 0.0 0
M  V30 6 C 1.3337 1.5400 0.0 0
M  V30 7 O 0.0000 3.8501 0.0 0
M  V30 8 O 1.3337 6.1601 0.0 0
M  V30 9 O 6.6685 4.6201 0.0 0
M  V30 10 O 5.3348 2.3101 0.0 0
M  V30 11 C 1.3337 0.0000 0.0 0
M  V30 12 C 0.0000 2.3101 0.0 0
M  V30 13 C 8.0023 3.8501 0.0 0
M  V30 14 C 7.2323 2.5164 0.0 0
M  V30 15 C 9.3360 3.0801 0.0 0
M  V30 16 C 8.7723 5.1838 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 6 12
M  V30 12 1 9 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-Bromo-3-methoxybenzenamine
C7H8BrNO
19056-40-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.5400 1.3338 0.0 0
M  V30 2 C 2.3100 0.0000 0.0 0
M  V30 3 Br 0.0000 4.0011 0.0 0
M  V30 4 N 6.1600 4.0011 0.0 0
M  V30 5 C 2.3100 2.6674 0.0 0
M  V30 6 C 1.5400 4.0011 0.0 0
M  V30 7 C 3.8500 2.6674 0.0 0
M  V30 8 C 2.3100 5.3349 0.0 0
M  V30 9 C 4.6200 4.0011 0.0 0
M  V30 10 C 3.8500 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 3 6
M  V30 4 1 4 9
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[(1R)-1-[[(4-bromo-3-methoxyphenyl)amino]carbonyl]-3-meth...
C18H27BrN2O4
1644249-96-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.1600 5.3347 0.0 0
M  V30 2 C 6.9300 4.0011 0.0 0
M  V30 3 C 8.4700 4.0011 0.0 0 CFG=1
M  V30 4 O 6.1600 2.6674 0.0 0
M  V30 5 N 9.2400 5.3347 0.0 0
M  V30 6 C 9.2400 2.6674 0.0 0
M  V30 7 C 10.7800 5.3347 0.0 0
M  V30 8 C 8.4700 1.3336 0.0 0
M  V30 9 O 11.5500 6.6684 0.0 0
M  V30 10 O 11.5500 4.0011 0.0 0
M  V30 11 C 9.2400 0.0000 0.0 0
M  V30 12 C 6.9300 1.3336 0.0 0
M  V30 13 C 13.0900 6.6684 0.0 0
M  V30 14 C 13.0900 8.2084 0.0 0
M  V30 15 C 14.6300 6.6684 0.0 0
M  V30 16 C 13.0900 5.1284 0.0 0
M  V30 17 O 1.5400 8.0021 0.0 0
M  V30 18 C 2.3100 9.3358 0.0 0
M  V30 19 Br 0.0000 5.3347 0.0 0
M  V30 20 C 4.6200 5.3347 0.0 0
M  V30 21 C 3.8500 6.6684 0.0 0
M  V30 22 C 3.8500 4.0011 0.0 0
M  V30 23 C 2.3100 6.6684 0.0 0
M  V30 24 C 2.3100 4.0011 0.0 0
M  V30 25 C 1.5400 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 3 6 CFG=3
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 17 18
M  V30 18 1 17 23
M  V30 19 1 19 25
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 2 22 24
M  V30 24 2 23 25
M  V30 25 1 24 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 3)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 16937-99-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 19056-40-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1644249-96-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34006665
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery, Structure-Activity Relationships, and In Vivo Evaluation of
Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase
1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hartz, Richard A.; Ahuja, Vijay T.; Nara, Susheel J.; Kumar, C. M.
Vijaya; Brown, Jeffrey M.; Bristow, Linda J.; Rajamani, Ramkumar;
Muckelbauer, Jodi K.; Camac, Daniel; Kiefer, Susan E.; Hunihan, Lisa;
Gulianello, Michael; Lewis, Martin; Easton, Amy; Lippy, Jonathan S.;
Surti, Neha; Pattipati, Sreenivasulu N.; Dokania, Manoj; Elavazhagan,
Saravanan; Dandapani, Kumaran; Hamman, Brian D.; Allen, Jason; Kostich,
Walter; Bronson, Joanne J.; Macor, John E.; Dzierba, Carolyn D.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(15), 11090-11128

$RFMT $RIREG SCHEME356 STEP1
$RXN



  2  1
$MOL
L-Tyrosine, methyl ester
C10H13NO3
1080-06-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 3.8501 2.6673 0.0 0 CFG=2
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 N 4.6201 4.0010 0.0 0
M  V30 5 O 1.5400 4.0010 0.0 0
M  V30 6 O 1.5400 1.3337 0.0 0
M  V30 7 C 0.0000 4.0010 0.0 0
M  V30 8 O 10.7802 1.3337 0.0 0
M  V30 9 C 6.1601 1.3337 0.0 0
M  V30 10 C 6.9302 0.0000 0.0 0
M  V30 11 C 6.9302 2.6673 0.0 0
M  V30 12 C 8.4702 0.0000 0.0 0
M  V30 13 C 8.4702 2.6673 0.0 0
M  V30 14 C 9.2402 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
BOC-L-Phenylalanine
C14H19NO4
13734-34-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 2 C 4.6201 4.0012 0.0 0
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6766 6.1048 0.0 0
M  V30 14 C 3.0801 4.0012 0.0 0
M  V30 15 C 2.3101 5.3348 0.0 0
M  V30 16 C 2.3101 2.6675 0.0 0
M  V30 17 C 0.7700 5.3348 0.0 0
M  V30 18 C 0.7700 2.6675 0.0 0
M  V30 19 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 14
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-phenylalanyl-L-tyrosine methyl ester
C24H30N2O6
66076-54-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 5.3347 0.0 0 CFG=2
M  V30 2 C 5.3900 4.0011 0.0 0
M  V30 3 C 7.7000 5.3347 0.0 0
M  V30 4 N 5.3900 6.6684 0.0 0
M  V30 5 N 8.4700 6.6684 0.0 0
M  V30 6 O 8.4700 4.0011 0.0 0
M  V30 7 C 3.8500 6.6684 0.0 0
M  V30 8 C 10.0100 6.6684 0.0 0 CFG=2
M  V30 9 O 3.0800 8.0021 0.0 0
M  V30 10 O 3.0800 5.3347 0.0 0
M  V30 11 C 10.7800 5.3347 0.0 0
M  V30 12 C 10.7800 8.0021 0.0 0
M  V30 13 C 1.5400 8.0021 0.0 0
M  V30 14 O 10.0100 9.3358 0.0 0
M  V30 15 O 12.3200 8.0020 0.0 0
M  V30 16 C 1.5400 9.5421 0.0 0
M  V30 17 C 0.0000 8.0021 0.0 0
M  V30 18 C 1.5400 6.4621 0.0 0
M  V30 19 C 10.7800 10.6694 0.0 0
M  V30 20 O 16.9400 5.3347 0.0 0
M  V30 21 C 6.1600 2.6673 0.0 0
M  V30 22 C 7.7000 2.6673 0.0 0
M  V30 23 C 5.3900 1.3336 0.0 0
M  V30 24 C 8.4700 1.3336 0.0 0
M  V30 25 C 6.1600 0.0000 0.0 0
M  V30 26 C 7.7000 0.0000 0.0 0
M  V30 27 C 12.3200 5.3347 0.0 0
M  V30 28 C 13.0900 6.6684 0.0 0
M  V30 29 C 13.0900 4.0011 0.0 0
M  V30 30 C 14.6300 6.6684 0.0 0
M  V30 31 C 14.6300 4.0011 0.0 0
M  V30 32 C 15.4000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 21
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11 CFG=3
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 11 27
M  V30 15 1 12 14
M  V30 16 2 12 15
M  V30 17 1 13 16
M  V30 18 1 13 17
M  V30 19 1 13 18
M  V30 20 1 14 19
M  V30 21 1 20 32
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 25
M  V30 26 2 24 26
M  V30 27 1 25 26
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 2 29 31
M  V30 32 2 30 32
M  V30 33 1 31 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1080-06-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13734-34-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 66076-54-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31824055
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine
structures to inhibit A oligomerisation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Falkenstein, Markus; Reiner-Link, David; Zivkovic, Aleksandra; Gering,
Ian; Willbold, Dieter; Stark, Holger
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 50116462

$RFMT $RIREG SCHEME357 STEP1
$RXN



  2  1
$MOL
2,5-Dichlorobenzoic acid
C7H4Cl2O2
50-79-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 Cl 1.3338 4.6201 0.0 0
M  V30 5 Cl 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C9H18N2O3S2.C2HF3O2
2760538-76-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 S 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 S 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C16H20Cl2N2O4S2
2760538-83-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 3.8500 0.0 0
M  V30 2 N 5.3348 4.6201 0.0 0
M  V30 3 O 4.0010 2.3100 0.0 0
M  V30 4 C 6.6684 3.8500 0.0 0 CFG=1
M  V30 5 C 8.0021 4.6201 0.0 0
M  V30 6 C 6.6684 2.3100 0.0 0
M  V30 7 N 9.3357 3.8500 0.0 0
M  V30 8 O 8.0021 6.1601 0.0 0
M  V30 9 S 8.0021 1.5400 0.0 0
M  V30 10 C 10.6695 4.6201 0.0 0 CFG=1
M  V30 11 C 8.0021 0.0000 0.0 0
M  V30 12 C 12.0032 3.8500 0.0 0
M  V30 13 C 10.6695 6.1601 0.0 0
M  V30 14 O 13.3369 4.6201 0.0 0
M  V30 15 O 12.0032 2.3100 0.0 0
M  V30 16 S 12.0032 6.9301 0.0 0
M  V30 17 C 14.6705 3.8500 0.0 0
M  V30 18 C 12.0032 8.4701 0.0 0
M  V30 19 Cl 1.3337 2.3100 0.0 0
M  V30 20 Cl 1.3337 8.4701 0.0 0
M  V30 21 C 2.6673 4.6201 0.0 0
M  V30 22 C 1.3337 3.8500 0.0 0
M  V30 23 C 2.6673 6.1601 0.0 0
M  V30 24 C 0.0000 4.6201 0.0 0
M  V30 25 C 1.3337 6.9301 0.0 0
M  V30 26 C 0.0000 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 21
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 10 13 CFG=1
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 22
M  V30 20 1 20 25
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 25
M  V30 25 2 24 26
M  V30 26 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 50-79-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-76-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-83-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545320
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME358 STEP1
$RXN



  2  1
$MOL
4-(Ethylsulfonyl)benzeneacetic acid
C10H12O4S
383135-47-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 2.3100 2.6673 0.0 0 VAL=6
M  V30 2 C 0.7700 2.6673 0.0 0
M  V30 3 O 2.3100 1.1273 0.0 0
M  V30 4 O 2.3100 4.2073 0.0 0
M  V30 5 C 0.0000 4.0011 0.0 0
M  V30 6 C 8.4700 2.6673 0.0 0
M  V30 7 C 9.2400 1.3336 0.0 0
M  V30 8 O 10.7800 1.3336 0.0 0
M  V30 9 O 8.4700 0.0000 0.0 0
M  V30 10 C 3.8500 2.6673 0.0 0
M  V30 11 C 4.6200 1.3336 0.0 0
M  V30 12 C 4.6200 4.0011 0.0 0
M  V30 13 C 6.1600 1.3336 0.0 0
M  V30 14 C 6.1600 4.0011 0.0 0
M  V30 15 C 6.9300 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 6 7
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-(4-amino-2-chloro[1,1-biphenyl]-2-yl)-
C15H13ClN2O
3032933-02-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 6.1600 0.0 0
M  V30 2 C 6.6684 6.9300 0.0 0
M  V30 3 C 8.0021 6.1600 0.0 0
M  V30 4 O 6.6684 8.4700 0.0 0
M  V30 5 C 9.3358 6.9300 0.0 0
M  V30 6 Cl 0.0000 4.6200 0.0 0
M  V30 7 N 2.6674 0.0000 0.0 0
M  V30 8 C 2.6674 6.1600 0.0 0
M  V30 9 C 4.0011 6.9300 0.0 0
M  V30 10 C 1.3336 6.9300 0.0 0
M  V30 11 C 4.0011 8.4700 0.0 0
M  V30 12 C 1.3336 8.4700 0.0 0
M  V30 13 C 2.6674 9.2400 0.0 0
M  V30 14 C 2.6674 4.6200 0.0 0
M  V30 15 C 1.3336 3.8500 0.0 0
M  V30 16 C 4.0011 3.8500 0.0 0
M  V30 17 C 1.3336 2.3100 0.0 0
M  V30 18 C 4.0011 2.3100 0.0 0
M  V30 19 C 2.6674 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 15
M  V30 7 1 7 19
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 14
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, N-[2-chloro-2-[(1-oxo-2-propen-1-yl)amino][1,1-biphenyl]-...
C25H23ClN2O4S
2983540-55-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.8500 4.0011 0.0 0
M  V30 2 C 2.3100 4.0011 0.0 0
M  V30 3 C 1.5400 5.3347 0.0 0
M  V30 4 O 1.5400 2.6674 0.0 0
M  V30 5 C 0.0000 5.3347 0.0 0
M  V30 6 Cl 9.2400 2.6674 0.0 0
M  V30 7 N 9.2400 8.0021 0.0 0
M  V30 8 C 10.7800 8.0021 0.0 0
M  V30 9 C 11.5500 9.3358 0.0 0
M  V30 10 O 11.5500 6.6684 0.0 0
M  V30 11 S 17.7100 9.3358 0.0 0 VAL=6
M  V30 12 C 19.2500 9.3358 0.0 0
M  V30 13 O 17.7100 7.7958 0.0 0
M  V30 14 O 17.7100 10.8758 0.0 0
M  V30 15 C 20.0200 10.6694 0.0 0
M  V30 16 C 6.1600 2.6674 0.0 0
M  V30 17 C 4.6200 2.6674 0.0 0
M  V30 18 C 6.9300 1.3336 0.0 0
M  V30 19 C 3.8500 1.3336 0.0 0
M  V30 20 C 6.1600 0.0000 0.0 0
M  V30 21 C 4.6200 0.0000 0.0 0
M  V30 22 C 6.9300 4.0011 0.0 0
M  V30 23 C 8.4700 4.0011 0.0 0
M  V30 24 C 6.1600 5.3347 0.0 0
M  V30 25 C 9.2400 5.3347 0.0 0
M  V30 26 C 6.9300 6.6684 0.0 0
M  V30 27 C 8.4700 6.6684 0.0 0
M  V30 28 C 13.0900 9.3358 0.0 0
M  V30 29 C 13.8600 10.6694 0.0 0
M  V30 30 C 13.8600 8.0021 0.0 0
M  V30 31 C 15.4000 10.6694 0.0 0
M  V30 32 C 15.4000 8.0021 0.0 0
M  V30 33 C 16.1700 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 23
M  V30 7 1 7 8
M  V30 8 1 7 27
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 28
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 2 11 14
M  V30 15 1 11 33
M  V30 16 1 12 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 16 22
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 1 29 31
M  V30 33 2 30 32
M  V30 34 2 31 33
M  V30 35 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 383135-47-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3032933-02-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-55-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256075
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME359 STEP1
$RXN



  2  1
$MOL
5-Bromonicotinic acid
C6H4BrNO2
20826-04-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 Br 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 N 4.0011 4.6201 0.0 0
M  V30 10 C 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3-Amino-4-methylphenyl)-3-(trifluoromethyl)benzamide
C15H13F3N2O
30069-31-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 3.0801 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 O 6.6685 4.6201 0.0 0
M  V30 4 C 12.0033 3.0801 0.0 0
M  V30 5 F 11.2333 4.4137 0.0 0
M  V30 6 F 13.3370 3.8501 0.0 0
M  V30 7 F 12.7733 1.7464 0.0 0
M  V30 8 N 0.0000 2.3101 0.0 0
M  V30 9 C 0.0000 5.3901 0.0 0
M  V30 10 C 8.0022 2.3101 0.0 0
M  V30 11 C 9.3360 3.0801 0.0 0
M  V30 12 C 8.0022 0.7700 0.0 0
M  V30 13 C 10.6697 2.3101 0.0 0
M  V30 14 C 9.3360 0.0000 0.0 0
M  V30 15 C 10.6697 0.7700 0.0 0
M  V30 16 C 4.0010 3.0801 0.0 0
M  V30 17 C 2.6673 2.3101 0.0 0
M  V30 18 C 4.0010 4.6201 0.0 0
M  V30 19 C 1.3337 3.0801 0.0 0
M  V30 20 C 2.6673 5.3901 0.0 0
M  V30 21 C 1.3337 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 16
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 4 13
M  V30 9 1 8 19
M  V30 10 1 9 21
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Bromo-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-3-pyridineca...
C21H15BrF3N3O2
2095848-27-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3900 2.6674 0.0 0
M  V30 2 C 4.6200 4.0011 0.0 0
M  V30 3 O 5.3900 5.3347 0.0 0
M  V30 4 C 6.9300 0.0000 0.0 0
M  V30 5 N 10.0100 5.3347 0.0 0
M  V30 6 C 11.5500 5.3347 0.0 0
M  V30 7 O 12.3200 4.0011 0.0 0
M  V30 8 Br 0.0000 6.6685 0.0 0
M  V30 9 C 16.1700 8.0021 0.0 0
M  V30 10 F 16.1700 6.4621 0.0 0
M  V30 11 F 17.7100 8.0021 0.0 0
M  V30 12 F 16.1700 9.5421 0.0 0
M  V30 13 C 6.9300 2.6674 0.0 0
M  V30 14 C 7.7000 4.0011 0.0 0
M  V30 15 C 7.7000 1.3336 0.0 0
M  V30 16 C 9.2400 4.0011 0.0 0
M  V30 17 C 9.2400 1.3336 0.0 0
M  V30 18 C 10.0100 2.6674 0.0 0
M  V30 19 C 3.0800 4.0011 0.0 0
M  V30 20 C 2.3100 5.3347 0.0 0
M  V30 21 C 2.3100 2.6674 0.0 0
M  V30 22 C 0.7700 5.3347 0.0 0
M  V30 23 N 0.7700 2.6674 0.0 0
M  V30 24 C 0.0000 4.0011 0.0 0
M  V30 25 C 12.3200 6.6685 0.0 0
M  V30 26 C 13.8600 6.6685 0.0 0
M  V30 27 C 11.5500 8.0021 0.0 0
M  V30 28 C 14.6300 8.0021 0.0 0
M  V30 29 C 12.3200 9.3358 0.0 0
M  V30 30 C 13.8600 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 2 2 3
M  V30 4 1 2 19
M  V30 5 1 4 15
M  V30 6 1 5 6
M  V30 7 1 5 16
M  V30 8 2 6 7
M  V30 9 1 6 25
M  V30 10 1 8 22
M  V30 11 1 9 10
M  V30 12 1 9 11
M  V30 13 1 9 12
M  V30 14 1 9 28
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 1 19 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 20826-04-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 30069-31-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2095848-27-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33309068
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Evaluation of carbon-11 labeled
5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide
as PET tracer for imaging of CSF-1R expression in the brain
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM van der Wildt, Berend; Nezam, Madina; Kooijman, Esther J. M.; Reyes,
Samantha T.; Shen, Bin; Windhorst, Albert D.; Chin, Frederick T.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 42116245

$RFMT $RIREG SCHEME360 STEP1
$RXN



  2  1
$MOL
4-(Ethylsulfonyl)benzeneacetic acid
C10H12O4S
383135-47-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 2.3100 2.6673 0.0 0 VAL=6
M  V30 2 C 0.7700 2.6673 0.0 0
M  V30 3 O 2.3100 1.1273 0.0 0
M  V30 4 O 2.3100 4.2073 0.0 0
M  V30 5 C 0.0000 4.0011 0.0 0
M  V30 6 C 8.4700 2.6673 0.0 0
M  V30 7 C 9.2400 1.3336 0.0 0
M  V30 8 O 10.7800 1.3336 0.0 0
M  V30 9 O 8.4700 0.0000 0.0 0
M  V30 10 C 3.8500 2.6673 0.0 0
M  V30 11 C 4.6200 1.3336 0.0 0
M  V30 12 C 4.6200 4.0011 0.0 0
M  V30 13 C 6.1600 1.3336 0.0 0
M  V30 14 C 6.1600 4.0011 0.0 0
M  V30 15 C 6.9300 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 6 7
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-(4-amino-2-fluoro[1,1-biphenyl]-2-yl)-
C15H13FN2O
3032933-01-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 6.1600 0.0 0
M  V30 2 C 6.6684 6.9300 0.0 0
M  V30 3 C 8.0021 6.1600 0.0 0
M  V30 4 O 6.6684 8.4700 0.0 0
M  V30 5 C 9.3358 6.9300 0.0 0
M  V30 6 F 0.0000 4.6200 0.0 0
M  V30 7 N 2.6674 0.0000 0.0 0
M  V30 8 C 2.6674 6.1600 0.0 0
M  V30 9 C 4.0011 6.9300 0.0 0
M  V30 10 C 1.3336 6.9300 0.0 0
M  V30 11 C 4.0011 8.4700 0.0 0
M  V30 12 C 1.3336 8.4700 0.0 0
M  V30 13 C 2.6674 9.2400 0.0 0
M  V30 14 C 2.6674 4.6200 0.0 0
M  V30 15 C 1.3336 3.8500 0.0 0
M  V30 16 C 4.0011 3.8500 0.0 0
M  V30 17 C 1.3336 2.3100 0.0 0
M  V30 18 C 4.0011 2.3100 0.0 0
M  V30 19 C 2.6674 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 15
M  V30 7 1 7 19
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 14
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, 4-(ethylsulfonyl)-N-[2-fluoro-2-[(1-oxo-2-propen-1-yl)amin...
C25H23FN2O4S
2983540-56-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.8500 4.0011 0.0 0
M  V30 2 C 2.3100 4.0011 0.0 0
M  V30 3 C 1.5400 5.3347 0.0 0
M  V30 4 O 1.5400 2.6674 0.0 0
M  V30 5 C 0.0000 5.3347 0.0 0
M  V30 6 F 9.2400 2.6674 0.0 0
M  V30 7 N 9.2400 8.0021 0.0 0
M  V30 8 C 10.7800 8.0021 0.0 0
M  V30 9 C 11.5500 9.3358 0.0 0
M  V30 10 O 11.5500 6.6684 0.0 0
M  V30 11 S 17.7100 9.3358 0.0 0 VAL=6
M  V30 12 C 19.2500 9.3358 0.0 0
M  V30 13 O 17.7100 7.7958 0.0 0
M  V30 14 O 17.7100 10.8758 0.0 0
M  V30 15 C 20.0200 10.6694 0.0 0
M  V30 16 C 6.1600 2.6674 0.0 0
M  V30 17 C 4.6200 2.6674 0.0 0
M  V30 18 C 6.9300 1.3336 0.0 0
M  V30 19 C 3.8500 1.3336 0.0 0
M  V30 20 C 6.1600 0.0000 0.0 0
M  V30 21 C 4.6200 0.0000 0.0 0
M  V30 22 C 6.9300 4.0011 0.0 0
M  V30 23 C 8.4700 4.0011 0.0 0
M  V30 24 C 6.1600 5.3347 0.0 0
M  V30 25 C 9.2400 5.3347 0.0 0
M  V30 26 C 6.9300 6.6684 0.0 0
M  V30 27 C 8.4700 6.6684 0.0 0
M  V30 28 C 13.0900 9.3358 0.0 0
M  V30 29 C 13.8600 10.6694 0.0 0
M  V30 30 C 13.8600 8.0021 0.0 0
M  V30 31 C 15.4000 10.6694 0.0 0
M  V30 32 C 15.4000 8.0021 0.0 0
M  V30 33 C 16.1700 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 23
M  V30 7 1 7 8
M  V30 8 1 7 27
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 28
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 2 11 14
M  V30 15 1 11 33
M  V30 16 1 12 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 16 22
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 1 29 31
M  V30 33 2 30 32
M  V30 34 2 31 33
M  V30 35 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 383135-47-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3032933-01-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-56-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256076
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME361 STEP1
$RXN



  2  1
$MOL
3-(1-Methyl-1H-1,2,3-triazol-4-yl)-4-(phenylmethoxy)benzoic acid
C17H15N3O3
2748688-40-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.9302 6.6365 0.0 0
M  V30 2 C 7.7002 7.9701 0.0 0
M  V30 3 C 0.7700 6.6365 0.0 0
M  V30 4 O 0.0000 7.9701 0.0 0
M  V30 5 O 0.0000 5.3028 0.0 0
M  V30 6 C 5.7473 0.0000 0.0 0
M  V30 7 C 4.6201 5.3028 0.0 0
M  V30 8 C 5.3901 6.6365 0.0 0
M  V30 9 C 3.0801 5.3028 0.0 0
M  V30 10 C 4.6201 7.9701 0.0 0
M  V30 11 C 2.3101 6.6365 0.0 0
M  V30 12 C 3.0801 7.9701 0.0 0
M  V30 13 C 5.3901 3.9690 0.0 0
M  V30 14 N 6.9217 3.8080 0.0 0
M  V30 15 C 4.7638 2.5622 0.0 0
M  V30 16 N 7.2419 2.3017 0.0 0
M  V30 17 N 5.9082 1.5317 0.0 0
M  V30 18 C 9.2402 7.9701 0.0 0
M  V30 19 C 10.0102 9.3040 0.0 0
M  V30 20 C 10.0102 6.6365 0.0 0
M  V30 21 C 11.5503 9.3040 0.0 0
M  V30 22 C 11.5503 6.6365 0.0 0
M  V30 23 C 12.3203 7.9701 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 18
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 3 11
M  V30 7 1 6 17
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 7 13
M  V30 11 1 8 10
M  V30 12 2 9 11
M  V30 13 2 10 12
M  V30 14 1 11 12
M  V30 15 1 13 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 17
M  V30 19 1 16 17
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 20 22
M  V30 24 2 21 23
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Ethylamine
C2H7N
75-04-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 C 0.0000 0.7700 0.0 0
M  V30 3 N 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-Ethyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-4-(phenylmethoxy)benzamide
C19H20N4O2
2748687-69-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3901 6.6363 0.0 0
M  V30 2 C 4.6201 7.9700 0.0 0
M  V30 3 C 11.5503 6.6363 0.0 0
M  V30 4 N 12.3203 7.9700 0.0 0
M  V30 5 O 12.3203 5.3026 0.0 0
M  V30 6 C 13.8603 7.9700 0.0 0
M  V30 7 C 14.6303 9.3037 0.0 0
M  V30 8 C 6.5730 0.0000 0.0 0
M  V30 9 C 7.7002 5.3026 0.0 0
M  V30 10 C 6.9302 6.6363 0.0 0
M  V30 11 C 9.2402 5.3026 0.0 0
M  V30 12 C 7.7002 7.9700 0.0 0
M  V30 13 C 10.0102 6.6363 0.0 0
M  V30 14 C 9.2402 7.9700 0.0 0
M  V30 15 C 6.9302 3.9688 0.0 0
M  V30 16 C 7.5565 2.5620 0.0 0
M  V30 17 N 5.3986 3.8079 0.0 0
M  V30 18 N 6.4121 1.5316 0.0 0
M  V30 19 N 5.0784 2.3016 0.0 0
M  V30 20 C 3.0801 7.9700 0.0 0
M  V30 21 C 2.3101 9.3037 0.0 0
M  V30 22 C 2.3101 6.6363 0.0 0
M  V30 23 C 0.7700 9.3037 0.0 0
M  V30 24 C 0.7700 6.6363 0.0 0
M  V30 25 C 0.0000 7.9700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 20
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 3 13
M  V30 7 1 4 6
M  V30 8 1 6 7
M  V30 9 1 8 18
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 9 15
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2748688-40-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 75-04-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2748687-69-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-25849885
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble
Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Aylott, Helen E.; Atkinson, Stephen J.; Bamborough, Paul; Bassil, Anna;
Chung, Chun-wa; Gordon, Laurie; Grandi, Paola; Gray, James R. J.;
Harrison, Lee A.; Hayhow, Thomas G.; Messenger, Cassie; Mitchell, Darren;
Phillipou, Alexander; Preston, Alex; Prinjha, Rab K.; Rianjongdee,
Francesco; Rioja, Inmaculada; Seal, Jonathan T.; Wall, Ian D.; Watson,
Robert J.; Woolven, James M.; Demont, Emmanuel H.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(6), 3249-3281

$RFMT $RIREG SCHEME362 STEP1
$RXN



  2  1
$MOL
2,5-Dichlorobenzoic acid
C7H4Cl2O2
50-79-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 Cl 1.3338 4.6201 0.0 0
M  V30 5 Cl 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C9H18N2O4S.C2HF3O2
2760538-75-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 O 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 S 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C16H20Cl2N2O5S
2760538-82-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 3.8500 0.0 0
M  V30 2 N 5.3348 4.6201 0.0 0
M  V30 3 O 4.0010 2.3100 0.0 0
M  V30 4 C 6.6684 3.8500 0.0 0 CFG=1
M  V30 5 C 8.0021 4.6201 0.0 0
M  V30 6 C 6.6684 2.3100 0.0 0
M  V30 7 N 9.3357 3.8500 0.0 0
M  V30 8 O 8.0021 6.1601 0.0 0
M  V30 9 S 8.0021 1.5400 0.0 0
M  V30 10 C 10.6695 4.6201 0.0 0 CFG=1
M  V30 11 C 8.0021 0.0000 0.0 0
M  V30 12 C 12.0032 3.8500 0.0 0
M  V30 13 C 10.6695 6.1601 0.0 0
M  V30 14 O 13.3369 4.6201 0.0 0
M  V30 15 O 12.0032 2.3100 0.0 0
M  V30 16 O 12.0032 6.9301 0.0 0
M  V30 17 C 14.6705 3.8500 0.0 0
M  V30 18 C 12.0032 8.4701 0.0 0
M  V30 19 Cl 1.3337 2.3100 0.0 0
M  V30 20 Cl 1.3337 8.4701 0.0 0
M  V30 21 C 2.6673 4.6201 0.0 0
M  V30 22 C 1.3337 3.8500 0.0 0
M  V30 23 C 2.6673 6.1601 0.0 0
M  V30 24 C 0.0000 4.6201 0.0 0
M  V30 25 C 1.3337 6.9301 0.0 0
M  V30 26 C 0.0000 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 21
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 10 13 CFG=1
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 22
M  V30 20 1 20 25
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 25
M  V30 25 2 24 26
M  V30 26 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 50-79-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2760538-75-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2760538-82-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545313
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME363 STEP1
$RXN



  2  1
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-L-threonine 2-propen-1-yl ester
C12H21NO5
545432-97-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0 CFG=2
M  V30 2 C 7.7000 2.6674 0.0 0
M  V30 3 N 5.3900 4.0011 0.0 0
M  V30 4 C 5.3900 1.3338 0.0 0 CFG=2
M  V30 5 O 8.4700 4.0011 0.0 0
M  V30 6 O 8.4700 1.3338 0.0 0
M  V30 7 C 3.8500 4.0011 0.0 0
M  V30 8 C 6.1600 0.0000 0.0 0
M  V30 9 O 3.8500 1.3338 0.0 0
M  V30 10 C 10.0100 4.0011 0.0 0
M  V30 11 O 3.0800 5.3349 0.0 0
M  V30 12 O 3.0800 2.6674 0.0 0
M  V30 13 C 10.7800 5.3349 0.0 0
M  V30 14 C 1.5400 5.3349 0.0 0
M  V30 15 C 12.3200 5.3349 0.0 0
M  V30 16 C 1.5400 6.8749 0.0 0
M  V30 17 C 0.0000 5.3349 0.0 0
M  V30 18 C 1.5400 3.7949 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 4 9 CFG=1
M  V30 9 1 5 10
M  V30 10 1 7 11
M  V30 11 2 7 12
M  V30 12 1 10 13
M  V30 13 1 11 14
M  V30 14 2 13 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 14 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-tert-Butoxycarbonyl-O-benzylserine
C15H21NO5
23680-31-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.0336 5.3347 0.0 0
M  V30 2 O 8.2636 4.0011 0.0 0
M  V30 3 C 6.7236 4.0011 0.0 0
M  V30 4 C 5.9536 2.6674 0.0 0 CFG=1
M  V30 5 N 4.4136 2.6674 0.0 0
M  V30 6 C 6.7236 1.3338 0.0 0
M  V30 7 C 3.6436 4.0011 0.0 0
M  V30 8 O 5.9536 0.0000 0.0 0
M  V30 9 O 8.2636 1.3338 0.0 0
M  V30 10 O 2.1036 4.0011 0.0 0
M  V30 11 O 4.4136 5.3347 0.0 0
M  V30 12 C 1.3336 5.3347 0.0 0
M  V30 13 C 0.0000 4.5647 0.0 0
M  V30 14 C 0.5636 6.6685 0.0 0
M  V30 15 C 2.6673 6.1047 0.0 0
M  V30 16 C 10.5736 5.3347 0.0 0
M  V30 17 C 11.3436 4.0011 0.0 0
M  V30 18 C 11.3436 6.6685 0.0 0
M  V30 19 C 12.8836 4.0011 0.0 0
M  V30 20 C 12.8836 6.6685 0.0 0
M  V30 21 C 13.6536 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 2 7 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C22H32N2O7
1863128-21-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9302 6.6685 0.0 0 CFG=2
M  V30 2 C 7.7002 8.0022 0.0 0
M  V30 3 N 7.7002 5.3348 0.0 0
M  V30 4 C 5.3901 6.6685 0.0 0
M  V30 5 N 9.2402 8.0022 0.0 0
M  V30 6 O 6.9302 9.3360 0.0 0
M  V30 7 C 6.9302 4.0012 0.0 0
M  V30 8 O 4.6201 8.0022 0.0 0
M  V30 9 C 10.0102 9.3360 0.0 0 CFG=1
M  V30 10 O 7.7002 2.6673 0.0 0
M  V30 11 O 5.3901 4.0012 0.0 0
M  V30 12 C 3.0801 8.0022 0.0 0
M  V30 13 C 11.5503 9.3360 0.0 0
M  V30 14 C 9.2402 10.6697 0.0 0 CFG=2
M  V30 15 C 6.9302 1.3337 0.0 0
M  V30 16 O 12.3203 10.6697 0.0 0
M  V30 17 O 12.3203 8.0022 0.0 0
M  V30 18 C 10.0102 12.0033 0.0 0
M  V30 19 O 7.7002 10.6697 0.0 0
M  V30 20 C 5.5965 2.1037 0.0 0
M  V30 21 C 6.1601 0.0000 0.0 0
M  V30 22 C 8.2638 0.5637 0.0 0
M  V30 23 C 13.8603 10.6697 0.0 0
M  V30 24 C 14.6303 12.0033 0.0 0
M  V30 25 C 16.1704 12.0033 0.0 0
M  V30 26 C 2.3101 9.3360 0.0 0
M  V30 27 C 3.0801 10.6697 0.0 0
M  V30 28 C 0.7700 9.3360 0.0 0
M  V30 29 C 2.3101 12.0033 0.0 0
M  V30 30 C 0.0000 10.6697 0.0 0
M  V30 31 C 0.7700 12.0033 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 9 5 CFG=1
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14
M  V30 14 1 10 15
M  V30 15 1 12 26
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 1 14 19 CFG=3
M  V30 20 1 15 20
M  V30 21 1 15 21
M  V30 22 1 15 22
M  V30 23 1 16 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 2 26 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 29 2 28 30
M  V30 30 2 29 31
M  V30 31 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 1 9 14)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 545432-97-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 23680-31-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1863128-21-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31592253
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 76-05-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel macrocyclic peptidomimetics targeting the Polo-box domain of
Polo-like kinase 1
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ryu, SeongShick; Park, Jung-Eun; Ham, Young Jin; Lim, Daniel C.;
Kwiatkowski, Nicholas P.; Kim, Do-Hee; Bhunia, Debabrata; Kim, Nam Doo;
Yaffe, Michael B.; Son, Woolim; Kim, Namkyoung; Choi, Tae-Ik; Swain,
Puspanjali; Kim, Cheol-Hee; Lee, Jin-Young; Gray, Nathanael S.; Lee,
Kyung S.; Sim, Taebo
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(3), 1915-1932

$RFMT $RIREG SCHEME364 STEP1
$RXN



  2  1
$MOL
3,4-Dimethoxyphenethylamine
C10H15NO2
120-20-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3349 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3349 0.0 0
M  V30 7 N 9.2400 5.3349 0.0 0
M  V30 8 C 3.0800 2.6674 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.0800 5.3349 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 4.6200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Indole-2-acetic acid
C10H9NO2
32588-36-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.5772 2.6673 0.0 0
M  V30 2 C 7.3472 1.3337 0.0 0
M  V30 3 O 6.5772 0.0000 0.0 0
M  V30 4 O 8.8872 1.3337 0.0 0
M  V30 5 C 2.6673 1.8973 0.0 0
M  V30 6 C 2.6673 3.4374 0.0 0
M  V30 7 C 4.1321 1.4215 0.0 0
M  V30 8 C 1.3337 1.1273 0.0 0
M  V30 9 N 4.1321 3.9132 0.0 0
M  V30 10 C 1.3337 4.2074 0.0 0
M  V30 11 C 5.0371 2.6673 0.0 0
M  V30 12 C 0.0000 1.8973 0.0 0
M  V30 13 C 0.0000 3.4374 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 1 10 13
M  V30 14 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)ethyl]-1H-indole-2-acetamide
C20H22N2O3
1195214-75-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6696 4.6200 0.0 0
M  V30 2 C 9.3358 3.8500 0.0 0
M  V30 3 N 8.0021 4.6200 0.0 0
M  V30 4 O 9.3358 2.3100 0.0 0
M  V30 5 C 6.6685 3.8500 0.0 0
M  V30 6 C 5.3347 4.6200 0.0 0
M  V30 7 O 0.0000 4.6200 0.0 0
M  V30 8 C 0.0000 6.1600 0.0 0
M  V30 9 O 0.0000 1.5400 0.0 0
M  V30 10 C 0.0000 0.0000 0.0 0
M  V30 11 C 14.4406 3.3319 0.0 0
M  V30 12 C 13.6706 1.9983 0.0 0
M  V30 13 C 13.4100 4.4763 0.0 0
M  V30 14 C 15.9806 3.3319 0.0 0
M  V30 15 N 12.1642 2.3185 0.0 0
M  V30 16 C 14.4406 0.6645 0.0 0
M  V30 17 C 12.0032 3.8500 0.0 0
M  V30 18 C 16.7506 1.9983 0.0 0
M  V30 19 C 15.9806 0.6645 0.0 0
M  V30 20 C 4.0011 3.8500 0.0 0
M  V30 21 C 2.6674 4.6200 0.0 0
M  V30 22 C 4.0011 2.3100 0.0 0
M  V30 23 C 1.3338 3.8500 0.0 0
M  V30 24 C 2.6674 1.5400 0.0 0
M  V30 25 C 1.3338 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 20
M  V30 8 1 7 8
M  V30 9 1 7 23
M  V30 10 1 9 10
M  V30 11 1 9 25
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 1 15 17
M  V30 20 1 16 19
M  V30 21 2 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 120-20-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 32588-36-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1195214-75-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23044991
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME365 STEP1
$RXN



  2  1
$MOL
-Bromo-1,3-dihydro-1,3-dioxo-2H-isoindole-2-butanoic acid
C12H10BrNO4
35197-64-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.0203 0.1773 0.0 0
M  V30 2 O 5.7309 4.8721 0.0 0
M  V30 3 C 6.0811 1.5400 0.0 0
M  V30 4 C 7.4148 2.3101 0.0 0
M  V30 5 C 8.7486 1.5400 0.0 0
M  V30 6 C 10.0823 2.3101 0.0 0
M  V30 7 Br 8.7486 0.0000 0.0 0
M  V30 8 O 11.4160 1.5400 0.0 0
M  V30 9 O 10.0823 3.8501 0.0 0
M  V30 10 C 2.3101 2.8281 0.0 0
M  V30 11 C 3.0801 4.1618 0.0 0
M  V30 12 C 3.3405 1.6836 0.0 0
M  V30 13 C 0.7700 2.8281 0.0 0
M  V30 14 C 4.5864 3.8416 0.0 0
M  V30 15 C 2.3101 5.4955 0.0 0
M  V30 16 N 4.7475 2.3101 0.0 0
M  V30 17 C 0.0000 4.1618 0.0 0
M  V30 18 C 0.7700 5.4955 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 12
M  V30 2 2 2 14
M  V30 3 1 3 4
M  V30 4 1 3 16
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 10 13
M  V30 13 1 11 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 13 17
M  V30 17 1 14 16
M  V30 18 1 15 18
M  V30 19 2 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluorobenzylamine
C7H8FN
140-75-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 F 6.9302 1.3337 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 3.0801 0.0000 0.0 0
M  V30 7 C 4.6201 2.6673 0.0 0
M  V30 8 C 4.6201 0.0000 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-Bromo-N-[(4-fluorophenyl)methyl]-1,3-dihydro-1,3-dioxo-2H-isoindole-2-butan...
C19H16BrFN2O3
1621341-92-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.6078 5.4211 0.0 0
M  V30 2 O 4.6078 0.0000 0.0 0
M  V30 3 C 6.5770 2.7106 0.0 0
M  V30 4 C 7.3470 4.0442 0.0 0
M  V30 5 C 8.8870 4.0442 0.0 0
M  V30 6 C 9.6570 5.3778 0.0 0
M  V30 7 Br 9.6570 2.7106 0.0 0
M  V30 8 N 11.1970 5.3778 0.0 0
M  V30 9 O 8.8870 6.7116 0.0 0
M  V30 10 C 11.9670 6.7116 0.0 0
M  V30 11 F 18.1270 6.7116 0.0 0
M  V30 12 C 2.6673 3.4806 0.0 0
M  V30 13 C 2.6673 1.9406 0.0 0
M  V30 14 C 4.1320 3.9564 0.0 0
M  V30 15 C 1.3336 4.2506 0.0 0
M  V30 16 C 4.1320 1.4647 0.0 0
M  V30 17 C 1.3336 1.1706 0.0 0
M  V30 18 N 5.0370 2.7106 0.0 0
M  V30 19 C 0.0000 3.4806 0.0 0
M  V30 20 C 0.0000 1.9406 0.0 0
M  V30 21 C 13.5070 6.7116 0.0 0
M  V30 22 C 14.2770 8.0453 0.0 0
M  V30 23 C 14.2770 5.3778 0.0 0
M  V30 24 C 15.8170 8.0453 0.0 0
M  V30 25 C 15.8170 5.3778 0.0 0
M  V30 26 C 16.5870 6.7116 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 14
M  V30 2 2 2 16
M  V30 3 1 3 4
M  V30 4 1 3 18
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 8 10
M  V30 11 1 10 21
M  V30 12 1 11 26
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 18
M  V30 21 1 17 20
M  V30 22 2 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 35197-64-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 140-75-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1621341-92-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23896526
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel mouse GABA uptake inhibitors with enhanced inhibitory activity
toward mGAT3/4 and their effect on pain threshold in mice
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zareba, Paula; Gryzlo, Beata; Malawska, Katarzyna; Salat, Kinga; Hofner,
Georg C.; Nowaczyk, Alicja; Fijalkowski, Lukasz; Rapacz, Anna; Podkowa,
Adrian; Furgala, Anna; Zmudzki, Pawel; Wanner, Klaus T.; Malawska,
Barbara; Kulig, Katarzyna
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 188111920

$RFMT $RIREG SCHEME366 STEP1
$RXN



  2  1
$MOL
-Bromo-1,3-dihydro-1,3-dioxo-2H-isoindole-2-butanoic acid
C12H10BrNO4
35197-64-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.0203 0.1773 0.0 0
M  V30 2 O 5.7309 4.8721 0.0 0
M  V30 3 C 6.0811 1.5400 0.0 0
M  V30 4 C 7.4148 2.3101 0.0 0
M  V30 5 C 8.7486 1.5400 0.0 0
M  V30 6 C 10.0823 2.3101 0.0 0
M  V30 7 Br 8.7486 0.0000 0.0 0
M  V30 8 O 11.4160 1.5400 0.0 0
M  V30 9 O 10.0823 3.8501 0.0 0
M  V30 10 C 2.3101 2.8281 0.0 0
M  V30 11 C 3.0801 4.1618 0.0 0
M  V30 12 C 3.3405 1.6836 0.0 0
M  V30 13 C 0.7700 2.8281 0.0 0
M  V30 14 C 4.5864 3.8416 0.0 0
M  V30 15 C 2.3101 5.4955 0.0 0
M  V30 16 N 4.7475 2.3101 0.0 0
M  V30 17 C 0.0000 4.1618 0.0 0
M  V30 18 C 0.7700 5.4955 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 12
M  V30 2 2 2 14
M  V30 3 1 3 4
M  V30 4 1 3 16
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 10 13
M  V30 13 1 11 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 13 17
M  V30 17 1 14 16
M  V30 18 1 15 18
M  V30 19 2 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Chlorobenzylamine
C7H8ClN
104-86-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 Cl 6.9302 1.3337 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 2.6673 0.0 0
M  V30 6 C 3.0801 0.0000 0.0 0
M  V30 7 C 4.6201 2.6673 0.0 0
M  V30 8 C 4.6201 0.0000 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-Bromo-N-[(4-chlorophenyl)methyl]-1,3-dihydro-1,3-dioxo-2H-isoindole-2-butan...
C19H16BrClN2O3
1621341-90-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.6078 5.4211 0.0 0
M  V30 2 O 4.6078 0.0000 0.0 0
M  V30 3 C 6.5770 2.7106 0.0 0
M  V30 4 C 7.3470 4.0442 0.0 0
M  V30 5 C 8.8870 4.0442 0.0 0
M  V30 6 C 9.6570 5.3778 0.0 0
M  V30 7 Br 9.6570 2.7106 0.0 0
M  V30 8 N 11.1970 5.3778 0.0 0
M  V30 9 O 8.8870 6.7116 0.0 0
M  V30 10 C 11.9670 6.7116 0.0 0
M  V30 11 Cl 18.1270 6.7116 0.0 0
M  V30 12 C 2.6673 3.4806 0.0 0
M  V30 13 C 2.6673 1.9406 0.0 0
M  V30 14 C 4.1320 3.9564 0.0 0
M  V30 15 C 1.3336 4.2506 0.0 0
M  V30 16 C 4.1320 1.4647 0.0 0
M  V30 17 C 1.3336 1.1706 0.0 0
M  V30 18 N 5.0370 2.7106 0.0 0
M  V30 19 C 0.0000 3.4806 0.0 0
M  V30 20 C 0.0000 1.9406 0.0 0
M  V30 21 C 13.5070 6.7116 0.0 0
M  V30 22 C 14.2770 8.0453 0.0 0
M  V30 23 C 14.2770 5.3778 0.0 0
M  V30 24 C 15.8170 8.0453 0.0 0
M  V30 25 C 15.8170 5.3778 0.0 0
M  V30 26 C 16.5870 6.7116 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 14
M  V30 2 2 2 16
M  V30 3 1 3 4
M  V30 4 1 3 18
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 8 10
M  V30 11 1 10 21
M  V30 12 1 11 26
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 18
M  V30 21 1 17 20
M  V30 22 2 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 35197-64-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 104-86-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1621341-90-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23897128
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel mouse GABA uptake inhibitors with enhanced inhibitory activity
toward mGAT3/4 and their effect on pain threshold in mice
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zareba, Paula; Gryzlo, Beata; Malawska, Katarzyna; Salat, Kinga; Hofner,
Georg C.; Nowaczyk, Alicja; Fijalkowski, Lukasz; Rapacz, Anna; Podkowa,
Adrian; Furgala, Anna; Zmudzki, Pawel; Wanner, Klaus T.; Malawska,
Barbara; Kulig, Katarzyna
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 188111920

$RFMT $RIREG SCHEME367 STEP1
$RXN



  2  1
$MOL
Benzylamine
C7H9N
100-46-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 N 5.3901 2.6673 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 2.3101 2.6673 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 0.7700 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N5-[(1,1-Dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-ornithine
C18H26N2O6
7733-29-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 13.6539 5.3348 0.0 0
M  V30 2 O 12.8839 4.0012 0.0 0
M  V30 3 C 11.3439 4.0012 0.0 0
M  V30 4 N 10.5739 2.6675 0.0 0
M  V30 5 O 10.5739 5.3348 0.0 0
M  V30 6 C 9.0338 2.6675 0.0 0 CFG=2
M  V30 7 C 8.2638 4.0012 0.0 0
M  V30 8 C 8.2638 1.3337 0.0 0
M  V30 9 C 6.7238 4.0012 0.0 0
M  V30 10 O 9.0338 0.0000 0.0 0
M  V30 11 O 6.7238 1.3337 0.0 0
M  V30 12 C 5.9538 5.3348 0.0 0
M  V30 13 N 4.4137 5.3348 0.0 0
M  V30 14 C 3.6437 6.6685 0.0 0
M  V30 15 O 2.1037 6.6685 0.0 0
M  V30 16 O 4.4137 8.0023 0.0 0
M  V30 17 C 1.3337 8.0023 0.0 0
M  V30 18 C 2.6673 8.7723 0.0 0
M  V30 19 C 0.5637 9.3360 0.0 0
M  V30 20 C 0.0000 7.2323 0.0 0
M  V30 21 C 15.1940 5.3348 0.0 0
M  V30 22 C 15.9640 6.6685 0.0 0
M  V30 23 C 15.9640 4.0012 0.0 0
M  V30 24 C 17.5040 6.6685 0.0 0
M  V30 25 C 17.5040 4.0012 0.0 0
M  V30 26 C 18.2740 5.3348 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 21
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 4 CFG=3
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 17 20
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 25
M  V30 25 2 24 26
M  V30 26 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Phenylmethyl N-[(1S)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-[[(phenylmethy...
C25H33N3O5
2524375-70-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.0337 8.0021 0.0 0 CFG=2
M  V30 2 C 8.2637 6.6684 0.0 0
M  V30 3 N 10.5738 8.0021 0.0 0
M  V30 4 C 8.2637 9.3357 0.0 0
M  V30 5 N 9.0337 5.3348 0.0 0
M  V30 6 O 6.7237 6.6684 0.0 0
M  V30 7 C 11.3438 9.3357 0.0 0
M  V30 8 C 6.7237 9.3357 0.0 0
M  V30 9 C 8.2637 4.0010 0.0 0
M  V30 10 O 12.8838 9.3357 0.0 0
M  V30 11 O 10.5738 10.6695 0.0 0
M  V30 12 C 5.9537 10.6695 0.0 0
M  V30 13 C 13.6538 10.6695 0.0 0
M  V30 14 N 4.4137 10.6695 0.0 0
M  V30 15 C 3.6437 12.0032 0.0 0
M  V30 16 O 2.1037 12.0032 0.0 0
M  V30 17 O 4.4137 13.3369 0.0 0
M  V30 18 C 1.3337 13.3369 0.0 0
M  V30 19 C 0.0000 12.5668 0.0 0
M  V30 20 C 0.5636 14.6705 0.0 0
M  V30 21 C 2.6673 14.1069 0.0 0
M  V30 22 C 9.0337 2.6673 0.0 0
M  V30 23 C 8.2637 1.3337 0.0 0
M  V30 24 C 10.5738 2.6673 0.0 0
M  V30 25 C 9.0337 0.0000 0.0 0
M  V30 26 C 11.3438 1.3337 0.0 0
M  V30 27 C 10.5738 0.0000 0.0 0
M  V30 28 C 15.1938 10.6695 0.0 0
M  V30 29 C 15.9638 9.3357 0.0 0
M  V30 30 C 15.9638 12.0032 0.0 0
M  V30 31 C 17.5038 9.3357 0.0 0
M  V30 32 C 17.5038 12.0032 0.0 0
M  V30 33 C 18.2738 10.6695 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 22
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 1 13 28
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 15 17
M  V30 19 1 16 18
M  V30 20 1 18 19
M  V30 21 1 18 20
M  V30 22 1 18 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 29 31
M  V30 32 2 30 32
M  V30 33 2 31 33
M  V30 34 1 32 33
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 100-46-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7733-29-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2524375-70-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40401252
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A -Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and
Improves the Tumor Immune Microenvironment against Triple-Negative Breast
Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhu, Di; Lu, Yu; Yan, Zhanchao; Deng, Qian; Hu, Bo; Wang, Yinsong; Wang,
Wenjing; Wang, Yanming; Wang, Yuji
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(10), 7973-7994

$RFMT $RIREG SCHEME368 STEP1
$RXN



  2  1
$MOL
2-Amino-6-fluorobenzoic acid
C7H6FNO2
434-76-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 1.3338 0.0 0
M  V30 3 O 0.0000 4.0012 0.0 0
M  V30 4 F 2.3101 5.3350 0.0 0
M  V30 5 N 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6675 0.0 0
M  V30 7 C 3.0801 4.0012 0.0 0
M  V30 8 C 3.0801 1.3338 0.0 0
M  V30 9 C 4.6201 4.0012 0.0 0
M  V30 10 C 4.6201 1.3338 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 8
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2,6-Piperidinedione, 3-amino-, hydrochloride (1:1)
C5H8N2O2.ClH
24666-56-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.5400 1.5400 0.0 0
M  V30 2 N 0.0000 4.2073 0.0 0
M  V30 3 O 6.1601 4.2073 0.0 0
M  V30 4 C 2.3101 2.8737 0.0 0
M  V30 5 C 1.5400 4.2073 0.0 0
M  V30 6 N 3.8501 2.8737 0.0 0
M  V30 7 C 2.3101 5.5410 0.0 0
M  V30 8 C 4.6201 4.2073 0.0 0
M  V30 9 C 3.8501 5.5410 0.0 0
M  V30 10 Cl 3.0801 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 4
M  V30 2 1 2 5
M  V30 3 2 3 8
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-N-(2,6-dioxo-3-piperidinyl)-6-fluorobenzamide
C12H12FN3O3
2250289-24-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6675 0.0 0
M  V30 2 N 5.3901 4.0012 0.0 0
M  V30 3 O 5.3901 1.3338 0.0 0
M  V30 4 F 3.0801 5.3348 0.0 0
M  V30 5 N 3.0801 0.0000 0.0 0
M  V30 6 O 6.9302 6.6687 0.0 0
M  V30 7 O 11.5503 4.0012 0.0 0
M  V30 8 C 3.0801 2.6675 0.0 0
M  V30 9 C 2.3101 4.0012 0.0 0
M  V30 10 C 2.3101 1.3338 0.0 0
M  V30 11 C 0.7700 4.0012 0.0 0
M  V30 12 C 0.7700 1.3338 0.0 0
M  V30 13 C 0.0000 2.6675 0.0 0
M  V30 14 C 6.9302 4.0012 0.0 0
M  V30 15 C 7.7002 5.3348 0.0 0
M  V30 16 C 7.7002 2.6675 0.0 0
M  V30 17 N 9.2402 5.3348 0.0 0
M  V30 18 C 9.2402 2.6675 0.0 0
M  V30 19 C 10.0102 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 14
M  V30 5 1 4 9
M  V30 6 1 5 10
M  V30 7 2 6 15
M  V30 8 2 7 19
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 434-76-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 24666-56-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2250289-24-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40486260
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and characterization of cereblon-mediated androgen receptor
proteolysis-targeting chimeras
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Takwale, Akshay D.; Jo, Seung-Hyun; Jeon, Yeong Uk; Kim, Hyung Soo; Shin,
Choong Hoon; Lee, Heung Kyoung; Ahn, Sunjoo; Lee, Chong Ock; Du Ha, Jae;
Kim, Jeong-Hoon; Hwang, Jong Yeon
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 208112769

$RFMT $RIREG SCHEME369 STEP1
$RXN



  2  1
$MOL
4-Fluoro-3-methylaniline
C7H8FN
452-69-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 0.0000 0.0 0
M  V30 2 F 0.0000 2.6673 0.0 0
M  V30 3 N 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) (3S)-1,3-piperidinedicarboxylate
C11H19NO4
88495-54-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0801 0.0 0
M  V30 2 O 2.6673 2.3101 0.0 0
M  V30 3 O 4.0012 4.6201 0.0 0
M  V30 4 C 1.3337 3.0801 0.0 0
M  V30 5 C 0.5637 1.7464 0.0 0
M  V30 6 C 0.0000 3.8501 0.0 0
M  V30 7 C 2.1037 4.4137 0.0 0
M  V30 8 C 9.3360 3.0801 0.0 0
M  V30 9 O 9.3360 4.6201 0.0 0
M  V30 10 O 10.6697 2.3101 0.0 0
M  V30 11 N 5.3348 2.3101 0.0 0
M  V30 12 C 6.6685 3.0801 0.0 0
M  V30 13 C 5.3348 0.7700 0.0 0
M  V30 14 C 8.0023 2.3101 0.0 0 CFG=1
M  V30 15 C 6.6685 0.0000 0.0 0
M  V30 16 C 8.0023 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 14 8 CFG=1
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 14)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl (3S)-3-[[(4-fluoro-3-methylphenyl)amino]carbonyl]-1-piperid...
C18H25FN2O3
1705585-08-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6687 3.0801 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 O 6.6687 4.6201 0.0 0
M  V30 4 C 12.0035 3.0801 0.0 0
M  V30 5 O 13.3372 2.3101 0.0 0
M  V30 6 O 12.0035 4.6201 0.0 0
M  V30 7 C 14.6708 3.0801 0.0 0
M  V30 8 C 15.4408 1.7464 0.0 0
M  V30 9 C 16.0046 3.8501 0.0 0
M  V30 10 C 13.9008 4.4137 0.0 0
M  V30 11 C 0.0000 2.3101 0.0 0
M  V30 12 F 0.0000 5.3901 0.0 0
M  V30 13 C 8.0023 2.3101 0.0 0 CFG=1
M  V30 14 C 9.3360 3.0801 0.0 0
M  V30 15 C 8.0023 0.7700 0.0 0
M  V30 16 N 10.6698 2.3101 0.0 0
M  V30 17 C 9.3360 0.0000 0.0 0
M  V30 18 C 10.6698 0.7700 0.0 0
M  V30 19 C 4.0012 3.0801 0.0 0
M  V30 20 C 2.6675 2.3101 0.0 0
M  V30 21 C 4.0012 4.6201 0.0 0
M  V30 22 C 1.3338 3.0801 0.0 0
M  V30 23 C 2.6675 5.3901 0.0 0
M  V30 24 C 1.3338 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 13 1 CFG=3
M  V30 4 1 2 19
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 16
M  V30 8 1 5 7
M  V30 9 1 7 8
M  V30 10 1 7 9
M  V30 11 1 7 10
M  V30 12 1 11 22
M  V30 13 1 12 24
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 13)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 452-69-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 88495-54-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1705585-08-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35443131
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide
derivatives as capsid assembly modulators inhibiting HBV in vitro and in
HBV-transgenic mice
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yin, Jiaxin; Feng, Zhongqi; Li, Zhi; Hu, Jieli; Hu, Yuan; Cai, Xuefei;
Zhou, Hui; Wang, Kai; Tang, Ni; Huang, Ailong; Huang, Luyi
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 249115141

$RFMT $RIREG SCHEME370 STEP1
$RXN



  3  1
$MOL
Methanol
CH4O
67-56-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  2 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0 0
M  V30 2 O 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Iodo-L-tyrosine methyl ester
C10H12INO3
70277-02-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 C 6.9300 4.0011 0.0 0 CFG=2
M  V30 3 C 8.4700 4.0011 0.0 0
M  V30 4 N 6.1600 5.3349 0.0 0
M  V30 5 O 9.2400 5.3349 0.0 0
M  V30 6 O 9.2400 2.6674 0.0 0
M  V30 7 C 10.7800 5.3349 0.0 0
M  V30 8 I 1.5400 0.0000 0.0 0
M  V30 9 O 0.0000 2.6674 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.8500 1.3338 0.0 0
M  V30 12 C 3.8500 4.0011 0.0 0
M  V30 13 C 2.3100 1.3338 0.0 0
M  V30 14 C 2.3100 4.0011 0.0 0
M  V30 15 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 8 13
M  V30 9 1 9 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
BOC--alanine
C8H15NO4
3303-84-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 O 2.6673 2.3101 0.0 0
M  V30 3 N 5.3348 2.3101 0.0 0
M  V30 4 O 4.0012 0.0000 0.0 0
M  V30 5 C 1.3337 1.5400 0.0 0
M  V30 6 C 6.6685 1.5400 0.0 0
M  V30 7 C 2.1037 0.2064 0.0 0
M  V30 8 C 0.0000 0.7700 0.0 0
M  V30 9 C 0.5637 2.8737 0.0 0
M  V30 10 C 8.0023 2.3101 0.0 0
M  V30 11 C 9.3360 1.5400 0.0 0
M  V30 12 O 10.6697 2.3101 0.0 0
M  V30 13 O 9.3360 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]--alanyl-3-iodo-, methyl ester
C18H25IN2O6
3078808-36-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 5.3348 0.0 0
M  V30 2 C 6.9302 4.0012 0.0 0 CFG=1
M  V30 3 N 8.4702 4.0012 0.0 0
M  V30 4 C 6.1601 2.6673 0.0 0
M  V30 5 C 9.2402 5.3348 0.0 0
M  V30 6 O 6.9302 1.3337 0.0 0
M  V30 7 O 4.6201 2.6673 0.0 0
M  V30 8 C 10.7802 5.3348 0.0 0
M  V30 9 O 8.4702 6.6685 0.0 0
M  V30 10 C 6.1601 0.0000 0.0 0
M  V30 11 C 11.5503 6.6685 0.0 0
M  V30 12 N 13.0903 6.6685 0.0 0
M  V30 13 C 13.8603 8.0023 0.0 0
M  V30 14 O 15.4003 8.0023 0.0 0
M  V30 15 O 13.0903 9.3360 0.0 0
M  V30 16 C 16.1704 9.3360 0.0 0
M  V30 17 C 14.8367 10.1060 0.0 0
M  V30 18 C 16.9404 10.6697 0.0 0
M  V30 19 C 17.5040 8.5660 0.0 0
M  V30 20 I 1.5400 8.0022 0.0 0
M  V30 21 O 0.0000 5.3348 0.0 0
M  V30 22 C 4.6201 5.3348 0.0 0
M  V30 23 C 3.8501 6.6685 0.0 0
M  V30 24 C 3.8501 4.0012 0.0 0
M  V30 25 C 2.3101 6.6685 0.0 0
M  V30 26 C 2.3101 4.0012 0.0 0
M  V30 27 C 1.5400 5.3348 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 1 22
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 16 19
M  V30 20 1 20 25
M  V30 21 1 21 27
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 67-56-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 70277-02-0
$DTYPE RXN:RCT(3):CAS_RN
$DATUM 3303-84-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3078808-36-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-44938486
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-56-1
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 67-68-5
$DTYPE RXN:VAR(1):NOTES
$DATUM alternate reaction conditions also shown
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of Novel Arylomycins against
Multidrug-Resistant Gram-Negative Bacteria
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Yinyong; Zhang, Dan; Zhao, Wenhao; Li, Hongyuan; Lu, Zhengyu; Guo,
Bin; Meng, Xin; Zhou, Xianli; Yang, Yushe
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(8), 6585-6609

$RFMT $RIREG SCHEME371 STEP1
$RXN



  2  1
$MOL
Indole-3-acetic acid
C10H9NO2
87-51-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7307 3.1885 0.0 0
M  V30 2 C 7.1954 2.7126 0.0 0
M  V30 3 O 7.5156 1.2061 0.0 0
M  V30 4 O 8.3398 3.7430 0.0 0
M  V30 5 C 3.0800 2.4782 0.0 0
M  V30 6 C 2.3100 1.1444 0.0 0
M  V30 7 C 4.5863 2.1580 0.0 0
M  V30 8 C 2.3100 3.8118 0.0 0
M  V30 9 N 3.3405 0.0000 0.0 0
M  V30 10 C 0.7700 1.1444 0.0 0
M  V30 11 C 4.7473 0.6263 0.0 0
M  V30 12 C 0.7700 3.8118 0.0 0
M  V30 13 C 0.0000 2.4782 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 1 10 13
M  V30 14 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,4-Dimethoxyphenethylamine
C10H15NO2
120-20-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3349 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3349 0.0 0
M  V30 7 N 9.2400 5.3349 0.0 0
M  V30 8 C 3.0800 2.6674 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.0800 5.3349 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 4.6200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)ethyl]-1H-indole-3-acetamide
C20H22N2O3
13433-48-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2308 6.6684 0.0 0
M  V30 2 C 6.7709 6.6684 0.0 0
M  V30 3 N 7.5409 5.3348 0.0 0
M  V30 4 O 7.5409 8.0021 0.0 0
M  V30 5 C 9.0809 5.3348 0.0 0
M  V30 6 C 9.8509 4.0011 0.0 0
M  V30 7 O 14.4710 1.3337 0.0 0
M  V30 8 C 13.7010 0.0000 0.0 0
M  V30 9 O 16.0110 4.0011 0.0 0
M  V30 10 C 16.7810 5.3348 0.0 0
M  V30 11 C 2.9293 8.1632 0.0 0
M  V30 12 C 4.4608 8.0021 0.0 0
M  V30 13 C 2.6091 9.6695 0.0 0
M  V30 14 C 1.7849 7.1326 0.0 0
M  V30 15 C 5.0873 9.4091 0.0 0
M  V30 16 N 3.9428 10.4395 0.0 0
M  V30 17 C 1.1444 10.1454 0.0 0
M  V30 18 C 0.3202 7.6086 0.0 0
M  V30 19 C 0.0000 9.1149 0.0 0
M  V30 20 C 11.3909 4.0011 0.0 0
M  V30 21 C 12.1609 2.6673 0.0 0
M  V30 22 C 12.1609 5.3348 0.0 0
M  V30 23 C 13.7010 2.6673 0.0 0
M  V30 24 C 13.7010 5.3348 0.0 0
M  V30 25 C 14.4710 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 20
M  V30 8 1 7 8
M  V30 9 1 7 23
M  V30 10 1 9 10
M  V30 11 1 9 25
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 1 15 16
M  V30 20 1 17 19
M  V30 21 2 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 87-51-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 120-20-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 13433-48-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23040320
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM key intermediate
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME372 STEP1
$RXN



  2  1
$MOL
-Alanine methyl ester
C4H9NO2
4138-35-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 1.5400 0.0 0
M  V30 2 C 4.0011 2.3100 0.0 0
M  V30 3 O 1.3338 2.3100 0.0 0
M  V30 4 O 2.6675 0.0000 0.0 0
M  V30 5 C 5.3348 1.5400 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 N 6.6686 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[[trans-4-[[(1,1-Dimethylethoxy)carbonyl]amino]cyclohexyl]oxy]benzoic acid
C18H25NO5
2847839-81-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 10.6697 4.6201 0.0 0
M  V30 2 C 16.0045 1.5400 0.0 0
M  V30 3 O 16.0045 0.0000 0.0 0
M  V30 4 O 17.3383 2.3101 0.0 0
M  V30 5 N 5.3348 1.5400 0.0 0
M  V30 6 C 4.0012 2.3101 0.0 0
M  V30 7 O 2.6675 1.5400 0.0 0
M  V30 8 O 4.0012 3.8501 0.0 0
M  V30 9 C 1.3338 2.3101 0.0 0
M  V30 10 C 0.5638 0.9764 0.0 0
M  V30 11 C 0.0000 3.0801 0.0 0
M  V30 12 C 2.1038 3.6437 0.0 0
M  V30 13 C 12.0035 3.8501 0.0 0
M  V30 14 C 13.3372 4.6201 0.0 0
M  V30 15 C 12.0035 2.3101 0.0 0
M  V30 16 C 14.6708 3.8501 0.0 0
M  V30 17 C 13.3372 1.5400 0.0 0
M  V30 18 C 14.6708 2.3101 0.0 0
M  V30 19 C 9.3360 3.8501 0.0 0 CFG=1
M  V30 20 C 9.3360 2.3101 0.0 0
M  V30 21 C 8.0023 4.6201 0.0 0
M  V30 22 C 8.0023 1.5400 0.0 0
M  V30 23 C 6.6687 3.8501 0.0 0
M  V30 24 C 6.6687 2.3101 0.0 0 CFG=1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 13
M  V30 2 1 19 1 CFG=3
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 18
M  V30 6 1 5 6
M  V30 7 1 24 5 CFG=1
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 7 9
M  V30 11 1 9 10
M  V30 12 1 9 11
M  V30 13 1 9 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(2 19 24)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C22H32N2O6
2847839-83-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 16.0045 1.5400 0.0 0
M  V30 2 N 17.3382 2.3101 0.0 0
M  V30 3 O 16.0045 0.0000 0.0 0
M  V30 4 C 18.6718 1.5400 0.0 0
M  V30 5 C 20.0057 2.3101 0.0 0
M  V30 6 C 21.3393 1.5400 0.0 0
M  V30 7 O 22.6730 2.3101 0.0 0
M  V30 8 O 21.3393 0.0000 0.0 0
M  V30 9 C 24.0067 1.5400 0.0 0
M  V30 10 O 10.6697 4.6201 0.0 0
M  V30 11 N 5.3348 1.5400 0.0 0
M  V30 12 C 4.0010 2.3101 0.0 0
M  V30 13 O 2.6673 1.5400 0.0 0
M  V30 14 O 4.0010 3.8501 0.0 0
M  V30 15 C 1.3337 2.3101 0.0 0
M  V30 16 C 0.5637 0.9764 0.0 0
M  V30 17 C 0.0000 3.0801 0.0 0
M  V30 18 C 2.1037 3.6437 0.0 0
M  V30 19 C 14.6708 2.3101 0.0 0
M  V30 20 C 14.6708 3.8501 0.0 0
M  V30 21 C 13.3370 1.5400 0.0 0
M  V30 22 C 13.3370 4.6201 0.0 0
M  V30 23 C 12.0033 2.3101 0.0 0
M  V30 24 C 12.0033 3.8501 0.0 0
M  V30 25 C 9.3360 3.8501 0.0 0 CFG=1
M  V30 26 C 9.3358 2.3101 0.0 0
M  V30 27 C 8.0022 4.6201 0.0 0
M  V30 28 C 8.0022 1.5400 0.0 0
M  V30 29 C 6.6685 3.8501 0.0 0
M  V30 30 C 6.6685 2.3101 0.0 0 CFG=1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 19
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 10 24
M  V30 11 1 25 10 CFG=3
M  V30 12 1 11 12
M  V30 13 1 30 11 CFG=1
M  V30 14 1 12 13
M  V30 15 2 12 14
M  V30 16 1 13 15
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 1 15 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(2 25 30)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4138-35-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2847839-81-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2847839-83-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39248170
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for
the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced
Mortality
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chen, Yuanguang; Sun, Jianwen; Tong, Hua; Wang, Jieru; Cao, Ruolin; Xu,
Huashen; Chen, Lu; Morisseau, Christophe; Zhang, Maoying; Shi, Yajie;
Han, Chao; Zhuang, Junning; Jing, Yongkui; Liu, Zhongbo; Hammock, Bruce
D.; Chen, Guoliang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(3), 2095-2117

$RFMT $RIREG SCHEME373 STEP1
$RXN



  2  1
$MOL
1-Ethyl 5-(phenylmethyl) N-[(1,1-dimethylethoxy)carbonyl]-L-glutamate
C19H27NO6
83173-71-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.9538 5.3348 0.0 0 CFG=2
M  V30 2 N 4.4137 5.3348 0.0 0
M  V30 3 C 6.7238 6.6685 0.0 0
M  V30 4 C 6.7238 4.0012 0.0 0
M  V30 5 C 3.6437 6.6685 0.0 0
M  V30 6 C 8.2638 6.6685 0.0 0
M  V30 7 O 5.9538 2.6673 0.0 0
M  V30 8 O 8.2638 4.0012 0.0 0
M  V30 9 O 2.1037 6.6685 0.0 0
M  V30 10 O 4.4137 8.0023 0.0 0
M  V30 11 C 9.0338 8.0023 0.0 0
M  V30 12 C 6.7238 1.3337 0.0 0
M  V30 13 C 1.3337 8.0023 0.0 0
M  V30 14 O 10.5739 8.0023 0.0 0
M  V30 15 O 8.2638 9.3360 0.0 0
M  V30 16 C 5.9538 0.0000 0.0 0
M  V30 17 C 2.6673 8.7723 0.0 0
M  V30 18 C 0.5637 9.3360 0.0 0
M  V30 19 C 0.0000 7.2323 0.0 0
M  V30 20 C 11.3439 9.3360 0.0 0
M  V30 21 C 12.8839 9.3360 0.0 0
M  V30 22 C 13.6539 8.0023 0.0 0
M  V30 23 C 13.6539 10.6697 0.0 0
M  V30 24 C 15.1940 8.0023 0.0 0
M  V30 25 C 15.1940 10.6697 0.0 0
M  V30 26 C 15.9640 9.3360 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 13 17
M  V30 17 1 13 18
M  V30 18 1 13 19
M  V30 19 1 14 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 25
M  V30 25 2 24 26
M  V30 26 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Boc-L-valine
C10H19NO4
13734-41-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 2.3101 0.0 0 CFG=2
M  V30 2 N 4.0012 1.5400 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 C 2.6675 3.8501 0.0 0
M  V30 5 C 5.3348 2.3101 0.0 0
M  V30 6 C 0.0000 2.3101 0.0 0
M  V30 7 C 1.3337 0.0000 0.0 0
M  V30 8 O 1.3337 4.6201 0.0 0
M  V30 9 O 4.0012 4.6201 0.0 0
M  V30 10 O 6.6685 1.5400 0.0 0
M  V30 11 O 5.3348 3.8501 0.0 0
M  V30 12 C 8.0023 2.3101 0.0 0
M  V30 13 C 8.7723 0.9764 0.0 0
M  V30 14 C 9.3360 3.0801 0.0 0
M  V30 15 C 7.2323 3.6437 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 2 4 9
M  V30 9 1 5 10
M  V30 10 2 5 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C24H36N2O7
2768856-81-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.0100 5.3347 0.0 0 CFG=1
M  V30 2 N 8.4700 5.3347 0.0 0
M  V30 3 C 10.7800 6.6684 0.0 0
M  V30 4 C 10.7800 4.0011 0.0 0
M  V30 5 C 7.7000 6.6684 0.0 0
M  V30 6 C 12.3200 6.6684 0.0 0
M  V30 7 O 10.0100 2.6673 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 C 6.1600 6.6684 0.0 0 CFG=2
M  V30 10 O 8.4700 8.0021 0.0 0
M  V30 11 C 13.0900 8.0021 0.0 0
M  V30 12 C 10.7800 1.3336 0.0 0
M  V30 13 N 5.3900 5.3347 0.0 0
M  V30 14 C 5.3900 8.0021 0.0 0
M  V30 15 O 14.6300 8.0021 0.0 0
M  V30 16 O 12.3200 9.3358 0.0 0
M  V30 17 C 10.0100 0.0000 0.0 0
M  V30 18 C 3.8500 5.3347 0.0 0
M  V30 19 C 3.8500 8.0021 0.0 0
M  V30 20 C 6.1600 9.3358 0.0 0
M  V30 21 C 15.4000 9.3358 0.0 0
M  V30 22 O 3.0800 4.0011 0.0 0
M  V30 23 O 3.0800 6.6684 0.0 0
M  V30 24 C 1.5400 4.0011 0.0 0
M  V30 25 C 1.5400 2.4611 0.0 0
M  V30 26 C 0.0000 4.0011 0.0 0
M  V30 27 C 1.5400 5.5411 0.0 0
M  V30 28 C 16.9400 9.3358 0.0 0
M  V30 29 C 17.7100 8.0021 0.0 0
M  V30 30 C 17.7100 10.6694 0.0 0
M  V30 31 C 19.2500 8.0021 0.0 0
M  V30 32 C 19.2500 10.6694 0.0 0
M  V30 33 C 20.0200 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 11 15
M  V30 15 2 11 16
M  V30 16 1 12 17
M  V30 17 1 13 18
M  V30 18 1 14 19
M  V30 19 1 14 20
M  V30 20 1 15 21
M  V30 21 1 18 22
M  V30 22 2 18 23
M  V30 23 1 21 28
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 24 27
M  V30 28 2 28 29
M  V30 29 1 28 30
M  V30 30 1 29 31
M  V30 31 2 30 32
M  V30 32 2 31 33
M  V30 33 1 32 33
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 83173-71-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 13734-41-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2768856-81-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34998076
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 76-05-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune
Potentiators
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guzelj, Samo; Weiss, Matjaz; Slutter, Bram; Frkanec, Ruza; Jakopin, Ziga
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(22), 15085-15101

$RFMT $RIREG SCHEME374 STEP1
$RXN



  2  1
$MOL
Cyanoacetic acid
C3H3NO2
372-09-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 2.6673 0.0 0
M  V30 2 C 1.5400 1.3336 0.0 0
M  V30 3 C 3.8500 2.6673 0.0 0
M  V30 4 O 2.3100 0.0000 0.0 0
M  V30 5 O 0.0000 1.3336 0.0 0
M  V30 6 N 5.3900 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 3 3 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-Cyclopropylurea
C4H8N2O
19757-64-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.8737 2.3101 0.0 0
M  V30 2 C 4.2074 1.5400 0.0 0
M  V30 3 N 5.5410 2.3101 0.0 0
M  V30 4 O 4.2074 0.0000 0.0 0
M  V30 5 C 1.5400 1.5400 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 0.7700 0.2064 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 5
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Amino-1-cyclopropyl-2,4(1H,3H)-pyrimidinedione
C7H9N3O2
75914-62-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.8736 0.0000 0.0 0
M  V30 2 O 2.8736 5.3349 0.0 0
M  V30 3 O 7.4936 2.6674 0.0 0
M  V30 4 N 2.8736 2.6674 0.0 0
M  V30 5 C 3.6436 1.3338 0.0 0
M  V30 6 C 3.6436 4.0011 0.0 0
M  V30 7 C 5.1836 1.3338 0.0 0
M  V30 8 N 5.1836 4.0011 0.0 0
M  V30 9 C 5.9536 2.6674 0.0 0
M  V30 10 C 1.3336 2.6674 0.0 0
M  V30 11 C 0.0000 3.4374 0.0 0
M  V30 12 C 0.0000 1.8974 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 5
M  V30 2 2 2 6
M  V30 3 2 3 9
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 4 10
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 9
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 372-09-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 19757-64-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 75914-62-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40592502
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 108-24-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1310-73-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and
Potent Tryptophan Hydroxylase Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Specker, Edgar; Matthes, Susann; Wesolowski, Radoslaw; Schuetz, Anja;
Grohmann, Maik; Alenina, Natalia; Pleimes, Dirk; Mallow, Keven;
Neuenschwander, Martin; Gogolin, Angelina; Weise, Marie; Pfeifer, Jochen;
Ziebart, Nandor; Heinemann, Udo; von Kries, Jens Peter; Nazare, Marc;
Bader, Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(16), 11126-11149

$RFMT $RIREG SCHEME375 STEP1
$RXN



  2  1
$MOL
1-Methyl octanedioate
C9H16O4
3946-32-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 2.3101 0.0 0
M  V30 2 C 9.3360 1.5400 0.0 0
M  V30 3 O 12.0033 1.5400 0.0 0
M  V30 4 O 10.6697 3.8501 0.0 0
M  V30 5 C 8.0022 2.3101 0.0 0
M  V30 6 C 13.3370 2.3101 0.0 0
M  V30 7 C 6.6685 1.5400 0.0 0
M  V30 8 C 5.3348 2.3101 0.0 0
M  V30 9 C 4.0010 1.5400 0.0 0
M  V30 10 C 2.6673 2.3101 0.0 0
M  V30 11 C 1.3337 1.5400 0.0 0
M  V30 12 O 1.3337 0.0000 0.0 0
M  V30 13 O 0.0000 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzenamine, 3-chloro-4-[3-(methyl-2-propyn-1-ylamino)propoxy]-
C13H17ClN2O
2927489-53-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3348 3.0801 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 3.0801 0.0 0
M  V30 4 C 9.3358 2.3101 0.0 0
M  V30 5 N 10.6697 3.0801 0.0 0
M  V30 6 C 12.0033 2.3101 0.0 0
M  V30 7 C 10.6697 4.6201 0.0 0
M  V30 8 C 13.3370 3.0801 0.0 0
M  V30 9 C 14.6707 3.8501 0.0 0
M  V30 10 Cl 2.6673 4.6201 0.0 0
M  V30 11 N 0.0000 0.0000 0.0 0
M  V30 12 C 4.0010 2.3101 0.0 0
M  V30 13 C 2.6673 3.0801 0.0 0
M  V30 14 C 4.0010 0.7700 0.0 0
M  V30 15 C 1.3337 2.3101 0.0 0
M  V30 16 C 2.6673 0.0000 0.0 0
M  V30 17 C 1.3337 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 3 8 9
M  V30 10 1 10 13
M  V30 11 1 11 17
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Octanoic acid, 8-[[3-chloro-4-[3-(methyl-2-propyn-1-ylamino)propoxy]phenyl]am...
C22H31ClN2O4
3031466-60-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 11.5500 2.6674 0.0 0
M  V30 2 C 10.7800 4.0011 0.0 0
M  V30 3 C 9.2400 4.0011 0.0 0
M  V30 4 O 11.5500 5.3347 0.0 0
M  V30 5 C 8.4700 5.3347 0.0 0
M  V30 6 C 6.9300 5.3347 0.0 0
M  V30 7 C 6.1600 6.6684 0.0 0
M  V30 8 C 4.6200 6.6684 0.0 0
M  V30 9 C 3.8500 8.0021 0.0 0
M  V30 10 C 2.3100 8.0021 0.0 0
M  V30 11 O 1.5400 9.3358 0.0 0
M  V30 12 O 1.5400 6.6684 0.0 0
M  V30 13 C 0.0000 9.3358 0.0 0
M  V30 14 Cl 16.1700 0.0000 0.0 0
M  V30 15 O 17.7100 2.6674 0.0 0
M  V30 16 C 18.4800 4.0011 0.0 0
M  V30 17 C 20.0200 4.0011 0.0 0
M  V30 18 C 20.7900 5.3347 0.0 0
M  V30 19 N 22.3300 5.3347 0.0 0
M  V30 20 C 23.1000 6.6684 0.0 0
M  V30 21 C 23.1000 4.0011 0.0 0
M  V30 22 C 24.6400 6.6684 0.0 0
M  V30 23 C 26.1800 6.6684 0.0 0
M  V30 24 C 13.0900 2.6674 0.0 0
M  V30 25 C 13.8600 1.3336 0.0 0
M  V30 26 C 13.8600 4.0011 0.0 0
M  V30 27 C 15.4000 1.3336 0.0 0
M  V30 28 C 15.4000 4.0011 0.0 0
M  V30 29 C 16.1700 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 24
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 11 13
M  V30 14 1 14 27
M  V30 15 1 15 16
M  V30 16 1 15 29
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 3 22 23
M  V30 24 2 24 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 2 26 28
M  V30 28 2 27 29
M  V30 29 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3946-32-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2927489-53-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031466-60-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39977098
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of
Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Mehndiratta, Samir; Qian, Bin; Chuang, Jian-Ying; Liou, Jing-Ping; Shih,
Jean C.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(3), 2208-2224

$RFMT $RIREG SCHEME376 STEP1
$RXN



  2  1
$MOL
Cyclobutanemethanamine, 1-methyl-, hydrochloride (1:1)
C6H13N.ClH
1245647-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.4374 3.6437 0.0 0
M  V30 2 N 4.7710 2.8737 0.0 0
M  V30 3 C 2.8737 1.5400 0.0 0
M  V30 4 C 2.1037 2.8737 0.0 0
M  V30 5 C 1.3337 4.2073 0.0 0
M  V30 6 C 0.7700 2.1037 0.0 0
M  V30 7 C 0.0000 3.4373 0.0 0
M  V30 8 Cl 2.3855 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
rel-(1R,2S,3R,4S)-3-[[(1,1-Dimethylethoxy)carbonyl]amino]bicyclo[2.2.2]oct-5-...
C14H21NO4
1335478-96-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.0244 2.0789 0.0 0
M  V30 2 C 6.3580 2.8489 0.0 0
M  V30 3 O 7.6917 2.0789 0.0 0
M  V30 4 O 6.3580 4.3889 0.0 0
M  V30 5 C 9.0254 2.8489 0.0 0
M  V30 6 C 8.2554 4.1826 0.0 0
M  V30 7 C 10.3592 3.6189 0.0 0
M  V30 8 C 9.7954 1.5152 0.0 0
M  V30 9 C 1.5400 1.3304 0.0 0
M  V30 10 O 2.3157 0.0000 0.0 0
M  V30 11 O 0.0000 1.3238 0.0 0
M  V30 12 C 3.6905 2.8489 0.0 0 CFG=2
M  V30 13 C 2.3044 2.6673 0.0 0 CFG=1
M  V30 14 C 3.0494 4.3937 0.0 0 CFG=2
M  V30 15 C 1.6756 4.1468 0.0 0 CFG=2
M  V30 16 C 3.6996 5.7582 0.0 0
M  V30 17 C 1.1493 4.6700 0.0 0
M  V30 18 C 0.0343 4.2336 0.0 0
M  V30 19 C 2.2988 5.4936 0.0 0
M  V30 20 H 4.5890 4.3541 0.0 0
M  V30 21 H 0.7922 2.8854 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 12 1 CFG=1
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 13 9 CFG=1
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 14 20 CFG=1
M  V30 18 1 15 18
M  V30 19 1 15 19
M  V30 20 1 15 21 CFG=3
M  V30 21 1 16 19
M  V30 22 2 17 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(4 12 13 14 15)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
rel-1,1-Dimethylethyl N-[(1R,2S,3R,4S)-3-[[[(1-methylcyclobutyl)methyl]amino]...
C20H32N2O3
2787517-62-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3843 2.8900 0.0 0
M  V30 2 C 3.8443 2.8835 0.0 0
M  V30 3 O 3.0800 1.5465 0.0 0
M  V30 4 O 3.0686 4.2139 0.0 0
M  V30 5 C 1.5400 1.5400 0.0 0
M  V30 6 C 1.5334 3.0800 0.0 0
M  V30 7 C 0.0000 1.5334 0.0 0
M  V30 8 C 1.5466 0.0000 0.0 0
M  V30 9 C 8.8684 3.6386 0.0 0
M  V30 10 N 10.2020 4.4086 0.0 0
M  V30 11 O 8.8684 2.0986 0.0 0
M  V30 12 C 11.5358 3.6386 0.0 0
M  V30 13 C 12.0995 5.7422 0.0 0
M  V30 14 C 6.1486 4.2270 0.0 0 CFG=2
M  V30 15 C 7.5348 4.4086 0.0 0 CFG=1
M  V30 16 C 5.5197 5.7065 0.0 0 CFG=2
M  V30 17 C 6.8937 5.9533 0.0 0 CFG=2
M  V30 18 C 3.8786 5.7932 0.0 0
M  V30 19 C 6.1429 7.0532 0.0 0
M  V30 20 C 7.5438 7.3178 0.0 0
M  V30 21 C 4.9935 6.2296 0.0 0
M  V30 22 C 12.8695 4.4086 0.0 0
M  V30 23 C 13.6395 3.0749 0.0 0
M  V30 24 C 14.2031 5.1786 0.0 0
M  V30 25 C 14.9731 3.8449 0.0 0
M  V30 26 H 4.6365 4.4451 0.0 0
M  V30 27 H 8.4332 5.9138 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 14 1 CFG=3
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 15 9 CFG=3
M  V30 12 1 10 12
M  V30 13 1 12 22
M  V30 14 1 13 22
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 16 19
M  V30 20 1 16 26 CFG=3
M  V30 21 1 17 20
M  V30 22 1 17 21
M  V30 23 1 17 27 CFG=1
M  V30 24 1 18 21
M  V30 25 2 19 20
M  V30 26 1 22 23
M  V30 27 1 22 24
M  V30 28 1 23 25
M  V30 29 1 24 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(4 14 15 16 17)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1245647-53-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1335478-96-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2787517-62-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40332110
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric
RXFP1 Agonist for Treatment of Heart Failure
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Granberg, Kenneth L.; Sakamaki, Shigeki; Larsson, Niklas; Bergstroem,
Fredrik; Fuchigami, Ryuichi; Niwa, Yasuki; Ryberg, Erik; Backmark, Anna;
Kato, Harutoshi; Miyazaki, Shiki; Iguchi, Kaori; Sakamoto, Toshiaki;
Persson, Mikael; Idei, Akiko; Prieto Garcia, Luna; Villar, Inmaculada C.;
Graden, Henrik; Bergonzini, Giulia; Arvidsson, Torbjoern; Fujita, Takuya;
Althage, Magnus; Ulander, Johan; Kimura, Junpei; Yoneda, Hikaru;
Fjellstroem, Ola; Mochida, Hideki; Lal, Mark
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(6), 4419-4441

$RFMT $RIREG SCHEME377 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)-3-(3-pyridyl)-L-alanine
C13H18N2O4
117142-26-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 2 C 4.6201 4.0012 0.0 0
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 5.3901 0.0000 0.0 0
M  V30 7 O 3.0801 1.3338 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 8.6766 6.1048 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 11.3439 4.5648 0.0 0
M  V30 14 C 3.0801 4.0012 0.0 0
M  V30 15 C 2.3101 5.3348 0.0 0
M  V30 16 C 2.3101 2.6675 0.0 0
M  V30 17 C 0.7700 5.3348 0.0 0
M  V30 18 N 0.7700 2.6675 0.0 0
M  V30 19 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 14
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Methyl 12-aminododecanoate
C13H27NO2
53005-24-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 2.3101 0.0 0
M  V30 2 C 5.3348 1.5400 0.0 0
M  V30 3 C 8.0023 1.5400 0.0 0
M  V30 4 C 4.0012 2.3101 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 2.6675 1.5400 0.0 0
M  V30 7 C 10.6697 1.5400 0.0 0
M  V30 8 O 1.3337 2.3101 0.0 0
M  V30 9 O 2.6675 0.0000 0.0 0
M  V30 10 C 12.0035 2.3101 0.0 0
M  V30 11 C 0.0000 1.5400 0.0 0
M  V30 12 C 13.3372 1.5400 0.0 0
M  V30 13 C 14.6708 2.3101 0.0 0
M  V30 14 C 16.0045 1.5400 0.0 0
M  V30 15 C 17.3383 2.3101 0.0 0
M  V30 16 N 18.6720 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C26H43N3O5
2580940-08-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 5.9538 0.0 0 CFG=1
M  V30 2 C 2.6673 6.7238 0.0 0
M  V30 3 N 4.0010 4.4137 0.0 0
M  V30 4 C 5.3348 6.7238 0.0 0
M  V30 5 C 2.6673 3.6437 0.0 0
M  V30 6 N 6.6685 5.9538 0.0 0
M  V30 7 O 5.3348 8.2638 0.0 0
M  V30 8 O 2.6673 2.1037 0.0 0
M  V30 9 O 1.3337 4.4137 0.0 0
M  V30 10 C 8.0022 6.7238 0.0 0
M  V30 11 C 1.3337 1.3337 0.0 0
M  V30 12 C 9.3358 5.9538 0.0 0
M  V30 13 C 2.1037 0.0000 0.0 0
M  V30 14 C 0.0000 0.5637 0.0 0
M  V30 15 C 0.5637 2.6673 0.0 0
M  V30 16 C 10.6697 6.7238 0.0 0
M  V30 17 C 12.0033 5.9538 0.0 0
M  V30 18 C 13.3370 6.7238 0.0 0
M  V30 19 C 14.6707 5.9538 0.0 0
M  V30 20 C 16.0045 6.7238 0.0 0
M  V30 21 C 17.3382 5.9538 0.0 0
M  V30 22 C 18.6718 6.7238 0.0 0
M  V30 23 C 20.0055 5.9538 0.0 0
M  V30 24 C 21.3393 6.7238 0.0 0
M  V30 25 C 22.6730 5.9538 0.0 0
M  V30 26 O 24.0067 6.7238 0.0 0
M  V30 27 O 22.6730 4.4137 0.0 0
M  V30 28 C 25.3403 5.9538 0.0 0
M  V30 29 C 2.6673 8.2638 0.0 0
M  V30 30 C 1.3337 9.0338 0.0 0
M  V30 31 C 4.0010 9.0338 0.0 0
M  V30 32 C 1.3337 10.5739 0.0 0
M  V30 33 N 4.0010 10.5739 0.0 0
M  V30 34 C 2.6673 11.3439 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 29
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 25 27
M  V30 28 1 26 28
M  V30 29 1 29 30
M  V30 30 2 29 31
M  V30 31 2 30 32
M  V30 32 1 31 33
M  V30 33 1 32 34
M  V30 34 2 33 34
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 117142-26-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 53005-24-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2580940-08-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31901530
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Biomimetic Macrocyclic Inhibitors of Human Cathepsin D:
Structure-Activity Relationship and Binding Mode Analysis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Houstecka, Radka; Hadzima, Martin; Fanfrlik, Jindrich; Brynda, Jiri;
Pallova, Lenka; Hanova, Iva; Mertlikova-Kaiserova, Helena; Lepsik,
Martin; Horn, Martin; Smrcina, Martin; Majer, Pavel; Mares, Michael
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(4), 1576-1596

$RFMT $RIREG SCHEME378 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-(1,1-Dimethylethyl) 7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate
C14H18N2O4
259809-49-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 4.6201 0.0 0
M  V30 2 O 2.6673 3.8501 0.0 0
M  V30 3 O 4.0010 6.1601 0.0 0
M  V30 4 C 1.3337 4.6201 0.0 0
M  V30 5 C 2.1037 5.9538 0.0 0
M  V30 6 C 0.0000 5.3901 0.0 0
M  V30 7 C 0.5637 3.2864 0.0 0
M  V30 8 C 12.0033 1.5400 0.0 0
M  V30 9 O 13.3370 2.3101 0.0 0
M  V30 10 O 12.0033 0.0000 0.0 0
M  V30 11 C 8.0022 3.8501 0.0 0
M  V30 12 C 8.0022 2.3101 0.0 0
M  V30 13 C 6.6685 4.6201 0.0 0
M  V30 14 C 9.3360 4.6201 0.0 0
M  V30 15 N 9.3360 1.5400 0.0 0
M  V30 16 C 6.6685 1.5400 0.0 0
M  V30 17 N 5.3348 3.8501 0.0 0
M  V30 18 C 10.6697 3.8501 0.0 0
M  V30 19 C 10.6697 2.3101 0.0 0
M  V30 20 C 5.3348 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 17
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 8 19
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 11 14
M  V30 14 2 12 15
M  V30 15 1 12 16
M  V30 16 1 13 17
M  V30 17 1 14 18
M  V30 18 1 15 19
M  V30 19 1 16 20
M  V30 20 1 17 20
M  V30 21 2 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 7,8-dihydro-2-[(methylamino)carbonyl]-1,6-naphthyridine-6(5...
C15H21N3O3
2868276-65-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 12.0033 1.5400 0.0 0
M  V30 2 N 13.3370 2.3101 0.0 0
M  V30 3 O 12.0033 0.0000 0.0 0
M  V30 4 C 14.6707 1.5400 0.0 0
M  V30 5 C 4.0010 4.6201 0.0 0
M  V30 6 O 2.6673 3.8501 0.0 0
M  V30 7 O 4.0010 6.1601 0.0 0
M  V30 8 C 1.3337 4.6201 0.0 0
M  V30 9 C 0.5637 3.2864 0.0 0
M  V30 10 C 0.0000 5.3901 0.0 0
M  V30 11 C 2.1037 5.9538 0.0 0
M  V30 12 C 8.0022 2.3101 0.0 0
M  V30 13 C 8.0022 3.8501 0.0 0
M  V30 14 N 9.3358 1.5400 0.0 0
M  V30 15 C 6.6685 1.5400 0.0 0
M  V30 16 C 6.6685 4.6201 0.0 0
M  V30 17 C 9.3358 4.6201 0.0 0
M  V30 18 C 10.6697 2.3101 0.0 0
M  V30 19 C 5.3348 2.3101 0.0 0
M  V30 20 N 5.3348 3.8501 0.0 0
M  V30 21 C 10.6697 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 18
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 20
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 8 11
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 12 15
M  V30 15 1 13 16
M  V30 16 2 13 17
M  V30 17 1 14 18
M  V30 18 1 15 19
M  V30 19 1 16 20
M  V30 20 1 17 21
M  V30 21 2 18 21
M  V30 22 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 259809-49-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2868276-65-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34894088
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and in vitro biological evaluation of
3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective
inhibitors and PARP-1 DNA trappers
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ren, Junkang; Quan, Xu; Liu, Ying; Li, Jiani; Zhang, Xiaoyu; Li, Zhiyu;
Zhang, Xiaomeng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2022), 78129046

$RFMT $RIREG SCHEME379 STEP1
$RXN



  2  1
$MOL
4-[(2-Methylphenyl)amino]-4-oxo-2-butenoic acid
C11H11NO3
37902-59-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 O 5.3348 0.7700 0.0 0
M  V30 5 C 8.0023 2.3101 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 O 9.3360 4.6201 0.0 0
M  V30 8 O 10.6697 2.3101 0.0 0
M  V30 9 C 1.3337 4.6201 0.0 0
M  V30 10 C 2.6673 2.3101 0.0 0
M  V30 11 C 1.3337 3.0801 0.0 0
M  V30 12 C 2.6673 0.7700 0.0 0
M  V30 13 C 0.0000 2.3101 0.0 0
M  V30 14 C 1.3337 0.0000 0.0 0
M  V30 15 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 11
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(2-Methylphenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C20H19N3O3
2416338-23-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9301 6.6684 0.0 0
M  V30 2 C 7.7001 5.3348 0.0 0
M  V30 3 C 9.2401 5.3348 0.0 0
M  V30 4 O 6.9301 4.0011 0.0 0
M  V30 5 C 10.0101 4.0011 0.0 0
M  V30 6 C 11.5501 4.0011 0.0 0
M  V30 7 N 12.3201 2.6675 0.0 0
M  V30 8 O 12.3201 5.3348 0.0 0
M  V30 9 O 5.3901 9.3359 0.0 0
M  V30 10 C 13.8602 0.0000 0.0 0
M  V30 11 C 3.0800 5.3348 0.0 0
M  V30 12 C 2.3100 6.6684 0.0 0
M  V30 13 C 4.6201 5.3348 0.0 0
M  V30 14 C 2.3100 4.0011 0.0 0
M  V30 15 N 3.0800 8.0022 0.0 0
M  V30 16 C 0.7700 6.6684 0.0 0
M  V30 17 C 5.3901 6.6684 0.0 0
M  V30 18 C 0.7700 4.0011 0.0 0
M  V30 19 C 4.6201 8.0022 0.0 0
M  V30 20 C 0.0000 5.3348 0.0 0
M  V30 21 C 13.8602 2.6675 0.0 0
M  V30 22 C 14.6302 1.3337 0.0 0
M  V30 23 C 14.6302 4.0011 0.0 0
M  V30 24 C 16.1702 1.3337 0.0 0
M  V30 25 C 16.1702 4.0011 0.0 0
M  V30 26 C 16.9402 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 22
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 37902-59-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-23-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822005
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME380 STEP1
$RXN



  2  1
$MOL
[(tert-Butoxycarbonyl)(methyl)amino]acetic acid
C8H15NO4
13734-36-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 2.3101 0.0 0
M  V30 2 N 5.3348 1.5400 0.0 0
M  V30 3 O 2.6675 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 6.6685 2.3101 0.0 0
M  V30 6 C 5.3348 0.0000 0.0 0
M  V30 7 C 1.3337 2.3101 0.0 0
M  V30 8 C 8.0023 1.5400 0.0 0
M  V30 9 C 0.5637 0.9764 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 2.1037 3.6437 0.0 0
M  V30 12 O 8.0023 0.0000 0.0 0
M  V30 13 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 2-(2-aminoethoxy)-5-fluorobenzoate
C10H12FNO3
2561412-98-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 2.3100 0.0 0
M  V30 2 O 1.3336 1.5400 0.0 0
M  V30 3 O 4.0011 1.5400 0.0 0
M  V30 4 C 1.3336 0.0000 0.0 0
M  V30 5 O 5.3347 3.8500 0.0 0
M  V30 6 C 6.6684 4.6200 0.0 0
M  V30 7 C 8.0021 3.8500 0.0 0
M  V30 8 N 9.3358 4.6200 0.0 0
M  V30 9 F 0.0000 6.9300 0.0 0
M  V30 10 C 2.6674 3.8500 0.0 0
M  V30 11 C 4.0011 4.6200 0.0 0
M  V30 12 C 1.3336 4.6200 0.0 0
M  V30 13 C 4.0011 6.1600 0.0 0
M  V30 14 C 1.3336 6.1600 0.0 0
M  V30 15 C 2.6674 6.9300 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 11
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 9 14
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 2-[2-[[2-[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]amino]ethox...
C18H25FN2O6
2755959-76-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3348 3.8501 0.0 0
M  V30 2 C 6.6685 4.6201 0.0 0
M  V30 3 C 8.0023 3.8501 0.0 0
M  V30 4 N 9.3360 4.6201 0.0 0
M  V30 5 C 10.6697 3.8501 0.0 0
M  V30 6 C 12.0035 4.6201 0.0 0
M  V30 7 O 10.6697 2.3101 0.0 0
M  V30 8 N 13.3372 3.8501 0.0 0
M  V30 9 C 14.6708 4.6201 0.0 0
M  V30 10 C 13.3372 2.3101 0.0 0
M  V30 11 O 16.0045 3.8501 0.0 0
M  V30 12 O 14.6708 6.1601 0.0 0
M  V30 13 C 17.3383 4.6201 0.0 0
M  V30 14 C 18.1083 3.2864 0.0 0
M  V30 15 C 18.6720 5.3901 0.0 0
M  V30 16 C 16.5683 5.9538 0.0 0
M  V30 17 C 2.6675 2.3101 0.0 0
M  V30 18 O 1.3337 1.5400 0.0 0
M  V30 19 O 4.0012 1.5400 0.0 0
M  V30 20 C 1.3337 0.0000 0.0 0
M  V30 21 F 0.0000 6.9302 0.0 0
M  V30 22 C 4.0012 4.6201 0.0 0
M  V30 23 C 2.6675 3.8501 0.0 0
M  V30 24 C 4.0012 6.1601 0.0 0
M  V30 25 C 1.3337 4.6201 0.0 0
M  V30 26 C 2.6675 6.9302 0.0 0
M  V30 27 C 1.3337 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 22
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 1 17 23
M  V30 20 1 18 20
M  V30 21 1 21 27
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 2 24 26
M  V30 26 2 25 27
M  V30 27 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 13734-36-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2561412-98-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2755959-76-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24003995
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a potent dual inhibitor of wild-type and mutant respiratory
syncytial virus fusion proteins through the modulation of atropisomer
interconversion properties
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yamaguchi-Sasaki, Toru; Kawaguchi, Takanori; Okada, Atsushi; Tokura,
Seiken; Tanaka-Yamamoto, Nozomi; Takeuchi, Tomoki; Ogata, Yuya;
Takahashi, Ryo; Kurimoto-Tsuruta, Risa; Tamaoki, Tomokazu; Sugaya,
Yutaka; Abe-Kumasaka, Tomoko; Arikawa, Kaho; Yoshida, Ippei; Sugiyama,
Hiroyuki; Kanuma, Kosuke; Yoshinaga, Mitsukane
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2020), 28(24), 115818

$RFMT $RIREG SCHEME381 STEP1
$RXN



  2  1
$MOL
Benzyloxycarbonylglycine
C10H11NO4
1138-80-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 1.5400 0.0 0
M  V30 2 O 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 1.5400 0.0 0
M  V30 4 N 8.0022 2.3101 0.0 0
M  V30 5 O 6.6685 0.0000 0.0 0
M  V30 6 C 9.3360 1.5400 0.0 0
M  V30 7 C 10.6697 2.3101 0.0 0
M  V30 8 O 12.0033 1.5400 0.0 0
M  V30 9 O 10.6697 3.8501 0.0 0
M  V30 10 C 2.6673 2.3101 0.0 0
M  V30 11 C 2.6673 3.8501 0.0 0
M  V30 12 C 1.3337 1.5400 0.0 0
M  V30 13 C 1.3337 4.6201 0.0 0
M  V30 14 C 0.0000 2.3101 0.0 0
M  V30 15 C 0.0000 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Tyrosine 1,1-dimethylethyl ester
C13H19NO3
16874-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 4.2073 0.0 0
M  V30 2 C 5.3900 2.8736 0.0 0 CFG=2
M  V30 3 C 3.8500 2.8736 0.0 0
M  V30 4 N 6.1600 1.5400 0.0 0
M  V30 5 O 3.0800 1.5400 0.0 0
M  V30 6 O 3.0800 4.2073 0.0 0
M  V30 7 C 1.5400 1.5400 0.0 0
M  V30 8 C 1.5400 3.0800 0.0 0
M  V30 9 C 0.0000 1.5400 0.0 0
M  V30 10 C 1.5400 0.0000 0.0 0
M  V30 11 O 12.3200 4.2073 0.0 0
M  V30 12 C 7.7000 4.2073 0.0 0
M  V30 13 C 8.4700 2.8736 0.0 0
M  V30 14 C 8.4700 5.5409 0.0 0
M  V30 15 C 10.0100 2.8736 0.0 0
M  V30 16 C 10.0100 5.5409 0.0 0
M  V30 17 C 10.7800 4.2073 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 1 11 17
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(Phenylmethoxy)carbonyl]glycyl-L-tyrosine 1,1-dimethylethyl ester
C23H28N2O6
2104077-53-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 4.4137 0.0 0 CFG=1
M  V30 2 C 5.3348 5.9538 0.0 0
M  V30 3 N 6.6685 3.6437 0.0 0
M  V30 4 C 4.0012 3.6437 0.0 0
M  V30 5 C 8.0023 4.4137 0.0 0
M  V30 6 O 4.0012 2.1037 0.0 0
M  V30 7 O 2.6675 4.4137 0.0 0
M  V30 8 C 9.3360 3.6437 0.0 0
M  V30 9 O 8.0023 5.9538 0.0 0
M  V30 10 C 2.6675 1.3337 0.0 0
M  V30 11 N 10.6697 4.4137 0.0 0
M  V30 12 C 1.8975 2.6673 0.0 0
M  V30 13 C 1.3337 0.5637 0.0 0
M  V30 14 C 3.4375 0.0000 0.0 0
M  V30 15 C 12.0033 3.6437 0.0 0
M  V30 16 O 13.3372 4.4137 0.0 0
M  V30 17 O 12.0033 2.1037 0.0 0
M  V30 18 C 14.6708 3.6437 0.0 0
M  V30 19 O 0.0000 9.0338 0.0 0
M  V30 20 C 4.0012 6.7238 0.0 0
M  V30 21 C 2.6675 5.9538 0.0 0
M  V30 22 C 4.0012 8.2638 0.0 0
M  V30 23 C 1.3337 6.7238 0.0 0
M  V30 24 C 2.6675 9.0338 0.0 0
M  V30 25 C 1.3337 8.2638 0.0 0
M  V30 26 C 16.0045 4.4137 0.0 0
M  V30 27 C 17.3383 3.6437 0.0 0
M  V30 28 C 16.0045 5.9538 0.0 0
M  V30 29 C 18.6720 4.4137 0.0 0
M  V30 30 C 17.3383 6.7238 0.0 0
M  V30 31 C 18.6720 5.9538 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 20
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 10 14
M  V30 15 1 11 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 16 18
M  V30 19 1 18 26
M  V30 20 1 19 25
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 2 28 30
M  V30 31 2 29 31
M  V30 32 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1138-80-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 16874-12-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2104077-53-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36846458
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM N-Alkyl Carbamoylimidazoles as Versatile Synthons for the Synthesis of
Urea-Based PSMA Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Gade, Narendar Reddy; Kaur, Jatinder; Bhardwaj, Atul; Ebrahimi, Edris;
Dufour, Jennifer; Wuest, Melinda; Wuest, Frank
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2023), 14(7), 943-948

$RFMT $RIREG SCHEME382 STEP1
$RXN



  2  1
$MOL
4-[(3-Methylphenyl)amino]-4-oxo-2-butenoic acid
C11H11NO3
54012-55-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 6.6685 3.8501 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 O 10.6697 0.0000 0.0 0
M  V30 8 O 12.0033 2.3101 0.0 0
M  V30 9 C 0.0000 1.5400 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 1.5400 0.0 0
M  V30 12 C 4.0012 3.8501 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 13
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(3-Methylphenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C20H19N3O3
2416338-24-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 5.3901 0.0 0
M  V30 2 C 6.6686 4.6201 0.0 0
M  V30 3 C 8.0022 5.3901 0.0 0
M  V30 4 O 6.6686 3.0800 0.0 0
M  V30 5 C 9.3359 4.6201 0.0 0
M  V30 6 C 10.6695 5.3901 0.0 0
M  V30 7 N 12.0034 4.6201 0.0 0
M  V30 8 O 10.6695 6.9301 0.0 0
M  V30 9 O 2.6675 6.9301 0.0 0
M  V30 10 C 17.3381 4.6201 0.0 0
M  V30 11 C 2.6675 2.3100 0.0 0
M  V30 12 C 1.3338 3.0800 0.0 0
M  V30 13 C 4.0011 3.0800 0.0 0
M  V30 14 C 2.6675 0.7700 0.0 0
M  V30 15 N 1.3338 4.6201 0.0 0
M  V30 16 C 0.0000 2.3100 0.0 0
M  V30 17 C 4.0011 4.6201 0.0 0
M  V30 18 C 1.3338 0.0000 0.0 0
M  V30 19 C 2.6675 5.3901 0.0 0
M  V30 20 C 0.0000 0.7700 0.0 0
M  V30 21 C 13.3370 5.3901 0.0 0
M  V30 22 C 14.6707 4.6201 0.0 0
M  V30 23 C 13.3370 6.9301 0.0 0
M  V30 24 C 16.0043 5.3901 0.0 0
M  V30 25 C 14.6707 7.7001 0.0 0
M  V30 26 C 16.0043 6.9301 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 24
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 54012-55-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-24-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822006
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME383 STEP1
$RXN



  2  1
$MOL
4-[(4-Methylphenyl)amino]-4-oxo-2-butenoic acid
C11H11NO3
37904-03-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 6.6685 3.8501 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 O 10.6697 0.0000 0.0 0
M  V30 8 O 12.0033 2.3101 0.0 0
M  V30 9 C 0.0000 4.6201 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 1.5400 0.0 0
M  V30 12 C 4.0012 3.8501 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(4-Methylphenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C20H19N3O3
2416338-25-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 C 9.2400 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 10.0100 5.3347 0.0 0
M  V30 6 C 11.5500 5.3347 0.0 0
M  V30 7 N 12.3200 6.6685 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 O 5.3900 0.0000 0.0 0
M  V30 10 C 18.4800 6.6685 0.0 0
M  V30 11 C 3.0800 4.0011 0.0 0
M  V30 12 C 2.3100 2.6674 0.0 0
M  V30 13 C 4.6200 4.0011 0.0 0
M  V30 14 C 2.3100 5.3347 0.0 0
M  V30 15 N 3.0800 1.3336 0.0 0
M  V30 16 C 0.7700 2.6674 0.0 0
M  V30 17 C 5.3900 2.6674 0.0 0
M  V30 18 C 0.7700 5.3347 0.0 0
M  V30 19 C 4.6200 1.3336 0.0 0
M  V30 20 C 0.0000 4.0011 0.0 0
M  V30 21 C 13.8600 6.6685 0.0 0
M  V30 22 C 14.6300 8.0021 0.0 0
M  V30 23 C 14.6300 5.3347 0.0 0
M  V30 24 C 16.1700 8.0021 0.0 0
M  V30 25 C 16.1700 5.3347 0.0 0
M  V30 26 C 16.9400 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 26
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 37904-03-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-25-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822007
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME384 STEP1
$RXN



  2  1
$MOL
5H-Benzocyclohepten-5-amine, 2-bromo-6,7,8,9-tetrahydro-, hydrochloride (1:1)
C11H14BrN.ClH
1798794-71-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.5124 1.5400 0.0 0
M  V30 2 Br 7.3748 6.3117 0.0 0
M  V30 3 C 3.3737 5.5417 0.0 0
M  V30 4 C 3.3737 4.0017 0.0 0
M  V30 5 C 4.7074 6.3117 0.0 0
M  V30 6 C 2.1697 6.5019 0.0 0
M  V30 7 C 4.7074 3.2317 0.0 0
M  V30 8 C 2.1697 3.0415 0.0 0
M  V30 9 C 6.0410 5.5417 0.0 0
M  V30 10 C 0.6682 6.1591 0.0 0
M  V30 11 C 6.0410 4.0017 0.0 0
M  V30 12 C 0.6682 3.3842 0.0 0
M  V30 13 C 0.0000 4.7717 0.0 0
M  V30 14 Cl 3.6874 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 2 9
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 11
M  V30 13 1 10 13
M  V30 14 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,3,4-Oxadiazole-2-carboxylic acid, 5-(1,1-dimethylethyl)-, potassium salt (1:1)
C7H10N2O3.K
2247616-84-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 4.7469 0.0 0
M  V30 2 C 1.5400 6.2869 0.0 0
M  V30 3 C 0.0000 4.7469 0.0 0
M  V30 4 C 1.5400 3.2069 0.0 0
M  V30 5 C 6.6958 3.0717 0.0 0
M  V30 6 O 8.1026 3.6980 0.0 0
M  V30 7 O 6.5347 1.5400 0.0 0
M  V30 8 C 3.0800 4.7469 0.0 0
M  V30 9 O 3.9852 3.5009 0.0 0
M  V30 10 N 3.9852 5.9928 0.0 0
M  V30 11 C 5.4498 3.9769 0.0 0
M  V30 12 N 5.4498 5.5169 0.0 0
M  V30 13 K 4.0513 0.0000 0.0 0 VAL=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(2-Bromo-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)-5-(1,1-dimethylethyl)...
C18H22BrN3O2
2763636-79-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.5636 3.9067 0.0 0
M  V30 2 C 8.0350 3.4527 0.0 0
M  V30 3 O 8.3779 1.9514 0.0 0
M  V30 4 Br 0.0000 5.7318 0.0 0
M  V30 5 C 12.9540 5.7315 0.0 0
M  V30 6 C 13.1379 4.2026 0.0 0
M  V30 7 C 14.4829 5.9154 0.0 0
M  V30 8 C 12.7701 7.2606 0.0 0
M  V30 9 C 4.0010 3.4218 0.0 0
M  V30 10 C 5.4346 2.8592 0.0 0
M  V30 11 C 2.6673 2.6518 0.0 0
M  V30 12 C 4.0010 4.9618 0.0 0
M  V30 13 C 5.8886 1.3876 0.0 0
M  V30 14 C 1.3337 3.4218 0.0 0
M  V30 15 C 2.4378 1.1290 0.0 0
M  V30 16 C 2.6673 5.7318 0.0 0
M  V30 17 C 5.0211 0.1152 0.0 0
M  V30 18 C 1.3337 4.9618 0.0 0
M  V30 19 C 3.4854 0.0000 0.0 0
M  V30 20 C 9.1640 4.5002 0.0 0
M  V30 21 O 10.6749 4.2026 0.0 0
M  V30 22 N 8.9802 6.0292 0.0 0
M  V30 23 C 11.4249 5.5476 0.0 0
M  V30 24 N 10.3776 6.6766 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 2 2 3
M  V30 4 1 2 20
M  V30 5 1 4 18
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 5 23
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 10 13
M  V30 14 2 11 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 2 16 18
M  V30 21 1 17 19
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1798794-71-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2247616-84-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2763636-79-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31808459
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Preclinical Characterization of BIIB091, a Reversible,
Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hopkins, Brian T.; Bame, Eris; Bajrami, Bekim; Black, Cheryl; Bohnert,
Tonika; Boiselle, Carrie; Burdette, Doug; Burns, Jeremy C.; Delva,
Luisette; Donaldson, Douglas; Grater, Richard; Gu, Chungang; Hoemberger,
Marc; Johnson, Josh; Kapadnis, Sudarshan; King, Kris; Lulla, Mukesh; Ma,
Bin; Marx, Isaac; Magee, Tom; Meissner, Robert; Metrick, Claire M.;
Mingueneau, Michael; Murugan, Paramasivam; Otipoby, Kevin L.; Polack,
Evelyne; Poreci, Urjana; Prince, Robin; Roach, Allie M.; Rowbottom,
Chris; Santoro, Joseph C.; Schroeder, Patricia; Tang, Hao; Tien, Eric;
Zhang, Fengmei; Lyssikatos, Joseph
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(2), 1206-1224

$RFMT $RIREG SCHEME385 STEP1
$RXN



  2  1
$MOL
(1S,3R)-3-[[(1,1-Dimethylethoxy)carbonyl]amino]cyclohexanecarboxylic acid
C12H21NO4
222530-34-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 O 2.6673 1.5400 0.0 0
M  V30 4 O 4.0012 3.8501 0.0 0
M  V30 5 C 1.3337 2.3101 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 10.6697 1.5400 0.0 0
M  V30 10 O 12.0033 2.3101 0.0 0
M  V30 11 O 10.6697 0.0000 0.0 0
M  V30 12 C 6.6685 2.3101 0.0 0 CFG=2
M  V30 13 C 8.0022 1.5400 0.0 0
M  V30 14 C 6.6685 3.8501 0.0 0
M  V30 15 C 9.3360 2.3101 0.0 0 CFG=1
M  V30 16 C 8.0022 4.6201 0.0 0
M  V30 17 C 9.3360 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 12 1 CFG=3
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 15 9 CFG=3
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 12 15)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
2-Amino-4-bromopyridine
C5H5BrN2
84249-14-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0.0000 3.0800 0.0 0
M  V30 2 N 5.3349 3.0800 0.0 0
M  V30 3 C 2.6675 3.0800 0.0 0
M  V30 4 C 1.3338 2.3100 0.0 0
M  V30 5 C 4.0011 2.3100 0.0 0
M  V30 6 C 1.3338 0.7700 0.0 0
M  V30 7 N 4.0011 0.7700 0.0 0
M  V30 8 C 2.6675 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 2 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl N-[(1R,3S)-3-[[(4-bromo-2-pyridinyl)amino]carbonyl]cyclohex...
C17H24BrN3O3
2057506-34-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 2.3101 0.0 0
M  V30 2 N 12.0035 3.0801 0.0 0
M  V30 3 O 10.6697 0.7700 0.0 0
M  V30 4 N 5.3348 2.3101 0.0 0
M  V30 5 C 4.0012 3.0801 0.0 0
M  V30 6 O 2.6675 2.3101 0.0 0
M  V30 7 O 4.0012 4.6201 0.0 0
M  V30 8 C 1.3338 3.0801 0.0 0
M  V30 9 C 0.5638 1.7464 0.0 0
M  V30 10 C 0.0000 3.8501 0.0 0
M  V30 11 C 2.1038 4.4137 0.0 0
M  V30 12 Br 17.3383 3.0801 0.0 0
M  V30 13 C 9.3360 3.0801 0.0 0 CFG=1
M  V30 14 C 8.0023 2.3101 0.0 0
M  V30 15 C 9.3360 4.6201 0.0 0
M  V30 16 C 6.6687 3.0801 0.0 0 CFG=2
M  V30 17 C 8.0023 5.3901 0.0 0
M  V30 18 C 6.6687 4.6201 0.0 0
M  V30 19 C 13.3372 2.3101 0.0 0
M  V30 20 C 14.6708 3.0801 0.0 0
M  V30 21 N 13.3372 0.7700 0.0 0
M  V30 22 C 16.0045 2.3101 0.0 0
M  V30 23 C 14.6708 0.0000 0.0 0
M  V30 24 C 16.0045 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 13 1 CFG=3
M  V30 4 1 2 19
M  V30 5 1 4 5
M  V30 6 1 16 4 CFG=3
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 1 6 8
M  V30 10 1 8 9
M  V30 11 1 8 10
M  V30 12 1 8 11
M  V30 13 1 12 22
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 13 16)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 222530-34-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 84249-14-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2057506-34-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31188278
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 26189-59-3
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That
Enables Short Duration of Target Engagement for the Treatment of
Hematological Malignancies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Barlaam, Bernard; Casella, Robert; Cidado, Justin; Cook, Calum; De Savi,
Chris; Dishington, Allan; Donald, Craig S.; Drew, Lisa; Ferguson, Andrew
D.; Ferguson, Douglas; Glossop, Steve; Grebe, Tyler; Gu, Chungang; Hande,
Sudhir; Hawkins, Janet; Hird, Alexander W.; Holmes, Jane; Horstick,
James; Jiang, Yun; Lamb, Michelle L.; McGuire, Thomas M.; Moore, Jane E.;
O'Connell, Nichole; Pike, Andy; Pike, Kurt G.; Proia, Theresa; Roberts,
Bryan; San Martin, Maryann; Sarkar, Ujjal; Shao, Wenlin; Stead, Darren;
Sumner, Neil; Thakur, Kumar; Vasbinder, Melissa M.; Varnes, Jeffrey G.;
Wang, Jianyan; Wang, Lei; Wu, Dedong; Wu, Liangwei; Yang, Bin; Yao,
Tieguang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(24), 15564-15590

$RFMT $RIREG SCHEME386 STEP1
$RXN



  2  1
$MOL
8-[(2-Aminophenyl)amino]-10,11-dihydro-5-oxo-5H-dibenzo[a,d]cycloheptene-3-ca...
C22H18N2O3
2614241-22-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 9.6766 2.3000 0.0 0
M  V30 2 C 14.3991 4.3502 0.0 0
M  V30 3 O 15.6714 5.2177 0.0 0
M  V30 4 O 14.5141 2.8145 0.0 0
M  V30 5 N 3.0800 4.0011 0.0 0
M  V30 6 N 0.0000 4.0011 0.0 0
M  V30 7 C 10.3516 4.8190 0.0 0
M  V30 8 C 10.2366 6.3547 0.0 0
M  V30 9 C 9.2228 3.7716 0.0 0
M  V30 10 C 11.7392 4.1509 0.0 0
M  V30 11 C 8.9642 7.2223 0.0 0
M  V30 12 C 11.5090 7.2223 0.0 0
M  V30 13 C 7.7000 4.0011 0.0 0
M  V30 14 C 13.0115 5.0184 0.0 0
M  V30 15 C 7.4926 6.7683 0.0 0
M  V30 16 C 12.8965 6.5541 0.0 0
M  V30 17 C 6.9300 5.3347 0.0 0
M  V30 18 C 6.9300 2.6674 0.0 0
M  V30 19 C 5.3900 5.3347 0.0 0
M  V30 20 C 5.3900 2.6674 0.0 0
M  V30 21 C 4.6200 4.0011 0.0 0
M  V30 22 C 2.3100 2.6674 0.0 0
M  V30 23 C 0.7700 2.6674 0.0 0
M  V30 24 C 3.0800 1.3338 0.0 0
M  V30 25 C 0.0000 1.3338 0.0 0
M  V30 26 C 2.3100 0.0000 0.0 0
M  V30 27 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 9
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 14
M  V30 5 1 5 21
M  V30 6 1 5 22
M  V30 7 1 6 23
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 2 8 12
M  V30 13 1 9 13
M  V30 14 1 10 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 2 13 18
M  V30 19 2 14 16
M  V30 20 1 15 17
M  V30 21 2 17 19
M  V30 22 1 18 20
M  V30 23 1 19 21
M  V30 24 2 20 21
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 23 25
M  V30 28 2 24 26
M  V30 29 2 25 27
M  V30 30 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-Alanine methyl ester
C4H9NO2
4138-35-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 1.5400 0.0 0
M  V30 2 C 4.0011 2.3100 0.0 0
M  V30 3 O 1.3338 2.3100 0.0 0
M  V30 4 O 2.6675 0.0000 0.0 0
M  V30 5 C 5.3348 1.5400 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 N 6.6686 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[[8-[(2-Aminophenyl)amino]-10,11-dihydro-5-oxo-5H-dibenzo[a,d]cyclohepten-3...
C26H25N3O4
2614243-00-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 9.7219 1.7430 0.0 0
M  V30 2 C 14.5843 3.4347 0.0 0
M  V30 3 N 15.9180 4.2047 0.0 0
M  V30 4 O 14.5843 1.8947 0.0 0
M  V30 5 C 17.2516 3.4347 0.0 0
M  V30 6 C 18.5853 4.2047 0.0 0
M  V30 7 C 19.9191 3.4347 0.0 0
M  V30 8 O 21.2527 4.2047 0.0 0
M  V30 9 O 19.9191 1.8947 0.0 0
M  V30 10 C 22.5864 3.4347 0.0 0
M  V30 11 N 3.2707 3.9324 0.0 0
M  V30 12 N 0.1993 4.1626 0.0 0
M  V30 13 C 10.5833 4.2047 0.0 0
M  V30 14 C 10.5833 5.7447 0.0 0
M  V30 15 C 9.3793 3.2445 0.0 0
M  V30 16 C 11.9169 3.4347 0.0 0
M  V30 17 C 9.3793 6.7049 0.0 0
M  V30 18 C 11.9169 6.5147 0.0 0
M  V30 19 C 7.8778 3.5871 0.0 0
M  V30 20 C 13.2505 4.2047 0.0 0
M  V30 21 C 7.8778 6.3621 0.0 0
M  V30 22 C 13.2505 5.7447 0.0 0
M  V30 23 C 7.2097 4.9747 0.0 0
M  V30 24 C 7.0103 2.3148 0.0 0
M  V30 25 C 5.6739 5.0897 0.0 0
M  V30 26 C 5.4746 2.4298 0.0 0
M  V30 27 C 4.8064 3.8174 0.0 0
M  V30 28 C 2.4032 2.6601 0.0 0
M  V30 29 C 0.8675 2.7751 0.0 0
M  V30 30 C 3.0714 1.2725 0.0 0
M  V30 31 C 0.0000 1.5026 0.0 0
M  V30 32 C 2.2039 0.0000 0.0 0
M  V30 33 C 0.6682 0.1152 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 15
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 20
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 10
M  V30 11 1 11 27
M  V30 12 1 11 28
M  V30 13 1 12 29
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 21
M  V30 22 1 18 22
M  V30 23 1 19 23
M  V30 24 2 19 24
M  V30 25 2 20 22
M  V30 26 1 21 23
M  V30 27 2 23 25
M  V30 28 1 24 26
M  V30 29 1 25 27
M  V30 30 2 26 27
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 29 31
M  V30 34 2 30 32
M  V30 35 2 31 33
M  V30 36 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2614241-22-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4138-35-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2614243-00-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31188036
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 99
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Synthesis of Highly Selective Brain Penetrant p38
Mitogen-Activated Protein Kinase Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tormaehlen, Niklas M.; Martorelli, Mariella; Kuhn, Annette; Maier,
Florian; Guezguez, Jamil; Burnet, Michael; Albrecht, Wolfgang; Laufer,
Stefan A.; Koch, Pierre
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(2), 1225-1242

$RFMT $RIREG SCHEME387 STEP1
$RXN



  2  1
$MOL
3-Amino-2,6-piperidinedione
C5H8N2O2
2353-44-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.5400 0.0000 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 O 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 N 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 4
M  V30 2 1 2 5
M  V30 3 2 3 8
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[[(tert-butoxycarbonyl)amino]methyl]benzoic acid
C13H17NO4
33233-67-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 N 5.3348 3.8501 0.0 0
M  V30 3 C 4.0010 4.6201 0.0 0
M  V30 4 O 2.6673 3.8501 0.0 0
M  V30 5 O 4.0010 6.1601 0.0 0
M  V30 6 C 1.3337 4.6201 0.0 0
M  V30 7 C 0.5637 3.2864 0.0 0
M  V30 8 C 0.0000 5.3901 0.0 0
M  V30 9 C 2.1037 5.9538 0.0 0
M  V30 10 C 12.0033 1.5400 0.0 0
M  V30 11 O 12.0033 0.0000 0.0 0
M  V30 12 O 13.3370 2.3101 0.0 0
M  V30 13 C 8.0022 3.8501 0.0 0
M  V30 14 C 8.0022 2.3101 0.0 0
M  V30 15 C 9.3360 4.6201 0.0 0
M  V30 16 C 9.3360 1.5400 0.0 0
M  V30 17 C 10.6697 3.8501 0.0 0
M  V30 18 C 10.6697 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 10 18
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C18H23N3O5
2946672-64-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1600 5.5411 0.0 0
M  V30 2 C 6.9300 4.2074 0.0 0
M  V30 3 O 6.1600 2.8738 0.0 0
M  V30 4 O 4.6200 8.2085 0.0 0
M  V30 5 O 0.0000 5.5411 0.0 0
M  V30 6 C 13.0900 4.2074 0.0 0
M  V30 7 N 13.8600 2.8738 0.0 0
M  V30 8 C 15.4000 2.8738 0.0 0
M  V30 9 O 16.1700 1.5400 0.0 0
M  V30 10 O 16.1700 4.2074 0.0 0
M  V30 11 C 17.7100 1.5400 0.0 0
M  V30 12 C 17.7100 0.0000 0.0 0
M  V30 13 C 19.2500 1.5400 0.0 0
M  V30 14 C 17.7100 3.0800 0.0 0
M  V30 15 C 4.6200 5.5411 0.0 0
M  V30 16 C 3.8500 6.8747 0.0 0
M  V30 17 C 3.8500 4.2074 0.0 0
M  V30 18 N 2.3100 6.8747 0.0 0
M  V30 19 C 2.3100 4.2074 0.0 0
M  V30 20 C 1.5400 5.5411 0.0 0
M  V30 21 C 8.4700 4.2074 0.0 0
M  V30 22 C 9.2400 2.8738 0.0 0
M  V30 23 C 9.2400 5.5411 0.0 0
M  V30 24 C 10.7800 2.8738 0.0 0
M  V30 25 C 10.7800 5.5411 0.0 0
M  V30 26 C 11.5500 4.2074 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 2 2 3
M  V30 4 1 2 21
M  V30 5 2 4 16
M  V30 6 2 5 20
M  V30 7 1 6 7
M  V30 8 1 6 26
M  V30 9 1 7 8
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 9 11
M  V30 13 1 11 12
M  V30 14 1 11 13
M  V30 15 1 11 14
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 20
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 25
M  V30 26 2 24 26
M  V30 27 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2353-44-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 33233-67-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2946672-64-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38469900
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and synthesis of novel cereblon binders for use in targeted
protein degradation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Norris, Stephen; Ba, Xiaochu; Rhodes, Jayce; Huang, Dehua; Khambatta,
Gody; Buenviaje, Jennifer; Nayak, Surendra; Meiring, Joseph; Reiss,
Samantha; Xu, Shuichan; Shi, Lihong; Whitefield, Brandon; Alexander,
Matt; Horn, Evan J.; Correa, Matthew; Tehrani, Lida; Hansen, Joshua D.;
Papa, Patrick; Mortensen, Deborah S.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(23), 16388-16409

$RFMT $RIREG SCHEME388 STEP1
$RXN



  2  1
$MOL
7-Bromobenzo[b]thiophene-2-carboxylic acid
C9H5BrO2S
19075-59-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0.0000 1.4944 0.0 0
M  V30 2 C 6.0811 1.5400 0.0 0
M  V30 3 O 6.0811 0.0000 0.0 0
M  V30 4 O 7.4149 2.3100 0.0 0
M  V30 5 C 3.0801 4.1618 0.0 0
M  V30 6 C 2.3100 2.8281 0.0 0
M  V30 7 C 4.5865 3.8416 0.0 0
M  V30 8 C 2.3100 5.4954 0.0 0
M  V30 9 S 3.3406 1.6836 0.0 0
M  V30 10 C 0.7700 2.8281 0.0 0
M  V30 11 C 4.7474 2.3100 0.0 0
M  V30 12 C 0.7700 5.4954 0.0 0
M  V30 13 C 0.0000 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 11
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 1 10 13
M  V30 14 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Piperidinamine, 1-(phenylmethyl)-, hydrochloride (1:2), (3R)-
C12H18N2.2ClH
876160-18-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 4.6200 0.0 0
M  V30 2 N 9.3358 4.6200 0.0 0
M  V30 3 N 5.3347 3.8500 0.0 0
M  V30 4 C 6.6684 4.6200 0.0 0
M  V30 5 C 5.3347 2.3100 0.0 0
M  V30 6 C 8.0021 3.8500 0.0 0 CFG=2
M  V30 7 C 6.6684 1.5400 0.0 0
M  V30 8 C 8.0021 2.3100 0.0 0
M  V30 9 C 2.6674 3.8500 0.0 0
M  V30 10 C 2.6674 2.3100 0.0 0
M  V30 11 C 1.3336 4.6200 0.0 0
M  V30 12 C 1.3336 1.5400 0.0 0
M  V30 13 C 0.0000 3.8500 0.0 0
M  V30 14 C 0.0000 2.3100 0.0 0
M  V30 15 Cl 4.6679 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 1 9
M  V30 3 1 6 2 CFG=3
M  V30 4 1 3 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 8
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
7-Bromo-N-[(3R)-1-(phenylmethyl)-3-piperidinyl]benzo[b]thiophene-2-carboxamide
C21H21BrN2OS
2831364-37-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Br 0.0000 4.0010 0.0 0
M  V30 2 C 6.0811 3.9554 0.0 0
M  V30 3 N 7.4149 3.1854 0.0 0
M  V30 4 O 6.0811 5.4954 0.0 0
M  V30 5 C 12.7497 3.1854 0.0 0
M  V30 6 C 3.0800 1.3337 0.0 0
M  V30 7 C 2.3100 2.6673 0.0 0
M  V30 8 C 4.5865 1.6538 0.0 0
M  V30 9 C 2.3100 0.0000 0.0 0
M  V30 10 S 3.3406 3.8119 0.0 0
M  V30 11 C 0.7700 2.6673 0.0 0
M  V30 12 C 4.7474 3.1854 0.0 0
M  V30 13 C 0.7700 0.0000 0.0 0
M  V30 14 C 0.0000 1.3337 0.0 0
M  V30 15 C 8.7486 3.9554 0.0 0 CFG=2
M  V30 16 C 10.0822 3.1854 0.0 0
M  V30 17 C 8.7486 5.4954 0.0 0
M  V30 18 N 11.4160 3.9554 0.0 0
M  V30 19 C 10.0822 6.2654 0.0 0
M  V30 20 C 11.4160 5.4954 0.0 0
M  V30 21 C 14.0834 3.9554 0.0 0
M  V30 22 C 14.0834 5.4954 0.0 0
M  V30 23 C 15.4170 3.1854 0.0 0
M  V30 24 C 15.4170 6.2654 0.0 0
M  V30 25 C 16.7508 3.9554 0.0 0
M  V30 26 C 16.7508 5.4954 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 12
M  V30 5 1 15 3 CFG=3
M  V30 6 1 5 18
M  V30 7 1 5 21
M  V30 8 1 6 7
M  V30 9 1 6 8
M  V30 10 2 6 9
M  V30 11 1 7 10
M  V30 12 2 7 11
M  V30 13 2 8 12
M  V30 14 1 9 13
M  V30 15 1 10 12
M  V30 16 1 11 14
M  V30 17 2 13 14
M  V30 18 1 15 16
M  V30 19 1 15 17
M  V30 20 1 16 18
M  V30 21 1 17 19
M  V30 22 1 18 20
M  V30 23 1 19 20
M  V30 24 2 21 22
M  V30 25 1 21 23
M  V30 26 1 22 24
M  V30 27 2 23 25
M  V30 28 2 24 26
M  V30 29 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 15)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 19075-59-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 876160-18-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2831364-37-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33998214
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM product further converted into HCl salt
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Preparation of Enantiopure 3-Aminopiperidine and 3-Aminoazepane
Derivatives from Ornithine and Lysine. Consecutive Syntheses of
Pharmacologically Active Analogs, Such as Besifloxacin
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Schiffers, Ingo; Frings, Marcus; Kuebber, Britta Maria; Truong,
Khai-Nghi; Rissanen, Kari; Bolm, Carsten
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2022), 26(10), 2811-2822

$RFMT $RIREG SCHEME389 STEP1
$RXN



  2  1
$MOL
4-(Ethylsulfonyl)benzeneacetic acid
C10H12O4S
383135-47-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 2.3100 2.6673 0.0 0 VAL=6
M  V30 2 C 0.7700 2.6673 0.0 0
M  V30 3 O 2.3100 1.1273 0.0 0
M  V30 4 O 2.3100 4.2073 0.0 0
M  V30 5 C 0.0000 4.0011 0.0 0
M  V30 6 C 8.4700 2.6673 0.0 0
M  V30 7 C 9.2400 1.3336 0.0 0
M  V30 8 O 10.7800 1.3336 0.0 0
M  V30 9 O 8.4700 0.0000 0.0 0
M  V30 10 C 3.8500 2.6673 0.0 0
M  V30 11 C 4.6200 1.3336 0.0 0
M  V30 12 C 4.6200 4.0011 0.0 0
M  V30 13 C 6.1600 1.3336 0.0 0
M  V30 14 C 6.1600 4.0011 0.0 0
M  V30 15 C 6.9300 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 6 7
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-[4-amino-2-(trifluoromethyl)[1,1-biphenyl]-2-yl]-
C16H13F3N2O
2983540-60-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6684 6.1600 0.0 0
M  V30 2 C 8.0021 6.9300 0.0 0
M  V30 3 C 9.3358 6.1600 0.0 0
M  V30 4 O 8.0021 8.4700 0.0 0
M  V30 5 C 10.6694 6.9300 0.0 0
M  V30 6 C 1.3336 4.6200 0.0 0
M  V30 7 F 2.1036 5.9536 0.0 0
M  V30 8 F 0.0000 5.3900 0.0 0
M  V30 9 F 0.5636 3.2864 0.0 0
M  V30 10 N 4.0011 0.0000 0.0 0
M  V30 11 C 4.0011 6.1600 0.0 0
M  V30 12 C 5.3347 6.9300 0.0 0
M  V30 13 C 2.6673 6.9300 0.0 0
M  V30 14 C 5.3347 8.4700 0.0 0
M  V30 15 C 2.6673 8.4700 0.0 0
M  V30 16 C 4.0011 9.2400 0.0 0
M  V30 17 C 4.0011 4.6200 0.0 0
M  V30 18 C 2.6673 3.8500 0.0 0
M  V30 19 C 5.3347 3.8500 0.0 0
M  V30 20 C 2.6673 2.3100 0.0 0
M  V30 21 C 5.3347 2.3100 0.0 0
M  V30 22 C 4.0011 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 6 18
M  V30 10 1 10 22
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 11 17
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, 4-(ethylsulfonyl)-N-[2-[(1-oxo-2-propen-1-yl)amino]-2-(tri...
C26H23F3N2O4S
2983540-57-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  36 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 9.2402 0.0 0
M  V30 2 F 1.8975 7.9065 0.0 0
M  V30 3 F 1.3337 10.0102 0.0 0
M  V30 4 F 3.4375 10.5739 0.0 0
M  V30 5 N 4.0012 3.8501 0.0 0
M  V30 6 C 4.0012 2.3101 0.0 0
M  V30 7 C 5.3348 1.5400 0.0 0
M  V30 8 O 2.6675 1.5400 0.0 0
M  V30 9 C 5.3348 0.0000 0.0 0
M  V30 10 N 8.0023 9.2402 0.0 0
M  V30 11 C 9.3360 8.4702 0.0 0
M  V30 12 C 10.6697 9.2402 0.0 0
M  V30 13 O 9.3360 6.9302 0.0 0
M  V30 14 S 16.0045 6.1601 0.0 0 VAL=6
M  V30 15 C 17.3383 5.3901 0.0 0
M  V30 16 O 15.2345 4.8265 0.0 0
M  V30 17 O 16.7745 7.4938 0.0 0
M  V30 18 C 18.6720 6.1601 0.0 0
M  V30 19 C 4.0012 6.9302 0.0 0
M  V30 20 C 4.0012 8.4702 0.0 0
M  V30 21 C 5.3348 6.1601 0.0 0
M  V30 22 C 5.3348 9.2402 0.0 0
M  V30 23 C 6.6685 6.9302 0.0 0
M  V30 24 C 6.6685 8.4702 0.0 0
M  V30 25 C 2.6675 6.1601 0.0 0
M  V30 26 C 2.6675 4.6201 0.0 0
M  V30 27 C 1.3337 6.9302 0.0 0
M  V30 28 C 1.3337 3.8501 0.0 0
M  V30 29 C 0.0000 6.1601 0.0 0
M  V30 30 C 0.0000 4.6201 0.0 0
M  V30 31 C 12.0035 8.4702 0.0 0
M  V30 32 C 13.3372 9.2402 0.0 0
M  V30 33 C 12.0035 6.9302 0.0 0
M  V30 34 C 14.6708 8.4702 0.0 0
M  V30 35 C 13.3372 6.1601 0.0 0
M  V30 36 C 14.6708 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 20
M  V30 5 1 5 6
M  V30 6 1 5 26
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 10 11
M  V30 11 1 10 24
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 12 31
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 2 14 17
M  V30 18 1 14 36
M  V30 19 1 15 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 19 25
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 33 2 31 32
M  V30 34 1 31 33
M  V30 35 1 32 34
M  V30 36 2 33 35
M  V30 37 2 34 36
M  V30 38 1 35 36
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 383135-47-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2983540-60-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-57-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256063
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME390 STEP1
$RXN



  2  1
$MOL
Cyclopropylamine
C3H7N
765-30-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.8737 2.1037 0.0 0
M  V30 2 C 1.5400 1.3337 0.0 0
M  V30 3 C 0.0000 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(Phenylmethyl) hydrogen N-[(phenylmethoxy)carbonyl]-L-glutamate
C20H21NO6
3705-42-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7002 5.3348 0.0 0 CFG=2
M  V30 2 C 9.2402 5.3348 0.0 0
M  V30 3 N 6.9302 6.6685 0.0 0
M  V30 4 C 6.9302 4.0012 0.0 0
M  V30 5 O 10.0102 6.6685 0.0 0
M  V30 6 O 10.0102 4.0012 0.0 0
M  V30 7 C 5.3901 6.6685 0.0 0
M  V30 8 C 7.7002 2.6673 0.0 0
M  V30 9 C 11.5503 6.6685 0.0 0
M  V30 10 O 4.6201 8.0022 0.0 0
M  V30 11 O 4.6201 5.3348 0.0 0
M  V30 12 C 6.9302 1.3337 0.0 0
M  V30 13 C 3.0801 8.0022 0.0 0
M  V30 14 O 7.7002 0.0000 0.0 0
M  V30 15 O 5.3901 1.3337 0.0 0
M  V30 16 C 12.3203 8.0022 0.0 0
M  V30 17 C 13.8603 8.0022 0.0 0
M  V30 18 C 11.5503 9.3360 0.0 0
M  V30 19 C 14.6303 9.3360 0.0 0
M  V30 20 C 12.3203 10.6697 0.0 0
M  V30 21 C 13.8603 10.6697 0.0 0
M  V30 22 C 2.3101 9.3360 0.0 0
M  V30 23 C 3.0801 10.6697 0.0 0
M  V30 24 C 0.7700 9.3360 0.0 0
M  V30 25 C 2.3101 12.0033 0.0 0
M  V30 26 C 0.0000 10.6697 0.0 0
M  V30 27 C 0.7700 12.0033 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 16
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 22
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-Cyclopropyl-N2-[(phenylmethoxy)carbonyl]-L-glutamine phenylmethyl ester
C23H26N2O5
2559759-42-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.7238 8.0022 0.0 0 CFG=2
M  V30 2 C 5.9538 6.6685 0.0 0
M  V30 3 N 8.2638 8.0022 0.0 0
M  V30 4 C 5.9538 9.3360 0.0 0
M  V30 5 O 6.7238 5.3348 0.0 0
M  V30 6 O 4.4137 6.6685 0.0 0
M  V30 7 C 9.0338 9.3360 0.0 0
M  V30 8 C 4.4137 9.3360 0.0 0
M  V30 9 C 5.9538 4.0012 0.0 0
M  V30 10 O 10.5739 9.3360 0.0 0
M  V30 11 O 8.2638 10.6697 0.0 0
M  V30 12 C 3.6437 10.6697 0.0 0
M  V30 13 C 11.3439 10.6697 0.0 0
M  V30 14 N 2.1037 10.6697 0.0 0
M  V30 15 O 4.4137 12.0033 0.0 0
M  V30 16 C 6.7238 2.6673 0.0 0
M  V30 17 C 8.2638 2.6673 0.0 0
M  V30 18 C 5.9538 1.3337 0.0 0
M  V30 19 C 9.0338 1.3337 0.0 0
M  V30 20 C 6.7238 0.0000 0.0 0
M  V30 21 C 8.2638 0.0000 0.0 0
M  V30 22 C 12.8839 10.6697 0.0 0
M  V30 23 C 13.6539 12.0033 0.0 0
M  V30 24 C 13.6539 9.3360 0.0 0
M  V30 25 C 15.1940 12.0033 0.0 0
M  V30 26 C 15.1940 9.3360 0.0 0
M  V30 27 C 15.9640 10.6697 0.0 0
M  V30 28 C 1.3337 12.0033 0.0 0
M  V30 29 C 1.3337 13.5434 0.0 0
M  V30 30 C 0.0000 12.7733 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 1 8 12
M  V30 12 1 9 16
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 22
M  V30 17 1 14 28
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 30 1 28 29
M  V30 31 1 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 765-30-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3705-42-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2559759-42-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37376179
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhu, Junjie; Lei, Saifei; Lu, Jie; Hao, Yixuan; Qian, Qi; Devanathan,
Aaron S.; Feng, Zhiwei; Xie, Xiang-Qun; Wipf, Peter; Ma, Xiaochao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 259115666

$RFMT $RIREG SCHEME391 STEP1
$RXN



  2  1
$MOL
Pentanoic acid, 5-amino-, methyl ester
C6H13NO2
63984-02-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 O 1.3337 2.3101 0.0 0
M  V30 4 O 2.6675 0.0000 0.0 0
M  V30 5 C 5.3348 1.5400 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 6.6685 2.3101 0.0 0
M  V30 8 C 8.0023 1.5400 0.0 0
M  V30 9 N 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-[[[(3,5-dimethyltricyclo[3.3.1.13,7]dec-1-yl)amino]carbonyl]a...
C20H26N2O3
3032415-34-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5213 4.6201 0.0 0
M  V30 2 C 6.8550 3.8501 0.0 0
M  V30 3 N 8.1887 4.6201 0.0 0
M  V30 4 O 6.8550 2.3101 0.0 0
M  V30 5 C 1.2902 5.4788 0.0 0
M  V30 6 C 3.4674 0.1329 0.0 0
M  V30 7 C 13.5235 1.5400 0.0 0
M  V30 8 O 14.8573 2.3101 0.0 0
M  V30 9 O 13.5235 0.0000 0.0 0
M  V30 10 C 4.1877 3.8501 0.0 0
M  V30 11 C 2.8994 4.6888 0.0 0
M  V30 12 C 4.2697 2.3153 0.0 0
M  V30 13 C 2.4938 3.8393 0.0 0
M  V30 14 C 1.6937 3.9925 0.0 0
M  V30 15 C 3.0641 1.6190 0.0 0
M  V30 16 C 1.2881 3.1431 0.0 0
M  V30 17 C 1.7760 2.4577 0.0 0
M  V30 18 C 0.0000 3.9814 0.0 0
M  V30 19 C 1.3703 1.6081 0.0 0
M  V30 20 C 9.5225 3.8501 0.0 0
M  V30 21 C 9.5225 2.3101 0.0 0
M  V30 22 C 10.8562 4.6201 0.0 0
M  V30 23 C 10.8562 1.5400 0.0 0
M  V30 24 C 12.1898 3.8501 0.0 0
M  V30 25 C 12.1898 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 20
M  V30 6 1 5 14
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 25
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 11 14
M  V30 15 1 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 1 15 17
M  V30 20 1 15 19
M  V30 21 1 16 18
M  V30 22 1 16 19
M  V30 23 2 20 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 2 22 24
M  V30 27 2 23 25
M  V30 28 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Pentanoic acid, 5-[[4-[[[(3,5-dimethyltricyclo[3.3.1.13,7]dec-1-yl)amino]carb...
C26H37N3O4
3032415-35-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5213 0.8587 0.0 0
M  V30 2 C 6.8550 1.6287 0.0 0
M  V30 3 N 8.1887 0.8587 0.0 0
M  V30 4 O 6.8550 3.1688 0.0 0
M  V30 5 C 1.2902 0.0000 0.0 0
M  V30 6 C 3.4674 5.3459 0.0 0
M  V30 7 C 13.5235 3.9388 0.0 0
M  V30 8 N 14.8573 3.1688 0.0 0
M  V30 9 O 13.5235 5.4788 0.0 0
M  V30 10 C 16.1910 3.9388 0.0 0
M  V30 11 C 17.5247 3.1688 0.0 0
M  V30 12 C 18.8585 3.9388 0.0 0
M  V30 13 C 20.1922 3.1688 0.0 0
M  V30 14 C 21.5258 3.9388 0.0 0
M  V30 15 O 22.8595 3.1688 0.0 0
M  V30 16 O 21.5258 5.4788 0.0 0
M  V30 17 C 24.1933 3.9388 0.0 0
M  V30 18 C 4.1877 1.6287 0.0 0
M  V30 19 C 2.8994 0.7900 0.0 0
M  V30 20 C 4.2697 3.1635 0.0 0
M  V30 21 C 2.4939 1.6395 0.0 0
M  V30 22 C 1.6937 1.4863 0.0 0
M  V30 23 C 3.0641 3.8598 0.0 0
M  V30 24 C 1.2881 2.3358 0.0 0
M  V30 25 C 1.7760 3.0211 0.0 0
M  V30 26 C 0.0000 1.4974 0.0 0
M  V30 27 C 1.3703 3.8707 0.0 0
M  V30 28 C 9.5225 1.6287 0.0 0
M  V30 29 C 10.8562 0.8587 0.0 0
M  V30 30 C 9.5225 3.1688 0.0 0
M  V30 31 C 12.1898 1.6287 0.0 0
M  V30 32 C 10.8562 3.9388 0.0 0
M  V30 33 C 12.1898 3.1688 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 18
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 28
M  V30 6 1 5 22
M  V30 7 1 6 23
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 33
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 14 16
M  V30 18 1 15 17
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 1 19 22
M  V30 23 1 20 23
M  V30 24 1 21 24
M  V30 25 1 22 25
M  V30 26 1 22 26
M  V30 27 1 23 25
M  V30 28 1 23 27
M  V30 29 1 24 26
M  V30 30 1 24 27
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 29 31
M  V30 34 2 30 32
M  V30 35 2 31 33
M  V30 36 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 63984-02-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3032415-34-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3032415-35-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39248128
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for
the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced
Mortality
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chen, Yuanguang; Sun, Jianwen; Tong, Hua; Wang, Jieru; Cao, Ruolin; Xu,
Huashen; Chen, Lu; Morisseau, Christophe; Zhang, Maoying; Shi, Yajie;
Han, Chao; Zhuang, Junning; Jing, Yongkui; Liu, Zhongbo; Hammock, Bruce
D.; Chen, Guoliang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(3), 2095-2117

$RFMT $RIREG SCHEME392 STEP1
$RXN



  2  1
$MOL
3-Amino-2,6-piperidinedione
C5H8N2O2
2353-44-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.5400 0.0000 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 O 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 N 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 4
M  V30 2 1 2 5
M  V30 3 2 3 8
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(tert-Butoxycarbonylamino)benzoic acid
C12H15NO4
66493-39-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6697 1.5400 0.0 0
M  V30 2 O 12.0033 2.3101 0.0 0
M  V30 3 O 10.6697 0.0000 0.0 0
M  V30 4 N 5.3348 4.6201 0.0 0
M  V30 5 C 4.0012 3.8501 0.0 0
M  V30 6 O 2.6673 4.6201 0.0 0
M  V30 7 O 4.0012 2.3101 0.0 0
M  V30 8 C 1.3337 3.8501 0.0 0
M  V30 9 C 2.1037 2.5164 0.0 0
M  V30 10 C 0.0000 3.0801 0.0 0
M  V30 11 C 0.5637 5.1838 0.0 0
M  V30 12 C 9.3360 2.3101 0.0 0
M  V30 13 C 9.3360 3.8501 0.0 0
M  V30 14 C 8.0022 1.5400 0.0 0
M  V30 15 C 8.0022 4.6201 0.0 0
M  V30 16 C 6.6685 2.3101 0.0 0
M  V30 17 C 6.6685 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 4 5
M  V30 5 1 4 17
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 8 11
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Carbamic acid, N-[4-[[(2,6-dioxo-3-piperidinyl)amino]carbonyl]phenyl]-, 1,1-d...
C17H21N3O5
2845386-65-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.5738 4.0011 0.0 0
M  V30 2 N 11.3438 2.6675 0.0 0
M  V30 3 O 11.3438 5.3348 0.0 0
M  V30 4 N 4.4137 4.0011 0.0 0
M  V30 5 C 3.6437 5.3348 0.0 0
M  V30 6 O 2.1037 5.3348 0.0 0
M  V30 7 O 4.4137 6.6686 0.0 0
M  V30 8 C 1.3337 6.6686 0.0 0
M  V30 9 C 0.0000 5.8986 0.0 0
M  V30 10 C 0.5636 8.0022 0.0 0
M  V30 11 C 2.6673 7.4386 0.0 0
M  V30 12 O 12.8838 0.0000 0.0 0
M  V30 13 O 17.5038 2.6675 0.0 0
M  V30 14 C 9.0337 4.0011 0.0 0
M  V30 15 C 8.2637 5.3348 0.0 0
M  V30 16 C 8.2637 2.6675 0.0 0
M  V30 17 C 6.7237 5.3348 0.0 0
M  V30 18 C 6.7237 2.6675 0.0 0
M  V30 19 C 5.9537 4.0011 0.0 0
M  V30 20 C 12.8838 2.6675 0.0 0
M  V30 21 C 13.6538 1.3337 0.0 0
M  V30 22 C 13.6538 4.0011 0.0 0
M  V30 23 N 15.1938 1.3337 0.0 0
M  V30 24 C 15.1938 4.0011 0.0 0
M  V30 25 C 15.9638 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 20
M  V30 5 1 4 5
M  V30 6 1 4 19
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 1 6 8
M  V30 10 1 8 9
M  V30 11 1 8 10
M  V30 12 1 8 11
M  V30 13 2 12 21
M  V30 14 2 13 25
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2353-44-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 66493-39-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2845386-65-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38469848
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and synthesis of novel cereblon binders for use in targeted
protein degradation
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Norris, Stephen; Ba, Xiaochu; Rhodes, Jayce; Huang, Dehua; Khambatta,
Gody; Buenviaje, Jennifer; Nayak, Surendra; Meiring, Joseph; Reiss,
Samantha; Xu, Shuichan; Shi, Lihong; Whitefield, Brandon; Alexander,
Matt; Horn, Evan J.; Correa, Matthew; Tehrani, Lida; Hansen, Joshua D.;
Papa, Patrick; Mortensen, Deborah S.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(23), 16388-16409

$RFMT $RIREG SCHEME393 STEP1
$RXN



  2  1
$MOL
3,4-Dimethoxyphenethylamine
C10H15NO2
120-20-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3349 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3349 0.0 0
M  V30 7 N 9.2400 5.3349 0.0 0
M  V30 8 C 3.0800 2.6674 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.0800 5.3349 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 4.6200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Methyl-3-indoleacetic acid
C11H11NO2
1912-47-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.5369 1.7847 0.0 0
M  V30 2 C 1.0304 1.4645 0.0 0
M  V30 3 O 0.0000 2.6091 0.0 0
M  V30 4 O 0.5546 0.0000 0.0 0
M  V30 5 C 8.4784 2.9553 0.0 0
M  V30 6 C 4.4773 3.7253 0.0 0
M  V30 7 C 4.4773 5.2653 0.0 0
M  V30 8 C 3.0127 3.2494 0.0 0
M  V30 9 C 5.8111 2.9553 0.0 0
M  V30 10 N 3.0127 5.7411 0.0 0
M  V30 11 C 5.8111 6.0353 0.0 0
M  V30 12 C 2.1075 4.4953 0.0 0
M  V30 13 C 7.1447 3.7253 0.0 0
M  V30 14 C 7.1447 5.2653 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 13
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 12
M  V30 14 1 11 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)ethyl]-5-methyl-1H-indole-3-acetamide
C21H24N2O3
2565618-07-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.0550 6.6684 0.0 0
M  V30 2 C 7.5950 6.6684 0.0 0
M  V30 3 N 8.3650 5.3348 0.0 0
M  V30 4 O 8.3650 8.0021 0.0 0
M  V30 5 C 9.9050 5.3348 0.0 0
M  V30 6 C 10.6750 4.0011 0.0 0
M  V30 7 C 0.0000 6.5780 0.0 0
M  V30 8 O 15.2951 1.3336 0.0 0
M  V30 9 C 14.5251 0.0000 0.0 0
M  V30 10 O 16.8351 4.0011 0.0 0
M  V30 11 C 17.6051 5.3348 0.0 0
M  V30 12 C 3.7535 8.1631 0.0 0
M  V30 13 C 3.4333 9.6694 0.0 0
M  V30 14 C 5.2850 8.0021 0.0 0
M  V30 15 C 2.6091 7.1326 0.0 0
M  V30 16 N 4.7670 10.4394 0.0 0
M  V30 17 C 1.9686 10.1453 0.0 0
M  V30 18 C 5.9115 9.4090 0.0 0
M  V30 19 C 1.1444 7.6086 0.0 0
M  V30 20 C 0.8242 9.1149 0.0 0
M  V30 21 C 12.2151 4.0011 0.0 0
M  V30 22 C 12.9851 2.6673 0.0 0
M  V30 23 C 12.9851 5.3348 0.0 0
M  V30 24 C 14.5251 2.6673 0.0 0
M  V30 25 C 14.5251 5.3348 0.0 0
M  V30 26 C 15.2951 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 21
M  V30 8 1 7 19
M  V30 9 1 8 9
M  V30 10 1 8 24
M  V30 11 1 10 11
M  V30 12 1 10 26
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 2 14 18
M  V30 19 1 15 19
M  V30 20 1 16 18
M  V30 21 1 17 20
M  V30 22 2 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 120-20-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1912-47-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2565618-07-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23040801
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME394 STEP1
$RXN



  2  1
$MOL
1H-Indole-3-propanoic acid
C11H11NO2
830-96-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7533 2.6218 0.0 0
M  V30 2 C 7.0869 1.8518 0.0 0
M  V30 3 C 8.4206 2.6218 0.0 0
M  V30 4 O 9.7544 1.8518 0.0 0
M  V30 5 O 8.4206 4.1618 0.0 0
M  V30 6 C 3.0127 2.4782 0.0 0
M  V30 7 C 4.4196 1.8518 0.0 0
M  V30 8 C 1.9823 1.3338 0.0 0
M  V30 9 C 2.5368 3.9429 0.0 0
M  V30 10 C 4.2586 0.3202 0.0 0
M  V30 11 N 2.7523 0.0000 0.0 0
M  V30 12 C 0.4759 1.6540 0.0 0
M  V30 13 C 1.0306 4.2630 0.0 0
M  V30 14 C 0.0000 3.1185 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 2 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 11
M  V30 14 1 12 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Ethoxy-3-methoxybenzeneethanamine
C11H17NO2
36377-59-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.8500 1.3338 0.0 0
M  V30 2 C 4.6200 0.0000 0.0 0
M  V30 3 O 2.3100 4.0011 0.0 0
M  V30 4 C 1.5400 5.3349 0.0 0
M  V30 5 C 0.0000 5.3349 0.0 0
M  V30 6 C 8.4700 4.0011 0.0 0
M  V30 7 C 9.2400 5.3349 0.0 0
M  V30 8 N 10.7800 5.3349 0.0 0
M  V30 9 C 4.6200 2.6674 0.0 0
M  V30 10 C 3.8500 4.0011 0.0 0
M  V30 11 C 6.1600 2.6674 0.0 0
M  V30 12 C 4.6200 5.3349 0.0 0
M  V30 13 C 6.9300 4.0011 0.0 0
M  V30 14 C 6.1600 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 3 4
M  V30 4 1 3 10
M  V30 5 1 4 5
M  V30 6 1 6 7
M  V30 7 1 6 13
M  V30 8 1 7 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(4-Ethoxy-3-methoxyphenyl)ethyl]-1H-indole-3-propanamide
C22H26N2O3
2358754-53-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 13.3372 4.6201 0.0 0
M  V30 2 C 12.0035 5.3901 0.0 0
M  V30 3 C 10.6697 4.6201 0.0 0
M  V30 4 N 9.3360 5.3901 0.0 0
M  V30 5 O 10.6697 3.0801 0.0 0
M  V30 6 C 8.0023 4.6201 0.0 0
M  V30 7 C 6.6687 5.3901 0.0 0
M  V30 8 O 1.3338 5.3901 0.0 0
M  V30 9 C 1.3338 6.9302 0.0 0
M  V30 10 O 1.3338 2.3101 0.0 0
M  V30 11 C 1.3338 0.7700 0.0 0
M  V30 12 C 0.0000 0.0000 0.0 0
M  V30 13 C 16.0778 4.7636 0.0 0
M  V30 14 C 14.6708 5.3901 0.0 0
M  V30 15 C 17.1082 5.9082 0.0 0
M  V30 16 C 16.5537 3.2991 0.0 0
M  V30 17 C 14.8318 6.9217 0.0 0
M  V30 18 N 16.3382 7.2419 0.0 0
M  V30 19 C 18.6145 5.5880 0.0 0
M  V30 20 C 18.0600 2.9789 0.0 0
M  V30 21 C 19.0906 4.1233 0.0 0
M  V30 22 C 5.3348 4.6201 0.0 0
M  V30 23 C 4.0012 5.3901 0.0 0
M  V30 24 C 5.3348 3.0801 0.0 0
M  V30 25 C 2.6675 4.6201 0.0 0
M  V30 26 C 4.0012 2.3101 0.0 0
M  V30 27 C 2.6675 3.0801 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 22
M  V30 9 1 8 9
M  V30 10 1 8 25
M  V30 11 1 10 11
M  V30 12 1 10 27
M  V30 13 1 11 12
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 2 14 17
M  V30 18 1 15 18
M  V30 19 2 15 19
M  V30 20 1 16 20
M  V30 21 1 17 18
M  V30 22 1 19 21
M  V30 23 2 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 830-96-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 36377-59-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2358754-53-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40818683
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Optimization of Tetrahydroisoquinoline Derivatives To
Enhance Lysosome Biogenesis as Preclinical Candidates for the Treatment
of Alzheimer's Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhou, Jianhui; Wang, Ning; Wang, Mengxue; Hu, Yuting; Zhang, Zhenwei; Gu,
Zhiyong; Wang, Jing; Shou, Haowen; Cheng, Xi; Liu, Hong; Li, Yang; Zhou,
Yu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(11), 8836-8861

$RFMT $RIREG SCHEME395 STEP1
$RXN



  2  1
$MOL
2,5-Dichlorobenzoic acid
C7H4Cl2O2
50-79-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 Cl 1.3338 4.6201 0.0 0
M  V30 5 Cl 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Cysteine, O-methyl-L-seryl-S-methyl-, methyl ester, 2,2,2-trifluoroacetate ...
C9H18N2O4S.C2HF3O2
2387522-87-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8501 9.1849 0.0 0 CFG=1
M  V30 2 N 4.6201 10.5186 0.0 0
M  V30 3 C 2.3101 9.1849 0.0 0
M  V30 4 C 4.6201 7.8512 0.0 0
M  V30 5 C 6.1601 10.5186 0.0 0
M  V30 6 O 1.5400 10.5186 0.0 0
M  V30 7 O 1.5400 7.8512 0.0 0
M  V30 8 S 3.8501 6.5174 0.0 0
M  V30 9 C 6.9302 11.8524 0.0 0 CFG=1
M  V30 10 O 6.9302 9.1849 0.0 0
M  V30 11 C 0.0000 10.5186 0.0 0
M  V30 12 C 4.6201 5.1837 0.0 0
M  V30 13 C 8.4702 11.8524 0.0 0
M  V30 14 N 6.1601 13.1860 0.0 0
M  V30 15 O 9.2402 13.1860 0.0 0
M  V30 16 C 10.7802 13.1860 0.0 0
M  V30 17 C 4.7233 2.3101 0.0 0
M  V30 18 C 6.0570 1.5400 0.0 0
M  V30 19 F 5.4933 3.6437 0.0 0
M  V30 20 F 3.3896 3.0801 0.0 0
M  V30 21 F 3.9533 0.9764 0.0 0
M  V30 22 O 7.3906 2.3101 0.0 0
M  V30 23 O 6.0570 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 1 17 20
M  V30 19 1 17 21
M  V30 20 1 18 22
M  V30 21 2 18 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(2,5-Dichlorobenzoyl)-O-methyl-L-seryl-S-methyl-L-cysteine methyl ester
C16H20Cl2N2O5S
2387522-88-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 3.8500 0.0 0
M  V30 2 N 5.3348 4.6201 0.0 0
M  V30 3 O 4.0010 2.3100 0.0 0
M  V30 4 C 6.6684 3.8500 0.0 0 CFG=1
M  V30 5 C 8.0021 4.6201 0.0 0
M  V30 6 C 6.6684 2.3100 0.0 0
M  V30 7 N 9.3357 3.8500 0.0 0
M  V30 8 O 8.0021 6.1601 0.0 0
M  V30 9 O 8.0021 1.5400 0.0 0
M  V30 10 C 10.6695 4.6201 0.0 0 CFG=1
M  V30 11 C 8.0021 0.0000 0.0 0
M  V30 12 C 12.0032 3.8500 0.0 0
M  V30 13 C 10.6695 6.1601 0.0 0
M  V30 14 O 13.3369 4.6201 0.0 0
M  V30 15 O 12.0032 2.3100 0.0 0
M  V30 16 S 12.0032 6.9301 0.0 0
M  V30 17 C 14.6705 3.8500 0.0 0
M  V30 18 C 12.0032 8.4701 0.0 0
M  V30 19 Cl 1.3337 2.3100 0.0 0
M  V30 20 Cl 1.3337 8.4701 0.0 0
M  V30 21 C 2.6673 4.6201 0.0 0
M  V30 22 C 1.3337 3.8500 0.0 0
M  V30 23 C 2.6673 6.1601 0.0 0
M  V30 24 C 0.0000 4.6201 0.0 0
M  V30 25 C 1.3337 6.9301 0.0 0
M  V30 26 C 0.0000 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 21
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 10 13 CFG=1
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 16 18
M  V30 19 1 19 22
M  V30 20 1 20 25
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 2 23 25
M  V30 25 2 24 26
M  V30 26 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 50-79-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2387522-87-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2387522-88-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545310
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME396 STEP1
$RXN



  2  1
$MOL
Picolinic acid
C6H5NO2
98-98-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 N 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Urea, N-[4-[(1E)-2-(3-aminophenyl)ethenyl]phenyl]-N-[(tetrahydro-2H-pyran-4-...
C21H25N3O2
3054131-11-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 13.3372 2.3101 0.0 0
M  V30 2 C 14.6708 3.0801 0.0 0
M  V30 3 N 8.0023 5.3901 0.0 0
M  V30 4 C 6.6685 4.6201 0.0 0
M  V30 5 N 5.3348 5.3901 0.0 0
M  V30 6 O 6.6685 3.0801 0.0 0
M  V30 7 C 4.0012 4.6201 0.0 0
M  V30 8 N 20.0057 3.0801 0.0 0
M  V30 9 C 12.0033 3.0801 0.0 0
M  V30 10 C 12.0033 4.6201 0.0 0
M  V30 11 C 10.6697 2.3101 0.0 0
M  V30 12 C 10.6697 5.3901 0.0 0
M  V30 13 C 9.3360 3.0801 0.0 0
M  V30 14 C 9.3360 4.6201 0.0 0
M  V30 15 C 16.0045 2.3101 0.0 0
M  V30 16 C 17.3382 3.0801 0.0 0
M  V30 17 C 16.0045 0.7700 0.0 0
M  V30 18 C 18.6720 2.3101 0.0 0
M  V30 19 C 17.3382 0.0000 0.0 0
M  V30 20 C 18.6720 0.7700 0.0 0
M  V30 21 C 2.6675 5.3901 0.0 0
M  V30 22 C 2.6675 6.9302 0.0 0
M  V30 23 C 1.3337 4.6201 0.0 0
M  V30 24 C 1.3337 7.7002 0.0 0
M  V30 25 C 0.0000 5.3901 0.0 0
M  V30 26 O 0.0000 6.9302 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 9
M  V30 3 1 2 15
M  V30 4 1 3 4
M  V30 5 1 3 14
M  V30 6 1 4 5
M  V30 7 2 4 6
M  V30 8 1 5 7
M  V30 9 1 7 21
M  V30 10 1 8 18
M  V30 11 2 9 10
M  V30 12 1 9 11
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 1 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Pyridinecarboxamide, N-[3-[(1E)-2-[4-[[[[(tetrahydro-2H-pyran-4-yl)methyl]a...
C27H28N4O3
3054131-12-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 4.6201 0.0 0
M  V30 2 C 4.0010 5.3901 0.0 0
M  V30 3 O 4.0010 6.9302 0.0 0
M  V30 4 C 10.6697 4.6201 0.0 0
M  V30 5 C 12.0033 5.3901 0.0 0
M  V30 6 N 17.3382 2.3101 0.0 0
M  V30 7 C 18.6718 3.0801 0.0 0
M  V30 8 N 20.0055 2.3101 0.0 0
M  V30 9 O 18.6718 4.6201 0.0 0
M  V30 10 C 21.3393 3.0801 0.0 0
M  V30 11 C 6.6685 5.3901 0.0 0
M  V30 12 C 8.0022 4.6201 0.0 0
M  V30 13 C 6.6685 6.9302 0.0 0
M  V30 14 C 9.3358 5.3901 0.0 0
M  V30 15 C 8.0022 7.7002 0.0 0
M  V30 16 C 9.3358 6.9302 0.0 0
M  V30 17 C 2.6673 4.6201 0.0 0
M  V30 18 C 2.6673 3.0801 0.0 0
M  V30 19 N 1.3337 5.3901 0.0 0
M  V30 20 C 1.3337 2.3101 0.0 0
M  V30 21 C 0.0000 4.6201 0.0 0
M  V30 22 C 0.0000 3.0801 0.0 0
M  V30 23 C 13.3370 4.6201 0.0 0
M  V30 24 C 14.6707 5.3901 0.0 0
M  V30 25 C 13.3370 3.0801 0.0 0
M  V30 26 C 16.0045 4.6201 0.0 0
M  V30 27 C 14.6707 2.3101 0.0 0
M  V30 28 C 16.0045 3.0801 0.0 0
M  V30 29 C 22.6730 2.3101 0.0 0
M  V30 30 C 22.6730 0.7700 0.0 0
M  V30 31 C 24.0067 3.0801 0.0 0
M  V30 32 C 24.0067 0.0000 0.0 0
M  V30 33 C 25.3403 2.3101 0.0 0
M  V30 34 O 25.3403 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 2 2 3
M  V30 4 1 2 17
M  V30 5 2 4 5
M  V30 6 1 4 14
M  V30 7 1 5 23
M  V30 8 1 6 7
M  V30 9 1 6 28
M  V30 10 1 7 8
M  V30 11 2 7 9
M  V30 12 1 8 10
M  V30 13 1 10 29
M  V30 14 2 11 12
M  V30 15 1 11 13
M  V30 16 1 12 14
M  V30 17 2 13 15
M  V30 18 2 14 16
M  V30 19 1 15 16
M  V30 20 2 17 18
M  V30 21 1 17 19
M  V30 22 1 18 20
M  V30 23 2 19 21
M  V30 24 2 20 22
M  V30 25 1 21 22
M  V30 26 2 23 24
M  V30 27 1 23 25
M  V30 28 1 24 26
M  V30 29 2 25 27
M  V30 30 2 26 28
M  V30 31 1 27 28
M  V30 32 1 29 30
M  V30 33 1 29 31
M  V30 34 1 30 32
M  V30 35 1 31 33
M  V30 36 1 32 34
M  V30 37 1 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 98-98-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3054131-11-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3054131-12-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39248683
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a novel lead characterized by a stilbene-extended scaffold
against sepsis as soluble epoxide hydrolase inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Feng, Zi-Qiang; Ding, Jing; Zhu, Min-Zhen; Xie, Wei-Song; Liu, Rui-Chen;
Liu, Si-Si; Liu, Si-Meng; Yu, Ming-Jia; Zhu, Xin-Hong; Liang, Jian-Hua
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 266116113

$RFMT $RIREG SCHEME397 STEP1
$RXN



  2  1
$MOL
Heptanoic acid, 7-amino-, methyl ester
C8H17NO2
39979-08-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 6.6685 2.3101 0.0 0
M  V30 4 C 2.6673 1.5400 0.0 0
M  V30 5 C 8.0022 1.5400 0.0 0
M  V30 6 O 1.3337 2.3101 0.0 0
M  V30 7 O 2.6673 0.0000 0.0 0
M  V30 8 C 9.3360 2.3101 0.0 0
M  V30 9 C 0.0000 1.5400 0.0 0
M  V30 10 C 10.6697 1.5400 0.0 0
M  V30 11 N 12.0033 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-[[[(3,5-dimethyltricyclo[3.3.1.13,7]dec-1-yl)amino]carbonyl]a...
C20H26N2O3
3032415-34-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5213 4.6201 0.0 0
M  V30 2 C 6.8550 3.8501 0.0 0
M  V30 3 N 8.1887 4.6201 0.0 0
M  V30 4 O 6.8550 2.3101 0.0 0
M  V30 5 C 1.2902 5.4788 0.0 0
M  V30 6 C 3.4674 0.1329 0.0 0
M  V30 7 C 13.5235 1.5400 0.0 0
M  V30 8 O 14.8573 2.3101 0.0 0
M  V30 9 O 13.5235 0.0000 0.0 0
M  V30 10 C 4.1877 3.8501 0.0 0
M  V30 11 C 2.8994 4.6888 0.0 0
M  V30 12 C 4.2697 2.3153 0.0 0
M  V30 13 C 2.4938 3.8393 0.0 0
M  V30 14 C 1.6937 3.9925 0.0 0
M  V30 15 C 3.0641 1.6190 0.0 0
M  V30 16 C 1.2881 3.1431 0.0 0
M  V30 17 C 1.7760 2.4577 0.0 0
M  V30 18 C 0.0000 3.9814 0.0 0
M  V30 19 C 1.3703 1.6081 0.0 0
M  V30 20 C 9.5225 3.8501 0.0 0
M  V30 21 C 9.5225 2.3101 0.0 0
M  V30 22 C 10.8562 4.6201 0.0 0
M  V30 23 C 10.8562 1.5400 0.0 0
M  V30 24 C 12.1898 3.8501 0.0 0
M  V30 25 C 12.1898 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 20
M  V30 6 1 5 14
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 25
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 11 14
M  V30 15 1 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 1 15 17
M  V30 20 1 15 19
M  V30 21 1 16 18
M  V30 22 1 16 19
M  V30 23 2 20 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 2 22 24
M  V30 27 2 23 25
M  V30 28 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Heptanoic acid, 7-[[4-[[[(3,5-dimethyltricyclo[3.3.1.13,7]dec-1-yl)amino]carb...
C28H41N3O4
3032415-37-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5213 0.8587 0.0 0
M  V30 2 C 6.8550 1.6287 0.0 0
M  V30 3 N 8.1887 0.8587 0.0 0
M  V30 4 O 6.8550 3.1688 0.0 0
M  V30 5 C 1.2902 0.0000 0.0 0
M  V30 6 C 3.4674 5.3459 0.0 0
M  V30 7 C 13.5235 3.9388 0.0 0
M  V30 8 N 14.8572 3.1688 0.0 0
M  V30 9 O 13.5235 5.4788 0.0 0
M  V30 10 C 16.1910 3.9388 0.0 0
M  V30 11 C 17.5247 3.1688 0.0 0
M  V30 12 C 18.8583 3.9388 0.0 0
M  V30 13 C 20.1922 3.1688 0.0 0
M  V30 14 C 21.5258 3.9388 0.0 0
M  V30 15 C 22.8595 3.1688 0.0 0
M  V30 16 C 24.1932 3.9388 0.0 0
M  V30 17 O 25.5270 3.1688 0.0 0
M  V30 18 O 24.1932 5.4788 0.0 0
M  V30 19 C 26.8607 3.9388 0.0 0
M  V30 20 C 4.1875 1.6287 0.0 0
M  V30 21 C 2.8994 0.7900 0.0 0
M  V30 22 C 4.2697 3.1635 0.0 0
M  V30 23 C 2.4938 1.6395 0.0 0
M  V30 24 C 1.6936 1.4863 0.0 0
M  V30 25 C 3.0639 3.8598 0.0 0
M  V30 26 C 1.2881 2.3358 0.0 0
M  V30 27 C 1.7760 3.0211 0.0 0
M  V30 28 C 0.0000 1.4974 0.0 0
M  V30 29 C 1.3703 3.8707 0.0 0
M  V30 30 C 9.5223 1.6287 0.0 0
M  V30 31 C 9.5223 3.1688 0.0 0
M  V30 32 C 10.8562 0.8587 0.0 0
M  V30 33 C 10.8562 3.9388 0.0 0
M  V30 34 C 12.1898 1.6287 0.0 0
M  V30 35 C 12.1898 3.1688 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 30
M  V30 6 1 5 24
M  V30 7 1 6 25
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 35
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 16 18
M  V30 20 1 17 19
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 1 20 23
M  V30 24 1 21 24
M  V30 25 1 22 25
M  V30 26 1 23 26
M  V30 27 1 24 27
M  V30 28 1 24 28
M  V30 29 1 25 27
M  V30 30 1 25 29
M  V30 31 1 26 28
M  V30 32 1 26 29
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 31 33
M  V30 36 2 32 34
M  V30 37 2 33 35
M  V30 38 1 34 35
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 39979-08-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3032415-34-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3032415-37-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39248143
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for
the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced
Mortality
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chen, Yuanguang; Sun, Jianwen; Tong, Hua; Wang, Jieru; Cao, Ruolin; Xu,
Huashen; Chen, Lu; Morisseau, Christophe; Zhang, Maoying; Shi, Yajie;
Han, Chao; Zhuang, Junning; Jing, Yongkui; Liu, Zhongbo; Hammock, Bruce
D.; Chen, Guoliang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(3), 2095-2117

$RFMT $RIREG SCHEME398 STEP1
$RXN



  2  1
$MOL
N-tert-Butoxycarbonyl-D-phenylalanine
C14H19NO4
18942-49-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=2
M  V30 2 C 4.6201 4.0012 0.0 0
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6766 6.1048 0.0 0
M  V30 14 C 3.0801 4.0012 0.0 0
M  V30 15 C 2.3101 5.3348 0.0 0
M  V30 16 C 2.3101 2.6675 0.0 0
M  V30 17 C 0.7700 5.3348 0.0 0
M  V30 18 C 0.7700 2.6675 0.0 0
M  V30 19 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 14
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Alanine, 2-methyl-, phenylmethyl ester, 2,2,2-trifluoroacetate (1:1)
C11H15NO2.C2HF3O2
923012-11-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 6.7238 0.0 0
M  V30 2 O 5.3348 7.4938 0.0 0
M  V30 3 C 6.6685 6.7238 0.0 0
M  V30 4 C 8.0023 7.4938 0.0 0
M  V30 5 O 6.6685 5.1837 0.0 0
M  V30 6 C 8.7723 6.1601 0.0 0
M  V30 7 C 9.3360 8.2638 0.0 0
M  V30 8 N 7.2323 8.8274 0.0 0
M  V30 9 C 2.6675 7.4938 0.0 0
M  V30 10 C 1.3337 6.7238 0.0 0
M  V30 11 C 2.6675 9.0338 0.0 0
M  V30 12 C 0.0000 7.4938 0.0 0
M  V30 13 C 1.3337 9.8038 0.0 0
M  V30 14 C 0.0000 9.0338 0.0 0
M  V30 15 C 4.0012 2.3101 0.0 0
M  V30 16 C 5.3348 1.5400 0.0 0
M  V30 17 F 4.7712 3.6437 0.0 0
M  V30 18 F 2.6675 3.0801 0.0 0
M  V30 19 F 3.2311 0.9764 0.0 0
M  V30 20 O 6.6685 2.3101 0.0 0
M  V30 21 O 5.3348 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 4 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 15 18
M  V30 18 1 15 19
M  V30 19 1 16 20
M  V30 20 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(1,1-Dimethylethoxy)carbonyl]-D-phenylalanyl-2-methylalanine phenylmethyl ...
C25H32N2O5
2413279-28-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 5.3348 0.0 0 CFG=1
M  V30 2 C 5.3901 4.0012 0.0 0
M  V30 3 C 7.7002 5.3348 0.0 0
M  V30 4 N 5.3901 6.6685 0.0 0
M  V30 5 N 8.4702 6.6685 0.0 0
M  V30 6 O 8.4702 4.0012 0.0 0
M  V30 7 C 3.8501 6.6685 0.0 0
M  V30 8 C 10.0102 6.6685 0.0 0
M  V30 9 O 3.0801 8.0022 0.0 0
M  V30 10 O 3.0801 5.3348 0.0 0
M  V30 11 C 11.5503 6.6685 0.0 0
M  V30 12 C 10.0102 8.2085 0.0 0
M  V30 13 C 10.4088 5.1810 0.0 0
M  V30 14 C 1.5400 8.0022 0.0 0
M  V30 15 O 12.3203 8.0022 0.0 0
M  V30 16 O 12.3203 5.3348 0.0 0
M  V30 17 C 1.5400 6.4621 0.0 0
M  V30 18 C 0.0000 8.0022 0.0 0
M  V30 19 C 1.5400 9.5422 0.0 0
M  V30 20 C 13.8603 8.0022 0.0 0
M  V30 21 C 6.1601 2.6673 0.0 0
M  V30 22 C 7.7002 2.6673 0.0 0
M  V30 23 C 5.3901 1.3337 0.0 0
M  V30 24 C 8.4702 1.3337 0.0 0
M  V30 25 C 6.1601 0.0000 0.0 0
M  V30 26 C 7.7002 0.0000 0.0 0
M  V30 27 C 14.6303 9.3360 0.0 0
M  V30 28 C 13.8603 10.6697 0.0 0
M  V30 29 C 16.1704 9.3360 0.0 0
M  V30 30 C 14.6303 12.0033 0.0 0
M  V30 31 C 16.9404 10.6697 0.0 0
M  V30 32 C 16.1704 12.0033 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 21
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 1 8 13
M  V30 14 1 9 14
M  V30 15 1 11 15
M  V30 16 2 11 16
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 1 14 19
M  V30 20 1 15 20
M  V30 21 1 20 27
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 25
M  V30 26 2 24 26
M  V30 27 1 25 26
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 2 29 31
M  V30 32 2 30 32
M  V30 33 1 31 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 18942-49-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 923012-11-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2413279-28-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21978535
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM key intermediate
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel cilengitide-based cyclic RGD peptides as v3 integrin inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Meena, Chhuttan L.; Singh, Dharmendra; Weinmuller, Michael; Reichart,
Florian; Dangi, Abha; Marelli, Udaya Kiran; Zahler, Stefan; Sanjayan,
Gangadhar J.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(8), 127039

$RFMT $RIREG SCHEME399 STEP1
$RXN



  3  1
$MOL
8-(9-Fluorenylmethoxycarbonylamino)-3,6-dioxaoctanoic acid
C21H23NO6
166108-71-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7533 5.2310 0.0 0
M  V30 2 O 7.0870 4.4610 0.0 0
M  V30 3 C 8.4207 5.2310 0.0 0
M  V30 4 N 9.7545 4.4610 0.0 0
M  V30 5 O 8.4207 6.7710 0.0 0
M  V30 6 C 11.0881 5.2310 0.0 0
M  V30 7 C 12.4218 4.4610 0.0 0
M  V30 8 O 13.7554 5.2310 0.0 0
M  V30 9 C 15.0892 4.4610 0.0 0
M  V30 10 C 16.4229 5.2310 0.0 0
M  V30 11 O 17.7565 4.4610 0.0 0
M  V30 12 C 19.0902 5.2310 0.0 0
M  V30 13 C 20.4240 4.4610 0.0 0
M  V30 14 O 21.7577 5.2310 0.0 0
M  V30 15 O 20.4240 2.9209 0.0 0
M  V30 16 C 4.4197 4.4610 0.0 0
M  V30 17 C 3.0127 5.0873 0.0 0
M  V30 18 C 4.2586 2.9293 0.0 0
M  V30 19 C 1.9823 3.9429 0.0 0
M  V30 20 C 2.5369 6.5520 0.0 0
M  V30 21 C 2.7523 2.6091 0.0 0
M  V30 22 C 5.2892 1.7849 0.0 0
M  V30 23 C 0.4759 4.2631 0.0 0
M  V30 24 C 1.0304 6.8722 0.0 0
M  V30 25 C 2.2765 1.1445 0.0 0
M  V30 26 C 4.8132 0.3202 0.0 0
M  V30 27 C 0.0000 5.7276 0.0 0
M  V30 28 C 3.3069 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 17 20
M  V30 20 1 18 21
M  V30 21 2 18 22
M  V30 22 1 19 21
M  V30 23 2 19 23
M  V30 24 1 20 24
M  V30 25 2 21 25
M  V30 26 1 22 26
M  V30 27 1 23 27
M  V30 28 2 24 27
M  V30 29 1 25 28
M  V30 30 2 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
8-(9-Fluorenylmethoxycarbonylamino)-3,6-dioxaoctanoic acid
C21H23NO6
166108-71-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7533 5.2310 0.0 0
M  V30 2 O 7.0870 4.4610 0.0 0
M  V30 3 C 8.4207 5.2310 0.0 0
M  V30 4 N 9.7545 4.4610 0.0 0
M  V30 5 O 8.4207 6.7710 0.0 0
M  V30 6 C 11.0881 5.2310 0.0 0
M  V30 7 C 12.4218 4.4610 0.0 0
M  V30 8 O 13.7554 5.2310 0.0 0
M  V30 9 C 15.0892 4.4610 0.0 0
M  V30 10 C 16.4229 5.2310 0.0 0
M  V30 11 O 17.7565 4.4610 0.0 0
M  V30 12 C 19.0902 5.2310 0.0 0
M  V30 13 C 20.4240 4.4610 0.0 0
M  V30 14 O 21.7577 5.2310 0.0 0
M  V30 15 O 20.4240 2.9209 0.0 0
M  V30 16 C 4.4197 4.4610 0.0 0
M  V30 17 C 3.0127 5.0873 0.0 0
M  V30 18 C 4.2586 2.9293 0.0 0
M  V30 19 C 1.9823 3.9429 0.0 0
M  V30 20 C 2.5369 6.5520 0.0 0
M  V30 21 C 2.7523 2.6091 0.0 0
M  V30 22 C 5.2892 1.7849 0.0 0
M  V30 23 C 0.4759 4.2631 0.0 0
M  V30 24 C 1.0304 6.8722 0.0 0
M  V30 25 C 2.2765 1.1445 0.0 0
M  V30 26 C 4.8132 0.3202 0.0 0
M  V30 27 C 0.0000 5.7276 0.0 0
M  V30 28 C 3.3069 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 17 20
M  V30 20 1 18 21
M  V30 21 2 18 22
M  V30 22 1 19 21
M  V30 23 2 19 23
M  V30 24 1 20 24
M  V30 25 2 21 25
M  V30 26 1 22 26
M  V30 27 1 23 27
M  V30 28 2 24 27
M  V30 29 1 25 28
M  V30 30 2 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) hydrogen N-[18-(1,1-dimethylethoxy)-1,18-dioxooctadecyl...
C31H57NO7
1188328-39-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  39 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 4.6201 0.0 0 CFG=1
M  V30 2 N 5.3348 5.3901 0.0 0
M  V30 3 C 2.6673 5.3901 0.0 0
M  V30 4 C 4.0012 3.0801 0.0 0
M  V30 5 C 6.6685 4.6201 0.0 0
M  V30 6 O 2.6673 6.9302 0.0 0
M  V30 7 O 1.3337 4.6201 0.0 0
M  V30 8 C 2.6673 2.3101 0.0 0
M  V30 9 C 8.0022 5.3901 0.0 0
M  V30 10 O 6.6685 3.0801 0.0 0
M  V30 11 C 1.3337 7.7002 0.0 0
M  V30 12 C 2.6673 0.7700 0.0 0
M  V30 13 C 9.3360 4.6201 0.0 0
M  V30 14 C 0.5637 6.3665 0.0 0
M  V30 15 C 0.0000 8.4702 0.0 0
M  V30 16 C 2.1037 9.0338 0.0 0
M  V30 17 O 1.3337 0.0000 0.0 0
M  V30 18 O 4.0012 0.0000 0.0 0
M  V30 19 C 10.6697 5.3901 0.0 0
M  V30 20 C 12.0033 4.6201 0.0 0
M  V30 21 C 13.3370 5.3901 0.0 0
M  V30 22 C 14.6708 4.6201 0.0 0
M  V30 23 C 16.0045 5.3901 0.0 0
M  V30 24 C 17.3382 4.6201 0.0 0
M  V30 25 C 18.6718 5.3901 0.0 0
M  V30 26 C 20.0057 4.6201 0.0 0
M  V30 27 C 21.3393 5.3901 0.0 0
M  V30 28 C 22.6730 4.6201 0.0 0
M  V30 29 C 24.0067 5.3901 0.0 0
M  V30 30 C 25.3405 4.6201 0.0 0
M  V30 31 C 26.6742 5.3901 0.0 0
M  V30 32 C 28.0078 4.6201 0.0 0
M  V30 33 C 29.3415 5.3901 0.0 0
M  V30 34 O 30.6753 4.6201 0.0 0
M  V30 35 O 29.3415 6.9302 0.0 0
M  V30 36 C 32.0090 5.3901 0.0 0
M  V30 37 C 32.7790 4.0564 0.0 0
M  V30 38 C 33.3427 6.1601 0.0 0
M  V30 39 C 31.2390 6.7238 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 1 11 15
M  V30 15 1 11 16
M  V30 16 1 12 17
M  V30 17 2 12 18
M  V30 18 1 13 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 2 33 35
M  V30 35 1 34 36
M  V30 36 1 36 37
M  V30 37 1 36 38
M  V30 38 1 36 39
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
41-(1,1-Dimethylethyl) (22S)-22-[(1,1-dimethylethoxy)carbonyl]-10,19,24-triox...
C43H79N3O13
1118767-16-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  59 58 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 26.1800 5.3347 0.0 0 CFG=2
M  V30 2 N 24.6400 5.3347 0.0 0
M  V30 3 C 26.9500 6.6684 0.0 0
M  V30 4 C 26.9500 4.0011 0.0 0
M  V30 5 C 23.8700 6.6684 0.0 0
M  V30 6 C 28.4900 6.6684 0.0 0
M  V30 7 O 26.1800 2.6673 0.0 0
M  V30 8 O 28.4900 4.0011 0.0 0
M  V30 9 C 22.3300 6.6684 0.0 0
M  V30 10 O 24.6400 8.0021 0.0 0
M  V30 11 C 29.2600 8.0021 0.0 0
M  V30 12 C 26.9500 1.3336 0.0 0
M  V30 13 C 21.5600 8.0020 0.0 0
M  V30 14 N 30.8000 8.0021 0.0 0
M  V30 15 O 28.4900 9.3358 0.0 0
M  V30 16 C 25.6164 0.5636 0.0 0
M  V30 17 C 27.7200 0.0000 0.0 0
M  V30 18 C 28.2836 2.1036 0.0 0
M  V30 19 C 20.0200 8.0020 0.0 0
M  V30 20 C 31.5700 9.3358 0.0 0
M  V30 21 C 19.2500 9.3358 0.0 0
M  V30 22 C 33.1100 9.3358 0.0 0
M  V30 23 C 17.7100 9.3358 0.0 0
M  V30 24 O 33.8800 10.6694 0.0 0
M  V30 25 C 16.9400 10.6694 0.0 0
M  V30 26 C 35.4200 10.6694 0.0 0
M  V30 27 C 15.4000 10.6694 0.0 0
M  V30 28 C 36.1900 12.0031 0.0 0
M  V30 29 C 14.6300 12.0031 0.0 0
M  V30 30 O 37.7300 12.0031 0.0 0
M  V30 31 C 13.0900 12.0031 0.0 0
M  V30 32 C 38.5000 13.3369 0.0 0
M  V30 33 C 12.3200 13.3367 0.0 0
M  V30 34 C 40.0400 13.3369 0.0 0
M  V30 35 C 10.7800 13.3367 0.0 0
M  V30 36 N 40.8100 14.6705 0.0 0
M  V30 37 O 40.8100 12.0031 0.0 0
M  V30 38 C 10.0100 14.6705 0.0 0
M  V30 39 C 42.3500 14.6705 0.0 0
M  V30 40 C 8.4700 14.6705 0.0 0
M  V30 41 C 43.1200 16.0041 0.0 0
M  V30 42 C 7.7000 16.0041 0.0 0
M  V30 43 O 44.6600 16.0041 0.0 0
M  V30 44 C 6.1600 16.0041 0.0 0
M  V30 45 C 45.4300 17.3378 0.0 0
M  V30 46 C 5.3900 17.3378 0.0 0
M  V30 47 C 46.9700 17.3378 0.0 0
M  V30 48 C 3.8500 17.3378 0.0 0
M  V30 49 O 47.7400 18.6716 0.0 0
M  V30 50 O 3.0800 18.6714 0.0 0
M  V30 51 O 3.0800 16.0041 0.0 0
M  V30 52 C 49.2800 18.6716 0.0 0
M  V30 53 C 1.5400 18.6714 0.0 0
M  V30 54 C 50.0500 20.0052 0.0 0
M  V30 55 C 1.5400 20.2114 0.0 0
M  V30 56 C 0.0000 18.6714 0.0 0
M  V30 57 C 1.5400 17.1314 0.0 0
M  V30 58 O 51.5900 20.0052 0.0 0
M  V30 59 O 49.2800 21.3389 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 12 17
M  V30 17 1 12 18
M  V30 18 1 13 19
M  V30 19 1 14 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 29 1 28 30
M  V30 30 1 29 31
M  V30 31 1 30 32
M  V30 32 1 31 33
M  V30 33 1 32 34
M  V30 34 1 33 35
M  V30 35 1 34 36
M  V30 36 2 34 37
M  V30 37 1 35 38
M  V30 38 1 36 39
M  V30 39 1 38 40
M  V30 40 1 39 41
M  V30 41 1 40 42
M  V30 42 1 41 43
M  V30 43 1 42 44
M  V30 44 1 43 45
M  V30 45 1 44 46
M  V30 46 1 45 47
M  V30 47 1 46 48
M  V30 48 1 47 49
M  V30 49 1 48 50
M  V30 50 2 48 51
M  V30 51 1 49 52
M  V30 52 1 50 53
M  V30 53 1 52 54
M  V30 54 1 53 55
M  V30 55 1 53 56
M  V30 56 1 53 57
M  V30 57 1 54 58
M  V30 58 2 54 59
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 166108-71-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1188328-39-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1118767-16-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24126943
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 8
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 108-24-7
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 110-89-4
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 693-13-0
$DTYPE RXN:VAR(1):RGT(5):CAS_RN
$DATUM 3849-21-6
$DTYPE RXN:VAR(1):RGT(6):CAS_RN
$DATUM 920-66-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 67-56-1
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM solid-supported reaction, CTC resin used (stage 1)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Copper(II) lysinate and pseudoproline assistance in the convergent
synthesis of the GLP-1 receptor agonists Liraglutide and Semaglutide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guryanov, Ivan; Orlandin, Andrea; De Paola, Ivan; Viola, Angelo; Biondi,
Barbara; Badocco, Denis; Formaggio, Fernando; Ricci, Antonio; Cabri,
Walter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(7), 1598-1611

$RFMT $RIREG SCHEME400 STEP1
$RXN



  2  1
$MOL
Hexanoic acid, 6-amino-, methyl ester
C7H15NO2
2780-89-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 O 1.3337 2.3101 0.0 0
M  V30 4 O 2.6673 0.0000 0.0 0
M  V30 5 C 5.3348 1.5400 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 6.6685 2.3101 0.0 0
M  V30 8 C 8.0023 1.5400 0.0 0
M  V30 9 C 9.3360 2.3101 0.0 0
M  V30 10 N 10.6697 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-[[[(3,5-dimethyltricyclo[3.3.1.13,7]dec-1-yl)amino]carbonyl]a...
C20H26N2O3
3032415-34-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5213 4.6201 0.0 0
M  V30 2 C 6.8550 3.8501 0.0 0
M  V30 3 N 8.1887 4.6201 0.0 0
M  V30 4 O 6.8550 2.3101 0.0 0
M  V30 5 C 1.2902 5.4788 0.0 0
M  V30 6 C 3.4674 0.1329 0.0 0
M  V30 7 C 13.5235 1.5400 0.0 0
M  V30 8 O 14.8573 2.3101 0.0 0
M  V30 9 O 13.5235 0.0000 0.0 0
M  V30 10 C 4.1877 3.8501 0.0 0
M  V30 11 C 2.8994 4.6888 0.0 0
M  V30 12 C 4.2697 2.3153 0.0 0
M  V30 13 C 2.4938 3.8393 0.0 0
M  V30 14 C 1.6937 3.9925 0.0 0
M  V30 15 C 3.0641 1.6190 0.0 0
M  V30 16 C 1.2881 3.1431 0.0 0
M  V30 17 C 1.7760 2.4577 0.0 0
M  V30 18 C 0.0000 3.9814 0.0 0
M  V30 19 C 1.3703 1.6081 0.0 0
M  V30 20 C 9.5225 3.8501 0.0 0
M  V30 21 C 9.5225 2.3101 0.0 0
M  V30 22 C 10.8562 4.6201 0.0 0
M  V30 23 C 10.8562 1.5400 0.0 0
M  V30 24 C 12.1898 3.8501 0.0 0
M  V30 25 C 12.1898 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 20
M  V30 6 1 5 14
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 25
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 11 14
M  V30 15 1 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 1 15 17
M  V30 20 1 15 19
M  V30 21 1 16 18
M  V30 22 1 16 19
M  V30 23 2 20 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 2 22 24
M  V30 27 2 23 25
M  V30 28 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Hexanoic acid, 6-[[4-[[[(3,5-dimethyltricyclo[3.3.1.13,7]dec-1-yl)amino]carbo...
C27H39N3O4
3032415-36-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5213 4.6201 0.0 0
M  V30 2 C 6.8550 3.8501 0.0 0
M  V30 3 N 8.1887 4.6201 0.0 0
M  V30 4 O 6.8550 2.3101 0.0 0
M  V30 5 C 1.2902 5.4788 0.0 0
M  V30 6 C 3.4674 0.1329 0.0 0
M  V30 7 C 13.5235 1.5400 0.0 0
M  V30 8 N 14.8573 2.3101 0.0 0
M  V30 9 O 13.5235 0.0000 0.0 0
M  V30 10 C 16.1910 1.5400 0.0 0
M  V30 11 C 17.5247 2.3101 0.0 0
M  V30 12 C 18.8583 1.5400 0.0 0
M  V30 13 C 20.1922 2.3101 0.0 0
M  V30 14 C 21.5258 1.5400 0.0 0
M  V30 15 C 22.8595 2.3101 0.0 0
M  V30 16 O 24.1932 1.5400 0.0 0
M  V30 17 O 22.8595 3.8501 0.0 0
M  V30 18 C 25.5270 2.3101 0.0 0
M  V30 19 C 4.1877 3.8501 0.0 0
M  V30 20 C 2.8994 4.6888 0.0 0
M  V30 21 C 4.2697 2.3153 0.0 0
M  V30 22 C 2.4938 3.8393 0.0 0
M  V30 23 C 1.6937 3.9925 0.0 0
M  V30 24 C 3.0641 1.6190 0.0 0
M  V30 25 C 1.2881 3.1431 0.0 0
M  V30 26 C 1.7760 2.4577 0.0 0
M  V30 27 C 0.0000 3.9814 0.0 0
M  V30 28 C 1.3703 1.6081 0.0 0
M  V30 29 C 9.5225 3.8501 0.0 0
M  V30 30 C 9.5225 2.3101 0.0 0
M  V30 31 C 10.8562 4.6201 0.0 0
M  V30 32 C 10.8562 1.5400 0.0 0
M  V30 33 C 12.1898 3.8501 0.0 0
M  V30 34 C 12.1898 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 29
M  V30 6 1 5 23
M  V30 7 1 6 24
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 34
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 15 17
M  V30 19 1 16 18
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 19 22
M  V30 23 1 20 23
M  V30 24 1 21 24
M  V30 25 1 22 25
M  V30 26 1 23 26
M  V30 27 1 23 27
M  V30 28 1 24 26
M  V30 29 1 24 28
M  V30 30 1 25 27
M  V30 31 1 25 28
M  V30 32 2 29 30
M  V30 33 1 29 31
M  V30 34 1 30 32
M  V30 35 2 31 33
M  V30 36 2 32 34
M  V30 37 1 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2780-89-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3032415-34-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3032415-36-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39248129
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for
the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced
Mortality
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chen, Yuanguang; Sun, Jianwen; Tong, Hua; Wang, Jieru; Cao, Ruolin; Xu,
Huashen; Chen, Lu; Morisseau, Christophe; Zhang, Maoying; Shi, Yajie;
Han, Chao; Zhuang, Junning; Jing, Yongkui; Liu, Zhongbo; Hammock, Bruce
D.; Chen, Guoliang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(3), 2095-2117

$RFMT $RIREG SCHEME401 STEP1
$RXN



  2  1
$MOL
5-Hydroxy-2-nitrobenzoic acid
C7H5NO5
610-37-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.7700 4.0011 0.0 0 VAL=5
M  V30 2 O 0.0000 5.3349 0.0 0
M  V30 3 O 0.0000 2.6674 0.0 0
M  V30 4 C 2.3100 1.3338 0.0 0
M  V30 5 O 0.7700 1.3338 0.0 0
M  V30 6 O 3.0800 0.0000 0.0 0
M  V30 7 O 6.9300 4.0011 0.0 0
M  V30 8 C 2.3100 4.0011 0.0 0
M  V30 9 C 3.0800 2.6674 0.0 0
M  V30 10 C 3.0800 5.3349 0.0 0
M  V30 11 C 4.6200 2.6674 0.0 0
M  V30 12 C 4.6200 5.3349 0.0 0
M  V30 13 C 5.3900 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 9
M  V30 7 1 7 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2,6-Piperidinedione, 3-amino-, hydrochloride (1:1)
C5H8N2O2.ClH
24666-56-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.5400 1.5400 0.0 0
M  V30 2 N 0.0000 4.2073 0.0 0
M  V30 3 O 6.1601 4.2073 0.0 0
M  V30 4 C 2.3101 2.8737 0.0 0
M  V30 5 C 1.5400 4.2073 0.0 0
M  V30 6 N 3.8501 2.8737 0.0 0
M  V30 7 C 2.3101 5.5410 0.0 0
M  V30 8 C 4.6201 4.2073 0.0 0
M  V30 9 C 3.8501 5.5410 0.0 0
M  V30 10 Cl 3.0801 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 4
M  V30 2 1 2 5
M  V30 3 2 3 8
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(2,6-Dioxo-3-piperidinyl)-5-hydroxy-2-nitrobenzamide
C12H11N3O6
1924692-26-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 4.0011 0.0 0
M  V30 2 N 5.3900 5.3347 0.0 0
M  V30 3 O 5.3900 2.6674 0.0 0
M  V30 4 N 3.0800 1.3336 0.0 0 VAL=5
M  V30 5 O 4.6200 1.3336 0.0 0
M  V30 6 O 2.3100 0.0000 0.0 0
M  V30 7 O 0.0000 6.6685 0.0 0
M  V30 8 O 6.9300 8.0021 0.0 0
M  V30 9 O 11.5500 5.3347 0.0 0
M  V30 10 C 3.0800 4.0011 0.0 0
M  V30 11 C 2.3100 2.6674 0.0 0
M  V30 12 C 2.3100 5.3347 0.0 0
M  V30 13 C 0.7700 2.6674 0.0 0
M  V30 14 C 0.7700 5.3347 0.0 0
M  V30 15 C 0.0000 4.0011 0.0 0
M  V30 16 C 6.9300 5.3347 0.0 0
M  V30 17 C 7.7000 6.6685 0.0 0
M  V30 18 C 7.7000 4.0011 0.0 0
M  V30 19 N 9.2400 6.6685 0.0 0
M  V30 20 C 9.2400 4.0011 0.0 0
M  V30 21 C 10.0100 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 16
M  V30 5 2 4 5
M  V30 6 2 4 6
M  V30 7 1 4 11
M  V30 8 1 7 14
M  V30 9 2 8 17
M  V30 10 2 9 21
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 610-37-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 24666-56-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1924692-26-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40486257
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and characterization of cereblon-mediated androgen receptor
proteolysis-targeting chimeras
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Takwale, Akshay D.; Jo, Seung-Hyun; Jeon, Yeong Uk; Kim, Hyung Soo; Shin,
Choong Hoon; Lee, Heung Kyoung; Ahn, Sunjoo; Lee, Chong Ock; Du Ha, Jae;
Kim, Jeong-Hoon; Hwang, Jong Yeon
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 208112769

$RFMT $RIREG SCHEME402 STEP1
$RXN



  3  3
$MOL
(Z)-2-[[(1,1-Dimethylethoxy)carbonyl]amino]--[[[1-[(diphenylmethoxy)carbony...
C27H27N3O7S
1225209-44-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  38 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6686 4.6201 0.0 0
M  V30 2 O 5.3348 5.3901 0.0 0
M  V30 3 O 6.6686 3.0800 0.0 0
M  V30 4 C 4.0011 4.6201 0.0 0
M  V30 5 O 8.9922 4.2104 0.0 0
M  V30 6 N 10.5088 4.4778 0.0 0
M  V30 7 C 11.4987 3.2981 0.0 0
M  V30 8 C 10.9721 1.8510 0.0 0
M  V30 9 O 11.9618 0.6711 0.0 0
M  V30 10 O 9.4553 1.5835 0.0 0
M  V30 11 N 16.8671 2.5437 0.0 0
M  V30 12 C 18.1438 3.4047 0.0 0
M  V30 13 O 19.5280 2.7297 0.0 0
M  V30 14 O 18.0363 4.9410 0.0 0
M  V30 15 C 20.8047 3.5909 0.0 0
M  V30 16 C 19.9435 4.8676 0.0 0
M  V30 17 C 22.0815 4.4521 0.0 0
M  V30 18 C 21.6658 2.3140 0.0 0
M  V30 19 C 8.0023 5.3901 0.0 0
M  V30 20 C 8.9922 6.5697 0.0 0
M  V30 21 C 7.4756 6.8372 0.0 0
M  V30 22 C 2.6675 5.3901 0.0 0
M  V30 23 C 1.3338 4.6201 0.0 0
M  V30 24 C 2.6675 6.9301 0.0 0
M  V30 25 C 0.0000 5.3901 0.0 0
M  V30 26 C 1.3338 7.7001 0.0 0
M  V30 27 C 0.0000 6.9301 0.0 0
M  V30 28 C 4.0011 3.0800 0.0 0
M  V30 29 C 2.6675 2.3100 0.0 0
M  V30 30 C 5.3348 2.3100 0.0 0
M  V30 31 C 2.6675 0.7700 0.0 0
M  V30 32 C 5.3348 0.7700 0.0 0
M  V30 33 C 4.0011 0.0000 0.0 0
M  V30 34 C 13.0154 3.5655 0.0 0
M  V30 35 N 14.1231 2.4958 0.0 0
M  V30 36 C 13.6904 4.9496 0.0 0
M  V30 37 C 15.4829 3.2187 0.0 0
M  V30 38 S 15.2154 4.7353 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 19
M  V30 4 1 2 4
M  V30 5 1 4 22
M  V30 6 1 4 28
M  V30 7 1 5 6
M  V30 8 1 5 19
M  V30 9 2 6 7
M  V30 10 1 7 8
M  V30 11 1 7 34
M  V30 12 1 8 9
M  V30 13 2 8 10
M  V30 14 1 11 12
M  V30 15 1 11 37
M  V30 16 1 12 13
M  V30 17 2 12 14
M  V30 18 1 13 15
M  V30 19 1 15 16
M  V30 20 1 15 17
M  V30 21 1 15 18
M  V30 22 1 19 20
M  V30 23 1 19 21
M  V30 24 1 20 21
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 23 25
M  V30 28 2 24 26
M  V30 29 2 25 27
M  V30 30 1 26 27
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 29 31
M  V30 34 2 30 32
M  V30 35 2 31 33
M  V30 36 1 32 33
M  V30 37 1 34 35
M  V30 38 2 34 36
M  V30 39 2 35 37
M  V30 40 1 36 38
M  V30 41 1 37 38
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Chloro-4,6-dimethoxy-1,3,5-triazine
C5H6ClN3O2
3140-73-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 4.6201 0.0 0
M  V30 2 C 0.0000 3.8501 0.0 0
M  V30 3 O 6.6687 4.6201 0.0 0
M  V30 4 C 8.0023 3.8501 0.0 0
M  V30 5 Cl 4.0012 0.0000 0.0 0
M  V30 6 C 2.6675 3.8501 0.0 0
M  V30 7 N 4.0012 4.6201 0.0 0
M  V30 8 N 2.6675 2.3101 0.0 0
M  V30 9 C 5.3348 3.8501 0.0 0
M  V30 10 C 4.0012 1.5400 0.0 0
M  V30 11 N 5.3348 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 10
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-[[(2R,3S)-3-Amino-4-oxo-2-azetidinyl]methyl]-2-oxazolidinone
C7H11N3O3
1810053-36-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.3320 2.6290 0.0 0
M  V30 2 N 5.9609 0.0000 0.0 0
M  V30 3 O 8.5899 2.6290 0.0 0
M  V30 4 O 0.0000 2.9792 0.0 0
M  V30 5 C 4.8720 2.6290 0.0 0 CFG=1
M  V30 6 C 5.9609 1.5400 0.0 0 CFG=2
M  V30 7 N 5.9609 3.7179 0.0 0
M  V30 8 C 7.0499 2.6290 0.0 0
M  V30 9 N 2.5620 3.9626 0.0 0
M  V30 10 C 1.0304 4.1237 0.0 0
M  V30 11 C 3.1884 5.3696 0.0 0
M  V30 12 O 0.7103 5.6300 0.0 0
M  V30 13 C 2.0439 6.4000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 5 1 CFG=1
M  V30 2 1 1 9
M  V30 3 1 6 2 CFG=1
M  V30 4 2 3 8
M  V30 5 2 4 10
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 1 7 8
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 1 12 13
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 5 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
2,2-Oxybis[4,6-dimethoxy-1,3,5-triazine]
C10H12N6O5
63910-63-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.6685 5.3901 0.0 0
M  V30 2 O 9.3360 0.7700 0.0 0
M  V30 3 C 10.6697 0.0000 0.0 0
M  V30 4 O 12.0033 5.3901 0.0 0
M  V30 5 C 13.3370 4.6201 0.0 0
M  V30 6 O 1.3337 5.3901 0.0 0
M  V30 7 C 0.0000 4.6201 0.0 0
M  V30 8 O 4.0010 0.7700 0.0 0
M  V30 9 C 2.6673 0.0000 0.0 0
M  V30 10 C 8.0022 4.6201 0.0 0
M  V30 11 N 8.0022 3.0801 0.0 0
M  V30 12 N 9.3360 5.3901 0.0 0
M  V30 13 C 9.3360 2.3101 0.0 0
M  V30 14 C 10.6697 4.6201 0.0 0
M  V30 15 N 10.6697 3.0801 0.0 0
M  V30 16 C 5.3348 4.6201 0.0 0
M  V30 17 N 4.0010 5.3901 0.0 0
M  V30 18 N 5.3348 3.0801 0.0 0
M  V30 19 C 2.6673 4.6201 0.0 0
M  V30 20 C 4.0010 2.3101 0.0 0
M  V30 21 N 2.6673 3.0801 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 2 13
M  V30 5 1 4 5
M  V30 6 1 4 14
M  V30 7 1 6 7
M  V30 8 1 6 19
M  V30 9 1 8 9
M  V30 10 1 8 20
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 15
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Diphenylmethyl 1-[[(Z)-[1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-thiazoly...
C34H36N6O9S
1810054-28-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  50 55 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 11.3024 0.0 0
M  V30 2 O 5.3347 12.0724 0.0 0
M  V30 3 O 6.6684 9.7624 0.0 0
M  V30 4 C 4.0011 11.3024 0.0 0
M  V30 5 O 8.9919 10.8927 0.0 0
M  V30 6 N 10.5087 11.1602 0.0 0
M  V30 7 C 11.4984 9.9804 0.0 0
M  V30 8 C 10.9717 8.5333 0.0 0
M  V30 9 N 11.9617 7.3537 0.0 0
M  V30 10 O 9.4551 8.2660 0.0 0
M  V30 11 N 16.2849 12.5255 0.0 0
M  V30 12 C 17.7792 12.1529 0.0 0
M  V30 13 O 18.8490 13.2606 0.0 0
M  V30 14 O 18.2037 10.6725 0.0 0
M  V30 15 C 20.3433 12.8881 0.0 0
M  V30 16 C 20.7158 14.3824 0.0 0
M  V30 17 C 21.8375 12.5156 0.0 0
M  V30 18 C 19.9707 11.3939 0.0 0
M  V30 19 C 13.5329 3.9840 0.0 0
M  V30 20 O 8.5921 5.7824 0.0 0
M  V30 21 O 16.5442 2.5153 0.0 0
M  V30 22 C 8.0022 12.0724 0.0 0
M  V30 23 C 8.9919 13.2522 0.0 0
M  V30 24 C 7.4753 13.5195 0.0 0
M  V30 25 C 4.0011 9.7624 0.0 0
M  V30 26 C 5.3347 8.9924 0.0 0
M  V30 27 C 2.6674 8.9924 0.0 0
M  V30 28 C 5.3347 7.4524 0.0 0
M  V30 29 C 2.6674 7.4524 0.0 0
M  V30 30 C 4.0011 6.6824 0.0 0
M  V30 31 C 2.6674 12.0724 0.0 0
M  V30 32 C 1.3336 11.3024 0.0 0
M  V30 33 C 2.6674 13.6124 0.0 0
M  V30 34 C 0.0000 12.0724 0.0 0
M  V30 35 C 1.3336 14.3824 0.0 0
M  V30 36 C 0.0000 13.6124 0.0 0
M  V30 37 C 13.0152 10.2479 0.0 0
M  V30 38 N 13.6902 11.6319 0.0 0
M  V30 39 C 14.1229 9.1781 0.0 0
M  V30 40 C 15.2152 11.4177 0.0 0
M  V30 41 S 15.4826 9.9011 0.0 0
M  V30 42 C 11.4350 5.9065 0.0 0 CFG=2
M  V30 43 C 12.0858 4.5108 0.0 0 CFG=1
M  V30 44 C 10.0393 5.2557 0.0 0
M  V30 45 N 10.6901 3.8599 0.0 0
M  V30 46 N 13.8003 2.4674 0.0 0
M  V30 47 C 15.1844 1.7924 0.0 0
M  V30 48 C 12.7306 1.3597 0.0 0
M  V30 49 O 14.9702 0.2673 0.0 0
M  V30 50 C 13.4536 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 22
M  V30 4 1 2 4
M  V30 5 1 4 25
M  V30 6 1 4 31
M  V30 7 1 5 6
M  V30 8 1 5 22
M  V30 9 2 6 7
M  V30 10 1 7 8
M  V30 11 1 7 37
M  V30 12 1 8 9
M  V30 13 2 8 10
M  V30 14 1 42 9 CFG=1
M  V30 15 1 11 12
M  V30 16 1 11 40
M  V30 17 1 12 13
M  V30 18 2 12 14
M  V30 19 1 13 15
M  V30 20 1 15 16
M  V30 21 1 15 17
M  V30 22 1 15 18
M  V30 23 1 43 19 CFG=1
M  V30 24 1 19 46
M  V30 25 2 20 44
M  V30 26 2 21 47
M  V30 27 1 22 23
M  V30 28 1 22 24
M  V30 29 1 23 24
M  V30 30 2 25 26
M  V30 31 1 25 27
M  V30 32 1 26 28
M  V30 33 2 27 29
M  V30 34 2 28 30
M  V30 35 1 29 30
M  V30 36 2 31 32
M  V30 37 1 31 33
M  V30 38 1 32 34
M  V30 39 2 33 35
M  V30 40 2 34 36
M  V30 41 1 35 36
M  V30 42 1 37 38
M  V30 43 2 37 39
M  V30 44 2 38 40
M  V30 45 1 39 41
M  V30 46 1 40 41
M  V30 47 1 42 43
M  V30 48 1 42 44
M  V30 49 1 43 45
M  V30 50 1 44 45
M  V30 51 1 46 47
M  V30 52 1 46 48
M  V30 53 1 47 49
M  V30 54 1 48 50
M  V30 55 1 49 50
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 42 43)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Diphenylmethyl 1-[[(Z)-[1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-thiazoly...
C34H36N6O10S
2412189-91-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  51 56 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 11.3025 0.0 0
M  V30 2 O 5.3348 12.0725 0.0 0
M  V30 3 O 6.6684 9.7624 0.0 0
M  V30 4 C 4.0011 11.3025 0.0 0
M  V30 5 O 8.9920 10.8928 0.0 0
M  V30 6 N 10.5087 11.1603 0.0 0
M  V30 7 C 11.4985 9.9805 0.0 0
M  V30 8 C 10.9718 8.5334 0.0 0
M  V30 9 N 11.9617 7.3537 0.0 0
M  V30 10 O 9.4552 8.2660 0.0 0
M  V30 11 N 16.2850 12.5255 0.0 0
M  V30 12 C 17.7793 12.1530 0.0 0
M  V30 13 O 18.8491 13.2607 0.0 0
M  V30 14 O 18.2039 10.6726 0.0 0
M  V30 15 C 20.3434 12.8882 0.0 0
M  V30 16 C 20.7159 14.3825 0.0 0
M  V30 17 C 21.8377 12.5157 0.0 0
M  V30 18 C 19.9709 11.3939 0.0 0
M  V30 19 C 13.5330 3.9840 0.0 0
M  V30 20 O 8.5922 5.7824 0.0 0
M  V30 21 O 11.2056 1.5740 0.0 0
M  V30 22 O 16.5443 2.5153 0.0 0
M  V30 23 C 8.0022 12.0725 0.0 0
M  V30 24 C 8.9920 13.2523 0.0 0
M  V30 25 C 7.4754 13.5196 0.0 0
M  V30 26 C 2.6675 12.0725 0.0 0
M  V30 27 C 2.6675 13.6125 0.0 0
M  V30 28 C 1.3336 11.3025 0.0 0
M  V30 29 C 1.3336 14.3825 0.0 0
M  V30 30 C 0.0000 12.0725 0.0 0
M  V30 31 C 0.0000 13.6125 0.0 0
M  V30 32 C 4.0011 9.7624 0.0 0
M  V30 33 C 5.3348 8.9924 0.0 0
M  V30 34 C 2.6675 8.9924 0.0 0
M  V30 35 C 5.3348 7.4524 0.0 0
M  V30 36 C 2.6675 7.4524 0.0 0
M  V30 37 C 4.0011 6.6824 0.0 0
M  V30 38 C 13.0153 10.2480 0.0 0
M  V30 39 N 13.6902 11.6320 0.0 0
M  V30 40 C 14.1230 9.1782 0.0 0
M  V30 41 C 15.2153 11.4178 0.0 0
M  V30 42 S 15.4827 9.9012 0.0 0
M  V30 43 C 11.4350 5.9066 0.0 0 CFG=2
M  V30 44 C 12.0859 4.5108 0.0 0 CFG=1
M  V30 45 C 10.0393 5.2558 0.0 0
M  V30 46 N 10.6901 3.8600 0.0 0
M  V30 47 N 13.8004 2.4674 0.0 0
M  V30 48 C 12.7307 1.3597 0.0 0 CFG=3
M  V30 49 C 15.1845 1.7924 0.0 0
M  V30 50 C 13.4537 0.0000 0.0 0
M  V30 51 O 14.9703 0.2673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 23
M  V30 4 1 2 4
M  V30 5 1 4 26
M  V30 6 1 4 32
M  V30 7 1 5 6
M  V30 8 1 5 23
M  V30 9 2 6 7
M  V30 10 1 7 8
M  V30 11 1 7 38
M  V30 12 1 8 9
M  V30 13 2 8 10
M  V30 14 1 43 9 CFG=1
M  V30 15 1 11 12
M  V30 16 1 11 41
M  V30 17 1 12 13
M  V30 18 2 12 14
M  V30 19 1 13 15
M  V30 20 1 15 16
M  V30 21 1 15 17
M  V30 22 1 15 18
M  V30 23 1 44 19 CFG=1
M  V30 24 1 19 47
M  V30 25 2 20 45
M  V30 26 1 21 48
M  V30 27 2 22 49
M  V30 28 1 23 24
M  V30 29 1 23 25
M  V30 30 1 24 25
M  V30 31 2 26 27
M  V30 32 1 26 28
M  V30 33 1 27 29
M  V30 34 2 28 30
M  V30 35 2 29 31
M  V30 36 1 30 31
M  V30 37 2 32 33
M  V30 38 1 32 34
M  V30 39 1 33 35
M  V30 40 2 34 36
M  V30 41 2 35 37
M  V30 42 1 36 37
M  V30 43 1 38 39
M  V30 44 2 38 40
M  V30 45 2 39 41
M  V30 46 1 40 42
M  V30 47 1 41 42
M  V30 48 1 43 44
M  V30 49 1 43 45
M  V30 50 1 44 46
M  V30 51 1 45 46
M  V30 52 1 47 48
M  V30 53 1 47 49
M  V30 54 1 48 50
M  V30 55 1 49 51
M  V30 56 1 50 51
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 43 44)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1225209-44-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3140-73-6
$DTYPE RXN:RCT(3):CAS_RN
$DATUM 1810053-36-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 63910-63-4
$DTYPE RXN:PRO(2):CAS_RN
$DATUM 1810054-28-4
$DTYPE RXN:PRO(3):CAS_RN
$DATUM 2412189-91-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21894967
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(2):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):PRO(3):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Process Development for the Synthesis of a Monobactam Antibiotic-LYS228
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fei, Zhongbo; Wu, Quanbing; Gong, Wanben; Fu, Peng; Li, Cheng; Wang,
Xianwen; Han, Yufeng; Li, Bin; Li, Lei; Wu, Bin; Zhao, Yi; Li, Jinjing;
Zhu, Wenya; Qiu, Wenlong; Guo, Jing; Zhou, Jianguang; Li, Yuanqiang;
Villa, Marco; Cheung, Chi Ming
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2020), 24(3), 363-370

$RFMT $RIREG SCHEME403 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(S)--Amino-N-(4-methoxyphenyl)-N-methylbenzenepropanamide
C17H20N2O2
1562441-91-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 8.0022 2.3101 0.0 0
M  V30 2 C 6.6685 3.0801 0.0 0
M  V30 3 C 8.0022 0.7700 0.0 0
M  V30 4 C 5.3348 2.3101 0.0 0 CFG=1
M  V30 5 O 6.6685 4.6201 0.0 0
M  V30 6 C 4.0010 3.0801 0.0 0
M  V30 7 N 5.3348 0.7700 0.0 0
M  V30 8 O 13.3370 5.3901 0.0 0
M  V30 9 C 14.6707 4.6201 0.0 0
M  V30 10 C 9.3358 3.0801 0.0 0
M  V30 11 C 10.6697 2.3101 0.0 0
M  V30 12 C 9.3358 4.6201 0.0 0
M  V30 13 C 12.0033 3.0801 0.0 0
M  V30 14 C 10.6697 5.3901 0.0 0
M  V30 15 C 12.0033 4.6201 0.0 0
M  V30 16 C 2.6673 2.3101 0.0 0
M  V30 17 C 1.3337 3.0801 0.0 0
M  V30 18 C 2.6673 0.7700 0.0 0
M  V30 19 C 0.0000 2.3101 0.0 0
M  V30 20 C 1.3337 0.0000 0.0 0
M  V30 21 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 4 6
M  V30 7 1 4 7 CFG=1
M  V30 8 1 6 16
M  V30 9 1 8 9
M  V30 10 1 8 15
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C24H31N3O5
2354397-14-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.0338 5.3348 0.0 0 CFG=2
M  V30 2 C 8.2638 4.0012 0.0 0
M  V30 3 C 10.5739 5.3348 0.0 0
M  V30 4 N 8.2638 6.6685 0.0 0
M  V30 5 N 11.3439 6.6685 0.0 0
M  V30 6 O 11.3439 4.0012 0.0 0
M  V30 7 C 6.7238 6.6685 0.0 0
M  V30 8 C 10.5739 8.0022 0.0 0
M  V30 9 C 5.9538 8.0022 0.0 0
M  V30 10 O 5.9538 5.3348 0.0 0
M  V30 11 N 4.4137 8.0022 0.0 0
M  V30 12 C 3.6437 9.3360 0.0 0
M  V30 13 O 2.1037 9.3360 0.0 0
M  V30 14 O 4.4137 10.6697 0.0 0
M  V30 15 C 1.3337 10.6697 0.0 0
M  V30 16 C 0.0000 9.8996 0.0 0
M  V30 17 C 0.5637 12.0033 0.0 0
M  V30 18 C 2.6673 11.4397 0.0 0
M  V30 19 O 17.5040 6.6685 0.0 0
M  V30 20 C 18.2740 8.0022 0.0 0
M  V30 21 C 9.0338 2.6673 0.0 0
M  V30 22 C 8.2638 1.3337 0.0 0
M  V30 23 C 10.5739 2.6673 0.0 0
M  V30 24 C 9.0338 0.0000 0.0 0
M  V30 25 C 11.3439 1.3337 0.0 0
M  V30 26 C 10.5739 0.0000 0.0 0
M  V30 27 C 12.8839 6.6685 0.0 0
M  V30 28 C 13.6539 5.3348 0.0 0
M  V30 29 C 13.6539 8.0022 0.0 0
M  V30 30 C 15.1940 5.3348 0.0 0
M  V30 31 C 15.1940 8.0022 0.0 0
M  V30 32 C 15.9640 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 21
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 5 27
M  V30 10 1 7 9
M  V30 11 2 7 10
M  V30 12 1 9 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 2 12 14
M  V30 16 1 13 15
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 1 15 18
M  V30 20 1 19 20
M  V30 21 1 19 32
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 25
M  V30 26 2 24 26
M  V30 27 1 25 26
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 2 29 31
M  V30 32 2 30 32
M  V30 33 1 31 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1562441-91-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2354397-14-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21911742
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing
Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved
Antiviral Activities
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sun, Lin; Dick, Alexej; Meuser, Megan E.; Huang, Tianguang; Zalloum,
Waleed A.; Chen, Chin-Ho; Cherukupalli, Srinivasulu; Xu, Shujing; Ding,
Xiao; Gao, Ping; Kang, Dongwei; De Clercq, Erik; Pannecouque, Christophe;
Cocklin, Simon; Lee, Kuo-Hsiung; Liu, Xinyong; Zhan, Peng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(9), 4790-4810

$RFMT $RIREG SCHEME404 STEP1
$RXN



  2  1
$MOL
Sodium pyruvate
C3H4O3.Na
113-24-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 3.0800 0.0 0
M  V30 2 C 1.3337 3.8501 0.0 0
M  V30 3 C 4.0010 3.8501 0.0 0
M  V30 4 O 2.6673 1.5400 0.0 0
M  V30 5 O 1.3337 5.3901 0.0 0
M  V30 6 O 0.0000 3.0800 0.0 0
M  V30 7 Na 2.0005 0.0000 0.0 0 VAL=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4,5-Dimethyl-1,2-phenylenediamine
C8H12N2
3171-45-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 2.6674 0.0 0
M  V30 2 C 1.5400 0.0000 0.0 0
M  V30 3 N 4.6200 5.3349 0.0 0
M  V30 4 N 6.1600 2.6674 0.0 0
M  V30 5 C 1.5400 2.6674 0.0 0
M  V30 6 C 2.3100 1.3338 0.0 0
M  V30 7 C 2.3100 4.0011 0.0 0
M  V30 8 C 3.8500 1.3338 0.0 0
M  V30 9 C 3.8500 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 5
M  V30 2 1 2 6
M  V30 3 1 3 9
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3,6,7-Trimethyl-2(1H)-quinoxalinone
C11H12N2O
28082-86-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 4.0011 0.0 0
M  V30 2 C 6.9300 0.0000 0.0 0
M  V30 3 O 8.4700 2.6674 0.0 0
M  V30 4 C 1.5400 6.6685 0.0 0
M  V30 5 C 3.8500 2.6674 0.0 0
M  V30 6 C 4.6200 4.0011 0.0 0
M  V30 7 C 2.3100 2.6674 0.0 0
M  V30 8 N 4.6200 1.3338 0.0 0
M  V30 9 N 6.1600 4.0011 0.0 0
M  V30 10 C 3.8500 5.3347 0.0 0
M  V30 11 C 1.5400 4.0011 0.0 0
M  V30 12 C 6.1600 1.3338 0.0 0
M  V30 13 C 6.9300 2.6674 0.0 0
M  V30 14 C 2.3100 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 1 2 12
M  V30 3 2 3 13
M  V30 4 1 4 14
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 14
M  V30 14 2 11 14
M  V30 15 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 113-24-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3171-45-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 28082-86-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39174754
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Exploring the Dispersion and Electrostatic Components in Arene-Arene
Interactions between Ligands and G4 DNA to Develop G4-Ligands
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Andreasson, Maans; Donzel, Maxime; Abrahamsson, Alva; Berner, Andreas;
Doimo, Mara; Quiroga, Anna; Eriksson, Anna; Chao, Yu-Kai; Overman,
Jeroen; Pemberton, Nils; Wanrooij, Sjoerd; Chorell, Erik
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(3), 2202-2219

$RFMT $RIREG SCHEME405 STEP1
$RXN



  2  1
$MOL
5-[2-(4-Iodophenyl)-4-methyl-5-thiazolyl]-1H-pyrazole-3-carboxylic acid
C14H10IN3O2S
2627559-46-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.6285 0.0000 0.0 0
M  V30 2 C 12.7246 4.9455 0.0 0
M  V30 3 O 14.1892 4.4696 0.0 0
M  V30 4 O 12.4044 6.4518 0.0 0
M  V30 5 I 0.0000 6.3386 0.0 0
M  V30 6 C 7.7722 2.7405 0.0 0
M  V30 7 S 6.7416 3.8850 0.0 0
M  V30 8 C 7.0022 1.4068 0.0 0
M  V30 9 C 5.3348 3.2585 0.0 0
M  V30 10 N 5.4957 1.7270 0.0 0
M  V30 11 C 9.3037 2.9016 0.0 0
M  V30 12 C 10.0738 4.2352 0.0 0
M  V30 13 N 10.3342 1.7570 0.0 0
M  V30 14 C 11.5801 3.9150 0.0 0
M  V30 15 N 11.7411 2.3833 0.0 0
M  V30 16 C 4.0011 4.0285 0.0 0
M  V30 17 C 2.6673 3.2585 0.0 0
M  V30 18 C 4.0011 5.5686 0.0 0
M  V30 19 C 1.3337 4.0285 0.0 0
M  V30 20 C 2.6673 6.3386 0.0 0
M  V30 21 C 1.3337 5.5686 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 14
M  V30 5 1 5 21
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 6 11
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 10
M  V30 12 1 9 16
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 1 13 15
M  V30 17 2 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Aniline
C6H7N
62-53-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-[2-(4-Iodophenyl)-4-methyl-5-thiazolyl]-N-phenyl-1H-pyrazole-3-carboxamide
C20H15IN4OS
2627559-47-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.2999 6.7877 0.0 0
M  V30 2 C 5.3900 2.6673 0.0 0
M  V30 3 N 4.6200 1.3336 0.0 0
M  V30 4 O 4.6200 4.0011 0.0 0
M  V30 5 I 19.0757 5.1125 0.0 0
M  V30 6 C 10.5458 4.3425 0.0 0
M  V30 7 S 12.0105 3.8666 0.0 0
M  V30 8 C 10.5458 5.8825 0.0 0
M  V30 9 C 12.9157 5.1125 0.0 0
M  V30 10 N 12.0105 6.3584 0.0 0
M  V30 11 C 9.2999 3.4373 0.0 0
M  V30 12 C 7.8352 3.9133 0.0 0
M  V30 13 N 9.2999 1.8973 0.0 0
M  V30 14 C 6.9302 2.6673 0.0 0
M  V30 15 N 7.8352 1.4214 0.0 0
M  V30 16 C 14.4557 5.1125 0.0 0
M  V30 17 C 15.2257 3.7789 0.0 0
M  V30 18 C 15.2257 6.4463 0.0 0
M  V30 19 C 16.7657 3.7789 0.0 0
M  V30 20 C 16.7657 6.4463 0.0 0
M  V30 21 C 17.5357 5.1125 0.0 0
M  V30 22 C 3.0802 1.3336 0.0 0
M  V30 23 C 2.3100 2.6673 0.0 0
M  V30 24 C 2.3102 0.0000 0.0 0
M  V30 25 C 0.7700 2.6673 0.0 0
M  V30 26 C 0.7700 0.0000 0.0 0
M  V30 27 C 0.0000 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 14
M  V30 5 1 3 22
M  V30 6 1 5 21
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 11
M  V30 10 1 7 9
M  V30 11 1 8 10
M  V30 12 2 9 10
M  V30 13 1 9 16
M  V30 14 2 11 12
M  V30 15 1 11 13
M  V30 16 1 12 14
M  V30 17 1 13 15
M  V30 18 2 14 15
M  V30 19 2 16 17
M  V30 20 1 16 18
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 19 21
M  V30 24 1 20 21
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 23 25
M  V30 28 2 24 26
M  V30 29 2 25 27
M  V30 30 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2627559-46-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 62-53-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2627559-47-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23580267
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and bioactivity evaluation of novel pyrazole linked
phenylthiazole derivatives in context of antibacterial activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Patel, Bhautikkumar; Zunk, Matthew; Grant, Gary; Rudrawar, Santosh
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2021), 39127853

$RFMT $RIREG SCHEME406 STEP1
$RXN



  2  1
$MOL
4-tert-Butylbenzoic acid
C11H14O2
98-73-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 1.5400 0.0 0
M  V30 2 C 6.9300 3.0800 0.0 0
M  V30 3 C 8.4700 1.5400 0.0 0
M  V30 4 C 6.9300 0.0000 0.0 0
M  V30 5 C 0.7700 1.5400 0.0 0
M  V30 6 O 0.0000 0.2064 0.0 0
M  V30 7 O 0.0000 2.8736 0.0 0
M  V30 8 C 5.3900 1.5400 0.0 0
M  V30 9 C 4.6200 2.8736 0.0 0
M  V30 10 C 4.6200 0.2064 0.0 0
M  V30 11 C 3.0800 2.8736 0.0 0
M  V30 12 C 3.0800 0.2064 0.0 0
M  V30 13 C 2.3100 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 5 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[(6-amino-1H-indol-1-yl)methyl]benzoate
C17H16N2O2
1096264-03-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.0550 3.7710 0.0 0
M  V30 2 N 0.0000 3.8614 0.0 0
M  V30 3 C 12.2150 3.7710 0.0 0
M  V30 4 O 12.9850 5.1048 0.0 0
M  V30 5 O 12.9850 2.4374 0.0 0
M  V30 6 C 14.5250 5.1048 0.0 0
M  V30 7 C 3.7534 2.2764 0.0 0
M  V30 8 N 5.2850 2.4374 0.0 0
M  V30 9 C 3.4333 0.7700 0.0 0
M  V30 10 C 2.6091 3.3068 0.0 0
M  V30 11 C 5.9114 1.0306 0.0 0
M  V30 12 C 4.7669 0.0000 0.0 0
M  V30 13 C 1.9686 0.2941 0.0 0
M  V30 14 C 1.1444 2.8310 0.0 0
M  V30 15 C 0.8242 1.3247 0.0 0
M  V30 16 C 7.5950 3.7710 0.0 0
M  V30 17 C 8.3650 5.1048 0.0 0
M  V30 18 C 8.3650 2.4374 0.0 0
M  V30 19 C 9.9050 5.1048 0.0 0
M  V30 20 C 9.9050 2.4374 0.0 0
M  V30 21 C 10.6750 3.7710 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 1 16
M  V30 3 1 2 14
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 3 21
M  V30 7 1 4 6
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 2 9 13
M  V30 14 1 10 14
M  V30 15 2 11 12
M  V30 16 1 13 15
M  V30 17 2 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[[6-[[4-(1,1-dimethylethyl)benzoyl]amino]-1H-indol-1-yl]methyl]benzoate
C28H28N2O3
2581825-97-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 13.9436 4.2504 0.0 0
M  V30 2 N 8.0020 3.0800 0.0 0
M  V30 3 C 6.6684 2.3100 0.0 0
M  V30 4 O 6.6684 0.7700 0.0 0
M  V30 5 C 19.9690 5.5312 0.0 0
M  V30 6 O 20.4449 6.9958 0.0 0
M  V30 7 O 20.9994 4.3867 0.0 0
M  V30 8 C 21.9512 7.3159 0.0 0
M  V30 9 C 1.3336 5.3900 0.0 0
M  V30 10 C 0.5636 4.0562 0.0 0
M  V30 11 C 0.0000 6.1600 0.0 0
M  V30 12 C 2.1036 6.7236 0.0 0
M  V30 13 C 12.0031 2.3100 0.0 0
M  V30 14 N 13.4678 2.7859 0.0 0
M  V30 15 C 12.0031 0.7700 0.0 0
M  V30 16 C 10.6694 3.0800 0.0 0
M  V30 17 C 14.3728 1.5400 0.0 0
M  V30 18 C 13.4678 0.2940 0.0 0
M  V30 19 C 10.6694 0.0000 0.0 0
M  V30 20 C 9.3356 2.3100 0.0 0
M  V30 21 C 9.3356 0.7700 0.0 0
M  V30 22 C 15.4499 4.5706 0.0 0
M  V30 23 C 16.4803 3.4262 0.0 0
M  V30 24 C 15.9258 6.0353 0.0 0
M  V30 25 C 17.9867 3.7464 0.0 0
M  V30 26 C 17.4322 6.3554 0.0 0
M  V30 27 C 18.4626 5.2111 0.0 0
M  V30 28 C 5.3347 3.0800 0.0 0
M  V30 29 C 4.0009 2.3100 0.0 0
M  V30 30 C 5.3347 4.6200 0.0 0
M  V30 31 C 2.6673 3.0800 0.0 0
M  V30 32 C 4.0009 5.3900 0.0 0
M  V30 33 C 2.6673 4.6200 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 14
M  V30 2 1 1 22
M  V30 3 1 2 3
M  V30 4 1 2 20
M  V30 5 2 3 4
M  V30 6 1 3 28
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 1 5 27
M  V30 10 1 6 8
M  V30 11 1 9 10
M  V30 12 1 9 11
M  V30 13 1 9 12
M  V30 14 1 9 33
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 2 13 16
M  V30 18 1 14 17
M  V30 19 1 15 18
M  V30 20 2 15 19
M  V30 21 1 16 20
M  V30 22 2 17 18
M  V30 23 1 19 21
M  V30 24 2 20 21
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 23 25
M  V30 28 2 24 26
M  V30 29 2 25 27
M  V30 30 1 26 27
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 29 31
M  V30 34 2 30 32
M  V30 35 2 31 33
M  V30 36 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 98-73-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1096264-03-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2581825-97-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23361600
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-66-3
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived
from Zafirlukast
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Schierle, Simone; Helmstaedter, Moritz; Schmidt, Jurema; Hartmann,
Markus; Horz, Maximiliane; Kaiser, Astrid; Weizel, Lilia; Heitel, Pascal;
Proschak, Anna; Hernandez-Olmos, Victor; Proschak, Ewgenij; Merk, Daniel
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2020), 15(1), 50-67

$RFMT $RIREG SCHEME407 STEP1
$RXN



  2  1
$MOL
4-Chloro-3-fluorobenzenamine
C6H5ClFN
367-22-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 1.5400 0.0000 0.0 0
M  V30 2 Cl 0.0000 2.6673 0.0 0
M  V30 3 N 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-(1,1-Dimethylethyl) (3S)-1,3-piperidinedicarboxylate
C11H19NO4
88495-54-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.0801 0.0 0
M  V30 2 O 2.6673 2.3101 0.0 0
M  V30 3 O 4.0012 4.6201 0.0 0
M  V30 4 C 1.3337 3.0801 0.0 0
M  V30 5 C 0.5637 1.7464 0.0 0
M  V30 6 C 0.0000 3.8501 0.0 0
M  V30 7 C 2.1037 4.4137 0.0 0
M  V30 8 C 9.3360 3.0801 0.0 0
M  V30 9 O 9.3360 4.6201 0.0 0
M  V30 10 O 10.6697 2.3101 0.0 0
M  V30 11 N 5.3348 2.3101 0.0 0
M  V30 12 C 6.6685 3.0801 0.0 0
M  V30 13 C 5.3348 0.7700 0.0 0
M  V30 14 C 8.0023 2.3101 0.0 0 CFG=1
M  V30 15 C 6.6685 0.0000 0.0 0
M  V30 16 C 8.0023 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 14 8 CFG=1
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 14)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl (3S)-3-[[(4-chloro-3-fluorophenyl)amino]carbonyl]-1-piperid...
C17H22ClFN2O3
2410447-06-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6687 3.0801 0.0 0
M  V30 2 N 5.3348 2.3101 0.0 0
M  V30 3 O 6.6687 4.6201 0.0 0
M  V30 4 C 12.0035 3.0801 0.0 0
M  V30 5 O 13.3372 2.3101 0.0 0
M  V30 6 O 12.0035 4.6201 0.0 0
M  V30 7 C 14.6708 3.0801 0.0 0
M  V30 8 C 15.4408 1.7464 0.0 0
M  V30 9 C 16.0046 3.8501 0.0 0
M  V30 10 C 13.9008 4.4137 0.0 0
M  V30 11 F 0.0000 2.3101 0.0 0
M  V30 12 Cl 0.0000 5.3901 0.0 0
M  V30 13 C 8.0023 2.3101 0.0 0 CFG=1
M  V30 14 C 9.3360 3.0801 0.0 0
M  V30 15 C 8.0023 0.7700 0.0 0
M  V30 16 N 10.6698 2.3101 0.0 0
M  V30 17 C 9.3360 0.0000 0.0 0
M  V30 18 C 10.6698 0.7700 0.0 0
M  V30 19 C 4.0012 3.0801 0.0 0
M  V30 20 C 2.6675 2.3101 0.0 0
M  V30 21 C 4.0012 4.6201 0.0 0
M  V30 22 C 1.3338 3.0801 0.0 0
M  V30 23 C 2.6675 5.3901 0.0 0
M  V30 24 C 1.3338 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 13 1 CFG=3
M  V30 4 1 2 19
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 16
M  V30 8 1 5 7
M  V30 9 1 7 8
M  V30 10 1 7 9
M  V30 11 1 7 10
M  V30 12 1 11 22
M  V30 13 1 12 24
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 13)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 367-22-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 88495-54-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2410447-06-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23182426
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to
Antibody-Dependent Cellular Cytotoxicity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Grenier, Melissa C.; Ding, Shilei; Vezina, Dani; Chapleau, Jean-Philippe;
Tolbert, William D.; Sherburn, Rebekah; Schon, Arne; Somisetti,
Sambasivarao; Abrams, Cameron F.; Pazgier, Marzena; Finzi, Andres; Smith,
Amos B.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2020), 11(3), 371-378

$RFMT $RIREG SCHEME408 STEP1
$RXN



  2  1
$MOL
4-Bromo-6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid
C9H7BrN2O3
1622303-52-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 4.6200 0.0000 0.0 0
M  V30 2 O 1.5400 5.3348 0.0 0
M  V30 3 C 7.6211 5.2890 0.0 0
M  V30 4 O 8.9549 4.5190 0.0 0
M  V30 5 O 7.6211 6.8290 0.0 0
M  V30 6 C 0.0000 2.6673 0.0 0
M  V30 7 C 4.6200 2.6673 0.0 0
M  V30 8 C 3.8500 4.0010 0.0 0
M  V30 9 C 6.1265 2.9875 0.0 0
M  V30 10 C 3.8500 1.3337 0.0 0
M  V30 11 N 4.8806 5.1455 0.0 0
M  V30 12 C 2.3100 4.0010 0.0 0
M  V30 13 C 6.2874 4.5190 0.0 0
M  V30 14 C 2.3100 1.3337 0.0 0
M  V30 15 N 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 2 2 12
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 13
M  V30 6 1 6 15
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 2 9 13
M  V30 13 2 10 14
M  V30 14 1 11 13
M  V30 15 1 12 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
tert-Butylamine
C4H11N
75-64-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5400 1.5400 0.0 0
M  V30 2 C 0.0000 1.5400 0.0 0
M  V30 3 C 1.5400 3.0800 0.0 0
M  V30 4 C 3.0800 1.5400 0.0 0
M  V30 5 N 1.5400 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromo-N-(1,1-dimethylethyl)-6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyr...
C13H16BrN3O2
2138863-24-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 2.6674 6.1600 0.0 0
M  V30 2 O 2.6674 0.0000 0.0 0
M  V30 3 C 7.9110 3.0800 0.0 0
M  V30 4 N 8.6810 4.4136 0.0 0
M  V30 5 O 8.6810 1.7464 0.0 0
M  V30 6 C 10.2210 4.4136 0.0 0
M  V30 7 C 10.2210 5.9536 0.0 0
M  V30 8 C 11.7610 4.4136 0.0 0
M  V30 9 C 10.2210 2.8736 0.0 0
M  V30 10 C 0.0000 1.5400 0.0 0
M  V30 11 C 4.0011 3.8500 0.0 0
M  V30 12 C 4.0011 2.3100 0.0 0
M  V30 13 C 5.4658 4.3259 0.0 0
M  V30 14 C 2.6674 4.6200 0.0 0
M  V30 15 N 5.4658 1.8341 0.0 0
M  V30 16 C 2.6674 1.5400 0.0 0
M  V30 17 C 6.3710 3.0800 0.0 0
M  V30 18 C 1.3338 3.8500 0.0 0
M  V30 19 N 1.3338 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 14
M  V30 2 2 2 16
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 17
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 10 19
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 11 14
M  V30 14 1 12 15
M  V30 15 1 12 16
M  V30 16 2 13 17
M  V30 17 2 14 18
M  V30 18 1 15 17
M  V30 19 1 16 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1622303-52-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 75-64-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2138863-24-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24358051
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of
N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
(ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second
Bromodomain
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sheppard, George S.; Wang, Le; Fidanze, Steven D.; Hasvold, Lisa A.; Liu,
Dachun; Pratt, John K.; Park, Chang H.; Longenecker, Kenton; Qiu, Wei;
Torrent, Maricel; Kovar, Peter J.; Bui, Mai; Faivre, Emily; Huang,
Xiaoli; Lin, Xiaoyu; Wilcox, Denise; Zhang, Lu; Shen, Yu; Albert, Daniel
H.; Magoc, Terrance J.; Rajaraman, Ganesh; Kati, Warren M.; McDaniel,
Keith F.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(10), 5585-5623

$RFMT $RIREG SCHEME409 STEP1
$RXN



  2  1
$MOL
6-Chloroimidazo[1,2-b]pyridazine-3-carboxylic acid
C7H4ClN3O2
1208084-53-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5063 1.1444 0.0 0
M  V30 2 O 0.0000 0.8242 0.0 0
M  V30 3 O 2.5367 0.0000 0.0 0
M  V30 4 Cl 7.4478 2.3150 0.0 0
M  V30 5 N 3.4469 3.0850 0.0 0
M  V30 6 C 3.4469 4.6250 0.0 0
M  V30 7 C 1.9822 2.6091 0.0 0
M  V30 8 N 4.7805 2.3150 0.0 0
M  V30 9 N 1.9822 5.1009 0.0 0
M  V30 10 C 4.7805 5.3950 0.0 0
M  V30 11 C 1.0769 3.8550 0.0 0
M  V30 12 C 6.1142 3.0850 0.0 0
M  V30 13 C 6.1142 4.6250 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 12
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 2 6 9
M  V30 9 1 6 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 1 9 11
M  V30 13 2 10 13
M  V30 14 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneethanamine
C8H11N
64-04-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 1.3337 0.0 0
M  V30 2 C 5.3901 2.6673 0.0 0
M  V30 3 N 6.9302 2.6673 0.0 0
M  V30 4 C 3.0801 1.3337 0.0 0
M  V30 5 C 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 0.7700 0.0000 0.0 0
M  V30 8 C 0.7700 2.6673 0.0 0
M  V30 9 C 0.0000 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 4
M  V30 3 1 2 3
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Chloro-N-(2-phenylethyl)imidazo[1,2-b]pyridazine-3-carboxamide
C15H13ClN4O
2891692-74-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7534 3.1059 0.0 0
M  V30 2 N 7.0871 3.8760 0.0 0
M  V30 3 O 5.7534 1.5659 0.0 0
M  V30 4 C 8.4208 3.1059 0.0 0
M  V30 5 C 9.7544 3.8760 0.0 0
M  V30 6 Cl 0.5546 0.0000 0.0 0
M  V30 7 N 3.0128 3.2495 0.0 0
M  V30 8 C 4.4196 3.8760 0.0 0
M  V30 9 C 1.9823 4.3940 0.0 0
M  V30 10 N 2.5369 1.7849 0.0 0
M  V30 11 C 4.2587 5.4075 0.0 0
M  V30 12 N 2.7523 5.7277 0.0 0
M  V30 13 C 0.4759 4.0739 0.0 0
M  V30 14 C 1.0304 1.4647 0.0 0
M  V30 15 C 0.0000 2.6091 0.0 0
M  V30 16 C 11.0882 3.1059 0.0 0
M  V30 17 C 12.4219 3.8760 0.0 0
M  V30 18 C 11.0882 1.5659 0.0 0
M  V30 19 C 13.7556 3.1059 0.0 0
M  V30 20 C 12.4219 0.7959 0.0 0
M  V30 21 C 13.7556 1.5659 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 16
M  V30 7 1 6 14
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 2 8 11
M  V30 12 2 9 12
M  V30 13 1 9 13
M  V30 14 2 10 14
M  V30 15 1 11 12
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1208084-53-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 64-04-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2891692-74-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35272077
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Function-oriented synthesis of Imidazo[1,2-a]pyrazine and
Imidazo[1,2-b]pyridazine derivatives as potent PI3K/mTOR dual inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Chuchu; Han, Yuqiao; Wang, Zhengyang; Yu, Yanan; Wang, Chen; Ren,
Ziwei; Guo, Yanzhi; Zhu, Tong; Li, XuWen; Dong, Suzhen; Ma, Mingliang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 247115030

$RFMT $RIREG SCHEME410 STEP1
$RXN



  2  1
$MOL
2-Methylisonicotinic acid
C7H7NO2
4021-11-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3338 0.0000 0.0 0
M  V30 4 C 6.6686 1.5400 0.0 0
M  V30 5 C 2.6675 2.3100 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 5.3348 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 N 5.3348 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1H-Inden-1-amine, 5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-, hydrochlorid...
C13H15N3O.ClH
2364561-75-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.8865 5.6934 0.0 0
M  V30 2 C 12.2933 5.0669 0.0 0
M  V30 3 N 0.0000 4.7284 0.0 0
M  V30 4 C 5.7307 4.0182 0.0 0
M  V30 5 C 4.9607 2.6845 0.0 0
M  V30 6 C 4.9607 5.3518 0.0 0
M  V30 7 C 3.4207 2.6845 0.0 0
M  V30 8 C 3.4207 5.3518 0.0 0
M  V30 9 C 2.6507 4.0182 0.0 0
M  V30 10 C 2.3902 1.5400 0.0 0
M  V30 11 C 1.1444 3.6980 0.0 0 CFG=2
M  V30 12 C 0.9834 2.1665 0.0 0
M  V30 13 C 7.2707 4.0182 0.0 0
M  V30 14 N 8.1759 5.2640 0.0 0
M  V30 15 N 8.1759 2.7723 0.0 0
M  V30 16 C 9.6406 4.7882 0.0 0
M  V30 17 O 9.6406 3.2482 0.0 0
M  V30 18 Cl 6.1466 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 11 3 CFG=1
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 13
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 2 8 9
M  V30 12 1 9 11
M  V30 13 1 10 12
M  V30 14 1 11 12
M  V30 15 1 13 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 17
M  V30 19 1 16 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 11)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1R)-5-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-2-methyl-...
C20H20N4O2
2364556-52-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 2.6218 0.0 0
M  V30 2 C 5.3348 1.8517 0.0 0
M  V30 3 O 5.3348 0.3117 0.0 0
M  V30 4 C 17.1167 5.8290 0.0 0
M  V30 5 C 18.6230 5.5089 0.0 0
M  V30 6 C 0.0000 1.8517 0.0 0
M  V30 7 C 9.4091 2.4781 0.0 0
M  V30 8 C 10.4396 1.3337 0.0 0
M  V30 9 C 8.0022 1.8517 0.0 0 CFG=2
M  V30 10 C 9.8850 3.9428 0.0 0
M  V30 11 C 11.9459 1.6538 0.0 0
M  V30 12 C 9.6696 0.0000 0.0 0
M  V30 13 C 8.1631 0.3202 0.0 0
M  V30 14 C 11.3913 4.2630 0.0 0
M  V30 15 C 12.4219 3.1186 0.0 0
M  V30 16 C 13.9282 3.4387 0.0 0
M  V30 17 N 14.5545 4.8456 0.0 0
M  V30 18 N 15.0726 2.4082 0.0 0
M  V30 19 C 16.0863 4.6846 0.0 0
M  V30 20 O 16.4064 3.1782 0.0 0
M  V30 21 C 4.0010 2.6218 0.0 0
M  V30 22 C 2.6673 1.8517 0.0 0
M  V30 23 C 4.0010 4.1618 0.0 0
M  V30 24 C 1.3337 2.6218 0.0 0
M  V30 25 C 2.6673 4.9318 0.0 0
M  V30 26 N 1.3337 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 9 1 CFG=1
M  V30 3 2 2 3
M  V30 4 1 2 21
M  V30 5 1 4 5
M  V30 6 1 4 19
M  V30 7 1 6 24
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 2 8 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 10 14
M  V30 15 1 11 15
M  V30 16 1 12 13
M  V30 17 2 14 15
M  V30 18 1 15 16
M  V30 19 1 16 17
M  V30 20 2 16 18
M  V30 21 2 17 19
M  V30 22 1 18 20
M  V30 23 1 19 20
M  V30 24 1 21 22
M  V30 25 2 21 23
M  V30 26 2 22 24
M  V30 27 1 23 25
M  V30 28 1 24 26
M  V30 29 2 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4021-11-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2364561-75-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2364556-52-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34638611
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin
Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chuang, Chihyuan; Collibee, Scott; Ashcraft, Luke; Wang, Wenyue; Vander
Wal, Mark; Wang, Xiaolin; Hwee, Darren T.; Wu, Yangsong; Wang, Jingying;
Chin, Eva R.; Cremin, Peadar; Zamora, Jeanelle; Hartman, James;
Schaletzky, Julia; Wehri, Eddie; Robertson, Laura A.; Malik, Fady I.;
Morgan, Bradley P.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(19), 14142-14152

$RFMT $RIREG SCHEME411 STEP1
$RXN



  2  1
$MOL
1-Methyl-1H-pyrazole-4-carboxylic acid
C5H6N2O2
5952-92-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 C 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 C 2.8284 3.8416 0.0 0
M  V30 8 N 5.1048 2.8281 0.0 0
M  V30 9 N 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(1R)-5-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-amine
C13H15N3O
2364560-36-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.8865 4.1534 0.0 0
M  V30 2 C 12.2933 3.5269 0.0 0
M  V30 3 N 0.0000 3.1884 0.0 0
M  V30 4 C 5.7307 2.4782 0.0 0
M  V30 5 C 4.9607 1.1445 0.0 0
M  V30 6 C 4.9607 3.8118 0.0 0
M  V30 7 C 3.4207 1.1445 0.0 0
M  V30 8 C 3.4207 3.8118 0.0 0
M  V30 9 C 2.6507 2.4782 0.0 0
M  V30 10 C 2.3902 0.0000 0.0 0
M  V30 11 C 1.1444 2.1580 0.0 0 CFG=2
M  V30 12 C 0.9834 0.6265 0.0 0
M  V30 13 C 7.2707 2.4782 0.0 0
M  V30 14 N 8.1759 3.7240 0.0 0
M  V30 15 N 8.1759 1.2323 0.0 0
M  V30 16 C 9.6406 3.2482 0.0 0
M  V30 17 O 9.6406 1.7082 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 11 3 CFG=1
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 13
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 2 8 9
M  V30 12 1 9 11
M  V30 13 1 10 12
M  V30 14 1 11 12
M  V30 15 1 13 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 17
M  V30 19 1 16 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 11)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1R)-5-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-...
C18H19N5O2
2364554-48-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.4171 2.7126 0.0 0
M  V30 2 C 4.9524 3.1884 0.0 0
M  V30 3 O 4.6322 4.6949 0.0 0
M  V30 4 C 17.3036 1.7476 0.0 0
M  V30 5 C 18.7106 2.3741 0.0 0
M  V30 6 C 0.0000 0.9835 0.0 0
M  V30 7 C 9.0679 3.4228 0.0 0
M  V30 8 C 9.8379 4.7565 0.0 0
M  V30 9 C 7.5615 3.7430 0.0 0 CFG=2
M  V30 10 C 9.8379 2.0892 0.0 0
M  V30 11 C 11.3779 4.7565 0.0 0
M  V30 12 C 8.8073 5.9010 0.0 0
M  V30 13 C 7.4005 5.2746 0.0 0
M  V30 14 C 11.3779 2.0892 0.0 0
M  V30 15 C 12.1479 3.4228 0.0 0
M  V30 16 C 13.6880 3.4228 0.0 0
M  V30 17 N 14.5932 2.1770 0.0 0
M  V30 18 N 14.5932 4.6687 0.0 0
M  V30 19 C 16.0577 2.6528 0.0 0
M  V30 20 O 16.0577 4.1928 0.0 0
M  V30 21 C 3.8080 2.1580 0.0 0
M  V30 22 C 3.9689 0.6265 0.0 0
M  V30 23 C 2.3016 2.4782 0.0 0
M  V30 24 N 2.5621 0.0000 0.0 0
M  V30 25 N 1.5315 1.1445 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 9 1 CFG=3
M  V30 3 2 2 3
M  V30 4 1 2 21
M  V30 5 1 4 5
M  V30 6 1 4 19
M  V30 7 1 6 25
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 2 8 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 10 14
M  V30 15 1 11 15
M  V30 16 1 12 13
M  V30 17 2 14 15
M  V30 18 1 15 16
M  V30 19 1 16 17
M  V30 20 2 16 18
M  V30 21 2 17 19
M  V30 22 1 18 20
M  V30 23 1 19 20
M  V30 24 1 21 22
M  V30 25 2 21 23
M  V30 26 2 22 24
M  V30 27 1 23 25
M  V30 28 1 24 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5952-92-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2364560-36-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2364554-48-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34638590
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 39968-33-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin
Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chuang, Chihyuan; Collibee, Scott; Ashcraft, Luke; Wang, Wenyue; Vander
Wal, Mark; Wang, Xiaolin; Hwee, Darren T.; Wu, Yangsong; Wang, Jingying;
Chin, Eva R.; Cremin, Peadar; Zamora, Jeanelle; Hartman, James;
Schaletzky, Julia; Wehri, Eddie; Robertson, Laura A.; Malik, Fady I.;
Morgan, Bradley P.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(19), 14142-14152

$RFMT $RIREG SCHEME412 STEP1
$RXN



  2  1
$MOL
Urea
CH4N2O
57-13-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 N 0.0000 2.3101 0.0 0
M  V30 3 N 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-methylbenzoic acid
C8H9NO2
2941-78-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 C 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Methyl-2,4(1H,3H)-quinazolinedione
C9H8N2O2
62484-16-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.8500 0.0000 0.0 0
M  V30 2 O 8.4700 2.6674 0.0 0
M  V30 3 C 0.0000 4.0011 0.0 0
M  V30 4 C 4.6200 4.0011 0.0 0
M  V30 5 C 3.8500 2.6674 0.0 0
M  V30 6 N 6.1600 4.0011 0.0 0
M  V30 7 C 3.8500 5.3349 0.0 0
M  V30 8 C 4.6200 1.3338 0.0 0
M  V30 9 C 2.3100 2.6674 0.0 0
M  V30 10 C 6.9300 2.6674 0.0 0
M  V30 11 C 2.3100 5.3349 0.0 0
M  V30 12 N 6.1600 1.3338 0.0 0
M  V30 13 C 1.5400 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 8
M  V30 2 2 2 10
M  V30 3 1 3 13
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 1 5 8
M  V30 8 2 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 57-13-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2941-78-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 62484-16-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32762777
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 4
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1310-73-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis of acyclic nucleoside phosphonates targeting flavin-dependent
thymidylate synthase in Mycobacterium tuberculosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Biteau, Nicolas G.; Roy, Vincent; Lambry, Jean-Christophe; Becker, Hubert
F.; Myllykallio, Hannu; Agrofoglio, Luigi A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 46116351

$RFMT $RIREG SCHEME413 STEP1
$RXN



  2  1
$MOL
5-(3-Chlorophenyl)-3-methoxy-2-pyridinecarboxylic acid
C13H10ClNO3
2543978-01-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3336 4.6200 0.0 0
M  V30 2 C 1.3336 6.1600 0.0 0
M  V30 3 Cl 10.6694 3.8500 0.0 0
M  V30 4 C 1.3336 1.5400 0.0 0
M  V30 5 O 0.0000 2.3100 0.0 0
M  V30 6 O 1.3336 0.0000 0.0 0
M  V30 7 C 5.3347 3.8500 0.0 0
M  V30 8 C 4.0011 4.6200 0.0 0
M  V30 9 C 5.3347 2.3100 0.0 0
M  V30 10 C 2.6673 3.8500 0.0 0
M  V30 11 N 4.0011 1.5400 0.0 0
M  V30 12 C 2.6673 2.3100 0.0 0
M  V30 13 C 6.6684 4.6200 0.0 0
M  V30 14 C 8.0021 3.8500 0.0 0
M  V30 15 C 6.6684 6.1600 0.0 0
M  V30 16 C 9.3358 4.6200 0.0 0
M  V30 17 C 8.0021 6.9300 0.0 0
M  V30 18 C 9.3358 6.1600 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 3 16
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 12
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 7 13
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Glycine methyl ester hydrochloride
C3H7NO2.ClH
5680-79-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.0800 0.0 0
M  V30 2 C 1.3338 3.8500 0.0 0
M  V30 3 O 4.0011 3.8500 0.0 0
M  V30 4 O 2.6674 1.5400 0.0 0
M  V30 5 N 0.0000 3.0800 0.0 0
M  V30 6 C 5.3349 3.0800 0.0 0
M  V30 7 Cl 2.6674 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[[5-(3-Chlorophenyl)-3-methoxy-2-pyridinyl]carbonyl]glycine methyl ester
C16H15ClN2O4
1007382-05-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3348 8.4701 0.0 0
M  V30 2 C 4.0010 9.2401 0.0 0
M  V30 3 Cl 1.3337 0.0000 0.0 0
M  V30 4 C 8.0021 6.9301 0.0 0
M  V30 5 N 9.3357 6.1601 0.0 0
M  V30 6 O 8.0021 8.4701 0.0 0
M  V30 7 C 10.6695 6.9301 0.0 0
M  V30 8 C 12.0032 6.1601 0.0 0
M  V30 9 O 13.3369 6.9301 0.0 0
M  V30 10 O 12.0032 4.6201 0.0 0
M  V30 11 C 14.6705 6.1601 0.0 0
M  V30 12 C 4.0010 4.6201 0.0 0
M  V30 13 C 4.0010 6.1601 0.0 0
M  V30 14 C 5.3348 3.8500 0.0 0
M  V30 15 C 5.3348 6.9301 0.0 0
M  V30 16 N 6.6684 4.6201 0.0 0
M  V30 17 C 6.6684 6.1601 0.0 0
M  V30 18 C 2.6673 3.8500 0.0 0
M  V30 19 C 2.6673 2.3100 0.0 0
M  V30 20 C 1.3337 4.6201 0.0 0
M  V30 21 C 1.3337 1.5400 0.0 0
M  V30 22 C 0.0000 3.8500 0.0 0
M  V30 23 C 0.0000 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 3 21
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 17
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 12 18
M  V30 15 2 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2543978-01-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5680-79-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1007382-05-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31605939
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of a Robust and Scalable Process for the Large-Scale
Preparation of Vadadustat
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Lin, Biyue; Kou, Jingping; Wu, Shuming; Cai, Xuerong; Xiao, Qingbo; Li,
Yinglong; Hu, Jian; Li, Jianbing; Wang, Zhongqing
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(4), 960-968

$RFMT $RIREG SCHEME414 STEP1
$RXN



  2  1
$MOL
Thiourea
CH4N2S
62-56-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 N 0.0000 2.3101 0.0 0
M  V30 3 N 2.6673 2.3101 0.0 0
M  V30 4 S 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Aminoisonicotinic acid
C6H6N2O2
7579-20-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 3.0801 4.0010 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 N 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 2 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2,3-Dihydro-2-thioxopyrido[3,4-d]pyrimidin-4(1H)-one
C7H5N3OS
412341-42-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 0.0000 0.0 0
M  V30 2 S 6.9300 2.6674 0.0 0
M  V30 3 C 2.3100 2.6674 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 3.0800 1.3338 0.0 0
M  V30 6 C 0.7700 2.6674 0.0 0
M  V30 7 N 4.6200 4.0011 0.0 0
M  V30 8 C 2.3100 5.3349 0.0 0
M  V30 9 N 4.6200 1.3338 0.0 0
M  V30 10 C 0.0000 4.0011 0.0 0
M  V30 11 C 5.3900 2.6674 0.0 0
M  V30 12 N 0.7700 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 62-56-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 7579-20-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 412341-42-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34611287
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and anti-tumor activity studies of novel pyrido[3,
4-d]pyrimidine derivatives
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guo, Wen-Ge; Zhao, Jun-Ru; Li, Min; Hu, Ting; Dan, Zengyangzong; Zhang,
Qian; Ma, Li-Ying; Zhang, Sai-Yang; Zhao, Bing
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2022), 76129020

$RFMT $RIREG SCHEME415 STEP1
$RXN



  2  1
$MOL
4-(Cyclopentylamino)-2-(methylthio)-5-pyrimidinecarboxylic acid
C11H15N3O2S
1065075-68-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.6217 4.0011 0.0 0
M  V30 2 C 4.1617 1.3337 0.0 0
M  V30 3 O 2.6217 1.3337 0.0 0
M  V30 4 O 4.9318 0.0000 0.0 0
M  V30 5 S 7.2418 6.6684 0.0 0
M  V30 6 C 8.7818 6.6684 0.0 0
M  V30 7 C 4.1617 4.0011 0.0 0
M  V30 8 C 4.9318 2.6675 0.0 0
M  V30 9 N 4.9318 5.3348 0.0 0
M  V30 10 C 6.4718 2.6675 0.0 0
M  V30 11 C 6.4718 5.3348 0.0 0
M  V30 12 N 7.2418 4.0011 0.0 0
M  V30 13 C 1.8517 5.3348 0.0 0
M  V30 14 C 0.3202 5.4957 0.0 0
M  V30 15 C 2.4782 6.7417 0.0 0
M  V30 16 C 0.0000 7.0021 0.0 0
M  V30 17 C 1.3337 7.7722 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 7
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 8
M  V30 6 1 5 6
M  V30 7 1 5 11
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 12
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-(3-Aminopropyl)-2-oxazolidinone
C6H12N2O2
1019391-02-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7710 1.3627 0.0 0
M  V30 2 C 5.1046 2.1327 0.0 0
M  V30 3 C 6.4384 1.3627 0.0 0
M  V30 4 N 7.7720 2.1327 0.0 0
M  V30 5 O 0.7102 0.0000 0.0 0
M  V30 6 N 2.4373 2.1327 0.0 0
M  V30 7 C 1.0304 1.5064 0.0 0
M  V30 8 C 2.2764 3.6643 0.0 0
M  V30 9 O 0.0000 2.6508 0.0 0
M  V30 10 C 0.7700 3.9846 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 6
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 5 7
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Cyclopentylamino)-2-(methylthio)-N-[3-(2-oxo-3-oxazolidinyl)propyl]-5-pyri...
C17H25N5O3S
2761545-99-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.7711 2.6217 0.0 0
M  V30 2 C 6.4386 4.1618 0.0 0
M  V30 3 N 7.7722 4.9318 0.0 0
M  V30 4 O 6.4386 2.6217 0.0 0
M  V30 5 C 9.1059 4.1618 0.0 0
M  V30 6 C 10.4397 4.9318 0.0 0
M  V30 7 C 11.7734 4.1618 0.0 0
M  V30 8 S 1.1037 7.2418 0.0 0
M  V30 9 C 1.1037 8.7819 0.0 0
M  V30 10 O 14.8342 2.7990 0.0 0
M  V30 11 C 3.7711 4.1618 0.0 0
M  V30 12 C 5.1047 4.9318 0.0 0
M  V30 13 N 2.4374 4.9318 0.0 0
M  V30 14 C 5.1047 6.4718 0.0 0
M  V30 15 C 2.4374 6.4718 0.0 0
M  V30 16 N 3.7711 7.2418 0.0 0
M  V30 17 C 2.4374 1.8517 0.0 0
M  V30 18 C 1.0306 2.4782 0.0 0
M  V30 19 C 2.2765 0.3202 0.0 0
M  V30 20 C 0.0000 1.3337 0.0 0
M  V30 21 C 0.7700 0.0000 0.0 0
M  V30 22 N 13.1070 4.9318 0.0 0
M  V30 23 C 14.5138 4.3055 0.0 0
M  V30 24 C 13.2680 6.4633 0.0 0
M  V30 25 O 15.5444 5.4499 0.0 0
M  V30 26 C 14.7744 6.7837 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 2 12
M  V30 6 1 3 5
M  V30 7 1 5 6
M  V30 8 1 6 7
M  V30 9 1 7 22
M  V30 10 1 8 9
M  V30 11 1 8 15
M  V30 12 2 10 23
M  V30 13 1 11 12
M  V30 14 2 11 13
M  V30 15 2 12 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 16
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 21
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1065075-68-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1019391-02-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2761545-99-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31592708
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Development of a Chemical Probe for Pseudokinase
Ca2+/calmodulin-Dependent Ser/Thr Kinase
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Russ, Nadine; Schroeder, Martin; Berger, Benedict-Tilman; Mandel,
Sebastian; Aydogan, Yagmur; Mauer, Sandy; Pohl, Christian; Drewry, David
H.; Chaikuad, Apirat; Mueller, Susanne; Knapp, Stefan
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(19), 14358-14376

$RFMT $RIREG SCHEME416 STEP1
$RXN



  2  1
$MOL
Acetic acid
C2H4O2
64-19-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 0.0000 2.3101 0.0 0
M  V30 3 O 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-N-[(4-chlorophenyl)methyl]-2-[[3-(10,11-dihydro-5H-dibenzo[a,d]cycloh...
C30H34ClN3O
2648234-35-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2066 5.3084 0.0 0
M  V30 2 C 6.5402 4.5384 0.0 0
M  V30 3 C 7.8740 5.3084 0.0 0
M  V30 4 N 9.2077 4.5384 0.0 0
M  V30 5 C 10.5413 5.3084 0.0 0
M  V30 6 C 9.2077 2.9984 0.0 0
M  V30 7 C 11.8750 4.5384 0.0 0
M  V30 8 C 10.5413 6.8484 0.0 0
M  V30 9 N 13.2088 5.3084 0.0 0
M  V30 10 O 11.8750 2.9984 0.0 0
M  V30 11 C 11.8750 7.6184 0.0 0
M  V30 12 C 14.5424 4.5384 0.0 0
M  V30 13 N 11.8750 9.1584 0.0 0
M  V30 14 Cl 19.8771 7.6184 0.0 0
M  V30 15 C 3.8730 4.5384 0.0 0
M  V30 16 C 3.9880 3.0027 0.0 0
M  V30 17 C 2.6005 5.4060 0.0 0
M  V30 18 C 2.8592 1.9553 0.0 0
M  V30 19 C 5.4596 2.5489 0.0 0
M  V30 20 C 1.1290 4.9520 0.0 0
M  V30 21 C 2.9433 6.9074 0.0 0
M  V30 22 C 1.3363 2.1848 0.0 0
M  V30 23 C 3.2018 0.4538 0.0 0
M  V30 24 C 5.8023 1.0474 0.0 0
M  V30 25 C 0.5663 3.5184 0.0 0
M  V30 26 C 0.0000 5.9996 0.0 0
M  V30 27 C 1.8143 7.9549 0.0 0
M  V30 28 C 4.6733 0.0000 0.0 0
M  V30 29 C 0.3427 7.5009 0.0 0
M  V30 30 C 15.8761 5.3084 0.0 0
M  V30 31 C 17.2097 4.5384 0.0 0
M  V30 32 C 15.8761 6.8484 0.0 0
M  V30 33 C 18.5435 5.3084 0.0 0
M  V30 34 C 17.2097 7.6184 0.0 0
M  V30 35 C 18.5435 6.8484 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 30
M  V30 15 1 14 35
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 16 19
M  V30 20 1 17 20
M  V30 21 2 17 21
M  V30 22 1 18 22
M  V30 23 2 18 23
M  V30 24 1 19 24
M  V30 25 1 20 25
M  V30 26 2 20 26
M  V30 27 1 21 27
M  V30 28 1 22 25
M  V30 29 1 23 28
M  V30 30 2 24 28
M  V30 31 1 26 29
M  V30 32 2 27 29
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 31 33
M  V30 36 2 32 34
M  V30 37 2 33 35
M  V30 38 1 34 35
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Acetylamino)-N-[(4-chlorophenyl)methyl]-2-[[3-(10,11-dihydro-5H-dibenzo[a,...
C32H36ClN3O2
2648234-40-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  38 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.5502 9.3358 0.0 0
M  V30 2 C 10.0101 9.3358 0.0 0
M  V30 3 C 9.2401 8.0021 0.0 0
M  V30 4 N 7.7001 8.0021 0.0 0
M  V30 5 C 6.9301 6.6684 0.0 0
M  V30 6 C 6.9301 9.3358 0.0 0
M  V30 7 C 5.3901 6.6684 0.0 0
M  V30 8 C 7.7001 5.3348 0.0 0
M  V30 9 N 4.6201 8.0021 0.0 0
M  V30 10 O 4.6201 5.3348 0.0 0
M  V30 11 C 6.9301 4.0010 0.0 0
M  V30 12 C 3.0800 8.0021 0.0 0
M  V30 13 N 7.7001 2.6673 0.0 0
M  V30 14 C 6.9301 1.3337 0.0 0
M  V30 15 C 5.3901 1.3337 0.0 0
M  V30 16 O 7.7001 0.0000 0.0 0
M  V30 17 Cl 0.0000 13.3369 0.0 0
M  V30 18 C 12.3202 10.6696 0.0 0
M  V30 19 C 11.4527 11.9419 0.0 0
M  V30 20 C 13.8559 10.5544 0.0 0
M  V30 21 C 11.9065 13.4136 0.0 0
M  V30 22 C 9.9512 11.5993 0.0 0
M  V30 23 C 14.9033 11.6834 0.0 0
M  V30 24 C 14.3097 9.0829 0.0 0
M  V30 25 C 13.3401 13.9762 0.0 0
M  V30 26 C 10.8590 14.5424 0.0 0
M  V30 27 C 8.9038 12.7281 0.0 0
M  V30 28 C 14.6738 13.2061 0.0 0
M  V30 29 C 16.4048 11.3407 0.0 0
M  V30 30 C 15.8113 8.7401 0.0 0
M  V30 31 C 9.3576 14.1998 0.0 0
M  V30 32 C 16.8586 9.8691 0.0 0
M  V30 33 C 2.3100 9.3358 0.0 0
M  V30 34 C 0.7700 9.3358 0.0 0
M  V30 35 C 3.0800 10.6696 0.0 0
M  V30 36 C 0.0000 10.6696 0.0 0
M  V30 37 C 2.3100 12.0032 0.0 0
M  V30 38 C 0.7700 12.0032 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 18
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 33
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 14 16
M  V30 18 1 17 38
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 19 22
M  V30 23 1 20 23
M  V30 24 2 20 24
M  V30 25 1 21 25
M  V30 26 2 21 26
M  V30 27 1 22 27
M  V30 28 1 23 28
M  V30 29 2 23 29
M  V30 30 1 24 30
M  V30 31 1 25 28
M  V30 32 1 26 31
M  V30 33 2 27 31
M  V30 34 1 29 32
M  V30 35 2 30 32
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 34 36
M  V30 39 2 35 37
M  V30 40 2 36 38
M  V30 41 1 37 38
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2648234-35-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2648234-40-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23747921
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as
inhibitors of GABA transporters mGAT1-4 with anticonvulsant,
antinociceptive, and antidepressant activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zareba, Paula; Salat, Kinga; Hofner, Georg C.; Latka, Kamil; Bajda,
Marek; Latacz, Gniewomir; Kotniewicz, Krzysztof; Rapacz, Anna; Podkowa,
Adrian; Maj, Maciej; Jozwiak, Krzysztof; Filipek, Barbara; Wanner, Klaus
T.; Malawska, Barbara; Kulig, Katarzyna
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 221113512

$RFMT $RIREG SCHEME417 STEP1
$RXN



  2  1
$MOL
Acetic acid
C2H4O2
64-19-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 0.0000 2.3101 0.0 0
M  V30 3 O 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-2-[[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]meth...
C30H34FN3O
2648234-36-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2066 5.3084 0.0 0
M  V30 2 C 6.5402 4.5384 0.0 0
M  V30 3 C 7.8740 5.3084 0.0 0
M  V30 4 N 9.2077 4.5384 0.0 0
M  V30 5 C 10.5413 5.3084 0.0 0
M  V30 6 C 9.2077 2.9984 0.0 0
M  V30 7 C 11.8750 4.5384 0.0 0
M  V30 8 C 10.5413 6.8484 0.0 0
M  V30 9 N 13.2088 5.3084 0.0 0
M  V30 10 O 11.8750 2.9984 0.0 0
M  V30 11 C 11.8750 7.6184 0.0 0
M  V30 12 C 14.5424 4.5384 0.0 0
M  V30 13 N 11.8750 9.1584 0.0 0
M  V30 14 F 19.8771 7.6184 0.0 0
M  V30 15 C 3.8730 4.5384 0.0 0
M  V30 16 C 3.9880 3.0027 0.0 0
M  V30 17 C 2.6005 5.4060 0.0 0
M  V30 18 C 2.8592 1.9553 0.0 0
M  V30 19 C 5.4596 2.5489 0.0 0
M  V30 20 C 1.1290 4.9520 0.0 0
M  V30 21 C 2.9433 6.9074 0.0 0
M  V30 22 C 1.3363 2.1848 0.0 0
M  V30 23 C 3.2018 0.4538 0.0 0
M  V30 24 C 5.8023 1.0474 0.0 0
M  V30 25 C 0.5663 3.5184 0.0 0
M  V30 26 C 0.0000 5.9996 0.0 0
M  V30 27 C 1.8143 7.9549 0.0 0
M  V30 28 C 4.6733 0.0000 0.0 0
M  V30 29 C 0.3427 7.5009 0.0 0
M  V30 30 C 15.8761 5.3084 0.0 0
M  V30 31 C 17.2097 4.5384 0.0 0
M  V30 32 C 15.8761 6.8484 0.0 0
M  V30 33 C 18.5435 5.3084 0.0 0
M  V30 34 C 17.2097 7.6184 0.0 0
M  V30 35 C 18.5435 6.8484 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 30
M  V30 15 1 14 35
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 16 19
M  V30 20 1 17 20
M  V30 21 2 17 21
M  V30 22 1 18 22
M  V30 23 2 18 23
M  V30 24 1 19 24
M  V30 25 1 20 25
M  V30 26 2 20 26
M  V30 27 1 21 27
M  V30 28 1 22 25
M  V30 29 1 23 28
M  V30 30 2 24 28
M  V30 31 1 26 29
M  V30 32 2 27 29
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 31 33
M  V30 36 2 32 34
M  V30 37 2 33 35
M  V30 38 1 34 35
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Acetylamino)-2-[[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)pro...
C32H36FN3O2
2648234-41-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  38 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.5502 9.3358 0.0 0
M  V30 2 C 10.0101 9.3358 0.0 0
M  V30 3 C 9.2401 8.0021 0.0 0
M  V30 4 N 7.7001 8.0021 0.0 0
M  V30 5 C 6.9301 6.6684 0.0 0
M  V30 6 C 6.9301 9.3358 0.0 0
M  V30 7 C 5.3901 6.6684 0.0 0
M  V30 8 C 7.7001 5.3348 0.0 0
M  V30 9 N 4.6201 8.0021 0.0 0
M  V30 10 O 4.6201 5.3348 0.0 0
M  V30 11 C 6.9301 4.0010 0.0 0
M  V30 12 C 3.0800 8.0021 0.0 0
M  V30 13 N 7.7001 2.6673 0.0 0
M  V30 14 C 6.9301 1.3337 0.0 0
M  V30 15 C 5.3901 1.3337 0.0 0
M  V30 16 O 7.7001 0.0000 0.0 0
M  V30 17 F 0.0000 13.3369 0.0 0
M  V30 18 C 12.3202 10.6696 0.0 0
M  V30 19 C 11.4527 11.9419 0.0 0
M  V30 20 C 13.8559 10.5544 0.0 0
M  V30 21 C 11.9065 13.4136 0.0 0
M  V30 22 C 9.9512 11.5993 0.0 0
M  V30 23 C 14.9033 11.6834 0.0 0
M  V30 24 C 14.3097 9.0829 0.0 0
M  V30 25 C 13.3401 13.9762 0.0 0
M  V30 26 C 10.8590 14.5424 0.0 0
M  V30 27 C 8.9038 12.7281 0.0 0
M  V30 28 C 14.6738 13.2061 0.0 0
M  V30 29 C 16.4048 11.3407 0.0 0
M  V30 30 C 15.8113 8.7401 0.0 0
M  V30 31 C 9.3576 14.1998 0.0 0
M  V30 32 C 16.8586 9.8691 0.0 0
M  V30 33 C 2.3100 9.3358 0.0 0
M  V30 34 C 0.7700 9.3358 0.0 0
M  V30 35 C 3.0800 10.6696 0.0 0
M  V30 36 C 0.0000 10.6696 0.0 0
M  V30 37 C 2.3100 12.0032 0.0 0
M  V30 38 C 0.7700 12.0032 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 18
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 33
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 14 16
M  V30 18 1 17 38
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 19 22
M  V30 23 1 20 23
M  V30 24 2 20 24
M  V30 25 1 21 25
M  V30 26 2 21 26
M  V30 27 1 22 27
M  V30 28 1 23 28
M  V30 29 2 23 29
M  V30 30 1 24 30
M  V30 31 1 25 28
M  V30 32 1 26 31
M  V30 33 2 27 31
M  V30 34 1 29 32
M  V30 35 2 30 32
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 34 36
M  V30 39 2 35 37
M  V30 40 2 36 38
M  V30 41 1 37 38
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2648234-36-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2648234-41-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23749117
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as
inhibitors of GABA transporters mGAT1-4 with anticonvulsant,
antinociceptive, and antidepressant activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zareba, Paula; Salat, Kinga; Hofner, Georg C.; Latka, Kamil; Bajda,
Marek; Latacz, Gniewomir; Kotniewicz, Krzysztof; Rapacz, Anna; Podkowa,
Adrian; Maj, Maciej; Jozwiak, Krzysztof; Filipek, Barbara; Wanner, Klaus
T.; Malawska, Barbara; Kulig, Katarzyna
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 221113512

$RFMT $RIREG SCHEME418 STEP1
$RXN



  2  1
$MOL
5-[2-(4-Iodophenyl)-4-methyl-5-thiazolyl]-1H-pyrazole-3-carboxylic acid
C14H10IN3O2S
2627559-46-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.6285 0.0000 0.0 0
M  V30 2 C 12.7246 4.9455 0.0 0
M  V30 3 O 14.1892 4.4696 0.0 0
M  V30 4 O 12.4044 6.4518 0.0 0
M  V30 5 I 0.0000 6.3386 0.0 0
M  V30 6 C 7.7722 2.7405 0.0 0
M  V30 7 S 6.7416 3.8850 0.0 0
M  V30 8 C 7.0022 1.4068 0.0 0
M  V30 9 C 5.3348 3.2585 0.0 0
M  V30 10 N 5.4957 1.7270 0.0 0
M  V30 11 C 9.3037 2.9016 0.0 0
M  V30 12 C 10.0738 4.2352 0.0 0
M  V30 13 N 10.3342 1.7570 0.0 0
M  V30 14 C 11.5801 3.9150 0.0 0
M  V30 15 N 11.7411 2.3833 0.0 0
M  V30 16 C 4.0011 4.0285 0.0 0
M  V30 17 C 2.6673 3.2585 0.0 0
M  V30 18 C 4.0011 5.5686 0.0 0
M  V30 19 C 1.3337 4.0285 0.0 0
M  V30 20 C 2.6673 6.3386 0.0 0
M  V30 21 C 1.3337 5.5686 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 14
M  V30 5 1 5 21
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 6 11
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 9 10
M  V30 12 1 9 16
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 1 13 15
M  V30 17 2 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Cyclohexylamine
C6H13N
108-91-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-Cyclohexyl-5-[2-(4-iodophenyl)-4-methyl-5-thiazolyl]-1H-pyrazole-3-carboxamide
C20H21IN4OS
2627559-48-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.2999 6.7877 0.0 0
M  V30 2 C 5.3900 2.6673 0.0 0
M  V30 3 N 4.6200 1.3336 0.0 0
M  V30 4 O 4.6200 4.0011 0.0 0
M  V30 5 I 19.0757 5.1125 0.0 0
M  V30 6 C 10.5458 4.3425 0.0 0
M  V30 7 S 12.0105 3.8666 0.0 0
M  V30 8 C 10.5458 5.8825 0.0 0
M  V30 9 C 12.9157 5.1125 0.0 0
M  V30 10 N 12.0105 6.3584 0.0 0
M  V30 11 C 9.2999 3.4373 0.0 0
M  V30 12 C 7.8352 3.9133 0.0 0
M  V30 13 N 9.2999 1.8973 0.0 0
M  V30 14 C 6.9302 2.6673 0.0 0
M  V30 15 N 7.8352 1.4214 0.0 0
M  V30 16 C 14.4557 5.1125 0.0 0
M  V30 17 C 15.2257 3.7789 0.0 0
M  V30 18 C 15.2257 6.4463 0.0 0
M  V30 19 C 16.7657 3.7789 0.0 0
M  V30 20 C 16.7657 6.4463 0.0 0
M  V30 21 C 17.5357 5.1125 0.0 0
M  V30 22 C 3.0802 1.3336 0.0 0
M  V30 23 C 2.3100 2.6673 0.0 0
M  V30 24 C 2.3102 0.0000 0.0 0
M  V30 25 C 0.7700 2.6673 0.0 0
M  V30 26 C 0.7700 0.0000 0.0 0
M  V30 27 C 0.0000 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 14
M  V30 5 1 3 22
M  V30 6 1 5 21
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 11
M  V30 10 1 7 9
M  V30 11 1 8 10
M  V30 12 2 9 10
M  V30 13 1 9 16
M  V30 14 2 11 12
M  V30 15 1 11 13
M  V30 16 1 12 14
M  V30 17 1 13 15
M  V30 18 2 14 15
M  V30 19 2 16 17
M  V30 20 1 16 18
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 19 21
M  V30 24 1 20 21
M  V30 25 1 22 23
M  V30 26 1 22 24
M  V30 27 1 23 25
M  V30 28 1 24 26
M  V30 29 1 25 27
M  V30 30 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2627559-46-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 108-91-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2627559-48-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23575722
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and bioactivity evaluation of novel pyrazole linked
phenylthiazole derivatives in context of antibacterial activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Patel, Bhautikkumar; Zunk, Matthew; Grant, Gary; Rudrawar, Santosh
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2021), 39127853

$RFMT $RIREG SCHEME419 STEP1
$RXN



  2  1
$MOL
2-Fluoro-3-nitrobenzoic acid
C7H4FNO4
317-46-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3336 3.0800 0.0 0
M  V30 2 O 0.0000 2.3100 0.0 0
M  V30 3 O 1.3336 4.6200 0.0 0
M  V30 4 F 4.0011 4.6200 0.0 0
M  V30 5 N 6.6685 3.0800 0.0 0 VAL=5
M  V30 6 O 6.6685 4.6200 0.0 0
M  V30 7 O 8.0021 2.3100 0.0 0
M  V30 8 C 2.6674 2.3100 0.0 0
M  V30 9 C 4.0011 3.0800 0.0 0
M  V30 10 C 2.6674 0.7700 0.0 0
M  V30 11 C 5.3347 2.3100 0.0 0
M  V30 12 C 4.0011 0.0000 0.0 0
M  V30 13 C 5.3347 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 4 9
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-[1,2,2,2-Tetrafluoro-1-(trifluoromethyl)ethyl]-2-(trifluoromethyl)benzenamine
C10H5F10N
1207314-85-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 5.3347 0.0 0
M  V30 2 C 1.3336 4.5647 0.0 0
M  V30 3 C 3.5506 6.5963 0.0 0
M  V30 4 F 1.5784 6.4237 0.0 0
M  V30 5 F 0.5636 5.8984 0.0 0
M  V30 6 F 0.0000 3.7947 0.0 0
M  V30 7 F 2.1036 3.2311 0.0 0
M  V30 8 F 2.2891 7.4795 0.0 0
M  V30 9 F 4.4340 7.8577 0.0 0
M  V30 10 F 4.8122 5.7130 0.0 0
M  V30 11 C 7.2873 2.6673 0.0 0
M  V30 12 F 7.2873 4.2073 0.0 0
M  V30 13 F 8.8273 2.6673 0.0 0
M  V30 14 F 7.2873 1.1273 0.0 0
M  V30 15 N 5.7473 0.0000 0.0 0
M  V30 16 C 3.4373 4.0011 0.0 0
M  V30 17 C 4.9773 4.0011 0.0 0
M  V30 18 C 2.6673 2.6673 0.0 0
M  V30 19 C 5.7473 2.6673 0.0 0
M  V30 20 C 3.4373 1.3336 0.0 0
M  V30 21 C 4.9773 1.3336 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 16
M  V30 5 1 2 5
M  V30 6 1 2 6
M  V30 7 1 2 7
M  V30 8 1 3 8
M  V30 9 1 3 9
M  V30 10 1 3 10
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 11 14
M  V30 14 1 11 19
M  V30 15 1 15 21
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Fluoro-3-nitro-N-[4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]-2-(trifl...
C17H7F11N2O3
2416320-48-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.5230 2.6673 0.0 0
M  V30 2 C 1.2616 3.5507 0.0 0
M  V30 3 C 3.2930 1.3337 0.0 0
M  V30 4 F 1.4341 1.5784 0.0 0
M  V30 5 F 0.3782 2.2892 0.0 0
M  V30 6 F 2.1448 4.8123 0.0 0
M  V30 7 F 0.0000 4.4340 0.0 0
M  V30 8 F 4.6267 2.1037 0.0 0
M  V30 9 F 4.0630 0.0000 0.0 0
M  V30 10 F 1.9594 0.5636 0.0 0
M  V30 11 C 5.1905 7.2874 0.0 0
M  V30 12 F 6.7305 7.2874 0.0 0
M  V30 13 F 5.1905 8.8274 0.0 0
M  V30 14 F 3.6505 7.2874 0.0 0
M  V30 15 N 7.8578 5.7474 0.0 0
M  V30 16 C 9.1916 4.9774 0.0 0
M  V30 17 O 9.1916 3.4373 0.0 0
M  V30 18 F 11.8590 3.4373 0.0 0
M  V30 19 N 14.5264 4.9774 0.0 0 VAL=5
M  V30 20 O 15.8601 5.7474 0.0 0
M  V30 21 O 14.5264 3.4373 0.0 0
M  V30 22 C 3.8568 3.4373 0.0 0
M  V30 23 C 3.8568 4.9774 0.0 0
M  V30 24 C 5.1905 2.6673 0.0 0
M  V30 25 C 5.1905 5.7474 0.0 0
M  V30 26 C 6.5242 3.4373 0.0 0
M  V30 27 C 6.5242 4.9774 0.0 0
M  V30 28 C 10.5253 5.7474 0.0 0
M  V30 29 C 11.8590 4.9774 0.0 0
M  V30 30 C 10.5253 7.2874 0.0 0
M  V30 31 C 13.1926 5.7474 0.0 0
M  V30 32 C 11.8590 8.0574 0.0 0
M  V30 33 C 13.1926 7.2874 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 22
M  V30 5 1 2 5
M  V30 6 1 2 6
M  V30 7 1 2 7
M  V30 8 1 3 8
M  V30 9 1 3 9
M  V30 10 1 3 10
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 11 14
M  V30 14 1 11 25
M  V30 15 1 15 16
M  V30 16 1 15 27
M  V30 17 2 16 17
M  V30 18 1 16 28
M  V30 19 1 18 29
M  V30 20 2 19 20
M  V30 21 2 19 21
M  V30 22 1 19 31
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 29 31
M  V30 32 2 30 32
M  V30 33 2 31 33
M  V30 34 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 317-46-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1207314-85-9
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416320-48-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22020035
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 497-19-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 1330-20-7
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM optimization study, optimized on solvent, temperature and time
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of an efficient synthetic process for broflanilide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Luo, Chunyan; Xu, Qiong; Huang, Chaoqun; Luo, Liangming; Zhu, Jintao;
Zhang, Rong; Huang, Geng; Yin, Dulin
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2020), 24(6), 1024-1031

$RFMT $RIREG SCHEME420 STEP1
$RXN



  2  1
$MOL
L-Phenylalanine, 3-(phenylmethoxy)-, phenylmethyl ester, hydrochloride (1:1)
C23H23NO3.ClH
2307266-42-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6694 3.8500 0.0 0
M  V30 2 C 12.0031 4.6200 0.0 0 CFG=2
M  V30 3 C 13.3369 3.8500 0.0 0
M  V30 4 N 12.0031 6.1600 0.0 0
M  V30 5 O 14.6705 4.6200 0.0 0
M  V30 6 O 13.3369 2.3100 0.0 0
M  V30 7 C 16.0041 3.8500 0.0 0
M  V30 8 O 5.3347 3.8500 0.0 0
M  V30 9 C 4.0011 4.6200 0.0 0
M  V30 10 C 9.3358 4.6200 0.0 0
M  V30 11 C 8.0021 3.8500 0.0 0
M  V30 12 C 9.3358 6.1600 0.0 0
M  V30 13 C 6.6684 4.6200 0.0 0
M  V30 14 C 8.0021 6.9300 0.0 0
M  V30 15 C 6.6684 6.1600 0.0 0
M  V30 16 C 2.6674 3.8500 0.0 0
M  V30 17 C 2.6674 2.3100 0.0 0
M  V30 18 C 1.3336 4.6200 0.0 0
M  V30 19 C 1.3336 1.5400 0.0 0
M  V30 20 C 0.0000 3.8500 0.0 0
M  V30 21 C 0.0000 2.3100 0.0 0
M  V30 22 C 17.3378 4.6200 0.0 0
M  V30 23 C 18.6716 3.8500 0.0 0
M  V30 24 C 17.3378 6.1600 0.0 0
M  V30 25 C 20.0052 4.6200 0.0 0
M  V30 26 C 18.6716 6.9300 0.0 0
M  V30 27 C 20.0052 6.1600 0.0 0
M  V30 28 Cl 10.0026 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 22
M  V30 9 1 8 9
M  V30 10 1 8 13
M  V30 11 1 9 16
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 2 12 14
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-Bromobutanoic acid
C4H7BrO2
2623-87-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 2.3100 0.0 0
M  V30 2 C 1.3338 1.5400 0.0 0
M  V30 3 C 4.0011 1.5400 0.0 0
M  V30 4 O 0.0000 2.3100 0.0 0
M  V30 5 O 1.3338 0.0000 0.0 0
M  V30 6 C 5.3348 2.3100 0.0 0
M  V30 7 Br 6.6686 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(4-Bromo-1-oxobutyl)-3-(phenylmethoxy)-L-phenylalanine phenylmethyl ester
C27H28BrNO4
2307267-73-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.2402 8.0022 0.0 0
M  V30 2 C 7.7002 8.0022 0.0 0 CFG=2
M  V30 3 C 6.9302 9.3360 0.0 0
M  V30 4 N 6.9302 6.6685 0.0 0
M  V30 5 O 5.3901 9.3360 0.0 0
M  V30 6 O 7.7002 10.6697 0.0 0
M  V30 7 C 7.7002 5.3348 0.0 0
M  V30 8 C 4.6201 10.6697 0.0 0
M  V30 9 C 6.9302 4.0010 0.0 0
M  V30 10 O 9.2402 5.3348 0.0 0
M  V30 11 C 7.7002 2.6673 0.0 0
M  V30 12 C 6.9302 1.3337 0.0 0
M  V30 13 Br 7.7002 0.0000 0.0 0
M  V30 14 O 13.8603 10.6697 0.0 0
M  V30 15 C 14.6303 12.0033 0.0 0
M  V30 16 C 10.0102 9.3360 0.0 0
M  V30 17 C 11.5503 9.3360 0.0 0
M  V30 18 C 9.2402 10.6697 0.0 0
M  V30 19 C 12.3203 10.6697 0.0 0
M  V30 20 C 10.0102 12.0033 0.0 0
M  V30 21 C 11.5503 12.0033 0.0 0
M  V30 22 C 16.1704 12.0033 0.0 0
M  V30 23 C 16.9404 10.6697 0.0 0
M  V30 24 C 16.9404 13.3370 0.0 0
M  V30 25 C 18.4804 10.6697 0.0 0
M  V30 26 C 18.4804 13.3370 0.0 0
M  V30 27 C 19.2504 12.0033 0.0 0
M  V30 28 C 3.0801 10.6697 0.0 0
M  V30 29 C 2.3101 12.0033 0.0 0
M  V30 30 C 2.3101 9.3360 0.0 0
M  V30 31 C 0.7700 12.0033 0.0 0
M  V30 32 C 0.7700 9.3360 0.0 0
M  V30 33 C 0.0000 10.6697 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=3
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 28
M  V30 12 1 9 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 14 15
M  V30 16 1 14 19
M  V30 17 1 15 22
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 2 18 20
M  V30 22 2 19 21
M  V30 23 1 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 1 29 31
M  V30 33 2 30 32
M  V30 34 2 31 33
M  V30 35 1 32 33
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2307266-42-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2623-87-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2307267-73-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36137356
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and optimization of macrocyclic peptides as
species-selective antimalaria proteasome inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Hao; Ginn, John; Zhan, Wenhu; Liu, Yi J.; Leung, Annie; Toita,
Akinori; Okamoto, Rei; Wong, Tzu-Tshin; Imaeda, Toshihiro; Hara, Ryoma;
Yukawa, Takafumi; Michino, Mayako; Vendome, Jeremie; Beuming, Thijs;
Sato, Kenjiro; Aso, Kazuyoshi; Meinke, Peter T.; Nathan, Carl F.;
Kirkman, Laura A.; Lin, Gang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(13), 9350-9375

$RFMT $RIREG SCHEME421 STEP1
$RXN



  2  1
$MOL
Aminoacetaldehyde dimethyl acetal
C4H11NO2
22483-09-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6676 0.7700 0.0 0
M  V30 2 C 1.3340 0.0000 0.0 0
M  V30 3 O 4.0013 0.0000 0.0 0
M  V30 4 O 2.6676 2.3101 0.0 0
M  V30 5 N 0.0000 0.7700 0.0 0
M  V30 6 C 5.3350 0.7700 0.0 0
M  V30 7 C 4.0013 3.0801 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
FMOC-L-phenylalanine
C24H21NO4
35661-40-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3360 5.2309 0.0 0
M  V30 2 O 8.0021 4.4608 0.0 0
M  V30 3 C 6.6685 5.2309 0.0 0
M  V30 4 N 5.3348 4.4608 0.0 0
M  V30 5 O 6.6685 6.7709 0.0 0
M  V30 6 C 4.0011 5.2309 0.0 0 CFG=2
M  V30 7 C 4.0011 6.7709 0.0 0
M  V30 8 C 2.6673 4.4608 0.0 0
M  V30 9 O 1.3337 5.2309 0.0 0
M  V30 10 O 2.6673 2.9208 0.0 0
M  V30 11 C 10.6696 4.4608 0.0 0
M  V30 12 C 10.8306 2.9293 0.0 0
M  V30 13 C 12.0764 5.0873 0.0 0
M  V30 14 C 12.3370 2.6091 0.0 0
M  V30 15 C 9.8001 1.7849 0.0 0
M  V30 16 C 13.1070 3.9428 0.0 0
M  V30 17 C 12.5523 6.5519 0.0 0
M  V30 18 C 12.8129 1.1444 0.0 0
M  V30 19 C 10.2760 0.3202 0.0 0
M  V30 20 C 14.6133 4.2630 0.0 0
M  V30 21 C 14.0588 6.8721 0.0 0
M  V30 22 C 11.7823 0.0000 0.0 0
M  V30 23 C 15.0892 5.7277 0.0 0
M  V30 24 C 2.6673 7.5409 0.0 0
M  V30 25 C 1.3337 6.7709 0.0 0
M  V30 26 C 2.6673 9.0809 0.0 0
M  V30 27 C 0.0000 7.5409 0.0 0
M  V30 28 C 1.3337 9.8509 0.0 0
M  V30 29 C 0.0000 9.0809 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7 CFG=3
M  V30 8 1 6 8
M  V30 9 1 7 24
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 16
M  V30 19 2 14 18
M  V30 20 1 15 19
M  V30 21 2 16 20
M  V30 22 1 17 21
M  V30 23 1 18 22
M  V30 24 2 19 22
M  V30 25 1 20 23
M  V30 26 2 21 23
M  V30 27 2 24 25
M  V30 28 1 24 26
M  V30 29 1 25 27
M  V30 30 2 26 28
M  V30 31 2 27 29
M  V30 32 1 28 29
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C28H30N2O5
2387654-03-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.2309 8.0022 0.0 0
M  V30 2 O 6.7709 8.0022 0.0 0
M  V30 3 C 7.5409 6.6685 0.0 0
M  V30 4 N 9.0810 6.6685 0.0 0
M  V30 5 O 6.7709 5.3348 0.0 0
M  V30 6 C 9.8510 5.3348 0.0 0 CFG=2
M  V30 7 C 9.0810 4.0012 0.0 0
M  V30 8 C 11.3910 5.3348 0.0 0
M  V30 9 N 12.1610 6.6685 0.0 0
M  V30 10 O 12.1610 4.0012 0.0 0
M  V30 11 C 13.7011 6.6685 0.0 0
M  V30 12 C 14.4711 8.0022 0.0 0
M  V30 13 O 13.7011 9.3360 0.0 0
M  V30 14 O 16.0111 8.0022 0.0 0
M  V30 15 C 14.4711 10.6697 0.0 0
M  V30 16 C 16.7811 6.6685 0.0 0
M  V30 17 C 4.4609 9.3360 0.0 0
M  V30 18 C 5.0873 10.7428 0.0 0
M  V30 19 C 2.9293 9.4969 0.0 0
M  V30 20 C 3.9428 11.7732 0.0 0
M  V30 21 C 6.5519 11.2187 0.0 0
M  V30 22 C 2.6091 11.0032 0.0 0
M  V30 23 C 1.7849 8.4665 0.0 0
M  V30 24 C 4.2630 13.2797 0.0 0
M  V30 25 C 6.8721 12.7251 0.0 0
M  V30 26 C 1.1444 11.4793 0.0 0
M  V30 27 C 0.3202 8.9424 0.0 0
M  V30 28 C 5.7277 13.7556 0.0 0
M  V30 29 C 0.0000 10.4487 0.0 0
M  V30 30 C 9.8510 2.6673 0.0 0
M  V30 31 C 11.3910 2.6673 0.0 0
M  V30 32 C 9.0810 1.3337 0.0 0
M  V30 33 C 12.1610 1.3337 0.0 0
M  V30 34 C 9.8510 0.0000 0.0 0
M  V30 35 C 11.3910 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7 CFG=3
M  V30 8 1 6 8
M  V30 9 1 7 30
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 9 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 12 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 18 21
M  V30 22 1 19 22
M  V30 23 2 19 23
M  V30 24 1 20 22
M  V30 25 2 20 24
M  V30 26 1 21 25
M  V30 27 2 22 26
M  V30 28 1 23 27
M  V30 29 1 24 28
M  V30 30 2 25 28
M  V30 31 1 26 29
M  V30 32 2 27 29
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 31 33
M  V30 36 2 32 34
M  V30 37 2 33 35
M  V30 38 1 34 35
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 22483-09-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 35661-40-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2387654-03-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40804566
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with
Antiproliferative Activity in Breast Cancer Models
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Winter-Holt, Jon J.; Bardelle, Catherine; Chiarparin, Elisabetta; Dale,
Ian L.; Davey, Paul R. J.; Davies, Nichola L.; Denz, Christopher;
Fillery, Shaun M.; Guerot, Carine M.; Han, Fujin; Hughes, Samantha J.;
Kulkarni, Meghana; Liu, Zhaoqun; Milbradt, Alexander; Moss, Thomas A.;
Niu, Huijun; Patel, Joe; Rabow, Alfred A.; Schimpl, Marianne; Shi,
Junjie; Sun, Dongqing; Yang, Dejian; Guichard, Sylvie
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(4), 3306-3331

$RFMT $RIREG SCHEME422 STEP1
$RXN



  2  1
$MOL
(1R,3R)-3-Aminocyclohexanol
C6H13NO
721884-82-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 3.0800 0.0 0
M  V30 2 O 5.3349 3.0800 0.0 0
M  V30 3 C 2.6675 3.0800 0.0 0
M  V30 4 C 1.3338 2.3100 0.0 0 CFG=2
M  V30 5 C 4.0011 2.3100 0.0 0 CFG=2
M  V30 6 C 1.3338 0.7700 0.0 0
M  V30 7 C 4.0011 0.7700 0.0 0
M  V30 8 C 2.6675 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 1 CFG=1
M  V30 2 1 5 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 5)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-Fluoro-7-methyl-1H-indole-2-carboxylic acid
C10H8FNO2
891724-25-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 0.0000 5.3348 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 C 6.0811 5.2891 0.0 0
M  V30 4 O 6.0811 6.8291 0.0 0
M  V30 5 O 7.4149 4.5190 0.0 0
M  V30 6 C 2.3100 4.0010 0.0 0
M  V30 7 C 3.0800 2.6673 0.0 0
M  V30 8 C 3.3406 5.1455 0.0 0
M  V30 9 C 0.7700 4.0010 0.0 0
M  V30 10 N 4.5865 2.9875 0.0 0
M  V30 11 C 2.3100 1.3337 0.0 0
M  V30 12 C 4.7474 4.5190 0.0 0
M  V30 13 C 0.0000 2.6673 0.0 0
M  V30 14 C 0.7700 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 1 2 11
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 12
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 12
M  V30 14 1 11 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluoro-N-[(1R,3R)-3-hydroxycyclohexyl]-7-methyl-1H-indole-2-carboxamide
C16H19FN2O2
2834724-50-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 F 3.0801 0.0000 0.0 0
M  V30 2 C 0.0000 5.3348 0.0 0
M  V30 3 C 6.0811 5.2891 0.0 0
M  V30 4 N 7.4148 4.5191 0.0 0
M  V30 5 O 6.0811 6.8291 0.0 0
M  V30 6 O 12.7496 4.5191 0.0 0
M  V30 7 C 3.0801 2.6673 0.0 0
M  V30 8 C 2.3101 4.0010 0.0 0
M  V30 9 C 4.5864 2.9875 0.0 0
M  V30 10 C 2.3101 1.3337 0.0 0
M  V30 11 N 3.3405 5.1456 0.0 0
M  V30 12 C 0.7700 4.0010 0.0 0
M  V30 13 C 4.7475 4.5191 0.0 0
M  V30 14 C 0.7700 1.3337 0.0 0
M  V30 15 C 0.0000 2.6673 0.0 0
M  V30 16 C 8.7485 5.2891 0.0 0 CFG=2
M  V30 17 C 10.0823 4.5191 0.0 0
M  V30 18 C 8.7485 6.8291 0.0 0
M  V30 19 C 11.4160 5.2891 0.0 0 CFG=2
M  V30 20 C 10.0823 7.5991 0.0 0
M  V30 21 C 11.4160 6.8291 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 2 12
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 13
M  V30 6 1 16 4 CFG=3
M  V30 7 1 19 6 CFG=1
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 2 8 12
M  V30 13 2 9 13
M  V30 14 1 10 14
M  V30 15 1 11 13
M  V30 16 1 12 15
M  V30 17 2 14 15
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 16 19)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 721884-82-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 891724-25-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2834724-50-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40910307
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent
SETD2 Inhibitor for Clinical Studies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Alford, Joshua S.; Lampe, John W.; Brach, Dorothy; Chesworth, Richard;
Cosmopoulos, Kat; Duncan, Kenneth W.; Eckley, Sean T.; Kutok, Jeffrey L.;
Raimondi, Alejandra; Riera, Thomas V.; Shook, Brian; Tang, Cuyue; Totman,
Jennifer; Farrow, Neil A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2022), 13(7), 1137-1143

$RFMT $RIREG SCHEME422 STEP1
$RXN



  2  1
$MOL
(1R,3R)-3-Aminocyclohexanol
C6H13NO
721884-82-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 3.0800 0.0 0
M  V30 2 O 5.3349 3.0800 0.0 0
M  V30 3 C 2.6675 3.0800 0.0 0
M  V30 4 C 1.3338 2.3100 0.0 0 CFG=2
M  V30 5 C 4.0011 2.3100 0.0 0 CFG=2
M  V30 6 C 1.3338 0.7700 0.0 0
M  V30 7 C 4.0011 0.7700 0.0 0
M  V30 8 C 2.6675 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 1 CFG=1
M  V30 2 1 5 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 5)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-Fluoro-7-methyl-1H-indole-2-carboxylic acid
C10H8FNO2
891724-25-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 0.0000 5.3348 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 C 6.0811 5.2891 0.0 0
M  V30 4 O 6.0811 6.8291 0.0 0
M  V30 5 O 7.4149 4.5190 0.0 0
M  V30 6 C 2.3100 4.0010 0.0 0
M  V30 7 C 3.0800 2.6673 0.0 0
M  V30 8 C 3.3406 5.1455 0.0 0
M  V30 9 C 0.7700 4.0010 0.0 0
M  V30 10 N 4.5865 2.9875 0.0 0
M  V30 11 C 2.3100 1.3337 0.0 0
M  V30 12 C 4.7474 4.5190 0.0 0
M  V30 13 C 0.0000 2.6673 0.0 0
M  V30 14 C 0.7700 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 1 2 11
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 12
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 12
M  V30 14 1 11 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluoro-N-[(1R,3R)-3-hydroxycyclohexyl]-7-methyl-1H-indole-2-carboxamide
C16H19FN2O2
2834724-50-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 F 3.0801 0.0000 0.0 0
M  V30 2 C 0.0000 5.3348 0.0 0
M  V30 3 C 6.0811 5.2891 0.0 0
M  V30 4 N 7.4148 4.5191 0.0 0
M  V30 5 O 6.0811 6.8291 0.0 0
M  V30 6 O 12.7496 4.5191 0.0 0
M  V30 7 C 3.0801 2.6673 0.0 0
M  V30 8 C 2.3101 4.0010 0.0 0
M  V30 9 C 4.5864 2.9875 0.0 0
M  V30 10 C 2.3101 1.3337 0.0 0
M  V30 11 N 3.3405 5.1456 0.0 0
M  V30 12 C 0.7700 4.0010 0.0 0
M  V30 13 C 4.7475 4.5191 0.0 0
M  V30 14 C 0.7700 1.3337 0.0 0
M  V30 15 C 0.0000 2.6673 0.0 0
M  V30 16 C 8.7485 5.2891 0.0 0 CFG=2
M  V30 17 C 10.0823 4.5191 0.0 0
M  V30 18 C 8.7485 6.8291 0.0 0
M  V30 19 C 11.4160 5.2891 0.0 0 CFG=2
M  V30 20 C 10.0823 7.5991 0.0 0
M  V30 21 C 11.4160 6.8291 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 1 2 12
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 13
M  V30 6 1 16 4 CFG=3
M  V30 7 1 19 6 CFG=1
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 2 8 12
M  V30 13 2 9 13
M  V30 14 1 10 14
M  V30 15 1 11 13
M  V30 16 1 12 15
M  V30 17 2 14 15
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 16 19)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 721884-82-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 891724-25-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2834724-50-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34440323
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase
SETD2 Suitable for Preclinical Studies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Lampe, John W.; Alford, Joshua S.; Boriak-Sjodin, P. Ann; Brach, Dorothy;
Cosmopoulos, Kat; Duncan, Kenneth W.; Eckley, Sean T.; Foley, Megan A.;
Harvey, Darren M.; Motwani, Vinny; Munchhof, Michael J.; Raimondi,
Alejandra; Riera, Thomas V.; Tang, Cuyue; Thomenius, Michael J.; Totman,
Jennifer; Farrow, Neil A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ACS Medicinal Chemistry Letters (2021), 12(10), 1539-1545

$RFMT $RIREG SCHEME423 STEP1
$RXN



  3  1
$MOL
L-Valine
C5H11NO2
72-18-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  8 7 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 2.3101 0.0 0 CFG=2
M  V30 2 C 2.6673 0.7700 0.0 0
M  V30 3 C 1.3337 3.0801 0.0 0
M  V30 4 N 4.0010 3.0801 0.0 0
M  V30 5 C 1.3337 0.0000 0.0 0
M  V30 6 C 4.0010 0.0000 0.0 0
M  V30 7 O 0.0000 2.3101 0.0 0
M  V30 8 O 1.3337 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 2 3 8
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Glutamic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 5-(1,1-dimethylethyl)...
C24H27NO6.H2O
204251-24-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7533 6.7709 0.0 0
M  V30 2 O 5.7533 8.3109 0.0 0
M  V30 3 C 7.0871 9.0809 0.0 0
M  V30 4 N 7.0871 10.6210 0.0 0
M  V30 5 O 8.4208 8.3109 0.0 0
M  V30 6 C 8.4208 11.3910 0.0 0 CFG=2
M  V30 7 C 9.7544 10.6210 0.0 0
M  V30 8 C 8.4208 12.9310 0.0 0
M  V30 9 C 11.0881 11.3910 0.0 0
M  V30 10 O 7.0871 13.7010 0.0 0
M  V30 11 O 9.7544 13.7010 0.0 0
M  V30 12 C 12.4219 10.6210 0.0 0
M  V30 13 O 13.7556 11.3910 0.0 0
M  V30 14 O 12.4219 9.0809 0.0 0
M  V30 15 C 15.0893 10.6210 0.0 0
M  V30 16 C 15.8593 11.9546 0.0 0
M  V30 17 C 16.4229 9.8509 0.0 0
M  V30 18 C 14.3192 9.2873 0.0 0
M  V30 19 C 3.0128 6.6273 0.0 0
M  V30 20 C 4.4196 6.0009 0.0 0
M  V30 21 C 1.9822 5.4828 0.0 0
M  V30 22 C 2.5367 8.0919 0.0 0
M  V30 23 C 4.2587 4.4693 0.0 0
M  V30 24 C 2.7522 4.1491 0.0 0
M  V30 25 C 0.4759 5.8030 0.0 0
M  V30 26 C 1.0304 8.4121 0.0 0
M  V30 27 C 5.2891 3.3249 0.0 0
M  V30 28 C 2.2763 2.6844 0.0 0
M  V30 29 C 0.0000 7.2677 0.0 0
M  V30 30 C 4.8132 1.8602 0.0 0
M  V30 31 C 3.3068 1.5400 0.0 0
M  V30 32 O 8.2115 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 20
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7 CFG=3
M  V30 8 1 6 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 2 19 22
M  V30 22 1 20 23
M  V30 23 1 21 24
M  V30 24 2 21 25
M  V30 25 1 22 26
M  V30 26 1 23 24
M  V30 27 2 23 27
M  V30 28 2 24 28
M  V30 29 1 25 29
M  V30 30 2 26 29
M  V30 31 1 27 30
M  V30 32 1 28 31
M  V30 33 2 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 6)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(6-Maleimidocaproyloxy)succinimide
C14H16N2O6
55750-63-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.7711 1.3628 0.0 0
M  V30 2 C 5.1048 2.1328 0.0 0
M  V30 3 C 6.4386 1.3628 0.0 0
M  V30 4 O 5.1048 3.6728 0.0 0
M  V30 5 C 7.7722 2.1328 0.0 0
M  V30 6 C 9.1059 1.3628 0.0 0
M  V30 7 C 10.4397 2.1328 0.0 0
M  V30 8 C 11.7734 1.3628 0.0 0
M  V30 9 O 3.4209 4.6949 0.0 0
M  V30 10 O 0.7103 0.0000 0.0 0
M  V30 11 O 14.8342 0.0000 0.0 0
M  V30 12 O 12.1236 4.6949 0.0 0
M  V30 13 N 2.4374 2.1328 0.0 0
M  V30 14 C 2.2765 3.6644 0.0 0
M  V30 15 C 1.0306 1.5065 0.0 0
M  V30 16 C 0.7700 3.9845 0.0 0
M  V30 17 C 0.0000 2.6509 0.0 0
M  V30 18 N 13.1071 2.1328 0.0 0
M  V30 19 C 14.5139 1.5065 0.0 0
M  V30 20 C 13.2680 3.6644 0.0 0
M  V30 21 C 15.5445 2.6509 0.0 0
M  V30 22 C 14.7745 3.9845 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 18
M  V30 10 2 9 14
M  V30 11 2 10 15
M  V30 12 2 11 19
M  V30 13 2 12 20
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 17
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C24H37N3O8
3034676-67-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 14.6705 8.4700 0.0 0
M  V30 2 C 13.3369 7.7000 0.0 0
M  V30 3 C 12.0031 8.4700 0.0 0
M  V30 4 C 10.6694 7.7000 0.0 0
M  V30 5 C 9.3358 8.4700 0.0 0
M  V30 6 C 8.0021 7.7000 0.0 0
M  V30 7 N 6.6684 8.4700 0.0 0
M  V30 8 O 8.0021 6.1600 0.0 0
M  V30 9 C 5.3347 7.7000 0.0 0 CFG=1
M  V30 10 C 4.0011 8.4700 0.0 0
M  V30 11 C 5.3347 6.1600 0.0 0
M  V30 12 N 4.0011 10.0100 0.0 0
M  V30 13 O 2.6674 7.7000 0.0 0
M  V30 14 C 4.0011 5.3900 0.0 0
M  V30 15 C 2.6674 10.7800 0.0 0 CFG=2
M  V30 16 C 4.0011 3.8500 0.0 0
M  V30 17 C 1.3336 10.0100 0.0 0
M  V30 18 C 2.6674 12.3200 0.0 0
M  V30 19 O 2.6674 3.0800 0.0 0
M  V30 20 O 5.3347 3.0800 0.0 0
M  V30 21 C 1.3336 8.4700 0.0 0
M  V30 22 C 0.0000 10.7800 0.0 0
M  V30 23 O 1.3336 13.0900 0.0 0
M  V30 24 O 4.0011 13.0900 0.0 0
M  V30 25 C 2.6674 1.5400 0.0 0
M  V30 26 C 4.2074 1.5400 0.0 0
M  V30 27 C 2.6674 0.0000 0.0 0
M  V30 28 C 1.1274 1.5400 0.0 0
M  V30 29 O 15.0207 5.1379 0.0 0
M  V30 30 O 17.7313 9.8327 0.0 0
M  V30 31 N 16.0041 7.7000 0.0 0
M  V30 32 C 16.1651 6.1685 0.0 0
M  V30 33 C 17.4111 8.3263 0.0 0
M  V30 34 C 17.6715 5.8483 0.0 0
M  V30 35 C 18.4415 7.1819 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 31
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 9 11 CFG=1
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 1 12 15
M  V30 16 1 14 16
M  V30 17 1 15 17 CFG=1
M  V30 18 1 15 18
M  V30 19 1 16 19
M  V30 20 2 16 20
M  V30 21 1 17 21
M  V30 22 1 17 22
M  V30 23 1 18 23
M  V30 24 2 18 24
M  V30 25 1 19 25
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 1 25 28
M  V30 29 2 29 32
M  V30 30 2 30 33
M  V30 31 1 31 32
M  V30 32 1 31 33
M  V30 33 1 32 34
M  V30 34 1 33 35
M  V30 35 2 34 35
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 9 15)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 72-18-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 204251-24-1
$DTYPE RXN:RCT(3):CAS_RN
$DATUM 55750-63-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3034676-67-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35039294
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 6
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 110-89-4
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 76-05-1
$DTYPE RXN:VAR(1):RGT(5):CAS_RN
$DATUM 920-66-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM H-valine-2-chlorotrityl resin used (stage 1)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug
Conjugates by Linker Stabilization and Conjugation to Transthyretin
Binding Ligand
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Amin, Toufiq Ul; Emara, Rasha; Pal, Arindom; Aldawod, Hala; Jiang,
Guanming; Liang, Dengpan; Haque Tuhin, Tariqul Md; Balgoname, Abdulmalek;
Patel, Arjun D.; Alhamadsheh, Mamoun M.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(22), 15473-15486

$RFMT $RIREG SCHEME424 STEP1
$RXN



  2  1
$MOL
3,4-Dimethoxyphenethylamine
C10H15NO2
120-20-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3349 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3349 0.0 0
M  V30 7 N 9.2400 5.3349 0.0 0
M  V30 8 C 3.0800 2.6674 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.0800 5.3349 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 4.6200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(1-Methyl-1H-indol-3-yl)acetic acid
C11H11NO2
1912-48-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7306 4.6948 0.0 0
M  V30 2 C 7.1953 4.2188 0.0 0
M  V30 3 O 7.5155 2.7126 0.0 0
M  V30 4 O 8.3397 5.2494 0.0 0
M  V30 5 C 3.0202 0.0000 0.0 0
M  V30 6 C 3.0800 3.9844 0.0 0
M  V30 7 C 4.5863 3.6643 0.0 0
M  V30 8 C 2.3100 2.6508 0.0 0
M  V30 9 C 2.3100 5.3182 0.0 0
M  V30 10 C 4.7472 2.1327 0.0 0
M  V30 11 N 3.3404 1.5064 0.0 0
M  V30 12 C 0.7700 2.6508 0.0 0
M  V30 13 C 0.7700 5.3182 0.0 0
M  V30 14 C 0.0000 3.9844 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 11
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 2 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 11
M  V30 14 1 12 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)ethyl]-1-methyl-1H-indole-3-acetamide
C21H24N2O3
688759-87-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2309 6.6686 0.0 0
M  V30 2 C 6.7709 6.6686 0.0 0
M  V30 3 N 7.5409 5.3348 0.0 0
M  V30 4 O 7.5409 8.0023 0.0 0
M  V30 5 C 9.0809 5.3348 0.0 0
M  V30 6 C 9.8509 4.0011 0.0 0
M  V30 7 C 4.1037 11.9713 0.0 0
M  V30 8 O 14.4710 1.3338 0.0 0
M  V30 9 C 13.7010 0.0000 0.0 0
M  V30 10 O 16.0111 4.0011 0.0 0
M  V30 11 C 16.7811 5.3348 0.0 0
M  V30 12 C 2.9293 8.1632 0.0 0
M  V30 13 C 4.4608 8.0023 0.0 0
M  V30 14 C 2.6091 9.6697 0.0 0
M  V30 15 C 1.7849 7.1328 0.0 0
M  V30 16 C 5.0873 9.4091 0.0 0
M  V30 17 N 3.9428 10.4397 0.0 0
M  V30 18 C 1.1444 10.1456 0.0 0
M  V30 19 C 0.3202 7.6087 0.0 0
M  V30 20 C 0.0000 9.1150 0.0 0
M  V30 21 C 11.3910 4.0011 0.0 0
M  V30 22 C 12.1610 2.6675 0.0 0
M  V30 23 C 12.1610 5.3348 0.0 0
M  V30 24 C 13.7010 2.6675 0.0 0
M  V30 25 C 13.7010 5.3348 0.0 0
M  V30 26 C 14.4710 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 21
M  V30 8 1 7 17
M  V30 9 1 8 9
M  V30 10 1 8 24
M  V30 11 1 10 11
M  V30 12 1 10 26
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 1 15 19
M  V30 20 1 16 17
M  V30 21 1 18 20
M  V30 22 2 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 120-20-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1912-48-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 688759-87-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23040326
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME425 STEP1
$RXN



  2  1
$MOL
Benzoic acid, 5-amino-2-bromo-4-iodo-, methyl ester
C8H7BrINO2
2092601-78-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 O 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 Br 4.6200 0.0000 0.0 0
M  V30 6 N 1.5400 5.3349 0.0 0
M  V30 7 I 0.0000 2.6674 0.0 0
M  V30 8 C 4.6200 2.6674 0.0 0
M  V30 9 C 3.8500 1.3338 0.0 0
M  V30 10 C 3.8500 4.0011 0.0 0
M  V30 11 C 2.3100 1.3338 0.0 0
M  V30 12 C 2.3100 4.0011 0.0 0
M  V30 13 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 5 9
M  V30 6 1 6 12
M  V30 7 1 7 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
trans-4-[(Phenylmethoxy)methyl]cyclohexanecarboxylic acid
C15H20O3
2304449-48-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 4.6201 0.0 0
M  V30 2 O 5.3348 3.8501 0.0 0
M  V30 3 C 4.0010 4.6201 0.0 0
M  V30 4 C 12.0033 1.5400 0.0 0
M  V30 5 O 13.3370 2.3101 0.0 0
M  V30 6 O 12.0033 0.0000 0.0 0
M  V30 7 C 8.0022 3.8501 0.0 0 CFG=1
M  V30 8 C 8.0022 2.3101 0.0 0
M  V30 9 C 9.3360 4.6201 0.0 0
M  V30 10 C 9.3360 1.5400 0.0 0
M  V30 11 C 10.6697 3.8501 0.0 0
M  V30 12 C 10.6697 2.3101 0.0 0 CFG=1
M  V30 13 C 2.6673 3.8501 0.0 0
M  V30 14 C 1.3337 4.6201 0.0 0
M  V30 15 C 2.6673 2.3101 0.0 0
M  V30 16 C 0.0000 3.8501 0.0 0
M  V30 17 C 1.3337 1.5400 0.0 0
M  V30 18 C 0.0000 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 7 1 CFG=1
M  V30 3 1 2 3
M  V30 4 1 3 13
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 12 4 CFG=3
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(2 7 12)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Methyl 2-bromo-4-iodo-5-[[[trans-4-[(phenylmethoxy)methyl]cyclohexyl]carbonyl...
C23H25BrINO4
2654056-19-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9301 2.6675 0.0 0
M  V30 2 C 7.7001 4.0011 0.0 0
M  V30 3 O 6.9301 5.3348 0.0 0
M  V30 4 I 5.3901 0.0000 0.0 0
M  V30 5 C 2.3100 5.3348 0.0 0
M  V30 6 O 0.7700 5.3348 0.0 0
M  V30 7 O 3.0800 6.6684 0.0 0
M  V30 8 C 0.0000 6.6684 0.0 0
M  V30 9 Br 0.7700 2.6675 0.0 0
M  V30 10 C 13.8602 4.0011 0.0 0
M  V30 11 O 14.6302 5.3348 0.0 0
M  V30 12 C 16.1702 5.3348 0.0 0
M  V30 13 C 5.3901 2.6675 0.0 0
M  V30 14 C 4.6201 4.0011 0.0 0
M  V30 15 C 4.6201 1.3337 0.0 0
M  V30 16 C 3.0800 4.0011 0.0 0
M  V30 17 C 3.0800 1.3337 0.0 0
M  V30 18 C 2.3100 2.6675 0.0 0
M  V30 19 C 9.2401 4.0011 0.0 0 CFG=1
M  V30 20 C 10.0101 5.3348 0.0 0
M  V30 21 C 10.0101 2.6675 0.0 0
M  V30 22 C 11.5501 5.3348 0.0 0
M  V30 23 C 11.5501 2.6675 0.0 0
M  V30 24 C 12.3201 4.0011 0.0 0 CFG=1
M  V30 25 C 16.9402 6.6684 0.0 0
M  V30 26 C 18.4802 6.6684 0.0 0
M  V30 27 C 16.1702 8.0022 0.0 0
M  V30 28 C 19.2502 8.0022 0.0 0
M  V30 29 C 16.9402 9.3359 0.0 0
M  V30 30 C 18.4802 9.3359 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 2 2 3
M  V30 4 1 19 2 CFG=3
M  V30 5 1 4 15
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 16
M  V30 9 1 6 8
M  V30 10 1 9 18
M  V30 11 1 10 11
M  V30 12 1 24 10 CFG=1
M  V30 13 1 11 12
M  V30 14 1 12 25
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(2 19 24)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2092601-78-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2304449-48-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2654056-19-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39101188
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD
Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Weiss, Matthew M.; Zheng, Xiaozhang; Ji, Nan; Browne, Chris M.; Campbell,
Veronica; Chen, Dapeng; Enerson, Brad; Fei, Xue; Huang, Xin; Klaus,
Christine R.; Li, Haoran; Mayo, Michele; McDonald, Alice A.; Paul, Atanu;
Rong, Haojing; Sharma, Kirti; Shi, Yatao; Slavin, Anthony; Walther, Dirk
M.; Yuan, Karen; Zhang, Yi; Zhu, Xiao; Kelleher, Joe; Walker, Duncan;
Mainolfi, Nello
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(13), 10548-10566

$RFMT $RIREG SCHEME426 STEP1
$RXN



  2  1
$MOL
rel-1-(1,1-Dimethylethyl) (3R,4R)-4-[bis(phenylmethyl)amino]-1,3-piperidinedi...
C25H32N2O4
2560515-61-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3900 5.3347 0.0 0
M  V30 2 C 4.6200 4.0011 0.0 0
M  V30 3 C 4.6200 6.6684 0.0 0
M  V30 4 C 6.9300 8.0021 0.0 0
M  V30 5 O 7.7000 9.3358 0.0 0
M  V30 6 O 5.3900 8.0021 0.0 0
M  V30 7 C 11.5500 5.3347 0.0 0
M  V30 8 O 12.3200 6.6684 0.0 0
M  V30 9 O 12.3200 4.0011 0.0 0
M  V30 10 C 13.8600 6.6684 0.0 0
M  V30 11 C 13.8600 8.2084 0.0 0
M  V30 12 C 15.4000 6.6684 0.0 0
M  V30 13 C 13.8600 5.1284 0.0 0
M  V30 14 C 6.9300 5.3347 0.0 0 CFG=1
M  V30 15 C 7.7000 6.6684 0.0 0 CFG=1
M  V30 16 C 7.7000 4.0011 0.0 0
M  V30 17 C 9.2400 6.6684 0.0 0
M  V30 18 C 9.2400 4.0011 0.0 0
M  V30 19 N 10.0100 5.3347 0.0 0
M  V30 20 C 5.3900 2.6674 0.0 0
M  V30 21 C 6.9300 2.6674 0.0 0
M  V30 22 C 4.6200 1.3336 0.0 0
M  V30 23 C 7.7000 1.3336 0.0 0
M  V30 24 C 5.3900 0.0000 0.0 0
M  V30 25 C 6.9300 0.0000 0.0 0
M  V30 26 C 3.0800 6.6684 0.0 0
M  V30 27 C 2.3100 8.0021 0.0 0
M  V30 28 C 2.3100 5.3347 0.0 0
M  V30 29 C 0.7700 8.0021 0.0 0
M  V30 30 C 0.7700 5.3347 0.0 0
M  V30 31 C 0.0000 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 14 1 CFG=3
M  V30 4 1 2 20
M  V30 5 1 3 26
M  V30 6 1 4 5
M  V30 7 2 4 6
M  V30 8 1 15 4 CFG=1
M  V30 9 1 7 8
M  V30 10 2 7 9
M  V30 11 1 7 19
M  V30 12 1 8 10
M  V30 13 1 10 11
M  V30 14 1 10 12
M  V30 15 1 10 13
M  V30 16 1 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 1 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 2 28 30
M  V30 32 2 29 31
M  V30 33 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(2 14 15)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Cyclohexylamine
C6H13N
108-91-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
rel-1,1-Dimethylethyl (3R,4R)-4-[bis(phenylmethyl)amino]-3-[(cyclohexylamino)...
C31H43N3O3
2540590-96-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3900 8.0020 0.0 0
M  V30 2 C 4.6200 9.3358 0.0 0
M  V30 3 C 4.6200 6.6684 0.0 0
M  V30 4 C 6.9300 5.3347 0.0 0
M  V30 5 N 7.7000 4.0009 0.0 0
M  V30 6 O 5.3900 5.3347 0.0 0
M  V30 7 C 11.5500 8.0020 0.0 0
M  V30 8 O 12.3200 9.3358 0.0 0
M  V30 9 O 12.3200 6.6684 0.0 0
M  V30 10 C 13.8600 9.3358 0.0 0
M  V30 11 C 13.8600 7.7958 0.0 0
M  V30 12 C 15.4000 9.3358 0.0 0
M  V30 13 C 13.8600 10.8758 0.0 0
M  V30 14 C 6.9300 8.0020 0.0 0 CFG=1
M  V30 15 C 7.7000 6.6684 0.0 0 CFG=1
M  V30 16 C 7.7000 9.3358 0.0 0
M  V30 17 C 9.2400 6.6684 0.0 0
M  V30 18 C 9.2400 9.3358 0.0 0
M  V30 19 N 10.0100 8.0020 0.0 0
M  V30 20 C 5.3900 10.6694 0.0 0
M  V30 21 C 4.6200 12.0031 0.0 0
M  V30 22 C 6.9300 10.6694 0.0 0
M  V30 23 C 5.3900 13.3367 0.0 0
M  V30 24 C 7.7000 12.0031 0.0 0
M  V30 25 C 6.9300 13.3367 0.0 0
M  V30 26 C 3.0800 6.6684 0.0 0
M  V30 27 C 2.3100 8.0020 0.0 0
M  V30 28 C 2.3100 5.3347 0.0 0
M  V30 29 C 0.7700 8.0020 0.0 0
M  V30 30 C 0.7700 5.3347 0.0 0
M  V30 31 C 0.0000 6.6684 0.0 0
M  V30 32 C 6.9300 2.6673 0.0 0
M  V30 33 C 7.7000 1.3336 0.0 0
M  V30 34 C 5.3900 2.6673 0.0 0
M  V30 35 C 6.9300 0.0000 0.0 0
M  V30 36 C 4.6200 1.3336 0.0 0
M  V30 37 C 5.3900 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 14 1 CFG=1
M  V30 4 1 2 20
M  V30 5 1 3 26
M  V30 6 1 4 5
M  V30 7 2 4 6
M  V30 8 1 15 4 CFG=3
M  V30 9 1 5 32
M  V30 10 1 7 8
M  V30 11 2 7 9
M  V30 12 1 7 19
M  V30 13 1 8 10
M  V30 14 1 10 11
M  V30 15 1 10 12
M  V30 16 1 10 13
M  V30 17 1 14 15
M  V30 18 1 14 16
M  V30 19 1 15 17
M  V30 20 1 16 18
M  V30 21 1 17 19
M  V30 22 1 18 19
M  V30 23 2 20 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 2 22 24
M  V30 27 2 23 25
M  V30 28 1 24 25
M  V30 29 2 26 27
M  V30 30 1 26 28
M  V30 31 1 27 29
M  V30 32 2 28 30
M  V30 33 2 29 31
M  V30 34 1 30 31
M  V30 35 1 32 33
M  V30 36 1 32 34
M  V30 37 1 33 35
M  V30 38 1 34 36
M  V30 39 1 35 37
M  V30 40 1 36 37
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEREL1 ATOMS=(2 14 15)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2560515-61-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 108-91-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2540590-96-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22988979
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the
Bromo and Extra Terminal Domain (BET) Proteins
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Watson, Robert J.; Bamborough, Paul; Barnett, Heather; Chung, Chun-wa;
Davis, Rob; Gordon, Laurie; Grandi, Paola; Petretich, Massimo; Phillipou,
Alex; Prinjha, Rab K.; Rioja, Inmaculada; Soden, Peter; Werner, Thilo;
Demont, Emmanuel H.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(17), 9045-9069

$RFMT $RIREG SCHEME427 STEP1
$RXN



  2  1
$MOL
Indole-2-carboxylic acid
C9H7NO2
1477-50-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.0811 1.5400 0.0 0
M  V30 2 O 7.4149 2.3100 0.0 0
M  V30 3 O 6.0811 0.0000 0.0 0
M  V30 4 C 2.3100 2.8281 0.0 0
M  V30 5 C 3.0800 4.1618 0.0 0
M  V30 6 C 3.3406 1.6836 0.0 0
M  V30 7 C 0.7700 2.8281 0.0 0
M  V30 8 N 4.5865 3.8416 0.0 0
M  V30 9 C 2.3100 5.4954 0.0 0
M  V30 10 C 4.7474 2.3100 0.0 0
M  V30 11 C 0.0000 4.1618 0.0 0
M  V30 12 C 0.7700 5.4954 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 1 5 8
M  V30 8 2 5 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 1 8 10
M  V30 12 1 9 12
M  V30 13 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Phenylalanine, 1,1-dimethylethyl ester, hydrochloride (1:1)
C13H19NO2.ClH
15100-75-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 5.7473 0.0 0
M  V30 2 C 5.3901 4.4137 0.0 0 CFG=2
M  V30 3 C 6.9301 4.4137 0.0 0
M  V30 4 N 4.6201 3.0800 0.0 0
M  V30 5 O 7.7001 3.0800 0.0 0
M  V30 6 O 7.7001 5.7473 0.0 0
M  V30 7 C 9.2401 3.0800 0.0 0
M  V30 8 C 9.2401 4.6200 0.0 0
M  V30 9 C 10.7801 3.0800 0.0 0
M  V30 10 C 9.2401 1.5400 0.0 0
M  V30 11 C 3.0800 5.7473 0.0 0
M  V30 12 C 2.3100 4.4137 0.0 0
M  V30 13 C 2.3100 7.0810 0.0 0
M  V30 14 C 0.7700 4.4137 0.0 0
M  V30 15 C 0.7700 7.0810 0.0 0
M  V30 16 C 0.0000 5.7473 0.0 0
M  V30 17 Cl 5.3901 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C22H24N2O3
3054277-59-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.7238 6.6684 0.0 0
M  V30 2 N 5.9538 5.3347 0.0 0
M  V30 3 O 5.9538 8.0021 0.0 0
M  V30 4 C 4.4138 5.3347 0.0 0 CFG=2
M  V30 5 C 3.6438 4.0011 0.0 0
M  V30 6 C 3.6438 6.6684 0.0 0
M  V30 7 O 2.1038 6.6684 0.0 0
M  V30 8 O 4.4138 8.0021 0.0 0
M  V30 9 C 1.3338 8.0021 0.0 0
M  V30 10 C 0.0000 7.2321 0.0 0
M  V30 11 C 0.5638 9.3358 0.0 0
M  V30 12 C 2.6674 8.7721 0.0 0
M  V30 13 C 10.6335 7.4384 0.0 0
M  V30 14 C 10.6335 5.8984 0.0 0
M  V30 15 C 9.1690 7.9144 0.0 0
M  V30 16 C 11.9672 8.2084 0.0 0
M  V30 17 N 9.1690 5.4225 0.0 0
M  V30 18 C 11.9672 5.1284 0.0 0
M  V30 19 C 8.2638 6.6684 0.0 0
M  V30 20 C 13.3010 7.4384 0.0 0
M  V30 21 C 13.3010 5.8984 0.0 0
M  V30 22 C 4.4138 2.6674 0.0 0
M  V30 23 C 5.9538 2.6674 0.0 0
M  V30 24 C 3.6438 1.3336 0.0 0
M  V30 25 C 6.7238 1.3336 0.0 0
M  V30 26 C 4.4138 0.0000 0.0 0
M  V30 27 C 5.9538 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 19
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 5 22
M  V30 8 1 6 7
M  V30 9 2 6 8
M  V30 10 1 7 9
M  V30 11 1 9 10
M  V30 12 1 9 11
M  V30 13 1 9 12
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 2 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 1 18 21
M  V30 23 2 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1477-50-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 15100-75-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3054277-59-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38275827
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Pyrazolidinone-based peptidomimetic SARS-CoV-2 Mpro inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Jelisejevs, Daniels; Bula, Anna Lina; Kinena, Linda
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2023), 96129530

$RFMT $RIREG SCHEME428 STEP1
$RXN



  3  1
$MOL
Cyclooctylamine
C8H17N
5452-37-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5167 2.4587 0.0 0
M  V30 2 C 3.9899 2.2575 0.0 0
M  V30 3 C 3.2199 3.5914 0.0 0
M  V30 4 C 3.5912 0.7700 0.0 0
M  V30 5 C 1.7322 3.9899 0.0 0
M  V30 6 C 2.2575 0.0000 0.0 0
M  V30 7 C 0.3986 3.2199 0.0 0
M  V30 8 C 0.7700 0.3986 0.0 0
M  V30 9 C 0.0000 1.7324 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromo-1H-pyrrole-2-carboxylic acid
C5H4BrNO2
27746-02-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 O 0.0000 2.3101 0.0 0
M  V30 3 O 1.3337 0.0000 0.0 0
M  V30 4 Br 6.6363 2.6672 0.0 0
M  V30 5 C 2.6673 2.3101 0.0 0
M  V30 6 C 4.0743 1.6836 0.0 0
M  V30 7 N 2.8284 3.8416 0.0 0
M  V30 8 C 5.1048 2.8281 0.0 0
M  V30 9 C 4.3347 4.1618 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 8
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Di-tert-butyl dicarbonate
C10H18O5
24424-99-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6673 0.5637 0.0 0
M  V30 2 C 1.3337 1.3337 0.0 0
M  V30 3 C 4.0012 1.3337 0.0 0
M  V30 4 C 0.5637 0.0000 0.0 0
M  V30 5 C 0.0000 2.1037 0.0 0
M  V30 6 C 2.1037 2.6673 0.0 0
M  V30 7 O 5.3348 0.5637 0.0 0
M  V30 8 O 4.0012 2.8737 0.0 0
M  V30 9 C 6.6685 1.3337 0.0 0
M  V30 10 O 8.0023 0.5637 0.0 0
M  V30 11 O 6.6685 2.8737 0.0 0
M  V30 12 C 9.3360 1.3337 0.0 0
M  V30 13 C 10.1060 0.0000 0.0 0
M  V30 14 C 10.6697 2.1037 0.0 0
M  V30 15 C 8.5660 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 2 3 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 4-bromo-2-[(cyclooctylamino)carbonyl]-1H-pyrrole-1-carboxylate
C18H27BrN2O3
2290532-73-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9757 4.9523 0.0 0
M  V30 2 N 8.4819 4.6321 0.0 0
M  V30 3 O 6.4998 6.4170 0.0 0
M  V30 4 C 3.6436 5.3025 0.0 0
M  V30 5 O 2.1036 5.3025 0.0 0
M  V30 6 O 4.4136 6.6363 0.0 0
M  V30 7 C 1.3336 6.6363 0.0 0
M  V30 8 C 0.0000 5.8663 0.0 0
M  V30 9 C 0.5636 7.9699 0.0 0
M  V30 10 C 2.6674 7.4063 0.0 0
M  V30 11 Br 4.7707 0.0000 0.0 0
M  V30 12 C 5.9453 3.8079 0.0 0
M  V30 13 N 4.4136 3.9689 0.0 0
M  V30 14 C 6.2654 2.3015 0.0 0
M  V30 15 C 3.7873 2.5621 0.0 0
M  V30 16 C 4.9317 1.5315 0.0 0
M  V30 17 C 9.5125 5.7766 0.0 0
M  V30 18 C 8.8494 7.1665 0.0 0
M  V30 19 C 10.9641 5.2624 0.0 0
M  V30 20 C 9.3636 8.6182 0.0 0
M  V30 21 C 12.3541 5.9256 0.0 0
M  V30 22 C 10.7534 9.2812 0.0 0
M  V30 23 C 12.8681 7.3772 0.0 0
M  V30 24 C 12.2052 8.7671 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 17
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 13
M  V30 8 1 5 7
M  V30 9 1 7 8
M  V30 10 1 7 9
M  V30 11 1 7 10
M  V30 12 1 11 16
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 16
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5452-37-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 27746-02-7
$DTYPE RXN:RCT(3):CAS_RN
$DATUM 24424-99-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2290532-73-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39885797
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide
Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for
Treating Drug-Resistant Tuberculosis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhao, Hongyi; Gao, Yongxin; Li, Wei; Sheng, Li; Cui, Keli; Wang, Bin; Fu,
Lei; Gao, Meng; Lin, Ziyun; Zou, Xiaowen; Jackson, Mary; Huang, Haihong;
Lu, Yu; Zhang, Dongfeng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(15), 10534-10553

$RFMT $RIREG SCHEME429 STEP1
$RXN



  2  1
$MOL
Acetic acid
C2H4O2
64-19-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 1.5400 0.0 0
M  V30 2 C 0.0000 2.3101 0.0 0
M  V30 3 O 2.6673 2.3101 0.0 0
M  V30 4 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Amino-N-[(2-chlorophenyl)methyl]-2-[[3-(10,11-dihydro-5H-dibenzo[a,d]cycloh...
C30H34ClN3O
2648234-34-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2066 5.3084 0.0 0
M  V30 2 C 6.5402 4.5384 0.0 0
M  V30 3 C 7.8740 5.3084 0.0 0
M  V30 4 N 9.2077 4.5384 0.0 0
M  V30 5 C 10.5413 5.3084 0.0 0
M  V30 6 C 9.2077 2.9984 0.0 0
M  V30 7 C 11.8749 4.5384 0.0 0
M  V30 8 C 10.5413 6.8484 0.0 0
M  V30 9 N 13.2087 5.3084 0.0 0
M  V30 10 O 11.8749 2.9984 0.0 0
M  V30 11 C 11.8749 7.6184 0.0 0
M  V30 12 C 14.5424 4.5384 0.0 0
M  V30 13 N 11.8749 9.1584 0.0 0
M  V30 14 Cl 17.2097 2.9984 0.0 0
M  V30 15 C 3.8729 4.5384 0.0 0
M  V30 16 C 3.9880 3.0027 0.0 0
M  V30 17 C 2.6006 5.4060 0.0 0
M  V30 18 C 2.8592 1.9553 0.0 0
M  V30 19 C 5.4596 2.5489 0.0 0
M  V30 20 C 1.1290 4.9520 0.0 0
M  V30 21 C 2.9432 6.9074 0.0 0
M  V30 22 C 1.3363 2.1848 0.0 0
M  V30 23 C 3.2018 0.4538 0.0 0
M  V30 24 C 5.8023 1.0474 0.0 0
M  V30 25 C 0.5663 3.5184 0.0 0
M  V30 26 C 0.0000 5.9995 0.0 0
M  V30 27 C 1.8143 7.9549 0.0 0
M  V30 28 C 4.6734 0.0000 0.0 0
M  V30 29 C 0.3426 7.5009 0.0 0
M  V30 30 C 15.8760 5.3084 0.0 0
M  V30 31 C 17.2097 4.5384 0.0 0
M  V30 32 C 15.8760 6.8484 0.0 0
M  V30 33 C 18.5434 5.3084 0.0 0
M  V30 34 C 17.2097 7.6184 0.0 0
M  V30 35 C 18.5434 6.8484 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 15
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 30
M  V30 15 1 14 31
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 16 19
M  V30 20 1 17 20
M  V30 21 2 17 21
M  V30 22 1 18 22
M  V30 23 2 18 23
M  V30 24 1 19 24
M  V30 25 1 20 25
M  V30 26 2 20 26
M  V30 27 1 21 27
M  V30 28 1 22 25
M  V30 29 1 23 28
M  V30 30 2 24 28
M  V30 31 1 26 29
M  V30 32 2 27 29
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 31 33
M  V30 36 2 32 34
M  V30 37 2 33 35
M  V30 38 1 34 35
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Acetylamino)-N-[(2-chlorophenyl)methyl]-2-[[3-(10,11-dihydro-5H-dibenzo[a,...
C32H36ClN3O2
2648234-39-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  38 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.5502 9.3358 0.0 0
M  V30 2 C 10.0101 9.3358 0.0 0
M  V30 3 C 9.2401 8.0021 0.0 0
M  V30 4 N 7.7001 8.0021 0.0 0
M  V30 5 C 6.9301 6.6684 0.0 0
M  V30 6 C 6.9301 9.3358 0.0 0
M  V30 7 C 5.3901 6.6684 0.0 0
M  V30 8 C 7.7001 5.3348 0.0 0
M  V30 9 N 4.6201 8.0021 0.0 0
M  V30 10 O 4.6201 5.3348 0.0 0
M  V30 11 C 6.9301 4.0010 0.0 0
M  V30 12 C 3.0800 8.0021 0.0 0
M  V30 13 N 7.7001 2.6673 0.0 0
M  V30 14 C 6.9301 1.3337 0.0 0
M  V30 15 C 5.3901 1.3337 0.0 0
M  V30 16 O 7.7001 0.0000 0.0 0
M  V30 17 Cl 0.0000 8.0021 0.0 0
M  V30 18 C 12.3202 10.6696 0.0 0
M  V30 19 C 11.4527 11.9419 0.0 0
M  V30 20 C 13.8559 10.5544 0.0 0
M  V30 21 C 11.9065 13.4136 0.0 0
M  V30 22 C 9.9512 11.5993 0.0 0
M  V30 23 C 14.9033 11.6834 0.0 0
M  V30 24 C 14.3097 9.0829 0.0 0
M  V30 25 C 13.3401 13.9762 0.0 0
M  V30 26 C 10.8590 14.5424 0.0 0
M  V30 27 C 8.9038 12.7281 0.0 0
M  V30 28 C 14.6738 13.2061 0.0 0
M  V30 29 C 16.4048 11.3407 0.0 0
M  V30 30 C 15.8113 8.7401 0.0 0
M  V30 31 C 9.3576 14.1998 0.0 0
M  V30 32 C 16.8586 9.8691 0.0 0
M  V30 33 C 2.3100 9.3358 0.0 0
M  V30 34 C 0.7700 9.3358 0.0 0
M  V30 35 C 3.0800 10.6696 0.0 0
M  V30 36 C 0.0000 10.6696 0.0 0
M  V30 37 C 2.3100 12.0032 0.0 0
M  V30 38 C 0.7700 12.0032 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 18
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 9 12
M  V30 13 1 11 13
M  V30 14 1 12 33
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 14 16
M  V30 18 1 17 34
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 19 22
M  V30 23 1 20 23
M  V30 24 2 20 24
M  V30 25 1 21 25
M  V30 26 2 21 26
M  V30 27 1 22 27
M  V30 28 1 23 28
M  V30 29 2 23 29
M  V30 30 1 24 30
M  V30 31 1 25 28
M  V30 32 1 26 31
M  V30 33 2 27 31
M  V30 34 1 29 32
M  V30 35 2 30 32
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 34 36
M  V30 39 2 35 37
M  V30 40 2 36 38
M  V30 41 1 37 38
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2648234-34-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2648234-39-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23749889
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as
inhibitors of GABA transporters mGAT1-4 with anticonvulsant,
antinociceptive, and antidepressant activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zareba, Paula; Salat, Kinga; Hofner, Georg C.; Latka, Kamil; Bajda,
Marek; Latacz, Gniewomir; Kotniewicz, Krzysztof; Rapacz, Anna; Podkowa,
Adrian; Maj, Maciej; Jozwiak, Krzysztof; Filipek, Barbara; Wanner, Klaus
T.; Malawska, Barbara; Kulig, Katarzyna
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 221113512

$RFMT $RIREG SCHEME430 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-bromobenzoic acid
C7H6BrNO2
20776-50-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 Br 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
7-Bromo-4(3H)-quinazolinone
C8H5BrN2O
194851-16-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 4.0010 0.0 0
M  V30 2 Br 6.9302 2.6673 0.0 0
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 C 3.0801 1.3337 0.0 0
M  V30 5 C 0.7700 2.6673 0.0 0
M  V30 6 C 3.0801 4.0010 0.0 0
M  V30 7 C 4.6201 1.3337 0.0 0
M  V30 8 N 2.3101 0.0000 0.0 0
M  V30 9 N 0.0000 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 12 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 20776-50-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 194851-16-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-28202897
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, biological evaluation and structure-activity
relationship study of quinazolin-4(3H)-one derivatives as novel USP7
inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Peng; Liu, Ying; Yang, Hua; Liu, Hong-Min
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 216113291

$RFMT $RIREG SCHEME430 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-bromobenzoic acid
C7H6BrNO2
20776-50-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 Br 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
7-Bromo-4(3H)-quinazolinone
C8H5BrN2O
194851-16-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 4.0010 0.0 0
M  V30 2 Br 6.9302 2.6673 0.0 0
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 C 3.0801 1.3337 0.0 0
M  V30 5 C 0.7700 2.6673 0.0 0
M  V30 6 C 3.0801 4.0010 0.0 0
M  V30 7 C 4.6201 1.3337 0.0 0
M  V30 8 N 2.3101 0.0000 0.0 0
M  V30 9 N 0.0000 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 12 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 20776-50-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 194851-16-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37481032
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 64-18-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel 4-Arylindolines Containing a Pyrido[3,2-d]pyrimidine Moiety as the
Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
Inhibitors for Tumor Immunotherapy
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Meng, Yangyang; Wang, Yidong; Zhang, Shaopeng; Yang, Yuan; Wu, Di; Cui,
Wei; Niu, Xinyu; Chu, Cuiping; Wang, Lihui; Qin, Mingze
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(17), 11815-11830

$RFMT $RIREG SCHEME431 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-fluorobenzoic acid
C7H6FNO2
446-32-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 F 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
7-Fluoroquinazolin-4(3H)-one
C8H5FN2O
16499-57-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 4.0010 0.0 0
M  V30 2 F 6.9302 2.6673 0.0 0
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 C 3.0801 1.3337 0.0 0
M  V30 5 C 0.7700 2.6673 0.0 0
M  V30 6 C 3.0801 4.0010 0.0 0
M  V30 7 C 4.6201 1.3337 0.0 0
M  V30 8 N 2.3101 0.0000 0.0 0
M  V30 9 N 0.0000 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 12 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 446-32-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 16499-57-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-25838983
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of new bivalent quinazoline
analogues as IAP antagonists
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bae, Inhwan; Kim, Daejin; Choi, Jaeyul; Kim, Jisook; Kim, Minjeong; Park,
Bokyung; Kim, Young Hoon; Ahn, Young Gil; Hyung Kim, Ha; Kim, Dae Kyong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2021), 34127676

$RFMT $RIREG SCHEME432 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-4-chlorobenzoic acid
C7H6ClNO2
89-77-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 N 2.3101 0.0000 0.0 0
M  V30 5 Cl 6.9302 2.6673 0.0 0
M  V30 6 C 2.3101 2.6673 0.0 0
M  V30 7 C 3.0801 1.3337 0.0 0
M  V30 8 C 3.0801 4.0010 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 11
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
7-Chloro-4(3H)-quinazolinone
C8H5ClN2O
31374-18-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 4.0010 0.0 0
M  V30 2 Cl 6.9302 2.6673 0.0 0
M  V30 3 C 2.3101 2.6673 0.0 0
M  V30 4 C 3.0801 1.3337 0.0 0
M  V30 5 C 0.7700 2.6673 0.0 0
M  V30 6 C 3.0801 4.0010 0.0 0
M  V30 7 C 4.6201 1.3337 0.0 0
M  V30 8 N 2.3101 0.0000 0.0 0
M  V30 9 N 0.0000 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 5.3901 2.6673 0.0 0
M  V30 12 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 89-77-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 31374-18-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38113256
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel quinazolinone inhibitors of the Pseudomonas aeruginosa quorum
sensing transcriptional regulator PqsR
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Grossman, Scott; Soukarieh, Fadi; Richardson, William; Liu, Ruiling;
Mashabi, Alaa; Emsley, Jonas; Williams, Paul; Camara, Miguel; Stocks,
Michael J.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 208112778

$RFMT $RIREG SCHEME433 STEP1
$RXN



  2  1
$MOL
4-(1-Naphthalenylamino)-4-oxo-2-butenoic acid
C14H11NO3
306935-75-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 2.3101 0.0 0
M  V30 2 C 6.6685 3.0801 0.0 0
M  V30 3 C 8.0022 2.3101 0.0 0
M  V30 4 O 6.6685 4.6201 0.0 0
M  V30 5 C 9.3360 3.0801 0.0 0
M  V30 6 C 10.6697 2.3101 0.0 0
M  V30 7 O 10.6697 0.7700 0.0 0
M  V30 8 O 12.0033 3.0801 0.0 0
M  V30 9 C 2.6673 2.3101 0.0 0
M  V30 10 C 4.0012 3.0801 0.0 0
M  V30 11 C 1.3337 3.0801 0.0 0
M  V30 12 C 2.6673 0.7700 0.0 0
M  V30 13 C 4.0012 4.6201 0.0 0
M  V30 14 C 1.3337 4.6201 0.0 0
M  V30 15 C 0.0000 2.3101 0.0 0
M  V30 16 C 1.3337 0.0000 0.0 0
M  V30 17 C 2.6673 5.3901 0.0 0
M  V30 18 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 9 12
M  V30 12 2 10 13
M  V30 13 1 11 14
M  V30 14 1 11 15
M  V30 15 2 12 16
M  V30 16 1 13 17
M  V30 17 2 14 17
M  V30 18 2 15 18
M  V30 19 1 16 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-1-Naphthalenyl-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C23H19N3O3
2416338-40-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 12.0032 4.6200 0.0 0
M  V30 2 C 10.6694 5.3900 0.0 0
M  V30 3 C 9.3358 4.6200 0.0 0
M  V30 4 O 10.6694 6.9300 0.0 0
M  V30 5 C 8.0021 5.3900 0.0 0
M  V30 6 C 6.6685 4.6200 0.0 0
M  V30 7 N 5.3347 5.3900 0.0 0
M  V30 8 O 6.6685 3.0800 0.0 0
M  V30 9 O 2.6674 6.9300 0.0 0
M  V30 10 C 14.6705 4.6200 0.0 0
M  V30 11 C 13.3369 5.3900 0.0 0
M  V30 12 C 16.0041 5.3900 0.0 0
M  V30 13 C 14.6705 3.0800 0.0 0
M  V30 14 C 13.3369 6.9300 0.0 0
M  V30 15 C 16.0041 6.9300 0.0 0
M  V30 16 C 17.3379 4.6200 0.0 0
M  V30 17 C 16.0041 2.3100 0.0 0
M  V30 18 C 14.6705 7.7000 0.0 0
M  V30 19 C 17.3379 3.0800 0.0 0
M  V30 20 C 4.0011 4.6200 0.0 0
M  V30 21 C 4.0011 3.0800 0.0 0
M  V30 22 C 2.6674 5.3900 0.0 0
M  V30 23 C 2.6674 2.3100 0.0 0
M  V30 24 N 1.3338 4.6200 0.0 0
M  V30 25 C 1.3338 3.0800 0.0 0
M  V30 26 C 2.6674 0.7700 0.0 0
M  V30 27 C 0.0000 2.3100 0.0 0
M  V30 28 C 1.3338 0.0000 0.0 0
M  V30 29 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 20
M  V30 10 2 9 22
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 10 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 1 12 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 2 15 18
M  V30 20 2 16 19
M  V30 21 1 17 19
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 23 26
M  V30 28 1 24 25
M  V30 29 2 25 27
M  V30 30 1 26 28
M  V30 31 1 27 29
M  V30 32 2 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 306935-75-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-40-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822022
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME434 STEP1
$RXN



  2  1
$MOL
1H-Indole-3-propanoic acid
C11H11NO2
830-96-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7533 2.6218 0.0 0
M  V30 2 C 7.0869 1.8518 0.0 0
M  V30 3 C 8.4206 2.6218 0.0 0
M  V30 4 O 9.7544 1.8518 0.0 0
M  V30 5 O 8.4206 4.1618 0.0 0
M  V30 6 C 3.0127 2.4782 0.0 0
M  V30 7 C 4.4196 1.8518 0.0 0
M  V30 8 C 1.9823 1.3338 0.0 0
M  V30 9 C 2.5368 3.9429 0.0 0
M  V30 10 C 4.2586 0.3202 0.0 0
M  V30 11 N 2.7523 0.0000 0.0 0
M  V30 12 C 0.4759 1.6540 0.0 0
M  V30 13 C 1.0306 4.2630 0.0 0
M  V30 14 C 0.0000 3.1185 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 2 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 11
M  V30 14 1 12 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,3-Benzodioxole-5-ethanamine
C9H11NO2
1484-85-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.3709 3.0800 0.0 0
M  V30 2 C 7.7047 2.3100 0.0 0
M  V30 3 N 9.0383 3.0800 0.0 0
M  V30 4 C 2.3699 2.3100 0.0 0
M  V30 5 C 2.3699 0.7700 0.0 0
M  V30 6 C 3.7036 3.0800 0.0 0
M  V30 7 O 0.9052 2.7859 0.0 0
M  V30 8 C 3.7036 0.0000 0.0 0
M  V30 9 O 0.9052 0.2941 0.0 0
M  V30 10 C 5.0372 2.3100 0.0 0
M  V30 11 C 0.0000 1.5400 0.0 0
M  V30 12 C 5.0372 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 7 2 5 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(1,3-Benzodioxol-5-yl)ethyl]-1H-indole-3-propanamide
C20H20N2O3
1036111-16-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7534 2.6217 0.0 0
M  V30 2 C 7.0870 1.8517 0.0 0
M  V30 3 C 8.4208 2.6217 0.0 0
M  V30 4 N 9.7545 1.8517 0.0 0
M  V30 5 O 8.4208 4.1618 0.0 0
M  V30 6 C 11.0881 2.6217 0.0 0
M  V30 7 C 12.4218 1.8517 0.0 0
M  V30 8 C 3.0127 2.4782 0.0 0
M  V30 9 C 4.4197 1.8517 0.0 0
M  V30 10 C 1.9823 1.3337 0.0 0
M  V30 11 C 2.5369 3.9428 0.0 0
M  V30 12 C 4.2588 0.3202 0.0 0
M  V30 13 N 2.7523 0.0000 0.0 0
M  V30 14 C 0.4760 1.6538 0.0 0
M  V30 15 C 1.0306 4.2629 0.0 0
M  V30 16 C 0.0000 3.1185 0.0 0
M  V30 17 C 13.7556 2.6217 0.0 0
M  V30 18 C 15.0893 1.8517 0.0 0
M  V30 19 C 13.7556 4.1618 0.0 0
M  V30 20 C 16.4229 2.6217 0.0 0
M  V30 21 C 15.0893 4.9318 0.0 0
M  V30 22 C 16.4229 4.1618 0.0 0
M  V30 23 O 17.8876 2.1459 0.0 0
M  V30 24 O 17.8876 4.6376 0.0 0
M  V30 25 C 18.7929 3.3917 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 17
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 2 9 12
M  V30 13 1 10 13
M  V30 14 2 10 14
M  V30 15 1 11 15
M  V30 16 1 12 13
M  V30 17 1 14 16
M  V30 18 2 15 16
M  V30 19 1 17 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 1 20 23
M  V30 25 2 21 22
M  V30 26 1 22 24
M  V30 27 1 23 25
M  V30 28 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 830-96-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1484-85-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1036111-16-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40818685
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery and Optimization of Tetrahydroisoquinoline Derivatives To
Enhance Lysosome Biogenesis as Preclinical Candidates for the Treatment
of Alzheimer's Disease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhou, Jianhui; Wang, Ning; Wang, Mengxue; Hu, Yuting; Zhang, Zhenwei; Gu,
Zhiyong; Wang, Jing; Shou, Haowen; Cheng, Xi; Liu, Hong; Li, Yang; Zhou,
Yu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(11), 8836-8861

$RFMT $RIREG SCHEME435 STEP1
$RXN



  2  1
$MOL
5-Methyl-3-indoleacetic acid
C11H11NO2
1912-47-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.5369 1.7847 0.0 0
M  V30 2 C 1.0304 1.4645 0.0 0
M  V30 3 O 0.0000 2.6091 0.0 0
M  V30 4 O 0.5546 0.0000 0.0 0
M  V30 5 C 8.4784 2.9553 0.0 0
M  V30 6 C 4.4773 3.7253 0.0 0
M  V30 7 C 4.4773 5.2653 0.0 0
M  V30 8 C 3.0127 3.2494 0.0 0
M  V30 9 C 5.8111 2.9553 0.0 0
M  V30 10 N 3.0127 5.7411 0.0 0
M  V30 11 C 5.8111 6.0353 0.0 0
M  V30 12 C 2.1075 4.4953 0.0 0
M  V30 13 C 7.1447 3.7253 0.0 0
M  V30 14 C 7.1447 5.2653 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 13
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 1 7 10
M  V30 10 2 7 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 12
M  V30 14 1 11 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Ethoxy-3-methoxybenzeneethanamine
C11H17NO2
36377-59-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.8500 1.3338 0.0 0
M  V30 2 C 4.6200 0.0000 0.0 0
M  V30 3 O 2.3100 4.0011 0.0 0
M  V30 4 C 1.5400 5.3349 0.0 0
M  V30 5 C 0.0000 5.3349 0.0 0
M  V30 6 C 8.4700 4.0011 0.0 0
M  V30 7 C 9.2400 5.3349 0.0 0
M  V30 8 N 10.7800 5.3349 0.0 0
M  V30 9 C 4.6200 2.6674 0.0 0
M  V30 10 C 3.8500 4.0011 0.0 0
M  V30 11 C 6.1600 2.6674 0.0 0
M  V30 12 C 4.6200 5.3349 0.0 0
M  V30 13 C 6.9300 4.0011 0.0 0
M  V30 14 C 6.1600 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 3 4
M  V30 4 1 3 10
M  V30 5 1 4 5
M  V30 6 1 6 7
M  V30 7 1 6 13
M  V30 8 1 7 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(4-Ethoxy-3-methoxyphenyl)ethyl]-5-methyl-1H-indole-3-acetamide
C22H26N2O3
2565618-12-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.0550 6.6684 0.0 0
M  V30 2 C 7.5950 6.6684 0.0 0
M  V30 3 N 8.3650 5.3347 0.0 0
M  V30 4 O 8.3650 8.0020 0.0 0
M  V30 5 C 9.9050 5.3347 0.0 0
M  V30 6 C 10.6750 4.0011 0.0 0
M  V30 7 C 0.0000 6.5780 0.0 0
M  V30 8 O 15.2950 1.3336 0.0 0
M  V30 9 C 14.5250 0.0000 0.0 0
M  V30 10 O 16.8350 4.0011 0.0 0
M  V30 11 C 17.6050 5.3347 0.0 0
M  V30 12 C 19.1450 5.3347 0.0 0
M  V30 13 C 3.7534 8.1631 0.0 0
M  V30 14 C 5.2850 8.0020 0.0 0
M  V30 15 C 3.4333 9.6694 0.0 0
M  V30 16 C 2.6091 7.1325 0.0 0
M  V30 17 C 5.9114 9.4089 0.0 0
M  V30 18 N 4.7669 10.4394 0.0 0
M  V30 19 C 1.9686 10.1452 0.0 0
M  V30 20 C 1.1444 7.6085 0.0 0
M  V30 21 C 0.8242 9.1148 0.0 0
M  V30 22 C 12.2150 4.0011 0.0 0
M  V30 23 C 12.9850 2.6673 0.0 0
M  V30 24 C 12.9850 5.3347 0.0 0
M  V30 25 C 14.5250 2.6673 0.0 0
M  V30 26 C 14.5250 5.3347 0.0 0
M  V30 27 C 15.2950 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 22
M  V30 8 1 7 20
M  V30 9 1 8 9
M  V30 10 1 8 25
M  V30 11 1 10 11
M  V30 12 1 10 27
M  V30 13 1 11 12
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 2 14 17
M  V30 18 1 15 18
M  V30 19 2 15 19
M  V30 20 1 16 20
M  V30 21 1 17 18
M  V30 22 1 19 21
M  V30 23 2 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1912-47-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 36377-59-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2565618-12-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23045015
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME436 STEP1
$RXN



  2  1
$MOL
1-[4-(Aminosulfonyl)phenyl]-5-phenyl-1H-pyrazole-3-carboxylic acid
C16H13N3O4S
586333-65-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.4068 7.3148 0.0 0
M  V30 2 O 0.0000 6.6885 0.0 0
M  V30 3 O 1.5679 8.8464 0.0 0
M  V30 4 S 11.1826 5.6396 0.0 0 VAL=6
M  V30 5 N 12.7226 5.6396 0.0 0
M  V30 6 O 11.1826 7.1796 0.0 0
M  V30 7 O 11.1826 4.0996 0.0 0
M  V30 8 N 5.0226 5.6396 0.0 0
M  V30 9 C 4.1173 4.3938 0.0 0
M  V30 10 N 4.1173 6.8856 0.0 0
M  V30 11 C 2.6528 4.8696 0.0 0
M  V30 12 C 2.6528 6.4096 0.0 0
M  V30 13 C 6.5626 5.6396 0.0 0
M  V30 14 C 7.3326 4.3060 0.0 0
M  V30 15 C 7.3326 6.9734 0.0 0
M  V30 16 C 8.8726 4.3060 0.0 0
M  V30 17 C 8.8726 6.9734 0.0 0
M  V30 18 C 9.6426 5.6396 0.0 0
M  V30 19 C 4.5932 2.9292 0.0 0
M  V30 20 C 3.5628 1.7847 0.0 0
M  V30 21 C 6.0996 2.6091 0.0 0
M  V30 22 C 4.0387 0.3202 0.0 0
M  V30 23 C 6.5755 1.1444 0.0 0
M  V30 24 C 5.5451 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 4 7
M  V30 7 1 4 18
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 8 13
M  V30 11 2 9 11
M  V30 12 1 9 19
M  V30 13 2 10 12
M  V30 14 1 11 12
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Cyclohexylamine
C6H13N
108-91-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-[4-(Aminosulfonyl)phenyl]-N-cyclohexyl-5-phenyl-1H-pyrazole-3-carboxamide
C22H24N4O3S
2474977-42-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3055 7.3150 0.0 0
M  V30 2 N 3.8987 6.6887 0.0 0
M  V30 3 O 5.4666 8.8466 0.0 0
M  V30 4 S 15.0813 5.6398 0.0 0 VAL=6
M  V30 5 N 16.6213 5.6398 0.0 0
M  V30 6 O 15.0813 4.0998 0.0 0
M  V30 7 O 15.0813 7.1798 0.0 0
M  V30 8 N 8.9213 5.6398 0.0 0
M  V30 9 C 8.0160 4.3940 0.0 0
M  V30 10 N 8.0160 6.8857 0.0 0
M  V30 11 C 6.5515 4.8698 0.0 0
M  V30 12 C 6.5515 6.4098 0.0 0
M  V30 13 C 10.4613 5.6398 0.0 0
M  V30 14 C 11.2313 4.3062 0.0 0
M  V30 15 C 11.2313 6.9735 0.0 0
M  V30 16 C 12.7713 4.3062 0.0 0
M  V30 17 C 12.7713 6.9735 0.0 0
M  V30 18 C 13.5413 5.6398 0.0 0
M  V30 19 C 8.4919 2.9292 0.0 0
M  V30 20 C 7.4615 1.7849 0.0 0
M  V30 21 C 9.9983 2.6091 0.0 0
M  V30 22 C 7.9374 0.3202 0.0 0
M  V30 23 C 10.4742 1.1445 0.0 0
M  V30 24 C 9.4438 0.0000 0.0 0
M  V30 25 C 2.6528 7.5939 0.0 0
M  V30 26 C 1.2459 6.9675 0.0 0
M  V30 27 C 2.8137 9.1255 0.0 0
M  V30 28 C 0.0000 7.8727 0.0 0
M  V30 29 C 1.5679 10.0307 0.0 0
M  V30 30 C 0.1609 9.4042 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 12
M  V30 4 1 2 25
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 2 4 7
M  V30 8 1 4 18
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 8 13
M  V30 12 2 9 11
M  V30 13 1 9 19
M  V30 14 2 10 12
M  V30 15 1 11 12
M  V30 16 2 13 14
M  V30 17 1 13 15
M  V30 18 1 14 16
M  V30 19 2 15 17
M  V30 20 2 16 18
M  V30 21 1 17 18
M  V30 22 2 19 20
M  V30 23 1 19 21
M  V30 24 1 20 22
M  V30 25 2 21 23
M  V30 26 2 22 24
M  V30 27 1 23 24
M  V30 28 1 25 26
M  V30 29 1 25 27
M  V30 30 1 26 28
M  V30 31 1 27 29
M  V30 32 1 28 30
M  V30 33 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 586333-65-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 108-91-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2474977-42-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-22486109
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel urea-diarylpyrazole hybrids as dual COX-2/sEH
inhibitors with improved anti-inflammatory activity and highly reduced
cardiovascular risks
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Abdelazeem, Ahmed H.; Safi El-Din, Asmaa G.; Abdel-Fattah, Maha M.; Amin,
Noha H.; El-Moghazy, Samir M.; El-Saadi, Mohammed T.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 205112662

$RFMT $RIREG SCHEME437 STEP1
$RXN



  2  1
$MOL
4-Bromo-6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid
C9H7BrN2O3
1622303-52-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 4.6200 0.0000 0.0 0
M  V30 2 O 1.5400 5.3348 0.0 0
M  V30 3 C 7.6211 5.2890 0.0 0
M  V30 4 O 8.9549 4.5190 0.0 0
M  V30 5 O 7.6211 6.8290 0.0 0
M  V30 6 C 0.0000 2.6673 0.0 0
M  V30 7 C 4.6200 2.6673 0.0 0
M  V30 8 C 3.8500 4.0010 0.0 0
M  V30 9 C 6.1265 2.9875 0.0 0
M  V30 10 C 3.8500 1.3337 0.0 0
M  V30 11 N 4.8806 5.1455 0.0 0
M  V30 12 C 2.3100 4.0010 0.0 0
M  V30 13 C 6.2874 4.5190 0.0 0
M  V30 14 C 2.3100 1.3337 0.0 0
M  V30 15 N 1.5400 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 2 2 12
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 13
M  V30 6 1 6 15
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 8 12
M  V30 12 2 9 13
M  V30 13 2 10 14
M  V30 14 1 11 13
M  V30 15 1 12 15
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Cyclopropylamine
C3H7N
765-30-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.8737 2.1037 0.0 0
M  V30 2 C 1.5400 1.3337 0.0 0
M  V30 3 C 0.0000 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Bromo-N-cyclopropyl-6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-...
C12H12BrN3O2
2138864-24-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 4.6200 0.0000 0.0 0
M  V30 2 O 1.5400 5.3347 0.0 0
M  V30 3 C 7.6210 5.2890 0.0 0
M  V30 4 N 8.9548 4.5190 0.0 0
M  V30 5 O 7.6210 6.8290 0.0 0
M  V30 6 C 0.0000 2.6673 0.0 0
M  V30 7 C 4.6200 2.6673 0.0 0
M  V30 8 C 3.8500 4.0009 0.0 0
M  V30 9 C 6.1264 2.9874 0.0 0
M  V30 10 C 3.8500 1.3336 0.0 0
M  V30 11 N 4.8806 5.1454 0.0 0
M  V30 12 C 2.3100 4.0009 0.0 0
M  V30 13 C 6.2874 4.5190 0.0 0
M  V30 14 C 2.3100 1.3336 0.0 0
M  V30 15 N 1.5400 2.6673 0.0 0
M  V30 16 C 10.2884 5.2890 0.0 0
M  V30 17 C 11.0584 6.6228 0.0 0
M  V30 18 C 11.8284 5.2890 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 10
M  V30 2 2 2 12
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 3 13
M  V30 6 1 4 16
M  V30 7 1 6 15
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 2 9 13
M  V30 14 2 10 14
M  V30 15 1 11 13
M  V30 16 1 12 15
M  V30 17 1 14 15
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1622303-52-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 765-30-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2138864-24-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-24358057
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-68-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of
N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
(ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second
Bromodomain
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sheppard, George S.; Wang, Le; Fidanze, Steven D.; Hasvold, Lisa A.; Liu,
Dachun; Pratt, John K.; Park, Chang H.; Longenecker, Kenton; Qiu, Wei;
Torrent, Maricel; Kovar, Peter J.; Bui, Mai; Faivre, Emily; Huang,
Xiaoli; Lin, Xiaoyu; Wilcox, Denise; Zhang, Lu; Shen, Yu; Albert, Daniel
H.; Magoc, Terrance J.; Rajaraman, Ganesh; Kati, Warren M.; McDaniel,
Keith F.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2020), 63(10), 5585-5623

$RFMT $RIREG SCHEME438 STEP1
$RXN



  2  1
$MOL
O-Methyl-N-[(5-methyl-3-isoxazolyl)carbonyl]-L-serylglycine
C11H15N3O6
2387522-99-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0287 5.3348 0.0 0
M  V30 2 N 5.5687 5.3348 0.0 0
M  V30 3 O 3.2587 4.0011 0.0 0
M  V30 4 C 6.3388 4.0011 0.0 0 CFG=1
M  V30 5 C 7.8788 4.0011 0.0 0
M  V30 6 C 5.5687 2.6673 0.0 0
M  V30 7 N 8.6488 5.3348 0.0 0
M  V30 8 O 8.6488 2.6673 0.0 0
M  V30 9 O 6.3388 1.3337 0.0 0
M  V30 10 C 10.1888 5.3348 0.0 0
M  V30 11 C 5.5687 0.0000 0.0 0
M  V30 12 C 10.9588 6.6685 0.0 0
M  V30 13 O 10.1888 8.0023 0.0 0
M  V30 14 O 12.4989 6.6685 0.0 0
M  V30 15 C 0.0000 8.9622 0.0 0
M  V30 16 C 3.2587 6.6685 0.0 0
M  V30 17 C 1.7271 6.8296 0.0 0
M  V30 18 N 3.8850 8.0754 0.0 0
M  V30 19 C 1.4070 8.3359 0.0 0
M  V30 20 O 2.7406 9.1059 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 15 19
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1-Pentanone, 2-amino-4-methyl-1-[(2R)-2-methyl-2-oxiranyl]-, (2S)-, 2,2,2-tri...
C9H17NO2.C2HF3O2
247068-85-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8504 6.7237 0.0 0
M  V30 2 C 4.1841 7.4937 0.0 0 CFG=1
M  V30 3 O 2.8504 5.1837 0.0 0
M  V30 4 C 5.5177 6.7237 0.0 0
M  V30 5 N 4.1841 9.0338 0.0 0
M  V30 6 C 6.8514 7.4937 0.0 0
M  V30 7 C 8.1852 6.7237 0.0 0
M  V30 8 C 6.8514 9.0338 0.0 0
M  V30 9 C 2.0434 8.9409 0.0 0
M  V30 10 C 1.5166 7.4937 0.0 0 CFG=2
M  V30 11 C 0.5268 6.3141 0.0 0
M  V30 12 O 0.0000 7.7611 0.0 0
M  V30 13 C 3.4257 2.3101 0.0 0
M  V30 14 C 4.7594 1.5400 0.0 0
M  V30 15 F 4.1958 3.6437 0.0 0
M  V30 16 F 2.0921 3.0801 0.0 0
M  V30 17 F 2.6557 0.9764 0.0 0
M  V30 18 O 6.0931 2.3101 0.0 0
M  V30 19 O 4.7594 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 10 1 CFG=1
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 11 12
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 16 1 13 17
M  V30 17 1 14 18
M  V30 18 2 14 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
O-Methyl-N-[(5-methyl-3-isoxazolyl)carbonyl]-L-seryl-N-[(1S)-3-methyl-1-[[(2R...
C20H30N4O7
935888-33-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.2172 8.0021 0.0 0
M  V30 2 C 3.7572 8.0021 0.0 0 CFG=2
M  V30 3 O 1.4472 9.3360 0.0 0
M  V30 4 N 4.5272 6.6685 0.0 0
M  V30 5 C 4.5272 9.3360 0.0 0
M  V30 6 C 6.0673 6.6685 0.0 0
M  V30 7 C 3.7572 10.6696 0.0 0
M  V30 8 C 6.8373 5.3348 0.0 0
M  V30 9 O 6.8373 8.0021 0.0 0
M  V30 10 C 4.5272 12.0033 0.0 0
M  V30 11 C 2.2172 10.6696 0.0 0
M  V30 12 N 8.3773 5.3348 0.0 0
M  V30 13 C 9.1473 4.0011 0.0 0
M  V30 14 C 10.6873 4.0011 0.0 0 CFG=2
M  V30 15 O 8.3773 2.6673 0.0 0
M  V30 16 N 11.4574 5.3348 0.0 0
M  V30 17 C 11.4574 2.6673 0.0 0
M  V30 18 C 12.9974 5.3348 0.0 0
M  V30 19 O 10.6873 1.3337 0.0 0
M  V30 20 O 13.7674 4.0011 0.0 0
M  V30 21 C 11.4574 0.0000 0.0 0
M  V30 22 C 2.6268 5.6785 0.0 0
M  V30 23 C 17.0259 8.9622 0.0 0
M  V30 24 C 1.4472 6.6685 0.0 0 CFG=2
M  V30 25 C 0.0000 7.1952 0.0 0
M  V30 26 O 0.2673 5.6785 0.0 0
M  V30 27 C 13.7674 6.6685 0.0 0
M  V30 28 N 13.1409 8.0755 0.0 0
M  V30 29 C 15.2990 6.8294 0.0 0
M  V30 30 O 14.2855 9.1059 0.0 0
M  V30 31 C 15.6191 8.3359 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 24 1 CFG=3
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=3
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 1 7 11
M  V30 12 1 8 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 14 16
M  V30 17 1 14 17 CFG=1
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 1 18 27
M  V30 22 1 19 21
M  V30 23 1 24 22 CFG=1
M  V30 24 1 23 31
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 25 26
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 2 29 31
M  V30 32 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 2 14 24)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2387522-99-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 247068-85-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 935888-33-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545372
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME439 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-chlorobenzoic acid
C7H6ClNO2
635-21-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 Cl 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Chloro-4(3H)-quinazolinone
C8H5ClN2O
16064-14-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.0800 0.0000 0.0 0
M  V30 2 Cl 6.9300 4.0011 0.0 0
M  V30 3 C 3.0800 2.6674 0.0 0
M  V30 4 C 2.3100 4.0011 0.0 0
M  V30 5 C 2.3100 1.3338 0.0 0
M  V30 6 C 4.6200 2.6674 0.0 0
M  V30 7 C 3.0800 5.3349 0.0 0
M  V30 8 N 0.7700 4.0011 0.0 0
M  V30 9 N 0.7700 1.3338 0.0 0
M  V30 10 C 5.3900 4.0011 0.0 0
M  V30 11 C 4.6200 5.3349 0.0 0
M  V30 12 C 0.0000 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 10
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 635-21-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 16064-14-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38113252
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel quinazolinone inhibitors of the Pseudomonas aeruginosa quorum
sensing transcriptional regulator PqsR
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Grossman, Scott; Soukarieh, Fadi; Richardson, William; Liu, Ruiling;
Mashabi, Alaa; Emsley, Jonas; Williams, Paul; Camara, Miguel; Stocks,
Michael J.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 208112778

$RFMT $RIREG SCHEME440 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-bromobenzoic acid
C7H6BrNO2
5794-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 Br 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Bromo-4(3H)-quinazolinone
C8H5BrN2O
32084-59-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.0800 0.0000 0.0 0
M  V30 2 Br 6.9300 4.0011 0.0 0
M  V30 3 C 3.0800 2.6674 0.0 0
M  V30 4 C 2.3100 4.0011 0.0 0
M  V30 5 C 2.3100 1.3338 0.0 0
M  V30 6 C 4.6200 2.6674 0.0 0
M  V30 7 C 3.0800 5.3349 0.0 0
M  V30 8 N 0.7700 4.0011 0.0 0
M  V30 9 N 0.7700 1.3338 0.0 0
M  V30 10 C 5.3900 4.0011 0.0 0
M  V30 11 C 4.6200 5.3349 0.0 0
M  V30 12 C 0.0000 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 10
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5794-88-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 32084-59-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-26205271
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, biological evaluation of
6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as
novel anticancer agents with Aurora kinase inhibition
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fan, Chengcheng; Zhong, Ting; Yang, Huarong; Yang, Ying; Wang, Daoping;
Yang, Xiaosheng; Xu, Yongnan; Fan, Yanhua
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 190112108pp.

$RFMT $RIREG SCHEME440 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-bromobenzoic acid
C7H6BrNO2
5794-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 Br 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Bromo-4(3H)-quinazolinone
C8H5BrN2O
32084-59-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.0800 0.0000 0.0 0
M  V30 2 Br 6.9300 4.0011 0.0 0
M  V30 3 C 3.0800 2.6674 0.0 0
M  V30 4 C 2.3100 4.0011 0.0 0
M  V30 5 C 2.3100 1.3338 0.0 0
M  V30 6 C 4.6200 2.6674 0.0 0
M  V30 7 C 3.0800 5.3349 0.0 0
M  V30 8 N 0.7700 4.0011 0.0 0
M  V30 9 N 0.7700 1.3338 0.0 0
M  V30 10 C 5.3900 4.0011 0.0 0
M  V30 11 C 4.6200 5.3349 0.0 0
M  V30 12 C 0.0000 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 10
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5794-88-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 32084-59-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32038501
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 88
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl)
quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K
inhibition
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yang, Huarong; Li, Qing; Su, Mingzhi; Luo, Fang; Liu, Yahua; Wang,
Daoping; Fan, Yanhua
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 46116346

$RFMT $RIREG SCHEME441 STEP1
$RXN



  2  1
$MOL
Formamidine acetate
C2H4O2.CH4N2
3473-63-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.8501 0.0 0
M  V30 2 N 0.0000 4.6201 0.0 0
M  V30 3 N 2.6673 4.6201 0.0 0
M  V30 4 C 1.3337 1.5400 0.0 0
M  V30 5 C 0.0000 2.3101 0.0 0
M  V30 6 O 2.6673 2.3101 0.0 0
M  V30 7 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 3
M  V30 3 1 4 5
M  V30 4 1 4 6
M  V30 5 2 4 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-bromobenzoic acid
C7H6BrNO2
5794-88-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 Br 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Bromo-4(3H)-quinazolinone
C8H5BrN2O
32084-59-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.0800 0.0000 0.0 0
M  V30 2 Br 6.9300 4.0011 0.0 0
M  V30 3 C 3.0800 2.6674 0.0 0
M  V30 4 C 2.3100 4.0011 0.0 0
M  V30 5 C 2.3100 1.3338 0.0 0
M  V30 6 C 4.6200 2.6674 0.0 0
M  V30 7 C 3.0800 5.3349 0.0 0
M  V30 8 N 0.7700 4.0011 0.0 0
M  V30 9 N 0.7700 1.3338 0.0 0
M  V30 10 C 5.3900 4.0011 0.0 0
M  V30 11 C 4.6200 5.3349 0.0 0
M  V30 12 C 0.0000 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 10
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3473-63-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 5794-88-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 32084-59-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-26768391
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 94
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 64-19-7
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel quinazoline derivatives as potent PI3K inhibitors
with high selectivity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Teng, Yu; Li, Xinyu; Ren, Shengnan; Cheng, Yu; Xi, Kun; Shen, Hongtao;
Ma, Wenzhuo; Luo, Guoshun; Xiang, Hua
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 208112865

$RFMT $RIREG SCHEME442 STEP1
$RXN



  2  1
$MOL
(2E)-3-(2,5-Dimethoxyphenyl)-2-propenoic acid
C11H12O4
38489-74-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6675 3.8501 0.0 0
M  V30 2 C 2.6675 2.3101 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 O 0.0000 2.3101 0.0 0
M  V30 5 O 1.3337 0.0000 0.0 0
M  V30 6 O 2.6675 6.9302 0.0 0
M  V30 7 C 2.6675 8.4702 0.0 0
M  V30 8 O 8.0023 3.8501 0.0 0
M  V30 9 C 9.3360 4.6201 0.0 0
M  V30 10 C 4.0012 4.6201 0.0 0
M  V30 11 C 4.0012 6.1601 0.0 0
M  V30 12 C 5.3348 3.8501 0.0 0
M  V30 13 C 5.3348 6.9302 0.0 0
M  V30 14 C 6.6685 4.6201 0.0 0
M  V30 15 C 6.6685 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 11
M  V30 8 1 8 9
M  V30 9 1 8 14
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Aminobenzothiazole
C7H6N2S
136-95-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.5772 1.5400 0.0 0
M  V30 2 C 2.6673 2.3101 0.0 0
M  V30 3 C 2.6673 0.7700 0.0 0
M  V30 4 N 4.1321 2.7859 0.0 0
M  V30 5 C 1.3337 3.0801 0.0 0
M  V30 6 S 4.1321 0.2941 0.0 0
M  V30 7 C 1.3337 0.0000 0.0 0
M  V30 8 C 5.0371 1.5400 0.0 0
M  V30 9 C 0.0000 2.3101 0.0 0
M  V30 10 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 8
M  V30 10 1 7 10
M  V30 11 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
(2E)-N-2-Benzothiazolyl-3-(2,5-dimethoxyphenyl)-2-propenamide
C18H16N2O3S
1162684-18-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 9.2400 6.6685 0.0 0
M  V30 2 C 8.4700 5.3347 0.0 0
M  V30 3 C 6.9300 5.3347 0.0 0
M  V30 4 O 9.2400 4.0011 0.0 0
M  V30 5 C 6.1600 4.0011 0.0 0
M  V30 6 O 4.6200 1.3338 0.0 0
M  V30 7 C 3.8500 0.0000 0.0 0
M  V30 8 O 1.5400 6.6685 0.0 0
M  V30 9 C 0.0000 6.6685 0.0 0
M  V30 10 C 13.1498 7.4385 0.0 0
M  V30 11 C 13.1498 5.8985 0.0 0
M  V30 12 N 11.6851 7.9144 0.0 0
M  V30 13 C 14.4834 8.2085 0.0 0
M  V30 14 S 11.6851 5.4225 0.0 0
M  V30 15 C 14.4834 5.1285 0.0 0
M  V30 16 C 10.7800 6.6685 0.0 0
M  V30 17 C 15.8170 7.4385 0.0 0
M  V30 18 C 15.8170 5.8985 0.0 0
M  V30 19 C 4.6200 4.0011 0.0 0
M  V30 20 C 3.8500 2.6674 0.0 0
M  V30 21 C 3.8500 5.3347 0.0 0
M  V30 22 C 2.3100 2.6674 0.0 0
M  V30 23 C 2.3100 5.3347 0.0 0
M  V30 24 C 1.5400 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 5 19
M  V30 7 1 6 7
M  V30 8 1 6 20
M  V30 9 1 8 9
M  V30 10 1 8 23
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 16
M  V30 19 1 15 18
M  V30 20 2 17 18
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 38489-74-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 136-95-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1162684-18-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40311346
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM In vitro inhibition of -Synuclein aggregation and disaggregation of
preformed fibers by polyphenol hybrids with 2-conjugated benzothiazole
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhao, Ya-Dong; Zhang, Wei; Xing, Li-Zi; Xu, Ji; Shi, Wei-Min; Zhang,
Yun-Xiao
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2024), 105129752

$RFMT $RIREG SCHEME443 STEP1
$RXN



  2  1
$MOL

C24H36N2O7
2768856-81-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.0100 5.3347 0.0 0 CFG=1
M  V30 2 N 8.4700 5.3347 0.0 0
M  V30 3 C 10.7800 6.6684 0.0 0
M  V30 4 C 10.7800 4.0011 0.0 0
M  V30 5 C 7.7000 6.6684 0.0 0
M  V30 6 C 12.3200 6.6684 0.0 0
M  V30 7 O 10.0100 2.6673 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 C 6.1600 6.6684 0.0 0 CFG=2
M  V30 10 O 8.4700 8.0021 0.0 0
M  V30 11 C 13.0900 8.0021 0.0 0
M  V30 12 C 10.7800 1.3336 0.0 0
M  V30 13 N 5.3900 5.3347 0.0 0
M  V30 14 C 5.3900 8.0021 0.0 0
M  V30 15 O 14.6300 8.0021 0.0 0
M  V30 16 O 12.3200 9.3358 0.0 0
M  V30 17 C 10.0100 0.0000 0.0 0
M  V30 18 C 3.8500 5.3347 0.0 0
M  V30 19 C 3.8500 8.0021 0.0 0
M  V30 20 C 6.1600 9.3358 0.0 0
M  V30 21 C 15.4000 9.3358 0.0 0
M  V30 22 O 3.0800 4.0011 0.0 0
M  V30 23 O 3.0800 6.6684 0.0 0
M  V30 24 C 1.5400 4.0011 0.0 0
M  V30 25 C 1.5400 2.4611 0.0 0
M  V30 26 C 0.0000 4.0011 0.0 0
M  V30 27 C 1.5400 5.5411 0.0 0
M  V30 28 C 16.9400 9.3358 0.0 0
M  V30 29 C 17.7100 8.0021 0.0 0
M  V30 30 C 17.7100 10.6694 0.0 0
M  V30 31 C 19.2500 8.0021 0.0 0
M  V30 32 C 19.2500 10.6694 0.0 0
M  V30 33 C 20.0200 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=1
M  V30 14 1 11 15
M  V30 15 2 11 16
M  V30 16 1 12 17
M  V30 17 1 13 18
M  V30 18 1 14 19
M  V30 19 1 14 20
M  V30 20 1 15 21
M  V30 21 1 18 22
M  V30 22 2 18 23
M  V30 23 1 21 28
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 24 27
M  V30 28 2 28 29
M  V30 29 1 28 30
M  V30 30 1 29 31
M  V30 31 2 30 32
M  V30 32 2 31 33
M  V30 33 1 32 33
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-(tert-Butoxycarbonyl)glycine
C7H13NO4
4530-20-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 1.5400 0.0 0
M  V30 2 C 4.0012 2.3101 0.0 0
M  V30 3 C 1.3337 2.3101 0.0 0
M  V30 4 N 5.3348 1.5400 0.0 0
M  V30 5 O 4.0012 3.8501 0.0 0
M  V30 6 C 0.5637 0.9764 0.0 0
M  V30 7 C 0.0000 3.0801 0.0 0
M  V30 8 C 2.1037 3.6437 0.0 0
M  V30 9 C 6.6685 2.3101 0.0 0
M  V30 10 C 8.0023 1.5400 0.0 0
M  V30 11 O 8.0023 0.0000 0.0 0
M  V30 12 O 9.3360 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C26H39N3O8
2768856-83-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  37 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 12.8836 5.3347 0.0 0 CFG=1
M  V30 2 N 11.3436 5.3347 0.0 0
M  V30 3 C 13.6536 6.6684 0.0 0
M  V30 4 C 13.6536 4.0009 0.0 0
M  V30 5 C 10.5736 6.6684 0.0 0
M  V30 6 C 15.1936 6.6684 0.0 0
M  V30 7 O 12.8836 2.6673 0.0 0
M  V30 8 O 15.1936 4.0011 0.0 0
M  V30 9 C 9.0336 6.6684 0.0 0 CFG=2
M  V30 10 O 11.3436 8.0020 0.0 0
M  V30 11 C 15.9636 8.0020 0.0 0
M  V30 12 C 13.6536 1.3336 0.0 0
M  V30 13 N 8.2636 8.0020 0.0 0
M  V30 14 C 8.2636 5.3347 0.0 0
M  V30 15 O 17.5036 8.0020 0.0 0
M  V30 16 O 15.1936 9.3358 0.0 0
M  V30 17 C 12.8836 0.0000 0.0 0
M  V30 18 C 6.7236 8.0020 0.0 0
M  V30 19 C 9.0336 4.0009 0.0 0
M  V30 20 C 6.7236 5.3347 0.0 0
M  V30 21 C 18.2736 9.3358 0.0 0
M  V30 22 C 5.9536 9.3358 0.0 0
M  V30 23 O 5.9536 6.6684 0.0 0
M  V30 24 N 4.4136 9.3358 0.0 0
M  V30 25 C 3.6436 10.6694 0.0 0
M  V30 26 O 2.1036 10.6694 0.0 0
M  V30 27 O 4.4136 12.0031 0.0 0
M  V30 28 C 1.3336 12.0031 0.0 0
M  V30 29 C 0.0000 11.2331 0.0 0
M  V30 30 C 0.5636 13.3367 0.0 0
M  V30 31 C 2.6673 12.7731 0.0 0
M  V30 32 C 19.8136 9.3358 0.0 0
M  V30 33 C 20.5836 10.6694 0.0 0
M  V30 34 C 20.5836 8.0020 0.0 0
M  V30 35 C 22.1236 10.6694 0.0 0
M  V30 36 C 22.1236 8.0020 0.0 0
M  V30 37 C 22.8936 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 9 14 CFG=3
M  V30 14 1 11 15
M  V30 15 2 11 16
M  V30 16 1 12 17
M  V30 17 1 13 18
M  V30 18 1 14 19
M  V30 19 1 14 20
M  V30 20 1 15 21
M  V30 21 1 18 22
M  V30 22 2 18 23
M  V30 23 1 21 32
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 25 27
M  V30 28 1 26 28
M  V30 29 1 28 29
M  V30 30 1 28 30
M  V30 31 1 28 31
M  V30 32 2 32 33
M  V30 33 1 32 34
M  V30 34 1 33 35
M  V30 35 2 34 36
M  V30 36 2 35 37
M  V30 37 1 36 37
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2768856-81-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4530-20-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2768856-83-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34998067
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 76-05-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 1892-57-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune
Potentiators
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guzelj, Samo; Weiss, Matjaz; Slutter, Bram; Frkanec, Ruza; Jakopin, Ziga
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(22), 15085-15101

$RFMT $RIREG SCHEME444 STEP1
$RXN



  2  1
$MOL
Oleic acid
C18H34O2
112-80-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.7000 5.3347 0.0 0
M  V30 2 C 9.2400 5.3347 0.0 0
M  V30 3 C 6.9300 4.0011 0.0 0
M  V30 4 C 10.0100 6.6685 0.0 0
M  V30 5 C 5.3900 4.0011 0.0 0
M  V30 6 C 11.5500 6.6685 0.0 0
M  V30 7 C 4.6200 2.6674 0.0 0
M  V30 8 C 12.3200 5.3347 0.0 0
M  V30 9 C 3.0800 2.6674 0.0 0
M  V30 10 C 13.8600 5.3347 0.0 0
M  V30 11 C 2.3100 1.3338 0.0 0
M  V30 12 C 14.6300 4.0011 0.0 0
M  V30 13 C 0.7700 1.3338 0.0 0
M  V30 14 C 16.1700 4.0011 0.0 0
M  V30 15 O 0.0000 0.0000 0.0 0
M  V30 16 O 0.0000 2.6674 0.0 0
M  V30 17 C 16.9400 2.6674 0.0 0
M  V30 18 C 18.4800 2.6674 0.0 0
M  V30 19 C 19.2500 1.3338 0.0 0
M  V30 20 C 20.7900 1.3338 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 2 4 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 13 16
M  V30 16 1 14 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Amino-1,10-phenanthroline
C12H9N3
54258-41-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.3100 0.0000 0.0 0
M  V30 2 C 4.6200 4.0011 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 5.3900 2.6674 0.0 0
M  V30 5 N 5.3900 5.3349 0.0 0
M  V30 6 C 2.3100 2.6674 0.0 0
M  V30 7 N 2.3100 5.3349 0.0 0
M  V30 8 C 4.6200 1.3338 0.0 0
M  V30 9 C 6.9300 2.6674 0.0 0
M  V30 10 C 6.9300 5.3349 0.0 0
M  V30 11 C 3.0800 1.3338 0.0 0
M  V30 12 C 0.7700 2.6674 0.0 0
M  V30 13 C 0.7700 5.3349 0.0 0
M  V30 14 C 7.7000 4.0011 0.0 0
M  V30 15 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 11
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 2 4 8
M  V30 8 1 4 9
M  V30 9 2 5 10
M  V30 10 2 6 11
M  V30 11 1 6 12
M  V30 12 2 7 13
M  V30 13 1 8 11
M  V30 14 2 9 14
M  V30 15 1 10 14
M  V30 16 2 12 15
M  V30 17 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
9-Octadecenamide, N-1,10-phenanthrolin-5-yl-, (9Z)-
C30H41N3O
2919143-32-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 4.0011 0.0 0
M  V30 2 C 7.7000 5.3347 0.0 0
M  V30 3 C 9.2400 5.3347 0.0 0
M  V30 4 O 6.9300 6.6684 0.0 0
M  V30 5 C 10.0100 6.6684 0.0 0
M  V30 6 C 11.5500 6.6684 0.0 0
M  V30 7 C 12.3200 8.0021 0.0 0
M  V30 8 C 13.8600 8.0021 0.0 0
M  V30 9 C 14.6300 9.3358 0.0 0
M  V30 10 C 16.1700 9.3358 0.0 0
M  V30 11 C 16.9400 10.6694 0.0 0
M  V30 12 C 18.4800 10.6694 0.0 0
M  V30 13 C 19.2500 9.3358 0.0 0
M  V30 14 C 20.7900 9.3358 0.0 0
M  V30 15 C 21.5600 8.0021 0.0 0
M  V30 16 C 23.1000 8.0021 0.0 0
M  V30 17 C 23.8700 6.6684 0.0 0
M  V30 18 C 25.4100 6.6684 0.0 0
M  V30 19 C 26.1800 5.3347 0.0 0
M  V30 20 C 27.7200 5.3347 0.0 0
M  V30 21 C 4.6200 2.6673 0.0 0
M  V30 22 C 3.0800 2.6673 0.0 0
M  V30 23 C 5.3900 4.0011 0.0 0
M  V30 24 C 5.3900 1.3336 0.0 0
M  V30 25 C 2.3100 4.0011 0.0 0
M  V30 26 N 2.3100 1.3336 0.0 0
M  V30 27 C 4.6200 5.3347 0.0 0
M  V30 28 C 4.6200 0.0000 0.0 0
M  V30 29 C 3.0800 5.3347 0.0 0
M  V30 30 N 0.7700 4.0011 0.0 0
M  V30 31 C 3.0800 0.0000 0.0 0
M  V30 32 C 2.3100 6.6684 0.0 0
M  V30 33 C 0.0000 5.3347 0.0 0
M  V30 34 C 0.7700 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 23
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 21 22
M  V30 22 2 21 23
M  V30 23 1 21 24
M  V30 24 2 22 25
M  V30 25 1 22 26
M  V30 26 1 23 27
M  V30 27 2 24 28
M  V30 28 1 25 29
M  V30 29 1 25 30
M  V30 30 2 26 31
M  V30 31 2 27 29
M  V30 32 1 28 31
M  V30 33 1 29 32
M  V30 34 2 30 33
M  V30 35 2 32 34
M  V30 36 1 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 112-80-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 54258-41-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2919143-32-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31909255
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of photoactivable phenanthroline-based manganese(I)
CO-Releasing molecules (PhotoCORMs) active against ESKAPE bacteria and
bacterial biofilms
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Toscani, Anita; Hind, Charlotte; Clifford, Melanie; Kim, Seong-Heun;
Gucic, Antonia; Woolley, Charlotte; Saeed, Naima; Rahman, Khondaker
Miraz; Sutton, J. Mark; Castagnolo, Daniele
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 213113172

$RFMT $RIREG SCHEME445 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-5-fluorobenzoic acid
C7H6FNO2
446-08-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3338 1.5400 0.0 0
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 N 1.3338 4.6201 0.0 0
M  V30 5 F 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Fluoro-4(3H)-quinazolinone
C8H5FN2O
16499-56-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.0800 0.0000 0.0 0
M  V30 2 F 6.9300 4.0011 0.0 0
M  V30 3 C 3.0800 2.6674 0.0 0
M  V30 4 C 2.3100 4.0011 0.0 0
M  V30 5 C 2.3100 1.3338 0.0 0
M  V30 6 C 4.6200 2.6674 0.0 0
M  V30 7 C 3.0800 5.3349 0.0 0
M  V30 8 N 0.7700 4.0011 0.0 0
M  V30 9 N 0.7700 1.3338 0.0 0
M  V30 10 C 5.3900 4.0011 0.0 0
M  V30 11 C 4.6200 5.3349 0.0 0
M  V30 12 C 0.0000 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 10
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 446-08-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 16499-56-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35040293
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Second generation Spautin-1 analogues targeting EGFR-mutant non-small
cell lung cancer cells
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Elsocht, Mathias; Giron, Philippe; De Greve, Jacques; Ballet, Steven
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2023), 79129066

$RFMT $RIREG SCHEME446 STEP1
$RXN



  2  1
$MOL
Leucine methyl ester hydrochloride
C7H15NO2.ClH
7517-19-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.8500 0.0 0 CFG=1
M  V30 2 C 5.3347 3.0800 0.0 0
M  V30 3 C 2.6674 3.0800 0.0 0
M  V30 4 N 4.0011 5.3900 0.0 0
M  V30 5 O 6.6685 3.8500 0.0 0
M  V30 6 O 5.3347 1.5400 0.0 0
M  V30 7 C 1.3336 3.8500 0.0 0
M  V30 8 C 8.0021 3.0800 0.0 0
M  V30 9 C 1.3336 5.3900 0.0 0
M  V30 10 C 0.0000 3.0800 0.0 0
M  V30 11 Cl 4.0011 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
4-Fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanine
C17H16FNO4
17543-58-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 2.6675 0.0 0
M  V30 2 C 4.6201 2.6675 0.0 0 CFG=1
M  V30 3 N 5.3901 4.0011 0.0 0
M  V30 4 C 5.3901 1.3337 0.0 0
M  V30 5 C 6.9301 4.0011 0.0 0
M  V30 6 O 4.6201 0.0000 0.0 0
M  V30 7 O 6.9301 1.3337 0.0 0
M  V30 8 O 7.7001 5.3348 0.0 0
M  V30 9 O 7.7001 2.6675 0.0 0
M  V30 10 C 9.2401 5.3348 0.0 0
M  V30 11 F 0.0000 8.0022 0.0 0
M  V30 12 C 2.3100 4.0011 0.0 0
M  V30 13 C 0.7700 4.0011 0.0 0
M  V30 14 C 3.0800 5.3348 0.0 0
M  V30 15 C 0.0000 5.3348 0.0 0
M  V30 16 C 2.3100 6.6684 0.0 0
M  V30 17 C 0.7700 6.6684 0.0 0
M  V30 18 C 10.0101 6.6684 0.0 0
M  V30 19 C 9.2401 8.0022 0.0 0
M  V30 20 C 11.5501 6.6684 0.0 0
M  V30 21 C 10.0101 9.3359 0.0 0
M  V30 22 C 12.3201 8.0022 0.0 0
M  V30 23 C 11.5501 9.3359 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 18
M  V30 12 1 11 17
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C24H29FN2O5
3070097-03-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9300 6.6684 0.0 0 CFG=2
M  V30 2 C 6.1600 8.0021 0.0 0
M  V30 3 C 6.1600 5.3347 0.0 0
M  V30 4 N 8.4700 6.6684 0.0 0
M  V30 5 N 6.9300 4.0011 0.0 0
M  V30 6 O 4.6200 5.3347 0.0 0
M  V30 7 C 9.2400 8.0021 0.0 0
M  V30 8 C 6.1600 2.6673 0.0 0 CFG=1
M  V30 9 O 10.7800 8.0021 0.0 0
M  V30 10 O 8.4700 9.3358 0.0 0
M  V30 11 C 6.9300 1.3336 0.0 0
M  V30 12 C 4.6200 2.6673 0.0 0
M  V30 13 C 11.5500 9.3358 0.0 0
M  V30 14 O 8.4700 1.3336 0.0 0
M  V30 15 O 6.1600 0.0000 0.0 0
M  V30 16 C 3.8500 1.3336 0.0 0
M  V30 17 C 9.2400 0.0000 0.0 0
M  V30 18 C 2.3100 1.3336 0.0 0
M  V30 19 C 4.6200 0.0000 0.0 0
M  V30 20 F 0.0000 8.0021 0.0 0
M  V30 21 C 4.6200 8.0021 0.0 0
M  V30 22 C 3.8500 9.3358 0.0 0
M  V30 23 C 3.8500 6.6684 0.0 0
M  V30 24 C 2.3100 9.3358 0.0 0
M  V30 25 C 2.3100 6.6684 0.0 0
M  V30 26 C 1.5400 8.0021 0.0 0
M  V30 27 C 13.0900 9.3358 0.0 0
M  V30 28 C 13.8600 8.0021 0.0 0
M  V30 29 C 13.8600 10.6694 0.0 0
M  V30 30 C 15.4000 8.0021 0.0 0
M  V30 31 C 15.4000 10.6694 0.0 0
M  V30 32 C 16.1700 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 21
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=3
M  V30 13 1 9 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 1 13 27
M  V30 18 1 14 17
M  V30 19 1 16 18
M  V30 20 1 16 19
M  V30 21 1 20 26
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 25
M  V30 26 2 24 26
M  V30 27 1 25 26
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 2 29 31
M  V30 32 2 30 32
M  V30 33 1 31 32
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 7517-19-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 17543-58-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3070097-03-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39485373
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 10043-52-4
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Exploration of the P1 residue in 3CL protease inhibitors leading to the
discovery of a 2-tetrahydrofuran P1 replacement
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Barton, Linda S.; Callahan, James F.; Cantizani, Juan; Concha, Nestor O.;
Cotillo Torrejon, Ignacio; Goodwin, Nicole C.; Joshi-Pangu, Amruta;
Kiesow, Terry J.; McAtee, Jeff J.; Mellinger, Mark; Nixon, Christopher
J.; Padron-Barthe, Laura; Patterson, Jaclyn R.; Pearson, Neil D.;
Pouliot, Jeffrey J.; Rendina, Alan R.; Buitrago Santanilla, Alexander;
Schneck, Jessica L.; Sanz, Olalla; Thalji, Reema K.; Ward, Paris;
Williams, Shawn P.; King, Bryan W.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2024), 100117618

$RFMT $RIREG SCHEME447 STEP1
$RXN



  2  1
$MOL
3-(Trifluoromethoxy)benzeneacetic acid
C9H7F3O3
203302-97-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6673 3.0801 0.0 0
M  V30 2 C 1.3337 2.3101 0.0 0
M  V30 3 F 1.3337 0.7700 0.0 0
M  V30 4 F 0.0000 1.5400 0.0 0
M  V30 5 F 0.0000 3.0801 0.0 0
M  V30 6 C 8.0023 3.0801 0.0 0
M  V30 7 C 9.3360 2.3101 0.0 0
M  V30 8 O 10.6697 3.0801 0.0 0
M  V30 9 O 9.3360 0.7700 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 5.3348 3.0801 0.0 0
M  V30 12 C 4.0012 0.7700 0.0 0
M  V30 13 C 6.6685 2.3101 0.0 0
M  V30 14 C 5.3348 0.0000 0.0 0
M  V30 15 C 6.6685 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 6 7
M  V30 7 1 6 13
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzamide, N-(3-amino-4-fluorophenyl)-4-[(2,2,2-trifluoroacetyl)amino]-
C15H11F4N3O2
3033385-15-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1600 2.6674 0.0 0
M  V30 2 C 6.9300 4.0011 0.0 0
M  V30 3 O 6.1600 5.3349 0.0 0
M  V30 4 N 1.5400 0.0000 0.0 0
M  V30 5 F 0.0000 2.6674 0.0 0
M  V30 6 N 13.0900 4.0011 0.0 0
M  V30 7 C 13.8600 5.3349 0.0 0
M  V30 8 C 15.4000 5.3349 0.0 0
M  V30 9 O 13.0900 6.6685 0.0 0
M  V30 10 F 15.4000 3.7949 0.0 0
M  V30 11 F 16.9400 5.3349 0.0 0
M  V30 12 F 15.4000 6.8749 0.0 0
M  V30 13 C 4.6200 2.6674 0.0 0
M  V30 14 C 3.8500 1.3338 0.0 0
M  V30 15 C 3.8500 4.0011 0.0 0
M  V30 16 C 2.3100 1.3338 0.0 0
M  V30 17 C 2.3100 4.0011 0.0 0
M  V30 18 C 1.5400 2.6674 0.0 0
M  V30 19 C 8.4700 4.0011 0.0 0
M  V30 20 C 9.2400 2.6674 0.0 0
M  V30 21 C 9.2400 5.3349 0.0 0
M  V30 22 C 10.7800 2.6674 0.0 0
M  V30 23 C 10.7800 5.3349 0.0 0
M  V30 24 C 11.5500 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 2 2 3
M  V30 4 1 2 19
M  V30 5 1 4 16
M  V30 6 1 5 18
M  V30 7 1 6 7
M  V30 8 1 6 24
M  V30 9 1 7 8
M  V30 10 2 7 9
M  V30 11 1 8 10
M  V30 12 1 8 11
M  V30 13 1 8 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, N-[5-[(4-aminobenzoyl)amino]-2-fluorophenyl]-3-(trifluorome...
C22H17F4N3O3
3033385-17-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6200 5.3347 0.0 0
M  V30 2 C 3.0800 5.3347 0.0 0
M  V30 3 O 2.3100 4.0011 0.0 0
M  V30 4 N 9.2400 2.6673 0.0 0
M  V30 5 C 10.0100 4.0011 0.0 0
M  V30 6 C 11.5500 4.0011 0.0 0
M  V30 7 O 9.2400 5.3347 0.0 0
M  V30 8 F 7.7000 0.0000 0.0 0
M  V30 9 N 0.0000 10.6694 0.0 0
M  V30 10 O 16.1700 6.6684 0.0 0
M  V30 11 C 16.9400 8.0021 0.0 0
M  V30 12 F 18.4800 8.0021 0.0 0
M  V30 13 F 17.7100 9.3358 0.0 0
M  V30 14 F 16.1700 9.3358 0.0 0
M  V30 15 C 5.3900 4.0011 0.0 0
M  V30 16 C 6.9300 4.0011 0.0 0
M  V30 17 C 4.6200 2.6673 0.0 0
M  V30 18 C 7.7000 2.6673 0.0 0
M  V30 19 C 5.3900 1.3336 0.0 0
M  V30 20 C 6.9300 1.3336 0.0 0
M  V30 21 C 2.3100 6.6684 0.0 0
M  V30 22 C 3.0800 8.0021 0.0 0
M  V30 23 C 0.7700 6.6684 0.0 0
M  V30 24 C 2.3100 9.3358 0.0 0
M  V30 25 C 0.0000 8.0021 0.0 0
M  V30 26 C 0.7700 9.3358 0.0 0
M  V30 27 C 12.3200 5.3347 0.0 0
M  V30 28 C 13.8600 5.3347 0.0 0
M  V30 29 C 11.5500 6.6684 0.0 0
M  V30 30 C 14.6300 6.6684 0.0 0
M  V30 31 C 12.3200 8.0021 0.0 0
M  V30 32 C 13.8600 8.0021 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 2 2 3
M  V30 4 1 2 21
M  V30 5 1 4 5
M  V30 6 1 4 18
M  V30 7 1 5 6
M  V30 8 2 5 7
M  V30 9 1 6 27
M  V30 10 1 8 20
M  V30 11 1 9 26
M  V30 12 1 10 11
M  V30 13 1 10 30
M  V30 14 1 11 12
M  V30 15 1 11 13
M  V30 16 1 11 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 1 28 30
M  V30 32 2 29 31
M  V30 33 2 30 32
M  V30 34 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 203302-97-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3033385-15-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3033385-17-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38259319
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 16940-66-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 64-17-5
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 67-56-1
$DTYPE RXN:VAR(1):NOTES
$DATUM intermediate yield 42% (stage 1)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Insight from Linker Investigations: Discovery of a Novel
Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting
Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual
RIPK1/3 Targeting Activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Jing-jie; Yao, Hou-Zong; Zhuang, Chunlin; Chen, Fen-Er
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(22), 15288-15308

$RFMT $RIREG SCHEME448 STEP1
$RXN



  2  1
$MOL
4-[(4-Bromophenyl)amino]-4-oxo-2-butenoic acid
C10H8BrNO3
36847-86-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 6.6685 3.8501 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 O 10.6697 0.0000 0.0 0
M  V30 8 O 12.0033 2.3101 0.0 0
M  V30 9 Br 0.0000 4.6201 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 1.5400 0.0 0
M  V30 12 C 4.0012 3.8501 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(4-Bromophenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H16BrN3O3
2416338-35-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 C 9.2400 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 10.0100 5.3347 0.0 0
M  V30 6 C 11.5500 5.3347 0.0 0
M  V30 7 N 12.3200 6.6685 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 O 5.3900 0.0000 0.0 0
M  V30 10 Br 18.4800 6.6685 0.0 0
M  V30 11 C 3.0800 4.0011 0.0 0
M  V30 12 C 2.3100 2.6674 0.0 0
M  V30 13 C 4.6200 4.0011 0.0 0
M  V30 14 C 2.3100 5.3347 0.0 0
M  V30 15 N 3.0800 1.3336 0.0 0
M  V30 16 C 0.7700 2.6674 0.0 0
M  V30 17 C 5.3900 2.6674 0.0 0
M  V30 18 C 0.7700 5.3347 0.0 0
M  V30 19 C 4.6200 1.3336 0.0 0
M  V30 20 C 0.0000 4.0011 0.0 0
M  V30 21 C 13.8600 6.6685 0.0 0
M  V30 22 C 14.6300 8.0021 0.0 0
M  V30 23 C 14.6300 5.3347 0.0 0
M  V30 24 C 16.1700 8.0021 0.0 0
M  V30 25 C 16.1700 5.3347 0.0 0
M  V30 26 C 16.9400 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 26
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 36847-86-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-35-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822017
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME449 STEP1
$RXN



  2  1
$MOL
8-[(2,4-Difluorophenyl)amino]-10,11-dihydro-5-oxo-5H-dibenzo[a,d]cycloheptene...
C22H15F2NO3
1417404-28-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.6505 1.9730 0.0 0
M  V30 2 C 1.5357 1.3874 0.0 0
M  V30 3 O 0.0000 1.5026 0.0 0
M  V30 4 O 2.2039 0.0000 0.0 0
M  V30 5 N 11.5129 6.7446 0.0 0
M  V30 6 F 14.1802 8.2846 0.0 0
M  V30 7 F 16.8476 3.6646 0.0 0
M  V30 8 C 4.8065 3.8172 0.0 0
M  V30 9 C 4.1383 5.2046 0.0 0
M  V30 10 C 6.3078 3.4745 0.0 0
M  V30 11 C 3.9389 2.5447 0.0 0
M  V30 12 C 4.8065 6.5921 0.0 0
M  V30 13 C 2.6026 5.3198 0.0 0
M  V30 14 C 7.5118 4.4346 0.0 0
M  V30 15 C 2.4032 2.6599 0.0 0
M  V30 16 C 6.3078 6.9348 0.0 0
M  V30 17 C 1.7350 4.0473 0.0 0
M  V30 18 C 7.5118 5.9746 0.0 0
M  V30 19 C 8.8455 3.6646 0.0 0
M  V30 20 C 8.8455 6.7446 0.0 0
M  V30 21 C 10.1792 4.4346 0.0 0
M  V30 22 C 10.1792 5.9746 0.0 0
M  V30 23 C 12.8465 5.9746 0.0 0
M  V30 24 C 14.1802 6.7446 0.0 0
M  V30 25 C 12.8465 4.4346 0.0 0
M  V30 26 C 15.5140 5.9746 0.0 0
M  V30 27 C 14.1802 3.6646 0.0 0
M  V30 28 C 15.5140 4.4346 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 10
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 15
M  V30 5 1 5 22
M  V30 6 1 5 23
M  V30 7 1 6 24
M  V30 8 1 7 28
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12
M  V30 13 2 9 13
M  V30 14 1 10 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 2 14 19
M  V30 20 2 15 17
M  V30 21 1 16 18
M  V30 22 2 18 20
M  V30 23 1 19 21
M  V30 24 1 20 22
M  V30 25 2 21 22
M  V30 26 2 23 24
M  V30 27 1 23 25
M  V30 28 1 24 26
M  V30 29 2 25 27
M  V30 30 2 26 28
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
-Alaninamide
C3H8N2O
4726-85-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 2.3100 0.0 0
M  V30 2 C 1.3338 1.5400 0.0 0
M  V30 3 C 4.0011 1.5400 0.0 0
M  V30 4 N 0.0000 2.3100 0.0 0
M  V30 5 O 1.3338 0.0000 0.0 0
M  V30 6 N 5.3349 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-(3-Amino-3-oxopropyl)-8-[(2,4-difluorophenyl)amino]-10,11-dihydro-5-oxo-5H-...
C25H21F2N3O3
2614241-78-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 10.1971 4.2878 0.0 0
M  V30 2 C 15.3119 3.7022 0.0 0
M  V30 3 N 16.8476 3.8174 0.0 0
M  V30 4 O 14.6437 2.3148 0.0 0
M  V30 5 C 17.7151 2.5448 0.0 0
M  V30 6 C 19.2508 2.6600 0.0 0
M  V30 7 C 20.1183 1.3875 0.0 0
M  V30 8 N 19.4500 0.0000 0.0 0
M  V30 9 O 21.6539 1.5026 0.0 0
M  V30 10 N 5.3347 9.0595 0.0 0
M  V30 11 F 2.6673 10.5995 0.0 0
M  V30 12 F 0.0000 5.9795 0.0 0
M  V30 13 C 12.0411 6.1320 0.0 0
M  V30 14 C 12.7093 7.5195 0.0 0
M  V30 15 C 10.5398 5.7893 0.0 0
M  V30 16 C 12.9086 4.8595 0.0 0
M  V30 17 C 12.0411 8.9069 0.0 0
M  V30 18 C 14.2450 7.6345 0.0 0
M  V30 19 C 9.3358 6.7495 0.0 0
M  V30 20 C 14.4443 4.9747 0.0 0
M  V30 21 C 10.5398 9.2495 0.0 0
M  V30 22 C 15.1125 6.3620 0.0 0
M  V30 23 C 9.3358 8.2895 0.0 0
M  V30 24 C 8.0020 5.9795 0.0 0
M  V30 25 C 8.0020 9.0595 0.0 0
M  V30 26 C 6.6684 6.7495 0.0 0
M  V30 27 C 6.6684 8.2895 0.0 0
M  V30 28 C 4.0011 8.2895 0.0 0
M  V30 29 C 2.6673 9.0595 0.0 0
M  V30 30 C 4.0011 6.7495 0.0 0
M  V30 31 C 1.3336 8.2895 0.0 0
M  V30 32 C 2.6673 5.9795 0.0 0
M  V30 33 C 1.3336 6.7495 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 15
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 20
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 10 27
M  V30 11 1 10 28
M  V30 12 1 11 29
M  V30 13 1 12 33
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 21
M  V30 22 1 18 22
M  V30 23 1 19 23
M  V30 24 2 19 24
M  V30 25 2 20 22
M  V30 26 1 21 23
M  V30 27 2 23 25
M  V30 28 1 24 26
M  V30 29 1 25 27
M  V30 30 2 26 27
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 29 31
M  V30 34 2 30 32
M  V30 35 2 31 33
M  V30 36 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1417404-28-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 4726-85-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2614241-78-8
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31187995
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 530-62-1
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design and Synthesis of Highly Selective Brain Penetrant p38
Mitogen-Activated Protein Kinase Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Tormaehlen, Niklas M.; Martorelli, Mariella; Kuhn, Annette; Maier,
Florian; Guezguez, Jamil; Burnet, Michael; Albrecht, Wolfgang; Laufer,
Stefan A.; Koch, Pierre
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(2), 1225-1242

$RFMT $RIREG SCHEME450 STEP1
$RXN



  2  1
$MOL
4-[(4-Chlorophenyl)amino]-4-oxo-2-butenoic acid
C10H8ClNO3
306935-74-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 6.6685 3.8501 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 O 10.6697 0.0000 0.0 0
M  V30 8 O 12.0033 2.3101 0.0 0
M  V30 9 Cl 0.0000 4.6201 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 1.5400 0.0 0
M  V30 12 C 4.0012 3.8501 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(4-Chlorophenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H16ClN3O3
2416338-32-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 C 9.2400 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 10.0100 5.3347 0.0 0
M  V30 6 C 11.5500 5.3347 0.0 0
M  V30 7 N 12.3200 6.6685 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 O 5.3900 0.0000 0.0 0
M  V30 10 Cl 18.4800 6.6685 0.0 0
M  V30 11 C 3.0800 4.0011 0.0 0
M  V30 12 C 2.3100 2.6674 0.0 0
M  V30 13 C 4.6200 4.0011 0.0 0
M  V30 14 C 2.3100 5.3347 0.0 0
M  V30 15 N 3.0800 1.3336 0.0 0
M  V30 16 C 0.7700 2.6674 0.0 0
M  V30 17 C 5.3900 2.6674 0.0 0
M  V30 18 C 0.7700 5.3347 0.0 0
M  V30 19 C 4.6200 1.3336 0.0 0
M  V30 20 C 0.0000 4.0011 0.0 0
M  V30 21 C 13.8600 6.6685 0.0 0
M  V30 22 C 14.6300 8.0021 0.0 0
M  V30 23 C 14.6300 5.3347 0.0 0
M  V30 24 C 16.1700 8.0021 0.0 0
M  V30 25 C 16.1700 5.3347 0.0 0
M  V30 26 C 16.9400 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 26
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 306935-74-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-32-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822014
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME451 STEP1
$RXN



  2  1
$MOL
4-[(4-Fluorophenyl)amino]-4-oxo-2-butenoic acid
C10H8FNO3
60252-79-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 6.6685 3.8501 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 O 10.6697 0.0000 0.0 0
M  V30 8 O 12.0033 2.3101 0.0 0
M  V30 9 F 0.0000 4.6201 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 4.0012 3.8501 0.0 0
M  V30 12 C 2.6673 1.5400 0.0 0
M  V30 13 C 2.6673 4.6201 0.0 0
M  V30 14 C 1.3337 2.3101 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 15
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(4-Fluorophenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H16FN3O3
2416338-37-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 C 9.2400 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 10.0100 5.3347 0.0 0
M  V30 6 C 11.5500 5.3347 0.0 0
M  V30 7 N 12.3200 6.6685 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 O 5.3900 0.0000 0.0 0
M  V30 10 F 18.4800 6.6685 0.0 0
M  V30 11 C 3.0800 4.0011 0.0 0
M  V30 12 C 2.3100 2.6674 0.0 0
M  V30 13 C 4.6200 4.0011 0.0 0
M  V30 14 C 2.3100 5.3347 0.0 0
M  V30 15 N 3.0800 1.3336 0.0 0
M  V30 16 C 0.7700 2.6674 0.0 0
M  V30 17 C 5.3900 2.6674 0.0 0
M  V30 18 C 0.7700 5.3347 0.0 0
M  V30 19 C 4.6200 1.3336 0.0 0
M  V30 20 C 0.0000 4.0011 0.0 0
M  V30 21 C 13.8600 6.6685 0.0 0
M  V30 22 C 14.6300 8.0021 0.0 0
M  V30 23 C 14.6300 5.3347 0.0 0
M  V30 24 C 16.1700 8.0021 0.0 0
M  V30 25 C 16.1700 5.3347 0.0 0
M  V30 26 C 16.9400 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 26
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 60252-79-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-37-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822019
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME452 STEP1
$RXN



  2  1
$MOL
(S)--[[(1,1-Dimethylethoxy)carbonyl]amino]benzenebutanoic acid
C15H21NO4
100564-78-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=2
M  V30 2 N 6.9301 2.6675 0.0 0
M  V30 3 C 4.6201 4.0011 0.0 0
M  V30 4 C 4.6201 1.3337 0.0 0
M  V30 5 C 7.7001 4.0011 0.0 0
M  V30 6 C 3.0800 4.0011 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 3.0800 1.3337 0.0 0
M  V30 9 O 9.2401 4.0011 0.0 0
M  V30 10 O 6.9301 5.3348 0.0 0
M  V30 11 C 10.0101 5.3348 0.0 0
M  V30 12 C 11.3438 4.5648 0.0 0
M  V30 13 C 10.7801 6.6686 0.0 0
M  V30 14 C 8.6765 6.1048 0.0 0
M  V30 15 C 2.3100 5.3348 0.0 0
M  V30 16 C 0.7700 5.3348 0.0 0
M  V30 17 C 3.0800 6.6686 0.0 0
M  V30 18 C 0.0000 6.6686 0.0 0
M  V30 19 C 2.3100 8.0022 0.0 0
M  V30 20 C 0.7700 8.0022 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 15
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 2 17 19
M  V30 19 2 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Norleucine, 6-(phenylmethoxy)-, methyl ester, hydrochloride (1:1)
C14H21NO3.ClH
1138018-69-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 O 5.3348 3.8500 0.0 0
M  V30 3 C 6.6686 3.0800 0.0 0
M  V30 4 C 8.0022 3.8500 0.0 0
M  V30 5 C 9.3359 3.0800 0.0 0
M  V30 6 C 10.6697 3.8500 0.0 0
M  V30 7 C 12.0034 3.0800 0.0 0 CFG=2
M  V30 8 C 13.3370 3.8500 0.0 0
M  V30 9 N 12.0034 1.5400 0.0 0
M  V30 10 O 14.6707 3.0800 0.0 0
M  V30 11 O 13.3370 5.3900 0.0 0
M  V30 12 C 16.0045 3.8500 0.0 0
M  V30 13 C 2.6675 3.8500 0.0 0
M  V30 14 C 1.3338 3.0800 0.0 0
M  V30 15 C 2.6675 5.3900 0.0 0
M  V30 16 C 0.0000 3.8500 0.0 0
M  V30 17 C 1.3338 6.1601 0.0 0
M  V30 18 C 0.0000 5.3900 0.0 0
M  V30 19 Cl 8.0022 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 7 9 CFG=1
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 10 12
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 2 15 17
M  V30 17 2 16 18
M  V30 18 1 17 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 7)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C29H40N2O6
2307267-76-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  37 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 6.9302 0.0 0 CFG=1
M  V30 2 C 8.0022 7.7002 0.0 0
M  V30 3 C 6.6685 5.3901 0.0 0
M  V30 4 N 5.3348 7.7002 0.0 0
M  V30 5 N 8.0022 9.2402 0.0 0
M  V30 6 O 9.3360 6.9302 0.0 0
M  V30 7 C 8.0022 4.6201 0.0 0
M  V30 8 C 4.0012 6.9302 0.0 0
M  V30 9 C 9.3360 10.0102 0.0 0 CFG=2
M  V30 10 O 2.6673 7.7002 0.0 0
M  V30 11 O 4.0012 5.3901 0.0 0
M  V30 12 C 10.6697 9.2402 0.0 0
M  V30 13 C 9.3360 11.5503 0.0 0
M  V30 14 C 1.3337 6.9302 0.0 0
M  V30 15 C 12.0033 10.0102 0.0 0
M  V30 16 O 8.0022 12.3203 0.0 0
M  V30 17 O 10.6697 12.3203 0.0 0
M  V30 18 C 0.5637 8.2638 0.0 0
M  V30 19 C 0.0000 6.1601 0.0 0
M  V30 20 C 2.1037 5.5965 0.0 0
M  V30 21 C 13.3372 9.2402 0.0 0
M  V30 22 C 8.0022 13.8603 0.0 0
M  V30 23 C 14.6708 10.0102 0.0 0
M  V30 24 O 16.0045 9.2402 0.0 0
M  V30 25 C 17.3382 10.0102 0.0 0
M  V30 26 C 8.0022 3.0801 0.0 0
M  V30 27 C 6.6685 2.3101 0.0 0
M  V30 28 C 9.3360 2.3101 0.0 0
M  V30 29 C 6.6685 0.7700 0.0 0
M  V30 30 C 9.3360 0.7700 0.0 0
M  V30 31 C 8.0022 0.0000 0.0 0
M  V30 32 C 18.6720 9.2402 0.0 0
M  V30 33 C 20.0057 10.0102 0.0 0
M  V30 34 C 18.6720 7.7002 0.0 0
M  V30 35 C 21.3393 9.2402 0.0 0
M  V30 36 C 20.0057 6.9302 0.0 0
M  V30 37 C 21.3393 7.7002 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 26
M  V30 10 1 8 10
M  V30 11 2 8 11
M  V30 12 1 9 12 CFG=3
M  V30 13 1 9 13
M  V30 14 1 10 14
M  V30 15 1 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 1 14 19
M  V30 20 1 14 20
M  V30 21 1 15 21
M  V30 22 1 16 22
M  V30 23 1 21 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 32
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 2 28 30
M  V30 31 2 29 31
M  V30 32 1 30 31
M  V30 33 2 32 33
M  V30 34 1 32 34
M  V30 35 1 33 35
M  V30 36 2 34 36
M  V30 37 2 35 37
M  V30 38 1 36 37
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 100564-78-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1138018-69-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2307267-76-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36137304
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 90
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and optimization of macrocyclic peptides as
species-selective antimalaria proteasome inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Hao; Ginn, John; Zhan, Wenhu; Liu, Yi J.; Leung, Annie; Toita,
Akinori; Okamoto, Rei; Wong, Tzu-Tshin; Imaeda, Toshihiro; Hara, Ryoma;
Yukawa, Takafumi; Michino, Mayako; Vendome, Jeremie; Beuming, Thijs;
Sato, Kenjiro; Aso, Kazuyoshi; Meinke, Peter T.; Nathan, Carl F.;
Kirkman, Laura A.; Lin, Gang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(13), 9350-9375

$RFMT $RIREG SCHEME453 STEP1
$RXN



  2  1
$MOL
6-Chloro-3-pyridazinecarboxylic acid
C5H3ClN2O2
5096-73-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 0.0000 0.0 0
M  V30 3 O 0.0000 2.6673 0.0 0
M  V30 4 Cl 6.9302 1.3337 0.0 0
M  V30 5 C 2.3101 1.3337 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 N 3.0801 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 N 4.6201 0.0000 0.0 0
M  V30 10 C 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 10
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 2-amino-4,5-difluoro-, methyl ester
C8H7F2NO2
207346-42-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 O 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 N 4.6200 0.0000 0.0 0
M  V30 6 F 1.5400 5.3349 0.0 0
M  V30 7 F 0.0000 2.6674 0.0 0
M  V30 8 C 4.6200 2.6674 0.0 0
M  V30 9 C 3.8500 1.3338 0.0 0
M  V30 10 C 3.8500 4.0011 0.0 0
M  V30 11 C 2.3100 1.3338 0.0 0
M  V30 12 C 2.3100 4.0011 0.0 0
M  V30 13 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 5 9
M  V30 6 1 6 12
M  V30 7 1 7 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 2-[[(6-chloro-3-pyridazinyl)carbonyl]amino]-4,5-difluoro-, meth...
C13H8ClF2N3O3
2913151-80-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 2.6674 0.0 0
M  V30 2 O 3.8500 1.3336 0.0 0
M  V30 3 O 6.1600 2.6674 0.0 0
M  V30 4 C 4.6200 0.0000 0.0 0
M  V30 5 N 6.1600 5.3347 0.0 0
M  V30 6 C 6.9300 6.6685 0.0 0
M  V30 7 O 6.1600 8.0021 0.0 0
M  V30 8 F 0.0000 5.3347 0.0 0
M  V30 9 F 1.5400 8.0021 0.0 0
M  V30 10 Cl 13.0900 6.6685 0.0 0
M  V30 11 C 3.8500 4.0011 0.0 0
M  V30 12 C 4.6200 5.3347 0.0 0
M  V30 13 C 2.3100 4.0011 0.0 0
M  V30 14 C 3.8500 6.6685 0.0 0
M  V30 15 C 1.5400 5.3347 0.0 0
M  V30 16 C 2.3100 6.6685 0.0 0
M  V30 17 C 8.4700 6.6685 0.0 0
M  V30 18 C 9.2400 8.0021 0.0 0
M  V30 19 N 9.2400 5.3347 0.0 0
M  V30 20 C 10.7800 8.0021 0.0 0
M  V30 21 N 10.7800 5.3347 0.0 0
M  V30 22 C 11.5500 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 11
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 2 6 7
M  V30 8 1 6 17
M  V30 9 1 8 15
M  V30 10 1 9 16
M  V30 11 1 10 22
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 12 14
M  V30 15 2 13 15
M  V30 16 2 14 16
M  V30 17 1 15 16
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 5096-73-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 207346-42-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2913151-80-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35647799
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-05-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of Bipyridazine Derivatives
as Stimulator of Interferon Genes (STING) Receptor Agonists
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Shan, Bin; Hou, Hui; Zhang, Keke; Li, Rui; Shen, Chang; Chen, Zhengyang;
Xu, Peijia; Cui, Rongrong; Su, Zhaoming; Zhang, Changfa; Yang, Ruirui;
Zhou, Guizhen; Liu, Yadan; Guo, Hao; Chen, Kaixian; Fu, Wei; Jiang,
Hualiang; Zhang, Sulin; Zheng, Mingyue
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3327-3347

$RFMT $RIREG SCHEME454 STEP1
$RXN



  2  1
$MOL
2,3-Dihydro-1,4-benzodioxin-6-carboxylic acid
C9H8O4
4442-54-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6686 1.5400 0.0 0
M  V30 2 O 8.0022 2.3100 0.0 0
M  V30 3 O 6.6686 0.0000 0.0 0
M  V30 4 C 2.6675 2.3100 0.0 0
M  V30 5 C 2.6675 3.8500 0.0 0
M  V30 6 C 4.0011 1.5400 0.0 0
M  V30 7 O 1.3337 1.5400 0.0 0
M  V30 8 C 4.0011 4.6201 0.0 0
M  V30 9 O 1.3337 4.6201 0.0 0
M  V30 10 C 5.3348 2.3100 0.0 0
M  V30 11 C 0.0000 2.3100 0.0 0
M  V30 12 C 5.3348 3.8500 0.0 0
M  V30 13 C 0.0000 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 7 2 5 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 2 10 12
M  V30 14 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Methyl-3-nitroaniline
C7H8N2O2
119-32-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3338 1.5400 0.0 0 VAL=5
M  V30 2 O 1.3338 0.0000 0.0 0
M  V30 3 O 0.0000 2.3101 0.0 0
M  V30 4 C 1.3338 4.6201 0.0 0
M  V30 5 N 6.6687 1.5400 0.0 0
M  V30 6 C 2.6675 2.3101 0.0 0
M  V30 7 C 2.6675 3.8501 0.0 0
M  V30 8 C 4.0012 1.5400 0.0 0
M  V30 9 C 4.0012 4.6201 0.0 0
M  V30 10 C 5.3348 2.3101 0.0 0
M  V30 11 C 5.3348 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2,3-Dihydro-N-(4-methyl-3-nitrophenyl)-1,4-benzodioxin-6-carboxamide
C16H14N2O5
1062259-61-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 2.3101 0.0 0
M  V30 2 N 8.0022 3.0801 0.0 0
M  V30 3 O 6.6685 0.7700 0.0 0
M  V30 4 N 13.3370 3.0801 0.0 0 VAL=5
M  V30 5 O 13.3370 4.6201 0.0 0
M  V30 6 O 14.6707 2.3101 0.0 0
M  V30 7 C 13.3370 0.0000 0.0 0
M  V30 8 C 2.6673 3.0801 0.0 0
M  V30 9 C 2.6673 4.6201 0.0 0
M  V30 10 C 4.0010 2.3101 0.0 0
M  V30 11 O 1.3337 2.3101 0.0 0
M  V30 12 C 4.0010 5.3901 0.0 0
M  V30 13 O 1.3337 5.3901 0.0 0
M  V30 14 C 5.3348 3.0801 0.0 0
M  V30 15 C 0.0000 3.0801 0.0 0
M  V30 16 C 5.3348 4.6201 0.0 0
M  V30 17 C 0.0000 4.6201 0.0 0
M  V30 18 C 9.3358 2.3101 0.0 0
M  V30 19 C 10.6697 3.0801 0.0 0
M  V30 20 C 9.3358 0.7700 0.0 0
M  V30 21 C 12.0033 2.3101 0.0 0
M  V30 22 C 10.6697 0.0000 0.0 0
M  V30 23 C 12.0033 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 18
M  V30 5 2 4 5
M  V30 6 2 4 6
M  V30 7 1 4 21
M  V30 8 1 7 23
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 2 9 12
M  V30 13 1 9 13
M  V30 14 1 10 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 13 17
M  V30 18 2 14 16
M  V30 19 1 15 17
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 2 20 22
M  V30 24 2 21 23
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 4442-54-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 119-32-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1062259-61-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39930090
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 98
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 110-86-1
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed
from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian
Cancer and Other Malignancies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Pasqua, A. Elisa; Sharp, Swee Y.; Chessum, Nicola E. A.; Hayes, Angela;
Pellegrino, Loredana; Tucker, Michael J.; Miah, Asadh; Wilding, Birgit;
Evans, Lindsay E.; Rye, Carl S.; Mok, N. Yi; Liu, Manjuan; Henley, Alan
T.; Gowan, Sharon; De Billy, Emmanuel; te Poele, Robert; Powers, Marissa;
Eccles, Suzanne A.; Clarke, Paul A.; Raynaud, Florence I.; Workman, Paul;
Jones, Keith; Cheeseman, Matthew D.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(8), 5907-5936

$RFMT $RIREG SCHEME455 STEP1
$RXN



  2  1
$MOL
2-Bromo-4-nitrobenzeneacetic acid
C8H6BrNO4
66949-40-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 4.6201 0.0 0
M  V30 2 C 8.0022 3.8500 0.0 0
M  V30 3 O 8.0022 2.3100 0.0 0
M  V30 4 O 9.3359 4.6201 0.0 0
M  V30 5 Br 4.0011 6.1601 0.0 0
M  V30 6 N 1.3337 1.5400 0.0 0 VAL=5
M  V30 7 O 0.0000 2.3100 0.0 0
M  V30 8 O 1.3337 0.0000 0.0 0
M  V30 9 C 5.3348 3.8500 0.0 0
M  V30 10 C 4.0011 4.6201 0.0 0
M  V30 11 C 5.3348 2.3100 0.0 0
M  V30 12 C 2.6675 3.8500 0.0 0
M  V30 13 C 4.0011 1.5400 0.0 0
M  V30 14 C 2.6675 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 2 6 8
M  V30 8 1 6 14
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Benzyloxy)-3-methoxyphenethylamine
C16H19NO2
22231-61-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3900 4.0011 0.0 0
M  V30 2 C 4.6200 5.3347 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 7.7000 0.0000 0.0 0
M  V30 5 C 11.5500 4.0011 0.0 0
M  V30 6 C 12.3200 5.3347 0.0 0
M  V30 7 N 13.8600 5.3347 0.0 0
M  V30 8 C 6.9300 4.0011 0.0 0
M  V30 9 C 7.7000 2.6674 0.0 0
M  V30 10 C 7.7000 5.3347 0.0 0
M  V30 11 C 9.2400 2.6674 0.0 0
M  V30 12 C 9.2400 5.3347 0.0 0
M  V30 13 C 10.0100 4.0011 0.0 0
M  V30 14 C 3.0800 5.3347 0.0 0
M  V30 15 C 2.3100 6.6685 0.0 0
M  V30 16 C 2.3100 4.0011 0.0 0
M  V30 17 C 0.7700 6.6685 0.0 0
M  V30 18 C 0.7700 4.0011 0.0 0
M  V30 19 C 0.0000 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 14
M  V30 4 1 3 4
M  V30 5 1 3 9
M  V30 6 1 5 6
M  V30 7 1 5 13
M  V30 8 1 6 7
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Bromo-N-[2-[3-methoxy-4-(phenylmethoxy)phenyl]ethyl]-4-nitrobenzeneacetamide
C24H23BrN2O5
2412564-68-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.0012 4.6201 0.0 0
M  V30 2 C 4.0012 3.0801 0.0 0
M  V30 3 O 4.0012 7.7002 0.0 0
M  V30 4 C 4.0012 9.2402 0.0 0
M  V30 5 C 9.3360 7.7002 0.0 0
M  V30 6 C 10.6697 6.9302 0.0 0
M  V30 7 N 12.0033 7.7002 0.0 0
M  V30 8 C 13.3372 6.9302 0.0 0
M  V30 9 C 14.6708 7.7002 0.0 0
M  V30 10 O 13.3372 5.3901 0.0 0
M  V30 11 Br 17.3382 9.2402 0.0 0
M  V30 12 N 20.0057 4.6201 0.0 0 VAL=5
M  V30 13 O 21.3393 5.3901 0.0 0
M  V30 14 O 20.0057 3.0801 0.0 0
M  V30 15 C 5.3348 5.3901 0.0 0
M  V30 16 C 5.3348 6.9302 0.0 0
M  V30 17 C 6.6685 4.6201 0.0 0
M  V30 18 C 6.6685 7.7002 0.0 0
M  V30 19 C 8.0022 5.3901 0.0 0
M  V30 20 C 8.0022 6.9302 0.0 0
M  V30 21 C 2.6673 2.3101 0.0 0
M  V30 22 C 1.3337 3.0801 0.0 0
M  V30 23 C 2.6673 0.7700 0.0 0
M  V30 24 C 0.0000 2.3101 0.0 0
M  V30 25 C 1.3337 0.0000 0.0 0
M  V30 26 C 0.0000 0.7700 0.0 0
M  V30 27 C 16.0045 6.9302 0.0 0
M  V30 28 C 17.3382 7.7002 0.0 0
M  V30 29 C 16.0045 5.3901 0.0 0
M  V30 30 C 18.6720 6.9302 0.0 0
M  V30 31 C 17.3382 4.6201 0.0 0
M  V30 32 C 18.6720 5.3901 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 21
M  V30 4 1 3 4
M  V30 5 1 3 16
M  V30 6 1 5 6
M  V30 7 1 5 20
M  V30 8 1 6 7
M  V30 9 1 7 8
M  V30 10 1 8 9
M  V30 11 2 8 10
M  V30 12 1 9 27
M  V30 13 1 11 28
M  V30 14 2 12 13
M  V30 15 2 12 14
M  V30 16 1 12 32
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 1 28 30
M  V30 32 2 29 31
M  V30 33 2 30 32
M  V30 34 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 66949-40-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 22231-61-4
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2412564-68-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21974286
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 96
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 94790-37-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Identification of C10 nitrogen-containing aporphines with dopamine D1
versus D5 receptor selectivity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Karki, Anupam; Juarez, Reecan; Namballa, Hari K.; Alberts, Ian; Harding,
Wayne W.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(8), 127053

$RFMT $RIREG SCHEME456 STEP1
$RXN



  2  1
$MOL
3-Iodo-4-methoxybenzoic acid
C8H7IO3
68507-19-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 4.6201 0.0 0
M  V30 2 O 0.0000 3.8500 0.0 0
M  V30 3 O 1.3337 6.1601 0.0 0
M  V30 4 I 4.0011 0.0000 0.0 0
M  V30 5 O 6.6686 1.5400 0.0 0
M  V30 6 C 8.0022 2.3100 0.0 0
M  V30 7 C 2.6675 3.8500 0.0 0
M  V30 8 C 2.6675 2.3100 0.0 0
M  V30 9 C 4.0011 4.6201 0.0 0
M  V30 10 C 4.0011 1.5400 0.0 0
M  V30 11 C 5.3348 3.8500 0.0 0
M  V30 12 C 5.3348 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 10
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(4-Methylpiperazin-1-ylmethyl)-3-trifluoromethylaniline
C13H18F3N3
694499-26-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 3.0800 0.0 0
M  V30 2 C 2.6673 1.5400 0.0 0
M  V30 3 F 4.2073 1.5400 0.0 0
M  V30 4 F 2.6673 0.0000 0.0 0
M  V30 5 F 1.1273 1.5400 0.0 0
M  V30 6 N 0.0000 6.1600 0.0 0
M  V30 7 C 10.6694 6.1600 0.0 0
M  V30 8 C 4.0011 3.8500 0.0 0
M  V30 9 C 2.6673 3.0800 0.0 0
M  V30 10 C 4.0011 5.3900 0.0 0
M  V30 11 C 1.3336 3.8500 0.0 0
M  V30 12 C 2.6673 6.1600 0.0 0
M  V30 13 C 1.3336 5.3900 0.0 0
M  V30 14 N 6.6684 3.8500 0.0 0
M  V30 15 C 6.6684 5.3900 0.0 0
M  V30 16 C 8.0021 3.0800 0.0 0
M  V30 17 C 8.0021 6.1600 0.0 0
M  V30 18 C 9.3358 3.8500 0.0 0
M  V30 19 N 9.3358 5.3900 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 8
M  V30 2 1 1 14
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 2 9
M  V30 7 1 6 13
M  V30 8 1 7 19
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 13
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Iodo-4-methoxy-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phe...
C21H23F3IN3O2
1701486-06-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 9.2401 0.0 0
M  V30 2 C 8.0022 10.7801 0.0 0
M  V30 3 F 9.5423 10.7801 0.0 0
M  V30 4 F 8.0022 12.3201 0.0 0
M  V30 5 F 6.4622 10.7801 0.0 0
M  V30 6 N 10.6695 6.1601 0.0 0
M  V30 7 C 10.6695 4.6201 0.0 0
M  V30 8 O 9.3359 3.8500 0.0 0
M  V30 9 C 0.0000 6.1601 0.0 0
M  V30 10 I 13.3370 0.0000 0.0 0
M  V30 11 O 16.0043 1.5400 0.0 0
M  V30 12 C 17.3381 2.3100 0.0 0
M  V30 13 C 6.6686 8.4701 0.0 0
M  V30 14 C 8.0022 9.2401 0.0 0
M  V30 15 C 6.6686 6.9301 0.0 0
M  V30 16 C 9.3359 8.4701 0.0 0
M  V30 17 C 8.0022 6.1601 0.0 0
M  V30 18 C 9.3359 6.9301 0.0 0
M  V30 19 N 4.0011 8.4701 0.0 0
M  V30 20 C 2.6675 9.2401 0.0 0
M  V30 21 C 4.0011 6.9301 0.0 0
M  V30 22 C 1.3338 8.4701 0.0 0
M  V30 23 C 2.6675 6.1601 0.0 0
M  V30 24 N 1.3338 6.9301 0.0 0
M  V30 25 C 12.0034 3.8500 0.0 0
M  V30 26 C 12.0034 2.3100 0.0 0
M  V30 27 C 13.3370 4.6201 0.0 0
M  V30 28 C 13.3370 1.5400 0.0 0
M  V30 29 C 14.6707 3.8500 0.0 0
M  V30 30 C 14.6707 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 13
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 1 2 4
M  V30 5 1 2 5
M  V30 6 1 2 14
M  V30 7 1 6 7
M  V30 8 1 6 18
M  V30 9 2 7 8
M  V30 10 1 7 25
M  V30 11 1 9 24
M  V30 12 1 10 28
M  V30 13 1 11 12
M  V30 14 1 11 30
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 14 16
M  V30 18 2 15 17
M  V30 19 2 16 18
M  V30 20 1 17 18
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 68507-19-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 694499-26-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1701486-06-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-33920075
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):NOTES
$DATUM alternate reaction conditions also shown
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with
Improved Cardiac Safety
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Pandrala, Mallesh; Bruyneel, Arne Antoon N.; Hnatiuk, Anna P.; Mercola,
Mark; Malhotra, Sanjay V.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(16), 10898-10919

$RFMT $RIREG SCHEME457 STEP1
$RXN



  2  1
$MOL
3,4-Dimethoxyphenethylamine
C10H15NO2
120-20-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.3100 1.3338 0.0 0
M  V30 2 C 3.0800 0.0000 0.0 0
M  V30 3 O 0.7700 4.0011 0.0 0
M  V30 4 C 0.0000 5.3349 0.0 0
M  V30 5 C 6.9300 4.0011 0.0 0
M  V30 6 C 7.7000 5.3349 0.0 0
M  V30 7 N 9.2400 5.3349 0.0 0
M  V30 8 C 3.0800 2.6674 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 4.6200 2.6674 0.0 0
M  V30 11 C 3.0800 5.3349 0.0 0
M  V30 12 C 5.3900 4.0011 0.0 0
M  V30 13 C 4.6200 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 3 4
M  V30 4 1 3 9
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 6 7
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Methoxyindoleacetic acid
C11H11NO3
3471-31-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.2707 3.1885 0.0 0
M  V30 2 C 8.7354 2.7126 0.0 0
M  V30 3 O 9.0556 1.2061 0.0 0
M  V30 4 O 9.8798 3.7430 0.0 0
M  V30 5 O 1.5400 5.1455 0.0 0
M  V30 6 C 0.0000 5.1455 0.0 0
M  V30 7 C 4.6201 2.4782 0.0 0
M  V30 8 C 3.8500 1.1444 0.0 0
M  V30 9 C 6.1263 2.1579 0.0 0
M  V30 10 C 3.8500 3.8118 0.0 0
M  V30 11 N 4.8805 0.0000 0.0 0
M  V30 12 C 2.3100 1.1444 0.0 0
M  V30 13 C 6.2873 0.6263 0.0 0
M  V30 14 C 2.3100 3.8118 0.0 0
M  V30 15 C 1.5400 2.4782 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 6
M  V30 6 1 5 14
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 2 9 13
M  V30 13 1 10 14
M  V30 14 1 11 13
M  V30 15 1 12 15
M  V30 16 2 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(3,4-Dimethoxyphenyl)ethyl]-5-methoxy-1H-indole-3-acetamide
C21H24N2O4
1990303-96-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.5500 6.6684 0.0 0
M  V30 2 C 10.0100 6.6684 0.0 0
M  V30 3 N 9.2400 5.3347 0.0 0
M  V30 4 O 9.2400 8.0020 0.0 0
M  V30 5 C 7.7000 5.3347 0.0 0
M  V30 6 C 6.9300 4.0011 0.0 0
M  V30 7 O 17.6051 6.5780 0.0 0
M  V30 8 C 19.0698 7.0538 0.0 0
M  V30 9 O 2.3100 1.3336 0.0 0
M  V30 10 C 3.0800 0.0000 0.0 0
M  V30 11 O 0.7700 4.0011 0.0 0
M  V30 12 C 0.0000 5.3347 0.0 0
M  V30 13 C 13.8517 8.1631 0.0 0
M  V30 14 C 14.1719 9.6694 0.0 0
M  V30 15 C 12.3200 8.0020 0.0 0
M  V30 16 C 14.9961 7.1325 0.0 0
M  V30 17 N 12.8381 10.4394 0.0 0
M  V30 18 C 15.6364 10.1452 0.0 0
M  V30 19 C 11.6937 9.4089 0.0 0
M  V30 20 C 16.4608 7.6085 0.0 0
M  V30 21 C 16.7809 9.1148 0.0 0
M  V30 22 C 5.3900 4.0011 0.0 0
M  V30 23 C 4.6200 2.6673 0.0 0
M  V30 24 C 4.6200 5.3347 0.0 0
M  V30 25 C 3.0800 2.6673 0.0 0
M  V30 26 C 3.0800 5.3347 0.0 0
M  V30 27 C 2.3100 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 22
M  V30 8 1 7 8
M  V30 9 1 7 20
M  V30 10 1 9 10
M  V30 11 1 9 25
M  V30 12 1 11 12
M  V30 13 1 11 27
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 2 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 1 18 21
M  V30 23 2 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 120-20-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3471-31-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1990303-96-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23040590
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME458 STEP1
$RXN



  2  1
$MOL
4-[(4-Nitrophenyl)amino]-4-oxo-2-butenoic acid
C10H8N2O5
36847-91-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 4.6201 0.0 0
M  V30 2 C 8.0022 3.8501 0.0 0
M  V30 3 C 9.3360 4.6201 0.0 0
M  V30 4 O 8.0022 2.3101 0.0 0
M  V30 5 C 10.6697 3.8501 0.0 0
M  V30 6 C 12.0033 4.6201 0.0 0
M  V30 7 O 12.0033 6.1601 0.0 0
M  V30 8 O 13.3370 3.8501 0.0 0
M  V30 9 N 1.3337 1.5400 0.0 0 VAL=5
M  V30 10 O 1.3337 0.0000 0.0 0
M  V30 11 O 0.0000 2.3101 0.0 0
M  V30 12 C 5.3348 3.8501 0.0 0
M  V30 13 C 5.3348 2.3101 0.0 0
M  V30 14 C 4.0010 4.6201 0.0 0
M  V30 15 C 4.0010 1.5400 0.0 0
M  V30 16 C 2.6673 3.8501 0.0 0
M  V30 17 C 2.6673 2.3101 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 2 9 10
M  V30 10 2 9 11
M  V30 11 1 9 17
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 2 14 16
M  V30 16 2 15 17
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(4-Nitrophenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H16N4O5
2416338-30-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 C 9.2400 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 10.0100 5.3347 0.0 0
M  V30 6 C 11.5500 5.3347 0.0 0
M  V30 7 N 12.3200 6.6685 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 O 5.3900 0.0000 0.0 0
M  V30 10 N 18.4800 6.6685 0.0 0 VAL=5
M  V30 11 O 19.2500 5.3347 0.0 0
M  V30 12 O 19.2500 8.0021 0.0 0
M  V30 13 C 3.0800 4.0011 0.0 0
M  V30 14 C 2.3100 2.6674 0.0 0
M  V30 15 C 4.6200 4.0011 0.0 0
M  V30 16 C 2.3100 5.3347 0.0 0
M  V30 17 N 3.0800 1.3336 0.0 0
M  V30 18 C 0.7700 2.6674 0.0 0
M  V30 19 C 5.3900 2.6674 0.0 0
M  V30 20 C 0.7700 5.3347 0.0 0
M  V30 21 C 4.6200 1.3336 0.0 0
M  V30 22 C 0.0000 4.0011 0.0 0
M  V30 23 C 13.8600 6.6685 0.0 0
M  V30 24 C 14.6300 8.0021 0.0 0
M  V30 25 C 14.6300 5.3347 0.0 0
M  V30 26 C 16.1700 8.0021 0.0 0
M  V30 27 C 16.1700 5.3347 0.0 0
M  V30 28 C 16.9400 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 19
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 23
M  V30 10 2 9 21
M  V30 11 2 10 11
M  V30 12 2 10 12
M  V30 13 1 10 28
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 21
M  V30 22 1 18 22
M  V30 23 1 19 21
M  V30 24 2 20 22
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 2 25 27
M  V30 29 2 26 28
M  V30 30 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 36847-91-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-30-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822012
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME459 STEP1
$RXN



  2  1
$MOL
N-(tert-Butoxycarbonyl)-4-nitro-L-phenylalanine
C14H18N2O6
33305-77-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9302 4.0012 0.0 0
M  V30 2 C 7.7002 2.6675 0.0 0 CFG=1
M  V30 3 N 9.2402 2.6675 0.0 0
M  V30 4 C 6.9302 1.3338 0.0 0
M  V30 5 C 10.0102 4.0012 0.0 0
M  V30 6 O 7.7002 0.0000 0.0 0
M  V30 7 O 5.3901 1.3338 0.0 0
M  V30 8 O 11.5503 4.0012 0.0 0
M  V30 9 O 9.2402 5.3348 0.0 0
M  V30 10 C 12.3203 5.3348 0.0 0
M  V30 11 C 10.9866 6.1048 0.0 0
M  V30 12 C 13.0903 6.6687 0.0 0
M  V30 13 C 13.6539 4.5648 0.0 0
M  V30 14 N 0.7700 4.0012 0.0 0 VAL=5
M  V30 15 O 0.0000 2.6675 0.0 0
M  V30 16 O 0.0000 5.3348 0.0 0
M  V30 17 C 5.3901 4.0012 0.0 0
M  V30 18 C 4.6201 2.6675 0.0 0
M  V30 19 C 4.6201 5.3348 0.0 0
M  V30 20 C 3.0801 2.6675 0.0 0
M  V30 21 C 3.0801 5.3348 0.0 0
M  V30 22 C 2.3101 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3 CFG=3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 2 14 16
M  V30 16 1 14 22
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 2 19 21
M  V30 21 2 20 22
M  V30 22 1 21 22
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[[4-(Aminomethyl)phenyl]methyl]-2,2,2-trifluoroacetamide
C10H11F3N2O
1515293-47-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3348 1.5400 0.0 0
M  V30 2 N 4.0012 2.3101 0.0 0
M  V30 3 C 2.6673 1.5400 0.0 0
M  V30 4 C 1.3337 2.3101 0.0 0
M  V30 5 O 2.6673 0.0000 0.0 0
M  V30 6 F 0.0000 3.0801 0.0 0
M  V30 7 F 0.5637 0.9764 0.0 0
M  V30 8 F 2.1037 3.6437 0.0 0
M  V30 9 C 10.6697 4.6201 0.0 0
M  V30 10 N 12.0033 3.8501 0.0 0
M  V30 11 C 6.6685 2.3101 0.0 0
M  V30 12 C 6.6685 3.8501 0.0 0
M  V30 13 C 8.0022 1.5400 0.0 0
M  V30 14 C 8.0022 4.6201 0.0 0
M  V30 15 C 9.3360 2.3101 0.0 0
M  V30 16 C 9.3360 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 4 8
M  V30 9 1 9 10
M  V30 10 1 9 16
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C24H27F3N4O6
2938349-12-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  37 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 6.6685 0.0 0 CFG=2
M  V30 2 C 4.6201 6.6685 0.0 0
M  V30 3 C 6.9302 8.0022 0.0 0
M  V30 4 N 6.9302 5.3348 0.0 0
M  V30 5 N 8.4702 8.0022 0.0 0
M  V30 6 O 6.1601 9.3360 0.0 0
M  V30 7 C 6.1601 4.0010 0.0 0
M  V30 8 C 9.2402 9.3360 0.0 0
M  V30 9 O 6.9302 2.6673 0.0 0
M  V30 10 O 4.6201 4.0010 0.0 0
M  V30 11 C 6.1601 1.3337 0.0 0
M  V30 12 C 7.4938 0.5637 0.0 0
M  V30 13 C 5.3901 0.0000 0.0 0
M  V30 14 C 4.8265 2.1037 0.0 0
M  V30 15 N 1.5400 12.0033 0.0 0 VAL=5
M  V30 16 O 2.3101 13.3370 0.0 0
M  V30 17 O 0.0000 12.0033 0.0 0
M  V30 18 C 15.4003 9.3360 0.0 0
M  V30 19 N 16.1704 10.6697 0.0 0
M  V30 20 C 17.7104 10.6697 0.0 0
M  V30 21 C 18.4804 12.0033 0.0 0
M  V30 22 O 18.4804 9.3360 0.0 0
M  V30 23 F 19.2504 13.3370 0.0 0
M  V30 24 F 17.1467 12.7733 0.0 0
M  V30 25 F 19.8141 11.2333 0.0 0
M  V30 26 C 3.8501 8.0022 0.0 0
M  V30 27 C 2.3101 8.0022 0.0 0
M  V30 28 C 4.6201 9.3360 0.0 0
M  V30 29 C 1.5400 9.3360 0.0 0
M  V30 30 C 3.8501 10.6697 0.0 0
M  V30 31 C 2.3101 10.6697 0.0 0
M  V30 32 C 10.7802 9.3360 0.0 0
M  V30 33 C 11.5503 10.6697 0.0 0
M  V30 34 C 11.5503 8.0022 0.0 0
M  V30 35 C 13.0903 10.6697 0.0 0
M  V30 36 C 13.0903 8.0022 0.0 0
M  V30 37 C 13.8603 9.3360 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 26
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 32
M  V30 12 1 9 11
M  V30 13 1 11 12
M  V30 14 1 11 13
M  V30 15 1 11 14
M  V30 16 2 15 16
M  V30 17 2 15 17
M  V30 18 1 15 31
M  V30 19 1 18 19
M  V30 20 1 18 37
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 1 21 23
M  V30 25 1 21 24
M  V30 26 1 21 25
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 2 28 30
M  V30 31 2 29 31
M  V30 32 1 30 31
M  V30 33 2 32 33
M  V30 34 1 32 34
M  V30 35 1 33 35
M  V30 36 2 34 36
M  V30 37 2 35 37
M  V30 38 1 36 37
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 33305-77-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1515293-47-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2938349-12-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36512482
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 543-27-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7646-93-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and Structural Characterization of Macrocyclic Plasmin
Inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wiedemeyer, Simon J. A.; Wu, Guojie; Pham, T. L. Phuong; Lang-Henkel,
Heike; Perez Urzua, Benjamin; Whisstock, James C.; Law, Ruby H. P.;
Steinmetzer, Torsten
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(6), e202200632

$RFMT $RIREG SCHEME460 STEP1
$RXN



  2  1
$MOL
3-Phenylisoxazole-5-carboxylic acid
C10H7NO3
14442-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.2358 1.5317 0.0 0
M  V30 2 O 9.6426 2.1580 0.0 0
M  V30 3 O 8.0747 0.0000 0.0 0
M  V30 4 C 4.6200 3.2067 0.0 0
M  V30 5 C 5.5252 1.9609 0.0 0
M  V30 6 N 5.5252 4.4528 0.0 0
M  V30 7 C 6.9898 2.4367 0.0 0
M  V30 8 O 6.9898 3.9767 0.0 0
M  V30 9 C 3.0800 3.2067 0.0 0
M  V30 10 C 2.3100 4.5405 0.0 0
M  V30 11 C 2.3100 1.8731 0.0 0
M  V30 12 C 0.7700 4.5405 0.0 0
M  V30 13 C 0.7700 1.8731 0.0 0
M  V30 14 C 0.0000 3.2067 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 4 9
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 7 8
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1,1-Dimethylethyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate
C11H20N2O2
1211586-09-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8500 2.8737 0.0 0
M  V30 2 O 3.0800 1.5400 0.0 0
M  V30 3 O 3.0800 4.2073 0.0 0
M  V30 4 C 1.5400 1.5400 0.0 0
M  V30 5 C 1.5400 3.0800 0.0 0
M  V30 6 C 0.0000 1.5400 0.0 0
M  V30 7 C 1.5400 0.0000 0.0 0
M  V30 8 N 11.2858 2.8737 0.0 0
M  V30 9 C 7.5679 2.8737 0.0 0
M  V30 10 C 6.4790 1.7847 0.0 0
M  V30 11 C 6.4790 3.9626 0.0 0
M  V30 12 C 8.6569 1.7847 0.0 0
M  V30 13 C 8.6569 3.9626 0.0 0
M  V30 14 N 5.3901 2.8737 0.0 0
M  V30 15 C 9.7458 2.8737 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 15
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 9 12
M  V30 12 1 9 13
M  V30 13 1 10 14
M  V30 14 1 11 14
M  V30 15 1 12 15
M  V30 16 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Azaspiro[3.3]heptane-2-carboxylic acid, 6-[[(3-phenyl-5-isoxazolyl)carbonyl...
C21H25N3O4
3054166-32-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 16.1394 1.5400 0.0 0
M  V30 2 O 17.4731 2.3101 0.0 0
M  V30 3 O 16.1394 0.0000 0.0 0
M  V30 4 C 18.8067 1.5400 0.0 0
M  V30 5 C 18.0367 0.2064 0.0 0
M  V30 6 C 20.1406 0.7700 0.0 0
M  V30 7 C 19.5768 2.8737 0.0 0
M  V30 8 N 9.6996 5.2580 0.0 0
M  V30 9 C 8.3659 4.4880 0.0 0
M  V30 10 O 8.3659 2.9479 0.0 0
M  V30 11 C 12.9195 3.3990 0.0 0
M  V30 12 C 14.4070 3.7976 0.0 0
M  V30 13 C 13.3181 1.9115 0.0 0
M  V30 14 C 11.4320 3.0004 0.0 0
M  V30 15 C 12.5209 4.8865 0.0 0
M  V30 16 N 14.8057 2.3101 0.0 0
M  V30 17 C 11.0334 4.4880 0.0 0
M  V30 18 C 7.0323 5.2580 0.0 0
M  V30 19 C 5.6253 4.6317 0.0 0
M  V30 20 O 6.8713 6.7895 0.0 0
M  V30 21 C 4.5948 5.7761 0.0 0
M  V30 22 N 5.3649 7.1097 0.0 0
M  V30 23 C 3.0633 5.6151 0.0 0
M  V30 24 C 2.4369 4.2081 0.0 0
M  V30 25 C 2.1580 6.8610 0.0 0
M  V30 26 C 0.9052 4.0472 0.0 0
M  V30 27 C 0.6265 6.7001 0.0 0
M  V30 28 C 0.0000 5.2931 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6
M  V30 7 1 4 7
M  V30 8 1 8 9
M  V30 9 1 8 17
M  V30 10 2 9 10
M  V30 11 1 9 18
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 1 13 16
M  V30 18 1 14 17
M  V30 19 1 15 17
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 22
M  V30 25 1 21 23
M  V30 26 2 23 24
M  V30 27 1 23 25
M  V30 28 1 24 26
M  V30 29 2 25 27
M  V30 30 2 26 28
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 14442-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1211586-09-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3054166-32-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-41860736
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and optimization of a series of 2-azaspiro[3.3]heptane
derivatives as orally bioavailable fetal hemoglobin inducers
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Katayama, Katsushi; Tsunemi, Tomoyuki; Miyazaki, Kazuo; Uoto, Kouichi;
Yoshioka, Ryosuke; Terashima, Hideki; Terakawa, Maki; Yamashiro, Kyoko;
Haruyama, Munetada; Maeda, Hiroaki; Makino, Tomohiro
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2020), 30(19), 127425

$RFMT $RIREG SCHEME461 STEP1
$RXN



  2  1
$MOL
Carprofen
C15H12ClNO2
53716-49-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0.0000 1.8035 0.0 0
M  V30 2 C 10.0251 2.6673 0.0 0
M  V30 3 C 10.7951 1.3336 0.0 0
M  V30 4 C 10.7951 4.0011 0.0 0
M  V30 5 O 12.3351 1.3336 0.0 0
M  V30 6 O 10.0251 0.0000 0.0 0
M  V30 7 C 5.4051 2.6673 0.0 0
M  V30 8 C 3.8987 2.9876 0.0 0
M  V30 9 C 6.1751 4.0011 0.0 0
M  V30 10 C 6.1751 1.3336 0.0 0
M  V30 11 C 3.7377 4.5191 0.0 0
M  V30 12 C 2.6528 2.0824 0.0 0
M  V30 13 N 5.1445 5.1454 0.0 0
M  V30 14 C 7.7151 4.0011 0.0 0
M  V30 15 C 7.7151 1.3336 0.0 0
M  V30 16 C 2.3308 5.1454 0.0 0
M  V30 17 C 1.2460 2.7087 0.0 0
M  V30 18 C 8.4851 2.6673 0.0 0
M  V30 19 C 1.0849 4.2402 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 17
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 18
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 2 9 14
M  V30 14 1 10 15
M  V30 15 1 11 13
M  V30 16 2 11 16
M  V30 17 1 12 17
M  V30 18 1 14 18
M  V30 19 2 15 18
M  V30 20 1 16 19
M  V30 21 2 17 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1,N1-Didodecyl-N2-methyl-1,2-ethanediamine
C27H59N2.I
2128731-38-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 13.8600 5.3900 0.0 0 CHG=1 VAL=4
M  V30 2 C 12.3200 5.3900 0.0 0
M  V30 3 C 15.4000 5.3900 0.0 0
M  V30 4 C 13.8600 3.8500 0.0 0
M  V30 5 C 13.8600 6.9300 0.0 0
M  V30 6 C 11.5500 6.7236 0.0 0
M  V30 7 C 16.1700 6.7236 0.0 0
M  V30 8 C 12.5264 3.0800 0.0 0
M  V30 9 C 10.0100 6.7236 0.0 0
M  V30 10 C 17.7100 6.7236 0.0 0
M  V30 11 N 12.5264 1.5400 0.0 0
M  V30 12 C 9.2400 8.0574 0.0 0
M  V30 13 C 18.4800 8.0574 0.0 0
M  V30 14 C 7.7000 8.0574 0.0 0
M  V30 15 C 20.0200 8.0574 0.0 0
M  V30 16 C 6.9300 9.3911 0.0 0
M  V30 17 C 20.7900 9.3911 0.0 0
M  V30 18 C 5.3900 9.3911 0.0 0
M  V30 19 C 22.3300 9.3911 0.0 0
M  V30 20 C 4.6200 10.7247 0.0 0
M  V30 21 C 23.1000 10.7247 0.0 0
M  V30 22 C 3.0800 10.7247 0.0 0
M  V30 23 C 24.6400 10.7247 0.0 0
M  V30 24 C 2.3100 12.0585 0.0 0
M  V30 25 C 25.4100 12.0585 0.0 0
M  V30 26 C 0.7700 12.0585 0.0 0
M  V30 27 C 26.9500 12.0585 0.0 0
M  V30 28 C 0.0000 13.3921 0.0 0
M  V30 29 C 27.7200 13.3921 0.0 0
M  V30 30 I 13.8600 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 6 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 1 9 12
M  V30 12 1 10 13
M  V30 13 1 12 14
M  V30 14 1 13 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 1 18 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
1-Dodecanaminium, N-[2-[[2-(6-chloro-9H-carbazol-2-yl)-1-oxopropyl]amino]ethy...
C42H69ClN3O.I
3055833-22-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  48 49 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0.0000 20.6818 0.0 0
M  V30 2 C 10.0252 21.5457 0.0 0
M  V30 3 C 10.7952 20.2120 0.0 0
M  V30 4 C 10.7952 22.8793 0.0 0
M  V30 5 N 12.3352 20.2120 0.0 0
M  V30 6 O 10.0252 18.8783 0.0 0
M  V30 7 C 13.1052 18.8783 0.0 0
M  V30 8 C 14.6453 18.8783 0.0 0
M  V30 9 N 15.4153 17.5445 0.0 0 CHG=1 VAL=4
M  V30 10 C 16.1853 16.2108 0.0 0
M  V30 11 C 16.7489 18.3145 0.0 0
M  V30 12 C 14.0816 16.7745 0.0 0
M  V30 13 C 15.4153 14.8772 0.0 0
M  V30 14 C 18.0828 17.5445 0.0 0
M  V30 15 C 16.1853 13.5435 0.0 0
M  V30 16 C 19.4164 18.3145 0.0 0
M  V30 17 C 15.4153 12.2097 0.0 0
M  V30 18 C 20.7501 17.5445 0.0 0
M  V30 19 C 16.1853 10.8760 0.0 0
M  V30 20 C 22.0838 18.3145 0.0 0
M  V30 21 C 15.4153 9.5423 0.0 0
M  V30 22 C 23.4176 17.5445 0.0 0
M  V30 23 C 16.1853 8.2087 0.0 0
M  V30 24 C 24.7513 18.3145 0.0 0
M  V30 25 C 15.4153 6.8748 0.0 0
M  V30 26 C 26.0849 17.5445 0.0 0
M  V30 27 C 16.1853 5.5412 0.0 0
M  V30 28 C 27.4186 18.3145 0.0 0
M  V30 29 C 15.4153 4.2075 0.0 0
M  V30 30 C 28.7524 17.5445 0.0 0
M  V30 31 C 16.1853 2.8738 0.0 0
M  V30 32 C 30.0861 18.3145 0.0 0
M  V30 33 C 15.4153 1.5400 0.0 0
M  V30 34 C 31.4198 17.5445 0.0 0
M  V30 35 C 5.4051 21.5457 0.0 0
M  V30 36 C 3.8987 21.8658 0.0 0
M  V30 37 C 6.1751 22.8793 0.0 0
M  V30 38 C 6.1751 20.2120 0.0 0
M  V30 39 C 3.7377 23.3974 0.0 0
M  V30 40 C 2.6527 20.9606 0.0 0
M  V30 41 N 5.1446 24.0239 0.0 0
M  V30 42 C 7.7151 22.8793 0.0 0
M  V30 43 C 7.7151 20.2120 0.0 0
M  V30 44 C 2.3308 24.0239 0.0 0
M  V30 45 C 1.2459 21.5871 0.0 0
M  V30 46 C 8.4851 21.5457 0.0 0
M  V30 47 C 1.0850 23.1186 0.0 0
M  V30 48 I 15.7099 0.0000 0.0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 45
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 46
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 1 10 13
M  V30 14 1 11 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 1 24 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 1 29 31
M  V30 32 1 30 32
M  V30 33 1 31 33
M  V30 34 1 32 34
M  V30 35 1 35 36
M  V30 36 1 35 37
M  V30 37 2 35 38
M  V30 38 1 36 39
M  V30 39 2 36 40
M  V30 40 1 37 41
M  V30 41 2 37 42
M  V30 42 1 38 43
M  V30 43 1 39 41
M  V30 44 2 39 44
M  V30 45 1 40 45
M  V30 46 1 42 46
M  V30 47 2 43 46
M  V30 48 1 44 47
M  V30 49 2 45 47
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 53716-49-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2128731-38-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3055833-22-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37275700
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):NOTES
$DATUM inert in stage 2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and Characterization of a New Cationic Lipid: Efficient siRNA
Delivery and Anticancer Activity of Survivin-siRNA Lipoplexes for the
Treatment of Lung and Breast Cancers
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Vaidya, Sandeep; Mohod, Annie; Eedara, Abhisheik Chowdary; Andugulapati,
Sai Balaji; Pabbaraja, Srihari
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(16), e202300097

$RFMT $RIREG SCHEME462 STEP1
$RXN



  2  1
$MOL
BOC-L-Phenylalanine
C14H19NO4
13734-34-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 2 C 4.6201 4.0012 0.0 0
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6766 6.1048 0.0 0
M  V30 14 C 3.0801 4.0012 0.0 0
M  V30 15 C 2.3101 5.3348 0.0 0
M  V30 16 C 2.3101 2.6675 0.0 0
M  V30 17 C 0.7700 5.3348 0.0 0
M  V30 18 C 0.7700 2.6675 0.0 0
M  V30 19 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 14
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Benzenepropanamine, -[(1E)-2-fluoro-2-[(phenylmethyl)sulfonyl]ethenyl]-, hyd...
C18H20FNO2S.ClH
2761157-71-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 3.0800 0.0 0
M  V30 2 S 5.3348 3.8500 0.0 0 VAL=6
M  V30 3 C 6.6686 4.6200 0.0 0
M  V30 4 O 6.1048 2.5164 0.0 0
M  V30 5 O 4.5648 5.1837 0.0 0
M  V30 6 C 8.0022 3.8500 0.0 0
M  V30 7 F 6.6686 6.1601 0.0 0
M  V30 8 C 9.3359 4.6200 0.0 0 CFG=1
M  V30 9 C 10.6697 3.8500 0.0 0
M  V30 10 N 9.3359 6.1601 0.0 0
M  V30 11 C 12.0034 4.6200 0.0 0
M  V30 12 C 2.6675 3.8500 0.0 0
M  V30 13 C 1.3338 3.0800 0.0 0
M  V30 14 C 2.6675 5.3900 0.0 0
M  V30 15 C 0.0000 3.8500 0.0 0
M  V30 16 C 1.3338 6.1601 0.0 0
M  V30 17 C 0.0000 5.3900 0.0 0
M  V30 18 C 13.3370 3.8500 0.0 0
M  V30 19 C 14.6707 4.6200 0.0 0
M  V30 20 C 13.3370 2.3100 0.0 0
M  V30 21 C 16.0045 3.8500 0.0 0
M  V30 22 C 14.6707 1.5400 0.0 0
M  V30 23 C 16.0045 2.3100 0.0 0
M  V30 24 Cl 8.0022 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 2 5
M  V30 6 2 3 6
M  V30 7 1 3 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10 CFG=1
M  V30 11 1 9 11
M  V30 12 1 11 18
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C32H37FN2O5S
2761157-79-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  41 43 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 9.3358 0.0 0 CFG=2
M  V30 2 C 3.0800 9.3358 0.0 0
M  V30 3 C 5.3900 8.0021 0.0 0
M  V30 4 N 5.3900 10.6696 0.0 0
M  V30 5 N 6.9300 8.0021 0.0 0
M  V30 6 O 4.6200 6.6685 0.0 0
M  V30 7 C 4.6200 12.0032 0.0 0
M  V30 8 C 7.7000 6.6685 0.0 0 CFG=2
M  V30 9 O 5.3900 13.3369 0.0 0
M  V30 10 O 3.0800 12.0032 0.0 0
M  V30 11 C 6.9300 5.3347 0.0 0
M  V30 12 C 9.2400 6.6685 0.0 0
M  V30 13 C 4.6200 14.6705 0.0 0
M  V30 14 C 7.7000 4.0011 0.0 0
M  V30 15 C 10.0100 8.0021 0.0 0
M  V30 16 C 5.9536 15.4405 0.0 0
M  V30 17 C 3.8500 16.0043 0.0 0
M  V30 18 C 3.2864 13.9005 0.0 0
M  V30 19 S 11.5500 8.0021 0.0 0 VAL=6
M  V30 20 F 9.2400 9.3358 0.0 0
M  V30 21 C 13.0900 8.0021 0.0 0
M  V30 22 O 11.5500 9.5421 0.0 0
M  V30 23 O 11.5500 6.4621 0.0 0
M  V30 24 C 2.3100 8.0021 0.0 0
M  V30 25 C 0.7700 8.0021 0.0 0
M  V30 26 C 3.0800 6.6685 0.0 0
M  V30 27 C 0.0000 6.6685 0.0 0
M  V30 28 C 2.3100 5.3347 0.0 0
M  V30 29 C 0.7700 5.3347 0.0 0
M  V30 30 C 6.9300 2.6674 0.0 0
M  V30 31 C 5.3900 2.6674 0.0 0
M  V30 32 C 7.7000 1.3338 0.0 0
M  V30 33 C 4.6200 1.3338 0.0 0
M  V30 34 C 6.9300 0.0000 0.0 0
M  V30 35 C 5.3900 0.0000 0.0 0
M  V30 36 C 13.8600 9.3358 0.0 0
M  V30 37 C 15.4000 9.3358 0.0 0
M  V30 38 C 13.0900 10.6696 0.0 0
M  V30 39 C 16.1700 10.6696 0.0 0
M  V30 40 C 13.8600 12.0032 0.0 0
M  V30 41 C 15.4000 12.0032 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 24
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11 CFG=3
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 11 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 13 17
M  V30 18 1 13 18
M  V30 19 1 14 30
M  V30 20 1 15 19
M  V30 21 1 15 20
M  V30 22 1 19 21
M  V30 23 2 19 22
M  V30 24 2 19 23
M  V30 25 1 21 36
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 2 26 28
M  V30 30 2 27 29
M  V30 31 1 28 29
M  V30 32 2 30 31
M  V30 33 1 30 32
M  V30 34 1 31 33
M  V30 35 2 32 34
M  V30 36 2 33 35
M  V30 37 1 34 35
M  V30 38 2 36 37
M  V30 39 1 36 38
M  V30 40 1 37 39
M  V30 41 2 38 40
M  V30 42 2 39 41
M  V30 43 1 40 41
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 13734-34-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2761157-71-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2761157-79-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31593448
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible
Inhibitors of the Trypanosomal Cysteine Protease Rhodesain:
Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In
Vivo Studies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Jung, Sascha; Fuchs, Natalie; Johe, Patrick; Wagner, Annika; Diehl,
Erika; Yuliani, Tri; Zimmer, Collin; Barthels, Fabian; Zimmermann, Robert
A.; Klein, Philipp; Waigel, Waldemar; Meyr, Jessica; Opatz, Till; Tenzer,
Stefan; Distler, Ute; Raeder, Hans-Joachim; Kersten, Christian; Engels,
Bernd; Hellmich, Ute A.; Klein, Jochen; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(16), 12322-12358

$RFMT $RIREG SCHEME463 STEP1
$RXN



  2  1
$MOL
Oxaprozin
C18H15NO3
21256-18-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.2358 7.3150 0.0 0
M  V30 2 C 9.6426 6.6887 0.0 0
M  V30 3 C 10.8884 7.5938 0.0 0
M  V30 4 O 10.7275 9.1254 0.0 0
M  V30 5 O 12.2954 6.9674 0.0 0
M  V30 6 C 4.6200 5.6398 0.0 0
M  V30 7 C 5.5252 4.3939 0.0 0
M  V30 8 N 5.5252 6.8857 0.0 0
M  V30 9 O 6.9899 4.8698 0.0 0
M  V30 10 C 6.9899 6.4098 0.0 0
M  V30 11 C 3.0800 5.6398 0.0 0
M  V30 12 C 2.3100 4.3062 0.0 0
M  V30 13 C 2.3100 6.9734 0.0 0
M  V30 14 C 0.7700 4.3062 0.0 0
M  V30 15 C 0.7700 6.9734 0.0 0
M  V30 16 C 0.0000 5.6398 0.0 0
M  V30 17 C 5.0494 2.9292 0.0 0
M  V30 18 C 6.0798 1.7849 0.0 0
M  V30 19 C 3.5429 2.6091 0.0 0
M  V30 20 C 5.6039 0.3202 0.0 0
M  V30 21 C 3.0671 1.1445 0.0 0
M  V30 22 C 4.0976 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 6 11
M  V30 9 1 7 9
M  V30 10 1 7 17
M  V30 11 2 8 10
M  V30 12 1 9 10
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 2 13 15
M  V30 17 2 14 16
M  V30 18 1 15 16
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 18 20
M  V30 22 2 19 21
M  V30 23 2 20 22
M  V30 24 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Propargylamine
C3H5N
2450-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.7700 0.0 0
M  V30 2 C 2.6673 0.0000 0.0 0
M  V30 3 C 0.0000 1.5400 0.0 0
M  V30 4 N 4.0010 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 1 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4,5-Diphenyl-N-2-propyn-1-yl-2-oxazolepropanamide
C21H18N2O2
1050586-90-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.3659 6.8424 0.0 0
M  V30 2 C 9.6996 6.0724 0.0 0
M  V30 3 C 11.0333 6.8424 0.0 0
M  V30 4 N 12.3669 6.0724 0.0 0
M  V30 5 O 11.0333 8.3824 0.0 0
M  V30 6 C 13.7008 6.8424 0.0 0
M  V30 7 C 15.0344 6.0724 0.0 0
M  V30 8 C 16.3681 5.3023 0.0 0
M  V30 9 C 4.5948 5.5543 0.0 0
M  V30 10 C 5.3649 4.2206 0.0 0
M  V30 11 N 5.6253 6.6988 0.0 0
M  V30 12 O 6.8712 4.5408 0.0 0
M  V30 13 C 7.0321 6.0724 0.0 0
M  V30 14 C 3.0631 5.7154 0.0 0
M  V30 15 C 2.4368 7.1222 0.0 0
M  V30 16 C 2.1579 4.4693 0.0 0
M  V30 17 C 0.9052 7.2831 0.0 0
M  V30 18 C 0.6263 4.6304 0.0 0
M  V30 19 C 0.0000 6.0372 0.0 0
M  V30 20 C 4.7384 2.8138 0.0 0
M  V30 21 C 3.2068 2.6527 0.0 0
M  V30 22 C 5.6436 1.5678 0.0 0
M  V30 23 C 2.5805 1.2459 0.0 0
M  V30 24 C 5.0173 0.1609 0.0 0
M  V30 25 C 3.4856 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 3 7 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 9 14
M  V30 12 1 10 12
M  V30 13 1 10 20
M  V30 14 2 11 13
M  V30 15 1 12 13
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 15 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 19
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 21256-18-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2450-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1050586-90-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37043010
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM NSAID-Au(I) Complexes Induce ROS-Driven DAMPs and Interpose Inflammation
to Stimulate the Immune Response against Ovarian Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Xu, Zhongren; Lu, Qiuyue; Shan, Min; Jiang, Guizhi; Liu, Yuanhao; Yang,
Zhibin; Lu, Yunlong; Liu, Wukun
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(12), 7813-7833

$RFMT $RIREG SCHEME464 STEP1
$RXN



  2  1
$MOL
4-[(4-Methoxyphenyl)amino]-4-oxo-2-butenoic acid
C11H11NO4
37902-60-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.6685 1.5400 0.0 0
M  V30 2 C 8.0022 2.3101 0.0 0
M  V30 3 C 9.3360 1.5400 0.0 0
M  V30 4 O 8.0022 3.8501 0.0 0
M  V30 5 C 10.6697 2.3101 0.0 0
M  V30 6 C 12.0033 1.5400 0.0 0
M  V30 7 O 12.0033 0.0000 0.0 0
M  V30 8 O 13.3370 2.3101 0.0 0
M  V30 9 O 1.3337 4.6201 0.0 0
M  V30 10 C 0.0000 3.8501 0.0 0
M  V30 11 C 5.3348 2.3101 0.0 0
M  V30 12 C 5.3348 3.8501 0.0 0
M  V30 13 C 4.0010 1.5400 0.0 0
M  V30 14 C 4.0010 4.6201 0.0 0
M  V30 15 C 2.6673 2.3101 0.0 0
M  V30 16 C 2.6673 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 10
M  V30 10 1 9 16
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 14 2 13 15
M  V30 15 2 14 16
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(4-Methoxyphenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C20H19N3O4
2416338-27-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 C 7.7000 4.0011 0.0 0
M  V30 3 C 9.2400 4.0011 0.0 0
M  V30 4 O 6.9300 5.3347 0.0 0
M  V30 5 C 10.0100 5.3347 0.0 0
M  V30 6 C 11.5500 5.3347 0.0 0
M  V30 7 N 12.3200 6.6685 0.0 0
M  V30 8 O 12.3200 4.0011 0.0 0
M  V30 9 O 5.3900 0.0000 0.0 0
M  V30 10 O 18.4800 6.6685 0.0 0
M  V30 11 C 19.2500 8.0021 0.0 0
M  V30 12 C 3.0800 4.0011 0.0 0
M  V30 13 C 2.3100 2.6674 0.0 0
M  V30 14 C 4.6200 4.0011 0.0 0
M  V30 15 C 2.3100 5.3347 0.0 0
M  V30 16 N 3.0800 1.3336 0.0 0
M  V30 17 C 0.7700 2.6674 0.0 0
M  V30 18 C 5.3900 2.6674 0.0 0
M  V30 19 C 0.7700 5.3347 0.0 0
M  V30 20 C 4.6200 1.3336 0.0 0
M  V30 21 C 0.0000 4.0011 0.0 0
M  V30 22 C 13.8600 6.6685 0.0 0
M  V30 23 C 14.6300 8.0021 0.0 0
M  V30 24 C 14.6300 5.3347 0.0 0
M  V30 25 C 16.1700 8.0021 0.0 0
M  V30 26 C 16.1700 5.3347 0.0 0
M  V30 27 C 16.9400 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 18
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 22
M  V30 10 2 9 20
M  V30 11 1 10 11
M  V30 12 1 10 27
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 21
M  V30 22 1 18 20
M  V30 23 2 19 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 37902-60-6
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-27-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822009
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME465 STEP1
$RXN



  2  1
$MOL
4-[(3-Bromophenyl)amino]-4-oxo-2-butenoic acid
C10H8BrNO3
326914-22-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 1.5400 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 C 8.0022 1.5400 0.0 0
M  V30 4 O 6.6685 3.8501 0.0 0
M  V30 5 C 9.3360 2.3101 0.0 0
M  V30 6 C 10.6697 1.5400 0.0 0
M  V30 7 O 10.6697 0.0000 0.0 0
M  V30 8 O 12.0033 2.3101 0.0 0
M  V30 9 Br 0.0000 1.5400 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 1.5400 0.0 0
M  V30 12 C 4.0012 3.8501 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 4.6201 0.0 0
M  V30 15 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 13
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(3-Bromophenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H16BrN3O3
2416338-34-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3348 5.3901 0.0 0
M  V30 2 C 6.6686 4.6201 0.0 0
M  V30 3 C 8.0022 5.3901 0.0 0
M  V30 4 O 6.6686 3.0800 0.0 0
M  V30 5 C 9.3359 4.6201 0.0 0
M  V30 6 C 10.6695 5.3901 0.0 0
M  V30 7 N 12.0034 4.6201 0.0 0
M  V30 8 O 10.6695 6.9301 0.0 0
M  V30 9 O 2.6675 6.9301 0.0 0
M  V30 10 Br 17.3381 4.6201 0.0 0
M  V30 11 C 2.6675 2.3100 0.0 0
M  V30 12 C 1.3338 3.0800 0.0 0
M  V30 13 C 4.0011 3.0800 0.0 0
M  V30 14 C 2.6675 0.7700 0.0 0
M  V30 15 N 1.3338 4.6201 0.0 0
M  V30 16 C 0.0000 2.3100 0.0 0
M  V30 17 C 4.0011 4.6201 0.0 0
M  V30 18 C 1.3338 0.0000 0.0 0
M  V30 19 C 2.6675 5.3901 0.0 0
M  V30 20 C 0.0000 0.7700 0.0 0
M  V30 21 C 13.3370 5.3901 0.0 0
M  V30 22 C 14.6707 4.6201 0.0 0
M  V30 23 C 13.3370 6.9301 0.0 0
M  V30 24 C 16.0043 5.3901 0.0 0
M  V30 25 C 14.6707 7.7001 0.0 0
M  V30 26 C 16.0043 6.9301 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 24
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 326914-22-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-34-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822016
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME466 STEP1
$RXN



  2  1
$MOL
Oxalic acid
C2H2O4
144-62-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6673 1.5400 0.0 0
M  V30 2 C 1.3337 2.3101 0.0 0
M  V30 3 O 4.0010 2.3101 0.0 0
M  V30 4 O 2.6673 0.0000 0.0 0
M  V30 5 O 1.3337 3.8501 0.0 0
M  V30 6 O 0.0000 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 1 4
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Fluoro-1,2-phenylenediamine
C6H7FN2
367-31-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.5400 0.0000 0.0 0
M  V30 2 N 0.0000 2.6673 0.0 0
M  V30 3 F 6.1601 2.6673 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 1.5400 2.6673 0.0 0
M  V30 6 C 3.8501 1.3337 0.0 0
M  V30 7 C 2.3101 4.0010 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 C 3.8501 4.0010 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 4
M  V30 2 1 2 5
M  V30 3 1 3 8
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 2 6 8
M  V30 8 2 7 9
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-Fluoro-1,4-dihydro-2,3-quinoxalinedione
C8H5FN2O2
61875-34-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.5400 0.0000 0.0 0
M  V30 2 F 8.4700 4.0011 0.0 0
M  V30 3 O 0.0000 2.6674 0.0 0
M  V30 4 C 4.6200 2.6674 0.0 0
M  V30 5 C 3.8500 4.0011 0.0 0
M  V30 6 N 3.8500 1.3338 0.0 0
M  V30 7 C 6.1600 2.6674 0.0 0
M  V30 8 N 2.3100 4.0011 0.0 0
M  V30 9 C 4.6200 5.3349 0.0 0
M  V30 10 C 2.3100 1.3338 0.0 0
M  V30 11 C 6.9300 4.0011 0.0 0
M  V30 12 C 1.5400 2.6674 0.0 0
M  V30 13 C 6.1600 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 10
M  V30 2 1 2 11
M  V30 3 2 3 12
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 4 7
M  V30 7 1 5 8
M  V30 8 2 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 13
M  V30 13 1 10 12
M  V30 14 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 144-62-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 367-31-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 61875-34-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-32519335
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Biophysical Survey of Small-Molecule -Catenin Inhibitors: A Cautionary
Tale
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM McCoy, Michael A.; Spicer, Dominique; Wells, Neil; Hoogewijs, Kurt;
Fiedler, Marc; Baud, Matthias G. J.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(10), 7246-7261

$RFMT $RIREG SCHEME467 STEP1
$RXN



  2  1
$MOL
(+)-L-Leucine methyl ester
C7H15NO2
2666-93-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0011 2.3100 0.0 0 CFG=1
M  V30 2 C 5.3347 1.5400 0.0 0
M  V30 3 C 2.6674 1.5400 0.0 0
M  V30 4 N 4.0011 3.8500 0.0 0
M  V30 5 O 6.6685 2.3100 0.0 0
M  V30 6 O 5.3347 0.0000 0.0 0
M  V30 7 C 1.3336 2.3100 0.0 0
M  V30 8 C 8.0021 1.5400 0.0 0
M  V30 9 C 1.3336 3.8500 0.0 0
M  V30 10 C 0.0000 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
(S)--[[(Phenylmethoxy)carbonyl]amino]-1-naphthalenepropanoic acid
C21H19NO4
65365-15-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0010 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0 CFG=1
M  V30 3 N 6.6685 3.0801 0.0 0
M  V30 4 C 5.3348 0.7700 0.0 0
M  V30 5 C 8.0022 2.3101 0.0 0
M  V30 6 O 4.0010 0.0000 0.0 0
M  V30 7 O 6.6685 0.0000 0.0 0
M  V30 8 O 9.3358 3.0801 0.0 0
M  V30 9 O 8.0022 0.7700 0.0 0
M  V30 10 C 10.6697 2.3101 0.0 0
M  V30 11 C 4.0010 4.6201 0.0 0
M  V30 12 C 2.6673 5.3901 0.0 0
M  V30 13 C 5.3348 5.3901 0.0 0
M  V30 14 C 2.6673 6.9302 0.0 0
M  V30 15 C 1.3337 4.6201 0.0 0
M  V30 16 C 5.3348 6.9302 0.0 0
M  V30 17 C 4.0010 7.7002 0.0 0
M  V30 18 C 1.3337 7.7002 0.0 0
M  V30 19 C 0.0000 5.3901 0.0 0
M  V30 20 C 0.0000 6.9302 0.0 0
M  V30 21 C 12.0033 3.0801 0.0 0
M  V30 22 C 13.3370 2.3101 0.0 0
M  V30 23 C 12.0033 4.6201 0.0 0
M  V30 24 C 14.6707 3.0801 0.0 0
M  V30 25 C 13.3370 5.3901 0.0 0
M  V30 26 C 14.6707 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 11
M  V30 3 1 2 3 CFG=3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 21
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 12 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 1 14 18
M  V30 19 2 15 19
M  V30 20 2 16 17
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
3-(1-Naphthalenyl)-N-[(phenylmethoxy)carbonyl]-L-alanyl-L-leucine methyl ester
C28H32N2O5
2148976-31-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  35 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 5.3900 0.0 0
M  V30 2 C 6.6685 6.9300 0.0 0 CFG=2
M  V30 3 C 5.3347 7.7000 0.0 0
M  V30 4 N 8.0021 7.7000 0.0 0
M  V30 5 N 5.3347 9.2400 0.0 0
M  V30 6 O 4.0011 6.9300 0.0 0
M  V30 7 C 9.3358 6.9300 0.0 0
M  V30 8 C 4.0011 10.0100 0.0 0 CFG=1
M  V30 9 O 10.6696 7.7000 0.0 0
M  V30 10 O 9.3358 5.3900 0.0 0
M  V30 11 C 4.0011 11.5500 0.0 0
M  V30 12 C 2.6674 9.2400 0.0 0
M  V30 13 C 12.0032 6.9300 0.0 0
M  V30 14 O 5.3349 12.3200 0.0 0
M  V30 15 O 2.6674 12.3200 0.0 0
M  V30 16 C 1.3338 10.0100 0.0 0
M  V30 17 C 5.3349 13.8600 0.0 0
M  V30 18 C 0.0000 9.2400 0.0 0
M  V30 19 C 1.3338 11.5500 0.0 0
M  V30 20 C 5.3347 3.0800 0.0 0
M  V30 21 C 5.3347 4.6200 0.0 0
M  V30 22 C 4.0011 2.3100 0.0 0
M  V30 23 C 6.6685 2.3100 0.0 0
M  V30 24 C 4.0011 5.3900 0.0 0
M  V30 25 C 2.6674 3.0800 0.0 0
M  V30 26 C 4.0011 0.7700 0.0 0
M  V30 27 C 6.6685 0.7700 0.0 0
M  V30 28 C 2.6674 4.6200 0.0 0
M  V30 29 C 5.3347 0.0000 0.0 0
M  V30 30 C 13.3369 7.7000 0.0 0
M  V30 31 C 13.3369 9.2400 0.0 0
M  V30 32 C 14.6705 6.9300 0.0 0
M  V30 33 C 14.6705 10.0100 0.0 0
M  V30 34 C 16.0043 7.7000 0.0 0
M  V30 35 C 16.0043 9.2400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 21
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11
M  V30 12 1 8 12 CFG=1
M  V30 13 1 9 13
M  V30 14 1 11 14
M  V30 15 2 11 15
M  V30 16 1 12 16
M  V30 17 1 13 30
M  V30 18 1 14 17
M  V30 19 1 16 18
M  V30 20 1 16 19
M  V30 21 1 20 21
M  V30 22 2 20 22
M  V30 23 1 20 23
M  V30 24 2 21 24
M  V30 25 1 22 25
M  V30 26 1 22 26
M  V30 27 2 23 27
M  V30 28 1 24 28
M  V30 29 2 25 28
M  V30 30 2 26 29
M  V30 31 1 27 29
M  V30 32 2 30 31
M  V30 33 1 30 32
M  V30 34 1 31 33
M  V30 35 2 32 34
M  V30 36 2 33 35
M  V30 37 1 34 35
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2666-93-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 65365-15-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2148976-31-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39721304
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and biological evaluation of novel peptidomimetic inhibitors of
the coronavirus 3C-like protease
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Amblard, Franck; LeCher, Julia C.; De, Ramyani; Zhou, Shaoman; Liu, Peng;
Goh, Shu Ling; Tao, Sijia; Patel, Dharmeshkumar; Downs-Bowen, Jessica;
Zandi, Keivan; Zhang, Huanchun; Chaudhry, Gitika; McBrayer, Tamara;
Muczynski, Michael; Al-Homoudi, Abdullah; Engel, Joseph; Lan, Shuiyun;
Sarafianos, Stefan G.; Kovari, Ladislau C.; Schinazi, Raymond F.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 268116263

$RFMT $RIREG SCHEME468 STEP1
$RXN



  2  1
$MOL
Methyl 2-amino-4-methoxybenzoate
C9H11NO3
50413-30-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3101 2.6673 0.0 0
M  V30 2 O 1.5400 4.0010 0.0 0
M  V30 3 O 1.5400 1.3337 0.0 0
M  V30 4 C 0.0000 4.0010 0.0 0
M  V30 5 N 3.8501 0.0000 0.0 0
M  V30 6 O 8.4702 2.6673 0.0 0
M  V30 7 C 9.2402 4.0010 0.0 0
M  V30 8 C 3.8501 2.6673 0.0 0
M  V30 9 C 4.6201 1.3337 0.0 0
M  V30 10 C 4.6201 4.0010 0.0 0
M  V30 11 C 6.1601 1.3337 0.0 0
M  V30 12 C 6.1601 4.0010 0.0 0
M  V30 13 C 6.9302 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 5 9
M  V30 6 1 6 7
M  V30 7 1 6 13
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
[3,4-Bipyridazine]-6-carboxylic acid
C9H6N4O2
2913152-05-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 5.3901 1.3337 0.0 0
M  V30 5 C 4.6201 0.0000 0.0 0
M  V30 6 N 4.6201 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 N 3.0801 2.6673 0.0 0
M  V30 9 C 2.3101 1.3337 0.0 0
M  V30 10 C 6.9302 1.3337 0.0 0
M  V30 11 C 7.7002 2.6673 0.0 0
M  V30 12 C 7.7002 0.0000 0.0 0
M  V30 13 C 9.2402 2.6673 0.0 0
M  V30 14 N 9.2402 0.0000 0.0 0
M  V30 15 N 10.0102 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 4 10
M  V30 7 1 5 7
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 8 9
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 2-[([3,4-bipyridazin]-6-ylcarbonyl)amino]-4-methoxy-, methyl e...
C18H15N5O4
2913152-09-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6200 2.6674 0.0 0
M  V30 2 O 3.8500 1.3336 0.0 0
M  V30 3 O 6.1600 2.6674 0.0 0
M  V30 4 C 4.6200 0.0000 0.0 0
M  V30 5 N 6.1600 5.3347 0.0 0
M  V30 6 C 6.9300 6.6685 0.0 0
M  V30 7 O 6.1600 8.0021 0.0 0
M  V30 8 O 1.5400 8.0021 0.0 0
M  V30 9 C 0.0000 8.0021 0.0 0
M  V30 10 C 3.8500 4.0011 0.0 0
M  V30 11 C 4.6200 5.3347 0.0 0
M  V30 12 C 2.3100 4.0011 0.0 0
M  V30 13 C 3.8500 6.6685 0.0 0
M  V30 14 C 1.5400 5.3347 0.0 0
M  V30 15 C 2.3100 6.6685 0.0 0
M  V30 16 C 8.4700 6.6685 0.0 0
M  V30 17 C 9.2400 8.0021 0.0 0
M  V30 18 N 9.2400 5.3347 0.0 0
M  V30 19 C 10.7800 8.0021 0.0 0
M  V30 20 N 10.7800 5.3347 0.0 0
M  V30 21 C 11.5500 6.6685 0.0 0
M  V30 22 C 13.0900 6.6685 0.0 0
M  V30 23 C 13.8600 8.0021 0.0 0
M  V30 24 C 13.8600 5.3347 0.0 0
M  V30 25 C 15.4000 8.0021 0.0 0
M  V30 26 N 15.4000 5.3347 0.0 0
M  V30 27 N 16.1700 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 11
M  V30 7 2 6 7
M  V30 8 1 6 16
M  V30 9 1 8 9
M  V30 10 1 8 15
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 2 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 50413-30-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2913152-05-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2913152-09-5
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35647835
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 107-06-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of Bipyridazine Derivatives
as Stimulator of Interferon Genes (STING) Receptor Agonists
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Shan, Bin; Hou, Hui; Zhang, Keke; Li, Rui; Shen, Chang; Chen, Zhengyang;
Xu, Peijia; Cui, Rongrong; Su, Zhaoming; Zhang, Changfa; Yang, Ruirui;
Zhou, Guizhen; Liu, Yadan; Guo, Hao; Chen, Kaixian; Fu, Wei; Jiang,
Hualiang; Zhang, Sulin; Zheng, Mingyue
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3327-3347

$RFMT $RIREG SCHEME469 STEP1
$RXN



  2  1
$MOL
Methyl 2-amino-5-bromobenzoate
C8H8BrNO2
52727-57-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6201 2.6675 0.0 0
M  V30 2 O 5.3901 4.0011 0.0 0
M  V30 3 O 5.3901 1.3338 0.0 0
M  V30 4 C 6.9301 4.0011 0.0 0
M  V30 5 N 3.0800 0.0000 0.0 0
M  V30 6 Br 0.0000 5.3349 0.0 0
M  V30 7 C 3.0800 2.6675 0.0 0
M  V30 8 C 2.3100 1.3338 0.0 0
M  V30 9 C 2.3100 4.0011 0.0 0
M  V30 10 C 0.7700 1.3338 0.0 0
M  V30 11 C 0.7700 4.0011 0.0 0
M  V30 12 C 0.0000 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 8
M  V30 6 1 6 11
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 8 10
M  V30 10 2 9 11
M  V30 11 2 10 12
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
[3,4-Bipyridazine]-6-carboxylic acid
C9H6N4O2
2913152-05-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 5.3901 1.3337 0.0 0
M  V30 5 C 4.6201 0.0000 0.0 0
M  V30 6 N 4.6201 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 N 3.0801 2.6673 0.0 0
M  V30 9 C 2.3101 1.3337 0.0 0
M  V30 10 C 6.9302 1.3337 0.0 0
M  V30 11 C 7.7002 2.6673 0.0 0
M  V30 12 C 7.7002 0.0000 0.0 0
M  V30 13 C 9.2402 2.6673 0.0 0
M  V30 14 N 9.2402 0.0000 0.0 0
M  V30 15 N 10.0102 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 4 10
M  V30 7 1 5 7
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 8 9
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 2-[([3,4-bipyridazin]-6-ylcarbonyl)amino]-5-bromo-, methyl ester
C17H12BrN5O3
2913152-13-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1600 5.3347 0.0 0
M  V30 2 C 6.9300 6.6685 0.0 0
M  V30 3 O 6.1600 8.0021 0.0 0
M  V30 4 C 4.6200 2.6674 0.0 0
M  V30 5 O 3.8500 1.3336 0.0 0
M  V30 6 O 6.1600 2.6674 0.0 0
M  V30 7 C 4.6200 0.0000 0.0 0
M  V30 8 Br 0.0000 5.3347 0.0 0
M  V30 9 C 4.6200 5.3347 0.0 0
M  V30 10 C 3.8500 4.0011 0.0 0
M  V30 11 C 3.8500 6.6685 0.0 0
M  V30 12 C 2.3100 4.0011 0.0 0
M  V30 13 C 2.3100 6.6685 0.0 0
M  V30 14 C 1.5400 5.3347 0.0 0
M  V30 15 C 8.4700 6.6685 0.0 0
M  V30 16 C 9.2400 8.0021 0.0 0
M  V30 17 N 9.2400 5.3347 0.0 0
M  V30 18 C 10.7800 8.0021 0.0 0
M  V30 19 N 10.7800 5.3347 0.0 0
M  V30 20 C 11.5500 6.6685 0.0 0
M  V30 21 C 13.0900 6.6685 0.0 0
M  V30 22 C 13.8600 8.0021 0.0 0
M  V30 23 C 13.8600 5.3347 0.0 0
M  V30 24 C 15.4000 8.0021 0.0 0
M  V30 25 N 15.4000 5.3347 0.0 0
M  V30 26 N 16.1700 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 2 2 3
M  V30 4 1 2 15
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 10
M  V30 8 1 5 7
M  V30 9 1 8 14
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 25
M  V30 27 1 24 26
M  V30 28 2 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 52727-57-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2913152-05-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2913152-13-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35647846
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 107-06-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of Bipyridazine Derivatives
as Stimulator of Interferon Genes (STING) Receptor Agonists
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Shan, Bin; Hou, Hui; Zhang, Keke; Li, Rui; Shen, Chang; Chen, Zhengyang;
Xu, Peijia; Cui, Rongrong; Su, Zhaoming; Zhang, Changfa; Yang, Ruirui;
Zhou, Guizhen; Liu, Yadan; Guo, Hao; Chen, Kaixian; Fu, Wei; Jiang,
Hualiang; Zhang, Sulin; Zheng, Mingyue
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3327-3347

$RFMT $RIREG SCHEME470 STEP1
$RXN



  2  1
$MOL
BOC-L-Phenylalanine
C14H19NO4
13734-34-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3901 2.6675 0.0 0 CFG=1
M  V30 2 C 4.6201 4.0012 0.0 0
M  V30 3 N 6.9302 2.6675 0.0 0
M  V30 4 C 4.6201 1.3338 0.0 0
M  V30 5 C 7.7002 4.0012 0.0 0
M  V30 6 O 3.0801 1.3338 0.0 0
M  V30 7 O 5.3901 0.0000 0.0 0
M  V30 8 O 9.2402 4.0012 0.0 0
M  V30 9 O 6.9302 5.3348 0.0 0
M  V30 10 C 10.0102 5.3348 0.0 0
M  V30 11 C 11.3439 4.5648 0.0 0
M  V30 12 C 10.7802 6.6687 0.0 0
M  V30 13 C 8.6766 6.1048 0.0 0
M  V30 14 C 3.0801 4.0012 0.0 0
M  V30 15 C 2.3101 5.3348 0.0 0
M  V30 16 C 2.3101 2.6675 0.0 0
M  V30 17 C 0.7700 5.3348 0.0 0
M  V30 18 C 0.7700 2.6675 0.0 0
M  V30 19 C 0.0000 4.0012 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 14
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 1 5 8
M  V30 9 2 5 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1-Pentene-1-sulfonic acid, 3-amino-1-fluoro-5-phenyl-, phenyl ester, hydrochl...
C17H18FNO3S.ClH
2761157-66-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.0011 3.4374 0.0 0
M  V30 2 S 5.3349 4.2074 0.0 0 VAL=6
M  V30 3 C 6.1049 2.8738 0.0 0
M  V30 4 O 6.6685 4.9774 0.0 0
M  V30 5 O 4.5649 5.5411 0.0 0
M  V30 6 C 7.6449 2.8738 0.0 0
M  V30 7 F 5.3349 1.5400 0.0 0
M  V30 8 C 8.4149 4.2074 0.0 0 CFG=1
M  V30 9 C 9.9549 4.2074 0.0 0
M  V30 10 N 7.6449 5.5411 0.0 0
M  V30 11 C 10.7249 5.5411 0.0 0
M  V30 12 C 2.6674 4.2074 0.0 0
M  V30 13 C 2.6674 5.7474 0.0 0
M  V30 14 C 1.3338 3.4374 0.0 0
M  V30 15 C 1.3338 6.5174 0.0 0
M  V30 16 C 0.0000 4.2074 0.0 0
M  V30 17 C 0.0000 5.7474 0.0 0
M  V30 18 C 12.2649 5.5411 0.0 0
M  V30 19 C 13.0349 6.8749 0.0 0
M  V30 20 C 13.0349 4.2074 0.0 0
M  V30 21 C 14.5749 6.8749 0.0 0
M  V30 22 C 14.5749 4.2074 0.0 0
M  V30 23 C 15.3449 5.5411 0.0 0
M  V30 24 Cl 7.6724 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 2 5
M  V30 6 2 3 6
M  V30 7 1 3 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 8 10 CFG=1
M  V30 11 1 9 11
M  V30 12 1 11 18
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 2 20 22
M  V30 23 2 21 23
M  V30 24 1 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Phenyl (1Z,3S)-3-[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-pheny...
C31H35FN2O6S
2761157-78-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  41 43 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 12.2651 5.3348 0.0 0 CFG=2
M  V30 2 C 13.0352 4.0010 0.0 0
M  V30 3 C 10.7251 5.3348 0.0 0
M  V30 4 N 13.0352 6.6685 0.0 0
M  V30 5 N 9.9551 6.6685 0.0 0
M  V30 6 O 9.9551 4.0010 0.0 0
M  V30 7 C 14.5752 6.6685 0.0 0
M  V30 8 C 8.4151 6.6685 0.0 0 CFG=2
M  V30 9 O 15.3452 8.0022 0.0 0
M  V30 10 O 15.3452 5.3348 0.0 0
M  V30 11 C 7.6450 8.0022 0.0 0
M  V30 12 C 7.6450 5.3348 0.0 0
M  V30 13 C 16.8852 8.0022 0.0 0
M  V30 14 C 8.4151 9.3360 0.0 0
M  V30 15 C 6.1050 5.3348 0.0 0
M  V30 16 C 16.8852 6.4621 0.0 0
M  V30 17 C 18.4253 8.0022 0.0 0
M  V30 18 C 16.8852 9.5422 0.0 0
M  V30 19 S 5.3350 6.6685 0.0 0 VAL=6
M  V30 20 F 5.3350 4.0010 0.0 0
M  V30 21 O 4.0012 5.8985 0.0 0
M  V30 22 O 6.6687 7.4385 0.0 0
M  V30 23 O 4.5650 8.0022 0.0 0
M  V30 24 C 12.2651 2.6673 0.0 0
M  V30 25 C 13.0352 1.3337 0.0 0
M  V30 26 C 10.7251 2.6673 0.0 0
M  V30 27 C 12.2651 0.0000 0.0 0
M  V30 28 C 9.9551 1.3337 0.0 0
M  V30 29 C 10.7251 0.0000 0.0 0
M  V30 30 C 7.6450 10.6697 0.0 0
M  V30 31 C 8.4151 12.0033 0.0 0
M  V30 32 C 6.1050 10.6697 0.0 0
M  V30 33 C 7.6450 13.3370 0.0 0
M  V30 34 C 5.3350 12.0033 0.0 0
M  V30 35 C 6.1050 13.3370 0.0 0
M  V30 36 C 2.6675 6.6685 0.0 0
M  V30 37 C 2.6675 8.2085 0.0 0
M  V30 38 C 1.3338 5.8985 0.0 0
M  V30 39 C 1.3338 8.9786 0.0 0
M  V30 40 C 0.0002 6.6685 0.0 0
M  V30 41 C 0.0000 8.2085 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=1
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 24
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 1 7 9
M  V30 10 2 7 10
M  V30 11 1 8 11 CFG=3
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 11 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 1 13 17
M  V30 18 1 13 18
M  V30 19 1 14 30
M  V30 20 1 15 19
M  V30 21 1 15 20
M  V30 22 1 19 21
M  V30 23 2 19 22
M  V30 24 2 19 23
M  V30 25 1 21 36
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 2 26 28
M  V30 30 2 27 29
M  V30 31 1 28 29
M  V30 32 2 30 31
M  V30 33 1 30 32
M  V30 34 1 31 33
M  V30 35 2 32 34
M  V30 36 2 33 35
M  V30 37 1 34 35
M  V30 38 2 36 37
M  V30 39 1 36 38
M  V30 40 1 37 39
M  V30 41 2 38 40
M  V30 42 2 39 41
M  V30 43 1 40 41
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 13734-34-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2761157-66-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2761157-78-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31593444
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible
Inhibitors of the Trypanosomal Cysteine Protease Rhodesain:
Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In
Vivo Studies
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Jung, Sascha; Fuchs, Natalie; Johe, Patrick; Wagner, Annika; Diehl,
Erika; Yuliani, Tri; Zimmer, Collin; Barthels, Fabian; Zimmermann, Robert
A.; Klein, Philipp; Waigel, Waldemar; Meyr, Jessica; Opatz, Till; Tenzer,
Stefan; Distler, Ute; Raeder, Hans-Joachim; Kersten, Christian; Engels,
Bernd; Hellmich, Ute A.; Klein, Jochen; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(16), 12322-12358

$RFMT $RIREG SCHEME471 STEP1
$RXN



  2  1
$MOL
N-[(5-Methyl-3-isoxazolyl)carbonyl]glycyl-O-methyl-L-serine
C11H15N3O6
2387523-00-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3359 4.6201 0.0 0
M  V30 2 N 8.0022 3.8500 0.0 0
M  V30 3 O 9.3359 6.1601 0.0 0
M  V30 4 C 6.6684 4.6201 0.0 0
M  V30 5 C 5.3348 3.8500 0.0 0
M  V30 6 N 4.0011 4.6201 0.0 0
M  V30 7 O 5.3348 2.3100 0.0 0
M  V30 8 C 2.6675 3.8500 0.0 0 CFG=2
M  V30 9 C 2.6675 2.3100 0.0 0
M  V30 10 C 1.3337 4.6201 0.0 0
M  V30 11 O 1.3337 1.5400 0.0 0
M  V30 12 O 0.0000 3.8500 0.0 0
M  V30 13 O 1.3337 6.1601 0.0 0
M  V30 14 C 1.3337 0.0000 0.0 0
M  V30 15 C 14.6385 3.4929 0.0 0
M  V30 16 C 10.6695 3.8500 0.0 0
M  V30 17 C 12.0763 4.4764 0.0 0
M  V30 18 N 10.8305 2.3185 0.0 0
M  V30 19 C 13.1069 3.3320 0.0 0
M  V30 20 O 12.3369 1.9983 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 6 8
M  V30 9 1 8 9 CFG=1
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 11 14
M  V30 15 1 15 19
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 8)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1-Pentanone, 2-amino-4-methyl-1-[(2R)-2-methyl-2-oxiranyl]-, (2S)-, 2,2,2-tri...
C9H17NO2.C2HF3O2
247068-85-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8504 6.7237 0.0 0
M  V30 2 C 4.1841 7.4937 0.0 0 CFG=1
M  V30 3 O 2.8504 5.1837 0.0 0
M  V30 4 C 5.5177 6.7237 0.0 0
M  V30 5 N 4.1841 9.0338 0.0 0
M  V30 6 C 6.8514 7.4937 0.0 0
M  V30 7 C 8.1852 6.7237 0.0 0
M  V30 8 C 6.8514 9.0338 0.0 0
M  V30 9 C 2.0434 8.9409 0.0 0
M  V30 10 C 1.5166 7.4937 0.0 0 CFG=2
M  V30 11 C 0.5268 6.3141 0.0 0
M  V30 12 O 0.0000 7.7611 0.0 0
M  V30 13 C 3.4257 2.3101 0.0 0
M  V30 14 C 4.7594 1.5400 0.0 0
M  V30 15 F 4.1958 3.6437 0.0 0
M  V30 16 F 2.0921 3.0801 0.0 0
M  V30 17 F 2.6557 0.9764 0.0 0
M  V30 18 O 6.0931 2.3101 0.0 0
M  V30 19 O 4.7594 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 10 1 CFG=1
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 11 12
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 16 1 13 17
M  V30 17 1 14 18
M  V30 18 2 14 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(5-Methyl-3-isoxazolyl)carbonyl]glycyl-O-methyl-N-[(1S)-3-methyl-1-[[(2R)-...
C20H30N4O7
2387523-24-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0009 2.2170 0.0 0
M  V30 2 C 4.0009 3.7570 0.0 0 CFG=2
M  V30 3 O 2.6673 1.4470 0.0 0
M  V30 4 N 5.3348 4.5270 0.0 0
M  V30 5 C 2.6673 4.5270 0.0 0
M  V30 6 C 5.3348 6.0670 0.0 0
M  V30 7 C 1.3336 3.7570 0.0 0
M  V30 8 C 6.6684 6.8370 0.0 0 CFG=2
M  V30 9 O 4.0009 6.8370 0.0 0
M  V30 10 C 1.3336 2.2170 0.0 0
M  V30 11 C 0.0000 4.5270 0.0 0
M  V30 12 N 8.0021 6.0670 0.0 0
M  V30 13 C 6.6684 8.3770 0.0 0
M  V30 14 C 9.3357 6.8370 0.0 0
M  V30 15 O 5.3348 9.1470 0.0 0
M  V30 16 C 10.6695 6.0670 0.0 0
M  V30 17 O 9.3357 8.3770 0.0 0
M  V30 18 C 5.3348 10.6871 0.0 0
M  V30 19 N 12.0032 6.8370 0.0 0
M  V30 20 C 13.3368 6.0670 0.0 0
M  V30 21 O 13.3368 4.5270 0.0 0
M  V30 22 C 6.3247 2.6268 0.0 0
M  V30 23 C 18.6394 7.1942 0.0 0
M  V30 24 C 5.3348 1.4470 0.0 0 CFG=2
M  V30 25 C 4.8079 0.0000 0.0 0
M  V30 26 O 6.3247 0.2673 0.0 0
M  V30 27 C 14.6705 6.8370 0.0 0
M  V30 28 N 14.8315 8.3687 0.0 0
M  V30 29 C 16.0774 6.2107 0.0 0
M  V30 30 O 16.3378 8.6889 0.0 0
M  V30 31 C 17.1078 7.3552 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 24 1 CFG=3
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=3
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 1 7 11
M  V30 12 1 8 12
M  V30 13 1 8 13 CFG=3
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 14 17
M  V30 18 1 15 18
M  V30 19 1 16 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 20 27
M  V30 23 1 24 22 CFG=1
M  V30 24 1 23 31
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 25 26
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 2 29 31
M  V30 32 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 2 8 24)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2387523-00-2
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 247068-85-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2387523-24-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545386
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME472 STEP1
$RXN



  2  1
$MOL
6-[[[(4-Fluoro-3-methylphenyl)methyl]amino]carbonyl]-4-pyrimidinecarboxylic acid
C14H12FN3O3
690998-35-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0022 1.5400 0.0 0
M  V30 2 N 6.6685 2.3101 0.0 0
M  V30 3 O 8.0022 0.0000 0.0 0
M  V30 4 C 5.3348 1.5400 0.0 0
M  V30 5 C 13.3370 1.5400 0.0 0
M  V30 6 O 13.3370 0.0000 0.0 0
M  V30 7 O 14.6707 2.3101 0.0 0
M  V30 8 C 0.0000 1.5400 0.0 0
M  V30 9 F 0.0000 4.6201 0.0 0
M  V30 10 C 9.3358 2.3101 0.0 0
M  V30 11 C 10.6697 1.5400 0.0 0
M  V30 12 N 9.3358 3.8501 0.0 0
M  V30 13 C 12.0033 2.3101 0.0 0
M  V30 14 C 10.6697 4.6201 0.0 0
M  V30 15 N 12.0033 3.8501 0.0 0
M  V30 16 C 4.0010 2.3101 0.0 0
M  V30 17 C 2.6673 1.5400 0.0 0
M  V30 18 C 4.0010 3.8501 0.0 0
M  V30 19 C 1.3337 2.3101 0.0 0
M  V30 20 C 2.6673 4.6201 0.0 0
M  V30 21 C 1.3337 3.8501 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 10
M  V30 4 1 2 4
M  V30 5 1 4 16
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 5 13
M  V30 9 1 8 19
M  V30 10 1 9 21
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 4-(aminomethyl-d2)-, methyl ester, hydrochloride (1:1)
C9H9D2NO2.ClH
1605324-71-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.7000 3.0800 0.0 0
M  V30 2 O 8.4700 4.4136 0.0 0
M  V30 3 O 8.4700 1.7464 0.0 0
M  V30 4 C 10.0100 4.4136 0.0 0
M  V30 5 C 1.5400 3.0800 0.0 0
M  V30 6 N 0.0000 3.0800 0.0 0
M  V30 7 C 6.1600 3.0800 0.0 0
M  V30 8 C 5.3900 1.7464 0.0 0
M  V30 9 C 5.3900 4.4136 0.0 0
M  V30 10 C 3.8500 1.7464 0.0 0
M  V30 11 C 3.8500 4.4136 0.0 0
M  V30 12 C 3.0800 3.0800 0.0 0
M  V30 13 H 1.5400 1.5400 0.0 0 MASS=2
M  V30 14 H 1.5400 4.6200 0.0 0 MASS=2
M  V30 15 Cl 5.0050 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 7
M  V30 4 1 2 4
M  V30 5 1 5 6
M  V30 6 1 5 12
M  V30 7 1 5 13
M  V30 8 1 5 14
M  V30 9 2 7 8
M  V30 10 1 7 9
M  V30 11 1 8 10
M  V30 12 2 9 11
M  V30 13 2 10 12
M  V30 14 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Methyl 4-[[[[6-[[[(4-fluoro-3-methylphenyl)methyl-d2]amino]carbonyl]-4-pyrimi...
C23H19D2FN4O4
1605324-86-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.0022 4.6201 0.0 0
M  V30 2 N 6.6685 3.8501 0.0 0
M  V30 3 O 8.0022 6.1601 0.0 0
M  V30 4 C 5.3348 4.6201 0.0 0
M  V30 5 C 13.3370 4.6201 0.0 0
M  V30 6 N 14.6708 3.8501 0.0 0
M  V30 7 O 13.3370 6.1601 0.0 0
M  V30 8 C 16.0045 4.6201 0.0 0
M  V30 9 C 0.0000 4.6201 0.0 0
M  V30 10 F 0.0000 7.7002 0.0 0
M  V30 11 C 21.3393 1.5400 0.0 0
M  V30 12 O 22.6730 2.3101 0.0 0
M  V30 13 O 21.3393 0.0000 0.0 0
M  V30 14 C 24.0067 1.5400 0.0 0
M  V30 15 C 9.3358 3.8501 0.0 0
M  V30 16 C 10.6697 4.6201 0.0 0
M  V30 17 N 9.3358 2.3101 0.0 0
M  V30 18 C 12.0033 3.8501 0.0 0
M  V30 19 C 10.6697 1.5400 0.0 0
M  V30 20 N 12.0033 2.3101 0.0 0
M  V30 21 C 4.0010 5.3901 0.0 0
M  V30 22 C 2.6673 4.6201 0.0 0
M  V30 23 C 4.0010 6.9302 0.0 0
M  V30 24 C 1.3337 5.3901 0.0 0
M  V30 25 C 2.6673 7.7002 0.0 0
M  V30 26 C 1.3337 6.9302 0.0 0
M  V30 27 C 17.3382 3.8501 0.0 0
M  V30 28 C 18.6718 4.6201 0.0 0
M  V30 29 C 17.3382 2.3101 0.0 0
M  V30 30 C 20.0057 3.8501 0.0 0
M  V30 31 C 18.6718 1.5400 0.0 0
M  V30 32 C 20.0057 2.3101 0.0 0
M  V30 33 H 6.1048 5.9538 0.0 0 MASS=2
M  V30 34 H 4.5648 3.2864 0.0 0 MASS=2
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 15
M  V30 4 1 2 4
M  V30 5 1 4 21
M  V30 6 1 4 33
M  V30 7 1 4 34
M  V30 8 1 5 6
M  V30 9 2 5 7
M  V30 10 1 5 18
M  V30 11 1 6 8
M  V30 12 1 8 27
M  V30 13 1 9 24
M  V30 14 1 10 26
M  V30 15 1 11 12
M  V30 16 2 11 13
M  V30 17 1 11 32
M  V30 18 1 12 14
M  V30 19 1 15 16
M  V30 20 2 15 17
M  V30 21 2 16 18
M  V30 22 1 17 19
M  V30 23 1 18 20
M  V30 24 2 19 20
M  V30 25 2 21 22
M  V30 26 1 21 23
M  V30 27 1 22 24
M  V30 28 2 23 25
M  V30 29 2 24 26
M  V30 30 1 25 26
M  V30 31 2 27 28
M  V30 32 1 27 29
M  V30 33 1 28 30
M  V30 34 2 29 31
M  V30 35 2 30 32
M  V30 36 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 690998-35-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1605324-71-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 1605324-86-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31806452
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 93
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 39968-33-7
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 109-02-4
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor
for the treatment of Osteoarthritis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Bendele, Alison M.; Neelagiri, Madhavi; Neelagiri, Venugopal; Sucholeiki,
Irving
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 224113666

$RFMT $RIREG SCHEME473 STEP1
$RXN



  2  1
$MOL
4-Aminotetrahydropyran
C5H11NO
38041-19-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6201 1.3337 0.0 0
M  V30 2 C 2.3101 0.0000 0.0 0
M  V30 3 C 3.0801 1.3337 0.0 0
M  V30 4 C 0.7700 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 O 0.0000 1.3337 0.0 0
M  V30 7 C 0.7700 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 3
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 3 5
M  V30 5 1 4 6
M  V30 6 1 5 7
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Thieno[2,3:4,5]pyrrolo[1,2-a]pyrazine-7(8H)-acetic acid, 5,6-dihydro-8-oxo-
C11H10N2O3S
3034891-94-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 7.0237 5.3349 0.0 0
M  V30 2 C 8.5638 2.6675 0.0 0
M  V30 3 C 9.3338 1.3338 0.0 0
M  V30 4 O 8.5638 0.0000 0.0 0
M  V30 5 O 10.8738 1.3338 0.0 0
M  V30 6 N 3.9437 2.6675 0.0 0
M  V30 7 C 4.7137 4.0011 0.0 0
M  V30 8 C 2.4374 2.9876 0.0 0
M  V30 9 C 4.7137 1.3338 0.0 0
M  V30 10 C 3.6833 5.1457 0.0 0
M  V30 11 C 6.2537 4.0011 0.0 0
M  V30 12 C 2.2763 4.5192 0.0 0
M  V30 13 C 1.0304 2.3613 0.0 0
M  V30 14 C 6.2537 1.3338 0.0 0
M  V30 15 N 7.0237 2.6675 0.0 0
M  V30 16 S 0.7700 4.8394 0.0 0
M  V30 17 C 0.0000 3.5057 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 11
M  V30 2 1 2 3
M  V30 3 1 2 15
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 2 7 10
M  V30 10 1 7 11
M  V30 11 2 8 12
M  V30 12 1 8 13
M  V30 13 1 9 14
M  V30 14 1 10 12
M  V30 15 1 11 15
M  V30 16 1 12 16
M  V30 17 2 13 17
M  V30 18 1 14 15
M  V30 19 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Thieno[2,3:4,5]pyrrolo[1,2-a]pyrazine-7(8H)-acetamide, 5,6-dihydro-8-oxo-N-...
C16H19N3O3S
3034891-87-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.1682 0.0000 0.0 0
M  V30 2 C 7.8355 1.5400 0.0 0
M  V30 3 C 9.1692 2.3100 0.0 0
M  V30 4 N 10.5030 1.5400 0.0 0
M  V30 5 O 9.1692 3.8500 0.0 0
M  V30 6 N 3.8344 3.8500 0.0 0
M  V30 7 C 3.8344 2.3100 0.0 0
M  V30 8 C 2.3699 4.3259 0.0 0
M  V30 9 C 5.1682 4.6200 0.0 0
M  V30 10 C 5.1682 1.5400 0.0 0
M  V30 11 C 2.3699 1.8341 0.0 0
M  V30 12 C 1.4647 3.0800 0.0 0
M  V30 13 C 1.4647 5.5717 0.0 0
M  V30 14 C 6.5019 3.8500 0.0 0
M  V30 15 N 6.5019 2.3100 0.0 0
M  V30 16 S 0.0000 3.5559 0.0 0
M  V30 17 C 0.0000 5.0959 0.0 0
M  V30 18 C 11.8366 2.3100 0.0 0
M  V30 19 C 13.1702 1.5400 0.0 0
M  V30 20 C 11.8366 3.8500 0.0 0
M  V30 21 C 14.5040 2.3100 0.0 0
M  V30 22 C 13.1702 4.6200 0.0 0
M  V30 23 O 14.5040 3.8500 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 10
M  V30 2 1 2 3
M  V30 3 1 2 15
M  V30 4 1 3 4
M  V30 5 2 3 5
M  V30 6 1 4 18
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 2 7 11
M  V30 12 2 8 12
M  V30 13 1 8 13
M  V30 14 1 9 14
M  V30 15 1 10 15
M  V30 16 1 11 12
M  V30 17 1 12 16
M  V30 18 2 13 17
M  V30 19 1 14 15
M  V30 20 1 16 17
M  V30 21 1 18 19
M  V30 22 1 18 20
M  V30 23 1 19 21
M  V30 24 1 20 22
M  V30 25 1 21 23
M  V30 26 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 38041-19-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3034891-94-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3034891-87-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-37984060
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 92
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3
Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative
Colitis
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Na; Jiang, Xueqin; Zhang, Ruijia; Ye, Neng; Tang, Minghai; Cai,
Xiaoying; Su, Kaiyue; Peng, Jing; Zhang, Xinlu; Zhao, Min; Wu, Wenshuang;
Ye, Haoyu
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(19), 13428-13451

$RFMT $RIREG SCHEME474 STEP1
$RXN



  2  1
$MOL
4-[(2-Amino-4,6-dichlorophenoxy)methyl]benzoic acid
C14H11Cl2NO3
2757502-15-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 7.7000 2.6674 0.0 0
M  V30 2 C 6.9300 4.0011 0.0 0
M  V30 3 Cl 9.2400 0.0000 0.0 0
M  V30 4 N 9.2400 5.3349 0.0 0
M  V30 5 Cl 13.8600 2.6674 0.0 0
M  V30 6 C 0.7700 4.0011 0.0 0
M  V30 7 O 0.0000 5.3349 0.0 0
M  V30 8 O 0.0000 2.6674 0.0 0
M  V30 9 C 9.2400 2.6674 0.0 0
M  V30 10 C 10.0100 1.3338 0.0 0
M  V30 11 C 10.0100 4.0011 0.0 0
M  V30 12 C 11.5500 1.3338 0.0 0
M  V30 13 C 11.5500 4.0011 0.0 0
M  V30 14 C 12.3200 2.6674 0.0 0
M  V30 15 C 5.3900 4.0011 0.0 0
M  V30 16 C 4.6200 2.6674 0.0 0
M  V30 17 C 4.6200 5.3349 0.0 0
M  V30 18 C 3.0800 2.6674 0.0 0
M  V30 19 C 3.0800 5.3349 0.0 0
M  V30 20 C 2.3100 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 2 15
M  V30 4 1 3 10
M  V30 5 1 4 11
M  V30 6 1 5 14
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 20
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 13
M  V30 14 2 12 14
M  V30 15 1 13 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 16 18
M  V30 19 2 17 19
M  V30 20 2 18 20
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-BOC-ethylenediamine
C7H16N2O2
57260-73-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6675 2.3101 0.0 0
M  V30 2 C 4.0012 1.5400 0.0 0
M  V30 3 C 1.3337 1.5400 0.0 0
M  V30 4 N 5.3348 2.3101 0.0 0
M  V30 5 O 4.0012 0.0000 0.0 0
M  V30 6 C 2.1037 0.2064 0.0 0
M  V30 7 C 0.0000 0.7700 0.0 0
M  V30 8 C 0.5637 2.8737 0.0 0
M  V30 9 C 6.6685 1.5400 0.0 0
M  V30 10 C 8.0023 2.3101 0.0 0
M  V30 11 N 9.3360 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 1 3 6
M  V30 6 1 3 7
M  V30 7 1 3 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL

C21H25Cl2N3O4
2757502-16-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3348 3.0801 0.0 0
M  V30 2 C 6.6685 2.3101 0.0 0
M  V30 3 Cl 5.3348 0.0000 0.0 0
M  V30 4 N 2.6673 4.6201 0.0 0
M  V30 5 Cl 0.0000 0.0000 0.0 0
M  V30 6 C 12.0033 5.3901 0.0 0
M  V30 7 N 13.3370 4.6201 0.0 0
M  V30 8 O 12.0033 6.9302 0.0 0
M  V30 9 C 14.6708 5.3901 0.0 0
M  V30 10 C 16.0045 4.6201 0.0 0
M  V30 11 N 17.3382 5.3901 0.0 0
M  V30 12 C 18.6718 4.6201 0.0 0
M  V30 13 O 20.0057 5.3901 0.0 0
M  V30 14 O 18.6718 3.0801 0.0 0
M  V30 15 C 21.3393 4.6201 0.0 0
M  V30 16 C 20.5693 3.2864 0.0 0
M  V30 17 C 22.6730 3.8501 0.0 0
M  V30 18 C 22.1093 5.9538 0.0 0
M  V30 19 C 4.0012 2.3101 0.0 0
M  V30 20 C 4.0012 0.7700 0.0 0
M  V30 21 C 2.6673 3.0801 0.0 0
M  V30 22 C 2.6673 0.0000 0.0 0
M  V30 23 C 1.3337 2.3101 0.0 0
M  V30 24 C 1.3337 0.7700 0.0 0
M  V30 25 C 8.0022 3.0801 0.0 0
M  V30 26 C 9.3360 2.3101 0.0 0
M  V30 27 C 8.0022 4.6201 0.0 0
M  V30 28 C 10.6697 3.0801 0.0 0
M  V30 29 C 9.3360 5.3901 0.0 0
M  V30 30 C 10.6697 4.6201 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 19
M  V30 3 1 2 25
M  V30 4 1 3 20
M  V30 5 1 4 21
M  V30 6 1 5 24
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 6 30
M  V30 10 1 7 9
M  V30 11 1 9 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 2 12 14
M  V30 16 1 13 15
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 1 15 18
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 2 22 24
M  V30 25 1 23 24
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 26 28
M  V30 29 2 27 29
M  V30 30 2 28 30
M  V30 31 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2757502-15-9
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 57260-73-8
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2757502-16-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-38181050
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 86
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7719-09-7
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of benzyloxy benzamide derivatives as potent neuroprotective
agents against ischemic stroke
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Chen, Weilin; Jiang, Bo; Zhao, Yifan; Yu, Wei; Zhang, Minyue; Liang,
Zhenchu; Liu, Xing; Ye, Binglin; Chen, Dongyin; Yang, Lei; Li, Fei
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2023), 261115871

$RFMT $RIREG SCHEME475 STEP1
$RXN



  2  1
$MOL
41-(1,1-Dimethylethyl) (22S)-22-[(1,1-dimethylethoxy)carbonyl]-10,19,24-triox...
C43H79N3O13
1118767-16-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  59 58 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 26.1800 5.3347 0.0 0 CFG=2
M  V30 2 N 24.6400 5.3347 0.0 0
M  V30 3 C 26.9500 6.6684 0.0 0
M  V30 4 C 26.9500 4.0011 0.0 0
M  V30 5 C 23.8700 6.6684 0.0 0
M  V30 6 C 28.4900 6.6684 0.0 0
M  V30 7 O 26.1800 2.6673 0.0 0
M  V30 8 O 28.4900 4.0011 0.0 0
M  V30 9 C 22.3300 6.6684 0.0 0
M  V30 10 O 24.6400 8.0021 0.0 0
M  V30 11 C 29.2600 8.0021 0.0 0
M  V30 12 C 26.9500 1.3336 0.0 0
M  V30 13 C 21.5600 8.0020 0.0 0
M  V30 14 N 30.8000 8.0021 0.0 0
M  V30 15 O 28.4900 9.3358 0.0 0
M  V30 16 C 25.6164 0.5636 0.0 0
M  V30 17 C 27.7200 0.0000 0.0 0
M  V30 18 C 28.2836 2.1036 0.0 0
M  V30 19 C 20.0200 8.0020 0.0 0
M  V30 20 C 31.5700 9.3358 0.0 0
M  V30 21 C 19.2500 9.3358 0.0 0
M  V30 22 C 33.1100 9.3358 0.0 0
M  V30 23 C 17.7100 9.3358 0.0 0
M  V30 24 O 33.8800 10.6694 0.0 0
M  V30 25 C 16.9400 10.6694 0.0 0
M  V30 26 C 35.4200 10.6694 0.0 0
M  V30 27 C 15.4000 10.6694 0.0 0
M  V30 28 C 36.1900 12.0031 0.0 0
M  V30 29 C 14.6300 12.0031 0.0 0
M  V30 30 O 37.7300 12.0031 0.0 0
M  V30 31 C 13.0900 12.0031 0.0 0
M  V30 32 C 38.5000 13.3369 0.0 0
M  V30 33 C 12.3200 13.3367 0.0 0
M  V30 34 C 40.0400 13.3369 0.0 0
M  V30 35 C 10.7800 13.3367 0.0 0
M  V30 36 N 40.8100 14.6705 0.0 0
M  V30 37 O 40.8100 12.0031 0.0 0
M  V30 38 C 10.0100 14.6705 0.0 0
M  V30 39 C 42.3500 14.6705 0.0 0
M  V30 40 C 8.4700 14.6705 0.0 0
M  V30 41 C 43.1200 16.0041 0.0 0
M  V30 42 C 7.7000 16.0041 0.0 0
M  V30 43 O 44.6600 16.0041 0.0 0
M  V30 44 C 6.1600 16.0041 0.0 0
M  V30 45 C 45.4300 17.3378 0.0 0
M  V30 46 C 5.3900 17.3378 0.0 0
M  V30 47 C 46.9700 17.3378 0.0 0
M  V30 48 C 3.8500 17.3378 0.0 0
M  V30 49 O 47.7400 18.6716 0.0 0
M  V30 50 O 3.0800 18.6714 0.0 0
M  V30 51 O 3.0800 16.0041 0.0 0
M  V30 52 C 49.2800 18.6716 0.0 0
M  V30 53 C 1.5400 18.6714 0.0 0
M  V30 54 C 50.0500 20.0052 0.0 0
M  V30 55 C 1.5400 20.2114 0.0 0
M  V30 56 C 0.0000 18.6714 0.0 0
M  V30 57 C 1.5400 17.1314 0.0 0
M  V30 58 O 51.5900 20.0052 0.0 0
M  V30 59 O 49.2800 21.3389 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=1
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 12 17
M  V30 17 1 12 18
M  V30 18 1 13 19
M  V30 19 1 14 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 29 1 28 30
M  V30 30 1 29 31
M  V30 31 1 30 32
M  V30 32 1 31 33
M  V30 33 1 32 34
M  V30 34 1 33 35
M  V30 35 1 34 36
M  V30 36 2 34 37
M  V30 37 1 35 38
M  V30 38 1 36 39
M  V30 39 1 38 40
M  V30 40 1 39 41
M  V30 41 1 40 42
M  V30 42 1 41 43
M  V30 43 1 42 44
M  V30 44 1 43 45
M  V30 45 1 44 46
M  V30 46 1 45 47
M  V30 47 1 46 48
M  V30 48 1 47 49
M  V30 49 1 48 50
M  V30 50 2 48 51
M  V30 51 1 49 52
M  V30 52 1 50 53
M  V30 53 1 52 54
M  V30 54 1 53 55
M  V30 55 1 53 56
M  V30 56 1 53 57
M  V30 57 1 54 58
M  V30 58 2 54 59
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Lysine monohydrochloride
C6H14N2O2.ClH
657-27-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 7.7000 0.0 0 CFG=2
M  V30 2 C 2.6674 6.1600 0.0 0
M  V30 3 C 1.3338 8.4700 0.0 0
M  V30 4 N 4.0011 8.4700 0.0 0
M  V30 5 C 4.0011 5.3900 0.0 0
M  V30 6 O 0.0000 7.7000 0.0 0
M  V30 7 O 1.3338 10.0100 0.0 0
M  V30 8 C 4.0011 3.8500 0.0 0
M  V30 9 C 5.3349 3.0800 0.0 0
M  V30 10 N 5.3349 1.5400 0.0 0
M  V30 11 Cl 2.6674 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 5 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
48-(1,1-Dimethylethyl) (2S,29S)-2-amino-29-[(1,1-dimethylethoxy)carbonyl]-8,1...
C49H91N5O14
2682856-38-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  68 67 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 20.0057 4.4137 0.0 0 CFG=2
M  V30 2 N 21.3393 3.6437 0.0 0
M  V30 3 C 20.0057 5.9538 0.0 0
M  V30 4 C 18.6720 3.6437 0.0 0
M  V30 5 C 22.6731 4.4137 0.0 0
M  V30 6 C 18.6720 6.7238 0.0 0
M  V30 7 O 18.6720 2.1037 0.0 0
M  V30 8 O 17.3383 4.4137 0.0 0
M  V30 9 C 24.0068 3.6437 0.0 0
M  V30 10 O 22.6731 5.9538 0.0 0
M  V30 11 C 18.6720 8.2638 0.0 0
M  V30 12 C 17.3383 1.3337 0.0 0
M  V30 13 C 25.3405 4.4137 0.0 0
M  V30 14 N 17.3383 9.0338 0.0 0
M  V30 15 O 20.0057 9.0338 0.0 0
M  V30 16 C 18.1083 0.0000 0.0 0
M  V30 17 C 16.0045 0.5637 0.0 0
M  V30 18 C 16.5683 2.6673 0.0 0
M  V30 19 C 26.6742 3.6437 0.0 0
M  V30 20 C 17.3383 10.5739 0.0 0
M  V30 21 C 28.0080 4.4137 0.0 0
M  V30 22 C 16.0045 11.3439 0.0 0
M  V30 23 C 29.3416 3.6437 0.0 0
M  V30 24 O 16.0045 12.8839 0.0 0
M  V30 25 C 30.6753 4.4137 0.0 0
M  V30 26 C 14.6708 13.6539 0.0 0
M  V30 27 C 32.0090 3.6437 0.0 0
M  V30 28 C 14.6708 15.1940 0.0 0
M  V30 29 C 33.3428 4.4137 0.0 0
M  V30 30 O 13.3372 15.9640 0.0 0
M  V30 31 C 34.6765 3.6437 0.0 0
M  V30 32 C 13.3372 17.5040 0.0 0
M  V30 33 C 36.0101 4.4137 0.0 0
M  V30 34 C 12.0035 18.2740 0.0 0
M  V30 35 C 37.3438 3.6437 0.0 0
M  V30 36 N 12.0035 19.8141 0.0 0
M  V30 37 O 10.6697 17.5040 0.0 0
M  V30 38 C 38.6776 4.4137 0.0 0
M  V30 39 C 10.6697 20.5841 0.0 0
M  V30 40 C 40.0113 3.6437 0.0 0
M  V30 41 C 10.6697 22.1241 0.0 0
M  V30 42 C 41.3450 4.4137 0.0 0
M  V30 43 O 9.3360 22.8941 0.0 0
M  V30 44 C 42.6786 3.6437 0.0 0
M  V30 45 C 9.3360 24.4342 0.0 0
M  V30 46 C 44.0125 4.4137 0.0 0
M  V30 47 C 8.0023 25.2042 0.0 0
M  V30 48 C 45.3461 3.6437 0.0 0
M  V30 49 O 8.0023 26.7442 0.0 0
M  V30 50 O 46.6798 4.4137 0.0 0
M  V30 51 O 45.3461 2.1037 0.0 0
M  V30 52 C 6.6687 27.5142 0.0 0
M  V30 53 C 48.0135 3.6437 0.0 0
M  V30 54 C 6.6687 29.0543 0.0 0
M  V30 55 C 48.7835 4.9775 0.0 0
M  V30 56 C 49.3473 2.8737 0.0 0
M  V30 57 C 47.2435 2.3101 0.0 0
M  V30 58 N 5.3348 29.8243 0.0 0
M  V30 59 O 8.0023 29.8243 0.0 0
M  V30 60 C 5.3348 31.3643 0.0 0
M  V30 61 C 4.0012 32.1343 0.0 0
M  V30 62 C 4.0012 33.6744 0.0 0
M  V30 63 C 2.6675 34.4444 0.0 0
M  V30 64 C 2.6675 35.9844 0.0 0 CFG=2
M  V30 65 C 1.3338 36.7544 0.0 0
M  V30 66 N 4.0012 36.7544 0.0 0
M  V30 67 O 0.0000 35.9844 0.0 0
M  V30 68 O 1.3338 38.2945 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 2 5 10
M  V30 10 1 6 11
M  V30 11 1 7 12
M  V30 12 1 9 13
M  V30 13 1 11 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 12 17
M  V30 17 1 12 18
M  V30 18 1 13 19
M  V30 19 1 14 20
M  V30 20 1 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 1 22 24
M  V30 24 1 23 25
M  V30 25 1 24 26
M  V30 26 1 25 27
M  V30 27 1 26 28
M  V30 28 1 27 29
M  V30 29 1 28 30
M  V30 30 1 29 31
M  V30 31 1 30 32
M  V30 32 1 31 33
M  V30 33 1 32 34
M  V30 34 1 33 35
M  V30 35 1 34 36
M  V30 36 2 34 37
M  V30 37 1 35 38
M  V30 38 1 36 39
M  V30 39 1 38 40
M  V30 40 1 39 41
M  V30 41 1 40 42
M  V30 42 1 41 43
M  V30 43 1 42 44
M  V30 44 1 43 45
M  V30 45 1 44 46
M  V30 46 1 45 47
M  V30 47 1 46 48
M  V30 48 1 47 49
M  V30 49 1 48 50
M  V30 50 2 48 51
M  V30 51 1 49 52
M  V30 52 1 50 53
M  V30 53 1 52 54
M  V30 54 1 53 55
M  V30 55 1 53 56
M  V30 56 1 53 57
M  V30 57 1 54 58
M  V30 58 2 54 59
M  V30 59 1 58 60
M  V30 60 1 60 61
M  V30 61 1 61 62
M  V30 62 1 62 63
M  V30 63 1 63 64
M  V30 64 1 64 65
M  V30 65 1 64 66 CFG=1
M  V30 66 1 65 67
M  V30 67 2 65 68
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 64)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1118767-16-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 657-27-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2682856-38-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-24132213
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 693-13-0
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 6066-82-6
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):RGT(4):CAS_RN
$DATUM 7758-98-7
$DTYPE RXN:VAR(1):RGT(5):CAS_RN
$DATUM 60-00-4
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 67-64-1
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):NOTES
$DATUM inverse addition after overnight (stage 2)
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Copper(II) lysinate and pseudoproline assistance in the convergent
synthesis of the GLP-1 receptor agonists Liraglutide and Semaglutide
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guryanov, Ivan; Orlandin, Andrea; De Paola, Ivan; Viola, Angelo; Biondi,
Barbara; Badocco, Denis; Formaggio, Fernando; Ricci, Antonio; Cabri,
Walter
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Organic Process Research & Development (2021), 25(7), 1598-1611

$RFMT $RIREG SCHEME476 STEP1
$RXN



  2  1
$MOL
S-Methyl-N-[(5-methyl-3-isoxazolyl)carbonyl]-L-cysteinylglycine
C11H15N3O5S
2387523-01-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0287 5.3348 0.0 0
M  V30 2 N 5.5687 5.3348 0.0 0
M  V30 3 O 3.2587 4.0011 0.0 0
M  V30 4 C 6.3388 4.0011 0.0 0 CFG=1
M  V30 5 C 7.8788 4.0011 0.0 0
M  V30 6 C 5.5687 2.6673 0.0 0
M  V30 7 N 8.6488 5.3348 0.0 0
M  V30 8 O 8.6488 2.6673 0.0 0
M  V30 9 S 6.3388 1.3337 0.0 0
M  V30 10 C 10.1888 5.3348 0.0 0
M  V30 11 C 5.5687 0.0000 0.0 0
M  V30 12 C 10.9588 6.6685 0.0 0
M  V30 13 O 10.1888 8.0023 0.0 0
M  V30 14 O 12.4989 6.6685 0.0 0
M  V30 15 C 0.0000 8.9622 0.0 0
M  V30 16 C 3.2587 6.6685 0.0 0
M  V30 17 C 1.7271 6.8296 0.0 0
M  V30 18 N 3.8850 8.0754 0.0 0
M  V30 19 C 1.4070 8.3359 0.0 0
M  V30 20 O 2.7406 9.1059 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 16
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 4 6 CFG=3
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 9 1 6 9
M  V30 10 1 7 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 15 19
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 20
M  V30 20 1 19 20
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1-Pentanone, 2-amino-4-methyl-1-[(2R)-2-methyl-2-oxiranyl]-, (2S)-, 2,2,2-tri...
C9H17NO2.C2HF3O2
247068-85-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8504 6.7237 0.0 0
M  V30 2 C 4.1841 7.4937 0.0 0 CFG=1
M  V30 3 O 2.8504 5.1837 0.0 0
M  V30 4 C 5.5177 6.7237 0.0 0
M  V30 5 N 4.1841 9.0338 0.0 0
M  V30 6 C 6.8514 7.4937 0.0 0
M  V30 7 C 8.1852 6.7237 0.0 0
M  V30 8 C 6.8514 9.0338 0.0 0
M  V30 9 C 2.0434 8.9409 0.0 0
M  V30 10 C 1.5166 7.4937 0.0 0 CFG=2
M  V30 11 C 0.5268 6.3141 0.0 0
M  V30 12 O 0.0000 7.7611 0.0 0
M  V30 13 C 3.4257 2.3101 0.0 0
M  V30 14 C 4.7594 1.5400 0.0 0
M  V30 15 F 4.1958 3.6437 0.0 0
M  V30 16 F 2.0921 3.0801 0.0 0
M  V30 17 F 2.6557 0.9764 0.0 0
M  V30 18 O 6.0931 2.3101 0.0 0
M  V30 19 O 4.7594 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 10 1 CFG=1
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 11 12
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 16 1 13 17
M  V30 17 1 14 18
M  V30 18 2 14 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
S-Methyl-N-[(5-methyl-3-isoxazolyl)carbonyl]-L-cysteinyl-N-[(1S)-3-methyl-1-[...
C20H30N4O6S
2387523-26-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.2172 8.0021 0.0 0
M  V30 2 C 3.7572 8.0021 0.0 0 CFG=2
M  V30 3 O 1.4472 9.3360 0.0 0
M  V30 4 N 4.5272 6.6685 0.0 0
M  V30 5 C 4.5272 9.3360 0.0 0
M  V30 6 C 6.0673 6.6685 0.0 0
M  V30 7 C 3.7572 10.6696 0.0 0
M  V30 8 C 6.8373 5.3348 0.0 0
M  V30 9 O 6.8373 8.0021 0.0 0
M  V30 10 C 4.5272 12.0033 0.0 0
M  V30 11 C 2.2172 10.6696 0.0 0
M  V30 12 N 8.3773 5.3348 0.0 0
M  V30 13 C 9.1473 4.0011 0.0 0
M  V30 14 C 10.6873 4.0011 0.0 0 CFG=2
M  V30 15 O 8.3773 2.6673 0.0 0
M  V30 16 N 11.4574 5.3348 0.0 0
M  V30 17 C 11.4574 2.6673 0.0 0
M  V30 18 C 12.9974 5.3348 0.0 0
M  V30 19 S 10.6873 1.3337 0.0 0
M  V30 20 O 13.7674 4.0011 0.0 0
M  V30 21 C 11.4574 0.0000 0.0 0
M  V30 22 C 2.6268 5.6785 0.0 0
M  V30 23 C 17.0259 8.9622 0.0 0
M  V30 24 C 1.4472 6.6685 0.0 0 CFG=2
M  V30 25 C 0.0000 7.1952 0.0 0
M  V30 26 O 0.2673 5.6785 0.0 0
M  V30 27 C 13.7674 6.6685 0.0 0
M  V30 28 N 13.1409 8.0755 0.0 0
M  V30 29 C 15.2990 6.8294 0.0 0
M  V30 30 O 14.2855 9.1059 0.0 0
M  V30 31 C 15.6191 8.3359 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 24 1 CFG=3
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=3
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 1 7 11
M  V30 12 1 8 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 14 16
M  V30 17 1 14 17 CFG=1
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 1 18 27
M  V30 22 1 19 21
M  V30 23 1 24 22 CFG=1
M  V30 24 1 23 31
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 25 26
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 28 30
M  V30 31 2 29 31
M  V30 32 1 30 31
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(3 2 14 24)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2387523-01-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 247068-85-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2387523-26-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545371
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME477 STEP1
$RXN



  2  1
$MOL
Butanedioic acid, 2-[4-(trifluoromethyl)phenyl]-, 1-methyl ester
C12H11F3O4
3043790-59-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0800 4.0011 0.0 0
M  V30 2 C 2.3100 2.6674 0.0 0
M  V30 3 C 2.3100 5.3347 0.0 0
M  V30 4 O 3.0800 1.3338 0.0 0
M  V30 5 O 0.7700 2.6674 0.0 0
M  V30 6 C 0.7700 5.3347 0.0 0
M  V30 7 C 2.3100 0.0000 0.0 0
M  V30 8 O 0.0000 4.0011 0.0 0
M  V30 9 O 0.0000 6.6685 0.0 0
M  V30 10 C 9.2400 4.0011 0.0 0
M  V30 11 F 9.2400 2.4611 0.0 0
M  V30 12 F 10.7800 4.0011 0.0 0
M  V30 13 F 9.2400 5.5411 0.0 0
M  V30 14 C 4.6200 4.0011 0.0 0
M  V30 15 C 5.3900 2.6674 0.0 0
M  V30 16 C 5.3900 5.3347 0.0 0
M  V30 17 C 6.9300 2.6674 0.0 0
M  V30 18 C 6.9300 5.3347 0.0 0
M  V30 19 C 7.7000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 2 2 5
M  V30 6 1 3 6
M  V30 7 1 4 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 13 1 10 19
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 15 17
M  V30 17 2 16 18
M  V30 18 2 17 19
M  V30 19 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-(Oxazol-2-yl)aniline
C9H8N2O
62882-11-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 8.5298 1.3336 0.0 0
M  V30 2 C 3.9098 1.3336 0.0 0
M  V30 3 C 4.6798 2.6673 0.0 0
M  V30 4 C 4.6798 0.0000 0.0 0
M  V30 5 C 6.2198 2.6673 0.0 0
M  V30 6 C 6.2198 0.0000 0.0 0
M  V30 7 C 6.9898 1.3336 0.0 0
M  V30 8 C 2.3698 1.3336 0.0 0
M  V30 9 N 1.4645 2.5795 0.0 0
M  V30 10 O 1.4645 0.0878 0.0 0
M  V30 11 C 0.0000 2.1037 0.0 0
M  V30 12 C 0.0000 0.5636 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 7
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 2 8
M  V30 5 1 3 5
M  V30 6 2 4 6
M  V30 7 2 5 7
M  V30 8 1 6 7
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetic acid, -[2-[[4-(2-oxazolyl)phenyl]amino]-2-oxoethyl]-4-(trifluo...
C21H17F3N2O4
3043790-32-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.7000 4.0011 0.0 0
M  V30 2 C 8.4700 5.3347 0.0 0
M  V30 3 C 8.4700 2.6674 0.0 0
M  V30 4 C 10.0100 5.3347 0.0 0
M  V30 5 O 7.7000 1.3336 0.0 0
M  V30 6 O 10.0100 2.6674 0.0 0
M  V30 7 N 10.7800 6.6685 0.0 0
M  V30 8 O 10.7800 4.0011 0.0 0
M  V30 9 C 8.4700 0.0000 0.0 0
M  V30 10 C 1.5400 4.0011 0.0 0
M  V30 11 F 1.5400 2.4611 0.0 0
M  V30 12 F 0.0000 4.0011 0.0 0
M  V30 13 F 1.5400 5.5411 0.0 0
M  V30 14 C 6.1600 4.0011 0.0 0
M  V30 15 C 5.3900 2.6674 0.0 0
M  V30 16 C 5.3900 5.3347 0.0 0
M  V30 17 C 3.8500 2.6674 0.0 0
M  V30 18 C 3.8500 5.3347 0.0 0
M  V30 19 C 3.0800 4.0011 0.0 0
M  V30 20 C 12.3200 6.6685 0.0 0
M  V30 21 C 13.0900 8.0021 0.0 0
M  V30 22 C 13.0900 5.3347 0.0 0
M  V30 23 C 14.6300 8.0021 0.0 0
M  V30 24 C 14.6300 5.3347 0.0 0
M  V30 25 C 15.4000 6.6685 0.0 0
M  V30 26 C 16.9400 6.6685 0.0 0
M  V30 27 N 17.8452 5.4225 0.0 0
M  V30 28 O 17.8452 7.9144 0.0 0
M  V30 29 C 19.3098 5.8985 0.0 0
M  V30 30 C 19.3098 7.4385 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 14
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 4 7
M  V30 8 2 4 8
M  V30 9 1 5 9
M  V30 10 1 7 20
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 10 19
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 15 17
M  V30 18 2 16 18
M  V30 19 2 17 19
M  V30 20 1 18 19
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 24
M  V30 25 2 23 25
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 1 28 30
M  V30 32 2 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 3043790-59-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 62882-11-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3043790-32-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-40877727
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 79-37-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7647-01-0
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Synthesis and biological characterization of an orally bioavailable
lactate dehydrogenase-A inhibitor against pancreatic cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Sharma, Horrick; Mondal, Somrita; Urquiza, Uzziah; Esparza, Colter;
Bartlett, Seth; Santa-Pinter, Landon; Hill, Hanna; White, Madalyn;
Sharma, Pragya; Luckett-Chastain, Lerin; Cooper, Anne; Rasel, Mohammad;
Gao, Philip; Battaile, Kevin P.; Shukla, Surendra K.; Lovell, Scott;
Ihnat, Michael A.
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2024), 275116598

$RFMT $RIREG SCHEME478 STEP1
$RXN



  2  1
$MOL
Salicylic acid
C7H6O3
69-72-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6673 0.0 0
M  V30 2 O 0.0000 4.0010 0.0 0
M  V30 3 O 0.0000 1.3337 0.0 0
M  V30 4 O 2.3101 0.0000 0.0 0
M  V30 5 C 2.3101 2.6673 0.0 0
M  V30 6 C 3.0801 1.3337 0.0 0
M  V30 7 C 3.0801 4.0010 0.0 0
M  V30 8 C 4.6201 1.3337 0.0 0
M  V30 9 C 4.6201 4.0010 0.0 0
M  V30 10 C 5.3901 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 5
M  V30 4 1 4 6
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 6 8
M  V30 8 2 7 9
M  V30 9 2 8 10
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl]-4-fluoro-N-(2-methylpropyl)benzen...
C20H27FN2O3S
772318-79-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.6686 3.8500 0.0 0
M  V30 2 S 5.3348 4.6201 0.0 0 VAL=6
M  V30 3 C 8.0022 4.6201 0.0 0
M  V30 4 C 6.6686 2.3100 0.0 0
M  V30 5 O 6.1048 5.9537 0.0 0
M  V30 6 O 4.5648 3.2864 0.0 0
M  V30 7 C 9.3359 3.8500 0.0 0 CFG=1
M  V30 8 C 5.3348 1.5400 0.0 0
M  V30 9 C 10.6697 4.6201 0.0 0 CFG=1
M  V30 10 O 9.3359 2.3100 0.0 0
M  V30 11 C 5.3348 0.0000 0.0 0
M  V30 12 C 4.0011 2.3100 0.0 0
M  V30 13 C 12.0034 3.8500 0.0 0
M  V30 14 N 10.6697 6.1601 0.0 0
M  V30 15 F 0.0000 7.7001 0.0 0
M  V30 16 C 4.0011 5.3901 0.0 0
M  V30 17 C 4.0011 6.9301 0.0 0
M  V30 18 C 2.6675 4.6201 0.0 0
M  V30 19 C 2.6675 7.7001 0.0 0
M  V30 20 C 1.3338 5.3901 0.0 0
M  V30 21 C 1.3338 6.9301 0.0 0
M  V30 22 C 13.3370 4.6201 0.0 0
M  V30 23 C 13.3370 6.1601 0.0 0
M  V30 24 C 14.6707 3.8500 0.0 0
M  V30 25 C 14.6707 6.9301 0.0 0
M  V30 26 C 16.0045 4.6201 0.0 0
M  V30 27 C 16.0045 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 2 2 5
M  V30 5 2 2 6
M  V30 6 1 2 16
M  V30 7 1 3 7
M  V30 8 1 4 8
M  V30 9 1 7 9
M  V30 10 1 7 10 CFG=3
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 9 14 CFG=1
M  V30 15 1 13 22
M  V30 16 1 15 21
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 7 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1S,2R)-3-[[(4-Fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(p...
C27H31FN2O5S
2892016-29-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  36 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.0020 8.4700 0.0 0 CFG=1
M  V30 2 C 6.6684 7.7000 0.0 0 CFG=2
M  V30 3 C 8.0020 10.0100 0.0 0
M  V30 4 N 9.3356 7.7000 0.0 0
M  V30 5 C 5.3347 8.4700 0.0 0
M  V30 6 O 6.6684 6.1600 0.0 0
M  V30 7 C 10.6694 8.4700 0.0 0
M  V30 8 N 4.0009 7.7000 0.0 0
M  V30 9 O 10.6694 10.0100 0.0 0
M  V30 10 S 4.0009 6.1600 0.0 0 VAL=6
M  V30 11 C 2.6673 8.4700 0.0 0
M  V30 12 O 2.4609 6.1600 0.0 0
M  V30 13 O 5.5409 6.1600 0.0 0
M  V30 14 C 1.3336 7.7000 0.0 0
M  V30 15 C 0.0000 8.4700 0.0 0
M  V30 16 C 1.3336 6.1600 0.0 0
M  V30 17 O 13.3367 10.0100 0.0 0
M  V30 18 F 4.0009 0.0000 0.0 0
M  V30 19 C 6.6684 10.7800 0.0 0
M  V30 20 C 6.6684 12.3200 0.0 0
M  V30 21 C 5.3347 10.0100 0.0 0
M  V30 22 C 5.3347 13.0900 0.0 0
M  V30 23 C 4.0009 10.7800 0.0 0
M  V30 24 C 4.0009 12.3200 0.0 0
M  V30 25 C 12.0031 7.7000 0.0 0
M  V30 26 C 13.3367 8.4700 0.0 0
M  V30 27 C 12.0031 6.1600 0.0 0
M  V30 28 C 14.6703 7.7000 0.0 0
M  V30 29 C 13.3367 5.3900 0.0 0
M  V30 30 C 14.6703 6.1600 0.0 0
M  V30 31 C 4.0009 4.6200 0.0 0
M  V30 32 C 2.6673 3.8500 0.0 0
M  V30 33 C 5.3347 3.8500 0.0 0
M  V30 34 C 2.6673 2.3100 0.0 0
M  V30 35 C 5.3347 2.3100 0.0 0
M  V30 36 C 4.0009 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=3
M  V30 6 1 3 19
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 2 7 9
M  V30 10 1 7 25
M  V30 11 1 8 10
M  V30 12 1 8 11
M  V30 13 2 10 12
M  V30 14 2 10 13
M  V30 15 1 10 31
M  V30 16 1 11 14
M  V30 17 1 14 15
M  V30 18 1 14 16
M  V30 19 1 17 26
M  V30 20 1 18 36
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 20 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 24
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 26 28
M  V30 30 2 27 29
M  V30 31 2 28 30
M  V30 32 1 29 30
M  V30 33 2 31 32
M  V30 34 1 31 33
M  V30 35 1 32 34
M  V30 36 2 33 35
M  V30 37 2 34 36
M  V30 38 1 35 36
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 69-72-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 772318-79-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2892016-29-2
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34382509
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 87
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A kind of HIV-1 protease inhibitors containing phenols with antiviral
activity against DRV-resistant variants
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hu, Shangjiu; Ma, Ling; Dong, Biao; Shan, Qi; Zhou, Jinming; Zhang,
Guoning; Wang, Minghua; Cen, Shan; Zhu, Mei; Wang, Juxian; Wang, Yucheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2022), 64116760

$RFMT $RIREG SCHEME479 STEP1
$RXN



  2  1
$MOL
N-tert-Butoxycarbonyl-O-benzylserine
C15H21NO5
23680-31-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.0336 5.3347 0.0 0
M  V30 2 O 8.2636 4.0011 0.0 0
M  V30 3 C 6.7236 4.0011 0.0 0
M  V30 4 C 5.9536 2.6674 0.0 0 CFG=1
M  V30 5 N 4.4136 2.6674 0.0 0
M  V30 6 C 6.7236 1.3338 0.0 0
M  V30 7 C 3.6436 4.0011 0.0 0
M  V30 8 O 5.9536 0.0000 0.0 0
M  V30 9 O 8.2636 1.3338 0.0 0
M  V30 10 O 2.1036 4.0011 0.0 0
M  V30 11 O 4.4136 5.3347 0.0 0
M  V30 12 C 1.3336 5.3347 0.0 0
M  V30 13 C 0.0000 4.5647 0.0 0
M  V30 14 C 0.5636 6.6685 0.0 0
M  V30 15 C 2.6673 6.1047 0.0 0
M  V30 16 C 10.5736 5.3347 0.0 0
M  V30 17 C 11.3436 4.0011 0.0 0
M  V30 18 C 11.3436 6.6685 0.0 0
M  V30 19 C 12.8836 4.0011 0.0 0
M  V30 20 C 12.8836 6.6685 0.0 0
M  V30 21 C 13.6536 5.3347 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 1 3 4
M  V30 5 1 4 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 2 7 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 12 15
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 17 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 21
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 4)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
D-Glutamic acid, 1,5-diethyl ester, hydrochloride (1:1)
C9H17NO4.ClH
1001-19-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 3.8501 0.0 0
M  V30 2 C 5.3348 3.0800 0.0 0 CFG=1
M  V30 3 C 8.0022 3.0800 0.0 0
M  V30 4 C 4.0010 3.8501 0.0 0
M  V30 5 N 5.3348 1.5400 0.0 0
M  V30 6 C 9.3360 3.8501 0.0 0
M  V30 7 O 2.6673 3.0800 0.0 0
M  V30 8 O 4.0010 5.3901 0.0 0
M  V30 9 O 10.6697 3.0800 0.0 0
M  V30 10 O 9.3360 5.3901 0.0 0
M  V30 11 C 1.3337 3.8501 0.0 0
M  V30 12 C 12.0033 3.8501 0.0 0
M  V30 13 C 0.0000 3.0800 0.0 0
M  V30 14 C 13.3370 3.0800 0.0 0
M  V30 15 Cl 6.6685 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 1 2 5 CFG=1
M  V30 5 1 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 6 9
M  V30 9 2 6 10
M  V30 10 1 7 11
M  V30 11 1 9 12
M  V30 12 1 11 13
M  V30 13 1 12 14
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL

C24H36N2O8
3031089-22-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.0023 7.7002 0.0 0 CFG=1
M  V30 2 C 9.3360 6.9302 0.0 0
M  V30 3 C 6.6687 6.9302 0.0 0
M  V30 4 N 8.0023 9.2402 0.0 0
M  V30 5 N 9.3360 5.3901 0.0 0
M  V30 6 O 10.6697 7.7002 0.0 0
M  V30 7 O 5.3348 7.7002 0.0 0
M  V30 8 C 9.3360 10.0102 0.0 0
M  V30 9 C 10.6697 4.6201 0.0 0 CFG=1
M  V30 10 C 4.0012 6.9302 0.0 0
M  V30 11 O 9.3360 11.5503 0.0 0
M  V30 12 O 10.6697 9.2402 0.0 0
M  V30 13 C 12.0035 5.3901 0.0 0
M  V30 14 C 10.6697 3.0801 0.0 0
M  V30 15 C 10.6697 12.3203 0.0 0
M  V30 16 C 13.3372 4.6201 0.0 0
M  V30 17 O 9.3360 2.3101 0.0 0
M  V30 18 O 12.0035 2.3101 0.0 0
M  V30 19 C 9.8996 13.6539 0.0 0
M  V30 20 C 12.0035 13.0903 0.0 0
M  V30 21 C 11.4397 10.9866 0.0 0
M  V30 22 C 14.6708 5.3901 0.0 0
M  V30 23 C 9.3360 0.7700 0.0 0
M  V30 24 O 16.0045 4.6201 0.0 0
M  V30 25 O 14.6708 6.9302 0.0 0
M  V30 26 C 8.0023 0.0000 0.0 0
M  V30 27 C 17.3383 5.3901 0.0 0
M  V30 28 C 18.6720 4.6201 0.0 0
M  V30 29 C 2.6675 7.7002 0.0 0
M  V30 30 C 2.6675 9.2402 0.0 0
M  V30 31 C 1.3337 6.9302 0.0 0
M  V30 32 C 1.3337 10.0102 0.0 0
M  V30 33 C 0.0000 7.7002 0.0 0
M  V30 34 C 0.0000 9.2402 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13 CFG=3
M  V30 13 1 9 14
M  V30 14 1 10 29
M  V30 15 1 11 15
M  V30 16 1 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 1 15 19
M  V30 20 1 15 20
M  V30 21 1 15 21
M  V30 22 1 16 22
M  V30 23 1 17 23
M  V30 24 1 22 24
M  V30 25 2 22 25
M  V30 26 1 23 26
M  V30 27 1 24 27
M  V30 28 1 27 28
M  V30 29 2 29 30
M  V30 30 1 29 31
M  V30 31 1 30 32
M  V30 32 2 31 33
M  V30 33 2 32 34
M  V30 34 1 33 34
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 23680-31-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1001-19-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 3031089-22-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34283447
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 83
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 538-75-0
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
In Vivo Adjuvant Activity
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Guzelj, Samo; Nabergoj, Sanja; Gobec, Martina; Pajk, Stane; Klancic,
Veronika; Slutter, Bram; Frkanec, Ruza; Stimac, Adela; Sket, Primoz;
Plavec, Janez; Mlinaric-Rascan, Irena; Jakopin, Ziga
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2021), 64(11), 7809-7838

$RFMT $RIREG SCHEME480 STEP1
$RXN



  2  1
$MOL
4-Pyridinecarboxylic acid
C6H5NO2
55-22-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 2.3101 1.3337 0.0 0
M  V30 5 C 3.0801 0.0000 0.0 0
M  V30 6 C 3.0801 2.6673 0.0 0
M  V30 7 C 4.6201 0.0000 0.0 0
M  V30 8 C 4.6201 2.6673 0.0 0
M  V30 9 N 5.3901 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 2 5 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
L-Tryptophan, ethyl ester, hydrochloride (1:1)
C13H16N2O2.ClH
2899-28-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7533 4.1618 0.0 0
M  V30 2 C 7.0869 3.3918 0.0 0 CFG=2
M  V30 3 C 8.4206 4.1618 0.0 0
M  V30 4 N 7.0869 1.8518 0.0 0
M  V30 5 O 9.7542 3.3918 0.0 0
M  V30 6 O 8.4206 5.7018 0.0 0
M  V30 7 C 11.0880 4.1618 0.0 0
M  V30 8 C 12.4216 3.3918 0.0 0
M  V30 9 C 3.0127 4.0182 0.0 0
M  V30 10 C 4.4195 3.3918 0.0 0
M  V30 11 C 1.9823 2.8738 0.0 0
M  V30 12 C 2.5368 5.4829 0.0 0
M  V30 13 C 4.2586 1.8602 0.0 0
M  V30 14 N 2.7523 1.5400 0.0 0
M  V30 15 C 0.4759 3.1940 0.0 0
M  V30 16 C 1.0304 5.8030 0.0 0
M  V30 17 C 0.0000 4.6585 0.0 0
M  V30 18 Cl 6.2108 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 1 2 4 CFG=1
M  V30 5 1 3 5
M  V30 6 2 3 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 9 12
M  V30 12 2 10 13
M  V30 13 1 11 14
M  V30 14 2 11 15
M  V30 15 1 12 16
M  V30 16 1 13 14
M  V30 17 1 15 17
M  V30 18 2 16 17
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
Tryptophan, N-isonicotinoyl-, ethyl ester, L-
C19H19N3O3
29523-23-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.0543 6.6684 0.0 0
M  V30 2 C 5.8243 5.3347 0.0 0 CFG=1
M  V30 3 N 7.3643 5.3347 0.0 0
M  V30 4 C 5.0543 4.0011 0.0 0
M  V30 5 C 8.1343 6.6684 0.0 0
M  V30 6 O 5.8243 2.6673 0.0 0
M  V30 7 O 3.5143 4.0011 0.0 0
M  V30 8 O 7.3643 8.0020 0.0 0
M  V30 9 C 5.0543 1.3336 0.0 0
M  V30 10 C 5.8243 0.0000 0.0 0
M  V30 11 C 2.6091 7.9143 0.0 0
M  V30 12 C 3.5143 6.6684 0.0 0
M  V30 13 C 1.1445 7.4384 0.0 0
M  V30 14 C 2.9292 9.4207 0.0 0
M  V30 15 C 2.6091 5.4225 0.0 0
M  V30 16 N 1.1445 5.8984 0.0 0
M  V30 17 C 0.0000 8.4688 0.0 0
M  V30 18 C 1.7849 10.4511 0.0 0
M  V30 19 C 0.3202 9.9752 0.0 0
M  V30 20 C 9.6743 6.6684 0.0 0
M  V30 21 C 10.4443 8.0020 0.0 0
M  V30 22 C 10.4443 5.3347 0.0 0
M  V30 23 C 11.9843 8.0020 0.0 0
M  V30 24 C 11.9843 5.3347 0.0 0
M  V30 25 N 12.7543 6.6684 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 12
M  V30 3 1 2 3 CFG=3
M  V30 4 1 2 4
M  V30 5 1 3 5
M  V30 6 1 4 6
M  V30 7 2 4 7
M  V30 8 2 5 8
M  V30 9 1 5 20
M  V30 10 1 6 9
M  V30 11 1 9 10
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 2 12 15
M  V30 16 1 13 16
M  V30 17 2 13 17
M  V30 18 1 14 18
M  V30 19 1 15 16
M  V30 20 1 17 19
M  V30 21 2 18 19
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 2 21 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 25
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 55-22-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2899-28-7
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 29523-23-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-36966243
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 100
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 125700-67-6
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing
Covalent Reversible -Fluorovinylsulfones and -Sulfonates as Potential
Immunomodulators in Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fuchs, Natalie; Meta, Mergim; Lantzberg, Bellinda; Bros, Matthias; Ling
Kuan, Seah; Weil, Tanja; Schirmeister, Tanja
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM ChemMedChem (2023), 18(15), e202300160

$RFMT $RIREG SCHEME481 STEP1
$RXN



  2  1
$MOL
Cyanoacetic acid
C3H3NO2
372-09-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3100 2.6673 0.0 0
M  V30 2 C 1.5400 1.3336 0.0 0
M  V30 3 C 3.8500 2.6673 0.0 0
M  V30 4 O 2.3100 0.0000 0.0 0
M  V30 5 O 0.0000 1.3336 0.0 0
M  V30 6 N 5.3900 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 2 4
M  V30 4 2 2 5
M  V30 5 3 3 6
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
6-(3-Aminophenyl)-N-(1-methyl-1H-pyrazol-4-yl)-4-pyrimidinamine
C14H14N6
2412733-73-2 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 9.3360 2.3101 0.0 0
M  V30 2 N 0.0000 3.0801 0.0 0
M  V30 3 C 14.6386 3.4372 0.0 0
M  V30 4 C 5.3348 3.0801 0.0 0
M  V30 5 C 6.6685 2.3101 0.0 0
M  V30 6 N 5.3348 4.6201 0.0 0
M  V30 7 C 8.0023 3.0801 0.0 0
M  V30 8 C 6.6685 5.3901 0.0 0
M  V30 9 N 8.0023 4.6201 0.0 0
M  V30 10 C 4.0012 2.3101 0.0 0
M  V30 11 C 2.6673 3.0801 0.0 0
M  V30 12 C 4.0012 0.7700 0.0 0
M  V30 13 C 1.3337 2.3101 0.0 0
M  V30 14 C 2.6673 0.0000 0.0 0
M  V30 15 C 1.3337 0.7700 0.0 0
M  V30 16 C 10.6697 3.0801 0.0 0
M  V30 17 C 10.8306 4.6116 0.0 0
M  V30 18 C 12.0765 2.4537 0.0 0
M  V30 19 N 12.3371 4.9318 0.0 0
M  V30 20 N 13.1071 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 7
M  V30 2 1 1 16
M  V30 3 1 2 13
M  V30 4 1 3 20
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 10
M  V30 8 2 5 7
M  V30 9 1 6 8
M  V30 10 1 7 9
M  V30 11 2 8 9
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 11 13
M  V30 15 2 12 14
M  V30 16 2 13 15
M  V30 17 1 14 15
M  V30 18 1 16 17
M  V30 19 2 16 18
M  V30 20 2 17 19
M  V30 21 1 18 20
M  V30 22 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Cyano-N-[3-[6-[(1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]phenyl]acetamide
C17H15N7O
2412734-02-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3028 2.3101 0.0 0
M  V30 2 N 14.6386 3.0801 0.0 0
M  V30 3 C 15.9725 2.3101 0.0 0
M  V30 4 C 17.3061 3.0801 0.0 0
M  V30 5 O 15.9725 0.7700 0.0 0
M  V30 6 C 18.6398 2.3101 0.0 0
M  V30 7 N 19.9736 1.5400 0.0 0
M  V30 8 C 0.0000 3.4372 0.0 0
M  V30 9 C 9.3038 3.0801 0.0 0
M  V30 10 C 7.9701 2.3101 0.0 0
M  V30 11 N 9.3038 4.6201 0.0 0
M  V30 12 C 6.6365 3.0801 0.0 0
M  V30 13 C 7.9701 5.3901 0.0 0
M  V30 14 N 6.6365 4.6201 0.0 0
M  V30 15 C 10.6376 2.3101 0.0 0
M  V30 16 C 11.9713 3.0801 0.0 0
M  V30 17 C 10.6376 0.7700 0.0 0
M  V30 18 C 13.3050 2.3101 0.0 0
M  V30 19 C 11.9713 0.0000 0.0 0
M  V30 20 C 13.3050 0.7700 0.0 0
M  V30 21 C 3.9690 3.0801 0.0 0
M  V30 22 C 3.8080 4.6116 0.0 0
M  V30 23 C 2.5622 2.4537 0.0 0
M  V30 24 N 2.3017 4.9318 0.0 0
M  V30 25 N 1.5317 3.5981 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 12
M  V30 2 1 1 21
M  V30 3 1 2 3
M  V30 4 1 2 18
M  V30 5 1 3 4
M  V30 6 2 3 5
M  V30 7 1 4 6
M  V30 8 3 6 7
M  V30 9 1 8 25
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 1 9 15
M  V30 13 2 10 12
M  V30 14 1 11 13
M  V30 15 1 12 14
M  V30 16 2 13 14
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 1 21 22
M  V30 24 2 21 23
M  V30 25 2 22 24
M  V30 26 1 23 25
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 372-09-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2412733-73-2
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2412734-02-0
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21607035
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 95
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 109-99-9
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and pharmacological evaluation of 4- or
6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3
inhibitors
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Shu, Lei; Chen, Chengjuan; Huan, Xueting; Huang, Hao; Wang, Manman;
Zhang, Jianqiu; Yan, Yile; Liu, Jianming; Zhang, Tiantai; Zhang, Dayong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 191112148pp.

$RFMT $RIREG SCHEME482 STEP1
$RXN



  2  1
$MOL
O-Methyl-N-(2-pyrazinylcarbonyl)-L-seryl-S-methyl-L-cysteine
C13H18N4O5S
2387522-91-8 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6685 3.8501 0.0 0 CFG=1
M  V30 2 N 5.3348 4.6201 0.0 0
M  V30 3 C 8.0022 4.6201 0.0 0
M  V30 4 C 6.6685 2.3101 0.0 0
M  V30 5 C 4.0010 3.8501 0.0 0
M  V30 6 N 8.0022 6.1601 0.0 0
M  V30 7 O 9.3360 3.8501 0.0 0
M  V30 8 O 8.0022 1.5400 0.0 0
M  V30 9 O 4.0010 2.3101 0.0 0
M  V30 10 C 9.3360 6.9302 0.0 0 CFG=2
M  V30 11 C 8.0022 0.0000 0.0 0
M  V30 12 C 10.6697 6.1601 0.0 0
M  V30 13 C 9.3360 8.4702 0.0 0
M  V30 14 S 12.0033 6.9302 0.0 0
M  V30 15 O 8.0022 9.2402 0.0 0
M  V30 16 O 10.6697 9.2402 0.0 0
M  V30 17 C 13.3370 6.1601 0.0 0
M  V30 18 C 2.6673 4.6201 0.0 0
M  V30 19 C 2.6673 6.1601 0.0 0
M  V30 20 N 1.3337 3.8501 0.0 0
M  V30 21 N 1.3337 6.9302 0.0 0
M  V30 22 C 0.0000 4.6201 0.0 0
M  V30 23 C 0.0000 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=3
M  V30 4 1 2 5
M  V30 5 1 3 6
M  V30 6 2 3 7
M  V30 7 1 4 8
M  V30 8 2 5 9
M  V30 9 1 5 18
M  V30 10 1 6 10
M  V30 11 1 8 11
M  V30 12 1 10 12 CFG=3
M  V30 13 1 10 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 1 18 19
M  V30 19 2 18 20
M  V30 20 2 19 21
M  V30 21 1 20 22
M  V30 22 1 21 23
M  V30 23 2 22 23
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
1-Pentanone, 2-amino-4-methyl-1-[(2R)-2-methyl-2-oxiranyl]-, (2S)-, 2,2,2-tri...
C9H17NO2.C2HF3O2
247068-85-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8504 6.7237 0.0 0
M  V30 2 C 4.1841 7.4937 0.0 0 CFG=1
M  V30 3 O 2.8504 5.1837 0.0 0
M  V30 4 C 5.5177 6.7237 0.0 0
M  V30 5 N 4.1841 9.0338 0.0 0
M  V30 6 C 6.8514 7.4937 0.0 0
M  V30 7 C 8.1852 6.7237 0.0 0
M  V30 8 C 6.8514 9.0338 0.0 0
M  V30 9 C 2.0434 8.9409 0.0 0
M  V30 10 C 1.5166 7.4937 0.0 0 CFG=2
M  V30 11 C 0.5268 6.3141 0.0 0
M  V30 12 O 0.0000 7.7611 0.0 0
M  V30 13 C 3.4257 2.3101 0.0 0
M  V30 14 C 4.7594 1.5400 0.0 0
M  V30 15 F 4.1958 3.6437 0.0 0
M  V30 16 F 2.0921 3.0801 0.0 0
M  V30 17 F 2.6557 0.9764 0.0 0
M  V30 18 O 6.0931 2.3101 0.0 0
M  V30 19 O 4.7594 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 10 1 CFG=1
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 6 8
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 11 12
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 16 1 13 17
M  V30 17 1 14 18
M  V30 18 2 14 19
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 2 10)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
O-Methyl-N-(2-pyrazinylcarbonyl)-L-seryl-S-methyl-N-[(1S)-3-methyl-1-[[(2R)-2...
C22H33N5O6S
2387523-05-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  34 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.5167 4.6200 0.0 0
M  V30 2 C 2.8504 3.8500 0.0 0 CFG=2
M  V30 3 O 0.1830 3.8500 0.0 0
M  V30 4 N 4.1840 4.6200 0.0 0
M  V30 5 C 2.8504 2.3100 0.0 0
M  V30 6 C 5.5177 3.8500 0.0 0
M  V30 7 C 1.5167 1.5400 0.0 0
M  V30 8 C 6.8515 4.6200 0.0 0 CFG=2
M  V30 9 O 5.5177 2.3100 0.0 0
M  V30 10 C 1.5167 0.0000 0.0 0
M  V30 11 C 0.1830 2.3100 0.0 0
M  V30 12 N 8.1851 3.8500 0.0 0
M  V30 13 C 6.8515 6.1600 0.0 0
M  V30 14 C 9.5187 4.6200 0.0 0
M  V30 15 S 5.5177 6.9300 0.0 0
M  V30 16 C 10.8524 3.8500 0.0 0 CFG=2
M  V30 17 O 9.5187 6.1600 0.0 0
M  V30 18 C 5.5177 8.4700 0.0 0
M  V30 19 N 12.1862 4.6200 0.0 0
M  V30 20 C 10.8524 2.3100 0.0 0
M  V30 21 C 13.5198 3.8500 0.0 0
M  V30 22 O 9.5187 1.5400 0.0 0
M  V30 23 O 13.5198 2.3100 0.0 0
M  V30 24 C 9.5187 0.0000 0.0 0
M  V30 25 C 3.0333 6.4273 0.0 0
M  V30 26 C 1.5167 6.1600 0.0 0 CFG=2
M  V30 27 C 0.0000 6.4273 0.0 0
M  V30 28 O 0.9899 7.6071 0.0 0
M  V30 29 C 14.8535 4.6200 0.0 0
M  V30 30 C 14.8535 6.1600 0.0 0
M  V30 31 N 16.1871 3.8500 0.0 0
M  V30 32 N 16.1871 6.9300 0.0 0
M  V30 33 C 17.5209 4.6200 0.0 0
M  V30 34 C 17.5209 6.1600 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 26 1 CFG=1
M  V30 4 1 2 4
M  V30 5 1 2 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 1 7 11
M  V30 12 1 8 12
M  V30 13 1 8 13 CFG=3
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 14 17
M  V30 18 1 15 18
M  V30 19 1 16 19
M  V30 20 1 16 20 CFG=1
M  V30 21 1 19 21
M  V30 22 1 20 22
M  V30 23 2 21 23
M  V30 24 1 21 29
M  V30 25 1 22 24
M  V30 26 1 26 25 CFG=3
M  V30 27 1 26 27
M  V30 28 1 26 28
M  V30 29 1 27 28
M  V30 30 1 29 30
M  V30 31 2 29 31
M  V30 32 2 30 32
M  V30 33 1 31 33
M  V30 34 1 32 34
M  V30 35 2 33 34
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(4 2 8 16 26)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2387522-91-8
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 247068-85-5
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2387523-05-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31545381
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of novel tripeptide propylene oxide proteasome inhibitors for
the treatment of multiple myeloma
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Wen; Wang, Xueyuan; Zhang, Haoyang; Wen, Tiantian; Yang, Lin;
Miao, Hang; Wang, Jia; Liu, Hailong; Yang, Xu; Lei, Meng; Zhu, Yongqiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2021), 40116182

$RFMT $RIREG SCHEME483 STEP1
$RXN



  2  1
$MOL
Formamide
CH3NO
75-12-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 0.0000 0.0 0
M  V30 2 N 0.0000 0.7700 0.0 0
M  V30 3 O 2.6673 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Amino-3-bromobenzoic acid
C7H6BrNO2
20776-51-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 3.0800 0.0 0
M  V30 2 O 6.6685 2.3100 0.0 0
M  V30 3 O 5.3347 4.6200 0.0 0
M  V30 4 N 2.6674 4.6200 0.0 0
M  V30 5 Br 0.0000 3.0800 0.0 0
M  V30 6 C 4.0011 2.3100 0.0 0
M  V30 7 C 2.6674 3.0800 0.0 0
M  V30 8 C 4.0011 0.7700 0.0 0
M  V30 9 C 1.3338 2.3100 0.0 0
M  V30 10 C 2.6674 0.0000 0.0 0
M  V30 11 C 1.3338 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 9
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
8-Bromo-4(3H)-quinazolinone
C8H5BrN2O
77150-35-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 3.0801 0.0 0
M  V30 2 Br 6.6687 2.3101 0.0 0
M  V30 3 C 2.6675 3.0801 0.0 0
M  V30 4 C 4.0012 2.3101 0.0 0
M  V30 5 C 1.3338 2.3101 0.0 0
M  V30 6 C 2.6675 4.6201 0.0 0
M  V30 7 C 5.3348 3.0801 0.0 0
M  V30 8 N 4.0012 0.7700 0.0 0
M  V30 9 N 1.3338 0.7700 0.0 0
M  V30 10 C 4.0012 5.3901 0.0 0
M  V30 11 C 5.3348 4.6201 0.0 0
M  V30 12 C 2.6675 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 7
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 75-12-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 20776-51-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 77150-35-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31670880
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of quinazoline derivatives as novel small-molecule inhibitors
targeting the programmed cell death-1/programmed cell death-ligand 1
(PD-1/PD-L1) interaction
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Wang, Yu; Kun Huang; Gao, Yali; Yuan, Dandan; Ling, Lin; Liu, Jieqing;
Wu, Sihai; Chen, Roufen; Li, He; Xiong, Yizu; Liu, Han; Ma, Junjie
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2022), 229113998

$RFMT $RIREG SCHEME484 STEP1
$RXN



  2  1
$MOL
2-Amino-6-chlorobenzoic acid
C7H6ClNO2
2148-56-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 1.3338 0.0 0
M  V30 3 O 0.0000 4.0012 0.0 0
M  V30 4 Cl 2.3101 5.3350 0.0 0
M  V30 5 N 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6675 0.0 0
M  V30 7 C 3.0801 4.0012 0.0 0
M  V30 8 C 3.0801 1.3338 0.0 0
M  V30 9 C 4.6201 4.0012 0.0 0
M  V30 10 C 4.6201 1.3338 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 8
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Formamidine acetate
C2H4O2.CH4N2
3473-63-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.8501 0.0 0
M  V30 2 N 0.0000 4.6201 0.0 0
M  V30 3 N 2.6673 4.6201 0.0 0
M  V30 4 C 1.3337 1.5400 0.0 0
M  V30 5 C 0.0000 2.3101 0.0 0
M  V30 6 O 2.6673 2.3101 0.0 0
M  V30 7 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 3
M  V30 3 1 4 5
M  V30 4 1 4 6
M  V30 5 2 4 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Chloro-4(3H)-quinazolinone
C8H5ClN2O
60233-66-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 1.3338 0.0 0
M  V30 2 Cl 2.3100 0.0000 0.0 0
M  V30 3 C 2.3100 2.6674 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 0.7700 2.6674 0.0 0
M  V30 6 C 3.0800 1.3338 0.0 0
M  V30 7 C 4.6200 4.0011 0.0 0
M  V30 8 N 2.3100 5.3349 0.0 0
M  V30 9 N 0.0000 4.0011 0.0 0
M  V30 10 C 4.6200 1.3338 0.0 0
M  V30 11 C 5.3900 2.6674 0.0 0
M  V30 12 C 0.7700 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 6
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2148-56-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3473-63-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 60233-66-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-42203010
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 89
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 64-17-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of Novel 5,6-Dihydro-4H-pyrido[2,3,4-de]quinazoline
Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA
Mutated HER2 Kinases
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Yang, Leifu; Li, Yaxin; Du, Yunling; Guo, Yan; Guo, Zhenke; Liu, Baoxiu;
Liu, Jianglin; Liu, Yanfei; Niu, Hongdan; Sun, Yueming; Yan, Henglin;
Yang, Yajuan; Yu, Shannan; Zhang, Yifan; Zhang, Yuan; Zheng, Kun; Zheng,
Nanqiao; Zhang, Xiaoqing; Zhang, Qiang; Hu, Liming
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(7), 5662-5682

$RFMT $RIREG SCHEME484 STEP1
$RXN



  2  1
$MOL
2-Amino-6-chlorobenzoic acid
C7H6ClNO2
2148-56-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 2.6675 0.0 0
M  V30 2 O 0.0000 1.3338 0.0 0
M  V30 3 O 0.0000 4.0012 0.0 0
M  V30 4 Cl 2.3101 5.3350 0.0 0
M  V30 5 N 2.3101 0.0000 0.0 0
M  V30 6 C 2.3101 2.6675 0.0 0
M  V30 7 C 3.0801 4.0012 0.0 0
M  V30 8 C 3.0801 1.3338 0.0 0
M  V30 9 C 4.6201 4.0012 0.0 0
M  V30 10 C 4.6201 1.3338 0.0 0
M  V30 11 C 5.3901 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 7
M  V30 5 1 5 8
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Formamidine acetate
C2H4O2.CH4N2
3473-63-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  7 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.8501 0.0 0
M  V30 2 N 0.0000 4.6201 0.0 0
M  V30 3 N 2.6673 4.6201 0.0 0
M  V30 4 C 1.3337 1.5400 0.0 0
M  V30 5 C 0.0000 2.3101 0.0 0
M  V30 6 O 2.6673 2.3101 0.0 0
M  V30 7 O 1.3337 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 1 3
M  V30 3 1 4 5
M  V30 4 1 4 6
M  V30 5 2 4 7
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
5-Chloro-4(3H)-quinazolinone
C8H5ClN2O
60233-66-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 1.3338 0.0 0
M  V30 2 Cl 2.3100 0.0000 0.0 0
M  V30 3 C 2.3100 2.6674 0.0 0
M  V30 4 C 3.0800 4.0011 0.0 0
M  V30 5 C 0.7700 2.6674 0.0 0
M  V30 6 C 3.0800 1.3338 0.0 0
M  V30 7 C 4.6200 4.0011 0.0 0
M  V30 8 N 2.3100 5.3349 0.0 0
M  V30 9 N 0.0000 4.0011 0.0 0
M  V30 10 C 4.6200 1.3338 0.0 0
M  V30 11 C 5.3900 2.6674 0.0 0
M  V30 12 C 0.7700 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 5
M  V30 2 1 2 6
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 2 4 7
M  V30 7 1 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 2 9 12
M  V30 13 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2148-56-3
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3473-63-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 60233-66-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35200662
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 64-17-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2H-[1,4]oxazino[2,3-f]quinazoline derivatives as EGFR-TKIs
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Qin, Xuemei; Liu, Peng; Li, Yihai; Hu, Liming; Liao, Yexin; Cao,
Tingting; Yang, Lifang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2023), 80129104

$RFMT $RIREG SCHEME485 STEP1
$RXN



  2  1
$MOL
(1-Methyl-1H-indol-3-yl)acetic acid
C11H11NO2
1912-48-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7306 4.6948 0.0 0
M  V30 2 C 7.1953 4.2188 0.0 0
M  V30 3 O 7.5155 2.7126 0.0 0
M  V30 4 O 8.3397 5.2494 0.0 0
M  V30 5 C 3.0202 0.0000 0.0 0
M  V30 6 C 3.0800 3.9844 0.0 0
M  V30 7 C 4.5863 3.6643 0.0 0
M  V30 8 C 2.3100 2.6508 0.0 0
M  V30 9 C 2.3100 5.3182 0.0 0
M  V30 10 C 4.7472 2.1327 0.0 0
M  V30 11 N 3.3404 1.5064 0.0 0
M  V30 12 C 0.7700 2.6508 0.0 0
M  V30 13 C 0.7700 5.3182 0.0 0
M  V30 14 C 0.0000 3.9844 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 7
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 5 11
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 6 9
M  V30 9 2 7 10
M  V30 10 1 8 11
M  V30 11 2 8 12
M  V30 12 1 9 13
M  V30 13 1 10 11
M  V30 14 1 12 14
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
4-Ethoxy-3-methoxybenzeneethanamine
C11H17NO2
36377-59-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.8500 1.3338 0.0 0
M  V30 2 C 4.6200 0.0000 0.0 0
M  V30 3 O 2.3100 4.0011 0.0 0
M  V30 4 C 1.5400 5.3349 0.0 0
M  V30 5 C 0.0000 5.3349 0.0 0
M  V30 6 C 8.4700 4.0011 0.0 0
M  V30 7 C 9.2400 5.3349 0.0 0
M  V30 8 N 10.7800 5.3349 0.0 0
M  V30 9 C 4.6200 2.6674 0.0 0
M  V30 10 C 3.8500 4.0011 0.0 0
M  V30 11 C 6.1600 2.6674 0.0 0
M  V30 12 C 4.6200 5.3349 0.0 0
M  V30 13 C 6.9300 4.0011 0.0 0
M  V30 14 C 6.1600 5.3349 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 9
M  V30 3 1 3 4
M  V30 4 1 3 10
M  V30 5 1 4 5
M  V30 6 1 6 7
M  V30 7 1 6 13
M  V30 8 1 7 8
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 10 12
M  V30 12 2 11 13
M  V30 13 2 12 14
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[2-(4-Ethoxy-3-methoxyphenyl)ethyl]-1-methyl-1H-indole-3-acetamide
C22H26N2O3
2565618-14-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2308 6.6686 0.0 0
M  V30 2 C 6.7709 6.6686 0.0 0
M  V30 3 N 7.5409 5.3348 0.0 0
M  V30 4 O 7.5409 8.0023 0.0 0
M  V30 5 C 9.0809 5.3348 0.0 0
M  V30 6 C 9.8509 4.0011 0.0 0
M  V30 7 C 4.1037 11.9712 0.0 0
M  V30 8 O 14.4710 1.3338 0.0 0
M  V30 9 C 13.7010 0.0000 0.0 0
M  V30 10 O 16.0110 4.0011 0.0 0
M  V30 11 C 16.7810 5.3348 0.0 0
M  V30 12 C 18.3211 5.3348 0.0 0
M  V30 13 C 2.9293 8.1632 0.0 0
M  V30 14 C 2.6091 9.6697 0.0 0
M  V30 15 C 4.4608 8.0023 0.0 0
M  V30 16 C 1.7849 7.1328 0.0 0
M  V30 17 N 3.9428 10.4397 0.0 0
M  V30 18 C 1.1444 10.1455 0.0 0
M  V30 19 C 5.0873 9.4091 0.0 0
M  V30 20 C 0.3202 7.6086 0.0 0
M  V30 21 C 0.0000 9.1149 0.0 0
M  V30 22 C 11.3909 4.0011 0.0 0
M  V30 23 C 12.1610 2.6675 0.0 0
M  V30 24 C 12.1610 5.3348 0.0 0
M  V30 25 C 13.7010 2.6675 0.0 0
M  V30 26 C 13.7010 5.3348 0.0 0
M  V30 27 C 14.4710 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 15
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 1 3 5
M  V30 6 1 5 6
M  V30 7 1 6 22
M  V30 8 1 7 17
M  V30 9 1 8 9
M  V30 10 1 8 25
M  V30 11 1 10 11
M  V30 12 1 10 27
M  V30 13 1 11 12
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 17 1 14 17
M  V30 18 2 14 18
M  V30 19 2 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 1 18 21
M  V30 23 2 20 21
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 23 25
M  V30 27 2 24 26
M  V30 28 2 25 27
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1912-48-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 36377-59-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2565618-14-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-23043310
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 85
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis, and biological evaluation of tetrahydroisoquinolines
derivatives as novel, selective PDE4 inhibitors for antipsoriasis
treatment
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Zhang, Rui; Li, Heng; Zhang, Xianglei; Li, Jian; Su, Haixia; Lu, Qiukai;
Dong, Guangyu; Dou, Huixia; Fan, Chen; Gu, Zhanni; Mu, Qianwen; Tang,
Wei; Xu, Yechun; Liu, Hong
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2021), 211113004

$RFMT $RIREG SCHEME486 STEP1
$RXN



  2  1
$MOL
Methyl 2-amino-5-methoxybenzoate
C9H11NO3
2475-80-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1600 2.6674 0.0 0
M  V30 2 O 6.9300 4.0011 0.0 0
M  V30 3 O 6.9300 1.3338 0.0 0
M  V30 4 C 8.4700 4.0011 0.0 0
M  V30 5 N 4.6200 0.0000 0.0 0
M  V30 6 O 1.5400 5.3349 0.0 0
M  V30 7 C 0.0000 5.3349 0.0 0
M  V30 8 C 4.6200 2.6674 0.0 0
M  V30 9 C 3.8500 4.0011 0.0 0
M  V30 10 C 3.8500 1.3338 0.0 0
M  V30 11 C 2.3100 4.0011 0.0 0
M  V30 12 C 2.3100 1.3338 0.0 0
M  V30 13 C 1.5400 2.6674 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 5 10
M  V30 6 1 6 7
M  V30 7 1 6 11
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 9 11
M  V30 11 2 10 12
M  V30 12 2 11 13
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
[3,4-Bipyridazine]-6-carboxylic acid
C9H6N4O2
2913152-05-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7700 1.3337 0.0 0
M  V30 2 O 0.0000 2.6673 0.0 0
M  V30 3 O 0.0000 0.0000 0.0 0
M  V30 4 C 5.3901 1.3337 0.0 0
M  V30 5 C 4.6201 0.0000 0.0 0
M  V30 6 N 4.6201 2.6673 0.0 0
M  V30 7 C 3.0801 0.0000 0.0 0
M  V30 8 N 3.0801 2.6673 0.0 0
M  V30 9 C 2.3101 1.3337 0.0 0
M  V30 10 C 6.9302 1.3337 0.0 0
M  V30 11 C 7.7002 2.6673 0.0 0
M  V30 12 C 7.7002 0.0000 0.0 0
M  V30 13 C 9.2402 2.6673 0.0 0
M  V30 14 N 9.2402 0.0000 0.0 0
M  V30 15 N 10.0102 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 9
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 4 10
M  V30 7 1 5 7
M  V30 8 2 6 8
M  V30 9 2 7 9
M  V30 10 1 8 9
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 11 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzoic acid, 2-[([3,4-bipyridazin]-6-ylcarbonyl)amino]-5-methoxy-, methyl e...
C18H15N5O4
2913152-08-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 5.3347 0.0 0
M  V30 2 C 7.7000 6.6685 0.0 0
M  V30 3 O 6.9300 8.0021 0.0 0
M  V30 4 C 5.3900 2.6674 0.0 0
M  V30 5 O 4.6200 1.3336 0.0 0
M  V30 6 O 6.9300 2.6674 0.0 0
M  V30 7 C 5.3900 0.0000 0.0 0
M  V30 8 O 0.7700 5.3347 0.0 0
M  V30 9 C 0.0000 6.6685 0.0 0
M  V30 10 C 5.3900 5.3347 0.0 0
M  V30 11 C 4.6200 4.0011 0.0 0
M  V30 12 C 4.6200 6.6685 0.0 0
M  V30 13 C 3.0800 4.0011 0.0 0
M  V30 14 C 3.0800 6.6685 0.0 0
M  V30 15 C 2.3100 5.3347 0.0 0
M  V30 16 C 9.2400 6.6685 0.0 0
M  V30 17 C 10.0100 5.3347 0.0 0
M  V30 18 N 10.0100 8.0021 0.0 0
M  V30 19 C 11.5500 5.3347 0.0 0
M  V30 20 N 11.5500 8.0021 0.0 0
M  V30 21 C 12.3200 6.6685 0.0 0
M  V30 22 C 13.8600 6.6685 0.0 0
M  V30 23 C 14.6300 8.0021 0.0 0
M  V30 24 C 14.6300 5.3347 0.0 0
M  V30 25 C 16.1700 8.0021 0.0 0
M  V30 26 N 16.1700 5.3347 0.0 0
M  V30 27 N 16.9400 6.6685 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 2 2 3
M  V30 4 1 2 16
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 11
M  V30 8 1 5 7
M  V30 9 1 8 9
M  V30 10 1 8 15
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 11 13
M  V30 14 2 12 14
M  V30 15 2 13 15
M  V30 16 1 14 15
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 26
M  V30 28 1 25 27
M  V30 29 2 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 2475-80-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2913152-05-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2913152-08-4
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35647834
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 84
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 68957-94-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 107-06-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, Synthesis, and Biological Evaluation of Bipyridazine Derivatives
as Stimulator of Interferon Genes (STING) Receptor Agonists
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Shan, Bin; Hou, Hui; Zhang, Keke; Li, Rui; Shen, Chang; Chen, Zhengyang;
Xu, Peijia; Cui, Rongrong; Su, Zhaoming; Zhang, Changfa; Yang, Ruirui;
Zhou, Guizhen; Liu, Yadan; Guo, Hao; Chen, Kaixian; Fu, Wei; Jiang,
Hualiang; Zhang, Sulin; Zheng, Mingyue
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2023), 66(5), 3327-3347

$RFMT $RIREG SCHEME487 STEP1
$RXN



  2  1
$MOL
4-[(2-Bromophenyl)amino]-4-oxo-2-butenoic acid
C10H8BrNO3
36847-85-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 O 5.3348 0.7700 0.0 0
M  V30 5 C 8.0023 2.3101 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 O 9.3360 4.6201 0.0 0
M  V30 8 O 10.6697 2.3101 0.0 0
M  V30 9 Br 1.3337 4.6201 0.0 0
M  V30 10 C 2.6673 2.3101 0.0 0
M  V30 11 C 1.3337 3.0801 0.0 0
M  V30 12 C 2.6673 0.7700 0.0 0
M  V30 13 C 0.0000 2.3101 0.0 0
M  V30 14 C 1.3337 0.0000 0.0 0
M  V30 15 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 11
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(2-Bromophenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H16BrN3O3
2416338-33-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9301 6.6684 0.0 0
M  V30 2 C 7.7001 5.3348 0.0 0
M  V30 3 C 9.2401 5.3348 0.0 0
M  V30 4 O 6.9301 4.0011 0.0 0
M  V30 5 C 10.0101 4.0011 0.0 0
M  V30 6 C 11.5501 4.0011 0.0 0
M  V30 7 N 12.3201 2.6675 0.0 0
M  V30 8 O 12.3201 5.3348 0.0 0
M  V30 9 O 5.3901 9.3359 0.0 0
M  V30 10 Br 13.8602 0.0000 0.0 0
M  V30 11 C 3.0800 5.3348 0.0 0
M  V30 12 C 2.3100 6.6684 0.0 0
M  V30 13 C 4.6201 5.3348 0.0 0
M  V30 14 C 2.3100 4.0011 0.0 0
M  V30 15 N 3.0800 8.0022 0.0 0
M  V30 16 C 0.7700 6.6684 0.0 0
M  V30 17 C 5.3901 6.6684 0.0 0
M  V30 18 C 0.7700 4.0011 0.0 0
M  V30 19 C 4.6201 8.0022 0.0 0
M  V30 20 C 0.0000 5.3348 0.0 0
M  V30 21 C 13.8602 2.6675 0.0 0
M  V30 22 C 14.6302 1.3337 0.0 0
M  V30 23 C 14.6302 4.0011 0.0 0
M  V30 24 C 16.1702 1.3337 0.0 0
M  V30 25 C 16.1702 4.0011 0.0 0
M  V30 26 C 16.9402 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 22
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 36847-85-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-33-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822015
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 82
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME488 STEP1
$RXN



  2  1
$MOL
4-[(2-Chlorophenyl)amino]-4-oxo-2-butenoic acid
C10H8ClNO3
36847-87-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 O 5.3348 0.7700 0.0 0
M  V30 5 C 8.0023 2.3101 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 O 9.3360 4.6201 0.0 0
M  V30 8 O 10.6697 2.3101 0.0 0
M  V30 9 Cl 1.3337 4.6201 0.0 0
M  V30 10 C 2.6673 2.3101 0.0 0
M  V30 11 C 1.3337 3.0801 0.0 0
M  V30 12 C 2.6673 0.7700 0.0 0
M  V30 13 C 0.0000 2.3101 0.0 0
M  V30 14 C 1.3337 0.0000 0.0 0
M  V30 15 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 11
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(2-Chlorophenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H16ClN3O3
2416338-31-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9301 6.6684 0.0 0
M  V30 2 C 7.7001 5.3348 0.0 0
M  V30 3 C 9.2401 5.3348 0.0 0
M  V30 4 O 6.9301 4.0011 0.0 0
M  V30 5 C 10.0101 4.0011 0.0 0
M  V30 6 C 11.5501 4.0011 0.0 0
M  V30 7 N 12.3201 2.6675 0.0 0
M  V30 8 O 12.3201 5.3348 0.0 0
M  V30 9 O 5.3901 9.3359 0.0 0
M  V30 10 Cl 13.8602 0.0000 0.0 0
M  V30 11 C 3.0800 5.3348 0.0 0
M  V30 12 C 2.3100 6.6684 0.0 0
M  V30 13 C 4.6201 5.3348 0.0 0
M  V30 14 C 2.3100 4.0011 0.0 0
M  V30 15 N 3.0800 8.0022 0.0 0
M  V30 16 C 0.7700 6.6684 0.0 0
M  V30 17 C 5.3901 6.6684 0.0 0
M  V30 18 C 0.7700 4.0011 0.0 0
M  V30 19 C 4.6201 8.0022 0.0 0
M  V30 20 C 0.0000 5.3348 0.0 0
M  V30 21 C 13.8602 2.6675 0.0 0
M  V30 22 C 14.6302 1.3337 0.0 0
M  V30 23 C 14.6302 4.0011 0.0 0
M  V30 24 C 16.1702 1.3337 0.0 0
M  V30 25 C 16.1702 4.0011 0.0 0
M  V30 26 C 16.9402 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 22
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 36847-87-7
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-31-1
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822013
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME489 STEP1
$RXN



  2  1
$MOL
4-(Ethylsulfonyl)benzeneacetic acid
C10H12O4S
383135-47-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 2.3100 2.6673 0.0 0 VAL=6
M  V30 2 C 0.7700 2.6673 0.0 0
M  V30 3 O 2.3100 1.1273 0.0 0
M  V30 4 O 2.3100 4.2073 0.0 0
M  V30 5 C 0.0000 4.0011 0.0 0
M  V30 6 C 8.4700 2.6673 0.0 0
M  V30 7 C 9.2400 1.3336 0.0 0
M  V30 8 O 10.7800 1.3336 0.0 0
M  V30 9 O 8.4700 0.0000 0.0 0
M  V30 10 C 3.8500 2.6673 0.0 0
M  V30 11 C 4.6200 1.3336 0.0 0
M  V30 12 C 4.6200 4.0011 0.0 0
M  V30 13 C 6.1600 1.3336 0.0 0
M  V30 14 C 6.1600 4.0011 0.0 0
M  V30 15 C 6.9300 2.6673 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 2 1 4
M  V30 4 1 1 10
M  V30 5 1 2 5
M  V30 6 1 6 7
M  V30 7 1 6 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
2-Propenamide, N-[2-(5-amino-2-pyridinyl)phenyl]-
C14H13N3O
3032933-04-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.6674 3.0800 0.0 0
M  V30 2 C 1.3336 2.3100 0.0 0
M  V30 3 C 1.3336 0.7700 0.0 0
M  V30 4 O 0.0000 3.0800 0.0 0
M  V30 5 C 0.0000 0.0000 0.0 0
M  V30 6 N 9.3358 2.3100 0.0 0
M  V30 7 C 4.0011 5.3900 0.0 0
M  V30 8 C 2.6674 4.6200 0.0 0
M  V30 9 C 4.0011 6.9300 0.0 0
M  V30 10 C 1.3336 5.3900 0.0 0
M  V30 11 C 2.6674 7.7000 0.0 0
M  V30 12 C 1.3336 6.9300 0.0 0
M  V30 13 C 5.3347 4.6200 0.0 0
M  V30 14 C 6.6684 5.3900 0.0 0
M  V30 15 N 5.3347 3.0800 0.0 0
M  V30 16 C 8.0021 4.6200 0.0 0
M  V30 17 C 6.6684 2.3100 0.0 0
M  V30 18 C 8.0021 3.0800 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 8
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 18
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 7 13
M  V30 10 1 8 10
M  V30 11 2 9 11
M  V30 12 2 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
Benzeneacetamide, 4-(ethylsulfonyl)-N-[6-[2-[(1-oxo-2-propen-1-yl)amino]pheny...
C24H23N3O4S
2983540-54-9 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.8500 4.0011 0.0 0
M  V30 2 C 2.3100 4.0011 0.0 0
M  V30 3 C 1.5400 5.3347 0.0 0
M  V30 4 O 1.5400 2.6674 0.0 0
M  V30 5 C 0.0000 5.3347 0.0 0
M  V30 6 N 9.2400 8.0021 0.0 0
M  V30 7 C 10.7800 8.0021 0.0 0
M  V30 8 C 11.5500 9.3358 0.0 0
M  V30 9 O 11.5500 6.6684 0.0 0
M  V30 10 S 17.7100 9.3358 0.0 0 VAL=6
M  V30 11 C 19.2500 9.3358 0.0 0
M  V30 12 O 17.7100 7.7958 0.0 0
M  V30 13 O 17.7100 10.8758 0.0 0
M  V30 14 C 20.0200 10.6694 0.0 0
M  V30 15 C 6.1600 2.6674 0.0 0
M  V30 16 C 4.6200 2.6674 0.0 0
M  V30 17 C 6.9300 1.3336 0.0 0
M  V30 18 C 3.8500 1.3336 0.0 0
M  V30 19 C 6.1600 0.0000 0.0 0
M  V30 20 C 4.6200 0.0000 0.0 0
M  V30 21 C 6.9300 4.0011 0.0 0
M  V30 22 C 8.4700 4.0011 0.0 0
M  V30 23 N 6.1600 5.3347 0.0 0
M  V30 24 C 9.2400 5.3347 0.0 0
M  V30 25 C 6.9300 6.6684 0.0 0
M  V30 26 C 8.4700 6.6684 0.0 0
M  V30 27 C 13.0900 9.3358 0.0 0
M  V30 28 C 13.8600 10.6694 0.0 0
M  V30 29 C 13.8600 8.0021 0.0 0
M  V30 30 C 15.4000 10.6694 0.0 0
M  V30 31 C 15.4000 8.0021 0.0 0
M  V30 32 C 16.1700 9.3358 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 16
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5
M  V30 6 1 6 7
M  V30 7 1 6 26
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 8 27
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 2 10 13
M  V30 14 1 10 32
M  V30 15 1 11 14
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 15 21
M  V30 19 1 16 18
M  V30 20 2 17 19
M  V30 21 2 18 20
M  V30 22 1 19 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 1 28 30
M  V30 32 2 29 31
M  V30 33 2 30 32
M  V30 34 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 383135-47-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 3032933-04-0
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2983540-54-9
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-39256077
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 1
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of the First-in-Class ROR Covalent Inhibitors for Treatment of
Castration-Resistant Prostate Cancer
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Fang, Wei; Zheng, Jianwei; Deng, Lin; An, Yana; Rong, Deqin; Wei,
Jianwei; Xiong, Xiao-Feng; Wang, Junjian; Wang, Yuanxiang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2024), 67(2), 1481-1499

$RFMT $RIREG SCHEME490 STEP1
$RXN



  2  1
$MOL
4-[(2-Fluorophenyl)amino]-4-oxo-2-butenoic acid
C10H8FNO3
198879-80-0 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.0012 3.0801 0.0 0
M  V30 2 C 5.3348 2.3101 0.0 0
M  V30 3 C 6.6685 3.0801 0.0 0
M  V30 4 O 5.3348 0.7700 0.0 0
M  V30 5 C 8.0023 2.3101 0.0 0
M  V30 6 C 9.3360 3.0801 0.0 0
M  V30 7 O 9.3360 4.6201 0.0 0
M  V30 8 O 10.6697 2.3101 0.0 0
M  V30 9 F 1.3337 4.6201 0.0 0
M  V30 10 C 2.6673 2.3101 0.0 0
M  V30 11 C 1.3337 3.0801 0.0 0
M  V30 12 C 2.6673 0.7700 0.0 0
M  V30 13 C 0.0000 2.3101 0.0 0
M  V30 14 C 1.3337 0.0000 0.0 0
M  V30 15 C 0.0000 0.7700 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 10
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 9 11
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 11 13
M  V30 13 2 12 14
M  V30 14 2 13 15
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Amino-3,4-dihydro-1H-quinolin-2-one
C9H10N2O
40615-17-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9300 2.6674 0.0 0
M  V30 2 O 5.3900 0.0000 0.0 0
M  V30 3 C 3.0800 4.0011 0.0 0
M  V30 4 C 2.3100 2.6674 0.0 0
M  V30 5 C 4.6200 4.0011 0.0 0
M  V30 6 C 2.3100 5.3349 0.0 0
M  V30 7 N 3.0800 1.3338 0.0 0
M  V30 8 C 0.7700 2.6674 0.0 0
M  V30 9 C 5.3900 2.6674 0.0 0
M  V30 10 C 0.7700 5.3349 0.0 0
M  V30 11 C 4.6200 1.3338 0.0 0
M  V30 12 C 0.0000 4.0011 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 9
M  V30 2 2 2 11
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 3 6
M  V30 6 1 4 7
M  V30 7 2 4 8
M  V30 8 1 5 9
M  V30 9 1 6 10
M  V30 10 1 7 11
M  V30 11 1 8 12
M  V30 12 1 9 11
M  V30 13 2 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N1-(2-Fluorophenyl)-N4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-2-butenediamide
C19H16FN3O3
2416338-36-6 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.9301 6.6684 0.0 0
M  V30 2 C 7.7001 5.3348 0.0 0
M  V30 3 C 9.2401 5.3348 0.0 0
M  V30 4 O 6.9301 4.0011 0.0 0
M  V30 5 C 10.0101 4.0011 0.0 0
M  V30 6 C 11.5501 4.0011 0.0 0
M  V30 7 N 12.3201 2.6675 0.0 0
M  V30 8 O 12.3201 5.3348 0.0 0
M  V30 9 O 5.3901 9.3359 0.0 0
M  V30 10 F 13.8602 0.0000 0.0 0
M  V30 11 C 3.0800 5.3348 0.0 0
M  V30 12 C 2.3100 6.6684 0.0 0
M  V30 13 C 4.6201 5.3348 0.0 0
M  V30 14 C 2.3100 4.0011 0.0 0
M  V30 15 N 3.0800 8.0022 0.0 0
M  V30 16 C 0.7700 6.6684 0.0 0
M  V30 17 C 5.3901 6.6684 0.0 0
M  V30 18 C 0.7700 4.0011 0.0 0
M  V30 19 C 4.6201 8.0022 0.0 0
M  V30 20 C 0.0000 5.3348 0.0 0
M  V30 21 C 13.8602 2.6675 0.0 0
M  V30 22 C 14.6302 1.3337 0.0 0
M  V30 23 C 14.6302 4.0011 0.0 0
M  V30 24 C 16.1702 1.3337 0.0 0
M  V30 25 C 16.1702 4.0011 0.0 0
M  V30 26 C 16.9402 2.6675 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 17
M  V30 3 1 2 3
M  V30 4 2 2 4
M  V30 5 2 3 5 CFG=2
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 2 6 8
M  V30 9 1 7 21
M  V30 10 2 9 19
M  V30 11 1 10 22
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 11 14
M  V30 15 1 12 15
M  V30 16 2 12 16
M  V30 17 1 13 17
M  V30 18 1 14 18
M  V30 19 1 15 19
M  V30 20 1 16 20
M  V30 21 1 17 19
M  V30 22 2 18 20
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 22 24
M  V30 26 2 23 25
M  V30 27 2 24 26
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 198879-80-0
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 40615-17-6
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2416338-36-6
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-367-CAS-21822018
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 81
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 121-44-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 122-52-1
$DTYPE RXN:VAR(1):CAT(2):CAS_RN
$DATUM 7553-56-2
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 75-09-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Design, synthesis and biological evaluation of novel
3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase
inhibitors and antifungal agents
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Li, Baihui; Shen, Yangli; Wu, Hu; Wu, Xiaobo; Yuan, Lvjiang; Ji, Qinggang
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM European Journal of Medicinal Chemistry (2020), 195112278

$RFMT $RIREG SCHEME491 STEP1
$RXN



  2  1
$MOL
3,5-Dihydroxybenzoic acid
C7H6O4
99-10-5 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 4.6200 0.0 0
M  V30 2 O 6.6685 3.8500 0.0 0
M  V30 3 O 5.3347 6.1600 0.0 0
M  V30 4 O 0.0000 4.6200 0.0 0
M  V30 5 O 2.6674 0.0000 0.0 0
M  V30 6 C 4.0011 3.8500 0.0 0
M  V30 7 C 2.6674 4.6200 0.0 0
M  V30 8 C 4.0011 2.3100 0.0 0
M  V30 9 C 1.3338 3.8500 0.0 0
M  V30 10 C 2.6674 1.5400 0.0 0
M  V30 11 C 1.3338 2.3100 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 6
M  V30 4 1 4 9
M  V30 5 1 5 10
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 7 9
M  V30 9 2 8 10
M  V30 10 2 9 11
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
N-[(2R,3S)-3-Amino-2-hydroxy-4-phenylbutyl]-4-fluoro-N-(2-methylpropyl)benzen...
C20H27FN2O3S
772318-79-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.6686 3.8500 0.0 0
M  V30 2 S 5.3348 4.6201 0.0 0 VAL=6
M  V30 3 C 8.0022 4.6201 0.0 0
M  V30 4 C 6.6686 2.3100 0.0 0
M  V30 5 O 6.1048 5.9537 0.0 0
M  V30 6 O 4.5648 3.2864 0.0 0
M  V30 7 C 9.3359 3.8500 0.0 0 CFG=1
M  V30 8 C 5.3348 1.5400 0.0 0
M  V30 9 C 10.6697 4.6201 0.0 0 CFG=1
M  V30 10 O 9.3359 2.3100 0.0 0
M  V30 11 C 5.3348 0.0000 0.0 0
M  V30 12 C 4.0011 2.3100 0.0 0
M  V30 13 C 12.0034 3.8500 0.0 0
M  V30 14 N 10.6697 6.1601 0.0 0
M  V30 15 F 0.0000 7.7001 0.0 0
M  V30 16 C 4.0011 5.3901 0.0 0
M  V30 17 C 4.0011 6.9301 0.0 0
M  V30 18 C 2.6675 4.6201 0.0 0
M  V30 19 C 2.6675 7.7001 0.0 0
M  V30 20 C 1.3338 5.3901 0.0 0
M  V30 21 C 1.3338 6.9301 0.0 0
M  V30 22 C 13.3370 4.6201 0.0 0
M  V30 23 C 13.3370 6.1601 0.0 0
M  V30 24 C 14.6707 3.8500 0.0 0
M  V30 25 C 14.6707 6.9301 0.0 0
M  V30 26 C 16.0045 4.6201 0.0 0
M  V30 27 C 16.0045 6.1601 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 2 2 5
M  V30 5 2 2 6
M  V30 6 1 2 16
M  V30 7 1 3 7
M  V30 8 1 4 8
M  V30 9 1 7 9
M  V30 10 1 7 10 CFG=3
M  V30 11 1 8 11
M  V30 12 1 8 12
M  V30 13 1 9 13
M  V30 14 1 9 14 CFG=1
M  V30 15 1 13 22
M  V30 16 1 15 21
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 17 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 7 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
N-[(1S,2R)-3-[[(4-Fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(p...
C27H31FN2O6S
2892016-32-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  37 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.0021 8.4700 0.0 0 CFG=1
M  V30 2 C 6.6685 7.7000 0.0 0 CFG=2
M  V30 3 C 8.0021 10.0100 0.0 0
M  V30 4 N 9.3358 7.7000 0.0 0
M  V30 5 C 5.3347 8.4700 0.0 0
M  V30 6 O 6.6685 6.1600 0.0 0
M  V30 7 C 10.6696 8.4700 0.0 0
M  V30 8 N 4.0011 7.7000 0.0 0
M  V30 9 O 10.6696 10.0100 0.0 0
M  V30 10 S 4.0011 6.1600 0.0 0 VAL=6
M  V30 11 C 2.6674 8.4700 0.0 0
M  V30 12 O 2.4611 6.1600 0.0 0
M  V30 13 O 5.5411 6.1600 0.0 0
M  V30 14 C 1.3338 7.7000 0.0 0
M  V30 15 C 0.0000 8.4700 0.0 0
M  V30 16 C 1.3338 6.1600 0.0 0
M  V30 17 O 16.0043 8.4700 0.0 0
M  V30 18 O 13.3369 3.8500 0.0 0
M  V30 19 F 4.0011 0.0000 0.0 0
M  V30 20 C 6.6685 10.7800 0.0 0
M  V30 21 C 6.6685 12.3200 0.0 0
M  V30 22 C 5.3347 10.0100 0.0 0
M  V30 23 C 5.3347 13.0900 0.0 0
M  V30 24 C 4.0011 10.7800 0.0 0
M  V30 25 C 4.0011 12.3200 0.0 0
M  V30 26 C 12.0032 7.7000 0.0 0
M  V30 27 C 13.3369 8.4700 0.0 0
M  V30 28 C 12.0032 6.1600 0.0 0
M  V30 29 C 14.6705 7.7000 0.0 0
M  V30 30 C 13.3369 5.3900 0.0 0
M  V30 31 C 14.6705 6.1600 0.0 0
M  V30 32 C 4.0011 4.6200 0.0 0
M  V30 33 C 2.6674 3.8500 0.0 0
M  V30 34 C 5.3347 3.8500 0.0 0
M  V30 35 C 2.6674 2.3100 0.0 0
M  V30 36 C 5.3349 2.3100 0.0 0
M  V30 37 C 4.0011 1.5400 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3 CFG=3
M  V30 3 1 1 4
M  V30 4 1 2 5
M  V30 5 1 2 6 CFG=3
M  V30 6 1 3 20
M  V30 7 1 4 7
M  V30 8 1 5 8
M  V30 9 2 7 9
M  V30 10 1 7 26
M  V30 11 1 8 10
M  V30 12 1 8 11
M  V30 13 2 10 12
M  V30 14 2 10 13
M  V30 15 1 10 32
M  V30 16 1 11 14
M  V30 17 1 14 15
M  V30 18 1 14 16
M  V30 19 1 17 29
M  V30 20 1 18 30
M  V30 21 1 19 37
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 21 23
M  V30 25 2 22 24
M  V30 26 2 23 25
M  V30 27 1 24 25
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 27 29
M  V30 31 2 28 30
M  V30 32 2 29 31
M  V30 33 1 30 31
M  V30 34 2 32 33
M  V30 35 1 32 34
M  V30 36 1 33 35
M  V30 37 2 34 36
M  V30 38 2 35 37
M  V30 39 1 36 37
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 1 2)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 99-10-5
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 772318-79-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2892016-32-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-34382512
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 80
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 2592-95-2
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 25952-53-8
$DTYPE RXN:VAR(1):CAT(1):CAS_RN
$DATUM 1122-58-3
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM A kind of HIV-1 protease inhibitors containing phenols with antiviral
activity against DRV-resistant variants
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Hu, Shangjiu; Ma, Ling; Dong, Biao; Shan, Qi; Zhou, Jinming; Zhang,
Guoning; Wang, Minghua; Cen, Shan; Zhu, Mei; Wang, Juxian; Wang, Yucheng
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry (2022), 64116760

$RFMT $RIREG SCHEME492 STEP1
$RXN



  2  1
$MOL
Methylamine hydrochloride
CH5N.ClH
593-51-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  3 1 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 1.5400 0.0 0
M  V30 2 N 1.5400 1.5400 0.0 0
M  V30 3 Cl 0.7700 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-[[2-Chloro-5-[(methylamino)carbonyl]-4-pyridinyl]amino]-2-methoxybenzoic acid
C15H14ClN3O4
1609531-36-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1601 5.3348 0.0 0
M  V30 2 O 4.6201 8.0022 0.0 0
M  V30 3 C 6.1601 8.0022 0.0 0
M  V30 4 C 1.5400 8.0022 0.0 0
M  V30 5 O 2.3100 9.3359 0.0 0
M  V30 6 O 0.0000 8.0022 0.0 0
M  V30 7 C 9.2401 5.3348 0.0 0
M  V30 8 N 10.7801 5.3348 0.0 0
M  V30 9 O 8.4701 6.6684 0.0 0
M  V30 10 C 11.5501 6.6684 0.0 0
M  V30 11 Cl 6.1601 0.0000 0.0 0
M  V30 12 C 4.6201 5.3348 0.0 0
M  V30 13 C 3.8500 6.6684 0.0 0
M  V30 14 C 3.8500 4.0011 0.0 0
M  V30 15 C 2.3100 6.6684 0.0 0
M  V30 16 C 2.3100 4.0011 0.0 0
M  V30 17 C 1.5400 5.3348 0.0 0
M  V30 18 C 6.9301 4.0011 0.0 0
M  V30 19 C 8.4701 4.0011 0.0 0
M  V30 20 C 6.1601 2.6675 0.0 0
M  V30 21 C 9.2401 2.6675 0.0 0
M  V30 22 C 6.9301 1.3337 0.0 0
M  V30 23 N 8.4701 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 12
M  V30 2 1 1 18
M  V30 3 1 2 3
M  V30 4 1 2 13
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 15
M  V30 8 1 7 8
M  V30 9 2 7 9
M  V30 10 1 7 19
M  V30 11 1 8 10
M  V30 12 1 11 22
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 13 15
M  V30 16 2 14 16
M  V30 17 2 15 17
M  V30 18 1 16 17
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 2 19 21
M  V30 22 1 20 22
M  V30 23 1 21 23
M  V30 24 2 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
$MOL
3-Pyridinecarboxamide, 6-chloro-4-[[2-methoxy-3-[(methylamino)carbonyl]phenyl...
C16H17ClN4O3
2921556-18-3 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.9302 8.0023 0.0 0
M  V30 2 C 5.3901 8.0023 0.0 0
M  V30 3 N 5.3901 5.3348 0.0 0
M  V30 4 C 10.0102 8.0023 0.0 0
M  V30 5 N 11.5503 8.0023 0.0 0
M  V30 6 O 9.2402 9.3360 0.0 0
M  V30 7 C 12.3203 9.3360 0.0 0
M  V30 8 C 2.3101 5.3348 0.0 0
M  V30 9 N 0.7700 5.3348 0.0 0
M  V30 10 O 3.0801 6.6685 0.0 0
M  V30 11 C 0.0000 6.6685 0.0 0
M  V30 12 Cl 5.3901 0.0000 0.0 0
M  V30 13 C 7.7002 6.6685 0.0 0
M  V30 14 C 6.9302 5.3348 0.0 0
M  V30 15 C 9.2402 6.6685 0.0 0
M  V30 16 C 7.7002 4.0012 0.0 0
M  V30 17 C 10.0102 5.3348 0.0 0
M  V30 18 C 9.2402 4.0012 0.0 0
M  V30 19 C 4.6201 4.0012 0.0 0
M  V30 20 C 3.0801 4.0012 0.0 0
M  V30 21 C 5.3901 2.6675 0.0 0
M  V30 22 C 2.3101 2.6675 0.0 0
M  V30 23 C 4.6201 1.3337 0.0 0
M  V30 24 N 3.0801 1.3337 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 13
M  V30 3 1 3 14
M  V30 4 1 3 19
M  V30 5 1 4 5
M  V30 6 2 4 6
M  V30 7 1 4 15
M  V30 8 1 5 7
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 8 20
M  V30 12 1 9 11
M  V30 13 1 12 23
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 2 20 22
M  V30 23 1 21 23
M  V30 24 1 22 24
M  V30 25 2 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 593-51-1
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 1609531-36-3
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 2921556-18-3
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-35040165
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 3
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 97
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 144-55-8
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 67-56-1
$DTYPE RXN:VAR(1):SOL(3):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):SOL(4):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Discovery of a potent and subtype-selective TYK2 degrader based on an
allosteric TYK2 inhibitor
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Kato, Jun-ya; Korenaga, Shigeru; Iwakura, Masaru
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Bioorganic & Medicinal Chemistry Letters (2023), 79129083

$RFMT $RIREG SCHEME493 STEP1
$RXN



  2  1
$MOL
Benzyloxycarbonyl-L-proline
C13H15NO4
1148-11-4 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  18 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.8384 3.7710 0.0 0
M  V30 2 O 6.3784 3.7710 0.0 0
M  V30 3 O 4.0684 5.1048 0.0 0
M  V30 4 C 7.1484 5.1048 0.0 0
M  V30 5 C 1.5063 3.4208 0.0 0
M  V30 6 O 1.9823 4.8855 0.0 0
M  V30 7 O 0.0000 3.1006 0.0 0
M  V30 8 N 4.0684 2.4374 0.0 0
M  V30 9 C 2.5368 2.2764 0.0 0 CFG=2
M  V30 10 C 4.6947 1.0306 0.0 0
M  V30 11 C 2.2167 0.7700 0.0 0
M  V30 12 C 3.5503 0.0000 0.0 0
M  V30 13 C 8.6884 5.1048 0.0 0
M  V30 14 C 9.4584 6.4384 0.0 0
M  V30 15 C 9.4584 3.7710 0.0 0
M  V30 16 C 10.9984 6.4384 0.0 0
M  V30 17 C 10.9984 3.7710 0.0 0
M  V30 18 C 11.7684 5.1048 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 8
M  V30 4 1 2 4
M  V30 5 1 4 13
M  V30 6 1 5 6
M  V30 7 2 5 7
M  V30 8 1 9 5 CFG=1
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 9 11
M  V30 12 1 10 12
M  V30 13 1 11 12
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 14 16
M  V30 17 2 15 17
M  V30 18 2 16 18
M  V30 19 1 17 18
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 9)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Methionine, methyl ester, hydrochloride
C6H13NO2S.ClH
2491-18-1 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0012 3.8501 0.0 0 CFG=1
M  V30 2 C 2.6675 3.0800 0.0 0
M  V30 3 C 5.3348 3.0800 0.0 0
M  V30 4 N 4.0012 5.3901 0.0 0
M  V30 5 O 1.3337 3.8501 0.0 0
M  V30 6 O 2.6675 1.5400 0.0 0
M  V30 7 C 6.6685 3.8501 0.0 0
M  V30 8 C 0.0000 3.0800 0.0 0
M  V30 9 S 8.0023 3.0800 0.0 0
M  V30 10 C 9.3360 3.8501 0.0 0
M  V30 11 Cl 4.6680 0.0000 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4 CFG=1
M  V30 4 1 2 5
M  V30 5 2 2 6
M  V30 6 1 3 7
M  V30 7 1 5 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(1 1)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$MOL
L-Methionine, N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-, methyl ester
C19H26N2O5S
17445-57-7 Copyright (C) 2025 ACS
  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS  27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1601 6.6685 0.0 0
M  V30 2 N 4.6201 6.6685 0.0 0
M  V30 3 O 6.9302 5.3348 0.0 0
M  V30 4 C 3.8501 5.3348 0.0 0 CFG=2
M  V30 5 C 4.6201 4.0012 0.0 0
M  V30 6 C 2.3101 5.3348 0.0 0
M  V30 7 C 3.8501 2.6673 0.0 0
M  V30 8 O 1.5400 6.6685 0.0 0
M  V30 9 O 1.5400 4.0012 0.0 0
M  V30 10 S 4.6201 1.3337 0.0 0
M  V30 11 C 0.0000 6.6685 0.0 0
M  V30 12 C 3.8501 0.0000 0.0 0
M  V30 13 C 9.4923 7.0187 0.0 0
M  V30 14 O 10.9986 7.3389 0.0 0
M  V30 15 O 9.0163 5.5541 0.0 0
M  V30 16 C 12.0290 6.1945 0.0 0
M  V30 17 C 6.9302 8.0022 0.0 0 CFG=2
M  V30 18 N 8.4617 8.1633 0.0 0
M  V30 19 C 6.3038 9.4091 0.0 0
M  V30 20 C 8.7819 9.6696 0.0 0
M  V30 21 C 7.4482 10.4396 0.0 0
M  V30 22 C 13.5355 6.5147 0.0 0
M  V30 23 C 14.5659 5.3703 0.0 0
M  V30 24 C 14.0114 7.9794 0.0 0
M  V30 25 C 16.0724 5.6904 0.0 0
M  V30 26 C 15.5178 8.2995 0.0 0
M  V30 27 C 16.5483 7.1550 0.0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 17 1 CFG=3
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=1
M  V30 6 1 4 6
M  V30 7 1 5 7
M  V30 8 1 6 8
M  V30 9 2 6 9
M  V30 10 1 7 10
M  V30 11 1 8 11
M  V30 12 1 10 12
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 13 18
M  V30 16 1 14 16
M  V30 17 1 16 22
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 18 20
M  V30 21 1 19 21
M  V30 22 1 20 21
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 23 25
M  V30 26 2 24 26
M  V30 27 2 25 27
M  V30 28 1 26 27
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STEABS ATOMS=(2 4 17)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
$DTYPE RXN:RCT(1):CAS_RN
$DATUM 1148-11-4
$DTYPE RXN:RCT(2):CAS_RN
$DATUM 2491-18-1
$DTYPE RXN:PRO(1):CAS_RN
$DATUM 17445-57-7
$DTYPE RXN:VAR(1):CAS_Reaction_Number
$DATUM 31-614-CAS-31592225
$DTYPE RXN:VAR(1):STEPS
$DATUM 1
$DTYPE RXN:VAR(1):STAGES
$DATUM 2
$DTYPE RXN:VAR(1):PRO(1):YIELD
$DATUM 91
$DTYPE RXN:VAR(1):RGT(1):CAS_RN
$DATUM 7087-68-5
$DTYPE RXN:VAR(1):RGT(2):CAS_RN
$DATUM 148893-10-1
$DTYPE RXN:VAR(1):RGT(3):CAS_RN
$DATUM 7732-18-5
$DTYPE RXN:VAR(1):SOL(1):CAS_RN
$DATUM 68-12-2
$DTYPE RXN:VAR(1):SOL(2):CAS_RN
$DATUM 141-78-6
$DTYPE RXN:VAR(1):REFERENCE(1):TITLE
$DATUM Novel macrocyclic peptidomimetics targeting the Polo-box domain of
Polo-like kinase 1
$DTYPE RXN:VAR(1):REFERENCE(1):AUTHOR
$DATUM Ryu, SeongShick; Park, Jung-Eun; Ham, Young Jin; Lim, Daniel C.;
Kwiatkowski, Nicholas P.; Kim, Do-Hee; Bhunia, Debabrata; Kim, Nam Doo;
Yaffe, Michael B.; Son, Woolim; Kim, Namkyoung; Choi, Tae-Ik; Swain,
Puspanjali; Kim, Cheol-Hee; Lee, Jin-Young; Gray, Nathanael S.; Lee,
Kyung S.; Sim, Taebo
$DTYPE RXN:VAR(1):REFERENCE(1):CITATION
$DATUM Journal of Medicinal Chemistry (2022), 65(3), 1915-1932

